PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sagara, J; Higuchi, T; Hattori, Y; Moriya, M; Sarvotham, H; Shima, H; Shirato, H; Kikuchi, K; Taniguchi, S				Sagara, J; Higuchi, T; Hattori, Y; Moriya, M; Sarvotham, H; Shima, H; Shirato, H; Kikuchi, K; Taniguchi, S			Scapinin, a putative protein phosphatase-1 regulatory subunit associated with the nuclear nonchromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEINS; GENE-EXPRESSION; CANCER; CELLS; LEUKEMIA; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION; ORGANIZATION; INTERPHASE	It is thought that the nuclear nonchromatin structures, such as the nuclear matrix and lamina, play regulatory roles in gene expression. In this study, we identified an insoluble protein that was associated with the chromatin-depleted nuclear structure of proliferating human leukemia HL-60 cells. Preparation of the chromatin-depleted nuclear structure, referred to as the nuclear matrix-intermediate filament scaffold (Fey, E., Krochmalnic, G., and Penman, S. (1986) J. Cell. Biol. 102, 1654-1665), involved cell extraction using a series of buffers containing Triton X-100, DNase I, and 2 M NaCl. A yeast two-hybrid assay revealed that this protein bound to the catalytic subunit of protein phosphatase-1 (PP1). Furthermore, it inhibited PP1 activity in vitro. We therefore named it scapinin ((s) under bar caffold-(a) under bar ssociated (P) under bar P1 (in) under bar hibiting prote (in) under bar). cDNA cloning revealed that scapinin had two splicing variants of 448 amino acids (scapinin-S) and 518 amino acids (scapinin-L). Scapinin was down-regulated by differentiation in HL-60 cells. These results suggest that scapinin is a putative regulatory subunit of PP1 and is involved in transformed or immature phenotypes of HL-60 cells. We also describe the presence of scapinin family proteins from worm to human.	Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Mol Oncol, Matsumoto, Nagano 3908621, Japan; Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Shinshu University; Hokkaido University	Sagara, J (corresponding author), Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Mol Oncol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.		Shirato, Hiroki/A-7068-2010					Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Ayukawa K, 2000, J BIOL CHEM, V275, P34465, DOI 10.1074/jbc.M003673200; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BIDWELL JP, 1994, CANCER RES, V54, P28; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; Cohen PTW, 2002, J CELL SCI, V115, P241; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; Getzenberg RH, 1996, CANCER RES, V56, P1690; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; KAUFMANN SH, 1992, CANCER RES, V52, P847; KEESEE SK, 1994, P NATL ACAD SCI USA, V91, P1913, DOI 10.1073/pnas.91.5.1913; KHANUJA PS, 1993, CANCER RES, V53, P3394; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; Ma H, 1999, J CELL BIOL, V146, P531, DOI 10.1083/jcb.146.3.531; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; MACKAY AM, 1993, J CELL BIOL, V123, P373, DOI 10.1083/jcb.123.2.373; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Oguchi M, 2002, BRIT J DERMATOL, V147, P853, DOI 10.1046/j.1365-2133.2002.04948.x; PAI CY, 1995, J CELL SCI, V108, P1911; PARTIN AW, 1993, CANCER RES, V53, P744; Shirato H, 2000, BIOCHEMISTRY-US, V39, P13848, DOI 10.1021/bi001326n; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; Stein GS, 2000, CANCER RES, V60, P2067; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Thompson LJ, 1997, J BIOL CHEM, V272, P29693, DOI 10.1074/jbc.272.47.29693; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4	34	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45611	45619		10.1074/jbc.M305227200	http://dx.doi.org/10.1074/jbc.M305227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925532	hybrid			2022-12-27	WOS:000186452300070
J	Iizuka, R; Yoshida, T; Shomura, Y; Miki, K; Maruyama, T; Odaka, M; Yohda, M				Iizuka, R; Yoshida, T; Shomura, Y; Miki, K; Maruyama, T; Odaka, M; Yohda, M			ATP binding is critical for the conformational change from an open to closed state in archaeal group II chaperonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOCOCCUS STRAIN KS-1; EUKARYOTIC CHAPERONIN; FUNCTIONAL-CHARACTERIZATION; HYPERTHERMOPHILIC ARCHAEUM; CYTOPLASMIC CHAPERONIN; THERMOSOME; TCP-1; HYDROLYSIS; SUBUNITS; DOMAINS	Group II chaperonins, found in archaea and in eukaryotic cytosol, do not have a co-chaperonin corresponding to GroES. Instead, it is suggested that the helical protrusion extending from the apical domain acts as a built-in lid for the central cavity and that the opening and closing of the lid is regulated by ATP binding and hydrolysis. However, details of this conformational change remain unclear. To investigate the conformational change associated with the ATP-driven cycle, we conducted protease sensitivity analyses and tryptophan fluorescence spectroscopy of alpha-chaperonin from a hyperthermophilic archaeum, Thermococcus strain KS-1. In the nucleotide-free or ADP-bound state, the chaperonin, especially in the helical protrusion region, was highly sensitive to proteases. Addition of ATP and ammonium sulfate induced the transition to the relatively protease-resistant form. The fluorescence intensity of the tryptophan residue introduced at the tip of the helical protrusion was enhanced by the presence of ATP or ammonium sulfate. We conclude that ATP binding induces the conformational change from the lid-open to lid-closed form in archaeal group II chaperonin.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan; Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; RIKEN Harima Inst SPring8, Mikazukicho, Hyogo 6795148, Japan; Japan Marine Sci & Technol Ctr, Marine Ecosyst Res Dept, Kanagawa 2370061, Japan; RIKEN, Bioengn Lab, Wako, Saitama 3510198, Japan	Tokyo University of Agriculture & Technology; Kyoto University; Kyoto University; RIKEN; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); RIKEN	Yohda, M (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Tokyo 1848588, Japan.	yohda@cc.tuat.ac.jp	Odaka, Masafumi/C-2378-2013; Yohda, Masafumi/A-5149-2013	Yohda, Masafumi/0000-0001-8307-9671; Iizuka, Ryo/0000-0002-9328-5628				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Gutsche I, 2000, CURR BIOL, V10, P405, DOI 10.1016/S0960-9822(00)00421-8; Gutsche I, 2000, J MOL BIOL, V300, P187, DOI 10.1006/jmbi.2000.3833; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Gutsche I, 2001, J STRUCT BIOL, V135, P139, DOI 10.1006/jsbi.2001.4373; Horwich AL, 1998, NAT STRUCT BIOL, V5, P333, DOI 10.1038/nsb0598-333; Iizuka R, 2001, BIOCHEM BIOPH RES CO, V289, P1118, DOI 10.1006/bbrc.2001.6139; Klumpp M, 1998, FEBS LETT, V430, P73, DOI 10.1016/S0014-5793(98)00541-9; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kusmierczyk AR, 2001, FEBS LETT, V505, P343, DOI 10.1016/S0014-5793(01)02838-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Sambrook J., 2002, MOL CLONING LAB MANU; Schoehn G, 2000, J MOL BIOL, V301, P323, DOI 10.1006/jmbi.2000.3952; Schoehn G, 2000, J MOL BIOL, V296, P813, DOI 10.1006/jmbi.2000.3505; Szpikowska BK, 1998, PROTEIN SCI, V7, P1524, DOI 10.1002/pro.5560070705; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Yoshida T, 2000, J MOL BIOL, V299, P1399, DOI 10.1006/jmbi.2000.3847; Yoshida T, 2002, FEBS LETT, V514, P269, DOI 10.1016/S0014-5793(02)02377-3; Yoshida T, 2002, MOL MICROBIOL, V44, P761, DOI 10.1046/j.1365-2958.2002.02909.x; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220; Yoshida T, 1997, J MOL BIOL, V273, P635, DOI 10.1006/jmbi.1997.1337; Yoshida T, 2001, MOL MICROBIOL, V39, P1406, DOI 10.1046/j.1365-2958.2001.02334.x	31	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44959	44965		10.1074/jbc.M305484200	http://dx.doi.org/10.1074/jbc.M305484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920124	hybrid			2022-12-27	WOS:000186306700132
J	Huang, SS; Tang, FM; Huang, YH; Liu, IH; Hsu, SC; Chen, ST; Huang, JS				Huang, SS; Tang, FM; Huang, YH; Liu, IH; Hsu, SC; Chen, ST; Huang, JS			Cloning, expression, characterization, and role in autocrine cell growth of cell surface retention sequence binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIS GENE-PRODUCT; V-SIS; EXTRACELLULAR-MATRIX; TRANSFORMED CELLS; ONCOGENE PRODUCT; MICE LACKING; FACTOR VEGF; IN-VIVO; B-CHAIN; RECEPTOR	Cell surface retention sequence binding protein-1 (CRSBP-1) is a cell surface binding protein for the cell surface retention sequence (CRS) motif of the v-sis gene product (platelet-derived growth factor-BB). It has been shown to be responsible for cell surface retention of the v-sis gene product in v-sis-transformed cells ( fibroblasts) and has been hypothesized to play a role in autocrine growth and transformation of these cells. Here we demonstrate that the CRSBP-1 cDNA cloned from bovine liver libraries encodes a 322-residue type I membrane protein containing a 23-residue signal peptide, a 215-residue cell surface domain, a 21-residue transmembrane domain, and a 63-residue cytoplasmic domain. CRSBP-1 expressed in transfected cells is an similar to 120-kDa disulfide-linked homodimeric glycoprotein and exhibits dual ligand (CRS-containing growth regulators (v-sis gene product and insulin-like growth factor binding protein-3, IGFBP-3) and hyaluronic acid) binding activity. CRSBP-1 overexpression (by stable transfection of cells with CRSBP-1 cDNA) enhances autocrine loop signaling, cell growth, and tumorigenicity ( in mice) of v-sis-transformed cells. CRSBP-1 expression also enhances autocrine cell growth mediated by IGFBP-3 in human lung carcinoma cells (H1299 cells), which express very little, if any, endogenous CRSBP-1 and exhibits a mitogenic response to exogenous IGFBP-3, stably transfected with IGFBP-3 cDNA. However, CRSBP-1 overexpression does not affect growth of normal and transformed cells that do not produce these CRS-containing growth regulators. These results suggest that CRSBP-1 plays a role in autocrine regulation of cell growth mediated by growth regulators containing CRS.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Taipei Med Univ, Dept Biochem, Taipei 110, Taiwan	Saint Louis University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Medical University	Huang, SS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangss@slu.edu; huangjs@slu.edu			NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Assmann V, 1998, J CELL SCI, V111, P1685; BACH LA, 1992, DIABETES METAB REV, V8, P229, DOI 10.1002/dmr.5610080304; Baghdiguian S, 1996, EUR J CANCER, V32A, P525, DOI 10.1016/0959-8049(95)00588-9; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; Boensch C, 1999, J BIOL CHEM, V274, P10582, DOI 10.1074/jbc.274.15.10582; BOENSCH C, 1995, J BIOL CHEM, V270, P1807, DOI 10.1074/jbc.270.4.1807; BOENSCH C, 1998, THESIS ST LOUIS U ST; BOWENPOPE DF, 1984, BLOOD, V64, P458; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carreira CM, 2001, CANCER RES, V61, P8079; COHICK WS, 1992, ENDOCRINOLOGY, V130, P1508, DOI 10.1210/en.130.3.1508; DAVIS SR, 1992, J ENDOCRINOL, V132, P339, DOI 10.1677/joe.0.1320339; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DEUEL TF, 1984, BLOOD, V64, P951; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; Devi GR, 2000, ENDOCRINOLOGY, V141, P4171, DOI 10.1210/en.141.11.4171; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GARGOSKY SE, 1990, J ENDOCRINOL, V127, P391, DOI 10.1677/joe.0.1270391; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; HELDIN CH, 1985, J CELL SCI, P65; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hofmann M, 1998, J CELL SCI, V111, P1673; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; Huang SS, 1997, FEBS LETT, V416, P297, DOI 10.1016/S0014-5793(97)01213-1; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUANG SS, 2003, IN PRESS FASEB J; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; LEAL SM, 1999, THESIS ST LOUIS U ST; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; Robinson CJ, 2001, J CELL SCI, V114, P853; Schryver B, 1996, ONCOGENE, V13, P333; Sleeman JP, 1997, J BIOL CHEM, V272, P31837, DOI 10.1074/jbc.272.50.31837; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1991, CANCER RES, V51, P5087	72	18	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43855	43869		10.1074/jbc.M306411200	http://dx.doi.org/10.1074/jbc.M306411200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912978	hybrid			2022-12-27	WOS:000186157000136
J	Li, BL; Dedman, JR; Kaetzel, MA				Li, BL; Dedman, JR; Kaetzel, MA			Intron disruption of the annexin IV gene reveals novel transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; FOLATE CARRIER GENE; OPEN READING FRAME; TRANSLATIONAL CONTROL; EXPRESSION; PROTEIN; PROMOTERS; IDENTIFICATION; VARIANTS; SEQUENCE	Annexin IV (AIV), a Ca2+-dependent membrane-binding protein, is expressed in many epithelia. Annexin IV modifies membrane bilayers by increasing rigidity, reducing water and H+ permeability, promoting vesicle aggregation, and regulating ion conductances, all in a Ca2+-dependent manner. We have characterized a mouse in which a gene trap has been inserted into the first intron of annexin IV. Processing of the primary transcript is disrupted. Northern blot and immunoblot data indicated that annexin IV expression was eliminated in many but not all tissues. Immunohistochemical analysis, however, demonstrated that annexin IV expression was eliminated in some cell types, but was unaltered in others. 5'-Rapid amplification of cDNA ends analysis of intestinal and kidney RNA revealed three transcripts, AIVa, AIVb, and AIVc. AIVa is widely distributed. AIVb is expressed only in the digestive tract. AIVc expression is very restricted. A selected number of epithelial cells of unique morphology demonstrate high concentrations. All three transcripts produce an identical annexin IV protein. The different tissue and cell-specific expression profiles of the three transcripts suggest that regulation of both the annexin IV gene expression and the cellular role of the protein are complex. The AIVa(-/-) mouse may become a valuable model to further study transcription and the physiological role of annexin IV.	Univ Cincinnati, Coll Med, Genome Res Inst, Dept Genome Sci, Cincinnati, OH 45237 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45237 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Kaetzel, MA (corresponding author), Univ Cincinnati, Coll Med, Genome Res Inst, Dept Genome Sci, 2180 E Galbraith Rd, Cincinnati, OH 45237 USA.	Marcia.Kaetzel@uc.edu						Bances P, 2000, GENOMICS, V69, P95, DOI 10.1006/geno.2000.6309; Beck CW, 1999, MECH DEVELOP, V88, P221, DOI 10.1016/S0925-4773(99)00217-8; Breslin MB, 2001, MOL ENDOCRINOL, V15, P1381, DOI 10.1210/me.15.8.1381; Carcedo MT, 2001, BIOCHEM J, V356, P571, DOI 10.1042/0264-6021:3560571; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Farber SA, 2003, GENOME RES, V13, P1082, DOI 10.1101/gr.479603; Fukuoka SI, 2002, BBA-GENE STRUCT EXPR, V1575, P148, DOI 10.1016/S0167-4781(02)00299-3; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; HAMMAN HC, 1998, BIOCH BIOPHYS COMMUN, V156, P660; Hanfrey C, 2002, J BIOL CHEM, V277, P44131, DOI 10.1074/jbc.M206161200; Hill WG, 2003, J GEN PHYSIOL, V121, P413, DOI 10.1085/jgp.200308803; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; IMAI Y, 1995, EUR J BIOCHEM, V232, P327, DOI 10.1111/j.1432-1033.1995.tb20815.x; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; KAETZEL MA, 1994, J BIOL CHEM, V269, P5297; Kaetzel MA, 2001, BIOCHEMISTRY-US, V40, P4192, DOI 10.1021/bi002507s; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAETZEL MA, 2002, WILEY ENCY MOL MED, V5, P208; Kos M, 2002, J BIOL CHEM, V277, P37131, DOI 10.1074/jbc.M206325200; KOWN HS, 2001, ARCH BIOCHEM BIOPHYS, V386, P163; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lee J, 2002, NUCLEIC ACIDS RES, V30, P5110, DOI 10.1093/nar/gkf664; Munch C, 2002, J NEUROCHEM, V82, P594, DOI 10.1046/j.1471-4159.2002.01012.x; Sable CL, 1999, BIOCHEM BIOPH RES CO, V258, P162, DOI 10.1006/bbrc.1999.0544; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Seville RA, 2002, DEVELOPMENT, V129, P1693; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; SUAR D, 2002, AM J PHYSIOL, V282, pG349; TAIT JF, 1992, GENOMICS, V12, P313, DOI 10.1016/0888-7543(92)90379-7; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; Whetstine JR, 2002, J BIOL CHEM, V277, P43873, DOI 10.1074/jbc.M208296200; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	36	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43276	43283		10.1074/jbc.M306361200	http://dx.doi.org/10.1074/jbc.M306361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912993	hybrid			2022-12-27	WOS:000186157000070
J	Stollar, EJ; Mayor, U; Lovell, SC; Federici, L; Freund, SMV; Fersht, AR; Luisi, BF				Stollar, EJ; Mayor, U; Lovell, SC; Federici, L; Freund, SMV; Fersht, AR; Luisi, BF			Crystal structures of engrailed homeodomain mutants - Implications for stability and dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTENNAPEDIA HOMEODOMAIN; X-RAY; MOLECULAR REPLACEMENT; MATA1 HOMEODOMAIN; NMR-SPECTROSCOPY; NK-2 HOMEODOMAIN; DNA COMPLEX; PROTEIN; BINDING; CRYSTALLOGRAPHY	We report the crystal structures and biophysical characterization of two stabilized mutants of the Drosophila Engrailed homeodomain that have been engineered to minimize electrostatic repulsion. Four independent copies of each mutant occupy the crystal lattice, and comparison of these structures illustrates variation that can be partly ascribed to networks of correlated conformational adjustments. Central to one network is leucine 26 (Leu(26)), which occupies alternatively two side chain rotameric conformations (-gauche and trans) and different positions within the hydrophobic core. Similar sets of conformational substates are observed in other Engrailed structures and in another homeodomain. The pattern of structural adjustments can account for NMR relaxation data and sequence co-variation networks in the wider homeodomain family. It may also explain the dysfunction associated with a P26L mutation in the human ARX homeodomain protein. Finally, we observe a novel dipolar interaction between a conserved tryptophan and a water molecule positioned along the normal to the indole ring. This interaction may explain the distinctive fluorescent properties of the homeodomain family.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge; University of Cambridge	Luisi, BF (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	Ben@cryst.bioc.cam.ac.uk	Fersht, Alan R/B-2189-2008; Mayor, Ugo/F-5890-2011	Mayor, Ugo/0000-0003-2812-8287; Lovell, Simon/0000-0002-4092-8458				Anderson JS, 2000, BIOCHEMISTRY-US, V39, P10045, DOI 10.1021/bi000677z; Banerjee-Basu S, 2001, NUCLEIC ACIDS RES, V29, P3258, DOI 10.1093/nar/29.15.3258; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carra JH, 1997, BIOCHEMISTRY-US, V36, P526, DOI 10.1021/bi962206b; CLARKE ND, 1994, PROTEIN SCI, V3, P1779, DOI 10.1002/pro.5560031018; CLARKE ND, 1995, PROTEIN SCI, V4, P2269, DOI 10.1002/pro.5560041104; COX M, 1995, J BIOMOL NMR, V6, P23, DOI 10.1007/BF00417488; Delbruck H, 2001, J MOL BIOL, V313, P359, DOI 10.1006/jmbi.2001.5051; Esposito G, 1996, EUR J BIOCHEM, V241, P101, DOI 10.1111/j.1432-1033.1996.0101t.x; Fraenkel E, 1998, NAT STRUCT BIOL, V5, P692, DOI 10.1038/1382; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Grant RA, 2000, BIOCHEMISTRY-US, V39, P8187, DOI 10.1021/bi000071a; GUYDOSH NR, 2002, THESIS U CAMBRIDGE C; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hovde S, 2001, BIOCHEMISTRY-US, V40, P12013, DOI 10.1021/bi0108148; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ippel H, 1999, J MOL BIOL, V288, P689, DOI 10.1006/jmbi.1999.2718; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; Ke A, 2003, PROTEIN SCI, V12, P306, DOI 10.1110/ps.0219103; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Kissinger CR, 2001, ACTA CRYSTALLOGR D, V57, P1474, DOI 10.1107/S0907444901012458; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurents DV, 2000, BIOCHEMISTRY-US, V39, P13963, DOI 10.1021/bi001388d; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Markley JL, 1998, EUR J BIOCHEM, V256, P1, DOI 10.1046/j.1432-1327.1998.2560001.x; Marshall SA, 2002, J MOL BIOL, V316, P189, DOI 10.1006/jmbi.2001.5326; Mayor U, 2000, P NATL ACAD SCI USA, V97, P13518, DOI 10.1073/pnas.250473497; Mayor U, 2003, NATURE, V421, P863, DOI 10.1038/nature01428; MAYOR U, 2003, THESIS U CAMBRIDGE C; MEIERING EM, 1992, J MOL BIOL, V225, P585, DOI 10.1016/0022-2836(92)90387-Y; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nanda V, 2000, PROTEINS, V40, P112, DOI 10.1002/(SICI)1097-0134(20000701)40:1<112::AID-PROT130>3.0.CO;2-C; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; QIAN YQ, 1994, J MOL BIOL, V238, P333, DOI 10.1006/jmbi.1994.1296; Rejto PA, 1996, PROG BIOPHYS MOL BIO, V66, P167, DOI 10.1016/S0079-6107(97)85629-5; Remenyi A, 2001, MOL CELL, V8, P569, DOI 10.1016/S1097-2765(01)00336-7; RICHARDSON DC, 1994, TRENDS BIOCHEM SCI, V19, P135, DOI 10.1016/0968-0004(94)90207-0; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; Scheffer IE, 2002, NEUROLOGY, V59, P348, DOI 10.1212/WNL.59.3.348; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Stromme P, 2002, NAT GENET, V30, P441, DOI 10.1038/ng862; Subramaniam V, 2001, J BIOL CHEM, V276, P21506, DOI 10.1074/jbc.M102292200; Tang KS, 1999, J MOL BIOL, V285, P1869, DOI 10.1006/jmbi.1998.2420; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; TSAO DHH, 1995, J MOL BIOL, V251, P297, DOI 10.1006/jmbi.1995.0435; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; Weiler S, 1998, J BIOL CHEM, V273, P10994, DOI 10.1074/jbc.273.18.10994; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Wilson MA, 2000, J MOL BIOL, V301, P1237, DOI 10.1006/jmbi.2000.4029; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Xiao L, 1999, J MOL BIOL, V289, P1435, DOI 10.1006/jmbi.1999.2810; ZHANG XJ, 1995, J MOL BIOL, V250, P527, DOI 10.1006/jmbi.1995.0396	62	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43699	43708		10.1074/jbc.M308029200	http://dx.doi.org/10.1074/jbc.M308029200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923178	hybrid			2022-12-27	WOS:000186157000119
J	Vergnes, L; Phan, J; Strauss, M; Tafuri, S; Reue, K				Vergnes, L; Phan, J; Strauss, M; Tafuri, S; Reue, K			Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN LEVELS; HIGH-FAT DIETS; STELLATE CELLS; ATHEROSCLEROSIS; MOUSE; SUSCEPTIBILITY; FIBROSIS; MICE; HYPERCHOLESTEROLEMIA; FIBROGENESIS	Atherosclerosis in inbred mouse strains has been widely studied by using an atherogenic (Ath) diet containing cholesterol, cholic acid, and fat, but the effect of these components on gene expression has not been systematically examined. We employed DNA microarrays to interrogate gene expression levels in liver of C57BL/6J mice fed the following five diets: mouse chow, the Ath diet, or modified versions of the Ath diet in which either cholesterol, cholate, or fat were omitted. Dietary cholesterol and cholate produced discrete gene expression patterns. Cholesterol was required for induction of genes involved in acute inflammation, including three genes of the serum amyloid A family, three major histocompatibility class II antigen genes, and various cytokine-related genes. In contrast, cholate induced expression of genes involved in extracellular matrix deposition in hepatic fibrosis, including five collagen family members, collagen-interacting proteins, and connective tissue growth factor. The gene expression findings were confirmed by biochemical measurements showing that cholesterol was required for elevation of circulating serum amyloid A, and cholate was required for accumulation of collagen in the liver. The possibility that these gene expression changes are relevant to atherogenesis in C57BL/6J mice was supported by the observation that the closely related, yet atherosclerosis-resistant, C57BL/ 6ByJ strain was largely resistant to dietary induction of the inflammatory and fibrotic response genes. These results establish that cholesterol and cholate components of the Ath diet have distinct proatherogenic effects on gene expression and suggest a strategy to study the contribution of acute inflammatory response and fibrogenesis independently through dietary manipulation.	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Pfizer	Reue, K (corresponding author), 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA.	Reuek@ucla.edu		vergnes, laurent/0000-0002-8804-589X; Phan, Jack/0000-0001-5977-6004	NHLBI NIH HHS [HL58627, HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058627, P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey DW, 1978, ORIGINS INBRED MICE, P197; Baroukh N, 2001, FEBS LETT, V502, P16, DOI 10.1016/S0014-5793(01)02621-7; Bissell DM, 1998, J GASTROENTEROL, V33, P295, DOI 10.1007/s005350050087; Brady LM, 1996, BIOCHEM J, V316, P765, DOI 10.1042/bj3160765; Canbay A, 2002, GASTROENTEROLOGY, V123, P1323, DOI 10.1053/gast.2002.35953; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; Fazio S, 2001, FRONT BIOSCI-LANDMRK, V6, pD515, DOI 10.2741/Fazio; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; Higuchi H, 2003, AM J PHYSIOL-GASTR L, V284, pG734, DOI 10.1152/ajpgi.00491.2002; Huebert RC, 2002, J BIOL CHEM, V277, P22710, DOI 10.1074/jbc.M202394200; Kersten S, 2001, FASEB J, V15, P1971, DOI 10.1096/fj.01-0147com; Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1; KNOLLE P, 1995, Z GASTROENTEROL, V33, P613; Knowles JW, 2000, ARTERIOSCL THROM VAS, V20, P2336, DOI 10.1161/01.ATV.20.11.2336; LEBOEUF RC, 1990, J LIPID RES, V31, P91; Li D, 1999, J GASTROEN HEPATOL, V14, P618, DOI 10.1046/j.1440-1746.1999.01928.x; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; Marra F, 1999, J HEPATOL, V31, P1120; Mouzeyan A, 2000, J LIPID RES, V41, P573; Neubauer K, 2001, CAN J GASTROENTEROL, V15, P187, DOI 10.1155/2001/870205; NISHINA PM, 1993, J LIPID RES, V34, P1413; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; Phan J, 2002, J BIOL CHEM, V277, P469, DOI 10.1074/jbc.M107107200; Reardon CA, 2001, CURR OPIN LIPIDOL, V12, P167, DOI 10.1097/00041433-200104000-00010; Sheth SS, 2002, CURR OPIN LIPIDOL, V13, P181, DOI 10.1097/00041433-200204000-00010; THOMPSON JS, 1969, J ATHEROSCLER RES, V10, P113, DOI 10.1016/S0368-1319(69)80090-6; Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Vergnes L, 2003, J LIPID RES, V44, P503, DOI 10.1194/jlr.M200399-JLR200; VESSELIN.D, 1968, J ATHEROSCLER RES, V8, P497, DOI 10.1016/S0368-1319(68)80105-X	35	149	156	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42774	42784		10.1074/jbc.M306022200	http://dx.doi.org/10.1074/jbc.M306022200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923166	hybrid			2022-12-27	WOS:000186157000008
J	Zhao, Z; Peng, Y; Hao, SF; Zeng, ZH; Wang, CC				Zhao, Z; Peng, Y; Hao, SF; Zeng, ZH; Wang, CC			Dimerization by domain hybridization bestows chaperone and isomerase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PEPTIDE-BINDING; THIOREDOXIN; RESIDUES; FOLD; DSBC	Thioredoxin, DsbA, the N-terminal active-site domain a and the non-active-site domain b of protein-disulfide isomerase are all monomeric with a thioredoxin fold, and each exhibits low or no isomerase and chaperone activity. We have linked the N terminus of the above four monomers, individually, to the C terminus of the N-terminal domain of DsbC via the flexible linker helix of the latter to produce four domain hybrids, DsbCn-Trx, DsbCn-DsbA, DsbCn-PDIa, and DsbCn-PDIb. These four hybrid proteins form homodimers, and except for DsbCn-PDIb they exhibit new or greatly elevated isomerase as well as chaperone activity. Three-dimensional structure prediction indicates that all the four domain hybrids adopt DsbC-like V-shaped structure with a broad uncharged cleft between the two arms for binding of non-native protein folding intermediates. The results provide strong evidence that dimerization creates chaperone and isomerase activity for monomeric thiol-protein oxidases or reductases, and suggesting a pathway for proteins to acquire new functions and/or higher biological efficiency during evolution.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Biophys, Ctr Mol Biol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, CC (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	chihwang@sun5.ibp.ac.cn	Peng, Yi/G-5945-2010					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CAI H, 1994, J BIOL CHEM, V269, P24550; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Hiniker A, 2003, BIOCHEMISTRY-US, V42, P1179, DOI 10.1021/bi027141t; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Katzen F, 2002, EMBO J, V21, P3960, DOI 10.1093/emboj/cdf405; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Liu XQ, 1999, PROTEIN SCI, V8, P2085, DOI 10.1110/ps.8.10.2085; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MARTINEZGALISTEO E, 1993, BIOCHIMIE, V75, P803, DOI 10.1016/0300-9084(93)90131-B; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Mossner E, 1998, PROTEIN SCI, V7, P1233; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWNALL HJ, 1977, BIOCHIM BIOPHYS ACTA, V488, P190, DOI 10.1016/0005-2760(77)90176-X; PUIG A, 1994, J BIOL CHEM, V269, P7764; Ruoppolo M, 2003, PROTEIN SCI, V12, P939, DOI 10.1110/ps.0242803; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; Sun XX, 2000, BBA-PROTEIN STRUCT M, V1481, P45, DOI 10.1016/S0167-4838(00)00122-9; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	45	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43292	43298		10.1074/jbc.M306945200	http://dx.doi.org/10.1074/jbc.M306945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933788	hybrid			2022-12-27	WOS:000186157000072
J	Brewer, L; Corzett, M; Lau, EY; Balhorn, R				Brewer, L; Corzett, M; Lau, EY; Balhorn, R			Dynamics of protamine 1 binding to single DNA molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-AMINO ACIDS; NUCLEIC-ACIDS; CHAIN LENGTHS; SPERM; IDENTIFICATION; CONDENSATION; COMPLEXES; PEPTIDES; PROTEINS; RESIDUES	Protamine molecules bind to and condense DNA in the sperm of most vertebrates, packaging the sperm genome in an inactive state until it can be reactivated following fertilization. By using methods that enable the analysis of protamine binding to individual DNA molecules, we have monitored the kinetics of DNA condensation and decondensation by protamine 1 (P1) and synthetic peptides corresponding to specific segments of the bull P1 DNA binding domain. Our results show that the number of clustered arginine residues present in the DNA binding domain is the most important factor affecting the condensation and stability of the DNA-protamine complex prior to the formation of inter-protamine disulfide cross-links. The high affinity of P1 for DNA is achieved by the coordinated binding of three anchoring domains, which together in bull P1 contain 19 Arg residues. The single DNA molecule experiments show that sequences containing two or more anchoring domains have an off-rate that is at least 3 orders of magnitude slower than those containing a single domain. The use of Arg, rather than Lys residues, and the inclusion of Tyr or Phe residues in the hinge regions between anchoring domains provide additional stability to the complex.	Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Balhorn, R (corresponding author), Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, POB 5508, Livermore, CA 94550 USA.	balhorn2@llnl.gov	Brewer, Laurence/G-4056-2012	Lau, Edmond/0000-0003-0619-7249	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K25HD001387] Funding Source: NIH RePORTER; NICHD NIH HHS [1K25 HD 01387-03] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; BALHORN R, 1992, ARCH BIOCHEM BIOPHYS, V296, P384, DOI 10.1016/0003-9861(92)90588-N; Balhorn R., 1989, P366; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; Balhorn R, 2000, MOL REPROD DEV, V56, P230, DOI 10.1002/(SICI)1098-2795(200006)56:2+<230::AID-MRD3>3.3.CO;2-M; BALHORN R, 1991, BIOCHEMISTRY-US, V30, P175, DOI 10.1021/bi00215a026; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; Brewer L, 2002, J BIOL CHEM, V277, P38895, DOI 10.1074/jbc.M204755200; Brewer LR, 1999, SCIENCE, V286, P120, DOI 10.1126/science.286.5437.120; BRUN F, 1975, BIOCHEMISTRY-US, V14, P558, DOI 10.1021/bi00674a015; BUCK F, 1983, EUR J BIOCHEM, V132, P321, DOI 10.1111/j.1432-1033.1983.tb07365.x; CHIRAT F, 1993, BIOCHIM BIOPHYS ACTA, V1203, P109, DOI 10.1016/0167-4838(93)90043-Q; COLEMAN JE, 1978, BIOCHEMISTRY-US, V17, P5038, DOI 10.1021/bi00616a028; COREY RB, 1953, REV SCI INSTRUM, V24, P621, DOI 10.1063/1.1770803; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Corzett M, 2002, MOL REPROD DEV, V61, P519, DOI 10.1002/mrd.10105; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FEUGHELMAN M, 1955, NATURE, V175, P834, DOI 10.1038/175834a0; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; HUANG XF, 1994, BIOCHEM BIOPH RES CO, V198, P712, DOI 10.1006/bbrc.1994.1103; HUD NV, 1993, BIOCHEM BIOPH RES CO, V193, P1347, DOI 10.1006/bbrc.1993.1773; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KAWASHIMA S, 1978, J BIOCHEM-TOKYO, V84, P343, DOI 10.1093/oxfordjournals.jbchem.a132134; KAWASHIMA S, 1969, BIOCHIM BIOPHYS ACTA, V186, P145, DOI 10.1016/0005-2787(69)90497-3; Kelley LA, 1997, PROTEIN ENG, V10, P737, DOI 10.1093/protein/10.6.737; LOUIE AJ, 1972, J BIOL CHEM, V247, P7962; Mascotti DP, 1997, BIOCHEMISTRY-US, V36, P7272, DOI 10.1021/bi970272n; MAZRIMAS JA, 1986, BIOCHIM BIOPHYS ACTA, V872, P11, DOI 10.1016/0167-4838(86)90141-X; Meistrich M., 1989, HISTONES OTHER BASIC, P165; NAKANO M, 1989, J BIOCHEM-TOKYO, V105, P133, DOI 10.1093/oxfordjournals.jbchem.a122607; OLINS DE, 1967, J MOL BIOL, V24, P157, DOI 10.1016/0022-2836(67)90324-5; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PIRHONEN A, 1994, EUR J BIOCHEM, V223, P165, DOI 10.1111/j.1432-1033.1994.tb18979.x; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; PORSCHKE D, 1978, EUR J BIOCHEM, V86, P291, DOI 10.1111/j.1432-1033.1978.tb12310.x; Prieto MC, 1997, BIOCHEMISTRY-US, V36, P11944, DOI 10.1021/bi971061l; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; SAUTIERE P, 1984, EUR J BIOCHEM, V144, P121, DOI 10.1111/j.1432-1033.1984.tb08439.x; SRIDHARAN S, 1992, FASEB J, V6, pA174; STANDKE KH, 1975, NUCLEIC ACIDS RES, V2, P1839, DOI 10.1093/nar/2.10.1839; TOBITA T, 1988, BIOCHEM INT, V16, P163; Toth G, 2001, PROTEINS, V43, P373, DOI 10.1002/prot.1050; Ward WS, 1996, CRIT REV EUKAR GENE, V6, P139, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.30; WEHLING K, 1975, NUCLEIC ACIDS RES, V2, P799, DOI 10.1093/nar/2.6.799; Wong B, 2002, BIOCHEMISTRY-US, V41, P5404, DOI 10.1021/bi012077l; WORTH GA, 1995, J PHYS CHEM-US, V99, P17473, DOI 10.1021/j100048a025; Zhang XD, 1996, J STRUCT BIOL, V116, P335, DOI 10.1006/jsbi.1996.0051	49	60	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42403	42408		10.1074/jbc.M303610200	http://dx.doi.org/10.1074/jbc.M303610200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912999	hybrid			2022-12-27	WOS:000185989500103
J	Guimaraes, CA; Benchimol, M; Amarante-Mendes, GP; Linden, R				Guimaraes, CA; Benchimol, M; Amarante-Mendes, GP; Linden, R			Alternative programs of cell death in developing retinal tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							APOPTOSIS-INDUCING FACTOR; L-DNASE-II; PROTEIN-SYNTHESIS; CASPASE ACTIVATION; NEURONAL DEATH; GANGLION-CELLS; MEMBRANE PERMEABILIZATION; SPINAL-CORD; AUTOPHAGY; INHIBITION	We examined cell death in developing retinal tissue, following inhibition of protein synthesis, which kills undifferentiated post-mitotic cells. Ultrastructural features were found of both apoptosis and autophagy. Only approximately half of the degenerating cells were either terminal dUTP nick-end labeling (TUNEL)-positive or reacted with antibodies specific for activated caspases-3 or -9. Bongkrekic acid completely inhibited any appearance of cell death, whereas inhibitors of autophagy, caspases-9 or -3, prevented only TUNEL-positive cell death. Interestingly, inhibition of caspase-6 blocked TUNEL-negative cell death. Simultaneous inhibition of caspases-9 and -6 prevented cell death almost completely, but degeneration dependent on autophagy/ caspase-9 still occurred under inhibition of both caspases-3 and -6. Thus, inhibition of protein synthesis induces in the developing retina various post-translational, mitochondria-dependent pathways of cell death. Autophagy precedes sequential activation of caspases-9 and -3, and DNA fragmentation, whereas, in parallel, caspase-6 leads to a TUNEL-negative form of cell death. Additional mechanisms of cell death may be engaged upon selective caspase inhibition.	Univ Fed Rio de Janeiro, Inst Biofis, CCS, BR-21949900 Rio De Janeiro, Brazil; Univ Santa Ursula, Rio De Janeiro, Brazil; Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo	Linden, R (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis, CCS, Bloco G,Cidade Univ, BR-21949900 Rio De Janeiro, Brazil.	rlinden@biof.ufrj.br	Linden, Rafael/F-2275-2011; Mendes, Gustavo P Amarante/C-8187-2012; Sternberg, Cinthya/K-4038-2012	Linden, Rafael/0000-0003-3287-336X; Mendes, Gustavo P Amarante/0000-0002-7851-6205; Sternberg, Cinthya/0000-0002-4760-6339				Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Altairac S, 2001, NEUROSCI LETT, V303, P41, DOI 10.1016/S0304-3940(01)01706-2; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; ARAKI T, 1990, ACTA NEUROPATHOL, V79, P501, DOI 10.1007/BF00296109; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; Bijl M, 2001, NETH J MED, V59, P66, DOI 10.1016/S0300-2977(01)00131-0; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BULTZINGSLOWEN I, 2001, ORAL ONCOL, V37, P537; Bursch W, 2000, J CELL SCI, V113, P1189; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Cataldo AM, 1996, J NEUROSCI, V16, P186; Cecconi F, 2001, CELL MOL LIFE SCI, V58, P1688, DOI 10.1007/PL00000806; Chang SH, 2002, EXP CELL RES, V277, P15, DOI 10.1006/excr.2002.5539; Chaudhary P, 1999, MOL BRAIN RES, V67, P36, DOI 10.1016/S0169-328X(99)00032-7; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Clarke G, 2001, HUM MOL GENET, V10, P2269, DOI 10.1093/hmg/10.20.2269; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; De Basilio V, 2001, POULTRY SCI, V80, P29, DOI 10.1093/ps/80.1.29; DEARAUJO EG, 1993, EUR J NEUROSCI, V5, P1181; Delshad A, 2001, FOLIA NEUROPATHOL, V39, P125; Domen J, 2000, IMMUNOL RES, V22, P83, DOI 10.1385/IR:22:2-3:83; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GARCIAPORRERO JA, 1979, EXPERIENTIA, V35, P375, DOI 10.1007/BF01964362; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JEFFREY M, 1992, ACTA NEUROPATHOL, V84, P559, DOI 10.1007/BF00304476; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; Joaquin AM, 2001, J AM GERIATR SOC, V49, P1234, DOI 10.1046/j.1532-5415.2001.04990.x; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Katai N, 1999, INVEST OPHTH VIS SCI, V40, P2697; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kermer P, 2000, MOL BRAIN RES, V85, P144, DOI 10.1016/S0169-328X(00)00256-4; Kermer P, 1998, J NEUROSCI, V18, P4656; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Linden R, 1999, PROG RETIN EYE RES, V18, P133, DOI 10.1016/S1350-9462(98)00020-2; Linden R, 2000, BRAIN RES REV, V32, P146, DOI 10.1016/S0165-0173(99)00073-9; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; McKinnon SJ, 2002, INVEST OPHTH VIS SCI, V43, P1077; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miyashita T, 1998, CELL DEATH DIFFER, V5, P1034, DOI 10.1038/sj.cdd.4400442; Monk CS, 2001, DEV NEUROPSYCHOL, V19, P211, DOI 10.1207/S15326942DN1902_5; MORIYA M, 1986, CELL TISSUE RES, V246, P607, DOI 10.1007/BF00215203; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakanishi K, 2001, J BIOL CHEM, V276, P41237, DOI 10.1074/jbc.M105648200; Namura S, 1998, J NEUROSCI, V18, P3659; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Paglin S, 2001, CANCER RES, V61, P439; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Pru JK, 2001, MOL ENDOCRINOL, V15, P845, DOI 10.1210/me.15.6.845; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Rehen SK, 1996, DEVELOPMENT, V122, P1439; Rehen SK, 1999, EUR J NEUROSCI, V11, P4349, DOI 10.1046/j.1460-9568.1999.00868.x; Reme CE, 1999, INVEST OPHTH VIS SCI, V40, P2398; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Singh M, 2001, J NEUROCHEM, V77, P466, DOI 10.1046/j.1471-4159.2001.00258.x; Sorimachi T, 2002, J NEUROSURG, V97, P104, DOI 10.3171/jns.2002.97.1.0104; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; Tezel G, 1999, INVEST OPHTH VIS SCI, V40, P2660; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; Torriglia A, 2001, EXP EYE RES, V72, P443, DOI 10.1006/exer.2000.0969; Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233; UCKER DS, 1989, J IMMUNOL, V143, P3461; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Varella MH, 1997, NEUROCHEM INT, V31, P217, DOI 10.1016/S0197-0186(96)00151-9; WEBER R, 1965, EXPERIENTIA, V21, P665, DOI 10.1007/BF02144069; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	101	66	66	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41938	41946		10.1074/jbc.M306547200	http://dx.doi.org/10.1074/jbc.M306547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917395	hybrid			2022-12-27	WOS:000185989500048
J	Deng, XB; Ewton, DZ; Pawlikowski, B; Maimone, M; Friedman, E				Deng, XB; Ewton, DZ; Pawlikowski, B; Maimone, M; Friedman, E			Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIRK PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATOR; TERMINAL DIFFERENTIATION; COLON-CANCER; DYRK FAMILY; MAP KINASE; CELL-CYCLE; SPECIFICITY; MYOD; EXPRESSION	The Rho family of small GTPases regulates numerous signaling pathways that control the organization of the cytoskeleton, transcription factor activity, and many aspects of the differentiation of skeletal myoblasts. We now demonstrate that the kinase Mirk (minibrain-related kinase)/dyrk1B is induced by members of the Rho-family in myoblasts and that Mirk is active in skeletal muscle differentiation. Mirk is an arginine-directed serine/ threonine kinase which is expressed at elevated levels in skeletal muscle compared with other normal tissues. A Mirk promoter construct was activated when C2C12 myoblasts were switched from growth to differentiation medium and was also activated by the Rho family members RhoA, Cdc42, and to a lesser degree Rac1, but not by MyoD or Myf5. Mirk protein levels increased following transient expression of constitutively active Cdc42-QL, RhoA-QL, or Rac1-QL in C2C12 cells. High concentrations of serum mitogens down-regulated Mirk through activation of the Ras-MEK-Erk pathway. As a result, Mirk transcription was induced by the MEK1 inhibitor PD98059 and by the switch from growth to differentiation medium. Mirk was induced with similar kinetics to another Rho-induced differentiation gene, myogenin. Mirk protein levels increased 10-fold within 24 - 48 h after primary cultured muscle cells; C2C12 mouse myoblasts or L6 rat myoblasts were induced to differentiate. Thus Mirk was induced following the commitment stage of myogenesis. Stable overexpression of Mirk enabled myoblasts to fuse more rapidly when placed in differentiation medium. The function of Mirk in muscle differentiation was established by depletion of endogenous Mirk by small interfering RNA, which prevented myoblast fusion into myotubes and inhibited induction of markers of differentiation, including myogenin, fast twitch troponin T, and muscle myosin heavy chain. Other members of the dyrk/minibrain/HIPK family of kinases in lower organisms have been shown to regulate the transition from growth to differentiation, and Mirk is now shown to participate in skeletal muscle development.	SUNY, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA; SUNY, Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College	Friedman, E (corresponding author), SUNY, Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.	friedmae@mail.upstate.edu			NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [CA67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Cabane C, 2003, AM J PHYSIOL-CELL PH, V284, pC658, DOI 10.1152/ajpcell.00078.2002; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Eskinazi R, 1999, AM J PATHOL, V155, P1105, DOI 10.1016/S0002-9440(10)65213-3; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Leder S, 2003, BIOCHEM J, V372, P881, DOI 10.1042/BJ20030182; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 2000, CANCER RES, V60, P3631; Lim S, 2002, J BIOL CHEM, V277, P49438, DOI 10.1074/jbc.M206840200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; Mullen AJ, 2000, GENE, V242, P313, DOI 10.1016/S0378-1119(99)00519-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Neufeld B, 2000, J BIOL CHEM, V275, P20239, DOI 10.1074/jbc.C901040199; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Rhee KH, 1997, J MOL BIOL, V265, P20, DOI 10.1006/jmbi.1996.0708; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Taminato A, 2002, MOL BIOL CELL, V13, P2266, DOI 10.1091/mbc.01-11-0555; Yan ZF, 2002, J BIOL CHEM, V277, P9870, DOI 10.1074/jbc.M107646200	32	65	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41347	41354		10.1074/jbc.M306780200	http://dx.doi.org/10.1074/jbc.M306780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902328	hybrid			2022-12-27	WOS:000185847200115
J	Yang, YS; Sharma, A; Sharma, R; Patrick, B; Singhal, SS; Zimniak, P; Awasthi, S; Awasthi, YC				Yang, YS; Sharma, A; Sharma, R; Patrick, B; Singhal, SS; Zimniak, P; Awasthi, S; Awasthi, YC			Cells preconditioned with mild, transient UVA irradiation acquire resistance to oxidative stress and UVA-induced apoptosis - Role of 4-hydroxynonenal in UVA-mediated signaling for apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCT; GLUTATHIONE S-TRANSFERASES; TERMINAL KINASE JNK; NF-KAPPA-B; ANTIOXIDANT ENZYMES; HUMAN KERATINOCYTES; SKIN FIBROBLASTS; HUMAN TISSUES; ACTIVATION; PATHWAYS	Because 4-hydroxynonenal (4-HNE) has been suggested to be involved in oxidative stress-mediated apoptosis (Cheng, J.Z., Sharma, R., Yang, Y., Singhal, S. S., Sharma, A., Saini, M. K., Singh, S. V., Zimniak, P., Awasthi, S., and Awasthi, Y. C. ( 2001) J. Biol. Chem. 276, 41213 - 41223) and UVA irradiation also causes lipid peroxidation, we have examined the role of 4-HNE in UVA-mediated apoptosis. K562 cells irradiated with UVA (3.0 milliwatts/cm(2)) for 5, 15, and 30 min showed a time dependent increase in 4-HNE levels. As judged by the activation of caspases, apoptosis was observed only in cells irradiated for 30 min. Within 2 h of recovery in normal medium, 4-HNE levels in 5 and 15 min UVA, irradiated cells returned to the basal or even lower levels but in cells irradiated for 30 min, 4-HNE levels remained consistently higher. The cells irradiated with UVA for 5 min and allowed to recover for 2 h in normal medium (UVA-preconditioned cells) showed a remarkable induction of hGST5.8, which catalyzes conjugation of 4-HNE to glutathione (GSH), and RLIP76 (Ral BP-1), which mediates the transport of the conjugate, GS-HNE. In cells irradiated with UVA for 30 min the induction of RLIP76 or hGST5.8 was not observed. The preconditioned cells transported GS-HNE into the medium at a rate about 2-fold higher than the controls and the transport was inhibited (65%) by coating the cells with anti-RLIP76 IgG. Upon treatment with xanthine/ xanthine oxidase (XA/XO), 4-HNE, or prolonged UVA exposure, the control cells showed a sustained activation of c-Jun N-terminal kinase (JNK) and apoptosis. However, in the UVA-preconditioned cells, apoptosis was not observed, and JNK activation was inhibited. This resistance of preconditioned cells to XA/ XO-, 4-HNE-, or UVA-induced apoptosis could be abrogated when these cells were coated with anti-RLIP76 IgG to block the efflux of GS-HNE. These studies strongly suggest a role of 4-HNE in UVA-mediated apoptosis.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Dept Chem & Biochem, Arlington, TX 76019 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Arlington; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Awasthi, YC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 551 Basic Sci Bldg, Galveston, TX 77555 USA.		Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717	NATIONAL CANCER INSTITUTE [R01CA077495] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004396, R55EY004396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032304] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77495] Funding Source: Medline; NEI NIH HHS [EY 04396] Funding Source: Medline; NIEHS NIH HHS [ES 07804] Funding Source: Medline; NIGMS NIH HHS [GM 32304] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; Awasthi S, 2002, DRUG METAB DISPOS, V30, P1300, DOI 10.1124/dmd.30.12.1300; BEERS RF, 1952, J BIOL CHEM, V195, P133; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P29, DOI 10.1006/abbi.1999.1479; Cheng JZ, 2001, J BIOL CHEM, V276, P41213, DOI 10.1074/jbc.M106838200; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; Cheng JZ, 2001, BIOCHEM BIOPH RES CO, V282, P1268, DOI 10.1006/bbrc.2001.4707; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HATCHARD CG, 1956, PROC R SOC LON SER-A, V235, P518, DOI 10.1098/rspa.1956.0102; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Hu YZ, 2003, J BIOL CHEM, V278, P17299, DOI 10.1074/jbc.M300788200; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kruman I, 1997, J NEUROSCI, V17, P5089; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORLIERE P, 1991, BIOCHIM BIOPHYS ACTA, V1084, P261, DOI 10.1016/0005-2760(91)90068-S; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; Pourzand C, 1999, P NATL ACAD SCI USA, V96, P6751, DOI 10.1073/pnas.96.12.6751; Pourzand C, 1997, CANCER RES, V57, P1405; PUNNONEN K, 1991, J INVEST DERMATOL, V96, P255, DOI 10.1111/1523-1747.ep12462271; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071; Sharutin VV, 2001, RUSS J GEN CHEM+, V71, P79, DOI 10.1023/A:1012385524010; SINGHAL SS, 1994, BBA-PROTEIN STRUCT M, V1204, P279, DOI 10.1016/0167-4838(94)90019-1; Singhal SS, 1999, BIOCHEM ARCH, V15, P163; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VILE GF, 1995, PHOTOCHEM PHOTOBIOL, V62, P463, DOI 10.1111/j.1751-1097.1995.tb02369.x; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yang YS, 2002, TOXICOL APPL PHARM, V182, P105, DOI 10.1006/taap.2002.9450; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200	45	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41380	41388		10.1074/jbc.M305766200	http://dx.doi.org/10.1074/jbc.M305766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888579	hybrid			2022-12-27	WOS:000185847200118
J	Hryciw, DH; Wang, YH; Devuyst, O; Pollock, CA; Poronnik, P; Guggino, WB				Hryciw, DH; Wang, YH; Devuyst, O; Pollock, CA; Poronnik, P; Guggino, WB			Cofilin interacts with ClC-5 and regulates albumin uptake in proximal tubule cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; CHLORIDE CHANNEL; IMPAIRS ENDOCYTOSIS; DENTS-DISEASE; H+-ATPASE; ACTIN; NHE3; PROTEINS; INHIBITION; TRANSPORT	Receptor-mediated endocytosis is a constitutive high capacity pathway for the reabsorption of proteins from the glomerular filtrate by the renal proximal tubule. ClC-5 is a voltage-gated chloride channel found in the proximal tubule where it has been shown to be essential for protein uptake, based on evidence from patients with Dent's disease and studies in ClC-5 knockout mice. To further delineate the role of ClC-5 in albumin uptake, we performed a yeast two-hybrid screen with the C-terminal tail of ClC-5 to identify any interactions of the channel with proteins involved in endocytosis. We found that the C-terminal tail of ClC-5 bound the actin depolymerizing protein, cofilin, a result that was confirmed by GST-fusion pulldown assays. In cultured proximal tubule cells, cofilin was distributed in nuclear, cytoplasmic, and microsomal fractions and co-localized with ClC-5. Phosphorylation of cofilin by overexpressing LIM kinase 1 resulted in a stabilization of the actin cytoskeleton. Phosphorylation of cofilin in two proximal tubule cell models (porcine renal proximal tubule and opossum kidney) was also accompanied by a pronounced inhibition of albumin uptake. This study identifies a novel interaction between the C-terminal tail of ClC-5 and cofilin, an actin-associated protein that is crucial in the regulation of albumin uptake by the proximal tubule.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Catholic Univ Louvain, Sch Med, Div Nephrol, B-1200 Brussels, Belgium; Univ Sydney, Royal N Shore Hosp, Dept Med, St Leonards, NSW 2065, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia	Johns Hopkins University; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Royal North Shore Hospital; University of Sydney; University of Queensland	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.	wguggino@jhmi.edu	Hryciw, Deanne/P-2642-2019	Hryciw, Deanne/0000-0003-1697-8890; Devuyst, Olivier/0000-0003-3744-4767; Poronnik, Philip/0000-0002-6246-528X	NHLBI NIH HHS [HL47122] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Ashworth SL, 2003, AM J PHYSIOL-RENAL, V284, pF852, DOI 10.1152/ajprenal.00210.2002; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; Brown D, 2000, KIDNEY INT, V57, P816, DOI 10.1046/j.1523-1755.2000.00920.x; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; Christensen EI, 2003, P NATL ACAD SCI USA, V100, P8472, DOI 10.1073/pnas.1432873100; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Drumm K, 2001, EUR J MED RES, V6, P422; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gekle M, 2002, AM J PHYSIOL-RENAL, V283, pF549, DOI 10.1152/ajprenal.00206.2001; Gekle M, 1997, AM J PHYSIOL-RENAL, V272, pF668, DOI 10.1152/ajprenal.1997.272.5.F668; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Jung JH, 2002, J BIOL CHEM, V277, P48931, DOI 10.1074/jbc.M208806200; Khurana S, 2000, J MEMBRANE BIOL, V178, P73, DOI 10.1007/s002320010016; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Kim M, 2002, BIOCHIMIE, V84, P1021, DOI 10.1016/S0300-9084(02)00004-4; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Lawler S, 1999, CURR BIOL, V9, pR800, DOI 10.1016/S0960-9822(99)80493-X; Lee K, 2001, BIOCHEM J, V353, P377, DOI 10.1042/0264-6021:3530377; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moulin P, 2003, KIDNEY INT, V63, P1285, DOI 10.1046/j.1523-1755.2003.00851.x; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; NEGOESCU A, 1994, J HISTOCHEM CYTOCHEM, V42, P433, DOI 10.1177/42.3.7508473; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Ponting CP, 1997, J MOL MED-JMM, V75, P160; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rueckschloss U, 2001, J PHYSIOL-LONDON, V537, P363, DOI 10.1111/j.1469-7793.2001.00363.x; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; SCHWEGLER JS, 1991, PFLUG ARCH EUR J PHY, V418, P383, DOI 10.1007/BF00550876; Shabahang S, 2002, BIOCHEM BIOPH RES CO, V298, P408, DOI 10.1016/S0006-291X(02)02483-X; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; Wang SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/hmg/9.20.2937; Weinman EJ, 2001, KIDNEY INT, V60, P450, DOI 10.1046/j.1523-1755.2001.060002450.x; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Wohlfarth V, 2003, KIDNEY INT, V63, pS103, DOI 10.1046/j.1523-1755.63.s84.13.x; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Zhai XY, 2000, KIDNEY INT, V58, P1523, DOI 10.1046/j.1523-1755.2000.00314.x	47	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40169	40176		10.1074/jbc.M307890200	http://dx.doi.org/10.1074/jbc.M307890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12904289	hybrid			2022-12-27	WOS:000185713800110
J	Liu, XW; Bernardo, MM; Fridman, R; Kim, HRC				Liu, XW; Bernardo, MM; Fridman, R; Kim, HRC			Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; MEDIATED GENE DELIVERY; MATRIX METALLOPROTEINASES; PHOSPHATIDYLINOSITOL 3-KINASE; EXTRACELLULAR-MATRIX; MELANOMA-CELLS; IN-VITRO; LIVER FIBROSIS; B-CELLS; KINASE	Tissue inhibitor of metalloproteinase (TIMP-1) is a natural protease inhibitor of matrix metalloproteinases ( MMPs). Recent studies revealed a novel function of TIMP-1 as a potent inhibitor of apoptosis in mammalian cells. However, the mechanisms by which TIMP-1 exerts its anti-apoptotic effect are not understood. Here we show that TIMP-1 activates cell survival signaling pathways involving focal adhesion kinase, phosphatidylinositol 3-kinase, and ERKs in human breast epithelial cells to TIMP-1. TIMP-1-activated cell survival signaling down-regulates caspase-mediated classical apoptotic pathways induced by a variety of stimuli including anoikis, staurosporine exposure, and growth factor withdrawal. Consistently, down-regulation of TIMP-1 expression greatly enhances apoptotic cell death. In a previous study, substitution of the second amino acid residue threonine for glycine in TIMP-1, which confers selective MMP inhibition, was shown to obliterate its anti-apoptotic activity in activated hepatic stellate cells suggesting that the anti-apoptotic activity of TIMP-1 is dependent on MMP inhibition. Here we show that the same mutant inhibits apoptosis of human breast epithelial cells, suggesting different mechanisms of TIMP-1 regulation of apoptosis depending on cell types. Neither TIMP-2 nor a synthetic MMP inhibitor protects breast epithelial cells from intrinsic apoptotic cell death. Furthermore, TIMP-1 enhances cell survival in the presence of the synthetic MMP inhibitor. Taken together, the present study unveils some of the mechanisms mediating the anti-apoptotic effects of TIMP-1 in human breast epithelial cells through TIMP-1-specific signal transduction pathways.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NCI NIH HHS [CA-82298, CA89113] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089113, R01CA082298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Ahonen M, 1998, CANCER RES, V58, P2310; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Barasch J, 1999, J CLIN INVEST, V103, P1299, DOI 10.1172/JCI4586; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; Guedez L, 2001, BLOOD, V97, P1796, DOI 10.1182/blood.V97.6.1796; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; Jiang YF, 2001, CANCER RES, V61, P2365; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kadri Z, 2000, CELL GROWTH DIFFER, V11, P573; Kim HRC, 1999, CANCER RES, V59, P4148; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAMBERT E, 2003, BIOCH J; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; Li GY, 1999, CANCER RES, V59, P6267; Lim MS, 1999, ANN NY ACAD SCI, V878, P522, DOI 10.1111/j.1749-6632.1999.tb07715.x; Lin HL, 2002, KIDNEY INT, V62, P60, DOI 10.1046/j.1523-1755.2002.00403.x; Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8; Majid MA, 2002, BRIT J OPHTHALMOL, V86, P97, DOI 10.1136/bjo.86.1.97; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Petitfrere E, 2000, FEBS LETT, V485, P117, DOI 10.1016/S0014-5793(00)02210-9; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Ree AH, 1997, CLIN CANCER RES, V3, P1623; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Tummalapalli CM, 2001, J CELL BIOCHEM, V80, P512, DOI 10.1002/1097-4644(20010315)80:4<512::AID-JCB1005>3.0.CO;2-N; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; Yamashita K, 1996, FEBS LETT, V396, P103, DOI 10.1016/0014-5793(96)01066-6; Yoshiji H, 2002, HEPATOLOGY, V36, P850, DOI 10.1053/jhep.2002.35625; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	63	144	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40364	40372		10.1074/jbc.M302999200	http://dx.doi.org/10.1074/jbc.M302999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12904305	hybrid			2022-12-27	WOS:000185713800130
J	Mulugeta, S; Beers, MF				Mulugeta, S; Beers, MF			Processing of surfactant protein C requires a type II transmembrane topology directed by juxtamembrane positively charged residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; INTEGRAL MEMBRANE-PROTEIN; STRUCTURAL REQUIREMENTS; AGGRESOME FORMATION; I/D POLYMORPHISM; GENE; PALMITOYLATION; BIOSYNTHESIS; ORIENTATION; PROPROTEIN	Surfactant protein C (SP-C) is a lung-specific protein that is synthesized as a 21-kDa integral membrane propeptide (pro-SP-C) and proteolytically processed to a 3.7-kDa secretory product. Previous studies have shown that palmitoylation of pro-SP-C is dependent on two N-terminal juxtamembrane positively charged residues. We hypothesized that these residues influence modification of pro-SP-C by directing transmembrane orientation. Double substitution mutation of these juxtaposed residues from positive to neutral charged species resulted in complete reversal of transmembrane orientation of pro-SP-C and total abrogation of post-translational processing. Mutation of a single residue resulted in mixed orientation. Protein trafficking studies in A549 cells showed that while the double mutant was retained in the endoplasmic reticulum, single mutants produced a mixed pattern of both endoplasmic reticulum ( double mutant-like) and vesicular (wild type-like) expression. Our study demonstrates the crucial role juxtamembrane positively charged residues play in establishing membrane topology and their influence on the trafficking and processing of pro-SP-C. Moreover this study provides a likely precedent for a mechanism in disorders associated with mutations in the membrane-flanking region of integral membrane proteins.	Univ Penn, Abramson Res Ctr, Pulm & Crit Care Div, Sch Med,Lung Epithelial Cell Biol Labs, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Mulugeta, S (corresponding author), Univ Penn, Abramson Res Ctr, Pulm & Crit Care Div, Sch Med,Lung Epithelial Cell Biol Labs, Room 1015 Hb,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	mulugeta@mail.med.upenn.edu			NHLBI NIH HHS [HL-19737, HL74064, P50-HL56401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, R01HL074064, P50HL056401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beers M. F., 1998, MED INTELL UNIT, P93; BELTZER JP, 1991, J BIOL CHEM, V266, P973; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Carter J., 2001, Current Molecular Medicine (Hilversum), V1, P733, DOI 10.2174/1566524013363177; Conkright JJ, 2001, J BIOL CHEM, V276, P14658, DOI 10.1074/jbc.M011770200; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; FISHER JH, 1989, BIOCHIM BIOPHYS ACTA, V995, P225, DOI 10.1016/0167-4838(89)90040-X; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hooper NM, 2000, BIOCHEM SOC T, V28, P441, DOI 10.1042/0300-5127:0280441; ISHIGAMI T, 1995, CIRCULATION, V91, P951, DOI 10.1161/01.CIR.91.4.951; Johnson AL, 2001, AM J RESP CELL MOL, V24, P253, DOI 10.1165/ajrcmb.24.3.4312; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kabore AF, 2001, J CELL SCI, V114, P293; KABORE AF, 2000, AM J RESP CRIT CARE, V161, pA41; Manoil C, 1995, ANNU REV GENET, V29, P131; Monne M, 1998, J MOL BIOL, V284, P1177, DOI 10.1006/jmbi.1998.2218; Niu TH, 2002, DRUGS, V62, P977, DOI 10.2165/00003495-200262070-00001; Nogee LM, 2002, CHEST, V121, p20S, DOI 10.1378/chest.121.3_suppl.20S; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Notterpek L, 1999, NEUROBIOL DIS, V6, P450, DOI 10.1006/nbdi.1999.0274; Ott CM, 2002, J CELL SCI, V115, P2003; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; Russo SJ, 1999, AM J PHYSIOL-LUNG C, V277, pL1034, DOI 10.1152/ajplung.1999.277.5.L1034; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Solarin KO, 1997, PEDIATR RES, V42, P356, DOI 10.1203/00006450-199709000-00017; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; Stefansson B, 2000, BLOOD PRESSURE, V9, P104, DOI 10.1080/080370500453429; Szolnoki Z, 2001, J NEUROL, V248, P756, DOI 10.1007/s004150170090; ten Brinke A, 2002, BIOCHEM BIOPH RES CO, V290, P532, DOI 10.1006/bbrc.2001.6223; ten Brinke A, 2001, AM J RESP CELL MOL, V25, P156, DOI 10.1165/ajrcmb.25.2.4423; Ten Brinke A, 2002, BIOCHEM J, V361, P663, DOI 10.1042/0264-6021:3610663; Thomas AQ, 2002, AM J RESP CRIT CARE, V165, P1322, DOI 10.1164/rccm.200112-123OC; Tobler AR, 1999, J NEUROSCI, V19, P2027; van Geest M, 2000, MICROBIOL MOL BIOL R, V64, P13, DOI 10.1128/MMBR.64.1.13-33.2000; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420; Wang WJ, 2003, J CELL SCI, V116, P683, DOI 10.1242/jcs.00267; Wang WJ, 2002, J BIOL CHEM, V277, P19929, DOI 10.1074/jbc.M201537200; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5	48	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47979	47986		10.1074/jbc.M308210200	http://dx.doi.org/10.1074/jbc.M308210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12933801	hybrid			2022-12-27	WOS:000186731400076
J	Huecas, S; Andreu, JM				Huecas, S; Andreu, JM			Energetics of the cooperative assembly of cell division protein FtsZ and the nucleotide hydrolysis switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA-TUBULIN; ESCHERICHIA-COLI; GTP HYDROLYSIS; CRYSTAL-STRUCTURE; BINDING; ACTIN; POLYMERIZATION; ASSOCIATION; DYNAMICS; RECONSTITUTION	FtsZis the first protein recruited to the bacterial division site, where it forms the cytokinetic Z ring. We have determined the functional energetics of FtsZ assembly, employing FtsZ from the thermophilic Archaea Methanococcus jannaschii bound to GTP, GMPCPP, GDP, or GMPCP, under different solution conditions. FtsZ oligomerizes in a magnesium-insensitive manner. FtsZ cooperatively assembles with magnesium and GTP or GMPCPP into large polymers, following a nucleated condensation polymerization mechanism, under nucleotide hydrolyzing and non-hydrolyzing conditions. The effect of temperature on the critical concentration indicates polymer elongation with an apparent heat capacity change of -800 +/- 100 cal mol(-1) K-1 and positive enthalpy and entropy changes, compatible with axial hydrophobic contacts of each FtsZ in the polymer, and predicts optimal polymer stability near 75 degreesC. Assembly entails the binding of one medium affinity magnesium ion and the uptake of one proton per FtsZ. Interestingly, GDP- or GMPCP-liganded FtsZ cooperatively form helically curved polymers, with an elongation only 1-2 kcal mol(-1) more unfavorable than the straight polymers formed with nucleotide triphosphate, suggesting a physiological requirement for FtsZ polymerization inhibitors. This GTP hydrolysis switch should provide the basic properties for FtsZ polymer disassembly and its functional dynamics.	CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Huecas, S (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9, E-28040 Madrid, Spain.	sonia@cib.csic.es; j.m.andreu@cib.csic.es	Huecas, Sonia/P-2542-2019; Huecas, Sonia/K-1754-2014	Huecas, Sonia/0000-0002-6419-441X; Huecas, Sonia/0000-0002-6419-441X; Andreu, Jose M/0000-0001-8064-6933				Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Andreu JM, 2002, J BIOL CHEM, V277, P43262, DOI 10.1074/jbc.M206723200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caplan MR, 2003, J BIOL CHEM, V278, P13784, DOI 10.1074/jbc.M300860200; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; CARLIER MF, 1991, J BIOL CHEM, V266, P12361; CARLIER MF, 1987, BIOCHEMISTRY-US, V26, P4428, DOI 10.1021/bi00388a036; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Cordell SC, 2003, P NATL ACAD SCI USA, V100, P7889, DOI 10.1073/pnas.1330742100; CORREIA JJ, 1988, J BIOL CHEM, V263, P10681; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; Diaz JF, 2001, J BIOL CHEM, V276, P17307, DOI 10.1074/jbc.M010920200; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LEE JC, 1975, BIOCHEMISTRY-US, V14, P5183, DOI 10.1021/bi00694a025; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; Levin PA, 1999, P NATL ACAD SCI USA, V96, P9642, DOI 10.1073/pnas.96.17.9642; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Luque I, 1998, PROTEINS, V30, P74, DOI 10.1002/(SICI)1097-0134(199801)30:1<74::AID-PROT7>3.3.CO;2-G; Luque I, 1998, METHOD ENZYMOL, V295, P100; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Meinhardt H, 2001, P NATL ACAD SCI USA, V98, P14202, DOI 10.1073/pnas.251216598; Menendez M, 1998, J BIOL CHEM, V273, P167, DOI 10.1074/jbc.273.1.167; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 2003, CURR OPIN STRUC BIOL, V13, P256, DOI 10.1016/S0959-440X(03)00029-0; Oliva MA, 2003, J BIOL CHEM, V278, P33562, DOI 10.1074/jbc.M303798200; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Oosawa F., 1975, THERMODYNAMICS POLYM; PERRONE PA, 1984, J CHROMATOGR, V317, P301, DOI 10.1016/S0021-9673(01)91668-1; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Pichoff S, 2001, J BACTERIOL, V183, P6630, DOI 10.1128/JB.183.22.6630-6635.2001; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Scheffers DJ, 2002, MOL MICROBIOL, V43, P1517, DOI 10.1046/j.1365-2958.2002.02828.x; Scheffers DJ, 2001, FEBS LETT, V506, P6, DOI 10.1016/S0014-5793(01)02855-1; SECKLER R, 1990, J BIOL CHEM, V265, P7655; Shapiro L, 2002, SCIENCE, V298, P1942, DOI 10.1126/science.1072163; Shapiro L, 2000, CELL, V100, P89, DOI 10.1016/S0092-8674(00)81686-4; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Sun Q, 1998, J BACTERIOL, V180, P2050, DOI 10.1128/JB.180.8.2050-2056.1998; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; van den Ent F, 2002, EMBO J, V21, P6935, DOI 10.1093/emboj/cdf672; van den Ent F, 2000, EMBO J, V19, P5300, DOI 10.1093/emboj/19.20.5300; Vicente Miguel, 2003, EMBO Reports, V4, P655, DOI 10.1038/sj.embor.embor885; Vulevic B, 1997, BIOPHYS J, V72, P1357, DOI 10.1016/S0006-3495(97)78782-4; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Wyman J, 1990, BINDING LINKAGE FUNC; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455	73	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46146	46154		10.1074/jbc.M307128200	http://dx.doi.org/10.1074/jbc.M307128200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933789	hybrid, Green Published			2022-12-27	WOS:000186452300132
J	Gupta, M; Sueblinvong, V; Raman, J; Jeevanandam, V; Gupta, MP				Gupta, M; Sueblinvong, V; Raman, J; Jeevanandam, V; Gupta, MP			Single-stranded DNA-binding proteins PUR alpha and PUR beta bind to a purine-rich negative regulatory element of the alpha-myosin heavy chain gene and control transcriptional and translational regulation of the gene expression - Implications in the repression of alpha-myosin heavy chain during heart failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VENTRICULAR SYSTOLIC RESISTANCE; Y-BOX PROTEIN; MESSENGER-RNA; CELL-CYCLE; PROMOTER; DOMAIN; HYPERTROPHY; SEQUENCE; SITES; MSY1	The alpha-myosin heavy chain is a principal molecule of the thick filament of the sarcomere, expressed primarily in cardiac myocytes. The mechanism for its cardiac-restricted expression is not yet fully understood. We previously identified a purine-rich negative regulatory (PNR) element in the first intron of the gene, which is essential for its cardiac-specific expression (Gupta, M., Zak, R., Libermann, T. A., and Gupta, M. P. (1998) Mol. Cell. Biol. 18, 7243-7258). In this study we cloned and characterized muscle and non-muscle factors that bind to this element. We show that two single-stranded DNA-binding proteins of the PUR family, PURalpha and PURbeta, which are derived from cardiac myocytes, bind to the plus strand of the PNR element. In functional assays, PURalpha and PURbeta repressed alpha-myosin heavy chain (alpha-MHC) gene expression in the presence of upstream regulatory sequences of the gene. However, from HeLa cells an Ets family of protein, Ets-related protein (ERP), binds to double-stranded PNR element. The ERP.PNR complex inhibited the activity of the basal transcription complex from homologous as well as heterologous promoters in a PNR position-independent manner, suggesting that ERP acts as a silencer of alpha-MHC gene expression in non-muscle cells. We also show that PUR proteins are capable of binding to alpha-MHC mRNA and attenuate its translational efficiency. Furthermore, we show robust expression of PUR proteins in failing hearts where alpha-MHC mRNA levels are suppressed. Together, these results reveal that (i) PUR proteins participate in transcriptional as well as translational regulation of alpha-MHC expression in cardiac myocytes and (ii) ERP may be involved in cardiac-restricted expression of the alpha-MHC gene by preventing its expression in nonmuscle cells.	Univ Chicago, Dept Surg, Cardiac & Thorac Div, Chicago, IL 60637 USA; Univ Chicago, Comm Mol Med, Chicago, IL 60637 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Hope Childrens Hosp, Chicago, IL 60612 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gupta, MP (corresponding author), Univ Chicago, Dept Surg, Cardiac & Thorac Div, MC 5040,5841 S Maryland Ave, Chicago, IL 60637 USA.				NHLBI NIH HHS [R0-1 HL68083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; Aikawa R, 2002, J BIOL CHEM, V277, P18979, DOI 10.1074/jbc.M201257200; ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; Ayadi A, 2001, MECH DEVELOP, V102, P205, DOI 10.1016/S0925-4773(01)00289-1; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; Davis FJ, 2002, AM J PHYSIOL-HEART C, V282, pH1521, DOI 10.1152/ajpheart.00844.2001; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; GALLIA GL, 1999, J CELL BIOCHEM, V75, P1; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; IVESTER CT, 1995, J BIOL CHEM, V270, P21950, DOI 10.1074/jbc.270.37.21950; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1999, J BIOL CHEM, V274, P38268, DOI 10.1074/jbc.274.53.38268; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Kim SJ, 1999, AM J PHYSIOL-HEART C, V276, pH1780, DOI 10.1152/ajpheart.1999.276.5.H1780; Kuo CH, 1999, BIOCHEM BIOPH RES CO, V255, P406, DOI 10.1006/bbrc.1999.0218; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MERCADIER JJ, 1981, CIRC RES, V49, P525, DOI 10.1161/01.RES.49.2.525; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; OJAMAA K, 1994, P NATL ACAD SCI USA, V91, P3468, DOI 10.1073/pnas.91.8.3468; OPREY J, 1995, NUCLEIC ACIDS RES, V23, P3664, DOI 10.1093/nar/23.18.3664; Sambrook J., 2002, MOL CLONING LAB MANU; Sanbe A, 2003, CIRC RES, V92, P609, DOI 10.1161/01.RES.0000065442.64694.9F; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SHROFF SG, 1990, AM J PHYSIOL, V258, pH381, DOI 10.1152/ajpheart.1990.258.2.H381; SHROFF SG, 1989, AM J PHYSIOL, V257, pH386, DOI 10.1152/ajpheart.1989.257.2.H386; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; Sucharov CC, 2003, J BIOL CHEM, V278, P31233, DOI 10.1074/jbc.M301917200; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; WEISNER RJ, 1997, CIRCULATION, V95, P1253; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	52	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44935	44948		10.1074/jbc.M307696200	http://dx.doi.org/10.1074/jbc.M307696200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933792	hybrid			2022-12-27	WOS:000186306700130
J	Tofaris, GK; Razzaq, A; Ghetti, B; Lilley, KS; Spillantini, MG				Tofaris, GK; Razzaq, A; Ghetti, B; Lilley, KS; Spillantini, MG			Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; PRECURSOR PROTEIN; HUMAN BRAIN; DEGRADATION; DEMENTIA; AGGREGATION; INCLUSIONS; FILAMENTS; MUTATION	Lewy bodies are intracellular fibrillar inclusions composed of alpha-synuclein. They constitute the pathological hallmark of Parkinson's disease, dementia with Lewy bodies, and other neurodegenerative diseases. Although the majority of Lewy bodies are stained for ubiquitin by immunohistochemistry, the substrate for this modification is poorly understood. Insoluble, urea-soluble alpha-synuclein was separated from soluble fractions and subjected to two-dimensional gel electrophoresis to further characterize pathogenic alpha-synuclein species from disease brains. By using this approach, we found that in sporadic Lewy body diseases a highly modified, disease-associated 22-24-kDa alpha-synuclein species is ubiquitinated. Conjugation of one, two, and, to a lesser extent, three ubiquitins was detected. This 22-24-kDa alpha-synuclein species represents partly phosphorylated protein. Furthermore, no generalized impairment of the proteolytic activity of the proteasome was detected in brain regions with Lewy body pathology. Because unmodified alpha-synuclein is degraded by the proteasome in a ubiquitin-independent manner, these data suggest that accumulation of modified 22-24-kDa alpha-synuclein is a disease-specific event which may overwhelm the proteolytic system, leading to aberrant ubiquitination. Accordingly, carboxyl-terminal-truncated alpha-synuclein, presumably the result of aberrant proteolysis, is found only in association with alpha-synuclein aggregates.	Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England; Dept Neurol, Cambridge CB2 2PY, England; Cambridge Ctr Proteom, Cambridge CB2 1QW, England; Dept Biochem, Cambridge CB2 1QW, England; Indiana Univ, Sch Med, Dept Pathol & Lab Med, Div Neuropathol, Indianapolis, IN 46202 USA	University of Cambridge; University of Cambridge; Indiana University System; Indiana University-Purdue University Indianapolis	Spillantini, MG (corresponding author), Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England.		Lilley, Kathryn/ABF-5787-2020	Lilley, Kathryn/0000-0003-0594-6543; Tofaris, George/0000-0002-9252-5933	NIA NIH HHS [P30AG10133] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Baba M, 1998, AM J PATHOL, V152, P879; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Gray DA, 2001, NEUROPATH APPL NEURO, V27, P89, DOI 10.1046/j.1365-2990.2001.00321.x; Grune T, 2001, J GERONTOL A-BIOL, V56, pB459, DOI 10.1093/gerona/56.11.B459; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hochstrasser M, 2002, SCIENCE, V298, P549, DOI 10.1126/science.1078097; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Miake H, 2002, J BIOL CHEM, V277, P19213, DOI 10.1074/jbc.M110551200; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rideout HJ, 2002, MOL CELL NEUROSCI, V21, P223, DOI 10.1006/mcne.2002.1173; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282	33	266	282	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44405	44411		10.1074/jbc.M308041200	http://dx.doi.org/10.1074/jbc.M308041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923179	hybrid			2022-12-27	WOS:000186306700066
J	Marcheselli, VL; Hong, S; Lukiw, WJ; Tian, XH; Gronert, K; Musto, A; Hardy, M; Gimenez, JM; Chiang, N; Serhan, CN; Bazan, NG				Marcheselli, VL; Hong, S; Lukiw, WJ; Tian, XH; Gronert, K; Musto, A; Hardy, M; Gimenez, JM; Chiang, N; Serhan, CN; Bazan, NG			Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; FREE FATTY-ACIDS; FACTOR-KAPPA-B; DOCOSAHEXAENOIC ACID; ARTERY OCCLUSION; INJURY; RAT; OMEGA-3-FATTY-ACIDS; CYCLOOXYGENASE-2; APOPTOSIS	Ischemic stroke triggers lipid peroxidation and neuronal injury. Docosahexaenoic acid released from membrane phospholipids during brain ischemia is a major source of lipid peroxides. Leukocyte infiltration and pro-inflammatory gene expression also contribute to stroke damage. In this study using lipidomic analysis, we have identified stereospecific messengers from docosahexaenoate-oxygenation pathways in a mouse stroke model. Aspirin, widely used to prevent cerebrovascular disease, activates an additional pathway, which includes the 17R-resolvins. The newly discovered brain messenger 10,17S-docosatriene potently inhibited leukocyte infiltration, NFkappaB, and cyclooxygenase-2 induction in experimental stroke and elicited neuroprotection. In addition, in neural cells in culture, this lipid messenger also inhibited both interleukin 1-beta-induced NFkappaB activation and cyclooxygenase-2 expression. Thus, the specific novel bioactive docosanoids generated in vivo counteract leukocyte-mediated injury as well as pro-inflammatory gene induction. These results challenge the view that docosahexaenoate only participates in brain damage and demonstrate that this fatty acid is also the endogenous precursor to a neuroprotective signaling response to ischemia-reperfusion.	Louisiana State Univ, Neurosci Ctr Excellence, Hlth Sci Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Brigham & Womens Hosp, Dept Anesthesiol Periooperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bazan, NG (corresponding author), Louisiana State Univ, Neurosci Ctr Excellence, Hlth Sci Ctr, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.		Chiang, Nan/ABA-4924-2021; Bazan, Nicolas/AAN-4121-2020	Chiang, Nan/0000-0003-1963-1585; Bazan, Nicolas/0000-0002-9243-5444	NCRR NIH HHS [P20 RR016816] Funding Source: Medline; NIA NIH HHS [AG18031] Funding Source: Medline; NIDCR NIH HHS [P01 DE13499] Funding Source: Medline; NIDDK NIH HHS [K01 DK060583-03] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline; NINDS NIH HHS [NS23002] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765, R29GM038765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018031] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; Bazan N. G., 1990, NUTR BRAIN, V8, P1; Bazan NG, 2002, J BIOL CHEM, V277, P30359, DOI 10.1074/jbc.M203201200; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1984, BIOCHEM BIOPH RES CO, V125, P741, DOI 10.1016/0006-291X(84)90601-6; BAZAN NG, 1998, CEREBROVASC DIS, P532; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; de Turco EBR, 2002, J NEUROCHEM, V83, P515, DOI 10.1046/j.1471-4159.2002.01121.x; Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4; GAUDET RJ, 1980, STROKE, V11, P648, DOI 10.1161/01.STR.11.6.648; GORDON WC, 1990, J NEUROSCI, V10, P2190; Gronert K, 1999, METH MOL B, V120, P119; HALLENBECK JM, 1998, CEREBROVASC DIS, V1, P489; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Huang J, 2000, STROKE, V31, P3047, DOI 10.1161/01.STR.31.12.3047; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lukiw WJ, 1998, J NEUROSCI RES, V53, P583, DOI 10.1002/(SICI)1097-4547(19980901)53:5<583::AID-JNR8>3.3.CO;2-B; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Mirnikjoo B, 2001, J BIOL CHEM, V276, P10888, DOI 10.1074/jbc.M008150200; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SHEAKIN DJ, 2000, HDB PARAMETRIC NONPA; YOSHIDA S, 1984, J NEUROCHEM, V42, P711, DOI 10.1111/j.1471-4159.1984.tb02741.x; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200	37	611	651	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43807	43817		10.1074/jbc.M305841200	http://dx.doi.org/10.1074/jbc.M305841200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923200	Green Published, hybrid			2022-12-27	WOS:000186157000131
J	Sugiyama, D; Kusuhara, H; Taniguchi, H; Ishikawa, S; Nozaki, Y; Aburatani, H; Sugiyama, Y				Sugiyama, D; Kusuhara, H; Taniguchi, H; Ishikawa, S; Nozaki, Y; Aburatani, H; Sugiyama, Y			Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier - High affinity transporter for thyroxine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID BARRIER; THYROID-HORMONES; EFFLUX TRANSPORT; CHOROID-PLEXUS; HUMAN LIVER; IDENTIFICATION; TAUROCHOLATE; XENOBIOTICS; POLYPEPTIDE	Oatp14/blood-brain barrier-specific anion transporter 1 (Slc21a14) is a novel member of the organic anion transporting polypeptide (Oatp/OATP) family. Northern blot analysis revealed predominant expression of Oatp14 in the brain, and Western blot analysis revealed its expression in the brain capillary and choroid plexus. Immunohistochemical staining indicated that Oatp14 is expressed in the border of the brain capillary endothelial cells. When expressed in human embryonic kidney 293 cells, Oatp14 transports thyroxine (T-4; prothyroid hormone) (K-m = 0.18 muM), as well as amphipathic organic anions such as 17beta estradiol-D-17beta-glucuronide (K-m = 10 muM), cerivastatin (K-m = 1.3 muM), and troglitazone sulfate (K-m = 0.76 muM). The uptake of triiodothyronine (T-3), an active form produced from T-4, was significantly greater in Oatp14-expressed cells than in vector-transfected cells, but the transport activity for T-3 was similar to 6-fold lower that for T-4. The efflux of T-4, preloaded into the cells, from Oatp14-expressed cells was more rapid than that from vector-transfected cells (0.032 versus 0.006 min(-1)). Therefore, Oatp14 can mediate a bidirectional transport of T-4. Sulfobromophthalein, taurocholate, and estrone sulfate were potent inhibitors for Oatp14, whereas digoxin, p-aminohippurate, or leukotriene C-4, or organic cations such as tetraetheylammonium or cimetidine had no effect. The expression levels of Oatp14 mRNA and protein were up- and down-regulated under hypo- and hyperthyroid conditions, respectively. Therefore, it may be speculated that Oatp14 plays a role in maintaining the concentration of T-4 and, ultimately, T-3 in the brain by transporting T-4 from the circulating blood to the brain.	Univ Tokyo, Dept Mol Pharmacokinet, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan	University of Tokyo; University of Tokyo	Sugiyama, Y (corresponding author), Univ Tokyo, Dept Mol Pharmacokinet, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; Akita H, 2001, BBA-BIOMEMBRANES, V1511, P7, DOI 10.1016/S0005-2736(00)00355-2; BANKS WA, 1985, LIFE SCI, V37, P2407, DOI 10.1016/0024-3205(85)90108-0; BOADO RJ, 1991, J NEUROCHEM, V57, P2136, DOI 10.1111/j.1471-4159.1991.tb06433.x; Burmeister LA, 1997, ENDOCRINOLOGY, V138, P5231, DOI 10.1210/en.138.12.5231; Dagenais C, 2001, NEUROSCI LETT, V301, P155, DOI 10.1016/S0304-3940(01)01640-8; DRATMAN MB, 1991, BRAIN RES, V554, P229, DOI 10.1016/0006-8993(91)90194-Z; Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1; Gao B, 2000, J PHARMACOL EXP THER, V294, P73; Gao P, 1999, J HISTOCHEM CYTOCHEM, V47, P1255, DOI 10.1177/002215549904701005; Groothuis DR, 1997, J NEUROVIROL, V3, P387, DOI 10.3109/13550289709031185; HAGEN GA, 1974, ENDOCRINOLOGY, V95, P1398, DOI 10.1210/endo-95-5-1398; Izumi T, 1997, J PHARMACOL EXP THER, V280, P1392; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Kullak-Ublick GA, 2001, GASTROENTEROLOGY, V120, P525, DOI 10.1053/gast.2001.21176; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; Kusuhara H, 2001, DRUG DISCOV TODAY, V6, P150, DOI 10.1016/S1359-6446(00)01632-9; Lee G, 2001, PHARMACOL REV, V53, P569; Li JY, 2001, J CEREBR BLOOD F MET, V21, P61, DOI 10.1097/00004647-200101000-00008; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINN A, 1991, BRAIN RES REV, V16, P65, DOI 10.1016/0165-0173(91)90020-9; Nishio T, 2000, BIOCHEM BIOPH RES CO, V275, P831, DOI 10.1006/bbrc.2000.3377; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; Pardridge W M, 1991, Semin Cell Biol, V2, P419; PARDRIDGE WM, 1979, ENDOCRINOLOGY, V105, P605, DOI 10.1210/endo-105-3-605; Pizzagalli F, 2002, MOL ENDOCRINOL, V16, P2283, DOI 10.1210/me.2001-0309; RAPOPORT SI, 1976, EXP NEUROL, V52, P467, DOI 10.1016/0014-4886(76)90218-1; Segal MB, 2000, CELL MOL NEUROBIOL, V20, P183, DOI 10.1023/A:1007045605751; Shi YB, 2002, PHARMACOL THERAPEUT, V94, P235, DOI 10.1016/S0163-7258(02)00219-X; Strazielle N, 1999, J NEUROSCI, V19, P6275; Sugiyama D, 2001, J PHARMACOL EXP THER, V298, P316; Suzuki H, 1997, ADV DRUG DELIVER REV, V25, P257, DOI 10.1016/S0169-409X(97)00503-6	35	229	235	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43489	43495		10.1074/jbc.M306933200	http://dx.doi.org/10.1074/jbc.M306933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923172	hybrid			2022-12-27	WOS:000186157000094
J	Harmon, FG; Brockman, JP; Kowalczykowski, SC				Harmon, FG; Brockman, JP; Kowalczykowski, SC			RecQ helicase stimulates both DNA catenation and changes in DNA topology by topoisomerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; SYNDROME GENE-PRODUCT; BLOOM-SYNDROME; SGS1; INTERACTS; HOMOLOG; CLONING; RECOMBINATION; PROTEIN; FAMILY	Together, RecQ helicase and topoisomerase III (Topo III) of Escherichia coli comprise a potent DNA strand passage activity that can catenate covalently closed DNA (Harmon, F. G., DiGate, R. J., and Kowalczykowski, S. C. (1999) Mol. Cell 3, 611-620). Here we directly assessed the structure of the catenated DNA species formed by RecQ helicase and Topo III using atomic force microscopy. The images show complex catenated DNA species involving crossovers between multiple double-stranded DNA molecules that are consistent with full catenanes. E. coli single-stranded DNA-binding protein significantly stimulated both the topoisomerase activity of Topo III alone and the DNA strand passage activity of RecQ helicase and Topo III. Titration data suggest that an intermediate of the RecQ helicase unwinding process, perhaps a RecQ helicase-DNA fork, is the target for Topo III action. Catenated DNA is the predominant product under conditions of molecular crowding; however, we also discovered that RecQ helicase and single-stranded DNA-binding protein greatly stimulated the intramolecular strand passage ("supercoiling") activity of Topo III, as revealed by changes in the linking number of uncatenated DNA. Together our results demonstrate that RecQ helicase and Topo III function together to comprise a potent and concerted single-strand DNA passage activity that can mediate both catenation-decatenation processes and changes in DNA topology.	Univ Calif Davis, Ctr Genet & Dev, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Div Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Ctr Genet & Dev, Div Biol Sci, Microbiol Sect, Briggs Hall,1 Shields Ave, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu						Bennett RJ, 2000, J BIOL CHEM, V275, P26898; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Hanai R, 1999, METH MOL B, V94, P19; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; HIASA H, 1994, J BIOL CHEM, V269, P32655; IRINO N, 1986, MOL GEN GENET, V205, P298, DOI 10.1007/BF00430442; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIM RA, 1992, J BIOL CHEM, V267, P17178; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KRASNOW MA, 1983, NATURE, V304, P559, DOI 10.1038/304559a0; Kusano K, 1999, GENETICS, V151, P1027; LEBOWITZ J, 1985, THESIS J HOPKINS U B; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; Nurse P, 2003, J BIOL CHEM, V278, P8653, DOI 10.1074/jbc.M211211200; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WHORISKEY SK, 1991, GENETICS, V127, P21; Wilson-Sali T, 2002, J BIOL CHEM, V277, P26865, DOI 10.1074/jbc.M204641200; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zerbib D, 1997, J MOL BIOL, V270, P663, DOI 10.1006/jmbi.1997.1157; Zhu Q, 2001, P NATL ACAD SCI USA, V98, P9766, DOI 10.1073/pnas.171579898	53	64	66	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42668	42678		10.1074/jbc.M302994200	http://dx.doi.org/10.1074/jbc.M302994200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909639	Green Published, hybrid			2022-12-27	WOS:000185989500133
J	Heller, MJ; Nili, M; Homsher, E; Tobacman, LS				Heller, MJ; Nili, M; Homsher, E; Tobacman, LS			Cardiomyopathic tropomyosin mutations that increase thin filament Ca2+ sensitivity and tropomyosin N-domain flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; RABBIT SKELETAL-MUSCLE; TROPONIN-T MUTATIONS; MYOSIN SUBFRAGMENT 1; VITRO MOTILITY ASSAY; ALPHA-TROPOMYOSIN; CARDIAC TROPONIN; MUTANT TROPOMYOSIN; 3-DIMENSIONAL RECONSTRUCTION; REGULATORY PROPERTIES	The relationship between tropomyosin thermal stability and thin filament activation was explored using two N-domain mutants of alpha-striated muscle tropomyosin, A63V and K70T, each previously implicated in familial hypertrophic cardiomyopathy. Both mutations had prominent effects on tropomyosin thermal stability as monitored by circular dichroism. Wild type tropomyosin unfolded in two transitions, separated by 10degreesC. The A63V and K70T mutations decreased the melting temperature of the more stable of these transitions by 4 and 10degreesC, respectively, indicating destabilization of the N-domain in both cases. Global analysis of all three proteins indicated that the tropomyosin N-domain and C-domain fold with a cooperative free energy of 1.0-1.5 kcal/mol. The two mutations increased the apparent affinity of the regulatory Ca2+ binding sites of thin filament in two settings: Ca2+-dependent sliding speed of unloaded thin filaments in vitro (at both pH 7.4 and 6.3), and Ca2+ activation of the thin filament-myosin S1 ATPase rate. Neither mutation had more than small effects on the maximal ATPase rate in the presence of saturating Ca2+ or on the maximal sliding speed. Despite the increased tropomyosin flexibility implied by destabilization of the N-domain, neither the cooperativity of thin filament activation by Ca2+ nor the cooperative binding of myosin S1-ADP to the thin filament was altered by the mutations. The combined results suggest that a more dynamic tropomyosin N-domain influences interactions with actin and/or troponin that modulate Ca2+ sensitivity, but has an unexpectedly small effect on cooperative changes in tropomyosin position on actin.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90025 USA	University of Iowa; University of Iowa; University of California System; University of California Los Angeles	Tobacman, LS (corresponding author), Univ Illinois, Dept Med, MC 787,840 W Wood St,Rm 317F CSN, Chicago, IL 60612 USA.							Bacchiocchi C, 2002, BIOPHYS J, V82, P1524, DOI 10.1016/S0006-3495(02)75505-7; Bing W, 2000, J MOL CELL CARDIOL, V32, P1489, DOI 10.1006/jmcc.2000.1182; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Butters CA, 1997, J BIOL CHEM, V272, P13196, DOI 10.1074/jbc.272.20.13196; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CLARK ID, 1990, BIOCHEMISTRY-US, V29, P10842, DOI 10.1021/bi00500a018; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; Evans CC, 2000, AM J PHYSIOL-HEART C, V279, pH2414, DOI 10.1152/ajpheart.2000.279.5.H2414; Fujita H, 2002, J PHYSIOL-LONDON, V539, P267, DOI 10.1113/jphysiol.2001.013220; Fukuda N, 2001, J PHYSIOL-LONDON, V536, P153, DOI 10.1111/j.1469-7793.2001.00153.x; GODT RE, 1989, J PHYSIOL-LONDON, V412, P155, DOI 10.1113/jphysiol.1989.sp017609; Golitsina N, 1997, BIOCHEMISTRY-US, V36, P4637, DOI 10.1021/bi962970y; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Graceffa P, 2000, J BIOL CHEM, V275, P17143, DOI 10.1074/jbc.M001979200; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hill T. L., 1985, COOPERATIVITY THEORY; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Holtzer ME, 2001, BIOPOLYMERS, V59, P257, DOI 10.1002/1097-0282(20011005)59:4<257::AID-BIP1022>3.0.CO;2-7; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; Homsher E, 2000, J PHYSIOL-LONDON, V524, P233, DOI 10.1111/j.1469-7793.2000.00233.x; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; INGRAHAM RH, 1985, BIOCHEMISTRY-US, V24, P5221, DOI 10.1021/bi00340a040; ISHII Y, 1991, J BIOL CHEM, V266, P6894; Karibe A, 2001, CIRCULATION, V103, P65; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Luque I, 2002, ANNU REV BIOPH BIOM, V31, P235, DOI 10.1146/annurev.biophys.31.082901.134215; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Michele DE, 1999, NAT MED, V5, P1413; Michele DE, 2002, CIRC RES, V91, P255, DOI 10.1161/01.RES.0000027530.58419.82; Michele DE, 2002, PHYSIOL GENOMICS, V9, P103, DOI 10.1152/physiolgenomics.00099.2001; Miki M, 1998, J BIOCHEM-TOKYO, V123, P1104; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MO JM, 1992, BIOPOLYMERS, V32, P751, DOI 10.1002/bip.360320704; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Morris CA, 2001, J BIOL CHEM, V276, P20245, DOI 10.1074/jbc.M007371200; MOSS RL, 1986, J PHYSIOL-LONDON, V377, P487, DOI 10.1113/jphysiol.1986.sp016199; Mukherjea P, 1999, BIOCHEMISTRY-US, V38, P13296, DOI 10.1021/bi9906120; Muthuchamy M, 1999, CIRC RES, V85, P47; NAKAJIMATANIGUCHI C, 1995, J MOL CELL CARDIOL, V27, P2053, DOI 10.1016/0022-2828(95)90026-8; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PATO MD, 1981, J BIOL CHEM, V256, P593; Paulucci AA, 2002, J BIOL CHEM, V277, P39574, DOI 10.1074/jbc.M204749200; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Resetar AM, 2002, BIOPHYS J, V83, P1039, DOI 10.1016/S0006-3495(02)75229-6; RICCIARDI L, 1994, J MOL CELL CARDIOL, V26, P601, DOI 10.1006/jmcc.1994.1072; Rosol M, 2000, BIOPHYS J, V78, P908, DOI 10.1016/S0006-3495(00)76648-3; Smith DA, 2001, J PHYS A-MATH GEN, V34, P4507, DOI 10.1088/0305-4470/34/21/307; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Strand J, 2001, J BIOL CHEM, V276, P34832, DOI 10.1074/jbc.M104750200; Suarez MC, 2001, BIOCHEMISTRY-US, V40, P1300, DOI 10.1021/bi0020978; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; Tobacman LS, 2002, J BIOL CHEM, V277, P27636, DOI 10.1074/jbc.M201768200; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; YamauchiTakihara K, 1996, HEART, V76, P63, DOI 10.1136/hrt.76.1.63; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806	71	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41742	41748		10.1074/jbc.M303408200	http://dx.doi.org/10.1074/jbc.M303408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12900417	hybrid			2022-12-27	WOS:000185989500025
J	Jensen, LT; Ajua-Alemanji, M; Culotta, VC				Jensen, LT; Ajua-Alemanji, M; Culotta, VC			The Saccharomyces cerevisiae high affinity phosphate transporter encoded by PHO84 also functions in manganese homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SUPEROXIDE-DISMUTASE; GENE ENCODES; COPPER TRANSPORTER; ZINC TRANSPORTER; ION-PUMP; PROTEIN; IRON; PERMEASE; SYSTEM	In the bakers' yeast Saccharomyces cerevisiae, high affinity manganese uptake and intracellular distribution involve two members of the Nramp family of genes, SMF1 and SMF2. In a search for other genes involved in manganese homeostasis, PHO84 was identified. The PHO84 gene encodes a high affinity inorganic phosphate transporter, and we find that its disruption results in a manganese-resistant phenotype. Resistance to zinc, cobalt, and copper ions was also demonstrated for pho84Delta yeast. When challenged with high concentrations of metals, pho84Delta yeast have reduced metal ion accumulation, suggesting that resistance is due to reduced uptake of metal ions. Pho84p accounted for virtually all the manganese accumulated under metal surplus conditions, demonstrating that this transporter is the major source of excess manganese accumulation. The manganese taken in via Pho84p is indeed biologically active and can not only cause toxicity but can also be incorporated into manganese-requiring enzymes. Pho84p is essential for activating manganese enzymes in smf2Delta mutants that rely on low affinity manganese transport systems. A role for Pho84p in manganese accumulation was also identified in a standard laboratory growth medium when high affinity manganese uptake is active. Under these conditions, cells lacking both Pho84p and the high affinity Smf1p transporter accumulated low levels of manganese, although there was no major effect on activity of manganese-requiring enzymes. We conclude that Pho84p plays a role in manganese homeostasis predominantly under manganese surplus conditions and appears to be functioning as a low affinity metal transporter.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Jensen, LT (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.			Jensen, Laran/0000-0003-3199-1743	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008996] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 08996] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Finley JW, 1999, BIOFACTORS, V10, P15, DOI 10.1002/biof.5520100102; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Fristedt U, 1999, BIOCHEMISTRY-US, V38, P16010, DOI 10.1021/bi991545c; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HARRISON MJ, 1995, NATURE, V378, P626, DOI 10.1038/378626a0; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; Jabalquinto AM, 1999, J PROTEIN CHEM, V18, P659, DOI 10.1023/A:1020602222808; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kaiser J, 2003, SCIENCE, V300, P926, DOI 10.1126/science.300.5621.926; KINNETT DG, 1982, INT J BIOCHEM, V14, P977, DOI 10.1016/0020-711X(82)90058-1; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; KUHN NJ, 1991, EUR J BIOCHEM, V195, P243, DOI 10.1111/j.1432-1033.1991.tb15700.x; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; Malecki EA, 2001, BRAIN RES BULL, V55, P225, DOI 10.1016/S0361-9230(01)00456-7; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; Muchhal US, 1996, P NATL ACAD SCI USA, V93, P10519, DOI 10.1073/pnas.93.19.10519; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; OEHME FW, 1978, TOXICITY HEAVY METAL, V2, P547; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pal PK, 1999, NEUROTOXICOLOGY, V20, P227; Petersson J, 1999, FEBS LETT, V462, P37, DOI 10.1016/S0014-5793(99)01471-4; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; PUTRAMENT A, 1973, MOL GEN GENET, V126, P357, DOI 10.1007/BF00269445; RAM BP, 1985, CRC CR REV BIOCH MOL, V17, P257, DOI 10.3109/10409238509113606; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; Sherman F., 1978, METHODS YEAST GENETI; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; VANVEEN HW, 1994, BIOCHEMISTRY-US, V33, P1766, DOI 10.1021/bi00173a020; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; Wedler FC., 1994, MANGANESE HLTH DIS, P1; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WEST AH, 1992, J BIOL CHEM, V267, P24625; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wykoff DD, 2001, GENETICS, V159, P1491; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	54	111	115	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42036	42040		10.1074/jbc.M307413200	http://dx.doi.org/10.1074/jbc.M307413200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923174	hybrid			2022-12-27	WOS:000185989500059
J	Leung, SW; Harreman, MT; Hodel, MR; Hodel, AE; Corbett, AH				Leung, SW; Harreman, MT; Hodel, MR; Hodel, AE; Corbett, AH			Dissection of the karyopherin alpha nuclear localization signal (NLS)-binding groove - Functional requirements for NLS binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN IMPORTIN-ALPHA; SACCHAROMYCES-CEREVISIAE; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; CRYSTALLOGRAPHIC ANALYSIS; STRUCTURAL BASIS; PROTEIN IMPORT; YEAST; SEQUENCE; RECOGNITION	Classical protein import, mediated by the binding of a classical nuclear localization signal (NLS) to the NLS receptor, karyopherin/importin alpha, is the most well studied nuclear transport process. Classical NLSs are either monopartite sequences that contain a single cluster of basic amino acids (Lys/Arg) or bipartite sequences that contain two clusters of basic residues separated by an unconserved linker region. We have created mutations in conserved residues in each of the three NLS-binding sites/regions in Saccharomyces cerevisiae karyopherin alpha (SRP1). For each mutant we have analyzed binding to both a monopartite and a bipartite NLS cargo in vitro. We have also expressed each karyopherin alpha mutant in vivo as the only cellular copy of the NLS receptor and examined the impact on cell growth and import of both monopartite and bipartite NLS-containing cargoes. Our results reveal the functional significance of specific residues within karyopherin alpha for NLS cargo binding. A karyopherin alpha variant with a mutation in the major NLS-binding site exhibits decreased binding to both monopartite and bipartite NLS cargoes, and this protein is not functional in vivo. However, we also find that a karyopherin alpha variant with a mutation in the minor NLS-binding site, which shows decreased binding only to bipartite NLS-containing cargoes, is also not functional in vivo. This suggests that the cell is dependent on the function of at least one bipartite NLS cargo that is imported into the nucleus by karyopherin alpha. Our experiments also reveal functional importance for the linker-binding region. This study provides insight into how changes in binding to cellular NLS sequences could impact cellular function. In addition, this work has led to the creation of conditional alleles of karyopherin alpha with well characterized defects in NLS binding that will be useful for identifying and characterizing novel NLS cargoes.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065442] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 065442-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; SIKORSKI RS, 1989, GENETICS, V122, P19; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	33	53	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41947	41953		10.1074/jbc.M307162200	http://dx.doi.org/10.1074/jbc.M307162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917403	hybrid			2022-12-27	WOS:000185989500049
J	Odriozola, L; Cruchaga, C; Andreola, M; Dolle, V; Nguyen, CH; Tarrago-Litvak, L; Perez-Mediavilla, A; Martinez-Irujo, JJ				Odriozola, L; Cruchaga, C; Andreola, M; Dolle, V; Nguyen, CH; Tarrago-Litvak, L; Perez-Mediavilla, A; Martinez-Irujo, JJ			Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3 '-azido-3 '-deoxythymidine (AZT)-resistant polymerase to AZT-5 '-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIVIRAL ACTIVITY; IN-VITRO; PYRIDINONE DERIVATIVES; SYNERGISTIC INHIBITION; RESISTANCE; MECHANISM; AZT; REPLICATION; COMBINATION	Removal of 3'-azido-3'deoxythymidine (AZT) 3'-azido-3'-deoxythymidine-5'-monophosphate (AZTMP) from the terminated primer mediated by the human HIV-1 reverse transcriptase (RT) has been proposed as a relevant mechanism for the resistance of HIV to AZT. Here we compared wild type and AZT-resistant (D67N/K70R/T215Y/K219Q) RTs for their ability to unblock the AZTMP-terminated primer by phosphorolysis in the presence of physiological concentrations of pyrophosphate or ATP. The AZT-resistant enzyme, as it has been previously described, showed an increased ability to unblock the AZTMP-terminated primer by an ATP-dependent mechanism. We found that only mutations in the p66 subunit were responsible for this ability. We also found that three structurally divergent non-nucleoside reverse transcriptase inhibitor (NNRTI), nevirapine, TIBO, and a 4-arylmethylpyridinone derivative, were able to inhibit the phosphorolytic activity of the enzyme, rendering the AZT-resistant RT sensitive to AZTTP. The 4-arylmethylpyridinone derivative proved to be about 1000-fold more potent in inhibiting phosphorolysis than nevirapine or TIBO. Moreover, combinations of AZTTP with NNRTIs exhibited an exceptionally high degree of synergy in the inhibition of AZT-resistant enzyme only when ATP or PPi were present, indicating that inhibition of phosphorolysis was responsible for the synergy found in the combination. Our results not only demonstrate the importance of phosphorolysis concerning HIV-1 RT resistance to AZT but also point to the implication of this activity in the strong synergy found in some combinations of NNRTIs with AZT.	Univ Navarra, Dept Biochem & Mol Biol, Pamplona 31008, Spain; Univ Bordeaux 2, CNRS, UMR 5097, F-33076 Bordeaux, France; IFR 66 Pathol Infect, F-33076 Bordeaux, France; Inst Curie, Sect Rech, CNRS, UMR 176, F-91405 Orsay, France	University of Navarra; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)	Martinez-Irujo, JJ (corresponding author), Univ Navarra, Dept Biochem & Mol Biol, Calle Irunlarrea S-N, Pamplona 31008, Spain.		Nguyen, Chi/GWR-1592-2022; Nguyen, Chi/GZG-5146-2022; Perez-Mediavilla, Alberto/A-5246-2011; Cruchaga, Carlos/ABF-4065-2020; Martinez-Irujo, Juan/N-3193-2014	Perez-Mediavilla, Alberto/0000-0003-1926-0972; Cruchaga, Carlos/0000-0002-0276-2899; Martinez-Irujo, Juan/0000-0003-4576-8139				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; BABA M, 1994, ANTIMICROB AGENTS CH, V38, P688, DOI 10.1128/AAC.38.4.688; BALZARINI J, 1992, J BIOL CHEM, V267, P11831; BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1; Borkow G, 1999, ANTIMICROB AGENTS CH, V43, P259, DOI 10.1128/AAC.43.2.259; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718; BUCKHEIT RW, 1993, AIDS RES HUM RETROV, V9, P1097, DOI 10.1089/aid.1993.9.1097; BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2; Cabodevilla JF, 2001, EUR J BIOCHEM, V268, P1163, DOI 10.1046/j.1432-1327.2001.01939.x; CARROLL SS, 1994, J BIOL CHEM, V269, P32351; CHATTOPADHYAY D, 1992, J BIOL CHEM, V267, P14227; CHONG KT, 1994, ANTIMICROB AGENTS CH, V38, P288, DOI 10.1128/AAC.38.2.288; Dolle V, 2000, J MED CHEM, V43, P3949, DOI 10.1021/jm0009437; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; Gu ZX, 1995, J BIOL CHEM, V270, P31046, DOI 10.1074/jbc.270.52.31046; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Martinez-Irujo JJ, 1998, BIOCHEM J, V329, P689, DOI 10.1042/bj3290689; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PAUWELS R, 1992, BIOCHEM SOC T, V220, P509; Ren JS, 1998, P NATL ACAD SCI USA, V95, P9518, DOI 10.1073/pnas.95.16.9518; Richman D D, 1991, AIDS, V5 Suppl 2, pS189, DOI 10.1097/00002030-199101001-00027; Rigourd M, 2002, J BIOL CHEM, V277, P18611, DOI 10.1074/jbc.M110836200; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; Villahermosa ML, 1997, BIOCHEMISTRY-US, V36, P13223, DOI 10.1021/bi970852k	31	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42710	42716		10.1074/jbc.M212673200	http://dx.doi.org/10.1074/jbc.M212673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917424	hybrid			2022-12-27	WOS:000185989500138
J	Wada, Y; Ohya, H; Yamaguchi, Y; Koizumi, N; Sano, H				Wada, Y; Ohya, H; Yamaguchi, Y; Koizumi, N; Sano, H			Preferential de Novo methylation of cytosine residues in non-CpG sequences by a domains rearranged DNA methyltransferase from tobacco plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; MOSAIC-VIRUS; GENES; RNA; DEMETHYLATION; MAINTENANCE; MAIZE; CELLS; CHROMOMETHYLASE3; TRANSFORMATION	In plant DNA, cytosines in symmetric CpG and CpNpG (N is A, T, or C) are thought to be methylated by DNA methyltransferases, MET1 and CMT3, respectively. Cytosines in asymmetric CpNpN are also methylated, and genetic analysis has suggested the responsible enzyme to be domains rearranged methyltransferase (DRM). We cloned a tobacco cDNA, encoding a novel protein consisting of 608 amino acids, that resembled DRMs found in maize and Arabidopsis and designated this as NtDRM1. The protein could be shown to be localized exclusively in the nucleus and exhibit methylation activity toward unmethylated synthetic as well as native DNA samples upon expression in Sf9 insect cells. It also methylated hemimethylated DNA, but the activity was lower than that for unmethylated substrates. Methylation mapping of a 962-bp DNA, treated with NtDRM1 in vitro, directly demonstrated methylation of similar to70% of the cytosines in methylatable CpNpN and CpNpG sequences but only 10% in CpG. Further analyses indicated that the enzyme apparently non-selectively methylates any cytosines except in CpG, regardless of the adjacent nucleotide at both 5' and 3' ends. Transcripts of NtDRM1 ubiquitously accumulated in all tissues and during the cell cycle in tobacco cultured BY2 cells. These results indicate that NtDRM1 is a de novo cytosine methyltransfease, which actively excludes CpG substrate.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Inforamt, Nara 6300192, Japan	Nara Institute of Science & Technology	Sano, H (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Inforamt, Nara 6300192, Japan.		Hu, Ruogu/B-2203-2008; Yamaguchi, Yube/B-9594-2012					AN GH, 1985, PLANT PHYSIOL, V79, P568, DOI 10.1104/pp.79.2.568; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Cao XF, 2002, P NATL ACAD SCI USA, V99, P16491, DOI 10.1073/pnas.162371599; Cao XF, 2000, P NATL ACAD SCI USA, V97, P4979, DOI 10.1073/pnas.97.9.4979; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464; Finnegan EJ, 2000, PLANT MOL BIOL, V43, P189, DOI 10.1023/A:1006427226972; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; Gong ZH, 2002, CELL, V111, P803, DOI 10.1016/S0092-8674(02)01133-9; Hara K, 2000, PLANT CELL PHYSIOL, V41, P684, DOI 10.1093/pcp/41.6.684; Hernandez A, 1998, BIOINFORMATICS, V14, P227, DOI 10.1093/bioinformatics/14.2.227; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HOOD EE, 1993, TRANSGENIC RES, V2, P208, DOI 10.1007/BF01977351; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NAGATA T, 1981, MOL GEN GENET, V184, P161, DOI 10.1007/BF00272899; Nakano Y, 2000, PLANT CELL PHYSIOL, V41, P448, DOI 10.1093/pcp/41.4.448; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Papa CM, 2001, PLANT CELL, V13, P1919, DOI 10.1105/tpc.13.8.1919; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Selker EU, 2002, P NATL ACAD SCI USA, V99, P16485, DOI 10.1073/pnas.182427299; Steward N, 2000, NUCLEIC ACIDS RES, V28, P3250, DOI 10.1093/nar/28.17.3250; Steward N, 2002, J BIOL CHEM, V277, P37741, DOI 10.1074/jbc.M204050200; Tompa R, 2002, CURR BIOL, V12, P65, DOI 10.1016/S0960-9822(01)00622-4; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Wassenegger M, 2000, PLANT MOL BIOL, V43, P203, DOI 10.1023/A:1006479327881; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; Yoda H, 2002, MOL GENET GENOMICS, V267, P154, DOI 10.1007/s00438-002-0651-z; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	41	54	66	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42386	42393		10.1074/jbc.M303892200	http://dx.doi.org/10.1074/jbc.M303892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917429	hybrid			2022-12-27	WOS:000185989500101
J	Wicksteed, B; Alarcon, C; Briaud, I; Lingohr, MK; Rhodes, CJ				Wicksteed, B; Alarcon, C; Briaud, I; Lingohr, MK; Rhodes, CJ			Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet beta-cells but not regulated via a positive feedback of secreted insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; GENE-EXPRESSION; DIFFERENTIAL ACTIVATION; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; RIN-5F CELLS; TRANSCRIPTION; RECEPTOR; INHIBITION; CALCIUM	Proinsulin biosynthesis is regulated in response to nutrients, most notably glucose. In the short term (less than or equal to2 h) this is due to increases in the translation of pre-existing mRNA. However, prolonging glucose stimulation (24 h) also increases preproinsulin mRNA levels. It has been proposed that secreted insulin from the pancreatic beta-cell regulates its own synthesis through a positive autocrine feedback mechanism. Here the comparative contributions of translation and mRNA levels on the levels of proinsulin biosynthesis were examined in isolated pancreatic islets. Also, the autocrine role of insulin upon four beta-cell functions (insulin secretion, proinsulin translation, preproinsulin mRNA levels, and total protein synthesis) was investigated in parallel. The results showed that proinsulin biosynthesis is regulated, in the short term (1 h), solely at the level of translation, through an similar to6-fold increase in response to glucose (2.8 mM versus 16.7 mM glucose). In the longer term, when preproinsulin mRNA levels have increased similar to2-fold, a corresponding increase was observed in the fold response of proinsulin translation to a stimulatory glucose concentration (greater than or equal to10-fold). Importantly, neither exogenously added nor secreted insulin were found to play any role in regulating insulin secretion, proinsulin translation, preproinsulin mRNA levels, or total protein synthesis. The results presented here indicate that long term nutritional state sets the preproinsulin mRNA level in the beta-cell at which translation control regulates short term changes in rates of proinsulin biosynthesis in response to glucose, but this is not mediated by any autocrine effect of insulin.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	University of Washington; University of Washington Seattle	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047919, R01DK050610, R56DK050610] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47919, DK 50610, DK 55269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; Alarcon C, 2002, DIABETES, V51, P2496, DOI 10.2337/diabetes.51.8.2496; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; BEST L, 1988, BIOCHEM PHARMACOL, V37, P4611, DOI 10.1016/0006-2952(88)90328-0; BODEN G, 1993, METABOLISM, V42, P786, DOI 10.1016/0026-0495(93)90250-R; Briaud I, 2000, HORM METAB RES, V32, P53, DOI 10.1055/s-2007-978588; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Briaud I, 2002, DIABETES, V51, P662, DOI 10.2337/diabetes.51.3.662; BRUNSTEDT J, 1982, BIOCHEM BIOPH RES CO, V106, P1383, DOI 10.1016/0006-291X(82)91267-0; Clemens MJ, 1989, CURR OPIN CELL BIOL, V1, P1160, DOI 10.1016/S0955-0674(89)80067-5; CRETTAZ M, 1984, DIABETES, V33, P477, DOI 10.2337/diabetes.33.5.477; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; ELAHI D, 1982, NEW ENGL J MED, V306, P1196, DOI 10.1056/NEJM198205203062002; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GIDDINGS SJ, 1982, DIABETES, V31, P624, DOI 10.2337/diabetes.31.7.624; GIDDINGS SJ, 1981, J CLIN INVEST, V67, P952, DOI 10.1172/JCI110145; GIDDINGS SJ, 1985, DIABETES, V34, P235, DOI 10.2337/diabetes.34.3.235; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; KORANYI L, 1992, J CLIN INVEST, V89, P432, DOI 10.1172/JCI115602; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Laedtke T, 2000, AM J PHYSIOL-ENDOC M, V279, pE520, DOI 10.1152/ajpendo.2000.279.3.E520; Leibiger B, 2000, J BIOL CHEM, V275, P30153, DOI 10.1074/jbc.M005216200; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 2002, FEBS LETT, V532, P1, DOI 10.1016/S0014-5793(02)03627-X; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Leibowitz G, 2002, ENDOCRINOLOGY, V143, P3214, DOI 10.1210/en.2002-220174; Leibowitz G, 2003, DIABETES, V52, P998, DOI 10.2337/diabetes.52.4.998; LEVY J, 1975, BIOCHEM PHARMACOL, V24, P235, DOI 10.1016/0006-2952(75)90282-8; LIN BJ, 1973, ENDOCRINOLOGY, V92, P735, DOI 10.1210/endo-92-3-735; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; LUZI L, 1992, DIABETES, V41, P1632, DOI 10.2337/diabetes.41.12.1632; MARSHALL S, 1980, J CLIN INVEST, V66, P763, DOI 10.1172/JCI109914; McDaniel ML, 2002, DIABETES, V51, P2877, DOI 10.2337/diabetes.51.10.2877; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; OLSON SE, 1976, DIABETS METAB REV, V2, P199; ORLAND MJ, 1987, DIABETES, V36, P341, DOI 10.2337/diabetes.36.3.341; PERMUTT MA, 1984, J CLIN INVEST, V73, P1344, DOI 10.1172/JCI111337; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; Rhodes CJ., 2000, DIABETES MELLITUS FU, P20; Robey RB, 1998, BIOCHEMISTRY-US, V37, P9894, DOI 10.1021/bi980857x; ROHILLA AMK, 1991, BIOCHEM BIOPH RES CO, V175, P520, DOI 10.1016/0006-291X(91)91595-4; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH M, 1985, J BIOL CHEM, V260, P3590; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; Xavier GD, 2000, J BIOL CHEM, V275, P36269, DOI 10.1074/jbc.M006597200; Zawalich WS, 2002, J BIOL CHEM, V277, P26233, DOI 10.1074/jbc.M202291200	61	92	96	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42080	42090		10.1074/jbc.M303509200	http://dx.doi.org/10.1074/jbc.M303509200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12928442	hybrid			2022-12-27	WOS:000185989500065
J	Yao, YL; Yang, WM				Yao, YL; Yang, WM			The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED-CELL DIFFERENTIATION; MAMMARY ADENOCARCINOMA; TRICHOSTATIN-A; BREAST-CANCER; BONE-MARROW; TRANSCRIPTIONAL REPRESSION; CHROMATIN STRUCTURE; CARCINOMA-CELLS; DNA METHYLATION; GASTRIC-CANCER	The metastasis-associated protein MTA1 has been shown to express differentially to high levels in metastatic cells. MTA2, which is homologous to MTA1, is a component of the NuRD ATP-dependent chromatin remodeling and histone deacetylase complex. Here we report evidence that although both human MTA1 and MTA2 repress transcription specifically, are located in the nucleus, and contain associated histone deacetylase activity, they exist in two biochemically distinct protein complexes and may perform different functions pertaining to tumor metastasis. Specifically, both MTA1 and MTA2 complexes exert histone deacetylase activity. However, the MTA1 complex contained HDAC1/2, RbAp46/48, and MBD3, but not Sin3 or Mi2, two important components of the MTA2 complex. Moreover, the MTA2 complex is similar to the HDAC1 complex, suggesting a housekeeping role of the MTA2 complex. The MTA1 complex could be further separated, resulting in a core MTA1-HDAC complex, showing that the histone deacetylase activity and transcriptional repression activity were integral properties of the MTA1 complex. Finally, MTA1, unlike MTA2, did not interact with the pleotropic transcription factor YY1 or the immunophilin FKBP25. We suggest that MTA1 associates with a different set of transcription factors from MTA2 and that this property may contribute to the metastatic potential of cells overexpressing MTA1. We also report the finding of human MTA3, which is highly homologous to both MTA1 and MTA2. However, MTA3 does not repress transcription to a significant level and appears to have a diffused pattern of subcellular localization, suggesting a biological role distinct from that of the other two MTA proteins.	Natl Chung Hsing Univ, Inst Mol Biol, Taichung 402, Taiwan; Acad Sinica, Inst Zool, Taipei 115, Taiwan	National Chung Hsing University; Academia Sinica - Taiwan	Yang, WM (corresponding author), Natl Chung Hsing Univ, Inst Mol Biol, 250 Kuo Kuang Rd, Taichung 402, Taiwan.	yangwm@mail.nchu.edu.tw		Yang, Wen-Ming/0000-0002-5871-5979				Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Callebaut I, 1999, FEBS LETT, V446, P189, DOI 10.1016/S0014-5793(99)00132-5; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; CLARKE R, 1993, BREAST CANCER RES TR, V24, P227, DOI 10.1007/BF01833263; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DEXTER DL, 1986, J CLIN ONCOL, V4, P244, DOI 10.1200/JCO.1986.4.2.244; Fenrick R, 1998, J CELL BIOCHEM, P194; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goodwin GH, 2001, GENE, V268, P1, DOI 10.1016/S0378-1119(01)00428-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HARLOW E, 1999, USING ANTIBODIES LAB, P490; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Herman MA, 1999, DEVELOPMENT, V126, P1055; HONG L, 1993, J BIOL CHEM, V268, P305; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KELLEY RI, 1973, BIOCHEM BIOPH RES CO, V54, P1588, DOI 10.1016/0006-291X(73)91168-6; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; Nicolas RH, 1996, GENE, V175, P233, DOI 10.1016/0378-1119(96)82845-9; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; ROARK DE, 1974, BIOCHEM BIOPH RES CO, V59, P542, DOI 10.1016/S0006-291X(74)80014-8; RON D, 1992, BIOTECHNIQUES, V13, P866; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Samid D, 1997, ADV EXP MED BIOL, V400, P501; SCHLIMOK G, 1991, EUR J CANCER, V27, P1461, DOI 10.1016/0277-5379(91)90032-9; SCHLIMOK G, 1995, EUR J CANCER, V31A, P1799, DOI 10.1016/0959-8049(95)00317-C; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Solakoglu O, 2002, P NATL ACAD SCI USA, V99, P2246, DOI 10.1073/pnas.042372199; Solari F, 1999, DEVELOPMENT, V126, P2483; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	70	114	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42560	42568		10.1074/jbc.M302955200	http://dx.doi.org/10.1074/jbc.M302955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920132	hybrid			2022-12-27	WOS:000185989500121
J	Muhlenhoff, U; Stadler, JA; Richhardt, N; Seubert, A; Eickhorst, T; Schweyen, RJ; Lill, R; Wiesenberger, G				Muhlenhoff, U; Stadler, JA; Richhardt, N; Seubert, A; Eickhorst, T; Schweyen, RJ; Lill, R; Wiesenberger, G			A specific role of the yeast mitochondrial carriers Mrs3/4p in mitochondrial iron acquisition under iron-limiting conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; FRATAXIN-DEFICIENT STRAIN; CYTOSOLIC FE/S PROTEINS; SACCHAROMYCES-CEREVISIAE; PUTATIVE HOMOLOG; SPLICING DEFECTS; SULFUR PROTEINS; GENE-EXPRESSION; NULL MUTATION; DNA-BINDING	The yeast genes MRS3 and MRS4 encode two members of the mitochondrial carrier family with high sequence similarity. To elucidate their function we utilized genome-wide expression profiling and found that both deletion and overexpression of MRS3/4 lead to up-regulation of several genes of the "iron regulon." We therefore analyzed the two major iron-utilizing processes, heme formation and Fe/S protein biosynthesis in vivo, in organello ( intact mitochondria), and in vitro ( mitochondrial extracts). Radiolabeling of yeast cells with Fe-55 revealed a clear correlation between MRS3/4 expression levels and the efficiency of these biosynthetic reactions indicating a role of the carriers in utilization and/or transport of iron in vivo. Similar effects on both heme formation and Fe/S protein biosynthesis were seen in organello using mitochondria isolated from cells grown under iron-limiting conditions. The correlation between MRS3/4 expression levels and the efficiency of the two iron-utilizing processes was lost upon detergent lysis of mitochondria. As no significant changes in the mitochondrial membrane potential were observed upon overexpression or deletion of MRS3/4, our results suggest that Mrs3/4p carriers are directly involved in mitochondrial iron uptake. Mrs3/4p function in mitochondrial iron transport becomes evident under iron-limiting conditions only, indicating that the two carriers do not represent the sole system for mitochondrial iron acquisition.	Univ Vienna, Dept Genet & Microbiol, Max F Perutz Labs, A-1030 Vienna, Austria; Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Marburg, Fachbereich Chem, D-35032 Marburg, Germany	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Philipps University Marburg; Philipps University Marburg	Wiesenberger, G (corresponding author), Univ Vienna, Dept Genet & Microbiol, Max F Perutz Labs, Dr Bohrgasse 9, A-1030 Vienna, Austria.	gerlinde@gem.univie.ac.at		Lill, Roland/0000-0002-8345-6518; Wiesenberger, Gerlinde/0000-0002-3788-7974				AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Belenkiy R, 2000, BBA-BIOMEMBRANES, V1467, P207, DOI 10.1016/S0005-2736(00)00222-4; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Cho JH, 1998, MOL CELL BIOL, V18, P5712, DOI 10.1128/MCB.18.10.5712; DAUM G, 1982, J BIOL CHEM, V257, P3028; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gerber J, 2002, MITOCHONDRION, V2, P71, DOI 10.1016/S1567-7249(02)00041-7; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gregan J, 2001, GENE DEV, V15, P2229, DOI 10.1101/gad.201301; Harlow E., 1988, ANTIBODIES LAB MANUA; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Kao LR, 1996, YEAST, V12, P1239, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1239::AID-YEA17>3.0.CO;2-8; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KISPAL G, 1988, J BIOL CHEM, V263, P11145; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; Labbe-Bois Rosine, 1994, V11, P413; LALO D, 1994, YEAST, V10, P523, DOI 10.1002/yea.320100412; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; MUHLENHOFF U, 2003, IN PRESS EMBO J, V22; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nyhus KJ, 2002, MED MYCOL, V40, P581, DOI 10.1080/mmy.40.6.581.591; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri L, 2000, J BIOENERG BIOMEMBR, V32, P67, DOI 10.1023/A:1005564429242; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Palmieri L, 2001, J BIOL CHEM, V276, P1916, DOI 10.1074/jbc.M004332200; Prohl C, 2001, MOL CELL BIOL, V21, P1089, DOI 10.1128/MCB.21.4.1089-1097.2001; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Sambrook J., 2001, MOL CLONING LAB MANU; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Tzagoloff A, 1996, J BIOL CHEM, V271, P7392, DOI 10.1074/jbc.271.13.7392; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; VANDYCK E, 1995, MOL GEN GENET, V246, P426, DOI 10.1007/BF00290446; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wach A, 1998, METHOD MICROBIOL, V26, P67; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	72	154	159	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40612	40620		10.1074/jbc.M307847200	http://dx.doi.org/10.1074/jbc.M307847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902335	hybrid			2022-12-27	WOS:000185847200025
J	Paromov, VM; Morton, RE				Paromov, VM; Morton, RE			Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN-PLASMA-LIPOPROTEINS; DEFICIENT PLASMA; MASS-TRANSFER; NORMOLIPIDEMIC SUBJECTS; HDL METABOLISM; HEPATIC LIPASE; HUMAN-SERUM; ACYLTRANSFERASE; TRIGLYCERIDE	Cholesterol ester transfer protein ( CETP) moves triglyceride (TG) and cholesteryl ester (CE) between lipoproteins. CETP has no apparent preference for high (HDL) or low (LDL) density lipoprotein as lipid donor to very low density lipoprotein ( VLDL), and the preference for HDL observed in plasma is due to suppression of LDL transfers by lipid transfer inhibitor protein ( LTIP). Given the heterogeneity of HDL, and a demonstrated ability of HDL subfractions to bind LTIP, we examined whether LTIP might also control CETP-facilitated lipid flux among HDL subfractions. CETP-mediated CE transfers from [H-3] CE VLDL to various lipoproteins, combined on an equal phospholipid basis, ranged 2-fold and followed the order: HDL3 > LDL > HDL2. LTIP inhibited VLDL to HDL2 transfer at one-half the rate of VLDL to LDL. In contrast, VLDL to HDL3 transfer was stimulated, resulting in a CETP preference for HDL3 that was 3-fold greater than that for LDL or HDL2. Long-term mass transfer experiments confirmed these findings and further established that the previously observed stimulation of CETP activity on HDL by LTIP is due solely to its stimulation of transfer activity on HDL3. TG enrichment of HDL2, which occurs during the HDL cycle, inhibited CETP activity by similar to2-fold and LTIP activity was blocked almost completely. This suggests that LTIP keeps lipid transfer activity on HDL2 low and constant regardless of its TG enrichment status. Overall, these results show that LTIP tailors CETP-mediated remodeling of HDL3 and HDL2 particles in subclass-specific ways, strongly implicating LTIP as a regulator of HDL metabolism.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NC 10, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Morton, RE (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NC 10, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL60934] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CHAIT A, 1984, BIOCHIM BIOPHYS ACTA, V795, P314, DOI 10.1016/0005-2760(84)90081-X; Curtiss LK, 2000, BIOCHEMISTRY-US, V39, P5712, DOI 10.1021/bi992902m; de Beer MC, 2001, J LIPID RES, V42, P309; de Grooth GJ, 2002, CIRCULATION, V105, P2159, DOI 10.1161/01.CIR.0000015857.31889.7B; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DECKELBAUM RJ, 1988, BIOCHIM BIOPHYS ACTA, V961, P223, DOI 10.1016/0005-2760(88)90117-8; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; DECKELBAUM RJ, 1986, J BIOL CHEM, V261, P5201; DECKELBAUM RJ, 1979, J BIOL CHEM, V254, P6079; DOBIASOVA M, 1992, J LIPID RES, V33, P1411; Edelstein C., 1986, BIOCH BIOL PLASMA LI, P495; FIELDING CJ, 1981, J BIOL CHEM, V256, P2102; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KO KWS, 1994, J BIOL CHEM, V269, P28206; Kosek AB, 1999, BIOCHEM BIOPH RES CO, V258, P548, DOI 10.1006/bbrc.1999.0690; LAGROST L, 1994, ARTERIOSCLER THROMB, V14, P1327, DOI 10.1161/01.ATV.14.8.1327; Lamarche B, 1999, CLIN CHIM ACTA, V286, P145, DOI 10.1016/S0009-8981(99)00098-4; Lamarche B, 1999, J CLIN INVEST, V103, P1191, DOI 10.1172/JCI5286; LASUNCION MA, 1990, BIOCHEM J, V270, P441, DOI 10.1042/bj2700441; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LIANG HQ, 1994, J LIPID RES, V35, P1187; Liu XQ, 1995, J LIPID RES, V36, P2574; LOPEZMIRANDA J, 1994, BBA-LIPID LIPID MET, V1214, P143, DOI 10.1016/0005-2760(94)90038-8; Morton RE, 1999, CURR OPIN LIPIDOL, V10, P321, DOI 10.1097/00041433-199908000-00006; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1994, J LIPID RES, V35, P836; MORTON RE, 1990, J LIPID RES, V31, P1559; MORTON RE, 1982, J LIPID RES, V23, P1058; MORTON RE, 1994, J LIPID RES, V35, P2094; MORTON RE, 1993, ARTERIOSCLER THROMB, V13, P1843, DOI 10.1161/01.ATV.13.12.1843; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MORTON RE, 1990, EXPERIENTIA, V46, P552, DOI 10.1007/BF01939693; Morton RE, 2000, BBA-MOL CELL BIOL L, V1486, P275, DOI 10.1016/S1388-1981(00)00064-0; MORTON RE, 1983, J BIOL CHEM, V258, P1751; MORTON RE, 1988, J LIPID RES, V29, P1367; Mowri HO, 1996, ARTERIOSCL THROM VAS, V16, P755, DOI 10.1161/01.ATV.16.6.755; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119; Oliveira HCF, 1997, ARTERIOSCL THROM VAS, V17, P1045, DOI 10.1161/01.ATV.17.6.1045; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rittershaus CW, 2000, ARTERIOSCL THROM VAS, V20, P2106, DOI 10.1161/01.ATV.20.9.2106; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; SCHECTMAN G, 1992, ARTERIOSCLER THROMB, V12, P1053, DOI 10.1161/01.ATV.12.9.1053; Serdyuk AP, 1999, ARTERIOSCL THROM VAS, V19, P718, DOI 10.1161/01.ATV.19.3.718; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SON YSC, 1984, BIOCHIM BIOPHYS ACTA, V795, P473; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Tall AR, 1999, ATHEROSCLEROSIS, V146, pS10, DOI 10.1016/S0021-9150(99)00229-4; TALL AR, 1986, J LIPID RES, V27, P361; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; VANTOL A, 1991, ARTERIOSCLER THROMB, V11, P55, DOI 10.1161/01.ATV.11.1.55; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019; Wang XX, 1999, J BIOL CHEM, V274, P1814, DOI 10.1074/jbc.274.3.1814; WEINBERG RB, 1994, J BIOL CHEM, V269, P29588; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112; Yoshikawa M, 1997, CLIN BIOCHEM, V30, P221, DOI 10.1016/S0009-9120(97)00031-3; ZECHNER R, 1987, BIOCHIM BIOPHYS ACTA, V918, P27, DOI 10.1016/0005-2760(87)90005-1	61	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40859	40866		10.1074/jbc.M306580200	http://dx.doi.org/10.1074/jbc.M306580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907677	hybrid			2022-12-27	WOS:000185847200055
J	Zito, CR; Oliver, D				Zito, CR; Oliver, D			Two-stage binding of SecA to the bacterial translocon regulates ribosome-translocon interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; DISTINCT ATP-BINDING; ESCHERICHIA-COLI; PROTEIN-TRANSLOCATION; PREPROTEIN TRANSLOCATION; MEMBRANE-PROTEIN; TARGETING PATHWAYS; CHANNEL; SECYEG; COMPONENTS	The bacterial translocon interacts with both SecA-bound preproteins and nascent chain-ribosome complexes during Sec and signal recognition particle-dependent protein translocation, respectively. In their inactive state, translocons are saturated with ribosomes and SecA protein, reflecting the inherent affinity of these components for one another. We found that SecA and ribosomes are bound simultaneously and noncompetitively to a common set of inactive translocons. Furthermore, we demonstrate that at a later stage in binding, SecA possesses a ribosome-translocon dissociation activity that is coupled to its ATP-dependent membrane insertion and retraction cycle that drives protein translocation. This novel activity is presumably important in the commitment of the translocon to the Sec-dependent pathway. These results also provide a rationale for the compatibility and regulation of multiple protein translocation pathways that each makes distinct demands on a common translocon core.	Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA	Wesleyan University	Oliver, D (corresponding author), Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA.	doliver@wesleyan.edu			NIGMS NIH HHS [GM42033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, BIOCH CHARACTERIZATI, P255; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; denBlaauwen T, 1997, FEBS LETT, V416, P35, DOI 10.1016/S0014-5793(97)01142-3; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIMURA E, 1991, J BIOL CHEM, V266, P6600; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Neidhardt F.C., 1996, ESCHERICHIA COLI SAL, Vvol. 1; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; Schmidt MO, 2001, J BIOL CHEM, V276, P37076, DOI 10.1074/jbc.M104584200; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Voorst F, 2000, FEBS LETT, V486, P57, DOI 10.1016/S0014-5793(00)02209-2; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577	57	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40640	40646		10.1074/jbc.M308025200	http://dx.doi.org/10.1074/jbc.M308025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907673	hybrid			2022-12-27	WOS:000185847200028
J	Price, LS; Langeslag, M; ten Klooster, JP; Hordijk, PL; Jalink, K; Collard, JG				Price, LS; Langeslag, M; ten Klooster, JP; Hordijk, PL; Jalink, K; Collard, JG			Calcium signaling regulates translocation and activation of Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; RHO FAMILY GTPASES; DISSOCIATION INHIBITOR; ACTIN CYTOSKELETON; MAST-CELLS; NEUTROPHILS; HOMOLOGY; COMPLEX; TIAM1	Rac is activated in response to various stimuli including growth factors and by adhesion to the extracellular matrix. However, how these stimuli ultimately result in Rac activation is poorly understood. The increase in intracellular calcium [Ca2+](i) represents a ubiquitous second messenger system in cells, linking receptor activation to downstream signaling pathways. Here we show that elevation of [Ca2+](i), either artificially or by thrombin receptor activation, potently induces Rac activation. Lamellipodia formation induced by artificial elevation of [Ca2+](i) is blocked by inhibition of Rac signaling, indicating that calcium-induced cytoskeletal changes are controlled by the activation of Rac. Calcium-dependent Rac activation was dependent on the activation of a conventional protein kinase C. Furthermore, both increased [Ca2+](i) and protein kinase C activation induce phosphorylation of RhoGDIalpha and induce the translocation of cytosolic Rac to the plasma membrane. Intracellular calcium signaling may thus contribute to the intracellular localization and activation of Rac to regulate the cytoskeletal changes in response to receptor stimulation.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands; CLB, Sanquin Res, Dept Expt Immunohematol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Collard, JG (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Jalink, Kees/0000-0001-7019-3440; ten Klooster, Jean Paul/0000-0002-4979-7482; Hordijk, Peter/0000-0002-3348-078X; Langeslag, Michiel/0000-0003-4883-7339				Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ho A, 2001, CANCER RES, V61, P474; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Meacci E, 2000, FEBS LETT, V482, P97, DOI 10.1016/S0014-5793(00)02039-1; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Michiels F, 2000, METHOD ENZYMOL, V325, P295; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORTON RA, 1993, CANCER RES, V53, P3585; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; Pierini LM, 2000, BLOOD, V95, P2471; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, DEV CELL, V1, P160, DOI 10.1016/S1534-5807(01)00029-6; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scaife RM, 2003, J CELL SCI, V116, P463, DOI 10.1242/jcs.00244; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Scherberich A, 2000, J CELL SCI, V113, P653; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Soulet C, 2001, FEBS LETT, V507, P253, DOI 10.1016/S0014-5793(01)02984-2; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; van Rheenen J, 2002, MOL BIOL CELL, V13, P3257, DOI 10.1091/mbc.E02-04-0231; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; WILLIAMS DA, 1990, CELL CALCIUM, V11, P589, DOI 10.1016/0143-4160(90)90013-K; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	56	165	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39413	39421		10.1074/jbc.M302083200	http://dx.doi.org/10.1074/jbc.M302083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888567	hybrid			2022-12-27	WOS:000185713800018
J	Khadaroo, RG; Kapus, A; Powers, KA; Cybulsky, MI; Marshall, JC; Rotstein, OD				Khadaroo, RG; Kapus, A; Powers, KA; Cybulsky, MI; Marshall, JC; Rotstein, OD			Oxidative stress reprograms lipopolysaccharide signaling via Src kinase-dependent pathway in RAW 264.7 macrophage cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; FAMILY KINASES; CYTOKINE EXPRESSION; HEMORRHAGIC-SHOCK; ACTIVATION; LUNG; INHIBITOR; INJURY	Oxidative stress generated during ischemia/reperfusion injury has been shown to augment cellular responsiveness. Whereas oxidants are themselves known to induce several intracellular signaling cascades, their effect on signaling pathways initiated by other inflammatory stimuli remains poorly elucidated. Previous work has suggested that oxidants are able to prime alveolar macrophages for increased NF-kappaB translocation in response to treatment with lipopolysaccharide (LPS). Because oxidants are known to stimulate the Src family of tyrosine kinases, we hypothesized that the oxidants might contribute to augmented NF-kappaB translocation by LPS via the involvement of Src family kinases. To model macrophage priming in vitro, the murine macrophage cell line, RAW 264.7, was first incubated with various oxidants and then exposed to low dose LPS. These studies show that oxidant stress is able to augment macrophage responsiveness to LPS as evidenced by earlier and increased NF-kappaB translocation. Inhibition of the Src family kinases by either pharmacological inhibition using PP2 or through a molecular approach by cell transfection with Csk was found to prevent the augmented LPS-induced NF-kappaB translocation caused by oxidants. Interestingly, while Src kinase inhibition was able to prevent the LPS-induced NF-kappaB translocation in oxidant-treated macrophages, this strategy had no effect on NF-kappaB translocation caused by LPS in the absence of oxidants. These findings suggested that oxidative stress might divert LPS signaling along an alternative signaling pathway. Further studies demonstrated that the Src-dependent pathway induced by oxidant pretreatment involved the activation of phosphatidylinositol 3-kinase. Involvement of this pathway appeared to be independent of traditional LPS signaling. Together, these studies provide a novel potential mechanism whereby oxidants might prime alveolar macrophages for altered responsiveness to subsequent inflammatory stimuli and suggest different cellular targets for immunomodulation following ischemia/reperfusion.	Univ Toronto, Dept Surg, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2C4, Canada; Univ Hlth Network, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Rotstein, OD (corresponding author), Toronto Gen Hosp, 200 Elizabeth St,EN9-232, Toronto, ON M5G 2C4, Canada.		Cybulsky, Myron I./AAD-6539-2019	Cybulsky, Myron/0000-0002-1696-2867				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Blackwell TS, 1996, J IMMUNOL, V157, P1630; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fan J, 1998, J IMMUNOL, V161, P440; Giron-Calle J, 2002, J PHARMACOL EXP THER, V301, P87, DOI 10.1124/jpet.301.1.87; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Imbert V, 1996, J INFLAMM, V46, P65; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mallozzi C, 2001, FREE RADICAL BIO MED, V30, P1108, DOI 10.1016/S0891-5849(01)00509-3; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCUTCHAN HJ, 1990, AM J PHYSIOL, V258, pH1415, DOI 10.1152/ajpheart.1990.258.5.H1415; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Monick MM, 2001, J IMMUNOL, V167, P5977, DOI 10.4049/jimmunol.167.10.5977; MOORE FA, 1995, SURG CLIN N AM, V75, P257, DOI 10.1016/S0039-6109(16)46587-4; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Parat MO, 2002, BIOCHEM J, V361, P681, DOI 10.1042/0264-6021:3610681; RICE KL, 1992, AM J PHYSIOL, V263, pL430, DOI 10.1152/ajplung.1992.263.4.L430; SCHWARTZ MC, 1995, AM J RESP CELL MOL, V12, P434, DOI 10.1165/ajrcmb.12.4.7695923; Su XH, 1999, AM J PHYSIOL-GASTR L, V276, pG853, DOI 10.1152/ajpgi.1999.276.4.G853; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Triantafilou M, 2002, J CELL SCI, V115, P2603; Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601	33	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47834	47841		10.1074/jbc.M302660200	http://dx.doi.org/10.1074/jbc.M302660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12896983	hybrid			2022-12-27	WOS:000186731400060
J	Huan, JN; Li, J; Han, YP; Chen, K; Wu, N; Zhao, AZ				Huan, JN; Li, J; Han, YP; Chen, K; Wu, N; Zhao, AZ			Adipocyte-selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FATTY-ACID OXIDATION; IN-VIVO; TNF-ALPHA; BODY-WEIGHT; OB PROTEIN; OBESE GENE; EXPRESSION; MICE; ACTIVATION	Although recent evidence suggests that leptin can directly regulate a wide spectrum of peripheral functions, including fat metabolism, genetic examples are still needed to illustrate the physiological significance of direct actions of leptin in a given peripheral tissue. To this end, we used a technical knock-out approach to reduce the expression of leptin receptors specifically in white adipose tissue. The evaluation of leptin receptor reduction in adipocytes was based on real time PCR analysis of the mRNA levels, Western blot analysis of the proteins, and biochemical analysis of leptin signaling capability. Despite a normal level of leptin receptors in the hypothalamus and normal food intake, mutant mice developed increased adiposity, decreased body temperature, hyperinsulinemia, hypertriglyceridemia, impaired glucose tolerance and insulin sensitivity, as well as elevated hepatic and skeletal muscle triglyceride levels. In addition, a variety of genes involved in regulating fat and glucose metabolism were dysregulated in white adipose tissue. These include tumor necrosis factor-alpha, adiponectin, leptin, fatty acid synthase, sterol regulatory element-binding protein 1, glycerol kinase, and beta(3)-adrenergic receptor. Furthermore, the mutant mice are significantly more sensitive to high fat feeding with regard to developing obesity and severe insulin resistance. Thus, we provide a genetic model demonstrating the physiological importance of a peripheral effect of leptin in vivo. Importantly, this suggests the possibility that leptin resistance at the adipocyte level might be a molecular link between obesity and type 2 diabetes.	Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ So Calif, Norris Canc Res Inst, Dept Biochem, Los Angeles, CA 90033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Southern California	Zhao, AZ (corresponding author), Univ Pittsburgh, Dept Cell Biol & Physiol, S-326,3500 Terrace St, Pittsburgh, PA 15261 USA.							Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Baskin DG, 1999, J HISTOCHEM CYTOCHEM, V47, P353, DOI 10.1177/002215549904700309; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Degerman E, 1998, METHODS, V14, P43, DOI 10.1006/meth.1997.0564; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; GalvinParton PA, 1997, J BIOL CHEM, V272, P4335, DOI 10.1074/jbc.272.7.4335; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kowalski TJ, 2001, DIABETES, V50, P425, DOI 10.2337/diabetes.50.2.425; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; LOWELL BB, 1995, J CLIN INVEST, V95, P923, DOI 10.1172/JCI117798; Magni P, 1999, ENDOCRINOLOGY, V140, P1581, DOI 10.1210/en.140.4.1581; Matsuda J, 1999, ENDOCRINOLOGY, V140, P5233, DOI 10.1210/en.140.11.5233; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MURRAY JAH, 1992, ANTISENSE RNA DNA; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Soukas A, 2000, GENE DEV, V14, P963; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Valladares A, 2001, FEBS LETT, V493, P6, DOI 10.1016/S0014-5793(01)02264-5; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; WANG HY, 1996, INT J OBESITY, V20, P26; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang ZW, 1999, P NATL ACAD SCI USA, V96, P10373, DOI 10.1073/pnas.96.18.10373; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	48	82	89	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45638	45650		10.1074/jbc.M304165200	http://dx.doi.org/10.1074/jbc.M304165200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925533	hybrid			2022-12-27	WOS:000186452300073
J	Burkert, E; Arnold, C; Hammarberg, T; Radmark, O; Steinhilber, D; Werz, O				Burkert, E; Arnold, C; Hammarberg, T; Radmark, O; Steinhilber, D; Werz, O			The C2-like beta-barrel domain mediates the Ca2+-dependent resistance of 5-lipoxygenase activity against inhibition by glutathione peroxidase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED HUMAN 5-LIPOXYGENASE; EXTRACELLULAR CALCIUM; MEMBRANE; CELLS; LEUKOTRIENES; STIMULATION; ACTIVATION; MECHANISM; SELENIUM; PHOSPHATIDYLCHOLINE	Recently, we reported that in crude enzyme preparations, a monocyte-derived soluble protein (M-DSP) renders 5-lipoxygenase (5-LO) activity Ca2+-dependent. Here we provide evidence that this M-DSP is glutathione peroxidase (GPx)-1. Thus, the inhibitory effect of the M-DSP on 5-LO could be overcome by the GPx-1 inhibitor mercaptosuccinate and by the broad spectrum GPx inhibitor iodoacetate, as well as by addition of 13(S)-hydroperoxy-9Z,11E-octadecadienoic acid (13(S)-HPODE). Also, the chromatographic characteristics and the estimated molecular mass ( 80 - 100 kDa) of the M-DSP fit to GPx-1 (87 kDa), and GPx-1, isolated from bovine erythrocytes, mimicked the effects of the M-DSP. Intriguingly, only a trace amount of thiol (10 muM GSH) was required for reduction of 5-LO activity by GPx-1 or the M-DSP. Moreover, the requirement of Ca2+ allowing 5-LO product synthesis in various leukocytes correlated with the respective GPx-1 activities. Mutation of the Ca2+ binding sites within the C2-like domain of 5-LO resulted in strong reduction of 5-LO activity by M-DSP and GPx-1, also in the presence of Ca2+. In summary, our data suggest that interaction of Ca2+ at the C2-like domain of 5-LO protects the enzyme against the effect of GPx-1. Apparently, in the presence of Ca2+, a low lipid hydroperoxide level is sufficient for 5-LO activation.	Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60439 Frankfurt, Germany; Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol, S-17177 Stockholm, Sweden	Goethe University Frankfurt; Karolinska Institutet	Werz, O (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	o.werz@pharmchem.uni-frankfurt.de	Steinhilber, Dieter/J-3221-2012					AHARONY D, 1986, J BIOL CHEM, V261, P1512; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; BRYANT RW, 1982, J BIOL CHEM, V257, P4937; Burkert E, 2003, J LEUKOCYTE BIOL, V73, P191, DOI 10.1189/jlb.0702354; Burkert E, 2002, BIOCHEM BIOPH RES CO, V295, P985, DOI 10.1016/S0006-291X(02)00791-X; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; Coffey MJ, 1998, PROSTAG OTH LIPID M, V56, P113; EGAN RW, 1983, ADV PROSTAG THROMB L, V11, P151; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; Fischer L, 2003, FASEB J, V17, P949, DOI 10.1096/fj.02-0815fje; FLOHE L, 1971, H-S Z PHYSIOL CHEM, V352, P159, DOI 10.1515/bchm2.1971.352.1.159; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2001, BIOCHEMISTRY-US, V40, P6371, DOI 10.1021/bi001595d; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; HATZELMANN A, 1989, EUR J BIOCHEM, V180, P527, DOI 10.1111/j.1432-1033.1989.tb14678.x; HAURAND M, 1988, BIOL CHEM H-S, V369, P133, DOI 10.1515/bchm3.1988.369.1.133; Huang HS, 1998, FEBS LETT, V424, P22, DOI 10.1016/S0014-5793(98)00130-6; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; JAKOBSSON PJ, 1995, EUR J BIOCHEM, V232, P37, DOI 10.1111/j.1432-1033.1995.tb20778.x; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; MAIORINO M, 1991, J BIOL CHEM, V266, P7728; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Mogul R, 2000, BIOCHEMISTRY-US, V39, P4801, DOI 10.1021/bi992805t; NOGUCHI M, 1994, BBA-LIPID LIPID MET, V1215, P300, DOI 10.1016/0005-2760(94)90057-4; PERCIVAL MD, 1992, EUR J BIOCHEM, V210, P109, DOI 10.1111/j.1432-1033.1992.tb17397.x; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; RIENDEAU D, 1989, BIOCHEM J, V263, P565, DOI 10.1042/bj2630565; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1986, FEBS LETT, V204, P293, DOI 10.1016/0014-5793(86)80831-6; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; Sailer ER, 1998, EUR J BIOCHEM, V256, P364, DOI 10.1046/j.1432-1327.1998.2560364.x; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHATZMUNDING M, 1991, EUR J BIOCHEM, V197, P487, DOI 10.1111/j.1432-1033.1991.tb15936.x; SCHEWE C, 1994, BIOCHEM PHARMACOL, V48, P65, DOI 10.1016/0006-2952(94)90224-0; SIES H, 1994, METHOD ENZYMOL, V234, P476; STEINHILBER D, 1989, J CHROMATOGR-BIOMED, V493, P361, DOI 10.1016/S0378-4347(00)82742-5; Straif D, 2000, BIOCHEM J, V349, P455, DOI 10.1042/0264-6021:3490455; Tappel A L, 1978, Methods Enzymol, V52, P506; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; Wendel A, 1981, Methods Enzymol, V77, P325; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Werz O, 2000, EUR J BIOCHEM, V267, P1263, DOI 10.1046/j.1432-1327.2000.01000.x; Werz O, 1998, MOL PHARMACOL, V54, P445, DOI 10.1124/mol.54.2.445; Werz O, 1996, PHARMAZIE, V51, P893; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; ZHANG YY, 1994, ANAL BIOCHEM, V220, P28, DOI 10.1006/abio.1994.1294	56	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42846	42853		10.1074/jbc.M302471200	http://dx.doi.org/10.1074/jbc.M302471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12893830	hybrid			2022-12-27	WOS:000186157000016
J	Hunzicker-Dunn, M; Barisas, G; Song, JM; Roess, DA				Hunzicker-Dunn, M; Barisas, G; Song, JM; Roess, DA			Membrane organization of luteinizing hormone receptors differs between actively signaling and desensitized receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN FOLLICULAR MEMBRANES; PROTEIN-COUPLED RECEPTORS; RESONANCE ENERGY-TRANSFER; DELTA-OPIOID RECEPTOR; ADENYLYL-CYCLASE; CELL-SURFACE; HORMONE/CHORIOGONADOTROPIN RECEPTOR; BETA-ARRESTIN; CHORIOGONADOTROPIN RECEPTOR; LEYDIG-CELLS	Signaling by the luteinizing hormone/choriogonadotropin receptor (LHR) is of considerable interest because of its requirement for successful reproduction. Time-resolved phosphorescence anisotropy and fluorescence resonance energy transfer were used to investigate the organization of endogenous LHRs in porcine follicular membranes in two distinct signaling states, active and desensitized. Desensitized LHRs exhibited similar to 3-fold slower rotational correlation times compared with active LHRs ( 59 +/- 4 and 21 +/- 9 mus, respectively), suggesting that with agonist-dependent desensitization the receptors are organized into larger protein complexes. Incubation of membranes with inhibitors of LHR desensitization, such as neutralizing anti-arrestin antibodies, a synthetic peptide corresponding to the third intracellular loop of the LHR but not the corresponding scrambled peptide, or catalytically inactive ARNO, resulted in faster rotational diffusion times equivalent to those of actively signaling LHRs. Furthermore, desensitized LHRs exhibited a 2.4-fold increase in fluorescence resonance energy transfer between LHRs suggesting that the larger protein aggregates formed during desensitization contain more self-associated LHRs. These results indicate that agonist-dependent LHR desensitization precedes organization of LHRs at the cells surface into larger protein aggregates.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Northwestern University; Colorado State University; Colorado State University	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.				NICHD NIH HHS [R01 HD38060, HD23226] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038060] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMSTERDAM A, 1980, P NATL ACAD SCI-BIOL, V77, P3440, DOI 10.1073/pnas.77.6.3440; Angers S, 2001, LIFE SCI, V68, P2243, DOI 10.1016/S0024-3205(01)01012-8; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BENDER FE, 1982, STAT METHODS FOOD AG; Bevington P. R, 1969, DATA REDUCTION ERROR; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CHAN SS, 1979, J HISTOCHEM CYTOCHEM, V27, P56, DOI 10.1177/27.1.374620; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1992, J BIOL CHEM, V267, P22183; EKSTROM RC, 1990, ENDOCRINOLOGY, V127, P2578, DOI 10.1210/endo-127-5-2578; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Horvat RD, 2001, MOL ENDOCRINOL, V15, P534, DOI 10.1210/me.15.4.534; Horvat RD, 1999, BIOCHEM BIOPH RES CO, V255, P382, DOI 10.1006/bbrc.1999.0185; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P185, DOI 10.1210/endo-99-1-185; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; JOHNSON GD, 1986, HDB EXPT IMMUNOLOGY; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; LAMM MLG, 1994, ENDOCRINOLOGY, V134, P1745, DOI 10.1210/en.134.4.1745; LAMM MLG, 1994, MOL ENDOCRINOL, V8, P1537, DOI 10.1210/me.8.11.1537; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LUBORSKY JL, 1984, ENDOCRINOLOGY, V115, P2217, DOI 10.1210/endo-115-6-2217; MARSH JM, 1973, BIOCHIM BIOPHYS ACTA, V304, P197, DOI 10.1016/0304-4165(73)90128-1; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, CELL MOL BIOL, V47, P575; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Mukherjee S, 2002, J BIOL CHEM, V277, P17916, DOI 10.1074/jbc.M110479200; Mukherjee S, 2001, J BIOL CHEM, V276, P6524, DOI 10.1074/jbc.C000725200; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; PHILPOTT CJ, 1995, BIOL REPROD, V53, P647, DOI 10.1095/biolreprod53.3.647; PODESTA EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3986, DOI 10.1073/pnas.80.13.3986; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; ROESS DA, 1977, BIOCHIM BIOPHYS ACTA, V1357, P98; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Salvador LM, 2001, J BIOL CHEM, V276, P33773, DOI 10.1074/jbc.M101498200; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; TSAI SC, 1991, J BIOL CHEM, V268, P8213; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; YOSHIMI T, 1969, J CLIN ENDOCR METAB, V29, P225, DOI 10.1210/jcem-29-2-225; YOUNG RM, 1994, BIOPHYS J, V67, P881, DOI 10.1016/S0006-3495(94)80549-1; ZHU X, 1993, J BIOL CHEM, V268, P1723	56	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42744	42749		10.1074/jbc.M306133200	http://dx.doi.org/10.1074/jbc.M306133200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930832	hybrid			2022-12-27	WOS:000186157000004
J	Noda, Y; Kohjima, M; Izaki, T; Ota, K; Yoshinaga, S; Inagaki, F; Ito, T; Sumimoto, H				Noda, Y; Kohjima, M; Izaki, T; Ota, K; Yoshinaga, S; Inagaki, F; Ito, T; Sumimoto, H			Molecular recognition in dimerization between PB1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-POLARITY; NADPH OXIDASE; EPITHELIAL TIGHT; PC MOTIF; COMPLEX; BINDING; APKC; CDC42; LINKS	The PB1 ( Phox and Bem 1) domain is a recently identified module that mediates formation of a heterodimeric complex with other PB1 domain, e. g. the complexes between the phagocyte oxidase activators p67(phox) and p40(phox) and between the yeast polarity proteins Bem1p and Cdc24p. These PB1 domains harbor either a conserved lysine residue on one side or an acidic OPCA (OPR/PC/AID) motif around the other side; the lysine of p67phox or Bem1p likely binds to the OPCA of p40phox or Cdc24p, respectively, via electrostatic interactions. To further understand molecular recognition by PB1 domains, here we investigate the interactions mediated by proteins presenting both the lysine and OPCA on a single PB1 domain, namely Par6, atypical protein kinase C ( aPKC), and ZIP. Par6 and aPKC form a complex via the interaction of the Par6 lysine with aPKC-OPCA but not via that between the aPKC lysine and Par6-OPCA, thereby localizing to the tight junction of epithelial cells. aPKC also uses its OPCA to interact with ZIP, another protein that has a PB1 domain presenting both the lysine and OPCA, whereas aPKC binds via the conserved lysine to MEK5 in the same manner as ZIP interacts with MEK5. In addition, ZIP can form a homotypic complex via the conserved electrostatic interactions. Thus the PB1 domain appears to be a protein module that fully exploits its two mutually interacting elements in molecular recognition to expand its repertoire of protein-protein interactions.	Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Kanazawa Univ, Canc Res Inst, Div Genome Biol, Kanazawa, Ishikawa 9200934, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan	Kyushu University; Kanazawa University; Hokkaido University	Sumimoto, H (corresponding author), Kyushu Univ, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hsumi@bioreg.kyushu-u.ac.jp		Ito, Takashi/0000-0001-6097-2803				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Endo M, 2003, J BIOL CHEM, V278, P843, DOI 10.1074/jbc.M209714200; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Mayer BJ, 2001, J CELL SCI, V114, P1253; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Otomo T, 2000, NAT STRUCT BIOL, V7, P658, DOI 10.1038/77957; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; YOSHINAGA S, 2003, IN PRESS EMBO J, V22; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	48	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43516	43524		10.1074/jbc.M306330200	http://dx.doi.org/10.1074/jbc.M306330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920115	hybrid			2022-12-27	WOS:000186157000097
J	Thoden, JB; Zhuang, ZH; Dunaway-Mariano, D; Holden, HM				Thoden, JB; Zhuang, ZH; Dunaway-Mariano, D; Holden, HM			The structure of 4-hydroxybenzoyl-CoA thioesterase from Arthrobacter sp strain SU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS SP; 4-CHLOROBENZOIC ACID; ACTIVE-SITE; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; DEHALOGENATION; BIOSYNTHESIS; DEGRADATION; BACTERIA; PROGRAM	The 4-chlorobenzoyl-CoA dehalogenation pathway in certain Arthrobacter and Pseudomonas bacterial species contains three enzymes: a ligase, a dehalogenase, and a thioesterase. Here we describe the high resolution x-ray crystallographic structure of the 4-hydroxybenzoyl-CoA thioesterase from Arthrobacter sp. strain SU. The tetrameric enzyme is a dimer of dimers with each subunit adopting the so-called "hot dog fold" composed of six strands of anti-parallel beta-sheet flanked on one side by a rather long alpha-helix. The dimers come together to form the tetramer with their alpha-helices facing outwards. This quaternary structure is in sharp contrast to that previously observed for the 4-hydroxybenzoyl-CoA thioesterase from Pseudomonas species strain CBS-3, whereby the dimers forming the tetramer pack with their alpha-helices projecting toward the interfacial region. In the Arthrobacter thioesterase, each of the four active sites is formed by three of the subunits of the tetramer. On the basis of both structural and kinetic data, it appears that Glu(73) is the active site base in the Arthrobacter thioesterase. Remarkably, this residue is located on the opposite side of the substrate-binding pocket compared with that observed for the Pseudomonas enzyme. Although these two bacterial thioesterases demonstrate equivalent catalytic efficiencies, substrate specificities, and metabolic functions, their quaternary structures, CoA-binding sites, and catalytic platforms are decidedly different.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of Wisconsin System; University of Wisconsin Madison; University of New Mexico	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28688, GM55513] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chae JC, 2000, GENE, V258, P109, DOI 10.1016/S0378-1119(00)00419-4; CORK DJ, 1991, ADV APPL MICROBIOL, V36, P1; Dunaway-Mariano Debra, 1994, Biodegradation, V5, P259, DOI 10.1007/BF00696464; Furukawa Kensuke, 1994, Biodegradation, V5, P289, DOI 10.1007/BF00696466; HAGGBLOM MM, 1992, FEMS MICROBIOL LETT, V103, P29; HIGSON FK, 1992, ADV APPL MICROBIOL, V37, P135, DOI 10.1016/S0065-2164(08)70254-5; Hisano T, 2003, J BIOL CHEM, V278, P617, DOI 10.1074/jbc.M205484200; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KLAGES U, 1980, ZBL BAKT MIK HYG I C, V1, P215, DOI 10.1016/S0172-5564(80)80002-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAYTON AC, 1992, APPL ENVIRON MICROB, V58, P399, DOI 10.1128/AEM.58.1.399-402.1992; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Li J, 2000, NAT STRUCT BIOL, V7, P555; Luo LS, 2001, BIOCHEMISTRY-US, V40, P15684, DOI 10.1021/bi011536f; MARKS TS, 1984, BIOCHEM BIOPH RES CO, V124, P669, DOI 10.1016/0006-291X(84)91607-3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ROUSSEL A, 1990, ACTA CRYSTALLOGR A, V4, P66; RUISINGER S, 1976, ARCH MICROBIOL, V110, P253, DOI 10.1007/BF00690235; SAVARD P, 1986, J BACTERIOL, V168, P81, DOI 10.1128/jb.168.1.81-85.1986; SCHOLTEN JD, 1991, SCIENCE, V253, P182, DOI 10.1126/science.1853203; Thoden JB, 2002, J BIOL CHEM, V277, P27468, DOI 10.1074/jbc.M203904200; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Yi HR, 2000, FEMS MICROBIOL ECOL, V31, P53, DOI 10.1111/j.1574-6941.2000.tb00671.x; Zhuang ZH, 2003, APPL ENVIRON MICROB, V69, P2707, DOI 10.1128/AEM.69.5.2707-2711.2003; Zhuang ZH, 2002, BIOCHEMISTRY-US, V41, P11152, DOI 10.1021/bi0262303	29	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43709	43716		10.1074/jbc.M308198200	http://dx.doi.org/10.1074/jbc.M308198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12907670	hybrid			2022-12-27	WOS:000186157000120
J	Garofano, A; Zwicker, K; Kerscher, S; Okun, P; Brandt, U				Garofano, A; Zwicker, K; Kerscher, S; Okun, P; Brandt, U			Two aspartic acid residues in the PSST-homologous NUKM subunit of complex I from Yarrowia lipolytica are essential for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; SULFUR CLUSTER N2; SITE-DIRECTED MUTAGENESIS; MITOCHONDRIAL NADH; ESCHERICHIA-COLI; 49-KDA SUBUNIT; CORE; HYDROGENASES; TYKY	Mitochondrial proton-translocating NADH: ubiquinone oxidoreductase ( complex I) couples the transfer of two electrons from NADH to ubiquinone to the translocation of four protons across the mitochondrial inner membrane. Subunit PSST is the most likely carrier of iron-sulfur cluster N2, which has been proposed to play a crucial role in ubiquinone reduction and proton pumping. To explore the function of this subunit we have generated site-directed mutants of all eight highly conserved acidic residues in the Yarrowia lipolytica homologue, the NUKM protein. Mutants D99N and D115N had only 5 and 8% of the wild type catalytic activity, respectively. In both cases complex I was stably assembled but electron paramagnetic resonance spectra of the purified enzyme showed a reduced N2 signal (about 50%). In terms of complex I catalytic activity, almost identical results were obtained when the aspartates were individually changed to glutamates or to glycines. Mutations of other conserved acidic residues had less dramatic effects on catalytic activity and did not prevent assembly of iron-sulfur cluster N2. This excludes all conserved acidic residues in the PSST subunit as fourth ligands of this redox center. The results are discussed in the light of the structural similarities to the homologous small subunit of water-soluble [NiFe] hydrogenases.	Univ Frankfurt, Fachbereich Med, Inst Biochem 1, Gustav Embden Zentrum Biol Chem, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Brandt, U (corresponding author), Univ Frankfurt, Fachbereich Med, Inst Biochem 1, Gustav Embden Zentrum Biol Chem, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.		Brandt, Ulrich/GLV-1242-2022; Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; Ahlers PM, 2000, BBA-BIOENERGETICS, V1459, P258, DOI 10.1016/S0005-2728(00)00160-2; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Chevallet M, 2003, BBA-BIOENERGETICS, V1557, P51, DOI 10.1016/S0005-2728(02)00398-5; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Duarte M, 2002, BIOCHEM J, V364, P833, DOI 10.1042/BJ20011750; Dutton P L, 1978, Methods Enzymol, V54, P411; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; Kerscher S, 2002, BBA-BIOENERGETICS, V1555, P83, DOI 10.1016/S0005-2728(02)00259-1; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 2001, J CELL SCI, V114, P3915; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; PRIEUR L, 2001, BIOCHIM BIOPHYS ACTA, V1504, P173; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; Schagger H., 2003, MEMBRANE PROTEIN PUR, P105, DOI DOI 10.1016/B978-012361776-7/50006-1; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; SLED VD, 1993, BIOCHIM BIOPHYS ACTA, V1141, P262, DOI 10.1016/0005-2728(93)90051-G; Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WIKSTROM M, 1984, FEBS LETT, V169, P300, DOI 10.1016/0014-5793(84)80338-5; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	29	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42435	42440		10.1074/jbc.M305819200	http://dx.doi.org/10.1074/jbc.M305819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12930834	hybrid			2022-12-27	WOS:000185989500107
J	Krauskopf, A; Lhote, P; Mutter, M; Dufour, JF; Ruegg, UT; Buetler, TM				Krauskopf, A; Lhote, P; Mutter, M; Dufour, JF; Ruegg, UT; Buetler, TM			Vasopressin type 1A receptor up-regulation by cyclosporin A in vascular smooth muscle cells is mediated by superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HYDROGEN-PEROXIDE; REACTIVE OXYGEN; OXIDATIVE STRESS; PROTEIN-KINASE; ENDOTHELIAL DYSFUNCTION; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; GENE-EXPRESSION; FREE-RADICALS	Based on our previous results, we investigated whether cyclosporin A (CsA)-induced vasopressin type 1A receptor up-regulation was mediated by free radicals. We report that CsA analogues with different affinities for cyclophilin and calcineurin were able to upregulate vasopressin type 1A receptor and to generate free radicals in smooth muscle cells independently of calcineurin. Further, we demonstrate that the antioxidant N-acetyl-L-cysteine blocked the increase in vasopressin type 1A receptor mRNA and protein levels induced by CsA and that low concentrations of prooxidants were able to directly increase vasopressin type 1A receptor mRNA and protein levels. In addition, short exposure to CsA or pro-oxidants was sufficient to significantly increase vasopressin type 1A receptor mRNA and protein levels. Using cell-permeable forms of superoxide dismutase and catalase, we finally show that superoxide mediates the CsA-induced effects on vasopressin type 1A receptor. These results provide strong evidence that CsA-induced superoxide generation is causally involved in vasopressin type 1A receptor expression and demonstrate for the first time that low physiological concentrations of radicals, most probably superoxide, are able to directly affect cellular signaling to increase vasopressin type 1A receptor expression in rat aortic smooth muscle cells.	Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland; Ecole Polytech Fed Lausanne, Inst Mol & Biol Chem, CH-1015 Lausanne, Switzerland; Univ Bern, Dept Clin Pharmacol, CH-3010 Bern, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Bern	Ruegg, UT (corresponding author), Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland.	urs.ruegg@dpharm.unil.ch	Dufour, Jean Francois Jacques/AAL-9866-2020	Dufour, Jean Francois Jacques/0000-0002-8062-1346; RUEGG, Urs/0000-0001-6078-8280				AHMED SS, 1993, J PHARMACOL EXP THER, V265, P1047; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Avdonin PV, 1999, KIDNEY INT, V55, P2407, DOI 10.1046/j.1523-1755.1999.00481.x; BAUMANN G, 1991, NEW BIOL, V3, P270; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200; Cai H, 2001, ARTERIOSCL THROM VAS, V21, P1571, DOI 10.1161/hq1001.097028; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chen HW, 2002, BRIT J PHARMACOL, V137, P771, DOI 10.1038/sj.bjp.0704908; Cottet-Maire F, 2001, BRIT J PHARMACOL, V132, P909, DOI 10.1038/sj.bjp.0703878; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; deLema GP, 1997, TRANSPL P, V29, P1241; DIEDERICH D, 1994, HYPERTENSION, V23, P957, DOI 10.1161/01.HYP.23.6.957; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRIDOVICH I, 1985, HARVEY LECT, V79, P51; Galle J, 2000, NEPHROL DIAL TRANSPL, V15, P339, DOI 10.1093/ndt/15.3.339; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Huang WC, 2002, EXP CELL RES, V277, P192, DOI 10.1006/excr.2002.5546; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Krauskopf A, 2002, BRIT J PHARMACOL, V135, P977, DOI 10.1038/sj.bjp.0704544; LAMB FS, 1987, LIFE SCI, V40, P2571, DOI 10.1016/0024-3205(87)90080-4; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Liochev SI, 1999, MET IONS BIOL SYST, V36, P1; Lopez-Ongil S, 1998, BRIT J PHARMACOL, V124, P447, DOI 10.1038/sj.bjp.0701847; LoRusso A, 1996, BRIT J PHARMACOL, V118, P885; LoRusso A, 1997, J RECEPT SIGNAL TR R, V17, P149; LoRusso A, 1997, BRIT J PHARMACOL, V121, P248, DOI 10.1038/sj.bjp.0701102; MASON J, 1989, PHARMACOL REV, V41, P423; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; REGO A, 1990, J PHARMACOL EXP THER, V254, P799; ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHIBATA N, 1988, EUR J CLIN PHARMACOL, V35, P443, DOI 10.1007/BF00561382; Sies H., 1991, OXIDATIVE STRESS OXI; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TEXTOR SC, 1994, MAYO CLIN PROC, V69, P1182, DOI 10.1016/S0025-6196(12)65772-3; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; Ullrich V, 2001, BBA-MOL CELL BIOL L, V1532, P1, DOI 10.1016/S1388-1981(01)00126-3; WANG CY, 1995, KIDNEY INT, V47, P927, DOI 10.1038/ki.1995.138; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; WOLF A, 1994, TRANSPLANT P, V26, P2902; Wolin MS, 2002, J VASC RES, V39, P191, DOI 10.1159/000063685; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Yang JQ, 2002, MOL CARCINOGEN, V33, P206, DOI 10.1002/mc.10037; Zhang JH, 1998, AM J RESP CELL MOL, V19, P324, DOI 10.1165/ajrcmb.19.2.3209; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	61	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41685	41690		10.1074/jbc.M301181200	http://dx.doi.org/10.1074/jbc.M301181200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923165	hybrid			2022-12-27	WOS:000185989500018
J	Yakovleva, L; Tian, LG; Sayer, JM; Kalena, GP; Kroth, H; Jerina, DM; Shuman, S				Yakovleva, L; Tian, LG; Sayer, JM; Kalena, GP; Kroth, H; Jerina, DM; Shuman, S			Site-specific DNA transesterification by vaccinia topoisomerase - Effects of benzo[a]pyrene-dA, 8-oxoguanine, 8-oxoadenine, and 2-aminopurine modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODON 61 SEQUENCE; DIOL EPOXIDE; VIRUS TOPOISOMERASE; COVALENT CATALYSIS; MINOR-GROOVE; MUTATIONAL ANALYSIS; IB TOPOISOMERASE; DUPLEX DNA; ADDUCT; MECHANISM	Vaccinia DNA topoisomerase forms a covalent DNA(3'-phosphotyrosyl)-enzyme intermediate at a specific target site 5'-C(+5)C(+4)C(+3)T(+2)T(+1)p down arrow N-1 in duplex DNA. Here we study the effects of base modifications on the rate and extent of single-turnover DNA transesterification. Chiral trans opened C-10 R and S adducts of benzo[a]pyrene (BP) 7,8-diol 9,10-epoxide were introduced at single N-6-deoxyadenosine (dA) positions within the 3'-G(+5)G(+4)G(+3)A(+2)A(+1)T(-1)A(-2) sequence of the nonscissile DNA strand. The R and S BPdA adducts intercalate from the major groove on the 5' and 3' sides of the modified base, respectively, and perturb local base stacking. We found that R and S BPdA modifications at +1A reduced the transesterification rate by a factor of 700-1000 without affecting the yield of the covalent topoisomerase-DNA complex. BPdA modifications at +2A reduced the extent of transesterification and elicited rate decrements of 200- and 7000-fold for the S and R diastereomers, respectively. In contrast, BPdA adducts at the -2 position had no effect on the extent of the reaction and relatively little impact on the rate of cleavage. A more subtle probe of major groove contacts entailed substituting each of the purines of the nonscissile strand with its 8-oxo analog. The +3 oxoG modification slowed transesterification 35-fold, whereas other 8-oxo modifications were benign. 8-Oxo substitutions at the -1 position in the scissile strand slowed single-turnover cleavage by a factor of six but had an even greater slowing effect on religation, which resulted in an increase in the cleavage equilibrium constant. 2-Aminopurine at positions +3, +4, or +5 in the nonscissile strand had no effect on transesterification per se but had synergistic effects when combined with 8-oxoA at position -1 in the scissile strand. These findings illuminate the functional interface of vaccinia topoisomerase with the DNA major groove.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; NIDDK, Bioorgan Chem Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.			Kroth, Heiko/0000-0002-6936-3921	NIAID NIH HHS [AI 053471] Funding Source: Medline; NIGMS NIH HHS [GM 46330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; CHRISTNER DF, 1994, BIOCHEMISTRY-US, V33, P14297, DOI 10.1021/bi00251a043; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Hwang Y, 1998, J VIROL, V72, P3401, DOI 10.1128/JVI.72.4.3401-3406.1998; Hwang Y, 1999, J BIOL CHEM, V274, P9160, DOI 10.1074/jbc.274.14.9160; Hwang Y, 1999, VIROLOGY, V262, P479, DOI 10.1006/viro.1999.9920; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P20907, DOI 10.1074/jbc.M102312200; Kwon K, 2002, J BIOL CHEM, V277, P345, DOI 10.1074/jbc.M109449200; Kwon K, 2002, J BIOL CHEM, V277, P353, DOI 10.1074/jbc.M109450200; LAKSHMAN MK, 1992, J ORG CHEM, V57, P4585, DOI 10.1021/jo00043a012; LAKSHMAN MK, 1991, J AM CHEM SOC, V113, P6589, DOI 10.1021/ja00017a034; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Mauro SA, 2003, J BIOL CHEM, V278, P12955, DOI 10.1074/jbc.M212667200; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pradhan P, 2001, BIOCHEMISTRY-US, V40, P5870, DOI 10.1021/bi002896q; Sayer JM, 1999, POLYCYCL AROMAT COMP, V17, P95, DOI 10.1080/10406639908020605; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; SCHURTER EJ, 1995, BIOCHEMISTRY-US, V34, P9009, DOI 10.1021/bi00028a009; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; Sekiguchi JA, 1996, J BIOL CHEM, V271, P2313, DOI 10.1074/jbc.271.4.2313; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; White S, 1998, NATURE, V391, P468, DOI 10.1038/35106; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Zegar IS, 1998, BIOCHEMISTRY-US, V37, P16516, DOI 10.1021/bi9817616; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P6212, DOI 10.1021/bi9524732; Zhang HL, 2001, P NATL ACAD SCI USA, V98, P10608, DOI 10.1073/pnas.191321998	54	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42170	42177		10.1074/jbc.M308079200	http://dx.doi.org/10.1074/jbc.M308079200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909623	hybrid			2022-12-27	WOS:000185989500075
J	Yokoyama, K; Nagata, K; Imamura, H; Ohkuma, S; Yoshida, M; Tamakoshi, M				Yokoyama, K; Nagata, K; Imamura, H; Ohkuma, S; Yoshida, M; Tamakoshi, M			Subunit arrangement in V-ATPase from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; MANDUCA-SEXTA MIDGUT; CROSS-LINKING; EXTREME THERMOPHILE; 100-KDA SUBUNIT; TERMINAL DOMAIN; GENE ENCODES; V-1 ATPASE; IN-VIVO	The V0V1-ATPase of Thermus thermophilus catalyzes ATP synthesis coupled with proton translocation. It consists of an ATPase-active V-1 part (ABDF) and a proton channel V-0 part (CLEGI), but the arrangement of each subunit is still largely unknown. Here we found that acid treatment of V0V1-ATPase induced its dissociation into two subcomplexes, one with subunit composition ABDFCL and the other with EGI. Exposure of the isolated V0 to acid or 8 M urea also produced two subcomplexes, EGI and CL. Thus, the C subunit (homologue of d subunit, yeast Vma6p) associates with the L subunit ring tightly, and I (homologue of 100-kDa subunit, yeast Vph1p), E, and G subunits constitute a stable complex. Based on these observations and our recent demonstration that D, F, and L subunits rotate relative to A(3)B(3) (Imamura, H., Nakano, M., Noji, H., Muneyuki, E., Ohkuma, S., Yoshida, M., and Yokoyama, K. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 2312-2315; Yokoyama, K., Nakano, M., Imamura, H., Yoshida, M., and Tamakoshi, M. (2003) J. Biol. Chem. 278, 24255-24258), we propose that C, D, F, and L subunits constitute the central rotor shaft and A, B, E, G, and I subunits comprise the surrounding stator apparatus in the V0V1-ATPase.	Japan Sci & Technol Corp, ERATO, ATP Syst Project, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol & Cellular Biol, Kanazawa, Ishikawa 9200934, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Tokyo 1920392, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Kanazawa University; Tokyo Institute of Technology; Tokyo University of Pharmacy & Life Sciences	Yokoyama, K (corresponding author), Japan Sci & Technol Corp, ERATO, ATP Syst Project, Midori Ku, 5800-3 Nagatsuta, Yokohama, Kanagawa 2260026, Japan.		Yokoyama, Ken/AAJ-3582-2020; Imamura, Hiromi/AAD-5109-2019	Yokoyama, Ken/0000-0002-6813-1096; Imamura, Hiromi/0000-0002-1896-0443; Nagata, Koji/0000-0002-4704-0603				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Chaban Y, 2002, EMBO REP, V3, P982, DOI 10.1093/embo-reports/kvf196; Fillingame RH, 1997, J EXP BIOL, V200, P217; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; Gruber G, 2001, J EXP BIOL, V204, P2597; Gruber G, 2001, BIOCHEMISTRY-US, V40, P1890, DOI 10.1021/bi002195t; Gruber G, 2000, J BIOL CHEM, V275, P30082, DOI 10.1074/jbc.M002976200; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oster G, 2000, BBA-BIOENERGETICS, V1458, P482, DOI 10.1016/S0005-2728(00)00096-7; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Tamakoshi M, 1998, GENE, V222, P125, DOI 10.1016/S0378-1119(98)00482-X; Tamakoshi M, 1999, FEMS MICROBIOL LETT, V173, P431, DOI 10.1016/S0378-1097(99)00101-9; Tamakoshi M, 1997, J BACTERIOL, V179, P4811, DOI 10.1128/jb.179.15.4811-4814.1997; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; Yokoyama K, 2000, J BIOL CHEM, V275, P13955, DOI 10.1074/jbc.275.18.13955; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	41	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42686	42691		10.1074/jbc.M305853200	http://dx.doi.org/10.1074/jbc.M305853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913005	hybrid			2022-12-27	WOS:000185989500135
J	Duan, HO; Simpson-Haidaris, PJ				Duan, HO; Simpson-Haidaris, PJ			Functional analysis of interleukin 6 response elements (IL-6REs) on the human gamma-fibrinogen promoter - Binding of hepatic Stat3 correlates negatively with transactivation potential of type IIIL-6REs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; 5-FLANKING REGION; GENE-EXPRESSION; C/EBP-DELTA; ACTIVATION; CHAIN; PROTEINS; CELLS	Several families of transcription factors play important roles in modulating liver-specific gene expression during an acute phase response (APR). Stat3/APR factor is the main transactivator of gene expression by the interleukin (IL)-6 family of cytokines signaling through gp130. During an APR, fibrinogen (FBG) genes are coordinately upregulated by IL-6 and glucocorticoids. Except for rat gammaFBG, attempts to demonstrate direct binding of IL-6-activated Stat3 to FBG CTGGGAA promoter elements have not been successful. Herein we show the presence of three functional type II IL-6 response elements (IL-6REs) on the human gammaFBG promoter and that the magnitude of Stat3 binding to these elements correlates negatively with their functional activity in reporter gene assays. Stat3-specific binding to gammaFBG IL-6REs was confirmed by cross-competition with alpha(2)-macroglobulin IL-6RE and specific interactions with anti-Stat3 in electrophoretic mobility shift assays. All type II IL-6REs contributed to full promoter activity; however, transactivation from Site II at - 306 to - 301 was strongest. In contrast to a previous report, IL-6 failed to induce activation of serum amyloid A-activating factor-1/c-Myc-associated zinc finger protein (SAF-1/MAZ), and mutation of the SAF-1RE had little effect on IL-6 induction of gammaFBG promoter activity. In the absence of a functional glucocorticoid receptor response element, dexamethasone potentiated IL-6-induced gammaFBG promoter activity 2-fold, requiring promoter-proximal Site I and Site II; the promoter-distal Site III had no effect on dexamethasone potentiation of IL-6-induced promoter activity. Notably the propensity for Stat3 binding to human gammaFBG IL-6REs was low compared with Stat3 binding to the alpha(2)-macroglobulin IL-6RE. Together these data suggest that Stat3 transactivation via IL-6REs on FBG promoters likely involves participation of additional transcription factors and/or coactivators to achieve optimal coordinated up-regulation during an APR.	Univ Rochester, Sch Med & Dent, Dept Med, Hematol Oncol Unit,Program Hemostasis & Thrombosi, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Simpson-Haidaris, PJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Hematol Oncol Unit,Program Hemostasis & Thrombosi, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.			, PJ/0000-0003-2778-2500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050615, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL50615, P01-HL30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 1995, IMMUNOL REV, V148, P221, DOI 10.1111/j.1600-065X.1995.tb00100.x; Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Alonzi T, 1997, IMMUNOBIOLOGY, V198, P144, DOI 10.1016/S0171-2985(97)80035-6; Alonzi T, 1998, CYTOKINE, V10, P13, DOI 10.1006/cyto.1997.0250; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Asselta R, 1998, THROMB HAEMOSTASIS, V79, P1144, DOI 10.1055/s-0037-1615031; BINI A, 2000, ENCY REFERENCE VASCU, P372; Bode JG, 2001, J IMMUNOL, V167, P1469, DOI 10.4049/jimmunol.167.3.1469; BROWN LF, 1993, AM J PATHOL, V142, P273; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Chan HM, 2001, J CELL SCI, V114, P2363; Chapman RS, 2000, ADV EXP MED BIOL, V480, P129; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; de Maat MPM, 2001, ANN NY ACAD SCI, V936, P509; deMaat MPM, 1997, THROMB HAEMOSTASIS, V77, P75; ESMON CT, 1993, ANNU REV CELL BIOL, V9, P1; FRANCIS CW, 1993, BLOOD CELLS, V19, P291; Fuller GM, 2001, ANN NY ACAD SCI, V936, P469; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Guadiz G, 1997, AM J RESP CELL MOL, V17, P60, DOI 10.1165/ajrcmb.17.1.2730; Guadiz G, 1997, BLOOD, V90, P2644, DOI 10.1182/blood.V90.7.2644.2644_2644_2653; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; He YZ, 2002, J BIOL CHEM, V277, P49256, DOI 10.1074/jbc.M205536200; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HU CH, 1995, J BIOL CHEM, V270, P28342; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; MIZUGUCHI J, 1995, J BIOL CHEM, V270, P28350; NAITO M, 1992, ATHEROSCLEROSIS, V96, P227, DOI 10.1016/0021-9150(92)90069-S; Odrljin TM, 1996, BBA-PROTEIN STRUCT M, V1298, P69, DOI 10.1016/S0167-4838(96)00090-8; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 2000, J IMMUNOL, V165, P3411, DOI 10.4049/jimmunol.165.6.3411; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray A, 1996, MOL CELL BIOL, V16, P1584; Redman CM, 2001, ANN NY ACAD SCI, V936, P480; SIMPSONHAIDARIS PJ, 1992, BLOOD, V79, P1218; SIMPSONHAIDARIS PJ, 1997, BLOOD, V89, P873; Song J, 1999, EUR J BIOCHEM, V259, P676, DOI 10.1046/j.1432-1327.1999.00081.x; Song J, 1998, J BIOL CHEM, V273, P20603, DOI 10.1074/jbc.273.32.20603; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; Zhang ZX, 1997, BIOCHEM BIOPH RES CO, V237, P90, DOI 10.1006/bbrc.1997.7082; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287	51	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41270	41281		10.1074/jbc.M304210200	http://dx.doi.org/10.1074/jbc.M304210200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900415	hybrid			2022-12-27	WOS:000185847200106
J	Mataraza, JM; Briggs, MW; Li, ZG; Entwistle, A; Ridley, AJ; Sacks, DB				Mataraza, JM; Briggs, MW; Li, ZG; Entwistle, A; Ridley, AJ; Sacks, DB			IQGAP1 promotes cell motility and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO FAMILY GTPASES; RNA INTERFERENCE; BINDING PROTEIN; CDC42; CALMODULIN; MIGRATION; RAC1; CYTOSKELETON; METASTASIS; FILOPODIA	The dynamic processes of cell migration and invasion are largely coordinated by Rho family GTPases. The scaffolding protein IQGAP1 binds to Cdc42, increasing the amount of active Cdc42 both in vitro and in cells. Here we show that overexpression of IQGAP1 in mammalian cells enhances cell migration in a Cdc42- and Rac1-dependent manner. Importantly, cell motility was significantly decreased both by knock down of endogenous IQGAP1 using small interfering RNA and by transfection of a dominant negative IQGAP1 construct, IQGAP1DeltaGRD. Cell invasion was similarly altered by manipulating intracellular IQGAP1 concentrations. Moreover, invasion mediated by constitutively active Cdc42 was attenuated by IQGAP1DeltaGRD. Thus, IQGAP1 has a fundamental role in cell motility and invasion.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735; Ridley, Anne/0000-0001-8186-5708	NCI NIH HHS [CA75205] Funding Source: Medline; NHLBI NIH HHS [HL07627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA075205, R01CA075205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Brill S, 1996, MOL CELL BIOL, V16, P4869; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keely PJ, 2001, METHODS ENZYMOL, V333, P256; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; Mathew AC, 1997, CLIN EXP METASTAS, V15, P393, DOI 10.1023/A:1018498120910; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sokol SY, 2001, J BIOL CHEM, V276, P48425, DOI 10.1074/jbc.M107975200; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Wojciak-Stothard B, 2003, J CELL BIOL, V161, P429, DOI 10.1083/jcb.200210135; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	32	168	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41237	41245		10.1074/jbc.M304838200	http://dx.doi.org/10.1074/jbc.M304838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900413	hybrid			2022-12-27	WOS:000185847200102
J	Pola, S; Cattaneo, MG; Vicentini, LM				Pola, S; Cattaneo, MG; Vicentini, LM			Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells - Involvement of Rac and MAP kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GENE-EXPRESSION; ACTIVATION; RECEPTORS; PROLIFERATION; CHEMOTAXIS; MECHANISMS; PATHWAY; BIOLOGY; ANALOGS	Cell motility and invasion are crucial events for the spread of cancer and, consequently, the metastatic process. Platelet-derived growth factor ( PDGF) is not only capable of stimulating the proliferation of SH-SY5Y human neuroblastoma cells, but also their migration and invasion through an extracellular matrix barrier. Experiments using wortmannin and PD98059, specific inhibitors of the phosphatidylinositol 3-kinase (PI3-K) and of the mitogen-activated protein kinases (ERK 1 and 2) signaling, respectively, show that the activation of both pathways is required for the PDGF-induced cell motility responses. We have previously shown that somatostatin inhibits cell division and ERK 1/2 and Ras activity in SH-SY5Y cells. We report here that it is also capable of potently and effectively inhibiting their PDGF-stimulated migration and invasion. The inhibitory effect of somatostatin is sensitive to pertussis toxin. Although somatostatin does not affect PI3-K, it inhibits ERK 1/2 and the small G-protein Rac activation and ruffle formation induced by PDGF. These results indicate that somatostatin can be considered an anti-migratory and antiinvasive agent that acts by inhibiting ERK 1/2 signaling and the PI3-K pathway via the inhibition of Rac in SH-SY5Y cells.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy	University of Milan	Vicentini, LM (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.		Cattaneo, Maria Grazia/H-3067-2017	Cattaneo, Maria Grazia/0000-0002-1582-9933; Vicentini, Lucia M./0000-0002-2446-1974				Albers AR, 2000, REGUL PEPTIDES, V88, P61, DOI 10.1016/S0167-0115(99)00121-4; Albini A, 1999, FASEB J, V13, P647, DOI 10.1096/fasebj.13.6.647; ALBINI A, 1987, CANCER RES, V47, P3239; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bousquet C, 2001, CHEMOTHERAPY, V47, P30, DOI 10.1159/000049159; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cattaneo MG, 1999, FEBS LETT, V459, P64, DOI 10.1016/S0014-5793(99)01218-1; Cattaneo MG, 2000, FEBS LETT, V481, P271, DOI 10.1016/S0014-5793(00)02012-3; Cattaneo MG, 1996, FEBS LETT, V397, P164, DOI 10.1016/S0014-5793(96)01159-3; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOUDHURY GG, 1997, AM J PHYSIOL, V273, P931; Csaba Z, 2001, NEUROPEPTIDES, V35, P1, DOI 10.1054/npep.2001.0848; de Herder WW, 2002, CURR OPIN ONCOL, V14, P53, DOI 10.1097/00001622-200201000-00010; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hinton DR, 1998, EXP CELL RES, V239, P11, DOI 10.1006/excr.1997.3873; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Kramer K, 2001, CANCER, V91, P1510, DOI 10.1002/1097-0142(20010415)91:8<1510::AID-CNCR1159>3.3.CO;2-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI T, 1993, J CLIN INVEST, V92, P1153, DOI 10.1172/JCI116684; Orlando C, 2001, MED PEDIATR ONCOL, V36, P224, DOI 10.1002/1096-911X(20010101)36:1<224::AID-MPO1054>3.0.CO;2-#; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; REUBI JC, 1995, TRENDS PHARMACOL SCI, V16, P110, DOI 10.1016/S0165-6147(00)88992-0; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; VANZOELEN EJJ, 1985, MOL CELL BIOL, V5, P2289, DOI 10.1128/MCB.5.9.2289	34	48	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40601	40606		10.1074/jbc.M306510200	http://dx.doi.org/10.1074/jbc.M306510200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902325	hybrid			2022-12-27	WOS:000185847200023
J	Schuh, K; Quaschning, T; Knauer, S; Hu, K; Kocak, S; Roethlein, N; Neyses, L				Schuh, K; Quaschning, T; Knauer, S; Hu, K; Kocak, S; Roethlein, N; Neyses, L			Regulation of vascular tone in animals overexpressing the sarcolemmal calcium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CA2+-ATPASE; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; NA+/CA2+ EXCHANGER; PROTEIN-KINASE; CA-2+ PUMP; ISOFORM 4B; CA2+ PUMP; PHOSPHORYLATION; EXPRESSION	The mechanisms governing vascular smooth muscle tone are incompletely understood. In particular, the role of the sarcolemmal calcium pump PMCA ( plasma membrane calmodulin-dependent calcium ATPase), which extrudes Ca2+ from the cytosol, and its importance compared with the sodium/calcium exchanger remain speculative. To test whether the PMCA is a regulator of vascular tone, we generated transgenic mice overexpressing the human PMCA4b under control of the arterial smooth muscle-specific SM22alpha promoter. This resulted in an elevated systolic blood pressure compared with littermate controls. In PMCA-overexpressing mice, endothelium-dependent relaxation of norepinephrine-preconstricted aortic rings to acetylcholine did not differ from wild type controls (76 +/- 8% versus 79 +/- 8% of maximum relaxation; n = 12, n.s.). De-endothelialized aortas of transgenic mice exhibited stronger maximum contraction to KCl (100 mmol/liter) compared with controls (86 +/- 6% versus 68 +/- 7% of reference KCl contraction at the beginning of the experiment; p < 0.05). Preincubation of de-endothelialized vessels with the nitric oxide synthase (NOS) inhibitor L-NAME (L-N(G)-nitroarginine methyl ester) (10(-5) mol/liter) resulted in a stronger contraction to KCl (p < 0.05 versus without L-NAME), thus unmasking vasodilatory effects of inherent NO production. Maximum contraction to KCl after preincubation with L-NAME did not differ between PMCA mice and controls. In analogy to the results in PMCA-overexpressing mice, contractions of de-endothelialized aortas of neuronal NOS-deficient mice to KCl were significantly increased compared with controls (151 +/- 5% versus 131 +/- 6% of reference KCl contraction; p < 0.05). In conclusion, our data suggest a model in which the sarcolemmal Ca2+ pump down-regulates activity of the vascular smooth muscle Ca2+/calmodulin-dependent neuronal NOS by a functionally relevant interaction. Therefore, the PMCA represents a novel regulator of vascular tone.	Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Inst Clin Biochem & Pathobiochem, D-97078 Wurzburg, Germany; Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany	University of Manchester; University of Wurzburg	Neyses, L (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Med, Oxford Rd, Manchester M13 9WL, Lancs, England.		Neyses, Ludwig/AGY-7446-2022					Barton M, 1998, HYPERTENSION, V31, P499, DOI 10.1161/01.HYP.31.1.499; Blaustein M. P., 1977, AM J PHYSIOL, V1, P165; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GROS R, 2003, IN PRESS CIRC RES, V93; Hammes A, 1998, CIRC RES, V83, P877; Hammes A, 1996, J BIOL CHEM, V271, P30816, DOI 10.1074/jbc.271.48.30816; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; Husain M, 1997, AM J PHYSIOL-CELL PH, V272, pC1947, DOI 10.1152/ajpcell.1997.272.6.C1947; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; Jaggar JH, 1998, ACTA PHYSIOL SCAND, V164, P577; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Lau KS, 2000, PHYSIOL GENOMICS, V2, P21, DOI 10.1152/physiolgenomics.2000.2.1.21; MOTLEY ED, 1993, AM J PHYSIOL, V264, pH1028, DOI 10.1152/ajpheart.1993.264.4.H1028; NEYSES L, 1985, J BIOL CHEM, V260, P283; Pfitzer G, 2001, J APPL PHYSIOL, V91, P497, DOI 10.1152/jappl.2001.91.1.497; Quaschning T, 2001, HYPERTENSION, V37, P1108, DOI 10.1161/01.HYP.37.4.1108; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Segal SS, 1999, AM J PHYSIOL-HEART C, V277, pH1167; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Strehler E E, 1990, Semin Cell Biol, V1, P283; Wakimoto K, 2000, J BIOL CHEM, V275, P36991, DOI 10.1074/jbc.M004035200; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; Wan TC, 2003, THROMB HAEMOSTASIS, V89, P122	33	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41246	41252		10.1074/jbc.M307606200	http://dx.doi.org/10.1074/jbc.M307606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900399	Green Published, hybrid			2022-12-27	WOS:000185847200103
J	Wang, WN; Lo, KWH; Kan, HM; Fan, JS; Zhang, MJ				Wang, WN; Lo, KWH; Kan, HM; Fan, JS; Zhang, MJ			Structure of the monomeric 8-kDa dynein light chain and mechanism of the domain-swapped dimer assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CYTOPLASMIC DYNEIN; PROTEIN INHIBITOR; MYOSIN-V; MOTOR COMPLEX; NMR; KDA; PROGRAM; DIMERIZATION; MUTATIONS	The 8-kDa light chain of dynein (DLC8) is ubiquitously expressed in various cell types. Other than serving as a light chain of the dynein complexes, this highly conserved protein has been shown to bind a larger number of proteins with diverse biological functions. DLC8 forms a homodimer via three-dimensional domain swapping of an internal beta-strand (the beta2-strand) at neutral pH. The protein undergoes non-reversible dimer-to-monomer dissociation when the pH value of the protein solution decreases. The three-dimensional structure of the DLC8 monomer determined by NMR spectroscopy at pH 3.0 showed that the protein is well folded. The major conformational change accompanied by dimer dissociation is in the beta2-strand of the protein, which undergoes transition from a beta-strand to a nascent alpha-helix. The monomer form of DLC8 is not capable of binding to target proteins. Insertion of two flexible amino acid residues in the tight beta1/beta2-loop dramatically stabilized the monomer conformation of the protein. NMR studies showed that the mutation altered the conformation as well as the three-dimensional domain swapping-mediated assembly of the DLC8 dimer. The mutant DLC8 was unable to bind to its targets even at physiological pH. The three-dimensional structure of the mutant protein in its monomeric form provides the structural basis of the mutation-induced stabilization of the monomer conformation. Based on the experimental data, we conclude that the formation of the beta2-strand swapping-mediated dimer is mandatory for the structure and function of DLC8. We further note that the DLC8 dimer represents a novel mode of three-dimensional domain swapping.	Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China	Hong Kong University of Science & Technology; Fudan University	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.			Zhang, Mingjie/0000-0001-9404-0190				Barbar E, 2001, BIOCHEMISTRY-US, V40, P1596, DOI 10.1021/bi002278+; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clore GM, 1997, NAT STRUCT BIOL, V4, P849; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dick T, 1996, MOL CELL BIOL, V16, P1966; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Fan JS, 2002, J BIOMOL NMR, V23, P103, DOI 10.1023/A:1016332918178; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HUGHES SM, 1995, J CELL SCI, V108, P17; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Newcomer ME, 2002, CURR OPIN STRUC BIOL, V12, P48, DOI 10.1016/S0959-440X(02)00288-9; Nicholls A., 1992, GRASP GRAPHICAL REPR; Phillis R, 1996, DEVELOPMENT, V122, P2955; PIPERNO G, 1979, J BIOL CHEM, V254, P3084; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rodriguez-Crespo I, 2001, FEBS LETT, V503, P135, DOI 10.1016/S0014-5793(01)02718-1; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Tochio H, 1998, NAT STRUCT BIOL, V5, P965, DOI 10.1038/2940; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Wuthrich K, 1986, NMR PROTEINS NUCL AC	45	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41491	41499		10.1074/jbc.M307118200	http://dx.doi.org/10.1074/jbc.M307118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904292	hybrid			2022-12-27	WOS:000185847200129
J	Hara, T; Matsuyama, S; Tokuda, H				Hara, T; Matsuyama, S; Tokuda, H			Mechanism underlying the inner membrane retention of Escherichia coli lipoproteins caused by Lol avoidance signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; CYTOPLASMIC MEMBRANE; SORTING SIGNALS; DEPENDENT RELEASE; LOCALIZATION; PROTEIN; TRANSLOCATION; TRANSPORTER; ACCUMULATION; VESICLES	Escherichia coli lipoproteins are localized to either the inner or outer membrane depending on the residue at position 2. The inner membrane retention signal, Asp at position 2 in combination with certain residues at position 3, functions as a Lol avoidance signal, i.e. the signal inhibits the recognition of lipoproteins by Lol-CDE that releases lipoproteins from the inner membrane. To understand the role of the residue at position 2, outer membrane-specific lipoproteins with Cys at position 2 were subjected to chemical modification followed by the release reaction in reconstituted proteoliposomes. Sulfhydryl-specific introduction of nonprotein molecules or a negative charge to Cys did not inhibit the LolCDE-dependent release. In contrast, oxidation of Cys to cysteic acid resulted in generation of the Lol avoidance signal, indicating that the Lol avoidance signal requires a critical length of negative charge at the second residue. Furthermore, not only modification of the carboxylic acid of Asp at position 2 but also that of the amine of phosphatidylethanolamine abolished the Lol avoidance function. Based on these results, the Lol avoidance mechanism is discussed.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fukuda A, 2002, J BIOL CHEM, V277, P43512, DOI 10.1074/jbc.M206816200; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Narita S, 2003, MOL MICROBIOL, V49, P167, DOI 10.1046/j.1365-2958.2003.03569.x; Narita S, 2002, J BACTERIOL, V184, P1417, DOI 10.1128/JB.184.5.1417-1422.2002; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Tanaka K, 2001, J BACTERIOL, V183, P6538, DOI 10.1128/JB.183.22.6538-6542.2001; TANI K, 1990, J BIOL CHEM, V265, P17341; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6	27	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40408	40414		10.1074/jbc.M307836200	http://dx.doi.org/10.1074/jbc.M307836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12896969	hybrid			2022-12-27	WOS:000185713800135
J	Gardocki, ME; Lopes, JM				Gardocki, ME; Lopes, JM			Expression of the yeast PIS1 gene requires multiple regulatory elements including a Rox1p binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAMES; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL SYNTHASE; PHOSPHOLIPID BIOSYNTHESIS; HYPOXIC GENES; CELL-WALL; FUNCTIONAL COMPLEMENTATION; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; PROMOTER ELEMENTS	The PIS1 gene is required for de novo synthesis of phosphatidylinositol ( PI), an essential phospholipid in Saccharomyces cerevisiae. PIS1 gene expression is unusual because it is uncoupled from the other phospholipid biosynthetic genes, which are regulated in response to inositol and choline. Relatively little is known about regulation of transcription of the PIS1 gene. We reported previously that PIS1 transcription is sensitive to carbon source. To further our understanding of the regulation of PIS1 transcription, we carried out a promoter deletion analysis that identified three regions required for PIS1 gene expression ( upstream activating sequence (UAS) elements 1-3). Deletion of either UAS1 or UAS2 resulted in an similar to 45% reduction in expression, whereas removal of UAS3 yielded an 84% decrease in expression. A comparison of promoters among several Saccharomyces species shows that these sequences are highly conserved. Curiously, the UAS3 element region ( - 149 to - 138) includes a Rox1p binding site. Rox1p is a repressor of hypoxic genes under aerobic growth conditions. Consistent with this, we have found that expression of a PIS1-cat reporter was repressed under aerobic conditions, and this repression was dependent on both Rox1p and its binding site. Furthermore, PI levels were elevated under anaerobic conditions. This is the first evidence that PI levels are affected by regulation of PIS1 transcription.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Lopes, JM (corresponding author), Wayne State Univ, Dept Biol Sci, 5047 Gullen Mall, Detroit, MI 48202 USA.							Abramova N, 2001, J BACTERIOL, V183, P2881, DOI 10.1128/JB.183.9.2881-2887.2001; Abramova NE, 2001, GENETICS, V157, P1169; Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ANDERSON MS, 1996, ANAL PISI GENE EXPRE; Antonsson B, 1997, BBA-LIPID LIPID MET, V1348, P179, DOI 10.1016/S0005-2760(97)00105-7; Antonsson BE, 1996, YEAST, V12, P449, DOI 10.1002/(SICI)1097-0061(199604)12:5<449::AID-YEA927>3.0.CO;2-P; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BARNETT JA, 1992, YEAST, V8, P1, DOI 10.1002/yea.320080102; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; COHEN R, 1986, MOL CELL BIOL, V6, P2287, DOI 10.1128/MCB.6.7.2287; Crowley JH, 1998, J BACTERIOL, V180, P4177, DOI 10.1128/JB.180.16.4177-4183.1998; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DECKERT J, 1995, MOL CELL BIOL, V15, P6109; Deckert J, 1999, NUCLEIC ACIDS RES, V27, P3518, DOI 10.1093/nar/27.17.3518; Deckert J, 1998, GENETICS, V150, P1429; Delbecq P, 2000, CURR GENET, V38, P105, DOI 10.1007/s002940000140; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Eiznhamer DA, 2001, MOL MICROBIOL, V39, P1395, DOI 10.1046/j.1365-2958.2001.02330.x; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Gonzalez CI, 2001, GENE, V274, P15, DOI 10.1016/S0378-1119(01)00552-2; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GRIGGS DW, 1993, MOL CELL BIOL, V13, P4999, DOI 10.1128/MCB.13.8.4999; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; Kastaniotis AJ, 2000, MOL CELL BIOL, V20, P7088, DOI 10.1128/MCB.20.19.7088-7098.2000; Kastaniotis AJ, 2000, ADV EXP MED BIOL, V475, P185; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLY BL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P144, DOI 10.1016/0005-2760(90)90181-V; KUMANO Y, 1995, FEMS MICROBIOL LETT, V126, P81, DOI 10.1111/j.1574-6968.1995.tb07394.x; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; LERAY C, 1987, J CHROMATOGR-BIOMED, V420, P411, DOI 10.1016/0378-4347(87)80198-6; LOWRY CV, 1984, P NATL ACAD SCI-BIOL, V81, P6129, DOI 10.1073/pnas.81.19.6129; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; Lykidis A, 1997, J BIOL CHEM, V272, P33402, DOI 10.1074/jbc.272.52.33402; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; Mead J, 2002, MOL CELL BIOL, V22, P4607, DOI 10.1128/MCB.22.13.4607-4621.2002; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKAWA JI, 1982, EUR J BIOCHEM, V125, P445, DOI 10.1111/j.1432-1033.1982.tb06703.x; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Seron K, 2000, EUR J BIOCHEM, V267, P6571, DOI 10.1046/j.1432-1327.2000.01749.x; Sertil O, 1997, GENE, V192, P199, DOI 10.1016/S0378-1119(97)00028-0; Shears SB, 2000, BIOESSAYS, V22, P786, DOI 10.1002/1521-1878(200009)22:9<786::AID-BIES3>3.3.CO;2-S; Shields D, 1999, CURR OPIN CELL BIOL, V11, P489, DOI 10.1016/S0955-0674(99)80070-2; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Tanaka S, 1996, FEBS LETT, V393, P89, DOI 10.1016/0014-5793(96)00858-7; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; Ter Linde JJM, 2002, YEAST, V19, P825, DOI 10.1002/yea.879; Vilela C, 1998, NUCLEIC ACIDS RES, V26, P1150, DOI 10.1093/nar/26.5.1150; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Xue HW, 2000, PLANT MOL BIOL, V42, P757, DOI 10.1023/A:1006308909105; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110	75	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38646	38652		10.1074/jbc.M305251200	http://dx.doi.org/10.1074/jbc.M305251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12890676	hybrid			2022-12-27	WOS:000185575100069
J	Guo, GL; Lambert, G; Negishi, M; Ward, JM; Brewer, HB; Kliewer, SA; Gonzalez, FJ; Sinal, CJ				Guo, GL; Lambert, G; Negishi, M; Ward, JM; Brewer, HB; Kliewer, SA; Gonzalez, FJ; Sinal, CJ			Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; NUCLEAR RECEPTOR; GENE-EXPRESSION; PROTEIN GENE; IDENTIFICATION; HOMEOSTASIS; CAR; DETOXIFICATION; TRANSCRIPTION; ACTIVATION	The nuclear receptors, farnesoid X receptor (FXR) and pregnane X receptor (PXR), are important in maintaining bile acid homeostasis. Deletion of both FXR and PXR in vivo by cross-breeding B6;129-Fxr(tm1Gonz) (FXR-null) and B6;129-Pxr(tm1Glaxo-Wellcome) (PXR-null) mice revealed a more severe disruption of bile acid, cholesterol, and lipid homeostasis in B6;129-Fxr(tm1Gonz) Pxr(tm1Glaxo-Wellcome) (FXR-PXR double null or FPXR-null) mice fed a 1% cholic acid (CA) diet. Hepatic expression of the constitutive androstane receptor (CAR) and its target genes was induced in FXR- and FPXR-null mice fed the CA diet. To test whether up-regulation of CAR represents a means of protection against bile acid toxicity to compensate for the loss of FXR and PXR, animals were pretreated with CAR activators, phenobarbital or 1,4- bis[2-(3,5-dichlorpyridyloxy)] benzene (TCPOBOP), followed by the CA diet. A role for CAR in protection against bile acid toxicity was confirmed by a marked reduction of serum bile acid and bilirubin concentrations, with an elevation of the expression of the hepatic genes involved in bile acid and/or bilirubin metabolism and excretion (CYP2B, CYP3A, MRP2, MRP3, UGT1A, and glutathione S-transferase alpha), following pretreatment with phenobarbital or TCPOBOP. In summary, the current study demonstrates a critical and combined role of FXR and PXR in maintaining not only bile acid but also cholesterol and lipid homeostasis in vivo. Furthermore, FXR, PXR, and CAR protect against hepatic bile acid toxicity in a complementary manner, suggesting that they serve as redundant but distinct layers of defense to prevent overt hepatic damage by bile acids during cholestasis.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; INSERM, U539, F-44035 Nantes, France; NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NCI, Vet & Tumor Pathol Sect, Ctr Canc Res, Frederick, MD 21702 USA; NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gonzalez, FJ (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 2A19A,9000 Rockville Pike, Bethesda, MD 20892 USA.		Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; Lambert, Gilles/0000-0001-5632-0685; Sinal, Christopher/0000-0001-8301-3349	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005, ZIAES080040, Z01ES080040] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKER M, 1984, EUR J PEDIATR, V143, P41, DOI 10.1007/BF00442746; BLOOMER JR, 1975, ANN INTERN MED, V82, P310, DOI 10.7326/0003-4819-82-3-310; CAPRON JP, 1975, DIGESTION, V12, P43, DOI 10.1159/000197653; CHEN CH, 1982, J LIPID RES, V23, P680; Elferink RO, 2002, BBA-MOL BASIS DIS, V1586, P129; Elferink RPJO, 1999, GASTROENTEROL CLIN N, V28, P59; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Guo GL, 2002, J PHARMACOL EXP THER, V300, P206, DOI 10.1124/jpet.300.1.206; HOFMANN AF, 1995, ITAL J GASTROENTEROL, V27, P106; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Lambert G, 2000, J LIPID RES, V41, P667; Longo M, 2002, GUT, V51, P265, DOI 10.1136/gut.51.2.265; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MCINTYRE N, 1975, GUT, V16, P379, DOI 10.1136/gut.16.5.379; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Salen G, 1999, GASTROENTEROL CLIN N, V28, P173, DOI 10.1016/S0889-8553(05)70049-2; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Strautnieks SS, 1996, J MED GENET, V33, P833, DOI 10.1136/jmg.33.10.833; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	37	236	242	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45062	45071		10.1074/jbc.M307145200	http://dx.doi.org/10.1074/jbc.M307145200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12923173	hybrid			2022-12-27	WOS:000186452300005
J	Paruchuri, S; Sjolander, A				Paruchuri, S; Sjolander, A			Leukotriene D-4 mediates survival and proliferation via separate but parallel pathways in the human intestinal epithelial cell line int 407	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ELEMENT-BINDING PROTEIN; HUMAN-MELANOMA CELLS; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; S6 KINASE; RESPONSIVE ELEMENT; COLORECTAL-CANCER; RECEPTOR; GROWTH	We demonstrated previously that leukotriene D-4 (LTD4) regulates proliferation of intestinal epithelial cells through a CysLT receptor by protein kinase C (PKC)epsilon-dependent stimulation of the mitogen-activated protein kinase ERK1/2. Our current study provides the first evidence that LTD4 can activate 90-kDa ribosomal S6 kinase (p90(RSK)) and cAMP-responsive element-binding protein (CREB) via pertussis-toxin-sensitive G(i) protein pathways. Transfection and inhibitor experiments revealed that activation of p90(RSK), but not CREB, is a PKCepsilon/Raf-1/ERK1/2-dependent process. LTD4-mediated CREB activation was not affected by expression of kinase-dead p90(RSK) but was abolished by transfection with the regulatory domain of PKCalpha (a specific dominant-inhibitor of PKCalpha). Kinase-negative mutants of p90(RSK) and CREB (K(-)p90(RSK) and K-CREB) blocked the LTD4-induced increase in cell number and DNA synthesis (thymidine incorporation). Compatible with these results, flow cytometry showed that LTD4 caused transition from the G(0)/G(1) to the S+G(2)/M cell cycle phase, indicating increased proliferation. Similar treatment of cells transfected with K-p90(RSK) resulted in cell cycle arrest in the G(0)/G(1) phase, consistent with a role of p90(RSK) in LTD4-induced proliferation. On the other hand, expression of K-CREB caused a substantial buildup in the sub-G(0)/G(1) phase, suggesting a role for CREB in mediating LTD4-mediated survival in intestinal epithelial cells. Our results show that LTD4 regulates proliferation and survival via distinct intracellular signaling pathways in intestinal epithelial cells.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Expt Pathol, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Expt Pathol, SE-20502 Malmo, Sweden.							Apati A, 2003, J BIOL CHEM, V278, P9235, DOI 10.1074/jbc.M205528200; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Braccioni F, 2002, J ALLERGY CLIN IMMUN, V110, P96, DOI 10.1067/mai.2002.125000; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHAN CC, 1990, EUR J PHARMACOL, V191, P273; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Choe ES, 2002, NEUROSCIENCE, V114, P557, DOI 10.1016/S0306-4522(02)00318-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Gogal RM, 2000, CYTOMETRY, V39, P310, DOI 10.1002/(SICI)1097-0320(20000401)39:4<310::AID-CYTO10>3.0.CO;2-V; Gubina E, 2001, J IMMUNOL, V167, P4303, DOI 10.4049/jimmunol.167.8.4303; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HENLE G, 1957, J IMMUNOL, V79, P54; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lynch KR, 1999, NATURE, V399, P789; Massoumi R, 1998, EUR J CELL BIOL, V76, P185, DOI 10.1016/S0171-9335(98)80033-2; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Ohd JF, 2002, ADV EXP MED BIOL, V507, P193; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; Paruchuri S, 2002, J CELL SCI, V115, P1883; Pende M, 1997, J NEUROSCI, V17, P1291; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SADOSHIMA J, 1995, CIRC RES, V76, P1; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SJOLANDER A, 1990, J BIOL CHEM, V265, P20976; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Swart JM, 2000, J IMMUNOL, V164, P2311, DOI 10.4049/jimmunol.164.5.2311; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Thodeti CK, 2001, EXP CELL RES, V262, P95, DOI 10.1006/excr.2000.5077; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Wikstrom K, 2003, BIOCHEM BIOPH RES CO, V302, P330, DOI 10.1016/S0006-291X(03)00187-6; Yang YM, 1996, ONCOGENE, V12, P2223; Zeidman R, 1999, INT J CANCER, V81, P494, DOI 10.1002/(SICI)1097-0215(19990505)81:3<494::AID-IJC26>3.0.CO;2-L	55	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45577	45585		10.1074/jbc.M302881200	http://dx.doi.org/10.1074/jbc.M302881200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12912998	hybrid			2022-12-27	WOS:000186452300066
J	Miranda-Vizuete, A; Tsang, K; Yu, Y; Jimenez, A; Pelto-Huikko, M; Flickinger, CJ; Sutovsky, P; Oko, R				Miranda-Vizuete, A; Tsang, K; Yu, Y; Jimenez, A; Pelto-Huikko, M; Flickinger, CJ; Sutovsky, P; Oko, R			Cloning and developmental analysis of murid spermatid-specific thioredoxin-2 (SPTRX-2), a novel sperm fibrous sheath protein and autoantigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER DENSE FIBERS; DYNEIN INTERMEDIATE CHAIN; KINASE ANCHOR PROTEINS; MOLECULAR-CLONING; RAT SPERM; TYROSINE PHOSPHORYLATION; MAMMALIAN SPERMATOZOA; BINDING-PROTEIN; TAIL PROTEIN; EXPRESSION	Thioredoxins compose a growing family of proteins that participate in different cellular processes via redox-mediated reactions. We report here the cloning, developmental expression, and location of murid Sptrx-2. Mouse and rat SPTRX-2 proteins display a high homology to their human ortholog in the thioredoxin and NDP kinase domains, and the coding genes are located at syntenic positions. Northern blotting and in situ hybridization confirmed the testis-specific expression of murine Sptrx-2 mRNA, mostly in round spermatids. Immunohistochemical analysis of the 19 steps of rat spermiogenesis showed that SPTRX-2 expression becomes prominent in the cytoplasmic lobe of step 15-18 spermatids and diminishes in step 19 just before spermiation. However, in the spermatid tail, SPTRX-2 immunoreactivity increased from step 15 to 19 and was confined to the principal piece. By immunogold electron microscopy, SPTRX-2 was first detected scattered throughout the cytoplasm of the axoneme in step 14-15 spermatids, but began to be incorporated by step 16 into the fibrous sheath (FS). During steps 17-18, the labeling increased over the ribs and columns of the assembled FS. It peaked in step 19 and remained in the FS of epididymal spermatozoa. Immunoblots of isolated FS obtained from spermatozoa confirmed that SPTRX-2 is an integral component of the FS and a post-obstruction autoantigen in vasectomized rats. Our data indicate that SPTRX-2 incorporation into the FS lags well behind FS assembly, suggesting it is required during the final stages of sperm tail maturation in the testis and/or epididymis, where extensive disulfide bonding of FS proteins occurs.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Tampere Univ, Sch Med, Dept Dev Biol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Pathol, FIN-33101 Tampere, Finland; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Obstet & Gynecol, Columbia, MO 65211 USA	Karolinska Institutet; Queens University - Canada; Tampere University; Tampere University; Tampere University Hospital; University of Virginia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Oko, R (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	ro3@post.queensu.ca	Miranda-Vizuete, Antonio/D-6927-2012; IBIS, REDOX/J-7473-2017; Jiménez, Alberto/A-6234-2009	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Jiménez, Alberto/0000-0003-3685-6479; Sutovsky, Peter/0000-0002-9231-2823	NICHD NIH HHS [HD U54-29009] Funding Source: Medline; NIDDK NIH HHS [P50 DK45179] Funding Source: Medline; NIOSH CDC HHS [OH07324-01] Funding Source: Medline; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R21OH007324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045179] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIOSH CDC HHS; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Aul RB, 2002, DEV BIOL, V242, P268, DOI 10.1006/dbio.2002.0575; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; Brohmann H, 1997, J BIOL CHEM, V272, P10327, DOI 10.1074/jbc.272.15.10327; Bunch DO, 1998, BIOL REPROD, V58, P834, DOI 10.1095/biolreprod58.3.834; BURFEIND P, 1991, DEV BIOL, V148, P195, DOI 10.1016/0012-1606(91)90329-2; Bush LA, 2002, MOL REPROD DEV, V62, P233, DOI 10.1002/mrd.10092; CALVIN HI, 1975, BIOL MALE GAMETE, P257; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; Catalano RD, 2001, BIOL REPROD, V65, P277, DOI 10.1095/biolreprod65.1.277; CLERMONT Y, 1990, ANAT RECORD, V227, P447, DOI 10.1002/ar.1092270408; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Curry M., 1995, GAMETES SPERMATOZOON, P45; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; de Carvalho CE, 2002, BIOL REPROD, V66, P785, DOI 10.1095/biolreprod66.3.785; Eddy EM, 2003, MICROSC RES TECHNIQ, V61, P103, DOI 10.1002/jemt.10320; El-Alfy M, 1999, J ANDROL, V20, P307; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Flickinger CJ, 2001, BIOL REPROD, V64, P1451, DOI 10.1095/biolreprod64.5.1451; Flickinger CJ, 1999, J REPROD IMMUNOL, V43, P35, DOI 10.1016/S0165-0378(98)00090-4; Fujita A, 2000, J CELL SCI, V113, P103; FULCHER KD, 1995, MOL REPROD DEV, V42, P415, DOI 10.1002/mrd.1080420407; FULCHER KD, 1995, BIOL REPROD, V52, P41, DOI 10.1095/biolreprod52.1.41; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Jimenez A, 2002, FEBS LETT, V530, P79, DOI 10.1016/S0014-5793(02)03417-8; Kleene KC, 1996, MOL REPROD DEV, V43, P268, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;268::AID-MRD17&gt;3.0.CO;2-#; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; KONONEN J, 1997, TECHNICAL TIPS ONLIN; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Mandal A, 1999, BIOL REPROD, V61, P1184, DOI 10.1095/biolreprod61.5.1184; Mei XH, 1997, EUR J BIOCHEM, V246, P425, DOI 10.1111/j.1432-1033.1997.t01-1-00425.x; Miki K, 2002, DEV BIOL, V248, P331, DOI 10.1006/dbio.2002.0728; Miranda-Vizuete A, 1998, BIOCHEM BIOPH RES CO, V243, P284, DOI 10.1006/bbrc.1997.8003; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; MORALES CR, 1994, MOL REPROD DEV, V37, P229, DOI 10.1002/mrd.1080370215; Mori C, 1998, MOL REPROD DEV, V49, P374, DOI 10.1002/(SICI)1098-2795(199804)49:4&lt;374::AID-MRD4&gt;3.0.CO;2-K; Naaby-Hansen S, 2002, DEV BIOL, V242, P236, DOI 10.1006/dbio.2001.0527; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; Nakamura K, 1999, FEBS LETT, V445, P9, DOI 10.1016/S0014-5793(99)00087-3; Nakamura Y, 2002, BIOL REPROD, V67, P1, DOI 10.1095/biolreprod67.1.1; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; O'Bryan MK, 2001, MOL REPROD DEV, V58, P116, DOI 10.1002/1098-2795(200101)58:1&lt;116::AID-MRD14&gt;3.0.CO;2-8; Ogawa K, 1996, MOL BIOL CELL, V7, P1895, DOI 10.1091/mbc.7.12.1895; Oko R, 1998, ANDROLOGIA, V30, P193; OKO R, 1989, ANAT REC, V225, P46, DOI 10.1002/ar.1092250108; OKO R, 2001, ANDROLOGY 21 CENTURY, P37; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; Padma P, 2001, GENE, V275, P177, DOI 10.1016/S0378-1119(01)00661-8; Petersen C, 2002, MOL REPROD DEV, V61, P102, DOI 10.1002/mrd.1136; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Sadek CM, 2003, J BIOL CHEM, V278, P13133, DOI 10.1074/jbc.M300369200; Sadek CM, 2001, GENES CELLS, V6, P1077, DOI 10.1046/j.1365-2443.2001.00484.x; Samant SA, 2002, DEV BIOL, V250, P24, DOI 10.1006/dbio.2002.0769; Schalles U, 1998, DEV BIOL, V199, P250, DOI 10.1006/dbio.1998.8931; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Sutovsky P, 1996, BIOL REPROD, V55, P1195, DOI 10.1095/biolreprod55.6.1195; Sutovsky P, 2000, INT REV CYTOL, V195, P1; Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P362, DOI 10.1002/jemt.10350; TASH JS, 1994, J ANDROL, V15, P505; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tres LL, 1996, MOL REPROD DEV, V44, P395, DOI 10.1002/(SICI)1098-2795(199607)44:3<395::AID-MRD13>3.0.CO;2-#; Tung K.S.K., 1985, AUTOIMMUNE DISEASES, P537; Turner RMO, 2001, J ANDROL, V22, P302; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; Williams AC, 2001, J ANDROL, V22, P680; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; Yanagimachi R., 1994, P189; Yu Y, 2002, BIOL REPROD, V67, P1546, DOI 10.1095/biolreprod.102.004838	76	40	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44874	44885		10.1074/jbc.M305475200	http://dx.doi.org/10.1074/jbc.M305475200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12909633	hybrid			2022-12-27	WOS:000186306700123
J	Orlandini, M; Semboloni, S; Oliviero, S				Orlandini, M; Semboloni, S; Oliviero, S			beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEGF-D; TRANSCRIPTIONAL ACTIVATION; COLORECTAL-CANCER; FACTOR FAMILY; DISEASE PROGRESSION; PERMEABILITY FACTOR; SIGNALING PATHWAY; FACTOR EXPRESSION; TYROSINE KINASES; FACTOR GENE	The angiogenic and lymphangiogenic vascular endothelial growth factor (VEGF)-D is the only member of the VEGF family that is not induced by hypoxia or by serum factors, but its induction is mediated by direct cell-cell contact. Here we show that VEGF-D mRNA is down-modulated either by beta-catenin mobilization from the cell membrane, by activation of the Wnt signaling pathway, or by transfection with the beta-catenin stable mutant. Down-modulation of beta-catenin by means of RNA interference showed an increase of VEGF-D mRNA steady state in fibroblasts. The beta-catenin-dependent decrease of VEGF-D mRNA is indirect and mainly due to reduced VEGF- D mRNA stability, as demonstrated by experiments of mRNA decay in the presence of transcription or translation inhibitors. By transient transfection of chimeric constructs carrying fusion of VEGF- D sequences under the control of the cytomegalovirus early promoter, we demonstrated that beta-catenin negative regulation is on the VEGF- D mRNA 3'-untranslated region. We mapped the VEGF- D mRNA-destabilizing element to a sequence, conserved between mouse and human VEGF- D, which contains an AU-rich element of group I. These results unveiled a new regulatory pathway for VEGF- D, which explains, at least in part, VEGF- D regulation in tumor progression.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy	University of Siena	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.		Orlandini, Maurizio/AAF-8247-2020; oliviero, salvatore/R-6657-2019	Orlandini, Maurizio/0000-0002-6112-4889; oliviero, salvatore/0000-0002-3405-765X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; Bankfalvi A, 2002, J PATHOL, V198, P343, DOI 10.1002/path.1204; Barker N, 2000, ADV CANCER RES, V77, P1; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Bright-Thomas RM, 2003, EUR J SURG ONCOL, V29, P107, DOI 10.1053/ejso.2002.1331; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOEN T, 1996, J BIOL CHEM, V271, P736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Easwaran V, 2003, CANCER RES, V63, P3145; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; George ML, 2001, NEOPLASIA, V3, P420, DOI 10.1038/sj.neo.7900186; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ishikawa M, 2003, JPN J CLIN ONCOL, V33, P21, DOI 10.1093/jjco/hyg008; Jenkins NA, 1997, CHROMOSOME RES, V5, P502; Joukov V, 1996, EMBO J, V15, P290; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kurebayashi J, 1999, JPN J CANCER RES, V90, P977, DOI 10.1111/j.1349-7006.1999.tb00844.x; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; MINCHENKO A, 1994, LAB INVEST, V71, P374; Nakamura Y, 2003, CLIN CANCER RES, V9, P716; Nicosia RF, 1998, AM J PATHOL, V153, P11, DOI 10.1016/S0002-9440(10)65539-3; Niki T, 2000, CLIN CANCER RES, V6, P2431; O-charoenrat P, 2001, CANCER-AM CANCER SOC, V92, P556, DOI 10.1002/1097-0142(20010801)92:3<556::AID-CNCR1355>3.0.CO;2-Q; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Orlandini M, 2001, J BIOL CHEM, V276, P6576, DOI 10.1074/jbc.M009573200; Osborne JE, 2002, BRIT J DERMATOL, V146, P1104, DOI 10.1046/j.1365-2133.2002.47322.x; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Pokutta S, 2002, CURR OPIN STRUC BIOL, V12, P255, DOI 10.1016/S0959-440X(02)00318-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Rocchigiani M, 1998, GENOMICS, V47, P207, DOI 10.1006/geno.1997.5079; Semplici F, 2002, ONCOGENE, V21, P3978, DOI 10.1038/sj.onc.1205574; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; White JD, 2002, CANCER RES, V62, P1669; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; Yokoyama Y, 2003, BRIT J CANCER, V88, P237, DOI 10.1038/sj.bjc.6600701; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	64	32	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44650	44656		10.1074/jbc.M304255200	http://dx.doi.org/10.1074/jbc.M304255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920128	hybrid, Green Published			2022-12-27	WOS:000186306700097
J	Bezzi, M; Hasmim, M; Bieler, G; Dormond, O; Ruegg, C				Bezzi, M; Hasmim, M; Bieler, G; Dormond, O; Ruegg, C			Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death - Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITROGEN-CONTAINING BISPHOSPHONATES; BREAST-CANCER CELLS; FARNESYL DIPHOSPHATE SYNTHASE; TYROSINE-PHOSPHATASE SHP-2; IN-VITRO; BONE-RESORPTION; MEVALONATE PATHWAY; INDUCED APOPTOSIS; TNF-ALPHA	Bisphosphonates are potent inhibitors of osteoclast function widely used to treat conditions of excessive bone resorption, including tumor bone metastases. Recent evidence indicates that bisphosphonates have direct cytotoxic activity on tumor cells and suppress angiogenesis, but the associated molecular events have not been fully characterized. In this study we investigated the effects of zoledronate, a nitrogen-containing bisphosphonate, and clodronate, a non-nitrogen-containing bisphosphonate, on human umbilical vein endothelial cell (HUVEC) adhesion, migration, and survival, three events essential for angiogenesis. Zoledronate inhibited HUVEC adhesion mediated by integrin alpha(V)beta(3), but not alpha(5)beta(1), blocked migration and disrupted established focal adhesions and actin stress fibers without modifying cell surface integrin expression level or affinity. Zoledronate treatment slightly decreased HUVEC viability and strongly enhanced tumor necrosis factor (TNF)-induced cell death. HUVEC treated with zoledronate and TNF died without evidence of enhanced annexin-V binding, chromatin condensation, or nuclear fragmentation and caspase dependence. Zoledronate inhibited sustained phosphorylation of focal adhesion kinase (FAK) and in combination with TNF, with and without interferon (IFN) gamma, of protein kinase B (PKB/Akt). Constitutive active PKB/Akt protected HUVEC from death induced by zoledronate and TNF/IFNgamma. Phosphorylation of c-Src and activation of NF-kappaB were not affected by zoledronate. Clodronate had no effect on HUVEC adhesion, migration, and survival nor did it enhanced TNF cytotoxicity. Taken together these data demonstrate that zoledronate sensitizes endothelial cells to TNF-induced, caspase-independent programmed cell death and point to the FAK-PKB/Akt pathway as a novel zoledronate target. These results have potential implications to the clinical use of zoledronate as an anti-angiogenic or anti-cancer agent.	Swiss Inst Expt Canc Res, Lab Ctr Pluridisciplinaire Oncol, Natl Ctr Competence Res Mol Oncol, CH-1066 Epalinges, Switzerland; Univ Lausanne, Sch Med, Ctr Pluridisciplinaire Oncol, CH-1011 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne	Ruegg, C (corresponding author), Swiss Inst Expt Canc Res, Lab Ctr Pluridisciplinaire Oncol, Natl Ctr Competence Res Mol Oncol, 155 Chemin Boveresses, CH-1066 Epalinges, Switzerland.	curzio.ruegg@isrec.unil.ch	Dormond, Olivier/B-5347-2017	Dormond, Olivier/0000-0002-6418-1782; Hasmim, Meriem/0000-0002-7920-2443				Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bartholomew PJ, 1998, J STEROID BIOCHEM, V67, P241, DOI 10.1016/S0960-0760(98)00098-3; Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756-3282(01)00412-4; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; Boissier S, 1997, CANCER RES, V57, P3890; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brown DL, 1999, J CLIN PHARMACOL, V39, P651, DOI 10.1177/00912709922008272; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Eliceiri BP, 2000, CANCER J, V6, pS245; Fang Y, 2001, EUR J BIOCHEM, V268, P4513, DOI 10.1046/j.1432-1327.2001.02376.x; Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80; Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414; Fournier P, 2002, CANCER RES, V62, P6538; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211; Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128; Green JR, 2002, CURR OPIN ONCOL, V14, P609, DOI 10.1097/00001622-200211000-00004; Gupta S, 2002, J CLIN IMMUNOL, V22, P185, DOI 10.1023/A:1016089607548; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hartman GD, 2000, EXPERT OPIN INV DRUG, V9, P1281, DOI 10.1517/13543784.9.6.1281; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Hiraga T, 2001, CANCER RES, V61, P4418; Honda O, 2000, INT J ONCOL, V16, P283; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1999, THROMB HAEMOSTASIS, V82, P481; Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727; Kabir J, 2002, BIOCHEM J, V367, P145, DOI 10.1042/BJ20020665; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood-2003-01-0305; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LASTER SM, 1988, J IMMUNOL, V141, P2629; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Neville-Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305-7372(02)00095-6; Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476; Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375; Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.3.CO;2-C; Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113; Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Sawada K, 2002, CANCER RES, V62, P6015; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297; Shipman CM, 1998, CANCER RES, V58, P5294; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Teitelbaum SL, 2000, J BONE MINER METAB, V18, P344, DOI 10.1007/s007740070007; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; VAN AD, 1996, SCIENCE, V274, P787; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yilmaz A, 1998, INT J CANCER, V77, P592; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang L, 2001, CELL DEATH DIFFER, V8, P528, DOI 10.1038/sj.cdd.4400838	90	129	131	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43603	43614		10.1074/jbc.M308114200	http://dx.doi.org/10.1074/jbc.M308114200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933798	hybrid			2022-12-27	WOS:000186157000108
J	Goldberg, MS; Fleming, SM; Palacino, JJ; Cepeda, C; Lam, HA; Bhatnagar, A; Meloni, EG; Wu, NP; Ackerson, LC; Klapstein, GJ; Gajendiran, M; Roth, BL; Chesselet, MF; Maidment, NT; Levine, MS; Shen, J				Goldberg, MS; Fleming, SM; Palacino, JJ; Cepeda, C; Lam, HA; Bhatnagar, A; Meloni, EG; Wu, NP; Ackerson, LC; Klapstein, GJ; Gajendiran, M; Roth, BL; Chesselet, MF; Maidment, NT; Levine, MS; Shen, J			Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-PROTEIN LIGASE; HUMAN ALPHA-SYNUCLEIN; BODY FORMATION; HUMAN BRAIN; GENE; DISEASE; MUTATIONS; SENSORIMOTOR; FAMILIES	Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Calif Los Angeles, Mental Retardat Res Ctr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Shen, J (corresponding author), Harvard Inst Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	jshen@rics.bwh.harvard.edu	Goldberg, Matthew/T-7827-2019; Roth, Bryan/ABE-7032-2020; Klapstein, Gloria J/AAQ-8614-2020; Shen, Jie/GXH-9449-2022; Roth, Bryan L/F-3928-2010	Roth, Bryan/0000-0002-0561-6520; Goldberg, Matthew/0000-0002-5172-9841				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Asakawa S, 2001, BIOCHEM BIOPH RES CO, V286, P863, DOI 10.1006/bbrc.2001.5490; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; CALABRESI P, 1987, NEUROSCIENCE, V20, P757, DOI 10.1016/0306-4522(87)90239-9; Cepeda C, 2001, J NEUROPHYSIOL, V85, P659, DOI 10.1152/jn.2001.85.2.659; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Cosford RJO, 1996, J NEUROSCI METH, V68, P39, DOI 10.1016/0165-0270(96)00057-X; Dluzen DE, 2001, EXP NEUROL, V170, P121, DOI 10.1006/exnr.2001.7698; DRUCKERCOLIN R, 1991, J NEUROSCI METH, V39, P153, DOI 10.1016/0165-0270(91)90081-A; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Finney N, 2003, J BIOL CHEM, V278, P16054, DOI 10.1074/jbc.C300051200; GARCIAHERNANDEZ F, 1993, PHYSIOL BEHAV, V54, P589, DOI 10.1016/0031-9384(93)90254-D; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; HADI AS, 1992, J ROY STAT SOC B MET, V54, P761; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hayashi S, 2000, MOVEMENT DISORD, V15, P884, DOI 10.1002/1531-8257(200009)15:5<884::AID-MDS1019>3.0.CO;2-8; Hock B J Jr, 2001, Trends Genet, V17, pS7, DOI 10.1016/S0168-9525(01)02449-0; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitada T, 2000, NEUROGENETICS, V2, P207, DOI 10.1007/s100489900083; Kitada T, 2000, MAMM GENOME, V11, P417, DOI 10.1007/s003350010080; Klapstein GJ, 2001, J NEUROPHYSIOL, V86, P2667, DOI 10.1152/jn.2001.86.6.2667; Klein C, 2000, ANN NEUROL, V48, P65, DOI 10.1002/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L; Kosel S, 1999, BIOL CHEM, V380, P865, DOI 10.1515/BC.1999.106; Kozak M, 2001, NUCLEIC ACIDS RES, V29, P5226, DOI 10.1093/nar/29.24.5226; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Levine MS, 1996, SYNAPSE, V24, P65, DOI 10.1002/syn.890240102; LJUNGBERG T, 1976, EXP NEUROL, V53, P585, DOI 10.1016/0014-4886(76)90140-0; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Menalled LB, 2002, TRENDS PHARMACOL SCI, V23, P32, DOI 10.1016/S0165-6147(00)01884-8; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Murphy NP, 2001, J NEUROCHEM, V79, P626, DOI 10.1046/j.1471-4159.2001.00599.x; PARSONS LH, 1994, CRIT REV NEUROBIOL, V8, P189; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ren Y, 2003, J NEUROSCI, V23, P3316; Richfield EK, 2002, EXP NEUROL, V175, P35, DOI 10.1006/exnr.2002.7882; ROTH BL, 1987, J NEUROCHEM, V49, P1833, DOI 10.1111/j.1471-4159.1987.tb02444.x; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; SCHALLERT T, 1988, ANN NY ACAD SCI, V515, P108, DOI 10.1111/j.1749-6632.1988.tb32972.x; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHALLERT T, 1983, PHARMACOL BIOCHEM BE, V18, P753, DOI 10.1016/0091-3057(83)90019-9; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schallert T, 2000, CONT NEUROS, P131; Shapiro DA, 2003, NEUROPSYCHOPHARMACOL, V28, P1400, DOI 10.1038/sj.npp.1300203; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; TANNER CM, 1990, NEUROLOGY, V40, P17; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; WALSH SL, 1992, J PHARMACOL EXP THER, V263, P617; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Yu HK, 2000, GENESIS, V26, P5, DOI 10.1002/(SICI)1526-968X(200001)26:1<5::AID-GENE3>3.0.CO;2-8; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	68	661	678	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43628	43635		10.1074/jbc.M308947200	http://dx.doi.org/10.1074/jbc.M308947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930822	Green Published, hybrid			2022-12-27	WOS:000186157000111
J	Higashi, K; Inagaki, Y; Fujimori, K; Nakao, A; Kaneko, H; Nakatsuka, I				Higashi, K; Inagaki, Y; Fujimori, K; Nakao, A; Kaneko, H; Nakatsuka, I			Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE-EXPRESSION; BOX-BINDING-PROTEIN; HUMAN SKIN FIBROBLASTS; MEDIATES TRANSCRIPTIONAL REPRESSION; NECROSIS-FACTOR-ALPHA; TGF-BETA; MESSENGER-RNA; INHIBITION; ELEMENT; STIMULATION	Transforming growth factor-beta (TGF-beta) and interferon-gamma ( IFN-gamma) exert antagonistic effects on collagen synthesis in human dermal fibroblasts. We have recently shown that Y box-binding protein YB-1 mediates the inhibitory effects of IFN-gamma on alpha2(I) procollagen gene (COL1A2) transcription through the IFN-gamma response element located between - 161 and - 150. Here we report that YB-1 counter-represses TGF-beta-stimulated COL1A2 transcription by interfering with Smad3 bound to the upstream sequence around - 265 and subsequently by interrupting the Smad3-p300 interaction. Western blot and immunofluorescence analyses using inhibitors for Janus kinases or casein kinase II suggested that the casein kinase II-dependent signaling pathway mediates IFN-gamma-induced nuclear translocation of YB-1. Down-regulation of endogenous YB-1 expression by double-stranded YB-1-specific RNA abrogated the transcriptional repression of COL1A2 by IFN-gamma in the absence and presence of TGF-beta. In transient transfection assays, overexpression of YB-1 in human dermal fibroblasts exhibited antagonistic actions against TGF-beta and Smad3. Physical interaction between Smad3 and YB- 1 was demonstrated by immunoprecipitation-Western blot analyses, and electrophoretic mobility shift assays using the recombinant Smad3 and YB- 1 proteins indicated that YB- 1 forms a complex with Smad3 bound to the Smad-binding element. Glutathione S-transferase pull-down assays showed that YB- 1 binds to the MH1 domain of Smad3, whereas the central and carboxyl-terminal regions of YB- 1 were required for its interaction with Smad3. YB- 1 also interferes with the Smad3-p300 interaction by its preferential binding to p300. Altogether, the results provide a novel insight into the mechanism by which IFN-gamma/ YB-1 counteracts TGF-beta/Smad3. They also indicate that IFN-gamma/YB-1 inhibits COL1A2 transcription by dual actions: via the IFN-gamma response element and through a cross-talk with the TGF-beta/Smad signaling pathway.	Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Konohana Ku, Osaka 5548558, Japan; Tokai Univ, Sch Med, Dept Community Hlth, Kanagawa 2591193, Japan; Juntendo Univ, Sch Med, Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan	Sumitomo Chem Co Ltd; Tokai University; Juntendo University	Higashi, K (corresponding author), Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Konohana Ku, Osaka 5548558, Japan.	higashik2@sc.sumitomo-chem.co.jp	Fujimori, Ko/AAD-5428-2021	Fujimori, Ko/0000-0002-2506-0769; HIGASHI, KIYOSHI/0000-0003-3577-0526				Chen CW, 2002, BRIT J PHARMACOL, V137, P1011, DOI 10.1038/sj.bjp.0704955; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; ELDER GA, 1992, NUCLEIC ACIDS RES, V20, P6281, DOI 10.1093/nar/20.23.6281; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Goodman RH, 2000, GENE DEV, V14, P1553; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Higashi K, 1998, MATRIX BIOL, V16, P447, DOI 10.1016/S0945-053X(98)90016-6; Higashi K, 2003, J BIOL CHEM, V278, P5156, DOI 10.1074/jbc.M208724200; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Hughes TR, 2002, J BIOL CHEM, V277, P11097, DOI 10.1074/jbc.M106774200; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; JACOB G, 1999, P NATL ACAD SCI USA, V96, P12719; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Mead JR, 2003, J BIOL CHEM, V278, P17741, DOI 10.1074/jbc.M301602200; Montani V, 1998, ENDOCRINOLOGY, V139, P280, DOI 10.1210/en.139.1.280; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Norman JT, 2001, J BIOL CHEM, V276, P29880, DOI 10.1074/jbc.M103145200; Ohga T, 1996, CANCER RES, V56, P4224; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Skabkin MA, 2001, J BIOL CHEM, V276, P44841, DOI 10.1074/jbc.M107581200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	51	135	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43470	43479		10.1074/jbc.M302339200	http://dx.doi.org/10.1074/jbc.M302339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917425	hybrid			2022-12-27	WOS:000186157000092
J	Jiang, XP; Newell, EW; Schlichter, LC				Jiang, XP; Newell, EW; Schlichter, LC			Regulation of a TRPM7-like current in rat brain microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC TYROSINE KINASE; T-LYMPHOCYTES; MIC CHANNELS; K+ CHANNELS; INTERMEDIATE CONDUCTANCE; CELLS; ACTIVATION; CRAC; TRP; PROTEIN	Non-excitable cells use Ca2+ influx for essential functions but usually lack voltage-gated Ca2+ channels. The main routes of Ca2+ entry appear to be store-operated channels or Ca2+-permeable non-selective cation channels, of which the magnesium-inhibited cation ( or magnesium-nucleotide-regulated metal cation) current has received considerable recent attention. This current appears to be produced by one of the recently cloned transient receptor potential (TRP) channels, TRPM7. In this study of rat microglia, we identified TRPM7 transcripts and a prevalent current with the hallmark biophysical and pharmacological features of TRPM7. This is the first identification of a TRPM7-like current in the brain. There is little known about how members of the TRPM sub-family normally become activated. Using whole-cell patch clamp recordings from rat microglia, we found that the TRPM7-like current activates spontaneously after break- in and that the current and its activation are inhibited by elevated intracellular Mg2+ but not affected by cell swelling or a wide range of intracellular Ca2+ concentrations. The TRPM7-like current in microglia appears to depend on tyrosine phosphorylation. It was inhibited by several tyrosine kinase inhibitors, including a peptide (Src 40 - 58) that was shown previously to inhibit Src actions, but not by inactive drugs or peptide analogues. The current did not depend on the cell activation state; i.e. it was the same in microglia recently removed from the brain or when cultured under a wide range of conditions that favor the resting or activated state. Because TRPM7 channels are permeable to Ca2+, this current may be important for microglia functions that depend on elevations in intracellular Ca2+.	Toronto Western Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Schlichter, LC (corresponding author), Toronto Western Inst, Div Cellular & Mol Biol, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Newell, Evan/F-9711-2012	Newell, Evan/0000-0002-2889-243X				Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Attali B, 1997, J NEUROSCI, V17, P8234; Aussel C, 1996, BIOCHEM J, V313, P909, DOI 10.1042/bj3130909; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; Cayabyab FS, 2002, J BIOL CHEM, V277, P13673, DOI 10.1074/jbc.M108211200; Chandy KG, 2001, TOXICON, V39, P1269, DOI 10.1016/S0041-0101(01)00120-9; Clapham DE, 2002, J GEN PHYSIOL, V120, P217, DOI 10.1085/jgp.20028618; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; COLTON CA, 1994, AM J PHYSIOL, V266, pC1650, DOI 10.1152/ajpcell.1994.266.6.C1650; Daeron M, 1997, Int Rev Immunol, V16, P1, DOI 10.3109/08830189709045701; Eder C, 1999, EUR J NEUROSCI, V11, P4251, DOI 10.1046/j.1460-9568.1999.00852.x; Fujishima H, 1998, INT J CANCER, V76, P423; Grubbs RD, 2002, BIOMETALS, V15, P251, DOI 10.1023/A:1016026831789; Hahn J, 2000, GLIA, V31, P118, DOI 10.1002/1098-1136(200008)31:2<118::AID-GLIA30>3.0.CO;2-0; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Illes P, 1996, NEUROCHEM INT, V29, P13; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 2001, CURR DRUG TARGETS, V2, P401, DOI 10.2174/1389450013348173; Kerschbaum HH, 2003, BIOPHYS J, V84, P2293, DOI 10.1016/S0006-3495(03)75035-8; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KODAMA I, 1987, J MOL CELL CARDIOL, V19, P367, DOI 10.1016/S0022-2828(87)80582-5; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Schilling T, 2000, AM J PHYSIOL-CELL PH, V279, pC1123, DOI 10.1152/ajpcell.2000.279.4.C1123; Schilling T, 2002, NEUROSCIENCE, V109, P827, DOI 10.1016/S0306-4522(01)00534-6; Schlichter LC, 1996, GLIA, V17, P225, DOI 10.1002/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#; SCHLICHTER LC, 2002, POTASSIUM CHANNELS P; SCHUMACHER PA, 1995, J MEMBRANE BIOL, V145, P217; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; WATSKY MA, 1995, AM J PHYSIOL-CELL PH, V268, pC1179, DOI 10.1152/ajpcell.1995.268.5.C1179; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	57	115	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42867	42876		10.1074/jbc.M304487200	http://dx.doi.org/10.1074/jbc.M304487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904301	hybrid			2022-12-27	WOS:000186157000018
J	McKallip, RJ; Fisher, M; Do, Y; Szakal, AK; Gunthert, U; Nagarkatti, PS; Nagarkatti, M				McKallip, RJ; Fisher, M; Do, Y; Szakal, AK; Gunthert, U; Nagarkatti, PS; Nagarkatti, M			Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT INTERLEUKIN-2; ADHESION MOLECULES; VARIANT ISOFORMS; HYALURONIC-ACID; T-CELLS; INVOLVEMENT; ACTIVATION; VASCULITIS; TOXICITY; RECEPTOR	In the current study, we investigated the nature and role of CD44 variant isoforms involved in endothelial cell (EC) injury and tumor cell cytotoxicity mediated by IL-2-activated killer (LAK) cells. Treatment of CD44 wild-type lymphocytes with IL-2 led to increased gene expression of CD44 v6 and v7 variant isoforms and to significant induction of vascular leak syndrome (VLS). CD44v6-v7 knockout (KO) and CD44v7 KO mice showed markedly reduced levels of IL-2-induced VLS. The decreased VLS in CD44v6-v7 KO and CD44v7 KO mice did not result from differential activation and expansion of CD8(+) T cells, NK, and NK-T cells or from altered degree of perivascular lymphocytic infiltration in the lungs. LAK cells from CD44v7 KO mice showed a significant decrease in their ability to adhere to and mediate lysis of EC but not lysis of P815 tumor cells in vitro. CD44v7-mediated lysis of EC by LAK cells was dependent on the activity of phosphatidylinositol 3-kinase and tyrosine kinases. Interestingly, IL-2-activated LAK cells expressing CD44(hi) but not CD44(lo) were responsible for EC lysis. Furthermore, lysis of EC targets could be blocked by addition of soluble or enzymatic cleavage of CD44v6-v7-binding glycosaminoglycans. Finally, anti-CD44v7 mAbs caused a significant reduction in the adherence to and killing of EC and led to suppression of IL-2-induced VLS. Together, this study suggests that the expression of CD44v7 on LAK cells plays a specific role in EC injury and that it may be possible to reduce EC injury but not tumor cell killing by specifically targeting CD44v7.	Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA; Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Basel	Nagarkatti, M (corresponding author), Virginia Commonwealth Univ, Dept Microbiol & Immunol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	mnagark@hsc.vcu.edu	Do, Yoonkyung/F-5231-2010	Do, Yoonkyung/0000-0001-7947-4767; Nagarkatti, Prakash/0000-0003-2663-0759	NCI NIH HHS [P30 CA 16059] Funding Source: Medline; NHLBI NIH HHS [R01 HL058641, F32 HL 10455] Funding Source: Medline; NIAID NIH HHS [R01AI053703] Funding Source: Medline; NIDA NIH HHS [R21 DA 014885, R01 DA016545] Funding Source: Medline; NIEHS NIH HHS [R01 ES09098, F32 ES011732] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010455, R01HL058641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES011732, R01ES009098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016545, R21DA014885] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Baluna R, 1997, IMMUNOPHARMACOLOGY, V37, P117, DOI 10.1016/S0162-3109(97)00041-6; Baluna R, 1999, P NATL ACAD SCI USA, V96, P3957, DOI 10.1073/pnas.96.7.3957; BECHARD DE, 1989, AM J MED SCI, V298, P28, DOI 10.1097/00000441-198907000-00005; Beekhuizen H, 1998, TRANSPL P, V30, P4251, DOI 10.1016/S0041-1345(98)01405-5; Chen DW, 2001, J IMMUNOL, V166, P5889, DOI 10.4049/jimmunol.166.10.5889; Christ O, 2001, J LEUKOCYTE BIOL, V69, P343; DAMLE NK, 1987, J IMMUNOL, V138, P1779; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DOHERTY PC, 1990, IMMUNOL TODAY, V11, P55; Estess P, 1999, J EXP MED, V190, P9, DOI 10.1084/jem.190.1.9; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; GALANDRINI R, 1994, J IMMUNOL, V153, P4399; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; HAMMOND DM, 1993, J EXP MED, V178, P2225, DOI 10.1084/jem.178.6.2225; HAMMONDMCKIBBEN DM, 1995, INT J CANCER, V60, P828, DOI 10.1002/ijc.2910600618; HEWICKER M, 1987, LAB ANIM, V21, P335, DOI 10.1258/002367787781363408; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; LESLEY J, 1992, EUR J IMMUNOL, V22, P2719, DOI 10.1002/eji.1830221036; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LI L, 1994, J IMMUNOL, V153, P3967; Liu DC, 1996, CELL IMMUNOL, V174, P73, DOI 10.1006/cimm.1996.0295; Malaguarnera M, 2001, EUR J CLIN PHARMACOL, V57, P267, DOI 10.1007/s002280100321; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Matsumoto G, 1998, J IMMUNOL, V160, P5781; MCCLUSKEY RT, 1983, HUM PATHOL, V14, P305, DOI 10.1016/S0046-8177(83)80116-6; McKallip RJ, 2002, INT IMMUNOL, V14, P1015, DOI 10.1093/intimm/dxf068; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; MOYER CF, 1984, AM J PATHOL, V117, P380; Nakajima T, 2002, CIRCULATION, V105, P570, DOI 10.1161/hc0502.103348; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; PEACE DJ, 1989, J EXP MED, V169, P161, DOI 10.1084/jem.169.1.161; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Rafi AQ, 1998, J IMMUNOL, V161, P3077; Rafi-Janajreh AQ, 1999, J IMMUNOL, V163, P1619; Rafi-Janajreh Asimah Q., 1998, Frontiers in Bioscience, V3, pD665; Robinson MJ, 2002, J BIOL CHEM, V277, P3658, DOI 10.1074/jbc.M102950200; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Sconocchia G, 1997, BLOOD, V90, P716, DOI 10.1182/blood.V90.2.716.716_716_725; Seiter S, 2000, INT IMMUNOL, V12, P37, DOI 10.1093/intimm/12.1.37; SETH A, 1991, P NATL ACAD SCI USA, V88, P7877, DOI 10.1073/pnas.88.17.7877; Sleeman JP, 1997, J BIOL CHEM, V272, P31837, DOI 10.1074/jbc.272.50.31837; TSUKADA N, 1993, J NEUROL SCI, V117, P140, DOI 10.1016/0022-510X(93)90166-V; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UDAKA K, 1970, P SOC EXP BIOL MED, V133, P1384; Van Driel M, 2002, LEUKEMIA, V16, P135, DOI 10.1038/sj.leu.2402336; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; VIAL T, 1995, DRUG SAFETY, V13, P371, DOI 10.2165/00002018-199513060-00006; Wittig B, 1998, J IMMUNOL, V161, P1069; Wittig BM, 2000, J EXP MED, V191, P2053, DOI 10.1084/jem.191.12.2053; Yoneda O, 2000, J IMMUNOL, V164, P4055, DOI 10.4049/jimmunol.164.8.4055	55	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43818	43830		10.1074/jbc.M304467200	http://dx.doi.org/10.1074/jbc.M304467200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904302	Green Accepted, hybrid			2022-12-27	WOS:000186157000132
J	Wick, MJ; Ramos, FJ; Chen, H; Quon, MJ; Dong, LQ; Liu, F				Wick, MJ; Ramos, FJ; Chen, H; Quon, MJ; Dong, LQ; Liu, F			Mouse 3-phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans-phosphorylation in the activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DOCKING SITE; PDK1; IDENTIFICATION; MECHANISM; POCKET; PKC	Activation of mouse 3-phosphoinositide-dependent protein kinase-1 (mPDK1) requires phosphorylation at a conserved serine residue, Ser(244), in the activation loop. However, the mechanism by which mPDK1 is phosphorylated at this site remains unclear. We have found that kinase-defective mPDK1 (mPDK1(KD)), but not a kinase-defective mPDK1 in which Ser(244) was replaced with alanine (mPDK1(KD/S244A)), is significantly phosphorylated in intact cells and is a direct substrate of wild-type mPDK1 fused to the yellow fluorescence protein. Phosphoamino acid analysis and phosphopeptide mapping studies revealed that mPDK1 trans-autophosphorylation occurred mainly on Ser(244). On the other hand, Ser(399) and Thr(516), two recently identified autophosphorylation sites of mPDK1, are phosphorylated primarily through a cis mechanism. In vivo labeling studies revealed that insulin stimulated both mPDK1KD and mPDK1(KD/S244A) phosphorylation in Chinese hamster ovary cells overexpressing the insulin receptor. However, Western blot analysis using a phosphospecific antibody revealed no increase in insulin-stimulated phosphorylation of Ser244 in these cells overexpressing mPDK1. mPDK1 undergoes dimerization in cells and this self-association is enhanced by kinase inactivation. Deletion of the extreme C terminus disrupts mPDK1 dimerization and Ser(244) trans-phosphorylation, suggesting that dimerization is important for mPDK1 transphosphorylation. Taken together, our results show that mPDK1 autophosphorylation occurs at multiple sites through both cis and trans mechanisms and suggest that dimerization and trans-phosphorylation may serve as mechanisms to regulate PDK1 activity in cells.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; NCCAM, Diabet Unit, Clin Invest Lab, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Quon, Michael/B-1970-2008	Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000002, ZIAAT000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56166] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen H, 2001, BIOCHEMISTRY-US, V40, P11851, DOI 10.1021/bi010743c; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2002, BIOCHEM BIOPH RES CO, V294, P136, DOI 10.1016/S0006-291X(02)00449-7; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209; Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	23	53	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42913	42919		10.1074/jbc.M304172200	http://dx.doi.org/10.1074/jbc.M304172200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923190	hybrid			2022-12-27	WOS:000186157000024
J	Yellaturu, CR; Rao, GN				Yellaturu, CR; Rao, GN			A requirement for calcium-independent phospholipase A(2) in thrombin-induced arachidonic acid release and growth in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P388D(1) MACROPHAGES; PHOSPHATIDATE PHOSPHOHYDROLASE; SIGNAL-TRANSDUCTION; BROMOENOL LACTONE; METABOLITES; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION	Thrombin is a potent mitogen for vascular smooth muscle cells (VSMC). To understand its mitogenic signaling events, we have studied the role of calcium-independent phospholipase A(2) (iPLA(2)). Without affecting its levels, thrombin increased iPLA(2) activity in a time-dependent manner in VSMC. Thrombin also induced arachidonic acid release and DNA synthesis by about 2-fold as compared with control. Down-regulation of iPLA(2) activity by its specific inhibitor, bromoenol lactone, or its expression by antisense oligonucleotides, significantly reduced thrombin-induced arachidonic acid release and DNA synthesis in VSMC. To learn the mechanism of thrombin-stimulated iPLA(2) activity, we next tested the role of p38 MAPK. Thrombin stimulated p38 MAPK phosphorylation and activity in a time-dependent manner in VSMC. Inhibition of p38 MAPK activity by SB203580 and SB202190 resulted in decreased iPLA(2) activity, arachidonic acid release, and DNA synthesis induced by thrombin in VSMC. Together, these results for the first time demonstrate that iPLA(2) plays a role in thrombin-induced arachidonic acid release and growth in VSMC and that these responses are mediated by p38 MAPK.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu			NHLBI NIH HHS [R01 HL64165] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; BACHHUBER BG, 1995, AM J PHYSIOL-CELL PH, V268, pC1141, DOI 10.1152/ajpcell.1995.268.5.C1141; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Ehsan A, 2000, VASC MED, V5, P103, DOI 10.1191/135886300668426194; Ettenson DS, 2000, VASC MED, V5, P97; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Ghosh SK, 2002, J BIOL CHEM, V277, P21325, DOI 10.1074/jbc.M201608200; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; Panini SR, 2001, J LIPID RES, V42, P1678; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Pfister SL, 1998, J BIOL CHEM, V273, P30879, DOI 10.1074/jbc.273.47.30879; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Steer SA, 2002, AM J PHYSIOL-CELL PH, V283, pC1621, DOI 10.1152/ajpcell.00109.2002; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Yellaturu CR, 2003, J BIOL CHEM, V278, P9986, DOI 10.1074/jbc.M211276200	46	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43831	43837		10.1074/jbc.M301472200	http://dx.doi.org/10.1074/jbc.M301472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928445	hybrid			2022-12-27	WOS:000186157000133
J	Christian, SL; Lee, RL; McLeod, SJ; Burgess, AE; Li, AHY; Dang-Lawson, M; Lin, KBL; Gold, MR				Christian, SL; Lee, RL; McLeod, SJ; Burgess, AE; Li, AHY; Dang-Lawson, M; Lin, KBL; Gold, MR			Activation of the Rap GTPases in B lymphocytes modulates B cell antigen receptor-induced activation of Akt but has no effect on MAPK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE-3; NUCLEOTIDE EXCHANGE FACTOR; SIGNAL-REGULATED KINASE; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; T-CELL; PHOSPHOINOSITIDE 3-KINASE-GAMMA; PHOSPHOLIPASE C-GAMMA-2	Signaling by the B cell antigen receptor (BCR) activates the Rap1 and Rap2 GTPases, putative antagonists of Ras-mediated signaling. Because Ras can activate the Raf-1/ERK pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, we asked whether Rap activation limits the ability of the BCR to signal via these pathways. To do this, we blocked the activation of endogenous Rap1 and Rap2 by expressing the Rap-specific GTPase-activating protein RapGAPII. Preventing Rap activation had no effect on BCR-induced activation of ERK. In contrast, BCR-induced phosphorylation of Akt on critical activating sites was increased 2- to 3-fold when Rap activation was blocked. Preventing Rap activation also increased the ability of the BCR to stimulate Akt-dependent phosphorylation of the FKHR transcription factor on negative regulatory sites and decreased the levels of p27(Kip1), a pro-apoptotic factor whose transcription is enhanced by FKHR. Moreover, preventing Rap activation reduced BCR-induced cell death in the WEHI-231 B cell line. Thus activation of endogenous Rap by the BCR limits BCR-induced activation of the PI3K/Akt pathway, opposes the subsequent inhibition of the FKHR/p27(Kip1) pro-apoptotic module, and enhances BCR-induced cell death. Consistent with the idea that Rap-GTP is a negative regulator of the PI3K/Akt pathway, expressing constitutively active Rap2 (Rap2V12) reduced BCR-induced phosphorylation of Akt and FKHR. Finally, our finding that Rap2V12 can bind PI3K and inhibit its activity in a manner that depends upon BCR engagement provides a potential mechanism by which Rap-GTP limits activation of the PI3K/Akt pathway, a central regulator of B cell growth and survival.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Gold, MR (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	mgold@interchange.ubc.ca	Gold, Michael/AAF-2081-2021	Gold, Michael/0000-0003-1222-3191; Christian, Sherri/0000-0002-4289-4386				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buensuceso CS, 2000, J BIOL CHEM, V275, P13118, DOI 10.1074/jbc.275.17.13118; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; Carey GB, 2000, IMMUNOL REV, V176, P105; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Christian SL, 2002, J IMMUNOL, V169, P758, DOI 10.4049/jimmunol.169.2.758; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Czyzyk J, 2000, MOL CELL BIOL, V20, P8740, DOI 10.1128/MCB.20.23.8740-8747.2000; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Gold MR, 2002, TRENDS PHARMACOL SCI, V23, P316, DOI 10.1016/S0165-6147(02)02045-X; Gold MR, 1999, J IMMUNOL, V163, P1894; GOLD MR, 1992, J IMMUNOL, V148, P2012; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Jacob A, 2002, J BIOL CHEM, V277, P23420, DOI 10.1074/jbc.M202485200; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katner AL, 2002, PROSTATE, V53, P77, DOI 10.1002/pros.10124; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; King LB, 1999, J IMMUNOL, V162, P2655; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Krebs Danielle L., 1999, Methods in Cell Science, V21, P57, DOI 10.1023/A:1009843325770; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marshall AJ, 2000, IMMUNOL REV, V176, P30; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; Onishi M, 1996, EXP HEMATOL, V24, P324; Ozes ON, 1999, NATURE, V401, P82; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; SATO KY, 1994, CANCER RES, V54, P552; Sawada Y, 2001, J CELL SCI, V114, P1221; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shimizu Y, 2000, Immunol Today, V21, P597, DOI 10.1016/S0167-5699(00)01783-7; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Ting HC, 2002, IMMUNOL LETT, V82, P205, DOI 10.1016/S0165-2478(02)00044-5; TORDAI A, 1994, J BIOL CHEM, V269, P7538; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Wu M, 1999, J IMMUNOL, V163, P6530; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	84	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41756	41767		10.1074/jbc.M303180200	http://dx.doi.org/10.1074/jbc.M303180200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904304	hybrid			2022-12-27	WOS:000185989500027
J	Mantovani, F; Banks, L				Mantovani, F; Banks, L			Regulation of the discs large tumor suppressor by a phosphorylation-dependent interaction with the beta-TrCP ubiquitin ligase receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; HUMAN-PAPILLOMAVIRUS E6; F-BOX PROTEIN; P105 REQUIRES PHOSPHORYLATION; HUMAN HOMOLOG; MEDIATED DEGRADATION; EPITHELIAL-CELLS; RECRUITS SAP97; CATENIN; KINASE	The discs large (hDlg) tumor suppressor is intimately involved in the control of cell contact, polarity, and proliferation by interacting with several components of the epithelial junctional complex and with the APC tumor suppressor protein. In epithelial cells, hDlg protein stability is regulated through the ubiquitin-proteasome pathway: hDlg is actively degraded in isolated cells, whereas it accumulates upon cell-cell contact. During neoplastic transformation of epithelial cells, loss of the differentiated morphology and progression toward a metastatic phenotype correlate with down-regulation of hDlg levels and loss of contact-dependent stabilization. Here we show that upon hyperphosphorylation, hDlg interacts with the beta-TrCP ubiquitin ligase receptor through a DSGLPS motif within its Src homology 3 domain. As a consequence, overexpression of beta-TrCP enhances ubiquitination of Dlg protein and decreases its stability, whereas a dominant negative beta-TrCP mutant inhibits this process. Furthermore, a mutant Dlg protein that is unable to bind beta-TrCP displays a higher protein stability and is insensitive to beta-TrCP. Using RNA interference, we also demonstrate that endogenous beta-TrCP regulates hDlg protein levels in epithelial cells. Finally, we show that beta-TrCP selectively induces the degradation of the membrane-cytoplasmic pool, without affecting the nuclear pool of hDlg.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Mantovani, F (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	mantovani@area.trieste.it; banks@icgeb.org						Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mantovani F, 2001, J CELL SCI, V114, P4285; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Reuver SM, 1998, J CELL SCI, V111, P1071; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	55	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42477	42486		10.1074/jbc.M302799200	http://dx.doi.org/10.1074/jbc.M302799200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902344	hybrid			2022-12-27	WOS:000185989500112
J	McAlinden, A; Smith, TA; Sandell, LJ; Ficheux, D; Parry, DAD; Hulmes, DJS				McAlinden, A; Smith, TA; Sandell, LJ; Ficheux, D; Parry, DAD; Hulmes, DJS			alpha-helical coiled-coil oligomerization domains are almost ubiquitous in the collagen superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TRIPLE-HELIX; CRYSTAL-STRUCTURE; METAPHYSEAL CHONDRODYSPLASIA; FIBRILLAR COLLAGEN; NC1 DOMAIN; OSTEOGENESIS IMPERFECTA; MOLECULAR RECOGNITION; PRO-ALPHA-1(I) CHAIN; EXTRACELLULAR-MATRIX	alpha-Helical coiled coils are widely occurring protein oligomerization motifs. Here we show that most members of the collagen superfamily contain short, repeating heptad sequences typical of coiled coils. Such sequences are found at the N-terminal ends of the C-propeptide domains in all fibrillar procollagens. When fused C-terminal to a reporter molecule containing a collagen-like sequence that does not spontaneously trimerize, the C-propeptide heptad repeats induced trimerization. C-terminal heptad repeats were also found in the oligomerization domains of the multiplexins (collagens XV and XVIII). N-terminal heptad repeats are known to drive trimerization in transmembrane collagens, whereas fibril-associated collagens with interrupted triple helices, as well as collagens VII, XIII, XXIII, and XXV, were found to contain heptad repeats between collagen domains. Finally, heptad repeats were found in the von Willebrand factor A domains known to be involved in trimerization of collagen VI, as well as in collagen VII. These observations suggest that coiled-coil oligomerization domains are widely used in the assembly of collagens and collagen-like proteins.	Univ Lyon 1, CNRS, UMR 5086, IBCP, F-69367 Lyon 07, France; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthoped Surg, St Louis, MO 63110 USA; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Barnes-Jewish Hospital; Washington University (WUSTL); Massey University	Hulmes, DJS (corresponding author), Univ Lyon 1, CNRS, UMR 5086, IBCP, 7 Passage Vercors, F-69367 Lyon 07, France.	d.hulmes@ibcp.fr		Hulmes, David/0000-0002-0651-1317; McAlinden, Audrey/0000-0001-8433-4224; Lynch, Thomasin/0000-0001-8253-2024	NIAMS NIH HHS [AR 48250-01, AR 36994] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR048250, R01AR036994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Areida SK, 2001, J BIOL CHEM, V276, P1594, DOI 10.1074/jbc.M008709200; Balding SD, 1997, BIOCHEMISTRY-US, V36, P8821, DOI 10.1021/bi970675n; Ball SG, 2001, J BIOL CHEM, V276, P7422, DOI 10.1074/jbc.M002816200; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; BATEMAN JF, 1989, J BIOL CHEM, V264, P10960; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; Brown JH, 1996, PROTEINS, V26, P134; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Engel J, 2000, MATRIX BIOL, V19, P283, DOI 10.1016/S0945-053X(00)00075-5; Exposito JY, 2002, ANAT RECORD, V268, P302, DOI 10.1002/ar.10162; Frank S, 2003, J BIOL CHEM, V278, P7747, DOI 10.1074/jbc.C200698200; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; Gordon MK, 2002, FASEB J, V16, pA359; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hohenester E, 2002, MATRIX BIOL, V21, P115, DOI 10.1016/S0945-053X(01)00191-3; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Illidge C, 2001, INT J BIOCHEM CELL B, V33, P521, DOI 10.1016/S1357-2725(01)00013-9; KADLER K, 1995, PROTEIN PROFILE, V2, P491; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Lamande SR, 2002, J BIOL CHEM, V277, P1949, DOI 10.1074/jbc.M109932200; Latvanlehto A, 2003, J BIOL CHEM, V278, P37590, DOI 10.1074/jbc.M305974200; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lesage A, 1996, BIOCHEMISTRY-US, V35, P9647, DOI 10.1021/bi952666p; Lim AL, 1998, J CELL BIOCHEM, V71, P216, DOI 10.1002/(SICI)1097-4644(19981101)71:2<216::AID-JCB7>3.3.CO;2-K; Litowski JR, 2001, J PEPT RES, V58, P477, DOI 10.1034/j.1399-3011.2001.10972.x; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Mazzorana M, 2001, J BIOL CHEM, V276, P27989, DOI 10.1074/jbc.M101633200; McAlinden A, 2002, J BIOL CHEM, V277, P41274, DOI 10.1074/jbc.M202257200; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; Oganesian A, 1997, J HISTOCHEM CYTOCHEM, V45, P1469, DOI 10.1177/002215549704501104; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; Sasaki T, 2000, J MOL BIOL, V301, P1179, DOI 10.1006/jmbi.2000.3996; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sato K, 2002, J BIOL CHEM, V277, P37678, DOI 10.1074/jbc.M205347200; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	68	68	85	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42200	42207		10.1074/jbc.M302429200	http://dx.doi.org/10.1074/jbc.M302429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920133	hybrid			2022-12-27	WOS:000185989500078
J	Pyhtila, B; Rexach, M				Pyhtila, B; Rexach, M			A gradient of affinity for the karyopherin Kap95p along the yeast nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IMPORTIN-BETA; PROTEIN INTERACTIONS; NUCLEOPORIN; NUP2P; TRANSPORT; EXPORT; SRP1P/IMPORTIN-ALPHA; IDENTIFICATION; TRANSLOCATION	Karyopherins (Kaps) transport cargo across the nuclear pore complex (NPC) by interacting with nucleoporins that contain phenylalanine-glycine (FG) peptide repeats (FG Nups). As a test of the "affinity gradient" model for Kap translocation, we measured the apparent affinity of Kap95p to FG Nups representing three distinct regions of the S. cerevisiae NPC. We find that the affinity of Kap95p-Kap60p-cargo complexes to Nup1p (a nuclear basket Nup) is 225-fold higher than to Nup100p (a central scaffold Nup) and 4000-fold higher than to Nup42p (a cytoplasmic filament Nup), revealing a steep gradient of affinity for Kap95p complexes along the yeast NPC. A high affinity binding site for a Kap95p import complex was mapped to the C terminus of Nup1p, and, surprisingly, deletion of all FG repeats in that region did not eliminate binding of the complex. Instead, a 36-amino acid truncation of the C terminus of Nup1p reduced its affinity for the Kap95p import complex by 450-fold. Mutant yeast that express Nup1pDelta36 instead of full-length Nup1p display specific defects in Kap95p localization and Kap95p-mediated nuclear import. We conclude that a high affinity binding site for Kap95p at the nuclear basket increases the translocation efficiency of Kap95p import complexes across the NPC.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Rexach, M (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.				NIGMS NIH HHS [R01 GM 61900-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen NPC, 2002, MOL CELL PROTEOMICS, V1, P930, DOI 10.1074/mcp.T200012-MCP200; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Blobel G, 1995, COLD SPRING HARB SYM, V60, P1; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Denning DP, 2003, P NATL ACAD SCI USA, V100, P2450, DOI 10.1073/pnas.0437902100; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 2000, J CELL SCI, V113, P1471; Huang L, 2002, MOL CELL PROTEOMICS, V1, P434, DOI 10.1074/mcp.M200027-MCP200; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Shulga N, 2000, J CELL BIOL, V149, P1027, DOI 10.1083/jcb.149.5.1027; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3	31	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42699	42709		10.1074/jbc.M307135200	http://dx.doi.org/10.1074/jbc.M307135200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917401	hybrid			2022-12-27	WOS:000185989500137
J	Scheinfeld, MH; Ghersi, E; Davies, P; D'Adamio, L				Scheinfeld, MH; Ghersi, E; Davies, P; D'Adamio, L			Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; CYTOPLASMIC DOMAIN; INTRACELLULAR DOMAIN; DEPENDENT REGULATION; A-BETA; ACTIVATION; NOTCH; FE65	Alzheimer's disease (AD) is genetically linked to the processing of amyloid beta protein precursor (AbetaPP). Aside from being the precursor of the amyloid beta (Abeta) found in plaques in the brains of patients with AD, little is known regarding the functional role of AbetaPP. We have recently reported biochemical evidence linking AbetaPP to the JNK signaling cascade by finding that JNK-interacting protein-1 (JIP-1) binds AbetaPP. In order to study the functional implications of this interaction we assayed the carboxyl-terminal of AbetaPP for phosphorylation. We found that the threonine 668 within the AbetaPP intracellular domain (AID or elsewhere AICD) is indeed phosphorylated by JNK1. We surprisingly found that although JIP-1 can facilitate this phosphorylation, it is not required for this process. We also found that JIP-1 only facilitated phosphorylation of AbetaPP but not of the two other family members APLP1 (amyloid precursor-like protein 1) and APLP2. Understanding the connection between AbetaPP phosphorylation and the JNK signaling pathway, which mediates cell response to stress may have important implications in understanding the pathogenesis of Alzheimer's disease.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	D'Adamio, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu		D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441; Scheinfeld, Meir H/0000-0001-8880-4318	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM 07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Aplin AE, 1996, J NEUROCHEM, V67, P699; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Coffey ET, 2000, J NEUROSCI, V20, P7602; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heber S, 2000, J NEUROSCI, V20, P7951; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Matsuda S, 2001, J NEUROSCI, V21, P6597; Niikura T, 2002, J NEUROSCI RES, V70, P380, DOI 10.1002/jnr.10354; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Shoji M, 2000, MOL BRAIN RES, V85, P221, DOI 10.1016/S0169-328X(00)00245-X; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zhu XW, 2001, MECH AGEING DEV, V123, P39, DOI 10.1016/S0047-6374(01)00342-6	36	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42058	42063		10.1074/jbc.M304853200	http://dx.doi.org/10.1074/jbc.M304853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917434	hybrid			2022-12-27	WOS:000185989500062
J	Zannini, L; Lecis, D; Lisanti, S; Benetti, R; Buscemi, G; Schneider, C; Delia, D				Zannini, L; Lecis, D; Lisanti, S; Benetti, R; Buscemi, G; Schneider, C; Delia, D			Karyopherin-alpha 2 protein interacts with Chk2 and contributes to its nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; RESPONSE PATHWAYS; KINASE; ALPHA; ACTIVATION; P53; PHOSPHORYLATION; DOMAIN; 53BP1; RCH1	Chk2 is a nuclear protein kinase involved in the DNA damage-induced ataxia telangiectasia mutated-dependent checkpoint arrest at multiple cell cycle phases. Searching for Chk2-binding proteins by a yeast two-hybrid system, we identified a strong interaction with karyopherin-alpha2 (KPNA-2), a gene product involved in active nuclear import of proteins bearing a nuclear localization signal (NLS). This finding was confirmed by glutathione S-transferase pull-down and co-immunoprecipitation assays. Of the three predicted Chk2 NLSs, located at amino acids 179-182 (NLS-1), 240-256 (NLS-2), and 515-522 (NLS-3), only the latter mediated the interaction with KPNA-2 in the yeast two-hybrid system, and in particular with its C terminus. Unlike mutations in NLS-1 or NLS-2, which left the nuclear localization of Chk2 unaffected, mutations in NLS-3 caused a cytoplasmic relocalization, indicating that the NLS-3 motif acts indeed as NLS for Chk2 in vivo. Finally, co-transfection experiments with green fluorescent protein (GFP)-Chk2 and wild type or mutant KPNA-2 confirmed the role of KPNA-2 in nuclear import of Chk2.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; AREA Sci Pk, Consorzio Interuniv Biotecnol, Lab Nazl, I-34012 Trieste, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Buscemi, Giacomo/ABI-1170-2020; Zannini, Laura/N-5646-2015; Lecis, Daniele/C-2113-2017	Buscemi, Giacomo/0000-0002-8404-7142; Lecis, Daniele/0000-0002-0564-0563; BENETTI, Roberta/0000-0001-8863-0821; Zannini, Laura/0000-0001-8731-6507	Telethon [GP0205Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahn JY, 2000, CANCER RES, V60, P5934; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Perez-Villar JJ, 2001, INT IMMUNOL, V13, P1265, DOI 10.1093/intimm/13.10.1265; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Shieh SY, 2000, GENE DEV, V14, P289; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	37	64	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42346	42351		10.1074/jbc.M303304200	http://dx.doi.org/10.1074/jbc.M303304200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909615	hybrid			2022-12-27	WOS:000185989500096
J	Zhou, YX; Zhao, MR; Li, D; Shimazu, K; Sakata, K; Deng, CX; Lu, B				Zhou, YX; Zhao, MR; Li, D; Shimazu, K; Sakata, K; Deng, CX; Lu, B			Cerebellar deficits and hyperactivity in mice lacking Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; RAT HIPPOCAMPAL-NEURONS; BONE MORPHOGENETIC PROTEINS; LONG-TERM POTENTIATION; MAD-RELATED PROTEIN; NERVOUS-SYSTEM; TUMOR-SUPPRESSOR; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNAL-TRANSDUCTION	Smad4 is a central mediator of TGF-beta signals, which are known to play essential roles in many biological processes. Using a Cre-loxP approach to overcome early embryonic lethality, we have studied functions of TGFbeta/Smad4 signals in the central nervous system (CNS). No obvious deficits were detected in mice carrying the targeted disruption of Smad4 in the CNS. The overall morphology of the hippocampus appeared normal. There was no change in the proliferation of neuronal precursor cells, nor in several forms of synaptic plasticity. In contrast, deletion of Smad4 resulted in a marked decrease in the number of cerebellar Purkinje cells and parvalbumin-positive interneurons. Accompanied by the abnormality in the cerebellum, mutant mice also exhibited significantly increased vertical activity. Thus, our study reveals an unexpected role for Smad4 in cerebellar development and in the control of motor function.	NIDDK, Mammalian Genet Sect, NIH, Bethesda, MD 20892 USA; NICHD, Sect Neural Dev & Plast, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Lu, B (corresponding author), NIDDK, Mammalian Genet Sect, NIH, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; Lu, Bai/A-4018-2012; Sakata, Kazuko/I-2351-2017	Lu, Bai/0000-0001-5418-9759				Abe K, 1996, BRAIN RES, V723, P206, DOI 10.1016/0006-8993(96)00253-3; Alder J, 1999, NAT NEUROSCI, V2, P535, DOI 10.1038/9189; Angley C, 2003, J NEUROSCI, V23, P260; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Bates B, 1999, NAT NEUROSCI, V2, P115, DOI 10.1038/5669; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; COLINO A, 1993, J NEUROPHYSIOL, V69, P1150, DOI 10.1152/jn.1993.69.4.1150; Combs SE, 2000, J NEUROSCI RES, V59, P379, DOI 10.1002/(SICI)1097-4547(20000201)59:3<379::AID-JNR12>3.0.CO;2-5; CONSTAM DB, 1994, EUR J NEUROSCI, V6, P766, DOI 10.1111/j.1460-9568.1994.tb00988.x; Crone SA, 2003, NEURON, V37, P29, DOI 10.1016/S0896-6273(02)01128-5; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAHL D, 1989, P NATL ACAD SCI USA, V86, P4776, DOI 10.1073/pnas.86.12.4776; deLuca A, 1996, J NEUROSCI, V16, P4174; DENNENBERG VH, 1969, ANN NY ACAD SCI, V159, P852; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dunker N, 2000, EUR J BIOCHEM, V267, P6982, DOI 10.1046/j.1432-1327.2000.01825.x; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; GAGELIN C, 1995, GLIA, V13, P283, DOI 10.1002/glia.440130405; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Harris-White ME, 1998, J NEUROSCI, V18, P10366; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; Ikegaya Y, 1997, JPN J PHARMACOL, V75, P87, DOI 10.1254/jjp.75.87; ISHIHARA A, 1994, BRAIN RES, V639, P21, DOI 10.1016/0006-8993(94)91759-0; Iwahori Y, 1997, BRAIN RES, V760, P52, DOI 10.1016/S0006-8993(97)00275-8; Kane CJM, 1996, DEV BRAIN RES, V96, P46, DOI 10.1016/S0165-3806(96)00092-2; Kim ES, 1998, MOL BRAIN RES, V62, P122, DOI 10.1016/S0169-328X(98)00217-4; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meucci O, 1996, J NEUROSCI, V16, P4080; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, DEVELOPMENT, V125, P857; PLETNIKOV MV, 1999, PHYSIOL BEHAV, V66, DOI UNSP 8230831; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Prehn JHM, 1996, NEUROPHARMACOLOGY, V35, P249, DOI 10.1016/0028-3908(96)00001-9; Ren RF, 1996, BRAIN RES, V732, P16, DOI 10.1016/0006-8993(96)00458-1; SAUREZ SD, 1981, LEARN MOTIV, V12, P342; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; TORUDELBAUFFE D, 1990, J NEUROCHEM, V54, P1056, DOI 10.1111/j.1471-4159.1990.tb02357.x; Trumpp A, 1999, GENE DEV, V13, P3136, DOI 10.1101/gad.13.23.3136; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; Unsicker K, 2000, EUR J BIOCHEM, V267, P6972, DOI 10.1046/j.1432-1327.2000.01824.x; VERGELLI M, 1995, J NEUROSCI RES, V40, P127, DOI 10.1002/jnr.490400114; Waite JJ, 1999, NEUROBIOL LEARN MEM, V71, P325, DOI 10.1006/nlme.1998.3884; Weinstein DC, 1997, CURR OPIN NEUROBIOL, V7, P7, DOI 10.1016/S0959-4388(97)80114-6; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Withers GS, 2000, EUR J NEUROSCI, V12, P106, DOI 10.1046/j.1460-9568.2000.00889.x; Wolf N, 1999, NEUROSCIENCE, V90, P629, DOI 10.1016/S0306-4522(98)00456-4; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	70	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42313	42320		10.1074/jbc.M308287200	http://dx.doi.org/10.1074/jbc.M308287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12896967	hybrid			2022-12-27	WOS:000185989500092
J	Flintoff, WF; Williams, FMR; Sadlish, H				Flintoff, WF; Williams, FMR; Sadlish, H			The region between transmembrane domains 1 and 2 of the reduced folate carrier forms part of the substrate-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMAGGLUTININ EPITOPE INSERTION; MURINE LEUKEMIA-CELLS; HAMSTER OVARY CELLS; METHOTREXATE UPTAKE; ANTIFOLATE RESISTANCE; SCANNING MUTAGENESIS; MEMBRANE TOPOLOGY; PLASMA-MEMBRANE; N-GLYCOSYLATION; ANION-EXCHANGER	A functional cysteine-less form of the hamster reduced folate carrier protein was generated by alanine replacement of the 14 cysteine residues. The predicted 12-transmembrane topology was examined by replacing selected amino acids, predicted to be exposed to the extracellular or cytosolic environments, with cysteines. The location of these cysteines was defined by their accessibility to biotin maleimide in the presence or absence of specific blocking agents. Amino acids predicted to be exposed to the extracellular environment (S46C, S179C, L300C, Y355C, and K430C) could be labeled with biotin maleimide; this modification could be blocked by prior treatment with nonpermeable reagents. Amino acids predicted to be within the cytosol (S152C, Cys(224), and L475C) could be labeled only after streptolysin O permeabilization. In addition, the cysteine-less reduced folate carrier was exploited to evaluate a potential substrate-binding domain as suggested by previous studies. Nineteen cysteine replacements were generated between residues 39 and 75, a region located between the first and second transmembrane segments. From the biotinylation of these sites and the ability of various reagents to block this labeling, it appears that L41C, E45C, S46C, T49C, I66C, and L70C are exposed to the extracellular environment, whereas Q54C, Q61C, and T63C are slightly less accessible. Cysteines 39, 42, 44, 47, 51, and 73 were inefficiently biotinylated, suggesting that these sites are located in the membrane or within a tightly folded domain of the protein. Furthermore, biotinylation of cysteines 41, 46, 49, 70, and 71 could be prevented by prior treatment with either methotrexate or folinic acid, indicating that these sites form part of a substrate-binding pocket.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Flintoff, WF (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, Dent Sci Bldg,Rm 3006B, London, ON N6A 5C1, Canada.							CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; Frillingos S, 1997, PROTEIN SCI, V6, P431; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rothem L, 2002, BIOCHEM J, V367, P741, DOI 10.1042/BJ20020801; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; Sadlish H, 2000, BIOCHEM J, V346, P509, DOI 10.1042/0264-6021:3460509; Sadlish H, 2002, BIOCHEM J, V364, P777, DOI 10.1042/BJ20011361; Sadlish H, 2002, J BIOL CHEM, V277, P42105, DOI 10.1074/jbc.M206459200; SAMBROOK J, 1989, MOL CLONING, V2, P9; Sharina IG, 2002, BIOCHEM PHARMACOL, V63, P1717, DOI 10.1016/S0006-2952(02)00955-3; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SIROTNAK FM, 1985, CANCER RES, V45, P3992; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; Wang YH, 2001, BBA-BIOMEMBRANES, V1513, P49, DOI 10.1016/S0005-2736(01)00340-6; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; Wong SC, 1998, BBA-BIOMEMBRANES, V1375, P6, DOI 10.1016/S0005-2736(98)00118-7; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 2000, BBA-BIOMEMBRANES, V1466, P7, DOI 10.1016/S0005-2736(00)00190-5; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68	33	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40867	40876		10.1074/jbc.M302102200	http://dx.doi.org/10.1074/jbc.M302102200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909642	hybrid			2022-12-27	WOS:000185847200056
J	Horie, C; Suzuki, H; Sakaguchi, M; Mihara, K				Horie, C; Suzuki, H; Sakaguchi, M; Mihara, K			Targeting and assembly of mitochondrial tail-anchored protein Tom5 to the TOM complex depend on a signal distinct from that of tail-anchored proteins dispersed in the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL IMPORT PORE; OUTER-MEMBRANE; RECEPTOR COMPLEX; ENDOPLASMIC-RETICULUM; PREPROTEIN TRANSLOCASE; YEAST MITOCHONDRIA; INSERTION PORE; AMINO-ACIDS; CHANNEL; COMPONENT	Mitochondrial outer membrane proteins are synthesized without a cleavable presequence but instead contain segments responsible for mitochondrial targeting and membrane integration within the molecule: the transmembrane segment (TMS) and N- or C-terminal flanking segment. We analyzed targeting and integration of Tom5, a C-tail anchor protein associated with the preprotein translocase of the outer membrane, to the yeast mitochondrial outer membrane in vivo using green fluorescent protein as the reporter and compared the signal with other signals for proteins dispersed in the membrane. The functional assembly of Tom5 into the TOM complex was assessed by blue native PAGE and complementation of temperature-sensitive Deltatom5 cells. Correct targeting and assembly required (i) an appropriate length TMS rather than hydrophobicity, (ii) a proline residue located at correct position in the TMS and specific residues near the proline, and (iii) that, in contrast to proteins dispersed in the outer membrane, the positive C-terminal segment was dispensable. Based on these findings, we constructed green fluorescent protein fusions with a C-terminal TMS in which the deduced sequences ( minimum: Ser-Pro-Met) were inserted at an appropriate position within artificial Leu-Ala repeats. They were targeted to mitochondria and complemented the temperature-sensitive growth phenotype of Deltatom5 yeast cells. The membrane-targeting mechanism of Tom5 appears to be distinct from that for proteins that are dispersed in the outer membrane.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan.							Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; Borgese N, 2001, MOL BIOL CELL, V12, P2482, DOI 10.1091/mbc.12.8.2482; CAO W, 1995, J BIOL CHEM, V270, P5674, DOI 10.1074/jbc.270.10.5674; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Egan B, 1999, FEBS LETT, V451, P243, DOI 10.1016/S0014-5793(99)00581-5; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Horie C, 2002, MOL BIOL CELL, V13, P1615, DOI 10.1091/mbc.01-12-0570; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; Miyazaki E, 2001, J BIOL CHEM, V276, P49221, DOI 10.1074/jbc.M106267200; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Motz C, 2002, J MOL BIOL, V323, P729, DOI 10.1016/S0022-2836(02)00995-6; Nemoto Y, 1999, EMBO J, V18, P2991, DOI 10.1093/emboj/18.11.2991; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	43	47	49	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41462	41471		10.1074/jbc.M307047200	http://dx.doi.org/10.1074/jbc.M307047200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896971	hybrid			2022-12-27	WOS:000185847200126
J	Matsumoto, K; Shionyu, M; Go, M; Shimizu, K; Shinomura, T; Kimata, K; Watanabe, H				Matsumoto, K; Shionyu, M; Go, M; Shimizu, K; Shinomura, T; Kimata, K; Watanabe, H			Distinct interaction of versican/PG-M with hyaluronan and link protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; LARGE AGGREGATING PROTEOGLYCAN; BINDING-SITE; CARTILAGE PROTEOGLYCAN; CELL-MIGRATION; CDNA CLONING; TISSUES; DOMAINS; BRAIN; AGGRECAN	The proteoglycan aggregate is the major structural component of the cartilage matrix, comprising hyaluronan (HA), link protein (LP), and a large chondroitin sulfate (CS) proteoglycan, aggrecan. Here, we found that another member of aggrecan family, versican, biochemically binds to both HA and LP. Functional analyses of recombinant looped domains (subdomains) A, B, and B' of the N-terminal G(1) domain revealed that the B-B' segment of versican is adequate for binding to HA and LP, whereas A and B-B' of aggrecan bound to LP and HA, respectively. BIAcore(TM) analyses showed that the A subdomain of versican G(1) enhances HA binding but has a negligible effect on LP binding. Overlay sensorgrams demonstrated that versican G(1) or its B-B' segment forms a complex with both HA and LP. We generated a molecular model of the B-B' segment, in which a deletion and an insertion of B' and B are critical for stable structure and HA binding. These results provide important insights into the mechanisms of formation of the proteoglycan aggregate and HA binding of molecules containing the link module.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan; Gifu Univ, Sch Med, Dept Orthopaed Surg, Gifu 5008705, Japan	Aichi Medical University; Nagoya University; Gifu University	Watanabe, H (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Karimata 21, Nagakute, Aichi 4801195, Japan.			Shionyu, Masafumi/0000-0002-0431-3456; Watanabe, Hideto/0000-0001-5291-0696				Almond A, 1998, J MOL BIOL, V284, P1425, DOI 10.1006/jmbi.1998.2245; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; Hascall V.C, 1991, PROTEOGLYCANS CELL B, P149, DOI 10.1007/978-1-4615-3770-0_6; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; Kishimoto J, 1999, P NATL ACAD SCI USA, V96, P7336, DOI 10.1073/pnas.96.13.7336; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; Nishida Y, 1994, Osteoarthritis Cartilage, V2, P43, DOI 10.1016/S1063-4584(05)80005-6; Ogata K, 2000, J MOL GRAPH MODEL, V18, P258, DOI 10.1016/S1093-3263(00)00037-1; PERKINS SJ, 1992, BIOCHEM J, V285, P263, DOI 10.1042/bj2850263; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; RAUCH U, 1992, J BIOL CHEM, V267, P19536; ROSENBERG L, 1988, J BIOL CHEM, V263, P18071; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, J CELL SCI, V106, P55; YU Q, 1995, BIOTECHNIQUES, V19, P122; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	35	108	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41205	41212		10.1074/jbc.M305060200	http://dx.doi.org/10.1074/jbc.M305060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888576	hybrid			2022-12-27	WOS:000185847200098
J	Moreno, H; Serrano, AL; Santalucia, T; Guma, A; Canto, C; Brand, NJ; Palacin, M; Schiaffino, S; Zorzano, A				Moreno, H; Serrano, AL; Santalucia, T; Guma, A; Canto, C; Brand, NJ; Palacin, M; Schiaffino, S; Zorzano, A			Differential regulation of the muscle-specific GLUT4 enhancer in regenerating and adult skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER EXPRESSION; BROWN ADIPOSE-TISSUE; GENE-EXPRESSION; THYROID-HORMONE; TRANSGENIC MICE; TRANSCRIPTIONAL REGULATION; SATELLITE CELLS; BINDING-SITE; FACTOR-I; INSULIN	We have reported a novel functional co-operation among MyoD, myocyte enhancer factor-2 (MEF2), and the thyroid hormone receptor in a muscle-specific enhancer of the rat GLUT4 gene in muscle cells. Here, we demonstrate that the muscle-specific enhancer of the GLUT4 gene operates in skeletal muscle and is muscle fiber-dependent and innervation-independent. Under normal conditions, both in soleus and in extensor digitorum longus muscles, the activity of the enhancer required the integrity of the MEF2-binding site. Cancellation of the binding site of thyroid hormone receptor enhanced its activity, suggesting an inhibitory role. Muscle regeneration of the soleus and extensor digitorum longus muscles caused a marked induction of GLUT4 and stimulation of the enhancer activity, which was independent of innervation. During muscle regeneration, the enhancer activity was markedly inhibited by cancellation of the binding sites of MEF2, MyoD, or thyroid hormone receptors. Different MEF2 isoforms expressed in skeletal muscle (MEF2A, MEF2C, and MEF2D) and all members of the MyoD family had the capacity to participate in the activity of the GLUT4 enhancer as assessed by transient transfection in cultured cells. Our data indicate that the GLUT4 enhancer operates in muscle fibers and its activity contributes to the differences in GLUT4 gene expression between oxidative and glycolytic muscle fibers and to the GLUT4 up-regulation that occurs during muscle regeneration. The activity of the enhancer is maintained in adult muscle by MEF2, whereas during regeneration the operation of the enhancer depends on MEF2, myogenic transcription factors of the MyoD family, and thyroid hormone receptors.	Univ Barcelona, Fac Biol, Parc Cient Barcelona, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Padua, Dept Biomed Sci, CNR, Inst Neurosci, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiothorac Surg, London SW3 6LY, England	University of Barcelona; University of Barcelona; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine; Imperial College London	Zorzano, A (corresponding author), Univ Barcelona, Fac Biol, Parc Cient Barcelona, Avda Diagonal 645, E-08028 Barcelona, Spain.	azorzano@porthos.bio.ub.es	Palacín, Manuel/G-9786-2015; Santalucia, Tomas/B-6140-2012; Serrano, A/I-9198-2014; Gumà, Anna/C-5165-2017; Zorzano, Antonio/R-5479-2018; Santalucia, Tomas/I-7411-2012	Santalucia, Tomas/0000-0003-4604-9195; Gumà, Anna/0000-0001-9390-5252; Santalucia, Tomas/0000-0003-4604-9195; Canto, Carles/0000-0002-5167-7922; Palacin, Manuel/0000-0002-8670-293X; Schiaffino, Stefano/0000-0002-5607-6421				Akkila WM, 1997, BIOCHEM J, V325, P87, DOI 10.1042/bj3250087; BANERJEE SS, 2002, J BIOL CHEM, V277, P34322; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; Buhl ES, 2001, DIABETES, V50, P12, DOI 10.2337/diabetes.50.1.12; CAMPBELL C, 1992, AM J PHYSIOL, V263, pE102; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; Escobar-Morreale HF, 1999, BIOCHIMIE, V81, P453, DOI 10.1016/S0300-9084(99)80095-9; GosteliPeter MA, 1996, J CLIN INVEST, V98, P1737, DOI 10.1172/JCI118972; Jones JP, 1998, J APPL PHYSIOL, V84, P1661, DOI 10.1152/jappl.1998.84.5.1661; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KOISHI K, 1995, DEV DYNAM, V202, P244, DOI 10.1002/aja.1002020304; LIU ML, 1994, J BIOL CHEM, V269, P28514; LIU ML, 1992, J BIOL CHEM, V267, P11673; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Mora S, 2000, J BIOL CHEM, V275, P16323, DOI 10.1074/jbc.M910259199; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; OLSON AL, 1995, J BIOL CHEM, V270, P23491, DOI 10.1074/jbc.270.40.23491; Oshel KM, 2000, J BIOL CHEM, V275, P23666, DOI 10.1074/jbc.M001452200; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; Santalucia T, 2001, J MOL BIOL, V314, P195, DOI 10.1006/jmbi.2001.5091; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SLIEKER LJ, 1992, DIABETES, V41, P187, DOI 10.2337/diabetes.41.2.187; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; Torrance CJ, 1997, ENDOCRINOLOGY, V138, P1204, DOI 10.1210/en.138.3.1204; Torrance CJ, 1997, ENDOCRINOLOGY, V138, P1215, DOI 10.1210/en.138.3.1215; Tsunoda N, 2000, BIOCHEM BIOPH RES CO, V267, P744, DOI 10.1006/bbrc.1999.2031; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; Vinals F, 1997, ENDOCRINOLOGY, V138, P2521, DOI 10.1210/en.138.6.2521; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; Yokomori N, 1999, DIABETES, V48, P2471, DOI 10.2337/diabetes.48.12.2471; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073; Zhou Z, 2001, J MUSCLE RES CELL M, V22, P311, DOI 10.1023/A:1013133616449	44	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40557	40564		10.1074/jbc.M306609200	http://dx.doi.org/10.1074/jbc.M306609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893821	hybrid, Green Published			2022-12-27	WOS:000185847200018
J	Liang, W; Austin, S; Hoang, Q; Fishman, PH				Liang, W; Austin, S; Hoang, Q; Fishman, PH			Resistance of the human beta(1)-adrenergic receptor to agonist-mediated down-regulation - Role of the C terminus in determining beta-subtype degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; CARDIAC MYOCYTES; BETA-1-ADRENERGIC RECEPTOR; DIFFERENTIAL REGULATION; ACTIVATED RECEPTOR-1; HEART-FAILURE; RAT-HEART	Prolonged agonist stimulation results in down-regulation of most G protein-coupled receptors. When we exposed baby hamster kidney cells stably expressing the human beta(1)-adrenergic receptor (beta(1)AR) to agonist over a 24-h period, we instead observed an increase of similar to30% in both beta(1)AR binding activity and immune-detected receptors. In contrast, beta(2)AR expressed in these cells exhibited a decrease of greater than or equal to50%. We determined that the basal turnover rates of the two subtypes were similar (t1/2 similar to 7 h) and that agonist stimulation increased beta(2)AR but not beta(1)AR turnover. Blocking receptor trafficking to lysosomes with bafilomycin A(1) had no effect on basal turnover of either subtype but blocked agonist-stimulated beta(2)AR turnover. As beta(1)AR mRNA levels increased in agonist-stimulated cells, beta(1)AR up-regulation appeared to result from increased synthesis with no change in degradation. To explore the basis for the subtype differences, we expressed chimeras in which the C termini had been exchanged. Each chimera responded to persistent agonist stimulation based on the source of its C-tail; beta(1)AR with a beta(2)AR C-tail underwent down-regulation, and beta(2)AR with a beta(1)AR C-tail underwent up-regulation. The C-tails had a corresponding effect on agonist-stimulated receptor phosphorylation and internalization with the order being beta(2)AR > beta(1)AR with beta(2)AR C-tail > beta(2)AR with a beta(1)AR C-tail > beta(1)AR. As internalization may be a prerequisite for down-regulation, we addressed this possibility by co-expressing each subtype with arrestin-2. Although beta(1)AR internalization was increased to that of beta(2)AR, down-regulation still did not occur. Instead, beta(1)AR accumulated inside the cells. We conclude that in unstimulated cells, both subtypes appear to be turned over by the same mechanism. Upon agonist stimulation, both subtypes are internalized, and beta(2)AR but not beta(1)AR undergoes lysosomal degradation, the fate of each subtype being regulated by determinants in its C-tail.	NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Fishman, PH (corresponding author), NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bldg 49,Rm 2A28,49 Convent Dr,MSC4440, Bethesda, MD 20892 USA.	fishmanp@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002366] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Blaxall BC, 2000, J BIOL CHEM, V275, P4290, DOI 10.1074/jbc.275.6.4290; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Curran PK, 1996, CELL SIGNAL, V8, P355, DOI 10.1016/0898-6568(96)00068-X; Dangel V, 1996, BIOCHEM J, V317, P925, DOI 10.1042/bj3170925; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; Devic E, 2001, MOL PHARMACOL, V60, P577; Dunigan CD, 2000, METH MOL B, V136, P329; Dunigan CD, 2002, BIOCHEMISTRY-US, V41, P8019, DOI 10.1021/bi025538r; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FISHMAN PH, 1994, J RECEPTOR RES, V14, P281, DOI 10.3109/10799899409066037; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1994, J BIOL CHEM, V269, P26215; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; JASPER JR, 1990, AM J PHYSIOL, V259, pC41, DOI 10.1152/ajpcell.1990.259.1.C41; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; MAHAN LC, 1987, ANNU REV PHARMACOL, V27, P215; McLean AJ, 2000, BRIT J PHARMACOL, V130, P1825, DOI 10.1038/sj.bjp.0703506; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Moore RH, 1999, J CELL SCI, V112, P329; NEVE KA, 1986, MOL PHARMACOL, V30, P104; NEVE KA, 1985, J PHARMACOL EXP THER, V235, P657; PORT JD, 1992, J BIOL CHEM, V267, P24103; Port JD, 2001, J MOL CELL CARDIOL, V33, P887, DOI 10.1006/jmcc.2001.1358; Rathz DA, 2002, J CARDIOVASC PHARM, V39, P155, DOI 10.1097/00005344-200202000-00001; Rousseau G, 1996, MOL PHARMACOL, V49, P752; Santini F, 2000, J CELL SCI, V113, P2463; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; VALET P, 1989, J PHARMACOL EXP THER, V249, P271; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Williams BR, 2000, MOL PHARMACOL, V58, P421, DOI 10.1124/mol.58.2.421; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; Xiao RP, 2000, CIRC RES, V87, P635, DOI 10.1161/01.RES.87.8.635; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; ZHANG LJ, 1994, MOL PHARMACOL, V45, P878; Zhao MM, 1996, AM J PHYSIOL-HEART C, V271, pH1762, DOI 10.1152/ajpheart.1996.271.5.H1762; ZHOU XM, 1995, CELL SIGNAL, V7, P207, DOI 10.1016/0898-6568(94)00091-O; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	58	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39773	39781		10.1074/jbc.M304482200	http://dx.doi.org/10.1074/jbc.M304482200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888573	hybrid			2022-12-27	WOS:000185713800063
J	Liao, YL; Willis, IM; Moir, RD				Liao, YL; Willis, IM; Moir, RD			The Brf1 and Bdp1 subunits of transcription factor TFIIIB bind to overlapping sites in the tetratricopeptide repeats of Tfc4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TPR DOMAIN; DNA; RECRUITMENT; INITIATION; MUTATION; ENCODES; COMPLEX; ROLES; AUTOINHIBITION	The RNA polymerase III initiation factor TFIIIB is assembled onto DNA through interactions involving the Tfc4 subunit of the assembly factor TFIIIC and two subunits of TFIIIB, Brf1 and Bdp1. Tfc4 contains two arrays of tetratricopeptide repeats (TPRs), each of which provides a binding site for Brf1. Dominant mutations in the ligand binding channel of the first TPR array, TPRs1-5, and on the back side of this array, increase Brf1 binding by Tfc4. Here we examine the biological importance of the second TPR array, TPRs6-9. Radical mutations at phylogenetically conserved residues in the ligand binding channel of TPRs6-9 impair pol III reporter gene transcription. Biochemical studies on one such mutation, L469K in TPR7, revealed a defect in the recruitment of Brf1 into TFIIIB-TFIIIC-DNA complexes and diminished the direct interaction between Tfc4 and Brf1. Multicopy suppression analysis implicates TPR9 in Brf1 binding and TPRs7 and 8 in binding to more than one ligand. Indeed, the L469K mutation also decreased the binding affinity for Bdp1 incorporation into TFIIIB-TFIIIC-DNA complexes and inhibited binary interactions between Bdp1 and Tfc4. The Bdp1 binding domain in Tfc4 was mapped to TPRs1-9, a domain that contains both TPR arrays and thus overlaps two of the known binding sites for Brf1. The properties of the L469K mutation identify both Brf1 and Bdp1 as ligands for the second TPR array.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Moir, RD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	moir@aecom.yu.edu		Willis, Ian/0000-0001-6599-2395	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042728] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Cloutier TE, 2001, P NATL ACAD SCI USA, V98, P9581, DOI 10.1073/pnas.161292298; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Ishiguro A, 2002, MOL CELL BIOL, V22, P3264, DOI 10.1128/MCB.22.10.3264-3275.2002; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Librizzi MD, 1996, J BIOL CHEM, V271, P32695, DOI 10.1074/jbc.271.51.32695; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; Main ERG, 2003, STRUCTURE, V11, P497, DOI 10.1016/S0969-2126(03)00076-5; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; Moir RD, 2000, J BIOL CHEM, V275, P26591, DOI 10.1074/jbc.M003991200; Moir RD, 2002, MOL CELL BIOL, V22, P6131, DOI 10.1128/MCB.22.17.6131-6141.2002; Moir RD, 2002, J BIOL CHEM, V277, P694, DOI 10.1074/jbc.M108924200; MOIR RD, 2004, ASSEMBLY INITIATION; Moore DD, 1995, GLOB MOB SURV; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Rozenfeld S, 2001, MOL GENET GENOMICS, V265, P705, DOI 10.1007/s004380100467; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sethy-Coraci I, 1998, NUCLEIC ACIDS RES, V26, P2344, DOI 10.1093/nar/26.10.2344; White RJ, 1998, INT J ONCOL, V12, P741; WILLIS I, 1989, EMBO J, V8, P4281, DOI 10.1002/j.1460-2075.1989.tb08614.x	37	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44467	44474		10.1074/jbc.M308354200	http://dx.doi.org/10.1074/jbc.M308354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930823	hybrid			2022-12-27	WOS:000186306700074
J	Melkozernov, AN; Blankenship, RE				Melkozernov, AN; Blankenship, RE			Structural modeling of the Lhca4 subunit of LHCI-730 peripheral antenna in photosystem I based on similarity with LHCII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; EXCITATION-ENERGY TRANSFER; CHLAMYDOMONAS-REINHARDTII; SYNECHOCOCCUS-ELONGATUS; STATE TRANSITIONS; MUTATION ANALYSIS; HIGHER-PLANTS; PROTEINS; BINDING; IDENTIFICATION	Peripheral chlorophyll a/b binding antenna of photosystem I (LHCI) from green algae and higher plants binds specific low energy absorbing chlorophylls ( red pigments) that give rise to a unique red-shifted emission. A three-dimensional structural model of the Lhca4 polypeptide from the LHCI from higher plants was constructed on the basis of comparative sequence analysis, secondary structure prediction, and homology modeling using LHCII as a template. The obtained model of Lhca4 helps to visualize protein ligands to nine chlorophylls (Chls) and three potential His residues to extra Chls. Central domain of the Lhca4 comprising the first ( A) and the third ( C) transmembrane (TM) helices that binds 6 Chl molecules and two carotenoids is conserved structurally, whereas the interface between the first and the second TM helices and the outer surface of the second TM helix differ significantly among the LHCI and LHCII polypeptides. The model of Lhca4 predicts a histidine residue in the second TM helix, a potential binding site for extra Chl in close proximity to Chls a5 and b5 (labeling by Kuhlbrandt). The interpigment interactions in the formed pigment cluster are suggested to cause a red spectral shift in absorption and emission. Modeling of the LHCI-730 heterodimer based on the model structures of Lhca1 and Lhca4 allowed us to suggest potential sites of pigment-pigment interactions that might be formed upon heterodimerization or docking of the LHCI dimers to the surface of PSI.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Melkozernov, AN (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 2002, PHOTOSYNTHETICA; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; Byrdin M, 2002, BIOPHYS J, V83, P433, DOI 10.1016/S0006-3495(02)75181-3; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Croce R, 2001, BIOPHYS J, V80, P901, DOI 10.1016/S0006-3495(01)76069-9; Damjanovic A, 2002, J PHYS CHEM B, V106, P10251, DOI 10.1021/jp020963f; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; Germano M, 2002, FEBS LETT, V525, P121, DOI 10.1016/S0014-5793(02)03100-9; Gobets B, 2001, BBA-BIOENERGETICS, V1507, P80, DOI 10.1016/S0005-2728(01)00203-1; GREEN BR, 2003, LIGHT HARVESTING ANT, P129; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kargul J, 2003, J BIOL CHEM, V278, P16135, DOI 10.1074/jbc.M300262200; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Knoetzel J, 1998, FEBS LETT, V436, P339, DOI 10.1016/S0014-5793(98)01158-2; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Melkozernov AN, 2000, FEBS LETT, V471, P89, DOI 10.1016/S0014-5793(00)01370-3; Melkozernov AN, 2001, PHOTOSYNTH RES, V70, P129, DOI 10.1023/A:1017909325669; Melkozernov AN, 2002, J PHYS CHEM B, V106, P4313, DOI 10.1021/jp014271n; MELKOZERNOV AN, 2001, P 12 INT C PHOT AUG; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2002, BIOCHEMISTRY-US, V41, P9126, DOI 10.1021/bi016042x; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; Schmid VHR, 2001, FEBS LETT, V499, P27, DOI 10.1016/S0014-5793(01)02509-1; Sener MK, 2002, J PHYS CHEM B, V106, P7948, DOI 10.1021/jp020708v; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Amerongen H, 2001, J PHYS CHEM B, V105, P604, DOI 10.1021/jp0028406; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623	35	13	15	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44542	44551		10.1074/jbc.M306777200	http://dx.doi.org/10.1074/jbc.M306777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923171	hybrid			2022-12-27	WOS:000186306700083
J	Gupta, S; Fanzo, JC; Hu, CM; Cox, D; Jang, SY; Lee, AE; Greenberg, S; Pernis, AB				Gupta, S; Fanzo, JC; Hu, CM; Cox, D; Jang, SY; Lee, AE; Greenberg, S; Pernis, AB			T cell receptor engagement leads to the recruitment of IBP, a novel guanine nucleotide exchange factor, to the immunological synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-THETA; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; VAV PROTEINS; RHO-GTPASES; ACTIVATION; TCR; CYTOSKELETON; MODULATION; SWAP-70	Reorganization of the actin cytoskeleton is crucial to the formation and function of the immunological synapse. Rho GTPases are critical mediators of cytoskeletal reorganization, and their activity at the synapse is likely to be stringently regulated. Guanine nucleotide exchange factors (GEFs) belonging to the Dbl family of proteins represent one major class of proteins that regulate the activity of Rho GTPases. Here we demonstrate that IBP, a homologue of SWAP-70, is a novel GEF for Rac1 and Cdc42 in T lymphocytes, which is recruited to the immunological synapse upon engagement of the antigen receptor. Mutational analysis supports a model whereby IBP is inactive in unstimulated cells. Upon engagement of the T cell receptor, its GEF activity is enhanced by tyrosine phosphorylation, as well as by binding newly generated phosphatidylinositol 3,4,5-trisphosphate. Although it is known that T cell receptor engagement leads to the recruitment of Vav to the immunological synapse, these findings indicate that other GEFs, such as IBP, also relocalize to this intercellular region. The recruitment and activation of distinct classes of GEFs may allow for precise control of Rho GTPase function at the crucial interface between T cells and antigen presenting cells.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Med & Pharmacol, New York, NY 10032 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Columbia University; Columbia University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Pernis, AB (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	abp1@columbia.edu	Fanzo, Jessica/HCH-3533-2022	Cox, Dianne/0000-0002-0591-9767; Fanzo, Jessica/0000-0002-6760-1359	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002158] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-62215] Funding Source: Medline; NIAID NIH HHS [P01 AI50514-01] Funding Source: Medline; NIAMS NIH HHS [K01 AR002158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Bauch A, 2000, ADV IMMUNOL, V75, P89, DOI 10.1016/S0065-2776(00)75002-4; Borggrefe T, 1999, EUR J IMMUNOL, V29, P1812, DOI 10.1002/(SICI)1521-4141(199906)29:06<1812::AID-IMMU1812>3.0.CO;2-J; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Clements JL, 1999, J CLIN INVEST, V103, P925, DOI 10.1172/JCI6562; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Delon J, 2000, CURR BIOL, V10, pR923, DOI 10.1016/S0960-9822(00)00870-8; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Fischer KD, 1998, SEMIN IMMUNOL, V10, P317, DOI 10.1006/smim.1998.0124; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2003, HUM IMMUNOL, V64, P389, DOI 10.1016/S0198-8859(03)00024-7; Gupta S, 1998, J IMMUNOL, V161, P5997; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Krawczyk C, 2001, J LEUKOCYTE BIOL, V69, P317; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; van der Merwe PA, 2002, CURR OPIN IMMUNOL, V14, P293, DOI 10.1016/S0952-7915(02)00350-3; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Ward SG, 2001, CURR OPIN IMMUNOL, V13, P332, DOI 10.1016/S0952-7915(00)00223-5; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	40	60	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43541	43549		10.1074/jbc.M308960200	http://dx.doi.org/10.1074/jbc.M308960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923183	hybrid			2022-12-27	WOS:000186157000100
J	Pirch, T; Landmeier, S; Jung, H				Pirch, T; Landmeier, S; Jung, H			Transmembrane domain II of the Na plus /proline transporter PutP of Escherichia coli forms part of a conformationally flexible, cytoplasmic exposed aqueous cavity within the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/PROLINE TRANSPORTER; SECONDARY STRUCTURE; LACTOSE PERMEASE; NA+/GLUCOSE COTRANSPORTER; SUBSTRATE-BINDING; SYMPORTER FAMILY; PROTEIN; TOPOLOGY; RECONSTITUTION; PURIFICATION	The Na+/proline transporter PutP of Escherichia coli is a member of a large family of Na+/substrate symporters. Previous work on PutP suggests an involvement of the region ranging from Asp-55 to Gly-58 in binding of Na+ and/or proline (Pirch, T., Quick, M., Nietschke, M., Langkamp, M., Jung, H. (2002) J. Biol. Chem. 277, 8790-8796). In this study, a complete Cys scanning mutagenesis of transmembrane domain II (TM II) of PutP was performed to further elucidate the role of the TM in the transport process. Strong defects of PutP function were observed upon substitution of Ala-48, Ala-53, Trp-59, and Gly-63 by Cys in addition to the previously characterized residues Asp-55, Ser-57, and Gly-58. However, except for Asp-55 none of these residues proved essential for function. The activity of eight mutants was sensitive to N-ethylmaleimide inhibition with the sensitive positions clustering predominantly on a hydrophilic face in the cytoplasmic half of TM II. The same face was also highly accessible to the bulky sulfhydryl reagent fluorescein 5-maleimide in randomly oriented membrane vesicles, suggesting an unrestricted accessibility of the corresponding amino acid positions via an aqueous pathway. Na+ stimulated the reactivity of Cys toward fluorescein 5-maleimide at two positions while proline inhibited reaction of the sulfhydryl group at nine positions. Taken together, the results demonstrate that TM II of PutP is of particular functional importance. It is proposed that hydrophilic residues in the cytoplasmic half of TM II participate in the formation of an aqueous cavity in the membrane that allows Na+ and/or proline binding to residues located in the middle of the TM (e.g. Asp-55 and Ser-57). In addition, the data indicate that TM II participates in Na+-and proline-induced conformational alterations.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, H (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.	jung_h@biologie.uni-osnabrueck.de	Jung, Heinrich/K-3790-2014	Jung, Heinrich/0000-0002-5450-3063				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CC, 1985, J MEMBRANE BIOL, V84, P157, DOI 10.1007/BF01872213; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Dave N, 2000, BIOPHYS J, V79, P747, DOI 10.1016/S0006-3495(00)76332-6; Fann MC, 2003, J BACTERIOL, V185, P3863, DOI 10.1128/JB.185.13.3863-3870.2003; HANADA K, 1988, J BIOL CHEM, V263, P7181; Jung H, 1998, BBA-BIOENERGETICS, V1365, P60, DOI 10.1016/S0005-2728(98)00044-9; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Jung H, 2002, FEBS LETT, V529, P73, DOI 10.1016/S0014-5793(02)03184-8; Jung H, 2001, BBA-BIOENERGETICS, V1505, P131, DOI 10.1016/S0005-2728(00)00283-8; JUNG K, 1995, BIOCHEMISTRY-US, V34, P1030, DOI 10.1021/bi00003a038; le Coutre J, 2002, BIOCHEMISTRY-US, V41, P8082, DOI 10.1021/bi025692d; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; Panayotova-Heiermann M, 1999, FEBS LETT, V459, P386, DOI 10.1016/S0014-5793(99)01292-2; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pirch T, 2002, J BIOL CHEM, V277, P8790, DOI 10.1074/jbc.M111008200; Poelarends GJ, 2002, J BIOL CHEM, V277, P42891, DOI 10.1074/jbc.M206508200; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1999, BIOCHEMISTRY-US, V38, P13523, DOI 10.1021/bi991256o; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Saier MH, 1999, J CELL BIOCHEM, P84; STALMACH ME, 1983, J BACTERIOL, V156, P481, DOI 10.1128/JB.156.2.481-486.1983; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Wegener C, 2000, BIOCHEMISTRY-US, V39, P4831, DOI 10.1021/bi992442x; Weinglass AB, 1999, P NATL ACAD SCI USA, V96, P11178, DOI 10.1073/pnas.96.20.11178; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	39	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42942	42949		10.1074/jbc.M308253200	http://dx.doi.org/10.1074/jbc.M308253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923181	hybrid			2022-12-27	WOS:000186157000028
J	Shen, WJ; Patel, S; Natu, V; Hong, R; Wang, J; Azhar, S; Kraemer, FB				Shen, WJ; Patel, S; Natu, V; Hong, R; Wang, J; Azhar, S; Kraemer, FB			Interaction of hormone-sensitive lipase with steroidogeneic acute regulatory protein - Facilitation of cholesterol transfer in adrenal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING PROTEIN; TARGETED DISRUPTION; MOLECULAR-CLONING; ESTER HYDROLASE; STAR; DOMAIN; TRAFFICKING; MECHANISM; TRANSPORT; IDENTIFICATION	Hormone-sensitive lipase (HSL) is responsible for the neutral cholesteryl ester hydrolase activity in steroidogenic tissues. Through its action, HSL is involved in regulating intracellular cholesterol metabolism and making unesterified cholesterol available for steroid hormone production. Steroidogenic acute regulatory protein ( StAR) facilitates the movement of cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane and is a critical regulatory step in steroidogenesis. In the current studies we demonstrate a direct interaction of HSL with StAR using in vitro glutathione S-transferase pull-down experiments. The 37-kDa StAR is coimmunoprecipitated with HSL from adrenals of animals treated with ACTH. Deletional mutations show that HSL interacts with the N-terminal as well as a central region of StAR. Coexpression of HSL and StAR in Chinese hamster ovary cells results in higher cholesteryl ester hydrolytic activity of HSL. Transient overexpression of HSL in Y1 adrenocortical cells increases mitochondrial cholesterol content under conditions in which StAR is induced. It is proposed that the interaction of HSL with StAR in cytosol increases the hydrolytic activity of HSL and that together HSL and StAR facilitate cholesterol movement from lipid droplets to mitochondria for steroidogenesis.	Stanford Univ, Div Endocrinol, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Kraemer, FB (corresponding author), Stanford Univ, Div Endocrinol, Dept Med, S-025, Stanford, CA 94305 USA.		Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807; Shen, Wen-Jun/0000-0001-5150-1698	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046942] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Brown RC, 2001, INT REV NEUROBIOL, V46, P117; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; DIBARTOLOMEIS MJ, 1986, J BIOL CHEM, V261, P4432; Fielding CJ, 1997, J LIPID RES, V38, P1503; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; Hoekstra D, 2000, CURR OPIN CELL BIOL, V12, P496, DOI 10.1016/S0955-0674(00)00122-8; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; Kraemer FB, 2002, ENDOCRINOLOGY, V143, P801, DOI 10.1210/en.143.3.801; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Miller WL, 1999, J STEROID BIOCHEM, V69, P131, DOI 10.1016/S0960-0760(98)00153-8; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osterlund T, 1999, J BIOL CHEM, V274, P15382, DOI 10.1074/jbc.274.22.15382; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Osterlund T, 2001, EUR J BIOCHEM, V268, P1899, DOI 10.1046/j.1432-1327.2001.02097.x; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; PROBST MR, 1994, J BIOL CHEM, V269, P21650; PROKOCIMER PG, 1988, MOL PHARMACOL, V33, P338; REAVEN E, 1990, J BIOL CHEM, V265, P19100; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 2001, J BIOL CHEM, V276, P49443, DOI 10.1074/jbc.M104095200; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Stocco DM, 1999, VITAM HORM, V55, P399; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Watari H, 2000, EXP CELL RES, V255, P56, DOI 10.1006/excr.1999.4774; Wei CJ, 1999, BIOCHEM J, V340, P345, DOI 10.1042/0264-6021:3400345; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	37	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43870	43876		10.1074/jbc.M303934200	http://dx.doi.org/10.1074/jbc.M303934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925534	hybrid, Green Submitted			2022-12-27	WOS:000186157000137
J	Sivaraman, J; Li, YG; Banks, J; Cane, DE; Matte, A; Cygler, M				Sivaraman, J; Li, YG; Banks, J; Cane, DE; Matte, A; Cygler, M			Crystal structure of Escherichia coli PdxA, an enzyme involved in the pyridoxal phosphate biosynthesis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; 3-ISOPROPYLMALATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE; THREONINE DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; VITAMIN-B-6 PYRIDOXINE; 5'-PHOSPHATE SYNTHASE; PROTEIN; COMPLEX; 1-DEOXY-D-XYLULOSE-5-PHOSPHATE	Pyridoxal 5'-phosphate is an essential cofactor for many enzymes responsible for the metabolic conversions of amino acids. Two pathways for its de novo synthesis are known. The pathway utilized by Escherichia coli consists of six enzymatic steps catalyzed by six different enzymes. The fourth step is catalyzed by 4-hydroxythreonine-4-phosphate dehydrogenase (PdxA, E.C. 1.1.1.262), which converts 4-hydroxy-L-threonine phosphate (HTP) to 3-amino-2-oxopropyl phosphate. This divalent metal ion-dependent enzyme has a strict requirement for the phosphate ester form of the substrate HTP, but can utilize either NADP(+) or NAD(+) as redox cofactor. We report the crystal structure of E. coli PdxA and its complex with HTP and Zn2+. The protein forms tightly bound dimers. Each monomer has an alpha/beta/alpha-fold and can be divided into two subdomains. The active site is located at the dimer interface, within a cleft between the two subdomains and involves residues from both monomers. A Zn2+ ion is bound within each active site, coordinated by three conserved histidine residues from both monomers. In addition two conserved amino acids, Asp(247) and Asp(267), play a role in maintaining integrity of the active site. The substrate is anchored to the enzyme by the interactions of its phospho group and by coordination of the amino and hydroxyl groups by the Zn2+ ion. PdxA is structurally similar to, but limited in sequence similarity with isocitrate dehydrogenase and isopropylmalate dehydrogenase. These structural similarities and the comparison with a NADP-bound isocitrate dehydrogenase suggest that the cofactor binding mode of PdxA is very similar to that of the other two enzymes and that PdxA catalyzes a stepwise oxidative decarboxylation of the substrate HTP.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; Brown Univ, Dept Chem, Providence, RI 02912 USA	National Research Council Canada; Brown University	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	Sivaraman, J/H-8028-2012	J, Sivaraman/0000-0001-9781-5326	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030301, R01GM030301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30301, GM20096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cane DE, 1998, J AM CHEM SOC, V120, P1936, DOI 10.1021/ja9742085; Cane DE, 1999, J AM CHEM SOC, V121, P7722, DOI 10.1021/ja9914947; Cane DE, 2000, J AM CHEM SOC, V122, P4213, DOI 10.1021/ja000224h; Doyle SA, 2001, BIOCHEMISTRY-US, V40, P4234, DOI 10.1021/bi002533q; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 1999, CURR GENET, V34, P478, DOI 10.1007/s002940050423; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Franco MG, 2001, STRUCTURE, V9, P245, DOI 10.1016/S0969-2126(01)00584-6; Garrido-Franco M, 2002, J BIOL CHEM, V277, P12396, DOI 10.1074/jbc.M108734200; GRISSOM CB, 1988, BIOCHEMISTRY-US, V27, P2934, DOI 10.1021/bi00408a040; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HILL RE, 1996, ESCHERICHIA COLI SAL, P695; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; Imada K, 1998, STRUCTURE, V6, P971, DOI 10.1016/S0969-2126(98)00099-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laber B, 1999, FEBS LETT, V449, P45, DOI 10.1016/S0014-5793(99)00393-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; MARCUS JP, 1993, J BACTERIOL, V175, P6505, DOI 10.1128/jb.175.20.6505-6511.1993; MARCUS JP, 1993, BIOCHEM BIOPH RES CO, V190, P1066, DOI 10.1006/bbrc.1993.1157; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Yang Y, 1998, J BACTERIOL, V180, P4294, DOI 10.1128/JB.180.16.4294-4299.1998; Yeh JI, 2002, BIOCHEMISTRY-US, V41, P11649, DOI 10.1021/bi026292t	36	31	35	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43682	43690		10.1074/jbc.M306344200	http://dx.doi.org/10.1074/jbc.M306344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12896974	hybrid			2022-12-27	WOS:000186157000117
J	Yoo, JY; Ghiassi, M; Jirmanova, L; Balliet, AG; Hoffman, B; Fornace, AJ; Liebermann, DA; Bottinger, EP; Roberts, AB				Yoo, JY; Ghiassi, M; Jirmanova, L; Balliet, AG; Hoffman, B; Fornace, AJ; Liebermann, DA; Bottinger, EP; Roberts, AB			Transforming growth factor-beta-induced apoptosis is mediated by SMad-dependent expression of GADD45b through p38 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOMA-CELL LINE; A-INDUCED APOPTOSIS; TGF-BETA; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; REGRESSING LIVER; MAP KINASES; CULTURED-HEPATOCYTES; POSSIBLE ASSOCIATION; TRANSGENIC MICE	Transforming growth factor-beta(TGF-beta)-dependent apoptosis is important in the elimination of damaged or abnormal cells from normal tissues in vivo. In this report, we identify GADD45b as an effector of TGF-beta-induced apoptosis. GADD45b has been shown to be a positive mediator of apoptosis induced by certain cytokines and oncogenes. We show that Gadd45b is an immediate-early response gene for TGF-beta and that the proximal Gadd45b promoter is activated by TGF-beta through the action of Smad2, Smad3, and Smad4. We show that ectopic expression of GADD45b in AML12 murine hepatocytes is sufficient to activate p38 and to trigger apoptotic cell death, whereas antisense inhibition of Gadd45b expression blocks TGF-beta-dependent p38 activation and apoptosis. Furthermore, we also show that TGF-beta can activate p38 and induce apoptosis in mouse primary hepatocytes from wild-type mice, but not from Gadd45b(-/-) mice. All of these findings suggest that GADD45b participates in TGF-beta-induced apoptosis by acting upstream of p38 activation.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Yeshiva University; Albert Einstein College of Medicine	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Rm C629,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Balliet AG, 2001, DNA CELL BIOL, V20, P239, DOI 10.1089/104454901750219125; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Buenemann CL, 2001, CARCINOGENESIS, V22, P447, DOI 10.1093/carcin/22.3.447; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; Haufel T, 1999, ANTICANCER RES, V19, P105; Hsing AY, 1996, CANCER RES, V56, P5146; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; JIRTLE RL, 1991, DIGEST DIS SCI, V36, P659, DOI 10.1007/BF01297035; Johansson N, 2000, J CELL SCI, V113, P227; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN JK, 1992, CANCER RES, V52, P385; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Moser GJ, 1996, CARCINOGENESIS, V17, P1835, DOI 10.1093/carcin/17.9.1835; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OBERHAMMER F, 1992, TOXICOL LETT, V64-5, P701, DOI 10.1016/0378-4274(92)90250-N; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; RIESENBICHLER H, 1994, CARCINOGENESIS LOND, V15, P2763; ROBERTS RL, 1998, PROG LIVER DIS, V3, P57; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schramek H, 2002, NEWS PHYSIOL SCI, V17, P62, DOI 10.1152/nips.01365.2001; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Wong C, 1999, MOL CELL BIOL, V19, P1821; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; YHILDESHEIM J, 2002, CANCER RES, V62, P7305; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	65	190	204	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43001	43007		10.1074/jbc.M307869200	http://dx.doi.org/10.1074/jbc.M307869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933797	hybrid			2022-12-27	WOS:000186157000035
J	Agerer, F; Michel, A; Ohlsen, K; Hauck, CR				Agerer, F; Michel, A; Ohlsen, K; Hauck, CR			Integrin-mediated invasion of Staphylococcus aureus into human cells requires Src family protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN-BINDING PROTEIN; FOCAL ADHESION KINASE; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; ADHERENCE; YERSINIA; GENES; INTERNALIZATION; EXPRESSION; REGULATOR	Staphylococcus aureus, a common cause of nosocomial infections, is able to invade eukaryotic cells by indirectly engaging beta(1) integrin-containing host receptors, whereas non-pathogenic Staphylococcus carnosus is not invasive. Here, we identify intracellular signals involved in integrin-initiated internalization of S. aureus. In particular, the host cell actin cytoskeleton and Src family protein-tyrosine kinases (PTKs) are essential to mediate S. aureus invasion. Src PTKs are activated in response to pathogenic S. aureus, but not S. carnosus. In addition, pharmacological and genetic interference with Src PTK function reduces bacterial internalization. Importantly, Src PTK-deficient cells are resistant to S. aureus invasion, demonstrating the essentiality of host Src PTKs in integrin-mediated uptake of this pathogen.	Univ Wurzburg, Zentrum Infekt Forsch, D-97070 Wurzburg, Germany; Univ Wurzburg, Inst Mol Infekt Biol, D-97070 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Hauck, CR (corresponding author), Univ Wurzburg, Zentrum Infekt Forsch, Rontgenring 11, D-97070 Wurzburg, Germany.							Aplin AE, 1998, PHARMACOL REV, V50, P197; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Clark MA, 1998, INFECT IMMUN, V66, P1237, DOI 10.1128/IAI.66.3.1237-1243.1998; Dziewanowska K, 1999, INFECT IMMUN, V67, P4673, DOI 10.1128/IAI.67.9.4673-4678.1999; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fischer B, 1996, J ORTHOPAED RES, V14, P914, DOI 10.1002/jor.1100140611; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Fowler T, 2000, EUR J CELL BIOL, V79, P672, DOI 10.1078/0171-9335-00104; Hauck CR, 2002, MED MICROBIOL IMMUN, V191, P55, DOI 10.1007/s00430-002-0119-0; Hauck CR, 2003, CURR OPIN MICROBIOL, V6, P43, DOI 10.1016/S1369-5274(03)00004-3; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Hauck CR, 2001, J BIOL CHEM, V276, P17653, DOI 10.1074/jbc.M009329200; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Isberg RR, 2001, J CELL SCI, V114, P21; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; Jett BD, 2002, INFECT IMMUN, V70, P4697, DOI 10.1128/IAI.70.8.4697-4700.2002; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; JONSSON K, 1991, EUR J BIOCHEM, V202, P1041, DOI 10.1111/j.1432-1033.1991.tb16468.x; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Massey RC, 2001, CELL MICROBIOL, V3, P839, DOI 10.1046/j.1462-5822.2001.00157.x; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozeri V, 2001, MOL MICROBIOL, V41, P561, DOI 10.1046/j.1365-2958.2001.02535.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Peacock SJ, 2000, J INFECTION, V41, P23, DOI 10.1053/jinf.2000.0657; PEPE JC, 1993, P NATL ACAD SCI USA, V90, P6473, DOI 10.1073/pnas.90.14.6473; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Steinberg JP, 1996, CLIN INFECT DIS, V23, P255, DOI 10.1093/clinids/23.2.255; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Zamir E, 2001, J CELL SCI, V114, P3583	39	94	96	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42524	42531		10.1074/jbc.M302096200	http://dx.doi.org/10.1074/jbc.M302096200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12893831	hybrid, Green Published			2022-12-27	WOS:000185989500117
J	Cadinanos, J; Varela, I; Mandel, DA; Schmidt, WK; Diaz-Perales, A; Lopez-Otin, C; Freije, JMP				Cadinanos, J; Varela, I; Mandel, DA; Schmidt, WK; Diaz-Perales, A; Lopez-Otin, C; Freije, JMP			AtFACE-2, a functional prenylated protein protease from Arabidopsis thaliana related to mammalian Ras-converting enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-ASSOCIATED METALLOPROTEASE; SACCHAROMYCES-CEREVISIAE; CAAX PROTEASES; IDENTIFICATION; STE24P; GENE; FARNESYLTRANSFERASE; ISOPRENYLATION; TRANSFERASE; EXPRESSION	Eukaryotic proteins containing a CAAX (A is aliphatic amino acid) C-terminal tetrapeptide sequence generally undergo a lipid modification, the addition of a prenyl group. Proteins that are modified by prenylation, such as Ras GTPases, can be subsequently modified by a proteolytic event that removes a C-terminal tripeptide (AAX). Two distinct proteases have been identified that are involved in the CAAX proteolytic step, FACE-1/Ste24 and FACE-2/Rce1. These proteases have different enzymatic properties, substrate specificities, and biological functions. However, a proposal has been made that plants lack a FACE-2/Rce1-type protease. Here, we describe the isolation of a cDNA from Arabidopsis thaliana that encodes a 311-aa protein with characteristics that are similar to the FACE-2/Rce1 group of enzymes. Northern blot analysis demonstrates widespread expression of this gene in plant tissues. Heterologous expression of the A. thaliana cDNA in yeast restores CAAX proteolytic activity to yeast lacking native CAAX proteases. The recombinant protein produced in this system displays an in vivo substrate specificity profile distinct from At-Ste24 and cleaves a farnesylated CAAX tetrapeptide in vitro. These results provide evidence for the existence of a previously unsuspected plant FACE-2/Rce1 ortholog and support the evolutionary conservation of dual CAAX proteolytic systems in eukaryotes.	Univ Oviedo, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University System of Georgia; University of Georgia	Freije, JMP (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Inst Univ Oncol, 4-9,Campus Cristo, E-33006 Oviedo, Spain.	jmpf@correo.uniovi.es	Varela, Ignacio/AAA-7680-2021; Varela, Ignacio/G-1699-2016; López-Otín, Carlos/AAB-2106-2020; Díaz-Perales, Araceli/D-8433-2016; Freije, José M.P./A-6535-2008	Varela, Ignacio/0000-0002-0969-506X; Varela, Ignacio/0000-0002-0969-506X; López-Otín, Carlos/0000-0001-6964-1904; Díaz-Perales, Araceli/0000-0002-1093-3627; Freije, José M.P./0000-0002-4688-8266; Cadinanos, Juan/0000-0001-7561-7759				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bergo MO, 2002, MOL CELL BIOL, V22, P171, DOI 10.1128/MCB.22.1.171-181.2002; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Bracha K, 2002, J BIOL CHEM, V277, P29856, DOI 10.1074/jbc.M202916200; Cadinanos J, 2003, BIOCHEM J, V370, P1047, DOI 10.1042/BJ20021514; Chary SN, 2002, PLANT J, V32, P735, DOI 10.1046/j.1365-313X.2002.01463.x; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Crowell DN, 2000, PROG LIPID RES, V39, P393, DOI 10.1016/S0163-7827(00)00010-2; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dolence JM, 2000, BIOCHEMISTRY-US, V39, P4096, DOI 10.1021/bi9923611; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Freije JMP, 1999, GENOMICS, V58, P270, DOI 10.1006/geno.1999.5834; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; GEORGOPAPADAKOU NH, 1994, ANAL BIOCHEM, V218, P273, DOI 10.1006/abio.1994.1178; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Kumagai H, 1999, BBA-GEN SUBJECTS, V1426, P468, DOI 10.1016/S0304-4165(98)00170-6; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Nijbroek GL, 1998, METHOD ENZYMOL, V292, P193; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; SIKORSKI RS, 1989, GENETICS, V122, P19; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Vernoud V, 2003, PLANT PHYSIOL, V131, P1191, DOI 10.1104/pp.013052; Vicient CM, 1999, ANAL BIOCHEM, V268, P412, DOI 10.1006/abio.1998.3045; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Yalovsky S, 2000, PLANT CELL, V12, P1267, DOI 10.1105/tpc.12.8.1267; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	40	43	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42091	42097		10.1074/jbc.M306700200	http://dx.doi.org/10.1074/jbc.M306700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12928436	hybrid			2022-12-27	WOS:000185989500066
J	Dadke, S; Chernoff, J				Dadke, S; Chernoff, J			Protein-tyrosine phosphatase 1B mediates the effects of insulin on the actin cytoskeleton in immortalized fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATOR; RHO-GTPASES; PTP 1B; C-SRC; CELL; ACTIVATION; RECEPTOR	Insulin regulates diverse cellular responses including actin reorganization. The mechanism by which insulin induces formation of lamellipodia in cultured cells is not known but is likely to involve activation of Src family protein-tyrosine kinases. Here we show that protein-tyrosine phosphatase 1B (PTPIB) activates Src, thereby initiating the activation of a Rac-dependent pathway leading to cytoskeletal remodeling. Conversely, expression of a proline to alanine (P309,310A) PTP1B mutant, which cannot activate Src, fails to activate Rho GTPases or cause changes in actin organization. Rat fibroblasts lacking PTP1B expression do not activate Src or Rac in response to insulin and cannot reorganize actin. These results show that PTP1B, best known as a negative regulator of the metabolic effects of insulin, is required for the effects of insulin on actin organization in immortalized fibroblasts.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [CA-06927, CA-58836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058836, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; AHMAD F, 1995, J BIOL CHEM, V270, P20502; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Buckley DA, 2002, MOL CELL BIOL, V22, P1998, DOI 10.1128/MCB.22.7.1998-2010.2002; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Dadke S, 2002, BIOCHEM J, V364, P377, DOI 10.1042/BJ20011372; Dadke S, 2001, MOL CELL BIOCHEM, V221, P147, DOI 10.1023/A:1010909031310; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fincham VJ, 1999, J CELL SCI, V112, P947; Goldstein Barry J., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P265, DOI 10.2174/1568008013341163; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hassid A, 1999, AM J PHYSIOL-HEART C, V277, pH192, DOI 10.1152/ajpheart.1999.277.1.H192; Johnson TO, 2002, NAT REV DRUG DISCOV, V1, P696, DOI 10.1038/nrd895; KENNER KA, 1993, J BIOL CHEM, V268, P25455; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; MIYATA Y, 1988, EXP CELL RES, V175, P286, DOI 10.1016/0014-4827(88)90193-0; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; NOBES CD, 1995, J CELL SCI, V108, P225; Pathre P, 2001, J NEUROSCI RES, V63, P143, DOI 10.1002/1097-4547(20010115)63:2<143::AID-JNR1006>3.0.CO;2-1; REN XD, 2000, METHODS ENZYMOL, V325; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Tao JC, 2001, J BIOL CHEM, V276, P29520, DOI 10.1074/jbc.M103721200; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; WIENER JR, 1994, AM J OBSTET GYNECOL, V170, P1177, DOI 10.1016/S0002-9378(94)70118-0; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372	50	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40607	40611		10.1074/jbc.M306772200	http://dx.doi.org/10.1074/jbc.M306772200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902327	hybrid			2022-12-27	WOS:000185847200024
J	Juntti-Berggren, L; Webb, DL; Arkhammar, POG; Schultz, V; Schweda, EKH; Tornheim, K; Berggren, PO				Juntti-Berggren, L; Webb, DL; Arkhammar, POG; Schultz, V; Schweda, EKH; Tornheim, K; Berggren, PO			Dihydroxyacetone-induced oscillations in cytoplasmic free Ca2+ and the ATP/ADP ratio in pancreatic beta-cells at substimulatory glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; ALPHA-KETOISOCAPROIC ACID; PURINE NUCLEOTIDE CYCLE; SENSITIVE K+ CHANNELS; PULSATILE INSULIN; MUSCLE EXTRACTS; B-CELLS; GLYCOLYTIC OSCILLATIONS; PYRIDINE-NUCLEOTIDES; INTRACELLULAR PH	Glucose stimulation of pancreatic beta-cells causes oscillatory influx of Ca2+, leading to pulsatile insulin secretion. We have proposed that this is due to oscillations of glycolysis and the ATP/ADP ratio, which modulate the activity of ATP-sensitive K+ channels. We show here that dihydroxyacetone, a secretagogue that feeds into glycolysis below the putative oscillator phosphofructokinase, could cause a single initial peak in cytoplasmic free Ca2+ ([Ca2+](i)) but did not by itself cause repeated oscillations in [Ca2+](i) in mouse pancreatic beta-cells. However, in the presence of a substimulatory concentration of glucose (4 mM), dihydroxyacetone induced [Ca2+](i) oscillations. Furthermore, these oscillations correlated with oscillations in the ATP/ADP ratio, as seen previously with glucose stimulation. Insulin secretion in response to dihydroxyacetone was transient in the absence of glucose but was considerably enhanced and somewhat prolonged in the presence of a substimulatory concentration of glucose, in accordance with the enhanced [Ca2+](i) response. These results are consistent with the hypothesized role of phosphofructokinase as the generator of the oscillations. Dihydroxyacetone may affect phosphofructokinase by raising the free concentration of fructose 1,6-bisphosphate to a critical level at which it activates the enzyme autocatalytically, thereby inducing the pulses of phosphofructokinase activity that cause the metabolic oscillations.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Karolinska Inst, Karolinska Hosp, Rolf Luft Ctr Diabet Res, Dept Mol Med, S-17176 Stockholm, Sweden; Karolinska Inst, Clin Res Ctr, S-14186 Huddinge, Sweden; Univ Coll S Stockholm, S-14186 Huddinge, Sweden	Boston University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Sodertorn University	Tornheim, K (corresponding author), Boston Univ, Sch Med, Dept Biochem, 650 Albany St,Rm 815, Boston, MA 02118 USA.	tornheim@bu.edu		Tornheim, Keith/0000-0002-6235-5128; Berggren, Per-Olof/0000-0001-8991-413X; Webb, Dominic-Luc/0000-0002-6979-9194	NIDDK NIH HHS [DK35914, DK58508, DK53064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, R01DK053064, R56DK035914, R01DK058508, R37DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIZAWA T, 1994, AM J PHYSIOL, V266, pC622, DOI 10.1152/ajpcell.1994.266.3.C622; ANDRES V, 1990, J BIOL CHEM, V265, P21441; ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; Asanuma N, 1997, ENDOCRINOLOGY, V138, P751, DOI 10.1210/en.138.2.751; AVIDOR Y, 1962, J BIOL CHEM, V237, P2377; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; BUSA WB, 1986, ANNU REV PHYSIOL, V48, P389; CHOU HF, 1992, AM J PHYSIOL, V262, pE800, DOI 10.1152/ajpendo.1992.262.6.E800; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DAVIES J, 1994, BIOCHEM J, V304, P295, DOI 10.1042/bj3040295; Deeney JT, 2001, J BIOL CHEM, V276, P36946, DOI 10.1074/jbc.M105056200; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GILON P, 1993, J BIOL CHEM, V268, P22265; GRANT AM, 1980, DIABETOLOGIA, V19, P114, DOI 10.1007/BF00421856; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HELLMAN B, 1974, ARCH BIOCHEM BIOPHYS, V162, P448, DOI 10.1016/0003-9861(74)90204-5; JUNTTIBERGGREN L, 1992, BIOCHEM J, V287, P59, DOI 10.1042/bj2870059; JUNTTIBERGGREN L, 1994, J BIOL CHEM, V269, P14391; KANATSUNA T, 1981, DIABETES, V30, P231, DOI 10.2337/diabetes.30.3.231; Kindmark H, 2001, J BIOL CHEM, V276, P34530, DOI 10.1074/jbc.M102492200; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Larsson O, 1996, P NATL ACAD SCI USA, V93, P5161, DOI 10.1073/pnas.93.10.5161; Lenzen S, 2000, BBA-GEN SUBJECTS, V1523, P65, DOI 10.1016/S0304-4165(00)00100-8; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LONGO EA, 1991, J BIOL CHEM, V266, P9314; LOWRY OH, 1964, J BIOL CHEM, V239, P31; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P168; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V270, P15, DOI 10.1016/0003-9861(89)90002-7; MALAISSE WJ, 1976, MOL CELL ENDOCRINOL, V4, P1, DOI 10.1016/0303-7207(76)90002-2; MATTHEWS DR, 1983, DIABETOLOGIA, V24, P231; MATTHEWS DR, 1983, DIABETES, V32, P617, DOI 10.2337/diabetes.32.7.617; MEGLASSON MD, 1987, DIABETES, V36, P477, DOI 10.2337/diabetes.36.4.477; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; PANTEN U, 1975, DIABETOLOGIA, V11, P569, DOI 10.1007/BF01222108; PAOLISSO G, 1987, DIABETES, V36, P566, DOI 10.2337/diabetes.36.5.566; Porksen N, 1997, AM J PHYSIOL-ENDOC M, V273, pE908; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Salgado AP, 1996, J BIOL CHEM, V271, P8738, DOI 10.1074/jbc.271.15.8738; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; SHEPHERD RM, 1995, J BIOL CHEM, V270, P7915, DOI 10.1074/jbc.270.14.7915; TORNHEIM K, 1976, J BIOL CHEM, V251, P7322; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; TORNHEIM K, 1975, J BIOL CHEM, V250, P6304; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; TSUURA Y, 1994, DIABETOLOGIA, V37, P1082, DOI 10.1007/s001250050220; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074; WEIGLE DS, 1987, DIABETES, V36, P764, DOI 10.2337/diab.36.6.764; YANEY GC, 1995, DIABETES, V44, P1285, DOI 10.2337/diabetes.44.11.1285; ZAWALICH WS, 1978, ENDOCRINOLOGY, V103, P2027, DOI 10.1210/endo-103-6-2027; ZAWALICH WS, 1979, DIABETES, V28, P252, DOI 10.2337/diab.28.3.252	56	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40710	40716		10.1074/jbc.M308248200	http://dx.doi.org/10.1074/jbc.M308248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917415	hybrid			2022-12-27	WOS:000185847200036
J	Kingsbury, TJ; Murray, PD; Bambrick, LL; Krueger, BK				Kingsbury, TJ; Murray, PD; Bambrick, LL; Krueger, BK			Ca2+-dependent regulation of TrkB expression in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIC FACTOR; TRANSCRIPTION FACTOR; FULL-LENGTH; HIPPOCAMPAL-NEURONS; SURFACE EXPRESSION; TYROSINE KINASE; CALCIUM INFLUX; MESSENGER-RNAS; RECEPTOR; BDNF	The neurotrophin brain-derived neurotrophic factor ( BDNF), via activation of its receptor, tyrosine receptor kinase B ( trkB), regulates a wide variety of cellular processes in the nervous system, including neuron survival and synaptic plasticity. Although the expression of BDNF is known to be Ca2+-dependent, the regulation of trkB expression has not been extensively studied. Here we report that depolarization of cultured mouse cortical neurons increased the expression of the full-length, catalytically active isoform of trkB without affecting expression of the truncated isoform. This increase in protein expression was accompanied by increased levels of transcripts encoding full-length, but not truncated, trkB. Depolarization also regulated transcription of the gene, TRKB, via entry of Ca2+ through voltage-gated Ca2+ channels and subsequent activation of Ca2+-responsive elements in the two TRKB promoters. Using transient transfection of neurons with TRKB promoter-luciferase constructs, we found that Ca2+ inhibited the upstream promoter P1 but activated the downstream promoter P2. Ca2+-dependent stimulation of TRKB expression requires two adjacent, non-identical CRE sites located within P2. The coordinated regulation of BDNF and trkB by Ca2+ may play a role in activity-dependent survival and synaptic plasticity by enhancing BDNF signaling in electrically active neurons.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Kingsbury, TJ (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.	tking001@umaryland.edu			NIA NIH HHS [AG10686] Funding Source: Medline; NIGMS NIH HHS [2T32GM08181] Funding Source: Medline; NINDS NIH HHS [5T32NS07375, NS40492] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007375, R01NS040492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010686] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balkowiec A, 2002, J NEUROSCI, V22, P10399; Barettino D, 1999, BBA-GENE STRUCT EXPR, V1446, P24, DOI 10.1016/S0167-4781(99)00056-1; Dorsey SG, 2002, J NEUROSCI, V22, P2571, DOI 10.1523/JNEUROSCI.22-07-02571.2002; Du J, 2000, J CELL BIOL, V150, P1423, DOI 10.1083/jcb.150.6.1423; Eide FF, 1996, J NEUROSCI, V16, P3123; ESCANDON E, 1994, J NEUROSCI, V14, P2054; Ferrer I, 1999, J NEUROPATH EXP NEUR, V58, P729, DOI 10.1097/00005072-199907000-00007; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; Gartner AG, 2002, P NATL ACAD SCI USA, V99, P6386, DOI 10.1073/pnas.092129699; Gonzalez M, 1999, NEURON, V24, P567, DOI 10.1016/S0896-6273(00)81113-7; Haapasalo A, 2002, J BIOL CHEM, V277, P43160, DOI 10.1074/jbc.M205202200; Hartmann M, 2001, EMBO J, V20, P5887, DOI 10.1093/emboj/20.21.5887; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Li YX, 1998, P NATL ACAD SCI USA, V95, P10884, DOI 10.1073/pnas.95.18.10884; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Righi M, 2000, J NEUROSCI, V20, P3165, DOI 10.1523/JNEUROSCI.20-09-03165.2000; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Schinder AF, 2000, TRENDS NEUROSCI, V23, P639, DOI 10.1016/S0166-2236(00)01672-6; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Stoilov P, 2002, BIOCHEM BIOPH RES CO, V290, P1054, DOI 10.1006/bbrc.2001.6301; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; Xia ZG, 1996, J NEUROSCI, V16, P5425	32	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40744	40748		10.1074/jbc.M303082200	http://dx.doi.org/10.1074/jbc.M303082200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900419	hybrid			2022-12-27	WOS:000185847200041
J	Serrano-Heras, G; Salas, M; Bravo, A				Serrano-Heras, G; Salas, M; Bravo, A			In vivo assembly of phage phi 29 replication protein p1 into membrane-associated multimeric structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR-SENSITIVE MUTANTS; BACTERIAL-CELL DIVISION; SUBTILIS PHAGE PHI-29; DNA-REPLICATION; BACILLUS-SUBTILIS; NUCLEAR-MATRIX; TERMINAL PROTEIN; ADENOVIRUS DNA; PROTOFILAMENT SHEETS; INFECTED-CELLS	The mechanisms underlying compartmentalization of prokaryotic DNA replication are largely unknown. In the case of the Bacillus subtilis phage phi29, the viral protein p1 enhances the rate of in vivo viral DNA replication. Previous work showed that p1 generates highly ordered structures in vitro. We now show that protein p1, like integral membrane proteins, has an amphiphilic nature. Furthermore, immunoelectron microscopy studies reveal that p1 has a peripheral subcellular location. By combining in vivo chemical cross-linking and cell fractionation techniques, we also demonstrate that p1 assembles in infected cells into multimeric structures that are associated with the bacterial membrane. These structures exist both during viral DNA replication and when phi29 DNA synthesis is blocked due to the lack of viral replisome components. In addition, protein p1 encoded by plasmid generates membrane-associated multimers and supports DNA replication of a p1-lacking mutant phage, suggesting that the pre-assembled structures are functional. We propose that a phage structure assembled on the cell membrane provides a specific site for phi29 DNA replication.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain.		Bravo, Alicia/Y-5060-2019; Salas, Margarita/J-9873-2014; Garcia, Pedro/L-2808-2017	Bravo, Alicia/0000-0002-4410-3584; Salas, Margarita/0000-0001-5939-3441; Garcia, Pedro/0000-0001-6717-8717; Serrano-Heras, Gemma/0000-0001-9368-4832	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01 GM27242-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Ahola T, 1999, EMBO J, V18, P3164, DOI 10.1093/emboj/18.11.3164; Angeletti PC, 1998, J VIROL, V72, P2896, DOI 10.1128/JVI.72.4.2896-2904.1998; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bravo A, 1997, J MOL BIOL, V269, P102, DOI 10.1006/jmbi.1997.1032; Bravo A, 1998, EMBO J, V17, P6096, DOI 10.1093/emboj/17.20.6096; Bravo A, 2000, EMBO J, V19, P5575, DOI 10.1093/emboj/19.20.5575; BRAVO A, 1994, MOL GEN GENET, V245, P529, DOI 10.1007/BF00282215; Bravo A, 2001, J BIOL CHEM, V276, P21250, DOI 10.1074/jbc.M011296200; Bridge E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P99; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; FREDMAN JN, 1993, J VIROL, V67, P3384, DOI 10.1128/JVI.67.6.3384-3395.1993; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; IVARIE RD, 1973, VIROLOGY, V52, P351, DOI 10.1016/0042-6822(73)90330-9; KONINGS WN, 1973, J BACTERIOL, V116, P1456, DOI 10.1128/JB.116.3.1456-1465.1973; Koppes LJH, 1999, BIOCHIMIE, V81, P803, DOI 10.1016/S0300-9084(00)87163-1; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lampio A, 2000, J BIOL CHEM, V275, P37853, DOI 10.1074/jbc.M004865200; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; Moir RD, 2000, J STRUCT BIOL, V129, P324, DOI 10.1006/jsbi.2000.4251; MORENO F, 1974, VIROLOGY, V62, P1, DOI 10.1016/0042-6822(74)90298-0; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; POMBO A, 1994, EMBO J, V13, P5075, DOI 10.1002/j.1460-2075.1994.tb06837.x; REILLY BE, 1973, J VIROL, V11, P756, DOI 10.1128/JVI.11.5.756-760.1973; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; SALAS M, 1996, DNA REPLICATION EUKA, P131; Salas Margarita, 1993, P843; Sambrook J., 1989, MOL CLONING, pA1; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; Schaad MC, 1997, EMBO J, V16, P4049, DOI 10.1093/emboj/16.13.4049; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; VERHEIJEN R, 1988, J CELL SCI, V90, P11; Yamanaka T, 2000, P NATL ACAD SCI USA, V97, P10107, DOI 10.1073/pnas.170295097; YOSHIKAWA H, 1982, GENE, V17, P323; YOUNGHUSBAND HB, 1982, J VIROL, V43, P705, DOI 10.1128/JVI.43.2.705-713.1982	44	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40771	40777		10.1074/jbc.M306935200	http://dx.doi.org/10.1074/jbc.M306935200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904294	hybrid, Green Published			2022-12-27	WOS:000185847200045
J	Smith, JL; Collins, I; Chandramouli, GVR; Butscher, WG; Zaitseva, E; Freebern, WJ; Haggerty, CM; Doseeva, V; Gardner, K				Smith, JL; Collins, I; Chandramouli, GVR; Butscher, WG; Zaitseva, E; Freebern, WJ; Haggerty, CM; Doseeva, V; Gardner, K			Targeting combinatorial transcriptional complex assembly at specific modules within the interleukin-2 promoter by the immunosuppressant SB203580	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; T-CELL ACTIVATION; P38 MAP KINASE; IL-2 GENE-EXPRESSION; C-REL; LYMPHOCYTE-PROLIFERATION; SELECTIVE-INHIBITION; HISTONE DEACETYLASE	The proximal promoter sequence of the interleukin-2 (IL-2) gene contains a series of composite sites or modules that controls much of its responsiveness to environmental stimuli. The integrated targeting of these modules is therefore a major mode of regulation. This report describes how multiple functional hierarchies, required for the recruitment of the p300 co-activator to the CD28RE/AP1 (TRE) module of the IL-2 promoter, are selectively disrupted in human T-cells by the immunosuppressive and anti-inflammatory actions of the p38 mitogen-activated protein kinase inhibitor ( MAPK), SB203580. The molecular hierarchies targeted by SB203580 include the combinatorial interaction of NF-kappaB and CREB at the CD28RE/AP1 element coupled with the subsequent dynamic co-assembly and activation of p300. Several aspects of this targeting are linked to the ability of SB203580 to inhibit p38 MAPK-controlled pathways. Together, these results provide the molecular basis through which the combinatorial structure and context of the composite elements of the IL-2 promoter dictates mitogen responsiveness and drug susceptibility that are quantitatively and qualitatively distinct from the isolated action of single consensus sequences and/or transcriptional motifs.	NCI, Ctr Adv Technol, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gardner, K (corresponding author), NCI, Ctr Adv Technol, Lab Receptor Biol & Gene Express, NIH, Rm 134C,8717 Grovemont Circle, Bethesda, MD 20892 USA.			Haggerty, Cynthia/0000-0002-6019-2724				Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Attema JL, 2002, J IMMUNOL, V169, P2466, DOI 10.4049/jimmunol.169.5.2466; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Butscher WG, 2001, J BIOL CHEM, V276, P27647, DOI 10.1074/jbc.M009614200; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chaudhry S, 2002, J IMMUNOL, V169, P6767, DOI 10.4049/jimmunol.169.12.6767; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Freebern WJ, 2003, J BIOL CHEM, V278, P2249, DOI 10.1074/jbc.M208517200; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; IHM P, 1965, METHOD INFORM MED, V4, P107; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lehner MD, 2002, J IMMUNOL, V168, P4667, DOI 10.4049/jimmunol.168.9.4667; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; Nambiar MP, 2002, J CELL BIOCHEM, V85, P459, DOI 10.1002/jcb.10160; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nebl G, 1998, J IMMUNOL, V161, P1803; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; PETRAK D, 1994, J IMMUNOL, V153, P2046; Powell JD, 1999, J IMMUNOL, V163, P6631; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; SANG N, 2003, J BIOL CHEM; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Solomou EE, 2001, J IMMUNOL, V166, P5665, DOI 10.4049/jimmunol.166.9.5665; Takahashi I, 1996, J ANTIBIOT, V49, P453, DOI 10.7164/antibiotics.49.453; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tenbrock K, 2003, J IMMUNOL, V170, P2971, DOI 10.4049/jimmunol.170.6.2971; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Ward SG, 1997, BIOCHEM SOC T, V25, pS304, DOI 10.1042/bst025304s; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wyrick JJ, 2002, CURR OPIN GENET DEV, V12, P130, DOI 10.1016/S0959-437X(02)00277-0; Yasui H, 1997, J BIOL CHEM, V272, P28762, DOI 10.1074/jbc.272.45.28762; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu CT, 2002, MOL CELL BIOL, V22, P4556, DOI 10.1128/MCB.22.13.4556-4566.2002; Yu CT, 2001, J IMMUNOL, V166, P284, DOI 10.4049/jimmunol.166.1.284; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	86	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41034	41046		10.1074/jbc.M305615200	http://dx.doi.org/10.1074/jbc.M305615200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896977	hybrid			2022-12-27	WOS:000185847200078
J	Tatsumi, Y; Ohta, S; Kimura, H; Tsurimoto, T; Obuse, C				Tatsumi, Y; Ohta, S; Kimura, H; Tsurimoto, T; Obuse, C			The ORC1 cycle in human cells - I. Cell cycle-regulated oscillation of human ORC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; MCM PROTEINS; S-PHASE; FISSION YEAST; CHROMATIN; ASSOCIATION; INITIATION; XENOPUS	Components of ORC ( the origin recognition complex) are highly conserved among eukaryotes and are thought to play an essential role in the initiation of DNA replication. The level of the largest subunit of human ORC (ORC1) during the cell cycle was studied in several human cell lines with a specific antibody. In all cell lines, ORC1 levels oscillate: ORC1 starts to accumulate in mid-G(1) phase, reaches a peak at the G(1)/S boundary, and decreases to a basal level in S phase. In contrast, the levels of other ORC subunits (ORCs 2 - 5) remain constant throughout the cell cycle. The oscillation of ORC1, or the ORC1 cycle, also occurs in cells expressing ORC1 ectopically from a constitutive promoter. Furthermore, the 26 S proteasome inhibitor MG132 blocks the decrease in ORC1, suggesting that the ORC1 cycle is mainly due to 26 S proteasome- dependent degradation. Arrest of the cell cycle in early S phase by hydroxyurea, aphidicolin, or thymidine treatment is associated with basal levels of ORC1, indicating that ORC1 proteolysis starts in early S phase and is independent of S phase progression. These observations indicate that the ORC1 cycle in human cells is highly linked with cell cycle progression, allowing the initiation of replication to be coordinated with the cell cycle and preventing origins from refiring.	Nara Inst Sci & Technol, Nara 6300101, Japan; Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138510, Japan	Nara Institute of Science & Technology; Tokyo Medical & Dental University (TMDU)	Obuse, C (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068502, Japan.		Kimura, Hiroshi/B-9524-2015; Obuse, Chikashi/F-5273-2011	Kimura, Hiroshi/0000-0003-0854-083X; Tsurimoto, Toshiki/0000-0001-7597-2216; Tatsumi, Yasutoshi/0000-0003-2646-7410				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; DEPAMPHILIS ML, 2003, GENE, V22, P1; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Fujita M, 1998, GENES CELLS, V3, P737, DOI 10.1046/j.1365-2443.1998.00226.x; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Hori Y, 1996, MOL BIOL CELL, V7, P409, DOI 10.1091/mbc.7.3.409; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lygerou Z, 1999, J CELL SCI, V112, P3703; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Ohta S, 2003, J BIOL CHEM, V278, P41535, DOI 10.1074/jbc.M307535200; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Romanowski P, 2000, J BIOL CHEM, V275, P4239, DOI 10.1074/jbc.275.6.4239; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sun WH, 2002, EMBO J, V21, P1437, DOI 10.1093/emboj/21.6.1437; Tadokoro R, 2002, J BIOL CHEM, V277, P15881, DOI 10.1074/jbc.M200322200; Takahashi T, 2003, EMBO J, V22, P964, DOI 10.1093/emboj/cdg079; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200	40	81	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41528	41534		10.1074/jbc.M307534200	http://dx.doi.org/10.1074/jbc.M307534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909627	hybrid			2022-12-27	WOS:000185847200133
J	Duval, DL; Jean, A; Gutierrez-Hartmann, A				Duval, DL; Jean, A; Gutierrez-Hartmann, A			Ras signaling and transcriptional synergy at a flexible Ets-1/Pit-1 composite DNA element is defined by the assembly of selective activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN PROMOTER; HOMEODOMAIN FACTOR; GENE-EXPRESSION; BINDING-SITES; MURINE ETS-1; FACTOR GHF-1; PIT-1; PROTEINS; BETA; PHOSPHORYLATION	Pit-1 and Ets-1 binding to a composite element synergistically activates and targets Ras-mitogen-activated protein kinase signaling to the rat prolactin promoter. These transcriptional responses appear to depend on three molecular features: organization of the Ets-1/Pit-1 composite element, physical interaction of these two factors via the Pit-1 homeodomain (amino acids 199 291) and the Ets-1 regulatory III domain (amino acids 190-257), and assembly of their transcriptional activation domains (TADs). Here we show that the organization of the Ets-1/Pit-1 composite element tolerates significant flexibility with regard to Ras stimulation and synergy. Specifically, the putative monomeric Pit-1 binding site can be substituted with bona fide binding sites for either a Pit-1 monomer or dimer, and these sites tolerated a separation of 28 bp. Additionally, we show that the physical interaction of Ets-1 and Pit-1 is not required for Ras responsiveness or synergy because block mutations of the Pit-1 interaction surface in Ets-1, which reduced Ets-1/Pit-1 binding in vitro, did not significantly affect Ets-1 stimulation of Ras responsiveness or synergy. We also show differential use of distinct TAD subtypes and Pit-1 TAD subregions to mediate either synergy or Ras responsiveness. Specifically, TADs from Gal4, VP16, or Ets-2 regulatory III domain linked to Ets-1 DNA binding domain constructs restored synergy to these TAD/Ets-1 DNA binding domain fusions. Conversely, deletion of the defined Pit-1 TAD (amino acids 2-80) retained synergy, but not Ras responsiveness. Consequently, we further defined the Pit-1 amino-terminal TAD into region 1 (R1, amino acids 2-45) and region 2 (R2, amino acids 46-80). R1 appears to regulate basal and synergistic responses, whereas the Ras response was mapped to R2. In summary, Ras responsiveness and Pit-1/Ets-1 synergy are mediated through the assembly of distinct TADs at a flexible composite element, indicating that different mechanisms underlie these two transcriptional responses and that the Pit-1 R2 subregion represents a novel, tissue-specific Ras-responsive TAD.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Duval, DL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011		NIDDK NIH HHS [DK46868, DK02946, K01 DK002946] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046868, R01DK046868, K01DK002946] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Augustijn KD, 2002, P NATL ACAD SCI USA, V99, P12657, DOI 10.1073/pnas.192693499; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; Budworth PR, 1997, MOL ENDOCRINOL, V11, P1669, DOI 10.1210/me.11.11.1669; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; CONRAD KE, 1992, ONCOGENE, V7, P1279; Courey AJ, 2001, CURR BIOL, V11, pR250, DOI 10.1016/S0960-9822(01)00130-0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diamond SE, 1996, J BIOL CHEM, V271, P28925, DOI 10.1074/jbc.271.46.28925; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Farrow KN, 1996, J BIOL CHEM, V271, P17139, DOI 10.1074/jbc.271.29.17139; GALANG CK, 1994, ONCOGENE, V9, P2913; Gordon DF, 2002, MOL CELL ENDOCRINOL, V196, P53, DOI 10.1016/S0303-7207(02)00223-X; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; Kel-Margoulis OV, 2002, NUCLEIC ACIDS RES, V30, P332, DOI 10.1093/nar/30.1.332; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kishimoto M, 2002, J BIOL CHEM, V277, P45141, DOI 10.1074/jbc.M202991200; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; NOWAKOWSKI BE, 1994, MOL ENDOCRINOL, V8, P1742, DOI 10.1210/me.8.12.1742; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Remenyi A, 2002, BIOCHEM PHARMACOL, V64, P979, DOI 10.1016/S0006-2952(02)01164-4; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P251; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270	48	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39684	39696		10.1074/jbc.M302433200	http://dx.doi.org/10.1074/jbc.M302433200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902343	hybrid			2022-12-27	WOS:000185713800054
J	Sheng, ST; Gao, Y; Khromov, AS; Somlyo, AV; Somlyo, AP; Shao, ZF				Sheng, ST; Gao, Y; Khromov, AS; Somlyo, AV; Somlyo, AP; Shao, ZF			Cryo-atomic force microscopy of unphosphorylated and thiophosphorylated single smooth muscle myosin molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; PHOSPHORYLATION-DEPENDENT REGULATION; HEAVY-MEROMYOSIN; IMAGE-RECONSTRUCTION; 2-HEADED STRUCTURE; SCALLOP MYOSIN; CROSS-BRIDGES; MOTOR DOMAIN; 2 HEADS; ACTIN	The purpose of this study was to determine whether steric blockage of one head by the second head of native two-headed myosin was responsible for the inactivity of nonphosphorylated two-headed myosin compared with the high activity of single-headed myosin, as suggested on the basis of electron microscopy of two-dimensional crystals of heavy meromyosin (Wendt, T., Taylor, D., Messier, T., Trybus, K. M., and Taylor, K. A. (1999) J. Cell Biol. 147, 1385-1390; and Wendt, T., Taylor, D., Trybus, K. M., and Taylor, K. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 4361-4366). Our earlier cryo-atomic force microscopy (cryo-AFM) (Zhang, Y., Shao, Z., Somlyo, A. P., and Somlyo, A. V. (1997) Biophys. J. 72, 1308-1318) indicates that thiophosphorylation of the regulatory light chain increases the separation of the two heads of a single myosin molecule, but the thermodynamic probability of steric hindrance by strong binding between the two heads was not determined. We now report this probability determined by cryo-AFM of single whole myosin molecules shown to have normal low ATPase activity (0.007 s(-1)). We found that the thermodynamic probability of the relative head positions of nonphosphorylated myosin was approximately equal between separated heads as compared with closely apposed heads (energy difference of 0.24 kT (where k is a Boltzman constant and T is the absolute temperature)), and thiophosphorylation increased the number of molecules having separated heads (energy advantage of -1.2 kT (where k is a Boltzman constant and I is the absolute temperature)). Our results do not support the suggestion that strong binding of one head to the other stabilizes the blocked conformation against thermal fluctuations resulting in steric blockage that can account for the low activity of nonphosphorylated two-headed myosin.	Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Shao, ZF (corresponding author), Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, POB 800736,Jordan Hall, Charlottesville, VA 22908 USA.	zs9q@virginia.edu	Shao, Zhifeng/B-6075-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002017] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48807] Funding Source: Medline; NIBIB NIH HHS [EB002017] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Baker JE, 2002, BIOPHYS J, V82, P2134, DOI 10.1016/S0006-3495(02)75560-4; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DREW JS, 1993, CELL MOTIL CYTOSKEL, V26, P291, DOI 10.1002/cm.970260404; Ellison PA, 2003, J BIOL CHEM, V278, P4410, DOI 10.1074/jbc.M211016200; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; HAN WH, 1995, BIOCHEMISTRY-US, V34, P8215, DOI 10.1021/bi00026a001; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; IKEBE M, 1986, J BIOL CHEM, V261, P8249; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; Katoh T, 1996, J BIOL CHEM, V271, P9992, DOI 10.1074/jbc.271.17.9992; Khromov AS, 1998, J PHYSIOL-LONDON, V512, P345, DOI 10.1111/j.1469-7793.1998.345be.x; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P17810, DOI 10.1021/bi981656w; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Liu J, 2003, J MOL BIOL, V329, P963, DOI 10.1016/S0022-2836(03)00516-3; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Matthew JD, 1998, J BIOL CHEM, V273, P31289, DOI 10.1074/jbc.273.47.31289; MOU JX, 1993, REV SCI INSTRUM, V64, P1483, DOI 10.1063/1.1144454; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; Sheng ST, 1998, JPN J APPL PHYS 1, V37, P3828, DOI 10.1143/JJAP.37.3828; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; TRYBUS KM, 1991, J CELL SCI, P87; Wahlstrom JL, 2003, J BIOL CHEM, V278, P5123, DOI 10.1074/jbc.M206963200; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; Wu XD, 1999, J BIOL CHEM, V274, P20328, DOI 10.1074/jbc.274.29.20328; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Zhang YY, 1997, BIOPHYS J, V72, P1308, DOI 10.1016/S0006-3495(97)78777-0; Zhang YY, 1996, BIOPHYS J, V71, P2168, DOI 10.1016/S0006-3495(96)79418-3	42	23	23	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39892	39896		10.1074/jbc.M306094200	http://dx.doi.org/10.1074/jbc.M306094200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12907680	hybrid			2022-12-27	WOS:000185713800076
J	Holden, HM; Rayment, I; Thoden, JB				Holden, HM; Rayment, I; Thoden, JB			Structure and function of enzymes of the Leloir pathway for galactose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GHMP KINASE SUPERFAMILY; ESCHERICHIA-COLI; UDP-GALACTOSE; CRYSTAL-STRUCTURE; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; LACTOCOCCUS-LACTIS; 3-DIMENSIONAL STRUCTURE; ALDOSE 1-EPIMERASE; MEVALONATE KINASE; SUGAR BINDING		Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLARD FJ, 1966, BIOCHEM J, V101, P70, DOI 10.1042/bj1010070; Beebe JA, 2003, BIOCHEMISTRY-US, V42, P4414, DOI 10.1021/bi020639a; Beebe JA, 1998, BIOCHEMISTRY-US, V37, P14989, DOI 10.1021/bi9816047; BORK P, 1993, PROTEIN SCI, V2, P31; BOUFFARD GG, 1994, J MOL BIOL, V244, P269, DOI 10.1006/jmbi.1994.1728; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; DEY PM, 1983, EUR J BIOCHEM, V136, P155, DOI 10.1111/j.1432-1033.1983.tb07720.x; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; ELSAS LJ, 1994, AM J HUM GENET, V54, P1030; Erlandson KA, 2001, APPL ENVIRON MICROB, V67, P1445, DOI 10.1128/AEM.67.4.1445-1452.2001; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; FREY PA, 1982, METHOD ENZYMOL, V87, P20; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Fu ZJ, 2002, J BIOL CHEM, V277, P18134, DOI 10.1074/jbc.M200912200; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; HESTER LS, 1987, J BIOL CHEM, V262, P12092; Holm L, 1997, STRUCTURE, V5, P165, DOI 10.1016/S0969-2126(97)00176-7; HUCHO F, 1971, EUR J BIOCHEM, V23, P489, DOI 10.1111/j.1432-1033.1971.tb01645.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KALCKAR HM, 1960, FED PROC, V19, P984; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; Novelli G, 2000, MOL GENET METAB, V71, P62, DOI 10.1006/mgme.2000.3073; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; Petry KG, 1998, TRENDS GENET, V14, P98, DOI 10.1016/S0168-9525(97)01379-6; Romanowski MJ, 2002, PROTEINS, V47, P568, DOI 10.1002/prot.10118; SCHELL MA, 1977, J BIOL CHEM, V252, P1162; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P10685, DOI 10.1021/bi9704313; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; Thoden JB, 2003, J BIOL CHEM, V278, P33305, DOI 10.1074/jbc.M304789200; Thoden JB, 2003, PROTEIN SCI, V12, P1051, DOI 10.1110/ps.0243203; Thoden JB, 2002, J BIOL CHEM, V277, P27528, DOI 10.1074/jbc.M204413200; Thoden JB, 2002, J BIOL CHEM, V277, P20854, DOI 10.1074/jbc.M201415200; Thoden JB, 2002, J BIOL CHEM, V277, P45458, DOI 10.1074/jbc.M208395200; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; Timson DJ, 2003, FEBS LETT, V543, P21, DOI 10.1016/S0014-5793(03)00364-8; Timson DJ, 2003, EUR J BIOCHEM, V270, P1767, DOI 10.1046/j.1432-1033.2003.03538.x; Timson DJ, 2002, BIOCHIMIE, V84, P265, DOI 10.1016/S0300-9084(02)01399-8; Verhees CH, 2002, BIOCHEM J, V366, P121, DOI 10.1042/BJ20011597; WALKER DG, 1968, BIOCHEM J, V108, P169, DOI 10.1042/bj1080169; WALLENFELS K, 1965, BIOCHEM Z, V343, P307; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; WILSON DB, 1969, J BIOL CHEM, V244, P2132; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	53	344	354	11	63	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43885	43888		10.1074/jbc.R300025200	http://dx.doi.org/10.1074/jbc.R300025200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923184	hybrid			2022-12-27	WOS:000186306700001
J	Jones, P; Messner, B; Nakajima, JI; Schaffner, AR; Saito, K				Jones, P; Messner, B; Nakajima, JI; Schaffner, AR; Saito, K			UGT73C6 and UGT78D1, glycosyltransferases involved in flavonol glycoside biosynthesis in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PETUNIA-HYBRIDA; UDP-GLUCOSE; BIOCHEMICAL-CHARACTERIZATION; HETEROLOGOUS EXPRESSION; MOLECULAR-CLONING; OXIDATIVE STRESS; GLUCOSYLTRANSFERASE; ANTHOCYANIN; FAMILY; GENES	Flavonol glycosides constitute one of the most prominent plant natural product classes that accumulate in the model plant Arabidopsis thaliana. To date there are no reports of functionally characterized flavonoid glycosyltransferases in Arabidopsis, despite intensive research efforts aimed at both flavonoids and Arabidopsis. In this study, flavonol glycosyltransferases were considered in a functional genomics approach aimed at revealing genes involved in determining the flavonol-glycoside profile. Candidate glycosyltransferase-encoding genes were selected based on homology to other known flavonoid glycosyltransferases and two T-DNA knockout lines lacking flavonol-3-O-rhamnoside-7-O-rhamnosides (ugt78D1) and quercetin-3-O-rhamnoside-7-O-glucoside (ugt73C6 and ugt78D1) were identified. To confirm the in planta results, cDNAs encoding both UGT78D1 and UGT73C6 were expressed in vitro and analyzed for their qualitative substrate specificity. UGT78D1 catalyzed the transfer of rhamnose from UDP-rhamnose to the 3-OH position of quercetin and kaempferol, whereas UGT73C6 catalyzed the transfer of glucose from UDPglucose to the 7-OH position of kaempferol-3-O-rhamnoside and quercetin-3-O-rhamnoside, respectively. The present results suggest that UGT78D1 and UGT73C6 should be classified as UDP-rhamnose:flavonol-3-O-rhamnosyltransferase and UDP-glucose:flavonol-3-O-glycoside-7-O-glucosyltransferase, respectively.	Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, JST,Core Res Evolut Sci & Techol,Inage Ku, Chiba 2638522, Japan; GSF, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, D-85764 Neuherberg, Germany	Chiba University; Japan Science & Technology Agency (JST); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Saito, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, JST,Core Res Evolut Sci & Techol,Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.		Saito, Kazuki/D-2670-2009	Saito, Kazuki/0000-0001-6310-5342				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARPELED M, 1991, J BIOL CHEM, V266, P20953; Bloor SJ, 2002, PHYTOCHEMISTRY, V59, P343, DOI 10.1016/S0031-9422(01)00460-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG S, 1993, PLANT MOL BIOL REP, V11; Chong J, 2002, PLANT CELL, V14, P1093, DOI 10.1105/tpc.010436; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; Gibeaut DM, 1997, PLANT PHYSIOL, V115, P317, DOI 10.1104/pp.115.2.317; Harborne J., 1999, HDB NATURAL FLAVONOI, P297; Hirotani M, 2000, PLANTA, V210, P1006, DOI 10.1007/PL00008158; Hollman PCH, 1999, FREE RADICAL RES, V31, P569, DOI 10.1080/10715769900301141; Jackson RG, 2001, J BIOL CHEM, V276, P4350, DOI 10.1074/jbc.M006185200; Jones P, 2001, PLANTA, V213, P164, DOI 10.1007/s004250000492; Jones PR, 2003, J BIOL CHEM, V278, P10291, DOI 10.1074/jbc.M212207200; KAMSTEEG J, 1979, ANAL BIOCHEM, V9, P457; Knekt P, 2002, AM J CLIN NUTR, V76, P560, DOI 10.1093/ajcn/76.3.560; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 2002, J BIOL CHEM, V277, P586, DOI 10.1074/jbc.M109287200; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; Liu CJ, 2002, P NATL ACAD SCI USA, V99, P14578, DOI 10.1073/pnas.212522099; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Martin RC, 1999, PLANT PHYSIOL, V120, P553, DOI 10.1104/pp.120.2.553; McElver J, 2001, GENETICS, V159, P1751; Milbury PE, 2002, MECH AGEING DEV, V123, P997, DOI 10.1016/S0047-6374(01)00383-9; Milkowski C, 2000, PLANTA, V211, P883, DOI 10.1007/s004250000411; Miller KD, 1999, J BIOL CHEM, V274, P34011, DOI 10.1074/jbc.274.48.34011; Olthof MR, 2000, J NUTR, V130, P1200, DOI 10.1093/jn/130.5.1200; Paquette S, 2003, PHYTOCHEMISTRY, V62, P399, DOI 10.1016/S0031-9422(02)00558-7; Quiel JA, 2003, J BIOL CHEM, V278, P6275, DOI 10.1074/jbc.M211822200; Richards KD, 1998, PLANT PHYSIOL, V116, P409, DOI 10.1104/pp.116.1.409; SESSION A, 2003, PLANT CELL, V14, P2985; Tattersall DB, 2001, SCIENCE, V293, P1826, DOI 10.1126/science.1062249; Tolstikov VV, 2002, ANAL BIOCHEM, V301, P298, DOI 10.1006/abio.2001.5513; Veit M, 1999, J NAT PROD, V62, P1301, DOI 10.1021/np990080o; Vogt T, 2000, TRENDS PLANT SCI, V5, P380, DOI 10.1016/S1360-1385(00)01720-9; Weig A, 1997, PLANT PHYSIOL, V114, P1347, DOI 10.1104/pp.114.4.1347; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405; Yamazaki M, 2003, PHYTOCHEMISTRY, V62, P987, DOI 10.1016/S0031-9422(02)00721-5; Yamazaki M, 2002, PLANT MOL BIOL, V48, P401, DOI 10.1023/A:1014043214943	41	248	280	8	73	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43910	43918		10.1074/jbc.M303523200	http://dx.doi.org/10.1074/jbc.M303523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12900416	hybrid			2022-12-27	WOS:000186306700006
J	Tabb, MM; Sun, AX; Zhou, CC; Grun, F; Errandi, J; Romero, K; Pham, H; Inoue, S; Mallick, S; Lin, M; Forman, BM; Blumberg, B				Tabb, MM; Sun, AX; Zhou, CC; Grun, F; Errandi, J; Romero, K; Pham, H; Inoue, S; Mallick, S; Lin, M; Forman, BM; Blumberg, B			Vitamin K-2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X RECEPTOR; ORPHAN NUCLEAR RECEPTORS; MATRIX GLA PROTEIN; ST JOHNS WORT; ALKALINE-PHOSPHATASE; MINERAL DENSITY; OSTEOBLASTIC CELLS; OSTEOSARCOMA CELLS; DRUG-METABOLISM; MESSENGER-RNA	Vitamin K-2 is a critical nutrient required for blood clotting that also plays an important role in bone formation. Vitamin K-2 supplementation up-regulates the expression of bone markers, increases bone density in vivo, and is used clinically in the management of osteoporosis. The mechanism of vitamin K-2 action in bone formation was thought to involve its normal role as an essential cofactor for gamma-carboxylation of bone matrix proteins. However, there is evidence that suggests vitamin K-2 also has a transcriptional regulatory function. Vitamin K-2 bound to and activated the orphan nuclear receptor SXR and induced expression of the SXR target gene, CYP3A4, identifying it as a bona fide SXR ligand. Vitamin K-2 treatment of osteosarcoma cells increased mRNA levels for the osteoblast markers bone alkaline phosphatase, osteoprotegerin, osteopontin, and matrix Gla protein. The known SXR activators rifampicin and hyperforin induced this panel of bone markers to an extent similar to vitamin K-2. Vitamin K-2 was able to induce bone markers in primary osteocytes isolated from wild-type murine calvaria but not in cells isolated from mice deficient in the SXR ortholog PXR. We infer that vitamin K-2 is a transcriptional regulator of bone-specific genes that acts through SXR to favor the expression of osteoblastic markers. Thus, SXR has a novel role as a mediator of bone homeostasis in addition to its role as a xenobiotic sensor. An important implication of this work is that a subset of SXR activators may function as effective therapeutic agents for the management of osteoporosis.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Tokyo, Dept Geriatr Med, Bunkyo Ku, Tokyo 1130033, Japan; City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Gonda Diabet Res Ctr, Duarte, CA 91010 USA	University of California System; University of California Irvine; University of Tokyo; City of Hope; Beckman Research Institute of City of Hope	Blumberg, B (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 5205 McGaugh Hall, Irvine, CA 92697 USA.		Grun, Felix/C-8271-2011	Zhou, Changcheng/0000-0001-7649-0710	NATIONAL CANCER INSTITUTE [R21CA087222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060572] Funding Source: NIH RePORTER; NCI NIH HHS [CA-87222] Funding Source: Medline; NIGMS NIH HHS [GM-60572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKEDO Y, 1992, BIOCHEM BIOPH RES CO, V187, P814, DOI 10.1016/0006-291X(92)91269-V; AKIYAMA Y, 1994, EUR J PHARMACOL, V263, P181, DOI 10.1016/0014-2999(94)90539-8; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; BINKLEY NC, 1995, J NUTR, V125, P1812, DOI 10.1093/jn/125.7.1812; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Blumberg B, 1998, GENE DEV, V12, P1269, DOI 10.1101/gad.12.9.1269; Booth SL, 2000, AM J CLIN NUTR, V71, P1201; BOUCKAERT JH, 1960, NATURE, V185, P849, DOI 10.1038/185849a0; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103; Dussault I, 2001, J BIOL CHEM, V276, P33309, DOI 10.1074/jbc.C100375200; FEDDE KN, 1992, BONE MINER, V17, P145, DOI 10.1016/0169-6009(92)90726-T; Feskanich D, 1999, AM J CLIN NUTR, V69, P74; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FRASER JD, 1990, CALCIFIED TISSUE INT, V46, P270, DOI 10.1007/BF02555007; Grun F, 2002, J BIOL CHEM, V277, P43691, DOI 10.1074/jbc.M206553200; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HARA K, 1993, J BONE MINER RES, V8, P535; HARA K, 1995, BONE, V16, P179, DOI 10.1016/8756-3282(94)00027-W; HART JP, 1985, J CLIN ENDOCR METAB, V60, P1268, DOI 10.1210/jcem-60-6-1268; Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394; Iwamoto I, 1999, MATURITAS, V31, P161, DOI 10.1016/S0378-5122(98)00114-5; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kameda T, 1996, BIOCHEM BIOPH RES CO, V220, P515, DOI 10.1006/bbrc.1996.0436; Kaneki M, 2001, NUTRITION, V17, P315, DOI 10.1016/S0899-9007(00)00554-2; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLIBANSKI A, 2000, NIH CONSENSUS STATE, V17, P1; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Koshihara Y, 1996, CALCIFIED TISSUE INT, V59, P466, DOI 10.1007/s002239900159; Koshihara Y, 1997, J BONE MINER RES, V12, P431, DOI 10.1359/jbmr.1997.12.3.431; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MAJESKA RJ, 1982, J BIOL CHEM, V257, P3362; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; MANOLAGAS SC, 1981, J BIOL CHEM, V256, P7115; Masuyama H, 2002, ENDOCRINOLOGY, V143, P55, DOI 10.1210/en.143.1.55; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; MULKINS MA, 1983, J BIOL CHEM, V258, P6219; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; ORIMO H, 1992, J BONE MINER RES, V7, pS122; Orwoll ES, 1996, ANN INTERN MED, V124, P187, DOI 10.7326/0003-4819-124-2-199601150-00001; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; PRINCE CW, 1987, COLLAGEN REL RES, V7, P305; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361; RODAN SB, 1987, CANCER RES, V47, P4961; SANO Y, 1995, J NUTR SCI VITAMINOL, V41, P499, DOI 10.3177/jnsv.41.499; Schmiedlin-Ren P, 2001, DRUG METAB DISPOS, V29, P1446; SEEMAN E, 1994, J BONE MINER RES, V9, P739; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9; Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sugawara Y, 2002, JPN J PHARMACOL, V88, P262, DOI 10.1254/jjp.88.262; Sumida A, 2000, BIOCHEM BIOPH RES CO, V267, P756, DOI 10.1006/bbrc.1999.2029; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tamada T, 2001, J BONE MINER METAB, V19, P45, DOI 10.1007/s007740170059; Torgerson DJ, 1996, J BONE MINER RES, V11, P293; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; Uematsu T, 1996, J PHARM SCI, V85, P1012, DOI 10.1021/js9600641; Urayama S, 2000, J LAB CLIN MED, V136, P181, DOI 10.1067/mlc.2000.108754; VERMEER C, 1995, ANNU REV NUTR, V15, P1, DOI 10.1146/annurev.nutr.15.1.1; Weber P, 1997, INT J VITAM NUTR RES, V67, P350; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; ZERNIK J, 1990, DIFFERENTIATION, V44, P207, DOI 10.1111/j.1432-0436.1990.tb00619.x; [No title captured]	75	272	298	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43919	43927		10.1074/jbc.M303136200	http://dx.doi.org/10.1074/jbc.M303136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920130	hybrid			2022-12-27	WOS:000186306700007
J	Barnham, KJ; Ciccotosto, GD; Tickler, AK; Ali, FE; Smith, DG; Williamson, NA; Lam, YH; Carrington, D; Tew, D; Kocak, G; Volitakis, I; Separovic, F; Barrow, CJ; Wade, JD; Masters, CL; Cherny, RA; Curtain, CC; Bush, AI; Cappai, R				Barnham, KJ; Ciccotosto, GD; Tickler, AK; Ali, FE; Smith, DG; Williamson, NA; Lam, YH; Carrington, D; Tew, D; Kocak, G; Volitakis, I; Separovic, F; Barrow, CJ; Wade, JD; Masters, CL; Cherny, RA; Curtain, CC; Bush, AI; Cappai, R			Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; HYDROGEN-PEROXIDE; PEPTIDE 1-40; IN-VITRO; DISEASE; PROTEIN; COPPER; ZINC; MECHANISMS; NEURODEGENERATION	The amyloid beta peptide is toxic to neurons, and it is believed that this toxicity plays a central role in the progression of Alzheimer's disease. The mechanism of this toxicity is contentious. Here we report that an Abeta peptide with the sulfur atom of Met-35 oxidized to a sulfoxide (Met(O)Abeta) is toxic to neuronal cells, and this toxicity is attenuated by the metal chelator clioquinol and completely rescued by catalase implicating the same toxicity mechanism as reduced Abeta. However, unlike the unoxidized peptide, Met(O)Abeta is unable to penetrate lipid membranes to form ion channel-like structures, and beta-sheet formation is inhibited, phenomena that are central to some theories for Abeta toxicity. Our results show that, like the unoxidized peptide, Met(O)Abeta will coordinate Cu2+ and reduce the oxidation state of the metal and still produce H2O2. We hypothesize that Met(O)Abeta production contributes to the elevation of soluble Abeta seen in the brain in Alzheimer's disease.	Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3010, Australia; Univ Melbourne, Sch Chem, Melbourne, Vic 3010, Australia; Howard Florey Inst Med Res, Melbourne, Vic 3010, Australia; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Lab Oxidat Biol,Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Psychiat, Charlestown, MA 02129 USA	University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Monash University; Harvard University; Harvard University	Barnham, KJ (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	kbarnham@unimelb.edu.au	Separovic, Frances/D-9698-2011; Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Williamson, Nicholas A/O-9812-2016	Separovic, Frances/0000-0002-6484-2763; Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Williamson, Nicholas A/0000-0002-2173-3452; Volitakis, Irene/0000-0003-0766-817X				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; ATHERTON E, 1983, J CHEM SOC CHEM COMM, P1060, DOI 10.1039/c39830001060; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOAS JF, 1978, BIOL MAGNETIC RESONA; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; CORNELL BA, 1988, BIOPHYS J, V53, P67, DOI 10.1016/S0006-3495(88)83066-2; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Curtain CC, 2003, J BIOL CHEM, V278, P2977, DOI 10.1074/jbc.M205455200; DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; GORDON LM, 1988, ADV MEMBRANE FLUIDIT, V1; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harkany T, 2000, REV NEUROSCIENCE, V11, P329; Harkany T, 1999, PROG NEURO-PSYCHOPH, V23, P963, DOI 10.1016/S0278-5846(99)00058-5; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hou LM, 2002, J BIOL CHEM, V277, P40173, DOI 10.1074/jbc.C200338200; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; Kourie JI, 2001, CELL MOL NEUROBIOL, V21, P173, DOI 10.1023/A:1010932603406; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; Multhaup G, 1998, ALZHEIMERS REP, V1, P147; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Nishino S, 2001, INORG CHEM COMMUN, V4, P86, DOI 10.1016/S1387-7003(00)00213-6; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Palmblad M, 2002, J BIOL CHEM, V277, P19506, DOI 10.1074/jbc.M112218200; PIKE CJ, 1993, J NEUROSCI, V13, P1676; RITCHIE CW, 2003, IN PRESS ARCH NEUROL; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SAITO H, 1986, MAGN RESON CHEM, V24, P835, DOI 10.1002/mrc.1260241002; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; Schoneich C, 2002, ARCH BIOCHEM BIOPHYS, V397, P370, DOI 10.1006/abbi.2001.2621; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Tickler AK, 2001, J PEPT SCI, V7, P488, DOI 10.1002/psc.342; TOMBS MP, 1959, BIOCHEM J, V73, P167, DOI 10.1042/bj0730167; Varadarajan S, 1999, BRAIN RES BULL, V50, P133, DOI 10.1016/S0361-9230(99)00093-3; Varadarajan S, 2001, J AM CHEM SOC, V123, P5625, DOI 10.1021/ja010452r; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yatin SM, 1999, NEUROBIOL AGING, V20, P325; Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200	60	158	168	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42959	42965		10.1074/jbc.M305494200	http://dx.doi.org/10.1074/jbc.M305494200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925530	Green Published, hybrid			2022-12-27	WOS:000186157000030
J	Kawagoe, J; Ohmichi, M; Takahashi, T; Ohshima, C; Mabuchi, S; Takahashi, K; Igarashi, H; Mori-Abe, A; Saitoh, M; Du, BT; Ohta, T; Kimura, A; Kyo, S; Inoue, M; Kurachi, H				Kawagoe, J; Ohmichi, M; Takahashi, T; Ohshima, C; Mabuchi, S; Takahashi, K; Igarashi, H; Mori-Abe, A; Saitoh, M; Du, BT; Ohta, T; Kimura, A; Kyo, S; Inoue, M; Kurachi, H			Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; OVARIAN-CANCER; AKT; TAMOXIFEN; PREVENTION; PHOSPHORYLATION; THERAPY; ACTIVATION	The mechanism by which raloxifene acts in the chemoprevention of breast cancer remains unclear. Because telomerase activity is involved in estrogen-induced carcinogenesis, we examined the effect of raloxifene on estrogen-induced up-regulation of telomerase activity in MCF-7 human breast cancer cell line. Raloxifene inhibited the induction of cell growth and telomerase activity by 17beta-estradiol (E2). Raloxifene inhibited the E2-induced expression of the human telomerase catalytic subunit ( hTERT), and transient expression assays using luciferase reporter plasmids containing various fragments of the hTERT promoter showed that the estrogen-responsive element appeared to be partially responsible for the action of raloxifene. E2 induced the phosphorylation of Akt, and pretreatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, attenuated the E2-induced increases of the telomerase activity and hTERT promoter activity. Raloxifene inhibited the E2-induced Akt phosphorylation. In addition, raloxifene also inhibited the E2-induced hTERT expression via the PI3K/Akt/NFkappaB cascade. Moreover, raloxifene also inhibited the E2-induced phosphorylation of hTERT, association of NFkappaB with hTERT, and nuclear accumulation of hTERT. These results show that raloxifene inhibited the E2-induced up-regulation of telomerase activity not only by transcriptional regulation of hTERT via an estrogen-responsive element-dependent mechanism and the PI3K/Akt/NFkappaB cascade but also by post-translational regulation via phosphorylation of hTERT and association with NFkappaB.	Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Div Nursing, Yamagata 9909585, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208640, Japan	Yamagata University; Yamagata University; Osaka University; Kanazawa University	Ohmichi, M (corresponding author), Yamagata Univ, Sch Med, Dept Obstet & Gynecol, 2-2-2 Iidanishi, Yamagata 9909585, Japan.	masa@med.id.yamagata-u.ac.jp	Mabuchi, Seiji/AAX-1986-2020					ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; ADAMS MR, 1987, ARTERIOSCLEROSIS, V7, P378, DOI 10.1161/01.ATV.7.4.378; Akalin A, 2001, CANCER RES, V61, P4791; Akiyama M, 2003, CANCER RES, V63, P18; Akiyama M, 2002, CANCER RES, V62, P3876; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BarrettConnor E, 1997, CIRCULATION, V95, P252, DOI 10.1161/01.CIR.95.1.252; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen SJ, 1996, CIRCULATION, V93, P577, DOI 10.1161/01.CIR.93.3.577; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Clark AS, 2002, MOL CANCER THER, V1, P707; Cuzick J, 2002, LANCET, V360, P817; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; JACOBSSON J, 1992, J HEART LUNG TRANSPL, V11, P1188; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kuschel B, 2000, EUR J CANCER PREV, V9, P139, DOI 10.1097/00008469-200006000-00001; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; Kyo S, 1999, CANCER RES, V59, P5917; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Markman M, 1996, GYNECOL ONCOL, V62, P4, DOI 10.1006/gyno.1996.0181; Marth C, 1997, INT J GYNECOL CANCER, V7, P256, DOI 10.1046/j.1525-1438.1997.00463.x; Ozes ON, 1999, NATURE, V401, P82; Paez Juan, 2003, Cancer Treat Res, V115, P145; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Powles T, 1998, LANCET, V352, P98; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Veronesi U, 1998, LANCET, V352, P93; Wang ZO, 2002, ONCOGENE, V21, P3517, DOI 10.1038/sj.onc.1205463; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	51	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43363	43372		10.1074/jbc.M304363200	http://dx.doi.org/10.1074/jbc.M304363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917431	hybrid			2022-12-27	WOS:000186157000080
J	Sun, Y; Mochizuki, Y; Majerus, PW				Sun, Y; Mochizuki, Y; Majerus, PW			Inositol 1,3,4-trisphosphate 5/6-kinase inhibits tumor necrosis factor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COP9 SIGNALOSOME; CASPASE ACTIVATION; PROTEIN-KINASE; DEATH DOMAIN; PHOSPHORYLATION; EXPRESSION; FAS; INDUCTION; CLEAVAGE	Tumor necrosis factor receptor 1 (TNF-R1) signaling elicits a wide range of biological responses, including inflammation, proliferation, differentiation, and apoptosis. TNF-R1 activates both caspase-mediated apoptosis and NF-kappaB transcription of anti-apoptotic factors. We now report a link between the TNF-R1 and inositol phosphate signaling pathways. We observed that overexpression of inositol 1,3,4-trisphosphate 5/6-kinase (5/6-kinase) inhibited apoptosis induced by TNFalpha. The antiapoptotic effect by 5/6-kinase is not attributable to NF-kappaB activation, as no changes were detected in the levels of NF-kappaB DNA binding, IkappaBalpha degradation, or antiapoptotic factors, such as x-linked inhibitor of apoptosis protein. Decreased expression of 5/6-kinase by RNA interference rendered HeLa cells more susceptible to TNFalpha-induced apoptosis. Overexpression of 5/6-kinase in human embryonic kidney 293 cells inhibited TNFalpha-induced activation of caspases-8, -3, and -9, BID, and poly(ADP-ribose) polymerase. However, 5/6-kinase did not protect against Fas-, etoposide-, or cycloheximide-induced apoptosis. Further, 5/6-kinase protected against apoptosis induced by the overexpression of TNF-R1-associated death domain but not Fas- associated death domain. Therefore, we suggest that 5/6-kinase modifies TNFalpha-induced apoptosis by interfering with the activation of TNF-R1-associated death domain.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.	phil@im.wustl.edu						Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HANSEN CA, 1988, FEBS LETT, V236, P53, DOI 10.1016/0014-5793(88)80284-9; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Kemp CJ, 2001, CANCER RES, V61, P327; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimada K, 2002, JPN J CANCER RES, V93, P1164, DOI 10.1111/j.1349-7006.2002.tb01219.x; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Sun Y, 2002, J BIOL CHEM, V277, P45759, DOI 10.1074/jbc.M208709200; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Yang BF, 2003, J BIOL CHEM, V278, P7043, DOI 10.1074/jbc.M211278200; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	38	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43645	43653		10.1074/jbc.M300674200	http://dx.doi.org/10.1074/jbc.M300674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925536	hybrid			2022-12-27	WOS:000186157000113
J	Bouma, B; Kroon-Batenburg, LMJ; Wu, YP; Brunjes, B; Posthuma, G; Kranenburg, O; de Groot, PG; Voest, EE; Gebbink, MFBG				Bouma, B; Kroon-Batenburg, LMJ; Wu, YP; Brunjes, B; Posthuma, G; Kranenburg, O; de Groot, PG; Voest, EE; Gebbink, MFBG			Glycation induces formation of amyloid cross-beta structure in albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CULTURED CORTICAL-NEURONS; B SCAVENGER RECEPTOR; HUMAN-SERUM-ALBUMIN; END-PRODUCTS AGE; ENDOTHELIAL-CELLS; FIBRIL FORMATION; ADVANCED GLYCOSYLATION; PLASMINOGEN-ACTIVATOR; ALZHEIMERS-DISEASE	Amyloid fibrils are components of proteinaceous plaques that are associated with conformational diseases such as Alzheimer's disease, transmissible spongiform encephalopathies, and familial amyloidosis. Amyloid polypeptides share a specific quarternary structure element known as cross-beta structure. Commonly, fibrillar aggregates are modified by advanced glycation end products (AGE). In addition, AGE formation itself induces protein aggregation. Both amyloid proteins and protein-AGE adducts bind multiligand receptors, such as receptor for AGE, CD36, and scavenger receptors A and B type I, and the serine protease tissue-type plasminogen activator (tPA). Based on these observations, we hypothesized that glycation induces refolding of globular proteins, accompanied by formation of cross-beta structure. Using transmission electron microscopy, we demonstrate here that glycated albumin condensates into fibrous or amorphous aggregates. These aggregates bind to amyloid-specific dyes Congo red and thioflavin T and to tPA. In contrast to globular albumin, glycated albumin contains amino acid residues in beta-sheet conformation, as measured with circular dichroism spectropolarimetry. Moreover, it displays cross-beta structure, as determined with x-ray fiber diffraction. We conclude that glycation induces refolding of initially globular albumin into amyloid fibrils comprising cross-beta structure. This would explain how glycated ligands and amyloid ligands can bind to the same multiligand "cross-beta structure" receptors and to tPA.	Univ Med Ctr Utrecht, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Med Oncol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Crystal & Struct Chem, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Cell Biol, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University Medical Center	Gebbink, MFBG (corresponding author), Univ Med Ctr Utrecht, Dept Haematol, Thrombosis & Haemostasis Lab, G-03-647,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Kranenburg, Onno/K-4115-2015; Kroon-Batenburg, Loes/J-9058-2016	Kranenburg, Onno/0000-0002-2112-4390; 				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; Bellotti V, 2000, J STRUCT BIOL, V130, P280, DOI 10.1006/jsbi.2000.4248; Bobbink IWG, 1997, DIABETES, V46, P87, DOI 10.2337/diabetes.46.1.87; Bobbink IWG, 1997, BIOCHEM BIOPH RES CO, V240, P595, DOI 10.1006/bbrc.1997.7718; Bornemann KD, 2001, AM J PATHOL, V158, P63, DOI 10.1016/S0002-9440(10)63945-4; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Cohen G, 2001, J AM SOC NEPHROL, V12, P1264, DOI 10.1681/ASN.V1261264; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; Cribbs DH, 2000, BIOCHEMISTRY-US, V39, P5988, DOI 10.1021/bi000029f; Crowther DC, 2002, HUM MUTAT, V20, P1, DOI 10.1002/humu.10100; Damas AM, 2000, J STRUCT BIOL, V130, P290, DOI 10.1006/jsbi.2000.4273; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; FRASER PE, 1991, J NEUROSCI RES, V28, P474, DOI 10.1002/jnr.490280404; GARLICK RL, 1983, J BIOL CHEM, V258, P6142; Gasic-Milenkovic J, 2001, Z GERONTOL GERIATR, V34, P457, DOI 10.1007/s003910170018; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Greten J, 1996, NEPHROL DIAL TRANSPL, V11, P786, DOI 10.1093/oxfordjournals.ndt.a027399; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Hoppener JWM, 2000, NEW ENGL J MED, V343, P411; Husemann J, 2001, J NEUROIMMUNOL, V114, P142, DOI 10.1016/S0165-5728(01)00239-9; Inouye H, 2000, J MOL BIOL, V300, P1283, DOI 10.1006/jmbi.2000.3926; Jackson GS, 2000, CURR OPIN STRUC BIOL, V10, P69, DOI 10.1016/S0959-440X(99)00051-2; Jaroniec CP, 2002, P NATL ACAD SCI USA, V99, P16748, DOI 10.1073/pnas.252625999; Kapurniotu A, 1998, EUR J BIOCHEM, V251, P208, DOI 10.1046/j.1432-1327.1998.2510208.x; Kikuchi S, 1999, J NEUROSCI RES, V57, P280, DOI 10.1002/(SICI)1097-4547(19990715)57:2<280::AID-JNR14>3.0.CO;2-U; Kirpichnikov D, 2001, TRENDS ENDOCRIN MET, V12, P225, DOI 10.1016/S1043-2760(01)00391-5; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; Krieger M, 2001, J CLIN INVEST, V108, P645, DOI 10.1172/JCI13932; KUME S, 1995, AM J PATHOL, V147, P654; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Loske C, 1998, J NEURAL TRANSM, V105, P1005, DOI 10.1007/s007020050108; Lyons TJ, 2000, INVEST OPHTH VIS SCI, V41, P1176; MARSH RE, 1955, ACTA CRYSTALLOGR, V8, P710, DOI 10.1107/S0365110X5500217X; MARSH RE, 1955, BIOCHIM BIOPHYS ACTA, V16, P1, DOI 10.1016/0006-3002(55)90178-5; Matsumoto K, 2000, BIOCHEM J, V352, P233, DOI 10.1042/0264-6021:3520233; Min C, 1999, DIABETES RES CLIN PR, V46, P197, DOI 10.1016/S0168-8227(99)00094-7; Munch G, 1997, BBA-MOL BASIS DIS, V1360, P17, DOI 10.1016/S0925-4439(96)00062-2; NGUYEN JT, 1995, J MOL BIOL, V252, P412, DOI 10.1006/jmbi.1995.0507; Nieuwenhuizen W, 2001, ANN NY ACAD SCI, V936, P237; Niwa T, 2001, SEMIN DIALYSIS, V14, P123, DOI 10.1046/j.1525-139x.2001.00031.x; Ohgami N, 2001, ANN NY ACAD SCI, V947, P350; Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2; Sakata N, 1999, ATHEROSCLEROSIS, V142, P67, DOI 10.1016/S0021-9150(98)00192-0; Sasaki N, 2002, NEUROSCI LETT, V326, P117, DOI 10.1016/S0304-3940(02)00310-5; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; Schmidt AM, 2000, SEMIN THROMB HEMOST, V26, P485, DOI 10.1055/s-2000-13204; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Symmons MF, 1997, FEBS LETT, V412, P397, DOI 10.1016/S0014-5793(97)00809-0; Takeuchi M, 2000, J NEUROPATH EXP NEUR, V59, P1094, DOI 10.1093/jnen/59.12.1094; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; TRUEB B, 1984, COLLAGEN REL RES, V4, P239; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; VLASSARA H, 1994, LAB INVEST, V70, P138; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; Westwood ME, 1997, BBA-MOL CELL RES, V1356, P84, DOI 10.1016/S0167-4889(96)00154-1; Yamagishi S, 2002, J BIOL CHEM, V277, P20309, DOI 10.1074/jbc.M202634200; YAN SD, 1994, J BIOL CHEM, V269, P9889	71	206	219	4	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41810	41819		10.1074/jbc.M303925200	http://dx.doi.org/10.1074/jbc.M303925200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909637	hybrid			2022-12-27	WOS:000185989500033
J	Falcon, AA; Aris, JP				Falcon, AA; Aris, JP			Plasmid accumulation reduces life span in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK BARRIER; RIBOSOMAL DNA; METABOLIC-CONTROL; CHROMATIN-STRUCTURE; SHUTTLE VECTORS; DAUGHTER CELLS; YEAST RDNA; GENES; RECOMBINATION; PROTEIN	Aging in the yeast Saccharomyces cerevisiae is under the control of multiple pathways. The production and accumulation of extrachromosomal rDNA circles (ERCs) is one pathway that has been proposed to bring about aging in yeast. To test this proposal, we have developed a plasmid-based model system to study the role of DNA episomes in reduction of yeast life span. Recombinant plasmids containing different replication origins, cis-acting partitioning elements, and selectable marker genes were constructed and analyzed for their effects on yeast replicative life span. Plasmids containing the ARS1 replication origin reduce life span to the greatest extent of the plasmids analyzed. This reduction in life span is partially suppressed by a CEN4 centromeric element on ARS1 plasmids. Plasmids containing a replication origin from the endogenous yeast 2 mu circle also reduce life span, but to a lesser extent than ARS1 plasmids. Consistent with this, ARS1 and 2 mu origin plasmids accumulate in similar to7-generation-old cells, but ARS1/CEN4 plasmids do not. Importantly, ARS1 plasmids accumulate to higher levels in old cells than 2 mu origin plasmids, suggesting a correlation between plasmid accumulation and life span reduction. Reduction in life span is neither an indirect effect of increased ERC levels nor the result of stochastic cessation of growth. The presence of a fully functional 9.1-kb rDNA repeat on plasmids is not required for, and does not augment, reduction in life span. These findings support the view that accumulation of DNA episomes, including episomes such as ERCs, cause cell senescence in yeast.	Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Aris, JP (corresponding author), Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.	johnaris@ufl.edu		Aris, John/0000-0002-6475-064X	NIA NIH HHS [R21 AG023719-02] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R21AG023719] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Benguria A, 2003, NUCLEIC ACIDS RES, V31, P893, DOI 10.1093/nar/gkg188; Bielinsky AK, 2001, J CELL SCI, V114, P643; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROACH JR, 1991, MOL CELLULAR BIOL YE, V1, P297; CARBON J, 1990, New Biologist, V2, P10; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Coelho PSR, 2002, GENE DEV, V16, P2755, DOI 10.1101/gad.1035002; CONRADWEBB H, 1995, MOL CELL BIOL, V15, P2420; Costa Vitor, 2001, Molecular Aspects of Medicine, V22, P217, DOI 10.1016/S0098-2997(01)00012-7; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; FUTCHER B, 1988, GENETICS, V118, P411; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; HOLM C, 1982, CELL, V29, P585, DOI 10.1016/0092-8674(82)90174-X; Hoopes LLM, 2002, MOL CELL BIOL, V22, P4136, DOI 10.1128/MCB.22.12.4136-4146.2002; Jazwinski SM, 2002, ANNU REV MICROBIOL, V56, P769, DOI 10.1146/annurev.micro.56.012302.160830; Jazwinski SM, 2000, TRENDS GENET, V16, P506, DOI 10.1016/S0168-9525(00)02119-3; Jazwinski SM, 2000, ANN NY ACAD SCI, V908, P21; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Kirchman PA, 1999, GENETICS, V152, P179; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; McVey M, 2001, GENETICS, V157, P1531; Merker RJ, 2002, MOL CELL BIOL, V22, P421, DOI 10.1128/MCB.22.2.421-429.2002; Miller CA, 1999, NUCLEIC ACIDS RES, V27, P3921, DOI 10.1093/nar/27.19.3921; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; Park PU, 2002, METHOD ENZYMOL, V351, P468; Park PU, 1999, MOL CELL BIOL, V19, P3848; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair D, 1998, ANNU REV MICROBIOL, V52, P533, DOI 10.1146/annurev.micro.52.1.533; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; Smith JS, 1998, GENETICS, V149, P1205; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; Ward TR, 2000, MOL CELL BIOL, V20, P4948, DOI 10.1128/MCB.20.13.4948-4957.2000; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221	51	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41607	41617		10.1074/jbc.M307025200	http://dx.doi.org/10.1074/jbc.M307025200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904293	hybrid, Green Accepted			2022-12-27	WOS:000185989500008
J	Li, HD; Ayer, LM; Lytton, J; Deans, JP				Li, HD; Ayer, LM; Lytton, J; Deans, JP			Store-operated cation entry mediated by CD20 in membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL RECEPTOR; FC-EPSILON-RI; AFFINITY IGE RECEPTOR; LIPID RAFTS; CALCIUM INFLUX; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; CA2+ CHANNELS; FAMILY; IDENTIFICATION	B cell activation requires sustained elevation of cytoplasmic free calcium, achieved by influx through store-operated calcium (SOC) channels. The molecular identity of these channels is not known. Ectopic expression of the raft-associated tetraspan protein CD20 in Chinese hamster ovary cells introduced a novel SOC entry pathway that was permeable to strontium as well as to calcium. The activity of this SOC pathway was abolished by deletion of a cytoplasmic sequence in CD20 essential for its efficient raft localization. Strontium-permeable SOC channels were detected in B cells, and B cell receptor-stimulated influx was significantly reduced by downregulation of CD20 expression using short interfering RNA and also by cholesterol depletion. This is the first evidence that raft-associated CD20 constitutes a component of a SOC entry pathway activated by the B cell receptor.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Immunol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Cardiovasc Res Grp, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Deans, JP (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Immunol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Lytton, Jonathan/0000-0003-4770-2512				Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Donato JL, 2002, J CLIN INVEST, V109, P51, DOI 10.1172/JCI200214025; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Guo BC, 2000, IMMUNITY, V13, P243, DOI 10.1016/S1074-7613(00)00024-8; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Ishibashi K, 2001, GENE, V264, P87, DOI 10.1016/S0378-1119(00)00598-9; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Liang YH, 2001, GENOMICS, V72, P119, DOI 10.1006/geno.2000.6472; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; O'Keefe TL, 1998, IMMUNOGENETICS, V48, P125, DOI 10.1007/s002510050412; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Petrie RJ, 2002, J IMMUNOL, V169, P2886, DOI 10.4049/jimmunol.169.6.2886; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; Polyak MJ, 1998, J IMMUNOL, V161, P3242; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920	48	128	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42427	42434		10.1074/jbc.M308802200	http://dx.doi.org/10.1074/jbc.M308802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920111	hybrid			2022-12-27	WOS:000185989500106
J	Poumbourios, P; Maerz, AL; Drummer, HE				Poumbourios, P; Maerz, AL; Drummer, HE			Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODY-RESPONSE; INTERMOLECULAR DISULFIDE BOND; V3 LOOP; SOLUBLE CD4; RECEPTOR-BINDING; ATOMIC-STRUCTURE; IN-VIVO; TRANSMEMBRANE GLYCOPROTEIN; CONFORMATIONAL-CHANGES	Protein-protein interaction surfaces can exhibit structural plasticity, a mechanism whereby an interface adapts to mutations as binding partners coevolve. The HIV-1 envelope glycoprotein gp120-gp41 complex, which is responsible for receptor attachment and membrane fusion, represents an extreme example of a coevolving complex as up to 35% amino acid sequence divergence has been observed in these proteins among HIV-1 isolates. In this study, the function of conserved gp120 contact residues, Leu(593), Trp(596), Gly(597), Lys(601), and Trp(610) within the disulfide-bonded region of gp41, was examined in envelope glycoproteins derived from diverse HIV-1 isolates. We found that the gp120-gp41 association function of the disulfide-bonded region is conserved. However, the contribution of individual residues to gp41 folding and/or stability, gp120-gp41 association, membrane fusion function, and viral entry varied from isolate to isolate. In gp120-gp41 derived from the dual-tropic isolate, HIV-1(89.6), the importance of Trp596 for fusion function was dependent on the chemokine receptor utilized as a fusion cofactor. Thus, the engagement of alternative chemokine receptors may evoke distinct fusion-activation signals involving the site of gp120-gp41 association. An examination of chimeric glycoproteins revealed that the isolate-specific functional contributions of particular gp120-contact residues are influenced by the sequence of gp120 hypervariable regions 1, 2, and 3. These data indicate that the gp120-gp41 association site is structurally and functionally adaptable, perhaps to maintain a functional glycoprotein complex in a setting of host selective pressures driving the rapid coevolution of gp120 and gp41.	St Vincents Inst Med Res, Virol Unit, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Poumbourios, P (corresponding author), St Vincents Inst Med Res, Virol Unit, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.			Drummer, Heidi/0000-0002-0042-6277				ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; Abrahamyan LG, 2003, J VIROL, V77, P5829, DOI 10.1128/JVI.77.10.5829-5836.2003; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Binley JM, 2003, J VIROL, V77, P5678, DOI 10.1128/JVI.77.10.5678-5684.2003; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Bjorndal A, 1997, J VIROL, V71, P7478; Blaak H, 2000, P NATL ACAD SCI USA, V97, P1269, DOI 10.1073/pnas.97.3.1269; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Carrillo A, 1996, J VIROL, V70, P1310, DOI 10.1128/JVI.70.2.1310-1316.1996; Cayabyab M, 1999, J VIROL, V73, P976, DOI 10.1128/JVI.73.2.976-984.1999; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chakrabarti LA, 2002, J VIROL, V76, P1588, DOI 10.1128/JVI.76.4.1588-1599.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002; Cho MW, 1998, J VIROL, V72, P2509, DOI 10.1128/JVI.72.3.2509-2515.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Cormier EG, 2002, J VIROL, V76, P8953, DOI 10.1128/JVI.76.17.8953-8957.2002; Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; Etemad-Moghadam B, 1999, J VIROL, V73, P8873, DOI 10.1128/JVI.73.10.8873-8879.1999; Farzan M, 1998, J VIROL, V72, P7620, DOI 10.1128/JVI.72.9.7620-7625.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fox DG, 1997, J VIROL, V71, P759, DOI 10.1128/JVI.71.1.759-765.1997; FREED EO, 1994, J VIROL, V68, P2503, DOI 10.1128/JVI.68.4.2503-2512.1994; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; Hallenberger S, 1997, J VIROL, V71, P1036, DOI 10.1128/JVI.71.2.1036-1045.1997; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATCH WC, 1992, J IMMUNOL, V148, P3055; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; Hoffman NG, 2002, J VIROL, V76, P3852, DOI 10.1128/JVI.76.8.3852-3864.2002; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; Hu QX, 2000, J VIROL, V74, P11858, DOI 10.1128/JVI.74.24.11858-11872.2000; HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Imamichi H, 2002, P NATL ACAD SCI USA, V99, P13813, DOI 10.1073/pnas.212511599; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Karlsson GB, 1996, J VIROL, V70, P6136, DOI 10.1128/JVI.70.9.6136-6142.1996; Kolchinsky P, 1999, J VIROL, V73, P8120, DOI 10.1128/JVI.73.10.8120-8126.1999; Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200; KUIKEN CL, 2000, HUMAN RETROVIRUSES A; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Labrosse B, 2001, J VIROL, V75, P5457, DOI 10.1128/JVI.75.12.5457-5464.2001; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Lineberger JE, 2002, J VIROL, V76, P3522, DOI 10.1128/JVI.76.7.3522-3533.2002; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Ly A, 2000, J VIROL, V74, P6769, DOI 10.1128/JVI.74.15.6769-6776.2000; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Maerz AL, 2001, J VIROL, V75, P6635, DOI 10.1128/JVI.75.14.6635-6644.2001; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; OBRIEN WA, 1994, J VIROL, V68, P5264, DOI 10.1128/JVI.68.8.5264-5269.1994; Palmer C, 1996, VIROLOGY, V220, P436, DOI 10.1006/viro.1996.0331; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rizzuto C, 2000, AIDS RES HUM RETROV, V16, P741, DOI 10.1089/088922200308747; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Ross TM, 1998, P NATL ACAD SCI USA, V95, P7682, DOI 10.1073/pnas.95.13.7682; Sanders RW, 2000, J VIROL, V74, P5091, DOI 10.1128/JVI.74.11.5091-5100.2000; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; Shioda T, 1997, J VIROL, V71, P4871, DOI 10.1128/JVI.71.7.4871-4881.1997; Singh A, 2000, J VIROL, V74, P10229, DOI 10.1128/JVI.74.21.10229-10235.2000; Smyth RJ, 1998, J VIROL, V72, P4478, DOI 10.1128/JVI.72.5.4478-4484.1998; Stamatatos L, 1998, J VIROL, V72, P7840, DOI 10.1128/JVI.72.10.7840-7845.1998; Sullivan N, 1998, J VIROL, V72, P6332, DOI 10.1128/JVI.72.8.6332-6338.1998; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Theodore TS, 1996, AIDS RES HUM RETROV, V12, P191, DOI 10.1089/aid.1996.12.191; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; van Rij RP, 2000, J CLIN INVEST, V106, P1039, DOI 10.1172/JCI7953; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Zhang CWH, 2001, J BIOL CHEM, V276, P39577, DOI 10.1074/jbc.M107147200; Zhang LQ, 2002, J VIROL, V76, P9465, DOI 10.1128/JVI.76.18.9465-9473.2002; Zhang PF, 2002, J VIROL, V76, P644, DOI 10.1128/JVI.76.2.644-655.2002	99	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42149	42160		10.1074/jbc.M305223200	http://dx.doi.org/10.1074/jbc.M305223200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923196	hybrid			2022-12-27	WOS:000185989500073
J	Truglio, JJ; Theis, K; Feng, YG; Gajda, R; Machutta, C; Tonge, PJ; Kisker, C				Truglio, JJ; Theis, K; Feng, YG; Gajda, R; Machutta, C; Tonge, PJ; Kisker, C			Crystal structure of Mycobacterium tuberculosis MenB, a key enzyme in vitamin K-2 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORTHO-SUCCINYLBENZOIC ACID; ENOYL-COA HYDRATASE; NICOTINAMIDE-ADENINE DINUCLEOTIDE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; MENAQUINONE VITAMIN-K-2; ISOPRENOID BIOSYNTHESIS; CROTONASE SUPERFAMILY; O-SUCCINYLBENZOATE; 1,4-DIHYDROXY-2-NAPHTHOIC ACID	Bacterial enzymes of the menaquinone (Vitamin K-2) pathway are potential drug targets because they lack human homologs. MenB, 1,4-dihydroxy-2-naphthoyl-CoA synthase, the fourth enzyme in the biosynthetic pathway leading from chorismate to menaquinone, catalyzes the conversion of O-succinylbenzoyl-CoA ( OSB-CoA) to 1,4-dihydroxy-2-naphthoyl-CoA (DHNA-CoA). Based on our interest in developing novel tuberculosis chemotherapeutics, we have solved the structures of MenB from Mycobacterium tuberculosis and its complex with acetoacetyl-coenzyme A at 1.8 and 2.3 Angstrom resolution, respectively. Like other members of the crotonase superfamily, MenB folds as an (alpha(3))(2) hexamer, but its fold is distinct in that the C terminus crosses the trimer-trimer interface, forming a flexible part of the active site within the opposing trimer. The highly conserved active site of MenB contains a deep pocket lined by Asp-192, Tyr-287, and hydrophobic residues. Mutagenesis shows that Asp-192 and Tyr-287 are essential for enzymatic catalysis. We postulate a catalytic mechanism in which MenB enables proton transfer within the substrate to yield an oxyanion as the initial step in catalysis. Knowledge of the active site geometry and characterization of the catalytic mechanism of MenB will aid in identifying new inhibitors for this potential drug target.	SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Ctr Struct Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kisker, C (corresponding author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.		Kisker, Caroline/T-1724-2019; Tonge, Peter J/A-7443-2009	Tonge, Peter J/0000-0003-1606-3471; Kisker, Caroline/0000-0002-0216-6026; Theis, Karsten/0000-0003-2697-6143	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044639, R21AI044639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM058190] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44639] Funding Source: Medline; NIGMS NIH HHS [GM 58190] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZERAD R, 1967, BIOCHEM BIOPH RES CO, V27, P253, DOI 10.1016/S0006-291X(67)80070-6; Bahnson BJ, 2002, BIOCHEMISTRY-US, V41, P2621, DOI 10.1021/bi015844p; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Begley TP, 1998, TOP CURR CHEM, V195, P93; Bell AF, 2002, CHEM BIOL, V9, P1247, DOI 10.1016/S1074-5521(02)00263-6; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; BISHOP DHL, 1962, BIOCHEM J, V83, P606, DOI 10.1042/bj0830606; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUNGER AT, 1992, XPLOR VERSION 3 1; CATALA F, 1970, INT Z VITAMINFORSCH, V40, P363; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COLLINS MD, 1977, J GEN MICROBIOL, V100, P221, DOI 10.1099/00221287-100-2-221; DANSETTE P, 1970, BIOCHEM BIOPH RES CO, V40, P1090, DOI 10.1016/0006-291X(70)90906-X; Daruwala R, 1996, FEMS MICROBIOL LETT, V140, P159, DOI 10.1016/0378-1097(96)00173-5; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P14733, DOI 10.1021/bi00253a011; DOWD P, 1995, ANNU REV NUTR, V15, P419, DOI 10.1146/annurev.nu.15.070195.002223; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; HEIDE L, 1982, J BIOL CHEM, V257, P7396; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; IGBAVBOA U, 1990, EUR J BIOCHEM, V192, P441, DOI 10.1111/j.1432-1033.1990.tb19246.x; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kemp LE, 2002, P NATL ACAD SCI USA, V99, P6591, DOI 10.1073/pnas.102679799; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurimoto K, 2001, STRUCTURE, V9, P1253, DOI 10.1016/S0969-2126(01)00686-4; KUSUNOSE E, 1963, BIOCHIM BIOPHYS ACTA, V73, P391; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDUC MM, 1970, EUR J BIOCHEM, V15, P428, DOI 10.1111/j.1432-1033.1970.tb01025.x; LESTER RL, 1959, J BIOL CHEM, V234, P2169; Lichtenthaler HK, 2000, Z NATURFORSCH C, V55, P305; MCGOVERN EP, 1978, ARCH BIOCHEM BIOPHYS, V188, P56, DOI 10.1016/0003-9861(78)90355-7; MEGANATHAN R, 1981, BIOCHEMISTRY-US, V20, P5336, DOI 10.1021/bi00521a038; MEGANATHAN R, 1981, J BIOL CHEM, V256, P9386; MEGANATHAN R, 1981, J BACTERIOL, V145, P328, DOI 10.1128/JB.145.1.328-332.1981; MEGANATHAN R, 1979, FED PROC, V38, P315; MEGANATHAN R, 1980, BIOCHEMISTRY-US, V19, P785, DOI 10.1021/bi00545a026; MEGANATHAN R, 1983, J BACTERIOL, V153, P739, DOI 10.1128/JB.153.2.739-746.1983; MEGANATHAN R, 1979, J BACTERIOL, V140, P92, DOI 10.1128/JB.140.1.92-98.1979; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; Meganathan R, 2001, VITAM HORM, V61, P173; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mursula AM, 2001, J MOL BIOL, V309, P845, DOI 10.1006/jmbi.2001.4671; NOLL H, 1958, J BIOL CHEM, V232, P919; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALANIAPPAN C, 1992, J BACTERIOL, V174, P8111, DOI 10.1128/JB.174.24.8111-8118.1992; Palmer DRJ, 1999, BIOCHEMISTRY-US, V38, P4252, DOI 10.1021/bi990140p; Pelletier DA, 1998, J BACTERIOL, V180, P2330, DOI 10.1128/JB.180.9.2330-2336.1998; Perlman DC, 1997, AIDS, V11, pS173; Putra SR, 1998, FEMS MICROBIOL LETT, V164, P169; Rattan A, 1998, EMERG INFECT DIS, V4, P195, DOI 10.3201/eid0402.980207; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Rowland B, 1995, GENE, V167, P105, DOI 10.1016/0378-1119(95)00662-1; Rowland BM, 1996, GENE, V178, P119, DOI 10.1016/0378-1119(96)00349-6; Rowland BM, 1996, J BACTERIOL, V178, P854, DOI 10.1128/jb.178.3.854-861.1996; Schwender J, 1996, BIOCHEM J, V316, P73, DOI 10.1042/bj3160073; SEGEL WP, 1963, BIOCHIM BIOPHYS ACTA, V73, P380, DOI 10.1016/0926-6569(63)90127-5; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; Sharma V, 1996, GENE, V168, P43, DOI 10.1016/0378-1119(95)00721-0; SHARMA V, 1993, J BACTERIOL, V175, P4917, DOI 10.1128/JB.175.15.4917-4921.1993; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; Thompson TB, 2000, BIOCHEMISTRY-US, V39, P10662, DOI 10.1021/bi000855o; Whittingham JL, 2003, J BIOL CHEM, V278, P1744, DOI 10.1074/jbc.M211188200; Wu WJ, 1997, BIOCHEMISTRY-US, V36, P2211, DOI 10.1021/bi962549+	73	79	84	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42352	42360		10.1074/jbc.M307399200	http://dx.doi.org/10.1074/jbc.M307399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909628	hybrid			2022-12-27	WOS:000185989500097
J	Watanabe, J; Miyazaki, Y; Zimmerman, GA; Albertine, KH; McIntyre, TM				Watanabe, J; Miyazaki, Y; Zimmerman, GA; Albertine, KH; McIntyre, TM			Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; TOLL-LIKE RECEPTOR-2; BACTERIAL LIPOPOLYSACCHARIDE; ESCHERICHIA-COLI; ALLERGIC-ASTHMA; KAPPA-B; MICE; HYPERRESPONSIVENESS; INFLAMMATION; EXPOSURE	The reversible airway hyper-reactivity (AHR) of asthma is modeled by sensitizing and challenging mice with aerosolized ovalbumin. However, the C57BL/6 murine strain does not display the large increase in circulating IgG and IgE antibodies found in human atopy and asthma. We found that commercial ovalbumin was contaminated with lipopolysaccharide (LPS) in amounts sufficient to fully activate endothelial cells in an in vitro assay of the first step of inflammation. Desensitization of TLR4 by LPS pretreatment suppressed the inflammatory effect of ovalbumin. The presence of LPS was occult, because it does not require serum presentation and, like the LPS of Salmonella minnesota, was not suppressed by polymyxin B. Purified ovalbumin did not activate endothelial cells in vitro; however, endotoxin-free ovalbumin was far more effective than commercial material in stimulating IgE production and respiratory dysfunction in a C57BL/6 murine model of AHR. Moreover, endotoxin-free ovalbumin induced lung inflammation with alveolar enlargement and destruction in a histologic pattern that differed from the changes caused by commercial, endotoxin-contaminated ovalbumin. Reconstitution of purified ovalbumin with S. minnesota LPS decreased lung inflammation, decreased changes in lung function, and suppressed anti-ovalbumin antibody production. We conclude endotoxin contaminates ovalbumin preparations and that endotoxin co-administration with the ovalbumin antigen creates a state of tolerance in a murine model of AHR. Co-exposure to endotoxin and antigen occurs in humans through organic dusts, so murine models of AHR may reflect the clinical situation, but models based on commercial ovalbumin do not accurately reflect the effect of protein antigen alone on animal physiology.	Univ Utah, Eccles Inst Human Genet 4130, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntyre, TM (corresponding author), Univ Utah, Eccles Inst Human Genet 4130, Dept Pathol, Salt Lake City, UT 84112 USA.			Albertine, Kurt/0000-0001-8497-0861	NHLBI NIH HHS [HL 44513, P50 HL 50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153, R01HL044513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albertine KH, 2002, AM J PHYSIOL-LUNG C, V283, pL219, DOI 10.1152/ajplung.00324.2001; AWADE AC, 1994, J CHROMATOGR A, V677, P279, DOI 10.1016/0021-9673(94)80156-8; Brass DM, 2003, AM J PHYSIOL-LUNG C, V285, pL755, DOI 10.1152/ajplung.00001.2003; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150, DOI 10.1164/ajrccm.160.4.9806034; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; CAVAILLON JM, 1986, MOL IMMUNOL, V23, P965, DOI 10.1016/0161-5890(86)90127-6; Drazen JM, 1999, CLIN EXP ALLERGY, V29, P37; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; FOTHERGI.LA, 1970, BIOCHEM J, V116, P555, DOI 10.1042/bj1160555; Gleich GJ, 1997, P NATL ACAD SCI USA, V94, P2101, DOI 10.1073/pnas.94.6.2101; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; HEGG PO, 1979, BIOCHIM BIOPHYS ACTA, V579, P73, DOI 10.1016/0005-2795(79)90088-6; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; JOHNSON JR, 1992, INFECT IMMUN, V60, P578, DOI 10.1128/IAI.60.2.578-583.1992; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Manthey CL, 1994, J ENDOTOXIN RES, V1, P84; McIntyre TM, 2003, CURR OPIN HEMATOL, V10, P150, DOI 10.1097/00062752-200303000-00009; Neilsen PO, 2001, J IMMUNOL, V167, P5231, DOI 10.4049/jimmunol.167.9.5231; Nightingale JA, 1998, THORAX, V53, P563, DOI 10.1136/thx.53.7.563; O'Byrne PM, 1999, AM J RESP CRIT CARE, V159, pS41; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591, DOI 10.1164/ajrccm.163.7.2009111; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Rylander R, 2002, J ENDOTOXIN RES, V8, P241, DOI 10.1179/096805102125000452; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305, DOI 10.1164/ajrccm.163.2.ed2000a; Strohmeier GR, 2001, J IMMUNOL, V166, P2063, DOI 10.4049/jimmunol.166.3.2063; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394, DOI 10.1152/ajplung.2001.281.2.L394; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; VACHIER MC, 1995, J CHROMATOGR B, V664, P201, DOI 10.1016/0378-4347(94)00411-W; Vasquez Y R, 2000, Respir Res, V1, P82; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Wilder JA, 1999, AM J RESP CELL MOL, V20, P1326, DOI 10.1165/ajrcmb.20.6.3561; Wooten RM, 1996, J IMMUNOL, V157, P4584; Zimmerman GA, 1997, J CLIN INVEST, V100, pS3; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	42	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42361	42368		10.1074/jbc.M307752200	http://dx.doi.org/10.1074/jbc.M307752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909619	hybrid			2022-12-27	WOS:000185989500098
J	Xu, KY; Kuppusamy, SP; Wang, JQ; Li, HQ; Cui, HM; Dawson, TM; Huang, PL; Burnett, AL; Kuppusamy, P; Becker, LC				Xu, KY; Kuppusamy, SP; Wang, JQ; Li, HQ; Cui, HM; Dawson, TM; Huang, PL; Burnett, AL; Kuppusamy, P; Becker, LC			Nitric oxide protects cardiac sarcolemmal membrane enzyme function and ion active transport against ischemia-induced inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; FREE-RADICALS; SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; MYOCARDIAL-ISCHEMIA; ENDOTHELIAL-CELLS; HYDROXYL RADICALS; SYNTHASE; ISOFORMS	Nitric oxide (NO.) generated from nitric oxide synthase (NOS) isoforms bound to cellular membranes may serve to modulate oxidative stresses in cardiac muscle and thereby regulate the function of key membrane-associated enzymes. Ischemia is known to inhibit the function of sarcolemmal enzymes, including the (Na+ + K+)-ATPase, but it is unknown whether concomitant injury to sarcolemma (SL)-associated NOS isoforms may contribute to this process by reducing the availability of locally generated NO.. Here we report that nNOS, as well as eNOS (SL NOSs), are tightly associated with cardiac SL membranes in several different species. In isolated perfused rat hearts, global ischemia caused a time-dependent irreversible injury to cardiac SL NOSs and a disruption of SL NO. generation. Pretreatment with low concentrations of the NO. donor 1-hydroxy-2-oxo-3-(N-3-methyl- aminopropyl)-3-methyl-1-triazene (NOC-7) markedly protected both SL NOS and (Na+ + K+)-ATPase functions against ischemia-induced inactivation. Moreover, ischemia impaired SL Na+/K+ binding, and NOC-7 significantly prevented ischemic injury to the ion binding sites on (Na+ + K+)-ATPase. These novel findings indicate that NO. can protect cardiac SL NOSs and (Na+ + K+)-ATPase against ischemia-induced inactivation and suggest that locally generated NO. may serve to regulate SL Na+/ K+ ion active transport in the heart.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Neurosci, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Inst Cell Engn, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21224 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02129 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02129 USA; Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University System of Ohio; Ohio State University	Xu, KY (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Rm 308,108 N Greene St, Baltimore, MD 21201 USA.			Huang, Paul/0000-0002-5436-8658	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052175, R01HL033360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52175, HL 33360] Funding Source: Medline; NIDDK NIH HHS [DK 02568] Funding Source: Medline; NINDS NIH HHS [NS 378090] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; HESS ML, 1995, ANN THORAC SURG, V60, P760, DOI 10.1016/0003-4975(95)00574-5; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Huang PL, 1998, PROG BRAIN RES, V118, P13; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Jennings R B, 1995, Monogr Pathol, V37, P47; JENNINGS RB, 1989, HOSP PRACT, V24, P89; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KIM MS, 1987, AM J PHYSIOL, V252, pH252, DOI 10.1152/ajpheart.1987.252.2.H252; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; KUKREJA RC, 1990, AM J PHYSIOL, V259, pH1330, DOI 10.1152/ajpheart.1990.259.5.H1330; KUKREJA RC, 1991, CIRC RES, V69, P1003, DOI 10.1161/01.RES.69.4.1003; KYTE J, 1971, J BIOL CHEM, V246, P4157; KYTE J, 1987, BIOCHEMISTRY-US, V26, P8350, DOI 10.1021/bi00399a049; Li HQ, 2000, J PHARMACOL EXP THER, V295, P563; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miethke A, 2003, ACTA HISTOCHEM, V105, P43, DOI 10.1078/0065-1281-00692; MURPHY JG, 1987, CIRCULATION, V75, P15; Nandagopal K, 2001, J PHARMACOL EXP THER, V297, P474; ONeill CA, 1996, AM J PHYSIOL-HEART C, V271, pH660, DOI 10.1152/ajpheart.1996.271.2.H660; ROSKAMS AJ, 1994, NEURON, V13, P289; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Skou JC, 1998, BIOSCIENCE REP, V18, P155, DOI 10.1023/A:1020196612909; SUN JZ, 1993, CIRC RES, V73, P534, DOI 10.1161/01.RES.73.3.534; Xu KY, 2000, BBA-PROTEIN STRUCT M, V1481, P156, DOI 10.1016/S0167-4838(00)00113-8; Xu KY, 1997, ANN NY ACAD SCI, V834, P680, DOI 10.1111/j.1749-6632.1997.tb52349.x; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Zhang P, 1996, CIRCULATION, V94, P2235, DOI 10.1161/01.CIR.94.9.2235	35	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41798	41803		10.1074/jbc.M306865200	http://dx.doi.org/10.1074/jbc.M306865200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904295	hybrid			2022-12-27	WOS:000185989500031
J	Suliman, HB; Carraway, MS; Welty-Wolf, KE; Whorton, AR; Piantadosi, CA				Suliman, HB; Carraway, MS; Welty-Wolf, KE; Whorton, AR; Piantadosi, CA			Lipopolysaccharide stimulates mitochondrial biogenesis via activation of nuclear respiratory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR-A; KAPPA-B ACTIVATION; REACTIVE OXYGEN; FACTOR-ALPHA; LIVER-MITOCHONDRIA; REDOX REGULATION; MAMMALIAN-CELLS; GENE-EXPRESSION; GROWTH-FACTOR	Exposure to bacterial lipopolysaccharide (LPS) in vivo damages mitochondrial DNA ( mtDNA) and interferes with mitochondrial transcription and oxidative phosphorylation (OXPHOS). Because this damage accompanies oxidative stress and is reversible, we postulated that LPS stimulates mtDNA replication and mitochondrial biogenesis via expression of factors responsive to reactive oxygen species, i.e. nuclear respiratory factor-1 (NRF-1) and mitochondrial transcription factor-A. In testing this hypothesis in rat liver, we found that LPS induces NRF-1 protein expression and activity accompanied by mRNA expression for mitochondrial transcription factor-A, mtDNA polymerase gamma, NRF-2, and single-stranded DNA-binding protein. These events restored the loss in mtDNA copy number and OXPHOS gene expression caused by LPS and increased hepatocyte mitotic index, nuclear cyclin D1 translocation, and phosphorylation of pro-survival kinase, Akt. Thus, NRF-1 was implicated in oxidant-mediated mitochondrial biogenesis to provide OXPHOS for proliferation. This implication was tested in novel mtDNA-deficient cells generated from rat hepatoma cells that overexpress NRF-1. Depletion of mtDNA (rho(o) clones) diminished oxidant production and caused loss of NRF-1 expression and growth delay. NRF-1 expression and growth were restored by exogenous oxidant exposure indicating that oxidative stress stimulates biogenesis in part via NRF-1 activation and corresponding to recovery events after LPS-induced liver damage.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Piantadosi, CA (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3315,Rm 0590,CRII Bldg, Durham, NC 27710 USA.							Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Arai T, 1998, BIOCHEM J, V331, P853, DOI 10.1042/bj3310853; ASUNCION JG, 1996, FASEB J, V10, P333; Au HC, 1998, EUR J BIOCHEM, V251, P164, DOI 10.1046/j.1432-1327.1998.2510164.x; BEYER HS, 1990, BIOCHEM INT, V22, P405; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Cunningham PN, 2002, J IMMUNOL, V168, P5817, DOI 10.4049/jimmunol.168.11.5817; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Enriquez JA, 1999, MOL CELL BIOL, V19, P657; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FAIRMAN MP, 1990, J CELL SCI, V95, P1; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Gao CH, 1999, HEPATOLOGY, V30, P1405, DOI 10.1002/hep.510300602; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kantrow SP, 1997, ARCH BIOCHEM BIOPHYS, V345, P278, DOI 10.1006/abbi.1997.0264; Kato A, 1998, BIOCHEM BIOPH RES CO, V245, P70, DOI 10.1006/bbrc.1998.8377; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kinnula VL, 1998, CANCER LETT, V125, P191, DOI 10.1016/S0304-3835(97)00511-9; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603; LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; Ozes ON, 1999, NATURE, V401, P82; PARAIDATHATHU T, 1992, FREE RADICAL BIO MED, V13, P289, DOI 10.1016/0891-5849(92)90176-H; Ramljak D, 2000, CARCINOGENESIS, V21, P1537, DOI 10.1093/carcin/21.8.1537; ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SIMONSON SG, 1994, CIRC SHOCK, V43, P34; Suliman HB, 2002, FREE RADICAL BIO MED, V32, P246, DOI 10.1016/S0891-5849(01)00797-3; Suliman HB, 2003, AM J RESP CRIT CARE, V167, P570, DOI 10.1164/rccm.200206-518OC; Suliman HB, 1996, GENE, V171, P275, DOI 10.1016/0378-1119(95)00895-0; Taylor DE, 1998, AM J PHYSIOL-LUNG C, V275, pL139, DOI 10.1152/ajplung.1998.275.1.L139; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Turpaev KT, 2002, BIOCHEMISTRY-MOSCOW+, V67, P281, DOI 10.1023/A:1014819832003; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WIESNER RJ, 1994, AM J PHYSIOL, V267, pC229, DOI 10.1152/ajpcell.1994.267.1.C229; WOLF HK, 1992, HEPATOLOGY, V15, P707, DOI 10.1002/hep.1840150426; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	58	144	156	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41510	41518		10.1074/jbc.M304719200	http://dx.doi.org/10.1074/jbc.M304719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902348	hybrid			2022-12-27	WOS:000185847200131
J	Fenton, MS; Gralla, JD				Fenton, MS; Gralla, JD			Roles for inhibitory interactions in the use of the-10 promoter element by sigma 70 holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; AROMATIC-AMINO-ACIDS; SINGLE-STRANDED-DNA; NONTEMPLATE STRAND; CONSERVED REGION-2; BACILLUS-SUBTILIS; OPEN COMPLEX; RECOGNITION; BINDING; TRANSCRIPTION	A panel of seven -10 region DNA mutants was tested for holoenzyme binding against a panel of 13 region 2 mutants of sigma70. No patterns were noticed that would indicate unique interactions between individual amino acids and individual -10 region bases. Instead, certain amino acid substitutions led to increased holoenzyme binding to DNA, implying that the wild type interactions are associated with an inhibitory component. These inhibitory interactions were stronger on DNA containing non-consensus sequences, like those of typical promoters. In addition, the DNA segment downstream from the -10 element was also inhibitory to binding when in duplex form but stimulated binding when in single strand form. Overall, the data suggest that -10 region duplex recognition and melting have a large component of overcoming unfavorable protein: DNA base interactions, particularly when the bases are non-consensus, and that this contributes to setting physiologically appropriate variations in transcription rate.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buckle M, 1999, J MOL BIOL, V285, P955, DOI 10.1006/jmbi.1998.2391; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Fenton MS, 2001, P NATL ACAD SCI USA, V98, P9020, DOI 10.1073/pnas.161085798; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Fenton MS, 2003, NUCLEIC ACIDS RES, V31, P2745, DOI 10.1093/nar/gkg400; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GOPAL V, 1994, J MOL BIOL, V242, P9, DOI 10.1006/jmbi.1994.1553; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; Lee SJ, 2003, J MOL BIOL, V329, P941, DOI 10.1016/S0022-2836(03)00369-3; Lee SJ, 2002, J BIOL CHEM, V277, P47420, DOI 10.1074/jbc.M208363200; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MEIKLEJOHN AL, 1989, J MOL BIOL, V207, P661, DOI 10.1016/0022-2836(89)90236-2; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; STEFANO JE, 1980, J BIOL CHEM, V255, P423; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; Wang L, 1999, J BACTERIOL, V181, P7558, DOI 10.1128/JB.181.24.7558-7565.1999; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; ZILLIG W, 1971, COLD SPRING HARB SYM, V35, P47	32	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39669	39674		10.1074/jbc.M307412200	http://dx.doi.org/10.1074/jbc.M307412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902332	hybrid			2022-12-27	WOS:000185713800052
J	Frouin, I; Maga, G; Denegri, M; Riva, F; Savio, M; Spadari, S; Prosperi, E; Scovassi, AI				Frouin, I; Maga, G; Denegri, M; Riva, F; Savio, M; Spadari, S; Prosperi, E; Scovassi, AI			Human proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21(waf1/cip1) - A dynamic exchange of partners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; PCNA; REPAIR; COMPLEX; IDENTIFICATION; ASSOCIATION; FIBROBLASTS; RECRUITMENT; IRRADIATION; EXPRESSION	We addressed the analysis of the physical and functional association of proliferating cell nuclear antigen (PCNA), a protein involved in many DNA transactions, with poly(ADP-ribose) polymerase (PARP-1), an enzyme that plays a crucial role in DNA repair and interacts with many DNA replication/repair factors. We demonstrated that PARP-1 and PCNA co-immunoprecipitated both from the soluble and the DNA-bound fraction isolated from S-phase-synchronized HeLa cells. Immunoprecipitation experiments with purified proteins further confirmed a physical association between PARP-1 and PCNA. To investigate the effect of this association on PARP-1 activity, an assay based on the incorporation of radioactive NAD was performed. Conversely, the effect of PARP-1 on PCNA-dependent DNA synthesis was assessed by a DNA polymerase delta assay. A marked inhibition of both reactions was found. Unexpectedly, PARP-1 activity also decreased in the presence of p21(waf1/cip1). By pull-down experiments, we provided the first evidence for an association between PARP- 1 and p21, which involves the C-terminal part of p21 protein. This association was further demonstrated to occur also in vivo in MNNG (N-methyl-N'-nitro-N-nitrosoguanidine)-treated human fibroblasts. These observations suggest that PARP-1 and p21 could cooperate in regulating the functions of PCNA during DNA replication/repair.	CNR, Ist Genet Mol, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Pavia	Scovassi, AI (corresponding author), CNR, Ist Genet Mol, Via Abbiategrasso 207, I-27100 Pavia, Italy.	scovassi@igm.cnr.it	Scovassi, Anna Ivana/F-2458-2010; Maga, Giovanni/C-5409-2009; denegri, marco/D-9307-2019; Prosperi, Ennio/A-3439-2014	Scovassi, Anna Ivana/0000-0003-3484-9881; Maga, Giovanni/0000-0001-8092-1552; denegri, marco/0000-0003-1665-0625; Prosperi, Ennio/0000-0001-5391-5157				Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; EKI T, 1991, J BIOL CHEM, V266, P3087; EKI T, 1994, FEBS LETT, V356, P261, DOI 10.1016/0014-5793(94)01280-6; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Frouin I, 2003, EMBO REP, V4, P666, DOI 10.1038/sj.embor.embor886; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; ROOS G, 1993, LAB INVEST, V68, P204; Savio M, 1998, CARCINOGENESIS, V19, P591, DOI 10.1093/carcin/19.4.591; Savio M, 1996, ONCOGENE, V13, P1591; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R	25	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39265	39268		10.1074/jbc.C300098200	http://dx.doi.org/10.1074/jbc.C300098200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12930846	hybrid			2022-12-27	WOS:000185713800002
J	Gitan, RS; Shababi, M; Kramer, M; Eide, DJ				Gitan, RS; Shababi, M; Kramer, M; Eide, DJ			A cytosolic domain of the yeast Zrt1 zinc transporter is required for its post-translational inactivation in response to zinc and cadmium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DEPENDENT PHOSPHORYLATION; A-FACTOR RECEPTOR; SACCHAROMYCES-CEREVISIAE; URACIL PERMEASE; UBIQUITIN CONJUGATION; VACUOLAR DEGRADATION; MALTOSE PERMEASE; GENE ENCODES; ENDOCYTOSIS; PROTEIN	Nutrient metals such as zinc are both essential to life and potentially toxic if overaccumulated by cells. Nonessential toxic metals like cadmium can enter cells through the uptake transporters responsible for nutrient metal acquisition. Therefore, in the face of ever changing extracellular metal levels, organisms tightly control their intracellular levels of nutrient metals and prevent accumulation of toxic metals. We show here that post-translational inactivation of the yeast Zrt1 zinc uptake transporter is important for zinc homeostasis. During the transition from zinc-limiting to zinc-replete growth conditions (i.e. zinc shock), the Zrt1 transporter is ubiquitinated, endocytosed, and subsequently degraded in the vacuole. To further understand this process at a molecular level, we mapped a region of Zrt1 required for ubiquitination and endocytosis in response to zinc to a domain located on the intracellular surface of the plasma membrane. This domain is a critical cis-acting component of the metal signaling pathway that controls Zrt1 protein trafficking. Using mutant alleles defective for metal-responsive inactivation, we also show that Zrt1 inactivation may be an important mechanism for preventing cadmium uptake and toxicity in zinc-limited cells.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Colwell R R, 2000, J Infect Chemother, V6, P121, DOI 10.1007/PL00012151; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; EIDE D, 1992, J BIOL CHEM, V267, P20774; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Gomes DS, 2002, BBA-GEN SUBJECTS, V1573, P21, DOI 10.1016/S0304-4165(02)00324-0; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Koch AL, 1997, MICROBIOL MOL BIOL R, V61, P305, DOI 10.1128/.61.3.305-318.1997; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Mason B., 1982, PRINCIPLES GEOCHEMIS; Medintz I, 1998, J BIOL CHEM, V273, P34454, DOI 10.1074/jbc.273.51.34454; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sherman F., 1986, METHODS YEAST GENETI; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WERTMAN KF, 1992, GENETICS, V132, P337; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	37	60	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39558	39564		10.1074/jbc.M302760200	http://dx.doi.org/10.1074/jbc.M302760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893829	hybrid			2022-12-27	WOS:000185713800037
J	Szurmant, H; Bunn, MW; Cannistraro, VJ; Ordal, GW				Szurmant, H; Bunn, MW; Cannistraro, VJ; Ordal, GW			Bacillus subtilis hydrolyzes CheY-P at the location of its action, the flagellar switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; CHEMOTACTIC RESPONSE; TRANSCRIPTION FACTOR; THERMOTOGA-MARITIMA; GENE; PHOSPHORYLATION; EXPRESSION; MECHANISM; PROTEIN	In this report we show that in Bacillus subtilis the flagellar switch, which controls direction of flagellar rotation based on levels of the chemotaxis primary response regulator, CheY-P, also causes hydrolysis of CheY-P to form CheY and P-i. This task is performed in Escherichia coli by CheZ, which interestingly enough is primarily located at the receptors, not at the switch. In particular we have identified the phosphatase as FliY, which resembles E. coli switch protein FliN only in its C-terminal part, while an additional N-terminal domain is homologous to another switch protein FliM and to CheC, a protein found in the archaea and many bacteria but not in E. coli. Previous E. coli studies have localized the CheY-P binding site of the switch to FliM residues 6 - 15. These residues are almost identical to the residues 6 - 15 in both B. subtilis FliM and FliY. We were able to show that both of these proteins are capable of binding CheY-P in vitro. Deletion of this binding region in B. subtilis mutant fliM caused the same phenotype as a cheY mutant ( clockwise flagellar rotation), whereas deletion of it in fliY caused the opposite. We showed that FliY increases the rate of CheY-P hydrolysis in vitro. Consequently, we imagine that the duration of enhanced CheY-P levels caused by activation of the CheA kinase upon attractant binding to receptors, is brief due both to adaptational processes and to phosphatase activity of FliY.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Liberal Arts & Sci, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Ordal, GW (corresponding author), Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054365] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM54365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA SI, 2002, ACILLUS SUBTILIS ITS, P437; Berg H C, 1974, Antibiot Chemother (1971), V19, P55; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; BISCHOFF DS, 1993, BIOCHEMISTRY-US, V32, P9256, DOI 10.1021/bi00086a035; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P2715, DOI 10.1111/j.1365-2958.1992.tb01448.x; BISCHOFF DS, 1991, J BIOL CHEM, V266, P12301; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P23, DOI 10.1111/j.1365-2958.1992.tb00833.x; Bren A, 1998, J MOL BIOL, V278, P507, DOI 10.1006/jmbi.1998.1730; Celandroni F, 2000, FEMS MICROBIOL LETT, V190, P247, DOI 10.1016/S0378-1097(00)00343-8; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; GLUCH MF, 1995, J BACTERIOL, V177, P5473, DOI 10.1128/jb.177.19.5473-5479.1995; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; Karatan E, 2001, J BIOL CHEM, V276, P43618, DOI 10.1074/jbc.M104955200; Kirby JR, 1999, J BIOL CHEM, V274, P11092, DOI 10.1074/jbc.274.16.11092; Kirby JR, 2000, MOL MICROBIOL, V35, P44, DOI 10.1046/j.1365-2958.2000.01676.x; Kirby JR, 2001, MOL MICROBIOL, V42, P573, DOI 10.1046/j.1365-2958.2001.02581.x; Kristich CJ, 2002, J BIOL CHEM, V277, P25356, DOI 10.1074/jbc.M201334200; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; Nelson KE, 2001, METHOD ENZYMOL, V330, P169; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Perego M, 2001, MOL MICROBIOL, V42, P133, DOI 10.1046/j.1365-2958.2001.02611.x; Senesi S, 2002, MICROBIOL-SGM, V148, P1785, DOI 10.1099/00221287-148-6-1785; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; Zhao R, 2002, NAT STRUCT BIOL, V9, P570; ZUBERI AR, 1991, J BACTERIOL, V173, P710, DOI 10.1128/jb.173.2.710-719.1991	34	52	55	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48611	48616		10.1074/jbc.M306180200	http://dx.doi.org/10.1074/jbc.M306180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12920116	hybrid, Green Submitted			2022-12-27	WOS:000186829000013
J	Belfort, GM; Kandror, KV				Belfort, GM; Kandror, KV			Cellugyrin and synaptogyrin facilitate targeting of synaptophysin to a ubiquitous synaptic vesicle-sized compartment in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; SUBCELLULAR-LOCALIZATION; MEMBRANE-PROTEINS; BIOGENESIS; TRANSPORT; SYNAPTOTAGMIN; MICROVESICLES; FIBROBLASTS; PC12-CELLS; SIGNALS	Cellugyrin represents a ubiquitously expressed four-transmembrane domain protein that is closely related to synaptic vesicle protein synaptogyrin and, more remotely, to synaptophysin. We report here that, in PC12 cells, cellugyrin is localized in synaptic-like microvesicles (SLMVs), along with synaptogyrin and synaptophysin. Upon overexpression of synaptophysin in PC12 cells, it is localized in rapidly sedimenting membranes and practically is not delivered to the SLMVs. On the contrary, the efficiency of the SLMV targeting of exogenously expressed cellugyrin and synaptogyrin is high. Moreover, expression of cellugyrin ( or synaptogyrin) in PC12 cells dramatically and specifically increases SLMV targeting of endogenous synaptophysin. Finally, we utilized the SLMV purification scheme on a series of non-neuroendocrine cell types including the mouse fibroblast cell line 3T3-L1, the Chinese hamster ovary cell line CHO-K1, and the monkey kidney epithelial cell line COS7 and found that a cellugyrin-positive microvesicular compartment was present in all cell types tested. We suggest that synaptic vesicles have evolved from cellugyrin-positive ubiquitous microvesicles and that neuroendocrine SLMVs represent a step along that pathway of evolution.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K124D,715 Albany St, Boston, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313				Blagoveshchenskaya AD, 1999, MOL BIOL CELL, V10, P3979, DOI 10.1091/mbc.10.11.3979; Blagoveshchenskaya AD, 2000, MOL BIOL CELL, V11, P1801, DOI 10.1091/mbc.11.5.1801; Blagoveshchenskaya AD, 1999, J CELL BIOL, V145, P1419, DOI 10.1083/jcb.145.7.1419; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; FEANY MB, 1993, J CELL BIOL, V123, P575, DOI 10.1083/jcb.123.3.575; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Haass NK, 1996, J CELL BIOL, V134, P731, DOI 10.1083/jcb.134.3.731; Hubner K, 2002, INT REV CYTOL, V214, P103; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; Kedra D, 1998, HUM GENET, V103, P131, DOI 10.1007/s004390050795; Kupriyanova TA, 2000, J BIOL CHEM, V275, P36263, DOI 10.1074/jbc.M002797200; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBE RE, 1994, J CELL BIOL, V127, P1589, DOI 10.1083/jcb.127.6.1589; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Thoidis G, 2001, TRAFFIC, V2, P577, DOI 10.1034/j.1600-0854.2001.20807.x; Xu Z, 2002, J BIOL CHEM, V277, P47972, DOI 10.1074/jbc.C200486200	30	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47971	47978		10.1074/jbc.M304174200	http://dx.doi.org/10.1074/jbc.M304174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12928441	hybrid			2022-12-27	WOS:000186731400075
J	Clement, MJ; Imberty, A; Phalipon, A; Perez, S; Simenel, C; Mulard, LA; Delepierre, M				Clement, MJ; Imberty, A; Phalipon, A; Perez, S; Simenel, C; Mulard, LA; Delepierre, M			Conformational studies of the O-specific polysaccharide of Shigella flexneri 5a and of four related synthetic pentasaccharide fragments using NMR and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSENTERIAE TYPE-1; CAPSULAR POLYSACCHARIDE; COUPLING-CONSTANTS; CONJUGATE VACCINES; FORCE-FIELD; SEROTYPE 5A; EPITOPE; MECHANICS; SPECTRA; ANTIGEN	As part of a program for the development of synthetic vaccines against the pathogen Shigella flexneri, we used a combination of NMR and molecular modeling methods to study the conformations of the O-specific polysaccharide (O-SP) of S. flexneri 5a and of four related synthetic pentasaccharide fragments. The NMR study, based on the analysis of H-1 and C-13 chemical shifts, the evaluation of inter-residue distances, and the measurement of one- and three-bond heteronuclear coupling constants, showed that the conformation of one of the four pentasaccharides is similar to that of the native O-SP in solution. Interestingly, inhibition enzyme-linked immunosorbent assay demonstrated that a protective monoclonal antibody specific for S. flexneri 5a has a greater affinity for this pentasaccharide than for the others. We carried out a complete conformational search on the pentasaccharides using the CICADA algorithm interfaced with MM3 force field. We calculated Boltzmann-averaged inter-residue distances and (3)J(C,H) coupling constants for the different conformational families and compared the results with NMR data for all pentasaccharides. Our experimental data are consistent with only one conformational family. We also used molecular modeling data to build models of the O-SP with the molecular builder program POLYS. The models that are in agreement with NMR data adopt right-handed 3-fold helical structures in which the branched glucosyl residue points outwards.	Inst Pasteur, CNRS, URA 2185, Unite RMN Biomol, F-75724 Paris 15, France; Univ Grenoble 1, CNRS, CERMAV, F-38041 Grenoble 09, France; Inst Pasteur, CNRS, URA 2128, Unite Chim Organ, F-75724 Paris 15, France; Inst Pasteur, Unite Pathogenie Microbienne Mol, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Delepierre, M (corresponding author), Inst Pasteur, CNRS, URA 2185, Unite RMN Biomol, 28 Rue Dr Roux, F-75724 Paris 15, France.	murield@pasteur.fr	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527				ALLINGER NL, 1989, J AM CHEM SOC, V111, P8551, DOI 10.1021/ja00205a001; ALLINGER NL, 1990, J AM CHEM SOC, V112, P8293, DOI 10.1021/ja00179a012; BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; BOCK K, 1982, J CHEM SOC PERK T 2, P59, DOI 10.1039/p29820000059; BOCK K, 1974, J CHEM SOC        P2, V2, P293; BOYD J, 1992, J MAGN RESON, V98, P660, DOI 10.1016/0022-2364(92)90021-X; Brisson JR, 1997, BIOCHEMISTRY-US, V36, P3278, DOI 10.1021/bi961819l; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; Cadoz M, 1998, VACCINE, V16, P1391, DOI 10.1016/S0264-410X(98)00097-8; Chandrasekaran R, 1997, ADV CARBOHYD CHEM BI, V52, P311, DOI 10.1016/S0065-2318(08)60094-3; CLORE GM, 1988, FEBS LETT, V238, P17, DOI 10.1016/0014-5793(88)80216-3; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; Delay C, 1997, CARBOHYD RES, V302, P67, DOI 10.1016/S0008-6215(97)00101-8; DESVAUX H, 1994, J MAGN RESON SER A, V108, P219, DOI 10.1006/jmra.1994.1114; EMSLEY L, 1992, J MAGN RESON, V97, P135, DOI 10.1016/0022-2364(92)90242-Y; Engelsen SB, 1996, BIOPOLYMERS, V39, P417, DOI 10.1002/(SICI)1097-0282(199609)39:3<417::AID-BIP13>3.3.CO;2-R; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Gunawardena S, 1999, BIOCHEMISTRY-US, V38, P12062, DOI 10.1021/bi9910272; IMBERTY A, 1994, GLYCOBIOLOGY, V4, P351, DOI 10.1093/glycob/4.3.351; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; *IUPAC IUB, 1971, ARCH BIOCHEM BIOPHYS, V145, P405; JANSSON PE, 1988, CARBOHYD RES, V179, P359, DOI 10.1016/0008-6215(88)84132-6; JANSSON PE, 1987, CARBOHYD RES, V166, P271, DOI 10.1016/0008-6215(87)80063-0; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KENNE L, 1977, CARBOHYD RES, V56, P363, DOI 10.1016/S0008-6215(00)83357-1; KOCA J, 1995, J COMPUT CHEM, V16, P296, DOI 10.1002/jcc.540160305; Koca J, 1998, PROG BIOPHYS MOL BIO, V70, P137, DOI 10.1016/S0079-6107(98)00029-7; KOCA J, 1994, J MOL STRUC-THEOCHEM, V114, P13, DOI 10.1016/0166-1280(94)80091-X; KOCA J, 1993, J MOL STRUCT, V291, P255, DOI 10.1016/0022-2860(93)85049-Z; Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651; Krishnamurthy VV, 1996, J MAGN RESON SER A, V121, P33, DOI 10.1006/jmra.1996.0132; Lemieux R. U., 1979, ACS SYM SER, V87, P17, DOI DOI 10.1021/BK-1979-0087.CH002; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; MacLennan JM, 2000, JAMA-J AM MED ASSOC, V283, P2795, DOI 10.1001/jama.283.21.2795; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; Mulard LA, 2002, TETRAHEDRON, V58, P2593, DOI 10.1016/S0040-4020(02)00148-5; Mulard LA, 2002, EUR J ORG CHEM, V2002, P2486; Mulard LA, 2000, J CARBOHYD CHEM, V19, P193, DOI 10.1080/07328300008544074; Mulard LA, 2000, J CARBOHYD CHEM, V19, P503, DOI 10.1080/07328300008544096; Mulard LA, 1999, J CARBOHYD CHEM, V18, P721, DOI 10.1080/07328309908544033; Nyholm PG, 2001, GLYCOBIOLOGY, V11, P945, DOI 10.1093/glycob/11.11.945; Passwell JH, 2001, INFECT IMMUN, V69, P1351, DOI 10.1128/IAI.69.3.1351-1357.2001; Perez S, 1998, CARBOHYD RES, V314, P141, DOI 10.1016/S0008-6215(98)00305-X; PEREZ S, 1991, CARBOHYD RES, V212, P253, DOI 10.1016/0008-6215(91)84062-J; PHALIPON A, 1995, J EXP MED, V182, P769, DOI 10.1084/jem.182.3.769; Pitner JB, 2000, CARBOHYD RES, V324, P17, DOI 10.1016/S0008-6215(99)00279-7; Pozsgay V, 1993, Bioorg Med Chem, V1, P237, DOI 10.1016/S0968-0896(00)82129-X; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROBBINS JB, 1997, NEW GENERATION VACCI, P803; SANSONETTI PJ, 1991, REV INFECT DIS, V13, pS285; SIMMONS DAR, 1971, BACTERIOL REV, V35, P117, DOI 10.1128/MMBR.35.2.117-148.1971; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STOTT K, 1995, J AM CHEM SOC, V117, P4199, DOI 10.1021/ja00119a048; TAYLOR DN, 1993, INFECT IMMUN, V61, P3678, DOI 10.1128/IAI.61.9.3678-3687.1993; TVAROSKA I, 1989, CARBOHYD RES, V189, P359, DOI 10.1016/0008-6215(89)84112-6; WENGER JD, 1997, NEW GENERATION VACCI, P489; WILLKER W, 1995, MAGN RESON CHEM, V33, P632, DOI 10.1002/mrc.1260330804; WILLKER W, 1993, MAGN RESON CHEM, V31, P287, DOI 10.1002/mrc.1260310315; Zou W, 1999, J IMMUNOL, V163, P820	59	36	37	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47928	47936		10.1074/jbc.M308259200	http://dx.doi.org/10.1074/jbc.M308259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12925526	hybrid			2022-12-27	WOS:000186731400071
J	Akhtar, MK; Kaderbhai, NN; Hopper, DJ; Kelly, SL; Kaderbhai, MA				Akhtar, MK; Kaderbhai, NN; Hopper, DJ; Kelly, SL; Kaderbhai, MA			Export of a heterologous cytochrome P450 (CYP105D1) in Escherichia coli is associated with periplasmic accumulation of uroporphyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHYRIA-CUTANEA-TARDA; DELTA-AMINOLEVULINIC-ACID; 5-AMINOLEVULINIC ACID; MOLECULAR-BIOLOGY; PROTEIN EXPORT; HEME-SYNTHESIS; OXIDATION; BINDING; LIVER; MICE	This report suggests an important physiological role of a CYP in the accumulation of uroporphyrin I arising from catalytic oxidative conversion of uroporphyrinogen I to uroporphyrin I in the periplasm of Escherichia coli cultured in the presence of 5-aminolevulinic acid. A structurally competent Streptomyces griseus CYP105D1 was expressed as an engineered, exportable form in aerobically grown E. coli. Its progressive induction in the presence of 5-aminolevulinic acid-supplemented medium was accompanied by an accumulation of a greater than 100-fold higher amount of uroporphyrin I in the periplasm relative to cells lacking CYP105D1. Expression of a cytoplasm-resident engineered CYP105D1 at a comparative level to the secreted form was far less effective in promoting porphyrin accumulation in the periplasm. Expression at a 10-fold molar excess over the exported CYP105D1 of another periplasmically exported hemoprotein, the globular core of cytochrome b(5), did not substitute the role of the periplasmically localized CYP105D1 in promoting porphyrin production. This, therefore, eliminated the possibility that uroporphyrin accumulation is merely a result of increased hemoprotein synthesis. Moreover, in the strain that secreted CYP105D1, uroporphyrin production was considerably reduced by azole-based P450 inhibitors. Production of both holo-CYP105D1 and uroporphyrin was dependent upon 5-aminolevulinic acid, except that at higher concentrations this resulted in a decrease in uroporphyrin. This study suggests that the exported CYP105D1 oxidatively catalyzes periplasmic conversion of uroporphyrinogen I to uroporphyrin I in E. coli. The findings have significant implications in the ontogenesis of human uroporphyria-related diseases.	Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DD, Ceredigion, Wales	Aberystwyth University	Kaderbhai, MA (corresponding author), Univ Wales, Inst Biol Sci, Cledwyn Bldg, Aberystwyth SY23 3DD, Ceredigion, Wales.							BEALE SI, 1994, CIBA F SYMP, V180, P156; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce JIE, 2000, BRIT J PHARMACOL, V131, P761, DOI 10.1038/sj.bjp.0703631; CHARTRAND P, 1979, J GEN MICROBIOL, V110, P61, DOI 10.1099/00221287-110-1-61; Constantin D, 1996, BIOCHEM PHARMACOL, V52, P1407, DOI 10.1016/S0006-2952(96)00475-3; COX R, 1973, J BACTERIOL, V113, P122, DOI 10.1128/JB.113.1.122-132.1973; CROCKETT N, 1991, TETRAHEDRON, V47, P6003, DOI 10.1016/S0040-4020(01)86492-9; DAWSON RMC, 1987, DATA BIOCH RES, P213; Doss MO, 2000, ALCOHOL ALCOHOLISM, V35, P109, DOI 10.1093/alcalc/35.2.109; Elder GH, 1998, SEMIN LIVER DIS, V18, P67, DOI 10.1055/s-2007-1007142; Estabrook R W, 1978, Methods Enzymol, V52, P212; Franklin MR, 2000, BIOCHEM PHARMACOL, V60, P1325, DOI 10.1016/S0006-2952(00)00449-4; GALLAGHER SR, 1999, CURRENT PROTOCOLS MO, V2, DOI DOI 10.12B.11-10.12B.15; Goldman BS, 1997, J MOL BIOL, V268, P724, DOI 10.1006/jmbi.1997.0992; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; Gorman N, 2002, HEPATOLOGY, V35, P912, DOI 10.1053/jhep.2002.32487; Gorman N, 1998, COMP BIOCHEM PHYS C, V121, P405, DOI 10.1016/S0742-8413(98)10059-2; HANSPETER K, 1988, FAT SOLUBLE PIGMENTS; HARDING V, 1993, BIOCHEM J, V293, P751, DOI 10.1042/bj2930751; HENDERSON MJ, 1989, CLIN CHEM, V35, P1043; JACOBS JM, 1990, J BIOCHEM TOXICOL, V5, P193, DOI 10.1002/jbt.2570050310; JACOBS JM, 1989, BIOCHEM J, V258, P247, DOI 10.1042/bj2580247; KADERBHAI MA, 1990, DNA CELL BIOL, V9, P11, DOI 10.1089/dna.1990.9.11; Kaderbhai MA, 2001, APPL ENVIRON MICROB, V67, P2136, DOI 10.1128/AEM.67.5.2136-2138.2001; Kaderbhai N, 1997, BIOTECHNOL APPL BIOC, V25, P53, DOI 10.1111/j.1470-8744.1997.tb00414.x; KARIM A, 1993, BIO-TECHNOL, V11, P612, DOI 10.1038/nbt0593-612; KIKUCHI Y, 1981, NUCLEIC ACIDS RES, V9, P5671, DOI 10.1093/nar/9.21.5671; Kim J, 2000, CELL STRESS CHAPERON, V5, P267, DOI 10.1379/1466-1268(2000)005<0267:SDPEAT>2.0.CO;2; Lamb D, 1999, DRUG RESIST UPDATE, V2, P390, DOI 10.1054/drup.1999.0112; LIM CK, 1986, METHOD ENZYMOL, V123, P383; MERCER EI, 1993, PROG LIPID RES, V32, P357, DOI 10.1016/0163-7827(93)90016-P; Moore MR, 1998, CLIN DERMATOL, V16, P203, DOI 10.1016/S0738-081X(97)00201-0; Mylchreest E, 1997, TOXICOL APPL PHARM, V145, P23, DOI 10.1006/taap.1997.8157; OMURA T, 1964, J BIOL CHEM, V239, P2370; PHILIPPDORMSTON WK, 1975, Z NATURFORSCH C, V30, P425; Rendic S, 2002, DRUG METAB REV, V34, P83, DOI 10.1081/DMR-120001392; RIMINGTON C, 1960, BIOCHEM J, V75, P620, DOI 10.1042/bj0750620; Sampietro M, 1999, HAEMATOLOGICA, V84, P248; Sarkany RPE, 1999, ADV EXP MED BIOL, V455, P235; SASARMAN A, 1968, J BACTERIOL, V96, P1882; Sassa S, 2000, J INTERN MED, V247, P169, DOI 10.1046/j.1365-2796.2000.00618.x; SINCLAIR P, 1987, BIOCHEM BIOPH RES CO, V146, P1324, DOI 10.1016/0006-291X(87)90794-7; Sinclair PR, 1997, J LAB CLIN MED, V130, P197, DOI 10.1016/S0022-2143(97)90096-2; Sinclair PR, 1998, DRUG METAB DISPOS, V26, P1019; Sinclair PR, 1997, DRUG METAB DISPOS, V25, P779; Sinclair PR, 1998, BIOCHEM J, V330, P149; SPENCER P, 1995, BIOCHEM J, V305, P151, DOI 10.1042/bj3050151; Tsukazaki N, 1998, BRIT J DERMATOL, V138, P1015; Verderber E, 1997, J BACTERIOL, V179, P4583, DOI 10.1128/jb.179.14.4583-4590.1997	50	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45555	45562		10.1074/jbc.M212685200	http://dx.doi.org/10.1074/jbc.M212685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12930844	hybrid			2022-12-27	WOS:000186452300063
J	Crisp, RJ; Pollington, A; Galea, C; Jaron, S; Yamaguchi-Iwai, Y; Kaplan, J				Crisp, RJ; Pollington, A; Galea, C; Jaron, S; Yamaguchi-Iwai, Y; Kaplan, J			Inhibition of heme biosynthesis prevents transcription of iron uptake genes in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SIDEROBLASTIC ANEMIA; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL; FRATAXIN; ATAXIA; TRANSPORTER; MUTATION; OXYGEN; DEFICIENCY; EXPRESSION	Yeast are capable of modifying their metabolism in response to environmental changes. We investigated the activity of the oxygen-dependent high-affinity iron uptake system of Saccharomyces cerevisiae under conditions of heme depletion. We found that the absence of heme, due to a deletion in the gene that encodes delta-aminolevulinic acid synthase (HEM1), resulted in decreased transcription of genes belonging to both the iron and copper regulons, but not the zinc regulon. Decreased transcription of the iron regulon was not due to decreased expression of the iron sensitive transcriptional activator Aft1p. Expression of the constitutively active allele AFT1-1(up) was unable to induce transcription of the high affinity iron uptake system in heme-depleted cells. We demonstrated that under heme-depleted conditions, Aft1p-GFP was able to cycle normally between the nucleus and cytosol in response to cytosolic iron. Despite the inability to induce transcription under low iron conditions, chromatin immunoprecipitation demonstrated that Aft1p binds to the FET3 promoter in the absence of heme. Finally, we provide evidence that under heme-depleted conditions, yeast are able to regulate mitochondrial iron uptake and do not accumulate pathologic iron concentrations, as is seen when iron-sulfur cluster synthesis is disrupted.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan	Utah System of Higher Education; University of Utah; St Jude Children's Research Hospital; Kyoto University	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu	Galea, Charles/C-5074-2013; Galea, Charles/O-8800-2014	Galea, Charles/0000-0003-0485-7709; Galea, Charles/0000-0003-2730-1105; McGehee, Annette/0000-0002-8175-3404	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052380, R37DK030534, R01DK030534, T32DK007115] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA 42014] Funding Source: Medline; NIDDK NIH HHS [NIDDK 30534, T32 DK07115-29, NIDDK 52380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; APARICIO O, 2003, CURRENT PROTOCOLS MO, V61; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Becerra M, 2002, MOL MICROBIOL, V43, P545, DOI 10.1046/j.1365-2958.2002.02724.x; Bekri S, 2000, BLOOD, V96, P3256; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Fleming MD, 2002, SEMIN HEMATOL, V39, P270, DOI 10.1053/shem.2002.35637; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Gaisne M, 1999, CURR GENET, V36, P195, DOI 10.1007/s002940050490; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; GRIMAL D, 1980, MOL GEN GENET, V178, P713, DOI 10.1007/BF00337883; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Jensen LT, 2002, J MOL BIOL, V318, P251, DOI 10.1016/S0022-2836(02)00093-1; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lascaris R, 2003, GENOME BIOL, V4; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Ponka P, 1997, BLOOD, V89, P1; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; THORSNESS M, 1989, MOL CELL BIOL, V9, P5702, DOI 10.1128/MCB.9.12.5702; Vasconcelles MJ, 2001, J BIOL CHEM, V276, P14374, DOI 10.1074/jbc.M009546200; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	36	68	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45499	45506		10.1074/jbc.M307229200	http://dx.doi.org/10.1074/jbc.M307229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12928433	hybrid			2022-12-27	WOS:000186452300056
J	Stewart, RS; Harris, DA				Stewart, RS; Harris, DA			Mutational analysis of topological determinants in prion protein (PrP) and measurement of transmembrane and cytosolic PrP during prion infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSLOCATION CHANNEL; SIGNAL SEQUENCES; MEMBRANE; DEGRADATION; BIOGENESIS; DISEASES; CONTAINS; PEPTIDE; DOMAIN	The prion protein (PrP) can adopt multiple membrane topologies, including a fully translocated form ((PrP)-Pr-Sec), two transmembrane forms ((PrP)-Pr-Ntm and (PrP)-Pr-Ctm), and a cytosolic form. It is important to understand the factors that influence production of these species, because two of them, (PrP)-Pr-Ctm and cytosolic PrP, have been proposed to be key neurotoxic intermediates in certain prion diseases. In this paper, we perform a mutational analysis of PrP synthesized using an in vitro translation system in order to further define sequence elements that influence the formation of (PrP)-Pr-Ctm. We find that substitution of charged residues in the hydrophobic core of the signal peptide increases synthesis of (PrP)-Pr-Ctm and also reduces the efficiency of translocation into microsomes. Combining these mutations with substitutions in the transmembrane domain causes the protein to be synthesized exclusively with the (PrP)-Pr-Ctm topology. Reducing the spacing between the signal peptide and the transmembrane domain also increases (PrP)-Pr-Ctm. In contrast, topology is not altered by mutations that prevent signal peptide cleavage or by deletion of the C-terminal signal for glycosylphosphatidylinositol anchor addition. Removal of the signal peptide completely blocks translocation. Taken together, our results are consistent with a model in which the signal peptide and transmembrane domain function in distinct ways as determinants of PrP topology. We also present characterization of an antibody that selectively recognizes (PrP)-Pr-Ctm and cytosolic PrP by virtue of their uncleaved signal peptides. By using this antibody, as well as the distinctive gel mobility of (PrP)-Pr-Ctm and cytosolic PrP, we show that the amounts of these two forms in cultured cells and rodent brain are not altered by infection with scrapie prions. We conclude that (PrP)-Pr-Ctm and cytosolic PrP are unlikely to be obligate neurotoxic intermediates in familial or infectiously acquired prion diseases.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS041500, R01NS035496] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41500, NS35496] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bosque PJ, 2000, J VIROL, V74, P4377, DOI 10.1128/JVI.74.9.4377-4386.2000; Brown Lesley R., 2002, P103; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kim SJ, 2002, MOL BIOL CELL, V13, P3775, DOI 10.1091/mbc.E02-05-0293; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	32	64	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45960	45968		10.1074/jbc.M307833200	http://dx.doi.org/10.1074/jbc.M307833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933795	hybrid			2022-12-27	WOS:000186452300110
J	Strutz-Seebohm, N; Werner, M; Madsen, DM; Seebohm, G; Zheng, Y; Walker, CS; Maricq, AV; Hollmann, M				Strutz-Seebohm, N; Werner, M; Madsen, DM; Seebohm, G; Zheng, Y; Walker, CS; Maricq, AV; Hollmann, M			Functional analysis of Caenorhabditis elegans glutamate receptor subunits by domain transplantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAINATE-BINDING-PROTEINS; CENTRAL-NERVOUS-SYSTEM; POINT MUTATION; ION CHANNELS; K+ CHANNELS; INWARD RECTIFICATION; CALCIUM PERMEABILITY; CONDUCTION PATHWAYS; N-GLYCOSYLATION; AMPA	Glutamate receptors are not only abundant and important mediators of fast excitatory synaptic transmission in vertebrates, but they also serve a similar function in invertebrates such as Drosophila and the nematode Caenorhabditis elegans. In C. elegans, an animal with only 302 neurons, 10 different glutamate receptor subunits have been identified and cloned. To study the ion channel properties of these receptor subunits, we recorded glutamate-gated currents from Xenopus oocytes that expressed either C. elegans glutamate receptor subunits or chimeric rat/C. elegans glutamate receptor subunits. The chimeras were constructed between the C. elegans glutamate receptor pore domains and either the rat kainate receptor subunit GluR6, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate ( AMPA) receptor subunit GluR1, or the N-methyl-D-aspartate ( NMDA) receptor subunit NMDAR1-1a. Although native subunits were nonfunctional, 9 of 10 ion pores were found to conduct current upon transplantation into rat receptor subunits. A provisional classification of the C. elegans glutamate receptor subunits was attempted based on functionality of the chimeras. C. elegans glutamate receptor ion pores, at a position homologous to a highly conserved site critical for ion permeation properties in vertebrate glutamate receptor pores, contain amino acids not found in vertebrate glutamate receptors. We show that the pore-constricting Q/R site, which in vertebrate receptors determines calcium permeability and rectification properties of the ion channel, in C. elegans can be occupied by other amino acids, including, surprisingly, lysine and proline, without loss of these properties.	Ruhr Univ Bochum, Dept Biochem 1, D-44780 Bochum, Germany; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Ruhr University Bochum; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Hollmann, M (corresponding author), Ruhr Univ Bochum, Dept Biochem 1, Bldg NC,Level 6,Rm 170, D-44780 Bochum, Germany.			Hollmann, Michael/0000-0001-8000-7787	NINDS NIH HHS [NS 35812] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035812] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Bahring R, 1997, J PHYSIOL-LONDON, V502, P575, DOI 10.1111/j.1469-7793.1997.575bj.x; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Brockie PJ, 2001, NEURON, V31, P617, DOI 10.1016/S0896-6273(01)00394-4; Brockie PJ, 2001, J NEUROSCI, V21, P1510, DOI 10.1523/JNEUROSCI.21-05-01510.2001; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Burnashev N, 1996, J PHYSIOL-LONDON, V496, P165, DOI 10.1113/jphysiol.1996.sp021674; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; CURUTCHET P, 1992, BIOCHEM BIOPH RES CO, V182, P1089, DOI 10.1016/0006-291X(92)91843-F; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Everts I, 1997, MOL PHARMACOL, V52, P861, DOI 10.1124/mol.52.5.861; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Hollmann M., 1999, V141, P3; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; Kuner T, 2003, TRENDS NEUROSCI, V26, P27, DOI 10.1016/S0166-2236(02)00010-3; KUNER T, 1999, HDB EXPT PHARM IONON, P219; Lerma J, 2001, PHYSIOL REV, V81, P971, DOI 10.1152/physrev.2001.81.3.971; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Mellem JE, 2002, NEURON, V36, P933, DOI 10.1016/S0896-6273(02)01088-7; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Panchenko VA, 1999, J PHYSIOL-LONDON, V520, P337, DOI 10.1111/j.1469-7793.1999.t01-1-00337.x; Panchenko VA, 2001, J GEN PHYSIOL, V117, P345, DOI 10.1085/jgp.117.4.345; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Sprengel R, 2001, TRENDS PHARMACOL SCI, V22, P7, DOI 10.1016/S0165-6147(00)01588-1; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Strutz N, 2002, J BIOL CHEM, V277, P48035, DOI 10.1074/jbc.M209647200; Tikhonov DB, 2002, BIOPHYS J, V82, P1884, DOI 10.1016/S0006-3495(02)75538-0; ULTSCH A, 1992, P NATL ACAD SCI USA, V89, P10484, DOI 10.1073/pnas.89.21.10484; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Villmann C, 1999, EUR J NEUROSCI, V11, P1765, DOI 10.1046/j.1460-9568.1999.00594.x; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882	46	13	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44691	44701		10.1074/jbc.M305497200	http://dx.doi.org/10.1074/jbc.M305497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930835	hybrid			2022-12-27	WOS:000186306700102
J	Arnold, SM; Kaufman, RJ				Arnold, SM; Kaufman, RJ			The noncatalytic portion of human UDP-glucose : glycoprotein glucosyltransferase I confers UDP-glucose binding and transferase function to the catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISFOLDED GLYCOPROTEINS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; CALNEXIN; CALRETICULIN; OLIGOSACCHARIDE; RECOGNITION; ACCEPTOR; ANALOGS; ERP57	The eukaryotic cell monitors the fidelity of protein folding in the endoplasmic reticulum and only permits properly folded and/or assembled proteins to transit to the Golgi compartment in a process termed "quality control." An endoplasmic reticulum (ER) lumenal sensor for quality control is the UDP-glucose: glycoprotein glucosyltransferase that targets unfolded glycoproteins for transient, calcium-dependent glucosylation. This modification mediates glycoprotein interaction with the folding machinery comprised of calnexin or calreticulin in conjunction with ERp57. Two human UGT homologues, HUGT1 and HUGT2, exist that share 55% identity. The highest degree of identity resides in the COOH-terminal 20% of these proteins, the putative catalytic domain of HUGT1. However, only HUGT1 displays the expected functional activity. The contribution of the NH2-terminal remainder of HUGT1 to glucosyltransferase function is presently unknown. In this report we demonstrate that HUGT2 is localized to the ER in a manner that overlaps the distribution of HUGT1. Analysis of a series of HUGT1 and HUGT2 chimeric proteins demonstrated that the carboxyl-terminal region of HUGT2 contains a catalytic domain that is functional in place of the analogous portion of HUGT1. Whereas neither catalytic domain displayed detectable activity when expressed alone, co-expression of either catalytic domain with the noncatalytic amino-terminal portion of HUGT1 conferred UDP-Glc binding and transfer of glucose that was specific for unfolded glycoprotein substrates. The results indicate that the amino-terminal 80% of HUGT1 is required for activation of the catalytic domain, whereas the homologous portion of HUGT2 cannot provide this function.	Univ Michigan, Med Ctr, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Sch Med, Howard Hughes Med Inst, 4570 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NHLBI NIH HHS [P01 HL57346] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Guerin M, 2003, J BIOL CHEM, V278, P20540, DOI 10.1074/jbc.M300891200; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	22	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43320	43328		10.1074/jbc.M305800200	http://dx.doi.org/10.1074/jbc.M305800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12913004	hybrid			2022-12-27	WOS:000186157000075
J	Dominguez, JE; Munoz, MC; Zafra, D; Sanchez-Perez, I; Baque, S; Caron, M; Mercurio, C; Barbera, A; Perona, R; Gomis, R; Guinovart, JJ				Dominguez, JE; Munoz, MC; Zafra, D; Sanchez-Perez, I; Baque, S; Caron, M; Mercurio, C; Barbera, A; Perona, R; Gomis, R; Guinovart, JJ			The antidiabetic agent sodium tungstate activates glycogen synthesis through an insulin receptor-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DIABETIC RATS; PROTEIN-KINASE-B; P70 S6 KINASE; SYNTHASE KINASE-3; SKELETAL-MUSCLE; MAP KINASE; GROWTH-FACTOR; PHOSPHATASE; INHIBITION; PHOSPHORYLATION	Sodium tungstate is a powerful antidiabetic agent when administered orally. In primary cultured hepatocytes, tungstate showed insulin-like actions, which led to an increase in glycogen synthesis and accumulation. However, this compound did not significantly alter the insulin receptor activation state or dephosphorylation rate in cultured cells (CHO-R) or in primary hepatocytes, in either short or long term treatments. In contrast, at low concentrations, tungstate induced a transient strong activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) after 5 - 10 min of treatment, in a similar way to insulin. Moreover, this compound did not significantly delay or inhibit the dephosphorylation of ERK1/2. ERK1/2 activation triggered a cascade of downstream events, which included the phosphorylation of p90rsk and glycogen synthase-kinase 3beta. Experiments with a specific inhibitor of ERK1/2 activation and kinase assays indicate that these proteins were directly involved in the stimulation of glycogen synthase and glycogen synthesis induced by tungstate without a direct involvement of protein kinase B (PKB/Akt). These results show a direct involvement of ERK1/2 in the mechanism of action of tungstate at the hepatic level.	IRBB, E-08028 Barcelona, Spain; Biomed Res Inst Alberto Sols, E-28029 Madrid, Spain; Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; INSERM, U402, Fac Med St Antoine, F-75571 Paris 12, France; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Hosp Clin Barcelona, Endocrinol & Diabet Unit, E-08036 Barcelona, Spain; Inst Invest Biomed August Pi & Sunyer, E-08036 Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Barcelona; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; IRCCS European Institute of Oncology (IEO); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Guinovart, JJ (corresponding author), IRBB, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	guinovart@pcb.ub.es	Sánchez-Pérez, Isabel/R-4107-2016	Sánchez-Pérez, Isabel/0000-0002-4829-201X; Zafra, Delia/0000-0003-4143-0659; Mercurio, Ciro/0000-0001-6240-4607; Barbera, Albert/0000-0003-4080-3572				AMMERMAN C, 1980, MINERAL TOLERANCE DO, P515; BARBERA A, 1994, J BIOL CHEM, V269, P20047; Barbera A, 1997, DIABETOLOGIA, V40, P143, DOI 10.1007/s001250050655; Barbera A, 2001, DIABETOLOGIA, V44, P507, DOI 10.1007/s001250100479; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHANG PY, 1995, J BIOL CHEM, V270, P29928; Cohen P, 1978, Biochem Soc Symp, P69; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CRANS DC, 1992, BIOCHEMISTRY-US, V31, P11731, DOI 10.1021/bi00162a009; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Domingo JL, 2002, BIOL TRACE ELEM RES, V88, P97, DOI 10.1385/BTER:88:2:097; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Foster JD, 1998, ARCH BIOCHEM BIOPHYS, V354, P125, DOI 10.1006/abbi.1998.0695; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Giron MD, 2003, FEBS LETT, V542, P84, DOI 10.1016/S0014-5793(03)00352-1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Le Lamer S, 2002, PHARMACOL TOXICOL, V90, P100, DOI 10.1034/j.1600-0773.2002.900208.x; Lee JY, 2001, NAT STRUCT BIOL, V8, P789, DOI 10.1038/nsb0901-789; LI JP, 1995, BIOCHEMISTRY-US, V34, P6218, DOI 10.1021/bi00018a026; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Muda M, 1996, J BIOL CHEM, V271, P4319; Munoz MC, 2001, DIABETES, V50, P131, DOI 10.2337/diabetes.50.1.131; Palanivel R, 1998, MED SCI RES, V26, P541; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Reiter NJ, 2002, BIOCHEMISTRY-US, V41, P1051, DOI 10.1021/bi011577b; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; Rodriguez-Gallardo J, 2000, EUR J PHARMACOL, V402, P199, DOI 10.1016/S0014-2999(00)00492-1; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; STANKIEWICZ PJ, 1988, BIOCHEMISTRY-US, V27, P206, DOI 10.1021/bi00401a031; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VANETTEN RL, 1974, J AM CHEM SOC, V96, P6782, DOI 10.1021/ja00828a053; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2	44	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42785	42794		10.1074/jbc.M308334200	http://dx.doi.org/10.1074/jbc.M308334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925525	hybrid			2022-12-27	WOS:000186157000009
J	Khanna, S; Roy, S; Ryu, H; Bahadduri, P; Swaan, PW; Ratan, RR; Sen, CK				Khanna, S; Roy, S; Ryu, H; Bahadduri, P; Swaan, PW; Ratan, RR; Sen, CK			Molecular basis of vitamin E action - Tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; OXIDATIVE STRESS; ALPHA-TOCOPHEROL; ARACHIDONATE 12-LIPOXYGENASE; GLUTATHIONE METABOLISM; SOYBEAN LIPOXYGENASE; NEURONAL CELLS; CYSTINE UPTAKE; CANINE BRAIN; GLIAL-CELLS	Vitamin E is a generic term for tocopherols and tocotrienols. This work is based on our striking evidence that, in neuronal cells, nanomolar concentrations of alpha-tocotrienol, but not alpha-tocopherol, block glutamate-induced death by suppressing early activation of c-Src kinase (Sen, C. K., Khanna, S., Roy, S., and Packer, L. (2000) J. Biol. Chem. 275, 13049 - 13055). This study on HT4 and immature primary cortical neurons suggests a central role of 12-lipoxygenase (12-LOX) in executing glutamate-induced neurodegeneration. BL15, an inhibitor of 12-LOX, prevented glutamate-induced neurotoxicity. Moreover, neurons isolated from 12-LOX-deficient mice were observed to be resistant to glutamate-induced death. In the presence of nanomolar alpha-tocotrienol, neurons were resistant to glutamate-, homocysteine, and L-buthionine sulfoximine-induced toxicity. Long-term time-lapse imaging studies revealed that neurons and their axo-dendritic network are fairly motile under standard culture conditions. Such motility was arrested in response to glutamate challenge. Tocotrienol-treated primary neurons maintained healthy growth and motility even in the presence of excess glutamate. The study of 12-LOX activity and metabolism revealed that this key mediator of glutamate- induced neurodegeneration is subject to control by the nutrient alpha-tocotrienol. In silico docking studies indicated that alpha-tocotrienol may hinder the access of arachidonic acid to the catalytic site of 12-LOX by binding to the opening of a solvent cavity close to the active site. These findings lend further support to alpha-tocotrienol as a potent neuroprotective form of vitamin E.	Ohio State Univ, Med Ctr, Dorothy M Davis Heart & Lung Res Inst 512, Bioinformat & Computat Biol Core Lab, Columbus, OH 43210 USA; Ohio State Univ, Med Ctr, Dept Surg, Mol Med Lab, Columbus, OH 43210 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Sen, CK (corresponding author), Ohio State Univ, Med Ctr, Dorothy M Davis Heart & Lung Res Inst 512, Bioinformat & Computat Biol Core Lab, 473 W 12th Ave, Columbus, OH 43210 USA.	sen-1@medctr.osu.edu	Sen, Chandan K/A-8762-2013; Khanna, Savita/E-3378-2011	Ryu, Hoon/0000-0001-6544-3732; Swaan, Peter/0000-0003-1767-1487	NINDS NIH HHS [R01 NS042617] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042617] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZZI A, 1995, AM J CLIN NUTR, V62, P1337, DOI 10.1093/ajcn/62.6.1337S; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BOSCOBOINIK DO, 1994, BBA-MOL CELL RES, V1224, P418, DOI 10.1016/0167-4889(94)90277-1; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; Dargusch R, 2002, J NEUROCHEM, V81, P1394, DOI 10.1046/j.1471-4159.2002.00950.x; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Eberhard J, 2000, ANAL BIOCHEM, V280, P258, DOI 10.1006/abio.2000.4540; Froissard P, 1997, EUR J PHARMACOL, V326, P93, DOI 10.1016/S0014-2999(97)00155-6; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; GROSSMAN S, 1984, INT J BIOCHEM, V16, P281, DOI 10.1016/0020-711X(84)90101-0; HAGMANN W, 1993, PROSTAGLANDINS, V46, P471, DOI 10.1016/0090-6980(93)90066-G; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; Han D, 1997, AM J PHYSIOL-REG I, V273, pR1771, DOI 10.1152/ajpregu.1997.273.5.R1771; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MORRIS GM, 2001, AUTODOCK REFERENCE M; MULLER DPR, 1989, ANN NY ACAD SCI, V570, P146; MULLER DPR, 1990, CRIT REV NEUROBIOL, V5, P239; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; NISHIYAMA M, 1993, J HISTOCHEM CYTOCHEM, V41, P111, DOI 10.1177/41.1.8417106; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; O'Byrne D, 2000, FREE RADICAL BIO MED, V29, P834, DOI 10.1016/S0891-5849(00)00371-3; OKA A, 1993, J NEUROSCI, V13, P1441; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; PEARCE BC, 1994, J MED CHEM, V37, P526, DOI 10.1021/jm00030a012; PEARCE BC, 1992, J MED CHEM, V35, P3595, DOI 10.1021/jm00098a002; Pereira CMF, 1997, FREE RADICAL BIO MED, V23, P637, DOI 10.1016/S0891-5849(97)00020-8; REDDANNA P, 1985, FEBS LETT, V193, P39, DOI 10.1016/0014-5793(85)80075-2; Roy S, 2002, METHOD ENZYMOL, V352, P326; Sagara Y, 2002, J BIOL CHEM, V277, P36204, DOI 10.1074/jbc.M203895200; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; SERBINOVA EA, 1994, METHOD ENZYMOL, V234, P354; SUARNA C, 1993, BIOCHIM BIOPHYS ACTA, V1166, P163, DOI 10.1016/0005-2760(93)90092-N; SUZUKI Y, 1993, BIOCHEMISTRY-US, V32, P10692, DOI 10.1021/bi00091a020; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tirosh O, 2000, NEUROSCIENCE, V97, P531, DOI 10.1016/S0306-4522(00)00028-2; TOMEO AC, 1995, LIPIDS, V30, P1179, DOI 10.1007/BF02536621; TRABER MG, 1995, AM J CLIN NUTR, V62, P1501; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	53	221	241	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43508	43515		10.1074/jbc.M307075200	http://dx.doi.org/10.1074/jbc.M307075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917400	hybrid, Green Accepted			2022-12-27	WOS:000186157000096
J	Wynn, RM; Machius, M; Chuang, JL; Li, J; Tomchick, DR; Chuang, DT				Wynn, RM; Machius, M; Chuang, JL; Li, J; Tomchick, DR; Chuang, DT			Roles of His(291)-alpha and His(146)-beta ' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase - Refined phosphorylation loop structure in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; SYRUP-URINE-DISEASE; ESCHERICHIA-COLI; MULTIENZYME COMPLEXES; THIAMINE DIPHOSPHATE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; E1 COMPONENT; LIPOIC ACID; TRANSKETOLASE	We report here that alterations of either His(291)-alpha or His(146)-beta' in the active site of human branched-chain alpha-ketoacid dehydrogenase (E1b) impede both the decarboxylation and the reductive acylation reactions catalyzed by E1b as well as the binding of cofactor thiamin diphosphate (ThDP). In a refined human E1b active-site structure, His(291)-alpha, which aligns with His(407) in Escherichia coli pyruvate dehydrogenase and His(263) in yeast transketolase, is on a largely ordered phosphorylation loop. The imidazole ring of His(291)-alpha in E1b coordinates to the terminal phosphate oxygen atoms of bound ThDP. The N3 atom of wild-type His(146)-beta', which can be protonated, binds a water molecule and points toward the aminopyrimidine ring of ThDP. Remarkably, the H291A-alpha mutation results in a complete order-to-disorder transition of the loop region, which precludes the binding of the substrate lipoyl-bearing domain to E1b. The H146A-beta' mutation, on the other hand, does not alter the loop structure, but nullifies the reductive acylation activity of E1b. Our results suggest that: 1) His(291)-alpha plays a structural rather than a catalytic role in the binding of cofactor ThDP and the lipoyl-bearing domain to E1b, and 2) His(146)-beta' is an essential catalytic residue, probably functioning as a proton donor in the reductive acylation of lipoamide on the lipoyl-bearing domain.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	david.chuang@utsouthwestern.edu	Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643; Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK62306, DK26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062306, R01DK062306, R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; ARJUNAN P, 1999, BIOCHEMISTRY-US, V41, P5213; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Chuang JL, 2002, J BIOL CHEM, V277, P36905, DOI 10.1074/jbc.C200430200; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fiedler E, 2001, J BIOL CHEM, V276, P16051, DOI 10.1074/jbc.M007936200; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; Hawes JW, 1995, J BIOL CHEM, V270, P31071, DOI 10.1074/jbc.270.52.31071; HENNIG J, 1966, BIOCH PHYSL THIAMIN, P243; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KICE JL, 1968, ACCOUNTS CHEM RES, V1, P58, DOI 10.1021/ar50002a004; LAKOWICZ JR, 1983, BIOCHEMISTRY-US, V22, P1741, DOI 10.1021/bi00277a001; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan K, 1998, BIOCHEMISTRY-US, V37, P1357, DOI 10.1021/bi971835y; Wynn RM, 2000, METHOD ENZYMOL, V324, P179; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200	24	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43402	43410		10.1074/jbc.M306204200	http://dx.doi.org/10.1074/jbc.M306204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12902323	hybrid			2022-12-27	WOS:000186157000084
J	Gu, XR; Meer, SG; Miyagi, M; Rayborn, ME; Hollyfield, JG; Crabb, JW; Salomon, RG				Gu, XR; Meer, SG; Miyagi, M; Rayborn, ME; Hollyfield, JG; Crabb, JW; Salomon, RG			Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED PHOSPHOLIPIDS; PATHOGENESIS; OXIDATION; DRUSEN; PRODUCTS; FAMILY	Age-related macular degeneration (AMD) is a slow, progressive disease with both genetic and environmental risk factors. Free radical-induced oxidation of docosahexaenoate (DHA)-containing lipids generates omega-(2-carboxyethyl)pyrrole (CEP) protein adducts that are more abundant in ocular tissues from AMD than normal human donors. To understand better the role of oxidative damage in AMD, we have synthesized CEP-modified proteins, produced anti-CEP antibodies, and initiated analysis of CEP immunoreactivity and autoantibodies in human plasma. A highly selective rabbit polyclonal anti-CEP antibody was raised that binds CEP 1000 times more strongly than carboxypropylpyrrole, a close structural analogue. The CEP adduct uniquely indicates oxidative modification from DHA derivatives because CEP protein modifications cannot arise from any other common polyunsaturated fatty acid. Immunocytochemistry localized CEP to photoreceptor rod outer segments and retinal pigment epithelium in mouse retina and demonstrated more intense CEP immunoreactivity in photoreceptors from a human AMD donor compared with healthy human retina. The mean level of anti-CEP immunoreactivity in AMD human plasma (n = 19 donors) was 1.5-fold higher (p = 0.004) than in age-matched controls (n = 19 donors). Sera from AMD patients demonstrated mean titers of anti-CEP autoantibody 2.3-fold higher than controls (p = 0.02). Of individuals (n = 13) exhibiting both antigen and autoantibody levels above the mean for non-AMD controls, 92% had AMD. These results suggest that together CEP immunoreactivity and autoantibody titer may have diagnostic utility in predicting AMD susceptibility.	Cleveland Clin Fdn, Cole Eye Inst i31, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Crabb, JW (corresponding author), Cleveland Clin Fdn, Cole Eye Inst i31, 9500 Euclid Ave, Cleveland, OH 44195 USA.	crabbj@ccf.org; rgs@po.cwru.edu	Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NATIONAL EYE INSTITUTE [R01EY014239, R56EY014240, R01EY014240, R01EY002362] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER; NEI NIH HHS [EY 6603, EY 2362, EY 14240, EY 14239] Funding Source: Medline; NHLBI NIH HHS [HL 53315] Funding Source: Medline; NIGMS NIH HHS [GM 21249] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7; ALVAREZ RA, 1994, INVEST OPHTH VIS SCI, V35, P402; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; DECAPRIO AP, 1987, MOL PHARMACOL, V32, P542; Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Salomon RG, 2000, BBA-MOL CELL BIOL L, V1485, P225, DOI 10.1016/S1388-1981(00)00038-X; Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285; Subbanagounder G, 2002, VASC PHARMACOL, V38, P201, DOI 10.1016/S1537-1891(02)00170-2; Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383; WANG N, 1992, CURR EYE RES, V11, P783, DOI 10.3109/02713689209000751; West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058	29	246	257	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42027	42035		10.1074/jbc.M305460200	http://dx.doi.org/10.1074/jbc.M305460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923198	hybrid			2022-12-27	WOS:000185989500058
J	Leech, HK; Raux, E; McLean, KJ; Munro, AW; Robinson, NJ; Borrelly, GPM; Malten, M; Jahn, D; Rigby, SEJ; Heathcote, P; Warren, MJ				Leech, HK; Raux, E; McLean, KJ; Munro, AW; Robinson, NJ; Borrelly, GPM; Malten, M; Jahn, D; Rigby, SEJ; Heathcote, P; Warren, MJ			Characterization of the cobaltochelatase CbiX(L) - Evidence for a 4Fe-4S center housed within an MXCXXC motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN VITAMIN-B-12 BIOSYNTHESIS; IDENTIFICATION; PROTEIN; HEME; FERROCHELATASE; INSERTION; PATHWAYS; GENES; HYPB; ZINC	CbiX is a cobaltochelatase required for the biosynthesis of vitamin B-12 and is found in Archaea as a short form (CbiX(S) containing 120 - 145 amino acids) and in some bacteria as a longer version ( CbiX(L) containing 300 - 350 amino acids). Purification of either recombinant Bacillus megaterium or Synechocystis CbiXL in Escherichia coli, which is facilitated by the presence of a naturally occurring histidine-rich region of the protein, results in the isolation of a dark brown protein solution. The UV/ visible spectrum of the protein is consistent with the presence of a redox group, and the lack of definition within the spectrum is suggestive of a 4Fe-4S center. The presence of an iron-sulfur center was confirmed by EPR analysis of the proteins, which produces a pseudoaxial spectrum with g values at 2.04, 1.94, and 1.90. The EPR spectrum was absent at 70 K, an observation that is diagnostic of a 4Fe-4S center. Redox potentiometry coupled with optical spectroscopy allowed the midpoint potential of the redox center to be determined for the CbiXL from both B. megaterium and Synechocystis. Sequence analysis of CbiXL proteins reveals only two conserved cysteine residues within the CbiXL proteins, which are part of an MXCXXC motif. Mutagenesis of the two cysteines leads to loss of both the EPR spectrum and UV/ visible spectral features of the Fe-S center in the protein, clearly indicating that these residues are involved in ligating the cofactor to the apoprotein possibly in a butterfly arrangement. The potential physiological role of the iron-sulfur center is discussed.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Med Sch Newcastle Upon Tyne, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Tech Univ Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany	University of London; Queen Mary University London; University of Leicester; Newcastle University - UK; Braunschweig University of Technology	Warren, MJ (corresponding author), Queen Mary Univ London, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	m.j.warren@qmul.ac.uk	McLean, Kirsty J/GXI-2853-2022; Heathcote, Peter/B-3749-2011; Munro, Andrew/G-5639-2019; Robinson, Nigel J/J-6363-2012	Munro, Andrew/0000-0002-4642-180X; Robinson, Nigel J/0000-0001-5586-1092; McLean, Kirsty/0000-0002-7193-5044; Warren, Martin/0000-0002-6028-6456; Jahn, Dieter/0000-0002-4064-9205				Al-Karadaghi S, 1997, STRUCTURE, V5, P1501, DOI 10.1016/S0969-2126(97)00299-2; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BATTERSBY AR, 1982, J CHEM SOC CHEM COMM, P1393, DOI 10.1039/c39820001393; Brindley AA, 2003, J BIOL CHEM, V278, P22388, DOI 10.1074/jbc.M302468200; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Dailey HA, 2000, CELL MOL LIFE SCI, V57, P1909, DOI 10.1007/PL00000672; Dailey TA, 2002, J BACTERIOL, V184, P2460, DOI 10.1128/JB.184.9.2460-2464.2002; Dutton P L, 1978, Methods Enzymol, V54, P411; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Raux E, 1998, BIOCHEM J, V335, P167, DOI 10.1042/bj3350167; Raux E, 1998, BIOCHEM J, V335, P159, DOI 10.1042/bj3350159; Raux E, 2003, BIOCHEM J, V370, P505, DOI 10.1042/BJ20021443; REY L, 1994, J BACTERIOL, V176, P6066, DOI 10.1128/jb.176.19.6066-6073.1994; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; RYGUS T, 1991, APPL MICROBIOL BIOT, V35, P594; Schubert HL, 1999, BIOCHEMISTRY-US, V38, P10660, DOI 10.1021/bi9906773; Schubert HL, 2002, EMBO J, V21, P2068, DOI 10.1093/emboj/21.9.2068; Scott AI, 2003, J ORG CHEM, V68, P2529, DOI 10.1021/jo020728t; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P486, DOI 10.1016/0968-0004(90)90304-T	27	39	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41900	41907		10.1074/jbc.M306112200	http://dx.doi.org/10.1074/jbc.M306112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917443	hybrid			2022-12-27	WOS:000185989500043
J	Mizukoshi, T; Tanaka, T; Arai, K; Kohda, D; Masai, H				Mizukoshi, T; Tanaka, T; Arai, K; Kohda, D; Masai, H			A critical role of the 3 ' terminus of nascent DNA chains in recognition of stalled replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PRIA; PROTEIN; RECG; RECOMBINATION; HELICASE; RESTART; BINDING; MUTANTS; STRAND; REVERSAL	Arrest of replication forks by various internal and external threats evokes a myriad of cellular reactions, collectively known as DNA replication checkpoint responses. In bacteria, PriA is essential for restoration of stalled replication forks and recombinational repair of double-stranded DNA breaks and is a candidate sensor protein that may recognize arrested forks. Here, we report that PriA protein specifically recognizes 3' termini of arrested nascent DNA chains at model stalled replication forks in vitro. Mutations in the putative "3' terminus binding pocket" present in the N-terminal segment of PriA result in reduced binding to stalled replication fork structures and loss of its biological functions. The results suggest a mechanism by which stalled replication forks are recognized by a sensor protein for checkpoint responses.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan; Univ Tokyo, Inst Med Sci, Dept mol & Dev Biol, Tokyo 1088639, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776				Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Fukuoh A, 1997, EMBO J, V16, P203, DOI 10.1093/emboj/16.1.203; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Grompone G, 2003, MOL MICROBIOL, V48, P845, DOI 10.1046/j.1365-2958.2003.03480.x; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jezewska MJ, 2000, J BIOL CHEM, V275, P27865; Jones JM, 2000, MOL MICROBIOL, V36, P519, DOI 10.1046/j.1365-2958.2000.01888.x; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; Masai H, 1999, BIOCHIMIE, V81, P847, DOI 10.1016/S0300-9084(99)00211-4; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; Polard P, 2002, NUCLEIC ACIDS RES, V30, P1593, DOI 10.1093/nar/30.7.1593; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 1996, GENETICS, V143, P5; Sharples GJ, 1999, J BACTERIOL, V181, P5543, DOI 10.1128/JB.181.18.5543-5550.1999; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; STAUDENBAUER WL, 1979, MOL GEN GENET, V177, P113, DOI 10.1007/BF00267260; Tanaka T, 2003, GENES CELLS, V8, P251, DOI 10.1046/j.1365-2443.2003.00630.x; Tanaka T, 2002, J BIOL CHEM, V277, P38062, DOI 10.1074/jbc.M204397200; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729	30	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42234	42239		10.1074/jbc.C300285200	http://dx.doi.org/10.1074/jbc.C300285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917421	hybrid			2022-12-27	WOS:000185989500082
J	Chao, C; Hergenhahn, M; Kaeser, MD; Wu, ZQ; Saito, S; Iggo, R; Hollstein, M; Appella, E; Xu, Y				Chao, C; Hergenhahn, M; Kaeser, MD; Wu, ZQ; Saito, S; Iggo, R; Hollstein, M; Appella, E; Xu, Y			Cell type- and promoter-specific roles of Ser(18) phosphorylation in regulating p53 responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; IN-VIVO; APOPTOSIS; MDM2; RECRUITMENT; DEGRADATION; EXPRESSION; SERINE-15; PATHWAYS	Phosphorylation of mouse p53 at Ser(18) occurs after DNA damage. To determine the physiological roles of this phosphorylation event in p53-dependent DNA damage responses, a Ser(18) to Ala missense mutation was introduced into the germline of mice. Thymocytes and fibroblasts from the knock-in mice show reduced transactivation of many p53 target genes following DNA damage. p53 protein stabilization and DNA binding are similar in knock-in and wild type mice, but C-terminal acetylation was defective, consistent with a role for Ser(18) in the recruitment of transcriptional co-activators. The apoptotic response of knock-in thymocytes to ionizing radiation is intermediate between that of wild type and p53 null thymocytes. Despite impaired transcriptional and apoptotic responses, the knock-in mice are not prone to spontaneous tumorigenesis. This indicates that neither phosphorylation of p53 on Ser(18) by ATM nor a full transcriptional response is essential to prevent spontaneous tumor formation in mice.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA; Deutsch Krebsforschungszentrum, Dept Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany; Swiss Inst Expt Canc Res, Oncogene Grp, CH-1066 Epalinges, Switzerland; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Diego; Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Institute Experimental Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Iggo, Richard/G-3546-2014	Xu, Yang/0000-0001-5574-921X; Kaeser, Matthias/0000-0003-0050-9408	NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER; NCI NIH HHS [CA94254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Boley SE, 2002, TOXICOL SCI, V66, P209, DOI 10.1093/toxsci/66.2.209; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	30	110	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41028	41033		10.1074/jbc.M306938200	http://dx.doi.org/10.1074/jbc.M306938200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909629	hybrid			2022-12-27	WOS:000185847200077
J	Leao-Helder, AN; Krikken, AM; van der Klei, IJ; Kiel, JAKW; Veenhuis, M				Leao-Helder, AN; Krikken, AM; van der Klei, IJ; Kiel, JAKW; Veenhuis, M			Transcriptional down-regulation of peroxisome numbers affects selective peroxisome degradation in Hansenula polymorpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NITRATE ASSIMILATION; ALCOHOL OXIDASE; BETA-OXIDATION; MATRIX PROTEIN; GENE ENCODES; IMPORT; INDUCTION; MEMBRANE; PEX3P	We have isolated and characterized a novel transcription factor of Hansenula polymorpha that is involved in the regulation of peroxisomal protein levels. This protein, designated Mpp1p, belongs to the family of Zn(II)(2)Cys(6) proteins. In cells deleted for the function of Mpp1p the levels of various proteins involved in peroxisome biogenesis (peroxins) and function ( enzymes) are reduced compared with wild type or, in the case of the matrix protein dihydroxyacetone synthase, fully absent. Also, upon induction of mpp1 cells on methanol, the number of peroxisomes was strongly reduced relative to wild type cells and generally amounted to one organelle per cell. Remarkably, this single organelle was not susceptible to selective peroxisome degradation (pexophagy) and remained unaffected during exposure of methanol-induced cells to excess glucose conditions. We show that this mechanism is a general phenomenon in H. polymorpha in the case of cells that contain only a single peroxisome.	Univ Groningen, GBB, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	University of Groningen	Veenhuis, M (corresponding author), Univ Groningen, GBB, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.	M.Veenhuis@biol.rug.nl	van der Klei, Ida J/D-1919-2012; Leao-Helder, Adriana Nivea/J-2086-2014	Leao-Helder, Adriana Nivea/0000-0002-0664-1533; Van der Klei, Ida J./0000-0001-7165-9679; krikken, arjen/0000-0002-6684-6303				Akache B, 2001, NUCLEIC ACIDS RES, V29, P2181, DOI 10.1093/nar/29.10.2181; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Avila J, 2002, YEAST, V19, P537, DOI 10.1002/yea.847; Avila J, 1998, BIOCHEM J, V335, P647, DOI 10.1042/bj3350647; Baerends RJS, 1997, YEAST, V13, P1437; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Baumgartner U, 1999, J BIOL CHEM, V274, P22208, DOI 10.1074/jbc.274.32.22208; Bellu AR, 2003, MICROSC RES TECHNIQ, V61, P161, DOI 10.1002/jemt.10325; Bellu AR, 2002, J BIOL CHEM, V277, P42875, DOI 10.1074/jbc.M205437200; Bellu AR, 2001, J BIOL CHEM, V276, P44570, DOI 10.1074/jbc.M107599200; BRUINENBERG PG, 1990, YEAST, V6, P245, DOI 10.1002/yea.320060309; DISTEL B, 1988, J CELL BIOL, V107, P1669, DOI 10.1083/jcb.107.5.1669; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; Faber KN, 2002, BBA-MOL CELL RES, V1591, P157, DOI 10.1016/S0167-4889(02)00274-4; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; Marshall PA, 1996, J CELL BIOL, V135, P123, DOI 10.1083/jcb.135.1.123; MERCKELBACH A, 1993, APPL MICROBIOL BIOT, V40, P361, DOI 10.1007/BF00170393; Nikolaev I, 1999, J BIOL CHEM, V274, P9795, DOI 10.1074/jbc.274.14.9795; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TITORENKO VI, 1995, J BACTERIOL, V177, P357, DOI 10.1128/jb.177.2.357-363.1995; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; van Dijk R, 2001, MOL GENET GENOMICS, V266, P646, DOI 10.1007/s004380100584; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; VEENHUIS M, 1989, ARCH MICROBIOL, V151, P105, DOI 10.1007/BF00414422; VEENHUIS M, 1979, ARCH MICROBIOL, V120, P167, DOI 10.1007/BF00409104; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; WATERHAM HR, 1992, YEAST, V8, P961, DOI 10.1002/yea.320081106	44	61	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40749	40756		10.1074/jbc.M304029200	http://dx.doi.org/10.1074/jbc.M304029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902346	hybrid			2022-12-27	WOS:000185847200042
J	Rieckhof, GE; Yoshihara, M; Guan, Z; Littleton, JT				Rieckhof, GE; Yoshihara, M; Guan, Z; Littleton, JT			Presynaptic N-type calcium channels regulate synaptic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DROSOPHILA MEMORY; ALPHA-1 SUBUNIT; ION CHANNELS; II RECEPTOR; TERM-MEMORY; PLASTICITY; GENE; MUTANTS; ACTIVATION	Voltage-gated calcium channels couple changes in membrane potential to neuronal functions regulated by calcium, including neurotransmitter release. Here we report that presynaptic N-type calcium channels not only control neurotransmitter release but also regulate synaptic growth at Drosophila neuromuscular junctions. In a screen for behavioral mutants that disrupt synaptic transmission, an allele of the N-type calcium channel locus (Dmca1A) was identified that caused synaptic undergrowth. The underlying molecular defect was identified as a neutralization of a charged residue in the third S4 voltage sensor. RNA interference reduction of N-type calcium channel expression also reduced synaptic growth. Hypomorphic mutations in syntaxin-1A or n-synaptobrevin, which also disrupt neurotransmitter release, did not affect synapse proliferation at the neuromuscular junction, suggesting calcium entry through presynaptic N-type calcium channels, not neurotransmitter release per se, is important for synaptic growth. The reduced synapse proliferation in Dmca1A mutants is not due to increased synapse retraction but instead reflects a role for calcium influx in synaptic growth mechanisms. These results suggest N-type channels participate in synaptic growth through signaling pathways that are distinct from those that mediate neurotransmitter release. Linking presynaptic voltage-gated calcium entry to downstream calcium-sensitive synaptic growth regulators provides an efficient activity-dependent mechanism for modifying synaptic strength.	MIT, Dept Biol, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Littleton, JT (corresponding author), MIT, Dept Biol, Picower Ctr Learning & Memory, E18-672,50 Ames St, Cambridge, MA 02139 USA.	troy@mit.edu		Littleton, J. Troy/0000-0001-5576-2887	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043244, R01NS040296] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS043244, R01 NS040296, R01 NS040296-03, R01 NS043244-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aberle H, 2002, NEURON, V33, P545, DOI 10.1016/S0896-6273(02)00589-5; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Beumer K, 2002, DEVELOPMENT, V129, P3381; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; BUDNIK V, 1990, J NEUROSCI, V10, P3754; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Eaton BA, 2002, NEURON, V34, P729, DOI 10.1016/S0896-6273(02)00721-3; Eberl DF, 1998, GENETICS, V148, P1159; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; Jarecki J, 1995, J NEUROSCI, V15, P8177; Jen J, 1999, CURR OPIN NEUROBIOL, V9, P274, DOI 10.1016/S0959-4388(99)80040-3; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; Kawasaki F, 2002, J NEUROSCI, V22, P5856; Kawasaki F, 2000, J NEUROSCI, V20, P4885; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; Lichtman JW, 2000, NEURON, V25, P269, DOI 10.1016/S0896-6273(00)80893-4; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; Littleton JT, 2001, P NATL ACAD SCI USA, V98, P12233, DOI 10.1073/pnas.221450198; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Marques G, 2002, NEURON, V33, P529, DOI 10.1016/S0896-6273(02)00595-0; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Mori Y, 2000, J NEUROSCI, V20, P5654, DOI 10.1523/JNEUROSCI.20-15-05654.2000; Pennetta G, 2002, NEURON, V35, P291, DOI 10.1016/S0896-6273(02)00769-9; RAISMAN G, 1969, BRAIN RES, V14, P25, DOI 10.1016/0006-8993(69)90029-8; Ren DJ, 1998, J NEUROSCI, V18, P2335; Roos J, 2000, NEURON, V26, P371, DOI 10.1016/S0896-6273(00)81170-8; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SCHWABE U, 1977, J PHARMACOL EXP THER, V202, P134; SHAO XM, 1993, NEURON, V11, P343, DOI 10.1016/0896-6273(93)90189-X; Smith LA, 1998, GENETICS, V149, P1407; Smith LA, 1996, J NEUROSCI, V16, P7868; Steinlein OK, 2000, CURR OPIN GENET DEV, V10, P286, DOI 10.1016/S0959-437X(00)00079-4; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; TSUKAHARA N, 1975, J NEUROPHYSIOL, V38, P1359, DOI 10.1152/jn.1975.38.6.1359; TYTGAT J, 1993, J BIOL CHEM, V268, P23777; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; WANG J, 1994, NEURON, V13, P1373, DOI 10.1016/0896-6273(94)90422-7; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200; Yoshihara M, 1997, J NEUROSCI, V17, P8408; Zhang N, 2002, J NEUROSCI, V22, P7065; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X; ZHONG Y, 1991, SCIENCE, V251, P198, DOI 10.1126/science.1670967; ZHONG Y, 1992, J NEUROSCI, V12, P644; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; Zito K, 1999, NEURON, V22, P719, DOI 10.1016/S0896-6273(00)80731-X; Zwingman TA, 2001, J NEUROSCI, V21, P1169	64	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41099	41108		10.1074/jbc.M306417200	http://dx.doi.org/10.1074/jbc.M306417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896973	hybrid			2022-12-27	WOS:000185847200085
J	Tannert, A; Wustner, D; Bechstein, J; Muller, P; Devaux, PF; Herrmann, A				Tannert, A; Wustner, D; Bechstein, J; Muller, P; Devaux, PF; Herrmann, A			Aminophospholipids have no access to the luminal side of the biliary canaliculus - Implications for the specific lipid composition of the bile fluid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-LABELED PHOSPHOLIPIDS; MDR1 P-GLYCOPROTEIN; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; HUMAN-ERYTHROCYTES; TRANSPORT; FLUORESCENT; HEPG2; TRANSLOCATION; ASYMMETRY	About 95% of the bile phospholipids are phosphatidylcholine. Although the fractions of phosphatidylcholine and of both aminophospholipids phosphatidylserine and phosphatidylethanolamine in the canalicular membrane are in the same order of about 35% of total lipids, both aminophospholipids are almost absent from the bile. To rationalize this observation, we studied the intracellular uptake of various fluorescent phospholipid analogues and their subsequent enrichment in the bile canaliculus (BC) of HepG2 cells. Diacylaminophospholipid analogues but not phosphatidylcholine analogues became rapidly internalized by an aminophospholipid translocase (APLT) activity in the plasma membrane of HepG2 cells. We observed only low labeling of BC by diacylaminophospholipids but extensive staining by phosphatidylcholine analogues. In the presence of suramin, known to inhibit APLT, a strong labeling of BC by diacylaminophospholipid analogues was found that declined to a level observed for control cells after removal of suramin. Unlike diacylphosphatidylserine, diether phosphatidylserine analogue, which is not an appropriate substrate of APLT, accumulated in the BC. The correlation between low labeling of BC and an APLT-mediated transbilayer movement suggests the presence of an APLT activity in the canalicular membrane that prevents exposure of aminophospholipids to the bile.	Humboldt Univ, Math Nat Wissensch Fak 1, Inst Biol, D-10115 Berlin, Germany; Max Delbruck Zentrum Mol Med, D-13125 Berlin, Germany; Inst Biol Physicochim, Lab Physicochim Mol Membranes Biol, Unite Mixte Rech 7099, F-75005 Paris, France	Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; UDICE-French Research Universities; Universite Paris Cite	Herrmann, A (corresponding author), Humboldt Univ, Math Nat Wissensch Fak 1, Inst Biol, Invalidenstr 43, D-10115 Berlin, Germany.	andreas.herrmann@rz.hu-berlin.de		Tannert, Astrid/0000-0003-4115-2564; Wustner, Daniel/0000-0003-4995-9709				Beleznay Z, 1997, EUR J BIOCHEM, V243, P58, DOI 10.1111/j.1432-1033.1997.58_1a.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOHME M, 1993, FEBS LETT, V333, P193, DOI 10.1016/0014-5793(93)80403-H; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Buton X, 2002, BIOCHEMISTRY-US, V41, P13106, DOI 10.1021/bi020385t; Cantz T, 2000, AM J PHYSIOL-GASTR L, V278, pG522, DOI 10.1152/ajpgi.2000.278.4.G522; COLEMAN R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P113, DOI 10.1016/0005-2760(92)90036-U; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; CONNOR J, 1992, J BIOL CHEM, V267, P19412; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; Daleke DL, 2000, BBA-MOL CELL BIOL L, V1486, P108, DOI 10.1016/S1388-1981(00)00052-4; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; Devaux PF, 2002, CHEM PHYS LIPIDS, V116, P115, DOI 10.1016/S0009-3084(02)00023-3; DRAGSTEN PR, 1982, FED PROC, V41, P48; Elferink RPJO, 1997, FASEB J, V11, P19, DOI 10.1096/fasebj.11.1.9034162; Ernest S, 1999, J AM SOC NEPHROL, V10, P2306; Fellmann P, 2000, BIOCHEMISTRY-US, V39, P4994, DOI 10.1021/bi992649q; Kipp H, 2002, ANNU REV PHYSIOL, V64, P595, DOI 10.1146/annurev.physiol.64.081501.155793; KullakUblick GA, 1996, HEPATOLOGY, V23, P1053; Lian WN, 1999, HEPATOLOGY, V30, P748, DOI 10.1002/hep.510300302; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; Muller P, 1996, HEPATOLOGY, V24, P1497; OKA JA, 1989, BIOCHEM BIOPH RES CO, V159, P488, DOI 10.1016/0006-291X(89)90019-3; Pohl A, 2002, BIOCHEM J, V365, P259, DOI 10.1042/BJ20011880; Pomorski T, 1996, J CELL SCI, V109, P687; RIGOTTI A, 1994, CURR TOP MEMBR, V40, P579, DOI 10.1016/S0070-2161(08)60997-1; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; SMIT JJM, 1994, LAB INVEST, V71, P638; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TILLEY L, 1986, FEBS LETT, V194, P21, DOI 10.1016/0014-5793(86)80044-8; Ujhazy P, 2001, HEPATOLOGY, V34, P768, DOI 10.1053/jhep.2001.27663; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; vanIjzendoorn SCD, 1997, J CELL BIOL, V137, P347, DOI 10.1083/jcb.137.2.347; Wustner D, 2001, TRAFFIC, V2, P277, DOI 10.1034/j.1600-0854.2001.9o135.x; Wustner D, 2000, J LIPID RES, V41, P395; Wustner D, 1998, BIOCHEMISTRY-US, V37, P17093, DOI 10.1021/bi981608b; YOUSEF IM, 1976, CAN J BIOCHEM CELL B, V54, P1040, DOI 10.1139/o76-152; Zegers MMP, 1997, J CELL BIOL, V138, P307, DOI 10.1083/jcb.138.2.307	43	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40631	40639		10.1074/jbc.M302131200	http://dx.doi.org/10.1074/jbc.M302131200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904307	hybrid			2022-12-27	WOS:000185847200027
J	Howes, AL; Arthur, JF; Zhang, T; Miyamoto, S; Adams, JW; Dorn, GW; Woodcock, EA; Brown, JH				Howes, AL; Arthur, JF; Zhang, T; Miyamoto, S; Adams, JW; Dorn, GW; Woodcock, EA; Brown, JH			Akt-mediated cardiomyocyte survival pathways are compromised by G alpha(q)-induced phosphoinositide 4,5-bisphosphate depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; PROTEIN-KINASE B; HEART-FAILURE; CARDIAC MYOCYTES; PHOSPHOLIPASE-C; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSGENIC MICE; MYOCARDIAL HYPERTROPHY; CELL-SURVIVAL	Expression of the wild type alpha subunit of G(q) (G(q)WT) in cardiomyocytes induces hypertrophy, whereas a constitutively active Galpha(q) subunit (G(q)Q209L) induces apoptosis. Akt phosphorylation increases with G(q)WT expression but is markedly attenuated in cardiomyocytes expressing G(q)Q209L or in those expressing G(q)WT and treated with agonist. A membrane-targeted Akt rescues G(q)Q209L-expressing cardiomyocytes from apoptotic cell death. In contrast, leukemia inhibitory factor fails to activate Akt or promote cell survival in these cells. Association of Akt and PDK-1 with the membrane is also diminished in G(q)Q209L-expressing cardiomyocytes. Phosphatidylinositol 3,4,5-trisphosphate (PIP3), the primary regulator of Akt, increases significantly in G(q)WT-expressing cells but not in cardiomyocytes expressing G(q)Q209L. Levels of phosphatidylinositol 4,5-bisphosphate (PIP2), the immediate precursor of PIP3, are also markedly lower in G(q)Q209L-expressing compared to control cells. Expression of a G(q)Q209L mutant that has diminished capacity to activate phospholipase C does not decrease PIP2 or Akt or induce apoptosis. In transgenic mice with cardiac Galpha(q) overexpression, heart failure and increased cardiomyocyte apoptosis develop during the peripartal period. Akt phosphorylation and PIP2 levels decrease concomitantly. Our findings suggest that an Akt-mediated cell survival pathway is compromised by the diminished availability of PIP2 elicited by pathological levels of G(q) activity.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Arena Pharmaceut, San Diego, CA 92121 USA; Baker Heart Res Inst, Cellular Biochem Lab, Melbourne, Vic, Australia; Univ Cincinnati, Med Ctr, Dept Internal Med, Div Cardiol, Cincinnati, OH 45267 USA	University of California System; University of California San Diego; Baker Heart and Diabetes Institute; University System of Ohio; University of Cincinnati	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,Mail Code 0636, La Jolla, CA 92093 USA.		ARTHUR, JANE/AAW-9983-2020		NHLBI NIH HHS [HL28143, HL46345, HL59888] Funding Source: Medline; NIGMS NIH HHS [T32 GM007752, GM-07752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL059888, R37HL028143, R01HL028143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Clerk A, 1999, AM J CARDIOL, V83, p64H; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; HAYAKAWA Y, 2003, IN PRESS CIRCULATION; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Ju HS, 1998, CIRCULATION, V97, P892, DOI 10.1161/01.CIR.97.9.892; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Kuwahara K, 2000, J MOL CELL CARDIOL, V32, P1385, DOI 10.1006/jmcc.2000.1177; Kuwahara K, 1999, CIRCULATION, V100, P1116, DOI 10.1161/01.CIR.100.10.1116; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Miao WF, 2000, J MOL CELL CARDIOL, V32, P2397, DOI 10.1006/jmcc.2000.1283; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MONACO ME, 1987, J BIOL CHEM, V262, P147; Negoro S, 2001, CIRCULATION, V103, P555, DOI 10.1161/01.CIR.103.4.555; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sakata Y, 1998, CIRCULATION, V97, P1488; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Speed CJ, 2000, J CELL SCI, V113, P2631; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Taniyama Y, 2002, J MOL CELL CARDIOL, V34, P1241, DOI 10.1006/jmcc.2002.2068; Tappia PS, 1999, AM J PHYSIOL-HEART C, V277, pH40, DOI 10.1152/ajpheart.1999.277.1.H40; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Woodcock EA, 1997, MOL CELL BIOCHEM, V172, P121, DOI 10.1023/A:1006871722652; WOODCOCK EA, 1995, CIRC RES, V76, P252, DOI 10.1161/01.RES.76.2.252; Ziegelhoffer A, 2001, CARDIOVASC RES, V49, P118, DOI 10.1016/S0008-6363(00)00209-1	50	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40343	40351		10.1074/jbc.M305964200	http://dx.doi.org/10.1074/jbc.M305964200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900409	hybrid			2022-12-27	WOS:000185713800128
J	Popescu, A; Miron, S; Blouquit, Y; Duchambon, P; Christova, P; Craescu, CT				Popescu, A; Miron, S; Blouquit, Y; Duchambon, P; Christova, P; Craescu, CT			Xeroderma pigmentosum group C protein possesses a high affinity binding site to human centrin 2 and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; NUCLEOTIDE EXCISION-REPAIR; MICROTUBULE-ORGANIZING CENTER; TARGET PEPTIDE RECOGNITION; YEAST CALMODULIN; TROPONIN-C; SACCHAROMYCES-CEREVISIAE; CENTROSOME DUPLICATION; MOLECULAR RECOGNITION; REGULATORY DOMAIN	Human centrin 2 (HsCen2), a member of the EF-hand superfamily of Ca2+-binding proteins, is commonly associated with centrosome-related structures. The protein is organized in two domains, each containing two EF-hand motifs, but only the C-terminal half exhibits Ca2+ sensor properties. A significant fraction of HsCen2 is localized in the nucleus, where it was recently found associated with the xeroderma pigmentosum group C protein (XPC), a component of the nuclear excision repair pathway. Analysis of the XPC sequence (940 residues), using a calmodulin target recognition software, enabled us to predict two putative binding sites. The binding properties of the two corresponding peptides were investigated by isothermal titration calorimetry. Only one of the peptides (P1-XPC) interacts strongly (K-a = 2.2 x 10(8) M-1, stoichiometry 1:1) with HsCen2 in a Ca2+-dependent manner. This peptide also binds, with a similar affinity (K-a = 1.1 x 10(8) M-1) to a C-terminal construct of HsCen2, indicating that the interaction with the integral protein is mainly the result of the contribution of the C-terminal half. The second peptide (P2-XPC) failed to show any detectable binding either to HsCen2 or to its C-terminal lobe. The two peptides interact with different affinities and mechanisms with calmodulin. Circular dichroism and nuclear magnetic resonance were used to structurally characterize the complex formed by the C-terminal domain of HsCen2 with P1-XPC.	Ctr Univ, INSERM, U350, F-91405 Orsay, France; Ctr Univ, Inst Curie Rech, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Craescu, CT (corresponding author), Ctr Univ, INSERM, U350, Batiments 110-112, F-91405 Orsay, France.		Miron, Simona/M-9223-2018					Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; Benhamou S, 2000, MUTAT RES-REV MUTAT, V462, P149, DOI 10.1016/S1383-5742(00)00032-6; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Brokx RD, 2001, J BIOL CHEM, V276, P14083, DOI 10.1074/jbc.M011026200; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Censarek P, 2002, BIOCHEMISTRY-US, V41, P8598, DOI 10.1021/bi025681k; Chavanne F, 2000, CANCER RES, V60, P1974; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Durussel I, 2000, FEBS LETT, V472, P208, DOI 10.1016/S0014-5793(00)01452-6; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; ERRABOLU R, 1994, J CELL SCI, V107, P9; Flory MR, 2000, P NATL ACAD SCI USA, V97, P5919, DOI 10.1073/pnas.97.11.5919; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Geier BM, 1996, J BIOL CHEM, V271, P28366, DOI 10.1074/jbc.271.45.28366; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Ivanovska I, 2001, GENETICS, V157, P503; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; Li CJ, 1999, J CELL SCI, V112, P1567; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; Luque I, 1998, BIOCHEMISTRY-US, V37, P5791, DOI 10.1021/bi9802521; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Matei E, 2003, BIOCHEMISTRY-US, V42, P1439, DOI 10.1021/bi0269714; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1995, NAT STRUCT BIOL, V2, P943, DOI 10.1038/nsb1195-943; Middendorp S, 1997, P NATL ACAD SCI USA, V94, P9141, DOI 10.1073/pnas.94.17.9141; Moisoi N, 2002, J CELL SCI, V115, P2367; Moorthy AK, 1999, FEBS LETT, V461, P19, DOI 10.1016/S0014-5793(99)01380-0; Moser MJ, 1997, J CELL SCI, V110, P1805; Murase T, 2002, BIOCHEMISTRY-US, V41, P1618, DOI 10.1021/bi011782r; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Osawa M, 1998, J MOL BIOL, V276, P165, DOI 10.1006/jmbi.1997.1524; Paoletti A, 1996, J CELL SCI, V109, P3089; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; Uchida A, 2002, DNA REPAIR, V1, P449, DOI 10.1016/S1568-7864(02)00031-9; VALLEN EA, 1994, GENETICS, V137, P407; Veeraraghavan S, 2002, J BIOL CHEM, V277, P28564, DOI 10.1074/jbc.M112232200; Wang EZ, 1997, BIOCHEMISTRY-US, V36, P15026, DOI 10.1021/bi963075h; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; Wolfrum U, 1998, EXP CELL RES, V242, P10, DOI 10.1006/excr.1998.4038; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YAP KL, 2001, J STRUCT FUNCT GENOM, V1, P8	65	74	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40252	40261		10.1074/jbc.M302546200	http://dx.doi.org/10.1074/jbc.M302546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890685	hybrid			2022-12-27	WOS:000185713800118
J	Zhang, YX; Manning, LR; Falcone, J; Platt, O; Manning, JM				Zhang, YX; Manning, LR; Falcone, J; Platt, O; Manning, JM			Human erythrocyte membrane band 3 protein influences hemoglobin cooperativity - Possible effect on oxygen transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; BINDING-SITES; 2,3-DIPHOSPHOGLYCERATE; CHLORIDE; POLYMERIZATION; ASSOCIATION; AFFINITY; FRAGMENT; MUTANT; ANIONS	Hemoglobin function can be modulated by the red cell membrane but some mechanistic details are incomplete. For example, the 43-kDa chymotryptic fragment of the cytoplasmic portion of red cell membrane Band 3 protein and its corresponding N-terminal 11-residue synthetic peptide lower the oxygen affinity of hemoglobin but effects on cooperativity are unclear. Using highly purified preparations, we also find a lowered Hill coefficient (n values < 2) at subequivalent ratios of Band 3 fragment or of synthetic peptide to Hb, resulting in an oxygen affinity that is moderately decreased and a partially hyperbolic shape for the O-2 binding curve. Both normal HbA and sickle HbS display this property. Thus, the determinant responsible for the Hb cooperativity decreases by the 43-kDa fragment resides within its first 11 N-terminal residues. This effect is observed in the absence of chloride and is reversed by its addition. As effector to Hb ratios approach equivalence or with saturating chloride normal cooperativity is restored, and oxygen affinity is further lowered because the shape of the oxygen binding curve becomes completely sigmoidal. The relative efficiencies of 2,3-diphosphoglycerate (DPG), the 43-kDa Band 3 fragment, and the 11-residue synthetic peptide in lowering cooperativity are very similar. The findings are explained based on the stereochemical mechanism of cooperativity because of two populations of T-state hemoglobin tetramers, one with bound effector and the other with free (Perutz, M. F. ( 1989) Q. Rev. Biophys. 22, 139 - 237). As a result of this property, hemoglobin at the membrane inner surface in contact with the N-terminal region of Band 3 could preferentially bind O-2 at low oxygen tension and then release it upon saturation with 2,3-diphosphoglycerate in the interior of the red cell. Membrane modulation of hemoglobin oxygen affinity has particularly interesting implications for the polymerization of hemoglobin S in the sickle red cell.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Northeastern University; Harvard University; Boston Children's Hospital	Manning, JM (corresponding author), Northeastern Univ, Dept Biol, Mugar Life Sci Bldg,360 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL-18819, HL-15157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018819, P60HL015157, R01HL018819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONINI E, 1970, ANNU REV BIOCHEM, V39, P977, DOI 10.1146/annurev.bi.39.070170.004553; APPELL KC, 1981, J BIOL CHEM, V256, P1104; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; Baldwin J.M., 1975, Progress Biophys Molec Biol, V29, P225; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BERGER RL, 1973, ANAL LETT, V6, P125; BONAVENTURA J, 1976, J BIOL CHEM, V251, P7563; CASSOLY R, 1983, J BIOL CHEM, V258, P3859; Chen WH, 2000, BIOCHEMISTRY-US, V39, P3774, DOI 10.1021/bi992691l; CHETRITE G, 1985, J MOL BIOL, V185, P639, DOI 10.1016/0022-2836(85)90076-2; DANISH EH, 1994, AM J HEMATOL, V47, P106, DOI 10.1002/ajh.2830470208; Dumoulin A, 1998, J BIOL CHEM, V273, P35032, DOI 10.1074/jbc.273.52.35032; Eaton WA, 1999, NAT STRUCT BIOL, V6, P351, DOI 10.1038/7586; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Himanen JP, 1996, J BIOL CHEM, V271, P25152, DOI 10.1074/jbc.271.41.25152; KISTER J, 1987, J BIOL CHEM, V262, P12085; LOW PS, 1989, RED BLOOD CELL MEMBR, P237; NIGEN AM, 1975, J BIOL CHEM, V250, P8248; NIGEN AM, 1980, J BIOL CHEM, V255, P5525; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; Platt Orah S., 1994, P125; SALHANY JM, 1980, BIOCHEMISTRY-US, V19, P1447, DOI 10.1021/bi00548a028; SALHANY JM, 1994, BIOCHEMISTRY-US, V33, P11909, DOI 10.1021/bi00205a029; TSUNESHIGE A, 1987, J BIOCHEM-TOKYO, V101, P695, DOI 10.1093/jb/101.3.695; UENO H, 1992, J PROTEIN CHEM, V11, P177, DOI 10.1007/BF01025223; WALDER JA, 1984, J BIOL CHEM, V259, P238; Wyman J, 1968, Q Rev Biophys, V1, P35; Zhang DC, 2000, BLOOD, V96, P2925	30	18	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39565	39571		10.1074/jbc.M303352200	http://dx.doi.org/10.1074/jbc.M303352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893828	hybrid			2022-12-27	WOS:000185713800038
J	Alter-Koltunoff, M; Ehrlich, S; Dror, N; Azriel, A; Eilers, M; Hauser, H; Bowen, H; Barton, CH; Tamura, T; Ozato, K; Levi, BZ				Alter-Koltunoff, M; Ehrlich, S; Dror, N; Azriel, A; Eilers, M; Hauser, H; Bowen, H; Barton, CH; Tamura, T; Ozato, K; Levi, BZ			Nramp1-mediated innate resistance to intraphagosomal pathogens is regulated by IRF-8, PU.1, and Miz-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; IL-18 GENE-EXPRESSION; TRANSCRIPTION FACTOR; GP91(PHOX) EXPRESSION; NATURAL-RESISTANCE; COMPLEX-FORMATION; MYC REPRESSES; C-MYC; MACROPHAGES; ICSBP	Natural resistance-associated macrophage protein 1 (Nramp1) is a proton/divalent cation antiporter exclusively expressed in monocyte/macrophage cells with a unique role in innate resistance to intraphagosomal pathogens. In humans, it is linked to several infectious diseases, including leprosy, pulmonary tuberculosis, visceral leishmaniasis, meningococcal meningitis, and human immunodeficiency virus as well as to autoimmune diseases such as rheumatoid arthritis and Crohn's disease. Here we demonstrate that the restricted expression of Nramp1 is mediated by the macrophage-specific transcription factor IRF-8. This factor exerts its activity via protein-protein interaction, which facilitates its binding to target DNA. Using yeast two-hybrid screen we identified Myc Interacting Zinc finger protein 1 (Miz-1) as new interacting partner. This interaction is restricted to immune cells and takes place on the promoter Nramp1 in association with PU.1, a transcription factor essential for myelopoiesis. Consistent with these data, IRF-8 knockout mice are sensitive to a repertoire of intracellular pathogens. Accordingly, IRF-8(-/-) mice express low levels of Nramp1 that can not be induced any further. Thus, our results explain in molecular terms the role of IRF-8 in conferring innate resistance to intracellular pathogens and point to its possible involvement in autoimmune diseases.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Univ Marburg, Inst Mol Biol & Tumour Res, D-35033 Marburg, Germany; GBF, Gesell Biotechnol Forsch GmbH, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany; Univ Southampton, Dept Biochem & Mol Biol, Southampton S016 7PX, Hants, England; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Technion Israel Institute of Technology; Philipps University Marburg; Gesellschaft fur Biotechnologische Forschung mbH; Helmholtz Association; Helmholtz-Center for Infection Research; University of Southampton; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Levi, BZ (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.			Eilers, Martin/0000-0002-0376-6533	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001310] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akira S, 2000, CURR OPIN IMMUNOL, V12, P59, DOI 10.1016/S0952-7915(99)00051-5; BARBER SA, 1995, INFECT IMMUN, V63, P601, DOI 10.1128/IAI.63.2.601-608.1995; Barton CH, 1999, J LEUKOCYTE BIOL, V66, P757, DOI 10.1002/jlb.66.5.757; Blackwell JM, 2003, IMMUNOL LETT, V85, P197, DOI 10.1016/S0165-2478(02)00231-6; Bowen H, 2002, J BIOL CHEM, V277, P34997, DOI 10.1074/jbc.M204232200; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; BRITTON W, 2001, IMMUNOLOGY, P371; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen H, 2000, J BIOL CHEM, V275, P39081, DOI 10.1074/jbc.M004900200; Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Giese NA, 1997, J EXP MED, V186, P1535, DOI 10.1084/jem.186.9.1535; Hashmueli S, 2003, INT IMMUNOL, V15, P807, DOI 10.1093/intimm/dxg077; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Kantakamalakul W, 1999, J IMMUNOL, V162, P7417; Kautz B, 2001, J BIOL CHEM, V276, P37868; Kim YM, 1999, J IMMUNOL, V163, P2000; Kim YM, 2000, J IMMUNOL, V165, P3198, DOI 10.4049/jimmunol.165.6.3198; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; Levi BZ, 2002, J INTERF CYTOK RES, V22, P153, DOI 10.1089/107999002753452764; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Masumi A, 2002, FEBS LETT, V531, P348, DOI 10.1016/S0014-5793(02)03556-1; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Meraro D, 1999, J IMMUNOL, V163, P6468; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; Perkel JM, 1998, J IMMUNOL, V160, P241; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schaper F, 1998, BIOCHEM J, V335, P147, DOI 10.1042/bj3350147; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; Sharf R, 1997, J BIOL CHEM, V272, P9785; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Wyllie S, 2002, MICROBES INFECT, V4, P351, DOI 10.1016/S1286-4579(02)01548-4; Xiong HB, 2003, J BIOL CHEM, V278, P2271, DOI 10.1074/jbc.M209583200	52	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44025	44032		10.1074/jbc.M307954200	http://dx.doi.org/10.1074/jbc.M307954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12904288	hybrid			2022-12-27	WOS:000186306700018
J	Petersen, J; Wilmann, PG; Beddoe, T; Oakley, AJ; Devenish, RJ; Prescott, M; Rossjohn, J				Petersen, J; Wilmann, PG; Beddoe, T; Oakley, AJ; Devenish, RJ; Prescott, M; Rossjohn, J			The 2.0-angstrom crystal structure of eqFP611, a far red fluorescent protein from the sea anemone Entacmaea quadricolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POCILLOPORIN PIGMENT; CORALS; ANTHOZOA; VARIANTS; HOMOLOG	We have crystallized and subsequently determined to 2.0-Angstrom resolution the crystal structure of eqFP611, a far red fluorescent protein from the sea anemone Entacmaea quadricolor. The structure of the protomer, which adopts a beta-can topology, is similar to that of the related monomeric green fluorescent protein (GFP). The quaternary structure of eqFP611, a tetramer exhibiting 222 symmetry, is similar to that observed for the more closely related red fluorescent protein DsRed and the chromoprotein Rtms5. The unique chromophore sequence (Met(63)-Tyr(64)-Gly(65)) of eqFP611, adopts a coplanar and trans conformation within the interior of the beta-can fold. Accordingly, the eqFP611 chromophore adopts a significantly different conformation in comparison to the chromophore conformation observed in GFP, DsRed, and Rtms5. The coplanar chromophore conformation and its immediate environment provide a structural basis for the far red, highly fluorescent nature of eqFP611. The eqFP611 structure extends our knowledge on the range of conformations a chromophore can adopt within closely related members of the green fluorescent protein family.	Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Sch Biomed Sci, Prot Crystallog, Clayton, Vic 3800, Australia; Univ Western Australia, Dept Pharmacol, Crystallog Ctr, Crawley, WA 6009, Australia	Monash University; Monash University; University of Western Australia	Prescott, M (corresponding author), Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton Campus, Clayton, Vic 3800, Australia.		Beddoe, Travis/F-3415-2014; Rossjohn, Jamie/F-9032-2013; Oakley, Aaron/A-9464-2013	Beddoe, Travis/0000-0003-4550-2277; Rossjohn, Jamie/0000-0002-2020-7522; Oakley, Aaron/0000-0002-4764-014X; Wilmann, Pascal/0000-0002-8376-5150				Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; Beddoe T, 2003, ACTA CRYSTALLOGR D, V59, P597, DOI 10.1107/S0907444902023466; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chudakov DM, 2003, NAT BIOTECHNOL, V21, P191, DOI 10.1038/nbt778; Chudakov DM, 2003, J BIOL CHEM, V278, P7215, DOI 10.1074/jbc.M211988200; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Dove SG, 2001, CORAL REEFS, V19, P197, DOI 10.1007/PL00006956; Gurskaya NG, 2001, FEBS LETT, V507, P16, DOI 10.1016/S0014-5793(01)02930-1; Jones RJ, 2001, PLANT CELL ENVIRON, V24, P89, DOI 10.1046/j.1365-3040.2001.00648.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lukyanov KA, 2000, J BIOL CHEM, V275, P25879, DOI 10.1074/jbc.C000338200; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Ostergaard H, 2001, EMBO J, V20, P5853, DOI 10.1093/emboj/20.21.5853; OTTWINOWSKI Z, 1993, DATA COLLECTION PROC, P56; Prescott M, 2003, STRUCTURE, V11, P275, DOI 10.1016/S0969-2126(03)00028-5; Salih A, 2000, NATURE, V408, P850, DOI 10.1038/35048564; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Wall MA, 2000, NAT STRUCT BIOL, V7, P1133; Wiedenmann J, 2002, P NATL ACAD SCI USA, V99, P11646, DOI 10.1073/pnas.182157199; Yarbrough D, 2001, P NATL ACAD SCI USA, V98, P462, DOI 10.1073/pnas.98.2.462	26	148	156	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44626	44631		10.1074/jbc.M307896200	http://dx.doi.org/10.1074/jbc.M307896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12909624	hybrid			2022-12-27	WOS:000186306700093
J	Ivanova, J; Salama, G; Clancy, RM; Schor, NF; Nylander, KD; Stoyanovsky, DA				Ivanova, J; Salama, G; Clancy, RM; Schor, NF; Nylander, KD; Stoyanovsky, DA			Formation of nitroxyl and hydroxyl radical in solutions of sodium trioxodinitrate - Effects of pH and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; NITRIC-OXIDE; ALDEHYDE DEHYDROGENASE; AQUEOUS-SOLUTION; ANGELIS SALT; HYDROGEN-PEROXIDE; HPLC-EC; ANION; PEROXYNITRITE; NO	Despite its negative redox potential, nitroxyl (HNO) can trigger reactions of oxidation. Mechanistically, these reactions were suggested to occur with the intermediate formation of either hydroxyl radical ((OH)-O-.) or peroxynitrite (ONOO-). In this work, we present further experimental evidence that HNO can generate (OH)-O-.. Sodium trioxodinitrate (Na2N2O3), a commonly used donor of HNO, oxidized phenol and Me2SO to benzene diols and .CH3, respectively. The oxidation of Me2SO was O-2-independent, suggesting that this process reflected neither the intermediate formation of ONOO- nor a redox cycling of transition metal ions that could initiate Fentonlike reactions. In solutions of phenol, Na2N2O3 yielded benzene-1,2-diol and benzene-1,4-diol at a ratio of 2: 1, which is consistent with the generation of free (OH)-O-.. Ethanol and Me2SO, which are efficient scavengers of (OH)-O-., impeded the hydroxylation of phenol. A mechanism for the hydrolysis of Na2N2O3 is proposed that includes dimerization of HNO to cis-hyponitrous acid (HO-N = N- OH) with a concomitant azo-type homolytic fission of the latter to N-2 and (OH)-O-.. The HNO-dependent production of (OH)-O-. was with 1 order of magnitude higher at pH 6.0 than at pH 7.4. Hence, we hypothesized that HNO can exert selective toxicity to cells subjected to acidosis. In support of this thesis, Na2N2O3 was markedly more toxic to human fibroblasts and SK-N-SH neuroblastoma cells at pH 6.2 than at pH 7.4. Scavengers of (OH)-O-. impeded the cytotoxicity of Na2N2O3. These results suggest that the formation of HNO may be viewed as a toxicological event in tissues subjected to acidosis.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; NYU, Sch Med, Dept Rheumatol, New York, NY 10016 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Pediat Ctr Neurosci, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; New York University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stoyanovsky, DA (corresponding author), Univ Pittsburgh, Dept Surg, MUH654 NW,3459 5th Ave, Pittsburgh, PA 15213 USA.		Ivanova, Juliana/AAN-3235-2021; Ivanova, Juliana/HGA-1586-2022	Ivanova, Juliana/0000-0002-3213-2046; Ivanova, Juliana/0000-0002-3213-2046; Schor, Nina/0000-0002-3817-7376; Stoyanovsky, Detcho/0000-0001-5591-4780	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009648] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09648-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al-Ajlouni AM, 1999, INORG CHEM, V38, P1592, DOI 10.1021/ic981194a; ANDERSON JH, 1963, ANALYST, V88, P494, DOI 10.1039/an9638800494; Andersson SE, 1999, J RHEUMATOL, V26, P2018; Bai P, 2001, FREE RADICAL BIO MED, V31, P1616, DOI 10.1016/S0891-5849(01)00756-0; Bartberger MD, 2001, P NATL ACAD SCI USA, V98, P2194, DOI 10.1073/pnas.041481598; Bartberger MD, 2002, P NATL ACAD SCI USA, V99, P10958, DOI 10.1073/pnas.162095599; BONNER FT, 1975, INORG CHEM, V14, P558, DOI 10.1021/ic50145a022; BUCHHOLZ JR, 1965, J AM CHEM SOC, V87, P2350, DOI 10.1021/ja01089a008; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; Chazotte-Aubert L, 1999, J BIOL CHEM, V274, P20909, DOI 10.1074/jbc.274.30.20909; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Conway TT, 1998, J MED CHEM, V41, P2903, DOI 10.1021/jm980200+; Daiber A, 1998, NITRIC OXIDE-BIOL CH, V2, P259, DOI 10.1006/niox.1998.0186; DeMaster EG, 1997, ALCOHOL, V14, P181, DOI 10.1016/S0741-8329(96)00142-5; DONALD CE, 1986, INORG CHEM, V25, P2676, DOI 10.1021/ic00236a004; DOYLE MP, 1988, J AM CHEM SOC, V110, P593, DOI 10.1021/ja00210a047; Ellis A, 2000, BRIT J PHARMACOL, V129, P315, DOI 10.1038/sj.bjp.0703058; FIELD RJ, 1982, J PHYS CHEM-US, V86, P2443, DOI 10.1021/j100210a040; GASBARRINI A, 1992, J BIOL CHEM, V267, P7545; HAGE JP, 1995, BIOORGAN MED CHEM, V3, P1383, DOI 10.1016/0968-0896(95)00123-X; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; HUGHES MN, 1976, J CHEM SOC DALTON, P703; ITO S, 1992, J ORG CHEM, V57, P6937, DOI 10.1021/jo00051a048; Jacobi J, 2002, AM J HEALTH-SYST PH, V59, pS3, DOI 10.1093/ajhp/59.suppl_1.S3; JANZEN EG, 1992, FREE RADICAL BIO MED, V12, P169, DOI 10.1016/0891-5849(92)90011-5; Jensen DE, 1998, BIOCHEM J, V331, P659, DOI 10.1042/bj3310659; KIGOSHI M, 1993, B CHEM SOC JPN, V66, P2954, DOI 10.1246/bcsj.66.2954; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; Kirsch M, 2002, J BIOL CHEM, V277, P13379, DOI 10.1074/jbc.M108079200; LEE MJC, 1992, J MED CHEM, V35, P3648, DOI 10.1021/jm00098a008; Lee MJC, 2001, NITRIC OXIDE-BIOL CH, V5, P278, DOI 10.1006/niox.2001.0349; LOECHLER EL, 1987, J AM CHEM SOC, V109, P3076, DOI 10.1021/ja00244a034; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; Miranda KM, 2001, J BIOL CHEM, V276, P1720, DOI 10.1074/jbc.M006174200; Miranda KM, 2003, J INORG BIOCHEM, V93, P52, DOI 10.1016/S0162-0134(02)00498-1; MOTOHASHI N, 1993, CHEM PHARM BULL, V41, P1842; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; NAGASAWA HT, 1995, J MED CHEM, V38, P1865, DOI 10.1021/jm00011a005; Naughton P, 2002, J BIOL CHEM, V277, P40666, DOI 10.1074/jbc.M203863200; Nelli S, 2000, BRIT J PHARMACOL, V131, P356, DOI 10.1038/sj.bjp.0703550; Novakov CP, 2001, CHEM RES TOXICOL, V14, P1239, DOI 10.1021/tx015507h; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; Ohshima H, 1998, FREE RADICAL BIO MED, V25, P1057, DOI 10.1016/S0891-5849(98)00141-5; Owens LM, 1996, CIRCULATION, V94, P10, DOI 10.1161/01.CIR.94.1.10; Paolocci N, 2003, P NATL ACAD SCI USA, V100, P5537, DOI 10.1073/pnas.0937302100; PIERCE GB, 1991, DIFFERENTIATION, V46, P181, DOI 10.1111/j.1432-0436.1991.tb00880.x; RAGHAVAN NV, 1980, J AM CHEM SOC, V102, P3495, DOI 10.1021/ja00530a031; Shafirovich V, 2002, P NATL ACAD SCI USA, V99, P7340, DOI 10.1073/pnas.112202099; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SMITH PAS, 1960, J AM CHEM SOC, V82, P5731, DOI 10.1021/ja01506a043; Stoyanovsky DA, 1999, CHEM RES TOXICOL, V12, P730, DOI 10.1021/tx9900371; Stoyanovsky DA, 1999, J AM CHEM SOC, V121, P5093, DOI 10.1021/ja990318v; Stoyanovsky DA, 1999, ANAL CHEM, V71, P715, DOI 10.1021/ac980657r; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; TOWELL J, 1991, ANAL BIOCHEM, V196, P111, DOI 10.1016/0003-2697(91)90126-E; Uppu RM, 1998, ARCH BIOCHEM BIOPHYS, V358, P1, DOI 10.1006/abbi.1998.0825; Vaananen AJ, 2003, FREE RADICAL RES, V37, P381, DOI 10.1080/1071576031000061011; VanUffelen BE, 1998, BIOCHEM J, V330, P719; VAUPEL PW, 1981, CANCER RES, V41, P2008; VELTWISCH D, 1980, J CHEM SOC PERK T 2, P146, DOI 10.1039/p29800000146; Waldmann R, 2001, ADV EXP MED BIOL, V502, P293; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Xia Y, 2000, FREE RADICAL BIO MED, V29, P793, DOI 10.1016/S0891-5849(00)00427-5	68	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42761	42768		10.1074/jbc.M305544200	http://dx.doi.org/10.1074/jbc.M305544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920123	hybrid			2022-12-27	WOS:000186157000006
J	Morais, VA; Crystal, AS; Pijak, DS; Carlin, D; Costa, J; Lee, VMY; Doms, RW				Morais, VA; Crystal, AS; Pijak, DS; Carlin, D; Costa, J; Lee, VMY; Doms, RW			The transmembrane domain region of nicastrin mediates direct interactions with APH-1 and the gamma-secretase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-APP; INTRACELLULAR DOMAIN; INTRAMEMBRANE PROTEOLYSIS; GLYCOSYLATED NICASTRIN; ALZHEIMERS-DISEASE; A-BETA; PRESENILIN; CLEAVAGE; NOTCH	Nicastrin (NCT) is a type I integral membrane protein that is one of the four essential components of the gamma-secretase complex, a protein assembly that catalyzes the intramembranous cleavage of the amyloid precursor protein and Notch. Other gamma-secretase components include presenilin-1 (PS1), APH-1, and PEN-2, all of which span the membrane multiple times. The mechanism by which NCT associates with the gamma-secretase complex and regulates its activity is unclear. To avoid the misfolding phenotype often associated with introducing deletions or mutations into heavily glycosylated and disulfide-bonded proteins such as NCT, we produced chimeras between human (hNCT) and Caenorhabditis elegans NCT (ceNCT). Although ceNCT did not associate with human gamma-secretase components, all of the ceNCT/hNCT chimeras interacted with gamma-secretase components from human, C. elegans, or both, indicating that they folded correctly. A region at the C-terminal end of hNCT, encompassing the last 50 residues of its ectodomain, the transmembrane domain, and the cytoplasmic domain was important for mediating interactions with human PS1, APH-1, and PEN-2. This finding is consistent with the fact that the bulk of the gamma-secretase complex proteins resides within the membrane, with relatively small extramembranous domains. Finally, hNCT associated with hAPH-1 in the absence of PS, consistent with NCT and APH-1 forming a subcomplex prior to association with PS1 and PEN-2 and indicating that the interactions between NCT with PS1 may be indirect or stabilized by the presence of APH-1.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Inst Biol Expt & Tecnol, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Doms, RW (corresponding author), Univ Penn, Sch Med, Dept Microbiol, 225 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.		Costa, Júlia C/B-7131-2008	Costa, Júlia C/0000-0001-7782-6319; Morais, Vanessa/0000-0002-0830-0548; Crystal, Adam/0000-0002-2302-2654	PHS HHS [P01-11542] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; Li T, 2003, J NEUROSCI, V23, P3272; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Murphy MP, 2003, FASEB J, V17, P1138, DOI 10.1096/fj.02-1050fje; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	46	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43284	43291		10.1074/jbc.M305685200	http://dx.doi.org/10.1074/jbc.M305685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917438	hybrid			2022-12-27	WOS:000186157000071
J	Calipel, A; Lefevre, G; Pouponnot, C; Mouriaux, F; Eychene, A; Mascarelli, F				Calipel, A; Lefevre, G; Pouponnot, C; Mouriaux, F; Eychene, A; Mascarelli, F			Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; UVEAL MELANOMA; CONSTITUTIVE ACTIVATION; GERMLINE MUTATIONS; SIGNALING PATHWAYS; ONCOGENIC RAS; HUMAN CANCER; CYCLIN D1; BRAF GENE; N-RAS	The BRAF gene, encoding a mitogen-activated protein kinase kinase kinase, is mutated in several human cancers, with the highest incidence occurring in cutaneous melanoma. The activating V599E mutation accounted for 80% of all mutations detected in cutaneous melanoma cell lines. Reconstitution experiments have shown that this mutation increases ectopically expressed B-Raf kinase activity and induces NIH3T3 cell transformation. Here we used tumor-derived cell lines to characterize the activity of endogenous mutated B-Raf protein and assess its specific role in transformation. We show that three cell lines (OCM-1, MKT-BR, and SP-6.5) derived from human choroidal melanoma, the most frequent primary ocular neoplasm in humans, express B-Raf containing the V599E mutation. These melanoma cells showed a 10-fold increase in endogenous B-Raf(V599E) kinase activity and a constitutive activation of the MEK/ERK pathway that is independent of Ras. This, as well as melanoma cell proliferation, was strongly diminished by siRNA-mediated depletion of the mutant B-Raf protein. Moreover, blocking B-Raf(V599E)-induced ERK activation by different experimental approaches significantly reduced cell proliferation and anchorage-independent growth of melanoma cells. Finally, quantitative immunoblot analysis allowed us to identify signaling and cell cycle proteins that are differentially expressed between normal melanocytes and melanoma cells. Although the expression of signaling molecules was not sensitive to U0126 in melanoma cells, the expression of a cluster of cell cycle proteins remained regulated by the B-Raf(V599E)/MEK/ERK pathway. Our results pinpoint this pathway as an important component in choroidal melanoma cell lines.	Inst Biomed Cordeliers, INSERM, U450, F-75006 Paris, France; Inst Curie, CNRS, Unite Mixte Rech 146, F-91406 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mascarelli, F (corresponding author), Inst Biomed Cordeliers, INSERM, U450, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Eychene, Alain/M-8838-2017; Mascarelli, Frederic/L-8916-2018; Mouriaux, Frederic/T-1440-2019	EYCHENE, Alain/0000-0002-6818-7225				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; BOS JL, 1989, CANCER RES, V49, P4682; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cacace AM, 1999, MOL CELL BIOL, V19, P229; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Coupland SE, 2000, J PATHOL, V191, P120; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919; Ewanowich C, 2001, ARCH PATHOL LAB MED, V125, P208; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Goding CR, 1997, CELL GROWTH DIFFER, V8, P935; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; Ito Y, 2000, ONCOLOGY-BASEL, V59, P68, DOI 10.1159/000012140; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; KANMITCHELL J, 1989, INVEST OPHTH VIS SCI, V30, P829; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kimura ET, 2003, CANCER RES, V63, P1454; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Lee JY, 1997, BIOCHEM BIOPH RES CO, V237, P667, DOI 10.1006/bbrc.1997.7212; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; Merbs SL, 1999, INVEST OPHTH VIS SCI, V40, P779; MOOY CM, 1991, BRIT J CANCER, V64, P411, DOI 10.1038/bjc.1991.319; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOURIAUX F, 2001, INVESTIG OPHTHALMOL, V41, P2837; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; OHTA M, 1994, CANCER RES, V54, P5269; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; Papp T, 1999, J MED GENET, V36, P610; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh AD, 1996, SEMIN ONCOL, V23, P768; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Soufir N, 2000, BRIT J CANCER, V82, P818, DOI 10.1054/bjoc.1999.1005; Treinies I, 1999, MOL CELL BIOL, V19, P321; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wang X, 1996, MELANOMA RES, V6, P405, DOI 10.1097/00008390-199612000-00001; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev	54	104	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42409	42418		10.1074/jbc.M308709200	http://dx.doi.org/10.1074/jbc.M308709200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917419	hybrid			2022-12-27	WOS:000185989500104
J	Horman, S; Beauloye, C; Vertommen, D; Vanoverschelde, JL; Hue, L; Rider, MH				Horman, S; Beauloye, C; Vertommen, D; Vanoverschelde, JL; Hue, L; Rider, MH			Myocardial ischemia and increased heart work modulate the phosphorylation state of eukaryotic elongation factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA TRANSLATION; CARDIAC MYOCYTES; S6 KINASE; RAT-HEART; FACTOR-II; INSULIN; INHIBITION; CARDIOMYOCYTES; DEPHOSPHORYLATION	Protein synthesis, in particular peptide chain elongation, is an energy-consuming biosynthetic process. AMP-activated protein kinase ( AMPK) is a key regulatory enzyme involved in cellular energy homeostasis. Therefore, we tested the hypothesis that, as in liver, it could mediate the inhibition of protein synthesis by oxygen deprivation in heart by modulating the phosphorylation of eukaryotic elongation factor-2 (eEF2), which becomes inactive in its phosphorylated form. In anoxic cardiomyocytes, AMPK activation was associated with an inhibition of protein synthesis and an increase in phosphorylation of eEF2. Rapamycin, an inhibitor of the mammalian target of rapamycin ( mTOR), did not mimic the effect of oxygen deprivation to inhibit protein synthesis in cardiomyocytes or lead to eEF2 phosphorylation in perfused hearts, suggesting that AMPK activation did not inhibit mTOR/p70 ribosomal protein S6 kinase (p70S6K) signaling. Human recombinant eEF2 kinase (eEF2K) was phosphorylated by AMPK in a time- and AMP-dependent fashion, and phosphorylation led to eEF2K activation, similar to that observed in extracts from ischemic hearts. In contrast, increasing the workload resulted in a dephosphorylation of eEF2, which was rapamycin-insensitive, thus excluding a role for mTOR in this effect. eEF2K activity was unchanged by increasing the workload, suggesting that the decrease in eEF2 phosphorylation could result from the activation of an eEF2 phosphatase.	Univ Louvain, Sch Med, Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Div Cardiol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Rider, MH (corresponding author), Univ Louvain, Sch Med, Christian de Duve Inst Cellular Pathol, HORM Unit, Ave Hippocrate 75,ICP UCL 7529, B-1200 Brussels, Belgium.		Vanoverschelde, Jean-Louis/A-6830-2008	Vanoverschelde, Jean-Louis/0000-0002-8133-8913; Vertommen, Didier/0000-0001-7648-8282				Alirezaei M, 2001, J NEUROCHEM, V76, P1080, DOI 10.1046/j.1471-4159.2001.00105.x; Beauloye C, 2001, CIRC RES, V88, P513, DOI 10.1161/01.RES.88.5.513; Beauloye C, 2002, FEBS LETT, V531, P324, DOI 10.1016/S0014-5793(02)03552-4; BERGMEYER HU, 1984, METHOD ENZYMAT AN, V8, P500; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Diggle TA, 1998, BIOCHEM J, V336, P525, DOI 10.1042/bj3360525; Dorovkov MV, 2002, BIOCHEMISTRY-US, V41, P13444, DOI 10.1021/bi026494p; Dubbelhuis PF, 2002, FEBS LETT, V521, P39, DOI 10.1016/S0014-5793(02)02815-6; Everett AD, 2001, AM J PHYSIOL-HEART C, V281, pH161, DOI 10.1152/ajpheart.2001.281.1.H161; Hait WN, 1996, FEBS LETT, V397, P55, DOI 10.1016/S0014-5793(96)01140-4; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Hovland R, 1999, FEBS LETT, V444, P97, DOI 10.1016/S0014-5793(99)00039-3; JEFFERSON LS, 1971, J BIOL CHEM, V246, P2171; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; KIRA Y, 1984, AM J PHYSIOL, V246, pC247, DOI 10.1152/ajpcell.1984.246.3.C247; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; McLeod LE, 2002, FEBS LETT, V531, P448, DOI 10.1016/S0014-5793(02)03582-2; McLeod LE, 2001, FEBS LETT, V489, P225, DOI 10.1016/S0014-5793(01)02100-7; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; STERN MD, 1988, P NATL ACAD SCI USA, V85, P6954, DOI 10.1073/pnas.85.18.6954; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; Wang LJ, 2002, FEBS LETT, V531, P285, DOI 10.1016/S0014-5793(02)03536-6; Wang LJ, 2000, AM J PHYSIOL-HEART C, V278, pH1056, DOI 10.1152/ajpheart.2000.278.4.H1056; Wang XM, 2002, BIOCHEM J, V367, P475, DOI 10.1042/BJ20020677; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WOLLENBERGER A, 1971, CARDIOLOGY, V56, P48, DOI 10.1159/000169341; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200	39	99	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41970	41976		10.1074/jbc.M302403200	http://dx.doi.org/10.1074/jbc.M302403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920134	hybrid			2022-12-27	WOS:000185989500052
J	Li, GY; Wang, SF; Gelehrter, TD				Li, GY; Wang, SF; Gelehrter, TD			Identification of glucocorticoid receptor domains involved in transrepression of transforming growth factor-beta action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; STEROID-HORMONE RECEPTORS; DEPENDENT TRANSCRIPTIONAL ACTIVATION; NEGATIVE CROSS-TALK; TGF-BETA; SMAD PROTEINS; DNA-BINDING; GENE-EXPRESSION; ANTIINFLAMMATORY ACTION; INHIBITOR-1 PROMOTER	The transforming growth factor-beta (TGF-beta) and glucocorticoid signaling pathways interact both positively and negatively in regulating a variety of physiological and pathologic processes. We previously reported that liganded glucocorticoid receptor (GR) repressed TGF-beta induction of human plasminogen activator inhibitor-1 gene transcription by directly targeting the transcriptional activation function of Smad3. To identify the domain( s) in the glucocorticoid receptor involved in this repression, we have examined the ability of various GR truncation, deletion, and substitution mutants to repress TGF-beta transactivation in Hep3B human hepatoma cells that lack functional endogenous GR. Partial deletions in the ligand-binding domain (LBD), including the tau2 and tauc regions, greatly reduced or eliminated GR repression, whereas deletion of the N-terminal AF1 (tau1) domain and substitution mutations in the DNA-binding domain had little or no effect. Liganded androgen receptor repressed TGF-beta transactivation, whereas mineralocorticoid receptor did not, and studies with rat GR-mineralocorticoid receptor chimeras confirmed that the GR C-terminal domains were required for repression. RU486, a strong antagonist of transactivation by GR, partially reversed repression by wild type GR. Co-immunoprecipitation experiments in Hep3B cells indicated that physical interaction between GR and Smad3 is necessary but not sufficient for repression. Physical interaction required activation of Smad3 by TGF-beta but not dexamethasone binding to GR. Glutathione S-transferase pull-down assays demonstrated that several regions of the LBD could mediate GR-Smad3 physical interaction. We conclude that the LBD of GR, but not the DNA-binding domain or the N-terminal activation domain, is required for GR-mediated transrepression of TGF-beta transactivation.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Gelehrter, TD (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, 4909 Buhl Bldg,Box 0618,1241 E Catherine St, Ann Arbor, MI 48109 USA.				NIAMS NIH HHS [P60 AR 20557] Funding Source: Medline; NIDDK NIH HHS [P60 DK 20572] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Chou WC, 2003, MOL BIOL CELL, V14, P1279, DOI 10.1091/mbc.E02-07-0375; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GULLER S, 1995, J CLIN ENDOCR METAB, V80, P3273, DOI 10.1210/jc.80.11.3273; Hayes SA, 2001, CANCER RES, V61, P2112; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; JOHNSON BH, 1993, CELL GROWTH DIFFER, V4, P25; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kanatani Y, 1996, CELL GROWTH DIFFER, V7, P187; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Milhon J, 1997, MOL ENDOCRINOL, V11, P1795, DOI 10.1210/me.11.12.1795; Miyazono K, 2000, J CELL SCI, V113, P1101; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; ONATE SA, 1995, SCIENCE, V270, P1354; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROBERTS AB, 1990, PHILOS T R SOC B, V327, P145, DOI 10.1098/rstb.1990.0050; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SLAVIN J, 1994, GROWTH FACTORS, V11, P205, DOI 10.3109/08977199409046918; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Su SM, 1996, DNA CELL BIOL, V15, P1039, DOI 10.1089/dna.1996.15.1039; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	73	21	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41779	41788		10.1074/jbc.M305350200	http://dx.doi.org/10.1074/jbc.M305350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902338	hybrid			2022-12-27	WOS:000185989500029
J	Sampson, LJ; Leyland, ML; Dart, C				Sampson, LJ; Leyland, ML; Dart, C			Direct interaction between the actin-binding protein filamin-A and the inwardly rectifying potassium channel, Kir2.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL SMOOTH-MUSCLE; CYTOPLASMIC DOMAIN; ANCHORING PROTEIN; FOCAL ADHESION; CELLS; CYTOSKELETON; IDENTIFICATION; PSD-95/SAP90; MUTATIONS; MEMBRANE	The role of filamins in actin cross-linking and membrane stabilization is well established, but recently their ability to interact with a variety of transmembrane receptors and signaling proteins has led to speculation of additional roles in scaffolding and signal transduction. Here we report a direct interaction between filamin-A and Kir2.1, an isoform of inwardly rectifying potassium channel expressed in vascular smooth muscle and an important regulator of vascular tone. Yeast two-hybrid screening of a porcine coronary artery cDNA library using the carboxyl terminus of Kir2.1 as bait yielded cDNA encoding a fragment of filamin-A (residues 2481-2647). Interaction between filamin-A and Kir2.1 was confirmed by in vitro overlay assay of membrane-bound Kir2.1 with glutathione S-transferase fusion protein of the isolated filamin clone. Additionally, antibodies directed against Kir2.1 coimmunoprecipitated filamin-A from arterial smooth muscle cell lysates, and immunocytochemical analysis of individual arterial smooth muscle cells showed that Kir2.1 and filamin co-localize in "hotspots" at the cell membrane. Interaction with filamin-A was found to have no effect on Kir2.1 channel behavior but, rather, increased the number of functional channels resident within the membrane. We conclude that filamin-A is potentially an important regulator of Kir2.1 surface expression and location within vascular smooth muscle.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Sampson, LJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138, Leicester LE1 9HN, Leics, England.			Dart, Caroline/0000-0002-3509-8349				Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Bradley KK, 1999, J PHYSIOL-LONDON, V515, P639, DOI 10.1111/j.1469-7793.1999.639ab.x; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BURRIDGE K, 1996, ANNU REV CELL DEV BI, V12, P487; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dart C, 2001, J BIOL CHEM, V276, P20499, DOI 10.1074/jbc.M101425200; DRAEGER A, 1989, J CELL SCI, V94, P703; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Inanobe A, 2002, AM J PHYSIOL-CELL PH, V282, pC1396, DOI 10.1152/ajpcell.00615.2001; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Leonoudakis D, 2001, J CELL SCI, V114, P987; LEONOUDAKIS D, 2003, BIOPHYS J, V84, P224; Leyland ML, 1999, PFLUG ARCH EUR J PHY, V438, P778, DOI 10.1007/s004240051106; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Petrecca K, 2000, J NEUROSCI, V20, P8736; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Quayle JM, 1996, J PHYSIOL-LONDON, V494, P715, DOI 10.1113/jphysiol.1996.sp021527; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341; STENDAHL OI, 1980, J CELL BIOL, V84, P215, DOI 10.1083/jcb.84.2.215; Stonehouse AH, 1999, HISTOCHEM CELL BIOL, V112, P457, DOI 10.1007/s004180050429; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tigges U, 2003, J BIOL CHEM, V278, P23561, DOI 10.1074/jbc.M302302200; TYLER JM, 1980, J CELL BIOL, V85, P489, DOI 10.1083/jcb.85.2.489; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; Zaritsky JJ, 2000, CIRC RES, V87, P160, DOI 10.1161/01.RES.87.2.160; Zhang WJ, 1998, J NEUROSCI, V18, P914	41	75	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41988	41997		10.1074/jbc.M307479200	http://dx.doi.org/10.1074/jbc.M307479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923176	hybrid			2022-12-27	WOS:000185989500054
J	Lodhi, KM; Ozdener, MH; Shayiq, RM				Lodhi, KM; Ozdener, MH; Shayiq, RM			The upstream open reading frame mediates constitutive effects on translation of cytochrome P-450c27 from the seventh in-frame AUG codon in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL RIBOSOME ENTRY; DECARBOXYLASE MESSENGER-RNA; SERINE-PROTEASE INHIBITOR; VITAMIN-D; INITIATION; CHOLESTEROL; GENE; REINITIATION; EXPRESSION; MECHANISM	The 2.3-kb mRNA that codes for cytochrome P-450c27 (CYP27) has an unexpectedly long 5'-untranslated region (UTR) that holds six AUGs, leading to several upstream open reading frames (uORFs). The initiation of translation from the seventh AUG forms a putative 55-kDa precursor, which is processed in mitochondria to form a 52-kDa mature protein. The first three AUGs form fully overlapping uORF1, uORF2, and uORF3 that are in-frame with the seventh AUG and next two form fully overlapping uORF4 and uORF5 that are out-of-frame with the seventh AUG. Although not recognized by the scanning ribosomes under normal conditions, the sixth in-frame AUG forms a putative 57-kDa extension of the main open reading frame. The purpose of this study was to identify the elements in the 5'-UTR that direct CYP27 mRNA translation exclusively from the seventh AUG. Expression of 5' deletion mutants in COS cells reveal that the intact 5'-UTR not only directs the initiation of translation from the seventh AUG but also acts as a negative regulator. A 2-kb deletion mutant that lacks uORF1 initiates translation equally from the sixth and the seventh AUGs, forming both 57- and 55-kDa precursor proteins with a 2-fold increase in rate of translation. However, induction in translation does not affect the levels of the mature 52-kDa form in mitochondria but causes accumulation of the precursor form in cytosol not seen in COS cells transfected with wild-type cDNA. Mutation of the stop codon that terminates uORF1 completely shifts the initiation of translation from the seventh to the first AUG, forming a 67-kDa precursor that is processed into a 52-kDa mature protein in mitochondria. Confirmation of the bicistronic nature of CYP27 mRNA by epitope mapping of uORF1 suggests that translation of CYP27 mRNA from the seventh AUG is directed and regulated by uORF1 expression.	Thomas Jefferson Univ, Dept Med, Div Clin Pharmacol, Philadelphia, PA 19107 USA	Jefferson University	Shayiq, RM (corresponding author), Thomas Jefferson Univ, Dept Med, Div Clin Pharmacol, Philadelphia, PA 19107 USA.	rmshayiq@hotmail.com	Ozdener, Mehmet Hakan/I-4097-2019		NIGMS NIH HHS [GM50290] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1991, BIOCHEMISTRY-US, V30, P19947; ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM J, 1985, STEROLS BILE ACIDS, P231; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; CANCELA L, 1988, HORMONES THEIR ACT 1, P269; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; Cao JH, 1996, MOL CELL BIOL, V16, P603; CARTER G, 1993, BRIT J CANCER, V67, P869, DOI 10.1038/bjc.1993.164; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGNIN CR, 1993, J VIROL, V67, P5514, DOI 10.1128/JVI.67.9.5514-5521.1993; DELUCA HF, 1981, HARVEY LECT, V75, P333; DELUCA HF, 1976, ANNU REV BIOCHEM, V45, P631, DOI 10.1146/annurev.bi.45.070176.003215; FRIEDLANDER EJ, 1975, ARCH BIOCHEM BIOPHYS, V170, P731, DOI 10.1016/0003-9861(75)90171-X; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; GRANT CM, 1994, MOL CELL BIOL, V14, P606, DOI 10.1128/MCB.14.1.606; GRANT CM, 1995, NUCLEIC ACIDS RES, V23, P3980, DOI 10.1093/nar/23.19.3980; HENERY HL, 1980, VITAMIN D MOL BIOL C, P127; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HILL JR, 1993, J BIOL CHEM, V268, P726; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; MORITA T, 1982, J BIOL CHEM, V257, P547; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; NIRANJAN BG, 1988, J BIOL CHEM, V263, P575; NISHIKURA K, 1992, ANN NY ACAD SCI, V660, P240, DOI 10.1111/j.1749-6632.1992.tb21076.x; Oumard A, 2000, MOL CELL BIOL, V20, P2755, DOI 10.1128/MCB.20.8.2755-2759.2000; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; Ritchie H, 1997, BIOCHEM BIOPH RES CO, V231, P425, DOI 10.1006/bbrc.1997.6126; ROSSI V, 1992, NUCLEIC ACIDS RES, V20, P1061, DOI 10.1093/nar/20.5.1061; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; SAKAKI T, 1992, J BIOL CHEM, V267, P16497; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAYIQ RM, 1989, BIOCHEMISTRY-US, V28, P7546, DOI 10.1021/bi00445a008; SHAYIQ RM, 1994, ANAL BIOCHEM, V221, P206, DOI 10.1006/abio.1994.1400; SHAYIQ RM, 1990, BIOCHEMISTRY-US, V29, P866, DOI 10.1021/bi00456a003; SHAYIQ RM, 1992, J BIOL CHEM, V267, P2421; Shayiq RM, 1997, J BIOL CHEM, V272, P4050; Sloan J, 1999, NUCLEIC ACIDS RES, V27, P854, DOI 10.1093/nar/27.3.854; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; USUI E, 1990, FEBS LETT, V274, P175, DOI 10.1016/0014-5793(90)81357-T; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vilela C, 1999, EMBO J, V18, P3139, DOI 10.1093/emboj/18.11.3139; Wang LJ, 1998, PLANT CELL, V10, P1733, DOI 10.1105/tpc.10.10.1733; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; Wikvall K, 2001, INT J MOL MED, V7, P201; Wu HJ, 1998, J BIOL CHEM, V273, P2532, DOI 10.1074/jbc.273.5.2532; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; YOON JB, 1990, J BIOL CHEM, V265, P19947	83	2	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40647	40657		10.1074/jbc.M302081200	http://dx.doi.org/10.1074/jbc.M302081200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909643	hybrid			2022-12-27	WOS:000185847200029
J	Miyanoiri, Y; Kobayashi, H; Imai, T; Watanabe, M; Nagata, T; Uesugi, S; Okano, H; Katahira, M				Miyanoiri, Y; Kobayashi, H; Imai, T; Watanabe, M; Nagata, T; Uesugi, S; Okano, H; Katahira, M			Origin of higher affinity to RNA of the N-terminal RNA-binding domain than that of the C-terminal one of a mouse neural protein, Musashi1, as revealed by comparison of their structures, modes of interaction, surface electrostatic potentials, and backbone dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASYMMETRIC CELL-DIVISION; MESSENGER-RNA; STEM-CELLS; HNRNP D0; CNS; RECOGNITION; MOUSE-MUSASHI-1; DETERMINANTS; SPECIFICITY; REPRESSION	Musashi1 is an RNA-binding protein abundantly expressed in the developing mouse central nervous system. Its restricted expression in neural precursor cells suggests that it is involved in maintenance of the character of progenitor cells. Musashi1 contains two ribonucleoprotein-type RNA-binding domains (RBDs), RBD1 and RBD2, the affinity to RNA of RBD1 being much higher than that of RBD2. We previously reported the structure and mode of interaction with RNA of RBD2. Here, we have determined the structure and mode of interaction with RNA of RBD1. We have also analyzed the surface electrostatic potential and backbone dynamics of both RBDs. The two RBDs exhibit the same ribonucleoprotein-type fold and commonly make contact with RNA on the beta-sheet side. On the other hand, there is a remarkable difference in surface electrostatic potential, the beta-sheet of RBD1 being positively charged, which is favorable for binding negatively charged RNA, but that of RBD2 being almost neutral. There is also a difference in backbone dynamics, the central portion of the beta-sheet of RBD1 being flexible, but that of RBD2 not being flexible. The flexibility of RBD1 may be utilized in the recognition process to facilitate an induced fit. Thus, comparative studies have revealed the origin of the higher affinity of RBD1 than that of RBD2 and indicated that the affinity of an RBD to RNA is not governed by its fold alone but is also determined by its surface electrostatic potential and/or backbone dynamics. The biological role of RBD2 with lower affinity is also discussed.	Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan; Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan	Yokohama National University; Keio University	Katahira, M (corresponding author), Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodogaya Ku, 79-7 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.		Nagata, Takashi/D-4547-2018; Imai, Takao/L-1232-2013; Okano, Hideyuki/I-7584-2019	Nagata, Takashi/0000-0002-3733-2709; Miyanoiri, Yohei/0000-0001-6889-5160				Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Giesen K, 1997, DEVELOPMENT, V124, P2307; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kurihara Y, 1997, GENE, V186, P21, DOI 10.1016/S0378-1119(96)00673-7; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; Mittermaier A, 1999, J MOL BIOL, V294, P967, DOI 10.1006/jmbi.1999.3311; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nagata T, 1999, J MOL BIOL, V287, P221, DOI 10.1006/jmbi.1999.2616; Nagata T, 1999, J MOL BIOL, V287, P315, DOI 10.1006/jmbi.1999.2596; NAKAMURA H, 1994, J LOW FREQ NOISE VIB, V13, P1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okabe M, 2001, NATURE, V411, P94, DOI 10.1038/35075094; Okano H, 2002, J CELL SCI, V115, P1355; Okano HJ, 1997, J NEUROSCI, V17, P3024; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Sakakibara S, 2002, P NATL ACAD SCI USA, V99, P15194, DOI 10.1073/pnas.232087499; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; Sakakibara S, 1997, J NEUROSCI, V17, P8300; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931	38	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41309	41315		10.1074/jbc.M306210200	http://dx.doi.org/10.1074/jbc.M306210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907678	hybrid			2022-12-27	WOS:000185847200110
J	Sawaya, R; Schwer, B; Shuman, S				Sawaya, R; Schwer, B; Shuman, S			Genetic and biochemical analysis of the functional domains of yeast tRNA ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHODIESTER BOND FORMATION; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; DNA-LIGASE; POLYNUCLEOTIDE KINASE; WHEAT-GERM; SPLICING ENDONUCLEASE; ADENYLYLATION SITE; JUNCTION PHOSPHATE; CAPPING ENZYME	Yeast tRNA ligase (Trl1) converts cleaved tRNA half-molecules into spliced tRNAs containing a 2'-PO4, 3'-5' phosphodiester at the splice junction. Trl1 performs three reactions: (i) the 2',3'-cyclic phosphate of the proximal fragment is hydrolyzed to a 3'-OH, 2'-PO4 by a cyclic phosphodiesterase (CPD); (ii) the 5'-OH of the distal fragment is phosphorylated by an NTP-dependent polynucleotide kinase; and (iii) the 3'-OH, 2'-PO4, and 5'-PO4 ends are sealed by an ATP-dependent RNA ligase. Trl1 consists of an N-terminal adenylyltransferase domain that resembles T4 RNA ligase 1, a central domain that resembles T4 polynucleotide kinase, and a C-terminal CPD domain that resembles the 2H phosphotransferase enzyme superfamily. Here we show that all three domains are essential in vivo, although they need not be linked in the same polypeptide. We identify five amino acids in the adenylyltransferase domain ( Lys(114), Glu(266), Gly(267), Lys(284), and Lys(286)) that are essential for Trl1 activity and are located within motifs I ((114)(K) under bar ANG(117)), IV ((266)(EG) under bar FVI270), and V ((FF)-F-282 (K) under barI (K) under bar (286)) that comprise the active sites of DNA ligases, RNA capping enzymes, and T4 RNA ligases 1 and 2. Mutations K404A and T405A in the P-loop ((401)GXGKT(405)) of the central kinase-like domain had no effect on Trl1 function in vivo. The K404A and T405A mutations eliminated ATP-dependent kinase activity but preserved GTP-dependent kinase activity. A double alanine mutant in the P-loop was lethal in vivo and abolished GTP-dependent kinase activity. These results suggest that GTP is the physiological substrate and that the Trl1 kinase has a single NTP binding site of which the P-loop is a component. Two other mutations in the central domain were lethal in vivo and either abolished (D425A) or severely reduced (R511A) GTP-dependent RNA kinase activity in vitro. Mutations of the signature histidines of the CPD domain were either lethal (H777A) or conferred a ts growth phenotype (H673A).	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org						Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; BAYMILLER J, 1994, GENE, V142, P129, DOI 10.1016/0378-1119(94)90367-0; BELFORD HG, 1993, J BIOL CHEM, V268, P2444; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; Fabbri S, 1998, SCIENCE, V280, P284, DOI 10.1126/science.280.5361.284; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; Fruscoloni P, 2001, EMBO REP, V2, P217, DOI 10.1093/embo-reports/kve040; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; GEGENHEIMER P, 1983, J BIOL CHEM, V258, P8365; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann A, 2000, EMBO J, V19, P6207, DOI 10.1093/emboj/19.22.6207; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; LASKI FA, 1983, J BIOL CHEM, V258, P1974; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Li H, 2000, J MOL BIOL, V302, P639, DOI 10.1006/jmbi.2000.3941; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645; Nasr F, 2000, NUCLEIC ACIDS RES, V28, P1676, DOI 10.1093/nar/28.8.1676; Negri ED, 1997, CELL, V89, P859, DOI 10.1016/S0092-8674(00)80271-8; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6684; PICK L, 1986, J BIOL CHEM, V261, P6694; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1979, J BIOL CHEM, V254, P396; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Spinelli SL, 1997, RNA, V3, P1388; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Wang LK, 2003, J BIOL CHEM, V278, P29454, DOI 10.1074/jbc.M304320200; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; Zofallova L, 2000, RNA, V6, P1019, DOI 10.1017/S1355838200000613	65	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43928	43938		10.1074/jbc.M307839200	http://dx.doi.org/10.1074/jbc.M307839200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933796	hybrid			2022-12-27	WOS:000186306700008
J	Tian, YN; Ke, S; Chen, M; Sheng, T				Tian, YN; Ke, S; Chen, M; Sheng, T			Interactions between the aryl hydrocarbon receptor and P-TEFb - Sequential recruitment of transcription factors and differential phosphorylation of C-terminal domain of RNA polymerase II at cyp1a1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEAT-SHOCK PROTEIN; MESSENGER-RNA; AH RECEPTOR; GLUCOCORTICOID-RECEPTOR; CYTOCHROME P4501A1; DIOXIN RECEPTOR; ELONGATION; COMPLEX; BINDING	The expression of the cytochrome P450 1A1 gene (cyp1a1) is regulated by the aryl hydrocarbon receptor (AhR), which is a ligand-activated transcription factor that mediates most toxic responses induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). In the nucleus, ligand-activated AhR binds to the xenobiotic response elements, initiating chromatin remodeling and recruitment of coregulators, leading to the formation of preinitiation complex followed by elongation. Here, we report that ligand-activated AhR recruits the positive transcription elongation factor (P-TEFb) and RNA polymerase II (RNA PII) to the cyp1a1 promoter with concomitant phosphorylation of the RNA PII carboxyl domain (CTD). Interestingly, the serine 2 and serine 5 of the heptapeptide repeats (YSPTSPS) were sequentially phosphorylated upon TCDD treatment. Inhibition of P-TEFb kinase activity by 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (DRB) suppressed CTD phosphorylation (especially serine 2 phosphorylation) and abolished processive elongation without disrupting the assembly of the preinitiation complex at the cyp1a1 promoter. Remarkably, we found that activation of NF-kappaB by TNF-alpha selectively inhibited TCDD-induced serine 2 phosphorylation in mouse liver cells, suggesting that residue-specific phosphorylation of RNA PII CTD at the cyp1a1 promoter is an important regulatory point upon which signal "cross-talk" converges. Finally, we show that ligand-activated AhR associated with P-TEFb through the C terminus of cyclin T1, suggesting that AhR recruit the P-TEFb to the cyp1a1 promoter whereupon its kinase subunit phosphorylates the RNA PII CTD.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Tian, YN (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, MS 4466, College Stn, TX 77843 USA.				NIEHS NIH HHS [ES 09859, ES 09106] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009859, P30ES009106] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Ma Q, 1997, J BIOL CHEM, V272, P8878; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; Moteki S, 2002, MOL CELL, V10, P599, DOI 10.1016/S1097-2765(02)00660-3; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Swanson HI, 1998, MOL PHARMACOL, V54, P671; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	37	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44041	44048		10.1074/jbc.M306443200	http://dx.doi.org/10.1074/jbc.M306443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12917420	hybrid			2022-12-27	WOS:000186306700020
J	Bizat, N; Hermel, JM; Humbert, S; Jacquard, C; Creminon, C; Escartin, C; Saudou, F; Krajewski, S; Hantraye, P; Brouillet, E				Bizat, N; Hermel, JM; Humbert, S; Jacquard, C; Creminon, C; Escartin, C; Saudou, F; Krajewski, S; Hantraye, P; Brouillet, E			In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration - Implication of a calpain-mediated cleavage of active caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE; CELL-DEATH; APOPTOSIS; ACTIVATION; MODEL; REPEAT; VULNERABILITY; MITOCHONDRIA; ISCHEMIA; PROTEASE	The role of caspases and calpains in neurodegeneration remains unclear. In this study, we focused on these proteases in a rat model of Huntington's disease using the mitochondrial toxin 3-nitropropionic acid (3NP). Results showed that 3NP-induced death of striatal neurons was preceded by cytochrome c redistribution, transient caspase-9 processing, and activation of calpain, whereas levels of the active/processed form of caspase-3 remained low and were even reduced as compared with control animals. We evidenced here that this decrease in active caspase-3 levels could be attributed to calpain activation. Several observations supported this conclusion. 1) Pharmacological blockade of calpain in 3NP-treated rats increased the levels of endogenous processed caspase-9 and caspase-3. 2) Cell-free extracts prepared from the striatum of 3NP-treated rats degraded in vitro the p34 and p20 subunits of active recombinant caspase-9 and caspase-3, respectively. 3) This degradation of p34 and p20 could be mimicked by purified mu-calpain and was prevented by calpain inhibitors. 4) mu-Calpain produced a loss of the DEVDase (Asp-Glu-Val-Asp) activity of active caspase-3. 5) Western blot analysis and experiments with S-35-radiolabeled caspase-3 showed that mu-calpain cleaved the p20 subunit of active caspase-3 near its catalytic site. 6) mu-Calpain activity was selectively inhibited (IC50 of 100 muM) by a 12 amino acid peptide corresponding to the C terminus of p20. Our results showed that calpain can down-regulate the caspase-9/caspase-3 cell death pathway during neurodegeneration due to chronic mitochondrial defects in vivo and that this effect may involve, at least in part, direct cleavage of the caspase-3 p20 subunit.	CEA, Serv Hosp Frederic Joliot, DSV, DRM,Unite Rech Associee CEA CNRS 2210, F-91401 Orsay, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France; CENS, CEA, Serv Pharmacol & Immunol, DRM,DSV, F-91191 Gif Sur Yvette, France; Burnham Inst, Program Cell Death & Apoptosis, Program Apoptosis Cell Death & Aging, La Jolla, CA 92037 USA; CEA, Serv Hosp Frederic Joliot, U2IBP, DRM,DSV, F-91401 Orsay, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CEA; UDICE-French Research Universities; Universite Paris Saclay; Sanford Burnham Prebys Medical Discovery Institute; CEA; UDICE-French Research Universities; Universite Paris Saclay	Brouillet, E (corresponding author), CEA, Serv Hosp Frederic Joliot, DSV, DRM,Unite Rech Associee CEA CNRS 2210, F-91401 Orsay, France.		Escartin, Carole/A-1952-2010; Humbert, Sandrine/S-2981-2016; SAUDOU, Frédéric/L-3454-2014; Brouillet, Emmanuel/B-4784-2014	Escartin, Carole/0000-0003-3613-4118; SAUDOU, Frédéric/0000-0001-6107-1046; Brouillet, Emmanuel/0000-0001-6322-7403; Humbert, Sandrine/0000-0002-9501-2658; Hermel, Jean-Michel/0000-0001-7902-8994; Jacquard, Carine/0000-0003-0972-8455	NINDS NIH HHS [NS36821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036821] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BEAL MF, 1993, J NEUROSCI, V13, P4181; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Bizat N, 2003, J NEUROSCI, V23, P5020; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Brouillet E, 1998, J NEUROCHEM, V70, P794; BROUILLET E, 1993, J NEUROCHEM, V60, P356, DOI 10.1111/j.1471-4159.1993.tb05859.x; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7101; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; COLES CJ, 1979, J BIOL CHEM, V255, P772; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Dash PK, 2000, NEUROREPORT, V11, P2811, DOI 10.1097/00001756-200008210-00040; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; FERRANTE RJ, 1993, EXP NEUROL, V119, P46, DOI 10.1006/exnr.1993.1006; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Garcia M, 2002, J NEUROSCI, V22, P2174, DOI 10.1523/JNEUROSCI.22-06-02174.2002; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Harper PS, 1991, HUNTINGTONS DIS; Jenkins BG, 1998, NEUROLOGY, V50, P1357, DOI 10.1212/WNL.50.5.1357; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Laforet GA, 2001, J NEUROSCI, V21, P9112, DOI 10.1523/JNEUROSCI.21-23-09112.2001; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McDonald MC, 2001, FASEB J, V15, P171, DOI 10.1096/fj.99-0645com; Mittoux V, 2002, J NEUROSCI, V22, P4478, DOI 10.1523/JNEUROSCI.22-11-04478.2002; Palfi SP, 1996, J NEUROSCI, V16, P3019; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	40	110	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43245	43253		10.1074/jbc.M305057200	http://dx.doi.org/10.1074/jbc.M305057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917435	Green Published, hybrid			2022-12-27	WOS:000186157000066
J	Much, B; Wahl-Schott, C; Zong, XG; Schneider, A; Baumann, L; Moosmang, S; Ludwig, A; Biel, M				Much, B; Wahl-Schott, C; Zong, XG; Schneider, A; Baumann, L; Moosmang, S; Ludwig, A; Biel, M			Role of subunit heteromerization and N-linked glycosylation in the formation of functional hyperpolarization-activated cyclic nucleotide-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE SUPPRESSION; PACEMAKER CHANNELS; HCN CHANNELS; ION CHANNELS; BETA-SUBUNIT; EXPRESSION; DOMAIN; MECHANISMS; CURRENTS; TERMINUS	The coassembly of homologous subunits to heteromeric complexes serves as an important mechanism in generating ion channel diversity. Here, we have studied heteromerization in the hyperpolarization- activated cyclic nucleotide-gated (HCN) channel family. Using a combination of fluorescence confocal microscopy, coimmunoprecipitation, and electrophysiology we found that upon coexpression in HEK293 cells almost all dimeric combinations of HCN channel subunits give rise to the formation of stable channel complexes in the plasma membrane. We also identified HCN1/HCN2 heteromers in mouse brain indicating that heteromeric channels exist in vivo. Surprisingly, HCN2 and HCN3 did not coassemble to heteromeric channels. This finding indicates that heteromerization requires specific structural determinants that are not present in all HCN channel combinations. Using N-glycosidase F we show that native as well as recombinant HCN channels are glycosylated resulting in a 10 - 20-kDa shift in the molecular weight. Tunicamycin, an inhibitor of N-linked glycosylation, blocked surface membrane expression of HCN2. Similarly, a mutant HCN2 channel in which the putative N-glycosylation site in the loop between S5 and the pore helix was replaced by glutamine (HCN2(N380Q)) was not inserted into the plasma membrane and did not yield detectable whole-cell currents. These results indicate that N-linked glycosylation is required for cell surface trafficking of HCN channels. Cotransfection of HCN2(N380Q) with HCN4, but not with HCN3, rescued cell surface expression of HCN2(N380Q). Immunoprecipitation revealed that this rescue was due to the formation of a HCN2(N380Q)/HCN4 heteromeric channel. Taken together our results indicate that subunit heteromerization and glycosylation are important determinants of the formation of native HCN channels.	Univ Munich, Dept Pharm Pharmakol Nat Wissensch, D-81377 Munich, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	University of Munich; Technical University of Munich	Biel, M (corresponding author), Univ Munich, Dept Pharm Pharmakol Nat Wissensch, Butenandtstr 7, D-81377 Munich, Germany.	mbiel@cup.uni-muenchen.de	Biel, Martin/G-1175-2014; Wahl-Schott, Christian A/J-2623-2015	Biel, Martin/0000-0002-9974-3052; 				Altomare C, 2003, J PHYSIOL-LONDON, V549, P347, DOI 10.1113/jphysiol.2002.027698; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Bonigk W, 1999, J NEUROSCI, V19, P5332; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; Demontis GC, 2002, J PHYSIOL-LONDON, V542, P89, DOI 10.1113/jphysiol.2002.017640; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Er F, 2003, CIRCULATION, V107, P485, DOI 10.1161/01.CIR.0000045672.32920.CB; Gerstner A, 2000, J NEUROSCI, V20, P1324; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; Mellor J, 2002, SCIENCE, V295, P143, DOI 10.1126/science.1064285; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Muller F, 2003, EUR J NEUROSCI, V17, P2084, DOI 10.1046/j.1460-9568.2003.02634.x; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Proenza C, 2002, J BIOL CHEM, V277, P29634, DOI 10.1074/jbc.M200504200; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Satler CA, 1998, HUM GENET, V102, P265, DOI 10.1007/s004390050690; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Schulze-Bahr E, 2003, J CLIN INVEST, V111, P1537, DOI 10.1172/JCI200316387; Stevens DR, 2001, NATURE, V413, P631, DOI 10.1038/35098087; Tran N, 2002, J BIOL CHEM, V277, P43588, DOI 10.1074/jbc.M208477200; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Weitz D, 2002, NEURON, V36, P881, DOI 10.1016/S0896-6273(02)01098-X; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201	33	146	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43781	43786		10.1074/jbc.M306958200	http://dx.doi.org/10.1074/jbc.M306958200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928435	hybrid			2022-12-27	WOS:000186157000128
J	Sneddon, WB; Syme, CA; Bisello, A; Magyar, CE; Rochdi, MD; Parent, JL; Weinman, EJ; Abou-Samra, AB; Friedman, PA				Sneddon, WB; Syme, CA; Bisello, A; Magyar, CE; Rochdi, MD; Parent, JL; Weinman, EJ; Abou-Samra, AB; Friedman, PA			Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CHRONIC-RENAL-FAILURE; PTH-RELATED PROTEIN; PDZ-DOMAIN; KINASE-A; SIGNAL-TRANSDUCTION; BINDING PROTEIN; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; EZRIN	Parathyroid hormone (PTH) regulates extracellular calcium homeostasis through the type 1 PTH receptor (PTH1R) expressed in kidney and bone. The PTH1R undergoes beta-arrestin/dynamin-mediated endocytosis in response to the biologically active forms of PTH, PTH-(1 34), and PTH-( 1 - 84). We now show that amino-truncated forms of PTH that do not activate the PTH1R nonetheless induce PTH1R internalization in a cell-specific pattern. Activation-independent PTH1R endocytosis proceeds through a distinct arrestin-independent mechanism that is operative in cells lacking the adaptor protein Na/H exchange regulatory factor 1 (NHERF1) (ezrin-binding protein 50). Using a combination of radioligand binding experiments and quantitative, live cell confocal microscopy of fluorescently tagged PTH1Rs, we show that in kidney distal tubule cells and rat osteosarcoma cells, which lack NHERF1, the synthetic antagonist PTH-( 7 - 34) and naturally circulating PTH-( 7 - 84) induce internalization of PTH1R in a beta-arrestin-independent but dynamin-dependent manner. Expression of NHERF1 in these cells inhibited antagonist-induced endocytosis. Conversely, expression of dominant-negative forms of NHERF1 conferred internalization sensitivity to PTH-( 7 - 34) in cells expressing NHERF1. Mutation of the PTH1R PDZ-binding motif abrogated interaction of the receptor with NHERF1. These mutated receptors were fully functional but were now internalized in response to PTH-( 7 - 34) even in NHERF1-expressing cells. Removing the NHERF1 ERM domain or inhibiting actin polymerization allowed otherwise inactive ligands to internalize the PTH1R. These results demonstrate that NHERF1 acts as a molecular switch that legislates the conditional efficacy of PTH fragments. Distinct endocytic pathways are determined by NHERF1 that are operative for the PTH1R in kidney and bone cells.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Div Endocrinol, Pittsburgh, PA 15261 USA; Univ Sherbrooke, Fac Med, Div Rheumatol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Clin Res Ctr, Sherbrooke, PQ J1H 5N4, Canada; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Dept Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Pittsburgh, Sch Med, Dept Med, Div Renal, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Sherbrooke; University of Sherbrooke; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Friedman, PA (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E-1347 Biomed Sci Tower, Pittsburgh, PA 15261 USA.		Abou-Samra, Abdul/ABE-8723-2020	Abou-Samra, Abdul/0000-0001-8735-1142	NIDDK NIH HHS [DK-62078, DK-54171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054171, R01DK062078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Bhowmick N, 1998, ENDOCRINOLOGY, V139, P3185, DOI 10.1210/en.139.7.3185; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002-0049; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; DOPPELT SH, 1986, P NATL ACAD SCI USA, V83, P7557, DOI 10.1073/pnas.83.19.7557; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Ferrari SL, 2000, J BONE MINER RES, V15, P198, DOI 10.1359/jbmr.2000.15.2.198; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Flannery PJ, 2001, BIOCHEM PHARMACOL, V62, P1047, DOI 10.1016/S0006-2952(01)00749-3; FLUECK JA, 1977, J CLIN INVEST, V60, P1367, DOI 10.1172/JCI108897; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Friedman PA, 1999, ENDOCRINOLOGY, V140, P301, DOI 10.1210/en.140.1.301; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936; Gentili C, 2001, CELL SIGNAL, V13, P131, DOI 10.1016/S0898-6568(00)00145-5; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GOLDMAN ME, 1988, ENDOCRINOLOGY, V123, P2597, DOI 10.1210/endo-123-5-2597; HABENER JF, 1977, RECENT PROG HORM RES, V33, P249; HASHIZUME Y, 1993, J HISTOCHEM CYTOCHEM, V41, P273, DOI 10.1177/41.2.8419463; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HORIUCHI N, 1983, SCIENCE, V220, P1053, DOI 10.1126/science.6302844; Huang ZM, 1999, ENDOCRINOLOGY, V140, P1294, DOI 10.1210/en.140.3.1294; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Ingraffea J, 2002, EUR J CELL BIOL, V81, P61, DOI 10.1078/0171-9335-00218; John MR, 1999, J CLIN ENDOCR METAB, V84, P4287, DOI 10.1210/jc.84.11.4287; Juppner H, 2001, ENDOCRINOLOGY, P969; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Khanna C, 2001, CANCER RES, V61, P3750; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Nguyen-Yamamoto L, 2002, EUR J ENDOCRINOL, V147, P123, DOI 10.1530/eje.0.1470123; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Rochdi MD, 2002, J BIOL CHEM, V277, P40751, DOI 10.1074/jbc.M207910200; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Roth BL, 1999, NEURON, V23, P629, DOI 10.1016/S0896-6273(02)23443-1; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Slatopolsky E, 2000, KIDNEY INT, V58, P753, DOI 10.1046/j.1523-1755.2000.00222.x; TAMURA T, 1989, BIOCHEM BIOPH RES CO, V159, P1352, DOI 10.1016/0006-291X(89)92259-6; Tawfeek HA, 1999, J BONE MINER RES, V14, pS542; Tawfeek HAW, 2002, MOL ENDOCRINOL, V16, P1, DOI 10.1210/me.16.1.1; Tawfeek HAW, 2001, AM J PHYSIOL-ENDOC M, V281, pE545, DOI 10.1152/ajpendo.2001.281.3.E545; TIAN J, 1994, AM J NEPHROL, V14, P41, DOI 10.1159/000168684; URENA P, 1994, KIDNEY INT, V45, P605, DOI 10.1038/ki.1994.79; Vilardaga JP, 2002, J BIOL CHEM, V277, P8121, DOI 10.1074/jbc.M110433200; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Weinman EJ, 2001, J BIOL CHEM, V276, P42339, DOI 10.1074/jbc.M106153200; Willins DL, 1999, NEUROSCIENCE, V91, P599, DOI 10.1016/S0306-4522(98)00653-8; Zhang P, 1998, J CLIN ENDOCR METAB, V83, P3365, DOI 10.1210/jc.83.9.3373	62	135	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43787	43796		10.1074/jbc.M306019200	http://dx.doi.org/10.1074/jbc.M306019200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920119	hybrid			2022-12-27	WOS:000186157000129
J	Sung, P; Krejci, L; Van Komen, S; Sehorn, MG				Sung, P; Krejci, L; Van Komen, S; Sehorn, MG			Rad51 recombinase and recombination mediators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							REPLICATION PROTEIN-A; DOUBLE-STRAND BREAK; YEAST RAD51; DNA-BINDING; REPAIR; CHROMATIN; EXCHANGE; COMPLEX; DOMAIN; ROLES		Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,SHM C130A, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu	Krejci, Lumir/B-7842-2009	Krejci, Lumir/0000-0002-4732-1405	NATIONAL CANCER INSTITUTE [R01CA096593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA96593] Funding Source: Medline; NIEHS NIH HHS [R01ES07061] Funding Source: Medline; NIGMS NIH HHS [R01GM57814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Aylon Y, 2003, MOL CELL BIOL, V23, P1403, DOI 10.1128/MCB.23.4.1403-1417.2003; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Eggler AL, 2002, J BIOL CHEM, V277, P39280, DOI 10.1074/jbc.M204328200; Foiani M, 2003, NATURE, V423, P234, DOI 10.1038/423234a; Fortin GS, 2002, EMBO J, V21, P3160, DOI 10.1093/emboj/cdf293; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Kolodner RD, 2000, NATURE, V407, P687, DOI 10.1038/35037701; Kowalczykowski SC, 2002, NAT STRUCT BIOL, V9, P897, DOI 10.1038/nsb1202-897; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Krejci L, 2002, J BIOL CHEM, V277, P40132, DOI 10.1074/jbc.M206511200; Lisby M, 2001, P NATL ACAD SCI USA, V98, P8276, DOI 10.1073/pnas.121006298; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Oakley TJ, 2002, DNA REPAIR, V1, P175, DOI 10.1016/S1568-7864(02)00002-2; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Richardson C, 2000, COLD SPRING HARB SYM, V65, P553, DOI 10.1101/sqb.2000.65.553; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Shinohara M, 2003, GENETICS, V163, P1273; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tanaka K, 2002, NUCLEIC ACIDS RES, V30, P1346, DOI 10.1093/nar/30.6.1346; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	62	330	340	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42729	42732		10.1074/jbc.R300027200	http://dx.doi.org/10.1074/jbc.R300027200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912992	hybrid			2022-12-27	WOS:000186157000001
J	Alves-Guerra, MC; Rousset, S; Pecqueur, C; Mallat, Z; Blanc, J; Tedgui, A; Bouillaud, F; Cassard-Doulcier, AM; Ricquier, D; Miroux, B				Alves-Guerra, MC; Rousset, S; Pecqueur, C; Mallat, Z; Blanc, J; Tedgui, A; Bouillaud, F; Cassard-Doulcier, AM; Ricquier, D; Miroux, B			Bone marrow transplantation reveals the in vivo expression of the mitochondrial uncoupling protein 2 in immune and nonimmune cells during inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; UP-REGULATION; N-ACETYLCYSTEINE; GENE-EXPRESSION; PROTON LEAK; OBESITY; ENDOTOXIN; OXYGEN; UCP2	The mitochondrial uncoupling protein 2 (UCP2) is expressed in spleen, lung, intestine, white adipose tissue, and immune cells. Bone marrow transplantation in mice was used to assess the contribution of immune cells to the expression of UCP2 in basal condition and during inflammation. Immune cells accounted for the total amount of UCP2 expression in the spleen, one-third of its expression in the lung, and did not participate in its expression in the intestine. LPS injection stimulated UCP2 expression in lung, spleen, and intestine in both immune and non-immune cells. Successive injections of LPS and dexamethasone or N-acetyl-cysteine prevented the induction of UCP2 in all three tissues, suggesting that oxygen free radical generation plays a role in UCP2 regulation. Finally, both previous studies and our data show that there is down-regulation of UCP2 in immune cells during their activation in the early stages of the LPS response followed by an up-regulation in UCP2 during the later stages to protect all cells against oxidative stress.	Fac Med Necker Enfants Malad, CNRS, UPR 9078, F-75730 Paris 15, France; Hop Lariboisiere, INSERM, F-75475 Paris 10, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Miroux, B (corresponding author), Fac Med Necker Enfants Malad, CNRS, UPR 9078, 156 Rue Vaugirard, F-75730 Paris 15, France.	miroux@necker.fr	Pecqueur, Claire/L-3073-2015; CASSARD, Anne-Marie/B-6095-2019; Alves-Guerra, Marie-Clotilde/P-4356-2017; Mallat, Ziad/D-4041-2012; Bouillaud, Frédéric R/L-3238-2017; Miroux, Bruno/E-9267-2017	Pecqueur, Claire/0000-0002-7612-1672; CASSARD, Anne-Marie/0000-0002-1813-5128; Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; Mallat, Ziad/0000-0003-0443-7878; Bouillaud, Frédéric R/0000-0002-7518-9237; Miroux, Bruno/0000-0002-3066-4700				ALVESGUERRA MC, 2002, CELL MOL RESPONSES S, V3, P257; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BERNARD GR, 1984, J CLIN INVEST, V73, P1772, DOI 10.1172/JCI111386; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Chen Z, 2002, BIOCHEM BIOPH RES CO, V290, P66, DOI 10.1006/bbrc.2001.6147; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Faggioni R, 1998, BIOCHEM BIOPH RES CO, V244, P75, DOI 10.1006/bbrc.1998.8219; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; GATTI S, 1993, CLIN EXP IMMUNOL, V91, P456; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; Lefort J, 1998, J IMMUNOL, V161, P474; Mallat Z, 2002, CIRC RES, V91, P441, DOI 10.1161/01.RES.0000033592.11674.D8; Memon RA, 2000, BBA-MOL CELL BIOL L, V1484, P41, DOI 10.1016/S1388-1981(99)00195-X; Nakata K, 1999, BLOOD, V93, P667, DOI 10.1182/blood.V93.2.667.402k25_667_673; Nakatani T, 2002, J BIOL CHEM, V277, P9562, DOI 10.1074/jbc.M110132200; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Rashid A, 1999, HEPATOLOGY, V29, P1131, DOI 10.1002/hep.510290428; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rocksen D, 2000, CLIN EXP IMMUNOL, V122, P249, DOI 10.1046/j.1365-2249.2000.01373.x; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	36	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42307	42312		10.1074/jbc.M306951200	http://dx.doi.org/10.1074/jbc.M306951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907675	hybrid			2022-12-27	WOS:000185989500091
J	Dong, WJ; Robinson, JM; Xing, J; Cheung, HC				Dong, WJ; Robinson, JM; Xing, J; Cheung, HC			Kinetics of conformational transitions in cardiac troponin induced by Ca2+ dissociation determined by Forster resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; REGULATORY DOMAIN; EXTENDED CONFORMATION; TROPOMYOSIN COMPLEX; INHIBITORY REGION; CALCIUM-BINDING; THIN-FILAMENTS; ACTIN	Upon Ca2+ activation of cardiac muscle, several structural changes occur in the troponin subunits. These changes include the opening of the cardiac troponin C (cTnC) N-domain, the change of secondary structure of the inhibitory region of cardiac troponin I (cTnI), and the change in the separation between these two proteins in the cTnC-cTnI interface. We have used Forster resonance energy transfer in Ca2+ titration and stopped-flow experiments to delineate these transitions using a reconstituted cardiac troponin. Energy transfer results were quantified to yield time-dependent profiles of changes in intersite distances during Ca2+ dissociation. The closing of the cTnC N-domain induced by release of regulatory Ca2+ from cTnC occurs in one step (t(1/2) similar to 5 ms), and this transition is not affected by Ca2+ release from the C-domain. The other two transitions triggered by Ca2+ dissociation are biphasic with the fast phase (t(1/2) similar to 5 ms) correlated with Ca2+ release from the cTnC N-domain. These transitions are slower than the release of bound regulatory Ca2+ (t(1/2) 3.6 ms) and are coupled to one another in a cooperative manner in restoring their conformations in the deactivated state. The kinetic results define the magnitudes of structural changes relevant in Ca2+ switching between activation and deactivation of cardiac muscle contraction.	Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Dong, WJ (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	wdong@uab.edu; hccheung@uab.edu	Dong, Wenji/A-8579-2011		NHLBI NIH HHS [HL 52508, R01 HL080186] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052508, R01HL080186] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; Dong WJ, 2003, J BIOL CHEM, V278, P8686, DOI 10.1074/jbc.M212886200; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; Dong WJ, 2001, J MOL BIOL, V314, P51, DOI 10.1006/jmbi.2001.5118; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GARLAND F, 1988, J BIOL CHEM, V263, P11621; Hernandez G, 1999, BIOCHEMISTRY-US, V38, P6911, DOI 10.1021/bi990150q; Kobayashi T, 2000, BIOCHEMISTRY-US, V39, P86, DOI 10.1021/bi991903b; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Luo Y, 2002, BIOCHEMISTRY-US, V41, P12891, DOI 10.1021/bi020396m; Luo Y, 2002, J MOL BIOL, V316, P429, DOI 10.1006/jmbi.2001.5358; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; She MD, 1998, J MOL BIOL, V281, P445, DOI 10.1006/jmbi.1998.1933; SMITH SJ, 1990, BRIT J PHARMACOL, V100, P779, DOI 10.1111/j.1476-5381.1990.tb14092.x; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356	24	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42394	42402		10.1074/jbc.M304858200	http://dx.doi.org/10.1074/jbc.M304858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909617	hybrid			2022-12-27	WOS:000185989500102
J	Mahajan, NP; Earp, HS				Mahajan, NP; Earp, HS			An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase - A mechanism for localizing guanine nucleotide-exchange factor action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; C-MER; RHO-GTPASES; RCS RAT; EXPRESSION ANALYSIS; APOPTOTIC CELLS; TYRO-3 FAMILY; PROTEIN-S; GENE 6; PHAGOCYTOSIS	Mer belongs to the Mer/Axl/Tyro3 receptor tyrosine kinase family, which regulates immune homeostasis in part by triggering monocyte ingestion of apoptotic cells. Mutations in Mer can also cause retinitis pigmentosa, again due to defective phagocytosis of apoptotic material. Although, some functional aspects of Mer have been deciphered, how receptor activation lead to the physiological consequences is not understood. By using yeast two-hybrid assays, we identified the carboxyl-terminal region of the guanine nucleotide-exchange factor (GEF) Vav1 as a Mer-binding partner. Unlike similar (related) receptors, Mer interacted with Vav1 constitutively and independently of phosphotyrosine, yet the site of binding localized to the Vav1 SH2 domain. Mer activation resulted in tyrosine phosphorylation of Vav1 and release from Mer, whereas Vav1 was neither phosphorylated nor released from kinase-dead Mer. Mutation of the Vav1 SH2 domain phosphotyrosine coordinating Arg-696 did not alter Mer/Vav1 constitutive binding or Vav1 tyrosine phosphorylation but did retard Vav1 release from autophosphorylated Mer. Ligand-dependent activation of Mer in human monocytes led to Vav1 release and stimulated GDP replacement by GTP on RhoA family members. This unusual constitutive, SH2 domain-dependent, but phosphotyrosine-independent, interaction and its regulated local release and subsequent activation of Rac1, Cdc42, and RhoA may explain how Mer coordinates precise cytoskeletal changes governing the ingestion of apoptotic material by macrophages and pigmented retinal epithelial cells.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Earp, HS (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.							Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Camenisch TD, 1999, J IMMUNOL, V162, P3498; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; FADOK VA, 1992, J IMMUNOL, V148, P2207; Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555; Georgescu MM, 1999, MOL CELL BIOL, V19, P1171; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; LING L, 1995, MOL CELL BIOL, V15, P6582; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MERENGERE LE, 1992, J BIOL CHEM, V267, P22779; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6	37	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42596	42603		10.1074/jbc.M305817200	http://dx.doi.org/10.1074/jbc.M305817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920122	hybrid			2022-12-27	WOS:000185989500125
J	Myers, JC; Moore, SA; Shamoo, Y				Myers, JC; Moore, SA; Shamoo, Y			Structure-based incorporation of 6-methyl-8-(2-deoxy-beta-ribofuranosyl)isoxanthopteridine into the human telomeric repeat DNA as a probe for UP1 binding and destabilization of G-tetrad structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; PTERIDINE NUCLEOSIDE ANALOGS; 3' SPLICE-SITE; G-RICH STRAND; HNRNP A1; RNA-BINDING; CRYSTAL-STRUCTURE; IN-VITRO; PROTEIN; QUADRUPLEX	Heterogeneous ribonucleoprotein A1 ( hnRNP A1) is an abundant nuclear protein that participates in RNA processing, alternative splicing, and chromosome maintenance. hnRNP A1 can be proteolyzed to unwinding protein (UP1), a 22.1-kDa protein that retains a high affinity for purine-rich single-stranded nucleic acids, including the human telomeric repeat (hTR) d(TTAGGG)n. Using the structure of UP1 bound to hTR as a guide, we have incorporated the fluorescent guanine analog 6-MI at one of two positions within the DNA to facilitate binding studies. One is where 6-MI remains stacked with an adjacent purine, and another is where it becomes fully unstacked upon UP1 binding. The structures of both modified oligonucleotides complexed to UP1 were determined by x-ray crystallography to validate the efficacy of our design, and 6-MI has proven to be an excellent reporter molecule for single-stranded nucleic acid interactions in positions where there is a change in stacking environment upon complex formation. We have shown that UP1 affinity for d( TTAGGG) 2 is similar to5 nM at 100 mM NaCl, pH 6.0, and our binding studies with d(TTAGG(6-MI)TTAGGG) show that binding is only modestly sensitive to salt and pH. UP1 also has a potent G-tetrad destabilizing activity that reduces the T-m of the hTR sequence d(TAGGGT)(4) from 67.0degreesC to 36.1degreesC at physiological conditions (150 mM KCl, pH 7.0). Consistent with the structures determined by x-ray crystallography, UP1 is able to bind the hTR sequence in solution as a dimer and supports a model for hnRNP A1 binding to nucleic acids in arrays that may make a contiguous set of anti-parallel single-stranded nucleic acid binding clefts. These data suggest that seemingly disparate roles for hnRNP A1 in alternative splice site selection, RNA processing, RNA transport, and chromosome maintenance reflect its ability to bind a purine-rich consensus sequence (nYAGGn) and destabilize potentially deleterious G-tetrad structures.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Rice University	Shamoo, Y (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS-140,6100 S Main St, Houston, TX 77005 USA.			Shamoo, Yousif/0000-0001-9241-8962	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R41HD036958] Funding Source: NIH RePORTER; NICHD NIH HHS [R03 HD 36958-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AbdulManan N, 1996, NUCLEIC ACIDS RES, V24, P4063, DOI 10.1093/nar/24.20.4063; Allers J, 2001, J MOL BIOL, V311, P75, DOI 10.1006/jmbi.2001.4857; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Blanchette M, 1997, RNA, V3, P405; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Fukuda H, 2002, P NATL ACAD SCI USA, V99, P12685, DOI 10.1073/pnas.152456899; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Hawkins ME, 1997, ANAL BIOCHEM, V244, P86, DOI 10.1006/abio.1996.9879; Hawkins ME, 2001, CELL BIOCHEM BIOPHYS, V34, P257, DOI 10.1385/CBB:34:2:257; Hutchison S, 2002, J BIOL CHEM, V277, P29745, DOI 10.1074/jbc.M203633200; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Katahira M, 1999, BIOCHEM BIOPH RES CO, V264, P327, DOI 10.1006/bbrc.1999.1521; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MERRILL BM, 1987, INT J PEPT PROT RES, V29, P21; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; Nasim FUH, 2002, RNA, V8, P1078, DOI 10.1017/S1355838202024056; Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Phan AT, 2002, NUCLEIC ACIDS RES, V30, P4618, DOI 10.1093/nar/gkf597; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RECORD MT, 1976, BIOPOLYMERS, V15, P893, DOI 10.1002/bip.1976.360150507; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; Simard MJ, 2000, MOL CELL BIOL, V20, P7353, DOI 10.1128/MCB.20.19.7353-7362.2000; Sun SY, 2003, J BIOL CHEM, V278, P3876, DOI 10.1074/jbc.M210497200; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740	50	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42300	42306		10.1074/jbc.M306147200	http://dx.doi.org/10.1074/jbc.M306147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904298	hybrid			2022-12-27	WOS:000185989500090
J	Villa, JP; Bertenshaw, GP; Bond, JS				Villa, JP; Bertenshaw, GP; Bond, JS			Critical amino acids in the active site of meprin metalloproteinases for substrate and peptide bond specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTACIN FAMILY; MOUSE KIDNEY; BETA-GENE; EXPRESSION; ALPHA; METALLOENDOPEPTIDASE; ACTIVATION; SECRETION; SUBUNITS; CANCER	The protease domains of the evolutionarily related alpha and beta subunits of meprin metalloproteases are similar to 55% identical at the amino acid level; however, their substrate and peptide bond specificities differ markedly. The meprin beta subunit favors acidic residues proximal to the scissile bond, while the alpha subunit prefers small or aromatic amino acids flanking the scissile bond. Thus gastrin, a peptide that contains a string of five Glu residues, is an excellent substrate for meprin beta, while it is not hydrolyzed by meprin alpha. Work herein aimed to identify critical amino acids in the meprin active sites that determine the substrate specificity differences. Sequence alignments and homology models, based on the crystal structure of the crayfish astacin, showed electrostatic differences within the meprin active sites. Site-directed mutagenesis of active site residues demonstrated that replacement of a hydrophobic residue by a basic amino acid enabled the meprin alpha protease to cleave gastrin. The meprin alphaY199K mutant was most effective; the corresponding mutation of meprin betaK185Y resulted in decreased activity toward gastrin. Peptide cleavage site determinations and kinetic analyses using a variety of peptides extended evidence that meprin alphaTyr-199/betaLys-185 are substrate specificity determinants in meprin active sites. These studies shed light on the molecular basis for the substrate specificity differences of astacin metalloproteinases.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Bond, JS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171, Hershey, PA 17033 USA.	jbond@psu.edu		Bertenshaw, Greg/0000-0003-4903-3412	NIDDK NIH HHS [R01 DK019691, DK 19691, R56 DK019691, R01 DK019691-27, DK 54625] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R01DK019691, R37DK019691, R01DK054625] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Bertenshaw GP, 2003, J BIOL CHEM, V278, P2522, DOI 10.1074/jbc.M208808200; Bertenshaw GP, 2002, BIOL CHEM, V383, P1175, DOI 10.1515/BC.2002.129; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, GENOMICS, V25, P300, DOI 10.1016/0888-7543(95)80142-9; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; Carmago S, 2002, KIDNEY INT, V61, P959, DOI 10.1046/j.1523-1755.2002.00209.x; Doll BA, 2002, BIOL CHEM, V383, P1167, DOI 10.1515/BC.2002.128; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Johnson G.S., 1998, HDB PROTEOLYTIC ENZY, P1222; Kumar JM, 2001, BBA-GENE STRUCT EXPR, V1518, P106, DOI 10.1016/S0167-4781(01)00188-9; LEE KS, 1994, FEBS LETT, V339, P281, DOI 10.1016/0014-5793(94)80431-1; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Norman LP, 2003, CURR TOP DEV BIOL, V54, P145, DOI 10.1016/S0070-2153(03)54008-X; Norman LP, 2003, MOL CELL BIOL, V23, P1221, DOI 10.1128/MCB.23.4.1221-1230.2003; Rosmann S, 2002, J BIOL CHEM, V277, P40650, DOI 10.1074/jbc.M206203200; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; STOCKER W, 1995, METHOD ENZYMOL, V248, P305; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V319, P281, DOI 10.1006/abbi.1995.1293; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; TRACHTMAN H, 1995, BIOCHEM BIOPH RES CO, V208, P498, DOI 10.1006/bbrc.1995.1366; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; WOLZ RL, 1994, ARCH BIOCHEM BIOPHYS, V310, P144, DOI 10.1006/abbi.1994.1150; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; Yiallouros I, 2000, FEBS LETT, V484, P224, DOI 10.1016/S0014-5793(00)02163-3	32	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42545	42550		10.1074/jbc.M303718200	http://dx.doi.org/10.1074/jbc.M303718200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888571	Green Accepted, hybrid			2022-12-27	WOS:000185989500119
J	Gronholm, M; Vossebein, L; Carlson, CR; Kuja-Panula, J; Teesalu, T; Alfthan, K; Vaheri, A; Rauvala, H; Herberg, FW; Tasken, K; Carpen, O				Gronholm, M; Vossebein, L; Carlson, CR; Kuja-Panula, J; Teesalu, T; Alfthan, K; Vaheri, A; Rauvala, H; Herberg, FW; Tasken, K; Carpen, O			Merlin links to the cAMP neuronal signaling pathway by anchoring the RI Chi subunit of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I REGULATORY SUBUNIT; TUMOR-SUPPRESSOR; MOLECULAR-CLONING; TERMINAL DOMAIN; EXPRESSION; GENE; EZRIN; NEUROFIBROMATOSIS-2; MEMBRANE; BETA	The cAMP-protein kinase A (PKA) pathway, important in neuronal signaling, is regulated by molecules that bind and target PKA regulatory subunits. Of four regulatory subunits, RIbeta is most abundantly expressed in brain. The RIbeta knockout mouse has defects in hippocampal synaptic plasticity, suggesting a role for RIbeta in learning and memory-related functions. Molecules that interact with or regulate RIbeta are still unknown. We identified the neurofibromatosis 2 tumor suppressor protein merlin (schwannomin), a molecule related to the ezrin-radixin-moesin family of membrane-cytoskeleton linker proteins, as a binding partner for RIbeta. Merlin and RIbeta demonstrated a similar expression pattern in central nervous system neurons and an overlapping subcellular localization in cultured hippocampal neurons and transfected cells. The proteins were coprecipitated from brain lysates by cAMP-agarose and coimmunoprecipited from cellular lysates with specific antibodies. In vitro binding studies verified that the interaction is direct. The interaction appeared to be under conformational regulation and was mediated via the alpha-helical region of merlin. Sequence comparison between merlin and known PKA anchoring proteins identified a conserved alpha-helical PKA anchoring protein motif in merlin. These results identify merlin as the first neuronal binding partner for PKA-RIbeta and suggest a novel function for merlin in connecting neuronal cytoskeleton to PKA signaling.	Univ Helsinki, Biomedicum Helsinki, Dept Pathol, Neurosci Program, FIN-00014 Helsinki, Finland; Univ Helsinki, Ctr Neurosci, Inst Biotechnol, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki 00014, Finland; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; Univ Oslo, Dept Med Biochem, N-0317 Oslo, Norway; Tartu Cent Hosp, EE-50406 Tartu, Estonia; Univ Kassel, Inst Biochem, D-34109 Kassel, Germany	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Ruhr University Bochum; University of Oslo; Universitat Kassel	Gronholm, M (corresponding author), Univ Helsinki, Biomedicum Helsinki, Dept Pathol, Neurosci Program, PB 63,Haartmanink 8, FIN-00014 Helsinki, Finland.	mikaela.gronholm@helsinki.fi	Herberg, Friedrich W/B-5572-2015; Vaheri, Antti/AAV-1523-2020; Gronholm, Mikaela/B-4225-2010; Teesalu, Tambet/J-1802-2015	Herberg, Friedrich W/0000-0001-7117-7653; Gronholm, Mikaela/0000-0002-2378-8924; Rauvala, Heikki/0000-0001-7809-9811				Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Bagorda A, 2002, J BIOL CHEM, V277, P21480, DOI 10.1074/jbc.M112245200; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Bohling T, 1996, AM J PATHOL, V148, P367; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CARR DW, 1991, J BIOL CHEM, V266, P14188; CLAUDIO JO, 1995, NEUROREPORT, V6, P1942, DOI 10.1097/00001756-199510020-00028; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; den Bakker MA, 1999, J HISTOCHEM CYTOCHEM, V47, P1471; DENBAKKER MA, 1995, ONCOGENE, V10, P757; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 1999, J CELL SCI, V112, P895; GUTMANN DH, 1995, HUM MOL GENET, V4, P471, DOI 10.1093/hmg/4.3.471; HARA T, 1994, CANCER RES, V54, P330; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Shaw RJ, 1998, CELL GROWTH DIFFER, V9, P287; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; StemmerRachamimov AO, 1997, J NEUROPATH EXP NEUR, V56, P735; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; TASKEN K, 1993, J BIOL CHEM, V268, P21276; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Weinman EJ, 2001, J BIOL CHEM, V276, P42339, DOI 10.1074/jbc.M106153200; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	43	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41167	41172		10.1074/jbc.M306149200	http://dx.doi.org/10.1074/jbc.M306149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896975	hybrid			2022-12-27	WOS:000185847200093
J	Mukherjee, A; Arnaud, L; Cooper, JA				Mukherjee, A; Arnaud, L; Cooper, JA			Lipid-dependent recruitment of neuronal Src to lipid rafts in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; ROUS-SARCOMA VIRUS; T-CELL-ACTIVATION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; FAMILY KINASES; C-SRC; FOCAL ADHESIONS; SH2 DOMAIN; PHOSPHORYLATION	Although most Src family tyrosine kinases are modified by palmitoylation as well as myristoylation, Src itself is only myristoylated. Dual acylation is important for attachment to liquid-ordered microdomains or lipid rafts. Accordingly, Src is excluded from lipid rafts in fibroblasts. Evidence of partial genetic redundancy between Src and Fyn for brain-specific targets suggests that these two kinases may occupy overlapping subcellular locations. Neuronal Src (NSrc), an alternative isoform of Src with a 6-amino acid insert in the Src homology 3 domain, is highly expressed in neurons. We investigated whether this structural difference in NSrc allows it to associate with lipid rafts. We found that perinatal mouse brains express predominantly NSrc, which is partly (10 - 20%) in a lipid raft fraction from brain but not fibroblasts. The association of Src with brain lipid rafts does not depend on the NSrc insert but depends on the amino-terminal myristoylation signal. A crude lipid fraction from brain promotes NSrc entry into rafts in vitro. Moreover, lipid raft-localized NSrc is more catalytically active than NSrc from the soluble fraction, possibly because raft localization alters access to other tyrosine kinases and phosphatases. These findings suggest that NSrc may be involved in signaling from lipid rafts in mouse brain.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Cooper, JA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,Mailstop A2-025, Seattle, WA 98109 USA.	jcooper@fhcrc.org			NCI NIH HHS [R37-CA41072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; BROWN DJ, 1984, J BIOL CHEM, V259, P9580; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kalka D, 2001, BIOCHEM BIOPH RES CO, V283, P989, DOI 10.1006/bbrc.2001.4864; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MAGEE AI, 1989, J CELL SCI, P149; MARIECARDINE A, 1992, J IMMUNOL, V148, P3879; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Prior IA, 2001, J CELL SCI, V114, P1603; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; Sheets ED, 1999, CURR OPIN CHEM BIOL, V3, P95, DOI 10.1016/S1367-5931(99)80017-9; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; Stehr M, 2003, J UROLOGY, V169, P1165, DOI 10.1097/01.ju.0000041501.01323.b9; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905; Young RM, 2003, J BIOL CHEM, V278, P20746, DOI 10.1074/jbc.M211402200; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914	71	83	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40806	40814		10.1074/jbc.M306440200	http://dx.doi.org/10.1074/jbc.M306440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912979	hybrid			2022-12-27	WOS:000185847200049
J	Shern, JF; Sharer, JD; Pallas, DC; Bartolini, F; Cowan, NJ; Reed, MS; Pohl, J; Kahn, RA				Shern, JF; Sharer, JD; Pallas, DC; Bartolini, F; Cowan, NJ; Reed, MS; Pohl, J; Kahn, RA			Cytosolic Arl2 is complexed with cofactor D and protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYOMAVIRUS MIDDLE-T; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; TUMOR-ANTIGEN; BETA-TUBULIN; CELL-GROWTH; 2A; MICROTUBULES; FAMILY; STATE	Arl2 is a member of the ADP-ribosylation factor family of 20-kDa GTPases that is highly conserved in eukaryotes. Recent results revealed that a portion of cellular Arl2 and its binding partner, BART, localize to mitochondria. Because similar to 90% of cellular Arl2 is cytosolic, we investigated properties of the soluble protein and found that it is stably bound in a complex that migrates in gel filtration medium with a predicted molecular mass of similar to 300 kDa. This complex was purified similar to 500-fold from the soluble fraction of bovine brain. Protein components were identified by mass spectroscopy and revealed the presence of four other proteins that include the tubulin folding cochaperone cofactor D and all three subunits of at least two protein phosphatase 2A ( PP2A) protein phosphatase trimers. The presence of more than one PP2A B-type subunit and the low stoichiometry of Arl2 indicate that the purified preparation still contains a mixture of complexes that cannot currently be completely resolved. Thus, although all the soluble Arl2 in bovine brain is in high molecular mass complexes, only a portion of the total cellular cofactor D and PP2A are associated with the Arl2. We further show that the Arl2 in the complex cannot bind GTP and that complexed cofactor D does not efficiently participate in tubulin refolding reactions in a manner comparable with free cofactor D. Our data suggest functional roles for the cytosolic Arl2 complex in modulating tubulin and microtubule behavior as well as a possible role in apoptosis.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Microchem Facil, Atlanta, GA 30322 USA; NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA	Emory University; Emory University; New York University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Shern, Jack/V-4002-2019; Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NCI NIH HHS [R01 CA057327, CA57327] Funding Source: Medline; NIGMS NIH HHS [GM68209] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartolini F, 2002, J BIOL CHEM, V277, P14629, DOI 10.1074/jbc.M200128200; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Carre M, 2002, J BIOL CHEM, V277, P33664, DOI 10.1074/jbc.M203834200; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hiraga A, 2000, BIOCHEM J, V346, P433, DOI 10.1042/0264-6021:3460433; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Hoyt MA, 1997, GENETICS, V146, P849; Hubalek F, 2002, ANAL BIOCHEM, V306, P124, DOI 10.1006/abio.2002.5693; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kobayashi A, 2003, FEBS LETT, V534, P26, DOI 10.1016/S0014-5793(02)03766-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Price NE, 1999, MOL BRAIN RES, V73, P68, DOI 10.1016/S0169-328X(99)00237-5; Radcliffe PA, 2000, FEBS LETT, V468, P84, DOI 10.1016/S0014-5793(00)01202-3; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; SCHONTHAL AH, 1998, FRONT BIOSCI, V3, P1262; Sharer JD, 1999, J BIOL CHEM, V274, P27553, DOI 10.1074/jbc.274.39.27553; SHARER JD, 2001, MOL BIOL CELL, P71; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Spengler B, 1997, J MASS SPECTROM, V32, P1019, DOI 10.1002/(SICI)1096-9888(199711)32:10<1019::AID-JMS595>3.0.CO;2-G; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Van Valkenburgh HA, 2002, METHOD ENZYMOL, V344, P186; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185	43	43	52	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40829	40836		10.1074/jbc.M308678200	http://dx.doi.org/10.1074/jbc.M308678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912990	hybrid			2022-12-27	WOS:000185847200051
J	Tsunenari, T; Sun, H; Williams, J; Cahill, H; Smallwood, P; Yau, KW; Nathans, J				Tsunenari, T; Sun, H; Williams, J; Cahill, H; Smallwood, P; Yau, KW; Nathans, J			Structure-function analysis of the bestrophin family of anion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; MEMBRANE TOPOLOGY; BEST-DISEASE; PROTEIN; DYSTROPHY; GENE; VMD2; IDENTIFICATION; PREDICTION; MUTATIONS	The bestrophins are a newly described family of anion channels unrelated in primary sequence to any previously characterized channel proteins. The human genome codes for four bestrophins, each of which confers a distinctive plasma membrane conductance on transfected 293 cells. Extracellular treatment with methanethiosulfonate ethyltrimethylammonium (MTSET) of a series of substitution mutants that eliminate one or more cysteines from human bestrophin1 demonstrates that cysteine 69 is the single endogenous cysteine responsible for MTSET inhibition of whole-cell current. Cysteines introduced between positions 78-99 and 223-226 are also accessible to external MTSET, with MTSET modification at positions 79, 80, 83, and 90 producing a 2-6-fold increase in whole-cell current. The latter set of four cysteine-substitution mutants define a region that appears to mediate allosteric control of channel activity. Mapping of transmembrane topography by insertion of N-linked glycosylation sites and tobacco etch virus protease cleavage sites provides evidence for cytosolic N and C termini and an unexpected transmembrane topography with at least three extracellular loops that include positions 60-63, 212-227, and 261-267. These experiments provide the first structural analysis of the bestrophin channel family.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Yau, KW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	kwyau@mail.jhmi.edu; jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460	NATIONAL EYE INSTITUTE [R37EY006837, R01EY006837, R01EY014596] Funding Source: NIH RePORTER; NEI NIH HHS [R37 EY006837, R01 EY006837, R01 EY014596, R37 EY006837-15, R01 EY006837-16A1, R37 EY006837-15S1, R01 EY014596-01, R37 EY006837-14, R37 EY006837-13] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bakall B, 1999, HUM GENET, V104, P383, DOI 10.1007/s004390050972; Betz H, 1999, ANN NY ACAD SCI, V868, P667, DOI 10.1111/j.1749-6632.1999.tb11343.x; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; DEUTMAN AF, 1969, ARCH OPHTHALMOL-CHIC, V81, P305, DOI 10.1001/archopht.1969.00990010307001; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Faber KN, 2001, J BIOL CHEM, V276, P36501, DOI 10.1074/jbc.M105828200; FRANCOIS J, 1967, ARCH OPHTHALMOL-CHIC, V77, P726; FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115; GALLEMORE RP, 1998, RETINAL PIGMENT EPIT, P175; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; George AL, 2001, CURR BIOL, V11, pR620, DOI 10.1016/S0960-9822(01)00368-2; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Iyer R, 2002, NATURE, V419, P715, DOI 10.1038/nature01000; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leahy DJ, 2000, PROTEIN EXPRES PURIF, V20, P500, DOI 10.1006/prep.2000.1331; Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; MACKE JP, 1993, AM J HUM GENET, V53, P80; Marchant D, 2001, Hum Mutat, V17, P235, DOI 10.1002/humu.9; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; Marmorstein LY, 2002, J BIOL CHEM, V277, P30591, DOI 10.1074/jbc.M204269200; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; MOHLER CW, 1981, OPHTHALMOLOGY, V88, P688; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Steinberg R. H., 1985, PROGR RETINAL RES, P33, DOI 10.1016/0278-4327(85)90004-5; Stohr H, 2002, EUR J HUM GENET, V10, P281, DOI 10.1038/sj.ejhg.5200796; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Urabe M, 1999, BIOCHEM BIOPH RES CO, V266, P92, DOI 10.1006/bbrc.1999.1788; WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108; White K, 2000, HUM MUTAT, V15, P301, DOI 10.1002/(SICI)1098-1004(200004)15:4<301::AID-HUMU1>3.0.CO;2-N; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	52	182	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41114	41125		10.1074/jbc.M306150200	http://dx.doi.org/10.1074/jbc.M306150200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907679	hybrid, Green Accepted			2022-12-27	WOS:000185847200087
J	Amraei, M; Jia, ZJ; Reboul, P; Nabi, IR				Amraei, M; Jia, ZJ; Reboul, P; Nabi, IR			Acid-induced conformational changes in phosphoglucose isomerase result in its increased cell surface association and deposition on fibronectin fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOCRINE MOTILITY FACTOR; RHEUMATOID KNEE-JOINTS; FACTOR-RECEPTOR; CRYSTAL-STRUCTURE; ENDOPLASMIC-RETICULUM; GLUCOSE-6-PHOSPHATE ISOMERASE; MONOCLONAL-ANTIBODIES; MEDIATED ENDOCYTOSIS; FACTOR NEUROLEUKIN; GLYCOLYTIC ENZYME	Phosphoglucose isomerase (PGI) is a glycolytic enzyme that exhibits extracellular cytokine activity as autocrine motility factor, neuroleukin, and maturation factor and that has been recently implicated as an autoantigen in rheumatoid arthritis. In contrast to its receptor-mediated endocytosis at neutral pH, addition of 25 mug/ml of either Alexa 568- or FITC-conjugated PGI to NIH-3T3 cells at progressively acid pH results in its quantitatively increased association with cell surface fibrillar structures that is particularly evident at pH 5. A similar pH-dependent cell surface association of PGI is observed for first passage human chondrocytes obtained from osteoarthritic joints. At acid pH, PGI colocalizes with fibronectin fibrils, and this association occurs directly upon addition of PGI to the cells. In contrast to the receptor-mediated endocytosis of PGI, fibril association of 25 mug/ml PGI at pH 5 is not competed with an excess (2 mg/ml) of unlabeled PGI. PGI binding at acid pH is therefore neither saturable nor mediated by its receptor. PGI is enzymatically active as a dimer and we show here by non-denaturing gel electrophoresis as well as by glutaraldehyde cross-linking that it exists at neutral pH in a tetrameric form. Increasingly acid pH results in the appearance of PGI monomers that correlates directly with its enhanced cell surface association. However, glutaraldehyde cross-linked PGI is endocytosed at neutral pH and still exhibits enhanced cell surface binding at pH 5. Circular dichroism analysis revealed pH-dependent changes in the near but not the far UV spectra indicating that the tertiary structure of the protein is specifically altered at pH 5. Conformational changes of PGI and exposure of the monomer-monomer interface under acidic conditions, such as those encountered in the synovial fluid of arthritic joints, could therefore result in its deposition on the surface of joints and the induction of an autoimmune response.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Ctr Hosp, Hop Notre Dame, Osteoarthrit Res Unit, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Nabi, IR (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, CP 6128,Succursale A, Montreal, PQ H3C 3J7, Canada.		REBOUL, Pascal/ABA-3774-2021; Nabi, Ivan R/C-5493-2009; Nabi, Ivan/GWZ-5144-2022	REBOUL, Pascal/0000-0003-3546-2152; Nabi, Ivan/0000-0002-0670-0513				ACCOLA MA, 2002, J BIOL CHEM, DOI UNSP M201641200; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Amraei M, 2002, FEBS LETT, V525, P151, DOI 10.1016/S0014-5793(02)03072-7; Arsenieva D, 2002, P NATL ACAD SCI USA, V99, P5872, DOI 10.1073/pnas.052131799; Barilla ML, 2000, SEMIN ARTHRITIS RHEU, V29, P252, DOI 10.1016/S0049-0172(00)80012-8; BENLIMAME N, 1995, J CELL BIOL, V129, P459, DOI 10.1083/jcb.129.2.459; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; BLACKBURN MN, 1972, J BIOL CHEM, V247, P5668; BODANSKY O, 1954, CANCER, V7, P1200, DOI 10.1002/1097-0142(195411)7:6<1200::AID-CNCR2820070612>3.0.CO;2-9; BRUCH P, 1976, EUR J BIOCHEM, V68, P153, DOI 10.1111/j.1432-1033.1976.tb10773.x; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; Chou CC, 2000, J BIOL CHEM, V275, P23154, DOI 10.1074/jbc.M002017200; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DYSON JED, 1968, J BIOL CHEM, V243, P1401; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; Funasaka T, 2001, BIOCHEM BIOPH RES CO, V285, P118, DOI 10.1006/bbrc.2001.5135; GOLDIE I, 1970, ACTA ORTHOP SCAND, V41, P354, DOI 10.3109/17453677008991521; GOLDIE I, 1969, ACTA ORTHOP SCAND, V40, P634, DOI 10.3109/17453676908989529; GURNEY ME, 1986, SCIENCE, V234, P574, DOI 10.1126/science.3020690; GURNEY ME, 1986, J CELL BIOL, V102, P2264, DOI 10.1083/jcb.102.6.2264; HERVE CA, 2003, RHEUMATOLOGY, V212, P986; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; Hirono Y, 1996, BRIT J CANCER, V74, P2003, DOI 10.1038/bjc.1996.667; Jeffery CJ, 2000, BIOCHEMISTRY-US, V39, P955, DOI 10.1021/bi991604m; Jeffery CJ, 2001, BIOCHEMISTRY-US, V40, P1560, DOI 10.1021/bi0018483; Kassahn D, 2002, NAT IMMUNOL, V3, P411, DOI 10.1038/ni0502-411b; Konttinen YT, 2002, ARTHRITIS RHEUM, V46, P953, DOI 10.1002/art.10185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le PU, 2000, J CELL SCI, V113, P3227; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Leclerc N, 2000, J NEUROSCI RES, V60, P602, DOI 10.1002/(SICI)1097-4547(20000601)60:5<602::AID-JNR5>3.0.CO;2-F; LU HS, 1981, J BIOL CHEM, V256, P785; Lui KEH, 2002, J CELL PHYSIOL, V192, P102, DOI 10.1002/jcp.10120; Luo YQ, 2002, J NEUROCHEM, V80, P354, DOI 10.1046/j.0022-3042.2001.00707.x; Maccioni M, 2002, J EXP MED, V195, P1071, DOI 10.1084/jem.20011941; Mandik-Nayak L, 2002, P NATL ACAD SCI USA, V99, P14368, DOI 10.1073/pnas.182549099; MARUYAMA K, 1995, INT J CANCER, V64, P316, DOI 10.1002/ijc.2910640506; MASTERS CJ, 1984, J CELL BIOL, V99, P222; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772; Matsumoto I, 2003, ARTHRITIS RHEUM-US, V48, P944, DOI 10.1002/art.10898; Menkin V, 1937, AM J PATHOL, V13, P25; NABI IR, 1990, CANCER RES, V50, P409; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nagai Y, 1996, DERMATOLOGY, V192, P8, DOI 10.1159/000246304; NAKAMORI S, 1994, CANCER-AM CANCER SOC, V74, P1855, DOI 10.1002/1097-0142(19941001)74:7<1855::AID-CNCR2820740705>3.0.CO;2-1; Niinaka Y, 2002, ORAL ONCOL, V38, P49, DOI 10.1016/S1368-8375(01)00022-7; OTTO T, 1994, CANCER RES, V54, P3120; PON NG, 1970, BIOCHEMISTRY-US, V9, P1506, DOI 10.1021/bi00809a005; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; Schaller M, 2001, NAT IMMUNOL, V2, P746, DOI 10.1038/90696; Schubert D, 2002, NAT IMMUNOL, V3, P411, DOI 10.1038/ni0502-411a; SCHWARTZ MK, 1973, CLIN CHEM, V19, P10; Shimizu K, 1999, FEBS LETT, V456, P295, DOI 10.1016/S0014-5793(99)00966-7; Silletti S., 1991, CANCER RES, V51, P3301; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P5412, DOI 10.1073/pnas.96.10.5412; Takanami I, 1998, TUMOR BIOL, V19, P384, DOI 10.1159/000030031; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; Tardif G, 1999, ARTHRITIS RHEUM, V42, P1147, DOI 10.1002/1529-0131(199906)42:6<1147::AID-ANR11>3.0.CO;2-Y; TREUHAFT PS, 1971, ARTHRITIS RHEUM, V14, P475, DOI 10.1002/art.1780140407; Tsutsumi S, 2003, FEBS LETT, V534, P49, DOI 10.1016/S0014-6793(02)03773-0; Tsutsumi S, 2003, CANCER RES, V63, P242; Wang HJ, 2000, J CELL BIOL, V150, P1489, DOI 10.1083/jcb.150.6.1489; Wang HJ, 1997, J CELL SCI, V110, P3043; WATANABE H, 1994, J RHEUMATOL, V21, P37; Watanabe H, 1996, CANCER RES, V56, P2960; Wipke BT, 2002, NAT IMMUNOL, V3, P366, DOI 10.1038/ni775; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867; Zhi J, 2001, J BONE MINER RES, V16, P1994, DOI 10.1359/jbmr.2001.16.11.1994	71	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38935	38941		10.1074/jbc.M304778200	http://dx.doi.org/10.1074/jbc.M304778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12888574	hybrid			2022-12-27	WOS:000185575100103
J	Motohashi, K; Koyama, F; Nakanishi, Y; Ueoka-Nakanishi, H; Hisabori, T				Motohashi, K; Koyama, F; Nakanishi, Y; Ueoka-Nakanishi, H; Hisabori, T			Chloroplast cyclophilin is a target protein of thioredoxin - Thiol modulation of the peptidyl-prolyl cis-trans isomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; PLANT; EXPRESSION; CLONING; IDENTIFICATION; PURIFICATION; PHOSPHATASE; CYSTEINES	Chloroplast cyclophilin has been identified as a potential candidate of enzymes in chloroplasts that are regulated by thioredoxin ( Motohashi, K., Kondoh, A., Stumpp, M. T., and Hisabori, T. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 11224 - 11229). In the present study we found that the peptidyl-prolyl cis-trans isomerase activity of cyclophilin is fully inactivated in the oxidized form. Reduction of cyclophilin by thioredoxin-m recovered the isomerase activity. Two crucial disulfide bonds were determined by disulfide-linked peptide mapping. The relevance of these cysteines for isomerase activity was confirmed by the mutagenesis studies. Because four cysteine residues in Arabidopsis thaliana cyclophilin were conserved in the isoforms from several organisms, it appears that this redox regulation must be one of the common regulation systems of cyclophilin.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; JST, ATP Syst Project, ERATO, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Hisabori, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277; zhong xi, hua dai/0000-0001-8619-9513				Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Baumann U, 2002, CELL MOL LIFE SCI, V59, P1042, DOI 10.1007/s00018-002-8485-8; Berardini TZ, 2001, SCIENCE, V291, P2405, DOI 10.1126/science.1057144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMAN A, 1992, J BIOL CHEM, V267, P21293; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; DOLINSKI K, 1997, GUIDEBOOK MOL CHAPER, P359; Dornan J, 1999, J BIOL CHEM, V274, P34877, DOI 10.1074/jbc.274.49.34877; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; Fulgosi H, 1998, EMBO J, V17, P1577, DOI 10.1093/emboj/17.6.1577; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; GLAZER AN, 1975, CHEM MODIFICATION PR, P21; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HAYMAN GT, 1994, BBA-GENE STRUCT EXPR, V1219, P536, DOI 10.1016/0167-4781(94)90083-3; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; LIPPUNER V, 1994, J BIOL CHEM, V269, P7863; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LUAN S, 1994, PLANT CELL, V6, P885, DOI 10.1105/tpc.6.6.885; LUAN S, 1994, P NATL ACAD SCI USA, V91, P984, DOI 10.1073/pnas.91.3.984; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; SAITO T, 1995, PLANT CELL PHYSIOL, V36, P377, DOI 10.1093/oxfordjournals.pcp.a078770; Saito T, 1999, PLANT CELL PHYSIOL, V40, P77, DOI 10.1093/oxfordjournals.pcp.a029477; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; Sheldon PS, 1996, BIOCHEM J, V315, P965, DOI 10.1042/bj3150965; Stumpp MT, 1999, BIOCHEM J, V341, P157, DOI 10.1042/0264-6021:3410157; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; WALSH CT, 1992, J BIOL CHEM, V267, P13115; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998	40	112	122	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31848	31852		10.1074/jbc.M304258200	http://dx.doi.org/10.1074/jbc.M304258200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12923164	hybrid			2022-12-27	WOS:000184782100049
J	Heinemann, FS; Korza, G; Ozols, J				Heinemann, FS; Korza, G; Ozols, J			A plasminogen-like protein selectively degrades stearoyl-CoA desaturase in liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RAT-LIVER; ELECTROPHORETIC ANALYSIS; POLYACRYLAMIDE GELS; SYSTEM; MICE; DEGRADATION; DEFICIENCY; COMPLEX; CELLS	Stearoyl-CoA desaturase (SCD) is an integral membrane protein of the endoplasmic reticulum that is rapidly and selectively degraded when isolated liver microsomes are incubated at 37degreesC. We previously reported the purification of a 90-kDa microsomal protein with SCD protease activity and characterized the inhibitor sensitivity of the protease. Here we show that the 90-kDa protein is a microsomal form of plasminogen (Pg) and that the purified SCD protease contains a spectrum of plasmin-like derivatives. The 90-kDa protein was identified as Pg by mass spectrometry of its tryptic peptides. The purified SCD protease reacted with Pg antibody, and immunoblotting demonstrated enrichment of Pg by the purification procedure established for the SCD protease. Analysis of microsomes by zymography demonstrated a single band of proteolytic activity at 70-kDa corresponding to the mobility of Pg in nonreduced polyacrylamide gels. When microsomes were incubated at 37degreesC prior to zymography, an intense band of proteolytic activity developed at 30-kDa. The purified SCD protease displayed a spectrum of proteolytic bands ranging from 70 to 30 kDa. Degradation of SCD by the purified protease and by microsomes was inhibited by bdellin, a plasmin inhibitor from the medicinal leech Hirudo medicinalis. To explore the role of Pg in the degradation of SCD in vivo, we examined SCD expression and degradation in microsomes isolated from Pg-deficient (Pg-/-) mice. Compared with microsomes from wild-type littermate control mice, liver microsomes from Pg-/- mice had significantly higher levels of SCD. Degradation of SCD in microsomes from Pg-/- mice was markedly diminished, whereas liver microsomes from control mice showed rapid SCD degradation similar to that observed in rat liver microsomes. These findings indicate that SCD is degraded by a protease related to Pg and suggest that plasmin moonlights as an intracellular protease.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA; Hoag Mem Hosp, Dept Pathol, Newport Beach, CA 92663 USA	University of Connecticut	Ozols, J (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026351] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26351] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN F, 2001, HEMOSTASIS THROMBOSI, P275; Bezerra JA, 1999, P NATL ACAD SCI USA, V96, P15143, DOI 10.1073/pnas.96.26.15143; Bisgaard HC, 1998, LAB INVEST, V78, P237; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Chen ZL, 1999, J NEUROSCI, V19, P9813; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; Heinemann FS, 2003, BIOCHEMISTRY-US, V42, P6929, DOI 10.1021/bi034071x; Heinemann FS, 2003, PROSTAG LEUKOTR ESS, V68, P123, DOI 10.1016/S0952-3278(02)00262-4; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Kates M., 1984, MEMBRANE FLUIDITY, P379; Kornblatt JA, 2003, BIOCHEM BIOPH RES CO, V305, P518, DOI 10.1016/S0006-291X(03)00804-0; KORZA G, 1988, J BIOL CHEM, V263, P3486; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Leyland H, 1996, HEPATOLOGY, V24, P1172, DOI 10.1002/hep.510240532; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARCUS G, 1979, J BIOL CHEM, V254, P1211; MARCUS G, 1978, J BIOL CHEM, V253, P733; Miles LA, 2003, TRENDS CARDIOVAS MED, V13, P21, DOI 10.1016/S1050-1738(02)00190-1; Moser M, 1998, EUR J BIOCHEM, V253, P212, DOI 10.1046/j.1432-1327.1998.2530212.x; MYRSET AH, 1991, BIOCHIM BIOPHYS ACTA, V1070, P229, DOI 10.1016/0005-2736(91)90169-9; Mziaut H, 2000, P NATL ACAD SCI USA, V97, P8883, DOI 10.1073/pnas.97.16.8883; Mziaut H, 2002, BBA-MOL CELL BIOL L, V1583, P45, DOI 10.1016/S1388-1981(02)00159-2; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; OSHINO N, 1972, ARCH BIOCHEM BIOPHYS, V149, P369, DOI 10.1016/0003-9861(72)90335-9; Ozols J, 1997, MOL BIOL CELL, V8, P2281, DOI 10.1091/mbc.8.11.2281; PirieShepherd SR, 1997, J BIOL CHEM, V272, P7408, DOI 10.1074/jbc.272.11.7408; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Rester U, 1999, J MOL BIOL, V293, P93, DOI 10.1006/jmbi.1999.3162; ROCHE PC, 1983, BIOCHIM BIOPHYS ACTA, V745, P82, DOI 10.1016/0167-4838(83)90172-3; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Yue CC, 1996, J BIOL CHEM, V271, P22245, DOI 10.1074/jbc.271.36.22245; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang L, 2002, THROMB HAEMOSTASIS, V87, P493; ZHEN L, 1995, J BIOL CHEM, V270, P11912, DOI 10.1074/jbc.270.20.11912; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446	43	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42966	42975		10.1074/jbc.M306240200	http://dx.doi.org/10.1074/jbc.M306240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928439	hybrid			2022-12-27	WOS:000186157000031
J	Holt, PJ; Morgan, DJ; Sazanov, LA				Holt, PJ; Morgan, DJ; Sazanov, LA			The location of NuoL and NuoM subunits in the membrane domain of the Escherichia coli complex I - Implications for the mechanism of proton pumping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; DNA-ENCODED SUBUNITS; 3-DIMENSIONAL STRUCTURE; QUINONE OXIDOREDUCTASE; NEUROSPORA-CRASSA; PARACOCCUS-DENITRIFICANS; STRUCTURAL ORGANIZATION; ELECTRON-MICROSCOPY; ND5 SUBUNIT; DEHYDROGENASE	The molecular organization of bacterial NADH: ubiquinone oxidoreductase (complex I or NDH-1) is not established, apart from a rough separation into dehydrogenase, connecting and membrane domains. In this work, complex I was purified from Escherichia coli and fragmented by replacing dodecylmaltoside with other detergents. Exchange into decyl maltoside led to the removal of the hydrophobic subunit NuoL from the otherwise intact complex. Diheptanoyl phosphocholine led to the loss of NuoL and NuoM subunits, whereas other subunits remained in the complex. The presence of N,N-dimethyldodecylamine N-oxide or Triton X-100 led to further disruption of the membrane domain into fragments containing NuoL/M/N, NuoA/K/N, and NuoH/J subunits. Among the hydrophilic subunits, NuoCD was most readily dissociated from the complex, whereas NuoB was partially dissociated from the peripheral arm assembly in N, N-dimethyldodecylamine N-oxide. A model of subunit arrangement in bacterial complex I based on these data is proposed. Subunits NuoL and NuoM, which are homologous to antiporters and are implicated in proton pumping, are located at the distal end of the membrane arm, spatially separated from the redox centers of the peripheral arm. This is consistent with proposals that the mechanism of proton pumping by complex I is likely to involve long range conformational changes.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Sazanov, LA (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Sazanov, Leonid A/ABF-2125-2021	Sazanov, Leonid A/0000-0002-0977-7989				Albracht SPJ, 2000, FEBS LETT, V485, P1, DOI 10.1016/S0014-5793(00)02172-4; Amarneh B, 2003, BIOCHEMISTRY-US, V42, P4800, DOI 10.1021/bi0340346; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Cardol P, 2002, J MOL BIOL, V319, P1211, DOI 10.1016/S0022-2836(02)00407-2; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Di Bernardo S, 2001, FEBS LETT, V508, P385, DOI 10.1016/S0014-5793(01)03111-8; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; EARLEY FGP, 1987, FEBS LETT, V219, P108, DOI 10.1016/0014-5793(87)81200-0; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; GALANTE YM, 1979, ARCH BIOCHEM BIOPHYS, V192, P559, DOI 10.1016/0003-9861(79)90126-7; Gemperli AC, 2003, P NATL ACAD SCI USA, V100, P839, DOI 10.1073/pnas.0237328100; Gemperli AC, 2002, J BIOL CHEM, V277, P33811, DOI 10.1074/jbc.M204860200; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Hauser H, 2000, BBA-BIOMEMBRANES, V1508, P164, DOI 10.1016/S0304-4157(00)00008-3; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; KIKUNO R, 1985, FEBS LETT, V189, P85, DOI 10.1016/0014-5793(85)80847-4; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; Peng GH, 2003, BIOCHEMISTRY-US, V42, P3032, DOI 10.1021/bi026876v; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; Sousa R, 1999, BBA-BIOENERGETICS, V1411, P142, DOI 10.1016/S0005-2728(99)00014-6; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	48	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43114	43120		10.1074/jbc.M308247200	http://dx.doi.org/10.1074/jbc.M308247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923180	hybrid			2022-12-27	WOS:000186157000051
J	Persson, T; Cuzic, S; Hartmann, RK				Persson, T; Cuzic, S; Hartmann, RK			Catalysis by RNase P RNA - Unique features and unprecedented active site plasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS RIBONUCLEASE-P; PRECURSOR-TRANSFER-RNA; GROUP-I RIBOZYME; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; CLEAVAGE SITE; M1 RNA; 5' LEADER; MAGNESIUM-IONS; ACCEPTOR STEM	Metal ions are essential cofactors for precursor tRNA (ptRNA) processing by bacterial RNase P. The ribose 2'-OH at nucleotide (nt) - 1 of ptRNAs is known to contribute to positioning of catalytic Me2+. To investigate the catalytic process, we used ptRNAs with single 2'-deoxy (2'-H), 2'-amino (2'-N), or 2'-fluoro (2'-F) modifications at the cleavage site (nt - 1). 2' modifications had small (2.4 - 7.7- fold) effects on ptRNA binding to E. coli RNase P RNA in the ground state, decreasing substrate affinity in the order 2'-OH > 2'-F > 2'-N > 2'-H. Effects on the rate of the chemical step (about 10-fold for 2'-F, almost 150-fold for 2'-H and 2'-N) were much stronger, and, except for the 2'-N modification, resembled strikingly those observed in the Tetrahymena ribozyme-catalyzed reaction at corresponding position. Mn2+ rescued cleavage of the 2'-N but also the 2'-H-modified ptRNA, arguing against a direct metal ion coordination at this location. Miscleavage between nt - 1 and - 2 was observed for the 2'-N- ptRNA at low pH ( further influenced by the base identities at nt - 1 and + 73), suggesting repulsion of a catalytic metal ion due to protonation of the amino group. Effects caused by the 2'-N modification at nt - 1 of the substrate allowed us to substantiate a mechanistic difference in phosphodiester hydrolysis catalyzed by Escherichia coli RNase P RNA and the Tetrahymena ribozyme: a metal ion binds next to the 2' substituent at nt - 1 in the reaction catalyzed by RNase P RNA, but not at the corresponding location in the Tetrahymena ribozyme reaction.	Med Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany	University of Lubeck	Hartmann, RK (corresponding author), Univ Marburg, Inst Pharmazeut Chem, Marbacher Weg 6, D-35037 Marburg, Germany.							Altman S., 1999, RNA WORLD, P351; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; Berger I, 1998, NUCLEIC ACIDS RES, V26, P2473, DOI 10.1093/nar/26.10.2473; Blanchard SC, 2001, P NATL ACAD SCI USA, V98, P3720, DOI 10.1073/pnas.051608498; Brannvall M, 2003, J MOL BIOL, V325, P697, DOI 10.1016/S0022-2836(02)01195-6; Brannvall M, 2002, BIOCHIMIE, V84, P693, DOI 10.1016/S0300-9084(02)01462-1; Brannvall M, 1999, J MOL BIOL, V292, P53, DOI 10.1006/jmbi.1999.3048; Brannvall M, 2001, P NATL ACAD SCI USA, V98, P12943, DOI 10.1073/pnas.221456598; Brown JW, 1998, NUCLEIC ACIDS RES, V26, P351, DOI 10.1093/nar/26.1.351; BURKARD U, 1988, NUCLEIC ACIDS RES, V16, P11617, DOI 10.1093/nar/16.24.11617; Busch S, 2000, J MOL BIOL, V299, P941, DOI 10.1006/jmbi.2000.3789; Chen Y, 1997, BIOCHEMISTRY-US, V36, P2425; Christian EL, 1998, BIOCHEMISTRY-US, V37, P17618, DOI 10.1021/bi982050a; Christian EL, 2002, EMBO J, V21, P2253, DOI 10.1093/emboj/21.9.2253; Crary SM, 1998, BIOCHEMISTRY-US, V37, P9409, DOI 10.1021/bi980613c; Eckstein F, 2002, BIOCHIMIE, V84, P841, DOI 10.1016/S0300-9084(02)01459-1; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1993, BIOCHEMISTRY-US, V32, P7152, DOI 10.1021/bi00079a012; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Hansen A, 2001, MOL MICROBIOL, V41, P131, DOI 10.1046/j.1365-2958.2001.02467.x; HARDT WD, 1995, J MOL BIOL, V247, P161, DOI 10.1006/jmbi.1994.0130; Hartmann R K, 1995, Biotechnol Annu Rev, V1, P215, DOI 10.1016/S1387-2656(08)70053-X; Heide C, 1999, RNA, V5, P102, DOI 10.1017/S1355838299981499; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; Juneau K, 2001, STRUCTURE, V9, P221, DOI 10.1016/S0969-2126(01)00579-2; KIRSEBOM LA, 1994, EMBO J, V13, P4870, DOI 10.1002/j.1460-2075.1994.tb06814.x; Kufel J, 1996, P NATL ACAD SCI USA, V93, P6085, DOI 10.1073/pnas.93.12.6085; Kufel J, 1998, RNA, V4, P777, DOI 10.1017/S1355838298970923; Kurz JC, 2002, BIOCHEMISTRY-US, V41, P9545, DOI 10.1021/bi025553w; Loria A, 1997, BIOCHEMISTRY-US, V36, P6317, DOI 10.1021/bi970115o; Loria A, 1998, BIOCHEMISTRY-US, V37, P10126, DOI 10.1021/bi980220d; MILLER PS, 1993, NUCLEOS NUCLEOT, V12, P785, DOI 10.1080/07328319308018549; ORELLANA O, 1986, MOL CELL BIOL, V6, P525, DOI 10.1128/MCB.6.2.525; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PERREAULT JP, 1993, J MOL BIOL, V230, P750, DOI 10.1006/jmbi.1993.1197; Persson T, 2002, CHEMBIOCHEM, V3, P1066, DOI 10.1002/1439-7633(20021104)3:11<1066::AID-CBIC1066>3.0.CO;2-G; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P55; Schon A, 1999, FEMS MICROBIOL REV, V23, P391, DOI 10.1016/S0168-6445(99)00014-5; Sigel H, 1996, MET IONS BIOL SYST, V32, P135; Sjogren AS, 1997, NUCLEIC ACIDS RES, V25, P648, DOI 10.1093/nar/25.3.648; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; Sreedhara A, 2002, BIOMETALS, V15, P211, DOI 10.1023/A:1016070614042; Strobel SA, 1999, CHEM BIOL, V6, P153, DOI 10.1016/S1074-5521(99)89007-3; Thomson JB, 1996, J ORG CHEM, V61, P6273, DOI 10.1021/jo960795l; Warnecke JM, 1999, J MOL BIOL, V290, P433, DOI 10.1006/jmbi.1999.2890; Warnecke JM, 1996, P NATL ACAD SCI USA, V93, P8924, DOI 10.1073/pnas.93.17.8924; Warnecke JM, 2000, NUCLEIC ACIDS RES, V28, P720, DOI 10.1093/nar/28.3.720; Willkomm DK, 2002, BIOCHIMIE, V84, P713, DOI 10.1016/S0300-9084(02)01447-5; Yoshida A, 2000, CHEM BIOL, V7, P85, DOI 10.1016/S1074-5521(00)00074-0; Zahler NH, 2003, RNA, V9, P734, DOI 10.1261/rna.5220703; Zuleeg T, 2001, J MOL BIOL, V305, P181, DOI 10.1006/jmbi.2000.4299	54	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43394	43401		10.1074/jbc.M305939200	http://dx.doi.org/10.1074/jbc.M305939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904300	hybrid			2022-12-27	WOS:000186157000083
J	Springhetti, EM; Istomina, NE; Whisstock, JC; Nikitina, T; Woodcock, CL; Grigoryev, SA				Springhetti, EM; Istomina, NE; Whisstock, JC; Nikitina, T; Woodcock, CL; Grigoryev, SA			Role of the M-loop and reactive center loop domains in the folding and bridging of nucleosome arrays by MENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING FORCE MICROSCOPY; GLOBIN CHROMOSOMAL DOMAIN; HIGHER-ORDER STRUCTURE; CHROMATIN STRUCTURE; LINKER HISTONES; GENE ACTIVITY; PROTEIN MENT; HETEROCHROMATIN; DNA; RESOLUTION	MENT is a developmentally regulated heterochromatin-associated protein that condenses chromatin in terminally differentiated avian blood cells. Its homology to the serpin protein family suggests that the conserved serpin reactive center loop (RCL) and the unique M-loop are important for its function. To examine the role of these domains, we studied the interaction of wild-type and mutant MENT with naked DNA and biochemically defined nucleosome arrays reconstituted from 12-mer repeats containing nucleosome positioning sequences. Wild-type MENT folded the naked DNA duplexes into closely juxtaposed parallel structures ("tramlines"). Deletion of the M-loop, but not inactivation of the RCL, prevented tramline formation and the cooperative interaction of MENT with DNA. Reconstitution of wildtype MENT with nucleosome arrays caused their tight folding and self-association. M-loop deletion inhibited nucleosome array folding, whereas the inactive RCL mutant was competent to fold the nucleosome arrays, but had a significantly impaired ability to cause their self-association. Bifunctional chemical cross-linking of MENT revealed oligomerization of wild-type MENT in the presence of chromatin and DNA. This oligomerization was severely reduced in the RCL mutant. We propose that the mechanism of MENT-induced heterochromatin formation involves two independent events: bringing together nucleosome linkers within a chromatin fiber and formation of protein bridges between chromatin fibers. Ordered binding of MENT to linker DNA via its unique M-loop domain promotes the folding of chromatin, whereas bridging of chromatin fibers is facilitated by MENT oligomerization mediated by the RCL.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Moscow MV Lomonosov State Univ, Dept Mol Biol, Moscow 119899, Russia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Lomonosov Moscow State University; Monash University; University of Massachusetts System; University of Massachusetts Amherst	Grigoryev, SA (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr,POB 850, Hershey, PA 17033 USA.			Whisstock, James/0000-0003-4200-5611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043786, R01GM059118] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43786, GM-59118] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; BOULIKAS T, 1980, P NATL ACAD SCI-BIOL, V77, P127, DOI 10.1073/pnas.77.1.127; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P369; Dunstone MA, 2000, PROTEIN SCI, V9, P417; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; FRENSTER JH, 1974, CELL NUCLEUS, P565; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; Grigoryev SA, 1998, J BIOL CHEM, V273, P3082, DOI 10.1074/jbc.273.5.3082; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Grigoryev SA, 2001, BIOCHEM CELL BIOL, V79, P227, DOI 10.1139/bcb-79-3-227; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; Irving JA, 2002, J BIOL CHEM, V277, P13192, DOI 10.1074/jbc.M108460200; Istomina NE, 2003, MOL CELL BIOL, V23, P6455, DOI 10.1128/MCB.23.18.6455-6468.2003; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leuba SH, 1998, BIOPHYS J, V74, P2830, DOI 10.1016/S0006-3495(98)77990-1; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lomas DA, 2000, RESP MED, V94, pS3, DOI 10.1053/rmed.2000.0850; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; RING D, 1979, J BIOL CHEM, V254, P1688; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Singh PB, 1998, DEV GENET, V22, P85, DOI 10.1002/(SICI)1520-6408(1998)22:1<85::AID-DVG9>3.0.CO;2-3; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL, P613; VERREAULT A, 1993, COLD SPRING HARB SYM, V58, P15, DOI 10.1101/SQB.1993.058.01.005; Wang GZ, 2000, MOL CELL BIOL, V20, P6970, DOI 10.1128/MCB.20.18.6970-6983.2000; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; WOOD WI, 1982, J BIOL CHEM, V257, P7730; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6; Woodcock CL, 1998, METHOD CELL BIOL, V53, P167; Zlatanova J, 2003, J MOL BIOL, V331, P1, DOI 10.1016/S0022-2836(03)00691-0; ZLATANOVA J, 1992, J CELL SCI, V103, P889	49	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43384	43393		10.1074/jbc.M307635200	http://dx.doi.org/10.1074/jbc.M307635200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930828	hybrid			2022-12-27	WOS:000186157000082
J	Casey, DM; Yagi, T; Kamiya, R; Witman, GB				Casey, DM; Yagi, T; Kamiya, R; Witman, GB			DC3, the smallest subunit of the Chlamydomonas flagellar outer dynein arm-docking complex, is a redox-sensitive calcium-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EF-HAND; LIGHT-CHAIN; CONFORMATIONAL CHANGE; TARGET RECOGNITION; MAGNESIUM BINDING; BENDING PATTERNS; TROPONIN-C; CALMODULIN; REINHARDTII; MUTANT	The outer dynein arm-docking complex (ODA-DC) targets the outer dynein arm to its correct binding site on the flagellar axoneme. The Chlamydomonas ODA-DC contains three proteins; loss of any one prevents normal assembly of the outer arm, leading to a slow, jerky swimming phenotype. We showed previously that the smallest ODA-DC subunit, DC3, has four EF-hands (Casey, D. M., Inaba, K., Pazour, G. J., Takada, S., Wakabayashi, K., Wilkerson, C. G., Kamiya, R., and Witman, G. B. (2003) Mol. Biol. Cell 14, <LF>3650-3663). Two of the EF-hands fit the consensus pattern for calcium binding, and one of these contains two cysteine residues within its binding loop. To determine whether the predicted EF-hands are functional, we purified bacterially expressed wild-type DC3 and analyzed its calcium-binding potential in the presence and absence of dithiothreitol and Mg2+. The protein bound one calcium ion with an affinity (K-d) of similar to1 x 10(-5) M. Calcium binding was observed only in the presence of dithiothreitol and thus is redox-sensitive. DC3 also bound Mg2+ at physiological concentrations but with a much lower affinity. Changing the essential glutamate to glutamine in both EF-hands eliminated the calcium binding activity of the bacterially expressed protein. To investigate the role of the EF-hands in vivo, we transformed the modified DC3 gene into a Chlamydomonas insertional mutant lacking DC3. The transformed strain swam normally, assembled a normal number of outer arms, and had a normal photoshock response, indicating that the Glu to Gln mutations did not affect ODA-DC assembly, outer arm assembly, or Ca2+-mediated outer arm activity. Thus, DC3 is a true calcium-binding protein, but the function of this activity remains unknown.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Tokyo	Witman, GB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	george.witman@umassmed.edu		Witman, George/0000-0002-9497-9218	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM130326, R01GM030626] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030626, GM 30326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ababou A, 2001, PROTEIN SCI, V10, P301, DOI 10.1110/ps.33601; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Berggard T, 2002, J BIOL CHEM, V277, P16662, DOI 10.1074/jbc.M200415200; BROKAW CJ, 1983, CELL MOTIL CYTOSKEL, V3, P131, DOI 10.1002/cm.970030204; Casey DM, 2003, MOL BIOL CELL, V14, P3650, DOI 10.1091/mbc.E03-01-0057; Davis JP, 2002, J BIOL CHEM, V277, P49716, DOI 10.1074/jbc.M208488200; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DUNAHAY TG, 1993, BIOTECHNIQUES, V15, P452; Evans JH, 1999, CELL CALCIUM, V26, P103, DOI 10.1054/ceca.1999.0060; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; GITELMAN SE, 1980, J CELL BIOL, V87, P764, DOI 10.1083/jcb.87.3.764; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HAIECH J, 1991, J BIOL CHEM, V266, P3427; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P1; Harrison A, 2002, CELL MOTIL CYTOSKEL, V52, P131, DOI 10.1002/cm.10044; Hayashi M, 2002, CELL MOTIL CYTOSKEL, V53, P273, DOI 10.1002/cm.10075; JAMIESON GA, 1979, P NATL ACAD SCI USA, V76, P6471, DOI 10.1073/pnas.76.12.6471; KAMIYA R, 1988, J CELL BIOL, V107, P2253, DOI 10.1083/jcb.107.6.2253; KAMIYA R, 1985, J CELL SCI, V74, P181; Kamiya R, 2000, METHODS, V22, P383, DOI 10.1006/meth.2000.1090; KING SM, 1995, J CELL SCI, V108, P3757; Koutoulis A, 1997, J CELL BIOL, V137, P1069, DOI 10.1083/jcb.137.5.1069; LADANT D, 1995, J BIOL CHEM, V270, P3179; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; MITCHELL DR, 1985, J CELL BIOL, V100, P1228, DOI 10.1083/jcb.100.4.1228; Mizoue LS, 2002, CURR OPIN STRUC BIOL, V12, P459, DOI 10.1016/S0959-440X(02)00348-2; MOSS AG, 1995, METHOD CELL BIOL, V47, P281, DOI 10.1016/S0091-679X(08)60821-3; MOSS AG, 1999, MICROSC ANAL, V34, P7; NAITOH Y, 1972, SCIENCE, V176, P523, DOI 10.1126/science.176.4034.523; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; Ohki SY, 1997, BIOCHEMISTRY-US, V36, P4309, DOI 10.1021/bi962759m; OLWIN BB, 1984, J BIOL CHEM, V259, P949; OMOTO CK, 1985, CELL MOTIL CYTOSKEL, V5, P53, DOI 10.1002/cm.970050105; PatelKing RS, 1996, J BIOL CHEM, V271, P6283, DOI 10.1074/jbc.271.11.6283; PAZOUR GJ, 1995, J CELL BIOL, V131, P427, DOI 10.1083/jcb.131.2.427; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PROCYSHYN RM, 1994, J BIOL CHEM, V269, P1641; REID RE, 1980, J THEOR BIOL, V84, P401, DOI 10.1016/S0022-5193(80)80013-0; REID RE, 1995, ARCH BIOCHEM BIOPHYS, V323, P115, DOI 10.1006/abbi.1995.0016; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; TAKADA S, 1994, J CELL BIOL, V126, P737, DOI 10.1083/jcb.126.3.737; Takada S, 2002, MOL BIOL CELL, V13, P1015, DOI 10.1091/mbc.01-04-0201; Tikunova SB, 2001, BIOCHEMISTRY-US, V40, P3348, DOI 10.1021/bi0021333; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; Witman George B., 1993, Trends in Cell Biology, V3, P403, DOI 10.1016/0962-8924(93)90091-E; Yanagimachi R., 1988, PHYSL REPRODUCTION, V1, P135; Yang PF, 2001, J CELL BIOL, V153, P1315, DOI 10.1083/jcb.153.6.1315	50	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42652	42659		10.1074/jbc.M303064200	http://dx.doi.org/10.1074/jbc.M303064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920131	hybrid			2022-12-27	WOS:000185989500131
J	Kim, SJ; Sung, JY; Um, JW; Hattori, N; Mizuno, Y; Tanaka, K; Paik, SR; Kim, J; Chung, KC				Kim, SJ; Sung, JY; Um, JW; Hattori, N; Mizuno, Y; Tanaka, K; Paik, SR; Kim, J; Chung, KC			Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; A-BETA COMPONENT; O-GLYCOSYLATION; HUMAN BRAIN; CELL-DEATH; DISEASE; GENE; EXPRESSION; MUTATIONS; SUBSTRATE	Mutations in the alpha-synuclein and parkin genes cause heritable forms of Parkinson's disease. In the present study, we examined the possible functional relationship between the parkin and alpha-synuclein genes in a conditionally immortalized embryonic hippocampal cell (H19-7) line. Whereas transient transfection of alpha-synuclein into neuronal H19-7 cells caused the formation of its intracytoplasmic inclusions and a significant cell death, the combined overexpression of parkin restored the alpha-synuclein-induced decrease in cell viability to control levels. In addition, the overexpression of parkin was found to generate selective cleavage of alpha-synuclein. Furthermore, the cytoprotective effect of parkin on alpha-synuclein-induced cell death was not inhibited in the presence of a proteasome inhibitor. Interestingly, the overexpression of parkin induced the activation of an intracellular cysteine protease, calpain, but not caspase, and the cytoprotective effect of parkin on alpha-synuclein cytotoxicity was significantly inhibited by the presence of calpain-specific inhibitors. In conclusion, our results suggest that parkin accelerates the degradation of alpha-synuclein via the activation of the nonproteasomal protease, calpain, leading to the prevention of alpha-synuclein-induced cell death in embryonic hippocampal progenitor cells.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Med Sci, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seoul 120749, South Korea; Inha Univ, Coll Med, Dept Biochem, Inchon 402751, South Korea; Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1138421, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Inha University; Juntendo University; Tokyo Metropolitan Institute of Medical Science	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr						Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; Chung KC, 1999, J NEUROCHEM, V72, P1482, DOI 10.1046/j.1471-4159.1999.721482.x; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; D'Agata V, 2000, MOL BRAIN RES, V75, P345, DOI 10.1016/S0169-328X(99)00286-7; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Gasser T, 2001, ADV NEUROL, V86, P23; Giasson BI, 2001, NEURON, V31, P885, DOI 10.1016/S0896-6273(01)00439-1; GOLBE LI, 1990, NEUROLOGY, V40, P7; Hattori N, 2000, NEUROPATHOLOGY, V20, pS85; Hirsch EC, 1997, J NEURAL TRANSM-SUPP, P79; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Munoz E, 1997, NEUROSCI LETT, V235, P57, DOI 10.1016/S0304-3940(97)00710-6; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Peng XR, 2002, MOL CELL BIOL, V22, P378, DOI 10.1128/MCB.22.1.378-387.2002; Pink JJ, 2000, EXP CELL RES, V255, P144, DOI 10.1006/excr.1999.4790; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rosser BG, 2000, METH MOL B, V144, P245; Saito M, 2000, BRAIN DEV-JPN, V22, pS115; SAITO Y, 1994, FEBS LETT, V353, P327, DOI 10.1016/0014-5793(94)01075-7; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shaw P, 1996, ONCOGENE, V12, P921; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sung JY, 2001, J BIOL CHEM, V276, P27441, DOI 10.1074/jbc.M101318200; Tamada Y, 2000, BIOCHEM BIOPH RES CO, V275, P300, DOI 10.1006/bbrc.2000.3298; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	48	58	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41890	41899		10.1074/jbc.M306017200	http://dx.doi.org/10.1074/jbc.M306017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917442	hybrid			2022-12-27	WOS:000185989500042
J	Pastore, A; Tozzi, G; Gaeta, LM; Bertini, E; Serafini, V; Di Cesare, S; Bonetto, V; Casoni, F; Carrozzo, R; Federici, G; Piemonte, F				Pastore, A; Tozzi, G; Gaeta, LM; Bertini, E; Serafini, V; Di Cesare, S; Bonetto, V; Casoni, F; Carrozzo, R; Federici, G; Piemonte, F			Actin glutathionylation increases in fibroblasts of patients with Friedreich's ataxia - A potential role in the pathogenesis of the disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN DNA-BINDING; OXIDATIVE STRESS; S-THIOLATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; MOLECULAR PATHOGENESIS; OXIDIZED GLUTATHIONE; RESPIRATORY BURST; MITOCHONDRIAL; IDENTIFICATION; PROTEINS	Increasing evidence suggests that iron-mediated oxidative stress might underlie the development of neurodegeneration in Friedreich's ataxia (FRDA), an autosomal recessive ataxia caused by decreased expression of frataxin, a protein implicated in iron metabolism. In this study, we demonstrate that, in fibroblasts of patients with FRDA, the cellular redox equilibrium is shifted toward more protein-bound glutathione. Furthermore, we found that actin is glutathionylated, probably as a result of the accumulation of reactive oxygen species, generated by iron overload in the disease. Indeed, high-pressure liquid chromatography analysis of control fibroblasts in vivo treated with FeSO4 showed a significant increase in the protein-bound/free GSH ratio, and Western blot analysis indicated a relevant rise in glutathionylation. Actin glutathionylation contributes to impaired microfilament organization in FRDA fibroblasts. Rhodamine phalloidin staining revealed a disarray of actin filaments and a reduced signal of F-actin fluorescence. The same hematoxylin/eosin-stained cells showed abnormalities in size and shape. When we treated FRDA fibroblasts with reduced glutathione, we obtained a complete rescue of cytoskeletal abnormalities and cell viability. Thus, we conclude that oxidative stress may induce actin glutathionylation and impairment of cytoskeletal functions in FRDA fibroblasts.	Childrens Hosp & Res Inst Bambino Gesu, Mol Med Unit, I-00165 Rome, Italy; Childrens Hosp & Res Inst Bambino Gesu, Flow Cytometr Unit, I-00165 Rome, Italy; Childrens Hosp & Res Inst Bambino Gesu, Biochem Lab, I-00165 Rome, Italy; Mario Negri Inst Pharmacol Res, Dulbecco Telethon Inst, I-20157 Milan, Italy	IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Piemonte, F (corresponding author), Childrens Hosp & Res Inst Bambino Gesu, Mol Med Unit, Piazza S Onofrio 4, I-00165 Rome, Italy.	piemonte@opbg.net	Pastore, Anna/J-8409-2014; Bonetto, Valentina/ABB-6383-2020; Piemonte, Fiorella/A-2809-2014; Bonetto, Valentina/I-4694-2018; Tozzi, Giulia/K-8605-2018; Carrozzo, Rosalba/A-2808-2014; Casoni, Filippo/AAN-8298-2020; DI CESARE, SILVIA/AAB-5754-2020; Casoni, Filippo/E-7531-2010; Bertini, Enrico/ABG-1278-2020; Bertini, Enrico/A-2284-2014; Tozzi, Giulia/ABB-3829-2021	Pastore, Anna/0000-0002-0990-9419; Bonetto, Valentina/0000-0003-0456-2054; Piemonte, Fiorella/0000-0003-1825-9347; Bonetto, Valentina/0000-0003-0456-2054; Carrozzo, Rosalba/0000-0002-3327-4054; Casoni, Filippo/0000-0002-1172-8377; DI CESARE, SILVIA/0000-0002-9912-7997; Bertini, Enrico/0000-0001-9276-4590; Tozzi, Giulia/0000-0002-1745-2797	Telethon [TCP01010] Funding Source: Medline	Telethon(Fondazione Telethon)		Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; BRANDWEIN HJ, 1981, J BIOL CHEM, V256, P2958; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2529, DOI 10.1016/0006-2952(83)90014-X; CAPPEL RE, 1989, J BIOL CHEM, V264, P9180; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Dalle-Donne I, 2000, J MUSCLE RES CELL M, V21, P171, DOI 10.1023/A:1005671319604; Dalle-Donne I, 2003, FREE RADICAL BIO MED, V34, P23, DOI 10.1016/S0891-5849(02)01182-6; Delatycki MB, 1999, ANN NEUROL, V45, P673, DOI 10.1002/1531-8249(199905)45:5<673::AID-ANA20>3.3.CO;2-H; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Emond M, 2000, NEUROLOGY, V55, P1752, DOI 10.1212/WNL.55.11.1752; ERNEST MJ, 1974, J BIOL CHEM, V249, P5011; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; HOUSSE AO, 2002, HEART LOND, V87, P346; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Knight SAB, 1999, AM J HUM GENET, V64, P365, DOI 10.1086/302270; Lamarche J., 1993, HDB CEREBELLAR DIS, P453; Lerman-Sagie T, 2001, J INHERIT METAB DIS, V24, P28, DOI 10.1023/A:1005642302316; Lodi R, 2001, ANN NEUROL, V49, P590; NAKASHIMA K, 1970, Archives of Biochemistry and Biophysics, V141, P579, DOI 10.1016/0003-9861(70)90177-3; Pandolfo M, 1999, ARCH NEUROL-CHICAGO, V56, P1201, DOI 10.1001/archneur.56.10.1201; Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6; Pastore A, 2001, CLIN CHEM, V47, P1467; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Piemonte F, 2001, EUR J CLIN INVEST, V31, P1007, DOI 10.1046/j.1365-2362.2001.00922.x; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; Reddy S, 2000, BIOCHEM J, V347, P821, DOI 10.1042/0264-6021:3470821; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SILVA CM, 1989, J BIOL CHEM, V264, P6638; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; STOURNARAS C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P86, DOI 10.1016/0167-4838(90)90105-O; Tozzi G, 2002, ARCH DIS CHILD, V86, P376, DOI 10.1136/adc.86.5.376; Tsapara A, 1999, FEBS LETT, V455, P117, DOI 10.1016/S0014-5793(99)00848-0; Vorgerd M, 2000, NEUROMUSCULAR DISORD, V10, P430, DOI 10.1016/S0960-8966(00)00108-5; WALVOGEL D, 1999, ANN NEUROL, V46, P123; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425	57	130	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42588	42595		10.1074/jbc.M301872200	http://dx.doi.org/10.1074/jbc.M301872200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12915401	hybrid			2022-12-27	WOS:000185989500124
J	Westman, BJ; Perdomo, J; Sunde, M; Crossley, M; Mackay, JP				Westman, BJ; Perdomo, J; Sunde, M; Crossley, M; Mackay, JP			The C-terminal domain of Eos forms a high order complex in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; IKAROS FAMILY; CENTROMERIC HETEROCHROMATIN; LYMPHOCYTE DEVELOPMENT; GENE-EXPRESSION; ZINC FINGERS; DIMERIZATION; HOMEOSTASIS	Ikaros family transcription factors play important roles in the control of hematopoiesis. Family members are predicted to contain up to six classic zinc fingers that are arranged into N- and C-terminal domains. The N- terminal domain is responsible for site-specific DNA binding, whereas the C-terminal domain primarily mediates the homo- and hetero-oligomerization between family members. Although the mechanisms of action of these proteins are not completely understood, the zinc finger domains are known to play a central role. In the current study, we have sought to understand the physical and functional properties of these domains, in particular the C-terminal domain. We show that the N- terminal domain from Eos, and not its C-terminal region, is required to recognize GGGA consensus sequences. Surprisingly, in contrast to the behavior exhibited by Ikaros, the C-terminal domain of Eos inhibits the DNA-binding activity of the full-length protein. In addition, we have used a range of biophysical techniques to demonstrate that the C-terminal domain of Eos mediates the formation of complexes that consist of nine or ten molecules. These results constitute the first direct demonstration that Ikaros family proteins can form higher order complexes in solution, and we discuss this unexpected result in the context of what is currently known about the family members and their possible mechanism of action.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Sydney	Mackay, JP (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia.		Crossley, Merlin/D-7888-2011; Sunde, Margaret/ABH-2584-2020; Sunde, Margaret/A-5186-2016; Perdomo, Jose/H-8871-2019; Mackay, Joel/D-6834-2011	Crossley, Merlin/0000-0003-2057-3642; Sunde, Margaret/0000-0002-0150-3203; Sunde, Margaret/0000-0002-0150-3203; Perdomo, Jose/0000-0002-1554-708X; Mackay, Joel/0000-0001-7508-8033				Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Casimiro DR, 1997, STRUCTURE, V5, P1407, DOI 10.1016/S0969-2126(97)00291-8; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Dixon MP, 2002, J BIOL CHEM, V277, P23186, DOI 10.1074/jbc.M112184200; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; Garmendia J, 2000, MICROBIOL-SGM, V146, P2555, DOI 10.1099/00221287-146-10-2555; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; Hayes D. B., 1995, SEDNTERP; Hernandez JA, 2002, BIOCHEM J, V366, P315, DOI 10.1042/BJ20020135; Honma Y, 1999, FEBS LETT, V447, P76, DOI 10.1016/S0014-5793(99)00265-3; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Koipally J, 2002, J BIOL CHEM, V277, P27697, DOI 10.1074/jbc.M201694200; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; Leonhartsberger S, 2000, EUR J BIOCHEM, V267, P3672, DOI 10.1046/j.1432-1327.2000.01399.x; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Momeni P, 2000, NAT GENET, V24, P71, DOI 10.1038/71717; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Nakayama H, 1999, CANCER RES, V59, P3931; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Nichogiannopoulou A, 1998, SEMIN IMMUNOL, V10, P119, DOI 10.1006/smim.1998.0113; Perdomo J, 2000, J BIOL CHEM, V275, P38347, DOI 10.1074/jbc.M005457200; Perdomo J, 2002, EUR J BIOCHEM, V269, P5885, DOI 10.1046/j.1432-1033.2002.03313.x; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Sambrook J., 2002, MOL CLONING LAB MANU; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658	43	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42419	42426		10.1074/jbc.M306817200	http://dx.doi.org/10.1074/jbc.M306817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917396	hybrid			2022-12-27	WOS:000185989500105
J	Huh, YH; Jeon, SH; Yoo, SH				Huh, YH; Jeon, SH; Yoo, SH			Chromogranin B-induced secretory granule biogenesis - Comparison with the similar role of chromogranin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; VESICLE MEMBRANE-BINDING; SECRETOGRANIN-II; MESSENGER-RNA; CDNA SEQUENCE; CONFORMATIONAL-CHANGE; POTENTIAL ROLE; PC12 CELLS; PH; AGGREGATION	The two major proteins of secretory granules of secretory cells, chromogranins A (CGA) and B (CGB), have previously been proposed to play key roles in secretory granule biogenesis. Recently, CGA was reported to play an on/off switch role for secretory granule biogenesis. In the present study we found CGB being more effective than CGA in inducing secretory granule formation in non-neuroendocrine NIH3T3 and COS-7 cells. The mean number of dense core granules formed/cell of CGA-transfected NIH3T3 cells was 2.51, whereas that of CGB-transfected cells was 4.02, indicating the formation of 60% more granules in the CGB-transfected cells. Similarly, there were 55% more dense core granules formed in the CGB-transfected COS-7 cells than in the CGA-transfected cells. Moreover, transfection of CGA- and CGB-short interfering RNA ( siRNA) into neuroendocrine PC12 cells not only decreased the amount of CGA and CGB expressed but also reduced the number of secretory granules by 41 and 78%, respectively, further suggesting the importance of CGB expression in secretory granule formation.	Inha Univ, Coll Med, Natl Creat Res Initiat Ctr Secretory Granule Res, Inchon 400712, South Korea; Inha Univ, Coll Med, Dept Biochem, Inchon 400712, South Korea	Inha University; Inha University	Yoo, SH (corresponding author), Inha Univ, Coll Med, Natl Creat Res Initiat Ctr Secretory Granule Res, Inchon 400712, South Korea.							AHN TG, 1987, P NATL ACAD SCI USA, V84, P5043, DOI 10.1073/pnas.84.14.5043; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; DAY R, 1995, DNA CELL BIOL, V14, P175, DOI 10.1089/dna.1995.14.175; FISCHERCOLBRIE R, 1990, J BIOL CHEM, V265, P9208; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GERDES HH, 1988, NUCLEIC ACIDS RES, V16, P11811, DOI 10.1093/nar/16.24.11811; GORR SU, 1989, AM J PHYSIOL, V257, P247; Grundschober C, 2002, J BIOL CHEM, V277, P36715, DOI 10.1074/jbc.M203777200; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; Hosaka M, 2002, MOL BIOL CELL, V13, P3388, DOI 10.1091/mbc.02-03-0040; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LINARD CG, 1990, NUCLEIC ACIDS RES, V18, P1298, DOI 10.1093/nar/18.5.1298; Murphy SM, 1998, J HISTOCHEM CYTOCHEM, V46, P1261, DOI 10.1177/002215549804601106; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Park HY, 2002, BIOCHEMISTRY-US, V41, P1259, DOI 10.1021/bi0156963; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; POHL TM, 1990, FEBS LETT, V262, P219, DOI 10.1016/0014-5793(90)80194-N; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Watanabe T, 1998, ENDOCRINOLOGY, V139, P2765, DOI 10.1210/en.139.6.2765; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130; YOO SH, 1995, BIOCHEMISTRY-US, V34, P8680, DOI 10.1021/bi00027a017; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; YOO SH, 1990, J BIOL CHEM, V265, P14414; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Yoo SH, 2002, J BIOL CHEM, V277, P16011, DOI 10.1074/jbc.M105594200; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; Yoo SH, 2001, J BIOL CHEM, V276, P45806, DOI 10.1074/jbc.M107532200; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023	44	121	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40581	40589		10.1074/jbc.M304942200	http://dx.doi.org/10.1074/jbc.M304942200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902350	hybrid			2022-12-27	WOS:000185847200021
J	Lim, IJ; Phan, TT; Tan, EK; Nguyen, TTT; Tran, E; Longaker, MT; Song, C; Lee, ST; Huynh, HT				Lim, IJ; Phan, TT; Tan, EK; Nguyen, TTT; Tran, E; Longaker, MT; Song, C; Lee, ST; Huynh, HT			Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; HYPERTROPHIC SCARS; IN-VITRO; FIBROBLASTS; KERATINOCYTES; PROLIFERATION; BETA(1); CELLS; GENE; CONTRACTION	Keloid fibroproliferation appears to be influenced by epithelial-mesenchymal interactions between keloid keratinocytes (KKs) and keloid fibroblasts (KFs). Keloid and normal fibroblasts exhibit accelerated proliferation and collagen I and III production in co-culture with KKs compared with single cell culture or co-culture with normal keratinocytes. ERK and phosphatidylinositol 3-kinase (PI3K) pathway activation has been observed in excessively proliferating KFs in co-culture with KKs. We hypothesized that ERK and PI3K pathways might be involved in collagen and extracellular matrix production in KFs. To test our hypothesis, four samples of KFs were co-cultured in defined serum-free medium with KKs for 2-5 days. KF cell lysate was subjected to Western blot analysis. Compared with KF single cell culture, phospho-ERK1/2 and downstream phospho-Elk-1 showed up-regulation in the co-culture groups, as did phospho-PI3K and phospho-Akt-1, indicating ERK and PI3K pathway activation. Western blotting of the conditioned medium demonstrated increased collagen I-III, laminin beta2, and fibronectin levels. Addition of the MEK1/2-specific inhibitor U0126 or the PI3K-specific inhibitor LY294002 (but not p38 kinase and JNK inhibitors) completely nullified collagen I-III production and significantly decreased laminin beta2 and fibronectin secretion. In the presence of the MEK1/2 or PI3K inhibitor, fibronectin demonstrated changes in molecular mass reflected by faster in-gel migration. These data strongly suggest that synchronous activation of both the ERK and PI3K pathways is essential for collagen I - III and laminin beta2 production. These pathways additionally appear to affect the side chain attachments of fibronectin. Modulation of these pathways may suggest a direction for keloid therapy.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Natl Univ Singapore, Dept Surg, Singapore 119074, Singapore; Natl Univ Singapore, Dept Orthopaed Surg, Singapore 119074, Singapore; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Singapore Gen Hosp, Burns Ctr, Dept Plast Surg, Singapore 169608, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore; Stanford University; Singapore General Hospital	Huynh, HT (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore.	cmrhth@nccs.com.sg	Phan, Toan Thang/A-5527-2009					Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; Bayat A, 2003, PLAST RECONSTR SURG, V111, P535, DOI 10.1097/01.PRS.0000041536.02524.A3; BOYCE ST, 1994, J INVEST DERMATOL, V102, P8, DOI 10.1111/1523-1747.ep12371721; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chen H, 1998, CELL GROWTH DIFFER, V9, P939; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; COHEN IK, 1990, KELOIDS HYPERTROPHIC, P732; D'Addario M, 2002, J BIOL CHEM, V277, P47541, DOI 10.1074/jbc.M207681200; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; EHRLICH HP, 1994, AM J PATHOL, V145, P105; FUSENIG NE, 1994, KERATINOCYTE HDB, P71; Garner WL, 1998, PLAST RECONSTR SURG, V102, P135, DOI 10.1097/00006534-199807000-00021; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hirano S, 2002, J SURG RES, V102, P77, DOI 10.1006/jsre.2001.6315; Ivarsson M, 1998, MATRIX BIOL, V16, P409, DOI 10.1016/S0945-053X(98)90014-2; Katz AB, 1999, J INVEST DERMATOL, V112, P818, DOI 10.1046/j.1523-1747.1999.00572.x; Lim IJ, 2002, AM J PHYSIOL-CELL PH, V283, pC212, DOI 10.1152/ajpcell.00555.2001; Lim IJ, 2001, PLAST RECONSTR SURG, V107, P797, DOI 10.1097/00006534-200103000-00022; Maas-Szabowski N, 1999, J CELL SCI, V112, P1843; MACKENZIE IC, 1994, KERATINOCYTE HDB, P243; Marneros AG, 2001, ARCH DERMATOL, V137, P1429; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Niessen FB, 1999, PLAST RECONSTR SURG, V104, P1435, DOI 10.1097/00006534-199910000-00031; NODA M, 1989, CONNECT TISSUE RES, V21, P401, DOI 10.3109/03008208909049997; Omo-Dare P, 1975, J Natl Med Assoc, V67, P428; Palcy S, 1999, BIOCHEM J, V343, P21, DOI 10.1042/0264-6021:3430021; Phan TT, 2003, AM J PHYSIOL-CELL PH, V284, pC860, DOI 10.1152/ajpcell.00350.2002; Ricupero DA, 2001, AM J PHYSIOL-CELL PH, V281, pC99, DOI 10.1152/ajpcell.2001.281.1.C99; ROCKWELL WB, 1989, PLAST RECONSTR SURG, V84, P827, DOI 10.1097/00006534-198911000-00021; Sato M, 2002, J INVEST DERMATOL, V118, P704, DOI 10.1046/j.1523-1747.2002.01719.x; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130, DOI 10.1053/jhep.2001.23788; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Urioste SS, 1999, SEMIN CUTAN MED SURG, V18, P159, DOI 10.1016/S1085-5629(99)80040-6; Xue H, 2000, J SURG RES, V89, P74, DOI 10.1006/jsre.1999.5805	38	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40851	40858		10.1074/jbc.M305759200	http://dx.doi.org/10.1074/jbc.M305759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907681	hybrid			2022-12-27	WOS:000185847200054
J	Zouzoulas, A; Therien, AG; Scanzano, R; Deber, CM; Blostein, R				Zouzoulas, A; Therien, AG; Scanzano, R; Deber, CM; Blostein, R			Modulation of Na,K-ATPase by the gamma subunit - Studies with transfected cells and transmembrane mimetic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SODIUM-PUMP; FUNCTIONAL-ROLE; ION-TRANSPORT; EXPRESSION; FAMILY; OLIGOMERIZATION; IDENTIFICATION; ACTIVATION; POTASSIUM	The enzymatic activity of the Na,K-ATPase, or sodium pump, is modulated by members of the so- called FXYD family of transmembrane proteins. The best characterized member, FXYD2, also referred to as the gamma subunit, has been shown to decrease the apparent Na+ affinity and increase the apparent ATP affinity of the pump. The effect on ATP affinity had been ascribed to the cytoplasmic C-terminal end of the protein, whereas recent observations suggest that the transmembrane (TM) segment of gamma mediates the Na+ affinity effect. Here we use a novel approach involving synthetic transmembrane mimetic peptides to demonstrate unequivocally that the TM domain of gamma effects the shift in apparent Na+ affinity. Specifically, we show that incubation of these peptides with membranes containing alphabeta pumps modulates Na+ affinity in a manner similar to transfected full-length gamma subunit. Using mutated gamma peptides and transfected proteins, we also show that a specific glycine residue, Gly-41, which is associated with a form of familial renal hypomagnesemia when mutated to Arg, is important for this kinetic effect, whereas Gly-35, located on an alternate face of the transmembrane helix, is not. The peptide approach allows for the analysis of mutants that fail to be expressed in a transfected system.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Blostein, R (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada.	rhoda.blostein@mcgill.ca	Therien, Alex/AAS-8437-2021					Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Partridge AW, 2003, J BIOL CHEM, V278, P22056, DOI 10.1074/jbc.M210685200; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SACHS JR, 1986, J PHYSIOL-LONDON, V374, P221, DOI 10.1113/jphysiol.1986.sp016076; Scheiner-Bobis G, 2002, EUR J BIOCHEM, V269, P2424, DOI 10.1046/j.1432-1033.2002.02909.x; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Tarasova NI, 1999, J BIOL CHEM, V274, P34911, DOI 10.1074/jbc.274.49.34911; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2002, J MOL BIOL, V322, P583, DOI 10.1016/S0022-2836(02)00781-7; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Xie HB, 2000, BIOCHEMISTRY-US, V39, P15462, DOI 10.1021/bi001432p	29	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40437	40441		10.1074/jbc.M308610200	http://dx.doi.org/10.1074/jbc.M308610200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907667	hybrid			2022-12-27	WOS:000185847200004
J	Lee, M; Hwang, JT; Lee, HJ; Jung, SN; Kang, IS; Chi, SG; Kim, SS; Ha, JH				Lee, M; Hwang, JT; Lee, HJ; Jung, SN; Kang, IS; Chi, SG; Kim, SS; Ha, JH			RETRACTED: AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells (Retracted article. See vol. 293, pg. 18013, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							ACETYL-COA CARBOXYLASE; FACTOR 1-ALPHA HIF-1-ALPHA; GLUCOSE-TRANSPORT; O-2 HOMEOSTASIS; NITRIC-OXIDE; FATTY-ACID; HIF-ALPHA; PHOSPHORYLATION; PATHWAY; STABILIZATION	AMP-activated protein kinase ( AMPK) functions as an energy sensor to provide metabolic adaptations under the ATP-deprived conditions such as hypoxia. In the present study, we considered a role of AMPK in the adaptive response to hypoxia by examining whether AMPK is involved in the regulation of hypoxia-inducible factor-1 (HIF-1), a heterodimeric transcription factor that is critical for hypoxic induction of physiologically important genes. We demonstrate that hypoxia or CoCl2 rapidly activated AMPK in DU145 human prostate cancer cells, and its activation preceded the induction of HIF-1alpha expression. Under these conditions, blockade of AMPK activity by a pharmacological or molecular approach significantly attenuated hypoxia-induced responses such as HIF-1 target gene expression, secretion of vascular endothelial growth factor, glucose uptake, and HIF-1-dependent reporter gene expression, indicating that AMPK is critical for the HIF-1 transcriptional activity and its target gene expression. Its functional requirement for HIF-1 activity was also demonstrated in several different cancer cell lines, but AMPK activation alone was not sufficient to stimulate the HIF-1 transcriptional activity. We further present data showing that AMPK transmits a positive signal for HIF-1 activity via a signaling pathway that is independent of phosphatidylinositol 3-kinase/AKT and several mitogen-activated protein kinases. Taken together, our results suggest that AMPK is a novel and critical component of HIF-1 regulation, implying its new roles in oxygen-regulated cellular phenomena.	Kyung Hee Univ, Coll Med, Dept Mol Biol, Seoul 130701, South Korea; Kyung Hee Univ, Coll Med, Dept Biochem, Seoul 130701, South Korea; Kyung Hee Univ, Coll Med, Dept Pathol, Med Res Ctr Bioreact React Oxygen Species, Seoul 130701, South Korea; Dong A Univ, Dept Pharmacol, Med Res Ctr Canc Mol Therapy, Pusan 602103, South Korea	Kyung Hee University; Kyung Hee University; Kyung Hee University; Dong A University	Ha, JH (corresponding author), Kyung Hee Univ, Coll Med, Dept Mol Biol, Hoegi Dong 1, Seoul 130701, South Korea.	hajh@khu.ac.kr	Kim, Sung Soo/S-2540-2017	Kim, Sung Soo/0000-0002-6817-7668				Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HA J, 1994, J BIOL CHEM, V269, P22162; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Leff T, 2003, BIOCHEM SOC T, V31, P224; Lopez JM, 2003, BIOCHEM J, V370, P1027, DOI 10.1042/BJ20021053; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; Mazure NM, 2003, CURR PHARM DESIGN, V9, P531, DOI 10.2174/1381612033391469; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Peralta C, 2001, HEPATOLOGY, V34, P1164, DOI 10.1053/jhep.2001.29197; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sambandam N, 2003, PROG LIPID RES, V42, P238, DOI 10.1016/S0163-7827(02)00065-6; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	59	215	225	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39653	39661		10.1074/jbc.M306104200	http://dx.doi.org/10.1074/jbc.M306104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900407	hybrid			2022-12-27	WOS:000185713800050
J	Yang, SZ; Abdulkadir, SA				Yang, SZ; Abdulkadir, SA			Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGR1 TARGET GENES; CANCER CELLS; EXPRESSION; TRANSCRIPTION; ACTIVATION; MECHANISM; ENCODES; PROTEIN; MOUSE; IDENTIFICATION	The transcription factor early growth response gene 1 (EGR1) has been implicated in diverse roles in the regulation of cell growth, apoptosis, and differentiation. Previous studies suggest that the effects of EGR1 on tumorigenesis are critically dependent on the cellular context. In a majority of prostate cancers, EGR1 is overexpressed and promotes prostate tumor progression. In contrast, in other tumor types such as breast cancers and glioblastomas, EGR1 is expressed at low levels and when overexpressed can inhibit tumor growth. To explore the role of EGR1 in prostate tumorigenesis, we examined the impact of EGR1 expression on the androgen receptor (AR) signaling pathway. We show here that EGR1 binds to the AR in prostate carcinoma cells, and an EGR1-AR complex can be detected by chromatin immunoprecipitation at the enhancer of an endogenous AR target gene. Overexpression of EGR1 enhanced AR-mediated transactivation, whereas EGR1 knockdown by small interfering RNA inhibited AR signaling pathway activity. Furthermore, Western blot and immunocytochemical analyses showed that constitutive overexpression of EGR1 promotes the translocation of AR from the cytoplasm to the nucleus. These results indicate that EGR1 may promote prostate cancer development by modulating the androgen receptor signaling pathway.	Univ Alabama, Sch Med, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Abdulkadir, SA (corresponding author), Univ Alabama, Sch Med, Dept Pathol, 701 19th St S, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [F32CA007901] Funding Source: NIH RePORTER; NCI NIH HHS [CA7901] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Calogero A, 2001, CLIN CANCER RES, V7, P2788; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1995, EUR UROL, V27, P45; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eid MA, 1998, CANCER RES, V58, P2461; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Gregory CW, 2001, CANCER RES, V61, P4315; Hobisch A, 1998, CANCER RES, V58, P4640; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; LEVIN WJ, 1995, ONCOGENE, V11, P1261; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200	30	52	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39906	39911		10.1074/jbc.M307250200	http://dx.doi.org/10.1074/jbc.M307250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890669	hybrid			2022-12-27	WOS:000185713800078
J	Kunji, ERS; Harding, M				Kunji, ERS; Harding, M			Projection structure of the atractyloside-inhibited mitochondrial ADP/ATP carrier of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; ESCHERICHIA-COLI; UNCOUPLING PROTEIN; ANGSTROM RESOLUTION; MEMBRANE; TRANSPORTER; TRANSLOCATION; ARCHITECTURE; RHODOPSIN; CRYSTALS	carriers in the inner mitochondrial membrane catalyze the exchange of cytosolic ADP for ATP synthesized in the mitochondrial matrix by ATP synthase and thereby replenish the eukaryotic cell with metabolic energy. The yeast ADP/ATP carrier (AAC3) was overexpressed, inhibited by atractyloside, purified, and reconstituted into two-dimensional crystals. Images of frozen hydrated crystals were recorded by electron microscopy, and a projection structure was calculated to 8-Angstrom resolution. The AAC3 molecule has pseudo 3-fold symmetry in agreement with the 3-fold sequence repeats that are typical of members of the mitochondrial carrier family. The density distribution is consistent with a bundle of six transmembrane alpha-helices with two or three short alpha-helical extensions closing the central pore on the matrix side. The AAC3 molecules in the crystal are arranged in symmetrical homo-dimers, but the translocation pore for adenine nucleotides lies in the center of the molecule and not along the dyad axis of the dimer.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Kunji, ERS (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Kunji, Edmund/AAH-2362-2020	Kunji, Edmund/0000-0002-0610-4500	MRC [MC_U105663139] Funding Source: UKRI; Medical Research Council [MC_U105663139] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; Bisaccia F, 1996, BBA-PROTEIN STRUCT M, V1292, P281, DOI 10.1016/0167-4838(95)00215-4; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; Hacksell I, 2002, EMBO J, V21, P3569, DOI 10.1093/emboj/cdf378; Hatanaka T, 1999, BIOCHEM BIOPH RES CO, V262, P726, DOI 10.1006/bbrc.1999.1283; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; Huang SG, 2001, ARCH BIOCHEM BIOPHYS, V394, P67, DOI 10.1006/abbi.2001.2520; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; Kotaria R, 1999, J BIOENERG BIOMEMBR, V31, P543, DOI 10.1023/A:1005460810527; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; Kunji ERS, 2001, J MOL BIOL, V308, P279, DOI 10.1006/jmbi.2001.4565; LIN CS, 1980, FEBS LETT, V113, P304, DOI 10.1016/0014-5793(80)80614-4; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Majima E, 1998, BIOCHEMISTRY-US, V37, P424, DOI 10.1021/bi9710683; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MIROUX B, 1993, EMBO J, V12, P3739, DOI 10.1002/j.1460-2075.1993.tb06051.x; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHOERS A, 1998, J BIOL CHEM, V273, P14269; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Trezeguet V, 2000, BBA-BIOENERGETICS, V1457, P81, DOI 10.1016/S0005-2728(99)00115-2; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; van der Giezen M, 2002, EMBO J, V21, P572, DOI 10.1093/emboj/21.4.572; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558	33	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36985	36988		10.1074/jbc.C300304200	http://dx.doi.org/10.1074/jbc.C300304200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12893834	hybrid			2022-12-27	WOS:000185437200002
J	Nakamura, K; Johnson, GL				Nakamura, K; Johnson, GL			PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL-GROWTH-FACTOR; N-TERMINAL KINASE; NADPH OXIDASE; SIGNALING PATHWAY; GENE-EXPRESSION; MAST-CELLS; PC MOTIF; 1 BMK1; P62	MEKK2 and MEKK3 are MAPK kinase kinases that activate the ERK5 pathway by phosphorylating and activating the MAPK kinase, MEK5. Activated MEK5 then phosphorylates and activates ERK5. PB1 domains were first defined in the p67(phox) and Bem1p proteins and have been shown to mediate protein-protein heterodimerization. A PB1 domain is encoded within the N-terminal portion of MEKK2, MEKK3, and MEK5. Herein, we analyze the functional role of MEKK2, MEKK3, and MEK5 PB1 domains in the ERK5 activation pathway. The PB1 domains of MEKK2 and MEKK3 bind the PB1 domain of MEK5 but do not significantly homo- or heterodimerize with one another in vitro. Furthermore, co-immunoprecipitation of MEKK2 and MEK5 from cell lysates shows that they form a complex in vivo. Deletion or mutation of the MEKK2 PB1 domain abolishes MEKK2-MEK5 complexes, demonstrating that the PB1 domain interaction is required for MEKK2-MEK5 interactions. Expression in cells of the MEKK2 or MEKK3 PB1 domain inhibits ERK5 activation, whereas expression of a mutant MEKK2 unable to bind the MEK5 PB1 domain or expression of the p67phox PB1 domain has no effect on ERK5 activation. These findings demonstrate that the PB1 domain mediates the association of MEKK2 and MEKK3 with MEK5 and that the respective PB1 domains of these kinases are critical for regulation of the ERK5 pathway. The free PB1 domain of MEKK2 or MEKK3 functions effectively to inhibit the ERK5 pathway but not the p38 or JNK pathways, demonstrating the specific and unique requirement of the MEKK2 and MEKK3 PB1 domain in regulating ERK5 activation.	Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Johnson, GL (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, 1108 Mary Ellen Jones Bldg,CB 7365, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068820] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM068820] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Geetha T, 2003, J BIOL CHEM, V278, P4730, DOI 10.1074/jbc.M208468200; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	26	68	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36989	36992		10.1074/jbc.C300313200	http://dx.doi.org/10.1074/jbc.C300313200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12912994	hybrid, Green Published			2022-12-27	WOS:000185437200003
J	Chesnel, L; Pernot, L; Lemaire, D; Champelovier, D; Croize, J; Dideberg, O; Vernet, T; Zapun, A				Chesnel, L; Pernot, L; Lemaire, D; Champelovier, D; Croize, J; Dideberg, O; Vernet, T; Zapun, A			The structural modifications induced by the M339F substitution in PBP2x from Streptococcus pneumoniae further decreases the susceptibility to beta-lactams of resistant strains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; CRYSTAL-STRUCTURE; ACTIVE-SITE; 2X; 2B; ANTIBIOTICS; MUTANTS; PROGRAM; DEACYLATION; KINETICS	PBP2x is a primary determinant of beta-lactams resistance in Streptococcus pneumoniae. Altered PBP2x with multiple mutations have a reduced "affinity" for the antibiotics. An important polymorphism is found in PBP2x sequences from clinical resistant strains. To understand the mechanism of resistance, it is necessary to identify and characterize the relevant substitutions. Many similar PBP2x sequences from resistant isolates have the previously studied T338A mutation, adjacent to the active site Ser(337). We report here the structural and functional analysis of the M339F substitution that is found in a subset of these sequences, originating from highly resistant strains. The M339F mutation causes a 4-10-fold reduction of the reaction rate with beta-lactams, depending on the molecular context. In addition, release of the inactivated antibiotic from the active site is up to 3-fold faster as a result from the M339F mutation. These effects measured in vitro are correlated with the level of beta-lactam resistance in vivo conferred by several PBP2x variants. Thus, a single amino acid difference between similar PBP2x from clinical isolates can strongly modulate the degree of beta-lactam resistance. The crystal structure of the double mutant T338A/M339F solved to a resolution of 2.4 Angstrom shows a distortion of the active site and a reorientation of the hydroxyl group of the active site Ser(337), which can explain the kinetic effects of the mutations.	UJF, CNRS,UMR 5075, CEA,Inst Biol Struct JP Ebel, Lab Ingn Macromol, F-38027 Grenoble, France; UJF, CNRS,UMR 5075, CEA,Inst Biol Struct JP Ebel, Lab Cristallog Macromol, F-38027 Grenoble, France; UJF, CNRS,UMR 5075, CEA,Inst Biol Struct JP Ebel, Lab Spectrometrie Masse Prot, F-38027 Grenoble, France; CHU Grenoble, Bacteriol Lab, F-38700 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Vernet, T (corresponding author), UJF, CNRS,UMR 5075, CEA,Inst Biol Struct JP Ebel, Lab Ingn Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	thierry.vernet@ibs.fr	Vernet, Thierry/G-1118-2012	chesnel, laurent/0000-0002-4947-5029; Lemaire, David/0000-0001-6874-3685; Zapun, Andre/0000-0001-8953-4399				APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; Asahi Y, 1999, ANTIMICROB AGENTS CH, V43, P1252, DOI 10.1128/AAC.43.5.1252; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beadle BM, 2002, J MOL BIOL, V321, P285, DOI 10.1016/S0022-2836(02)00599-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COFFEY TJ, 1995, ANTIMICROB AGENTS CH, V39, P1306, DOI 10.1128/AAC.39.6.1306; Dessen A, 2001, J BIOL CHEM, V276, P45106, DOI 10.1074/jbc.M107608200; Di Guilmi AM, 2000, ANAL BIOCHEM, V284, P240, DOI 10.1006/abio.2000.4735; Dowson Christopher G., 1994, Trends in Microbiology, V2, P361, DOI 10.1016/0966-842X(94)90612-2; Ferroni A, 2001, J MED MICROBIOL, V50, P828, DOI 10.1099/0022-1317-50-9-828; Filipe SR, 2002, P NATL ACAD SCI USA, V99, P1550, DOI 10.1073/pnas.032671699; Ghuysen Jean-Marie, 1994, Trends in Microbiology, V2, P372, DOI 10.1016/0966-842X(94)90614-9; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1986, BIOCHEM J, V235, P159, DOI 10.1042/bj2350159; Gordon E, 2000, J MOL BIOL, V299, P477, DOI 10.1006/jmbi.2000.3740; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; Hakenbeck R, 1999, MICROB DRUG RESIST, V5, P91, DOI 10.1089/mdr.1999.5.91; JAMIN M, 1993, BIOCHEM J, V292, P735, DOI 10.1042/bj2920735; JAMIN M, 1993, FEBS LETT, V331, P101, DOI 10.1016/0014-5793(93)80305-E; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauss J, 1996, MICROB DRUG RESIST, V2, P183, DOI 10.1089/mdr.1996.2.183; LAIBLE G, 1989, MOL MICROBIOL, V3, P1337, DOI 10.1111/j.1365-2958.1989.tb00115.x; LAIBLE G, 1987, MOL MICROBIOL, V1, P355; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGM, 2002, MOSFLM USER GUIDE MO; Lu WP, 2001, J BIOL CHEM, V276, P31494, DOI 10.1074/jbc.M102499200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; Mouz N, 1999, J BIOL CHEM, V274, P19175, DOI 10.1074/jbc.274.27.19175; MUNOZ R, 1992, MOL MICROBIOL, V6, P2461; Nagai K, 2002, ANTIMICROB AGENTS CH, V46, P1273, DOI 10.1128/AAC.46.5.1273-1280.2002; Sifaoui F, 1996, ANTIMICROB AGENTS CH, V40, P152, DOI 10.1128/AAC.40.1.152; Smith AM, 2001, ANTIMICROB AGENTS CH, V45, P2648, DOI 10.1128/AAC.45.9.2648-2650.2001; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; Zhao GS, 1997, J BACTERIOL, V179, P4901, DOI 10.1128/jb.179.15.4901-4908.1997	39	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44448	44456		10.1074/jbc.M305948200	http://dx.doi.org/10.1074/jbc.M305948200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923202	hybrid			2022-12-27	WOS:000186306700072
J	Polgar, J; Lane, WS; Chung, SH; Houng, AK; Reed, GL				Polgar, J; Lane, WS; Chung, SH; Houng, AK; Reed, GL			Phosphorylation of SNAP-23 in activated human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SYNAPTOSOME-ASSOCIATED PROTEIN; SYNAPTIC SNARE COMPLEX; MOLECULAR-MECHANISMS; GRANULE SECRETION; ALPHA-GRANULE; SYNTAXIN 4; ISOCITRATE DEHYDROGENASE; NEUROTRANSMITTER RELEASE; CRYSTAL-STRUCTURE	Phosphorylation of SNARE proteins may provide a critical link between cell activation and secretory processes. Platelets contain all three members of the SNAP23/25/29 gene family, but by comparison to brain tissue, SNAP-23 is the most highly enriched of these proteins in platelets. SNAP-23 function is required for exocytosis from platelet alpha, dense, and lysosomal granules. SNAP-23 was phosphorylated largely on serine residues in platelets activated with thrombin. Phosphorylation kinetics paralleled or preceded granule secretion. Inhibition studies suggested that SNAP-23 phosphorylation proceeds largely through a protein kinase C (PKC) mechanism and purified PKC directly phosphorylated recombinant (r-) SNAP-23 (up to 0.3 mol of phosphate/mol of protein). Five major tryptic phosphopeptides were identified in cellular SNAP-23 isolated from activated platelets; three phosphopeptides co-migrated with those identified in PKC-phosphorylated r-SNAP-23. In contrast, only one major phosphopeptide was identified when SNAP-23, engaged in a ternary SNARE complex, was phosphorylated by PKC. Ion trap mass spectrometry revealed that platelet SNAP-23 was phosphorylated at Ser(23)/Thr(24) and Ser(161), after cell activation by thrombin; these sites were also identified in PKC-phosphorylated r-SNAP-23. SNAP-23 mutants that mimic phosphorylation at Ser(23)/Thr(24) inhibited syntaxin 4 interactions, whereas a phosphorylation mutant of Ser(161) had only minor effects. Taken together these studies show that SNAP-23 is phosphorylated in platelets during cell activation through a PKC-related mechanism at two or more sites with kinetics that parallel or precede granule secretion. Because mutants that mimic SNAP-23 phosphorylation affect syntaxin 4 interactions, we hypothesize that SNAP-23 phosphorylation may be important for modulating SNARE-complex interactions during membrane trafficking and fusion.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 665 Huntington Ave, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064057] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64057] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Bernstein AM, 1999, BLOOD, V93, P571, DOI 10.1182/blood.V93.2.571.402k05_571_579; BROEKMAN MJ, 1992, METHOD ENZYMOL, V215, P21; Cabaniols JP, 1999, MOL BIOL CELL, V10, P4033, DOI 10.1091/mbc.10.12.4033; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DEAN AM, 1989, J BIOL CHEM, V264, P20482; Elzagallaai A, 2000, BLOOD, V95, P894, DOI 10.1182/blood.V95.3.894.003k15_894_902; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Feng D, 2002, BLOOD, V99, P4006, DOI 10.1182/blood.V99.11.4006; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Genoud S, 1999, J NEUROCHEM, V72, P1699, DOI 10.1046/j.1471-4159.1999.721699.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KNIGHT DE, 1993, METHOD ENZYMOL, V221, P123, DOI 10.1016/0076-6879(93)21012-W; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; MEISENHELDER J, 1999, CURRENT PROTOCOLS PR; MICHELSON AD, 1996, PRACT APPROACH SER, P111; NIELANDER HB, 1995, J NEUROCHEM, V65, P1712; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Polgar J, 2002, BLOOD, V100, P1081, DOI 10.1182/blood.V100.3.1081; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Reed GL, 2000, BLOOD, V96, P3334; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SEFTON BM, 1995, CURRENT PROTOCOLS MO; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200	49	71	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44369	44376		10.1074/jbc.M307864200	http://dx.doi.org/10.1074/jbc.M307864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930825	hybrid			2022-12-27	WOS:000186306700061
J	Baxa, U; Taylor, KL; Wall, JS; Simon, MN; Cheng, NQ; Wickner, RB; Steven, AC				Baxa, U; Taylor, KL; Wall, JS; Simon, MN; Cheng, NQ; Wickner, RB; Steven, AC			Architecture of Ure2p prion filaments - The N-terminal domains form a central core fiber	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; YEAST SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; PROTEIN DETERMINANT; PODOSPORA-ANSERINA; MASS ANALYSIS; IN-VITRO; SCRAPIE; GENE; ORGANIZATION	The [URE3] prion is an inactive, self-propagating, filamentous form of the Ure2 protein, a regulator of nitrogen catabolism in yeast. The N-terminal "prion" domain of Ure2p determines its in vivo prion properties and in vitro amyloid-forming ability. Here we determined the overall structures of Ure2p filaments and related polymers of the prion domain fused to other globular proteins. Protease digestion of 25-nm diameter Ure2p filaments trimmed them to 4-nm filaments, which mass spectrometry showed to be composed of prion domain fragments, primarily residues similar to1-70. Fusion protein filaments with diameters of 14-25 nm were also reduced to 4-nm filaments by proteolysis. The prion domain transforms from the most to the least protease-sensitive part upon filament formation in each case, implying that it undergoes a conformational change. Intact filaments imaged by cryo-electron microscopy or after vanadate staining by scanning transmission electron microscopy (STEM) revealed a central 4-nm core with attached globular appendages. STEM mass per unit length measurements of unstained filaments yielded 1 monomer per 0.45 nm in each case. These observations strongly support a unifying model whereby subunits in Ure2p filaments, as well as in fusion protein filaments, are connected by interactions between their prion domains, which form a 4-nm amyloid filament backbone, surrounded by the corresponding C-terminal moieties.	NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; Brookhaven Natl Labs, Dept Biol, Upton, NY 11973 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Energy (DOE); Brookhaven National Laboratory	Steven, AC (corresponding author), Bldg 50,Rm 1517,50 South Dr,MSC 8025, Bethesda, MD 20892 USA.	Alasdair_Steven@nih.gov		Baxa, Ulrich/0000-0002-7263-5078	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK024943] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balguerie A, 2003, EMBO J, V22, P2071, DOI 10.1093/emboj/cdg213; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Caffrey M, 2000, J BIOL CHEM, V275, P19877, DOI 10.1074/jbc.M001036200; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cerritelli ME, 1996, J MOL BIOL, V260, P767, DOI 10.1006/jmbi.1996.0436; Cheng N, 1999, J STRUCT BIOL, V127, P169, DOI 10.1006/jsbi.1999.4120; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Edskes HK, 2002, P NATL ACAD SCI USA, V99, P16384, DOI 10.1073/pnas.162349599; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; KIRKLAND EJ, 1998, ADV COMPUTING ELECT, P33; Komar AA, 1998, BIOL CHEM, V379, P1295; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; Liebman SW, 1999, J BIOL CHEM, V274, P1181, DOI 10.1074/jbc.274.3.1181; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Muller SA, 2001, MICRON, V32, P21, DOI 10.1016/S0968-4328(00)00022-6; Nazabal A, 2003, BIOCHEMISTRY-US, V42, P8852, DOI 10.1021/bi0344275; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Priola SA, 2001, ADV PROTEIN CHEM, V57, P1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Schlumpberger M, 2000, PROTEIN SCI, V9, P440; Speransky VV, 2001, J CELL BIOL, V153, P1327, DOI 10.1083/jcb.153.6.1327; Steinmetz MO, 1998, J MOL BIOL, V276, P1, DOI 10.1006/jmbi.1997.1529; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; TERAVANESYAN MD, 1994, GENETICS, V137, P671; THOMAS D, 1994, BIOL CELL, V80, P181, DOI 10.1016/0248-4900(94)90041-8; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Wall JS, 1998, METHOD CELL BIOL, V53, P139; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109	46	136	137	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43717	43727		10.1074/jbc.M306004200	http://dx.doi.org/10.1074/jbc.M306004200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917441	hybrid			2022-12-27	WOS:000186157000121
J	Blom, AM; Villoutreix, BO; Dahlback, B				Blom, AM; Villoutreix, BO; Dahlback, B			Mutations in alpha-chain of C4BP that selectively affect its factor I cofactor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4B-BINDING PROTEIN; HUMAN FACTOR-H; COMPLEMENT REGULATORY DOMAINS; CONFORMATIONAL-CHANGES; C3B INACTIVATOR; STRUCTURAL REQUIREMENTS; NEISSERIA-GONORRHOEAE; C3B/C4B RECEPTOR; SERUM RESISTANCE; BINDING-PROTEIN	C4b-binding protein (C4BP) inhibits all pathways of complement activation, acting as a cofactor to the serine protease factor I (FI) in the degradation of activated complement factors C4b and C3b. C4BP is a disulfide-linked polymer of seven alpha-chains and a unique beta-chain, the alpha- and beta-chains being composed of eight and three complement control protein (CCP) domains, respectively. In previous studies we have localized cofactor activity and binding of C4b to alpha-chain CCP1-3 of C4BP, whereas the binding of C3b required additionally CCP4. Likewise, introduced point mutations that decreased binding of C4b/C3b caused a decrease in cofactor activity. In the present study, we describe two mutants of C4BP, K126Q/K128Q and F144S/F149S, clustered on alpha-chain CCP3, which selectively lost their ability to act as cofactors in the cleavage of both C4b and C3b. Both mutants show the same binding affinity for C4b/C3b as measured by surface plasmon resonance and have the same inhibitory effect on formation and decay of the classical pathway C3-convertase as the wild type C4BP. It appears that C4b and C3b do not undergo the same conformational changes upon binding to the C4BP mutants as during the interaction with the wild type C4BP, which then results in the observed loss of the cofactor activity.	Lund Univ, Dept Clin Chem, Malmo Univ Hosp, Wallenberg Lab, S-20502 Malmo, Sweden; Univ Paris 06, INSERM, U428, F-75006 Paris, France	Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Blom, AM (corresponding author), Lund Univ, Dept Clin Chem, Malmo Univ Hosp, Wallenberg Lab, Entrance 46,Floor 6, S-20502 Malmo, Sweden.		Blom, Anna/B-9607-2009; Villoutreix, Bruno/I-4565-2015; Blom, Anna/AFS-7369-2022	Blom, Anna/0000-0002-1348-1734; Villoutreix, Bruno/0000-0002-6456-7730; Dahlback, Bjorn/0000-0003-1546-0328				ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; Berggard K, 2001, EUR J IMMUNOL, V31, P2771, DOI 10.1002/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO;2-0; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Blom AM, 2001, J IMMUNOL, V166, P6764, DOI 10.4049/jimmunol.166.11.6764; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; COOPER NR, 1975, J EXP MED, V141, P890; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; EKDAHL KN, 1990, J IMMUNOL, V144, P4269; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; GORDON DL, 1995, J IMMUNOL, V155, P348; HESSING M, 1990, J IMMUNOL, V144, P204; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1983, J BIOL CHEM, V258, P4238; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Kask L, 2002, BIOCHEMISTRY-US, V41, P9349, DOI 10.1021/bi025980+; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; Oran AE, 1999, J BIOL CHEM, V274, P5120, DOI 10.1074/jbc.274.8.5120; Prasadarao NV, 2002, J IMMUNOL, V169, P6352, DOI 10.4049/jimmunol.169.11.6352; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; RUDDY S, 1971, J IMMUNOL, V107, P742; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; THERN A, 1995, J IMMUNOL, V154, P375; Villoutreix BO, 1998, PROTEINS, V31, P391, DOI 10.1002/(SICI)1097-0134(19980601)31:4<391::AID-PROT6>3.0.CO;2-L; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	44	27	27	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43437	43442		10.1074/jbc.M306620200	http://dx.doi.org/10.1074/jbc.M306620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12893820	hybrid			2022-12-27	WOS:000186157000088
J	Smyth, SS; Sciorra, VA; Sigal, YJ; Pamuklar, Z; Wang, ZC; Xu, Y; Prestwich, GD; Morris, AJ				Smyth, SS; Sciorra, VA; Sigal, YJ; Pamuklar, Z; Wang, ZC; Xu, Y; Prestwich, GD; Morris, AJ			Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets - Studies using chemical inhibitors of lipid phosphate phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATING GERM-CELLS; LYSOPHOSPHOLIPID RECEPTORS; IDENTIFICATION; ANALOGS; PHOSPHOHYDROLASES; CLONING; SURFACE; ISOFORM; GROWTH; WUNEN	Blood platelets play an essential role in ischemic heart disease and stroke contributing to acute thrombotic events by release of potent inflammatory agents within the vasculature. Lysophosphatidic acid (LPA) is a bioactive lipid mediator produced by platelets and found in the blood and atherosclerotic plaques. LPA receptors on platelets, leukocytes, endothelial cells, and smooth muscle cells regulate growth, differentiation, survival, motility, and contractile activity. Definition of the opposing pathways of synthesis and degradation that control extracellular LPA levels is critical to understanding how LPA bioactivity is regulated. We show that intact platelets and platelet membranes actively dephosphorylate LPA and identify the major enzyme responsible as lipid phosphate phosphatase 1 (LPP1). Localization of LPP1 to the platelet surface is increased by exposure to LPA. A novel receptor-inactive sn-3-substituted difluoromethylenephosphonate analog of phosphatidic acid that is a potent competitive inhibitor of LPP1 activity potentiates platelet aggregation and shape change responses to LPA and amplifies LPA production by agonist-stimulated platelets. Our results identify LPP1 as a pivotal regulator of LPA signaling in the cardiovascular system. These findings are consistent with genetic and cell biological evidence implicating LPPs as negative regulators of lysophospholipid signaling and suggest that the mechanisms involve both attenuation of lysophospholipid actions at cell surface receptors and opposition of lysophospholipid production.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA; Univ N Carolina, Dept Med, Div Cardiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; University of California System; University of California San Diego; Utah System of Higher Education; University of Utah; University of North Carolina; University of North Carolina Chapel Hill	Morris, AJ (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.		Morris, Andrew/B-7869-2010		NCI NIH HHS [CA12451, K22 CA124517] Funding Source: Medline; NHLBI NIH HHS [K08 HL070304, HL070304] Funding Source: Medline; NIDDK NIH HHS [R21 DK064183, DK064183] Funding Source: Medline; NIGMS NIH HHS [GM 50388, R01 GM050388] Funding Source: Medline; NINDS NIH HHS [R01 NS029632, NS029632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL070304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alderton F, 2001, J BIOL CHEM, V276, P13452, DOI 10.1074/jbc.M006582200; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; BROEKMAN MJ, 1992, METHOD ENZYMOL, V215, P21; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Humtsoe JO, 2003, EMBO J, V22, P1539, DOI 10.1093/emboj/cdg165; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; Luquain C, 2003, TRENDS BIOCHEM SCI, V28, P377, DOI 10.1016/S0968-0004(03)00139-7; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P289, DOI 10.1016/S1388-1981(02)00183-X; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Olorundare OE, 2001, BLOOD, V98, P117, DOI 10.1182/blood.V98.1.117; Pilquil C, 2001, PROSTAG OTH LIPID M, V64, P83, DOI 10.1016/S0090-6980(01)00101-0; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Roberts RZ, 2000, BBA-MOL CELL BIOL L, V1487, P33, DOI 10.1016/S1388-1981(00)00081-0; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Sciorra VA, 1999, MOL BIOL CELL, V10, P3863, DOI 10.1091/mbc.10.11.3863; Siess W, 2002, BBA-MOL CELL BIOL L, V1582, P204, DOI 10.1016/S1388-1981(02)00173-7; Starz-Gaiano M, 2001, DEVELOPMENT, V128, P983; Tanyi JL, 2003, CANCER RES, V63, P1073; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; TOKUMURA A, 1981, J PHARMACOL EXP THER, V219, P219; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xu J, 2000, J BIOL CHEM, V275, P27520; Xu Y, 2002, ORG LETT, V4, P4021, DOI 10.1021/ol026684s; Xu Y, 2002, J ORG CHEM, V67, P7158, DOI 10.1021/jo0203037; Yang AH, 2002, BBA-MOL CELL BIOL L, V1582, P197, DOI 10.1016/S1388-1981(02)00172-5; Zhang N, 2000, GENESIS, V27, P137, DOI 10.1002/1526-968X(200008)27:4<137::AID-GENE10>3.0.CO;2-4; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	41	63	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43214	43223		10.1074/jbc.M306709200	http://dx.doi.org/10.1074/jbc.M306709200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12909631	hybrid			2022-12-27	WOS:000186157000062
J	Vaz, FM; Houtkooper, RH; Valianpour, F; Barth, PG; Wanders, RJA				Vaz, FM; Houtkooper, RH; Valianpour, F; Barth, PG; Wanders, RJA			Only one splice variant of the human TAZ gene encodes a functional protein with a role in cardiolipin metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARDIOSKELETAL MYOPATHY; LEFT-VENTRICULAR NONCOMPACTION; N-TRIMETHYLLYSINE HYDROXYLASE; BARTH-SYNDROME; G4.5 GENE; SACCHAROMYCES-CEREVISIAE; CARNITINE BIOSYNTHESIS; ESSENTIAL REQUIREMENT; MUTATION; IDENTIFICATION	Barth syndrome (BTHS) is an X-linked recessive disorder caused by mutations in the TAZ gene and is characterized by cardiomyopathy, short stature, neutropenia, and 3-methylglutaconic aciduria. Recently it was found that BTHS patients exhibit a profound cardiolipin deficiency although the biosynthetic capacity to synthesize this lipid from its precursor phosphatidylglycerol is entirely normal. Like BTHS patients, a Saccharomyces cerevisiae strain, in which the yeast orthologue of the human TAZ gene has been disrupted, exhibits an abnormal cardiolipin profile as determined by tandem mass spectrometry. Additionally, this yeast strain grows poorly on non-fermentable carbon sources. We have used both properties of this yeast disruptant as a readout system to test the physiological functionality of each of 12 different splice variants that have been reported for the human TAZ gene. Our results demonstrate that only the splice variant lacking exon 5 was able to complement the retarded growth of the yeast disruptant on selective plates and restore the cardiolipin profile to the wild type pattern. We conclude that this splice variant most likely represents the only physiologically important mRNA, at least with regard to cardiolipin metabolism.	Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis F0 224, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pediat, Lab Genet Metab Dis F0 224, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Vaz, FM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis F0 224, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Houtkooper, Riekelt/P-5001-2019; Houtkooper, Riekelt H/E-1602-2011	Houtkooper, Riekelt H/0000-0001-9961-0842; Vaz, Frederic/0000-0002-9048-1041				Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936; BECKER D M, 1991, P182; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; BOLHUIS PA, 1991, AM J HUM GENET, V48, P481; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantlay AM, 1999, J PEDIATR-US, V135, P311, DOI 10.1016/S0022-3476(99)70126-5; Chen R, 2002, MOL GENET METAB, V77, P319, DOI 10.1016/S1096-7192(02)00195-6; DAdamo P, 1997, AM J HUM GENET, V61, P862, DOI 10.1086/514886; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANZUSOFF A, 1991, P662; Hatch GM, 1998, INT J MOL MED, V1, P33; Hogenboom S, 2002, J LIPID RES, V43, P90; Ichida F, 2001, CIRCULATION, V103, P1256; Johnston J, 1997, AM J HUM GENET, V61, P1053, DOI 10.1086/301604; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; Neuwald AF, 1997, CURR BIOL, V7, pR465; NOEL H, 1986, EUR J BIOCHEM, V155, P99, DOI 10.1111/j.1432-1033.1986.tb09463.x; Orstavik KH, 1998, AM J HUM GENET, V63, P1457, DOI 10.1086/302095; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; Sakamoto O, 2001, HUM GENET, V109, P559, DOI 10.1007/s00439-001-0612-3; Swiegers JH, 2002, FEMS MICROBIOL LETT, V210, P19, DOI 10.1016/S0378-1097(02)00520-7; Valianpour F, 2002, CLIN CHEM, V48, P1390; Vaz FM, 2001, J BIOL CHEM, V276, P33512, DOI 10.1074/jbc.M105929200; Vesel S, 2003, EUR J HUM GENET, V11, P97, DOI 10.1038/sj.ejhg.5200926; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C	28	113	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43089	43094		10.1074/jbc.M305956200	http://dx.doi.org/10.1074/jbc.M305956200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930833	hybrid			2022-12-27	WOS:000186157000047
J	von Roepenack-Lahaye, E; Newman, MA; Schornack, S; Hammond-Kosack, KE; Lahaye, T; Jones, JDG; Daniels, MJ; Dow, JM				von Roepenack-Lahaye, E; Newman, MA; Schornack, S; Hammond-Kosack, KE; Lahaye, T; Jones, JDG; Daniels, MJ; Dow, JM			p-coumaroylnoradrenaline, a novel plant metabolite implicated in tomato defense against pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; COA-TYRAMINE N-(HYDROXYCINNAMOYL)TRANSFERASE; WALL-BOUND PHENOLICS; DISEASE RESISTANCE; CLADOSPORIUM-FULVUM; HYDROXYCINNAMOYL-COA; SOLANUM-TUBEROSUM; NICOTIANA-TABACUM; GENE FAMILY; OPIUM POPPY	The Avr9 peptide elicitor from the fungus Cladosporium fulvum, the bacterial pathogen Pseudomonas syringae pathovar tomato carrying the avirulence gene avrPto (Pst (avrPto)), and the organophosphorous insecticide fenitrothion induce resistance-related responses in tomato lines carrying the Cf-9, Pto, and Fen genes, respectively. These responses were associated with synthesis of p-coumaroyloctopamine and p-coumaroyl-noradrenaline, a novel compound for plants. In susceptible near isogenic tomato lines (Cf-0, pto, fen) and wounded tomato leaves, the levels of these compounds were reduced or undetectable. The elevated levels of p-coumaroyloctopamine and p-coumaroylnoradrenaline were accompanied by elevated mRNA levels of genes encoding phenylalanine ammonia lyase, p-coumarate CoA ligase, and hydroxycinnamoyl-CoA: tyramine N-(hydroxycinnamoyl) transferase (THT), enzymes that are involved in the hydroxycinnamic acid amide biosynthesis. Southern hybridization indicated that THT is encoded by a multigene family in tomato. Four different THT full-length cDNAs were derived by reverse transcriptase-PCR using degenerate primers based on potato and tobacco THT sequences. Transcripts for all four homologs were present in unchallenged tomato leaves, but only tomTHT1-3 was highly expressed following challenge with Pst ( avrPto). Furthermore, tomTHT1-3 showed a more substantial and rapid induction in the incompatible interaction than in the compatible interaction. The cDNAs tomTHT1-3, tomTHT7-1, and tomTHT7-8 encoded proteins with a high degree of amino acid sequence homology, although the recombinant proteins had different preferences for octopamine and noradrenaline. The fourth cDNA, tomTHT1-4, directed synthesis of a truncated enzymatically inactive protein due to the presence of a premature stop codon.	Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Univ Halle Wittenberg, Inst Genet, D-06120 Halle Saale, Saale, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Martin Luther University Halle Wittenberg	von Roepenack-Lahaye, E (corresponding author), Inst Pflanzenbioch, D-06120 Halle Saale, Saale, Germany.		Schornack, Sebastian/AAE-4897-2020; Schornack, Sebastian/A-3650-2011; Newman, Mari-Anne/M-1550-2013; Jones, Jonathan DG/J-5129-2012	Schornack, Sebastian/0000-0002-7836-5881; Schornack, Sebastian/0000-0002-7836-5881; Newman, Mari-Anne/0000-0001-5782-6071; Jones, Jonathan DG/0000-0002-4953-261X				AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; Back K, 2001, PLANT CELL PHYSIOL, V42, P475, DOI 10.1093/pcp/pce060; Bonas U, 2002, CURR OPIN MICROBIOL, V5, P44, DOI 10.1016/S1369-5274(02)00284-9; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Dixon RA, 2002, MOL PLANT PATHOL, V3, P371, DOI 10.1046/j.1364-3703.2002.00131.x; Facchini PJ, 1998, PHYTOCHEMISTRY, V49, P481, DOI 10.1016/S0031-9422(98)00136-8; Farmer MJ, 1999, EUR J BIOCHEM, V263, P686, DOI 10.1046/j.1432-1327.1999.00538.x; Fouts DE, 2002, P NATL ACAD SCI USA, V99, P2275, DOI 10.1073/pnas.032514099; GRANDMAISON J, 1993, MYCORRHIZA, V3, P155, DOI 10.1007/BF00203609; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HammondKosack KE, 1996, PLANT PHYSIOL, V110, P1381, DOI 10.1104/pp.110.4.1381; Hohlfeld H, 1996, PLANTA, V199, P166, DOI 10.1007/BF00196893; Joosten MHAJ, 1999, ANNU REV PHYTOPATHOL, V37, P335, DOI 10.1146/annurev.phyto.37.1.335; Karsai A, 2002, BIOTECHNIQUES, V32, P790, DOI 10.2144/02324st05; Keller H, 1996, PHYTOCHEMISTRY, V42, P389, DOI 10.1016/0031-9422(95)00866-7; KING EO, 1954, J LAB CLIN MED, V44, P301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahaye T, 1996, BIOTECHNIQUES, V21, P1067; Laterrot H., 1985, TOMATO GENET COOP RE, V35, P6; Lee D, 1996, PLANT PHYSIOL, V112, P193, DOI 10.1104/pp.112.1.193; LEE SW, 1992, PLANT MOL BIOL, V18, P345, DOI 10.1007/BF00034961; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; McLusky SR, 1999, PLANT J, V17, P523, DOI 10.1046/j.1365-313X.1999.00403.x; Meng HB, 1997, PHYTOCHEMISTRY, V44, P605, DOI 10.1016/S0031-9422(96)00594-8; Muhlenbeck U, 1996, PHYTOCHEMISTRY, V42, P1573, DOI 10.1016/0031-9422(96)00173-2; NEGREL J, 1987, PHYTOCHEMISTRY, V26, P2185, DOI 10.1016/S0031-9422(00)84681-6; Negrel J, 1997, EUR J BIOCHEM, V247, P1127, DOI 10.1111/j.1432-1033.1997.01127.x; NEGREL J, 1984, PHYTOCHEMISTRY, V23, P2797, DOI 10.1016/0031-9422(84)83018-6; Newman MA, 2002, PLANT J, V29, P487, DOI 10.1046/j.0960-7412.2001.00233.x; Newman MA, 2001, MOL PLANT MICROBE IN, V14, P785, DOI 10.1094/MPMI.2001.14.6.785; Nurnberger T, 1999, CELL MOL LIFE SCI, V55, P167, DOI 10.1007/s000180050283; Oldroyd GED, 1998, P NATL ACAD SCI USA, V95, P10300, DOI 10.1073/pnas.95.17.10300; Pearce G, 1998, PHYTOCHEMISTRY, V47, P659, DOI 10.1016/S0031-9422(97)00620-1; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Scheel D, 1998, CURR OPIN PLANT BIOL, V1, P305, DOI 10.1016/1369-5266(88)80051-7; Schmidt A, 1999, J BIOL CHEM, V274, P4273, DOI 10.1074/jbc.274.7.4273; Schmidt A, 1998, PLANTA, V205, P51, DOI 10.1007/s004250050295; SIEDLER H, 1991, MOL GEN GENET, V226, P177, DOI 10.1007/BF00273601; SMITH TA, 1983, ADV POLYAMINE RES, V4, P347; THOMAS CM, 1995, PLANT J, V8, P785, DOI 10.1046/j.1365-313X.1995.08050785.x; von Ropenack E, 1998, J BIOL CHEM, V273, P9013, DOI 10.1074/jbc.273.15.9013; Yu M, 1999, PLANTA, V209, P33, DOI 10.1007/s004250050604	44	74	75	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43373	43383		10.1074/jbc.M305084200	http://dx.doi.org/10.1074/jbc.M305084200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12900412	hybrid			2022-12-27	WOS:000186157000081
J	Wakabayashi, S; Hisamitsu, T; Pang, TX; Shigekawa, M				Wakabayashi, S; Hisamitsu, T; Pang, TX; Shigekawa, M			Kinetic dissection of two distinct proton binding sites in Na+/H+ exchangers by measurement of reverse mode reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; CYTOPLASMIC DOMAIN; THYMIC LYMPHOCYTES; GROWTH-FACTORS; PH REGULATION; ANTIPORTER; H+; AMILORIDE; DEPENDENCE; HISTIDINE-226	We examined the effect of intracellular acidification on the reverse mode of Na+/ H+ exchange by measuring Na-22(+) efflux from Na-22(+)-loaded PS120 cells expressing the Na+/ H+ exchanger (NHE) isoforms NHE1, NHE2, and NHE3. The 5-(N- ethyl-N-isopropyl) amiloride (EIPA)- or amiloride- sensitive fraction of Na-22(+) efflux was dramatically accelerated by cytosolic acidification as opposed to thermodynamic prediction, supporting the concept that these NHE isoforms are activated by protonation of an internal binding site(s) distinct from the H+ transport site. Intracellular pH (pH(i)) dependence of Na-22(+) efflux roughly exhibited a bell-shaped profile; mild acidification from pH(i) 7.5 to 7 dramatically accelerated Na-22(+) efflux, whereas acidification from pH(i) 6.6 gradually decreased it. Alkalinization above pHi 7.5 completely suppressed EIPA-sensitive Na-22(+) efflux. Cell ATP depletion and mutation of NHE1 at Arg(440) (R440D) caused a large acidic shift of the pH(i) profile for Na-22(+) efflux, whereas mutation at Gly(455) (G455Q) caused a significant alkaline shift. Because these mutations and ATP depletion cause correspondingly similar effects on the forward mode of Na+/H+ exchange, it is most likely that they alter exchange activity by modulating affinity of the internal modifier site for protons. The data provide substantial evidence that a proton modifier site( s) distinct from the transport site controls activities of at least three NHE isoforms through cooperative interaction with multiple protons.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishirodai 5-7-1, Osaka 5658565, Japan.	wak@ri.ncvc.go.jp						ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; CASSEL D, 1986, J BIOL CHEM, V261, P5460; Cha B, 2003, J MEMBRANE BIOL, V191, P49, DOI 10.1007/s00232-002-1044-2; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Dibrov P, 1998, BIOCHEMISTRY-US, V37, P8282, DOI 10.1021/bi9801457; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GREEN J, 1988, J GEN PHYSIOL, V92, P239, DOI 10.1085/jgp.92.2.239; GREEN J, 1988, J BIOL CHEM, V263, P5012; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P585, DOI 10.1085/jgp.84.4.585; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; Haworth RS, 2003, J BIOL CHEM, V278, P31676, DOI 10.1074/jbc.M304400200; Hayashi H, 2002, J BIOL CHEM, V277, P11090, DOI 10.1074/jbc.M111868200; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; Kinsella JL, 1998, BIOCHEM CELL BIOL, V76, P743, DOI 10.1139/bcb-76-5-743; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; OTSU K, 1993, J BIOL CHEM, V268, P3184; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; Segel IH, 1975, ENZYME KINETICS, P346; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; VAUGHANJONES RD, 1990, J PHYSIOL-LONDON, V428, P441, DOI 10.1113/jphysiol.1990.sp018221; VIGNE P, 1984, EMBO J, V3, P1865, DOI 10.1002/j.1460-2075.1984.tb02060.x; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; Wakabayashi S, 2003, J BIOL CHEM, V278, P11828, DOI 10.1074/jbc.M213243200; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; Wiebe CA, 2001, BIOCHEM J, V357, P1, DOI 10.1042/0264-6021:3570001	36	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43580	43585		10.1074/jbc.M306690200	http://dx.doi.org/10.1074/jbc.M306690200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928437	hybrid			2022-12-27	WOS:000186157000105
J	Bartosch, B; Vitelli, A; Granier, C; Goujon, C; Dubuisson, J; Pascale, S; Scarselli, E; Cortese, R; Nicosia, A; Cosset, FL				Bartosch, B; Vitelli, A; Granier, C; Goujon, C; Dubuisson, J; Pascale, S; Scarselli, E; Cortese, R; Nicosia, A; Cosset, FL			Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TYPE-I; DC-SIGN; HYPERVARIABLE REGION-1; LOW-DENSITY; FUNCTIONAL-ANALYSIS; CANDIDATE RECEPTOR; ENVELOPE PROTEIN; E2 GLYCOPROTEIN; DENDRITIC CELLS; INFECTION	Several cell surface molecules have been proposed as receptor candidates, mediating cell entry of hepatitis C virus (HCV) on the basis of their physical association with virions or with soluble HCV E2 glycoproteins. However, due to the lack of infectious HCV particles, evidence that these receptor candidates support infection was missing. Using our recently described infectious HCV pseudotype particles (HCVpp) that display functional E1E2 glycoprotein complexes, here we show that HCV is a pH-dependent virus, implying that its receptor component(s) mediate virion internalization by endocytosis. Expression of the CD81 tetraspanin in non-permissive CD81-negative hepato-carcinoma cells was sufficient to restore susceptibility to HCVpp infection, confirming its critical role as a cell attachment factor. As a cell surface molecule likely to mediate endosomal trafficking, we demonstrate that the human scavenger receptor class B type 1 (SR-B1), a high-density lipoprotein-internalization molecule that we previously proposed as a novel HCV receptor candidate due to its affinity with E2 glycoproteins, is required for infection of CD81-expressing hepatic cells. By receptor competition assays, we found that SR-B1 antibodies that blocked binding of soluble E2 could prevent HCVpp infectivity. Furthermore, we establish that the hyper-variable region 1 of the HCV E2 glycoprotein is a critical determinant mediating entry in SR-B1-positive cells. Finally, by correlating expression of HCV receptors and infectivity, we suggest that, besides CD81 and SR-B1, additional hepatocyte-specific co-factor(s) are necessary for HCV entry.	Ecole Normale Super Lyon, Inst Federat Rech 128, INSERM, U412,Lab Vectorol Retrovirale & Therapie Genique, F-69364 Lyon 07, France; Inst Recerche Biol Mol P Angeletti, I-00040 Rome, Italy; Inst Pasteur, Inst Biol Lille, CNRS, UPR2511, F-59021 Lille, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Cosset, FL (corresponding author), Ecole Normale Super Lyon, Inst Federat Rech 128, INSERM, U412,Lab Vectorol Retrovirale & Therapie Genique, 46 Allee Italie, F-69364 Lyon 07, France.	flcosset@ens-lyon.fr	Bartosch, Birke/I-7255-2018; Cosset, François-Loïc/M-5862-2019; Goujon, Caroline/B-3914-2014; Dubuisson, Jean/E-6813-2016	Bartosch, Birke/0000-0001-6354-4660; Cosset, François-Loïc/0000-0001-8842-3726; Goujon, Caroline/0000-0001-8571-1108; Christelle, GRANIER/0000-0001-8987-0632; Scarselli, Elisa/0000-0002-5393-6713; Dubuisson, Jean/0000-0003-1626-7693				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Akbar SMF, 2001, INTERVIROLOGY, V44, P199, DOI 10.1159/000050047; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Auffermann-Gratzinger S, 2001, BLOOD, V97, P3171, DOI 10.1182/blood.V97.10.3171; Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Breiner KM, 2001, HEPATOLOGY, V34, P803, DOI 10.1053/jhep.2001.27810; Buonocore L, 2002, J VIROL, V76, P6865, DOI 10.1128/JVI.76.14.6865-6872.2002; CALVO D, 1993, J BIOL CHEM, V268, P18929; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Flint M, 1999, J VIROL, V73, P6782, DOI 10.1128/JVI.73.8.6782-6790.1999; Flint M, 2000, J VIROL, V74, P702, DOI 10.1128/JVI.74.2.702-709.2000; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Forns X, 2000, P NATL ACAD SCI USA, V97, P13318, DOI 10.1073/pnas.230453597; Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Heinz FX, 2001, CURR OPIN MICROBIOL, V4, P450, DOI 10.1016/S1369-5274(00)00234-4; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Lagging LM, 1998, J VIROL, V72, P3539, DOI 10.1128/JVI.72.5.3539-3546.1998; Lavillette D, 2002, J VIROL, V76, P9673, DOI 10.1128/JVI.76.19.9673-9685.2002; Lerat H, 1998, BLOOD, V91, P3841, DOI 10.1182/blood.V91.10.3841.3841_3841_3849; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; LOZACH PY, 2003, J BIOL CHEM; MAJOR ME, 2001, FIELDS VIROLOGY, V1, P1127; Matsuura Y, 2001, VIROLOGY, V286, P263, DOI 10.1006/viro.2001.0971; MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Navas MC, 2002, J MED VIROL, V67, P152, DOI 10.1002/jmv.2204; Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; Penin F, 2001, J VIROL, V75, P5703, DOI 10.1128/JVI.75.12.5703-5710.2001; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479; Roccasecca R, 2003, J VIROL, V77, P1856, DOI 10.1128/JVI.77.3.1856-1867.2003; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Shaw ML, 2003, J MED VIROL, V70, P361, DOI 10.1002/jmv.10404; Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/0022-1317-83-7-1535; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Triyatni M, 2002, J VIROL, V76, P9335, DOI 10.1128/JVI.76.18.9335-9344.2002; VISHNYAKOVA TG, 2003, J BIOL CHEM; Wellnitz S, 2002, J VIROL, V76, P1181, DOI 10.1128/JVI.76.3.1181-1193.2002; Wensel DL, 2003, J VIROL, V77, P3460, DOI 10.1128/JVI.77.6.3460-3469.2003; Yagnik AT, 2000, PROTEINS, V40, P355, DOI 10.1002/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K; Zucchelli S, 2001, HEPATOLOGY, V33, P692, DOI 10.1053/jhep.2001.22175	55	469	518	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41624	41630		10.1074/jbc.M305289200	http://dx.doi.org/10.1074/jbc.M305289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913001	hybrid			2022-12-27	WOS:000185989500010
J	Kittendorf, JD; Sgraja, T; Reuter, K; Klebe, G; Garcia, GA				Kittendorf, JD; Sgraja, T; Reuter, K; Klebe, G; Garcia, GA			An essential role for aspartate 264 in catalysis by tRNA-guanine transglycosylase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; COVALENT INTERMEDIATE; ACID/BASE CATALYST; SHIGELLA-FLEXNERI; CRYSTAL-STRUCTURE; IDENTIFICATION; NUCLEOPHILE; MECHANISM; RECOGNITION; AMIDOTRANSFERASE	tRNA-guanine transglycosylase (TGT) catalyzes a post-transcriptional base-exchange reaction involved in the incorporation of the modified base queuine (Q) into the wobble position of certain tRNAs. Catalysis by TGT occurs through a double-displacement mechanism that involves the formation of a covalent enzyme-RNA intermediate (Kittendorf, J. D., Barcomb, L. M., Nonekowski, S. T., and Garcia, G. A. (2001) Biochemistry 40, 14123 14133). The TGT chemical mechanism requires the protonation of the displaced guanine and the deprotonation of the incoming heterocyclic base. Based on its position in the active site, it is likely that aspartate 264 is involved in these proton transfer events. To investigate this possibility, site-directed mutagenesis was employed to convert aspartate 264 to alanine, asparagine, glutamate, glutamine, lysine, and histidine. Biochemical characterization of these TGT mutants revealed that only the conservative glutamate mutant retained catalytic activity, with K-m values for both tRNA and guanine 3-fold greater than those for wild-type, whereas the k(cat) was depressed by an order of magnitude. Furthermore, of these six TGT mutants, only the TGT(D264E) was capable of forming a TGT.RNA covalent intermediate; however, unlike wild-type TGT, only hydroxylamine is capable of cleaving the TGT(D264E).RNA covalent complex. In an effort to better understand the unique biochemical properties of the D264E TGT mutant, we solved the crystal structure of the Zymomonas mobilis TGT with the analogous mutation (D280E). The results of these studies support two roles for aspartate 264 in catalysis by TGT, protonation of the leaving guanine and deprotonation of the incoming preQ(1).	Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Marburg, Inst Pharmazeut Chem, D-35037 Marburg, Germany	University of Michigan System; University of Michigan; Philipps University Marburg	Garcia, GA (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.			Reuter, Klaus/0000-0003-3673-7971	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007767, GM 07767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai Y, 2000, J BIOL CHEM, V275, P28731, DOI 10.1074/jbc.M002174200; Brenk R, 2003, J MED CHEM, V46, P1133, DOI 10.1021/jm0209937; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; Durand JMB, 1997, J BACTERIOL, V179, P5777, DOI 10.1128/jb.179.18.5777-5782.1997; FREY B, 1988, J BACTERIOL, V170, P2078, DOI 10.1128/jb.170.5.2078-2082.1988; Garcia GA, 1997, J PROTEIN CHEM, V16, P11, DOI 10.1023/A:1026334726357; Goodenough-Lashua DM, 2003, BIOORG CHEM, V31, P331, DOI 10.1016/S0045-2068(03)00069-5; Gradler U, 1999, FEBS LETT, V454, P142, DOI 10.1016/S0014-5793(99)00793-0; Gradler U, 2001, J MOL BIOL, V306, P455, DOI 10.1006/jmbi.2000.4256; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; Hoops GC, 1996, J HETEROCYCLIC CHEM, V33, P767, DOI 10.1002/jhet.5570330341; HOOPS GC, 1995, BIOCHEMISTRY-US, V34, P15381, DOI 10.1021/bi00046a047; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kittendorf JD, 2001, BIOCHEMISTRY-US, V40, P14123, DOI 10.1021/bi0110589; Kung FL, 2000, RNA, V6, P233, DOI 10.1017/S135583820099191X; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; MIAO S, 1994, BIOCHEMISTRY-US, V33, P7029; Nonekowski ST, 2002, J BIOL CHEM, V277, P7178, DOI 10.1074/jbc.M111077200; OKADA N, 1979, J BIOL CHEM, V254, P3067; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Romier C, 1996, BIOCHEMISTRY-US, V35, P15734, DOI 10.1021/bi962003n; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; Schnizer HG, 1999, BIOCHEMISTRY-US, V38, P3677, DOI 10.1021/bi981450v; Short SA, 1996, J BIOL CHEM, V271, P4978; SLANY RK, 1994, BIOCHIMIE, V76, P389, DOI 10.1016/0300-9084(94)90113-9; TSANG TH, 1983, BIOCHIM BIOPHYS ACTA, V741, P180, DOI 10.1016/0167-4781(83)90058-1; Vocadlo DJ, 1998, BIOCHEM J, V335, P449, DOI 10.1042/bj3350449; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; WANG Q, 1995, BIOCHEMISTRY-US, V34, P14554, DOI 10.1021/bi00044a034; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; Wong AW, 1998, J BIOL CHEM, V273, P34057, DOI 10.1074/jbc.273.51.34057; Xiong HS, 1999, J BIOL CHEM, V274, P35059, DOI 10.1074/jbc.274.49.35059; Xu YM, 1998, BIOCHEMISTRY-US, V37, P4114, DOI 10.1021/bi972519m; Zechel DL, 1998, BIOCHEM J, V336, P139, DOI 10.1042/bj3360139	41	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42369	42376		10.1074/jbc.M304323200	http://dx.doi.org/10.1074/jbc.M304323200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909636	hybrid			2022-12-27	WOS:000185989500099
J	Wu, H; Wang, ZX				Wu, H; Wang, ZX			The mechanism of p21-activated kinase 2 autoactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED ACTIVATION; DEPENDENT PROTEIN-KINASE; GAMMA-PAK; SUBSTRATE REACTION; IRREVERSIBLE MODIFICATION; CATALYTIC MECHANISM; KINETIC MECHANISM; ENZYME-ACTIVITY; CHAIN KINASE; ALPHA-PAK	The p21-activated kinases (PAKs) play an important role in diverse cellular processes. PAK2 is activated by autophosphorylation upon binding of small G proteins such as Cdc42 and Rac in the GTP-bound state. However, the mechanism of PAK2 autophosphorylation in vitro is unclear. In the present study, the kinetic theory of the substrate reaction during modification of enzyme activity has been applied to a study of the autoactivation of PAK2. On the basis of the kinetic equation of the substrate reaction during the autophosphorylation of PAK2, the activation rate constants for the free enzyme and enzyme-substrate complex have been determined. The results indicate that 1) in the presence of Cdc42, PAK2 autophosphorylation is a bipartite mechanism, with the regulatory domain autophosphorylated at multiple residues, whereas activation coincides with autophosphorylation of the catalytic domain at Thr-402; 2) the autophosphorylation reactions in regulatory domain are either a nonlimiting step or not required for activation of enzyme; 3) the autophosphorylation at site Thr-402 on the catalytic domain occurs by an intermolecular mechanism and is required for phosphorylation of exogenous substrates examined; 4) binding of the exogenous protein/ peptide substrates at the active site of PAK2 has little or no effect on the autoactivation of PAK2, suggesting that multiple regions of PAK2 are involved in the enzyme-substrate recognition. The present method also provides a novel approach for studying autophosphorylation reactions. Since the experimental conditions used resemble more closely the in vivo situation where the substrate is constantly being turned over while the enzyme is being modified, this new method would be particularly useful when the regulatory mechanisms of the reversible phosphorylation reaction toward certain enzymes are being assessed.	Acad Sinica, Inst Biophys, Ctr Mol Biol, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, ZX (corresponding author), Acad Sinica, Inst Biophys, Ctr Mol Biol, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	zxwang@sun5.ibp.ac.cn			FOGARTY INTERNATIONAL CENTER [R03TW001501] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW 01501] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; DUGGLEBY RG, 1986, J THEOR BIOL, V123, P67, DOI 10.1016/S0022-5193(86)80236-3; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; LAIDLER KJ, 1973, CHEM KINETICS ENZYME, P175; Lee SR, 2002, MOL ENDOCRINOL, V16, P85, DOI 10.1210/me.16.1.85; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TSOU CL, 1988, ADV ENZYMOL RAMB, V61, P381; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Waas WF, 2002, J BIOL CHEM, V277, P12532, DOI 10.1074/jbc.M110523200; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang MH, 1996, BIOCHEM J, V320, P187, DOI 10.1042/bj3200187; Wang ZX, 1999, BIOCHEM J, V341, P545, DOI 10.1042/0264-6021:3410545; Wang ZX, 2002, BIOCHEMISTRY-US, V41, P7849, DOI 10.1021/bi025776m; WANG ZX, 1987, J THEOR BIOL, V127, P253, DOI 10.1016/S0022-5193(87)80106-6; Wang ZX, 2002, BIOCHEM J, V368, P947, DOI 10.1042/BJ20020557; WANG ZX, 1990, J THEOR BIOL, V142, P531, DOI 10.1016/S0022-5193(05)80107-9; WANG ZX, 1995, BIOCHEMISTRY-US, V34, P6863, DOI 10.1021/bi00020a033; Wu H, 2003, BIOCHEMISTRY-US, V42, P1129, DOI 10.1021/bi026857l; Wu JW, 1998, BIOCHEM J, V335, P181, DOI 10.1042/bj3350181; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	63	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41768	41778		10.1074/jbc.M308196200	http://dx.doi.org/10.1074/jbc.M308196200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907671	hybrid			2022-12-27	WOS:000185989500028
J	Das, S; Gerwin, C; Sheng, ZH				Das, S; Gerwin, C; Sheng, ZH			Syntaphilin binds to dynamin-1 and inhibits dynamin-dependent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; VESICLE RELEASE; MEMBRANE; AMPHIPHYSIN-1; EXPRESSION; DOMAIN	Syntaphilin is a brain-specific syntaxin-binding partner first characterized as an inhibitor of SNARE complex formation and neurotransmitter release. Here we show that syntaphilin also binds to dynamin-1 and through this interaction inhibits dynamin-mediated endocytosis. Immunoprecipitation studies from crosslinked rat synaptosomes demonstrate that an endogenous syntaphilin-dynamin-1 complex exists independently of dynamin-1 binding to amphiphysin. Functionally, syntaphilin expression inhibits transferrin internalization in COS-7 cells. These data reveal that syntaphilin is an inhibitor of both SNARE-based fusion and dynamin-mediated endocytosis.	NINDS, Synapt Funct Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Sheng, ZH (corresponding author), NINDS, Synapt Funct Unit, NIH, Bethesda, MD 20892 USA.	shengz@ninds.nih.gov	Das, Sunit/J-3903-2015	Das, Sunit/0000-0002-2146-4168				Atwood HL, 2002, NAT REV NEUROSCI, V3, P497, DOI 10.1038/nrn876; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; Das S, 2003, MOL BRAIN RES, V116, P38, DOI 10.1016/S0169-328X(03)00212-2; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Lai MM, 2000, J BIOL CHEM, V275, P34017, DOI 10.1074/jbc.C000429200; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Liu JP, 1997, MOL CELL ENDOCRINOL, V132, P61, DOI 10.1016/S0303-7207(97)00120-2; Ma L, 1999, NAT NEUROSCI, V2, P24, DOI 10.1038/4525; Markram H, 1998, NEUROPHARMACOLOGY, V37, P489, DOI 10.1016/S0028-3908(98)00049-5; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Martin TFJ, 2002, NEURON, V34, P9, DOI 10.1016/S0896-6273(02)00651-7; Park JS, 2001, FASEB J, V15, P1625, DOI 10.1096/fj.00-0723fje; Ryan TA, 2003, P NATL ACAD SCI USA, V100, P2171, DOI 10.1073/pnas.0530260100; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Zakharenko SS, 2002, NEURON, V35, P1099, DOI 10.1016/S0896-6273(02)00898-X	28	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41221	41226		10.1074/jbc.M304851200	http://dx.doi.org/10.1074/jbc.M304851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896979	hybrid			2022-12-27	WOS:000185847200100
J	Chattopadhyay, S; Sun, P; Wang, PC; Abonyo, B; Cross, NL; Liu, L				Chattopadhyay, S; Sun, P; Wang, PC; Abonyo, B; Cross, NL; Liu, L			Fusion of lamellar body with plasma membrane is driven by the dual action of annexin II tetramer and arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SURFACTANT SECRETION; PHOSPHOLIPID-BINDING; FLUORESCENCE ASSAY; CHROMAFFIN CELLS; PORE EXPANSION; VESICLE FUSION; AGGREGATION; CALCIUM; EXOCYTOSIS	Annexin II has been implicated in membrane fusion during the exocytosis of lamellar bodies from alveolar epithelial type II cells. Most previous studies were based on the fusion assays by using model membranes. In the present study, we investigated annexin II-mediated membrane fusion by using isolated lamellar bodies and plasma membrane as determined by the relief of octadecyl rhodamine B (R18) self-quenching. Immunodepletion of annexin II from type II cell cytosol reduced its fusion activity. Purified annexin II tetramer (AIIt) induced the fusion of lamellar bodies with the plasma membrane in a dose-dependent manner. This fusion is Ca2+-dependent and is highly specific to AIIt because other annexins (I and II monomer, III, IV, V, and VI) were unable to induce the fusion. Modification of the different functional residues of AIIt by N-ethylmaleimide, nitric oxide, or peroxynitrite abolished AIIt-mediated fusion. Arachidonic acid enhanced AIIt-mediated fusion and reduced its Ca2+ requirement to an intracellularly achievable level. This effect is due to membrane-bound arachidonic acid, not free arachidonic acid. Other fatty acids including linolenic acid, palmitoleic acid, myristoleic acid, stearic acid, palmitic acid, and myristic acid had little effect. AIIt-mediated fusion was suppressed by the removal of arachidonic acid from lamellar body and plasma membrane using bovine serum albumin. The addition of arachidonic acid back to the arachidonic acid-depleted membranes restored its fusion activity. Our results suggest that the fusion between lamellar bodies with the plasma membrane is driven by the synergistic action of AIIt and arachidonic acid.	Oklahoma State Univ, Dept Physiol Sci, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Liu, L (corresponding author), Oklahoma State Univ, Dept Physiol Sci, 264 McElroy Hall, Stillwater, OK 74078 USA.		Wang, Pa-Chun/AAD-4094-2019		NHLBI NIH HHS [HL-52146] Funding Source: Medline; NICHD NIH HHS [HD30763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030763] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052146, R01HL052146] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Arrastua L, 2003, BIOCHEM J, V370, P641, DOI 10.1042/BJ20021736; Ayala-Sanmartin J, 2001, BIOCHEM BIOPH RES CO, V283, P72, DOI 10.1006/bbrc.2001.4748; Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER KNJ, 1990, EXPERIENTIA, V46, P631, DOI 10.1007/BF01939702; Caohuy H, 2002, J BIOL CHEM, V277, P25217, DOI 10.1074/jbc.M202452200; Chander A, 2001, AM J PHYSIOL-LUNG C, V280, pL991, DOI 10.1152/ajplung.2001.280.5.L991; CHANDER A, 1983, BIOCHIM BIOPHYS ACTA, V753, P119, DOI 10.1016/0005-2760(83)90105-4; CHANDER A, 1990, AM J PHYSIOL, V258, P241; CHERNOMORDIK L, 1995, BIOPHYS J, V69, P922, DOI 10.1016/S0006-3495(95)79966-0; CHERNOMORDIK L, 1995, J VIROL, V69, P3049, DOI 10.1128/JVI.69.5.3049-3058.1995; COBALEDA C, 1994, BIOCHEM J, V300, P347, DOI 10.1042/bj3000347; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Della Gaspera B, 2001, DEV DYNAM, V222, P206, DOI 10.1002/dvdy.1183; DOBBS LG, 1985, BIOCHIM BIOPHYS ACTA, V846, P155, DOI 10.1016/0167-4889(85)90121-1; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EDWARDS HC, 1991, EUR J BIOCHEM, V198, P121, DOI 10.1111/j.1432-1033.1991.tb15994.x; Faure AV, 2002, EXP CELL RES, V276, P79, DOI 10.1006/excr.2002.5512; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GILFILLAN AM, 1985, BIOCHIM BIOPHYS ACTA, V833, P336, DOI 10.1016/0005-2760(85)90207-3; Haller T, 2001, J CELL BIOL, V155, P279, DOI 10.1083/jcb.200102106; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HONG K, 1982, P NATL ACAD SCI-BIOL, V79, P4642, DOI 10.1073/pnas.79.15.4642; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; JOBE A, 1977, BIOCHIM BIOPHYS ACTA, V489, P440, DOI 10.1016/0005-2760(77)90165-5; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; KARLI UO, 1990, P NATL ACAD SCI USA, V87, P5912, DOI 10.1073/pnas.87.15.5912; KENDALL DA, 1982, J BIOL CHEM, V257, P3892; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KLIEWER M, 1985, EXP LUNG RES, V9, P351, DOI 10.3109/01902148509057533; LIEBICH HM, 1991, J CHROMATOGR-BIOMED, V572, P1, DOI 10.1016/0378-4347(91)80468-R; LIU L, 1995, BBA-LIPID LIPID MET, V1259, P166, DOI 10.1016/0005-2760(95)00159-A; Liu L, 1996, AM J PHYSIOL-LUNG C, V270, pL668, DOI 10.1152/ajplung.1996.270.4.L668; Liu L, 1999, CELL SIGNAL, V11, P317, DOI 10.1016/S0898-6568(98)00047-3; Liu L, 1997, CELL SIGNAL, V9, P299, DOI 10.1016/S0898-6568(97)89891-9; Liu L, 2002, EUR J BIOCHEM, V269, P4277, DOI 10.1046/j.1432-1033.2002.03118.x; LIU L, 1995, BBA-LIPID LIPID MET, V1254, P274, DOI 10.1016/0005-2760(94)00188-5; MACLEAN CM, 1992, BIOCHEM J, V286, P747, DOI 10.1042/bj2860747; MARSHALL BC, 1988, BIOCHIM BIOPHYS ACTA, V966, P403, DOI 10.1016/0304-4165(88)90091-8; Mason RJ, 1998, BBA-MOL BASIS DIS, V1408, P226, DOI 10.1016/S0925-4439(98)00070-2; Massey-Harroche D, 1998, J CELL SCI, V111, P3007; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; McIntosh TJ, 1999, BIOPHYS J, V76, P2090, DOI 10.1016/S0006-3495(99)77365-0; Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Nunes-Correia I, 2002, BBA-BIOMEMBRANES, V1561, P65, DOI 10.1016/S0005-2736(01)00457-6; Ohki S, 1998, BIOCHEMISTRY-US, V37, P7496, DOI 10.1021/bi972016g; Pecheur EI, 2002, BIOCHEMISTRY-US, V41, P9813, DOI 10.1021/bi0259195; Puisieux A, 1996, BIOCHEM J, V313, P51, DOI 10.1042/bj3130051; PURI A, 1993, VIROLOGY, V195, P855, DOI 10.1006/viro.1993.1444; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; Rooney SA, 2001, COMP BIOCHEM PHYS A, V129, P233, DOI 10.1016/S1095-6433(01)00320-8; Rowan WH, 2002, BIOCHEMISTRY-US, V41, P1409, DOI 10.1021/bi0119767; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Singh TK, 2000, ARCH BIOCHEM BIOPHYS, V381, P235, DOI 10.1006/abbi.2000.1994; STEGMANN T, 1995, BIOCHEM J, V307, P875, DOI 10.1042/bj3070875; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Troyer KP, 2002, J BIOL CHEM, V277, P29101, DOI 10.1074/jbc.M202856200; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WEINMAN JS, 1994, CELL TISSUE RES, V278, P389, DOI 10.1007/BF00414181; Yamane T, 2002, BBA-PROTEIN STRUCT M, V1596, P108, DOI 10.1016/S0167-4838(02)00209-1; Zarkik S, 1997, J VIROL, V71, P738, DOI 10.1128/JVI.71.1.738-740.1997	69	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39675	39683		10.1074/jbc.M212594200	http://dx.doi.org/10.1074/jbc.M212594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902340	hybrid			2022-12-27	WOS:000185713800053
J	Miyake, T; Hiraishi, H; Sammoto, H; Ono, BI				Miyake, T; Hiraishi, H; Sammoto, H; Ono, BI			Involvement of the VDE homing endonuclease and rapamycin in regulation of the Saccharomyces cerevisiae GSH11 gene encoding the high affinity glutathione transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; SULFUR SOURCE; YEAST; DEATH; GENERATION; PATHWAY; ELEMENT; FAMILY; TARGET; DNA	The Saccharomyces cerevisiae gene HGT1/GSH11 encodes the high affinity glutathione transporter and is repressed by cysteine added to the culture medium. It has been found previously that a 5'-upstream cis-element, CCGCCACAC, is responsible for regulating GSH11 expression and that several proteins bind to this element (Miyake, T., Kanayama, M., Sammoto, H., and Ono, B. (2002) Mol. Genet. Genomics 266, 1004 - 1011). In this report we present evidence that the most prominent of these proteins is VDE, known previously as the homing endonuclease encoded by VMA1. We show also that GSH11 is not expressed in a VDE-deleted strain and that inability to express the GSH11 of this strain is overcome by introduction of the coding region of VDE or the entire VMA1 gene. It is also found that VDE does not cut DNA in the vicinity of the GSH11 cis-element. Rapamycin, an inhibitor of the target of rapamycin (TOR) signal-transduction system, is found to enhance expression of GSH11 in a VDE-dependent manner under conditions of sulfur starvation. These results indicate that GSH11 is regulated by a system sensitive to sulfur starvation ( presumably via cysteine depletion) and a more general system involving the nutritional starvation signal mediated by the TOR system. Both systems need to be operational ( inhibition of TOR and sulfur starvation) for full expression of GSH11.	Ind Technol Ctr, Okayama 7011296, Japan; Ritsumeikan Univ, Fac Sci & Engn, Dept Biotechnol, Shiga 5258577, Japan	Ritsumeikan University	Miyake, T (corresponding author), Ind Technol Ctr, 5301 Haga, Okayama 7011296, Japan.	tsuyoshi_miyake@pref.okayama.jp						Anraku Y, 1997, GENES CELLS, V2, P359, DOI 10.1046/j.1365-2443.1997.1270325.x; Aoshima H, 1999, BIOSCI BIOTECH BIOCH, V63, P1025, DOI 10.1271/bbb.63.1025; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; DESCHAVANNE PJ, 1981, BRIT J RADIOL, V54, P361, DOI 10.1259/0007-1285-54-640-361; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; Gimble FS, 2001, NUCLEIC ACIDS RES, V29, P4215, DOI 10.1093/nar/29.20.4215; Goddard MR, 2001, P ROY SOC B-BIOL SCI, V268, P2537, DOI 10.1098/rspb.2001.1830; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Hauser M, 2000, J BIOL CHEM, V275, P3037, DOI 10.1074/jbc.275.5.3037; HIRATA R, 1990, J BIOL CHEM, V265, P6726; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Koh S, 2002, PLANT PHYSIOL, V128, P21, DOI 10.1104/pp.010332; Lubkowitz MA, 1998, MOL MICROBIOL, V28, P729, DOI 10.1046/j.1365-2958.1998.00827.x; MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Miyake T, 1999, YEAST, V15, P1449, DOI 10.1002/(SICI)1097-0061(199910)15:14<1449::AID-YEA469>3.0.CO;2-S; Miyake T, 1998, BIOSCI BIOTECH BIOCH, V62, P1858, DOI 10.1271/bbb.62.1858; Miyake T, 2002, MOL GENET GENOMICS, V266, P1004, DOI 10.1007/s00438-001-0625-6; Nagai Y, 2003, MOL CELL BIOL, V23, P1726, DOI 10.1128/MCB.23.5.1726-1736.2003; Nogami S, 2002, YEAST, V19, P773, DOI 10.1002/yea.872; ONO BI, 1991, YEAST, V7, P843, DOI 10.1002/yea.320070809; PENNINCKX MJ, 1982, B I PASTEUR, V80, P291; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; RENNENBERG H, 1982, PHYTOCHEMISTRY, V21, P2771, DOI 10.1016/0031-9422(80)85045-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sherman F, 1986, LAB COURSE MANUAL ME; Stephen DWS, 1996, FEMS MICROBIOL LETT, V141, P207, DOI 10.1111/j.1574-6968.1996.tb08386.x; Sugiyama K, 2000, BIOCHEM J, V352, P71, DOI 10.1042/0264-6021:3520071; Taniguchi N, 1988, Tanpakushitsu Kakusan Koso, V33, P1397; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946	37	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39632	39636		10.1074/jbc.M302084200	http://dx.doi.org/10.1074/jbc.M302084200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900422	hybrid			2022-12-27	WOS:000185713800047
J	Nagano, S; Li, HY; Shimizu, H; Nishida, C; Ogura, H; de Montellano, PRO; Poulos, TL				Nagano, S; Li, HY; Shimizu, H; Nishida, C; Ogura, H; de Montellano, PRO; Poulos, TL			Crystal structures of epothilone D-bound, epothilone B-bound, and substrate-free forms of cytochrome P450epoK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-STABILIZING AGENTS; PACLITAXEL TAXOL; PURIFIED TUBULIN; ANTITUMOR AGENT; AMINO-ACID; BINDING; RESISTANT; DISCODERMOLIDE; ELEUTHEROBIN; RECOGNITION	Epothilones are potential anticancer drugs that stabilize microtubules by binding to tubulin in a manner similar to paclitaxel. Cytochrome P450epoK (P450epoK), a heme containing monooxygenase involved in epothilone biosynthesis in the myxobacterium Sorangium cellulosum, catalyzes the epoxidation of epothilones C and D into epothilones A and B, respectively. The 2.10-, 1.93-, and 2.65-Angstrom crystal structures reported here for the epothilone D-bound, epothilone B-bound, and substrate-free forms, respectively, are the first crystal structures of an epothilone-binding protein. Although the substrate for P450epoK is the largest of a P450 whose x-ray structure is known, the structural changes along with substrate binding or product release are very minor and the overall fold is similar to other P450s. The epothilones are positioned with the macrolide ring roughly perpendicular to the heme plane and I helix, and the thiazole moiety provides key interactions that very likely are critical in determining substrate specificity. Interestingly, there are strong parallels between the epothilone/P450epoK and paclitaxel/tubulin interactions. Based on structural similarities, a plausible epothilone tubulin-binding mode is proposed.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Francisco	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	poulos@uci.edu	Shimizu, Hideaki/C-4142-2017	Shimizu, Hideaki/0000-0003-0174-5947	NIGMS NIH HHS [GM33688, GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R01GM033688, R37GM025515] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992; BOLLAG DM, 1995, CANCER RES, V55, P2325; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chou TC, 1998, P NATL ACAD SCI USA, V95, P9642, DOI 10.1073/pnas.95.16.9642; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DAMBROSIO M, 1987, HELV CHIM ACTA, V70, P2019, DOI 10.1002/hlca.19870700807; DEMONTELLANO PRO, 1997, CYTOCHROME P450 STRU; GERBER NC, 1994, J BIOL CHEM, V269, P4260; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GOTOH O, 1992, J BIOL CHEM, V267, P83; Hamel E, 1999, BIOCHEMISTRY-US, V38, P5490, DOI 10.1021/bi983023n; Hofle GH, 1996, ANGEW CHEM INT EDIT, V35, P1567, DOI 10.1002/anie.199615671; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAGAWA N, 1997, CYTOCHROME P450 STRU, P419; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kowalski RJ, 1997, J BIOL CHEM, V272, P2534; Kowalski RJ, 1997, MOL PHARMACOL, V52, P613, DOI 10.1124/mol.52.4.613; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DS, 2003, J BIOL CHEM, V278, P9761, DOI 10.1074/jbc.M211575200; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; LI HY, 1995, J AM CHEM SOC, V117, P6297, DOI 10.1021/ja00128a019; Lindel T, 1997, J AM CHEM SOC, V119, P8744, DOI 10.1021/ja9717828; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Molnar I, 1996, GENE, V169, P1, DOI 10.1016/0378-1119(95)00799-7; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nicolaou KC, 1998, ANGEW CHEM INT EDIT, V37, P2015, DOI 10.1002/(SICI)1521-3773(19980817)37:15<2014::AID-ANIE2014>3.0.CO;2-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; Tang L, 2000, SCIENCE, V287, P640, DOI 10.1126/science.287.5453.640; terHaar E, 1996, BIOCHEMISTRY-US, V35, P243, DOI 10.1021/bi9515127; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Williams D, 2000, PERFORM RES, V5, P131; Winn PJ, 2002, P NATL ACAD SCI USA, V99, P5361, DOI 10.1073/pnas.082522999; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200	46	71	74	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44886	44893		10.1074/jbc.M308115200	http://dx.doi.org/10.1074/jbc.M308115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933799	hybrid			2022-12-27	WOS:000186306700124
J	Brooks, DR; Hooper, NM; Isaac, RE				Brooks, DR; Hooper, NM; Isaac, RE			The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-DEGRADING AMINOPEPTIDASES; NEURON-SPECIFIC AMINOPEPTIDASE; CYSTEINE PROTEASE GENE; C-ELEGANS; RAT-BRAIN; FUNCTIONAL EXPRESSION; NEUROPEPTIDE GENE; IDENTIFICATION; PURIFICATION; NEMATODE	Mammals possess membrane-associated and cytosolic forms of the puromycin-sensitive aminopeptidase (PSA; EC 3.4.11.14). Increasing evidence suggests the membrane PSA is involved in neuromodulation within the central nervous system and in reproductive biology. The functional roles of the cytosolic PSA are less clear. The genome of the nematode Caenorhabditis elegans encodes an aminopeptidase, F49E8.3 (PAM-1), that is orthologous to PSA, and sequence analysis predicts it to be cytosolic. We have determined the spatio/temporal gene expression pattern of pam-1 by using the promoter region of F49E8.3 to control expression in the nematode of a second exon translational fusion of the aminopeptidase to green fluorescent protein. Cytosolic fluorescence was observed throughout development in the intestine and nerve cells of the head. Neuronal expression was also observed in the tail of adult males. Recombinant PAM-1, expressed and purified from Escherichia coli, hydrolyzed the N-terminal amino acid from peptide substrates. Favored substrates had positively charged or small neutral amino acids in the N-terminal position. Peptide hydrolysis was inhibited by the metal-chelating agent 1,10-phenanthroline and by the aminopeptidase inhibitors actinonin, amastatin, and leuhistin. However, the enzyme was similar to 100-fold less sensitive toward puromycin (IC50, 135 muM) than other PSA homologues. Following inactivation of the enzyme, aminopeptidase activity was recovered with Zn2+, Co2+, and Ni2+. Silencing expression of pam-1 by RNA interference resulted in 30% embryonic lethality. Surviving adult hermaphrodites deposited large numbers of oocytes throughout the self-fertile period. The overall brood size was, however, unaffected. We conclude that pam-1 encodes an aminopeptidase that clusters phylogenetically with the PSAs, despite attenuated sensitivity toward puromycin, and that it functions in embryo development and reproduction of the nematode.	Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Brooks, DR (corresponding author), Univ Leeds, Fac Biol Sci, Miall Bldg, Leeds LS2 9JT, W Yorkshire, England.	bgydrb@leeds.ac.uk		Hooper, Nigel/0000-0002-5811-3484				Baset HA, 1998, J BIOL CHEM, V273, P27978, DOI 10.1074/jbc.273.43.27978; Blelloch R, 1999, DEV BIOL, V216, P382, DOI 10.1006/dbio.1999.9491; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; Bui YK, 2002, MOL BIOL CELL, V13, P1641, DOI 10.1091/mbc.02-01-0008; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CONSTAM DB, 1995, J BIOL CHEM, V270, P26931, DOI 10.1074/jbc.270.45.26931; de Gandarias JM, 1999, BRAIN RES BULL, V50, P283, DOI 10.1016/S0361-9230(99)00189-6; DYER SH, 1990, J NEUROCHEM, V54, P547, DOI 10.1111/j.1471-4159.1990.tb01906.x; Ferro ES, 1999, DNA CELL BIOL, V18, P781, DOI 10.1089/104454999314926; GROS C, 1985, NEUROPEPTIDES, V5, P485, DOI 10.1016/0143-4179(85)90060-5; Hashmi S, 2002, J BIOL CHEM, V277, P3477, DOI 10.1074/jbc.M106117200; Hishida R, 1996, EMBO J, V15, P4111, DOI 10.1002/j.1460-2075.1996.tb00786.x; Hui KS, 1998, J BIOL CHEM, V273, P31053, DOI 10.1074/jbc.273.47.31053; Hui M, 2003, NEUROCHEM RES, V28, P855, DOI 10.1023/A:1023263123911; Jacob TC, 2003, J NEUROSCI, V23, P2122; Joshua GWP, 2001, MOL BIOCHEM PARASIT, V113, P223, DOI 10.1016/S0166-6851(01)00221-3; Kagechika H, 1999, BIOL PHARM BULL, V22, P1010; Kakuta H, 2003, BIOORG MED CHEM LETT, V13, P83, DOI 10.1016/S0960-894X(02)00845-4; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kelly WG, 1997, GENETICS, V146, P227; Komoda M, 2001, BIOORGAN MED CHEM, V9, P121, DOI 10.1016/S0968-0896(00)00231-5; Laurent V, 2001, EUR J BIOCHEM, V268, P5430, DOI 10.1046/j.0014-2956.2001.02483.x; Laustsen PG, 2001, EUR J BIOCHEM, V268, P98, DOI 10.1046/j.1432-1327.2001.01848.x; Lee MC, 2002, SYNAPSE, V43, P102, DOI 10.1002/syn.10014; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MCLELLAN S, 1988, J NEUROCHEM, V51, P1552, DOI 10.1111/j.1471-4159.1988.tb01124.x; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; Nelson LS, 1998, MOL BRAIN RES, V58, P103, DOI 10.1016/S0169-328X(98)00106-5; Nguyen HMK, 2002, NEUROPHARMACOLOGY, V42, P1089, DOI 10.1016/S0028-3908(02)00054-0; Nishiwaki K, 2000, SCIENCE, V288, P2205, DOI 10.1126/science.288.5474.2205; Osada T, 1999, J NEUROSCI, V19, P6068, DOI 10.1523/JNEUROSCI.19-14-06068.1999; Osada T, 2001, MOL ENDOCRINOL, V15, P960, DOI 10.1210/me.15.6.960; Osada T, 2001, MOL ENDOCRINOL, V15, P882, DOI 10.1210/me.15.6.882; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Podbilewicz B, 1996, MOL BIOL CELL, V7, P1877, DOI 10.1091/mbc.7.12.1877; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; RAY C, 1992, MOL BIOCHEM PARASIT, V51, P239, DOI 10.1016/0166-6851(92)90074-T; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Santos AN, 2000, CELL IMMUNOL, V201, P22, DOI 10.1006/cimm.2000.1629; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; SCHINKMANN K, 1992, J COMP NEUROL, V316, P251, DOI 10.1002/cne.903160209; SCHNEBLI HP, 1979, BIOCHIM BIOPHYS ACTA, V569, P89, DOI 10.1016/0005-2744(79)90084-6; Schulz C, 2001, DEV GENES EVOL, V211, P581, DOI 10.1007/s00427-001-0194-z; Scott AL, 1996, PARASITOL TODAY, V12, P425, DOI 10.1016/0169-4758(96)10063-6; SHARROCK WJ, 1983, DEV BIOL, V96, P182, DOI 10.1016/0012-1606(83)90321-4; Shrimpton CN, 2002, ENDOCR REV, V23, P647, DOI 10.1210/er.2001-0032; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Singson A, 2001, DEV BIOL, V230, P101, DOI 10.1006/dbio.2000.0118; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Tcherepanova I, 2000, J BIOL CHEM, V275, P26359, DOI 10.1074/jbc.M000956200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thompson MW, 1999, BIOCHEM BIOPH RES CO, V258, P234, DOI 10.1006/bbrc.1999.0604; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tobler AR, 1997, J NEUROCHEM, V68, P889; Vincent B, 1996, J NEUROSCI, V16, P5049; Waggoner LF, 2000, GENETICS, V154, P1181; Wen CH, 1997, DEVELOPMENT, V124, P4759; Yamamoto Y, 2000, FORENSIC SCI INT, V113, P143, DOI 10.1016/S0379-0738(00)00280-2; Zhang Y, 2002, NATURE, V418, P331, DOI 10.1038/nature00891	62	27	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42795	42801		10.1074/jbc.M306216200	http://dx.doi.org/10.1074/jbc.M306216200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930831	hybrid			2022-12-27	WOS:000186157000010
J	Senawong, T; Peterson, VJ; Avram, D; Shepherd, DM; Frye, RA; Minucci, S; Leid, M				Senawong, T; Peterson, VJ; Avram, D; Shepherd, DM; Frye, RA; Minucci, S; Leid, M			Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; YEAST SIR2; N-COR; GENE; COREPRESSOR; FAMILY; NAD; INTERACTS; COMPLEX; HP1	Chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting proteins 1 and 2 (CTIP1 and CTIP2) enhance transcriptional repression mediated by COUP-TF II and have been implicated in hematopoietic cell development and malignancies. CTIP1 and CTIP2 are also sequence-specific DNA-binding proteins that repress transcription through direct, COUP-TF-independent binding to a GC-rich response element. CTIP1- and CTIP2-mediated transcriptional repression is insensitive to trichostatin A, an inhibitor of known class I and II histone deacetylases. However, chromatin immunoprecipitation assays revealed that expression of CTIP2 in mammalian cells resulted in deacetylation of histones H3 and/or H4 that were associated with the promoter region of a reporter gene. CTIP2-mediated transcriptional repression, as well as deacetylation of promoter-associated histones H3/H4 in CTIP2-transfected cells, was reversed by nicotinamide, an inhibitor of class III histone deacetylases such as the mammalian homologs of yeast Silent Information Regulator 2 (Sir2). The human homolog of yeast Sir2, SIRT1, was found to interact directly with CTIP2 and was recruited to the promoter template in a CTIP2-dependent manner. Moreover, SIRT1 enhanced the deacetylation of template-associated histones H3/H4 in CTIP2-transfected cells, and stimulated CTIP2-dependent transcriptional repression. Finally, endogenous SIRT1 and CTIP2 co-purified from Jurkat cell nuclear extracts in the context of a large (1-2 mDa) complex. These findings implicate SIRT1 as a histone H3/H4 deacetylase in mammalian cells and in transcriptional repression mediated by CTIP2.	Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Mol Pharmacol Lab, Corvallis, OR 97331 USA; Oregon State Univ, Coll Pharm, Mol & Cellular Biol Program, Corvallis, OR 97331 USA; Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Univ Montana, Coll Pharm, Dept Pharmaceut Sci, Ctr Environm Hlth Sci, Missoula, MT 59812 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh Vet Affairs Med Ctr 132L, Pittsburgh, PA 15240 USA; Univ Milan, Dept Physiol & Biochem, European Inst Oncol, Dept Expt Oncol, I-20126 Milan, Italy	Oregon State University; Oregon State University; Oregon State University; Albany Medical College; University of Montana System; University of Montana; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; IRCCS European Institute of Oncology (IEO); University of Milan	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Mol Pharmacol Lab, Corvallis, OR 97331 USA.	Mark.Leid@oregonstate.edu	Senawong, Thanaset/GSE-3777-2022; Minucci, Saverio/J-9669-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060852] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210, P30 ES000210, P30 ES000210-35] Funding Source: Medline; NIGMS NIH HHS [R01 GM060852, R01 GM060852-02] Funding Source: Medline; PHS HHS [EM60852] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; de Haan G, 2000, J BIOL CHEM, V275, P13493, DOI 10.1074/jbc.275.18.13493; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2000, GENE DEV, V14, P1021; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; Lorenz P, 2001, BIOL CHEM, V382, P637, DOI 10.1515/BC.2001.075; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Rohr O, 2003, J VIROL, V77, P5415, DOI 10.1128/JVI.77.9.5415-5427.2003; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Saiki Y, 2000, GENOMICS, V70, P387, DOI 10.1006/geno.2000.6385; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	55	105	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43041	43050		10.1074/jbc.M307477200	http://dx.doi.org/10.1074/jbc.M307477200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930829	Green Accepted, hybrid			2022-12-27	WOS:000186157000041
J	Ukomadu, C; Dutta, A				Ukomadu, C; Dutta, A			p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G(1) cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA REDUCTASE; S-PHASE; A GENE; P21; LOVASTATIN; ARREST; PHOSPHORYLATION; P21(WAF1/CIP1); TRANSCRIPTION; PATHWAY	Mevastatin arrested HCT116 colon cancer cells at the G(1)/S transition and increased cellular levels of p21(CIP1/WAF1). p21-deficient colon cancer cells continued to proliferate in the presence of mevastatin. Although p21 was necessary for the G(1)/S block, the G(1) cyclin-dependent kinases (Cdks) cyclin E-Cdk2 and cyclin D-Cdk4 remained active. Despite the activity of the G(1) Cdks the retinoblastoma protein was hypophosphorylated due to unknown mechanisms that were dependent on the p21 protein. The resulting decrease in cyclin A mRNA and protein led to a decrease in the activity of cyclin A-Cdk2. Therefore, although p21 was required for the G(1)/S arrest of HCT116 colon cancer cells by mevastatin, its mode of action was more complicated than the simple formation of a physical complex with cyclin-Cdk2. This mechanism of inhibition is different from that seen in prostate cancer cells (Ukomadu, C., and Dutta, A. (2003) J. Biol. Chem. 278, 4840-4846) where the activating phosphorylation of cyclin E-Cdk2 is suppressed and p21 is not required, suggesting the existence of cell line-specific differences in the mechanism by which statins arrest the cell cycle.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Gastroenterol, Boston, MA 02115 USA	University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01 CA 89406] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; DECLUE JE, 1991, CANCER RES, V51, P712; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Fouty BW, 2003, CIRC RES, V92, P501, DOI 10.1161/01.RES.0000061180.03813.0F; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kim WS, 2001, INVEST NEW DRUG, V19, P81, DOI 10.1023/A:1006481423298; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rao S, 1999, EXP CELL RES, V252, P211, DOI 10.1006/excr.1999.4620; Retterstol K, 1996, AM J CARDIOL, V78, P1369, DOI 10.1016/S0002-9149(96)00649-2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Ukomadu C, 2003, J BIOL CHEM, V278, P4840, DOI 10.1074/jbc.M208658200; Vega GL, 2003, ARCH NEUROL-CHICAGO, V60, P510, DOI 10.1001/archneur.60.4.510; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yamaguchi R, 2000, EXP CELL RES, V261, P271, DOI 10.1006/excr.2000.5053; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	29	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43586	43594		10.1074/jbc.M307194200	http://dx.doi.org/10.1074/jbc.M307194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930830	hybrid			2022-12-27	WOS:000186157000106
J	Beck, GR; Knecht, N				Beck, GR; Knecht, N			Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; SMOOTH-MUSCLE-CELLS; FIBROBLAST-GROWTH-FACTOR; P-I TRANSPORT; MC3T3-E1 CELLS; EXTRACELLULAR SIGNAL; PARATHYROID-HORMONE; GENE-EXPRESSION; DOWN-REGULATION; STIMULATION	The generation of inorganic phosphate by alkaline phosphatase during osteoblast differentiation represents an important signaling event, although the molecular and cellular consequences are currently undefined. We have previously described osteopontin as a gene regulated by an increase in inorganic phosphate not only in osteoblasts but also in other cell types. We describe here the identification of specific signaling pathways required for the stimulation of osteopontin expression by inorganic phosphate. We have determined that phosphate selectively activates the extracellular signal-regulated kinase (ERK1/2) signaling pathway but does not activate the other mitogen-activated protein kinase signaling proteins, p38, or the c-Jun N-terminal kinase. In addition, our results suggest that cellular exposure to 10 mM inorganic phosphate causes a biphasic ERK1/2 activation. The second ERK1/2 activation is required for osteopontin regulation, whereas the first is not sufficient. Analysis of common protein kinase families has revealed that phosphate-induced osteopontin expression specifically uses a protein kinase C-dependent signaling pathway. In addition, our results suggest that protein kinase C and ERK1/2 are not part of the same pathway but constitute two distinct pathways. Finally, we have determined that the proteasomal activity is required not only for phosphate-induced expression of osteopontin but also for the induction of osteopontin in response to 12-O-tetradecanoylphorbol 13-acetate and okadaic acid. The data presented here define for the first time the ability of increased inorganic phosphate to stimulate specific signaling pathways resulting in functionally significant changes in gene expression and identify three important signaling pathways in the regulation of osteopontin.	NCI, Ctr Canc Res, Basic Res Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Beck, GR (corresponding author), NCI, Ctr Canc Res, Basic Res Lab, Bldg 576,Rm 110, Frederick, MD 21702 USA.	gbeck@ncifcrf.gov	Beck, George/AAO-2117-2020		DIVISION OF BASIC SCIENCES - NCI [Z01BC010434] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K22CA084573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84573] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams CS, 2001, J BIOL CHEM, V276, P20316, DOI 10.1074/jbc.M006492200; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; AHMADO A, 1990, BIOCHEM SOC T, V18, P624, DOI 10.1042/bst0180624; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Atkins KB, 1997, ARCH BIOCHEM BIOPHYS, V343, P157, DOI 10.1006/abbi.1997.0151; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; BAYLINK D, 1971, J CLIN INVEST, V50, P2519, DOI 10.1172/JCI106752; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097-4644(19980201)68:2<269::AID-JCB13>3.0.CO;2-A; Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014-4827(03)00213-1; BELLOWS CG, 1992, BONE MINER, V17, P15, DOI 10.1016/0169-6009(92)90707-K; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; BINGHAM PJ, 1974, CALC TISS RES, V14, P31, DOI 10.1007/BF02060281; Caverzasio J, 1996, KIDNEY INT, V49, P975, DOI 10.1038/ki.1996.138; Chang PL, 2002, INT J BIOCHEM CELL B, V34, P1142, DOI 10.1016/S1357-2725(02)00035-3; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Goekjian PG, 1999, CURR MED CHEM, V6, P877; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Hullinger TG, 2000, J CELL BIOCHEM, V78, P607, DOI 10.1002/1097-4644(20000915)78:4<607::AID-JCB10>3.0.CO;2-F; Imai T, 1996, AM J PHYSIOL-ENDOC M, V271, pE694, DOI 10.1152/ajpendo.1996.271.4.E694; Kanatani M, 2002, J CELL PHYSIOL, V190, P306, DOI 10.1002/jcp.10067; Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135; Kim HJ, 2002, J CELL BIOCHEM, V87, P93, DOI 10.1002/jcb.10280; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUNKLER KJ, 1991, AM J PHYSIOL, V260, pE751, DOI 10.1152/ajpendo.1991.260.5.E751; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Masukawa H, 2001, J CELL BIOCHEM, V83, P47, DOI 10.1002/jcb.1206; Moses S, 2001, ARCH BIOCHEM BIOPHYS, V396, P133, DOI 10.1006/abbi.2001.2578; Murray EJB, 1998, EXP CELL RES, V242, P460, DOI 10.1006/excr.1998.4090; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Oates AJ, 1997, INVAS METAST, V17, P1; PIZURKI L, 1991, J BONE MINER RES, V6, P1235; Sanders JL, 1996, J BONE MINER RES, V11, P1862; SELZ T, 1991, AM J PHYSIOL, V260, pE833, DOI 10.1152/ajpendo.1991.260.6.E833; SELZ T, 1989, AM J PHYSIOL, V256, pE93, DOI 10.1152/ajpendo.1989.256.1.E93; ShiokawaSawada M, 1997, J BONE MINER RES, V12, P1165, DOI 10.1359/jbmr.1997.12.8.1165; SMITH JH, 1989, J CELL PHYSIOL, V139, P189, DOI 10.1002/jcp.1041390126; Suzuki A, 2001, BONE, V28, P589, DOI 10.1016/S8756-3282(01)00459-8; Suzuki A, 2000, J BONE MINER RES, V15, P95, DOI 10.1359/jbmr.2000.15.1.95; Takemoto M, 1999, BIOCHEM BIOPH RES CO, V258, P722, DOI 10.1006/bbrc.1999.0701; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Tokuda H, 2002, J ENDOCRINOL, V172, P271, DOI 10.1677/joe.0.1720271; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Veldman CM, 1997, BONE, V21, P41, DOI 10.1016/S8756-3282(97)00077-X; Veldman CR, 1998, ENDOCRINOLOGY, V139, P89, DOI 10.1210/en.139.1.89; Wang XD, 2002, J CELL BIOCHEM, V87, P417, DOI 10.1002/jcb.10323; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; Xie ZL, 2001, J CELL PHYSIOL, V188, P132, DOI 10.1002/jcp.1104; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200; Zhen XC, 1997, J BONE MINER RES, V12, P36, DOI 10.1359/jbmr.1997.12.1.36	61	128	131	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41921	41929		10.1074/jbc.M304470200	http://dx.doi.org/10.1074/jbc.M304470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920127	hybrid			2022-12-27	WOS:000185989500046
J	Chi, SW; Park, KH; Suk, JE; Olivera, BM; McIntosh, JM; Han, KH				Chi, SW; Park, KH; Suk, JE; Olivera, BM; McIntosh, JM; Han, KH			Solution conformation of alpha A-conotoxin EIVA, a potent neuromuscular nicotinic acetylcholine receptor antagonist from Conus ermineus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 1.1 ANGSTROM RESOLUTION; NMR SOLUTION STRUCTURE; CRYSTAL-STRUCTURE; BINDING-SITES; 3-DIMENSIONAL STRUCTURE; PROTEIN CONFORMATIONS; PAIRWISE INTERACTIONS; EXTRACELLULAR DOMAIN; AMINO-ACIDS	We report the solution three-dimensional structure of an alphaA-conotoxin EIVA determined by nuclear magnetic resonance spectroscopy and restrained molecular dynamics. The alphaA-conotoxin EIVA consists of 30 amino acids representing the largest peptide among the alpha/alphaA-family conotoxins discovered so far and targets the neuromuscular nicotinic acetylcholine receptor with high affinity. alphaA-Conotoxin EIVA consists of three distinct structural domains. The first domain is mainly composed of the Cys(3)-Cys(11)-disulfide loop and is structurally ill-defined with a large backbone root mean square deviation of 1.91 Angstrom. The second domain formed by residues His(12)-Hyp(21) is extremely well defined with a backbone root mean square deviation of 0.52 Angstrom, thus forming a sturdy stem for the entire molecule. The third C-terminal domain formed by residues Hyp(22)-Gly(29) shows an intermediate structural order having a backbone root mean square deviation of 1.04 Angstrom. A structurally ill-defined N-terminal first loop domain connected to a rigid central molecular stem seems to be the general structural feature of the alphaA-conotoxin subfamily. A detailed structural comparison between alphaA-conotoxin EIVA and alphaA-conotoxin PIVA suggests that the higher receptor affinity of alphaA-conotoxin EIVA than alphaA-conotoxin PIVA might originate from different steric disposition and charge distribution in the second loop "handle" motif.	Korea Res Inst Biosci & Biotechnol, Div Genom & Proteom, Proteome Anal Lab, Taejon, South Korea; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Han, KH (corresponding author), Korea Res Inst Biosci & Biotechnol, Div Genom & Proteom, Proteome Anal Lab, Yusong POB 115, Taejon, South Korea.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053631, R29MH053631] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48677] Funding Source: Medline; NIMH NIH HHS [MH 53631] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abbott R. T., 1986, COMPENDIUM SEASHELLS; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; Alexeev T, 1999, EUR J BIOCHEM, V259, P310, DOI 10.1046/j.1432-1327.1999.00041.x; [Anonymous], 1995, MANUAL LIVING CONIDA; Arias HR, 2000, INT J BIOCHEM CELL B, V32, P1017, DOI 10.1016/S1357-2725(00)00051-0; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Benie AJ, 2000, FEBS LETT, V476, P287, DOI 10.1016/S0014-5793(00)01724-5; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BORGIAS BA, 1988, J MAGN RESON, V79, P493, DOI 10.1016/0022-2364(88)90085-6; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Bren N, 2000, J BIOL CHEM, V275, P12692, DOI 10.1074/jbc.275.17.12692; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; Cho JH, 2000, J BIOL CHEM, V275, P8680, DOI 10.1074/jbc.275.12.8680; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P1732, DOI 10.1021/bi00380a037; Dutton JL, 2001, CURR MED CHEM, V8, P327, DOI 10.2174/0929867013373453; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; Favreau P, 1999, BIOCHEMISTRY-US, V38, P6317, DOI 10.1021/bi982817z; GALZI JL, 1990, J BIOL CHEM, V265, P10430; Grant MA, 1999, BIOCHEMISTRY-US, V38, P10730, DOI 10.1021/bi983007q; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guddat LW, 1996, BIOCHEMISTRY-US, V35, P11329, DOI 10.1021/bi960820h; Han KH, 1997, BIOCHEMISTRY-US, V36, P1669, DOI 10.1021/bi962301k; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; Hu SH, 1998, BIOCHEMISTRY-US, V37, P11425, DOI 10.1021/bi9806549; Jacobsen R, 1997, J BIOL CHEM, V272, P22531, DOI 10.1074/jbc.272.36.22531; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; Lamthanh H, 1999, FEBS LETT, V454, P293, DOI 10.1016/S0014-5793(99)00831-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu H, 1995, J BIOMOL NMR, V6, P390; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; Maslennikov IV, 1999, FEBS LETT, V444, P275, DOI 10.1016/S0014-5793(99)00069-1; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Mok KH, 1999, BIOCHEMISTRY-US, V38, P11895, DOI 10.1021/bi990558n; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; Park KH, 2001, J BIOL CHEM, V276, P49028, DOI 10.1074/jbc.M107798200; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; Rogers JP, 1999, BIOCHEMISTRY-US, V38, P3874, DOI 10.1021/bi9826254; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; Samson AO, 2002, NEURON, V35, P319, DOI 10.1016/S0896-6273(02)00773-0; Scarselli M, 2002, BIOCHEMISTRY-US, V41, P1457, DOI 10.1021/bi011012f; Shon KJ, 1997, BIOCHEMISTRY-US, V36, P15693, DOI 10.1021/bi971443r; STEPHANIE AD, 2000, J BIOL CHEM, V275, P29594; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; THOMAS PD, 1991, P NATL ACAD SCI USA, V88, P1237, DOI 10.1073/pnas.88.4.1237; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; Walls J.G., 1979, CONE SHELLS SYNOPSIS; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Xie Y, 2001, J BIOL CHEM, V276, P2417, DOI 10.1074/jbc.M009085200; Yao Y, 2002, J BIOL CHEM, V277, P12613, DOI 10.1074/jbc.M108845200	57	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42208	42213		10.1074/jbc.M303342200	http://dx.doi.org/10.1074/jbc.M303342200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12900418	hybrid			2022-12-27	WOS:000185989500079
J	Nienhaus, K; Deng, PC; Olson, JS; Warren, JJ; Nienhaus, GU				Nienhaus, K; Deng, PC; Olson, JS; Warren, JJ; Nienhaus, GU			Structural dynamics of myoglobin - Ligand migration and binding in valine 68 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; DISTAL POCKET POLARITY; CARBON-MONOXIDE; HEME-PROTEINS; CRYSTAL-STRUCTURES; CONFORMATIONAL RELAXATION; VIBRATIONAL FREQUENCIES; DERIVATIVE SPECTROSCOPY; GEMINATE RECOMBINATION	We have combined Fourier transform infrared/temperature derivative (FTIR-TDS) spectroscopy at cryogenic temperatures and flash photolysis at ambient temperature to examine the effects of polar and bulky amino acid replacements of the highly conserved distal valine 68 in sperm whale myoglobin. In FTIR-TDS experiments, the CO ligand can serve as an internal voltmeter that monitors the local electrostatic field not only at the active site but also at intermediate ligand docking sites. Mutations of residue 68 alter size, shape, and electric field of the distal pocket, especially in the vicinity of the primary docking site ( state B). As a consequence, the infrared bands associated with the ligand at site B are shifted. The effect is most pronounced in mutants with large aromatic side chains. Polar side chains ( threonine or serine) have only little effect on the peak frequencies. Ligands that migrate toward more remote sites C and D give rise to IR bands with altered frequencies. TDS experiments separate the photoproducts according to their recombination temperatures. The rates and extent of ligand migration among internal cavities at cryogenic temperatures can be used to interpret geminate and bimolecular O-2 and CO recombination at room temperature. The kinetics of geminate recombination can be explained by steric arguments alone, whereas both the polarity and size of the position 68 side chain play major roles in regulating bimolecular ligand binding from the solvent.	Univ Ulm, Dept Biophys, D-89081 Ulm, Germany; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	Ulm University; Rice University; University of Illinois System; University of Illinois Urbana-Champaign	Nienhaus, GU (corresponding author), Univ Ulm, Dept Biophys, Albert Einstein Allee 11, D-89081 Ulm, Germany.		Nienhaus, Gerd Ulrich/G-8698-2012	Nienhaus, Gerd Ulrich/0000-0002-5027-3192; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BERENDZEN J, 1990, P NATL ACAD SCI USA, V87, P1, DOI 10.1073/pnas.87.1.1; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BRUNORI M, 1972, P NATL ACAD SCI USA, V69, P868, DOI 10.1073/pnas.69.4.868; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CAUGHEY WS, 1970, ANN NY ACAD SCI, V174, P148, DOI 10.1111/j.1749-6632.1970.tb49781.x; Christian JF, 1997, BIOCHEMISTRY-US, V36, P11198, DOI 10.1021/bi9710075; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; Dantsker D, 2002, J MOL BIOL, V315, P239, DOI 10.1006/jmbi.2001.5218; Dou Y, 2002, BIOPHYS CHEM, V98, P127, DOI 10.1016/S0301-4622(02)00090-X; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; Franzen S, 2002, J AM CHEM SOC, V124, P13271, DOI 10.1021/ja017708d; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; FRONTICELLI C, 1993, BIOCHEMISTRY-US, V32, P1235, DOI 10.1021/bi00056a006; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HONG MK, 1990, BIOPHYS J, V58, P429, DOI 10.1016/S0006-3495(90)82388-2; Ishikawa H, 2001, BIOPHYS J, V80, P1507, DOI 10.1016/S0006-3495(01)76123-1; Johnson JB, 1996, BIOPHYS J, V71, P1563, DOI 10.1016/S0006-3495(96)79359-1; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; Kriegl JM, 2003, P NATL ACAD SCI USA, V100, P7069, DOI 10.1073/pnas.1231856100; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; MILLER LM, 1996, J AM CHEM SOC, V34, P10170; MOURANT JR, 1993, BIOPHYS J, V65, P1496, DOI 10.1016/S0006-3495(93)81218-9; Muller JD, 1999, BIOPHYS J, V77, P1036, DOI 10.1016/S0006-3495(99)76954-7; NIENHAUS GU, 1992, P NATL ACAD SCI USA, V89, P2902, DOI 10.1073/pnas.89.7.2902; NIENHAUS GU, 1994, BIOCHEMISTRY-US, V33, P13413, DOI 10.1021/bi00249a030; Nienhaus GU, 2002, J BIOL PHYS, V28, P163, DOI 10.1023/A:1019990522433; Nienhaus GU, 1998, BIOCHEMISTRY-US, V37, P6819, DOI 10.1021/bi972843h; NIENHAUS GU, 1996, PROTEIN DYNAMICS, P163; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9633, DOI 10.1021/bi034787s; Nienhaus K, 2002, BIOPHYS J, V82, P1059, DOI 10.1016/S0006-3495(02)75465-9; NIENHAUS K, 2003, SPECTROSCOPIC STUDIE; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Park ES, 1999, J PHYS CHEM B, V103, P9813, DOI 10.1021/jp992329g; Park ES, 2002, J PHYS CHEM B, V106, P5800, DOI 10.1021/jp0203043; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; Pechik I, 1996, BIOCHEMISTRY-US, V35, P1935, DOI 10.1021/bi9519967; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; POWERS L, 1987, BIOCHEMISTRY-US, V26, P4785, DOI 10.1021/bi00389a028; POWERS LS, 1988, BIOPHYS J, V54, P181, DOI 10.1016/S0006-3495(88)82943-6; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPIRO TG, 1995, SCIENCE, V270, P221; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P4886, DOI 10.1021/bi00234a008; Sugimoto T, 1998, BIOPHYS J, V75, P2188, DOI 10.1016/S0006-3495(98)77662-3; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; Ye X, 2002, J AM CHEM SOC, V124, P5914, DOI 10.1021/ja017359n	78	65	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42532	42544		10.1074/jbc.M306888200	http://dx.doi.org/10.1074/jbc.M306888200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907676	hybrid			2022-12-27	WOS:000185989500118
J	Chaturvedi, S; Bhakuni, V				Chaturvedi, S; Bhakuni, V			Unusual structural, functional, and stability properties of serine hydroxymethyltransferase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SHEEP LIVER; D-ALANINE; PURIFICATION; TRANSHYDROXYMETHYLASE; COMPARTMENTATION; TRANSAMINATION; MITOCHONDRIAL	From the genome analysis of the Mycobacterium tuberculosis two putative genes namely GlyA and GlyA2 have been proposed to encode for the enzyme serine hydroxymethyltransferase. We have cloned, overexpressed, and purified to homogeneity their respective protein products, serine hydroxymethyltransferase, SHM1 and SHM2. The recombinant SHM1 and SHM2 exist as homodimers of molecular mass about 90 kDa under physiological conditions, however, SHM2 has more compact conformation and higher thermal stability than SHM1. The most interesting structural observation was that the SHM1 contains 1 mol of pyridoxal 5'-phosphate (PLP)/mol of enzyme dimer. This is the first report of such a unique stoichiometry of PLP and enzyme dimer for SHMT. The SHM2 contains 2 mol of PLP/mol of enzyme dimer, which is the usual stoichiometry reported for SHMT. Functionally both the recombinant enzymes showed catalysis of reversible interconversion of serine and glycine and aldol cleavage of a 3-hydroxyamino acid. However, unlike SHMT from other sources both SHM1 and SHM2 do not undergo half-transamination reaction with D-alanine resulting in formation of apoenzyme but L-cysteine removed the prosthetic group, PLP, from both the recombinant enzymes leaving the respective inactive apoenzymes. Comparative structural studies on the two enzymes showed that the SHM1 is resistant to alkaline denaturation up to pH 10.5, whereas the native SHM2 dimer dissociates into monomer at pH 9. Urea- and guanidinium chloride-induced two-step unfolding of SHM1 and SHM2 with the first step being dissociation of dimer into apomonomer at low denaturant concentrations followed by unfolding of the stabilized monomer at higher denaturant concentrations.	Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Bhakuni, V (corresponding author), Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India.	bhakuniv@rediffmail.com						ANDREWS P, 1965, BIOCHEM J, V96, P569; ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BESSON V, 1995, PLANT PHYSIOL BIOCH, V33, P665; Bhatt AN, 2002, BIOCHEMISTRY-US, V41, P12115, DOI 10.1021/bi020356i; Cai K, 1996, J BIOL CHEM, V271, P2987, DOI 10.1074/jbc.271.6.2987; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; Cai K, 1996, J BIOL CHEM, V271, P27311, DOI 10.1074/jbc.271.44.27311; Capelluto DGS, 1999, MOL BIOCHEM PARASIT, V98, P187, DOI 10.1016/S0166-6851(98)00166-2; Capelluto DGS, 2000, EUR J BIOCHEM, V267, P712, DOI 10.1046/j.1432-1327.2000.01047.x; Contestabile R, 2001, EUR J BIOCHEM, V268, P6508, DOI 10.1046/j.0014-2956.2001.02606.x; GARROW TA, 1993, J BIOL CHEM, V268, P11910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MALKIN LI, 1964, BIOCHIM BIOPHYS ACTA, V85, P117, DOI 10.1016/0926-6569(64)90172-5; MANOHAR R, 1982, J BIOSCIENCES, V4, P31, DOI 10.1007/BF02702579; McNeil JB, 1996, GENETICS, V142, P371; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; SAKAMOTO M, 1996, Z BIOSCI BIOTECH BIO, V60, P1914; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; SCHIRCH L, 1964, J BIOL CHEM, V239, P3797; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH L, 1962, J BIOL CHEM, V237, P2578; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SHANE B, 1989, VITAM HORM, V45, P263; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; TAYLOR RT, 1965, ANAL BIOCHEM, V13, P80, DOI 10.1016/0003-2697(65)90120-X; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; Venkatesha B, 1998, BBA-PROTEIN STRUCT M, V1384, P141, DOI 10.1016/S0167-4838(98)00013-2	30	30	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40793	40805		10.1074/jbc.M306192200	http://dx.doi.org/10.1074/jbc.M306192200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12913008	hybrid			2022-12-27	WOS:000185847200048
J	Linseman, DA; Bartley, CM; Le, SS; Laessig, TA; Bouchard, RJ; Meintzer, MK; Li, MT; Heidenreich, KA				Linseman, DA; Bartley, CM; Le, SS; Laessig, TA; Bouchard, RJ; Meintzer, MK; Li, MT; Heidenreich, KA			Inactivation of the myocyte enhancer factor-2 repressor histone deacetylase-5 by endogenous Ca2+/calmodulin-dependent kinase II promotes depolarization-mediated cerebellar granule neuron survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MEF2 TRANSCRIPTION FACTOR; CULTURED HIPPOCAMPAL-NEURONS; INDUCED NEURITE-OUTGROWTH; CENTRAL-NERVOUS-SYSTEM; FACTOR 2C EXPRESSION; MUSCLE FIBER-TYPE; GROWTH-FACTOR-I; CARDIAC-HYPERTROPHY; BRAIN-DEVELOPMENT	Cerebellar granule neuron (CGN) survival depends on activity of the myocyte enhancer factor-2 (MEF2) transcription factors. Neuronal MEF2 activity is regulated by depolarization via a mechanism that is presently unclear. Here, we show that depolarization-mediated MEF2 activity and CGN survival are compromised by overexpression of the MEF2 repressor histone deacetylase-5 (HDAC5). Furthermore, removal of depolarization induced rapid cytoplasm-to-nuclear translocation of endogenous HDAC5. This effect was mimicked by addition of the calcium/calmodulin-dependent kinase ( CaMK) inhibitor KN93 to depolarizing medium. Removal of depolarization or KN93 addition resulted in dephosphorylation of HDAC5 and its co-precipitation with MEF2D. HDAC5 nuclear translocation triggered by KN93 induced a marked loss of MEF2 activity and subsequent apoptosis. To selectively decrease CaMKII, CGNs were incubated with an antisense oligonucleotide to CaMKIIalpha. This antisense decreased CaMKIIalpha expression and induced nuclear shuttling of HDAC5 in CGNs maintained in depolarizing medium. Selectivity of the CaMKIIalpha antisense was demonstrated by its lack of effect on CaMKIV-mediated CREB phosphorylation. Finally, antisense to CaMKIIalpha induced caspase-3 activation and apoptosis, whereas a missense control oligonucleotide had no effect on CGN survival. These results indicate that depolarization-mediated calcium influx acts through CaMKII to inhibit HDAC5, thereby sustaining high MEF2 activity in CGNs maintained under depolarizing conditions.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Heidenreich, KA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol C236, 4200 E 9th Ave, Denver, CO 80262 USA.		Linseman, Daniel/L-3846-2019; Bartley, Christopher/G-4226-2012	Bartley, Christopher/0000-0002-1391-4130	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007205] Funding Source: Medline; NINDS NIH HHS [NS38619-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babcock AM, 1999, J NEUROSCI RES, V56, P36, DOI 10.1002/(SICI)1097-4547(19990401)56:1<36::AID-JNR5>3.0.CO;2-4; Babcock AM, 2002, J NEUROSCI RES, V67, P804, DOI 10.1002/jnr.10169; BEAMANHALL CM, 1992, J NEUROCHEM, V58, P1259, DOI 10.1111/j.1471-4159.1992.tb11337.x; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Borodinsky LN, 2002, J NEUROCHEM, V80, P1062, DOI 10.1046/j.1471-4159.2002.00795.x; Borodinsky LN, 2003, J NEUROCHEM, V84, P1411, DOI 10.1046/j.1471-4159.2003.01638.x; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BURGIN KE, 1990, J NEUROSCI, V10, P1788; Chawla S, 2003, J NEUROCHEM, V85, P151, DOI 10.1046/j.1471-4159.2003.01648.x; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Churn SB, 2000, P NATL ACAD SCI USA, V97, P5604, DOI 10.1073/pnas.080071697; CHURN SB, 1995, J NEUROSCI, V15, P3200; Condon JC, 2002, ENDOCRINOLOGY, V143, P3651, DOI 10.1210/en.2001-211359; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kato T, 2000, CIRC RES, V87, P937, DOI 10.1161/01.RES.87.10.937; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; Leifer D, 1997, J MOL NEUROSCI, V8, P131, DOI 10.1007/BF02736778; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Linseman DA, 2002, J NEUROSCI, V22, P9287; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; SHACKELFORD DA, 1995, J CEREBR BLOOD F MET, V15, P450, DOI 10.1038/jcbfm.1995.56; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	59	104	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41472	41481		10.1074/jbc.M307245200	http://dx.doi.org/10.1074/jbc.M307245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896970	hybrid			2022-12-27	WOS:000185847200127
J	Okuno, T; Ago, H; Terawaki, K; Miyano, M; Shimizu, T; Yokomizo, T				Okuno, T; Ago, H; Terawaki, K; Miyano, M; Shimizu, T; Yokomizo, T			Helix 8 of the leukotriene B-4 receptor is required for the conformational change to the low affinity state after G-protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT CHANGES; COUPLED RECEPTOR; CYTOPLASMIC TAIL; C-TERMINUS; PHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; GABA(B) RECEPTORS; RHODOPSIN; KINASE; DESENSITIZATION	Recent studies have revealed that G-protein-coupled receptors contain a putative cytoplasmic helical domain, helix 8. Leukotriene B-4 (LTB4) receptor 1 derivatives with truncated or mutated helix 8 showed much higher LTB4 binding than wild-type (WT) receptors. Similar to the WT receptor, LTB4 promoted guanosine 5'-3-O-(thio) triphosphate (GTPgammaS) binding in these mutants. Unlike the WT receptor, however, the addition of GTPgammaS did not inhibit LTB4 binding to the mutant receptors. Scatchard analyses revealed that mutants maintained high affinity for LTB4, even in the presence of excess GTPgammaS. Consistently, mutant receptors showed a more prolonged Ca2+ mobilization and cellular metabolic activation than the WT receptor. From mutational studies and three-dimensional modeling based on the structure of bovine rhodopsin, we conclude that the helix 8 of LTB4 receptor 1 plays an important role in the conformational change of the receptor to the low affinity state after G-protein activation, possibly by sensing the status of coupling Galpha subunits as GTP-bound.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, PRESTO, CREST, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Harima Inst SPring 8, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan	University of Tokyo; Japan Science & Technology Agency (JST); RIKEN	Yokomizo, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Miyano, Masashi/R-2785-2016; Shimizu, Takao/AAV-7052-2021; Yokomizo, Takehiko/P-5673-2016	Miyano, Masashi/0000-0003-2253-6175; Yokomizo, Takehiko/0000-0002-5219-1553; Ago, Hideo/0000-0002-9040-488X				Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bohm SK, 1997, BIOCHEM J, V322, P1; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen ZG, 2002, J BIOL CHEM, V277, P7356, DOI 10.1074/jbc.M110058200; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; DRYDEN P, 1992, PROSTAGLANDINS, V44, P11, DOI 10.1016/0090-6980(92)90103-Z; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gaudreau R, 2002, J BIOL CHEM, V277, P31567, DOI 10.1074/jbc.M202723200; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Masuda K, 1999, BIOCHEM J, V342, P79, DOI 10.1042/0264-6021:3420079; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Moepps Barbara, 2003, EMBO Reports, V4, P237, DOI 10.1038/sj.embor.embor777; OFLAHERTY JT, 1986, FEBS LETT, V206, P279, DOI 10.1016/0014-5793(86)80996-6; Ohshima N, 2002, J BIOL CHEM, V277, P9722, DOI 10.1074/jbc.M112406200; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Pagano A, 2001, J NEUROSCI, V21, P1189; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Sambrook J., 2001, MOL CLONING; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SHOWELL HJ, 1982, J IMMUNOL, V128, P811; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Tager AM, 2000, J EXP MED, V192, P439, DOI 10.1084/jem.192.3.439; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Toda A, 1999, BIOCHEM BIOPH RES CO, V262, P806, DOI 10.1006/bbrc.1999.1284; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yokomizo T, 2000, AM J RESP CRIT CARE, V161, pS51, DOI 10.1164/ajrccm.161.supplement_1.ltta-11; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	54	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41500	41509		10.1074/jbc.M307335200	http://dx.doi.org/10.1074/jbc.M307335200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902330	hybrid			2022-12-27	WOS:000185847200130
J	Tuli, R; Tuli, S; Nandi, S; Huang, XX; Manner, PA; Hozack, WJ; Danielson, KG; Hall, DJ; Tuan, RS				Tuli, R; Tuli, S; Nandi, S; Huang, XX; Manner, PA; Hozack, WJ; Danielson, KG; Hall, DJ; Tuan, RS			Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogenactivated protein kinase and Wnt signaling cross-talk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRABECULAR BONE; HUMAN ADIPOSE-TISSUE; CHICK LIMB BUD; STEM-CELLS; IN-VITRO; MORPHOGENETIC PROTEIN-2; GENE-EXPRESSION; ATDC5 CELLS; DIFFERENTIATION; MARROW	The multilineage differentiation potential of adult tissue-derived mesenchymal progenitor cells (MPCs), such as those from bone marrow and trabecular bone, makes them a useful model to investigate mechanisms regulating tissue development and regeneration, such as cartilage. Treatment with transforming growth factor-beta( TGF-beta) superfamily members is a key requirement for the in vitro chondrogenic differentiation of MPCs. Intracellular signaling cascades, particularly those involving the mitogen-activated protein ( MAP) kinases, p38, ERK-1, and JNK, have been shown to be activated by TGF-betas in promoting cartilage-specific gene expression. MPC chondrogenesis in vitro also requires high cell seeding density, reminiscent of the cellular condensation requirements for embryonic mesenchymal chondrogenesis, suggesting common chondro-regulatory mechanisms. Prompted by recent findings of the crucial role of the cell adhesion protein, N-cadherin, and Wnt signaling in condensation and chondrogenesis, we have examined here their involvement, as well as MAP kinase signaling, in TGF-beta1-induced chondrogenesis of trabecular bone-derived MPCs. Our results showed that TGF-beta1 treatment initiates and maintains chondrogenesis of MPCs through the differential chondro-stimulatory activities of p38, ERK-1, and to a lesser extent, JNK. This regulation of MPC chondrogenic differentiation by the MAP kinases involves the modulation of N-cadherin expression levels, thereby likely controlling condensation-like cell-cell interaction and progression to chondrogenic differentiation, by the sequential up-regulation and progressive down-regulation of N-cadherin. TGF-beta1-mediated MAP kinase activation also controls WNT-7A gene expression and Wnt-mediated signaling through the intracellular beta-catenin-TCF pathway, which likely regulates N-cadherin expression and subsequent N-cadherin-mediated cell-adhesion complexes during the early steps of MPC chondrogenesis.	NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; George Washington Univ, Dept Orthopaed Surg, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Jefferson University; George Washington University	Tuan, RS (corresponding author), NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Dept Hlth & Human Serv, Bldg 50,Rm 1503,50 South Dr,MSC 8022, Bethesda, MD 20892 USA.	Tuanr@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041141, ZIAAR041131, Z01AR041141, Z01AR041131] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi N, 2002, J RHEUMATOL, V29, P1920; ANTONIO JDS, 1986, DEV BIOL, V115, P313, DOI 10.1016/0012-1606(86)90252-6; Barry F, 2001, EXP CELL RES, V268, P189, DOI 10.1006/excr.2001.5278; Behrens J, 2000, J CELL SCI, V113, P911; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Bosch P, 2000, J ORTHOP RES, V18, P933, DOI 10.1002/jor.1100180613; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429; Caterson E, 2002, MOL BIOTECHNOL, V20, P245, DOI 10.1385/MB:20:3:245; De Bari C, 2001, ARTHRITIS RHEUM, V44, P85, DOI 10.1002/1529-0131(200101)44:1<85::AID-ANR12>3.0.CO;2-6; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; DeLise AM, 2002, J CELL BIOCHEM, V87, P342, DOI 10.1002/jcb.10308; Delise AM, 2002, DEV DYNAM, V225, P195, DOI 10.1002/dvdy.10151; Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432-0436.1999.6420067.x; Fischer L, 2002, J CELL BIOCHEM, V84, P816, DOI 10.1002/jcb.10091; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138; Haas AR, 1999, DIFFERENTIATION, V64, P77, DOI 10.1046/j.1432-0436.1999.6420077.x; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Horner A, 1998, BONE, V23, P95, DOI 10.1016/S8756-3282(98)00080-5; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; Majumdar MK, 2001, J CELL PHYSIOL, V189, P275, DOI 10.1002/jcp.10025; NAKAHARA H, 1991, J ORTHOP RES, V9, P465, DOI 10.1002/jor.1100090402; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Noth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736-0266(02)00018-9; OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Osyczka AM, 2002, ANN NY ACAD SCI, V961, P73, DOI 10.1111/j.1749-6632.2002.tb03054.x; Osyczka AM, 2002, CALCIFIED TISSUE INT, V71, P447, DOI 10.1007/s00223-001-1090-2; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; Sekiya I, 2001, BIOCHEM BIOPH RES CO, V284, P411, DOI 10.1006/bbrc.2001.4898; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Stott NS, 1999, J CELL PHYSIOL, V180, P314, DOI 10.1002/(SICI)1097-4652(199909)180:3<314::AID-JCP2>3.3.CO;2-P; Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614; Tufan AC, 2002, EXP CELL RES, V273, P197, DOI 10.1006/excr.2001.5448; Tufan AC, 2001, FASEB J, V15, P1436, DOI 10.1096/fj.00-0784fje; Tuli R, 2003, MOL BIOTECHNOL, V23, P37, DOI 10.1385/MB:23:1:37; Tuli R, 2002, ANN NY ACAD SCI, V961, P172, DOI 10.1111/j.1749-6632.2002.tb03077.x; Wada MR, 2002, DEVELOPMENT, V129, P2987; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	54	374	406	0	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41227	41236		10.1074/jbc.M305312200	http://dx.doi.org/10.1074/jbc.M305312200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893825	hybrid			2022-12-27	WOS:000185847200101
J	Yu, SSF; Wu, LY; Chen, KHC; Luo, WI; Huang, DS; Chan, SI				Yu, SSF; Wu, LY; Chen, KHC; Luo, WI; Huang, DS; Chan, SI			The stereospecific hydroxylation of [2,2-H-2(2)]butane and chiral dideuteriobutanes by the particulate methane monooxygenase from Methylococcus capsulatus (bath)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXYGEN ACTIVATION; COPPER IONS; OXIDATION; CATALYSTS; MECHANISM; ALCOHOLS; ENZYMES; SYSTEM	Experiments on cryptically chiral ethanes have indicated that the particulate methane monooxygenase ( pMMO) from Methylococcus capsulatus ( Bath) catalyzes the hydroxylation of ethane with total retention of configuration at the carbon center attacked. This result would seem to rule out a radical mechanism for the hydroxylation chemistry, at least as mediated by this enzyme. The interpretation of subsequent experiments on n-propane, n-butane, and n-pentane has been complicated by hydroxylation at both the pro-R and pro-S secondary C - H bonds, where the hydroxylation takes place. It has been suggested that these results merely reflect presentation of both the pro-R and pro-S C - H bonds to the hot "oxygen atom" species generated at the active site, and that the oxo-transfer chemistry, in fact, proceeds concertedly with retention of configuration. In the present work, we have augmented these earlier studies with experiments on [2,2-H-2(2)] butane and designed d,l form chiral dideuteriobutanes. Essentially equal amounts of (2R)-[3,3-H-2(2)] butan-2-ol and (2R)-[2-H-2(1)] butan-2-ol are produced upon hydroxylation of [2,2(2)H(2)] butane. The chemistry is stereospecific with full retention of configuration at the secondary carbon oxidized. In the case of the various chiral deuterated butanes, the extent of configurational inversion has been shown to be negligible for all the chiral butanes examined. Thus, the hydroxylation of butane takes place with full retention of configuration in butane as well as in the case of ethane. These results are interpreted in terms of an oxo-transfer mechanism based on side-on singlet oxene insertion across the C - H bond similar to that previously noted for singlet carbene insertion (Kirmse, W., and Ozkir, I. S. ( 1992) J. Am. Chem. Soc. 114, 7590 - 7591). Finally, we discuss how even the oxene insertion mechanism, with "spin crossover" in the transition state, could lead to small amounts of radical rearrangement products, if and when such products are observed. A scheme is described that unifies the two extreme mechanistic limits, namely the concerted oxene insertion and the hydrogen abstraction radical rebound mechanism within the same over-arching framework.	Acad Sinica, Inst Chem, Taipei 115, Taiwan; Natl Cheng Kung Univ, Dept Chem, Tainan 701, Taiwan	Academia Sinica - Taiwan; National Cheng Kung University	Chan, SI (corresponding author), Acad Sinica, Inst Chem, Taipei 115, Taiwan.	chans@chem.sinica.edu.tw	Yu, Steve Sheng-Fa/E-4866-2015	Yu, Steve Sheng-Fa/0000-0002-3462-065X				Baik MH, 2003, CHEM REV, V103, P2385, DOI 10.1021/cr950244f; Choi SY, 1996, J AM CHEM SOC, V118, P6547, DOI 10.1021/ja952226l; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; de Visser SP, 2001, ANGEW CHEM INT EDIT, V40, P2871, DOI 10.1002/1521-3773(20010803)40:15<2871::AID-ANIE2871>3.0.CO;2-R; Elliott SJ, 1997, J AM CHEM SOC, V119, P9949, DOI 10.1021/ja971049g; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; FORLANI O, 1992, MATER CHEM PHYS, V31, P155, DOI 10.1016/0254-0584(92)90169-9; GETZ E, 1987, J AM CHEM SOC, V109, P8109; HELMKAMP GK, 1957, J ORG CHEM, V22, P479, DOI 10.1021/jo01356a001; Huang DS, 2002, CHEMBIOCHEM, V3, P760, DOI 10.1002/1439-7633(20020802)3:8<760::AID-CBIC760>3.0.CO;2-K; KIRMSE W, 1992, J AM CHEM SOC, V114, P7590, DOI 10.1021/ja00045a057; KRISHNAMURTHY S, 1976, J ORG CHEM, V41, P3064, DOI 10.1021/jo00880a045; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; MAITRA AM, 1993, APPL CATAL A-GEN, V104, P11, DOI 10.1016/0926-860X(93)80209-9; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; Newcomb M, 2002, J AM CHEM SOC, V124, P6879, DOI 10.1021/ja017858o; Nguyen HHAT, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P150; Nguyen HHT, 1998, J BIOL CHEM, V273, P7957, DOI 10.1074/jbc.273.14.7957; NGUYEN HHT, 1994, J BIOL CHEM, V269, P14995; Nguyen HHT, 1996, J AM CHEM SOC, V118, P12766, DOI 10.1021/ja961778g; OLAH GA, 1987, ACCOUNTS CHEM RES, V20, P422, DOI 10.1021/ar00143a006; PARKER D, 1983, J CHEM SOC PERK T 2, P83, DOI 10.1039/p29830000083; Periana RA, 1998, SCIENCE, V280, P560, DOI 10.1126/science.280.5363.560; PERIANA RA, 1993, SCIENCE, V259, P340, DOI 10.1126/science.259.5093.340; PRIESTLEY ND, 1992, J AM CHEM SOC, V114, P7561, DOI 10.1021/ja00045a037; RAJA R, 1997, APPL CATAL A-GEN, V158, P7; Valentine AM, 1997, J AM CHEM SOC, V119, P1818, DOI 10.1021/ja963971g; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Wilkinson B, 1996, J AM CHEM SOC, V118, P921, DOI 10.1021/ja953407q; Wolf D, 1998, ANGEW CHEM INT EDIT, V37, P3351, DOI 10.1002/(SICI)1521-3773(19981231)37:24<3351::AID-ANIE3351>3.0.CO;2-U; YU SSF, 2003, IN PRESS J BACTERIOL, V185	32	36	37	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40658	40669		10.1074/jbc.M301018200	http://dx.doi.org/10.1074/jbc.M301018200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909646	hybrid			2022-12-27	WOS:000185847200030
J	Olson, MR; Holley, CL; Gan, EC; Colon-Ramos, DA; Kaplan, B; Kornbluth, S				Olson, MR; Holley, CL; Gan, EC; Colon-Ramos, DA; Kaplan, B; Kornbluth, S			A GH3-like domain in reaper is required for mitochondrial localization and induction of IAP degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; DROSOPHILA-REAPER; HEAD INVOLUTION; REGULATING APOPTOSIS; MAMMALIAN-CELLS; GRIM; HID; DIAP1; INHIBITION	Reaper is a potent pro-apoptotic protein originally identified in a screen for Drosophila mutants defective in apoptotic induction. Multiple functions have been ascribed to this protein, including inhibition of IAPs (inhibitors of apoptosis); induction of IAP degradation; inhibition of protein translation; and when expressed in vertebrate cells, induction of mitochondrial cytochrome c release. Structure/function analysis of Reaper has identified an extreme N-terminal motif that appears to be sufficient for inhibition of IAP function. We report here that this domain, although required for IAP destabilization, is not sufficient. Moreover, we have identified a small region of Reaper, similar to the GH3 domain of Grim, that is required for localization of Reaper to mitochondria, induction of IAP degradation, and potent cell killing. Although a mutant Reaper protein lacking the GH3 domain was deficient in these properties, these defects could be fully rectified by appending either the C-terminal mitochondrial targeting sequence from Bcl-x(L) or a homologous region from the pro-apoptotic protein HID. Together, these data strongly suggest that IAP destabilization by Reaper in intact cells requires Reaper localization to mitochondria and that induction of IAP instability by Reaper is important for the potent induction of apoptosis in Drosophila cells.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	Duke University; City of Hope; Beckman Research Institute of City of Hope	Kornbluth, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813,C370 LSRC Res Dr, Durham, NC 27710 USA.		Holley, Christopher/T-1312-2019; Holley, Christopher/ABB-6677-2020	Holley, Christopher/0000-0002-2870-3352; 	NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061919] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NIGMS NIH HHS [R01 GM61919, R01 GM061919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT MK, 1991, GENETICS, V129, P783; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Claveria C, 2002, EMBO J, V21, P3327, DOI 10.1093/emboj/cdf354; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lisi S, 2000, GENETICS, V154, P669; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Silke J, 2001, J CELL SCI, V114, P1821; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Thress K, 2001, EMBO J, V20, P1033, DOI 10.1093/emboj/20.5.1033; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	41	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44758	44768		10.1074/jbc.M308055200	http://dx.doi.org/10.1074/jbc.M308055200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12917412	hybrid			2022-12-27	WOS:000186306700110
J	Hsieh, T; Gordon, RE; Clemmons, DR; Busby, WH; Duan, CM				Hsieh, T; Gordon, RE; Clemmons, DR; Busby, WH; Duan, CM			Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FACTOR (IGF)-BINDING PROTEINS; FACTOR-I; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; FACTOR ISOFORMS; AMINO-ACIDS; IGFBP-5; MIGRATION	Insulin-like growth factor (IGF)-I is a pleiotropic hormone that regulates vascular smooth muscle cell (VSMC) migration, proliferation, apoptosis, and differentiation. These actions are mediated by the IGF-I receptor. How activation of the same receptor by the same ligand leads to these diverse cellular responses is not well understood. Here we describe a novel mechanism specifying VSMC responses to IGF-I stimulation, distinctive for the pivotal roles of local IGF-binding proteins (IGFBPs). The role of local IGFBPs was indicated by comparing the activities of IGF-I and des-1-3-IGF-I, an IGF-I analog with reduced binding affinity to IGF-BPs. Compared with IGF-I, des-1-3-IGF-I was more potent in stimulating DNA synthesis but much less potent in inducing directed migration of VSMCs. When the effects of individual IGFBPs were tested, IGFBP-2 and IGFBP-4 were found to inhibit IGF-I-stimulated DNA synthesis and migration. IGFBP-5 had an inhibitory effect on IGF-I-stimulated DNA synthesis, but it strongly potentiated IGF-I-induced VSMC migration. By using a non-IGF-binding IGFBP- 5 mutant and an IGF-I-neutralizing antibody, it was demonstrated that IGFBP- 5 also stimulates VSMC migration in an IGF-independent manner. This effect of IGFBP- 5 was inhibited by soluble heparin and by treating cells with heparinase. Mutation of the heparin-binding motif of IGFBP-5 reduced its migration promoting activity. These findings suggest that local IGFBPs are important determinants of cellular responses to IGF-I stimulation, and a key player in this paradigm is IGFBP-5. IGFBP-5 not only modulates IGF-I actions, but it also stimulates cell migration by interacting with cell-surface heparan sulfate proteoglycans.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg,Rm 3065B, Ann Arbor, MI 48109 USA.				NHLBI NIH HHS [R01HL60679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; ALBERCHTBUEHLER G, 1977, CELL, V11, P395; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; Anwar A, 2002, CIRCULATION, V105, P1220, DOI 10.1161/hc1002.105187; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Busby WH, 2000, J BIOL CHEM, V275, P37638, DOI 10.1074/jbc.M006107200; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; Clemmons DR, 1997, DIABETES REV, V5, P353; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; COHICK WS, 1995, J CELL PHYSIOL, V164, P187, DOI 10.1002/jcp.1041640123; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; DUAN C, 1996, J BIOL CHEM, V272, P4280; Duan CM, 1999, P NATL ACAD SCI USA, V96, P15274, DOI 10.1073/pnas.96.26.15274; Duan CM, 2003, MOL CELL ENDOCRINOL, V206, P75, DOI 10.1016/S0303-7207(03)00212-0; Duan CM, 1998, J BIOL CHEM, V273, P16836, DOI 10.1074/jbc.273.27.16836; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KAMYAR A, 1994, CIRC RES, V74, P576, DOI 10.1161/01.RES.74.4.576; LINHARDT RJ, 1994, CURRENT PROTOCOLS MO, V3; Maures TJ, 2002, ENDOCRINOLOGY, V143, P2722, DOI 10.1210/en.143.7.2722; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; Patel VA, 2001, CIRC RES, V88, P895, DOI 10.1161/hh0901.090305; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P995, DOI 10.1016/S0006-291X(02)00570-3; Rees C, 1998, J CELL BIOCHEM, V71, P375, DOI 10.1002/(SICI)1097-4644(19981201)71:3<375::AID-JCB6>3.0.CO;2-M; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schneider MR, 2001, BIOCHEM BIOPH RES CO, V288, P435, DOI 10.1006/bbrc.2001.5785; Sowers JR, 1997, HYPERTENSION, V29, P691, DOI 10.1161/01.HYP.29.3.691; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Zaina S, 2002, J BIOL CHEM, V277, P4505, DOI 10.1074/jbc.M108061200; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994	56	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42886	42892		10.1074/jbc.M303835200	http://dx.doi.org/10.1074/jbc.M303835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917428	hybrid			2022-12-27	WOS:000186157000020
J	Ilangumaran, S; Finan, D; Raine, J; Rottapel, R				Ilangumaran, S; Finan, D; Raine, J; Rottapel, R			Suppressor of cytokine signaling 1 regulates an endogenous inhibitor of a mast cell protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELLS; NEGATIVE REGULATION; JAK/STAT PATHWAY; KINASE-ACTIVITY; SOCS BOX; MOUSE; DEGRADATION; TRYPTASE; EXPRESSION; ACTIVATION	Suppressor of cytokine signaling 1 (SOCS1) is a negative regulator of c-Kit and interleukin-3 (IL-3) receptor signaling. We examined the role of SOCS1 in regulating IL-3-induced cell growth of primary bone marrow-derived mast cells (BMMCs) from SOCS1(-/-) mice. Instead of showing increased proliferation, SOCS1-deficient BMMCs responded poorly to IL-3 and stem cell factor. SOCS1(-/-) BMMCs showed increased apoptosis and defective cell cycle entry. We show that the growth retardation of SOCS1(-/-) BMMCs was due to a cell intrinsic defect. Protein tyrosine phosphorylation following IL-3 stimulation was markedly diminished in SOCS1(-/-) BMMCs. Intriguingly, JAK2 and STAT5 proteins were selectively diminished in SOCS1(-/-) BMMCs, which also showed lower molecular mass products of p85 and Vav suggesting proteolytic degradation. Incubation of the SOCS1(-/-) BMMC lysate with STAT5, p85, and Vav immunoprecipitated from SOCS1(+/+) cells directly demonstrated the dysregulated proteolytic activity in SOCS1(-/-) BMMCs. The proteolytic activity in SOCS1(-/-) BMMCs was selectively inhibited by phenylmethylsulfonyl fluoride and soybean trypsin inhibitor, suggesting that the protease regulated by SOCS1 is a tryptase. The dysregulated tryptase in SOCS1(-/-) BMMCs is unlikely to be mMCP6 or mMCP7, because the enzyme activity was not inhibited by Polybrene but was inhibited by normal mouse plasma. SOCS1(+/+) BMMC lysate inhibited the proteolytic activity present in SOCS1(-/-) BMMC lysate, indicating that SOCS1(-/-) BMMCs lack an endogenous protease inhibitor. These results show that SOCS1 is required for the expression and/or stability of an endogenous protease inhibitor, which protects mast cells from their own proteolytic enzymes.	Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto	Rottapel, R (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Rm 10-108,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rottapel@uhnres.utoronto.ca		Rottapel, Robert/0000-0002-6024-5558; Ilangumaran, Subburaj/0000-0002-7563-576X				Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ATKINS FM, 1985, LAB INVEST, V52, P278; Cairns JA, 1996, J IMMUNOL, V156, P275; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Galli S J, 1994, Curr Opin Hematol, V1, P33; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; Gurish MF, 2001, J EXP MED, V194, pF1, DOI 10.1084/jem.194.1.F1; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ilangumaran S, 2002, J IMMUNOL, V169, P5010, DOI 10.4049/jimmunol.169.9.5010; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; Malaviya R, 2001, IMMUNITY, V15, P313, DOI 10.1016/S1074-7613(01)00184-4; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sommerhoff CP, 2001, AM J RESP CRIT CARE, V164, pS52, DOI 10.1164/ajrccm.164.supplement_2.2106058; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Ward AC, 2000, BLOOD, V95, P19; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Wong GW, 2001, J BIOL CHEM, V276, P20648, DOI 10.1074/jbc.M010422200; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	50	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41871	41880		10.1074/jbc.M308382200	http://dx.doi.org/10.1074/jbc.M308382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917417	hybrid			2022-12-27	WOS:000185989500040
J	Schweizer, A; Briand, C; Grutter, MG				Schweizer, A; Briand, C; Grutter, MG			Crystal structure of caspase-2, apical initiator of the intrinsic apoptotic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; 3-DIMENSIONAL STRUCTURE; ACTIVATION; FAMILY; INHIBITOR; PROTEASE; MECHANISM; COMPLEX; SPECIFICITIES	The cell death protease caspase-2 has recently been recognized as the most apical caspase in the apoptotic cascade ignited during cell stress signaling. Cytotoxic stress, such as that caused by cancer therapies, leads to activation of caspase-2, which acts as a direct effector of the mitochondrion-dependent apoptotic pathway resulting in programmed cell death. Here we report the x-ray structure of caspase-2 in complex with the inhibitor acetyl-Leu-Asp-Glu-Ser-Asp-aldehyde at 1.65-Angstrom resolution. Compared with other caspases, significant structural differences prevail in the active site region and the dimer interface. The structure reveals the hydrophobic properties of the S5 specificity pocket, which is unique to caspase-2, and provides the details of the inhibitorprotein interactions in subsites S1-S4. These features form the basis of caspase-2 specificity and allow the design of caspase-2-directed ligands for medical and analytical use. Another unique feature of caspase-2 is a disulfide bridge at the dimer interface, which covalently links the two monomers. Consistent with this finding, caspase-2 exists as a (p19/p12)(2) dimer in solution, even in the absence of substrates or inhibitors. The intersubunit disulfide bridge stabilizes the dimeric form of caspase-2, whereas all other long prodomain caspases exist as monomers in solution, and dimer formation is driven by ligand binding. Therefore, the central disulfide bridge appears to represent a novel way of dimer stabilization in caspases.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Grutter, MG (corresponding author), Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland.	gruetter@bioc.unizh.ch						Baliga B, 2003, CELL DEATH DIFFER, V10, P16, DOI 10.1038/sj.cdd.4401166; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Blanchard H, 2000, J MOL BIOL, V302, P9, DOI 10.1006/jmbi.2000.4041; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chang DW, 2003, J BIOL CHEM, V278, P16466, DOI 10.1074/jbc.C300089200; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; Faderl S, 1999, CLIN CANCER RES, V5, P4041; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Himi T, 1998, EUR J NEUROSCI, V10, P777, DOI 10.1046/j.1460-9568.1998.00073.x; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sevignani C, 2003, CANCER RES, V63, P1183; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Talanian RV, 1996, J BIOL CHEM, V271, P21853, DOI 10.1074/jbc.271.36.21853; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	48	85	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42441	42447		10.1074/jbc.M304895200	http://dx.doi.org/10.1074/jbc.M304895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920126	hybrid, Green Published			2022-12-27	WOS:000185989500108
J	Torres, AM; Bansal, PS; Sunde, M; Clarke, CE; Bursill, JA; Smith, DJ; Bauskin, A; Breit, SN; Campbell, TJ; Alewood, PF; Kuchel, PW; Vandenberg, JI				Torres, AM; Bansal, PS; Sunde, M; Clarke, CE; Bursill, JA; Smith, DJ; Bauskin, A; Breit, SN; Campbell, TJ; Alewood, PF; Kuchel, PW; Vandenberg, JI			Structure of the HERG K+ channel S5P extracellular linker - Role of an amphipathic alpha-helix in C-type inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; I-KR; MOLECULAR DETERMINANTS; SECONDARY STRUCTURE; CARDIAC-ARRHYTHMIA; CRYSTAL-STRUCTURE; NMR; PROGRAM; MUTATIONS; BLOCK	The HERG K+ channel has very unusual kinetic behavior that includes slow activation but rapid inactivation. These features are critical for normal cardiac repolarization as well as in preventing lethal ventricular arrhythmias. Mutagenesis studies have shown that the extracellular peptide linker joining the fifth transmembrane domain to the pore helix is critical for rapid inactivation of the HERG K+ channel. This peptide linker is also considerably longer in HERG K+ channels, 40 amino acids, than in most other voltage-gated K+ channels. In this study we show that a synthetic 42-residue peptide corresponding to this linker region of the HERG K+ channel does not have defined structural elements in aqueous solution; however, it displays two well defined helical regions when in the presence of SDS micelles. The helices correspond to Trp(585)-Ile(593) and Gly(604)-Tyr(611) of the channel. The Trp(585)-Ile(593) helix has distinct hydrophilic and hydrophobic surfaces. The Gly(604)-Tyr(611) helix corresponds to an N-terminal extension of the pore helix. Electrophysiological studies of HERG currents following application of exogenous S5P peptides show that the amphipathic helix in the S5P linker interacts with the pore region of the channel in a voltage-dependent manner.	Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Univ New S Wales, Dept Med, St Lucia, Qld 4072, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Sydney, NSW 2010, Australia	Victor Chang Cardiac Research Institute; University of Sydney; University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Vandenberg, JI (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	j.vandenberg@victorchang.unsw.edu.au	Vandenberg, Jamie I/B-6608-2013; Torres, Allan/GSN-4624-2022; Sunde, Margaret/A-5186-2016; Sunde, Margaret/ABH-2584-2020	Vandenberg, Jamie I/0000-0002-3859-3716; Sunde, Margaret/0000-0002-0150-3203; Sunde, Margaret/0000-0002-0150-3203; Campbell, Terry/0000-0003-0055-4137; Gregory, Catherine/0000-0002-3100-2741; Kuchel, Philip/0000-0003-4100-7332				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chiang CE, 2000, J AM COLL CARDIOL, V36, P1, DOI 10.1016/S0735-1097(00)00716-6; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; Fan JS, 1999, BIOPHYS J, V76, P3128, DOI 10.1016/S0006-3495(99)77464-3; FERSHT A, 1999, STRUCTURE MECH PROTE, P527; Ficker E, 1998, CIRC RES, V82, P386, DOI 10.1161/01.RES.82.3.386; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; Halsall A, 1999, J MOL BIOL, V293, P901, DOI 10.1006/jmbi.1999.3194; Hancox JC, 1998, PFLUG ARCH EUR J PHY, V436, P843, DOI 10.1007/s004240050713; Haverkamp W, 2000, EUR HEART J, V21, P1216, DOI 10.1053/euhj.2000.2249; Herzberg IM, 1998, J PHYSIOL-LONDON, V511, P3, DOI 10.1111/j.1469-7793.1998.003bi.x; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korolkova Y, 2003, BIOPHYS J, V84, p8A; Korolkova YV, 2001, J BIOL CHEM, V276, P9868, DOI 10.1074/jbc.M005973200; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Liu J, 2002, J GEN PHYSIOL, V120, P723, DOI 10.1085/jgp.20028687; Lu Y, 2001, J PHYSIOL-LONDON, V537, P843, DOI 10.1113/jphysiol.2001.012690; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Mullins FM, 2002, J GEN PHYSIOL, V120, P517, DOI 10.1085/jgp.20028589; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Pardo-Lopez L, 2002, J BIOL CHEM, V277, P16403, DOI 10.1074/jbc.M200460200; PeledZehavi H, 1996, BIOCHEMISTRY-US, V35, P6828, DOI 10.1021/bi952988t; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rosenbusch JP, 2001, J STRUCT BIOL, V136, P144, DOI 10.1006/jsbi.2001.4431; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Tseng GN, 2001, J MOL CELL CARDIOL, V33, P835, DOI 10.1006/jmcc.2000.1317; Vandenberg JI, 2001, TRENDS PHARMACOL SCI, V22, P240, DOI 10.1016/S0165-6147(00)01662-X; Walker BD, 1999, BRIT J PHARMACOL, V127, P243, DOI 10.1038/sj.bjp.0702502; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Weerapura M, 2000, J PHYSIOL-LONDON, V526, P265, DOI 10.1111/j.1469-7793.2000.t01-1-00265.x; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	54	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42136	42148		10.1074/jbc.M212824200	http://dx.doi.org/10.1074/jbc.M212824200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902341	hybrid			2022-12-27	WOS:000185989500072
J	Calzada, MJ; Sipes, JM; Krutzsch, HC; Yurchenco, PD; Annis, DS; Mosher, DF; Roberts, DD				Calzada, MJ; Sipes, JM; Krutzsch, HC; Yurchenco, PD; Annis, DS; Mosher, DF; Roberts, DD			Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha(6)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; VEIN ENDOTHELIAL-CELLS; IN-VITRO; ALPHA(3)BETA(1) INTEGRIN; PROMOTES ANGIOGENESIS; SYNTHETIC PEPTIDES; TYPE-1 REPEATS; BINDING SITES; TUMOR-GROWTH; CYR61 CCN1	In addition to its recognition by alpha(3)beta(1) and alpha(4)beta(1) integrins, the N-terminal pentraxin module of thrombospondin-1 is a ligand for alpha(6)beta(1) integrin. alpha(6)beta(1) integrin mediates adhesion of human microvascular endothelial and HT-1080 fibrosarcoma cells to immobilized thrombospondin-1 and recombinant N-terminal regions of thrombospondin-1 and thrombospondin-2. alpha(6)beta(1) also mediates chemotaxis of microvascular cells to thrombospondin-1 and thrombospondin-2. Using synthetic peptides, LALERKDHSG was identified as an alpha(6)beta(1)-binding sequence in thrombospondin-1. This peptide inhibited alpha(6)beta(1)-dependent cell adhesion to thrombospondin-1, thrombospondin-2, and the E8 fragment of murine laminin-1. The Glu residue in this peptide was required for activity, and the corresponding residue (Glu(90)) in the N-terminal module of thrombospondin-1 was required for its recognition by alpha(6)beta(1), but not by alpha(4)beta(1). alpha(6)beta(1) was also expressed in human umbilical vein endothelial cells; but in these cells, only certain agonists could activate the integrin to recognize thrombospondins. Selective activation of alpha(6)beta(1) integrin in microvascular endothelial cells by the anti-beta(1) antibody TS2/16 therefore accounts for their adhesion responses to thrombospondins and explains the distinct functions of alpha(4)beta(1) and alpha(6)beta(1) integrins as thrombospondin receptors in microvascular and large vessel endothelial cells.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Wisconsin System; University of Wisconsin Madison	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.		Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Yurchenco, Peter/0000-0003-0387-2317	NATIONAL CANCER INSTITUTE [Z01SC009172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Davis TL, 2001, J BIOL CHEM, V276, P26099, DOI 10.1074/jbc.M102811200; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Le Bellego F, 2002, J ENDOCRINOL, V172, P45, DOI 10.1677/joe.0.1720045; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Murayama O, 1996, J BIOCHEM-TOKYO, V120, P445; Nath D, 2000, J CELL SCI, V113, P2319; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; SWERLICK RA, 1992, J IMMUNOL, V148, P78; Taraboletti G, 2000, FASEB J, V14, P1674; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yoon CS, 2001, BIOCHEM BIOPH RES CO, V283, P668, DOI 10.1006/bbrc.2001.4838; Yu HN, 2000, ARCH BIOCHEM BIOPHYS, V374, P13, DOI 10.1006/abbi.1999.1597; YURCHENCO PD, 1994, METHOD ENZYMOL, V245, P489; Zhu XL, 2000, J BIOL CHEM, V275, P7677, DOI 10.1074/jbc.275.11.7677	55	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40679	40687		10.1074/jbc.M302014200	http://dx.doi.org/10.1074/jbc.M302014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909644	hybrid			2022-12-27	WOS:000185847200032
J	Ohta, S; Tatsumi, Y; Fujita, M; Tsurimoto, T; Obuse, C				Ohta, S; Tatsumi, Y; Fujita, M; Tsurimoto, T; Obuse, C			The ORC1 cycle in human cells - II. Dynamic changes in the human ORC complex during the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; CHROMOSOMAL REPLICATION ORIGINS; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; NUCLEAR MATRIX; HOMOLOG; PROTEIN; IDENTIFICATION; ASSOCIATION; DROSOPHILA	The origin recognition complex (ORC) plays a central role in regulating the initiation of DNA replication in eukaryotes. The level of the ORC1 subunit oscillates throughout the cell cycle, defining an ORC1 cycle. ORC1 accumulates in G(1) and is degraded in S phase, although other ORC subunits (ORCs 2 - 5) remain at almost constant levels. The behavior of ORC components in human cell nuclei with respect to the ORC1 cycle demonstrates that ORCs 2 - 5 form a complex that is present throughout the cell cycle and that associates with ORC1 when it accumulates in G(1) nuclei. ORCs 2 - 5 are found in both nuclease-insoluble and - soluble fractions. The appearance of nuclease-insoluble ORCs 2 - 5 parallels the increase in the level of ORC1 associating with nuclease-insoluble, non-chromatin nuclear structures. Thus, ORCs 2 - 5 are temporally recruited to nuclease-insoluble structures by formation of the ORC1 - 5 complex. An artificial reduction in the level of ORC1 in human cells by RNA interference results in a shift of ORC2 to the nuclease-soluble fraction, and the association of MCM proteins with chromatin fractions is also blocked by this treatment. These results indicate that ORC1 regulates the status of the ORC complex in human nuclei by tethering ORCs 2 - 5 to nuclear structures. This dynamic shift is further required for the loading of MCM proteins onto chromatin. Thus, the pre-replication complex in human cells may be regulated by the temporal accumulation of ORC1 in G(1) nuclei.	Nara Inst Sci & Technol, Nara 6300101, Japan; Natl Canc Ctr, Res Inst, Chuoh Ku, Tokyo 1040045, Japan	Nara Institute of Science & Technology; National Cancer Center - Japan	Obuse, C (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068502, Japan.		Obuse, Chikashi/F-5273-2011	Tsurimoto, Toshiki/0000-0001-7597-2216; Fujita, Masatoshi/0000-0001-6617-2452; Tatsumi, Yasutoshi/0000-0003-2646-7410				Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; DePamphilis ML, 2003, GENE, V310, P1, DOI 10.1016/S0378-1119(03)00546-8; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dijkwel PA, 1995, INT REV CYTOL, V162A, P455; Djeliova V, 2001, NUCLEIC ACIDS RES, V29, P3181, DOI 10.1093/nar/29.15.3181; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fujita M, 1998, GENES CELLS, V3, P737, DOI 10.1046/j.1365-2443.1998.00226.x; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 1996, J BIOL CHEM, V271, P4349; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MICHELLE FP, 2001, DEVELOPMENT, V128, P1697; Ogawa Y, 1999, MOL CELL BIOL, V19, P7228; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Tadokoro R, 2002, J BIOL CHEM, V277, P15881, DOI 10.1074/jbc.M200322200; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; TATSUMI Y, UNPUB; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200	42	64	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41535	41540		10.1074/jbc.M307535200	http://dx.doi.org/10.1074/jbc.M307535200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909626	hybrid			2022-12-27	WOS:000185847200134
J	Chen, K; Albano, A; Ho, A; Keaney, JF				Chen, K; Albano, A; Ho, A; Keaney, JF			Activation of p53 by oxidative stress involves platelet-derived growth factor-beta receptor-mediated ataxia telangiectasia mutated (ATM) kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; PROTEIN-TYROSINE PHOSPHATASES; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; REVERSIBLE INACTIVATION; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; CELLS; H2O2; TRANSACTIVATION	Phosphorylation of the p53 tumor suppressor protein is a critical event in the up-regulation and activation of p53 during cellular stress. In this study, we characterized the signaling pathway linking oxidative stress to p53 through the platelet-derived growth factor beta (PDGFbeta) receptor and the ataxia telangiectasia mutated (ATM) kinase. In response to H2O2, we observed phosphorylation of p53 specifically at serine 15, but not serine 9, 20, or 392. Phosphorylation of Ser-15 was correlated with enhanced induction and functional activation of p53 manifest as transcription of the p53 target p21(CIP/WAF). We found that H2O2 induced phosphorylation of the PDGFbeta receptor and increased ATM kinase activity, two events integral to p53 activation as either AG1433 (a PDGFbeta receptor inhibitor) or caffeine (an ATM kinase inhibitor) inhibited Ser-15 phosphorylation. Similarly, p53 activation by H2O2 was inhibited by kinase-inactive forms of the PDGFbeta receptor or ATM. Inhibition of ATM kinase had no effect on H2O2-induced PDGFbeta receptor tyrosine phosphorylation, whereas PDGFbeta receptor suppression with RNA interference impaired H2O2-induced ATM activation, indicating that ATM lies downstream to the PDGFbeta receptor in this signaling cascade. Functionally, inhibition of the PDGFbeta receptor abrogated the inhibition of cell proliferation, and promotion of apoptosis due to H2O2 treatment. Thus, these data link PDGFbeta receptor transactivation to H2O2-induced p53 phosphorylation and suggest a functional role for growth factor receptors in modulation of p53 function.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Mem Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Keaney, JF (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,Rm W507, Boston, MA 02118 USA.			Keaney, John/0000-0002-0866-1837	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60886] Funding Source: Medline; NIDDK NIH HHS [DK55656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cartel NJ, 2001, AM J PHYSIOL-LUNG C, V281, pL786, DOI 10.1152/ajplung.2001.281.4.L786; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Chen K, 1996, BIOCHEM BIOPH RES CO, V224, P703, DOI 10.1006/bbrc.1996.1087; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; Green MHL, 1997, FREE RADICAL BIO MED, V22, P343, DOI 10.1016/S0891-5849(96)00336-X; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin WC, 2001, GENE DEV, V15, P1833; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MAYR GA, 1995, CANCER RES, V55, P2410; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; NGHIEM P, 2001, J BIOL CHEM; PRYOR WA, 1994, NATURAL ANTIOXIDANTS, P1; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Vile GF, 1997, FEBS LETT, V412, P70, DOI 10.1016/S0014-5793(97)00748-5; VUILLAUME M, 1989, CARCINOGENESIS, V10, P1375, DOI 10.1093/carcin/10.8.1375; WANG RJ, 1980, RADIAT RES, V82, P269, DOI 10.2307/3575378; WARD AJ, 1994, ENVIRON MOL MUTAGEN, V24, P103, DOI 10.1002/em.2850240205; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	46	83	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39527	39533		10.1074/jbc.M304423200	http://dx.doi.org/10.1074/jbc.M304423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890678	hybrid			2022-12-27	WOS:000185713800033
J	Emerson, JP; Coulter, ED; Phillips, RS; Kurtz, DM				Emerson, JP; Coulter, ED; Phillips, RS; Kurtz, DM			Kinetics of the superoxide reductase catalytic cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; OXIDATIVE STRESS PROTECTION; RBO GENE-PRODUCT; DESULFOARCULUS-BAARSII; ESCHERICHIA-COLI; RUBREDOXIN OXIDOREDUCTASE; TREPONEMA-PALLIDUM; ACTIVE-SITE; OXYGEN DETOXIFICATION; PYROCOCCUS-FURIOSUS	The steady state kinetics of a Desulfovibrio ( D.) vulgaris superoxide reductase (SOR) turnover cycle, in which superoxide is catalytically reduced to hydrogen peroxide at a [Fe( His)(4)(Cys)] active site, are reported. A proximal electron donor, rubredoxin, was used to supply reducing equivalents from NADPH via ferredoxin: NADP(+) oxidoreductase, and xanthine/xanthine oxidase was used to provide a calibrated flux of superoxide. SOR turnover in this system was well coupled, i.e. similar to 2O(2)(radical anion) reduced: NADPH oxidized over a 10-fold range of superoxide flux. The reduction of the ferric SOR active site by reduced rubredoxin was independently measured to have a second-order rate constant of similar to 1 x 10(6) M-1 s(-1). Analysis of the kinetics showed that: ( i) 1 muM SOR can convert a 10 muM/min superoxide flux to a steady state superoxide concentration of 10(-10) M, during which SOR turns over about once every 6 s, (ii) the diffusion-controlled reaction of reduced SOR with superoxide is the slowest process during turnover, and (iii) neither ligation nor deligation of the active site carboxylate of SOR limits the turnover rate. An intracellular SOR concentration on the order of 10 muM is estimated to be the minimum required for lowering superoxide to sublethal levels in aerobically growing SOD knockout mutants of Escherichia coli. SORs from Desulfovibrio gigas and Treponema pallidum showed similar turnover rates when substituted for the D. vulgaris SOR, whereas superoxide dismutases showed no SOR activity in our assay. These results provide quantitative support for previous suggestions that, in times of oxidative stress, SORs efficiently divert intracellular reducing equivalents to superoxide.	Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Kurtz, DM (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.			Phillips, Robert/0000-0001-8710-562X; Emerson, Joseph/0000-0002-7556-1393				Abreu IA, 2002, J BIOL INORG CHEM, V7, P668, DOI 10.1007/s00775-002-0363-1; Abreu IA, 2001, J BIOL CHEM, V276, P38995, DOI 10.1074/jbc.M103232200; Baumgarten A, 2001, ARCH MICROBIOL, V176, P306, DOI 10.1007/s002030100329; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Clay MD, 2002, J AM CHEM SOC, V124, P788, DOI 10.1021/ja016889g; COEHLO AV, 1997, J BIOL INORG CHEM, V2, P680; Coulter ED, 2001, ARCH BIOCHEM BIOPHYS, V394, P76, DOI 10.1006/abbi.2001.2531; Coulter ED, 2000, J AM CHEM SOC, V122, P11555, DOI 10.1021/ja005583r; Cypionka H, 2000, ANNU REV MICROBIOL, V54, P827, DOI 10.1146/annurev.micro.54.1.827; Das A, 2001, J BACTERIOL, V183, P1560, DOI 10.1128/JB.183.5.1560-1567.2001; Eidsness MK, 1999, BIOCHEMISTRY-US, V38, P14803, DOI 10.1021/bi991661f; Emerson JP, 2003, P NATL ACAD SCI USA, V100, P3802, DOI 10.1073/pnas.0537177100; Emerson JP, 2002, BIOCHEMISTRY-US, V41, P4348, DOI 10.1021/bi0119159; Eschemann A, 1999, ENVIRON MICROBIOL, V1, P489, DOI 10.1046/j.1462-2920.1999.00057.x; Fournier M, 2003, J BACTERIOL, V185, P71, DOI 10.1128/JB.185.1.71-79.2003; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; Imlay JA, 2002, J BIOL INORG CHEM, V7, P659, DOI 10.1007/s00775-002-0361-3; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Johnson MS, 1997, J BACTERIOL, V179, P5598, DOI 10.1128/jb.179.17.5598-5601.1997; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; Kurtz DM, 2002, J BIOL INORG CHEM, V7, P653, DOI 10.1007/s00775-002-0360-4; KURTZ DM, 2001, CHEMTRACTS INORG CHE, V14, P407; Lemos RS, 2001, FEBS LETT, V496, P40, DOI 10.1016/S0014-5793(01)02399-7; Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; Lombard M, 2000, J BIOL CHEM, V275, P27021; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; Lombard M, 2001, BIOCHEMISTRY-US, V40, P5032, DOI 10.1021/bi0023908; Lovenberg W, 1978, Methods Enzymol, V53, P340; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; Mathe C, 2002, J AM CHEM SOC, V124, P4966, DOI 10.1021/ja025707v; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Niviere V, 2001, FEBS LETT, V497, P171, DOI 10.1016/S0014-5793(01)02468-1; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Richie KA, 1996, PROTEIN SCI, V5, P883; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; Shearer J, 2003, P NATL ACAD SCI USA, V100, P3671, DOI 10.1073/pnas.0637029100; Silaghi-Dumitrescu R, 2003, INORG CHEM, V42, P446, DOI 10.1021/ic025684l; Silva G, 1999, EUR J BIOCHEM, V259, P235, DOI 10.1046/j.1432-1327.1999.00025.x; Silva G, 2001, J BACTERIOL, V183, P4413, DOI 10.1128/JB.183.4.4413-4420.2001; WALEY SG, 1992, BIOCHEM J, V286, P357, DOI 10.1042/bj2860357; Yeh AP, 2000, BIOCHEMISTRY-US, V39, P2499, DOI 10.1021/bi992428k	48	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39662	39668		10.1074/jbc.M306488200	http://dx.doi.org/10.1074/jbc.M306488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900405	hybrid			2022-12-27	WOS:000185713800051
J	Giraudo, CG; Maccioni, HJF				Giraudo, CG; Maccioni, HJF			Ganglioside glycosyltransferases organize in distinct multienzyme complexes in CHO-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL RETINA CELLS; GOLGI-APPARATUS; BREFELDIN-A; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MANNOSYLTRANSFERASE COMPLEX; MICROTUBULE DISRUPTION; GA2/GM2/GD2 SYNTHASE; HEPARAN-SULFATE; RAT-LIVER	The synthesis of gangliosides is compartmentalized in the Golgi complex. In most cells, glycosylation of LacCer, GM3, and GD3 to form higher order species (GA2, GM2, GD2, GM1, GD1b) is displaced toward the most distal aspects of the Golgi and the trans-Golgi network, where the involved transferases (GalNAcT and GalT2) form physical and functional associations. Glycosylation of the simple species LacCer, GM3, and GD3, on the other hand, is displaced toward more proximal Golgi compartments, and we investigate here whether the involved transferases (GalT1, SialT1, and SialT2) share the property of forming physical associations. Co-immunoprecipitation experiments from membranes of CHO-K1 cells expressing epitope-tagged versions of these enzymes indicate that GalT1, SialT1, and SialT2 associate physically in a SialT1-dependent manner and that their N-terminal domains participate in these interactions. Microscopic fluorescence resonance energy transfer and fluorescence recovery after photobleaching in living cells confirmed the interactions, and in addition to showing a Golgi apparatus localization of the complexes, mapped their formation to the endoplasmic reticulum. Neither co-immunoprecipitation nor fluorescence resonance energy transfer detected interactions between either GalT2 or GalNAcT and GalT1 or SialT1 or SialT2. These results, and triple color imaging of Golgi-derived microvesicles in nocodazole-treated cells, suggest that ganglioside synthesis is organized in distinct units each formed by associations of particular glycosyltransferases, which concentrate in different sub-Golgi compartments.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CONICET,CIQUIBIC, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Maccioni, HJF (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CONICET,CIQUIBIC, Ciudad Univ, RA-5000 Cordoba, Argentina.							Allende ML, 2000, GLYCOBIOLOGY, V10, P1025, DOI 10.1093/glycob/10.10.1025; Bieberich E, 2002, BIOCHEMISTRY-US, V41, P11479, DOI 10.1021/bi0259958; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; FRITZ VMR, 1995, J NEUROCHEM, V65, P1859; Fritz VMR, 1996, J NEUROCHEM, V67, P1393; Giraudo CG, 1999, BIOCHEM J, V342, P633, DOI 10.1042/0264-6021:3420633; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; KEENAN TW, 1974, J BIOL CHEM, V249, P310; Lannert H, 1998, J BIOL CHEM, V273, P2939, DOI 10.1074/jbc.273.5.2939; Maccioni HJF, 1999, BBA-MOL CELL BIOL L, V1437, P101, DOI 10.1016/S1388-1981(99)00002-5; Maccioni HJF, 2002, NEUROCHEM RES, V27, P629, DOI 10.1023/A:1020271932760; Maxzud MK, 2000, NEUROCHEM RES, V25, P145, DOI 10.1023/A:1007555903335; MAXZUD MK, 1995, J BIOL CHEM, V270, P20207, DOI 10.1074/jbc.270.34.20207; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; MILLERPRODRAZA H, 1984, BIOCHIM BIOPHYS ACTA, V804, P44, DOI 10.1016/0167-4889(84)90097-1; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; NORES GA, 1986, NEUROCHEM INT, V8, P501, DOI 10.1016/0197-0186(86)90183-X; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Stolz J, 2002, J BIOL CHEM, V277, P44801, DOI 10.1074/jbc.M208023200; Todorow Z, 2000, P NATL ACAD SCI USA, V97, P13643, DOI 10.1073/pnas.250472397; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yang W, 1998, MOL BIOL CELL, V9, P191, DOI 10.1091/mbc.9.1.191; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; Yu R K, 1980, Adv Exp Med Biol, V125, P33	35	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40262	40271		10.1074/jbc.M305455200	http://dx.doi.org/10.1074/jbc.M305455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900410	hybrid			2022-12-27	WOS:000185713800119
J	Saito, Y; Yoshida, Y; Akazawa, T; Takahashi, K; Niki, E				Saito, Y; Yoshida, Y; Akazawa, T; Takahashi, K; Niki, E			Cell death caused by selenium deficiency and protective effect of antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; HUMAN SELENOPROTEIN P; VITAMIN-E-DEFICIENCY; LIPID-PEROXIDATION; THIOREDOXIN REDUCTASE; FLUORESCENT-PROBE; ALPHA-TOCOTRIENOL; PROSTATE-CANCER; APOPTOTIC DEATH; HUMAN-PLASMA	Selenium is an essential trace element and it is well known that selenium is necessary for cell culture. However, the mechanism underlying the role of selenium in cellular proliferation and survival is still unknown. The present study using Jurkat cells showed that selenium deficiency in a serum-free medium decreased the selenium-dependent enzyme activity (glutathione peroxidases and thioredoxin reductase) within cells and cell viability. To understand the mechanism of this effect of selenium, we examined the effect of other antioxidants, which act by different mechanisms. Vitamin E, a lipid-soluble radical-scavenging antioxidant, completely blocked selenium deficiency-induced cell death, although alpha-tocopherol (biologically the most active form of vitamin E) could not preserve selenium-dependent enzyme activity. Other antioxidants, such as different isoforms and derivatives of vitamin E, BO-653 and deferoxamine mesylate, also exerted an inhibitory effect. However, the water-soluble antioxidants, such as ascorbic acid, N-acetyl cysteine, and glutathione, displayed no such effect. Dichlorodihydrofluorescein (DCF) assay revealed that cellular reactive oxygen species (ROS) increased before cell death, and sodium selenite and alpha-tocopherol inhibited ROS increase in a dose-dependent manner. The generation of lipid hydroperoxides was observed by fluorescence probe diphenyl-1-pyrenylphosphine (DPPP) and HPLC chemiluminescence only in selenium-deficient cells. These results suggest that the ROS, especially lipid hydroperoxides, are involved in the cell death caused by selenium deficiency and that selenium and vitamin E cooperate in the defense against oxidative stress upon cells by detoxifying and inhibiting the formation of lipid hydroperoxides.	Natl Inst Adv Ind Sci & Technol, HSSRC, Osaka 5638577, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Hokkaido University	Saito, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, HSSRC, 1-8-31 Midorigaoka, Osaka 5638577, Japan.		Saito, Yoshiro/H-4597-2019; Yoshida, Yasukazu/H-8510-2016	Saito, Yoshiro/0000-0002-0559-5889; Yoshida, Yasukazu/0000-0001-6034-2502				Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Beck MA, 2003, FREE RADICAL BIO MED, V34, P1263, DOI 10.1016/S0891-5849(03)00101-1; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Duffield-Lillico AJ, 2003, BJU INT, V91, P608, DOI 10.1046/j.1464-410X.2003.04167.x; Field CJ, 2002, J LEUKOCYTE BIOL, V71, P16; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2001, J NUTR, V131, P1798, DOI 10.1093/jn/131.6.1798; Hurst R, 2001, FREE RADICAL BIO MED, V31, P1051, DOI 10.1016/S0891-5849(01)00685-2; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Keaney JF, 1999, FASEB J, V13, P965, DOI 10.1096/fasebj.13.9.965; Knekt P, 1998, AM J EPIDEMIOL, V148, P975, DOI 10.1093/oxfordjournals.aje.a009574; Lewin MH, 2001, BBA-GEN SUBJECTS, V1526, P237, DOI 10.1016/S0304-4165(01)00133-7; Matot I, 2003, FREE RADICAL BIO MED, V34, P785, DOI 10.1016/S0891-5849(02)01435-1; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; McKenzie RC, 1998, IMMUNOL TODAY, V19, P342, DOI 10.1016/S0167-5699(98)01294-8; Meydani SN, 1998, NUTR REV, V56, pS49; MIYAZAWA T, 1994, METHOD ENZYMOL, V233, P324; Navarro F, 1998, FASEB J, V12, P1665, DOI 10.1096/fasebj.12.15.1665; Noguchi N, 2003, FREE RADICAL BIO MED, V34, P1614, DOI 10.1016/S0891-5849(03)00216-8; Noguchi N, 1997, ARCH BIOCHEM BIOPHYS, V342, P236, DOI 10.1006/abbi.1997.9994; Okimoto Y, 2000, FEBS LETT, V474, P137, DOI 10.1016/S0014-5793(00)01587-8; Packer L, 2001, J NUTR, V131, p369S, DOI 10.1093/jn/131.2.369S; Persson HL, 2003, FREE RADICAL BIO MED, V34, P1295, DOI 10.1016/S0891-5849(03)00106-0; PIGAULT C, 1994, J MOL BIOL, V236, P199, DOI 10.1006/jmbi.1994.1129; Ricciarelli R, 2001, FASEB J, V15, P2314, DOI 10.1096/fj.01-0258rev; Saito Y, 2000, J HEALTH SCI, V46, P409; Saito Y, 1999, J BIOL CHEM, V274, P2866, DOI 10.1074/jbc.274.5.2866; Saito Y, 2002, EUR J BIOCHEM, V269, P5746, DOI 10.1046/j.1432-1033.2002.03298.x; Saito Y, 2001, J HEALTH SCI, V47, P346, DOI 10.1248/jhs.47.346; SALONEN JT, 1991, BRIT MED J, V302, P756, DOI 10.1136/bmj.302.6779.756; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; SUADICANI P, 1992, ATHEROSCLEROSIS, V96, P33, DOI 10.1016/0021-9150(92)90035-F; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Takahashi M, 2001, FREE RADICAL BIO MED, V31, P164, DOI 10.1016/S0891-5849(01)00575-5; Takebe G, 2002, J BIOL CHEM, V277, P41254, DOI 10.1074/jbc.M202773200; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Yarimizu J, 2000, ANTIOXID REDOX SIGN, V2, P643, DOI 10.1089/ars.2000.2.4-643; Yoshida Y, 2003, FREE RADICAL RES, V37, P861, DOI 10.1080/1071576031000148736; Yoshida Y, 2003, BIOCHEM BIOPH RES CO, V305, P747, DOI 10.1016/S0006-291X(03)00813-1; Yoshida Y, 2003, CHEM PHYS LIPIDS, V123, P63, DOI 10.1016/S0009-3084(02)00164-0; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6; Zeng HW, 2002, J NUTR, V132, P674, DOI 10.1093/jn/132.4.674	52	187	203	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39428	39434		10.1074/jbc.M305542200	http://dx.doi.org/10.1074/jbc.M305542200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888577	hybrid			2022-12-27	WOS:000185713800020
J	Tanner, JA; Watt, RM; Chai, YB; Lu, LY; Lin, MC; Peiris, JSM; Poon, LLM; Kung, HF; Huang, JD				Tanner, JA; Watt, RM; Chai, YB; Lu, LY; Lin, MC; Peiris, JSM; Poon, LLM; Kung, HF; Huang, JD			The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5 ' to 3 ' viral helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; MESSENGER-RNA SYNTHESIS; PRIMASE INHIBITORS; DOMAIN; ARTERIVIRUS; SEQUENCE; PROTEINS; INSIGHTS; THERAPY; DISEASE	The putative NTPase/helicase protein from severe acute respiratory syndrome coronavirus (SARS-CoV) is postulated to play a number of crucial roles in the viral life cycle, making it an attractive target for anti-SARS therapy. We have cloned, expressed, and purified this protein as an N-terminal hexahistidine fusion in Escherichia coli and have characterized its helicase and NTPase activities. The enzyme unwinds doublestranded DNA, dependent on the presence of a 5' single-stranded overhang, indicating a 5' to 3' polarity of activity, a distinct characteristic of coronaviridae helicases. We provide the first quantitative analysis of the polynucleic acid binding and NTPase activities of a Nidovirus helicase, using a high throughput phosphate release assay that will be readily adaptable to the future testing of helicase inhibitors. All eight common NTPs and dNTPs were hydrolyzed by the SARS helicase in a magnesium-dependent reaction, stimulated by the presence of either single-stranded DNA or RNA. The enzyme exhibited a preference for ATP, dATP, and dCTP over the other NTP/dNTP substrates. Homopolynucleotides significantly stimulated the ATPase activity ( 15 - 25-fold) with the notable exception of poly(G) and poly(dG), which were non-stimulatory. We found a large variation in the apparent strength of binding of different homopolynucleotides, with dT(24) binding over 10 times more strongly than dA(24) as observed by the apparent K-m.	Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Huang, JD (corresponding author), Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.		Watt, Rory M./B-2177-2009; Tanner, Julian A./C-4412-2009; Chai, Yubo/I-1896-2013; Peiris, Joseph/C-4380-2009; Poon, Leo/AAP-6887-2020; Chai, Yubo/AAP-5928-2020; Poon, Leo Lit Man/C-4382-2009; /C-4277-2009	Watt, Rory M./0000-0002-8718-1988; Tanner, Julian A./0000-0002-5459-1526; Chai, Yubo/0000-0002-2316-8071; Chai, Yubo/0000-0002-2316-8071; Poon, Leo Lit Man/0000-0002-9101-7953; /0000-0001-7531-2816				Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Bautista EM, 2002, VIROLOGY, V298, P258, DOI 10.1006/viro.2002.1495; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Borowski P, 2002, ANTIVIR RES, V55, P397, DOI 10.1016/S0166-3542(02)00096-7; Borowski P, 2001, J VIROL, V75, P3220, DOI 10.1128/JVI.75.7.3220-3229.2001; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Crute JJ, 2002, NAT MED, V8, P386, DOI 10.1038/nm0402-386; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]; Kadare G, 1997, J VIROL, V71, P2583; Kalinina NO, 2002, VIROLOGY, V296, P321, DOI 10.1006/viro.2001.1328; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kleymann G, 2002, NAT MED, V8, P392, DOI 10.1038/nm0402-392; Kleymann G, 2003, EXPERT OPIN INV DRUG, V12, P165, DOI 10.1517/13543784.12.2.165; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Li YI, 2001, J VIROL, V75, P12114, DOI 10.1128/JVI.75.24.12114-12120.2001; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000; Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728; Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0; van Dinten LC, 2000, J VIROL, V74, P5213, DOI 10.1128/JVI.74.11.5213-5223.2000; van Marle G, 1999, J VIROL, V73, P5274, DOI 10.1128/JVI.73.7.5274-5281.1999; Wardell AD, 1999, J GEN VIROL, V80, P701, DOI 10.1099/0022-1317-80-3-701; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	30	133	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39578	39582		10.1074/jbc.C300328200	http://dx.doi.org/10.1074/jbc.C300328200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12917423	hybrid, Green Published			2022-12-27	WOS:000185713800040
J	Hirano, S; Tominaga, Y; Ichinoe, A; Ushijima, Y; Tsuchimoto, D; Honda-Ohnishi, Y; Ohtsubo, T; Sakumi, K; Nakabeppu, Y				Hirano, S; Tominaga, Y; Ichinoe, A; Ushijima, Y; Tsuchimoto, D; Honda-Ohnishi, Y; Ohtsubo, T; Sakumi, K; Nakabeppu, Y			Mutator phenotype of MUTYH-null mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SCHIZOSACCHAROMYCES-POMBE; NUCLEAR ANTIGEN; FISSION YEAST; DNA; PROTEINS; HOMOLOG; MYH; MUTATIONS; MITOCHONDRIA	To evaluate the antimutagenic role of a mammalian mutY homolog, namely the Mutyh gene, which encodes adenine DNA glycosylase excising adenine misincorporated opposite 8-oxoguanine in the template DNA, we generated MUTYH-null mouse embryonic stem (ES) cells. In the MUTYH-null cells carrying no adenine DNA glycosylase activity, the spontaneous mutation rate increased 2-fold in comparison with wild type cells. The expression of wild type mMUTYH or mutant mMUTYH protein with amino acid substitutions at the proliferating cell nuclear antigen binding motif restored the increased spontaneous mutation rates of the MUTYH-null ES cells to the wild type level. The expression of a mutant mMUTYH protein with an amino acid substitution (G365D) that corresponds to a germ-line mutation (G382D) found in patients with multiple colorectal adenomas could not suppress the elevated spontaneous mutation rate of the MUTYH-null ES cells. Although the recombinant mMUTYH(G365D) purified from Escherichia coli cells had a substantial level of adenine DNA glycosylase activity as did wild type MUTYH, no adenine DNA glycosylase activity was detected in the MUTYH-null ES cells expressing the mMUTYH(G365D) mutant protein. The germ-line mutation (G382D) of the human MUTYH gene is therefore likely to be responsible for the occurrence of a mutator phenotype in these patients.	Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Fukuoka 8128582, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakabeppu, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Fukuoka 8128582, Japan.		Nakabeppu, Yusaku/A-8902-2011; Sakumi, Kunihiko/G-4808-2011	Nakabeppu, Yusaku/0000-0002-6739-242X; 				Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Chang DY, 2002, J BIOL CHEM, V277, P11853, DOI 10.1074/jbc.M111739200; Chang DY, 2001, MOL GENET GENOMICS, V266, P336, DOI 10.1007/s004380100567; Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200; Hayashi H, 2002, CURR BIOL, V12, P335, DOI 10.1016/S0960-9822(02)00686-3; Ide Y, 2003, GENOMICS, V81, P47, DOI 10.1016/S0888-7543(02)00009-5; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Luria SE, 1943, GENETICS, V28, P491; Nakabeppu Y, 2001, PROG NUCLEIC ACID RE, V68, P75; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; ROSSMAN TG, 1995, MUTAT RES-FUND MOL M, V328, P21, DOI 10.1016/0027-5107(94)00190-G; Rossman TG, 1997, MUTAT RES-FUND MOL M, V373, P75, DOI 10.1016/S0027-5107(96)00192-3; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798	20	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38121	38124		10.1074/jbc.C300316200	http://dx.doi.org/10.1074/jbc.C300316200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12917422	hybrid			2022-12-27	WOS:000185575100005
J	Fulco, M; Costanzo, A; Merlo, P; Mangiacasale, R; Strano, S; Blandino, G; Balsano, C; Lavia, P; Levrero, M				Fulco, M; Costanzo, A; Merlo, P; Mangiacasale, R; Strano, S; Blandino, G; Balsano, C; Lavia, P; Levrero, M			p73 is regulated by phosphorylation at the G2/M transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-DAMAGE; P53 HOMOLOG; C-ABL; TRANSCRIPTIONAL ACTIVITY; APOPTOTIC RESPONSE; P53-HOMOLOG P73; TARGET GENES; P63; CELLS	p73 is a p53 paralog that encodes proapoptotic (transactivation-competent (TA)) and antiapoptotic ( dominant negative) isoforms. TAp73 transcription factors mediate cell cycle arrest and/or apoptosis in response to DNA damage and are involved in developmental processes in the central nervous system and the immune system. p73 proteins may also play a role in the regulation of cell growth. Indeed, p73 expression is itself modulated during the cell cycle and TAp73 proteins accumulate in S phase cells. In addition, the function of p73 proteins is also regulated by post-translational modifications and protein-protein interactions in different cellular and pathophysiological contexts. Here we show that p73 is a physiological target of the p34(cdc2)-cyclin B mitotic kinase complex in vivo. Both p73beta and p73alpha isoforms are hyperphosphorylated in normal mitotic cells and during mitotic arrest induced by microtubule-targeting drugs. p34(cdc2)-cyclin B phosphorylates and associates with p73 in vivo, which results in a decreased ability of p73 to both bind DNA and activate transcription in mitotic cells. Indeed, p73 is excluded from condensed chromosomes in meta- and anaphase, redistributes throughout the mitotic cytoplasm, and unlike p53, shows no association with centrosomes. Together these results indicate that M phase-specific phosphorylation of p73 by p34(cdc2)- cyclin B is associated with negative regulation of its transcriptional activating function.	Univ Roma La Sapienza, Policlin Umberto I, Fdn Andrea Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; CNR, Ctr Evolutionary Genet, I-00185 Rome, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Univ Aquila, Dept Internal Med, I-67100 Laquila, Italy; Univ Cagliari, Dept Internal Med, I-09124 Cagliari, Italy	Sapienza University Rome; University Hospital Sapienza Rome; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila; University of Cagliari	Levrero, M (corresponding author), Univ Roma La Sapienza, Policlin Umberto I, Fdn Andrea Cesalpino, Gene Express Lab, Viale Policlin 155, I-00161 Rome, Italy.		Costanzo, Antonio/GZG-2433-2022; Lavia, Patrizia/J-5793-2019; Balsano, Clara/AAK-9870-2020; Strano, Sabrina/K-9654-2016; Costanzo, Antonio/D-3896-2012; Blandino, Giovanni/B-1137-2013; Merlo, Paola/K-5330-2014; Lavia, Patrizia/AAL-3982-2021; strano, sabrina/B-6743-2013; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Lavia, Patrizia/0000-0003-3310-6701; Balsano, Clara/0000-0002-9615-7031; Blandino, Giovanni/0000-0002-6970-2241; Merlo, Paola/0000-0003-0105-7044; strano, sabrina/0000-0002-6341-4230; Levrero, Massimo/0000-0002-4978-0875	Telethon [E.1325] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; BOYER JC, 1995, CANCER RES, V55, P6063; Chen DY, 2002, MOL BIOL CELL, V13, P276, DOI 10.1091/mbc.01-10-0523; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Gong JG, 1999, NATURE, V399, P806; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Levrero M, 2000, J CELL SCI, V113, P1661; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; PEDICONI N, 2003, IN PRESS NAT CELL BI; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	43	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49196	49202		10.1074/jbc.M304921200	http://dx.doi.org/10.1074/jbc.M304921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12920125	hybrid			2022-12-27	WOS:000186829000084
J	Vicente, R; Escalada, A; Coma, M; Fuster, G; Sanchez-Tillo, E; Lopez-Iglesias, C; Soler, C; Solsona, C; Celada, A; Felipe, A				Vicente, R; Escalada, A; Coma, M; Fuster, G; Sanchez-Tillo, E; Lopez-Iglesias, C; Soler, C; Solsona, C; Celada, A; Felipe, A			Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-LINE J774.1; POTASSIUM CHANNELS; MURINE MACROPHAGES; BETA-SUBUNITS; ION CHANNELS; WHOLE-CELL; TYROSINE PHOSPHORYLATION; BRAIN MACROPHAGES; MOUSE MACROPHAGES	Voltage-dependent K+ channels (VDPC) are expressed in most mammalian cells and involved in the proliferation and activation of lymphocytes. However, the role of VDPC in macrophage responses is not well established. This study was undertaken to characterize VDPC in macrophages and determine their physiological role during proliferation and activation. Macrophages proliferate until an endotoxic shock halts cell growth and they become activated. By inducing a schedule that is similar to the physiological pattern, we have identified the VDPC in non-transformed bone marrow-derived macrophages and studied their regulation. Patch clamp studies demonstrated that cells expressed outward delayed and inwardly rectifying K+ currents. Pharmacological data, mRNA, and protein analysis suggest that these currents were mainly mediated by Kv1.3 and Kir2.1 channels. Macrophage colony-stimulating factor-dependent proliferation induced both channels. Lipopolysaccharide (LPS)-induced activation differentially regulated VDPC expression. While Kv1.3 was further induced, Kir2.1 was down-regulated. TNF-alpha mimicked LPS effects, and studies with TNF-alpha receptor I/II double knockout mice demonstrated that LPS regulation mediates such expression by TNF-alpha-dependent and -independent mechanisms. This modulation was dependent on mRNA and protein synthesis. In addition, bone marrow-derived macrophages expressed Kv1.5 mRNA with no apparent regulation. VDPC activities seem to play a critical role during proliferation and activation because not only cell growth, but also inducible nitric-oxide synthase expression were inhibited by blocking their activities. Taken together, our results demonstrate that the differential regulation of VDPC is crucial in intracellular signals determining the specific macrophage response.	Univ Barcelona, Biomed Res Inst Barcelona, Macrophage Biol Grp, E-08028 Barcelona, Spain; Univ Barcelona, Dept Bioquim & Biol Mol, Mol Physiol Lab, E-08028 Barcelona, Spain; Univ Barcelona, Serv Cientificotecn, Unitat Reconeixement Mol In Situ, E-08028 Barcelona, Spain; Univ Barcelona, Dept Fisiol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Biol Cellular & Anat Patol, Cellular & Mol Neurobiol Lab, E-08907 Lhospitalet De Llobregat, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Barcelona; University of Barcelona; University of Barcelona; University of Barcelona	Celada, A (corresponding author), Univ Barcelona, Biomed Res Inst Barcelona, Macrophage Biol Grp, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.		García, Rubén Vicente/L-1097-2014; Fuster, Gemma/B-5468-2019; Fuster, Gemma/ACH-5814-2022; Celada, Antonio/I-1714-2016; Soler, Concepció/L-1185-2014; Felipe, Antonio/M-8297-2015	García, Rubén Vicente/0000-0003-0401-4808; Fuster, Gemma/0000-0002-4501-2422; Soler, Concepció/0000-0001-6502-5012; Felipe, Antonio/0000-0002-7294-6431; Celada, Antonio/0000-0003-3883-2171				ATTALI B, 1992, J BIOL CHEM, V267, P8650; Autieri MV, 1997, J NEUROIMMUNOL, V77, P8, DOI 10.1016/S0165-5728(97)00050-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Blunck R, 2001, J IMMUNOL, V166, P1009, DOI 10.4049/jimmunol.166.2.1009; Bock J, 2002, BIOCHEM BIOPH RES CO, V295, P526, DOI 10.1016/S0006-291X(02)00695-2; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; CELADA A, 1994, IMMUNOL TODAY, V15, P100, DOI 10.1016/0167-5699(94)90150-3; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; Colden-Stanfield M, 1998, AM J PHYSIOL-CELL PH, V275, pC267, DOI 10.1152/ajpcell.1998.275.1.C267; Coma M, 2003, FEBS LETT, V536, P45, DOI 10.1016/S0014-5793(03)00009-7; Cullell-Young M, 2001, IMMUNOGENETICS, V53, P136, DOI 10.1007/s002510100312; Dallaporta B, 1999, J IMMUNOL, V162, P6534; DeCoursey TE, 1996, J MEMBRANE BIOL, V152, P141, DOI 10.1007/s002329900093; DECOURSEY TE, 1999, INFLAMMATION BASIC P, P141; Eder C, 1997, N-S ARCH PHARMACOL, V355, P198, DOI 10.1007/PL00004932; Eder C, 1997, N-S ARCH PHARMACOL, V356, P233, DOI 10.1007/PL00005046; Eder C, 1998, AM J PHYSIOL-CELL PH, V275, pC327, DOI 10.1152/ajpcell.1998.275.2.C327; Fischer-Lougheed J, 2001, J CELL BIOL, V153, P677, DOI 10.1083/jcb.153.4.677; FREEDMAN BD, 1992, J IMMUNOL, V149, P3784; FREEDMAN BD, 1995, J BIOL CHEM, V270, P22406, DOI 10.1074/jbc.270.38.22406; Fuster G, 2002, METHOD FIND EXP CLIN, V24, P253, DOI 10.1358/mf.2002.24.5.802301; GALLIN EK, 1989, AM J PHYSIOL, V257, pC77, DOI 10.1152/ajpcell.1989.257.1.C77; GALLIN EK, 1988, J MEMBRANE BIOL, V103, P55, DOI 10.1007/BF01871932; GALLIN EK, 1984, BIOPHYS J, V46, P821, DOI 10.1016/S0006-3495(84)84080-1; GALLIN EK, 1985, J PHYSIOL-LONDON, V369, P475, DOI 10.1113/jphysiol.1985.sp015911; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GALLIN EK, 1981, AM J PHYSIOL, V241, pC9, DOI 10.1152/ajpcell.1981.241.1.C9; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; Ghiani CA, 1999, J NEUROSCI, V19, P5380; Grande M, 2003, J CELL PHYSIOL, V195, P187, DOI 10.1002/jcp.10203; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1997, J NEUROSCI, V17, P8964; JUDGE SIV, 1994, AM J PHYSIOL-CELL PH, V267, pC1691, DOI 10.1152/ajpcell.1994.267.6.C1691; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; LeppleWienhues A, 1996, J MEMBRANE BIOL, V151, P149, DOI 10.1007/s002329900066; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Lowry MAR, 1998, CLIN EXP IMMUNOL, V111, P597; LU L, 1993, J MEMBRANE BIOL, V132, P267; MARUYAMA N, 1994, AM J RESP CELL MOL, V10, P514, DOI 10.1165/ajrcmb.10.5.8179913; McCormack T, 1999, J BIOL CHEM, V274, P20123, DOI 10.1074/jbc.274.29.20123; MCKINNEY LC, 1988, J MEMBRANE BIOL, V103, P41, DOI 10.1007/BF01871931; MCKINNEY LC, 1992, J MEMBRANE BIOL, V130, P265; NELSON DJ, 1992, J MEMBRANE BIOL, V125, P201; OGAWA M, 1993, BLOOD, V81, P2844; Qiu MR, 2002, CLIN EXP IMMUNOL, V130, P67, DOI 10.1046/j.1365-2249.2002.01965.x; Schilling T, 2000, AM J PHYSIOL-CELL PH, V279, pC1123, DOI 10.1152/ajpcell.2000.279.4.C1123; Schmid-Antomarchi H, 1997, J IMMUNOL, V159, P6209; Sobko A, 1998, J NEUROSCI, V18, P10398; Soler C, 2001, FASEB J, V15, P1979, DOI 10.1096/fj.01-0022com; Soler C, 2001, J BIOL CHEM, V276, P30043, DOI 10.1074/jbc.M101807200; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; VICENTE R, 2003, J PHYSL P, V548, DOI UNSP 020; WIELAND SJ, 1990, J CELL PHYSIOL, V142, P643, DOI 10.1002/jcp.1041420326; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Xaus J, 2000, BLOOD, V95, P3823; YPEY DL, 1984, P NATL ACAD SCI-BIOL, V81, P3083, DOI 10.1073/pnas.81.10.3083; Yu SP, 1999, J NEUROCHEM, V73, P933, DOI 10.1046/j.1471-4159.1999.0730933.x	66	138	148	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46307	46320		10.1074/jbc.M304388200	http://dx.doi.org/10.1074/jbc.M304388200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12923194	hybrid, Green Published			2022-12-27	WOS:000186569400014
J	Zhang, Z; Palzkill, T				Zhang, Z; Palzkill, T			Determinants of binding affinity and specificity for the interaction of TEM-1 and SME-1 beta-lactamase with beta-lactamase inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOT-SPOTS; RESIDUES; SCHEME; POTENT; ENERGY	The hydrolysis of beta-lactam antibiotics by class A beta-lactamases is a common cause of bacterial resistance to these agents. The beta-lactamase inhibitory protein (BLIP) is able to bind and inhibit several class A beta-lactamases, including TEM-1 beta-lactamase and SME-1 beta-lactamase. Although the TEM-1 and SME-1 enzymes share 33% amino acid sequence identity and a similar fold, they differ substantially in surface electrostatic properties and the conformation of a loop-helix region that BLIP binds. Alanine-scanning mutagenesis was performed to identify the residues on BLIP that contribute to its binding affinity for each of these enzymes. The results indicate that the sequence requirements for binding are similar for both enzymes with most of the binding free energy provided by two patches of aromatic residues on the surface of BLIP. Polar residues such as several serines in the interface do not make significant contributions to affinity for either enzyme. In addition, the specificity of binding is significantly altered by mutation of two charged residues, Glu(73) and Lys(74), that are buried in the structure of the TEM-1.BLIP complex as well as by residues located on two loops that insert into the active site pocket. Based on the results, a E73A/Y50A double mutant was constructed that exhibited a 220,000-fold change in binding specificity for the TEM-1 versus SME-1 enzymes.	Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu						Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; del Alamo M, 2003, J BIOL CHEM, V278, P27923, DOI 10.1074/jbc.M304466200; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG W, 2000, J BIOL CHEM, V275, P14984; Huang WZ, 1998, ANTIMICROB AGENTS CH, V42, P2893, DOI 10.1128/AAC.42.11.2893; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Majiduddin FK, 2003, ANTIMICROB AGENTS CH, V47, P1062, DOI 10.1128/AAC.47.3.1062-1067.2003; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Queenan AM, 2000, ANTIMICROB AGENTS CH, V44, P3035, DOI 10.1128/AAC.44.11.3035-3039.2000; Rudgers GW, 1999, J BIOL CHEM, V274, P6963, DOI 10.1074/jbc.274.11.6963; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Sougakoff W, 2002, ACTA CRYSTALLOGR D, V58, P267, DOI 10.1107/S0907444901019606; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Thorn KS, 2001, BIOINFORMATICS, V17, P284, DOI 10.1093/bioinformatics/17.3.284; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	39	48	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45706	45712		10.1074/jbc.M308572200	http://dx.doi.org/10.1074/jbc.M308572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933802	hybrid			2022-12-27	WOS:000186452300080
J	Iwamura, K; Furukawa, K; Uchikawa, M; Sojka, BN; Kojima, Y; Wiels, J; Shiku, H; Urano, T; Furukawa, K				Iwamura, K; Furukawa, K; Uchikawa, M; Sojka, BN; Kojima, Y; Wiels, J; Shiku, H; Urano, T; Furukawa, K			The blood group P1 synthase gene is identical to the Gb3/CD77 synthase gene - A clue to the solution of the P1/P2/p puzzle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA-ASSOCIATED ANTIGEN; GDP-L-FUCOSE; MONOCLONAL-ANTIBODY; DETERMINES EXPRESSION; MOLECULAR-CLONING; TRANSFECTED CELLS; BURKITT-LYMPHOMA; GROUP SYSTEM; GROUP LOCUS; LEWIS	Blood group P1/P2 is a glycolipid antigen system for which the genetic mechanism has not yet been clarified. We analyzed the potential of the cloned Gb3/CD77 synthase to synthesize P1 antigen, because Gb3/CD77 and P1 share a common structure, Galalpha1,4Galbeta1,4Glc (NAc)-. L cell transfectants with Gb3/CD77 synthase cDNA expressed marginal levels of P1 on the cell surface but contained high levels of P1 in the cytoplasm. P2-type erythrocytes, which were serotyped as P2, also contained definite P1 antigen inside cells, although the amounts were lower than those of P1 cells. Only p erythrocytes lacked P1 antigen corresponding with function-losing mutations in the Gb3/CD77 synthase gene. Synthesis of P1 antigen from paragloboside in vitro was demonstrated using membrane fraction of the transfectants and a fusion enzyme with protein A. These results strongly suggested that P1 synthase is identical to Gb3/CD77 synthase and appear to propose a clue for the solution of the long-pending P1/P2/p puzzle. The P1/P2 difference might result from the difference in P1 quantity based on either different enzyme activity or the presence/absence of other enzyme modulators. Because P2 erythrocytes showed lower levels of Gb3/CD77 synthase mRNA than P1, 5'-upstream promoter regions were analyzed, resulting in the identification of two P2-specific homozygous mutations. Differences in the transcriptional regulation in erythrocytes might be a major factor determining P1/P2.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Japanese Red Cross, Tokyo Blood Ctr, Shibuya Ku, Tokyo 1500012, Japan; Mie Univ, Sch Med, Dept Internal Med 2, Tsu, Mie 5148507, Japan; Umea Univ Hosp, Dept Transfus Med, S-90185 Umea, Sweden; Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France	Nagoya University; Japanese Red Cross Medical Center; Mie University; Umea University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Iwamura, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.		Wiels, Joëlle/AGL-2319-2022	Wiels, Joëlle/0000-0002-3313-2937; Urano, Takeshi/0000-0003-3383-3554; Shiku, Hiroshi/0000-0002-0362-755X				BAILLY P, 1992, CARBOHYD RES, V228, P277, DOI 10.1016/S0008-6215(00)90565-2; BAILLY P, 1987, MOL IMMUNOL, V24, P171, DOI 10.1016/0161-5890(87)90089-7; DAHR W, 1974, VOX SANG, V27, P29, DOI 10.1111/j.1423-0410.1974.tb02386.x; Daniels GL, 1999, VOX SANG, V77, P52, DOI 10.1159/000031074; FEIZI T, 1978, BIOCHEM J, V173, P245, DOI 10.1042/bj1730245; FLETCHER KS, 1979, J BIOL CHEM, V254, P1196; Furukawa K, 2000, J BIOL CHEM, V275, P37752, DOI 10.1074/jbc.C000625200; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; Furukawa K, 2002, J BIOL CHEM, V277, P11247, DOI 10.1074/jbc.M109519200; Ishikawa D, 2000, METHOD ENZYMOL, V312, P157; Kaneko M, 1997, BLOOD, V90, P839, DOI 10.1182/blood.V90.2.839.839_839_849; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Kudo T, 1996, J BIOL CHEM, V271, P9830, DOI 10.1074/jbc.271.16.9830; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Landsteiner K, 1927, P SOC EXP BIOL MED, V24, P941; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LOMBERG H, 1981, LANCET, V1, P551; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcus D M, 1989, Immunol Ser, V43, P701; MCALPINE PJ, 1978, CYTOGENET CELL GENET, V22, P629, DOI 10.1159/000131040; MYOGA A, 1988, CANCER RES, V48, P1512; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; REARDEN A, 1981, VOX SANG, V41, P160, DOI 10.1111/j.1423-0410.1981.tb01030.x; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; Watkins W M, 1980, Adv Hum Genet, V10, P1; WATKINS WM, 1976, J IMMUNOGENET, V3, P15; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; WIELS J, 1984, J BIOL CHEM, V259, P4783; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149	35	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44429	44438		10.1074/jbc.M301609200	http://dx.doi.org/10.1074/jbc.M301609200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12888565	hybrid			2022-12-27	WOS:000186306700070
J	Carr, MD; Bloemink, MJ; Dentten, E; Whelan, AO; Gordon, SV; Kelly, G; Frenkiel, TA; Hewinson, RG; Williamson, RA				Carr, MD; Bloemink, MJ; Dentten, E; Whelan, AO; Gordon, SV; Kelly, G; Frenkiel, TA; Hewinson, RG; Williamson, RA			Solution structure of the Mycobacterium tuberculosis complex protein MPB70 - From tuberculosis pathogenesis to inherited human corneal disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORSION ANGLE DYNAMICS; T-CELL; ANTIGENIC PROTEIN; NMR; ASSIGNMENT; MPB83; GENE; IDENTIFICATION; VACCINATION; RESOLUTION	The closely related mycobacteria responsible for tuberculosis produce an unusually high number of secreted proteins, many of which are clearly implicated in pathogenesis and protective immunity. Falling within this category are the closely related proteins MPB70 and MPB83. The structure of MPB70 reveals a complex and novel bacterial fold, which has clear structural homology to the two C-terminal FAS1 domains of the cell adhesion protein fasciclin I, whose structures were reported very recently. Assessment of the surface features of MPB70, the sequence divergence between MPB70 and MPB83, the conservation of residues across a group of FAS1 domains, and the locations of disease-inducing mutations in betaig-h3 strongly suggests that MPB70 and MPB83 contain two functional surfaces on opposite faces, which are probably involved in binding to host cell proteins. This analysis also suggests that these functional surfaces are retained in the FAS1 proteins associated with mediating interactions between cells and the extracellular matrix (fasciclin I, periostin, and betaig-h3) and furthermore that some of the human corneal disease-inducing substitutions identified in betaig-h3 will perturb interactions at these sites.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Vet Labs Agcy, Dept Bacterial Dis, TB Res Grp, Addlestone KT15 3NB, Surrey, England; Natl Inst Med Res, MRC, Biomed NMR Ctr, London NW7 1AA, England	University of Leicester; University of Kent; Veterinary Laboratories Agency; MRC National Institute for Medical Research	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	mdc12@le.ac.uk	Hewinson, Glyn/AAA-2364-2019; Hewinson, Glyn/J-1902-2014; Hewinson, Glyn/F-7077-2010; Whelan, Adam O/C-9497-2011	Bloemink, Marieke Johanna/0000-0001-9441-2783; Hewinson, Glyn/0000-0002-5517-4281; Carr, Mark/0000-0002-3939-0996; Gordon, Stephen/0000-0002-4833-5542				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; BILLMANJACOBE H, 1990, IMMUNOL CELL BIOL, V68, P359, DOI 10.1038/icb.1990.49; Bloemink MJ, 2001, J BIOMOL NMR, V20, P185, DOI 10.1023/A:1011239727839; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Chambers MA, 2002, INFECT IMMUN, V70, P2159, DOI 10.1128/IAI.70.4.2159-2165.2002; Clout NJ, 2003, STRUCTURE, V11, P197, DOI 10.1016/S0969-2126(03)00002-9; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOLORES M, 2001, FEMS MICROBIOL LETT, V203, P95; FIFIS T, 1994, SCAND J IMMUNOL, V39, P267, DOI 10.1111/j.1365-3083.1994.tb03370.x; FIFIS T, 1991, INFECT IMMUN, V59, P800, DOI 10.1128/IAI.59.3.800-807.1991; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; Harboe M, 1998, INFECT IMMUN, V66, P289, DOI 10.1128/IAI.66.1.289-296.1998; HARBOE M, 1984, AM REV RESPIR DIS, V129, P444; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HEWINSON RG, 1993, J GEN MICROBIOL, V139, P1253, DOI 10.1099/00221287-139-6-1253; Hewinson RG, 1996, SCAND J IMMUNOL, V43, P490, DOI 10.1046/j.1365-3083.1996.d01-78.x; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kupce E, 1996, J MAGN RESON SER A, V118, P299, DOI 10.1006/jmra.1996.0042; Lemercinier X, 2001, BIOCHEMISTRY-US, V40, P9552, DOI 10.1021/bi010184+; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; McIntosh PB, 1998, BIOCHEMISTRY-US, V37, P9619, DOI 10.1021/bi972861z; Michell SL, 2003, J BIOL CHEM, V278, P16423, DOI 10.1074/jbc.M207959200; MIURA K, 1983, INFECT IMMUN, V39, P540, DOI 10.1128/IAI.39.2.540-545.1983; Morris S, 2000, VACCINE, V18, P2155, DOI 10.1016/S0264-410X(99)00540-X; Munier FL, 2002, INVEST OPHTH VIS SCI, V43, P949; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988; POLLOCK JM, 1994, IMMUNOLOGY, V82, P9; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; ROCHE PW, 1994, J INFECT DIS, V170, P1326, DOI 10.1093/infdis/170.5.1326; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Williamson RA, 1999, J BIOL CHEM, V274, P37226, DOI 10.1074/jbc.274.52.37226; Young DB, 1999, SCIENCE, V284, P1479, DOI 10.1126/science.284.5419.1479; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	48	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43736	43743		10.1074/jbc.M307235200	http://dx.doi.org/10.1074/jbc.M307235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917404	hybrid			2022-12-27	WOS:000186157000123
J	Hundahl, C; Fago, A; Malte, H; Weber, RE				Hundahl, C; Fago, A; Malte, H; Weber, RE			Allosteric effect of water in fish and human hemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN EQUILIBRIA; ANGUILLA-ANGUILLA; EEL HEMOGLOBIN; OSMOTIC-STRESS; HYDRATION; TROUT; BINDING; TRANSITIONS; ACCLIMATION; MODEL	Prompted by the reported lack of solvation effects on the oxygen affinity of fish ( trout I) hemoglobin that questioned allosteric water binding in human hemoglobin A (Bellelli, A., Brancaccio, A., and Brunori, M. ( 1993) J. Biol. Chem. 268, 4742 - 4744), we have investigated solvation effects in fish and human hemoglobins by means of the osmotic stress method and allosteric analysis. In contrast to the earlier report, we demonstrate that water potential does affect oxygen affinity of trout hemoglobin I in the presence of inert solutes like betaine. Moreover, we show that upon oxygenation electrophoretically anodic hemoglobin from trout and eel bind a similar number of water molecules as does human hemoglobin A, whereas the cathodic hemoglobins of trout and eel bind smaller, but mutually similar, numbers of water molecules. Addition of cofactors strongly increases the number of water molecules bound to eel hemoglobin A ( as in human hemoglobin) but only weakly affects water binding to eel hemoglobin C.	Univ Aarhus, Dept Zoophysiol, Inst Biol Sci, DK-8000 Aarhus C, Denmark	Aarhus University	Weber, RE (corresponding author), Univ Aarhus, Dept Zoophysiol, Inst Biol Sci, CF Mollers Alle 131, DK-8000 Aarhus C, Denmark.		Malte, Hans/J-6018-2013; Fago, Angela/J-5946-2013; Hundahl, Christian Ansgar/H-3938-2015	Fago, Angela/0000-0001-7315-2628; 				Arosio D, 2002, BIOPOLYMERS, V63, P1, DOI 10.1002/bip.1057; BELLELLI A, 1993, J BIOL CHEM, V268, P4742; BINOTTI I, 1971, ARCH BIOCHEM BIOPHYS, V142, P274, DOI 10.1016/0003-9861(71)90284-0; BRITTAIN T, 1987, COMP BIOCHEM PHYS B, V86, P473, DOI 10.1016/0305-0491(87)90434-2; Brunori M, 1975, Curr Top Cell Regul, V9, P1; BRUNORI M, 1978, P NATL ACAD SCI USA, V75, P4310, DOI 10.1073/pnas.75.9.4310; CHOTHIA C, 1976, P NATL ACAD SCI USA, V73, P3793, DOI 10.1073/pnas.73.11.3793; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; Colombo MF, 1999, BIOCHEMISTRY-US, V38, P11741, DOI 10.1021/bi9905361; COLOMBO MF, 1994, P NATL ACAD SCI USA, V91, P10517, DOI 10.1073/pnas.91.22.10517; Colombo MF, 1996, J BIOL CHEM, V271, P4895; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; DIPRISCO G, 1992, COMP BIOCHEM PHYS B, V102, P661, DOI 10.1016/0305-0491(92)90062-V; Fago A, 1997, J BIOL CHEM, V272, P15628, DOI 10.1074/jbc.272.25.15628; FAGO A, 1995, J BIOL CHEM, V270, P18897, DOI 10.1074/jbc.270.32.18897; Feuerlein RJ, 1996, J COMP PHYSIOL B, V165, P597, DOI 10.1007/BF00301127; GIARDINA B, 1978, BIOCHEM J, V175, P407, DOI 10.1042/bj1750407; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Rand RP, 2000, CELL MOL LIFE SCI, V57, P1018, DOI 10.1007/PL00000742; Royer WE, 1996, P NATL ACAD SCI USA, V93, P14526, DOI 10.1073/pnas.93.25.14526; Tame JRH, 1996, J MOL BIOL, V259, P749, DOI 10.1006/jmbi.1996.0355; WEBER RE, 1976, J EXP BIOL, V65, P333; WEBER RE, 1976, J EXP BIOL, V64, P75; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J., 1990, BINDING LINKAGE FUNC, P123	28	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42769	42773		10.1074/jbc.M307515200	http://dx.doi.org/10.1074/jbc.M307515200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925528	hybrid			2022-12-27	WOS:000186157000007
J	Ren, XM; Shand, SH; Takimoto, K				Ren, XM; Shand, SH; Takimoto, K			Effective association of Kv channel-interacting proteins with Kv4 channel is mediated with their unique core peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM SENSOR-1; TRANSIENT OUTWARD CURRENT; 3-DIMENSIONAL STRUCTURE; CA2+-BINDING PROTEIN; POTASSIUM CHANNELS; CRYSTAL-STRUCTURE; K+-CURRENTS; EXPRESSION; MODULATION; VENTRICLE	Kv channel-interacting proteins (KChIPs) and neuronal calcium sensor-1 (NCS-1) have been shown to interact with Kv4 channel alpha-subunits to regulate the expression and/or gating of these channels. Here we examine the specificity and sites of these proteins for interaction with Kv channel proteins. Immunoprecipitation and green fluorescent protein imaging show that KChIPs ( but not NCS-1) effectively bind to Kv4.3 protein and localize at the plasma membrane when channel proteins are coexpressed. Analysis with chimeric proteins between KChIP2 and NCS-1 reveals that the three regions of KChIP2 ( the linker between the first and second EF hands, the one between the third and fourth EF hands, and the C-terminal peptide after the fourth EF hand) are necessary and sufficient for its effective binding to Kv4.3 protein. The chimera with these three KChIP2 portions slowed inactivation and facilitated recovery from inactivation of Kv4.3 current. These results indicate that the sequence difference in these three regions between KChIPs and NCS-1 determines the specificity and affinity for interaction with Kv4 protein. Because the three identified regions surround the large hydrophobic crevice based on the NCS-1 crystal structure, this crevice may be the association site of KChIPs for the channel protein.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Ctr Biol Imaging, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Takimoto, K (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, 3343 Forbes Ave, Pittsburgh, PA 15260 USA.							Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Decher N, 2001, CARDIOVASC RES, V52, P255, DOI 10.1016/S0008-6363(01)00374-1; Deschenes I, 2002, FEBS LETT, V528, P183, DOI 10.1016/S0014-5793(02)03296-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Holmqvist MH, 2001, J NEUROSCI, V21, P4154, DOI 10.1523/JNEUROSCI.21-12-04154.2001; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; Nakamura TY, 2001, FEBS LETT, V499, P205, DOI 10.1016/S0014-5793(01)02560-1; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; Patel SP, 2002, J PHYSIOL-LONDON, V539, P649, DOI 10.1113/jphysiol.2001.015156; Rosati B, 2003, J PHYSIOL-LONDON, V548, P815, DOI 10.1113/jphysiol.2002.033704; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Takimoto K, 2002, J BIOL CHEM, V277, P26904, DOI 10.1074/jbc.M203651200; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200	22	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43564	43570		10.1074/jbc.M302337200	http://dx.doi.org/10.1074/jbc.M302337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928444	hybrid			2022-12-27	WOS:000186157000103
J	Suen, DF; Wu, SSH; Chang, HC; Dhugga, KS; Huang, AHC				Suen, DF; Wu, SSH; Chang, HC; Dhugga, KS; Huang, AHC			Cell wall reactive proteins in the coat and wall of maize pollen - Potential role in pollen tube growth on the stigma and through the style	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; BRASSICA-NAPUS; GRASS-POLLEN; GENE FAMILIES; EXPRESSION; INHIBITOR; TAPETUM; GLYCOPROTEINS; PURIFICATION; ALLERGENS	The surface of a pollen grain consists of an outermost coat and an underlying wall. In maize (Zea mays L.), the pollen coat contains two major proteins derived from the adjacent tapetum cells in the anthers. One of the proteins is a 35-kDa endoxylanase (Wu, S.S.H., Suen, D.F., Chang, H.C., and Huang, A.H.C. (2002) J. Biol. Chem. 277, 49055-49064). The other protein of 70 kDa was purified to homogeneity and shown to be a beta-glucanase. Its gene sequence and the developmental pattern of its mRNA differ from those of the known beta-glucanases that hydrolyze the callose wall of the microspore tetrad. Mature pollen placed in a liquid medium released about nine major proteins. These proteins were partially sequenced and identified via GenBank(TM) data bases, and some had not been previously reported to be in pollen. They appear to have wall-loosening, structural, and enzymatic functions. A novel pollen wall-bound protein of 17 kDa has a unique pattern of cysteine distribution in its sequence (six tandem repeats of CX3CX10-15) that could chelate cations and form signal-receiving finger motifs. These pollen-released proteins were synthesized in the pollen interior, and their mRNA increased during pollen maturation and germination. They were localized mainly in the pollen tube wall. The pollen shell was isolated and found to contain no detectable proteins. We suggest that the pollen-coat beta-glucanase and xylanase hydrolyze the stigma wall for pollen tube entry and that the pollen secrete proteins to loosen or become new wall constituents of the tube and to break the wall of the transmitting track for tube advance.	Univ Calif Riverside, Dept Bot & Plant Sci, Ctr Plant Cell Biol, Riverside, CA 92521 USA; DuPont Co Inc, Pioneer Hi Bred Int Inc, Agron Traits Dept, Johnston, IA 50131 USA	University of California System; University of California Riverside; DuPont; Pioneer Hi-Bred International, Inc.	Huang, AHC (corresponding author), Univ Calif Riverside, Dept Bot & Plant Sci, Ctr Plant Cell Biol, Riverside, CA 92521 USA.		Suen, Der-Fen/ACF-7547-2022	Dhugga, Kanwarpal/0000-0003-2477-3422				ALLEN RL, 1993, PLANT J, V3, P261, DOI 10.1046/j.1365-313X.1993.t01-14-00999.x; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Baumberger N, 2001, GENE DEV, V15, P1128, DOI 10.1101/gad.200201; Bewley JD, 2000, BIOCH MOL BIOL PLANT, P988; BIELY P, 1980, EUR J BIOCHEM, V108, P313, DOI 10.1111/j.1432-1033.1980.tb04725.x; Bih FY, 1999, J BIOL CHEM, V274, P22884, DOI 10.1074/jbc.274.32.22884; BROADWATER AH, 1993, GENE, V131, P227, DOI 10.1016/0378-1119(93)90297-G; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; Camardella L, 2000, EUR J BIOCHEM, V267, P4561, DOI 10.1046/j.1432-1327.2000.01510.x; Cosgrove DJ, 1997, P NATL ACAD SCI USA, V94, P6559, DOI 10.1073/pnas.94.12.6559; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; Ferris PJ, 2001, BIOCHEMISTRY-US, V40, P2978, DOI 10.1021/bi0023605; Greiner S, 1998, PLANT PHYSIOL, V116, P733, DOI 10.1104/pp.116.2.733; Harvey AJ, 2001, PHYSIOL PLANTARUM, V113, P108, DOI 10.1034/j.1399-3054.2001.1130115.x; HIRD DL, 1993, PLANT J, V4, P1023, DOI 10.1046/j.1365-313X.1993.04061023.x; Hrmova M, 1996, J BIOL CHEM, V271, P5277, DOI 10.1074/jbc.271.9.5277; Kim HU, 2002, J BIOL CHEM, V277, P22677, DOI 10.1074/jbc.M109298200; Kim JB, 2000, PLANT PHYSIOL, V123, P471, DOI 10.1104/pp.123.2.471; Ladomery M, 2002, ANN HUM GENET, V66, P331, DOI [10.1046/j.1469-1809.2002.00121.x, 10.1017/S0003480002001215]; LEVER M, 1977, ANAL BIOCHEM, V81, P21, DOI 10.1016/0003-2697(77)90594-2; Levy I, 2002, BIOMOL ENG, V19, P17, DOI 10.1016/S1389-0344(02)00007-2; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; Mayfield JA, 2001, SCIENCE, V292, P2482, DOI 10.1126/science.1060972; McCormick S, 1998, CURR OPIN PLANT BIOL, V1, P18, DOI 10.1016/S1369-5266(98)80122-2; Piffanelli P, 1997, PLANT J, V11, P549, DOI 10.1046/j.1365-313X.1997.11030549.x; RUBINSTEIN AL, 1995, P NATL ACAD SCI USA, V92, P3086, DOI 10.1073/pnas.92.8.3086; SAINI JP, 1986, MAYDICA, V31, P227; Sambrook J., 2002, MOL CLONING LAB MANU; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Soloaga A, 1996, EUR J BIOCHEM, V238, P418, DOI 10.1111/j.1432-1033.1996.0418z.x; Sommer-Knudsen J, 1998, PHYTOCHEMISTRY, V47, P483, DOI 10.1016/S0031-9422(97)00724-3; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STIEGLITZ H, 1977, DEV BIOL, V57, P87, DOI 10.1016/0012-1606(77)90356-6; Stratford S, 2001, PLANT MOL BIOL, V46, P43, DOI 10.1023/A:1010659425399; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; Wu SSH, 2002, J BIOL CHEM, V277, P49055, DOI 10.1074/jbc.M208804200; Wu SSH, 1997, P NATL ACAD SCI USA, V94, P12711, DOI 10.1073/pnas.94.23.12711; Wu YJ, 2001, PLANT PHYSIOL, V126, P222, DOI 10.1104/pp.126.1.222	39	57	65	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43672	43681		10.1074/jbc.M307843200	http://dx.doi.org/10.1074/jbc.M307843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930826	hybrid			2022-12-27	WOS:000186157000116
J	Takeda, M; Terasawa, H; Sakakura, M; Yamaguchi, Y; Kajiwara, M; Kawashima, H; Miyasaka, M; Shimada, I				Takeda, M; Terasawa, H; Sakakura, M; Yamaguchi, Y; Kajiwara, M; Kawashima, H; Miyasaka, M; Shimada, I			Hyaluronan recognition mode of CD44 revealed by cross-saturation and chemical shift perturbation experiments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CARBOHYDRATE INTERACTIONS; 3-DIMENSIONAL SOLUTION STRUCTURE; NMR INVESTIGATIONS; BINDING-SITES; LINK MODULE; SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; ESCHERICHIA-COLI; HEVEIN DOMAINS; CELL-MIGRATION	CD44 is the main cell surface receptor for hyaluronic acid (HA) and contains a functional HA-binding domain (HABD) composed of a Link module with N- and C-terminal extensions. The contact residues of human CD44 HABD for HA have been determined by cross-saturation experiments and mapped on the topology of CD44 HABD, which we elucidated by NMR. The contact residues are distributed in both the consensus fold for the Link module superfamily and the additional structural elements consisting of the flanking regions. Interestingly, the contact residues exhibit small changes in chemical shift upon HA binding. In contrast, the residues with large chemical shift changes are localized in the C-terminal extension and the first alpha-helix and are generally inconsistent with the contact residues. These results suggest that, upon ligand binding, the C-terminal extension and the first alpha-helix undergo significant conformational changes, which may account for the broad ligand specificity of CD44 HABD.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Ctr, Chuo Ku, Tokyo 1040032, Japan; Meiji Pharmaceut Univ, Dept Med Chem, Kiyose, Tokyo 2048588, Japan; Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Meiji Pharmaceutical University; Osaka University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp	Miyasaka, Masayuki/AAM-6343-2020; Yamaguchi, Yoshiki/N-5246-2015	Yamaguchi, Yoshiki/0000-0003-0100-5439				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Asensio JL, 2000, CHEM BIOL, V7, P529, DOI 10.1016/S1074-5521(00)00136-8; Asensio JL, 1998, GLYCOBIOLOGY, V8, P569, DOI 10.1093/glycob/8.6.569; Asensio JL, 2000, PROTEINS, V40, P218, DOI 10.1002/(SICI)1097-0134(20000801)40:2<218::AID-PROT50>3.3.CO;2-G; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Espinosa JF, 2000, EUR J BIOCHEM, V267, P3965, DOI 10.1046/j.1432-1327.2000.01415.x; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; Fujisaki T, 1999, CANCER RES, V59, P4427; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; Goddard T. D., 2001, SPARKY 3; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Jimenez-Barbero J, 1999, CURR OPIN STRUC BIOL, V9, P549, DOI 10.1016/S0959-440X(99)00004-4; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 1998, FRONT BIOSCI, V3, P616; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; ROSENBERG L, 1988, J BIOL CHEM, V263, P18071; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 2000, NAT STRUCT BIOL, V7, P188, DOI 10.1038/73278; YU Q, 1995, BIOTECHNIQUES, V19, P122	45	48	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43550	43555		10.1074/jbc.M308199200	http://dx.doi.org/10.1074/jbc.M308199200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928429	hybrid			2022-12-27	WOS:000186157000101
J	Bergantino, E; Brunetta, A; Touloupakis, E; Segalla, A; Szabo, I; Giacometti, GM				Bergantino, E; Brunetta, A; Touloupakis, E; Segalla, A; Szabo, I; Giacometti, GM			Role of the PSII-H subunit in photoprotection - Novel aspects of D1 turnover in Synechocystis 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERBICIDE-RESISTANT MUTANTS; PHOTOSYSTEM-II COMPLEX; SP PCC-6803; CHLAMYDOMONAS-REINHARDTII; PROTEIN-PHOSPHORYLATION; 9-KDA PHOSPHOPROTEIN; STRUCTURAL-CHANGES; ELECTRON-TRANSFER; PSBA TRANSCRIPT; ACCEPTOR-SIDE	Photosystem I-less Synechocystis 6803 mutants carrying modified PsbH proteins, derived from different combinations of wild-type cyanobacterial and maize genes, were constructed. The mutants were analyzed in order to determine the relative importance of the intra- and extramembrane domains of the PsbH subunit in the functioning of photosystem ( PS) II, by a combination of biochemical, biophysical, and physiological approaches. The results confirmed and extended previously published data showing that, besides D1, the whole PsbH protein is necessary to determine the correct structure of a Q(B)/herbicide-binding site. The different turnover of the D1 protein and chlorophyll photobleaching displayed by mutant cells in response to photoinhibitory treatment revealed for the first time the actual role of the PsbH subunit in photoprotection. A functional PsbH protein is necessary for (i) rapid degradation of photodamaged D1 molecules, which is essential to avoid further oxidative damage to the PSII core, and (ii) insertion of newly synthesized D1 molecules into the thylakoid membrane. PsbH is thus required for both initiation and completion of the repair cycle of the PSII complex in cyanobacteria.	Univ Padua, Dept Biol, I-35121 Padua, Italy	University of Padua	Giacometti, GM (corresponding author), Univ Padua, Dept Biol, Viale G Colombo 3, I-35121 Padua, Italy.		Touloupakis, Eleftherios/AAA-1902-2019; Szabo, Ildiko/AAW-5972-2021; Padova, Ildiko/K-5344-2016	Touloupakis, Eleftherios/0000-0002-5133-0849; Szabo, Ildiko/0000-0002-3637-3947; 				Alfonso M, 1999, J PHOTOCH PHOTOBIO B, V48, P104, DOI 10.1016/S1011-1344(99)00038-X; Alfonso M, 2000, PLANT PHYSIOL, V122, P505, DOI 10.1104/pp.122.2.505; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Bailey S, 2001, BIOCHEM SOC T, V29, P455, DOI 10.1042/BST0290455; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNOUN P, 1994, BBA-BIOENERGETICS, V1186, P59, DOI 10.1016/0005-2728(94)90135-X; Bergantino E, 2002, FUNCT PLANT BIOL, V29, P1181, DOI 10.1071/FP02021; Buchel C, 2001, J MOL BIOL, V312, P371, DOI 10.1006/jmbi.2001.4951; Chiaramonte S, 1999, EUR J BIOCHEM, V260, P833, DOI 10.1046/j.1432-1327.1999.00226.x; Constant S, 2000, BIOCHEMISTRY-US, V39, P2032, DOI 10.1021/bi9914154; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; DallaChiesa M, 1997, EUR J BIOCHEM, V248, P731, DOI 10.1111/j.1432-1033.1997.00731.x; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; ERICKSON JM, 1989, PLANT CELL, V1, P361, DOI 10.1105/tpc.1.3.361; Funk C, 2000, PLANT MOL BIOL, V44, P815, DOI 10.1023/A:1026764728846; Golden S. S., 1994, MOL BIOL CYANOBACTER, P693; He QF, 1998, P NATL ACAD SCI USA, V95, P5830, DOI 10.1073/pnas.95.10.5830; Inagaki N, 2001, FEBS LETT, V509, P197, DOI 10.1016/S0014-5793(01)03180-5; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; Jansen T, 2002, J PLANT PHYSIOL, V159, P1205, DOI 10.1078/0176-1617-00829; KLEINFELD D, 1984, BIOCHEMISTRY-US, V23, P5780, DOI 10.1021/bi00319a017; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; Komenda J, 1999, J PHOTOCH PHOTOBIO B, V48, P114, DOI 10.1016/S1011-1344(99)00025-1; KOMENDA J, 1995, EUR J BIOCHEM, V233, P677, DOI 10.1111/j.1432-1033.1995.677_2.x; Komenda J, 2000, PLANT MOL BIOL, V42, P635, DOI 10.1023/A:1006305308196; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; KUHN M, 1988, Z NATURFORSCH C, V43, P413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; MAYES SR, 1991, PLANT MOL BIOL, V17, P289, DOI 10.1007/BF00039508; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; O'Connor HE, 1998, BBA-BIOENERGETICS, V1364, P63, DOI 10.1016/S0005-2728(98)00013-9; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; Summer EJ, 1997, PLANT PHYSIOL, V113, P1359, DOI 10.1104/pp.113.4.1359; Szabo I, 2001, J BIOL CHEM, V276, P13784, DOI 10.1074/jbc.M008081200; Tyystjarvi T, 1998, FEBS LETT, V436, P483, DOI 10.1016/S0014-5793(98)01181-8; Tyystjarvi T, 2001, MOL MICROBIOL, V40, P476, DOI 10.1046/j.1365-2958.2001.02402.x; Vass I, 1999, BIOCHEMISTRY-US, V38, P12786, DOI 10.1021/bi991094w; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Westphal S, 2001, P NATL ACAD SCI USA, V98, P4243, DOI 10.1073/pnas.061501198; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	46	23	26	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41820	41829		10.1074/jbc.M303096200	http://dx.doi.org/10.1074/jbc.M303096200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909614	hybrid			2022-12-27	WOS:000185989500034
J	Kawasaki-Nishi, S; Nishi, T; Forgac, M				Kawasaki-Nishi, S; Nishi, T; Forgac, M			Interacting helical surfaces of the transmembrane segments of subunits a and c ' of the yeast V-ATPase defined by disulfide-mediated cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL DOMAIN; H+-ATPASE; PROTON TRANSLOCATION; MUTATIONAL ANALYSIS; VACUOLAR ATPASE; MOLECULAR ARCHITECTURE; LUMINAL ACIDIFICATION; MUTAGENIC ANALYSIS; GENE DUPLICATION; PERIPHERAL STALK	Proton translocation by the vacuolar (H+)-ATPase (or V-ATPase) has been shown by mutagenesis to be dependent upon charged residues present within transmembrane segments of subunit a as well as the three proteolipid subunits (c, c', and c"). Interaction between R735 in TM7 of subunit a and the glutamic acid residue in the middle of TM4 of subunits c and c' or TM2 of subunit c" has been proposed to be essential for proton release to the luminal compartment. In order to determine whether the helical face of TM7 of subunit a containing R735 is capable of interacting with the helical face of TM4 of subunit c' containing the essential glutamic acid residue (Glu-145), cysteine-mediated crosslinking between these subunits in yeast has been performed. Cys-less forms of subunits a and c' as well as forms containing unique cysteine residues were constructed, introduced together into a strain disrupted in both endogenous subunits, and tested for growth at neutral pH, for assembly competence and for cross-linking in the presence of cupric-phenanthroline by SDS-PAGE and Western blot analysis. Four different cysteine mutants of subunit a were each tested pairwise with ten different unique cysteine mutants of subunit c'. Strong cross-linking was observed for the pairs aS728C/c'I142C, aA731C/c'E145C, aA738C/c'F143C, aA738C/c'L147C, and aL739C/c'L147C. Partial cross-linking was observed for an additional 13 of 40 pairs analyzed. When arrayed on a helical wheel diagram, the results suggest that the helical face of TM7 of subunit a containing Arg-735 interacts with the helical face of TM4 of subunit c' centered on Val-146 and bounded by Glu-145 and Leu-147. The results are consistent with a possible rotational flexibility of one or both of these transmembrane segments as well as some flexibility of movement perpendicular to the membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [R37 GM034478, R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brown D, 2000, J EXP BIOL, V203, P137; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Capaldi RA, 2000, J EXP BIOL, V203, P29; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Graham LA, 2000, J EXP BIOL, V203, P61; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; KANE PM, 1989, J BIOL CHEM, V264, P19236; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Vasilyeva E, 2000, J BIOL CHEM, V275, P255, DOI 10.1074/jbc.275.1.255; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; VIK SB, 1994, J BIOL CHEM, V269, P30364; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	77	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41908	41913		10.1074/jbc.M308026200	http://dx.doi.org/10.1074/jbc.M308026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917411	hybrid			2022-12-27	WOS:000185989500044
J	Kim, TG; Kraus, JC; Chen, JQ; Lee, Y				Kim, TG; Kraus, JC; Chen, JQ; Lee, Y			JUMONJI, a critical factor for cardiac development, functions as a transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNALS; HEART TUBE FORMATION; HOLT-ORAM-SYNDROME; VENTRAL MORPHOGENESIS; HISTONE DEACETYLASE; ENHANCER FACTOR-2; BINDING-PROTEINS; GENETIC-BASIS; MUTANT MICE; DNA	JUMONJI (JMJ) is a nuclear factor that is critical for normal cardiovascular development, evidenced by the analysis of jmj homozygous mutant mice. However, the molecular function of JMJ remains to be elucidated. In the present study, we investigated whether JMJ is a transcriptional modulator. Reporter gene assays using the GAL4-DNA binding domain fused to JMJ and a reporter gene consisting of the GAL4 binding sites upstream of a luciferase reporter gene indicated that JMJ functions as a powerful transcriptional repressor. The DNA binding motif of JMJ was determined using CAST-ing experiments by incubating a random oligonucleotide library with the GST-JMJ fusion protein coupled to agarose beads. Among the selected binding oligonucleotides, the high affinity DNA binding sequences were identified by gel retardation assays. JMJ repressed expression of the reporter genes containing the high affinity JMJ binding sequences, indicating that JMJ is a DNA-binding transcriptional repressor. The domains for transcriptional repression, DNA binding, and nuclear localization signal were mapped by mutational analyses using reporter gene assays, gel retardation assays, and immunostaining experiments, respectively. The present data demonstrate for the first time that JMJ functions as a DNA-binding transcriptional repressor. Therefore, JMJ may play a critical role in transcription factor cascade to regulate expression of heart-specific genes and normal cardiac development.	Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Cardiovasc Res Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lee, Y (corresponding author), Univ Wisconsin, Sch Med, Dept Anat, 1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067050] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67050] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amendt BA, 1999, J BIOL CHEM, V274, P11635, DOI 10.1074/jbc.274.17.11635; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; Gregory SL, 1996, MOL CELL BIOL, V16, P792; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Kim YB, 1999, ANN NY ACAD SCI, V886, P200, DOI 10.1111/j.1749-6632.1999.tb09416.x; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEE Y, 1993, J BIOL CHEM, V268, P2021; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lee Y, 2000, CIRC RES, V86, P932, DOI 10.1161/01.RES.86.9.932; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Lyons GE, 1996, CURR OPIN GENET DEV, V6, P454, DOI 10.1016/S0959-437X(96)80067-0; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Motoyama J, 1997, MECH DEVELOP, V66, P27, DOI 10.1016/S0925-4773(97)00082-8; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Rao S, 1999, J BIOL CHEM, V274, P11115, DOI 10.1074/jbc.274.16.11115; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TAKEUCHI T, 1995, GENE DEV, V9, P1211, DOI 10.1101/gad.9.10.1211; Toyoda M, 2000, BIOCHEM BIOPH RES CO, V274, P332, DOI 10.1006/bbrc.2000.3138; WANG GF, 1999, HEART DEV, P357; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yamagishi H, 1999, SCIENCE, V283, P1158, DOI 10.1126/science.283.5405.1158; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Zaffran S, 2002, CIRC RES, V91, P457, DOI 10.1161/01.RES.0000034152.74523.A8; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	50	76	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42247	42255		10.1074/jbc.M307386200	http://dx.doi.org/10.1074/jbc.M307386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12890668	hybrid			2022-12-27	WOS:000185989500084
J	Li, MX; Zhou, JY; Ge, YB; Matherly, LH; Wu, GS				Li, MX; Zhou, JY; Ge, YB; Matherly, LH; Wu, GS			The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR P53; IMMEDIATE-EARLY GENE; WILD-TYPE P53; MAP KINASE; P53-DEPENDENT APOPTOSIS; TYROSINE-PHOSPHATASE; UV-RADIATION; CONDITIONAL EXPRESSION; P53-INDUCED APOPTOSIS	The tumor suppressor p53 protein suppresses cell growth by inducing cell cycle arrest or apoptosis. Despite the fact that p53-dependent p21-mediated G(1) arrest induced by DNA damage is well defined, the role of p53 in the cell cycle in response to the MAKP signaling remains to be determined. Here we show that MKP1, a member of the dual specificity protein phosphatase family capable of inactivating MAPKs, is a transcriptional target of p53. MKP1 mRNA and protein levels were increased upon p53 activation in several well defined p53-regulated cell systems. p53 bound to a consensus p53 binding site located in the second intron of the MKP1 gene and transactivated MKP1 in reporter gene assays. Inhibition of phosphatase activity impaired p53-mediated G(1) arrest in arrested human glioblastoma GM cells in response to growth factor stimuli. Importantly conditional expression of MKP1 prevented arrested human cancer cells from entering into the cell cycle. Thus, these results provide a novel mechanism by which p53 controls the cell cycle in response to the MAPK signaling in the absence of DNA damage and suggest that p53 may negatively control the MAKP pathway via MKP1.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pharmacol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Wu, GS (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.			Ge, Yubin/0000-0002-8748-716X				Attardi LD, 2000, GENE DEV, V14, P704; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHARLES CH, 1992, ONCOGENE, V7, P187; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Ge YB, 2001, J BIOL CHEM, V276, P43570, DOI 10.1074/jbc.M104930200; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xu QH, 2002, J BIOL CHEM, V277, P41693, DOI 10.1074/jbc.M207095200; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhao RB, 2000, GENE DEV, V14, P981	71	88	89	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41059	41068		10.1074/jbc.M307149200	http://dx.doi.org/10.1074/jbc.M307149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890671	hybrid			2022-12-27	WOS:000185847200080
J	Salas, TR; Reddy, SA; Clifford, JL; Davis, RJ; Kikuchi, A; Lippman, SM; Menter, DG				Salas, TR; Reddy, SA; Clifford, JL; Davis, RJ; Kikuchi, A; Lippman, SM; Menter, DG			Alleviating the suppression of glycogen synthase kinase-3 beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN MUTATIONS; PROSTATE-CANCER CELLS; KINASE 3-BETA; SUBSTRATE-SPECIFICITY; SIGNAL-TRANSDUCTION; PATHWAY; INSULIN; CREB; ACTIVATION; TUMORIGENESIS	Glycogen synthase kinase-3beta (GSK-3beta) activity is suppressed when it becomes phosphorylated on serine 9 by protein kinase B (Akt). To determine how GSK-3beta activity opposes Akt function we used various methods to alleviate GSK-3beta suppression in prostate carcinoma cells. In some experiments, LY294002, a specific inhibitor of phosphatidylinositol 3-kinase ( a kinase involved in activating Akt) and tumor necrosis factor-alpha (TNF-alpha) were used to activate GSK-3beta. In other experiments mutant forms of GSK-3beta, GSK-3beta(Delta9) (a constitutively active deletion mutant of GSK-3beta) and GSK-3beta(Y216F) ( an inactive point mutant of GSK-3beta) were used to alter GSK-3beta activity. LY294002, TNF-alpha, and overexpression of wild-type GSK-3beta or of GSK-3beta(Delta9), but not GSK-3beta(Y216F), alleviated the suppression of GSK-3beta activity in prostate carcinoma cells and enhanced the turnover of beta-catenin. Forced expression of wild-type GSK-3beta or of GSK-3beta(Delta9), but not GSK-3beta(Y216F), suppressed cell growth and showed that the phosphorylation status of GSK-3beta can affect its intracellular distribution. When transcription factors activator protein-1 and cyclic AMP-response element (CRE)-binding protein were analyzed as targets of GSK-3beta activity, overexpression of wild-type GSK-3beta suppressed AP1-mediated transcription and activated CRE-mediated transcription. Overexpression of GSK-3beta(Delta9) caused an (80-fold) increase in CRE-mediated transcription, which was further amplified ( up to 130-fold) by combining GSK-3betaDelta9 overexpression with the suppression of Jun activity. This study also demonstrated for the first time that expression of constitutively active GSK-3beta(Delta9) results in the phosphorylation of CRE-binding protein on serine 129 and enhancement of CRE-mediated transcription in intact cell nuclei.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Massachusetts, Sch Med, Program Mol Med, Howard Hughes Med Inst,Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Hiroshima University	Menter, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Box 236,1515 Holcombe Blvd, Houston, TX 77030 USA.	dmenter@mdanderson.org			NATIONAL CANCER INSTITUTE [R25CA057730] Funding Source: NIH RePORTER; NCI NIH HHS [R25 CA57730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angelloz-Nicoud P, 1998, GROWTH HORM IGF RES, V8, P71, DOI 10.1016/S1096-6374(98)80324-9; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Beresford SA, 2001, J INTERF CYTOK RES, V21, P313, DOI 10.1089/107999001300177501; Bevan P, 2001, J CELL SCI, V114, P1429; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Dupont J, 2001, J CLIN PATHOL-MOL PA, V54, P149, DOI 10.1136/mp.54.3.149; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huynh H, 1998, INT J ONCOL, V13, P137; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kimura G, 1996, Int J Urol, V3, P39; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P1163, DOI 10.1093/nar/21.5.1163; Menter DG, 2000, CANCER EPIDEM BIOMAR, V9, P1171; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; Rosenberg D, 2002, ANN NY ACAD SCI, V968, P65, DOI 10.1111/j.1749-6632.2002.tb04327.x; SASSONECORSI P, 1990, ONCOGENE, V5, P427; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Scheid MP, 2001, J MAMMARY GLAND BIOL, V6, P83, DOI 10.1023/A:1009520616247; Son H, 2001, NEUROSCI LETT, V308, P37, DOI 10.1016/S0304-3940(01)01984-X; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; Voeller HJ, 1998, CANCER RES, V58, P2520; Walczak J, 2001, UROLOGY, V57, P81, DOI 10.1016/S0090-4295(00)00947-X; WANG QM, 1994, ANAL BIOCHEM, V220, P397, DOI 10.1006/abio.1994.1356; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; WOODGETT JR, 2001, SCI STKE; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	48	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41338	41346		10.1074/jbc.M302972200	http://dx.doi.org/10.1074/jbc.M302972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900420	hybrid			2022-12-27	WOS:000185847200114
J	Zou, WQ; Capellari, S; Parchi, P; Sy, MS; Gambetti, P; Chen, SG				Zou, WQ; Capellari, S; Parchi, P; Sy, MS; Gambetti, P; Chen, SG			Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PRION PROTEIN; STRAUSSLER-SCHEINKER-DISEASE; SCRAPIE PRION; TRANSGENIC MICE; MOLECULAR-CLONING; TRUNCATED FORMS; AMYLOID PROTEIN; NORMAL BRAIN; PHENOTYPE; ISOFORMS	The central event in the pathogenesis of prion diseases, a group of fatal, transmissible neurodegenerative disorders including Creutzfeldt-Jakob disease (CJD) in humans, is the conversion of the normal or cellular prion protein ( PrPC) into the abnormal or scrapie isoform ( PrPSc). The basis of the PrPC to PrPSc conversion is thought to involve the diminution of alpha-helical domains accompanied by the increase of beta structures within the PrP molecule. Consequently, treatment of PrPSc with proteinase K (PK) generates a large PK-resistant C-terminal core fragment termed PrP27-30 that in human prion diseases has a gel mobility of similar to19-21 kDa for the unglycosylated form, and a ragged N terminus between residues 78 and 103. PrP27-30 is considered the pathogenic and infectious core of PrPSc. Here we report the identification of two novel PK-resistant, but much smaller C-terminal fragments of PrP (PrP-CTF 12/13) in brains of subjects with sporadic CJD. PrP-CTF 12/13, like PrP27-30, derive from both glycosylated as well as unglycosylated forms. The unglycosylated PrP-CTF 12/13 migrate at 12 and 13 kDa and have the N terminus at residues 162/167 and 154/156, respectively. Therefore, PrP-CTF12/13 are 64-76 amino acids N-terminally shorter than PrP27-30 and are about half of the size of PrP27-30. PrP-CTF12/13 are likely to originate from a subpopulation of PrPSc distinct from that which generates PrP27-30. The finding of PrP-CTF12/13 in CJD brains widens the heterogeneity of the PK-resistant PrP fragments associated with prion diseases and may provide useful insights toward the understanding of the PrPSc structure and its formation.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA	Case Western Reserve University	Chen, SG (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	sxc59@cwru.edu	Parchi, Piero/L-9833-2015; Chen, Shu/Z-2943-2019; Zou, Wenquan/GWQ-3489-2022; Chen, Shu G./AAK-7301-2021; Chen, Shu G./O-4750-2014; Zou, Wenquan/ABF-2875-2020; capellari, sabina/F-5545-2012	Parchi, Piero/0000-0002-9444-9524; Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; capellari, sabina/0000-0003-1631-1439	NATIONAL INSTITUTE ON AGING [R03AG015162, P01AG014359] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG014359-050003, P01 AG014359-030003, P01 AG014359-010003, P01 AG014359-040003, P01 AG014359-060003, AG14359, P01 AG014359, AG15162, P01 AG014359-020003] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chen SG, 1997, NAT MED, V3, P1009, DOI 10.1038/nm0997-1009; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; DeArmond SJ, 1999, COLD SPRING HARBOR M, V38, P585; Eberl H, 2002, BIOPHYS CHEM, V96, P293, DOI 10.1016/S0301-4622(02)00015-7; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; Kaneko K, 2000, J MOL BIOL, V295, P997, DOI 10.1006/jmbi.1999.3386; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; LIAO YCJ, 1986, SCIENCE, V233, P364, DOI 10.1126/science.3014653; MA J, 2002, SCIENCE, V298, P1758; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pan T, 2001, J BIOL CHEM, V276, P37284, DOI 10.1074/jbc.M107358200; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1998, P NATL ACAD SCI USA, V95, P8322, DOI 10.1073/pnas.95.14.8322; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PARCHI P, 1995, CURR OPIN NEUROL, V8, P286, DOI 10.1097/00019052-199508000-00007; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Supattapone S, 2001, MOL CELL BIOL, V21, P2608, DOI 10.1128/MCB.21.7.2608-2616.2001; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; Tagliavini F, 2001, J BIOL CHEM, V276, P6009, DOI 10.1074/jbc.M007062200; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zanusso G, 2002, ELECTROPHORESIS, V23, P347, DOI 10.1002/1522-2683(200202)23:2<347::AID-ELPS347>3.0.CO;2-1; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200; ZOU WQ, 2002, CHARACTERIZATION PRI, P305	53	117	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40429	40436		10.1074/jbc.M308550200	http://dx.doi.org/10.1074/jbc.M308550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917418	hybrid			2022-12-27	WOS:000185847200003
J	Ahn, JH; Beharry, S; Molday, LL; Molday, RS				Ahn, JH; Beharry, S; Molday, LL; Molday, RS			Functional interaction between the two halves of the photoreceptor-specific ATP binding cassette protein ABCR (ABCA4) - Evidence for a non-exchangeable ADP in the first nucleotide binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; STARGARDT MACULAR DYSTROPHY; ESCHERICHIA-COLI F1-ATPASE; HUMAN P-GLYCOPROTEIN; ROD OUTER SEGMENTS; DISEASE GENE ABCR; ADENINE-NUCLEOTIDE; ADENOSINE-TRIPHOSPHATASE; RETINITIS-PIGMENTOSA; DIMETHYL-SULFOXIDE	ABCR, also known as ABCA4, is a member of the superfamily of ATP binding cassette transporters that is believed to transport retinal or retinylidene-phosphatidylethanolamine across photoreceptor disk membranes. Mutations in the ABCR gene are responsible for Stargardt macular dystrophy and related retinal dystrophies that cause severe loss in vision. ABCR consists of two tandemly arranged halves each containing a membrane spanning segment followed by a large extracellular/ lumen domain, a multi-spanning membrane domain, and a nucleotide binding domain (NBD). To define the role of each NBD, we examined the nucleotide binding and ATPase activities of the N and C halves of ABCR individually and co-expressed in COS-1 cells and derived from trypsin-cleaved ABCR in disk membranes. When disk membranes or membranes from co-transfected cells were photoaffinity labeled with 8-azido-ATP and 8-azido-ADP, only the NBD2 in the C-half bound and trapped the nucleotide. Co-expressed half-molecules displayed basal and retinal-stimulated ATPase activity similar to full-length ABCR. The individually expressed N-half displayed weak 8-azido-ATP labeling and low basal ATPase activity that was not stimulated by retinal, whereas the C-half did not bind ATP and exhibited little if any ATPase activity. Purified ABCR contained one tightly bound ADP, presumably in NBD1. Our results indicate that only NBD2 of ABCR binds and hydrolyzes ATP in the presence or absence of retinal. NBD1, containing a bound ADP, associates with NBD2 to play a crucial, non-catalytic role in ABCR function.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.				NEI NIH HHS [EY 02422] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Ahn J, 2000, METHOD ENZYMOL, V315, P864; Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Beharry S, 1996, EUR J BIOCHEM, V240, P165, DOI 10.1111/j.1432-1033.1996.0165h.x; BEHARRY S, 1992, BIOCHEM BIOPH RES CO, V182, P697, DOI 10.1016/0006-291X(92)91788-R; BEHARRY S, 1992, BIOCHEM J, V286, P603, DOI 10.1042/bj2860603; BEHARRY S, 1991, BIOCHEM CELL BIOL, V69, P291, DOI 10.1139/o91-044; Biswas EE, 2001, BIOCHEMISTRY-US, V40, P8181, DOI 10.1021/bi0106686; Biswas EE, 2000, BIOCHEMISTRY-US, V39, P15879, DOI 10.1021/bi0015966; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GARRETT NE, 1975, J SUPRAMOL STR CELL, V3, P469, DOI 10.1002/jss.400030507; HAMPP R, 1984, METHOD ENZYMAT AN, V2, P370; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Muller M, 1996, J BIOL CHEM, V271, P1877; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; PAPERMASTER DS, 1982, VISION RES, V22, P1417, DOI 10.1016/0042-6989(82)90204-8; Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, METHOD ENZYMOL, V292, P514; Souied EH, 1999, INVEST OPHTH VIS SCI, V40, P2740; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	50	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39600	39608		10.1074/jbc.M304236200	http://dx.doi.org/10.1074/jbc.M304236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888572	hybrid			2022-12-27	WOS:000185713800043
J	Chadjichristos, C; Ghayor, C; Kypriotou, M; Martin, G; Renard, E; Ala-Kokko, L; Suske, G; de Crombrugghe, B; Pujol, JP; Galera, P				Chadjichristos, C; Ghayor, C; Kypriotou, M; Martin, G; Renard, E; Ala-Kokko, L; Suske, G; de Crombrugghe, B; Pujol, JP; Galera, P			Sp1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HUMAN COL2A1 GENE; TRANSFORMING GROWTH-FACTOR-BETA-1 TGF-BETA-1; MESSENGER-RNA LEVELS; NF-KAPPA-B; INTERFERON-GAMMA; INDUCED ARTHRITIS; BINDING-PROTEINS; UP-REGULATION; SOX9 GENE	Interleukin-1beta (IL-1beta) is a pleiotropic cytokine that was shown to inhibit the biosynthesis of articular cartilage components. Here we demonstrate that IL-1beta inhibits the production of newly synthesized collagens in proliferating rabbit articular chondrocytes and that this effect is accompanied by a decrease in the steady-state levels of type II collagen mRNA. IL-1beta down-regulates COL2A1 gene transcription through a -41/-33 bp sequence that binds a multimeric complex including Sp1 and Sp3 transcription factors. Specificity of IL-1beta effects on COL2A1 promoter activity was demonstrated in experiments in which transfection of a wild type -50/+1 sequence of COL2A1 promoter as a decoy oligonucleotide abolished the IL-1beta inhibition of a -63/+47 COL2A1-mediated transcription. By contrast, transfection of the related oligonucleotide harboring a targeted mutation in the -41/-33 sequence did not modify the negative effect the cytokine. Because we demonstrated previously that Sp1 was a strong activator of COL2A1 gene expression via the -63/+1 promoter region, whereas Sp3 overexpression blocked Sp1-induced promoter activity and inhibited COL2A1 gene transcription, we conclude that IL-1beta down-regulation of that gene, as we found previously for transforming growth factor-beta1, is mediated by an increase in the Sp3/Sp1 ratio. Moreover, IL-1beta increased steady-state levels of Sp1 and Sp3 mRNAs, whereas it enhanced Sp3 protein expression and inhibited Sp1 protein biosynthesis. Nevertheless, IL-1beta decreased the binding activity of both Sp1 and Sp3 to the 63-bp short COL2A1 promoter, suggesting that the cytokine exerts a post-transcriptional regulatory mechanism on Sp1 and Sp3 gene expressions. Altogether, these data indicate that modulation of Sp3/Sp1 ratio in cartilage could be a potential target to prevent or limit the tissue degradation.	CHU Niveau, Fac Med, Lab Biochim Tissu Conjonct, F-14032 Caen, France; Div Malad Osseuses, CH-1211 Geneva 14, Switzerland; Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem, SF-90220 Oulu, Finland; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	CHU de Caen NORMANDIE; Universite de Caen Normandie; University of Geneva; University of Oulu; University of Oulu; Philipps University Marburg; University of Texas System; UTMD Anderson Cancer Center	Galera, P (corresponding author), CHU Niveau, Fac Med, Lab Biochim Tissu Conjonct, 3 Ave Cote Nacre, F-14032 Caen, France.		Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Suske, Guntram/0000-0002-4807-0513; Ghayor, Chafik/0000-0002-3016-3412; Martin, Gregoire/0000-0001-8240-6108				ANDREWS HJ, 1989, BIOCHIM BIOPHYS ACTA, V1012, P128, DOI 10.1016/0167-4889(89)90085-2; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P105, DOI 10.1016/0014-4827(90)90042-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; GALERA P, 1992, J CELL PHYSIOL, V153, P596, DOI 10.1002/jcp.1041530322; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; INAGAKI Y, 1995, HEPATOLOGY, V22, P573, DOI 10.1016/0270-9139(95)90582-0; Inagaki Y, 2001, J BIOL CHEM, V276, P16573, DOI 10.1074/jbc.M010485200; Joosten LAB, 1996, ARTHRITIS RHEUM, V39, P797, DOI 10.1002/art.1780390513; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Kypriotou M, 2003, DNA CELL BIOL, V22, P119, DOI 10.1089/104454903321515922; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; Mayne R. u. M. H. I., 1986, ARTICULAR CARTILAGE, P23; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Osaki M, 2003, BIOCHEM J, V369, P103, DOI 10.1042/BJ20020928; Peterkofsky B, 1999, J CELL BIOCHEM, V73, P408, DOI 10.1002/(SICI)1097-4644(19990601)73:3<408::AID-JCB12>3.3.CO;2-4; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PUJOL JP, 1987, LIFE SCI, V41, P1187, DOI 10.1016/0024-3205(87)90196-2; PUJOL JP, 1984, BIOCHEM BIOPH RES CO, V119, P499, DOI 10.1016/S0006-291X(84)80276-4; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Robbins JR, 2000, ARTHRITIS RHEUM, V43, P2189, DOI 10.1002/1529-0131(200010)43:10<2189::AID-ANR6>3.0.CO;2-S; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; VANDELOO FAJ, 1995, ARTHRITIS RHEUM, V38, P164; Xu SC, 2001, DNA CELL BIOL, V20, P359, DOI 10.1089/10445490152122479; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	44	105	109	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39762	39772		10.1074/jbc.M303541200	http://dx.doi.org/10.1074/jbc.M303541200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888570	hybrid			2022-12-27	WOS:000185713800062
J	Kovacic, S; Soltys, CLM; Barr, AJ; Shiojima, I; Walsh, K; Dyck, JRB				Kovacic, S; Soltys, CLM; Barr, AJ; Shiojima, I; Walsh, K; Dyck, JRB			Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; INSULIN-RESISTANCE; RAT HEARTS; GLUCOSE-OXIDATION; MAMMALIAN TARGET; MICE LACKING; IN-VITRO; ISCHEMIA; TRANSLOCATION; INHIBITION	In the heart, insulin stimulates a variety of kinase cascades and controls glucose utilization. Because insulin is able to activate Akt and inactivate AMP-activated protein kinase (AMPK) in the heart, we hypothesized that Akt can regulate the activity of AMPK. To address the potential existence of this novel signaling pathway, we used a number of experimental protocols to activate Akt in cardiac myocytes and monitored the activation status of AMPK. Mouse hearts perfused in the presence of insulin demonstrated accelerated glycolysis and glucose oxidation rates as compared with non-insulin-perfused hearts. In addition, insulin caused an increase in Akt phosphorylation and a decrease in AMPK phosphorylation at its major regulatory site (threonine 172 of the alpha catalytic subunit). Transgenic mice overexpressing a constitutively active mutant form of Akt1 displayed decreased phosphorylation of cardiac alpha-AMPK. Isolated neonatal cardiac myocytes infected with an adenovirus expressing constitutively active mutant forms of either Akt1 or Akt2 also suppressed AMPK phosphorylation. However, Akt-dependent depression of alpha-AMPK phosphorylation could be overcome in the presence of the AMPK activator, metformin, suggesting that an override mechanism exists that can restore AMPK activity. Taken together, this study suggests that there is crosstalk between the AMPK and Akt pathways and that Akt activation can lead to decreased AMPK activity. In addition, our data suggest that the ability of insulin to inhibit AMPK may be controlled via an Akt-mediated mechanism.	Univ Alberta, Fac Med, Dept Pediat, Cardiovasc Res Grp,Heritage Med Res Ctr 474, Edmonton, AB T6G 2S2, Canada; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Univ Alberta, Fac Med, Dept Pharmacol, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada	University of Alberta; Boston University; University of Alberta	Dyck, JRB (corresponding author), Univ Alberta, Fac Med, Dept Pediat, Cardiovasc Res Grp,Heritage Med Res Ctr 474, Edmonton, AB T6G 2S2, Canada.			Dyck, Jason/0000-0002-7045-2884				Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; Beauloye C, 2001, CIRC RES, V88, P513, DOI 10.1161/01.RES.88.5.513; Belke DD, 2001, AM J PHYSIOL-ENDOC M, V280, pE420, DOI 10.1152/ajpendo.2001.280.3.E420; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Campbell FM, 2002, J BIOL CHEM, V277, P4098, DOI 10.1074/jbc.M106054200; Carvalho E, 2000, MOL CELL BIOCHEM, V206, P7, DOI 10.1023/A:1007009723616; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clarke B, 1996, J MOL CELL CARDIOL, V28, P341, DOI 10.1006/jmcc.1996.0032; Depre C, 1998, EUR J BIOCHEM, V258, P277, DOI 10.1046/j.1432-1327.1998.2580277.x; FANTINI E, 1994, J MOL CELL CARDIOL, V26, P949, DOI 10.1006/jmcc.1994.1116; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 2001, CELL DEATH DIFFER, V8, P1207, DOI 10.1038/sj.cdd.4400919; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; GOODWIN GW, 1995, J BIOL CHEM, V270, P9234, DOI 10.1074/jbc.270.16.9234; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; JESSEN N, 2002, J APPL PHYSIOL, V4, P1373; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; LAUGHLIN MR, 1992, AM J PHYSIOL, V262, pE875, DOI 10.1152/ajpendo.1992.262.6.E875; LOPASCHUK GD, 1990, CIRC RES, V66, P546, DOI 10.1161/01.RES.66.2.546; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Proud CG, 1997, BIOCHEM J, V328, P329; ROSEN P, 1984, BASIC RES CARDIOL, V79, P307; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; SCHONEKESS BO, 1995, CIRC RES, V77, P726, DOI 10.1161/01.RES.77.4.726; Scott JW, 2002, J MOL BIOL, V317, P309, DOI 10.1006/jmbi.2001.5316; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Soltys CLM, 2002, AM J PHYSIOL-HEART C, V283, pH1056, DOI 10.1152/ajpheart.00275.2002; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; VANOVERSCHELDE JL, 1994, AM J PHYSIOL, V267, pH1785; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	47	314	329	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39422	39427		10.1074/jbc.M305371200	http://dx.doi.org/10.1074/jbc.M305371200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890675	hybrid			2022-12-27	WOS:000185713800019
J	Park-Lee, S; Kim, S; Laird-Offringa, IA				Park-Lee, S; Kim, S; Laird-Offringa, IA			Characterization of the interaction between neuronal RNA-binding protein HuD and AU-rich RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; IN-VIVO STABILITY; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; 3-UNTRANSLATED REGION; GENE-EXPRESSION; POLY(A) TAIL; ELAV; SEQUENCE; ELEMENTS	Hu proteins have been shown to bind to AU-rich elements (AREs) in the 3'-untranslated region of unstable mRNAs. They can thereby inhibit the decay of labile transcripts by antagonizing destabilizing proteins that target these AU-rich sequences. Here we examine the sequence preferences of HuD to elucidate its possible role in counteracting mRNA decay. Using repeats of the prototype destabilizing sequence UU(AUUU)(n)AUU, we show that all three HuD RNA-binding domains participate in binding to AU-tracts that can be as short as 13 residues, depending on the position of the remaining As. Removal of the A residues, resulting in a poly(U)-tract, increased the affinity of HuD for RNA, suggesting that the presence of As in destabilizing elements might favor the recruitment of other proteins and/or prevent HuD from binding too tightly to AREs. In vitro selection experiments with randomized RNAs confirmed the preference of HuD for poly(U). RNA binding analysis of the related protein HuB showed a similar preference for poly(U). In contrast, tristetraprolin, an mRNA destabilizing protein, strongly prefers AU-rich RNA. Many labile mRNAs contain U-tracts in or near their AREs. Individual AREs may thus differentially affect mRNA half-life by recruiting a unique complement of stabilizing and destabilizing factors.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Surg, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Laird-Offringa, IA (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.	ilaird@usc.edu	Offringa, Ite/R-4101-2019		NCI NIH HHS [R29CA78407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Beckel-Mitchener AC, 2002, J BIOL CHEM, V277, P27996, DOI 10.1074/jbc.M201982200; Bernasconi NL, 2000, AM J RESP CELL MOL, V23, P560, DOI 10.1165/ajrcmb.23.4.4233; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chagnovich D, 1997, EUR J CANCER, V33, P2064, DOI 10.1016/S0959-8049(97)00208-6; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Cuadrado A, 2002, NUCLEIC ACIDS RES, V30, P2202, DOI 10.1093/nar/30.10.2202; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Jain R G, 1995, Nucleic Acids Symp Ser, P209; Katsamba PS, 2002, METHODS, V26, P95, DOI 10.1016/S1046-2023(02)00012-9; Kenan DJ, 1999, METH MOL B, V118, P217; Kwon YS, 1999, J BIOL CHEM, V274, P29149, DOI 10.1074/jbc.274.41.29149; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; Malter JS, 2001, J NEUROSCI RES, V66, P311, DOI 10.1002/jnr.10021; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Okano HJ, 1997, J NEUROSCI, V17, P3024; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335; Quattrone A, 2001, P NATL ACAD SCI USA, V98, P11668, DOI 10.1073/pnas.191388398; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Ross RA, 1997, EUR J CANCER, V33, P2071, DOI 10.1016/S0959-8049(97)00331-6; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; van Hoof A, 2002, CURR BIOL, V12, pR285, DOI 10.1016/S0960-9822(02)00802-3; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Zarudnaya MI, 1999, IUBMB LIFE, V48, P581; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	68	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39801	39808		10.1074/jbc.M307105200	http://dx.doi.org/10.1074/jbc.M307105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900401	hybrid			2022-12-27	WOS:000185713800066
J	Akira, S				Akira, S			Toll-like receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NF-KAPPA-B; ADAPTER MOLECULE; IFN-BETA; CUTTING EDGE; IMMUNE CELLS; MICE LACKING; IRAK FAMILY; IL-1; ACTIVATION; KINASE		Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, ERATO, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Akira, S (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Host Def, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	sakira@biken.osaka-u.ac.jp						Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chung JY, 2002, J CELL SCI, V115, P679; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; LORD KA, 1990, ONCOGENE, V5, P1095; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113; Thomas JA, 1999, J IMMUNOL, V163, P978; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yu KY, 2002, J IMMUNOL, V169, P4075, DOI 10.4049/jimmunol.169.8.4075; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	53	559	627	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38105	38108		10.1074/jbc.R300028200	http://dx.doi.org/10.1074/jbc.R300028200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12893815	hybrid			2022-12-27	WOS:000185575100001
J	Ghosh, S; Moore, S; Bell, RM; Dush, M				Ghosh, S; Moore, S; Bell, RM; Dush, M			Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase - Mutations in the phosphatidate binding domain lead to tail and trunk abnormalities in developing zebrafish embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-D; CRYSTAL-STRUCTURE; EXPRESSION; C-RAF-1; TRANSLOCATION; MECHANISMS; LIPOSOMES; PATHWAY; RAS	Previously, we and others identified a 35-amino acid segment within human Raf-1 kinase that preferentially binds phosphatidic acid. The presence of phosphatidic acid was found to be necessary for the translocation of Raf-1 to the plasma membrane. We have now employed a combination of alanine-scanning and deletion mutagenesis to identify the critical amino acid residues in Raf-1 necessary for interaction with phosphatidic acid. Progressive mutations within a tetrapeptide motif (residues 398-401 of human Raf-1) reduced and finally eliminated binding of Raf-1 to phosphatidic acid. We then injected zebrafish embryos with RNA encoding wild-type Raf-1 kinase or a mutant version with triple alanine mutations in the tetrapeptide motif and followed the morphological fate of embryonic development. Embryos with mutant but not wild-type Raf-1 exhibited defects in posterior axis formation exemplified by bent trunk and tail structures. Molecular evidence for lack of signaling through mutated Raf-1 was obtained by aberrant in situ hybridization of the ntl ((n) under baro (t) under bar ail) gene, which functions downstream of Raf-1. Our results demonstrate that a functional phosphatidate binding site is necessary for Raf-1 function in embryonic development.	GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Ghosh, S (corresponding author), GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA.	sg45653@gsk.com	Ghosh, Sujoy/I-3729-2017	Ghosh, Sujoy/0000-0002-7601-165X				Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; Bechoua S, 2001, J BIOL CHEM, V276, P31752, DOI 10.1074/jbc.M101265200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Daniel LW, 1999, BBA-MOL CELL BIOL L, V1439, P265, DOI 10.1016/S1388-1981(99)00099-2; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Ghosh Sujoy, 2002, Methods Mol Biol, V199, P49; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; Lu KK, 1998, CELL GROWTH DIFFER, V9, P367; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; QUEST AFG, 1994, PROTEIN KINASE C, P64; Renault Andrew D., 2002, Gene Expression Patterns, V2, P337, DOI 10.1016/S0925-4773(02)00389-1; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; Shinya M, 2001, DEVELOPMENT, V128, P4153; Xie Z, 2002, J BIOL CHEM, V277, P11979, DOI 10.1074/jbc.M109751200; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	40	73	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45690	45696		10.1074/jbc.M302933200	http://dx.doi.org/10.1074/jbc.M302933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925535	hybrid			2022-12-27	WOS:000186452300078
J	Han, SY; Xie, WS; Hammes, SR; DeJong, J				Han, SY; Xie, WS; Hammes, SR; DeJong, J			Expression of the germ cell-specific transcription factor ALF in Xenopus oocytes compensates for translational inactivation of the somatic factor TFIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; TBP-LIKE FACTOR; POLYMERASE-II TRANSCRIPTION; GENE-EXPRESSION; CYTOPLASMIC POLYADENYLATION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; MICE LACKING; DNA-BINDING; C-ELEGANS	The discovery of germ cell-specific general transcription factor and coactivator variants has suggested that reproductive tissues control gene expression somewhat differently than somatic tissues. One of these factors, ALF (TFIIAtau), was first described as a testis-specific counterpart of the large (alpha/beta) subunit of TFIIA. Here we characterize endogenous ALF and TFIIA activities in the African clawed frog Xenopus laevis. ALF is present in both testis and ovary in this organism, and it completely replaces TFIIA in immature oocytes. When oocytes undergo progesterone-induced maturation, ALF activity disappears, and TFIIA activity is restored. Reactivation occurs through the translational up-regulation of two maternal TFIIAalpha/beta mRNAs and involves polyadenylation of a conserved 3'-untranslated region module. The effects of ALF overexpression and ALF immunodepletion on a thymidine kinase promoter construct demonstrate that this factor serves as an active replacement for TFIIA. In contrast, overexpression of TFIIA inhibits transcription, indicating that the somatic factor fails to function properly in the context of the oocyte transcription machinery. Overall, the results show that the translationally regulated reciprocal expression of ALF and TFIIA allows for the production of an active TFIIA-like general transcription factor throughout oogenesis.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75080 USA; Univ Texas, SW Med Sch, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Sch, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DeJong, J (corresponding author), Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75080 USA.							Aoyagi N, 2000, J CELL BIOL, V150, pF45, DOI 10.1083/jcb.150.2.F45; Bell P, 1999, EXP CELL RES, V248, P122, DOI 10.1006/excr.1999.4411; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Eddy EM, 2002, RECENT PROG HORM RES, V57, P103, DOI 10.1210/rp.57.1.103; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Han SY, 2001, BIOL REPROD, V64, P507, DOI 10.1095/biolreprod64.2.507; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; Kashiwabara S, 2002, SCIENCE, V298, P1999, DOI 10.1126/science.1074632; Kay B. K., 1991, XENOPUS LAEVIS PRACT; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Martianov I, 2002, DEVELOPMENT, V129, P945; Moore PA, 1999, MOL CELL BIOL, V19, P7610; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Ozer J, 2000, J BIOL CHEM, V275, P122, DOI 10.1074/jbc.275.1.122; Ozer J, 1998, MOL CELL BIOL, V18, P2559, DOI 10.1128/MCB.18.5.2559; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Salles FJ, 1999, METHODS, V17, P38, DOI 10.1006/meth.1998.0705; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; Upadhyaya AB, 1999, J BIOL CHEM, V274, P18040, DOI 10.1074/jbc.274.25.18040; Upadhyaya AB, 2003, BBA-GENE STRUCT EXPR, V1625, P88, DOI 10.1016/S0167-4781(02)00541-9; Upadhyaya AB, 2002, J BIOL CHEM, V277, P34208, DOI 10.1074/jbc.M204808200; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Wang PJ, 2002, HUM MOL GENET, V11, P2341, DOI 10.1093/hmg/11.19.2341; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927; Xie WS, 2002, J BIOL CHEM, V277, P17765, DOI 10.1074/jbc.M200954200; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188	40	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45586	45593		10.1074/jbc.M302884200	http://dx.doi.org/10.1074/jbc.M302884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12923189	hybrid			2022-12-27	WOS:000186452300067
J	Pratta, MA; Yao, WQ; Decicco, C; Tortorella, MD; Liu, RQ; Copeland, RA; Magolda, R; Newton, RC; Trzaskos, JM; Arner, EC				Pratta, MA; Yao, WQ; Decicco, C; Tortorella, MD; Liu, RQ; Copeland, RA; Magolda, R; Newton, RC; Trzaskos, JM; Arner, EC			Aggrecan protects cartilage collagen from proteolytic cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOARTHRITIC ARTICULAR-CARTILAGE; BOVINE NASAL CARTILAGE; II COLLAGEN; MATRIX METALLOPROTEINASE-13; PROTEOGLYCAN DEGRADATION; INTERGLOBULAR DOMAIN; SYNTHETIC INHIBITOR; ADAMTS FAMILY; CHONDROCYTES; CLONING	The matrix components responsible for cartilage mechanical properties, type II collagen and aggrecan, are degraded in osteoarthritis through proteolytic cleavage by matrix metalloproteinases (MMPs) and aggrecanases, respectively. We now show that aggrecan may serve to protect cartilage collagen from degradation. Although collagen in freeze-thawed cartilage depleted of aggrecan was completely degraded following incubation with MMP-1, collagen in cartilage with intact aggrecan was not. Using interleukin-1-stimulated bovine nasal cartilage explants where aggrecan depletion occurs during the first week of culture, followed by collagen loss during the second week, we evaluated the effect of selective MMP and aggrecanase inhibitors on degradation. A selective MMP inhibitor did not block aggrecan degradation but caused complete inhibition of collagen breakdown. Similar inhibition was seen with inhibitor addition following aggrecan depletion on day 6-8, suggesting that MMPs are not causing significant collagen degradation prior to the second week of culture. Inclusion of a selective aggrecanase inhibitor blocked aggrecan degradation, and, in addition, inhibited collagen degradation. When the inhibitor was introduced following aggrecan depletion, it had no effect on collagen breakdown, ruling out a direct effect through inhibition of collagenase. These data suggest that aggrecan plays a protective role in preventing degradation of collagen fibrils, and that an aggrecanase inhibitor may impart overall cartilage protection.	Bristol Myers Squibb Pharmaceut Co, Wilmington, DE 19898 USA	Bristol-Myers Squibb	Pratta, MA (corresponding author), GlaxoSmithKline, UP1340 1250 S Collegeville Rd,POB 5089, Collegeville, PA 19426 USA.	michael_a_pratta@gsk.com						Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1999, ANN NY ACAD SCI, V878, P92, DOI 10.1111/j.1749-6632.1999.tb07676.x; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; ARNER EC, 1989, ARTHRITIS RHEUM, V32, P288, DOI 10.1002/anr.1780320310; Beekman B, 1998, OSTEOARTHR CARTILAGE, V6, P330, DOI 10.1053/joca.1998.0132; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Bottomley KM, 1997, BIOCHEM J, V323, P483, DOI 10.1042/bj3230483; Creemers LB, 1997, BIOTECHNIQUES, V22, P656, DOI 10.2144/97224bm19; Dahlberg L, 2000, ARTHRITIS RHEUM, V43, P673, DOI 10.1002/1529-0131(200003)43:3<673::AID-ANR25>3.0.CO;2-8; ELLIS AJ, 1994, BIOCHEM BIOPH RES CO, V201, P94, DOI 10.1006/bbrc.1994.1673; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; HARDINGHAM TE, 1995, J RHEUMATOL, V22, P86; Hedlund H, 1999, J BIOL CHEM, V274, P5777, DOI 10.1074/jbc.274.9.5777; Hollander AP, 1995, J CLIN INVEST, V96, P2859, DOI 10.1172/JCI118357; HOLLANDER AP, 1994, J CLIN INVEST, V93, P1722, DOI 10.1172/JCI117156; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kozaci LD, 1997, ARTHRITIS RHEUM-US, V40, P164, DOI 10.1002/art.1780400121; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945-053X(02)00004-5; Little CB, 2002, ARTHRITIS RHEUM-US, V46, P124, DOI 10.1002/1529-0131(200201)46:1<124::AID-ART10121>3.0.CO;2-X; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MAROUDAS A, 1976, NATURE, V260, P808, DOI 10.1038/260808a0; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; NAGASE H, 2001, CONNECT TISSUE, V33, P27; ORFORD CR, 1984, CONNECT TISSUE RES, V12, P345, DOI 10.3109/03008208409013696; PRATTA MA, 1998, T ORTHOP RES SOC, V23, P81; SCOTT JE, 1991, INT J BIOL MACROMOL, V13, P157, DOI 10.1016/0141-8130(91)90041-R; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Taylor P. C., 1997, Arthritis and Rheumatism, V40, pS80; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TORTORELLA MD, 1995, T ORTHOP RES SOC, V20, P341; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; VISCO DM, 1993, ARTHRITIS RHEUM, V36, P1718, DOI 10.1002/art.1780361211; XUE CB, 1997, Patent No. 97182072; YAO W, 2001, J MED CHEM, V11, P3317; Yasuda T, 2002, ARTHRITIS RHEUM, V46, P138, DOI 10.1002/1529-0131(200201)46:1<138::AID-ART10051>3.0.CO;2-K	39	215	224	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45539	45545		10.1074/jbc.M303737200	http://dx.doi.org/10.1074/jbc.M303737200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12890681	hybrid			2022-12-27	WOS:000186452300061
J	Lundasen, T; Liao, W; Angelin, B; Rudling, M				Lundasen, T; Liao, W; Angelin, B; Rudling, M			Leptin induces the hepatic high density lipoprotein receptor scavenger receptor B type I (SR-BI) but not cholesterol 7 alpha-hydroxylase (Cyp7a1) in leptin-deficient (ob/ob) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIETARY-CHOLESTEROL; ACID SYNTHESIS; OBESE GENE; GROWTH-HORMONE; ZUCKER RAT; WEIGHT; FATTY; STIMULATION; EXPRESSION; METABOLISM	Cholesterol elimination from the body involves reverse cholesterol transport from peripheral tissues in which the elimination of high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol by the liver and subsequent biliary excretion as free cholesterol and bile acids are important. In situations of peripheral fat and cholesterol accumulation, such as obesity, these pathways may be overloaded, contributing to increased cholesterol deposition. Leptin has an important role in obesity, suppressing food intake and increasing energy expenditure. This hormone, which is absent in genetically obese ob/ob mice, is also thought to be involved in the coordination of lipid excretion pathways, although available data are somewhat inconsistent. We therefore studied the expression of the hepatic HDL receptor, scavenger receptor class B type I (SR-BI), and the LDL receptor as well as the rate-limiting enzyme in bile acid synthesis, cholesterol 7alpha-hydroxylase (Cyp7a1), in leptin-deficient ob/ob mice and their wildtype controls. In ob/ob mice, protein levels of both LDL receptor and SR-BI were reduced, whereas LDL receptor mRNA levels were increased and those of SR-BI were reduced, regardless of challenge with a 2% cholesterol diet. In ob/ob mice, the enzymatic activity and mRNA for Cyp7a1 were reduced, and the increase in response to dietary cholesterol was blunted. Upon short-term (2 days) treatment with leptin, a dose-dependent increase was seen in the SR-BI protein and mRNA, whereas the Cyp7a1 protein and mRNA were reduced. Our findings indicate that leptin is an important regulator of hepatic SR-BI expression and, thus, HDL cholesterol levels, whereas it does not stimulate Cyp7a1 and bile acid synthesis.	Huddinge Univ Hosp, Karolinska Inst, Novum, Dept Med,Ctr Metab & Endocrinol,Metab Unit, S-14186 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Novum, Ctr Nutr & Toxicol,Mol Nutr Unit, S-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Rudling, M (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Novum, Dept Med,Ctr Metab & Endocrinol,Metab Unit, S-14186 Stockholm, Sweden.							Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; BRASSIL PJ, 1995, BIOCHEM PHARMACOL, V50, P311, DOI 10.1016/0006-2952(95)00144-O; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; EINARSSON K, 1986, J LIPID RES, V27, P82; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Galman C, 2003, J LIPID RES, V44, P859, DOI 10.1194/jlr.D200043-JLR200; Galman C, 2002, ENDOCRINOLOGY, V143, P1809, DOI 10.1210/en.143.5.1809; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hyogo H, 2002, J BIOL CHEM, V277, P34117, DOI 10.1074/jbc.M203912200; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Liang CP, 2001, J BIOL CHEM, V276, P49066, DOI 10.1074/jbc.M107250200; Liao W, 1997, ENDOCRINOLOGY, V138, P3276, DOI 10.1210/en.138.8.3276; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; ROACH PD, 1993, BIOCHIM BIOPHYS ACTA, V1170, P165, DOI 10.1016/0005-2760(93)90067-J; RUDLING M, 1993, P NATL ACAD SCI USA, V90, P8851, DOI 10.1073/pnas.90.19.8851; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUDLING M, 1993, J CLIN INVEST, V91, P2796, DOI 10.1172/JCI116522; SHARKEY MF, 1990, J LIPID RES, V31, P2167; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 1999, J BIOL CHEM, V274, P4140, DOI 10.1074/jbc.274.7.4140; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; Wang DP, 1996, J LIPID RES, V37, P1831; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	31	64	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43224	43228		10.1074/jbc.M302645200	http://dx.doi.org/10.1074/jbc.M302645200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917427	hybrid			2022-12-27	WOS:000186157000063
J	Takada, T; Katagiri, T; Ifuku, M; Morimura, N; Kobayashi, M; Hasegawa, K; Ogamo, A; Kamijo, R				Takada, T; Katagiri, T; Ifuku, M; Morimura, N; Kobayashi, M; Hasegawa, K; Ogamo, A; Kamijo, R			Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; FIBROBLAST-GROWTH; CRYSTAL-STRUCTURE; BMP; PROTEOGLYCANS; RECEPTORS; BINDING; MEMBERS	Bone morphogenetic proteins (BMPs), which have been shown to be heparin-binding proteins, induce osteoblast differentiation in mesenchymal cells. In the present study, we examined the effects of heparin on the BMP activities in C2C12 myoblasts. Heparin dose dependently enhanced the osteoblast differentiation induced by not only homodimers of BMP-2 or BMP-4 but also heterodimers of BMP-2/6 or BMP-2/7. However, the osteoblast differentiation induced by the constitutively active BMPR-IA, a functional BMP type I receptor, was not affected by heparin. Heparan sulfate and dextran sulfate also enhanced the BMP-2 activity, although the chemically desulfated heparin-derivatives have lost this stimulatory capacity. Heparin dose-dependently suppressed the accumulation of BMP-2 from the culture media into the cell layer or BMPR-IA, and retained a large amount of BMP-2 in the culture media. The biological activity of BMP-2, which was evaluated using a BMP-responsive reporter gene expression, was prolonged in the presence of heparin. Taken together, these results suggest that sulfated polysaccharides enhance the biological activity of both homodimers and heterodimers of BMPs by continuously serving the ligands to their signaling receptors expressed on cell membranes.	Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Dent, Dept Periodontol, Tokyo 1428515, Japan; Kitasato Univ, Tokyo 1088641, Japan	Showa University; Showa University; Kitasato University	Katagiri, T (corresponding author), Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	katagiri@dent.showa-u.ac.jp						Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; BARROWCLIFFE TW, 1978, BRIT MED BULL, V34, P143, DOI 10.1093/oxfordjournals.bmb.a071484; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DODGSON KS, 1962, BIOCHEM J, V84, P106, DOI 10.1042/bj0840106; Dudley AT, 1997, DEV DYNAM, V208, P349; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601-0825.2002.01829.x; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P575, DOI 10.1006/bbrc.1997.7497; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; Ohkawara B, 2002, CURR BIOL, V12, P205, DOI 10.1016/S0960-9822(01)00684-4; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rauch C, 2002, AM J PHYSIOL-CELL PH, V283, pC235, DOI 10.1152/ajpcell.00234.2001; Reddi AH, 2001, J BONE JOINT SURG AM, V83A, pS1, DOI 10.2106/00004623-200100001-00001; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; Storm EE, 1996, DEVELOPMENT, V122, P3969; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	51	225	230	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43229	43235		10.1074/jbc.M300937200	http://dx.doi.org/10.1074/jbc.M300937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912996	hybrid			2022-12-27	WOS:000186157000064
J	Bannert, N; Vollhardt, K; Asomuddinov, B; Haag, M; Konig, H; Norley, S; Kurth, R				Bannert, N; Vollhardt, K; Asomuddinov, B; Haag, M; Konig, H; Norley, S; Kurth, R			PDZ domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; BINDING SUBUNIT; SMOOTH-MUSCLE; RHO-KINASE; FUNCTIONAL-ANALYSIS; ACTIN CYTOSKELETON; MOLECULAR-CLONING; NMDA RECEPTOR; EXPRESSION; PHOSPHORYLATION	The cytokine interleukin-16 is generated by posttranscriptional cleavage by caspase-3 of two large precursor isoforms. The smaller protein of 67 kDa (pro-IL-16) is expressed in cells of the immune system and contains three PDZ (postsynaptic density/disc large/zona occludens-1) domains, whereas the larger 141-kDa neuronal variant (npro-IL-16) has two additional PDZ domains in its N-terminal extension that interact with neuronal ion channels. Using the yeast two-hybrid approach we have identified three closely related myosin phosphatase targeting subunits, MYPT1, MYPT2, and MBS85, as binding partners of the IL-16 precursor proteins. These interactions were verified using pull-down assays, coimmunoprecipitations, and plasmon resonance experiments. Binding requires the intact PDZ2 domain of pro-IL-16 and highly related C-terminal regions in the ligands consisting of a short leucine zipper and an indispensable serine at the -1 position, suggesting a novel unconventional PDZ binding mode. Pro-IL-16 and the myosin phosphatase targeting subunits colocalize along actomyosin filaments and stress fibers in transfected COS-7 cells. By modulating and targeting the catalytic phosphatase subunit to its substrates, MYPT1, MYPT2, and MBS85 regulate various contractile processes in muscle and non-muscle cells. Our findings indicate an involvement of the IL-16 precursor molecules in myosin-based contractile processes, most likely in cell motility, providing a functional link to the chemotactic activity of the mature cytokine. Alternatively, an intracellular complex of npro-IL-16, ion channels, and components of myosin motors in neurons suggests a role in protein targeting.	Robert Koch Inst, D-13353 Berlin, Germany; Paul Ehrlich Inst, D-63225 Langen, Germany	Robert Koch Institute; Paul Ehrlich Institute	Bannert, N (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.			Haag, Marion/0000-0002-9162-5131				Arimura T, 2001, J BIOL CHEM, V276, P6073, DOI 10.1074/jbc.M008566200; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Baier M, 1997, P NATL ACAD SCI USA, V94, P5273, DOI 10.1073/pnas.94.10.5273; Bannert N, 1996, NATURE, V381, P30, DOI 10.1038/381030a0; Bannert N, 1998, IMMUNOGENETICS, V47, P390, DOI 10.1007/s002510050374; Biddison WE, 1998, J IMMUNOL, V160, P444; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Brozovich FV, 2002, CIRC RES, V90, P500, DOI 10.1161/01.RES.0000014224.43774.03; Center DM, 2000, IMMUNOL TODAY, V21, P273, DOI 10.1016/S0167-5699(00)01629-7; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Feng W, 2002, J BIOL CHEM, V277, P41140, DOI 10.1074/jbc.M207206200; Fujioka M, 1998, GENOMICS, V49, P59, DOI 10.1006/geno.1998.5222; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Hofmann F, 2000, J CELL SCI, V113, P1671; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Klimiuk PA, 1999, J IMMUNOL, V162, P4293; Kurschner C, 1999, J NEUROSCI, V19, P7770; Lei SB, 2001, J NEUROSCI, V21, P8464, DOI 10.1523/JNEUROSCI.21-21-08464.2001; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; Mathy NL, 2000, IMMUNOLOGY, V100, P63, DOI 10.1046/j.1365-2567.2000.00997.x; Muhlhahn P, 1998, NAT STRUCT BIOL, V5, P682, DOI 10.1038/1376; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; Qi JC, 2002, J IMMUNOL, V168, P4127, DOI 10.4049/jimmunol.168.8.4127; Seegert Dirk, 2002, Curr Opin Investig Drugs, V3, P562; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Solaro RJ, 2000, CIRC RES, V87, P173, DOI 10.1161/01.RES.87.3.173; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Vaccaro P, 2002, FEBS LETT, V512, P345, DOI 10.1016/S0014-5793(02)02220-2; Weick JP, 2003, J NEUROSCI, V23, P3446; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Wilson KC, 2003, VIROLOGY, V306, P60, DOI 10.1016/S0042-6822(02)00056-9; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144	48	27	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42190	42199		10.1074/jbc.M306669200	http://dx.doi.org/10.1074/jbc.M306669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923170	hybrid			2022-12-27	WOS:000185989500077
J	Okajima, T; Xu, AG; Irvine, KD				Okajima, T; Xu, AG; Irvine, KD			Modulation of Notch-ligand binding by protein O-Fucosyltransferase 1 and Fringe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE REPEATS; SIGNALING PATHWAY; O-FUCOSE; SERRATE; DELTA; GLYCOSYLTRANSFERASE; GLYCOSYLATION; GENES	Notch receptors are glycoproteins that mediate a wide range of developmental processes. Notch is modified in its epidermal growth factor-like domains by the addition of fucose to serine or threonine residues. O-Fucosylation is mediated by protein O-fucosyltransferase 1, and down-regulation of this enzyme by RNA interference or mutation of the Ofut1 gene in Drosophila or by mutation of the Pofut1 gene in mouse prevents Notch signaling. To investigate the molecular basis for the requirement for O-linked fucose on Notch, we assayed the ability of tagged, soluble forms of the Notch extracellular domain to bind to its ligands, Delta and Serrate. Down-regulation of OFUT1 by RNA interference in Notch-secreting cells inhibits both Delta-Notch and Serrate-Notch binding, demonstrating a requirement for O-linked fucose for efficient binding of Notch to its ligands. Conversely, overexpression of OFUT1 in cultured cells increases Serrate-Notch binding but inhibits Delta-Notch binding. These effects of OFUT1 are consistent with the consequences of OFUT1 overexpression on Notch signaling in vivo. Intriguingly, they are also opposite to, and are suppressed by, expression of the glycosyltransferase Fringe, which specifically modifies O-linked fucose. Thus, Notch-ligand interactions are dependent upon both the presence and the type of O-fucose glycans.	Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, POB 759, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054594] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 54594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES DA, 1991, J BIOL CHEM, V266, P14277; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Duvic B, 2002, CURR BIOL, V12, P1923, DOI 10.1016/S0960-9822(02)01297-6; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; HAINES N, 2003, IN PRESS NAT REV MOL; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Klein T, 1998, DEVELOPMENT, V125, P2951; Klueg KM, 1999, J CELL SCI, V112, P3289; Lebestky T, 2003, GENE DEV, V17, P348, DOI 10.1101/gad.1052803; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Oh SW, 2003, GENETICS, V163, P195; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Shimizu K, 2001, J BIOL CHEM, V276, P25753, DOI 10.1074/jbc.M103473200; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; XU T, 1993, DEVELOPMENT, V117, P1223; Zeng CY, 1998, GENE DEV, V12, P1086, DOI 10.1101/gad.12.8.1086	31	155	159	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42340	42345		10.1074/jbc.M308687200	http://dx.doi.org/10.1074/jbc.M308687200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909620	hybrid			2022-12-27	WOS:000185989500095
J	Seki, K; Fujimori, T; Savagner, P; Hata, A; Aikawa, T; Ogata, N; Nabeshima, Y; Kaechoong, L				Seki, K; Fujimori, T; Savagner, P; Hata, A; Aikawa, T; Ogata, N; Nabeshima, Y; Kaechoong, L			Mouse Snail family transcription repressors regulate chondrocyte, extracellular matrix, type II collagen, and aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; NEURAL CREST; GENE-EXPRESSION; ALGINATE BEADS; PROTEIN; CARTILAGE; SLUG; DIFFERENTIATION; IDENTIFICATION; ENHANCER	Snail family genes are conserved among species during evolution and encode transcription factors expressed at different stages of development in different tissues. These genes are involved in a broad spectrum of biological functions: cell differentiation, cell motility, cell cycle regulation, and apoptosis. However, little is known about the target genes involved in these functions. Here we show that mouse Snail family members, Snail (Sna) and Slug (Slugh), are involved in chondrocyte differentiation by controlling the expression of type II collagen (Col2a1) and aggrecan. In situ hybridization analysis of developing mouse limb demonstrated that Snail and Slug mRNAs were highly expressed in hypertrophic chondrocytes. Inversely, the expression of collagen type II mRNA disappeared during hypertrophic differentiation. Snail and Slug mRNA expression was down-regulated during differentiation of the mouse chondrogenic cell line ATDC5 and overexpression of exogenous Snail or Slug in ATDC5 cells inhibited expression of collagen type II and aggrecan mRNA. Reporter analysis revealed Snail and Slug suppressed the promoter activity of Col2a1, and the E-boxes in the promoter region were the responsible element. Gel shift assay demonstrated the binding of Snail to the E-box. Because type II collagen and aggrecan are major functional components of extracellular matrix in cartilage, these results suggest an important role for Snail-related transcription repressors during chondrocyte differentiation.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto 6068501, Japan; INSERM 0229, F-34000 Montpellier, France; Tufts Univ, Sch Med, Dept Biochem, MCRI,Tufts New England Med Ctr, Boston, MA 02111 USA	Harvard University; Massachusetts General Hospital; Kyoto University; Institut National de la Sante et de la Recherche Medicale (Inserm); Tufts Medical Center; Tufts University	Seki, K (corresponding author), Kyoto Univ, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 8501, Japan.	kseki@anat1.med.kyoto-u.ac.jp	Aikawa, Tomonao/AAV-2302-2021; Fujimori, Toshihiko/L-7711-2016; Savagner, Pierre/AAD-9357-2020	Fujimori, Toshihiko/0000-0001-5200-4634; Aikawa, Tomonao/0000-0001-6906-6874				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Ashraf SI, 1999, EMBO J, V18, P6426, DOI 10.1093/emboj/18.22.6426; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carl TF, 1999, DEV BIOL, V213, P101, DOI 10.1006/dbio.1999.9320; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; Fuse N, 1996, DEVELOPMENT, V122, P1059; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; Kataoka H, 2000, NUCLEIC ACIDS RES, V28, P626, DOI 10.1093/nar/28.2.626; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Lemare F, 1998, J CELL PHYSIOL, V176, P303, DOI 10.1002/(SICI)1097-4652(199808)176:2<303::AID-JCP8>3.0.CO;2-S; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; Mayor R, 2000, MECH DEVELOP, V97, P47, DOI 10.1016/S0925-4773(00)00412-3; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; Newman B, 2001, J CELL BIOL, V154, P659, DOI 10.1083/jcb.200106040; NIETO MA, 1992, DEVELOPMENT, V116, P227; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Perissinotto D, 2000, DEVELOPMENT, V127, P2823; Petit B, 1996, EXP CELL RES, V225, P151, DOI 10.1006/excr.1996.0166; Savagner P, 1998, DEV DYNAM, V213, P182, DOI 10.1002/(SICI)1097-0177(199810)213:2<182::AID-AJA3>3.0.CO;2-C; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SMITH DE, 1992, DEVELOPMENT, V116, P1033; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; THOROGOOD P, 1986, DEV BIOL, V116, P497, DOI 10.1016/0012-1606(86)90150-8; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016	47	69	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41862	41870		10.1074/jbc.M308336200	http://dx.doi.org/10.1074/jbc.M308336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917416	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000185989500039
J	Waizenegger, T; Stan, T; Neupert, W; Rapaport, D				Waizenegger, T; Stan, T; Neupert, W; Rapaport, D			Signal-anchor domains of proteins of the outer membrane of mitochondria - Structural and functional characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT RECEPTOR; PREPROTEIN TRANSLOCASE; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; RAT-LIVER; INSERTION; TOM70; TOM20; BIOGENESIS; COMPLEXES	We have studied the topogenesis of a class of mitochondrial outer membrane proteins that expose a hydrophilic domain to the cytosol and are anchored to the membrane by a single transmembrane domain in the N-terminal region. To determine the role of these latter sequences in the targeting and insertion of such proteins we took two approaches. First, a functional complementation assay was used to define the structural elements that together with the anchor domain make up the topogenic signal. Moderate hydrophobicity of the transmembrane domain was found to be the most important requirement. Variants with a scrambled sequence of the membrane-spanning segment were only partially functional suggesting that specificity in the amino acid sequence is also of considerable importance. A net positive charge at both flanking regions of the transmembrane domain contributes to the efficiency of targeting and membrane integration but is not an essential structural feature of this signal. Second, chimeras of Tom20, Tom70, and OM45 were generated that contained the cytosolic domain of Tom20 or Tom70 and the anchor domain of one of the other members of the class. These hybrid proteins were able to rescue the growth of cells lacking Tom20 or Tom70. Thus, anchor domains of outer membrane proteins are functionally interchangeable. They play only a minor role in the specific function of these proteins, but have a decisive role in topogenic signaling.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Rapaport, D (corresponding author), Univ Munich, Inst Physiol Chem, Butenandtstr 5,Haus B, D-81377 Munich, Germany.							Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; DAUM G, 1982, J BIOL CHEM, V257, P3028; de Kroon AIPM, 1999, MOL MEMBR BIOL, V16, P205; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; MILLAR DG, 1994, J BIOL CHEM, V269, P12229; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; Sherman F., 1986, METHODS YEAST GENETI; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Suzuki H, 2002, J CELL SCI, V115, P1895; van den Brink-van der Laan E, 2001, BIOCHEMISTRY-US, V40, P9677, DOI 10.1021/bi002903a; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; YAFFE MP, 1989, J BIOL CHEM, V264, P21091; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	32	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42064	42071		10.1074/jbc.M305736200	http://dx.doi.org/10.1074/jbc.M305736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917440	hybrid			2022-12-27	WOS:000185989500063
J	Busch, A; Engemann, S; Lurz, R; Okazawa, H; Lehrach, H; Wanker, EE				Busch, A; Engemann, S; Lurz, R; Okazawa, H; Lehrach, H; Wanker, EE			Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin - A potential mechanism for loss of huntingtin function in Huntington's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE TRACT-BINDING; AMYLOID-LIKE FIBRILS; MAMMALIAN-CELLS; IN-VIVO; PROTEIN; TRANSCRIPTION; MICE; GENE; AGGREGATION	Aggregation of huntingtin (htt) in neuronal inclusions is associated with the development of Huntington's disease (HD). Previously, we have shown that mutant htt fragments with polyglutamine ( polyQ) tracts in the pathological range (> 37 glutamines) form SDS-resistant aggregates with a fibrillar morphology, whereas wildtype htt fragments with normal polyQ domains do not aggregate. In this study we have investigated the coaggregation of mutant and wild-type htt fragments. We found that mutant htt promotes the aggregation of wildtype htt, causing the formation of SDS-resistant co-aggregates with a fibrillar morphology. Conversely, mutant htt does not promote the fibrillogenesis of the polyQ-containing protein NOCT3 or the polyQ-binding protein PQBP1, although these proteins are recruited into inclusions containing mutant htt aggregates in mammalian cells. The formation of mixed htt fibrils is a highly selective process that not only depends on polyQ tract length but also on the surrounding amino acid sequence. Our data suggest that mutant and wild-type htt fragments may also co-aggregate in neurons of HD patients and that a loss of wild-type htt function may contribute to HD pathogenesis.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Tokyo Metropolitan Inst Neurosci, Dept Mol Therapeut, Tokyo 1838526, Japan	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Wanker, EE (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		busch, anne/AAB-9805-2022	busch, anne/0000-0001-9560-0057; Wanker, Erich/0000-0001-8072-1630				Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; HARPER PS, 1991, MAJOR PROBLEMS NEURO; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kim M, 1999, J NEUROSCI, V19, P964; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Maniatis T., 1982, MOL CLONING LAB MANU; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; O'Kusky JR, 1999, BRAIN RES, V818, P468, DOI 10.1016/S0006-8993(98)01312-2; Okazawa H, 2001, BRAIN RES BULL, V56, P273, DOI 10.1016/S0361-9230(01)00579-2; Okazawa H, 2002, NEURON, V34, P701, DOI 10.1016/S0896-6273(02)00697-9; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wanker EE, 1999, METHOD ENZYMOL, V309, P375; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	47	90	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41452	41461		10.1074/jbc.M303354200	http://dx.doi.org/10.1074/jbc.M303354200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888569	hybrid			2022-12-27	WOS:000185847200125
J	Kim, JR; Gibson, TJ; Murphy, RM				Kim, JR; Gibson, TJ; Murphy, RM			Targeted control of kinetics of beta-amyloid self-association by surface tension-modifying peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-METHYLATED DERIVATIVES; FIBRIL FORMATION; ALZHEIMERS-DISEASE; COMMON MECHANISM; SHEET BREAKER; IN-VITRO; TOXICITY; INHIBITION; PROTEIN; LIGANDS	Brain tissue from Alzheimer's patients contains extracellular senile plaques composed primarily of deposits of fibrillar aggregates of beta-amyloid peptide. beta-Amyloid aggregation is postulated to be a major factor in the onset of this neurodegenerative disease. Recently proposed is the hypothesis that oligomeric intermediates, rather than fully formed insoluble fibrils, are cytotoxic. Previously, we reported the discovery of peptides that accelerate beta-amyloid aggregation yet inhibit toxicity in vitro, in support of this hypothesis. These peptides contain two domains: a recognition element designed to bind to beta-amyloid and a disrupting element that alters beta-amyloid aggregation kinetics. Here we show that the aggregation rate-enhancing activity of the disrupting element correlates strongly with its ability to increase surface tension of aqueous solutions. Using the Hofmeister series as a guide, we designed a novel peptide with terminal side-chain trimethylammonium groups in the disrupting domain. The derivatized peptide greatly increased solvent surface tension and accelerated beta-amyloid aggregation kinetics by severalfold. Equivalent increases in surface tension in the absence of a recognition domain had no effect on beta-amyloid aggregation. These results suggest a novel strategy for targeting localized changes in interfacial energy to specific proteins, as a way to selectively alter protein folding, stability, and aggregation.	Univ Wisconsin, Dept Chem Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Murphy, RM (corresponding author), Univ Wisconsin, Dept Chem Engn, 1415 Engn Dr, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037728] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37728] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad A, 2001, BIOCHEMISTRY-US, V40, P1945, DOI 10.1021/bi001933a; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363; Cairo CW, 2002, BIOCHEMISTRY-US, V41, P8620, DOI 10.1021/bi0156254; Chow MKM, 2001, BIOL CHEM, V382, P1593, DOI 10.1515/BC.2001.194; Doig AJ, 2002, BIOCHEM SOC T, V30, P537, DOI 10.1042/bst0300537; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; Gordon DJ, 2003, BIOCHEMISTRY-US, V42, P475, DOI 10.1021/bi0259857; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; Hughes E, 2000, J BIOL CHEM, V275, P25109, DOI 10.1074/jbc.M003554200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim YS, 2001, J BIOL CHEM, V276, P1626, DOI 10.1074/jbc.M007766200; Klunk WE, 1998, LIFE SCI, V63, P1807, DOI 10.1016/S0024-3205(98)00454-8; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lin TY, 1996, PROTEIN SCI, V5, P372; Lowe TL, 2001, BIOCHEMISTRY-US, V40, P7882, DOI 10.1021/bi002734u; Nakagami Y, 2002, BRIT J PHARMACOL, V137, P676, DOI 10.1038/sj.bjp.0704911; Pallitto MM, 2001, BIOPHYS J, V81, P1805, DOI 10.1016/S0006-3495(01)75831-6; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Ratnaparkhi GS, 2001, J BIOL CHEM, V276, P28789, DOI 10.1074/jbc.M101906200; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1997, J BIOL CHEM, V272, P12601, DOI 10.1074/jbc.272.19.12601; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	36	25	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40730	40735		10.1074/jbc.M305466200	http://dx.doi.org/10.1074/jbc.M305466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917437	hybrid			2022-12-27	WOS:000185847200039
J	Rathore, D; Hrstka, SCL; Sacci, JB; De la Vega, P; Linhardt, RJ; Kumar, S; McCutchan, TF				Rathore, D; Hrstka, SCL; Sacci, JB; De la Vega, P; Linhardt, RJ; Kumar, S; McCutchan, TF			Molecular mechanism of host specificity in Plasmodium falciparum infection - Role of circumsporozoite protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA SPOROZOITES; HEPARIN; GENE; THROMBOSPONDIN; DNA; GLYCOSAMINOGLYCANS; MITOCHONDRIAL; PARASITES; MEMBRANE; INVASION	Plasmodium falciparum sporozoites invade liver cells in humans and set the stage for malaria infection. Circumsporozoite protein ( CSP), a predominant surface antigen on sporozoite surface, has been associated with the binding and invasion of liver cells by the sporozoites. Although CSP across the Plasmodium genus has homology and conserved structural organization, infection of a non-natural host by a species is rare. We investigated the role of CSP in providing the host specificity in P. falciparum infection. CSP from P. falciparum, P. gallinaceum, P. knowlesi, and P. yoelii species representing human, avian, simian, and rodent malaria species were recombinantly expressed, and the proteins were purified to homogeneity. The recombinant proteins were evaluated for their capacity to bind to human liver cell line HepG2 and to prevent P. falciparum sporozoites from invading these cells. The proteins showed significant differences in the binding and sporozoite invasion inhibition activity. Differences among proteins directly correlate with changes in the binding affinity to the sporozoite receptor on liver cells. P. knowlesi CSP (PkCSP) and P. yoelii CSP (PyCSP) had 4,790- and 17,800-fold lower affinity for heparin in comparison to P. falciparum CSP (PfCSP). We suggest that a difference in the binding affinity for the liver cell receptor is a mechanism involved in maintaining the host specificity by the malaria parasite.	NIAID, Growth & Dev Sect, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; US FDA, Bacterial & Parasit Dis Sect, Div Emerging TRansfus & Transmitted Dis, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Virginia Polytechnic Institute & State University; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University System of Maryland; University of Maryland Baltimore; United States Department of Defense; United States Navy; US Food & Drug Administration (FDA)	McCutchan, TF (corresponding author), NIAID, Growth & Dev Sect, Lab Malaria & Vector Res, NIH, Rm 126,Bldg 4,4 Ctr Dr,MSC 0425, Bethesda, MD 20892 USA.	tmccutchan@niaid.nih.gov		Hrstka, Sybil/0000-0003-1442-5707	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000208, ZIAAI000208] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; COLLINS WE, 1973, J PARASITOL, V59, P855, DOI 10.2307/3278423; COLLINS WE, 1994, AM J TROP MED HYG, V51, P224, DOI 10.4269/ajtmh.1994.51.224; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; Escalante AA, 1998, P NATL ACAD SCI USA, V95, P8124, DOI 10.1073/pnas.95.14.8124; FASMAN GD, 1990, BIOPOLYMERS, V29, P123, DOI 10.1002/bip.360290117; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; GOMES PB, 1982, COMP BIOCHEM PHYS B, V73, P857, DOI 10.1016/0305-0491(82)90329-7; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; Naitza S, 1998, PARASITOL TODAY, V14, P479, DOI 10.1016/S0169-4758(98)01346-5; Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; Rathore D, 2000, INFECT IMMUN, V68, P740, DOI 10.1128/IAI.68.2.740-743.2000; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Rathore D, 1996, FEBS LETT, V392, P259, DOI 10.1016/0014-5793(96)00825-3; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; Rathore D, 2001, MOL BIOCHEM PARASIT, V114, P89, DOI 10.1016/S0166-6851(01)00241-9; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Rogers WO, 2002, INFECT IMMUN, V70, P4329, DOI 10.1128/IAI.70.8.4329-4335.2002; Roggero MA, 1995, MOL IMMUNOL, V32, P1301, DOI 10.1016/0161-5890(95)00136-0; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHMIDT LH, 1978, AM J TROP MED HYG, V27, P671, DOI 10.4269/ajtmh.1978.27.671; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Templeton TJ, 1997, MOL BIOCHEM PARASIT, V84, P13, DOI 10.1016/S0166-6851(96)02775-2; Tewari R, 2002, J BIOL CHEM, V277, P47613, DOI 10.1074/jbc.M208453200; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WATERS AP, 1991, P NATL ACAD SCI USA, V88, P3140, DOI 10.1073/pnas.88.8.3140; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhang FM, 2002, ANAL BIOCHEM, V304, P271, DOI 10.1006/abio.2002.5617	33	39	49	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40905	40910		10.1074/jbc.M306250200	http://dx.doi.org/10.1074/jbc.M306250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904297	hybrid			2022-12-27	WOS:000185847200061
J	Richardt, A; Kemme, T; Wagner, S; Schwarzer, D; Marahiel, MA; Hovemann, BT				Richardt, A; Kemme, T; Wagner, S; Schwarzer, D; Marahiel, MA; Hovemann, BT			Ebony, a novel nonribosomal peptide synthetase for beta-alanine conjugation with biogenic amines in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; VISUAL MUTANTS; NERVOUS-SYSTEM; HISTAMINE; PROTEIN; BIOSYNTHESIS; LOCUS; EXPRESSION; DOMAINS; PCP	Using Ebony protein either expressed in Escherichia coli or in Schneider S2 cells, we provide evidence for its substrate specificity and reaction mechanism. Ebony activates beta-alanine to aminoacyladenylate by an adenylation domain and covalently attaches it as a thioester to a thiolation domain in a nonribosomal peptide synthetase (NRPS) related mechanism. In a second reaction, biogenic amines act as external nucleophiles on beta-alanyl-S-pantetheine- Ebony, thereby releasing in a fast reaction the dipeptide (peptidoamine) in a process that is novel in higher eucaryotes. Therefore, we define Ebony as a beta-alanyl-biogenic amine synthetase. Insight into the reaction mechanism stems from mutational analysis of an invariant serine that disclosed Ebony as a multienzyme with functional analogy to the starting modules of NRPSs. In light of a putative biogenic amine-deactivating capacity, Ebony function in the nervous system must be reconsidered. We propose that in the Drosophila eye Ebony is involved in the transmission process by inactivation of histamine through beta-alanyl conjugation.	Ruhr Univ Bochum, Fak Chem, AG Mol Zellbiochem, D-44780 Bochum, Germany; Univ Marburg, Fachbereich Chem Biochem, D-35032 Marburg, Germany	Ruhr University Bochum; Philipps University Marburg	Hovemann, BT (corresponding author), Ruhr Univ Bochum, Fak Chem, AG Mol Zellbiochem, Univ Str 150, D-44780 Bochum, Germany.	bernhard.hovemann@rub.de		Schwarzer, Dirk/0000-0002-7477-3319; Kemme, Tobias/0000-0002-5595-160X				BENZER S, 1967, P NATL ACAD SCI USA, V58, P1112, DOI 10.1073/pnas.58.3.1112; BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; Borycz J, 2002, J NEUROSCI, V22, P10549; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRIDGES CB, 1923, PUBL CARNEGIE I, V327, P50; CAIZZI R, 1987, MOL GEN GENET, V206, P66, DOI 10.1007/BF00326537; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; FLANCBAUM L, 1990, LIFE SCI, V47, P1587, DOI 10.1016/0024-3205(90)90188-W; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HEISENBERG M, 1971, J EXP BIOL, V55, P85; HEISENBERG M, 1972, J COMP PHYSIOL, V80, P119, DOI 10.1007/BF00696485; HOTTA Y, 1969, NATURE, V222, P354, DOI 10.1038/222354a0; Hovemann BT, 1998, GENE, V221, P1, DOI 10.1016/S0378-1119(98)00440-5; KYRIACOU CP, 1978, ANIM BEHAV, V26, P1195, DOI 10.1016/0003-3472(78)90109-4; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Melzig J, 1998, J NEUROSCI, V18, P7160; Morgan JR, 1999, J NEUROSCI, V19, P1217; Nassel D.R., 1988, Journal of Chemical Neuroanatomy, V1, P311; NEWBY LM, 1991, J NEUROGENET, V7, P85, DOI 10.3109/01677069109066213; Perez M, 2002, INSECT BIOCHEM MOLEC, V32, P617, DOI 10.1016/S0965-1748(01)00140-0; PFEIFER E, 1995, BIOCHEMISTRY-US, V34, P7450, DOI 10.1021/bi00022a019; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Richardt A, 2002, J COMP NEUROL, V452, P93, DOI 10.1002/cne.10360; SARTHY PV, 1991, J NEUROCHEM, V57, P1757, DOI 10.1111/j.1471-4159.1991.tb06378.x; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; Stuart AE, 1996, J NEUROSCI, V16, P3178; TURGAY K, 1992, MOL MICROBIOL, V6, P2743, DOI 10.1111/j.1365-2958.1992.tb01451.x; VOLLENBROICH D, 1993, FEBS LETT, V325, P220, DOI 10.1016/0014-5793(93)81077-D; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5	35	98	108	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41160	41166		10.1074/jbc.M304303200	http://dx.doi.org/10.1074/jbc.M304303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900414	hybrid			2022-12-27	WOS:000185847200092
J	Shen, MR; Chou, CY; Hsu, KF; Hsu, YM; Chiu, WT; Tang, MJ; Alper, SL; Ellory, JC				Shen, MR; Chou, CY; Hsu, KF; Hsu, YM; Chiu, WT; Tang, MJ; Alper, SL; Ellory, JC			KCl cotransport is an important modulator of human cervical cancer growth and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELLS; CL-COTRANSPORTER; VOLUME; EXPRESSION; CHLORIDE; ACTIVATION; SYSTEM; INTEGRINS; CARCINOMA; BETA(2)	Cervical cancer is a major world health problem for women, but the pathophysiology of this disease has received scant attention. Here we show that the growth and invasion of cervical cancer cells are strongly linked the expression and activity of the KCl cotransporter (KCC), an important regulator of the ionic and cellular osmotic homeostasis. Functional assays of KCl cotransport activation by osmotic swelling, staurosporine, and N-ethylmaleimide indicate that removal of the N-terminal 117 amino acids from KCC1 produces a dominant-negative loss-of-function phenotype for KCl cotransport in human cervical cancer cells. The capability for regulatory volume decrease is much attenuated in the loss-of-function KCC mutant cervical cancer cells. The lossoffunction KCC mutant cervical cancer cells exhibit inhibited cell growth accompanied by decreased activity of the cell cycle gene products retinoblastoma and cdc2 kinase. Reduced cellular invasiveness is in parallel by reduced expression of alpha(v)beta(3) and alpha(6)beta(4) integrins, accompanied by decreased activity of matrix metalloproteinase 2 and 9. Inhibition of tumor growth in SCID mice confirms the crucial role of KCC in promoting cervical cancer growth and invasion. Thus, blockade of KCl cotransport may be a useful therapeutic adjunctive strategy to retard or prevent cervical cancer invasion.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 704, Taiwan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Mol Med & Renal Unit, Boston, MA 02215 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; University of Oxford; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Shen, MR (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.	mrshen@mail.ncku.edu.tw	Hsu, Keng-Fu/C-1441-2009	Tang, Ming-Jer/0000-0002-0883-4363				ALBINI A, 1987, CANCER RES, V47, P3239; Aplin JD, 1996, BRIT J CANCER, V74, P240, DOI 10.1038/bjc.1996.344; Casula S, 2001, J BIOL CHEM, V276, P41870, DOI 10.1074/jbc.M107155200; Chattopadhyay N, 1999, GYNECOL ONCOL, V75, P215, DOI 10.1006/gyno.1999.5574; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Ellory JC, 1998, CONTRIB NEPHROL, V123, P220, DOI 10.1159/000059915; GARAY RP, 1988, MOL PHARMACOL, V33, P696; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Jeffers MD, 1997, GYNECOL ONCOL, V64, P481, DOI 10.1006/gyno.1996.4578; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; LEE YC, 1995, AM J PHYSIOL-RENAL, V268, pF862, DOI 10.1152/ajprenal.1995.268.5.F862; Menegazzi R, 1999, J IMMUNOL, V162, P423; Menegazzi R, 2000, J IMMUNOL, V165, P4606, DOI 10.4049/jimmunol.165.8.4606; Mercado A, 2000, J BIOL CHEM, V275, P30326, DOI 10.1074/jbc.M003112200; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; ROUSSA E, 2001, CELL BIOL, V117, P335; Saga Y, 2001, ONCOLOGY-BASEL, V60, P367, DOI 10.1159/000058534; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Shen MR, 2000, PFLUG ARCH EUR J PHY, V440, P751, DOI 10.1007/s004240000338; Shen MR, 2001, P NATL ACAD SCI USA, V98, P14714, DOI 10.1073/pnas.251388798; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; Yamani MH, 2002, CIRCULATION, V105, P1955, DOI 10.1161/01.CIR.0000014971.09169.BC	31	58	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39941	39950		10.1074/jbc.M308232200	http://dx.doi.org/10.1074/jbc.M308232200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902337	hybrid			2022-12-27	WOS:000185713800082
J	van Pesch, V; Michiels, T				van Pesch, V; Michiels, T			Characterization of interferon-alpha 13, a novel constitutive murine interferon-alpha subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUG INITIATOR CODON; THEILERS-VIRUS; MESSENGER-RNA; REGULATORY FACTOR-7; MOUSE MACROPHAGES; GENE-EXPRESSION; DISEASE VIRUS; I INTERFERONS; CROSS-TALK; A GENES	Type-I interferons (IFNs), also called IFNs-alpha/beta, are a family of cytokines induced by viral infection and are primarily involved in antiviral defense of the cells. IFNs-alpha/beta were also reported to be produced constitutively at low levels in mouse and human cells. These so-called endogenous or constitutive IFNs are thought to exert important homeostatic functions in the uninfected host. By searching IFN genes that were not repressed by the leader protein of Theiler's virus, we identified three uncharacterized IFN-alpha genes that are constitutively expressed in uninfected mouse cells, in vitro and in vivo. Two of these genes corresponded to pseudogenes and were tentatively called IFN-alpha(psi2) and IFN-alpha(psi3). IFN-alpha(psi2) transcripts are the most abundant IFN-alpha transcripts detected in several mouse organs in the absence of viral infection. The third gene codes for a new IFN-alpha subtype called IFN-alpha13, which exhibits acid-stable antiviral activity against Theiler's virus, Mengo virus, and vesicular stomatitis virus. IFN-alpha13 displays unusual characteristics, suggesting that it might have a particular function. Firstly, it is transcribed constitutively, independent of viral infection and of interferon regulatory factor-7 induction. Secondly, it contains two N-glycosylation sites, in contrast to other murine IFN-alpha subtypes that contain either one or no N-glycosylation site. In addition to the genes described here above, several other IFN-alpha subtype genes, including a new gene (IFN-alpha14), were expressed in tissues of uninfected mice. In contrast to IFN-alpha13, IFN-alpha14 was found to lack N-glycosylation and have its expression induced in response to viral infection.	Univ Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, MIPA VIRO 74 49, B-1200 Brussels, Belgium	Universite Catholique Louvain	Michiels, T (corresponding author), Univ Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, MIPA VIRO 74 49, 74 Ave Hippocrate, B-1200 Brussels, Belgium.		Michiels, Thomas/ABE-3203-2021; van Pesch, Vincent/AAK-9506-2020	Michiels, Thomas/0000-0001-9615-8053; van Pesch, Vincent/0000-0003-2885-9004				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Braganca J, 1998, BIOCHIMIE, V80, P673, DOI 10.1016/S0300-9084(99)80021-2; Chinsangaram J, 1999, J VIROL, V73, P9891, DOI 10.1128/JVI.73.12.9891-9898.1999; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; COULOMBEL C, 1991, GENE, V104, P187, DOI 10.1016/0378-1119(91)90249-B; DAUGHERTY B, 1984, J INTERFERON RES, V4, P635, DOI 10.1089/jir.1984.4.635; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; DION M, 1986, BIOCHEM BIOPH RES CO, V138, P826, DOI 10.1016/S0006-291X(86)80571-X; DUCGOIRAN P, 1994, EXP CELL RES, V214, P570, DOI 10.1006/excr.1994.1295; DUKE GM, 1989, J VIROL, V63, P1822, DOI 10.1128/JVI.63.4.1822-1826.1989; Fujii GH, 1999, ONCOGENE, V18, P1765, DOI 10.1038/sj.onc.1202492; GESSANI S, 1991, J VIROL, V65, P989, DOI 10.1128/JVI.65.2.989-991.1991; GOEDDEL DV, 1981, NATURE, V290, P20, DOI 10.1038/290020a0; Gresser I, 2002, CYTOKINE GROWTH F R, V13, P111, DOI 10.1016/S1359-6101(01)00035-1; HALLER O, 1979, J EXP MED, V149, P601, DOI 10.1084/jem.149.3.601; Hata N, 2001, BIOCHEM BIOPH RES CO, V285, P518, DOI 10.1006/bbrc.2001.5159; Hida S, 2000, IMMUNITY, V13, P643, DOI 10.1016/S1074-7613(00)00064-9; Jnaoui K, 1998, VIROLOGY, V244, P397, DOI 10.1006/viro.1998.9134; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P805, DOI 10.1093/nar/13.3.805; KHAN NUD, 1990, IMMUNOLOGY, V71, P230; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUGA T, 1989, NUCLEIC ACIDS RES, V17, P3291, DOI 10.1093/nar/17.8.3291; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; LEROSCOUET D, 1985, MOL CELL BIOL, V5, P1343, DOI 10.1128/MCB.5.6.1343; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Meager A, 2002, J IMMUNOL METHODS, V261, P21, DOI 10.1016/S0022-1759(01)00570-1; Michiels T, 1997, J VIROL, V71, P9549, DOI 10.1128/JVI.71.12.9549-9556.1997; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; Mitani Y, 2001, GENES CELLS, V6, P631, DOI 10.1046/j.1365-2443.2001.00448.x; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Morin P, 2002, J MOL BIOL, V316, P1009, DOI 10.1006/jmbi.2001.5401; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; NAVARRO S, 1989, J GEN VIROL, V70, P1381, DOI 10.1099/0022-1317-70-6-1381; NICKOLAUS P, 1994, J VIROL, V68, P6763, DOI 10.1128/JVI.68.10.6763-6766.1994; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SEIF I, 1986, GENE, V43, P111, DOI 10.1016/0378-1119(86)90014-4; Servant MJ, 2002, J INTERF CYTOK RES, V22, P49, DOI 10.1089/107999002753452656; SHAW GD, 1983, NUCLEIC ACIDS RES, V11, P555, DOI 10.1093/nar/11.3.555; Shaw-Jackson C, 1999, J VIROL, V73, P2729, DOI 10.1128/JVI.73.4.2729-2738.1999; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; TRAPMAN J, 1988, J GEN VIROL, V69, P67, DOI 10.1099/0022-1317-69-1-67; van Pesch V, 2001, J VIROL, V75, P7811, DOI 10.1128/JVI.75.17.7811-7817.2001; VANHEUVEL M, 1986, J GEN VIROL, V67, P2215, DOI 10.1099/0022-1317-67-10-2215; ZAWATZKY R, 1991, J VIROL, V65, P4839, DOI 10.1128/JVI.65.9.4839-4846.1991; ZWARTHOFF EC, 1985, NUCLEIC ACIDS RES, V13, P791, DOI 10.1093/nar/13.3.791	56	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46321	46328		10.1074/jbc.M302554200	http://dx.doi.org/10.1074/jbc.M302554200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12930842	hybrid			2022-12-27	WOS:000186569400015
J	Evans, HR; Sutton, JM; Holloway, DE; Ayriss, J; Shone, CC; Acharya, KR				Evans, HR; Sutton, JM; Holloway, DE; Ayriss, J; Shone, CC; Acharya, KR			The crystal structure of C3stau2 from Staphylococcus aureus and its complex with NAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATING EXOENZYME; RHO GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; EXFOLIATIVE TOXIN; C3 EXOENZYME; RIBOSYLTRANSFERASE; PROTEIN; IDENTIFICATION; PURIFICATION; EXPRESSION	The C3stau2 exoenzyme from Staphylococcus aureus is a C3-like ADP-ribosyltransferase that ADP-ribosylates not only RhoA-C but also RhoE/Rnd3. In this study we have crystallized and determined the structure of C3stau2 in both its native form and in complex with NAD at 1.68- and 2.02-Angstrom resolutions, respectively. The topology of C3stau2 is similar to that of C3bot1 from Clostridium botulinum (with which it shares 35% amino acid sequence identity) with the addition of two extra helices after strand beta1. The native structure also features a novel orientation of the catalytic ARTT loop, which approximates the conformation seen for the "NAD bound" form of C3bot1. C3stau2 orients NAD similarly to C3bot1, and on binding NAD, C3stau2 undergoes a clasping motion and a rearrangement of the phosphate-nicotinamide binding loop, enclosing the NAD in the binding site. Comparison of these structures with those of C3bot1 and related toxins reveals a degree of divergence in the interactions with the adenine moiety among the ADP-ribosylating toxins that contrasts with the more conserved interactions with the nicotinamide. Comparison with C3bot1 gives some insight into the different protein substrate specificities of these enzymes.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Hlth Protect Agcy, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England	University of Bath; Health Protection Agency	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Claverton Down, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Holloway, Daniel E/S-4944-2016	Holloway, Daniel E/0000-0003-0155-6978; Sutton, J. Mark/0000-0002-2288-0446; Acharya, K. Ravi/0000-0002-3009-4058				Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Czech A, 2001, J INFECT DIS, V184, P785, DOI 10.1086/322983; Dolan KM, 2000, BIOCHEMISTRY-US, V39, P8266, DOI 10.1021/bi992856q; Foster R, 1996, MOL CELL BIOL, V16, P2689; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUST I, 1995, BIOCHEMISTRY-US, V34, P334, DOI 10.1021/bi00001a041; JUST I, 1992, J BIOL CHEM, V267, P10274; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Menetrey J, 2002, J BIOL CHEM, V277, P30950, DOI 10.1074/jbc.M201844200; Nagahama M, 2000, J BACTERIOL, V182, P2096, DOI 10.1128/JB.182.8.2096-2103.2000; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; RIDLEY AJ, 2001, GTPASES, P89; Sakurai J, 2003, ADV ENZYME REGUL, V43, P361, DOI 10.1016/S0065-2571(02)00044-4; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; Tsuge H, 2003, J MOL BIOL, V325, P471, DOI 10.1016/S0022-2836(02)01247-0; Wilde C, 2003, BIOCHEMISTRY-US, V42, P9694, DOI 10.1021/bi034583b; Wilde C, 2002, J BIOL CHEM, V277, P14771, DOI 10.1074/jbc.M201072200; Wilde C, 2002, BIOCHEMISTRY-US, V41, P1539, DOI 10.1021/bi015809i; Wilde C, 2001, J BIOL CHEM, V276, P9537, DOI 10.1074/jbc.M011035200; Yamada Y, 2001, ARCH DIS CHILD-FETAL, V84, pF38, DOI 10.1136/fn.84.1.F38; Yamaguchi T, 2002, INFECT IMMUN, V70, P5835, DOI 10.1128/IAI.70.10.5835-5845.2002; Yamaguchi T, 2001, INFECT IMMUN, V69, P7760, DOI 10.1128/IAI.69.12.7760-7771.2001	40	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45924	45930		10.1074/jbc.M307719200	http://dx.doi.org/10.1074/jbc.M307719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933793	hybrid			2022-12-27	WOS:000186452300105
J	Lee, KA; Fuda, H; Lee, YC; Negishi, M; Strott, CA; Pedersen, LC				Lee, KA; Fuda, H; Lee, YC; Negishi, M; Strott, CA; Pedersen, LC			Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of pregnenolone and 3 '-phosphoadenosine 5 '-phosphate - Rationale for specificity differences between prototypical SULT2A1 and the SULT2B1 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HYDROXYSTEROID SULFOTRANSFERASE; ESTROGEN SULFOTRANSFERASE; MUTATIONAL ANALYSIS; NEUROSTEROIDS; SULFATE; COMPLEX; GENE; KERATINOCYTES; DIFFERENTIATION; TRANSCRIPTION	The gene for human hydroxysteroid sulfotransferase (SULT2B1) encodes two peptides, SULT2B1a and SULT2B1b, that differ only at their amino termini. SULT2B1b has a predilection for cholesterol but is also capable of sulfonating pregnenolone, whereas SULT2B1a preferentially sulfonates pregnenolone and only minimally sulfonates cholesterol. We have determined the crystal structure of SULT2B1a and SULT2B1b bound to the substrate donor product 3'-phosphoadenosine 5'-phosphate at 2.9 and 2.4 Angstrom, respectively, as well as SULT2B1b in the presence of the acceptor substrate pregnenolone at 2.3 Angstrom. These structures reveal a different catalytic binding orientation for the substrate from a previously determined structure of hydroxysteroid sulfotransferase (SULT2A1) binding dehydroepiandrosterone. In addition, the amino-terminal helix comprising residues Asp(19) to Lys(26), which determines the specificity difference between the SULT2B1 isoforms, becomes ordered upon pregnenolone binding, covering the substrate binding pocket.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NICHD, Sect Steroid Regulat, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Pedersen, LC (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040, Z01ES071005, ZIAES080040] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alomary AA, 2001, INT REV NEUROBIOL, V46, P97; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Coughtrie MWH, 1998, CHEM-BIOL INTERACT, V109, P3, DOI 10.1016/S0009-2797(97)00117-8; Engel SR, 2001, INT REV NEUROBIOL, V46, P321; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Fuda H, 2002, J BIOL CHEM, V277, P36161, DOI 10.1074/jbc.M207165200; Geese WJ, 2001, BIOCHEM BIOPH RES CO, V288, P280, DOI 10.1006/bbrc.2001.5746; Hanley K, 2001, J LIPID RES, V42, P390; Her C, 1998, GENOMICS, V53, P284, DOI 10.1006/geno.1998.5518; JETTEN AM, 1989, J INVEST DERMATOL, V92, P203, DOI 10.1111/1523-1747.ep12276731; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kawabe S, 1998, J INVEST DERMATOL, V111, P1098, DOI 10.1046/j.1523-1747.1998.00441.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuroki T, 2000, MUTAT RES-REV MUTAT, V462, P189, DOI 10.1016/S1383-5742(00)00036-3; Lascombe MB, 2002, ACTA CRYSTALLOGR D, V58, P1442, DOI 10.1107/S0907444902011745; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mellon SH, 2001, INT REV NEUROBIOL, V46, P33; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Plassart-Schiess E, 2001, BRAIN RES REV, V37, P133, DOI 10.1016/S0165-0173(01)00113-8; Rehse PH, 2002, BIOCHEM J, V364, P165, DOI 10.1042/bj3640165; Shimizu C, 2003, ENDOCRINOLOGY, V144, P1186, DOI 10.1210/en.2002-221011; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040	32	52	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44593	44599		10.1074/jbc.M308312200	http://dx.doi.org/10.1074/jbc.M308312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923182	hybrid			2022-12-27	WOS:000186306700089
J	Romero, N; Radi, R; Linares, E; Augusto, O; Detweiler, CD; Mason, RP; Denicola, A				Romero, N; Radi, R; Linares, E; Augusto, O; Detweiler, CD; Mason, RP; Denicola, A			Reaction of human hemoglobin with peroxynitrite Isomerization to nitrate and secondary formation of protein radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; NITRIC-OXIDE; CYTOCHROME-C; HORSERADISH-PEROXIDASE; MEDIATED OXIDATION; HUMAN MYOGLOBIN; KINETICS; HEME; IDENTIFICATION; OXYHEMOGLOBIN	Peroxynitrite, a strong oxidant formed intravascularly in vivo, can diffuse onto erythrocytes and be largely consumed via a fast reaction (2x10(4) M-1 s(-1)) with oxyhemoglobin. The reaction mechanism of peroxynitrite with oxyhemoglobin that results in the formation of methemoglobin remains to be elucidated. In this work, we studied the reaction under biologically relevant conditions using millimolar oxyhemoglobin concentrations and a stoichiometric excess of oxyhemoglobin over peroxynitrite. The results support a reaction mechanism that involves the net one-electron oxidation of the ferrous heme, isomerization of peroxynitrite to nitrate, and production of superoxide radical and hydrogen peroxide. Homolytic cleavage of peroxynitrite within the heme iron allows the formation of ferrylhemoglobin in similar to10% yields, which can decay to methemoglobin at the expense of reducing equivalents of the globin moiety. Indeed, spin-trapping studies using 2-methyl-2-nitroso propane and 5,5 dimethyl-1-pyrroline-N-oxide ( DMPO) demonstrated the formation of tyrosyl- and cysteinyl-derived radicals. DMPO also inhibited covalently linked dimerization products and led to the formation of DMPO-hemoglobin adducts. Hemoglobin nitration was not observed unless an excess of peroxynitrite over oxyhemoglobin was used, in agreement with a marginal formation of nitrogen dioxide. The results obtained support a role of oxyhemoglobin as a relevant intravascular sink of peroxynitrite.	Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Fac Med, Ctr Free Rad & Biomed Res, Montevideo 11800, Uruguay; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-0513970 Sao Paulo, Brazil; NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Univ Republica, Fac Ciencias, Inst Quim Biol, Montevideo 11400, Uruguay	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Universidade de Sao Paulo; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Universidad de la Republica, Uruguay	Denicola, A (corresponding author), Fac Med, Dept Bioquim, Avda Gral Flores 2125, Montevideo 11800, Uruguay.	denicola@fcien.edu.uy	Mason, Ronald P/G-5967-2019; Linares, Edlaine/AAR-8753-2020; Augusto, Ohara/D-3839-2012	Mason, Ronald P/0000-0002-1859-9109; Linares, Edlaine/0000-0001-8164-3013; Augusto, Ohara/0000-0002-7220-4286; Denicola, Ana/0000-0002-5181-9708	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050139, ZIAES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; Alayash AI, 1998, ARCH BIOCHEM BIOPHYS, V349, P65, DOI 10.1006/abbi.1997.0449; Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Augusto O, 2002, BIOCHEMISTRY-US, V41, P14323, DOI 10.1021/bi0262202; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bose-Basu B, 2001, FREE RADICAL BIO MED, V31, P383, DOI 10.1016/S0891-5849(01)00599-8; Bourassa JL, 2001, J AM CHEM SOC, V123, P5142, DOI 10.1021/ja015621m; Brito C, 1999, J IMMUNOL, V162, P3356; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; BYTHEWAY I, 1994, CHEM REV, V94, P639, DOI 10.1021/cr00027a005; Castro L, 1996, ARCH BIOCHEM BIOPHYS, V333, P179, DOI 10.1006/abbi.1996.0379; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; D'Agnillo F, 2000, AM J PHYSIOL-HEART C, V279, pH1880, DOI 10.1152/ajpheart.2000.279.4.H1880; Daiber A, 2002, METHOD ENZYMOL, V359, P379; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Detweiler CD, 2002, FREE RADICAL BIO MED, V33, P364, DOI 10.1016/S0891-5849(02)00895-X; Exner M, 2000, CHEM RES TOXICOL, V13, P287, DOI 10.1021/tx990201k; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Gatti RM, 1998, ARCH BIOCHEM BIOPHYS, V349, P36, DOI 10.1006/abbi.1997.0451; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; Gunther MR, 1998, BIOCHEM J, V330, P1293; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; Herold S, 2003, FREE RADICAL BIO MED, V34, P531, DOI 10.1016/S0891-5849(02)01355-2; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jensen MP, 2002, INORG CHEM, V41, P4788, DOI 10.1021/ic011089s; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KOSAKA H, 1982, BIOCHIM BIOPHYS ACTA, V702, P237; MAO GD, 1994, FREE RADICAL BIO MED, V16, P493, DOI 10.1016/0891-5849(94)90127-9; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; Minetti M, 1999, BIOCHEMISTRY-US, V38, P2078, DOI 10.1021/bi982311g; Minetti M, 2000, BIOCHEMISTRY-US, V39, P6689, DOI 10.1021/bi9927991; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; MOMENTEAU M, 1994, CHEM REV, V94, P659, DOI 10.1021/cr00027a006; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; NOHL H, 1993, FREE RADICAL BIO MED, V15, P257, DOI 10.1016/0891-5849(93)90072-3; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Patel RP, 1996, FREE RADICAL RES, V25, P117, DOI 10.3109/10715769609149916; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; Romero N, 1999, ARCH BIOCHEM BIOPHYS, V368, P23, DOI 10.1006/abbi.1999.1272; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Schmidt H. H. W., 1996, METHODS NITRIC OXIDE, P491; Torchinsky Y, 1981, SULFUR PROTEINS; Wade RS, 1996, CHEM RES TOXICOL, V9, P1382, DOI 10.1021/tx9600457; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; Witting PK, 2001, J BIOL CHEM, V276, P16540, DOI 10.1074/jbc.M011707200; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430	61	106	108	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44049	44057		10.1074/jbc.M305895200	http://dx.doi.org/10.1074/jbc.M305895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920120	hybrid			2022-12-27	WOS:000186306700021
J	Ishima, R; Torchia, DA; Lynch, SM; Gronenborn, AM; Louis, JM				Ishima, R; Torchia, DA; Lynch, SM; Gronenborn, AM; Louis, JM			Solution structure of the mature HIV-1 protease monomer - Insight into the tertiary fold and stability of a precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; GAG-POL POLYPROTEIN; HUMAN-IMMUNODEFICIENCY; RETROVIRAL PROTEASES; TRANSFRAME PROTEIN; CRYSTAL-STRUCTURES; SUBSTRATE COMPLEX; VIRAL INFECTIVITY; ACTIVE-SITE; NMR	We present the first solution structure of the HIV-1 protease monomer spanning the region Phe(1)-Ala(95) (PR1-95). Except for the terminal regions (residues 1-10 and 91-95) that are disordered, the tertiary fold of the remainder of the protease is essentially identical to that of the individual subunit of the dimer. In the monomer, the side chains of buried residues stabilizing the active site interface in the dimer, such as Asp(25), Asp(29), and Arg(87), are now exposed to solvent. The flap dynamics in the monomer are similar to that of the free protease dimer. We also show that the protease domain of an optimized precursor flanked by 56 amino acids of the N-terminal transframe region is predominantly monomeric, exhibiting a tertiary fold that is quite similar to that of PR1-95 structure. This explains the very low catalytic activity observed for the protease prior to its maturation at its N terminus as compared with the mature protease, which is an active stable dimer under identical conditions. Adding as few as 2 amino acids to the N terminus of the mature protease significantly increases its dissociation into monomers. Knowledge of the protease monomer structure and critical features of its dimerization may aid in the screening and design of compounds that target the protease prior to its maturation from the Gag-Pol precursor.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Struct Mol Biol Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Louis, JM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Room 411, Bethesda, MD 20892 USA.	jmlouis@helix.nih.gov		Louis, John M/0000-0002-0052-1899; Gronenborn, Angela M/0000-0001-9072-3525	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029025, Z01DK029022] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beissinger M, 1996, EUR J BIOCHEM, V237, P383, DOI 10.1111/j.1432-1033.1996.0383k.x; CANDOTTI D, 1994, CR ACAD SCI III-VIE, V317, P183; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Clore GM, 1998, CURR OPIN CHEM BIOL, V2, P564, DOI 10.1016/S1367-5931(98)80084-7; Condra JH, 1998, HAEMOPHILIA, V4, P610, DOI 10.1046/j.1365-2516.1998.440610.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Freedberg DI, 2002, PROTEIN SCI, V11, P221, DOI 10.1110/ps.33202; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Hubbard S. J., 1993, COMPUTER PROGRAM; Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5; Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARACOSTAS V, 1993, VIROLOGY, V193, P661, DOI 10.1006/viro.1993.1174; Katoh E, 2003, PROTEIN SCI, V12, P1376, DOI 10.1110/ps.0300703; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; Louis JM, 2003, J BIOL CHEM, V278, P6085, DOI 10.1074/jbc.M209726200; Louis JM, 1999, NAT STRUCT BIOL, V6, P868; Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Paulus C, 1999, J BIOL CHEM, V274, P21539, DOI 10.1074/jbc.274.31.21539; PEARL L, 1984, FEBS LETT, V174, P96, DOI 10.1016/0014-5793(84)81085-6; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; Rick SW, 1998, PROTEINS, V32, P7, DOI 10.1002/(SICI)1097-0134(19980701)32:1&lt;7::AID-PROT3&gt;3.0.CO;2-K; ROSE JR, 1993, J BIOL CHEM, V268, P11939; ROSE JR, 1995, J VIROL, V69, P2751; SCHRAMM HJ, 1993, BIOCHEM BIOPH RES CO, V194, P595, DOI 10.1006/bbrc.1993.1863; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Tessmer U, 1998, J VIROL, V72, P3459, DOI 10.1128/JVI.72.4.3459-3463.1998; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; Tycko R, 2000, J AM CHEM SOC, V122, P9340, DOI 10.1021/ja002133q; Vondrasek J, 1997, NAT STRUCT BIOL, V4, P8, DOI 10.1038/nsb0197-8; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j	51	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43311	43319		10.1074/jbc.M307549200	http://dx.doi.org/10.1074/jbc.M307549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933791	hybrid			2022-12-27	WOS:000186157000074
J	Weigel, JA; Weigel, PH				Weigel, JA; Weigel, PH			Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; MEDIATED ENDOCYTOSIS; ASIALOGLYCOPROTEIN RECEPTORS; CARTILAGE PROTEOGLYCANS; EXTRACELLULAR-MATRIX; LYMPHATIC TISSUE; BINDING PROTEINS; ACID; DEGRADATION	Hyaluronan ( HA) and chondroitin sulfate ( CS) clearance from lymph and blood in mammals is mediated by the HA receptor for endocytosis ( HARE), which is present as two isoforms in rat and human (175/300 kDa and 190/315 kDa, respectively) in the sinusoidal endothelial cells of liver, spleen, and lymph nodes (Zhou, B., McGary, C. T., Weigel, J. A., Saxena, A., and Weigel, P. H. (2003) Glycobiology 13, 339 - 349). The small rat and human HARE proteins are not encoded directly by mRNA but are derived from larger precursors. Here we characterize the specificity and function of the 175-kDa HARE, expressed in the absence of the 300-kDa species, in stably transfected SK-Hep-1 cells. The HARE cDNA was fused with a leader sequence to allow correct orientation of the membrane protein. The recombinant rHARE contained similar to 25 kDa of N-linked oligosaccharides and, like the native protein, was able to bind HA in a ligand blot assay, even after de-N-glycosylation. SK-HARE cell lines demonstrated specific I-125-HA endocytosis, receptor recycling, and delivery of HA to lysosomes for degradation. The K-d for the binding of HA (number-average molecular mass similar to 133 kDa) to the 175-kDa HARE at 4 degreesC was 4.1 nM with 160,000 to 220,000 HA-binding sites per cell. The 175-kDa rHARE binds HA, dermatan sulfate, and chondroitin sulfates A, C, D, and E, but not chondroitin, heparin, heparan sulfate, or keratan sulfate. Surprisingly, recognition of glycosaminoglycans (GAGs) other than HA by native or recombinant HARE was temperature-dependent. Although competition was observed at 37 degreesC, none of the other GAGs competed for I-125-HA binding to SK- HARE cells at 4 degreesC. Anti-HARE monoclonal antibody-174 showed a similar temperature-dependence in its ability to block HA endocytosis. These data suggest that temperature-induced conformational changes may alter the GAG specificity of HARE. The results confirm that the 175-kDa rHARE does not require the larger HARE isoform to mediate endocytosis of multiple GAGs.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 2000, NEW FRONTIERS MED SC; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMLEY PN, 1991, J HEPATOL, V13, P8, DOI 10.1016/0168-8278(91)90856-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; EVERED D, 1989, CIBA F SYMP, V143, P1; FRASER JRE, 1988, BIOCHEM J, V256, P153, DOI 10.1042/bj2560153; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; Freitas JP, 1996, DERMATOLOGY, V192, P46, DOI 10.1159/000246314; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HASCALL VC, 1977, J SUPRAMOL STR CELL, V7, P101, DOI 10.1002/jss.400070110; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; HEFFELFINGER SC, 1992, IN VITRO CELL DEV-AN, V28A, P136; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Knudson CB, 2001, SEMIN CELL DEV BIOL, V12, P69, DOI 10.1006/scdb.2000.0243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai KN, 1998, J LAB CLIN MED, V131, P354, DOI 10.1016/S0022-2143(98)90186-X; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LAURENT UBG, 1991, EXP PHYSIOL, V76, P695, DOI 10.1113/expphysiol.1991.sp003536; LEBEL L, 1988, J APPL PHYSIOL, V64, P1327, DOI 10.1152/jappl.1988.64.4.1327; LEBOEUF RD, 1987, BIOCHEMISTRY-US, V26, P6052, DOI 10.1021/bi00393a016; LEBOEUF RD, 1986, J BIOL CHEM, V261, P2586; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LUNDIN A, 1985, BRIT J DERMATOL, V112, P663, DOI 10.1111/j.1365-2133.1985.tb02334.x; Luo W, 2000, J BONE MINER METAB, V18, P51, DOI 10.1007/s007740050011; Manicourt DH, 1999, ARTHRITIS RHEUM, V42, P1861, DOI 10.1002/1529-0131(199909)42:9<1861::AID-ANR10>3.0.CO;2-I; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703; OKA JA, 1989, J BIOL CHEM, V264, P12016; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schwartz NB, 1999, PROG NUCLEIC ACID RE, V62, P177; SCOTT JE, 1995, J ANAT, V187, P259; STROBEL JL, 1985, ARCH BIOCHEM BIOPHYS, V240, P635, DOI 10.1016/0003-9861(85)90071-2; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Thylen A, 1999, CANCER-AM CANCER SOC, V86, P2000, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.3.CO;2-E; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TURLEY EA, 1993, BLOOD, V81, P446; TZAICOS C, 1989, BIOCHEM J, V264, P823, DOI 10.1042/bj2640823; Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166; Weigel JA, 2003, J BIOL CHEM, V278, P9808, DOI 10.1074/jbc.M211462200; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Yik JHN, 2002, BIOCHEM BIOPH RES CO, V297, P980, DOI 10.1016/S0006-291X(02)02298-2; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	63	45	45	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42802	42811		10.1074/jbc.M307201200	http://dx.doi.org/10.1074/jbc.M307201200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933790	hybrid			2022-12-27	WOS:000186157000011
J	Wen, RR; Chen, YH; Xue, LQ; Schuman, J; Yang, S; Morris, SW; Wang, DM				Wen, RR; Chen, YH; Xue, LQ; Schuman, J; Yang, S; Morris, SW; Wang, DM			Phospholipase C gamma 2 provides survival signals via Bcl2 and A1 in different subpopulations of B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECEPTOR-INDUCED ACTIVATION; LYN-DEFICIENT MICE; TARGETED DISRUPTION; IMMUNE-RESPONSES; PHOSPHOINOSITIDE 3-KINASE; SURFACE-IMMUNOGLOBULIN; LYMPHOID DEVELOPMENT; INDUCED APOPTOSIS; MEMBRANE EXON	PLCgamma2 plays a critical role in B cell receptor (BCR) signaling and its targeted deletion results in defective B cell development and function. Here, we show that PLCgamma2 deficiency specifically blocks B cell maturation at the transitional type 2 (T2) to follicular (FO) B cell transition and the PLCgamma2 pathway regulates survival of B cells. BCR-induced apoptosis is dramatically enhanced in all subsets of splenic PLCgamma2-deficient B cells, especially in T2 and FO B cell subpopulations. We also find that all splenic PLCgamma2-deficient B cell subpopulations express abnormally low levels of Bcl-2 protein. In addition, PLCgamma2 deficiency disrupts BCR-mediated induction of A1 expression. Enforced expression of Bcl-2 prevents BCR-induced apoptosis in all splenic PLCgamma2-deficient B cell subpopulations and partially restores the numbers of PLCgamma2-deficient FO B cells. In contrast to Bcl-2, enforced expression of A1 preferentially prevents BCR-induced apoptosis in PLCgamma2-deficient FO B cells and partially restores the numbers of these B cells. Therefore, the PLCgamma2 pathway provides a survival signal via regulation of Bcl-2 in all splenic B cell subpopulations and via additional induction of A1 in mature FO B cells.	Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Nanjing Univ, Inst Mol Med, Model Anim Res Ctr, Nanjing 210008, Peoples R China; Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Versiti Blood Center of Wisconsin; St Jude Children's Research Hospital; Nanjing University; Medical College of Wisconsin	Wang, DM (corresponding author), Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA.	dwang@bcsew.edu			NATIONAL CANCER INSTITUTE [R01CA087064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87064] Funding Source: Medline; NHLBI NIH HHS [HL073284] Funding Source: Medline; NIAID NIH HHS [AI52327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIN EY, 1993, J IMMUNOL, V151, P1979; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Martin F, 2000, IMMUNITY, V12, P39, DOI 10.1016/S1074-7613(00)80157-0; Martin F, 2001, CURR OPIN IMMUNOL, V13, P195, DOI 10.1016/S0952-7915(00)00204-1; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Oliver AM, 1997, EUR J IMMUNOL, V27, P2366, DOI 10.1002/eji.1830270935; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rothstein TL, 1996, CURR OPIN IMMUNOL, V8, P362, DOI 10.1016/S0952-7915(96)80126-9; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tarlinton DM, 1997, INT IMMUNOL, V9, P1481, DOI 10.1093/intimm/9.10.1481; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tomayko MM, 1998, J IMMUNOL, V160, P107; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wen RR, 2001, MOL CELL BIOL, V21, P678, DOI 10.1128/MCB.21.2.678-689.2001; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3	62	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43654	43662		10.1074/jbc.M307318200	http://dx.doi.org/10.1074/jbc.M307318200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928432	hybrid			2022-12-27	WOS:000186157000114
J	Zomot, E; Kanner, BI				Zomot, E; Kanner, BI			The interaction of the gamma-aminobutyric acid transporter GAT-1 with the neurotransmitter is selectively impaired by sulfhydryl modification of a conformationally sensitive cysteine residue engineered into extracellular loop IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; GABA TRANSPORTER; SUBSTRATE-BINDING; XENOPUS OOCYTES; SUBTYPE-A; SITE; IDENTIFICATION; EXPRESSION	The (Na++Cl-)-coupled gamma-aminobutyric acid (GABA) transporter GAT-1 keeps synaptic levels of this neurotransmitter low and thereby enables efficient GABAergic transmission. Extracellular loops (III, IV, and V) have been shown to contain determinants for GABA selectivity and affinity. Here we analyze the role of extracellular loop IV in transport by cysteine scanning mutagenesis. Fourteen residues of this loop have been replaced by cysteine. GABA transport by eight of the fourteen mutants is markedly more sensitive to inhibition by membrane-impermeant methane thiosulfate reagents than wild-type. Mutant A364C has high activity and is potently inhibited by the sulfhydryl reagent. GABA transport by the A364C/C74A double mutant, where the only externally accessible cysteine residue of the wild-type has been replaced by alanine, is also highly sensitive to the sulfhydryl reagents. Maximal sensitivity is observed in the presence of the cosubstrates sodium and chloride. A marked protection is afforded by GABA, provided sodium is present. This protection is also observed at 4degreesC. The non-transportable analogue SKF100330A also protects the double mutant against sulfhydryl modification in the presence of sodium but has the opposite effect in its absence. Electrophysiological analysis shows that upon sulfhydryl modification of this mutant, GABA can no longer induce transport currents. The voltage dependence of the transient currents indicates an increased apparent affinity for sodium. Moreover, GABA is unable to suppress the transient currents. Our results indicate that part of extracellular loop IV is conformationally sensitive, and its modification selectively abolishes the interaction of the transporter with GABA.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.							ALI FE, 1985, J MED CHEM, V28, P653, DOI 10.1021/jm50001a020; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; Barker EL, 1999, J NEUROSCI, V19, P4705; Bennett ER, 2000, J BIOL CHEM, V275, P34106, DOI 10.1074/jbc.M004229200; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; CHIN JG, 1997, J BIOL CHEM, V272, P28321; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Hirayama BA, 2001, BRIT J PHARMACOL, V134, P484, DOI 10.1038/sj.bjp.0704274; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; KANNER BI, 1994, FEBS LETT, V356, P191, DOI 10.1016/0014-5793(94)01255-5; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; MacAulay N, 2003, J BIOL CHEM, V278, P28771, DOI 10.1074/jbc.M213023200; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MAGER S, 1996, J NEUROSCI, V16, P5404; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; WANG JB, 1995, J NEUROCHEM, V64, P1416	36	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42950	42958		10.1074/jbc.M209307200	http://dx.doi.org/10.1074/jbc.M209307200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925537	hybrid			2022-12-27	WOS:000186157000029
J	Malygin, EG; Lindstrom, WM; Zinoviev, VV; Evdokimov, AA; Schlagman, SL; Reich, NO; Hattman, S				Malygin, EG; Lindstrom, WM; Zinoviev, VV; Evdokimov, AA; Schlagman, SL; Reich, NO; Hattman, S			Bacteriophage T4Dam (DNA-(adenine-N-6)-methyltransferase) - Evidence for two distinct stages of methylation under single turnover conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORI DNA METHYLTRANSFERASE; DAM DNA-<N-6-ADENINE> METHYLTRANSFERASE; ADENOSYL-L-METHIONINE; CRYSTAL-STRUCTURE; S-ADENOSYLMETHIONINE; OLIGONUCLEOTIDE DUPLEXES; RECOGNITION SITES; STATE KINETICS; TARGET BASE; MOTIF-IV	We compared the (pre) steady-state and single turnover methylation kinetics of bacteriophage T4Dam (DNA-(adenine-N-6)-methyltransferase)-mediated methyl group transfer from S-adenosyl-L-methionine (AdoMet) to oligodeoxynucleotide duplexes containing a single recognition site (palindrome 5'-GATC/5'-GATC) or some modified variant. T4Dam-AdoMet functions as a monomer under steady-state conditions (enzyme/DNA << 1), whereas under single turnover conditions (enzyme/DNA > 1), a catalytically active complex containing two Dam-AdoMet molecules is formed initially, and two methyl groups are transferred per duplex (to produce a methylated duplex and S-adenosyl-L-homocysteine (AdoHcy)). We propose that the single turnover reaction proceeds in two stages. First, two preformed T4Dam-AdoMet complexes bind opposite strands of the unmodified target site, and one enzyme molecule catalyzes the rapid transfer of the AdoMet-methyl group (k(meth1) = 0.21 s(-1)); this is 2.5-fold slower than the rate observed with monomeric T4Dam-AdoMet bound under pre-steady-state conditions for burst determination. In the second stage, methyl transfer to adenine in GATC on the complementary strand occurs at a rate that is 1 order of magnitude slower (k(meth2) = 0.023 s(-1)). We suggest that under single turnover conditions, methylation of the second strand is rate-limited by Dam-AdoHcy dissociation or its clearance from the methylated complementary strand. The hemimethylated duplex 5'-GATC/5'-GMTC also interacts with T4Dam-AdoMet complexes in two stages under single turnover reaction conditions. The first stage (kmeth1) reflects methylation by dimeric T4Dam-AdoMet productively oriented to the strand with the adenine residue capable of methylation. The slower second stage (kmeth2) reflects methylation by enzyme molecules non-productively oriented to the GMTC chain, which then have to re-orient to the opposite productive chain. Substitutions of bases and deletions in the recognition site affect the kinetic parameters in different fashions. When the GAT portion of GATC was disrupted, the proportion of the initial productive enzyme-substrate complexes was sharply reduced.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; State Res Ctr Virol & Biotechnol Vector, Inst Mol Biol, Koltsov 630559, Novosibirsk Reg, Russia; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93103 USA	University of Rochester; State Research Center of Virology & Biotechnology VECTOR; University of California System; University of California Santa Barbara	Hattman, S (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.		Ernst, Malygin/A-6741-2014; Evdokimov, Alexey/A-6485-2014		FOGARTY INTERNATIONAL CENTER [R03TW005755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046333] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW 05755] Funding Source: Medline; NIGMS NIH HHS [GM 46333 3, GM 29227] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVNOV MG, 1995, GENE, V157, P149, DOI 10.1016/0378-1119(94)00738-E; BURYANOV YI, 1988, GENE, V74, P67, DOI 10.1016/0378-1119(88)90253-3; CHENG X, 1993, COLD SPRING HARB SYM, V58, P331, DOI 10.1101/SQB.1993.058.01.039; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; FERSHT A, 1985, ENZYME STRUCTURE MEC, P133; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Gromova ES, 1995, BIOCHEM MOL BIOL INT, V36, P247; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Jeltsch A, 1999, J MOL BIOL, V285, P1121, DOI 10.1006/jmbi.1998.2389; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOSSYKH VG, 1995, J BIOL CHEM, V270, P14389, DOI 10.1074/jbc.270.24.14389; KOSSYKH VG, 1995, FEBS LETT, V370, P75, DOI 10.1016/0014-5793(95)00795-B; KURGANOV BI, 1982, ALLOSTERIC ENZYMES K, P151; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Malygin EG, 1999, NUCLEIC ACIDS RES, V27, P1135, DOI 10.1093/nar/27.4.1135; Malygin EG, 1997, NUCLEIC ACIDS RES, V25, P4393, DOI 10.1093/nar/25.21.4393; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; Malygin EG, 2001, NUCLEIC ACIDS RES, V29, P2361, DOI 10.1093/nar/29.11.2361; NARDONE G, 1984, J BIOL CHEM, V259, P357; Pues H, 1999, BIOCHEMISTRY-US, V38, P1426, DOI 10.1021/bi9818016; REICH NO, 1991, NUCLEIC ACIDS RES, V19, P6587, DOI 10.1093/nar/19.23.6587; REICH NO, 1993, J BIOL CHEM, V268, P9191; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Scavetta R, 2000, NUCLEIC ACIDS RES, V28, P3950, DOI 10.1093/nar/28.20.3950; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1998, BIOL CHEM, V379, P389; Thielking V, 1997, BIOL CHEM, V378, P407, DOI 10.1515/bchm.1997.378.5.407; Tran PH, 1998, STRUCT FOLD DES, V6, P1563, DOI 10.1016/S0969-2126(98)00154-3; WU JC, 1987, J BIOL CHEM, V262, P4778; YANG Z, 2003, IN PRESS NAT STRUCT, V10; Zinov'ev V. V., 1996, Molekulyarnaya Biologiya (Moscow), V30, P1203; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41749	41755		10.1074/jbc.M306397200	http://dx.doi.org/10.1074/jbc.M306397200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12893823	hybrid			2022-12-27	WOS:000185989500026
J	Sugawara, T; Shimizu, H; Hoshi, N; Nakajima, A; Fujimoto, S				Sugawara, T; Shimizu, H; Hoshi, N; Nakajima, A; Fujimoto, S			Steroidogenic acute regulatory protein-binding protein cloned by a yeast two-hybrid system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; LIPOID ADRENAL-HYPERPLASIA; STAR GENE; MOLECULAR-CLONING; MOLTEN GLOBULE; TUMOR-CELLS; FACTOR-I; CHOLESTEROL; EXPRESSION; PROMOTER	Steroidogenic acute regulatory ( StAR) protein plays a key role in the transport of cholesterol from the outer mitochondrial membrane to the inner membrane. A StAR mutant protein lacking the first 62 amino acids (N-62 StAR protein) has been reported to be as effective as wild-type StAR protein. In the present study, we examined the mechanism by which StAR protein stimulates steroidogenesis. A Gal4-based yeast two-hybrid system was used to identify proteins interacting with N-62 StAR protein. Nine positive clones were obtained from screening 1 x 10(6) clones. The results of pull-down assays and mammalian two-hybrid assays confirmed interaction between N-62 StAR protein and the clone 4 translated product. The clone 4 translated product was named StAR-binding protein (SBP). We prepared an expression plasmid (pSBP) by inserting SBP cDNA into the pTarget vector. After cotransfection with the human cytochrome P450scc system, StAR expression vector, and pSBP, the amount of pregnenolone produced by COS-1 cells was increased. The amount of steroid hormones produced by steroidogenic cells subjected to small interfering RNA treatment was less than that produced by control cells. In conclusion, SBP binds StAR protein in cells and enhances the ability of StAR protein to promote syntheses of steroid hormones.	Hokkaido Univ, Grad Sch Med, Dept Biochem, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido 0608638, Japan; Kitasato Univ, Sch Vet Med & Anim Sci, Lab Expt Anim Sci, Towada, Aomori 0348628, Japan	Hokkaido University; Hokkaido University; Kitasato University	Sugawara, T (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Biochem, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.							Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; Balasubramanian K, 1997, ENDOCRINOLOGY, V138, P433, DOI 10.1210/en.138.1.433; BARNIKOLWATANABE S, 1994, BIOL CHEM H-S, V375, P497, DOI 10.1515/bchm3.1994.375.8.497; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Brand C, 1998, J BIOL CHEM, V273, P6410, DOI 10.1074/jbc.273.11.6410; Budnik LT, 1999, MOL CELL ENDOCRINOL, V150, P39, DOI 10.1016/S0303-7207(99)00029-5; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; Christenson LK, 2001, ENDOCRINOLOGY, V142, P28, DOI 10.1210/endo.142.1.7867; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hall PF, 1997, STEROIDS, V62, P185, DOI 10.1016/S0039-128X(96)00179-1; Hardwick M, 1999, CANCER RES, V59, P831; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; Hemenway CS, 1999, ANAL BIOCHEM, V268, P161, DOI 10.1006/abio.1998.3034; Ishii T, 2002, MOL ENDOCRINOL, V16, P2297, DOI 10.1210/me.2001-0320; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Oka A, 1999, HUM MOL GENET, V8, P2165, DOI 10.1093/hmg/8.12.2165; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; SHIVER TM, 1992, ENDOCRINOLOGY, V131, P201, DOI 10.1210/en.131.1.201; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 2001, BBA-MOL CELL BIOL L, V1533, P277, DOI 10.1016/S1388-1981(01)00160-3; Sugawara T, 2001, ENDOCRINOLOGY, V142, P3570, DOI 10.1210/en.142.8.3570; Takemori H, 2002, J BIOL CHEM, V277, P42334, DOI 10.1074/jbc.M204602200; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	51	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42487	42494		10.1074/jbc.M302291200	http://dx.doi.org/10.1074/jbc.M302291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909641	hybrid			2022-12-27	WOS:000185989500113
J	Yeh, TS; Lin, YM; Hsieh, RH; Tseng, MJ				Yeh, TS; Lin, YM; Hsieh, RH; Tseng, MJ			Association of transcription factor YY1 with the high molecular weight notch complex suppresses the transactivation activity of notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR-VIRUS EBNA2; SIGNALING PATHWAY; ANKYRIN REPEATS; INTRACELLULAR DOMAIN; PHYSICAL INTERACTION; BINDING-PROTEIN; HUMAN HOMOLOG; GENE; DIFFERENTIATION; COACTIVATOR	Notch receptors are evolutionarily conserved from Drosophila to human and play important roles in cell fate decisions. After ligand binding, Notch receptors are cleaved to release their intracellular domains. The intracellular domains, the activated form of Notch receptors, are then translocated into the nucleus where they interact with other transcriptional machinery to regulate the expression of cellular genes. To dissect the molecular mechanisms of Notch signaling, the cellular targets that interact with Notch1 receptor intracellular domain (N1IC) were screened. In this study, we found that endogenous transcription factor Ying Yang 1 (YY1) was associated with exogenous N1IC in human K562 erythroleukemic cells. The ankyrin (ANK) domain of N1IC and zinc finger domains of YY1 were essential for the association of N1IC and YY1 according to the pull-down assay of glutathione S-transferase fusion proteins. Furthermore, both YY1 and N1IC were present in a large complex of the nucleus to suppress the luciferase reporter activity transactivated by Notch signaling. The transcription factor YY1 indirectly regulated the transcriptional activity of the wild-type CBF1-response elements via the direct interaction of N1IC and CBF1. We also demonstrated the association between endogenous N1IC and intrinsic YY1 in human acute T-cell lymphoblastic leukemia cell lines. Taken together, these results indicate that transcription factor YY1 may modulate Notch signaling via association with the high molecular weight Notch complex.	Taipei Med Univ, Grad Inst Cell & Mol Biol, Taipei 110, Taiwan; Taipei Med Univ, Wan Fang Hosp, Ctr Stem Cells Res, Taipei 110, Taiwan; Taipei Med Univ, Grad Inst Nutr & Hlth Sci, Taipei 110, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University	Yeh, TS (corresponding author), Taipei Med Univ, Grad Inst Cell & Mol Biol, Taipei 110, Taiwan.	cmbtsyeh@tmu.edu.tw; cmbtseng@tmu.edu.tw						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chan HM, 2001, J CELL SCI, V114, P2363; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen HW, 2000, BIOCHEMISTRY-US, V39, P1675, DOI 10.1021/bi991786k; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jehn BM, 1999, J IMMUNOL, V162, P635; Kopan R, 2002, J CELL SCI, V115, P1095; Krebs LT, 2001, DEV BIOL, V238, P110, DOI 10.1006/dbio.2001.0408; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; LARSSON C, 1994, GENOMICS, V24, P253, DOI 10.1006/geno.1994.1613; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nekrep N, 2001, MOL CELL BIOL, V21, P5566, DOI 10.1128/MCB.21.16.5566-5576.2001; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; OTSUKA F, 1994, J BIOL CHEM, V269, P23700; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Reizis B, 2002, GENE DEV, V16, P295, DOI 10.1101/gad.960702; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Sugaya K, 1997, GENE, V189, P235, DOI 10.1016/S0378-1119(96)00857-8; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yan B, 2002, J BIOL CHEM, V277, P29760, DOI 10.1074/jbc.M204721200; Yeh TS, 1996, J VIROL, V70, P6190, DOI 10.1128/JVI.70.9.6190-6198.1996; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	57	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41963	41969		10.1074/jbc.M304353200	http://dx.doi.org/10.1074/jbc.M304353200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913000	hybrid			2022-12-27	WOS:000185989500051
J	Hihi, AK; Kebir, H; Hekimi, S				Hihi, AK; Kebir, H; Hekimi, S			Sensitivity of Caenorhabditis elegans clk-1 mutants to ubiquinone side-chain length reveals multiple ubiquinone-dependent processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVED CLK-1 MUTANTS; COENZYME-Q; SACCHAROMYCES-CEREVISIAE; CARBOXYLATE PROTEINS; ALTERNATIVE OXIDASE; GENETIC-EVIDENCE; ACTIVE-SITE; ELEGANS; MITOCHONDRIAL; BIOSYNTHESIS	Ubiquinone ( coenzyme Q, or Q) is a membrane constituent, whose head group is capable of accepting and donating electrons and whose lipidic side chain is composed of a variable number of isoprene subunits. A possible role for Q as a dietary antioxidant for treating conditions that involve altered cellular redox states is being intensely studied. Mutations in the clk-1 gene of the nematode Caenorhabditis elegans affect numerous physiological rates including behavioral rates, developmental rates, reproduction, and life span. clk-1 encodes a protein associated with the inner mitochondrial membrane that is necessary for Q biosynthesis in C. elegans. clk-1 mutants do not synthesize Q but accumulate demethoxyubiquinone, a Q synthesis intermediate that is able to partially sustain mitochondrial respiration in worms as well as in mammals. Recently, we and others have found that exogenous Q is necessary for the fertility and development of clk-1 mutants. Here, we take advantage of the clk-1 genetic model to identify structural features of Q that are functionally important in vivo. We show that clk-1 mutants are exquisitely sensitive to the length of the side chain of the Q they consume. We also identified differential sensitivity to Q side-chain length between null alleles of clk-1 (qm30 and qm51) and the weaker allele e2519. This allows us to propose a model where we distinguish several types of Q-dependent processes in vivo: processes that are very sensitive to Q side-chain length and processes that are permissive to Q with shorter chains.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Dr Penfield, Montreal, PQ H3A 1B1, Canada.			Kebir, Hania/0000-0001-6174-8846				Ajayi WU, 2002, J BIOL CHEM, V277, P8187, DOI 10.1074/jbc.M111477200; Albury MS, 2002, J BIOL CHEM, V277, P1190, DOI 10.1074/jbc.M109853200; Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891-5849(00)00307-5; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; EDLUND C, 1994, J NEUROCHEM, V63, P634; Ernster L., 1993, CLIN INVESTIGATOR, V71, P60; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; FORSMARK P, 1991, FEBS LETT, V285, P39, DOI 10.1016/0014-5793(91)80720-N; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kainou T, 2001, J BIOL CHEM, V276, P7876, DOI 10.1074/jbc.M007472200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Miyadera H, 2002, FEBS LETT, V512, P33, DOI 10.1016/S0014-5793(02)02282-2; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Nakai D, 2001, BIOCHEM BIOPH RES CO, V289, P463, DOI 10.1006/bbrc.2001.5977; Nohl H, 1998, ANN NY ACAD SCI, V854, P394, DOI 10.1111/j.1749-6632.1998.tb09919.x; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; Okada K, 1996, BBA-LIPID LIPID MET, V1302, P217, DOI 10.1016/0005-2760(96)00064-1; Okada K, 1998, FEBS LETT, V431, P241, DOI 10.1016/S0014-5793(98)00753-4; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; WONG A, 1995, GENETICS, V139, P1247	30	29	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41013	41018		10.1074/jbc.M305034200	http://dx.doi.org/10.1074/jbc.M305034200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893826	hybrid			2022-12-27	WOS:000185847200075
J	Caroppo, R; Colella, M; Colasuonno, A; DeLuisi, A; Debellis, L; Curci, S; Hofer, AM				Caroppo, R; Colella, M; Colasuonno, A; DeLuisi, A; Debellis, L; Curci, S; Hofer, AM			A reassessment of the effects of luminal [Ca2+] on inositol 1,4,5-trisphosphate-induced Ca2+ release from internal stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE-SENSITIVE STORES; ENDOPLASMIC-RETICULUM CA2+; STEADY-STATE MECHANISM; CALCIUM-RELEASE; CYTOSOLIC CA2+; INTRALUMINAL CA2+; INTACT-CELLS; IN-SITU; RECEPTOR; CHANNELS	Inositol 1,4,5-trisphosphate (InsP(3))-induced Ca2+ release from intracellular stores displays complex kinetic behavior. While it well established that cytosolic [Ca2+] can modulate release by acting on the InsP(3) receptor directly, the role of the filling state of internal Ca2+ stores in modulating Ca2+ release remains unclear. Here we have reevaluated this topic using a technique that permits rapid and reversible changes in free [Ca2+] in internal stores of living intact cells without altering cytoplasmic [Ca2+], InsP(3) receptors, or sarcoendoplasmic reticulum Ca2+ ATPases (SERCAs). N, N, N', N'-Tetrakis( 2-pyridylmethyl) ethylene diamine (TPEN), a membrane-permeant, low affinity Ca2+ chelator was used to manipulate [Ca2+] in intracellular stores, while [Ca2+] changes within the store were monitored directly with the low-affinity Ca2+ indicator, mag-fura-2, in intact BHK-21 cells. 200 muM TPEN caused a rapid drop in luminal free [Ca2+] and significantly reduced the extent of the response to stimulation with 100 nM bradykinin, a calcium-mobilizing agonist. The same effect was observed when intact cells were pretreated with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid(acetoxymethyl ester) (BAPTA-AM) to buffer cytoplasmic [Ca2+] changes. Although inhibition of Ca2+ uptake using the SERCA inhibitor tBHQ permitted significantly larger release of Ca2+ from stores, TPEN still attenuated the release in the presence of tBHQ in BAPTA-AM-loaded cells. These results demonstrate that the filling state of stores modulates the magnitude of InsP(3)-induced Ca2+ release by additional mechanism(s) that are independent of regulation by cytoplasmic [Ca2+] or effects on SERCA pumps.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, W Roxbury, MA 02132 USA; Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Boston Vet Affairs Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Universita degli Studi di Bari Aldo Moro	Hofer, AM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.		Colella, Matilde/G-9246-2011	Colella, Matilde/0000-0002-9584-7030; Debellis, Lucantonio/0000-0002-7571-0969; CAROPPO, Rosa/0000-0002-8773-8985	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34854] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; Hofer AM, 1999, METH MOL B, V114, P249; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; HOFER AM, 2001, CALCIUM SIGNALLING P, P111; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Meldolesi J, 2001, PROG NEUROBIOL, V65, P309, DOI 10.1016/S0301-0082(01)00004-1; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARYS JB, 1993, J BIOL CHEM, V268, P25206; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RAJU B, 1989, AM J PHYSIOL, V256, P540; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SHUTTLEWORTH TJ, 1995, CELL CALCIUM, V17, P393, DOI 10.1016/0143-4160(95)90085-3; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Snitsarev VA, 1996, BIOPHYS J, V71, P1048, DOI 10.1016/S0006-3495(96)79305-0; Steenbergen JF, 1996, J BIOL CHEM, V271, P1821, DOI 10.1074/jbc.271.4.1821; Tanimura A, 2000, J BIOL CHEM, V275, P27488; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200; Yule DI, 2001, J GEN PHYSIOL, V117, P431, DOI 10.1085/jgp.117.5.431	60	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39503	39508		10.1074/jbc.M305823200	http://dx.doi.org/10.1074/jbc.M305823200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888563	hybrid			2022-12-27	WOS:000185713800030
J	Deeds, L; Teodorescu, S; Chu, M; Yu, Q; Chen, CY				Deeds, L; Teodorescu, S; Chu, M; Yu, Q; Chen, CY			A p53-independent G(1) cell cycle checkpoint induced by the suppression of protein kinase C alpha and theta isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTING PHORBOL ESTERS; DEPENDENT KINASES; DOWN-REGULATION; TUMOR-SUPPRESSOR; DNA-REPLICATION; CDK-INHIBITOR; GROWTH; P21; ARREST; EXPRESSION	The protein kinase C (PKC) family consists of multiple isoforms that are involved in the regulation of diverse cellular responses. Suppression of PKC induces growth arrest in various types of cells. However, the underlying molecular mechanisms have not been thoroughly investigated. In this report, we demonstrated that the concurrent inhibition, rather than separate inhibition, of phorbol ester-dependent PKC alpha and theta isoforms is crucial for the induction of G(1) cell cycle arrest and that this negative cell cycle regulation is via p53-independent mechanisms. PKC suppression-mediated growth arrest is associated with the induction of cell cycle inhibitor p21(WAF1/CIP1) and the occurrence of hypophosphorylated Rb. The G(1) checkpoint induced by the suppression of PKC occurs not only in murine Swiss3T3 but also in p53-deficient cells and human lung cancer cells containing mutated p53. Luciferase and nuclear run-off assays demonstrated that p21(WAF1/CIP1) is, in part, transcriptionally regulated in response to the suppression of PKC alpha and theta. However, the stability of p21 mRNA is also augmented after the addition of PKC alpha and theta antisense oligonucleotides, indicating the involvement of post-transcriptional mechanisms in p21(WAF1/CIP1) expression. These data suggest the existence of a cell cycle checkpoint pathway regulated by PKC alpha and theta isoforms. Furthermore, our findings support the notion that G(1) checkpoint control can be restored in tumor cells containing abnormal p53, by targeting the PKC-regulated p21(WAF1/CIP1) induction.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Chen, CY (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 80 E Concord St,K522, Boston, MA 02118 USA.	yanyan@bu.edu						AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1990, J CELL PHYSIOL, V145, P381, DOI 10.1002/jcp.1041450225; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; GRANA X, 1995, ONCOGENE, V11, P211; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kiley SC, 1996, J MAMMARY GLAND BIOL, V1, P177, DOI 10.1007/BF02013641; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Loignon M, 1997, CANCER RES, V57, P3390; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1989, CANCER RES, V49, P3215; PHILLIPS MA, 1983, J BIOL CHEM, V258, P2875; RAVIPRAKASH K, 1995, J VIROL, V69, P69, DOI 10.1128/JVI.69.1.69-74.1995; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; STEVE C, 1996, SCIENCE, V272, P877; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Weiss RH, 1996, AM J PHYSIOL-CELL PH, V270, pC619, DOI 10.1152/ajpcell.1996.270.2.C619; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	64	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39782	39793		10.1074/jbc.M306854200	http://dx.doi.org/10.1074/jbc.M306854200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12896972	hybrid			2022-12-27	WOS:000185713800064
J	Frank, J; Roux, J; Kawakatsu, H; Su, G; Dagenais, A; Berthiaume, Y; Howard, M; Canessa, CM; Fang, XH; Sheppard, D; Matthay, MA; Pittet, JF				Frank, J; Roux, J; Kawakatsu, H; Su, G; Dagenais, A; Berthiaume, Y; Howard, M; Canessa, CM; Fang, XH; Sheppard, D; Matthay, MA; Pittet, JF			Transforming growth factor-beta 1 decreases expression of the epithelial sodium channel alpha ENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; GROWTH-FACTOR-BETA; ACUTE LUNG INJURY; ACTIVATED PROTEIN-KINASE; III PROCOLLAGEN PEPTIDE; LIQUID CLEARANCE; PULMONARY-FIBROSIS; GENE-EXPRESSION; CELLS; MICE	Acute lung injury (ALI) is characterized by the flooding of the alveolar airspaces with protein-rich edema fluid and diffuse alveolar damage. We have previously reported that transforming growth factor-beta1 (TGF-beta1) is a critical mediator of ALI after intratracheal administration of bleomycin or Escherichia coli endotoxin, at least in part due to effects on lung endothelial and alveolar epithelial permeability. In the present study, we hypothesized that TGF-beta1 would also decrease vectorial ion and water transport across the distal lung epithelium. Therefore, we studied the effect of active TGF-beta1 on Na-22(+) uptake across monolayers of primary rat and human alveolar type II (ATII) cells. TGF-beta1 significantly reduced the amiloride-sensitive fraction of Na-22(+) uptake and fluid transport across monolayers of both rat and human ATII cells. TGF-beta1 also significantly decreased alphaENaC mRNA and protein expression and inhibited expression of a luciferase reporter downstream of the alphaENaC promoter in lung epithelial cells. The inhibitory effect of TGF-beta1 on sodium uptake and alphaENaC expression in ATII cells was mediated by activation of the MAPK, ERK1/2. Consistent with the in vitro results, TGF-beta1 inhibited the amiloride-sensitive fraction of the distal airway epithelial fluid transport in an in vivo rat model at a dose that was not associated with any change in epithelial protein permeability. These data indicate that increased TGF-beta1 activity in the distal airspaces during ALI promotes alveolar edema by reducing distal airway epithelial sodium and fluid clearance. This reduction in sodium and fluid transport is attributable in large part to a reduction in apical membrane alphaENaC expression mediated through an ERK1/2-dependent inhibition of the alphaENaC promoter activity.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Anesthesia, Surg Res Lab, Cardiovasc Res Inst,Lung Biol Ctr, San Francisco, CA 94110 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Montreal, Dept Med, Montreal, PQ H2W 1T7, Canada; Univ Montreal, CHU Montreal, Ctr Rech, Montreal, PQ H2W 1T7, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yale University; Universite de Montreal; Universite de Montreal	Pittet, JF (corresponding author), San Francisco Gen Hosp, Dept Anesthesia, Rm 3C-38,1001 Potrero Ave, San Francisco, CA 94110 USA.	pittetj@anesthesia.ucsf.edu	Berthiaume, Yves/K-7588-2012; Roux, Jeremie/A-9746-2013	Roux, Jeremie/0000-0001-5712-8660	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL069900, R56HL088440, R01HL051854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062188] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL069900-04, K08 HL069900, HL-69900, R56 HL088440, HL-51854] Funding Source: Medline; NIGMS NIH HHS [GM-62188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CHEN XJ, 2002, AM J RESP CRIT CARE, V165, P751; Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124; CLARK JG, 1995, ANN INTERN MED, V122, P17, DOI 10.7326/0003-4819-122-1-199501010-00003; Dagenais A, 2001, AM J PHYSIOL-LUNG C, V281, pL217, DOI 10.1152/ajplung.2001.281.1.L217; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Fahy RJ, 2003, AM J RESP CELL MOL, V28, P499, DOI 10.1165/rcmb.2002-0092OC; FANG X, 2003, AM J RESP CRIT CARE, V167, P564; Fang XH, 2003, FASEB J, V17, pA87; Folkesson HG, 2000, J APPL PHYSIOL, V88, P416, DOI 10.1152/jappl.2000.88.2.416; Frank JA, 2002, AM J RESP CRIT CARE, V165, P242, DOI 10.1164/ajrccm.165.2.2108087; Furuichi S, 2002, RESPIROLOGY, V7, P193, DOI 10.1046/j.1440-1843.2002.00401.x; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634, DOI 10.1164/ajrccm.159.2.9712090; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Hurst V, 1999, AM J PHYSIOL-LUNG C, V276, pL582, DOI 10.1152/ajplung.1999.276.4.L582; Itani OA, 2003, AM J PHYSIOL-RENAL, V284, pF778, DOI 10.1152/ajprenal.00088.2002; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Mairbaurl H, 2002, AM J PHYSIOL-LUNG C, V282, pL659, DOI 10.1152/ajplung.00355; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Pittet JF, 2001, J IMMUNOL, V166, P6301, DOI 10.4049/jimmunol.166.10.6301; PITTET JF, 1994, J CLIN INVEST, V94, P663, DOI 10.1172/JCI117383; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Sartori C, 2002, J APPL PHYSIOL, V93, P1875, DOI 10.1152/japplphysiol.00275.2002; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SUZUKI S, 1995, AM J PHYSIOL-LUNG C, V268, pL983, DOI 10.1152/ajplung.1995.268.6.L983; WANG A, 1991, J BIOL CHEM, V266, P15598; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2002, LANCET, V360, P619, DOI 10.1016/S0140-6736(02)09774-X; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	40	126	134	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43939	43950		10.1074/jbc.M304882200	http://dx.doi.org/10.1074/jbc.M304882200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930837	hybrid			2022-12-27	WOS:000186306700009
J	David, G; Blondeau, K; Schiltz, M; Penel, S; Lewit-Bentley, A				David, G; Blondeau, K; Schiltz, M; Penel, S; Lewit-Bentley, A			YodA from Escherichia coli is a metal-binding, lipocalin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FED-BATCH; CADMIUM; REFINEMENT; SITE; INDUCTION; IDENTIFICATION; INHIBITION; EXPRESSION; CULTURES	We have determined the crystal structure of YodA, an Escherichia coli protein of unknown function. YodA had been identified under conditions of cadmium stress, and we confirm that it binds metals such as cadmium and zinc. We have also found nickel bound in one of the crystal forms. YodA is composed of two domains: a main lipocalin/calycin-like domain and a helical domain. The principal metal-binding site lies on one side of the calycin domain, thus making YodA the first metal-binding lipocalin known. Our experiments suggest that YodA expression may be part of a more general stress response. From sequence analogy with the C-terminal domain of a metal-binding receptor of a member of bacterial ATP-binding cassette transporters, we propose a three-dimensional model for this receptor and suggest that YodA may have a receptor-type partner in E. coli.	CNRS, CEA, MdR, Lab Utilisat Rayonnement Electromagnet, F-91898 Orsay, France; Ctr Sci Paris Sud, Inst Genet & Microbiol, F-91405 Orsay, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lewit-Bentley, A (corresponding author), CNRS, CEA, MdR, Lab Utilisat Rayonnement Electromagnet, BP 34, F-91898 Orsay, France.	Anita.Bentley@lure.u-psud.fr		Schiltz, Marc/0000-0003-3529-0223				Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; Andersson L, 1996, J BIOTECHNOL, V46, P255, DOI 10.1016/0168-1656(96)00004-1; Babai R, 1998, FEMS MICROBIOL LETT, V167, P107, DOI 10.1111/j.1574-6968.1998.tb13215.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEARD SJ, 1995, FEMS MICROBIOL LETT, V131, P205, DOI 10.1111/j.1574-6968.1995.tb07778.x; Binet MRB, 2000, FEBS LETT, V473, P67, DOI 10.1016/S0014-5793(00)01509-X; Birch RM, 2003, PROTEOMICS, V3, P764, DOI 10.1002/pmic.200300397; BISHOP RE, 1995, J BIOL CHEM, V270, P23097, DOI 10.1074/jbc.270.39.23097; Bishop RE, 2000, BBA-PROTEIN STRUCT M, V1482, P73, DOI 10.1016/S0167-4838(00)00138-2; Blindauer CA, 2002, MOL MICROBIOL, V45, P1421, DOI 10.1046/j.1365-2958.2002.03109.x; BOLLAG DM, 1996, PROTEIN METHODS, P195; BRISSAUD I, 1989, J RADIOAN NUCL CH AR, V131, P399, DOI 10.1007/BF02060606; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; David G, 2002, ACTA CRYSTALLOGR D, V58, P1243, DOI 10.1107/S0907444902008326; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL, 2002, PYMOL USERS MANUAL; DeLisa MP, 2001, RECOMBINANT PROTEIN PRODUCTION WITH PROKARYOTIC AND EUKARYOTIC CELLS: A COMPARATIVE VIEW ON HOST PHYSIOLOGY, P43; Dintilhac A, 1997, MOL MICROBIOL, V25, P727, DOI 10.1046/j.1365-2958.1997.5111879.x; Ferianc P, 1998, MICROBIOL-UK, V144, P1045, DOI 10.1099/00221287-144-4-1045; Ferianc P, 2000, BIOLOGIA, V55, P653; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; FURRSCHMID K, 2003, ELECTROPHORESIS, V24, P303; Gomes DS, 2002, BBA-GEN SUBJECTS, V1573, P21, DOI 10.1016/S0304-4165(02)00324-0; Hieber AD, 2000, BBA-PROTEIN STRUCT M, V1482, P84, DOI 10.1016/S0167-4838(00)00141-2; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huang KF, 2002, ACTA CRYSTALLOGR D, V58, P1118, DOI 10.1107/S090744490200656X; INBAR O, 1993, FEMS MICROBIOL LETT, V113, P197, DOI 10.1016/0378-1097(93)90268-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAR H, 1991, J MOL BIOL, V218, P427, DOI 10.1016/0022-2836(91)90723-J; Neubauer P, 2001, RECOMBINANT PROTEIN PRODUCTION WITH PROKARYOTIC AND EUKARYOTIC CELLS: A COMPARATIVE VIEW ON HOST PHYSIOLOGY, P195; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nystrom T, 2003, MOL MICROBIOL, V48, P17, DOI 10.1046/j.1365-2958.2003.03385.x; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; Petering DH, 2000, MAR ENVIRON RES, V50, P89, DOI 10.1016/S0141-1136(00)00099-4; Puskarova A, 2002, MICROBIOL-SGM, V148, P3801, DOI 10.1099/00221287-148-12-3801; Puskarova A, 2001, BIOLOGIA, V56, P337; Rosen BP, 1999, ESSAYS BIOCHEM, V34, P1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Skerra A, 2000, BBA-PROTEIN STRUCT M, V1482, P337, DOI 10.1016/S0167-4838(00)00145-X; Stark A, 2003, J MOL BIOL, V326, P1307, DOI 10.1016/S0022-2836(03)00045-7; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Teich A, 1999, BIOTECHNOL PROGR, V15, P123, DOI 10.1021/bp980102h; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; VANYSEK P, 1997, CRC HDB CHEM PHYSICS, V77, P8; VANYSEK P, 1997, CRC HDB CHEM PHYSICS, V77, P30; VANYSEK P, 1997, CRC HDB CHEM PHYSICS, V77, P20; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200	62	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43728	43735		10.1074/jbc.M304484200	http://dx.doi.org/10.1074/jbc.M304484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12909634	hybrid			2022-12-27	WOS:000186157000122
J	Gagliardi, M; Maynard, S; Miyake, T; Rodrigues, N; Tjew, SL; Cabannes, E; Bedard, PA				Gagliardi, M; Maynard, S; Miyake, T; Rodrigues, N; Tjew, SL; Cabannes, E; Bedard, PA			Opposing roles of C/EBP beta and AP-1 in the control of fibroblast proliferation and growth arrest-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-BETA; CHICKEN-EMBRYO FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; CEF-4/9E3 CYTOKINE GENE; ROUS-SARCOMA VIRUS; C-JUN; TRANSCRIPTIONAL ACTIVATION; HEPATOCYTE PROLIFERATION; INHIBITORY PROTEIN; CYCLE PROGRESSION	Chicken embryo fibroblasts (CEF) express several growth arrest-specific (GAS) gene products in G(0). In contact-inhibited cells, the expression of the most abundant of these proteins, the p20K lipocalin, is activated at the transcriptional level by C/EBPbeta. In this report, we describe the role of C/EBPbeta in CEF proliferation. We show that the expression of a dominant negative mutant of C/EBPbeta (designated Delta184-C/EBPbeta) completely inhibited p20K expression at confluence and stimulated the proliferation of CEF without inducing transformation. Mouse embryo fibroblasts nullizygous for C/EBPbeta had a proliferative advantage over cells with one or two functional copies of this gene. C/EBP inhibition enhanced the expression of the three major components of AP-1 in cycling CEF, namely c-Jun, JunD, and Fra-2, and stimulated AP-1 activity. In contrast, the over-expression of C/EBPbeta caused a dramatic reduction in the levels of AP-1 proteins. Therefore, C/EBPbeta is a negative regulator of AP-1 expression and activity in CEF. The expression of cyclin D1 and cell proliferation were stimulated by the dominant negative mutant of C/EBPbeta but not in the presence of TAM67, a dominant negative mutant of c-Jun and AP-1. CEF over-expressing c-Jun, and to a lesser extent JunD and Fra-2, did not growth arrest at high cell density and did not express p20K. Therefore, AP-1 interfered with the action of C/EBPbeta at high cell density, indicating that these factors play opposing roles in the control of GAS gene expression and CEF proliferation.	McMaster Univ, Dept Biol, Hamilton, ON L8S 1K4, Canada; York Univ, Dept Biol, N York, ON M3J 1P3, Canada	McMaster University; York University - Canada	Bedard, PA (corresponding author), McMaster Univ, Dept Biol, Hamilton, ON L8S 1K4, Canada.			Maynard, Scott/0000-0001-5625-936X				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; Bojovic B, 1996, J BIOL CHEM, V271, P22528, DOI 10.1074/jbc.271.37.22528; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cancedda FD, 1996, J BIOL CHEM, V271, P20163, DOI 10.1074/jbc.271.33.20163; Casado FJ, 1996, MECH DEVELOP, V54, P237, DOI 10.1016/0925-4773(95)00482-3; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Gagliardi M, 2001, ONCOGENE, V20, P2301, DOI 10.1038/sj.onc.1204354; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim S, 1999, MOL CELL BIOL, V19, P5718; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; MAO PL, 1993, J BIOL CHEM, V268, P8131; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SONOBE MH, 1995, ONCOGENE, V10, P689; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zahnow CA, 2001, CANCER RES, V61, P261; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	54	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43846	43854		10.1074/jbc.M304085200	http://dx.doi.org/10.1074/jbc.M304085200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12896981	hybrid			2022-12-27	WOS:000186157000135
J	Liu, LJ; Bortnick, AE; Nickel, M; Dhanasekaran, P; Subbaiah, PV; Lund-Katz, S; Rothblat, GH; Phillips, MC				Liu, LJ; Bortnick, AE; Nickel, M; Dhanasekaran, P; Subbaiah, PV; Lund-Katz, S; Rothblat, GH; Phillips, MC			Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol - Formation of nascent high density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIR-WATER-INTERFACE; C-TERMINAL DOMAIN; CELLULAR CHOLESTEROL; LIPID EFFLUX; ABCA1; HDL; CELLS; MEMBRANE; PROTEIN; MECHANISMS	The mechanism of formation of high density lipoprotein (HDL) particles by the action of ATP-binding cassette transporter A1 (ABCA1) is not defined completely. To address this issue, we monitored efflux to apoA-I of phosphatidylcholine (PC), sphingomyelin (SM), and unesterified (free) cholesterol (FC) from J774 macrophages, in which ABCA1 is up-regulated, and investigated the nature of the particles formed. The various apoA-I/lipid particles appearing in the extracellular medium were separated by gel filtration chromatography. The presence of apoA-I in the extracellular medium led to the simultaneous formation of more than one type of poorly lipidated apoA-I-containing particle: there were 9- and 12-nm diameter particles containing similar to3:1 and 1:1 phospholipid/FC (mol/mol), respectively, which were present together with 6-nm monomeric apoA-I. Removal of the C-terminal alpha-helix (residues 223-243) of apoA-I reduced phospholipid and FC efflux and prevented formation of the 9- and 12-nm HDL particles; the apoA-I variant formed larger particles that eluted in the void volume. FC loading of the J774 cells also led to the formation of larger apoA-I-containing particles that were highly enriched in FC. Besides creating HDL particles, ABCA1 mediated release of larger (20-450-nm diameter) FC-rich particles that were not involved in HDL formation and that are probably membrane vesicles. These particles contained 1:1 PC/SM in contrast to the HDL particles, which contained 2:1 PC/SM. This is consistent with lipid raft and non-raft plasma membrane domains being involved primarily in ABCA1-mediated vesicle release and nascent HDL formation, respectively.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Gastrointestinal Nutr D, Philadelphia, PA 19104 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Rush University	Phillips, MC (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Gastrointestinal Nutr D, Abramson Res Bldg,Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.		Subbaiah, Papasani/U-1104-2019; Bortnick, Anna/V-5983-2019	Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052597, R01HL068585, R56HL068585, P01HL022633, T32HL007443, R01HL063768] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07443, HL22633, HL68585, HL63768, HL52597] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Attie AD, 2001, J LIPID RES, V42, P1717; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; Bielicki JK, 1999, J LIPID RES, V40, P85; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1084, P7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Cockerill GW, 1999, INT REV CYTOL, V188, P257; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Favari E, 2002, BIOCHEM BIOPH RES CO, V299, P801, DOI 10.1016/S0006-291X(02)02745-6; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; FORTE TM, 1993, J LIPID RES, V34, P317; FORTE TM, 1995, J LIPID RES, V36, P148; FORTE TM, 1990, BIOCHIM BIOPHYS ACTA, V1047, P11, DOI 10.1016/0005-2760(90)90254-U; Gargalovic P, 2003, J LIPID RES, V44, P11, DOI 10.1194/jlr.R200005-JLR200; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1991, J BIOL CHEM, V266, P3080; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; Khovidhunkit W, 2003, J LIPID RES, V44, P1728, DOI 10.1194/jlr.M300100-JLR200; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; KRAMER MF, 1999, CURRENT PROTOCOLS MO; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; Lund-Katz S, 2003, FRONT BIOSCI-LANDMRK, V8, pD1044, DOI 10.2741/1077; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Pruzanski W, 2000, J LIPID RES, V41, P1035; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; Saito H, 1997, J LIPID RES, V38, P287; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; Schultz Joshua R., 1994, Current Opinion in Lipidology, V5, P126, DOI 10.1097/00041433-199404000-00009; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Sparks DL, 1999, BIOCHEMISTRY-US, V38, P1727, DOI 10.1021/bi981945k; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SUBBAIAH PV, 2000, HDB LIPOPROTEIN TEST; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9; Zha XH, 2003, J BIOL CHEM, V278, P10002, DOI 10.1074/jbc.C300024200; Zhang WW, 1998, J LIPID RES, V39, P1601	67	113	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42976	42984		10.1074/jbc.M308420200	http://dx.doi.org/10.1074/jbc.M308420200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928428	hybrid			2022-12-27	WOS:000186157000032
J	Riebeling, C; Allegood, JC; Wang, E; Merrill, AH; Futerman, AH				Riebeling, C; Allegood, JC; Wang, E; Merrill, AH; Futerman, AH			Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; SPHINGANINE N-ACYLTRANSFERASE; F-SP LYCOPERSICI; CERAMIDE SYNTHESIS; FUMONISIN B-1; SERINE PALMITOYLTRANSFERASE; ENDOPLASMIC-RETICULUM; CELL-DEATH; SPHINGOSINE; SYNTHASE	Overexpression of upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene (LAG1), selectively induces the synthesis of stearoyl-containing sphingolipids in mammalian cells ( Venkataraman, K., Riebeling, C., Bodennec, J., Riezman, H., Allegood, J. C., Sullards, M. C., Merrill, A. H. Jr., and Futerman, A. H. (2002) J. Biol. Chem. 277, 35642 - 35649). Gene data base analysis subsequently revealed a new subfamily of proteins containing the Lag1p motif, previously characterized as translocating chain-associating membrane ( TRAM) protein homologs (TRH). We now report that two additional members of this family regulate the synthesis of ( dihydro) ceramides with specific fatty acid(s) when overexpressed in human embryonic kidney 293T cells. TRH1 or TRH4-overexpression elevated [H-3]( dihydro) ceramide synthesis from L-[3-H-3] serine and the increase was not blocked by the ( dihydro) ceramide synthase inhibitor, fumonisin B-1 (FB1). Analysis of sphingolipids by liquid chromatography-electrospray tandem mass spectrometry revealed that TRH4-overexpression elevated mainly palmitic acid-containing sphingolipids whereas TRH1 overexpression increased mainly stearic acid and arachidic acid, which in both cases were further elevated upon incubation with FB1. A similar fatty acid specificity was obtained upon analysis of ( dihydro) ceramide synthase activity in vitro using various fatty acyl-CoA substrates, although in a FB1-sensitive manner. Moreover, in homogenates from TRH4-overexpressing cells, sphinganine, rather than sphingosine was the preferred substrate, whereas no preference was seen in homogenates from TRH1-overexpressing cells. These findings lend support to our hypothesis ( Venkataraman, K., and Futerman, A. H. (2002) FEBS Lett. 528, 3 - 4) that Lag1p family members regulate ( dihydro) ceramide synthases responsible for production of sphingolipids containing different fatty acids.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	Weizmann Institute of Science; University System of Georgia; Georgia Institute of Technology	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.			Riebeling, Christian/0000-0003-1991-0170; Futerman, Anthony/0000-0003-0013-0115; Merrill, Alfred/0000-0002-6673-968X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodennec J, 2000, J LIPID RES, V41, P1524; Brandwagt BF, 2000, P NATL ACAD SCI USA, V97, P4961, DOI 10.1073/pnas.97.9.4961; Brandwagt BF, 2002, MOL PLANT MICROBE IN, V15, P35, DOI 10.1094/MPMI.2002.15.1.35; Cai XF, 2003, DNA SEQUENCE, V14, P79, DOI 10.1080/1042517021000041831; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUTERMAN AH, 2003, CERAMIDE SIGNALING; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; HAREL R, 1993, J BIOL CHEM, V268, P14476; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Koyanagi S, 2003, INT J CANCER, V105, P1, DOI 10.1002/ijc.11024; Linn SC, 2001, BIOCHEM SOC T, V29, P831, DOI 10.1042/0300-5127:0290831; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 2003, CERAMIDE SIGNALING, P1; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MORELL P, 1970, J BIOL CHEM, V245, P342; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NURMINEN T, 1971, BIOCHEM J, V125, P963, DOI 10.1042/bj1250963; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Pelled D, 2003, J BIOL CHEM, V278, P29496, DOI 10.1074/jbc.M302964200; RIEBELING C, 2003, CERAMIDE SIGNALING, P101; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Sullards M C, 2001, Sci STKE, V2001, ppl1; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; van der Bijl P, 1996, BIOCHEM J, V317, P589, DOI 10.1042/bj3170589; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Venkataraman K, 2001, BBA-MOL CELL BIOL L, V1530, P219, DOI 10.1016/S1388-1981(01)00085-3; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; WAGNER H, 1966, BIOCHEM Z, V344, P314; Wang E, 2000, METHOD ENZYMOL, V311, P15; WANG E, 1991, J BIOL CHEM, V266, P14486; Wang E, 1999, J NUTR, V129, P214, DOI 10.1093/jn/129.1.214; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0	46	232	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43452	43459		10.1074/jbc.M307104200	http://dx.doi.org/10.1074/jbc.M307104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912983	hybrid			2022-12-27	WOS:000186157000090
J	Tschan, MP; Fischer, KM; Fung, VS; Pirnia, F; Borner, MM; Fey, MF; Tobler, A; Torbett, BE				Tschan, MP; Fischer, KM; Fung, VS; Pirnia, F; Borner, MM; Fey, MF; Tobler, A; Torbett, BE			Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE ISOFORM; ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; AMINOPEPTIDASE N/CD13; GENE-EXPRESSION; MESSENGER-RNA; CELLS; INDUCTION; ARREST	We have cloned two novel, alternatively spliced messages of human cyclin D-binding Myb-like protein (hDMP1). The known, full-length protein has been named hDMP1alpha and the new isoforms, hDMP1beta and hDMP1gamma. The hDMP1alpha, -beta, and -gamma splice variants have unique expression patterns in normal hematopoietic cells; hDMP1beta mRNA transcripts are strongly expressed in quiescent CD34(+) cells and freshly isolated peripheral blood leukocytes, as compared with hDMP1alpha. In contrast, activated T-cells and developing myeloid cells, macrophages, and granulocytes express low levels of hDMP1beta transcripts, and hDMP1gamma is ubiquitously and weakly expressed. Mouse Dmp1 has been shown to activate CD13/aminopeptidase N (APN) and p19(ARF) gene expression via binding to canonical DNA recognition sites in the respective promoters. Assessment of CD13/APN promoter responsiveness demonstrated that hDMP1alpha but not hDMP1beta and -gamma, is a transcriptional activator. Furthermore, hDMP1beta was found to inhibit the CD13/ APN promoter transactivation ability of hDMP1alpha. Stable, ectopic expression of hDMP1beta and, to a lesser extent hDMP1gamma, reduced endogenous cell surface levels of CD13/ APN in U937 cells. Moreover, stable, ectopic expression of hDMP1beta altered phorbol 12-myristate 13-acetate- induced terminal differentiation of U937 cells to macrophages and resulted in maintenance of proliferation. These results demonstrate that hDMP1beta antagonizes hDMP1alpha activity and suggest that cellular functions of hDMP1 may be regulated by cellular hDMP1 isoform levels.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Univ Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Univ Bern, Cent Hematol Lab, CH-3010 Bern, Switzerland; Inselspital Bern, CH-3010 Bern, Switzerland	Scripps Research Institute; University of Bern; University of Bern; University of Bern	Torbett, BE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	betorbet@scripps.edu	Borner, Markus/B-7583-2011	Tschan, Mario P./0000-0001-5897-3647	NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIDDK NIH HHS [DK49886] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049886] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; BERLINER N, 1995, BLOOD, V85, P799, DOI 10.1182/blood.V85.3.799.bloodjournal853799; Bhagwat SV, 2003, BLOOD, V101, P1818, DOI 10.1182/blood-2002-05-1422; Bodner SM, 1999, GENE, V229, P223, DOI 10.1016/S0378-1119(98)00591-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chun YS, 2002, BIOCHEM J, V362, P71, DOI 10.1042/0264-6021:3620071; Chun YS, 2001, J CELL SCI, V114, P4051; DREXLER HG, 1987, LEUKEMIA, V1, P697; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Galimi F, 2002, BLOOD, V100, P2732, DOI 10.1182/blood-2002-04-1245; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; HASS R, 1989, EUR J CELL BIOL, V48, P282; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Hur E, 2002, MOL PHARMACOL, V62, P975, DOI 10.1124/mol.62.5.975; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2000, GENE DEV, V14, P1797; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Kehlen A, 2000, ADV EXP MED BIOL, V477, P49; Kuo ML, 2003, CANCER RES, V63, P1046; Lendeckel U, 1996, BIOCHEM J, V319, P817, DOI 10.1042/bj3190817; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; MENRAD A, 1993, CANCER RES, V53, P1450; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Nakase K, 2000, CANCER RES, V60, P4062; Nakayama H, 2000, EXP HEMATOL, V28, P1232, DOI 10.1016/S0301-472X(00)00530-0; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; PUI CH, 1993, BLOOD, V82, P889; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; Riemann D, 1997, J IMMUNOL, V158, P3425; Rosenzwajg M, 2000, BLOOD, V95, P453, DOI 10.1182/blood.V95.2.453; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shin SW, 2002, P NATL ACAD SCI USA, V99, P9978, DOI 10.1073/pnas.162345999; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Sun GQ, 2002, MOL CELL ENDOCRINOL, V190, P147, DOI 10.1016/S0303-7207(01)00726-2; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Tschan MP, 2001, LEUKEMIA LYMPHOMA, V42, P1077, DOI 10.3109/10428190109097728; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Zwahlen D, 2000, INT J CANCER, V88, P66	47	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42750	42760		10.1074/jbc.M307067200	http://dx.doi.org/10.1074/jbc.M307067200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917399	hybrid			2022-12-27	WOS:000186157000005
J	Veeraraghavan, J; Rossi, ML; Bambara, RA				Veeraraghavan, J; Rossi, ML; Bambara, RA			Analysis of DNA replication intermediates suggests mechanisms of repeat sequence expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY-DISEASE GENES; TRINUCLEOTIDE REPEAT; SACCHAROMYCES-CEREVISIAE; TRIPLET REPEAT; IN-VITRO; SECONDARY STRUCTURE; CTG REPEATS; ESCHERICHIA-COLI; CAG REPEATS; INSTABILITY	We previously developed a system to investigate the mechanism of repeat sequence expansion during eukaryotic Okazaki fragment processing. Upstream and downstream primers were annealed to a complementary template to overlap across a CAG repeat region. Annealing by the competing primers lead to structural intermediates that ligated to expand the repeat segment. When an equal number of repeats overlapped on the upstream and downstream primers, a 2-fold expansion was expected, but no expansion occurred. We show here that such substrates do not expand irrespective of their repeat length. To reveal mechanism, we tested different hairpin loop intermediates expected to form and facilitate ligation. Substrates configured to form large loops in either the upstream or downstream primer alone allowed expansion. Large or small fixed position single loops allowed expansion when located at least six nucleotides up- or downstream of the nick. Fixed loops in both primers, simulating a double loop intermediate, allowed expansion as long as each loop was nine nucleotides from the nick. Thus, neither the double loop configuration required to form with equal length overlaps nor the large single loop configuration are fundamental structural impediments to expansion. We propose a model for the expansion mechanism based on the relative stabilities of single loop, double loop, hairpin, and flap intermediates that is consistent with the observed expansion efficiency of equal and unequal overlap substrates. The model suggests that the equilibrium concentration of double loop intermediates is so vanishingly small that they are not likely contributors to sequence expansion.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14624 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bennett P, 2000, J CLIN PATHOL-MOL PA, V53, P177; Chastain PD, 1998, J MOL BIOL, V275, P405, DOI 10.1006/jmbi.1997.1502; Cleary JD, 2002, NAT GENET, V31, P37, DOI 10.1038/ng870; Debrauwere H, 2001, P NATL ACAD SCI USA, V98, P8263, DOI 10.1073/pnas.121075598; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gacy AM, 1998, BIOCHEMISTRY-US, V37, P9426, DOI 10.1021/bi980157s; GACY AM, 1995, CELL, V81, P533; Goellner GM, 1997, AM J HUM GENET, V60, P879; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Hartenstine MJ, 2000, J BIOL CHEM, V275, P18382, DOI 10.1074/jbc.275.24.18382; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; Ireland MJ, 2000, GENETICS, V155, P1657; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jakupciak JP, 2000, IUBMB LIFE, V50, P355, DOI 10.1080/152165400300089358; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Nichol K, 2002, GENOME RES, V12, P1246, DOI 10.1101/gr.74502; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Panigrahi GB, 2002, J BIOL CHEM, V277, P13926, DOI 10.1074/jbc.M109761200; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 2002, NUCLEIC ACIDS RES, V30, P4534, DOI 10.1093/nar/gkf572; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Rolfsmeier ML, 2000, MOL CELL BIOL, V20, P173, DOI 10.1128/MCB.20.1.173-180.2000; Rolfsmeier ML, 2001, GENETICS, V157, P1569; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; Usdin K, 2000, CELL MOL LIFE SCI, V57, P914, DOI 10.1007/PL00000734; Volker J, 2002, P NATL ACAD SCI USA, V99, P14700, DOI 10.1073/pnas.222519799; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Zuker M, 2000, CURR OPIN STRUC BIOL, V10, P303, DOI 10.1016/S0959-440X(00)00088-9	45	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42854	42866		10.1074/jbc.M305137200	http://dx.doi.org/10.1074/jbc.M305137200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12902352	hybrid			2022-12-27	WOS:000186157000017
J	Donaldson, JG				Donaldson, JG			Multiple roles for Arf6: Sorting, structuring, and signaling at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RIBOSYLATION FACTOR 6; REGULATED EXOCYTOSIS; EXCHANGE FACTOR; CHROMAFFIN CELLS; ACTIVATION; PROTEIN; FACTOR-6; RECEPTOR; RAC1; ENDOCYTOSIS		NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Donaldson, JG (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 50,Rm 2503, Bethesda, MD 20892 USA.	jdonalds@helix.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000517, Z01HL000517] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Albertinazzi C, 2003, MOL BIOL CELL, V14, P1295, DOI 10.1091/mbc.E02-07-0406; Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; ARNAOUTOVA I, 2003, MOL BIOL CELL, DOI DOI 10.1091/MBC.02-11-0758; Austin C, 2002, BIOCHEMISTRY-US, V41, P4669, DOI 10.1021/bi016064j; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chies R, 2003, J CELL SCI, V116, P987, DOI 10.1242/jcs.00326; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Czech MP, 2003, ANNU REV PHYSIOL, V65, P791, DOI 10.1146/annurev.physiol.65.092101.142522; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; Dana RR, 2000, J BIOL CHEM, V275, P32566, DOI 10.1074/jbc.M005406200; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; Ge MT, 2001, BIOPHYS J, V81, P994, DOI 10.1016/S0006-3495(01)75757-8; Hernandez-Deviez DJ, 2002, NAT NEUROSCI, V5, P623, DOI 10.1038/nn865; Hickson GRX, 2003, MOL BIOL CELL, V14, P2908, DOI 10.1091/mbc.E03-03-0160; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HUANG CF, 2003, MOL BIOL CELL, DOI DOI 10.1091/MBC.03-01-0013; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Maranda B, 2001, J BIOL CHEM, V276, P18540, DOI 10.1074/jbc.M011577200; Melendez AJ, 2001, CURR BIOL, V11, P869, DOI 10.1016/S0960-9822(01)00260-3; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Mukherjee S, 2002, J BIOL CHEM, V277, P17916, DOI 10.1074/jbc.M110479200; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2003, J BIOL CHEM, V278, P17395, DOI 10.1074/jbc.M300998200; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Pasqualato S, 2001, EMBO REP, V2, P234, DOI 10.1093/embo-reports/kve043; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Powner DJ, 2002, MOL BIOL CELL, V13, P1252, DOI 10.1091/mbc.01-05-0235; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Salvador LM, 2001, J BIOL CHEM, V276, P33773, DOI 10.1074/jbc.M101498200; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Santy LC, 2002, J BIOL CHEM, V277, P40185, DOI 10.1074/jbc.C200481200; Schafer DA, 2000, TRAFFIC, V1, P892; Shin OH, 2001, BIOCHEMISTRY-US, V40, P10846, DOI 10.1021/bi0107391; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Song J, 1998, J CELL SCI, V111, P2257; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; Weber KSC, 2001, CURR BIOL, V11, P1969, DOI 10.1016/S0960-9822(01)00597-8; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	61	370	374	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41573	41576		10.1074/jbc.R300026200	http://dx.doi.org/10.1074/jbc.R300026200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912991	hybrid			2022-12-27	WOS:000185989500001
J	Ono, M; Shimizugawa, T; Shimamura, M; Yoshida, K; Noji-Sakikawa, C; Ando, Y; Koishi, R; Furukawa, H				Ono, M; Shimizugawa, T; Shimamura, M; Yoshida, K; Noji-Sakikawa, C; Ando, Y; Koishi, R; Furukawa, H			Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3) - ANGPTL3 is cleaved and activated in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-LIPASE; MICE; ADENOVIRUS; LIGAND; TIE2	Angiopoietin-like 3 (ANGPTL3) is a secreted protein that is mainly expressed in the liver and regulates lipid metabolism by inhibiting the lipolysis of triglyceride-rich lipoproteins. Using deletion mutants of human ANGPTL3, we demonstrated that the N-terminal coiled-coil domain-containing fragment-(17-207) and not the C-terminal fibrinogen-like domain-containing fragment( 207 - 460) increased the plasma triglyceride levels in mice. We also found that the N-terminal region 17 - 165 was required to increase plasma triglyceride levels in mice and that a substitution of basic amino acid residues in the region 61 - 66 of the fragment showed no increase in the plasma triglyceride levels and no inhibition of lipolysis by lipoprotein lipase. In addition, when we analyzed ANGPTL3 in human plasma, we detected cleaved fragments of ANGPTL3. By analyzing recombinant ANGPTL3 in mouse plasma, we found that it was cleaved at two sites, Arg(221)down arrowAla(222) and Arg(224)down arrowThr(225), which are located in the linker region between the coiled-coil domain and the fibrinogen-like domain. Furthermore, a cleavage-resistant mutant of ANGPTL3 was determined to be less active than wild-type ANGPTL3 in increasing mouse plasma triglyceride levels but not in inhibiting lipoprotein lipase activity. These findings suggest that the cleavage of ANGPTL3 is important for the activation of ANGPTL3 in vivo.	Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Med Safety Res Labs, Shizuoka 4370065, Japan	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Ono, M (corresponding author), Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1408710, Japan.			Ando, Yukio/0000-0001-7115-9105				Camenisch G, 2002, J BIOL CHEM, V277, P17281, DOI 10.1074/jbc.M109768200; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Fowlkes JL, 2002, CYTOKINE GROWTH F R, V13, P277, DOI 10.1016/S1359-6101(02)00005-9; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; LITHELL H, 1977, SCAND J CLIN LAB INV, V37, P551, DOI 10.3109/00365517709101845; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Naoumova RP, 2002, LANCET, V359, P2215, DOI 10.1016/S0140-6736(02)09315-7; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Rossetti L, 2002, NAT MED, V8, P112, DOI 10.1038/nm0202-112; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V301, P604, DOI 10.1016/S0006-291X(02)03058-9; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; SHIRAKI T, 1993, DIABETES FRONTIER, V4, P641; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200	20	165	192	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41804	41809		10.1074/jbc.M302861200	http://dx.doi.org/10.1074/jbc.M302861200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909640	hybrid			2022-12-27	WOS:000185989500032
J	Chow, JPH; Siu, WY; Ho, HTB; Ma, KHT; Ho, CC; Poon, RYC				Chow, JPH; Siu, WY; Ho, HTB; Ma, KHT; Ho, CC; Poon, RYC			Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE 2; S-PHASE; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; HUMAN MYT1; B1 GENE; ULTRAVIOLET-IRRADIATION; G(1)/S TRANSITION; DAMAGE CHECKPOINT; PROTEIN-KINASE	Inhibition of cyclin-dependent kinases (CDKs) by Thr(14)/Tyr(15) phosphorylation is critical for normal cell cycle progression and is a converging event for several cell cycle checkpoints. In this study, we compared the relative contribution of inhibitory phosphorylation for cyclin A/B1-CDC2 and cyclin A/E-CDK2 complexes. We found that inhibitory phosphorylation plays a major role in the regulation of CDC2 but only a minor role for CDK2 during the unperturbed cell cycle of HeLa cells. The relative importance of inhibitory phosphorylation of CDC2 and CDK2 may reflect their distinct cellular functions. Despite this, expression of nonphosphorylation mutants of both CDC2 and CDK2 triggered unscheduled histone H3 phosphorylation early in the cell cycle and was cytotoxic. DNA damage by a radiomimetic drug or replication block by hydroxyurea stimulated a buildup of cyclin B1 but was accompanied by an increase of inhibitory phosphorylation of CDC2. After DNA damage and replication block, all cyclin-CDK pairs that control S phase and mitosis were to different degrees inhibited by phosphorylation. Ectopic expression of nonphosphorylated CDC2 stimulated DNA replication, histone H3 phosphorylation, and cell division even after DNA damage. Similarly, a nonphosphorylation mutant of CDK2, but not CDK4, disrupted the G(2) DNA damage checkpoint. Finally, CDC25A, CDC25B, a dominant-negative CHK1, but not CDC25C or a dominant-negative WEE1, stimulated histone H3 phosphorylation after DNA damage. These data suggest differential contributions for the various regulators of Thr(14)/Tyr(15) phosphorylation in normal cell cycle and during the DNA damage checkpoint.	Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.			Poon, Randy/0000-0001-5571-6231; MA, Hoi Tang/0000-0001-5876-0107				AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; CHOW JPH, 2003, IN PRESS MOL BIOL CE; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Coverley D, 2000, J CELL SCI, V113, P1929; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Farina A, 1996, ONCOGENE, V13, P1287; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jiang W, 1998, BIOTECHNIQUES, V24, P349; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Lane ME, 2000, GENETICS, V155, P233; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Li KKW, 2002, LIVER, V22, P259, DOI 10.1046/j.0106-9543.2002.01629.x; Liu F, 1999, MOL CELL BIOL, V19, P5113; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 2002, ENCY CANC, P393; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wells NJ, 1999, J CELL SCI, V112, P3361; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yam CH, 1999, CANCER RES, V59, P5075; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	71	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40815	40828		10.1074/jbc.M306683200	http://dx.doi.org/10.1074/jbc.M306683200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912980	hybrid			2022-12-27	WOS:000185847200050
J	Fernandez, CA; Butterfield, C; Jackson, G; Moses, MA				Fernandez, CA; Butterfield, C; Jackson, G; Moses, MA			Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2) - Loop 6 is a novel angiogenesis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; GROWTH-PROMOTING ACTIVITY; N-TERMINAL DOMAIN; MATRIX-METALLOPROTEINASE; CELL-DEATH; PICHIA-PASTORIS; B-CELLS; BINDING; NEOVASCULARIZATION; APOPTOSIS	Tissue inhibitors of metalloproteinases (TIMPs) regulate tumor growth, progression, and angiogenesis in a variety of experimental cancer models and in human malignancies. Results from numerous studies have revealed important differences between TIMP family members in their ability to inhibit angiogenic processes in vitro and angiogenesis in vivo despite their universal ability to inhibit matrix metalloproteinase (MMP) activity. To address these differences, a series of structure-function studies were conducted to identify and to characterize the anti-angiogenic domains of TIMP-2, the endogenous MMP inhibitor that uniquely inhibits capillary endothelial cell (EC) proliferation as well as angiogenesis in vivo. We demonstrate that the COOH-terminal domain of TIMP-2 (T2C) inhibits the proliferation of capillary EC at molar concentrations comparable with those previously reported for intact TIMP-2, while the NH2-terminal domain (T2N), which inhibits MMP activity, has no significant anti-proliferative effect. Interestingly, although both T2N and T2C inhibited embryonic angiogenesis, only T2C resulted in the potent inhibition of angiogenesis driven by the exogenous addition of angiogenic mitogen, suggesting that MMP inhibition alone may not be sufficient to inhibit the aggressive neovascularization characteristic of aberrant angiogenesis. We further mapped the anti-proliferative activity of T2C to a 24-amino acid peptide corresponding to Loop 6 of TIMP-2 and show that Loop 6 is a potent inhibitor of both embryonic and mitogen-stimulated angiogenesis in vivo. These findings demonstrate that TIMP-2 possesses two distinct types of anti-angiogenic activities which can be uncoupled from each other, the first represented by its MMP-dependent inhibitory activity which can inhibit only embryonic neovascularization and the second represented by an MMP-independent activity which inhibits both normal angiogenesis and mitogen-driven angiogenesis in vivo. In addition, we report, for the first time, the discovery of Loop 6 as a novel and potent inhibitor of angiogenesis.	Childrens Hosp, Surg Res Lab, Vasc Biol Program, Boston, MA 02115 USA; MIT, Div Biol Engn, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Moses, MA (corresponding author), Childrens Hosp, Surg Res Lab, Vasc Biol Program, Enders 1009,320 Longwood Ave, Boston, MA 02115 USA.				NCI NIH HHS [2P01CA455] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Brand K, 2000, CANCER RES, V60, P5723; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; BURT HM, 1995, CANCER LETT, V88, P73, DOI 10.1016/0304-3835(94)03614-O; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Ikegaya K, 1997, ANAL CHEM, V69, P1986, DOI 10.1021/ac961316l; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Li GY, 1999, CANCER RES, V59, P6267; Lim MS, 1999, ANN NY ACAD SCI, V878, P522, DOI 10.1111/j.1749-6632.1999.tb07715.x; MONSKY WL, 1993, CANCER RES, V53, P3159; MOSES MA, 1992, J CELL BIOL, V119, P475, DOI 10.1083/jcb.119.2.475; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; Moses MA, 1999, P NATL ACAD SCI USA, V96, P2645, DOI 10.1073/pnas.96.6.2645; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MOSES MA, 1991, BIO-TECHNOL, V9, P630, DOI 10.1038/nbt0791-630; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Sun JR, 1997, BIOCHEM BIOPH RES CO, V238, P920, DOI 10.1006/bbrc.1997.7370; TOLLEY S, 1993, J MOL BIOL, V229, P1163, DOI 10.1006/jmbi.1993.1114; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200	53	84	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40989	40995		10.1074/jbc.M306176200	http://dx.doi.org/10.1074/jbc.M306176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900406	hybrid			2022-12-27	WOS:000185847200072
J	Mutze, S; Hebling, U; Stremmel, W; Wang, J; Arnhold, J; Pantopoulos, K; Mueller, S				Mutze, S; Hebling, U; Stremmel, W; Wang, J; Arnhold, J; Pantopoulos, K; Mueller, S			Myeloperoxidase-derived hypochlorous acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; CHEMI-LUMINESCENCE; TYROSINE NITRATION; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; NITRIC-OXIDE; COMPOUNDS I; DNA-DAMAGE; LUMINOL; MECHANISM	Hypochlorous acid (HOCl) is a highly reactive product generated by the myeloperoxidase reaction during the oxidative burst of activated neutrophils, which is implicated in many bactericidal and cytotoxic responses. Recent evidence suggests that HOCl may also play a role in the modulation of redox sensitive signaling pathways. The short half-life of HOCl and the requirement for a continuous presence of H2O2 as a substrate for its myeloperoxidase-catalyzed generation make the study of HOCl-mediated responses very difficult. We describe here an enzymatic model consisting of glucose/glucose oxidase, catalase, and myeloperoxidase (GOX/CAT/ MPO) that allows the controlled generation of both HOCl and H2O2 and thus, mimics the oxidative burst of activated neutrophils. By employing this model we show that HOCl prevents the H2O2-mediated activation of iron regulatory protein 1 (IRP1), a central post-transcriptional regulator of mammalian iron metabolism. Activated IRP1 binds to "iron-responsive elements" (IREs) within the mRNAs encoding proteins of iron metabolism and thereby controls their translation or stability. The inhibitory effect of HOCl is not a result of a direct modification of IRP1 by this oxidant. Kinetics experiments provide evidence that HOCl intervenes with the signaling cascade, which results in the activation of IRP1. We further demonstrate that HOCl antagonizes the H2O2-mediated increase in the levels of transferrin receptor, which is a downstream target of IRP1. Our findings suggest that HOCl can modulate signaling pathways in a concerted action with H2O2. The GOX/CAT/ MPO system provides a valuable tool for studying the regulatory function of HOCl.	Univ Heidelberg, Dept Internal Med 4, D-69115 Heidelberg, Germany; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Univ Leipzig, Inst Med Phys & Biophys, D-04103 Leipzig, Germany; McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada	Ruprecht Karls University Heidelberg; Lady Davis Institute; McGill University; Leipzig University; McGill University	Mueller, S (corresponding author), Univ Heidelberg, Dept Internal Med 4, Bergheimer Str 58, D-69115 Heidelberg, Germany.		Pantopoulos, Kostas/A-9668-2008	Pantopoulos, Kostas/0000-0002-2305-0057; Stremmel, Wolfgang/0000-0002-8545-1753				ALBRECHT D, 1993, J LEUKOCYTE BIOL, V54, P300, DOI 10.1002/jlb.54.4.300; ARNHOLD J, 1990, BIOMED BIOCHIM ACTA, V49, P991; BAGGIOLINI M, 1991, OXIDATIVE STRESS OXI; Baldus S, 2001, J CLIN INVEST, V108, P1759; Baldus S, 2002, FREE RADICAL BIO MED, V33, P1010, DOI 10.1016/S0891-5849(02)00993-0; BEERS RF, 1952, J BIOL CHEM, V195, P133; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; Burner U, 1999, FEBS LETT, V443, P290, DOI 10.1016/S0014-5793(98)01727-X; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; CALTAGIRONE A, 2001, J BIOL CHEM, V22, P22; Capeillere-Blandin C, 1998, BIOCHEM J, V336, P395, DOI 10.1042/bj3360395; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; Chapman ALP, 2002, J BIOL CHEM, V277, P9757, DOI 10.1074/jbc.M106134200; CORMIER MJ, 1968, J BIOL CHEM, V243, P4706; DAHLGREN C, 1983, INFECT IMMUN, V39, P736, DOI 10.1128/IAI.39.2.736-741.1983; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; ELEY DW, 1991, CAN J PHYSIOL PHARM, V69, P1677, DOI 10.1139/y91-249; Engelmann I, 2000, REDOX REP, V5, P207, DOI 10.1179/135100000101535762; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MASHINO T, 1988, BIOCHIM BIOPHYS ACTA, V956, P63, DOI 10.1016/0167-4838(88)90298-1; McKenzie SJ, 1996, J CLIN INVEST, V98, P136, DOI 10.1172/JCI118757; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Midwinter RG, 2001, ARCH BIOCHEM BIOPHYS, V394, P13, DOI 10.1006/abbi.2001.2530; MISRA HP, 1982, ARCH BIOCHEM BIOPHYS, V215, P59, DOI 10.1016/0003-9861(82)90278-8; MORRIS JC, 1966, J PHYS CHEM-US, V70, P2798; Mueller S, 1997, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P338; Mueller S, 1997, ANAL BIOCHEM, V245, P55, DOI 10.1006/abio.1996.9939; Mueller S, 2000, FREE RADICAL BIO MED, V29, P410, DOI 10.1016/S0891-5849(00)00261-6; MUELLER S, 1995, J BIOLUM CHEMILUM, V10, P229, DOI 10.1002/bio.1170100406; Mueller S, 1997, BLOOD, V90, P4973, DOI 10.1182/blood.V90.12.4973.4973_4973_4978; Mueller S, 2002, METHOD ENZYMOL, V348, P324, DOI 10.1016/S0076-6879(02)48651-X; Mueller S, 2001, J BIOL CHEM, V276, P23192, DOI 10.1074/jbc.M100654200; Nakamura M, 1998, FREE RADICAL BIO MED, V24, P537, DOI 10.1016/S0891-5849(97)00326-2; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Pullar JM, 2002, ANTIOXID REDOX SIGN, V4, P5, DOI 10.1089/152308602753625807; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; Vile GF, 1998, ARCH BIOCHEM BIOPHYS, V359, P51, DOI 10.1006/abbi.1998.0881; Vissers MCM, 1998, BIOCHEM J, V330, P131; VISSERS MCM, 1995, BIOCHEM J, V307, P57, DOI 10.1042/bj3070057; Vissers MCM, 1997, FREE RADICAL BIO MED, V23, P401, DOI 10.1016/S0891-5849(96)00619-3; VOGT W, 1994, IMMUNOBIOLOGY, V192, P1; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5	56	61	65	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40542	40549		10.1074/jbc.M307159200	http://dx.doi.org/10.1074/jbc.M307159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888561	hybrid			2022-12-27	WOS:000185847200016
J	Li, XT; O'Malley, BW				Li, XT; O'Malley, BW			Unfolding the action of progesterone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEAR HORMONE-RECEPTOR; BREAST-CANCER CELLS; PROLIFERATOR-ACTIVATED RECEPTOR; LIGAND-INDEPENDENT ACTIVATION; RING FINGER PROTEIN; MEDIATED TRANSCRIPTION; REPRODUCTIVE FUNCTIONS; SIGNALING PATHWAYS; ESTROGEN-RECEPTOR; CROSS-TALK		Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	berto@bcm.tmc.edu						Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; BAULIEU EE, 1978, NATURE, V275, P593, DOI 10.1038/275593a0; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Bramley T, 2003, REPRODUCTION, V125, P3, DOI 10.1530/reprod/125.1.3; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Conneely OM, 2002, RECENT PROG HORM RES, V57, P339, DOI 10.1210/rp.57.1.339; Conneely OM, 2000, STEROIDS, V65, P571, DOI 10.1016/S0039-128X(00)00115-X; De Vivo I, 2002, P NATL ACAD SCI USA, V99, P12263, DOI 10.1073/pnas.192172299; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; Edwards DP, 2002, J STEROID BIOCHEM, V83, P173, DOI 10.1016/S0960-0760(02)00265-0; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hewitt SC, 2000, STEROIDS, V65, P551, DOI 10.1016/S0039-128X(00)00113-6; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; Kim SW, 2002, MOL CELL BIOL, V22, P8409, DOI 10.1128/MCB.22.24.8409-8414.2002; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Liu Z, 2002, P NATL ACAD SCI USA, V99, P7940, DOI 10.1073/pnas.122225699; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Mani SK, 2000, SCIENCE, V287, P1053, DOI 10.1126/science.287.5455.1053; MANI SK, 1994, SCIENCE, V265, P1246, DOI 10.1126/science.7915049; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Medina D, 2001, ANN NY ACAD SCI, V952, P23, DOI 10.1111/j.1749-6632.2001.tb02725.x; Melvin VS, 2002, J BIOL CHEM, V277, P25115, DOI 10.1074/jbc.M110400200; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Ogle TF, 2002, STEROIDS, V67, P1, DOI 10.1016/S0039-128X(01)00137-4; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Richer JK, 1998, BREAST CANCER RES TR, V48, P231, DOI 10.1023/A:1005941117247; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sauve FD, 2001, MOL CELL BIOL, V21, P343, DOI 10.1128/MCB.21.1.343-353.2001; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Smid-Koopman E, 2003, J SOC GYNECOL INVEST, V10, P49, DOI 10.1016/S1071-5576(02)00217-4; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takamoto N, 2002, MOL ENDOCRINOL, V16, P2338, DOI 10.1210/me.2001-0154; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; WEI LL, 1994, CANCER RES, V54, P340; Xu Jianming, 2002, Rev Endocr Metab Disord, V3, P185, DOI 10.1023/A:1020016208071; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	66	153	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39261	39264		10.1074/jbc.R300024200	http://dx.doi.org/10.1074/jbc.R300024200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893816	hybrid			2022-12-27	WOS:000185713800001
J	Sugiura, N; Adams, SM; Corriveau, RA				Sugiura, N; Adams, SM; Corriveau, RA			An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC NEURODEGENERATION; SACCHAROMYCES-CEREVISIAE; ALPHA-ACETYLTRANSFERASE; DEVELOPING BRAIN; RECEPTOR GENES; ARD1 GENE; EXPRESSION; YEAST; CELLS; MICE	We previously identified mNAT1 (murine N-terminal acetyltransferase 1) as an embryonic gene that is expressed in the developing brain and subsequently down-regulated, in part, by the onset of N-methyl-D-aspartate (NMDA) receptor function. By searching the data base we discovered a second closely related gene, mNAT2. mNAT1 and mNAT2 are highly homologous to yeast NAT1, a gene known to regulate entry into the G(0) phase of the cell cycle. However, in the absence of further characterization, including evidence that mammalian homologues of NAT1 encode functional acetyltransferases, the significance of this relationship has been unclear. Here we focus on mNAT1. Biochemical analysis demonstrated that mNAT1 and its evolutionarily conserved co-subunit, mARD1, assemble to form a functional acetyltransferase. Transfection of mammalian cells with mNAT1 and mARD1 followed by immunofluorescent staining revealed that these proteins localize to the cytoplasm in both overlapping and separate compartments. In situ hybridization demonstrated that throughout brain development mNAT1 and mARD1 are highly expressed in areas of cell division and migration and are down-regulated as neurons differentiate. Finally, mNAT1 and mARD1 are expressed in proliferating mouse P19 embryonic carcinoma cells; treatment of these cells with retinoic acid initiates exit from the cell cycle, neuronal differentiation, and down-regulation of mNAT1 and mARD1 as the NMOA receptor 1 gene is induced. The results provide the first direct evidence that vertebrate homologues of NAT1 and ARD1 form an evolutionarily conserved N-terminal acetyltransferase and suggest that expression and down-regulation of this enzyme complex plays an important role in the generation and differentiation of neurons.	Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Corriveau, RA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, 1901 Perdido St, New Orleans, LA 70112 USA.							BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; Choi SC, 2001, BIOCHEM BIOPH RES CO, V285, P1338, DOI 10.1006/bbrc.2001.5300; Constantine-Paton M, 1998, CURR OPIN NEUROBIOL, V8, P139, DOI 10.1016/S0959-4388(98)80017-2; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Gould E, 1997, BEHAV NEUROSCI, V111, P49; HUSMANN M, 1989, DEV BIOL, V136, P194, DOI 10.1016/0012-1606(89)90141-3; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Komuro H, 1998, J NEUROBIOL, V37, P110, DOI 10.1002/(SICI)1097-4695(199810)37:1<110::AID-NEU9>3.3.CO;2-Q; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MacPherson PA, 1997, NEUROSCIENCE, V80, P487, DOI 10.1016/S0306-4522(97)00102-4; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NEY RL, 1964, P INT C END, V2, P1184; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Poon CS, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-09-j0003.2000; Poser S, 2001, INT J DEV NEUROSCI, V19, P387, DOI 10.1016/S0736-5748(00)00094-0; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Sugiura N, 2001, J BIOL CHEM, V276, P14257, DOI 10.1074/jbc.M100011200; SYMTH DG, 1979, NATURE, V279, P252; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1010, DOI 10.1021/bi00218a018	35	65	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40113	40120		10.1074/jbc.M301218200	http://dx.doi.org/10.1074/jbc.M301218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888564	hybrid			2022-12-27	WOS:000185713800103
J	Breslin, MB; Zhu, M; Lan, MS				Breslin, MB; Zhu, M; Lan, MS			NeuroD1/E47 regulates the e-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROENDOCRINE DIFFERENTIATION; MOTOR NEURONS; BHLH PROTEIN; GENE; CELLS; EXPRESSION; ELEGANS; IDENTIFICATION; BETA2/NEUROD; NEUROGENIN	IA-1 is a novel zinc finger transcription factor with a restricted tissue distribution in the embryonic nervous system and tumors of neuroendocrine origin. The 1.7-kilobase 5'-upstream DNA sequence of the human IA-1 gene directed transgene expression predominantly in the developing nervous system including forebrain, midbrain, hindbrain, spinal cord, retina, olfactory bulb, and cerebellum, which recapitulated the expression patterns of neuroendocrine tissues and childhood brain tumors. The IA-1 promoter deletion reporter gene constructs revealed that the sequence between -426 and -65 bp containing three putative E-boxes (similar to361 bp) upstream of the transcription start site was sufficient to confer tissue-specific transcriptional activity. Further mutation analysis revealed that the proximal E-box (E3) closest to the start site is critical to confer transcriptional activity. Electrophoretic mobility shift assay and transient transfection studies demonstrated that the NeuroD1 and E47 heterodimer are the key transcription factors that regulate the proximal E-box of the IA-1 promoter. Therefore, we concluded that the IA-1 gene is developmentally expressed in the nervous system and the NeuroD1/E47 transcription factors up-regulate IA-1 gene expression through the proximal E-box element of the IA-1 promoter.	Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Childrens Hosp,Res Inst Children, New Orleans, LA 70118 USA	Children's Hospital of New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lan, MS (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Childrens Hosp,Res Inst Children, 200 Henry Clay Ave,Res & Educ Bldg,Rm 2211, New Orleans, LA 70118 USA.	mlan@chnola-research.org	Lan, Michael/CAF-1839-2022		NIDDK NIH HHS [R01 DK061436, DK61436] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061436] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Breslin MB, 2002, NUCLEIC ACIDS RES, V30, P1038, DOI 10.1093/nar/30.4.1038; Castanon I, 2001, DEVELOPMENT, V128, P3145; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Dumonteil E, 1998, J BIOL CHEM, V273, P19945, DOI 10.1074/jbc.273.32.19945; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Heremans Y, 2002, J CELL BIOL, V159, P303, DOI 10.1083/jcb.200203074; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Ito T, 2000, DEVELOPMENT, V127, P3913; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; LAN MS, 1993, CANCER RES, V53, P4169; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Li Q, 1997, BIOCHEM BIOPH RES CO, V236, P776, DOI 10.1006/bbrc.1997.7054; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Morrow EM, 1999, DEVELOPMENT, V126, P23; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PEARSE AGE, 1978, GUT HORM, P33; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; Rostomily RC, 1997, CANCER RES, V57, P3526; Stivers C, 2000, MECH DEVELOP, V97, P205, DOI 10.1016/S0925-4773(00)00409-3; Verzi MP, 2002, DEV BIOL, V249, P174, DOI 10.1006/dbio.2002.0753; Wu J, 2001, GENE DEV, V15, P789, DOI 10.1101/gad.857401; Xie JP, 2002, GENOMICS, V80, P54, DOI 10.1006/geno.2002.6800; Zhu M, 2002, PANCREAS, V24, P139, DOI 10.1097/00006676-200203000-00004	35	78	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38991	38997		10.1074/jbc.M306795200	http://dx.doi.org/10.1074/jbc.M306795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12890672	hybrid, Green Accepted			2022-12-27	WOS:000185575100110
J	Fux, L; Nussbaum-Shochat, A; Amster-Choder, O				Fux, L; Nussbaum-Shochat, A; Amster-Choder, O			Interactions between the PTS regulation domains of the BglG transcriptional antiterminator from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; BACILLUS-SUBTILIS; CATALYZED PHOSPHORYLATION; PHOSPHOTRANSFERASE SYSTEM; NEGATIVE REGULATION; CRYSTAL-STRUCTURE; LEUCINE-ZIPPER; PROTEIN; OPERON; LICT	The E. coli BglG protein inhibits transcription termination within the bgl operon in the presence of beta-glucosides. BglG represents a family of transcriptional antiterminators that bind to RNA sequences, which partially overlap rho-independent terminators, and prevent termination by stabilizing an alternative structure of the transcript. The activity of BglG is determined by its dimeric state, which is modulated by reversible phosphorylation catalyzed by BglF, a PTS permease. Only the non-phosphorylated BglG dimer binds to RNA and allows read-through of transcription. BglG is composed of three domains: an RNA-binding domain followed by two domains, PRD1 and PRD2 (PTS regulation domains), which are similar in their sequence and folding. Based on the three-dimensional structure of dimeric LicT, a BglG homologue from Bacillus subtilis, the interactions within the dimer are PRD1-PRD1 and PRD2-PRD2. We have shown before that PRD2 mediates homodimerization very efficiently. Using genetic systems and in vitro techniques that assay and characterize protein-protein interactions, we show here that the PRD1 dimerizes very slowly, but once it does, the homodimers are stable. These results support our model that formation of BglG dimers initiates with PRD2 dimerization followed by zipping up of two BglG monomers to create the active RNA-binding domain. Moreover, our results demonstrate that PRD1 and PRD2 heterodimerize efficiently in vitro and in vivo. The affinity among the PRDs is in the following order: PRD2-PRD2>PRD1-PRD2>PRD1-PRD1. The interaction between PRD1 and PRD2 offers an explanation for the requirement of conserved residues in PRD1 for the phosphorylation of PRD2 by BglF.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Amster-Choder, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.							AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Boss A, 1999, J BACTERIOL, V181, P1755, DOI 10.1128/JB.181.6.1755-1766.1999; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; Chen Q, 1999, J BACTERIOL, V181, P462, DOI 10.1128/JB.181.2.462-468.1999; Chen Q, 1997, J BIOL CHEM, V272, P17263, DOI 10.1074/jbc.272.28.17263; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Declerck N, 1999, J MOL BIOL, V294, P389, DOI 10.1006/jmbi.1999.3256; Dmitrova M, 1998, MOL GEN GENET, V257, P205; Ducat T, 2002, J BIOMOL NMR, V23, P325, DOI 10.1023/A:1020264611438; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kruger S, 1996, J BACTERIOL, V178, P2637; Lindner C, 1999, MOL MICROBIOL, V31, P995, DOI 10.1046/j.1365-2958.1999.01262.x; Lopian L, 2003, P NATL ACAD SCI USA, V100, P7099, DOI 10.1073/pnas.1037608100; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; Manival X, 1997, EMBO J, V16, P5019, DOI 10.1093/emboj/16.16.5019; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; Miller J.H., 1972, EXPT MOL GENETICS; Nussbaum-Shochat A, 1999, P NATL ACAD SCI USA, V96, P4336, DOI 10.1073/pnas.96.8.4336; Reizer J, 1997, CURR OPIN STRUC BIOL, V7, P407, DOI 10.1016/S0959-440X(97)80059-0; Stulke J, 2002, ARCH MICROBIOL, V177, P433, DOI 10.1007/s00203-002-0407-5; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tortosa P, 2001, MOL MICROBIOL, V41, P1381, DOI 10.1046/j.1365-2958.2001.02608.x; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; van Tilbeurgh H, 2001, CURR OPIN STRUC BIOL, V11, P685, DOI 10.1016/S0959-440X(01)00267-6; van Tilbeurgh H, 2001, EMBO J, V20, P3789, DOI 10.1093/emboj/20.14.3789; vanTilbeurgh H, 1997, EMBO J, V16, P5030, DOI 10.1093/emboj/16.16.5030; Yang YS, 2002, EMBO J, V21, P1987, DOI 10.1093/emboj/21.8.1987	34	14	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46203	46209		10.1074/jbc.M306506200	http://dx.doi.org/10.1074/jbc.M306506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12923168	hybrid			2022-12-27	WOS:000186569400003
J	Ris, L; Dewachter, I; Reverse, D; Godaux, E; Van Leuven, F				Ris, L; Dewachter, I; Reverse, D; Godaux, E; Van Leuven, F			Capacitative calcium entry induces hippocampal long term potentiation in the absence of presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; TRANSGENIC MICE; LOCALIZATION; BRAIN; EXPRESSION; KINASE; STORES; GENE; APP	Presenilins, whose mutant forms are the most common cause of early onset familial Alzheimer's disease, are involved in two very distinct processes: (i) proteolytic activity as gamma-secretase acting on amyloid precursor protein to produce amyloid peptides and (ii) storage of Ca2+ in the endoplasmic reticulum (ER). In particular, absence of presenilin-1 (PS1) was claimed to potentiate capacitative calcium entry (CCE), i.e. the mechanism of replenishment of ER Ca2+ stores. However, until now, evidence in favor of the latter role has been obtained only in isolated or cultured cells and not on neurons in situ. Here, we studied the strength of the synapses between Schaffer's collaterals and CA1 neurons in hippocampal slices when they were submitted first to Ca2+-free medium containing thapsigargin and subsequently to normal artificial cerebrospinal fluid, a procedure known to trigger CCE. We demonstrate that Ca2+ influx via the CCE mechanism is sufficient to trigger robust long term potentiation of the synapses in hippocampal slices from transgenic mice with a postnatal, neuron-specific ablation of PS1, but remarkably not from wildtype mice. Our data establish for the first time in neurons confined in normal neuronal networks that PS1 acts on the refilling mechanism of ER Ca2+ stores.	Univ Mons, Neurosci Lab, B-7000 Mons, Belgium; Katholieke Univ Leuven, Dept Human Genet, Expt Genet Grp, B-3000 Louvain, Belgium	University of Mons; KU Leuven	Godaux, E (corresponding author), Univ Mons, Neurosci Lab, Pl Parc 20, B-7000 Mons, Belgium.			, Ilse Dewachter/0000-0001-7202-515X				Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DEADWYLER SA, 1987, SYNAPSE, V1, P90, DOI 10.1002/syn.890010112; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Dewachter I, 2002, J NEUROSCI, V22, P3445; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Emptage NJ, 2001, NEURON, V29, P197, DOI 10.1016/S0896-6273(01)00190-8; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Llano I, 2000, NAT NEUROSCI, V3, P1256, DOI 10.1038/81781; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; SHARP AH, 1993, J NEUROSCI, V13, P3051; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Van Leuven F, 2002, NEUROBIOL AGING, V23, pS243; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2	35	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44393	44399		10.1074/jbc.M300971200	http://dx.doi.org/10.1074/jbc.M300971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12902342	hybrid			2022-12-27	WOS:000186306700064
J	Lu, D; Shen, JQ; Vil, MD; Zhang, HF; Jimenez, X; Bohlen, P; Witte, L; Zhu, ZP				Lu, D; Shen, JQ; Vil, MD; Zhang, HF; Jimenez, X; Bohlen, P; Witte, L; Zhu, ZP			Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; MIMICKING SOMATIC HYPERMUTATION; PHAGE DISPLAY LIBRARY; GROWTH-FACTOR; SURFACE DISPLAY; TUMOR-GROWTH; MONOCLONAL-ANTIBODIES; PROTEIN AFFINITY; RIBOSOME DISPLAY; BINDING-SITE	Vascular endothelial growth factor ( VEGF) and its receptors have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. We previously identified several fully human neutralizing anti-VEGF receptor 2 (or kinase inserting domain-containing receptor (KDR)) antibodies from a large antibody phage display library. These antibodies bind specifically to KDR, block VEGF/KDR interaction, and inhibit VEGF-induced proliferation of human endothelial cells and migration of KDR+ leukemia cells. Three of these antibodies, interestingly, share an identical heavy chain variable (VH) sequence. In this report, we constructed a new library comprising the single VH paired with the variable light chain (VL) repertoire obtained from the original naive human library. Initial in vitro selection revealed that the single VH could pair with a number of different VL while retaining its specificity for KDR. However, a consensus VH/VL pair, clone 1121, was identified after three or four rounds of selection by tailoring the stringency of the panning conditions. Clone 1121 showed a > 30-fold higher binding affinity to KDR (K-d, 100 pM) because of improvement on both association and dissociation constants and blocked VEGF/KDR interaction with an IC50 of similar to 1 nM, compared with that of 3-4 nM for the parent Fab fragments. Further, clone 1121 was more potent in inhibiting VEGF-stimulated KDR phosphorylation in endothelial cells. A binding epitope mapping study on clone 1121 and one of the parent clones, 2C6, demonstrated that both antibodies interacted with the third immunoglobulin domain within the extracellular region of KDR. Several peptide phage display libraries were utilized to further examine the fine binding specificities of the two antibodies. All of the 2C6-binding peptides are cysteine-constrained, whereas clone 1121 binds to both cysteine-constrained and linear peptides. It is noteworthy that most of the 2C6-binding peptides also cross-react with clone 1121, but none of the clone 1121-specific peptides binds to 2C6, indicating that clone 1121 retained part of the original binding epitope(s) of 2C6 while gaining new binding specificity. Taken together, our observation suggests that clone 1121 may have great clinical potential in anti-angiogenesis therapy. It further underscores the efforts to identify antibodies of high affinity for enhanced biological activities.	ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA; ImClone Syst Inc, Dept Mol & Cell Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Res, New York, NY 10014 USA	Eli Lilly; Eli Lilly; Eli Lilly	Zhu, ZP (corresponding author), ImClone Syst Inc, Dept Antibody Technol, 180 Varick St, New York, NY 10014 USA.							Adams GP, 2001, CANCER RES, V61, P4750; Adams GP, 1998, CANCER RES, V58, P485; Amstutz P, 2001, CURR OPIN BIOTECH, V12, P400, DOI 10.1016/S0958-1669(00)00234-2; Cannon J B, 1990, Targeted Diagn Ther, V3, P121; Chen G, 2001, NAT BIOTECHNOL, V19, P537, DOI 10.1038/89281; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; Chowdhury PS, 1999, NAT BIOTECHNOL, V17, P568, DOI 10.1038/9872; Coia G, 2001, J IMMUNOL METHODS, V251, P187, DOI 10.1016/S0022-1759(01)00300-3; Daugherty PS, 1999, PROTEIN ENG, V12, P613, DOI 10.1093/protein/12.7.613; Daugherty PS, 1998, PROTEIN ENG, V11, P825, DOI 10.1093/protein/11.9.825; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Feldhaus MJ, 2003, NAT BIOTECHNOL, V21, P163, DOI 10.1038/nbt785; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fong TAT, 1999, CANCER RES, V59, P99; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Irving RA, 2001, J IMMUNOL METHODS, V248, P31, DOI 10.1016/S0022-1759(00)00341-0; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; JUWEID M, 1992, CANCER RES, V52, P5144; Kabat EA, 1991, SEQUENCES PROTEINS I; Kanai T, 1998, INT J CANCER, V77, P933, DOI 10.1002/(SICI)1097-0215(19980911)77:6<933::AID-IJC23>3.0.CO;2-0; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Little M, 2000, IMMUNOL TODAY, V21, P364, DOI 10.1016/S0167-5699(00)01668-6; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321; Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634; Margerum DW, 2002, J ENVIRON MONITOR, V4, P20, DOI 10.1039/b105541k; Margolin K, 2001, J CLIN ONCOL, V19, P851, DOI 10.1200/JCO.2001.19.3.851; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Olson TA, 1997, INT J CANCER, V73, P865; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Prewett M, 1999, CANCER RES, V59, P5209; RIECHMANN L, 1993, BIOCHEMISTRY-US, V32, P8848, DOI 10.1021/bi00085a016; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SCHLOM J, 1992, CANCER RES, V52, P1067; VanAntwerp JJ, 2000, BIOTECHNOL PROGR, V16, P31, DOI 10.1021/bp990133s; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Wood JM, 2000, CANCER RES, V60, P2178; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831; Zhu ZP, 2002, CURR CANCER DRUG TAR, V2, P135, DOI 10.2174/1568009023333881; Zhu ZP, 1999, CANCER LETT, V136, P203, DOI 10.1016/S0304-3835(98)00324-3; Zhu ZP, 1998, CANCER RES, V58, P3209; ZHU ZP, 2001, RRD CANCER 2, V3, P369, DOI DOI 10.1016/j.compbiolchem.2004.11.003; Zogakis TG, 2001, EXPERT OPIN BIOL TH, V1, P253, DOI 10.1517/14712598.1.2.253	55	162	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43496	43507		10.1074/jbc.M307742200	http://dx.doi.org/10.1074/jbc.M307742200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917408	hybrid			2022-12-27	WOS:000186157000095
J	Wang, DY; Visser, NV; Veenhuis, M; van der Klei, IJ				Wang, DY; Visser, NV; Veenhuis, M; van der Klei, IJ			Physical interactions of the peroxisomal targeting signal 1 receptor Pex5p, studied by fluorescence correlation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANSENULA-POLYMORPHA; IMPORT MACHINERY; MATRIX PROTEIN; BIOGENESIS; COMPLEX; PEX8P; CELLS; GENE	We have studied Hansenula polymorpha Pex5p and Pex8p using fluorescence correlation spectroscopy (FCS). Pex5p is the Peroxisomal Targeting Signal 1 (PTS1) receptor and Pex8p is an intraperoxisomal protein. Both proteins are essential for PTS1 protein import and have been shown to physically interact. We used FCS to analyze the molecular role of this interaction. FCS is a very sensitive technique that allows analysis of dynamic processes of fluorescently marked molecules at equilibrium in a very tiny volume. We used this technique to determine the oligomeric state of both peroxins and to analyze binding of Pex5p to PTS1 peptides and Pex8p. HpPex5p and HpPex8p were overproduced in Escherichia coli, purified by affinity chromatography, and, when required, labeled with the fluorescent dye Alexa Fluor 488. FCS measurements revealed that the oligomeric state of HpPex5p varied, ranging from monomers at slightly acidic pH to tetramers at neutral pH. HpPex8p formed monomers at all pH values tested. Using fluorescein-labeled PTS1 peptide and unlabeled HpPex5p, we established that PTS1 peptide only bound to tetrameric HpPex5p. Upon addition of HpPex8p, a heterodimeric complex was formed consisting of one HpPex8p and one HpPex5p molecule. This process was paralleled by dissociation of PTS1 peptide from HpPex5p, indicating that Pex8p may play an important role in cargo release from the PTS1 receptor. Our data show that FCS is a powerful technique to explore dynamic physical interactions that occur between peroxins during peroxisomal matrix protein import.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	University of Groningen	van der Klei, IJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.		van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Gatto GJ, 2003, BIOCHEMISTRY-US, V42, P1660, DOI 10.1021/bi027034z; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hink MA, 2002, PLANT MOL BIOL, V50, P871, DOI 10.1023/A:1021282619035; Hink MA, 2003, METHOD ENZYMOL, V361, P93; Hink MA, 2000, J BIOL CHEM, V275, P17556, DOI 10.1074/jbc.M001348200; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; Medina MA, 2002, BIOESSAYS, V24, P758, DOI 10.1002/bies.10118; NICOLAY K, 1987, ARCH MICROBIOL, V147, P37, DOI 10.1007/BF00492902; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; vanderKlei IJ, 1996, ANN NY ACAD SCI, V804, P47; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; WIDENGREN J, 1995, J PHYS CHEM-US, V99, P13368, DOI 10.1021/j100036a009	22	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43340	43345		10.1074/jbc.M307789200	http://dx.doi.org/10.1074/jbc.M307789200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930827	Green Published, hybrid			2022-12-27	WOS:000186157000077
J	de Meis, L				de Meis, L			Brown adipose tissue Ca2+-ATPase - Uncoupled ATP hydrolysis and thermogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; BETA-ADRENERGIC POTENTIATION; HEAT-PRODUCTION; CA2+ RELEASE; TRANSPORT; ACCUMULATION; MECHANISM; ISOFORMS; FLUXES	In this report a sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) was identified in rats brown adipose tissue. Electrophoretic analysis of brown fat microssomal protein yields a 110-kDa band that is reactive to SERCA 1 antibody but is not reactive to SERCA 2 antibodies. Nevertheless, the kinetics properties of the brown fat SERCA differ from the skeletal muscle SERCA 1 inasmuch they manifest a different Ca2+ affinity and a much higher degree of ATPase/Ca2+ uncoupling. A SERCA enzyme is not found in white fat. Fatty acids promoted Ca2+ leakage from brown fat vesicles. The heat released during ATP hydrolysis was - 24.7 kcal/mol when a Ca2+ gradient was formed across the vesicles membrane and - 14.4 kcal/mol in the absence of a gradient. The data reported suggest that in addition to storing Ca2+ inside the endoplasmic reticulum, the Ca2+-ATPase may represent a source of heat production contributing to the thermogenic function of brown adipose tissue.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@bioqmed.ufjr.br						Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Barata H, 2002, J BIOL CHEM, V277, P16868, DOI 10.1074/jbc.M200648200; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Breitwieser GE, 2002, AM J PHYSIOL-CELL PH, V282, pC980, DOI 10.1152/ajpcell.00023.2002; CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049; CHIESI M, 1979, J BIOL CHEM, V254, P370; de Meis L, 2002, J MEMBRANE BIOL, V188, P1, DOI 10.1007/s00232-001-0171-5; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leaver EV, 2002, AM J PHYSIOL-CELL PH, V282, pC1016, DOI 10.1152/ajpcell.00204.2001; Logan-Smith MJ, 2001, J BIOL CHEM, V276, P46905, DOI 10.1074/jbc.M108778200; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MAKINOSE M, 1965, BIOCHEM Z, V343, P360; MCWHIRTER JM, 1987, BIOCHEM J, V245, P731, DOI 10.1042/bj2450731; MELTZER S, 1984, J BIOL CHEM, V259, P4244; MICHELANGELI F, 1991, BIOCHEMISTRY-US, V30, P342, DOI 10.1021/bi00216a006; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Nicholls DG, 1999, J BIOENERG BIOMEMBR, V31, P399, DOI 10.1023/A:1005436121005; Reis M, 2002, MOL MEMBR BIOL, V19, P301, DOI 10.1080/09687680210166217; Reis M, 2001, J BIOL CHEM, V276, P42793, DOI 10.1074/jbc.M107625200; Ribeiro MO, 2001, J CLIN INVEST, V108, P97, DOI 10.1172/JCI12584; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; Wolosker H, 1997, BIOCHEM J, V321, P545, DOI 10.1042/bj3210545; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	41	34	34	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41856	41861		10.1074/jbc.M308280200	http://dx.doi.org/10.1074/jbc.M308280200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912988	hybrid			2022-12-27	WOS:000185989500038
J	Venkatraman, G; Harada, K; Gomes, AV; Kerrick, WGL; Potter, JD				Venkatraman, G; Harada, K; Gomes, AV; Kerrick, WGL; Potter, JD			Different functional properties of troponin T mutants that cause dilated cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CARDIAC-MUSCLE CONTRACTION; THIN FILAMENT REGULATION; ALTERED REGULATION; TERNARY COMPLEX; HEART-FAILURE; MUTATIONS; IDENTIFICATION; PROGRESSION; EXPRESSION	The effects of Troponin T (TnT) mutants R141W and DeltaK210, the only two currently known mutations in TnT that cause dilated cardiomyopathy(DCM) independent of familial hypertrophic cardiomyopathy (FHC), and TnT-K273E, a mutation that leads to a progression from FHC to DCM, were investigated. Studies on the Ca2+ sensitivity of force development in porcine cardiac fibers demonstrated that TnT-DeltaK210 caused a significant decrease in Ca2+ sensitivity, whereas the TnT-R141W did not result in any change in Ca2+ sensitivity when compared with human cardiac wild-type TnT (HC-WTnT). TnT-DeltaK210 also caused a decrease in maximal force when compared with HCWTnT and TnT-R141W. In addition, the TnT-DeltaK210 mutant decreased maximal ATPase activity in the presence of Ca2+. However, the TnT-K273E mutation caused a significant increase in Ca2+ sensitivity but behaved similarly to HCWTnT in actomyosin activation assays. Inhibition of ATPase activity in reconstituted actin-activated myosin ATPase assays was similar for all three TnT mutants and HCWTnT. Additionally, circular dichroism studies suggest that the secondary structure of all three TnT mutants was similar to that of the HCWTnT. These results suggest that a rightward shift in Ca2+ sensitivity is not the only determinant for the phenotype of DCM.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA	University of Miami; University of Miami	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.		Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NHLBI NIH HHS [HL 42325, HL 67415] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL067415, R01HL042325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chandra M, 2001, AM J PHYSIOL-HEART C, V280, pH705, DOI 10.1152/ajpheart.2001.280.2.H705; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Cohn JN, 1997, CIRCULATION, V95, P766; Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002; Fiske CH, 1925, J BIOL CHEM, V66, P375; Freeman K, 2001, AM J PHYSIOL-HEART C, V280, pH151, DOI 10.1152/ajpheart.2001.280.1.H151; Fujino N, 2001, CLIN CARDIOL, V24, P397, DOI 10.1002/clc.4960240510; Fujino N, 2002, AM J CARDIOL, V89, P29, DOI 10.1016/S0002-9149(01)02158-0; Gergely J, 1998, ADV EXP MED BIOL, V453, P169; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hinkle A, 2003, J BIOL CHEM, V278, P506, DOI 10.1074/jbc.M209194200; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; Li DX, 2001, CIRCULATION, V104, P2188, DOI 10.1161/hc4301.098285; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; Moore DD, 1995, GLOB MOB SURV; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; MURAKAMI U, 1976, J BIOCHEM, V80, P611, DOI 10.1093/oxfordjournals.jbchem.a131316; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; PAN BS, 1992, J BIOL CHEM, V267, P23052; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; Redwood C, 2000, CIRC RES, V86, P1146; Robinson P, 2002, J BIOL CHEM, V277, P40710, DOI 10.1074/jbc.M203446200; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; STRZELECKAGOLASZEWSKA H, 1975, EUR J BIOCHEM, V55, P221, DOI 10.1111/j.1432-1033.1975.tb02154.x; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takahashi-Yanaga F, 2001, J BIOCHEM-TOKYO, V130, P127, DOI 10.1093/oxfordjournals.jbchem.a002950; Takeda S, 2002, BIOPHYS J, V82, p170A; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	56	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41670	41676		10.1074/jbc.M302148200	http://dx.doi.org/10.1074/jbc.M302148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923187	hybrid			2022-12-27	WOS:000185989500016
J	Zhang, R; Cho, HY; Kim, HS; Ma, YG; Osaki, T; Kawabata, S; Soderhall, K; Lee, BL				Zhang, R; Cho, HY; Kim, HS; Ma, YG; Osaki, T; Kawabata, S; Soderhall, K; Lee, BL			Characterization and properties of a 1,3-beta-D-glucan pattern recognition protein of Tenebrio molitor larvae that is specifically degraded by serine protease during prophenoloxidase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; HOLOTRICHIA-DIOMPHALIA LARVAE; FRESH-WATER CRAYFISH; BOMBYX-MORI; MOLECULAR-CLONING; BINDING PROTEIN; INNATE IMMUNITY; MANDUCA-SEXTA; CDNA CLONING; PACIFASTACUS-LENIUSCULUS	Although many different pattern recognition receptors recognizing peptidoglycan and 1,3-beta-D-glucan have been identified in vertebrates and insects, the molecular mechanism of these molecules in the pattern recognition and subsequent signaling is largely unknown. To gain insights into the action mechanism of 1,3-beta-D-glucan pattern recognition protein in the insect prophenoloxidase ( proPO) activation system, we purified a 53-kDa 1,3-beta-D-glucan recognition protein (Tm-GRP) to homogeneity from the hemolymph of the mealworm, Tenebrio molitor, by using a 1,3-beta-D-glucan affinity column. The purified protein specifically bound to 1,3-beta-D-glucan but not to peptidoglycan. Subsequent molecular cloning revealed that Tm-GRP contains a region with close sequence similarity to bacterial glucanases. Strikingly, two catalytically important residues in glucanases are replaced with other nonhomologous amino acids in Tm-GRP. The finding suggests that Tm-GRP has evolved from an ancestral gene of glucanases but retained only the ability to recognize 1,3-beta-D-glucan. A Western blot analysis of the protein level of endogenous Tm-GRP showed that the protein was specifically degraded following the activation of proPO with 1,3-beta-D-glucan and calcium ion. The degradation was significantly retarded by the addition of serine protease inhibitors but not by cysteine or acidic protease inhibitor. These results suggest that 1,3-beta-D-glucan pattern recognition protein is specifically degraded by serine protease(s) during proPO activation, and we propose that this degradation is an important regulatory mechanism of the activation of the proPO system.	Pusan Natl Univ, Coll Pharm, Kumjeong Ku 609735, Busan, South Korea; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden	Pusan National University; Kyushu University; Uppsala University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Kumjeong Ku 609735, Busan, South Korea.		Jie, Ying/AAJ-4697-2021	Jie, Ying/0000-0003-4003-2579; Osaki, Tsukasa/0000-0002-9487-3253				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ashida Masaaki, 1998, P135; Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; Cho MY, 1999, EUR J BIOCHEM, V262, P737, DOI 10.1046/j.1432-1327.1999.00416.x; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; DIMOPOULOS G, P NATL ACAD SCI US, V94, P11506; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; RAO P, 1989, ANAL BIOCHEM, V181, P18, DOI 10.1016/0003-2697(89)90387-4; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Sugumaran M, 2001, ADV EXP MED BIOL, V484, P289; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; Takeda K, 2003, CELL MICROBIOL, V5, P143, DOI 10.1046/j.1462-5822.2003.00264.x; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Young SH, 2000, J BIOL CHEM, V275, P11874, DOI 10.1074/jbc.275.16.11874	50	76	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42072	42079		10.1074/jbc.M307475200	http://dx.doi.org/10.1074/jbc.M307475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923175	hybrid			2022-12-27	WOS:000185989500064
J	Delmas, D; Rebe, C; Lacour, S; Filomenko, R; Athias, A; Gambert, P; Cherkaoui-Malki, M; Jannin, B; Dubrez-Daloz, L; Latruffe, N; Solary, E				Delmas, D; Rebe, C; Lacour, S; Filomenko, R; Athias, A; Gambert, P; Cherkaoui-Malki, M; Jannin, B; Dubrez-Daloz, L; Latruffe, N; Solary, E			Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CHEMOPREVENTIVE AGENT; INDEPENDENT APOPTOSIS; INDUCED ACTIVATION; CARCINOMA CELLS; MEMBRANE RAFTS; KAPPA-B; BAX; PROTEIN; FADD	Resveratrol, a polyphenol found in grape skin and various other food products, may function as a cancer chemopreventive agent for colon and other malignant tumors and possesses a chemotherapeutic potential through its ability to trigger apoptosis in tumor cells. The present study analyses the molecular mechanisms of resveratrol-induced apoptosis in colon cancer cells, with special attention to the role of the death receptor Fas in this pathway. We show that, in the 10 - 100 muM range of concentrations, resveratrol activates various caspases and triggers apoptosis in SW480 human colon cancer cells. Caspase activation is associated with accumulation of the pro-apoptotic proteins Bax and Bak that undergo conformational changes and relocalization to the mitochondria. Resveratrol does not modulate the expression of Fas and Fas-ligand ( FasL) at the surface of cancer cells, and inhibition of the Fas/FasL interaction does not influence the apoptotic response to the molecule. Resveratrol induces the clustering of Fas and its redistribution in cholesterol and sphingolipid-rich fractions of SW480 cells, together with FADD and procaspase-8. This redistribution is associated with the formation of a death-inducing signaling complex ( DISC). Transient transfection of either a dominant-negative mutant of FADD, E8, or MC159 viral proteins that interfere with the DISC function, decreases the apoptotic response of SW480 cells to resveratrol and partially prevents resveratrol-induced Bax and Bak conformational changes. Altogether, these results indicate that the ability of resveratrol to induce the redistribution of Fas receptor in membrane rafts may contribute to the molecule's ability to trigger apoptosis in colon cancer cells.	INSERM, U517, Fac Med, F-21000 Dijon, France; CHU Bocage, INSERM, U498, F-21034 Dijon, France; CNRS, Fac Life Sci, Mol & Cellular Biol Lab, F-21000 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne	Solary, E (corresponding author), INSERM, U517, Fac Med, IFR100,7 Blvd Jeanne Arc, F-21000 Dijon, France.	esolary@u-bourgogne.fr	Cherkaoui-Malki, Mustapha/B-2412-2012; Delmas, Dominique/AAD-9749-2019; Dubrez, Laurence/I-4971-2016; REBE, Cédric/AAD-4316-2019; Laurence, Dubrez/P-9472-2019	Cherkaoui-Malki, Mustapha/0000-0001-5010-739X; Delmas, Dominique/0000-0003-3576-0248; Dubrez, Laurence/0000-0002-7030-2181; REBE, Cédric/0000-0001-8831-145X; Laurence, Dubrez/0000-0002-7030-2181; Solary, Eric/0000-0002-8629-1341; Delmas, Dominique/0000-0002-8911-8499				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Banerjee S, 2002, CANCER RES, V62, P4945; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Ciolino HP, 1999, MOL PHARMACOL, V56, P760; Clement MV, 1998, BLOOD, V92, P996; Delmas D, 2002, INT J MOL MED, V10, P193; Dorrie J, 2001, CANCER RES, V61, P4731; Dubrez L, 2001, J BIOL CHEM, V276, P38980, DOI 10.1074/jbc.M102683200; Ducoroy P, 2003, BLOOD, V101, P194, DOI 10.1182/blood-2002-02-0603; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fulda S, 1997, CANCER RES, V57, P3823; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gao XH, 2002, J NUTR, V132, P2076, DOI 10.1093/jn/132.7.2076; GOLDBERG DM, 1995, CLIN CHIM ACTA, V237, P155, DOI 10.1016/0009-8981(95)06069-P; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hsieh TC, 1999, INT J ONCOL, V15, P245; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jeandet P., 1993, J WINE RES, V4, P79, DOI [10.1080/09571269308717954, DOI 10.1080/09571269308717954]; LAMUELARAVENTOS RM, 1993, J AGR FOOD CHEM, V41, P521, DOI 10.1021/jf00028a001; Liang YC, 2003, BIOCHEM PHARMACOL, V65, P1053, DOI 10.1016/S0006-2952(03)00011-X; Lu JB, 2001, CARCINOGENESIS, V22, P321, DOI 10.1093/carcin/22.2.321; Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Martinez J, 2000, BIOCHEM PHARMACOL, V59, P865, DOI 10.1016/S0006-2952(99)00380-9; Memon SA, 1998, J IMMUNOL, V160, P2046; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Mutoh M, 2000, CARCINOGENESIS, V21, P959, DOI 10.1093/carcin/21.5.959; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; Renaud SC, 1998, EPIDEMIOLOGY, V9, P184, DOI 10.1097/00001648-199803000-00014; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Schneider Y, 2001, NUTR CANCER, V39, P102, DOI 10.1207/S15327914nc391_14; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; She QB, 2001, CANCER RES, V61, P1604; Solary E, 2003, LEUKEMIA LYMPHOMA, V44, P563, DOI 10.1080/1042819021000038001; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Tsan MF, 2000, BRIT J HAEMATOL, V109, P405, DOI 10.1046/j.1365-2141.2000.01980.x; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	54	243	260	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41482	41490		10.1074/jbc.M304896200	http://dx.doi.org/10.1074/jbc.M304896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902349	hybrid			2022-12-27	WOS:000185847200128
J	Li, K; Miller, C; Hegde, S; Wojchowski, D				Li, K; Miller, C; Hegde, S; Wojchowski, D			Roles for an Epo receptor Tyr-343 Stat5 pathway in proliferative co-signaling with Kit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL-FACTOR; PROTOONCOGENE C-KIT; ERYTHROPOIETIN RECEPTOR; TYROSINE KINASE; ACTIVATION; JAK2; IDENTIFICATION; PROTEIN; GENE; DOMAIN	Erythroid progenitor cell expansion depends upon cosignaling by Epo receptor (EpoR) and Kit, but underlying mechanisms are incompletely understood. To quantitatively analyze EpoR contributions to co-signaling, phosphotyrosine (Tyr(P)) mutants were expressed as human epidermal growth factor ( hEGF) receptor-mEpoR EE chimeras at matched and physiological levels in FDCW2 hematopoietic progenitor cells and were assayed for proliferative activities in the absence or presence of endogenous Kit stimulation. Two Tyr( P)-null ( but Jak2-coupled) EpoR forms each retained less than or equal to 25% of the wild-type activity, whereas the add-back of single Tyr( P) sites in the EpoR forms EE-T-Y343 (Stat5 binding site), EE-Y479 (p85/phosphatidylinositol 3-kinase binding site), or EE-Y464 (Src kinase binding site) significantly enhanced activities ( to 100, 95, and 50% of EE-WT ( wild type) levels, respectively). EE-Y343&Y401 and EE-F343& F401 double add-back and deletion constructs were also prepared and were shown to possess 90 and less than or equal to 50% of wild-type activity. In contrast, efficient Kit cosignaling activity was retained only by EE-T-Y343 and EE-Y343&Y401 EpoR forms. EE-T-Y343 together with EE-T-Y343F and EE-WT EpoR forms were also analyzed in embryonic stem cell-derived erythroid G1E-2 cells with highly comparable outcomes, including the ability of EE-T-Y343 ( but not EE-T-Y-343F) to synergize with Kit. Despite specific connection of EE-T-Y343 to Stat5, the contributions of Kit to EpoR-dependent proliferation did not involve Kit effects on Stat5 activation ( but was limited by the mutation of Kit Tyr( P)-567 and Tyr( P)-569 Src kinase recruitment sites). Instead, cosignaling appears to depend upon the downstream integration of Kit signals with the targets of an EpoR/Jak2/ Y343/Stat 5 response axis.	Penn State Univ, Program Immunol, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, D (corresponding author), Penn State Univ, Program Immunol, 115 Henning Bldg, University Pk, PA 16802 USA.	dmw1@psu.edu			NHLBI NIH HHS [R01 HL44491] Funding Source: Medline; NIDDK NIH HHS [R01 DK40242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Bittorf T, 2001, CELL SIGNAL, V13, P673, DOI 10.1016/S0898-6568(01)00189-9; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chin H, 1998, BLOOD, V91, P3734; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Divoky V, 2001, P NATL ACAD SCI USA, V98, P986, DOI 10.1073/pnas.98.3.986; Escribano L, 1998, LEUKEMIA LYMPHOMA, V30, P459, DOI 10.3109/10428199809057558; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Hao Z, 2002, BLOOD, V100, p718A; Hirota S, 2002, GASTROENTEROLOGY, V122, P1493, DOI 10.1053/gast.2002.33024; Hortner M, 2002, EUR J BIOCHEM, V269, P2516, DOI 10.1046/j.1432-1033.2002.02916.x; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; Jegalian AG, 2002, BLOOD, V99, P2603, DOI 10.1182/blood.V99.7.2603; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; LI K, 2003, IN PRESS BLOOD; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Miller CP, 2002, BLOOD, V99, P898, DOI 10.1182/blood.V99.3.898; MIURA O, 1994, BLOOD, V84, P1501; PACIFICI RE, 1994, J BIOL CHEM, V269, P1571; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pharr PN, 2000, INT J HEMATOL, V72, P178; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Tan BL, 2003, J BIOL CHEM, V278, P11686, DOI 10.1074/jbc.M207068200; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Tilbrook PA, 1999, GROWTH FACTORS, V17, P25, DOI 10.3109/08977199909001060; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V203, P1912, DOI 10.1006/bbrc.1994.2411; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WOGNUM AW, 1990, BLOOD, V76, P697; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156; Zhao SM, 2002, EMBO J, V21, P2159, DOI 10.1093/emboj/21.9.2159; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500	56	18	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40702	40709		10.1074/jbc.M307182200	http://dx.doi.org/10.1074/jbc.M307182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909618	hybrid			2022-12-27	WOS:000185847200035
J	Witting, SR; Maiorano, JN; Davidson, WS				Witting, SR; Maiorano, JN; Davidson, WS			Ceramide enhances cholesterol efflux to apolipoprotein A-I by increasing the cell surface presence of ATP-binding cassette transporter A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; TANGIER-DISEASE; PLASMA-MEMBRANE; LIPID EFFLUX; INTRACELLULAR CHOLESTEROL; DOWN-REGULATION; APOA-I; ABCA1; STEROL; SPHINGOMYELIN	It is widely accepted that functional ATP-binding cassette transporter A1 (ABCA1) is critical for the formation of nascent high density lipoprotein particles. However, the cholesterol pool(s) and the cellular signaling processes utilized by the ABCA1-mediated pathway remain unclear. Sphingomyelin maintains a preferential interaction with cholesterol in membranes, and its catabolites, especially ceramide, are potent signaling molecules that could play a role in ABCA1 regulation or function. To study the potential role of ceramide in this process, we treated a variety of cell lines with 20 muM C-2-ceramide and examined apolipoprotein-mediated cholesterol efflux to lipid-free apoA-I. We found that cell lines expressing ABCA1 displayed 2-3-fold increases in cholesterol efflux to apoA-I. Cell lines not expressing ABCA1 were unaffected by ceramide. We further characterized the cholesterol efflux effect in Chinese hamster ovary cells. Ceramide treatment did not cause significant cytotoxicity or apoptosis and did not affect cholesterol efflux to non-apolipoprotein acceptors. Raising endogenous ceramide levels increased cholesterol efflux to apoA-I. Using a cell surface biotinylation method, we found that the total cellular ABCA1 and that at the plasma membrane were increased with ceramide treatment. Also ceramide enhanced the binding of fluorescently labeled apoA-I to Chinese hamster ovary cells. These data suggest that ceramide may increase the plasma membrane content of ABCA1, leading to increased apoA-I binding and cholesterol efflux.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067093, R01HL062542] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62542, HL67093] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arakawa R, 2000, J LIPID RES, V41, P1952; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; CLEJAN S, 1984, J BIOL CHEM, V259, P441; Costet P, 2000, J BIOL CHEM, V275, P28240; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FUGLER L, 1985, J BIOL CHEM, V260, P4098; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Haidar B, 2001, J LIPID RES, V42, P249; Hess KL, 2001, J LEUKOCYTE BIOL, V70, P405; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; Karasawa K, 1999, J BIOL CHEM, V274, P8655, DOI 10.1074/jbc.274.13.8655; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LADENSON RC, 1993, J BIOL CHEM, V268, P7650; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; Lin GR, 2000, ATHEROSCLEROSIS, V149, P359, DOI 10.1016/S0021-9150(99)00503-1; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PATTON S, 1970, J THEOR BIOL, V29, P489, DOI 10.1016/0022-5193(70)90111-6; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PORN MI, 1993, J LIPID RES, V34, P1385; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCHAEFER EJ, 1994, J LIPID RES, V35, P871; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Sviridov D, 2001, BIOCHEM J, V358, P79, DOI 10.1042/0264-6021:3580079; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Zha XH, 2003, J BIOL CHEM, V278, P10002, DOI 10.1074/jbc.C300024200	70	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40121	40127		10.1074/jbc.M305193200	http://dx.doi.org/10.1074/jbc.M305193200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890677	hybrid			2022-12-27	WOS:000185713800104
J	Fiorani, P; Bruselles, A; Falconi, M; Chillemi, G; Desideri, A; Benedetti, P				Fiorani, P; Bruselles, A; Falconi, M; Chillemi, G; Desideri, A; Benedetti, P			Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICLE MESH EWALD; MOLECULAR-DYNAMICS; DNA TOPOISOMERASES; SENSITIVITY; EXPRESSION; MECHANISM; CATALYSIS; CELLS; COVALENT; ENZYMES	DNA topoisomerase I relaxes supercoiled DNA by the formation of a covalent intermediate in which the active-site tyrosine is transiently bound to the cleaved DNA strand. The antineoplastic agent camptothecin specifically targets DNA topoisomerase I, and several mutations have been isolated that render the enzyme camptothecin-resistant. The catalytic and structural dynamical properties of a human DNA topoisomerase I mutant in which Ala-653 in the linker domain was mutated into Pro have been investigated. The mutant is resistant to camptothecin and in the absence of the drug displays a cleavage-religation equilibrium strongly shifted toward religation. The shift is mainly because of an increase in the religation rate relative to the wild type enzyme, indicating that the unperturbed linker is involved in slowing religation. Molecular dynamics simulation indicates that the Ala to Pro mutation increases the linker flexibility allowing it to sample a wider conformational space. The increase in religation rate of the mutant, explained by means of the enhanced linker flexibility, provides an explanation for the mutant camptothecin resistance.	Univ Roma Tor Vergata, Natl Inst Phys Matter, I-00133 Rome, Italy; Univ Padua, Dept Biol, I-35131 Padua, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Consorzio Interuniv Applicaz Supercalculo Univ &, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; University of Padua; University of Rome Tor Vergata	Desideri, A (corresponding author), Univ Roma Tor Vergata, Natl Inst Phys Matter, Via Ric Sci, I-00133 Rome, Italy.	desideri@uniroma2.it	Chillemi, Giovanni/E-5201-2010; Bruselles, Alessandro/M-7908-2017; Bruselles, Alessandro/M-6012-2019; Chillemi, Giovanni/O-2825-2019; Bruselles, Alessandro/G-3251-2011	Chillemi, Giovanni/0000-0003-3901-6926; Bruselles, Alessandro/0000-0002-1556-4998; Bruselles, Alessandro/0000-0002-1556-4998; Chillemi, Giovanni/0000-0003-3901-6926; FALCONI, MATTIA/0000-0002-3990-4758; desideri, alessandro/0000-0003-1541-4217				BENEDETTI P, 1993, CANCER RES, V53, P4343; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Chang JY, 2002, CANCER RES, V62, P3716; CHEATHAM TE, 1995, J AM CHEM SOC, V117, P4193, DOI 10.1021/ja00119a045; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chillemi G, 2003, NUCLEIC ACIDS RES, V31, P1525, DOI 10.1093/nar/gkg242; Chillemi G, 2001, BIOPHYS J, V81, P490, DOI 10.1016/S0006-3495(01)75716-5; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2000, METH MOL B, V95, P291; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Ireton GC, 2000, J BIOL CHEM, V275, P25820, DOI 10.1074/jbc.M002144200; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200	35	72	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43268	43275		10.1074/jbc.M303899200	http://dx.doi.org/10.1074/jbc.M303899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904303	hybrid			2022-12-27	WOS:000186157000069
J	Gozdz, A; Habas, A; Jaworski, J; Zielinska, M; Albrecht, J; Chlystun, M; Jalili, A; Hetman, M				Gozdz, A; Habas, A; Jaworski, J; Zielinska, M; Albrecht, J; Chlystun, M; Jalili, A; Hetman, M			Role of N-methyl-D-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; NEURONAL APOPTOSIS; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; GANGLION NEURONS; TOPOISOMERASE-I; NMDA RECEPTORS; NERVOUS-SYSTEM; AMINO-ACIDS; CELL-CYCLE	Neurons are exposed to damaging stimuli that can trigger cell death and subsequently cause serious neurological disorders. Therefore, it is important to define defense mechanisms that can be activated in response to damage to reduce neuronal loss. Here we report that cisplatin (CPDD), a neurotoxic anticancer drug that damages DNA, triggered apoptosis and activated the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in cultured rat cortical neurons. Inhibition of ERK1/2 activation using either pharmacological inhibitors or a dominant-negative mutant of the ERK1/2 activator, mitogen-activated protein kinase kinase 1, increased the toxicity of CPDD. Interestingly, N-methyl-D-aspartate (NMDA) receptor (NMDAR) antagonists reduced the ERK1/2 activation and exacerbated apoptosis in CPDD-treated neurons. Pre-treatment with CPDD increased ERK1/2 activation triggered by exogenous NMDA, suggesting that CPDD augmented NMDAR responsiveness. CPDD-enhanced response of NMDAR and CPDD-mediated ERK1/2 activation were both decreased by inhibition of poly(ADP-ribose) polymerase (PARP). Interestingly, PARP activation did not produce ATP depletion, suggesting involvement of a non-energetic mechanism in NMDAR regulation by PARP. Finally, CPDD toxicity was reduced by brain-derived neurotrophic factor, and this protection required ERK1/2. In summary, our data identify a novel compensatory circuit in central nervous system neurons that couples the DNA injury, through PARP and NMDAR, to the defensive ERK1/2 activation.	Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Grad Program Pharmacol & Toxicol, Louisville, KY 40292 USA; Grad Program Mol Med, PL-02109 Warsaw, Poland; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; Polish Acad Sci, Med Res Ctr, PL-02106 Warsaw, Poland	University of Louisville; University of Louisville; University of Louisville; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Polish Academy of Sciences	Hetman, M (corresponding author), Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR626, Louisville, KY 40292 USA.		Gozdz, Agata/AAD-2974-2022; Albrecht, Jan/AAQ-1158-2021; Zielińska, Magdalena/S-6624-2019	Gozdz, Agata/0000-0001-8421-0598; Albrecht, Jan/0000-0001-6063-6228; Zielińska, Magdalena/0000-0001-7388-3092; Jaworski, Jacek/0000-0001-8760-7865	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015576] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR15576] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Anderson CNG, 1999, J NEUROSCI, V19, P664; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Bowman KJ, 2001, BRIT J CANCER, V84, P106, DOI 10.1054/bjoc.2000.1555; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Gill JS, 1998, J CLIN INVEST, V101, P2842, DOI 10.1172/JCI1130; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Hilgier W, 1999, J NEUROSCI RES, V56, P76, DOI 10.1002/(SICI)1097-4547(19990401)56:1<76::AID-JNR10>3.0.CO;2-Y; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Keime-Guibert F, 1998, J NEUROL, V245, P695, DOI 10.1007/s004150050271; Komatsu N, 2000, J BIOCHEM-TOKYO, V128, P463, DOI 10.1093/oxfordjournals.jbchem.a022775; Lafon-Cazal M, 2002, EUR J NEUROSCI, V16, P575, DOI 10.1046/j.1460-9568.2002.02124.x; Le DA, 2001, DRUG AGING, V18, P717, DOI 10.2165/00002512-200118100-00001; Liu W, 1998, NEUROREPORT, V9, P2609, DOI 10.1097/00001756-199808030-00034; Llado J, 1999, J NEUROSCI, V19, P10803, DOI 10.1523/JNEUROSCI.19-24-10803.1999; LUKASIUK K, 1995, NEUROCHEM INT, V26, P173, DOI 10.1016/0197-0186(94)00121-A; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Stewart DJ, 1991, NEUROLOGICAL COMPLIC, P143; Terro F, 2000, NEUROSCI LETT, V278, P149, DOI 10.1016/S0304-3940(99)00911-8; Trimmer EE, 1999, ESSAYS BIOCHEM, V34, P191, DOI 10.1042/bse0340191; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; WILLIAMSON JR, 1964, METHOD ENZYMOL, V13, P488; WILLIAMSON JR, 1964, METHOD ENZYMOL, V13, P481; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; ZHENG JL, 1995, J NEUROSCI, V15, P5079; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43663	43671		10.1074/jbc.M301554200	http://dx.doi.org/10.1074/jbc.M301554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930843	hybrid			2022-12-27	WOS:000186157000115
J	Venkateswarlu, K				Venkateswarlu, K			Interaction protein for cytohesin exchange factors 1 (IPCEF1) binds cytohesin 2 and modifies its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; ARF; ACTIVATION; PLECKSTRIN; FAMILY; DOMAIN; ARNO; RECRUITMENT	The ADP-ribosylation factor 6 (ARF6) small GTPase functions as a GDP/GTP-regulated switch in the pathways that stimulate actin reorganization and membrane ruffling. The formation of active ARF6(GTP) is stimulated by guanine nucleotide exchange factors (GEFs) such as cytohesins, which translocate to the plasma membrane in agonist-stimulated cells by binding the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate through the pleckstrin homology domain with subsequent ARF6 activation. Using cytohesin 2 as bait in yeast two-hybrid screening, we have isolated a cDNA encoding a protein termed interaction protein for cytohesin exchange factors 1 (IPCEF1). Using yeast two-hybrid and glutathione S-transferase pull-down assays coupled with deletion mutational analysis, the specific domains required for the cytohesin 2-IPCEF1 interaction were mapped to the coiled-coil domain of cytohesin 2 and the C-terminal 121 amino acids of IPCEF1. IPCEF1 also interacts with the other members of the cytohesin family of ARF GEFs, suggesting that the interaction with IPCEF1 is highly conserved among the cytohesin family of ARF GEFs. The interaction of cytohesin 2 and IPCEF1 in mammalian cells was demonstrated by immunoprecipitation. Immunofluorescence analysis revealed that IPCEF1 co-localizes with cytohesin 2 to the cytosol in unstimulated cells and translocates to the plasma membrane via binding to cytohesin 2 in epidermal growth factor-stimulated cells. However, a deletion mutant of IPCEF1 that lacks the cytohesin 2 binding site failed to co-migrate with cytohesin 2 to the membrane in stimulated cells. The functional significance of the IPCEF1-cytohesin 2 interaction is demonstrated by showing that IPCEF1 increases the in vitro and in vivo stimulation of ARF(GTP) formation by cytohesin 2.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol	Venkateswarlu, K (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Univ Walk, Bristol BS8 1TD, Avon, England.	k.venkateswarlu@bristol.ac.uk	Kanamarlapudi, Venkateswarlu/A-9864-2011	Kanamarlapudi, Venkateswarlu/0000-0002-8739-1483				Bourgoin SG, 2002, J LEUKOCYTE BIOL, V71, P718; Cullen PJ, 2000, CURR BIOL, V10, pR876, DOI 10.1016/S0960-9822(00)00818-6; Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; Glenn DE, 1998, J NEUROCHEM, V71, P2023; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Klarlund JK, 2001, J BIOL CHEM, V276, P40065, DOI 10.1074/jbc.M105260200; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kliche S, 2001, MOL CELL, V7, P833, DOI 10.1016/S1097-2765(01)00227-1; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Korthauer U, 2000, J IMMUNOL, V164, P308, DOI 10.4049/jimmunol.164.1.308; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lee SY, 2000, J CELL SCI, V113, P1883; Lippincott-Schwartz J, 1998, HISTOCHEM CELL BIOL, V109, P449, DOI 10.1007/s004180050247; Mansour M, 2002, J BIOL CHEM, V277, P32302, DOI 10.1074/jbc.M202898200; Monier S, 1998, J CELL SCI, V111, P3427; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; RANDAZZO P, 2000, SCI STKE; Schweitzer JK, 2002, J BIOL CHEM, V277, P27210, DOI 10.1074/jbc.M201569200; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Stephens DJ, 1999, J BIOL CHEM, V274, P30080, DOI 10.1074/jbc.274.42.30080; Tang PT, 2002, P NATL ACAD SCI USA, V99, P2625, DOI 10.1073/pnas.052712999; Telemenakis I, 1997, EUR J CELL BIOL, V74, P143; Venkateswarlu K, 1999, BIOCHEM BIOPH RES CO, V262, P237, DOI 10.1006/bbrc.1999.1065; Venkateswarlu K, 2000, BIOCHEM J, V345, P719, DOI 10.1042/0264-6021:3450719; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	42	50	51	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43460	43469		10.1074/jbc.M304078200	http://dx.doi.org/10.1074/jbc.M304078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920129	hybrid			2022-12-27	WOS:000186157000091
J	Froeschke, M; Basler, M; Groettrup, M; Dobberstein, B				Froeschke, M; Basler, M; Groettrup, M; Dobberstein, B			Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; T-CELL EPITOPE; PROTEASOME INHIBITOR LACTACYSTIN; I MEMBRANE-PROTEIN; HLA-E BINDS; SEQUENCE; CLEAVAGE; IDENTIFICATION; CONTAINS; ALPHAVIRUSES	Signal peptides (SPs) direct nascent secretory and membrane proteins to the membrane of the endoplasmic reticulum. They are usually cleaved from the nascent polypeptide by signal peptidase and then further proteolytically processed. The SP of the pre-glycoprotein (pGP-C) of the lymphocytic choriomeningitis virus SPGP-C (signal peptide of pGP-C) shows different properties: 1) The SPGP-C is unusually long ( 58 amino acid residues) and contains two hydrophobic segments interrupted by a lysine residue. 2) The SPGP-C is cleaved only from a subset of pGP-C proteins. A substantial portion of pGP-C accumulates that still contains the SPGP-C. 3) The cleaved SPGP-C is rather long-lived (t(1/2) of more than 6 h). 4) The cleaved SPGP-C resides in the membrane and is resistant to digestion with proteinase K even in the presence of detergents, suggesting a very compact structure. 5) SPGP-C accumulates in virus particles. These unusual features of the cleaved SPGP-C suggest that SPGP-C not only targets the nascent pGP-C to the endoplasmic reticulum membrane but also has additional functions in lymphocytic choriomeningitis virus life cycle.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Constance, Dept Immunol, D-78457 Constance, Germany	Ruprecht Karls University Heidelberg; University of Konstanz	Dobberstein, B (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.			Basler, Michael/0000-0002-9428-2349				ADEN DP, 1976, IMMUNOGENETICS, V3, P209, DOI 10.1007/BF01576954; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; Bai AL, 1997, J IMMUNOL, V159, P2139; Beyer WR, 2001, J VIROL, V75, P1061, DOI 10.1128/JVI.75.2.1061-1064.2001; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; BRUNS M, 1983, VIROLOGY, V130, P247, DOI 10.1016/0042-6822(83)90135-6; BUCHMEIER MJ, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142; BUCHMEIER MJ, 1978, VIROLOGY, V89, P133, DOI 10.1016/0042-6822(78)90047-8; BURNS JW, 1993, ARENAVIRIDAE, P17; Eichler R, 2003, FEBS LETT, V538, P203, DOI 10.1016/S0014-5793(03)00160-1; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; Gallimore A, 1998, MOL IMMUNOL, V35, P581, DOI 10.1016/S0161-5890(98)00053-4; GAROFF H, 1982, CURR TOP MICROBIOL, V99, P1; Gewurz BE, 2002, J BIOL CHEM, V277, P11306, DOI 10.1074/jbc.M107904200; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOMBACH J, 1995, J EXP MED, V182, P1615, DOI 10.1084/jem.182.5.1615; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; Klappa P, 1996, EUR J BIOCHEM, V239, P509, DOI 10.1111/j.1432-1033.1996.0509u.x; KLAVINSKIS LS, 1990, VIROLOGY, V178, P393, DOI 10.1016/0042-6822(90)90336-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Li Y, 2000, VIROLOGY, V272, P417, DOI 10.1006/viro.2000.0357; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; LILJESTROM P, 1991, J VIROL, V65, P4107; Lindemann D, 2001, J VIROL, V75, P5762, DOI 10.1128/JVI.75.13.5762-5771.2001; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LOEWY A, 1995, J VIROL, V69, P469, DOI 10.1128/JVI.69.1.469-475.1995; LUSA S, 1991, VIROLOGY, V185, P843, DOI 10.1016/0042-6822(91)90556-Q; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Maniatis T., 1982, MOL CLONING LAB MANU; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; ROMANOWSKI V, 1985, VIRUS RES, V3, P101, DOI 10.1016/0168-1702(85)90001-2; RUSSEL M, 1981, P NATL ACAD SCI-BIOL, V78, P1717, DOI 10.1073/pnas.78.3.1717; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P196; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Yao JS, 1996, J VIROL, V70, P7910, DOI 10.1128/JVI.70.11.7910-7920.1996	47	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41914	41920		10.1074/jbc.M302343200	http://dx.doi.org/10.1074/jbc.M302343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917426	hybrid, Green Published			2022-12-27	WOS:000185989500045
J	Jung, KM; Tan, S; Landman, N; Petrova, K; Murray, S; Lewis, R; Kim, PK; Kim, DS; Ryu, SH; Chao, MV; Kim, TW				Jung, KM; Tan, S; Landman, N; Petrova, K; Murray, S; Lewis, R; Kim, PK; Kim, DS; Ryu, SH; Chao, MV; Kim, TW			Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR RECEPTOR; GAMMA-SECRETASE ACTIVITY; NOTCH INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; TRUNCATED FORM; CLEAVAGE; PRESENILIN; COMPLEX; P75(NTR)	The generation of biologically active proteins by regulated intramembrane proteolysis is a highly conserved mechanism in cell signaling. Presenilin-dependent gamma-secretase activity is responsible for the intramembrane proteolysis of selected type I membrane proteins, including beta-amyloid precursor protein (APP) and Notch. A small fraction of intracellular domains derived from both APP and Notch translocates to and appears to function in the nucleus, suggesting a generic role for gamma-secretase cleavage in nuclear signaling. Here we show that the p75 neurotrophin receptor (p75(NTR)) undergoes presenilin-dependent intramembrane proteolysis to yield the soluble p75-intracellular domain. The p75(NTR) is a multifunctional type I membrane protein that promotes neurotrophin-induced neuronal survival and differentiation by forming a heteromeric co-receptor complex with the Trk receptors. Mass spectrometric analysis revealed that gamma-secretase-mediated cleavage of p75(NTR) occurs at a position located in the middle of the transmembrane (TM) domain, which is reminiscent of the amyloid beta-peptide 40 (Abeta40) cleavage of APP and is topologically distinct from the major TM cleavage site of Notch 1. Size exclusion chromatography and co-immunoprecipitation analyses revealed that TrkA forms a molecular complex together with either full-length p75 or membrane-tethered C-terminal fragments. The p75-ICD was not recruited into the TrkA-containing high molecular weight complex, indicating that gamma-secretase-mediated removal of the p75 TM domain may perturb the interaction with TrkA. Independent of the possible nuclear function, our studies suggest that gamma-secretase-mediated p75(NTR) proteolysis plays a role in the formation/disassembly of the p75-TrkA receptor complex by regulating the availability of the p75 TM domain that is required for this interaction.	Columbia Univ, Coll Phys & Surg, Dept Pathol,Ctr Neurobiol & Behav, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program, New York, NY 10016 USA; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Columbia University; New York University; Pohang University of Science & Technology (POSTECH)	Kim, TW (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol,Ctr Neurobiol & Behav, Taub Inst Res Alzheimers Dis & Aging Brain, P&S 14-442, New York, NY 10032 USA.		Jung, Kwang-Mook/F-1035-2018; Tan, Serena/R-6997-2019; Tan, Serena C/G-5423-2012; Petrová, Klaudia/ABB-2954-2021	Jung, Kwang-Mook/0000-0003-4096-6953; Murray, Simon/0000-0001-6671-192X; Tan, Serena/0000-0002-6356-6541; Ryu, Sung Ho/0000-0003-0913-3048; Chao, Moses/0000-0002-6969-3744	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043467] Funding Source: NIH RePORTER; NCI NIH HHS [CA 056490] Funding Source: Medline; NINDS NIH HHS [NS 43467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BARKER PA, 1991, J BIOL CHEM, V266, P19113; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BLUSZTAJN JK, 1992, J NEUROSCI, V12, P793; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714; ZUPAN AA, 1991, J BIOL CHEM, V266, P15384	44	175	179	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42161	42169		10.1074/jbc.M306028200	http://dx.doi.org/10.1074/jbc.M306028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913006	hybrid			2022-12-27	WOS:000185989500074
J	Li, XW; Yang, YJ; Hu, YM; Dang, DM; Regezi, J; Schmidt, BL; Atakilit, A; Chen, B; Ellis, D; Ramos, DM				Li, XW; Yang, YJ; Hu, YM; Dang, DM; Regezi, J; Schmidt, BL; Atakilit, A; Chen, B; Ellis, D; Ramos, DM			alpha(nu)beta(6)-Fyn signaling promotes oral cancer progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASES; SRC FAMILY KINASES; SQUAMOUS-CELL CARCINOMAS; IN-VIVO; INTEGRIN ALPHA-V-BETA-6; 3-DIMENSIONAL COLLAGEN; BETA-6 INTEGRIN; EXPRESSION; GROWTH	We have previously shown that the integrin beta(6) is neo-expressed in invasive oral squamous cell carcinoma (SCC) and is correlated with oral tumor progression. However, the mechanism by which the integrin beta(6) promotes oral tumor progression is not well understood. The purpose of the present study was to determine whether integrin beta(6) signaling activates Fyn and thus promotes oral squamous cell carcinoma progression. We analyzed the integrin beta(6) signaling complex and investigated the function of these signaling molecules in oral SCC cells. We found that, upon ligation of the integrin beta(6) with fibronectin, beta(6) complexed with Fyn and activated it. The activation of Fyn recruited and activated focal adhesion kinase to this complex. This complex was necessary to activate Shc and to couple beta6 signaling to the Raf-ERK/MAPK pathway. This pathway transcriptionally activated the matrix metalloproteinase-3 gene and promoted oral SCC cell proliferation and experimental metastasis in vivo. These findings indicate that integrin beta(6) signaling activates Fyn and thus promotes oral cancer progression.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ramos, DM (corresponding author), Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA.			Schmidt, Brian/0000-0002-2409-8984	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012856, R29DE011930, P01DE013904] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01 DE 13904, R01 DE 12856, R29/R01 DE 11930] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agrez MV, 1997, VIROLOGY, V239, P71, DOI 10.1006/viro.1997.8831; Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BREUSS JM, 1995, J CELL SCI, V108, P2241; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; BUSK M, 1992, J BIOL CHEM, V267, P5790; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Ellerbroek SM, 1999, CANCER RES, V59, P1635; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamidi S, 2000, BRIT J CANCER, V82, P1433, DOI 10.1054/bjoc.1999.1130; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Kanazawa S, 1996, BLOOD, V87, P865, DOI 10.1182/blood.V87.3.865.bloodjournal873865; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Li XW, 2001, J CELL SCI, V114, P2665; Li XW, 1998, INVAS METAST, V18, P1, DOI 10.1159/000024494; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Regezi JA, 2002, ORAL ONCOL, V38, P332, DOI 10.1016/S1368-8375(01)00062-8; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SMYTHE WR, 1995, CANCER METAST REV, V14, P229, DOI 10.1007/BF00690294; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Volberg T, 2001, J CELL SCI, V114, P2279; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WERB Z, 1989, J BIOL CHEM, V264, P9111; Xue H, 2001, BIOCHEM BIOPH RES CO, V288, P610, DOI 10.1006/bbrc.2001.5813	59	81	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41646	41653		10.1074/jbc.M306274200	http://dx.doi.org/10.1074/jbc.M306274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917446	hybrid			2022-12-27	WOS:000185989500013
J	Udayakumar, D; Bladen, CL; Hudson, FZ; Dynan, WS				Udayakumar, D; Bladen, CL; Hudson, FZ; Dynan, WS			Distinct pathways of nonhomologous end joining that are differentially regulated by DNA-dependent protein kinase-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; TARGETED DISRUPTION; DAMAGE CHECKPOINT; CATALYTIC SUBUNIT; EARLY PARTICIPANT; VERTEBRATE CELLS; REPAIR; KU; COMPLEX; GENE	Nonhomologous end joining is the most common mechanism of DNA double-strand break repair in human cells. Here we show that nonhomologous end joining can occur by two biochemically distinct pathways. One requires a fraction containing the Mre11-Rad50-NBS1 complex. The other requires a fraction containing a novel, similar to200-kDa factor that does not correspond to any of the previously described double-strand break repair proteins. The two pathways converge, sharing a common requirement for the DNA ligase IV-XRCC4 complex to catalyze the final step of phosphodiester bond formation. Whereas the Mre11-Rad50-NBS1-dependent pathway does not require, and may be inhibited by, DNA-dependent protein kinase-mediated phosphorylation, the new pathway depends on this phosphorylation for release from a DNA-dependent protein kinase-mediated reaction checkpoint. The existence of two distinct pathways, which are differentially regulated by the DNA-dependent protein kinase, provides a possible explanation for the selective repair defects seen in DNA-dependent protein kinase-deficient mutants.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.			Dynan, William/0000-0002-4045-5662	NIGMS NIH HHS [GM 35866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bloomfield V.A., 2000, NUCL ACIDS STRUCTURE, V1st ed.; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Cooper MP, 2000, GENE DEV, V14, P907; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Manolis KG, 2001, EMBO J, V20, P210, DOI 10.1093/emboj/20.1.210; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; MAY Y, 2002, CELL, V108, P892; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Sonoda E, 2001, P NATL ACAD SCI USA, V98, P8388, DOI 10.1073/pnas.111006398; Soubeyrand S, 2001, P NATL ACAD SCI USA, V98, P9605, DOI 10.1073/pnas.171211398; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang Y, 2000, GENE DEV, V14, P927; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619	37	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41631	41635		10.1074/jbc.M306470200	http://dx.doi.org/10.1074/jbc.M306470200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917393	hybrid			2022-12-27	WOS:000185989500011
J	Watanabe, K; Wang, CCC; Boddy, CN; Cane, DE; Khosla, C				Watanabe, K; Wang, CCC; Boddy, CN; Cane, DE; Khosla, C			Understanding substrate specificity of polyketide synthase modules by generating hybrid multimodular synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BIOSYNTHETIC GENE-CLUSTER; INTERMODULAR COMMUNICATION; DIRECTED MUTAGENESIS; KINETIC-ANALYSIS; ERYTHROMYCIN; EXPRESSION; DOMAIN; ARCHITECTURE; RIFAMYCIN	Modular polyketide biosynthesis can be harnessed to generate rationally designed complex natural products through bioengineering. A detailed understanding of the features that govern transfer and processing of polyketide biosynthetic intermediates is crucial to successfully engineer new polyketide pathways. Previous studies have shown that substrate stereochemistry and protein-protein interactions between polyketide synthase modules are both important factors in this process. Here we investigated the substrate tolerance of different polyketide modules and assessed the relative importance of inter-module chain transfer versus chain elongation activity of some of these modules. By constructing a variety of hybrid modular polyketide synthase systems and assaying their ability to generate polyketide products, it was determined that the substrate tolerance of each individual ketosynthase domain is an important parameter for the successful recombination of polyketide synthase modules. Surprisingly, however, failure by a module to process a candidate substrate was not due to its inability to bind to it. Rather, it appeared to result from a blockage in carbon-carbon bond formation, suggesting that proper orientation of the initially formed acyl thioester in the ketosynthase active site was important for the enzyme-catalyzed decarboxylative condensation reaction.	Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA	Stanford University; Stanford University; Stanford University; Brown University	Khosla, C (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.	ck@chemeng.stanford.edu	Boddy, Christopher N./H-8084-2019; Watanabe, Kenji/N-2012-2015	Watanabe, Kenji/0000-0002-0463-4831; Boddy, Christopher/0000-0002-3259-3184; Khosla, Chaitan/0000-0001-6529-495X; Wang, Clay/0000-0003-2955-7569	NCI NIH HHS [CA 091636] Funding Source: Medline; NIAID NIH HHS [AI 77248] Funding Source: Medline; NIGMS NIH HHS [GM 22172, GM 65035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA091636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI077248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022172, F32GM065035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Cane DE, 2002, CHEM BIOL, V9, P131, DOI 10.1016/S1074-5521(02)00089-3; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; Hans M, 2003, J AM CHEM SOC, V125, P5366, DOI 10.1021/ja029539i; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; Kao CM, 1996, J AM CHEM SOC, V118, P9184, DOI 10.1021/ja9617552; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; Kim BS, 2002, BIOCHEMISTRY-US, V41, P10827, DOI 10.1021/bi0256779; Kumar P, 2003, J AM CHEM SOC, V125, P4097, DOI 10.1021/ja0297537; Lu HX, 2002, BIOCHEMISTRY-US, V41, P12590, DOI 10.1021/bi026006d; Molnar I, 2000, CHEM BIOL, V7, P97, DOI 10.1016/S1074-5521(00)00075-2; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Ranganathan A, 1999, CHEM BIOL, V6, P731, DOI 10.1016/S1074-5521(00)80020-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schupp T, 1998, FEMS MICROBIOL LETT, V159, P201, DOI 10.1111/j.1574-6968.1998.tb12861.x; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Tang L, 1999, CHEM BIOL, V6, P553, DOI 10.1016/S1074-5521(99)80087-8; Tang L, 2000, CHEM BIOL, V7, P77, DOI 10.1016/S1074-5521(00)00073-9; Tang L, 2000, SCIENCE, V287, P640, DOI 10.1126/science.287.5453.640; Tsai SC, 2002, BIOCHEMISTRY-US, V41, P12598, DOI 10.1021/bi0260177; Tsuji SY, 2001, BIOCHEMISTRY-US, V40, P2326, DOI 10.1021/bi002463n; Wu N, 2000, J AM CHEM SOC, V122, P4847, DOI 10.1021/ja000023d; Wu N, 2002, BIOCHEMISTRY-US, V41, P5056, DOI 10.1021/bi012086u; Wu N, 2001, J AM CHEM SOC, V123, P6465, DOI 10.1021/ja010219t; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111; Yin YF, 2003, J AM CHEM SOC, V125, P5671, DOI 10.1021/ja034574q; Yoon YJ, 2002, CHEM BIOL, V9, P203, DOI 10.1016/S1074-5521(02)00095-9	32	56	57	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42020	42026		10.1074/jbc.M305339200	http://dx.doi.org/10.1074/jbc.M305339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923197	hybrid			2022-12-27	WOS:000185989500057
J	Beugnet, A; Wang, XM; Proud, CG				Beugnet, A; Wang, XM; Proud, CG			Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D1 MESSENGER-RNA; P70 S6 KINASE; PHAS-I; MTOR; TRANSLATION; REGULATORS; GROWTH; RAPTOR; 4E-BP1; IDENTIFICATION	The translational repressor protein eIF4E-binding protein 1 (4E-BP1, also termed PHAS-I) is regulated by phosphorylation through the rapamycin-sensitive mTOR ( mammalian target of rapamycin) pathway. Recent studies have identified two regulatory motifs in 4E-BP1, an mTOR-signaling (TOS) motif in the C terminus of 4E-BP1 and an RAIP motif ( named after its sequence) in the N terminus. Other recent work has shown that the protein raptor binds to mTOR and 4E-BP1. We show that raptor binds to full-length 4E-BP1 or a C-terminal fragment containing the TOS motif but not to an N-terminal fragment containing the RAIP motif. Mutation of several residues within the TOS motif abrogates binding to raptor, indicating that the TOS motif is required for this interaction. 4E-BP1 undergoes phosphorylation at multiple sites in intact cells. The effects of removal or mutation of the RAIP and TOS motifs differ. The RAIP motif is absolutely required for phosphorylation of sites in the N and C termini of 4E-BP1, whereas the TOS motif primarily affects phosphorylation of Ser-64/65, Thr-69/70, and also the rapamycin-insensitive site Ser-101. Phosphorylation of N-terminal sites that are dependent upon the RAIP motif is sensitive to rapamycin. The RAIP motif thus promotes the mTOR-dependent phosphorylation of multiple sites in 4E-BP1 independently of the 4E-BP1/raptor interaction.	Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk		Proud, Christopher/0000-0003-0704-6442				Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Gingras AC, 2001, PROG MOLEC, V27, P143; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball S R, 2001, Prog Mol Subcell Biol, V26, P155; Lai HK, 2000, ONCOGENE, V19, P1623, DOI 10.1038/sj.onc.1203473; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Wang XM, 2002, BIOCHEM J, V367, P475, DOI 10.1042/BJ20020677; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	38	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40717	40722		10.1074/jbc.M308573200	http://dx.doi.org/10.1074/jbc.M308573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912989	hybrid			2022-12-27	WOS:000185847200037
J	Massillon, D; Arinze, IJ; Xu, C; Bone, F				Massillon, D; Arinze, IJ; Xu, C; Bone, F			Regulation of glucose-6-phosphatase gene expression in cultured hepatocytes and H4IIE cells by short-chain fatty acids - Role of hepatic nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYKINASE GTP GENE; TISSUE-SPECIFIC EXPRESSION; SODIUM-BUTYRATE; HISTONE DEACETYLASE; ORPHAN RECEPTOR; TRANSCRIPTIONAL REPRESSION; METABOLIC-REGULATION; TRICHOSTATIN-A; SP1 SITES; IN-VIVO	Mechanisms underlying dietary nutrient regulation of glucose-6-phosphatase (Glc-6-Pase) gene expression are not well understood. Here we investigated the effects of short-chain fatty acids on the expression of this gene in primary cultures of rat hepatocytes and H4IIE hepatoma cells. Propionate, butyrate, valerate, and caproate induced severalfold increases in the expression of Glc-6-Pase mRNA. In reporter gene assays, propionate, valerate, caproate, and also octanoate increased Glc-6-Pase promoter activity by 6 - 16-fold. Butyrate, by itself, had little or no effect on promoter activity, but it induced a robust increase (45-fold) in promoter activity in cells co-transfected with a plasmid expressing the transcription factor HNF-4alpha(alpha isoforms of hepatic nuclear factor 4). HNF-4alpha also enhanced promoter activity induced by other short-chain fatty acids. A dominant negative form of HNF-4alpha abrogated the fatty acid-induced promoter activity, a finding that accentuates a role for HNF-4alpha in the transcription process studied here. In cells transfected with HNF-4alpha, short-chain fatty acids and trichostatin A, an inhibitor of histone deacetylase, synergistically enhanced promoter activity, suggesting that hyperacetylation of histones is an important component of the transactivation of the Glc-6-Pase gene promoter by HNF-4alpha. Region - 751/ - 466 of this promoter contains seven putative HNF-4alpha-binding motifs. Binding of HNF-4alpha to this region was confirmed by electrophoretic mobility shift and chromatin immunoprecipitation assays, indicating that HNF-4alpha is recruited to the Glc-6-Pase gene promoter during short-chain fatty acid-induced transcription from this promoter.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol, Cleveland, OH 44106 USA; Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA	Case Western Reserve University; Case Western Reserve University; Meharry Medical College	Massillon, D (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	dxm71@po.cwru.edu						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; ARION WJ, 1980, J BIOL CHEM, V255, P396; BIRREN BW, 1986, NUCLEIC ACIDS RES, V14, P853, DOI 10.1093/nar/14.2.853; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1985, BIOCHEM J, V230, P489, DOI 10.1042/bj2300489; CAREY M, 2000, TRANSCRIPTIONAL REGU, P266; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Davie JR, 1999, J CELL BIOCHEM, P141; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Duplus E, 2002, BIOCHEM PHARMACOL, V64, P893, DOI 10.1016/S0006-2952(02)01157-7; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hodny Z, 2000, BIOCHEM J, V346, P93, DOI 10.1042/0264-6021:3460093; Hung WC, 1999, BRIT J CANCER, V80, P705, DOI 10.1038/sj.bjc.6690413; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU ZR, 1995, BIOCHEM J, V308, P105, DOI 10.1042/bj3080105; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Massillon D, 2001, J BIOL CHEM, V276, P4055, DOI 10.1074/jbc.M007939200; MORROW CS, 1994, J BIOL CHEM, V269, P10739; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NORDLIE RC, 1993, P SOC EXP BIOL MED, V203, P274; PATEL YM, 1994, J BIOL CHEM, V269, P5619; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Taylor DG, 1996, NUCLEIC ACIDS RES, V24, P2930, DOI 10.1093/nar/24.15.2930; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Towle HC, 1996, BIOCHEM SOC T, V24, P364, DOI 10.1042/bst0240364; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wasner C, 2001, BBA-GENE STRUCT EXPR, V1521, P126, DOI 10.1016/S0167-4781(01)00303-7; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	51	35	37	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40694	40701		10.1074/jbc.M303182200	http://dx.doi.org/10.1074/jbc.M303182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12915406	hybrid			2022-12-27	WOS:000185847200034
J	Mohanty, AK; Bishop, CM; Bishop, TC; Wimley, WC; Wiener, MC				Mohanty, AK; Bishop, CM; Bishop, TC; Wimley, WC; Wiener, MC			Enzymatic E-colicins bind to their target receptor BtuB by presentation of a small binding epitope on a coiled-coil scaffold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; COBALAMIN TRANSPORTER; CRYSTAL-STRUCTURE; PROTEIN; CELLS; VITAMIN-B12; ENVELOPE; DOMAINS; ENTRY	Toxins and viruses often initiate their attacks by binding to specific proteins on the surfaces of target cells. Bacterial toxins (e.g. bacteriocins) and viruses (bacteriophages) targeting Gram-negative bacteria typically bind to outer membrane proteins. Bacterial E-colicins target Escherichia coli by binding to the outer membrane cobalamin transporter BtuB. Colicins are tripartite molecules possessing receptor-binding, translocation, and toxin domains connected by long coiled-coil alpha-helices. Surprisingly, the crystal structure of colicin E3 does not possess a recognizable globular fold in its receptor-binding domain. We hypothesized that the binding epitope of enzymatic E-colicins is a short loop connecting the two alpha-helices that comprise the coiled-coil region and that this flanking coiled-coil region serves to present the loop in a binding-capable conformation. To test this hypothesis, we designed and synthesized a 34-residue peptide (E-peptide-1) corresponding to residues Ala(366)-Arg(399) of the helix-loop-helix region of colicin E3. Cysteines placed near the ends of the peptide (I372C and A393C) enabled crosslinking for reduction of conformational entropy and formation of a peptide structure that would present the loop epitope. A fluorescent analog was also made for characterization of binding by measurement of fluorescence polarization. Our analysis shows the following. (i) E-peptide-1 is predominantly random coil in aqueous solution, but disulfide bond formation increases its alpha-helical content in both aqueous buffer and solvents that promote helix formation. (ii) Fluorescein-labeled E-peptide-1 binds to purified BtuB in a calcium-dependent manner with a K-d of 43.6 +/- 4.9 nM or 2370 +/- 670 nM in the presence or absence of calcium, respectively. (iii) In the presence of calcium, cyanocobalamin (CN-Cbl) displaces E-peptide-1 with a nanomolar inhibition constant (K-i = 78.9 +/- 5.6 nM). We conclude that the BtuB binding sites for cobalamins and enzymatic E-colicins are overlapping but inequivalent and that the distal loop and (possibly) the short alpha-helical flanking regions are sufficient for high affinity binding.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA; Xavier Univ, Div Pharmaceut Sci, New Orleans, LA 70125 USA	University of Virginia; Tulane University; Xavier University of Louisiana	Wiener, MC (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.	mwiener@virginia.edu			NIDDK NIH HHS [DK59999] Funding Source: Medline; NIGMS NIH HHS [R01 GM060000, R01 GM060000-05, GM60000] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060000] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atherton E., 1990, SOLID PHASE PEPTIDE; Bano SF, 2002, BIOPHYS J, V82, p555A; Boetzel R, 2003, FARADAY DISCUSS, V122, P145, DOI 10.1039/b201127a; BRADBEER C, 1986, J BIOL CHEM, V261, P2520; BRAUN V, 1994, ARCH MICROBIOL, V161, P199, DOI 10.1007/s002030050042; BUDAVARI S, 1996, MERCK INDEX ENCY CHE, P1710; Cao Z, 2002, BIOCHIMIE, V84, P399, DOI 10.1016/S0300-9084(02)01455-4; CAVARD D, 1994, FEMS MICROBIOL LETT, V116, P37; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; Chimento DP, 2003, ACTA CRYSTALLOGR D, V59, P509, DOI 10.1107/S0907444903000052; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; DIMASI DR, 1973, J BACTERIOL, V115, P506, DOI 10.1128/JB.115.2.506-513.1973; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Grant G. A, 1992, SYNTHETIC PEPTIDES U; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HELLER K, 1985, J BACTERIOL, V161, P896, DOI 10.1128/JB.161.3.896-903.1985; Hocart SJ, 1999, J MED CHEM, V42, P1863, DOI 10.1021/jm9806289; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kenakin T., 1997, PHARM ANAL DRUG RECE, P242; Knodler LA, 2001, NAT REV MOL CELL BIO, V2, P578, DOI 10.1038/35085062; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; Penfold CN, 2000, MOL MICROBIOL, V38, P639, DOI 10.1046/j.1365-2958.2000.02160.x; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Smarda J, 2000, FOLIA MICROBIOL, V45, P379, DOI 10.1007/BF02817609; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Tam JP, 2000, EUR J BIOCHEM, V267, P3289, DOI 10.1046/j.1432-1327.2000.01359.x; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; Wimley WC, 1996, BIOCHEMISTRY-US, V35, P5109, DOI 10.1021/bi9600153; Zakharov SD, 2003, BIOPHYS J, V84, p324A	33	10	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40953	40958		10.1074/jbc.M308227200	http://dx.doi.org/10.1074/jbc.M308227200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902336	hybrid			2022-12-27	WOS:000185847200067
J	Numakawa, T; Nakayama, H; Suzuki, S; Kubo, T; Nara, F; Numakawa, Y; Yokomaku, D; Araki, T; Ishimoto, T; Ogura, A; Taguchi, T				Numakawa, T; Nakayama, H; Suzuki, S; Kubo, T; Nara, F; Numakawa, Y; Yokomaku, D; Araki, T; Ishimoto, T; Ogura, A; Taguchi, T			Nerve growth factor-induced glutamate release is via p75 receptor, ceramide, and Ca2+ from ryanodine receptor in developing cerebellar neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; AFFINITY NEUROTROPHIN RECEPTOR; PC12 CELLS; GRANULE NEURONS; NEUTRAL SPHINGOMYELINASE; RECOMBINANT ADENOVIRUS; SYNAPTIC-TRANSMISSION; INTRACELLULAR CA2+; INDUCED APOPTOSIS; CORTICAL-NEURONS	Very little is known about the contribution of a low affinity neurotrophin receptor, p75, to neurotransmitter release. Here we show that nerve growth factor (NGF) induced a rapid release of glutamate and an increase of Ca2+ in cerebellar neurons through a p75-dependent pathway. The NGF-induced release occurred even in the presence of the Trk inhibitor K252a. The release caused by NGF but not brain-derived neurotrophic factor was enhanced in neurons overexpressing p75. Further, after transfection of p75-small interfering RNA, which downregulated the endogenous p75 expression, the NGF-induced release was inhibited, suggesting that the NGF-induced glutamate release was through p75. We found that the NGF-increased Ca2+ was derived from the ryanodine-sensitive Ca2+ receptor and that the NGF-increased Ca2+ was essential for the NGF-induced glutamate release. Furthermore, scyphostatin, a sphingomyelinase inhibitor, blocked the NGF-dependent Ca2+ increase and glutamate release, suggesting that a ceramide produced by sphingomyelinase was required for the NGF-stimulated Ca2+ increase and glutamate release. This action of NGF only occurred in developing neurons whereas the brain-derived neurotrophic factor-mediated Ca2+ increase and glutamate release was observed at the mature neuronal stage. Thus, we demonstrate that NGF-mediated neurotransmitter release via the p75-dependent pathway has an important role in developing neurons.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Disorder Res, Kodaira, Tokyo 1878502, Japan; Natl Inst Adv Ind Sci & Technol, Neuron RG Special Div Human Life Technol, Osaka 5638577, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Nara Med Univ, Nara 6348521, Japan; Sankyo Co Ltd, Shinagawa Ku, Tokyo 1408710, Japan; AIST, Human Stress, Ikeda, Osaka 5638577, Japan; Osaka Univ, Fac Sci, Grad Sch Frontier Biosci, Osaka 4600043, Japan	National Center for Neurology & Psychiatry - Japan; National Institute of Advanced Industrial Science & Technology (AIST); Osaka University; Nara Medical University; Daiichi Sankyo Company Limited; National Institute of Advanced Industrial Science & Technology (AIST); Osaka University	Numakawa, T (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Disorder Res, 4-1-1 Ogawahigashicho, Kodaira, Tokyo 1878502, Japan.	numakawa@ncnp.go.jp		Araki, Toshiyuki/0000-0002-1179-4534				Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Blochl A, 1996, J BIOL CHEM, V271, P21100; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Bui NT, 2002, J NEUROCHEM, V81, P594, DOI 10.1046/j.1471-4159.2002.00841.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.0.CO;2-0; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DeFreitas MF, 2001, J NEUROSCI, V21, P5121, DOI 10.1523/JNEUROSCI.21-14-05121.2001; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Fagan AM, 1997, J NEUROSCI, V17, P7644; Frade JM, 1998, BIOESSAYS, V20, P137, DOI 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; FURUYA S, 1995, J NEUROCHEM, V65, P1551; GalveRoperh I, 1997, J NEUROSCI RES, V49, P569, DOI 10.1002/(SICI)1097-4547(19970901)49:5<569::AID-JNR7>3.0.CO;2-9; Halpain S, 1998, J NEUROSCI, V18, P9835; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HATANAKA H, 1988, DEV BRAIN RES, V39, P85, DOI 10.1016/0165-3806(88)90069-7; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Higuchi H, 2003, BIOCHEM BIOPH RES CO, V301, P804, DOI 10.1016/S0006-291X(03)00029-9; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HUBER LJ, 1995, DEV BIOL, V167, P227, DOI 10.1006/dbio.1995.1019; Hughes AL, 2001, J NEUROSCI RES, V63, P10, DOI 10.1002/1097-4547(20010101)63:1<10::AID-JNR2>3.0.CO;2-R; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; Korkotian E, 1999, P NATL ACAD SCI USA, V96, P12068, DOI 10.1073/pnas.96.21.12068; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Kurihara H, 1997, J NEUROSCI, V17, P9613; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LESSMANN V, 1994, NEUROREPORT, V6, P21; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MURAKAMI T, 1991, CHEMOTHERAPY, V37, P327, DOI 10.1159/000238875; Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525; Numakawa T, 1999, BRAIN RES, V842, P431, DOI 10.1016/S0006-8993(99)01867-3; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Numakawa T, 2002, J BIOL CHEM, V277, P28861, DOI 10.1074/jbc.M202927200; Numakawa T, 2001, J NEUROSCI RES, V66, P96, DOI 10.1002/jnr.1201; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wang SY, 2000, AM J PATHOL, V157, P1247, DOI 10.1016/S0002-9440(10)64640-8; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Xu AG, 2001, WORLD J GASTROENTERO, V7, P403; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Yang F, 2001, NAT NEUROSCI, V4, P19, DOI 10.1038/82858	65	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41259	41269		10.1074/jbc.M304409200	http://dx.doi.org/10.1074/jbc.M304409200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902347	hybrid			2022-12-27	WOS:000185847200105
J	Spinella, F; Rosano, L; Di Castro, V; Nicotra, MR; Natali, PG; Bagnato, A				Spinella, F; Rosano, L; Di Castro, V; Nicotra, MR; Natali, PG; Bagnato, A			Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; GROWTH-FACTOR; PROTEIN CONNEXIN-43; RECEPTOR BLOCKADE; EPITHELIAL-CELLS; CARDIAC MYOCYTES; A RECEPTOR; C-SRC; EXPRESSION; ACTIVATION	Endothelin-1 (ET-1) is overexpressed in ovarian carcinoma and acts as an autocrine factor selectively through the ETA receptor (ETAR) to promote tumor cell proliferation, survival, neovascularization, and invasiveness. Loss of gap junctional intercellular communication (GJIC) is critical for tumor progression by allowing the cells to escape growth control. Exposure of HEY and OVCA 433 ovarian carcinoma cell lines to ET-1 led to a 50 - 75% inhibition in intercellular communication and to a decrease in the connexin 43 (Cx43)- based gap junction plaques. To investigate the phosphorylation state of Cx43, ovarian carcinoma cell lysates were immunoprecipitated and transient tyrosine phosphorylation of Cx43 was detected in ET-1-treated cells. BQ 123, a selective ETAR antagonist, blocked the ET-1-induced Cx43 phosphorylation and cellular uncoupling. Gap junction closure was prevented by tyrphostin 25 and by the selective c-Src inhibitor, PP2. Furthermore, the increased Cx43 tyrosine phosphorylation was correlated with ET-1-induced increase of c-Src activity, and PP2 suppressed the ET-1-induced Cx43 tyrosine phosphorylation, indicating that inhibition of Cx43-based GJIC is mainly mediated by the Src tyrosine kinase pathway. In vivo, the inhibition of human ovarian tumor growth in nude mice induced by the potent ETAR antagonist, ABT-627, was associated with a reduction of Cx43 phosphorylation. These findings indicate that the signaling mechanisms involved in GJIC disruption on ovarian carcinoma cells depend on ETAR activation, which leads to the Cx43 tyrosine phosphorylation mediated by c-Src, suggesting that ETAR blockade may contribute to the control of ovarian carcinoma growth and progression also by preventing the loss of GJIC.	Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Dept Immunol, I-00158 Rome, Italy; CNR, Inst Mol Biol & Pathol, I-00137 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Bagnato, A (corresponding author), Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, Via Messi Oro 156, I-00158 Rome, Italy.	bagnato@ifo.it	Di Castro, Valeriana/H-8873-2017; ROSANO', Laura/AAK-1424-2020; spinella, francesca/AAZ-8982-2020; Bagnato, Anna/G-9747-2016; Rosanò, Laura/I-9266-2012; Rosanò, Laura/AAB-7821-2019; Rosanò, Laura/B-2863-2018	Di Castro, Valeriana/0000-0002-1899-3683; ROSANO', Laura/0000-0002-9962-6411; Bagnato, Anna/0000-0002-7269-9522; Rosanò, Laura/0000-0002-3981-8593; Rosanò, Laura/0000-0002-9962-6411				Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; Bagnato A, 2002, CANCER RES, V62, P6381; Bagnato A, 2001, AM J PATHOL, V158, P841, DOI 10.1016/S0002-9440(10)64032-1; BALEY PA, 1990, J CLIN INVEST, V85, P1320, DOI 10.1172/JCI114570; Blomstrand F, 1999, AM J PHYSIOL-CELL PH, V277, pC616, DOI 10.1152/ajpcell.1999.277.4.C616; Carducci MA, 2002, J CLIN ONCOL, V20, P2171, DOI 10.1200/JCO.2002.08.028; Carruba G, 2002, PROSTATE, V50, P73; Cruciani V, 2002, BIOL CELL, V94, P433, DOI 10.1016/S0248-4900(02)00014-X; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; ECONOMOS K, 1992, CANCER RES, V52, P554; Egidy G, 2000, AM J PATHOL, V157, P1863, DOI 10.1016/S0002-9440(10)64825-0; Fernstrom MJ, 2002, EXP MOL PATHOL, V73, P54, DOI 10.1006/exmp.2002.2436; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; Giepmans BNG, 2001, CURR BIOL, V11, P1364, DOI 10.1016/S0960-9822(01)00424-9; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Giusti AF, 2000, J BIOL CHEM, V275, P16788, DOI 10.1074/jbc.M001091200; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Govindarajan R, 2002, J BIOL CHEM, V277, P50087, DOI 10.1074/jbc.M202652200; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; Lahav R, 1999, P NATL ACAD SCI USA, V96, P11496, DOI 10.1073/pnas.96.20.11496; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laing JG, 2001, J BIOL CHEM, V276, P23051, DOI 10.1074/jbc.M100303200; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lidington D, 2002, J CELL PHYSIOL, V193, P373, DOI 10.1002/jcp.10179; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Polontchouk L, 2001, FASEB J, V15, P87, DOI 10.1096/fj.01-0381fje; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Rosano L, 2003, CANCER RES, V63, P2447; Rosano L, 2001, CANCER RES, V61, P8340; RUBANJI GM, 1999, PHARMACOL REV, V46, P325; Ruch RJ, 2001, J CELL BIOCHEM, V83, P163, DOI 10.1002/jcb.1227; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8; Salani D, 2002, CLIN SCI, V103, p318S, DOI 10.1042/CS103S318S; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; Spinella F, 2002, J BIOL CHEM, V277, P27850, DOI 10.1074/jbc.M202421200; Sumitomo M, 2001, CANCER RES, V61, P3294; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Trosko JE, 2001, MUTAT RES-FUND MOL M, V480, P219, DOI 10.1016/S0027-5107(01)00181-6; Umhauer S, 2000, AM J OBSTET GYNECOL, V182, P999, DOI 10.1016/S0002-9378(00)70135-9; van der Boon J, 2002, LANCET ONCOL, V3, P201, DOI 10.1016/S1470-2045(02)00704-0; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Venuti A, 2000, FASEB J, V14, P2277, DOI 10.1096/fj.00-0024com	51	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41294	41301		10.1074/jbc.M304785200	http://dx.doi.org/10.1074/jbc.M304785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907686	hybrid			2022-12-27	WOS:000185847200108
J	Torkko, JM; Koivuranta, KT; Kastaniotis, AJ; Airenne, TT; Glumoff, T; Ilves, M; Hartig, A; Gurvitz, A; Hiltunen, JK				Torkko, JM; Koivuranta, KT; Kastaniotis, AJ; Airenne, TT; Glumoff, T; Ilves, M; Hartig, A; Gurvitz, A; Hiltunen, JK			Candida tropicalis expresses two mitochondrial 2-enoyl thioester reductases that are able to form both homodimers and heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; ALKANE-ASSIMILATING YEAST; FATTY-ACID SYNTHESIS; SACCHAROMYCES-CEREVISIAE; HEMIASCOMYCETOUS YEASTS; GENOMIC EXPLORATION; GENETIC EVALUATION; NEUROSPORA-CRASSA; THIOLASE ISOZYMES; CREATINE-KINASE	Here we report on the cloning of a Candida tropicalis gene, ETR2, that is closely related to ETR1. Both genes encode enzymatically active 2-enoyl thioester reductases involved in mitochondrial synthesis of fatty acids ( fatty acid synthesis type II) and respiratory competence. The 5'- and 3'-flanking (coding) regions of ETR2 and ETR1 are about 90% (97%) identical, indicating that the genes have evolved via gene duplication. The gene products differ in three amino acid residues: Ile(67) (Val), Ala(92) (Thr), and Lys(251) (Arg) in Etr2p (Etr1p). Quantitative PCR analysis and reverse transcriptase-PCR indicated that both genes were expressed about equally in fermenting and ETR1 predominantly respiring yeast cells. Like the situation with ETR1, expression of ETR2 in respiration-deficient Saccharomyces cerevisiae mutant cells devoid of Ybr026p/Etr1p was able to restore growth on glycerol. Triclosan that is used as an antibacterial agent against fatty acid synthesis type II 2-enoyl thioester reductases inhibited growth of FabI overexpressing mutant yeast cells but was not able to inhibit respiratory growth of the ETR2- or ETR1-complemented mutant yeast cells. Resolving of crystal structures obtained via Etr2p and Etr1p co-crystallization indicated that all possible dimer variants occur in the same asymmetric unit, suggesting that similar dimer formation also takes place in vivo.	Univ Oulu, Dept Biochem, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Physiol, FIN-90014 Oulu, Finland; VTT Biotechnol, FIN-02044 Espoo, Finland; Univ Vienna, Dept Biochem & Mol Cell Biol, Vienna Bioctr, Univ Dept,Max F Perutz Labs, A-1030 Vienna, Austria	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; VTT Technical Research Center Finland; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, Bioctr Oulu, POB 3000, FIN-90014 Oulu, Finland.			Hartig, Andreas/0000-0003-3334-2763; Hiltunen, Kalervo/0000-0002-3073-9602; Kastaniotis, Alexander/0000-0003-3624-9214				Airenne TT, 2003, J MOL BIOL, V327, P47, DOI 10.1016/S0022-2836(03)00038-X; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; Blandin G, 2000, FEBS LETT, V487, P91, DOI 10.1016/S0014-5793(00)02287-0; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DODSON EJ, 1994, ACTA CRYSTALLOGR D, V50, P760; DOI M, 1992, J GEN MICROBIOL, V138, P2243, DOI 10.1099/00221287-138-10-2243; Glanz S, 1992, PRIMER BIOSTATISTICS; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARINGTON A, 1994, EMBO J, V13, P5531, DOI 10.1002/j.1460-2075.1994.tb06890.x; Heath RJ, 2000, J BIOL CHEM, V275, P40128, DOI 10.1074/jbc.M005611200; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; Johnston J.R., 1994, MOL GENETICS YEAST P; JONES EW, 1977, GENETICS, V85, P23; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; KAMIRYO T, 1991, YEAST, V7, P503, DOI 10.1002/yea.320070510; Kanayama N, 1998, J BACTERIOL, V180, P690, DOI 10.1128/JB.180.3.690-698.1998; KAWAMOTO S, 1978, EUR J BIOCHEM, V83, P609, DOI 10.1111/j.1432-1033.1978.tb12130.x; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Llorente B, 2000, FEBS LETT, V487, P122, DOI 10.1016/S0014-5793(00)02291-2; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; Nordling E, 2002, EUR J BIOCHEM, V269, P4267, DOI 10.1046/j.1432-1033.2002.03114.x; Nowak MA, 1997, NATURE, V388, P167, DOI 10.1038/40618; OCARRA P, 1990, BIOCHEM SOC T, V18, P272, DOI 10.1042/bst0180272; OKAZAKI K, 1987, GENE, V58, P37; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PICATAGGIO S, 1991, MOL CELL BIOL, V11, P4333, DOI 10.1128/MCB.11.9.4333; QUEST AFG, 1990, FEBS LETT, V262, P299, DOI 10.1016/0014-5793(90)80214-4; Rachubinski R. A., 1990, The genetics of Candida., P177; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; ROSENBERG UB, 1981, EUR J BIOCHEM, V116, P87, DOI 10.1111/j.1432-1033.1981.tb05304.x; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; Sugita T, 1999, SYST APPL MICROBIOL, V22, P79, DOI 10.1016/S0723-2020(99)80030-7; TANAKA A, 1993, MYCOL RES, V97, P1025, DOI 10.1016/S0953-7562(09)80504-2; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Ueda M, 1998, BBA-GENE STRUCT EXPR, V1397, P213, DOI 10.1016/S0167-4781(98)00009-8; Ueda M, 2000, CELL BIOCHEM BIOPHYS, V32, P285, DOI 10.1385/CBB:32:1-3:285; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; YAMAZOE M, 1994, J BIOL CHEM, V269, P15244; ZEELEN JP, 1992, J MOL BIOL, V224, P273, DOI 10.1016/0022-2836(92)90591-7; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F	52	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41213	41220		10.1074/jbc.M307664200	http://dx.doi.org/10.1074/jbc.M307664200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890667	hybrid			2022-12-27	WOS:000185847200099
J	Mohamed, MR; Niles, EG				Mohamed, MR; Niles, EG			UUUUUNU stimulation of vaccinia virus early gene transcription termination - Oligonucleotide sequence and structural requirements for stimulation of premature termination in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA POLYMERASE; TRIPHOSPHATE PHOSPHOHYDROLASE-I; TEMPERATURE-SENSITIVE MUTANTS; H4L SUBUNIT; CAPPING ENZYME; ESCHERICHIA-COLI; EXPRESSION; MUTATIONS; IDENTIFICATION; PURIFICATION	Vaccinia virus early genes are unique in that transcription terminates in a signal- and factor-dependent manner. Recent results from this laboratory demonstrated that a 22-mer RNA oligonucleotide containing a central U9 sequence exhibited sequence- and concentration-dependent stimulation of premature transcription termination and transcript release in trans. In an effort to better understand the different aspects of the U5NU stimulation of premature termination, we evaluated the activity of various oligonucleotides in vitro. Neither RNA containing a mutant U5NU signal nor single-stranded DNA containing T5NT was able to stimulate premature termination, demonstrating both sequence specificity and a requirement for ribose. Furthermore, neither oligonucleotide was able to compete with U5NU, demonstrating that each failed to bind to the U5NU recognition factor. Substitution of the U9 signal with either BrU9 or BrdU9 inhibited normal termination but did not stimulate premature termination. The addition of BrdU5NdU inhibited U5NU stimulation of premature termination, demonstrating that both oligonucleotides bind to the same site on the U5NU recognition factor. Finally, U5NU containing RNA as short as nine bases served as an effective stimulator of premature termination. These observations impact directly on the development of oligonucleotide based anti-poxvirus therapeutic agents.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Niles, EG (corresponding author), SUNY Buffalo, Sch Med, Dept Microbiol, 138 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	eniles@buffalo.edu	Mohamed, Mohamed Ragaa/V-9143-2019	Mohamed, Mohamed Ragaa/0000-0002-9269-3128	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043933] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI 43933] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1992, J VIROL, V66, P971, DOI 10.1128/JVI.66.2.971-982.1992; Christen LA, 1999, BIOCHEMISTRY-US, V38, P8072, DOI 10.1021/bi9903749; Christen LM, 1998, VIROLOGY, V245, P360, DOI 10.1006/viro.1998.9177; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; Condit RC, 1996, VIROLOGY, V220, P10, DOI 10.1006/viro.1996.0280; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; Deng L, 1997, J BIOL CHEM, V272, P695; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; Mohamed MR, 2000, J BIOL CHEM, V275, P25798, DOI 10.1074/jbc.M002250200; Mohamed MR, 2003, J BIOL CHEM, V278, P11794, DOI 10.1074/jbc.M213263200; Mohamed MR, 2002, VIROLOGY, V299, P142, DOI 10.1006/viro.2002.1498; Mohamed MR, 2001, J BIOL CHEM, V276, P20758, DOI 10.1074/jbc.M101641200; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; Moss B, 2001, FIELDS VIROLOGY, P2849; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; Piacente SC, 2003, VIROLOGY, V310, P109, DOI 10.1016/S0042-6822(03)00092-8; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSALES R, 1994, J BIOL CHEM, V269, P14260; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; Smith GL, 1997, IMMUNOL REV, V159, P137, DOI 10.1111/j.1600-065X.1997.tb01012.x; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998	35	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39534	39541		10.1074/jbc.M306048200	http://dx.doi.org/10.1074/jbc.M306048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890673	hybrid			2022-12-27	WOS:000185713800034
J	Wang, LX; Cummings, R; Zhao, YT; Kazlauskas, A; Sham, JKS; Morris, A; Georas, S; Brindley, DN; Natarajan, V				Wang, LX; Cummings, R; Zhao, YT; Kazlauskas, A; Sham, JKS; Morris, A; Georas, S; Brindley, DN; Natarajan, V			Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; AIRWAY SMOOTH-MUSCLE; OVARIAN-CANCER CELLS; COUPLED RECEPTORS; TYROSINE PHOSPHORYLATION; SPHINGOSINE 1-PHOSPHATE; EGF RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; ENDOTHELIAL-CELLS; MEDIATED ACTIVATION	Lysophosphatidate (LPA) mediates multiple cellular responses via heterotrimeric G protein coupled LPA-1, LPA-2, and LPA-3 receptors. Many G protein-coupled receptors stimulate ERK following tyrosine phosphorylation of growth factor receptors; however, the mechanism(s) of transactivation of receptor tyrosine kinases are not well defined. Here, we provide evidence for the involvement of phospholipase D (PLD) in LPA-mediated transactivation of platelet-derived growth factor receptorbeta (PDGF-Rbeta). In primary cultures of human bronchial epithelial cells (HBEpCs), LPA stimulated tyrosine phosphorylation of PDGF-Rbeta and threonine/tyrosine phosphorylation of ERK1/2. The LPA-mediated activation of ERK and tyrosine phosphorylation of PDGF-Rbeta was attenuated by tyrphostin AG 1296, an inhibitor of PDGF-R kinase, suggesting transactivation of PDGF-R by LPA. Furthermore, LPA-, but not PDGF beta-chain homodimer-induced tyrosine phosphorylation of PDGF-Rbeta was partially blocked by pertussis toxin, indicating coupling of LPA-R(s) to G(i). Exposure of HBEpCs to LPA activated PLD. Butan-1-ol, which acts as an acceptor of phosphatidate generated by the PLD pathway, blocked LPA- mediated transactivation of PDGF-Rbeta. This effect was not seen with butan-3-ol, suggesting PLD involvement. The role of PLD1 and PLD2 in the PDGF-Rbeta transactivation by LPA was investigated by infection of cells with adenoviral constructs of wild type and catalytically inactive mutants of PLD. LPA activated both PLD1 and PLD2 in HBEpCs; however, infection of cells with cDNA for wild type PLD2, but not PLD1, increased the tyrosine phosphorylation of PDGF-Rbeta in response to LPA. Also, the LPA- mediated tyrosine phosphorylation of PDGF-Rbeta was attenuated by the catalytically inactive mutant mPLD2-K758R. Infection of HBEpCs with adenoviral constructs of wild type hPLD1, mPLD2, and the inactive mutants of hPLD1 and mPLD2 resulted in association of PLD2 wild type and inactive mutant proteins with the PDGF-Rbeta compared with PLD1. These results show for the first time that transactivation of PDGF-Rbeta by LPA in HBEpCs is regulated by PLD2.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care, Baltimore, MD 21224 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada	Johns Hopkins University; Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of North Carolina; University of North Carolina Chapel Hill; University of Alberta	Natarajan, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care, Mason F Lord Bldg,Rm 675,5200 Eastern Ave, Baltimore, MD 21224 USA.		Wang, Lai-Xi/E-8755-2019; wang, xl/Y-8251-2019					Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; BUCH S, 1994, AM J RESP CELL MOL, V11, P251, DOI 10.1165/ajrcmb.11.3.8086163; Cerutis DR, 1997, AM J PHYSIOL-LUNG C, V273, pL10, DOI 10.1152/ajplung.1997.273.1.L10; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fishman DA, 2001, CANCER RES, V61, P3194; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GSCHWIND A, 2000, CANCER RES, V62, P6329; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Kanda Y, 2001, BRIT J PHARMACOL, V132, P1657, DOI 10.1038/sj.bjp.0703952; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; Kim SN, 2000, J CELL BIOCHEM, V76, P386, DOI 10.1002/(SICI)1097-4644(20000301)76:3<386::AID-JCB6>3.0.CO;2-9; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; KOVALENKO M, 1994, CANCER RES, V54, P6106; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Kue PF, 2002, INT J CANCER, V102, P572, DOI 10.1002/ijc.10734; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Liebmann C, 2000, CURR MED CHEM, V7, P911, DOI 10.2174/0929867003374589; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; Min DS, 2001, MOL CELLS, V11, P369; Natarajan V, 1998, MOL CELL BIOCHEM, V183, P113, DOI 10.1023/A:1006872230910; NATARAJAN V, 1995, J LIPID RES, V36, P2005; Ohata H, 1997, LIFE SCI, V60, P1287, DOI 10.1016/S0024-3205(97)00072-6; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Parinandi NL, 2001, ARCH BIOCHEM BIOPHYS, V396, P231, DOI 10.1006/abbi.2001.2609; PIAZZA GA, 1995, EXP CELL RES, V216, P51, DOI 10.1006/excr.1995.1007; Pietruck F, 1997, N-S ARCH PHARMACOL, V355, P1; Qi C, 1998, J CELL PHYSIOL, V174, P261, DOI 10.1002/(SICI)1097-4652(199802)174:2<261::AID-JCP13>3.0.CO;2-F; Racke K, 2000, PULM PHARMACOL THER, V13, P99, DOI 10.1006/pupt.2000.0241; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Shimizu S, 2000, AM J PHYSIOL-LUNG C, V279, pL503, DOI 10.1152/ajplung.2000.279.3.L503; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Toews ML, 2002, BBA-MOL CELL BIOL L, V1582, P240, DOI 10.1016/S1388-1981(02)00177-4; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wang LX, 2002, BIOCHEM J, V367, P751, DOI 10.1042/BJ20020586; Wu J, 2002, BBA-MOL CELL BIOL L, V1582, P100, DOI 10.1016/S1388-1981(02)00143-9; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200	64	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39931	39940		10.1074/jbc.M302896200	http://dx.doi.org/10.1074/jbc.M302896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890682	hybrid, Green Published			2022-12-27	WOS:000185713800081
J	Hosoda, N; Kobayashi, T; Uchida, N; Funakoshi, Y; Kikuchi, Y; Hoshino, S; Katada, T				Hosoda, N; Kobayashi, T; Uchida, N; Funakoshi, Y; Kikuchi, Y; Hoshino, S; Katada, T			Translation termination factor eRF3 mediates mRNA decay through the regulation of deadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; ENCODES; NUCLEASE; SUBUNIT; TAIL	Messenger RNA decay, which is a regulated process intimately linked to translation, begins with the dead-enylation of the poly(A) tail at the 3' end. However, the precise mechanism triggering the first step of mRNA decay and its relationship to translation have not been elucidated. Here, we show that the translation termination factor eRF3 mediates mRNA deadenylation and decay in the yeast Saccharomyces cerevisiae. The N-domain of eRF3, which is not necessarily required for translation termination, interacts with the poly(A)-binding protein PABP. When this interaction is blocked by means of deletion or overexpression of the N-domain of eRF3, half-lives of all mRNAs are prolonged. The eRF3 mutant lacking the N-domain is deficient in the poly(A) shortening. Furthermore, the eRF3-mediated mRNA decay requires translation to proceed, especially ribosomal transition through the termination codon. These results indicate that the N-domain of eRF3 mediates mRNA decay by regulating deadenylation in a manner coupled to translation.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Hoshino, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hoshino@mol.f.u-tokyo.ac.jp		Uchida, Naoyuki/0000-0002-4123-6154; Hoshino, Shinichi/0000-0001-6135-7896				BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Cosson B, 2002, MOL CELL BIOL, V22, P3301, DOI 10.1128/MCB.22.10.3301-3315.2002; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Jacobson A, 2000, COLD SPRING HARBOR M, V39, P827; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Maquat LE, 2000, COLD SPRING HARBOR M, V39, P849; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	24	122	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38287	38291		10.1074/jbc.C300300200	http://dx.doi.org/10.1074/jbc.C300300200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12923185	hybrid			2022-12-27	WOS:000185575100026
J	Casamassima, M; D'Adamo, MC; Pessia, M; Tucker, SJ				Casamassima, M; D'Adamo, MC; Pessia, M; Tucker, SJ			Identification of a heteromeric interaction that influences the rectification, gating, and pH sensitivity of Kir4.1/Kir5.1 potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROMK K(IR)1.1 CHANNELS; RECTIFIER K+ CHANNEL; ATP; SUBUNIT; RESIDUE; KIR4.1; KIR5.1; CONDUCTANCE; MODULATION; DOMAINS	Heteromultimerization between different potassium channel subunits can generate channels with novel functional properties and thus contributes to the rich functional diversity of this gene family. The inwardly rectifying potassium channel subunit Kir5.1 exhibits highly selective heteromultimerization with Kir4.1 to generate heteromeric Kir4.1/Kir5.1 channels with unique rectification and kinetic properties. These novel channels are also inhibited by intracellular pH within the physiological range and are thought to play a key role in linking K+ and H+ homeostasis by the kidney. However, the mechanisms that control heteromeric K+ channel assembly and the structural elements that generate their unique functional properties are poorly understood. In this study we identify residues at an intersubunit interface between the cytoplasmic domains of Kir5.1 and Kir4.1 that influence the novel rectification and gating properties of heteromeric Kir4.1/Kir5.1 channels and that also contribute to their pH sensitivity. Furthermore, this interaction presents a structural mechanism for the functional coupling of these properties and explains how specific heteromeric interactions can contribute to the novel functional properties observed in heteromeric Kir channels. The highly conserved nature of this structural association between Kir subunits also has implications for understanding the general mechanisms of Kir channel gating and their regulation by intracellular pH.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ Perugia, Sch Med, Sect Human Physiol, I-06126 Perugia, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy	University of Oxford; University of Perugia; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Tucker, SJ (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.	stephen.tucker@physiol.ox.ac.uk	Tucker, Stephen J./ABE-7468-2020; D'Adamo, Maria Cristina/AAD-3701-2022; Tucker, Stephen J./ABE-6741-2020	Tucker, Stephen J./0000-0001-8996-2000; D'Adamo, Maria Cristina/0000-0002-6758-6064; Tucker, Stephen J./0000-0001-8996-2000; Pessia, Mauro/0000-0002-2857-6795				Babenko AP, 2000, J BIOL CHEM, V275, P31563, DOI 10.1074/jbc.C000553200; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Cui N, 2003, J MEMBRANE BIOL, V192, P111, DOI 10.1007/s00232-002-1069-6; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Giebisch G, 2001, KIDNEY INT, V60, P436, DOI 10.1046/j.1523-1755.2001.060002436.x; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hommers LG, 2003, J BIOL CHEM, V278, P1037, DOI 10.1074/jbc.M205325200; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; Konstas AA, 2003, AM J PHYSIOL-CELL PH, V284, pC910, DOI 10.1152/ajpcell.00479.2002; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lancaster MK, 2000, J BIOL CHEM, V275, P35831, DOI 10.1074/jbc.M006565200; Lin YW, 2003, J GEN PHYSIOL, V122, P225, DOI 10.1085/jgp.200308822; Lippiat JD, 2002, DIABETES, V51, pS377, DOI 10.2337/diabetes.51.2007.S377; Lourdel S, 2002, J PHYSIOL-LONDON, V538, P391, DOI 10.1113/jphysiol.2001.012961; Nichols CG, 1999, CURR TOP MEMBR, V46, P159; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; Qu ZQ, 2000, J BIOL CHEM, V275, P31573, DOI 10.1074/jbc.M003473200; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; Riven I, 2003, NEURON, V38, P225, DOI 10.1016/S0896-6273(03)00193-4; Schram G, 2002, J PHYSIOL-LONDON, V544, P337, DOI 10.1113/jphysiol.2002.026047; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Tanemoto M, 2000, J PHYSIOL-LONDON, V525, P587, DOI 10.1111/j.1469-7793.2000.00587.x; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Tucker SJ, 2000, J BIOL CHEM, V275, P16404, DOI 10.1074/jbc.C000127200; Xu HX, 2000, J PHYSIOL-LONDON, V524, P725, DOI 10.1111/j.1469-7793.2000.00725.x; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x; Yi BA, 2001, NEURON, V29, P657, DOI 10.1016/S0896-6273(01)00241-0	34	42	42	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43533	43540		10.1074/jbc.M306596200	http://dx.doi.org/10.1074/jbc.M306596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923169	Green Published, hybrid			2022-12-27	WOS:000186157000099
J	Stefanovic, D; Stanojcic, S; Vindigni, A; Ochem, A; Falaschi, A				Stefanovic, D; Stanojcic, S; Vindigni, A; Ochem, A; Falaschi, A			In vitro protein-DNA interactions at the human lamin B2 replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION COMPLEX; CELL-CYCLE; BINDING; GENE	The complexity of mammalian origins of DNA replication has prevented, so far, the in vitro studies of the modalities of initiator protein binding and origin selection. We approached this problem by utilizing the human lamin B2 origin, wherein the precise start sites of replication initiation have been identified and known to be bound in vivo by the origin recognition complex (ORC). In order to analyze the in vitro interactions occurring at this origin, we have compared the DNA binding requirements and patterns of the human recombinant Orc4 with those of preparations of HeLa nuclear proteins containing the ORC complex. Here we show that both HsOrc4 alone and HeLa nuclear proteins recognize multiple sites within a 241-bp DNA sequence encompassing the lamin B2 origin. The DNA binding activity of HeLa cells requires the presence of ORC and can be reproduced in the absence of all the other proteins known to be recruited to origins by ORC. Both HsOrc4 alone and HeLa nuclear proteins exhibit cooperative and ATP-independent binding. This binding covers nucleotides 3853 - 3953 and then spreads outward. Because this region contains the start sites of DNA synthesis as well as the area protected in vivo and preserves protein binding capacity in vitro after removal of a fraction of the protected region, we suggest that it could contain the primary binding site. Thus the in vitro approach points to the sequence requirements for ORC binding as a key element for origin recognition.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Falaschi, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; Abdurashidova G, 2003, EMBO J, V22, P4294, DOI 10.1093/emboj/cdg404; Abdurashidova G, 1998, EMBO J, V17, P2961, DOI 10.1093/emboj/17.10.2961; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BIAMONTI G, 1992, MOL CELL BIOL, V12, P3499, DOI 10.1128/MCB.12.8.3499; Bielinsky AK, 2001, CURR BIOL, V11, P1427, DOI 10.1016/S0960-9822(01)00444-4; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Chuang RY, 2002, J BIOL CHEM, V277, P16920, DOI 10.1074/jbc.M107710200; de Stanchina E, 2000, J MOL BIOL, V299, P667, DOI 10.1006/jmbi.2000.3782; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimitrova DS, 1996, P NATL ACAD SCI USA, V93, P1498, DOI 10.1073/pnas.93.4.1498; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kong DC, 2002, EMBO J, V21, P5567, DOI 10.1093/emboj/cdf546; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Kumar S, 1996, NUCLEIC ACIDS RES, V24, P3289, DOI 10.1093/nar/24.17.3289; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Lee JK, 2001, P NATL ACAD SCI USA, V98, P13589, DOI 10.1073/pnas.251530398; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200	26	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42737	42743		10.1074/jbc.M307058200	http://dx.doi.org/10.1074/jbc.M307058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12902329	hybrid			2022-12-27	WOS:000186157000003
J	Csordas, G; Hajnoczky, G				Csordas, G; Hajnoczky, G			Plasticity of mitochondrial calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RYANODINE-RECEPTORS; CA2+ RELEASE; INOSITOL TRISPHOSPHATE; CYTOSOLIC CA2+; ACINAR-CELLS; CALMODULIN; PROPAGATION; ACTIVATION; LIVER	Evidence is emerging that a quasisynaptic local communication facilitates the calcium signaling between endoplasmic reticulum and mitochondria. However, it remains elusive whether the machinery of mitochondrial calcium signaling displays plasticity similar to the synaptic transmission. Here we studied the relationship between inositol 1,4,5-trisphosphate (IP3)-linked cytosolic [Ca2+] ([Ca2+](c)) oscillations and the associated rise in mitochondrial matrix [Ca2+] ([Ca2+](m)) in RBL-2H3 mast cells. We observed that the second [Ca2+](c) spike is often associated with a larger rise in the [Ca2+](m) than the first. It would appear that this phenomenon was not due to a change in the driving force for Ca2+ uptake and therefore must be due to an enhanced Ca2+ permeability of the mitochondrial Ca2+ uptake sites ( uniporter). To investigate the activation and deactivation kinetics of the uniporter during IP3 receptor-mediated Ca2+ mobilization, we established novel methods. Using these approaches, we demonstrated that the IP3-induced increase in the permeability of the uniporter lasted longer than the Ca2+ signal. The sustained increase in Ca2+ permeability was bidirectional. Furthermore, the addition of Ca2+ during the decay of the IP3 effect evoked a large further increase in the uniporter permeability. Calmodulin inhibitors did not interfere with the IP3-induced initial activation of the uniporter but inhibited the sustained phase. These results suggest that the uniporter displays a calmodulin-mediated facilitation. This plasticity may allow cooperation among sequential IP3 receptor-mediated [Ca2+] transients in the control of calcium signal propagation to the mitochondria.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Hajnoczky, G (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Suite 253 JAH, Philadelphia, PA 19107 USA.	Gyorgy.Hajnoczky@jefferson.edu		Csordas, Gyorgy/0000-0003-3156-1460				ALI H, 1990, J BIOL CHEM, V265, P745; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Csordas G, 2001, CELL CALCIUM, V29, P249, DOI 10.1054/ceca.2000.0191; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; David G, 1999, J NEUROSCI, V19, P7495, DOI 10.1523/JNEUROSCI.19-17-07495.1999; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Falcke M, 1999, BIOPHYS J, V77, P37, DOI 10.1016/S0006-3495(99)76870-0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 2001, IUBMB LIFE, V52, P237, DOI 10.1080/15216540152846055; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HIROSE K, 1994, NATURE, V372, P791; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; KWAN CY, 1990, J BIOL CHEM, V265, P678; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Marchant JS, 2002, AM J PHYSIOL-CELL PH, V282, pC1374, DOI 10.1152/ajpcell.00446.2001; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; Striggow F, 1996, J GEN PHYSIOL, V108, P115, DOI 10.1085/jgp.108.2.115; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; VINOGRADOV A, 1973, J BIOL CHEM, V248, P5527; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; Wang XD, 2001, GENE DEV, V15, P2922; Wilson BS, 1998, MOL BIOL CELL, V9, P1465, DOI 10.1091/mbc.9.6.1465	62	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42273	42282		10.1074/jbc.M305248200	http://dx.doi.org/10.1074/jbc.M305248200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907683				2022-12-27	WOS:000185989500087
J	Julien, C; Coulombe, P; Meloche, S				Julien, C; Coulombe, P; Meloche, S			Nuclear export of ERK3 by a CRM1-dependent mechanism regulates its inhibitory action on cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; GENE-EXPRESSION; FISSION YEAST; HUMAN HOMOLOG; SIGNAL; TRANSLOCATION; CRM1	Extracellular signal-regulated kinase 3 (ERK3) is an atypical member of the mitogen-activated protein kinase family of serine/threonine kinases. Little is known on the regulation of ERK3 function. Here, we report that ERK3 is constitutively localized in the cytoplasmic and nuclear compartments. In contrast to other mitogen-activated protein kinases, the cellular distribution of ERK3 remains unchanged in response to common mitogenic or stress stimuli and is independent of the enzymatic activity or phosphorylation of the kinase. The cytoplasmic localization of ERK3 is directed by a CRM1-dependent nuclear export mechanism. Treatment of cells with leptomycin B causes the nuclear accumulation of ERK3 in a high percentage of cells. Moreover, ectopic expression of CRM1 promotes the cytoplasmic relocalization of ERK3, whereas overexpression of snurportin 1, which binds CRM1 with high affinity, inhibits the nuclear export of ERK3. We also show that CRM1 binds to ERK3 in vitro. Importantly, we show that enforced localization of ERK3 in the nucleus or cytoplasm markedly attenuates the ability of the kinase to induce cell cycle arrest in fibroblasts. Our results suggest that nucleocytoplasmic shuttling of ERK3 is required for its negative regulatory effect on cell cycle progression.	Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Rech Clin Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			COULOMBE, Philippe/0000-0002-4638-9694				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Coulombe P, 2002, ANAL BIOCHEM, V310, P219, DOI 10.1016/S0003-2697(02)00319-6; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; Meloche S, 1996, ONCOGENE, V13, P1575; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Turgeon B, 2002, GENOMICS, V80, P673, DOI 10.1006/geno.2002.7013; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	53	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42615	42624		10.1074/jbc.M302724200	http://dx.doi.org/10.1074/jbc.M302724200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12915405	Green Published, hybrid			2022-12-27	WOS:000185989500127
J	Kim, BT; Kitagawa, H; Tanaka, J; Tamura, J; Sugahara, K				Kim, BT; Kitagawa, H; Tanaka, J; Tamura, J; Sugahara, K			In vitro heparan sulfate polymerization - Crucial roles of core protein moieties of primer substrates in addition to the EXT1-EXT2 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; EXT GENE FAMILY; TUMOR SUPPRESSORS EXT1; CAENORHABDITIS-ELEGANS; GOLGI-APPARATUS; LINKAGE REGION; TOUT-VELU; BIOSYNTHESIS; PROTEOGLYCANS; EXPRESSION	Heparan, the common unsulfated precursor of heparan sulfate (HS) and heparin, is synthesized on the glycosaminoglycan-protein linkage region tetrasaccharide GlcUA-Gal-Gal-Xyl attached to the respective core proteins presumably by HS co-polymerases encoded by EXT1 and EXT2, the genetic defects of which result in hereditary multiple exostoses in humans. Although both EXT1 and EXT2 exhibit GlcNAc transferase and GlcUA transferase activities required for the HS synthesis, no HS chain polymerization has been demonstrated in vitro using recombinant enzymes. Here we report in vitro HS polymerization. Recombinant soluble enzymes expressed by co-transfection of EXT1 and EXT2 synthesized heparan polymers with average molecular weights greater than 1.7 x 10(5) using UDP-[H-3]GlcNAc and UDP-GlcUA as donors on the recombinant glypican-1 core protein and also on the synthetic linkage region analog GlcUA-Gal-O-C2H4NH-benzyloxycarbonyl. Moreover, in our in vitro polymerization system, a part time proteoglycan, alpha-thrombomodulin, that is normally modified with chondroitin sulfate served as a polymerization primer for heparan chain. In contrast, no polymerization was achieved with a mixture of individually expressed EXT1 and EXT2 or with acceptor substrates such as N-acetylheparosan oligosaccharides or the linkage region tetrasaccharide-Ser, which are devoid of a hydrophobic aglycon, suggesting the critical requirement of core protein moieties in addition to the interaction between EXT1 and EXT2 for HS polymerization.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Tottori Univ, Fac Educ & Reg Sci, Dept Environm Sci, Tottori 6808551, Japan	Kobe Pharmaceutical University; Tottori University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; COOK A, 1993, AM J HUM GENET, V53, P71; Dong SC, 2003, J BIOL CHEM, V278, P1700, DOI 10.1074/jbc.M209276200; Francannet C, 2001, J MED GENET, V38, P430, DOI 10.1136/jmg.38.7.430; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HAN C, 2001, ANN DROS RES C WASH; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Hecht JT, 1997, AM J HUM GENET, V60, P80; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V268, P860, DOI 10.1006/bbrc.2000.2219; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LIN JH, 1994, J BIOL CHEM, V269, P25021; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; LINHARDT RJ, 1992, BIOCHEMISTRY-US, V31, P12441, DOI 10.1021/bi00164a020; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Morimoto K, 2002, BIOCHEM BIOPH RES CO, V292, P999, DOI 10.1006/bbrc.2002.6770; Morio H, 2003, BIOCHEM BIOPH RES CO, V301, P317, DOI 10.1016/S0006-291X(02)03031-0; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Neumann KW, 1995, BIOORGAN MED CHEM, V3, P1637, DOI 10.1016/0968-0896(95)00151-4; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; POOLE AR, 1986, BIOCHEM J, V236, P1; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Tamura J, 1996, LIEBIGS ANN, P1239; Tamura J, 2002, BIOORG MED CHEM LETT, V12, P1901, DOI 10.1016/S0960-894X(02)00327-X; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; ZHANG L, 1995, J BIOL CHEM, V270, P12557, DOI 10.1074/jbc.270.21.12557; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	51	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41618	41623		10.1074/jbc.M304831200	http://dx.doi.org/10.1074/jbc.M304831200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907685	hybrid			2022-12-27	WOS:000185989500009
J	McCarthy, KM; McDevit, D; Andreucci, A; Reeves, R; Nikolajczyk, BS				McCarthy, KM; McDevit, D; Andreucci, A; Reeves, R; Nikolajczyk, BS			HMGA1 co-activates transcription in B cells through indirect association with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN GENE ENHANCER; GROUP PROTEIN I(Y); IG-HEAVY-CHAIN; IFN-BETA GENE; INTRONIC ENHANCER; BINDING-FACTOR; ETS; EXPRESSION; PU.1; SEQUENCES	The immunoglobulin heavy chain enhancer, or mu enhancer, is required for B cell development. Only the appropriate combination of transcription factors results in B cell-specific enhancer activation. HMGA1 (formerly (HMG-I(Y)) is a proposed co-activator of the ETS transcription factors required for mu enhancer activity. HMGA1 associates with the ETS factor PU.1, resulting in changes in PU.1 structure, and enhanced transcriptional synergy with Ets-1 on the mu enhancer in nonlymphoid cells. New data show HMGA1 directly interacts with Ets-1 in addition to PU.1. In vitro HMGA1/Ets-1 interaction facilitates Ets-1/mu enhancer binding in the absence of an HMGA1.Ets-1.DNA complex. To address whether HMGA1 is present in the transcriptionally active mu nucleoprotein complex, we completed DNA pull-down assays to detect protein tethering in the context of protein/DNA interaction. Results show that HMGA1 is not tightly associated with mu enhancer DNA through PU.1 or Ets-1, despite strong associations between these proteins in solution. However, chromatin immunoprecipitation assays show HMGA1 associates with the endogenous enhancer in B cells. Furthermore, antisense HMGA1 substantially decreases mu enhancer activity in B cells. Taken together, these data suggest that HMGA1 functions as a transcriptional mu enhancer co-activator in B cells through indirect association with DNA.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Med Ctr, Evans Mem Dept Clin Res, Dept Med, Immunobiol Unit, Boston, MA 02118 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Boston University; Boston Medical Center; Washington State University	Nikolajczyk, BS (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.				NATIONAL CANCER INSTITUTE [T32CA064070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054611] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 64070] Funding Source: Medline; NIAID NIH HHS [AI 54611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreucci A, 2002, BIOCHEM BIOPH RES CO, V292, P427, DOI 10.1006/bbrc.2002.6672; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; Chowdhury D, 2003, IMMUNITY, V18, P229, DOI 10.1016/S1074-7613(03)00030-X; Chowdhury D, 2001, EMBO J, V20, P6394, DOI 10.1093/emboj/20.22.6394; Cowley DO, 2000, GENE DEV, V14, P366; Dang W, 1998, MOL CELL BIOL, V18, P6870, DOI 10.1128/MCB.18.11.6870; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FERNEX C, 1994, NUCLEIC ACIDS RES, V22, P792, DOI 10.1093/nar/22.5.792; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Lewis RT, 2001, J BIOL CHEM, V276, P9550, DOI 10.1074/jbc.M008726200; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Merrell K, 1997, MOL CELL BIOL, V17, P3335, DOI 10.1128/MCB.17.6.3335; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nikolajczyk BS, 1997, MOL CELL BIOL, V17, P3527, DOI 10.1128/MCB.17.7.3527; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; REIK W, 1987, EUR J IMMUNOL, V17, P465, DOI 10.1002/eji.1830170405; Sakai E, 1999, P NATL ACAD SCI USA, V96, P1526, DOI 10.1073/pnas.96.4.1526; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tian G, 1999, MOL CELL BIOL, V19, P2946; Wang DZ, 1997, J BIOL CHEM, V272, P25083, DOI 10.1074/jbc.272.40.25083; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649	49	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42106	42114		10.1074/jbc.M308586200	http://dx.doi.org/10.1074/jbc.M308586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907668	hybrid			2022-12-27	WOS:000185989500068
J	Tokoro, M; Asai, T; Kobayashi, S; Takeuchi, T; Nozaki, T				Tokoro, M; Asai, T; Kobayashi, S; Takeuchi, T; Nozaki, T			Identification and characterization of two isoenzymes of methionine gamma-lyase from Entamoeba histolytica - A key enzyme of sulfur-amino acid degradation in an anaerobic parasitic protist that lacks forward and reverse trans-sulfuration pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS PCC 6803; PSEUDOMONAS-PUTIDA; TRICHOMONAS-VAGINALIS; MERCAPTOMETHANE-LYASE; METABOLISM; PURIFICATION; CYSTEINE; GENES; SYNTHASE; CLONING	To better understand the metabolism of sulfur-containing amino acids, which likely plays a key role in a variety of cell functions, in Entamoeba histolytica, we searched the genome data base for genes encoding putative orthologs of enzymes known to be involved in the metabolism. The search revealed that E. histolytica possesses only incomplete cysteine-methionine conversion pathways in both directions. Instead, this parasite possesses genes encoding two isoenzymes of methionine gamma-lyase (EC 4.4.1.11, EhMGL1/2), which has been implicated in the degradation of sulfur-containing amino acids. The two amebic MGL isoenzymes, showing 69% identity to each other, encode 389- and 392-amino acid polypeptides with predicted molecular masses of 42.3 and 42.7 kDa and pIs of 6.01 and 6.63, respectively. Amino acid comparison and phylogenetic analysis suggested that these amebic MGLs are likely to have been horizontally transferred from the Archaea, whereas an MGL from another anaerobic protist Trichomonas vaginalis has MGL isotypes that share a common ancestor with bacteria. Enzymological and immunoblot analyses of the partially purified native amebic MGL confirmed that both of the MGL isotypes are expressed in a comparable amount predominantly in the cytosol and form a homotetramer. Recombinant EhMGL1 and 2 proteins catalyzed degradation of L-methionine, DL-homocysteine, L-cysteine, and O-acetyl-L-serine to form alpha-keto acid, ammonia, and hydrogen sulfide or methanethiol, whereas activity toward cystathionine was negligible. These two isoenzymes showed notable differences in substrate specificity and pH optimum. In addition, we showed that EhMGL is an ideal target for the development of new chemotherapeutic agents against amebiasis by demonstrating an amebicidal effect of the methionine analog trifluoromethionine on trophozoites in culture (IC50 18 muM) and that this effect of trifluoromethionine was completely abolished by the addition of the MGL-specific inhibitor DL-propargylglycine.	Keio Univ, Sch Med, Dept Trop Med & Parasitol, Tokyo 1608582, Japan; Natl Inst Infect Dis, Dept Parasitol, Tokyo 1628640, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Tokyo 1900012, Japan	Keio University; National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST)	Nozaki, T (corresponding author), 1-23-1 Toyama,Shinjuku Ku, Tokyo 1628640, Japan.		Kobayashi, seiki/L-4026-2013					Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; ALSTON TA, 1983, BIOCHEM PHARMACOL, V32, P947, DOI 10.1016/0006-2952(83)90608-1; Behbehani K, 1998, Bull World Health Organ, V76 Suppl 2, P64; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Coombs GH, 2001, ANTIMICROB AGENTS CH, V45, P1743, DOI 10.1128/AAC.45.6.1743-1745.2001; CUHEL RL, 1981, J BACTERIOL, V147, P340, DOI 10.1128/JB.147.2.340-349.1981; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIAMOND LS, 1972, J VIROL, V9, P326, DOI 10.1128/JVI.9.2.326-341.1972; Dias B, 1998, APPL ENVIRON MICROB, V64, P3327; ESAKI N, 1987, METHOD ENZYMOL, V143, P459; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; Faleev NG, 1996, ENZYME MICROB TECH, V19, P590, DOI 10.1016/S0141-0229(96)00071-3; Field J, 2000, MOL MICROBIOL, V38, P446, DOI 10.1046/j.1365-2958.2000.02143.x; GILLIN FD, 1980, J PROTOZOOL, V27, P474, DOI 10.1111/j.1550-7408.1980.tb05402.x; Hori H, 1996, CANCER RES, V56, P2116; ITO S, 1976, J BIOCHEM-TOKYO, V80, P1327, DOI 10.1093/oxfordjournals.jbchem.a131405; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; JOHNSTON M, 1979, BIOCHEMISTRY-US, V18, P4690, DOI 10.1021/bi00588a033; Kapatral V, 2002, J BACTERIOL, V184, P2005, DOI 10.1128/JB.184.7.2005-2018.2002; KASHIWAMATA S, 1970, BIOCHIM BIOPHYS ACTA, V212, P488, DOI 10.1016/0005-2744(70)90255-X; KREIS W, 1973, CANCER RES, V33, P1862; KUHNER MK, 1994, MOL BIOL EVOL, V11, P459; LAAKSO S, 1976, ANAL BIOCHEM, V72, P600, DOI 10.1016/0003-2697(76)90572-8; Lancero H, 1996, J DENT RES, V75, P1994, DOI 10.1177/00220345960750121201; LOCKWOOD BC, 1991, BIOCHEM J, V279, P675, DOI 10.1042/bj2790675; Mai ZM, 1999, MOL CELL BIOL, V19, P2198; Mazzuco A, 1997, MICRON, V28, P241, DOI 10.1016/S0968-4328(97)00024-3; McKie AE, 1998, J BIOL CHEM, V273, P5549, DOI 10.1074/jbc.273.10.5549; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Motoshima H, 2000, J BIOCHEM, V128, P349, DOI 10.1093/oxfordjournals.jbchem.a022760; MULLER M, 1992, BIOSYSTEMS, V28, P33, DOI 10.1016/0303-2647(92)90005-J; NAKAYAMA T, 1988, BIOCHEMISTRY-US, V27, P1587, DOI 10.1021/bi00405a029; NAKAYAMA T, 1984, ANAL BIOCHEM, V138, P421, DOI 10.1016/0003-2697(84)90832-7; Nozaki T, 1999, J BIOL CHEM, V274, P32445, DOI 10.1074/jbc.274.45.32445; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; RAVDIN JI, 2000, AMEBIASIS SERIES TRO, V2, P1; REEVES RE, 1984, ADV PARASIT, V23, P105, DOI 10.1016/S0065-308X(08)60286-9; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schneider D, 2000, INDIAN J BIOCHEM BIO, V37, P441; Shimizu H, 2001, BBA-PROTEIN STRUCT M, V1549, P61, DOI 10.1016/S0167-4838(01)00245-X; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; SODA K, 1967, AGR BIOL CHEM TOKYO, V31, P1054, DOI 10.1080/00021369.1967.10858916; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Steegborn C, 1999, J BIOL CHEM, V274, P12675, DOI 10.1074/jbc.274.18.12675; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON JF, 1951, ANAL CHEM, V23, P1153, DOI 10.1021/ac60056a029; THONG KW, 1987, MOL BIOCHEM PARASIT, V23, P223, DOI 10.1016/0166-6851(87)90029-6; Tovar J, 1999, MOL MICROBIOL, V32, P1013, DOI 10.1046/j.1365-2958.1999.01414.x; Upcroft JA, 1999, J EUKARYOT MICROBIOL, V46, P447, DOI 10.1111/j.1550-7408.1999.tb04628.x; Walker J, 1997, INT J PARASITOL, V27, P883, DOI 10.1016/S0020-7519(97)00039-8; Wassmann C, 1999, J BIOL CHEM, V274, P26051, DOI 10.1074/jbc.274.37.26051; ZANIN VA, 1989, VOP MED KHIM, V35, P84	54	93	102	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42717	42727		10.1074/jbc.M212414200	http://dx.doi.org/10.1074/jbc.M212414200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920135	hybrid			2022-12-27	WOS:000185989500139
J	Gibson, KJC; Eggeling, L; Maughan, WN; Krumbach, K; Gurcha, SS; Nigou, J; Puzo, G; Sahm, H; Besra, GS				Gibson, KJC; Eggeling, L; Maughan, WN; Krumbach, K; Gurcha, SS; Nigou, J; Puzo, G; Sahm, H; Besra, GS			Disruption of Cg-Ppm1, a polyprenyl monophosphomannose synthase, and the generation of lipoglycan-less mutants in Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE MANNOSE SYNTHASE; BACILLUS-CALMETTE-GUERIN; MYCOBACTERIUM-TUBERCULOSIS; PHOSPHATIDYLINOSITOL MANNOSIDES; CORYNEFORM BACTERIA; MEDIATED ACTIVATION; ACYLATION STATE; LIPOARABINOMANNAN; BIOSYNTHESIS; PROTEIN	The glycosyl donor, polyprenyl monophosphomannose (PPM), has been shown to be involved in the biosynthesis of the mycobacterial lipoglycans: lipomannan and lipoarabinomannan. The mycobacterial PPM synthase (Mt-ppm1) catalyzes the transfer of mannose from GDP-mannose to polyprenyl phosphates. Based on sequence homology to Mt-ppm1, we have identified the PPM synthase from Corynebacterium glutamicum. In the present study, we demonstrate that the corynebacterial synthase is composed of two distinct domains; a catalytic domain (Cg-ppm1) and a membrane domain (Cg-ppm2). Through the inactivation of Cg-ppm1, we observed a complex phenotype that included altered cell growth rate and inability to synthesize PPM molecules and lipoglycans. When Cg-ppm2 was deleted, no observable phenotype was noted, indicating the clear organization of the two domains. The complementation of the inactivated Cg-ppm1 strain with the corresponding mycobacterial enzyme (Mt-Ppm1/D2) led to the restoration of a wild type phenotype. The present study illustrates, for the first time, the generation of a lipoglycan-less mutant based on a molecular strategy in a member of the Corynebacterianeae family. Lipoglycans are important immunomodulatory molecules involved in determining the outcome of infection, and so the generation of defined mutants and their subsequent immunological characterization is timely.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; REs Ctr Juelich, Inst Biotechnol 1, D-52425 Julich, Germany; CNRS, Inst Pharmacol & Biol Struct, Dept Mol Mech Mycobacterial Infect, UMR 5089, F-31077 Toulouse 4, France	University of Birmingham; Helmholtz Association; Research Center Julich; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Besra, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	g.besra@bham.ac.uk	Nigou, Jérôme/D-6802-2019	Nigou, Jérôme/0000-0002-6233-2487; Besra, Gurdyal/0000-0002-5605-0395				Baulard AR, 2003, J BIOL CHEM, V278, P2242, DOI 10.1074/jbc.M207922200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COYLE MB, 1990, CLIN MICROBIOL REV, V3, P227, DOI 10.1128/CMR.3.3.227-246.1990; Eggeling L, 2001, J BIOSCI BIOENG, V92, P201, DOI 10.1263/jbb.92.201; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Funke G, 1997, CLIN MICROBIOL REV, V10, P125, DOI 10.1128/CMR.10.1.125; Garton NJ, 2002, J BIOL CHEM, V277, P31722, DOI 10.1074/jbc.M203008200; Gibson KJC, 2003, BIOCHEM J, V372, P821, DOI 10.1042/BJ20030197; Gibson KJC, 2003, MICROBIOL-SGM, V149, P1437, DOI 10.1099/mic.0.26161-0; Gilleron M, 1997, J BIOL CHEM, V272, P117; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; Jakoby M, 1999, BIOTECHNOL TECH, V13, P437, DOI 10.1023/A:1008968419217; KEILHAUER C, 1993, J BACTERIOL, V175, P5595, DOI 10.1128/JB.175.17.5595-5603.1993; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Kordulakova J, 2003, J BIOL CHEM, V278, P36285, DOI 10.1074/jbc.M303639200; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; KRAMER R, 1994, FEMS MICROBIOL REV, V13, P74; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Means TK, 1999, J IMMUNOL, V163, P3920; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PITULLE C, 1992, INT J SYST BACTERIOL, V42, P337, DOI 10.1099/00207713-42-3-337; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; Puech V, 2000, MOL MICROBIOL, V35, P1026, DOI 10.1046/j.1365-2958.2000.01738.x; Salim K, 1997, APPL ENVIRON MICROB, V63, P4392, DOI 10.1128/AEM.63.11.4392-4400.1997; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SIBLEY LD, 1990, CLIN EXP IMMUNOL, V80, P141; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; Sutcliffe IC, 1995, ARCH ORAL BIOL, V40, P1119, DOI 10.1016/0003-9969(95)00086-0; VENISSE A, 1993, J BIOL CHEM, V268, P12401; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83	50	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40842	40850		10.1074/jbc.M307988200	http://dx.doi.org/10.1074/jbc.M307988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904287	hybrid			2022-12-27	WOS:000185847200053
J	Lee, MG; Pedersen, PL				Lee, MG; Pedersen, PL			Glucose metabolism in cancer - Importance of transcription factor-DNA interactions within a short segment of the proximal region of the type II hexokinase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; MITOCHONDRIAL BOUND HEXOKINASE; HEPATOMA-CELL LINE; RAT HEPATOMA; BREAST-CANCER; CYCLIC-AMP; GENE-TRANSCRIPTION; RESPONSE ELEMENTS; GLUCOKINASE GENE; BINDING ACTIVITY	A common signature of many cancers is a high glucose catabolic rate frequently dependent on the overexpression of Type II hexokinase (HKII), a mitochondrial bound enzyme that also suppresses cell death. As the tumor HKII promoter plays a significant role in HKII overexpression, studies reported here were undertaken to identify both the major regions and transcription factors involved under tumor-like conditions. Reporter gene assays following transfection of hepatoma cells with decreasing segments of the HKII promoter traced its known strength to the proximal region (- 281 to - 35). Mutational analyses showed that in this short region GC boxes 1, 2, 5, and 6, a CCAAT box, an inverted CCAAT box, and CRE are involved in promoter activation. Other studies demonstrated binding of transcription factors Sp1, Sp2, and Sp3 to GC boxes 1 and 6, Sp1 and Sp2 to GC boxes 2 and 5, NF-Y to CCAAT boxes, and CREB, ATF1, and CREM to CRE. In addition, transfection studies involving Sp1, Sp2, Sp3, CREB, and NFY ( dominant negative form) provided evidence that these proteins are promoter activators. Finally, alignment of available HK proximal promoters showed strong conservation only among HKII sequences. These findings implicate signaling pathways directed to a short segment of the proximal region of the HKII promoter as major contributors to HKII overexpression in many cancers.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.				NCI NIH HHS [CA80118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Aisenberg AC, 1961, GLYCOLYSIS RESP TUMO; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; ARORA KK, 1988, J BIOL CHEM, V263, P17422; BURK D, 1967, JNCI-J NATL CANCER I, V38, P839; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Dose J, 2002, NUCL MED COMMUN, V23, P857, DOI 10.1097/00006231-200209000-00009; Geschickter C.F., 1930, J CHEM EDUC, DOI [10.1021/ed007p179, DOI 10.1021/ED007P179]; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Heikkinen S, 2000, MAMM GENOME, V11, P91, DOI 10.1007/s003350010019; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Iynedjian PB, 1998, BIOCHEM J, V333, P705, DOI 10.1042/bj3330705; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHANSSON T, 1985, BIOCHEM BIOPH RES CO, V133, P608, DOI 10.1016/0006-291X(85)90948-9; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Liu WJ, 1997, ARCH BIOCHEM BIOPHYS, V346, P142, DOI 10.1006/abbi.1997.0295; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Malkki M, 1997, DIABETOLOGIA, V40, P1461, DOI 10.1007/s001250050850; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; NAKASHIMA RA, 1988, CANCER RES, V48, P913; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; PARRY DM, 1983, J BIOL CHEM, V258, P904; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; PATRONAS NJ, 1985, J NEUROSURG, V62, P816, DOI 10.3171/jns.1985.62.6.0816; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Rempel A, 1996, CANCER RES, V56, P2468; Rempel A, 1996, FEBS LETT, V385, P233, DOI 10.1016/0014-5793(96)00399-7; REMPEL A, 1994, BBA-GENE STRUCT EXPR, V1219, P660, DOI 10.1016/0167-4781(94)90225-9; Rose C, 2002, NUCL MED COMMUN, V23, P613, DOI 10.1097/00006231-200207000-00004; Rostom AY, 1999, BRIT J RADIOL, V72, P1064, DOI 10.1259/bjr.72.863.10700822; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Sebastian S, 1999, J BIOL CHEM, V274, P31700, DOI 10.1074/jbc.274.44.31700; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; SMITH DF, 1970, CANCER RES, V30, P2306; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAGNER HN, 1993, J NUCL MED, V34, pN13; White JA, 1996, ARCH BIOCHEM BIOPHYS, V335, P161, DOI 10.1006/abbi.1996.0494	52	49	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41047	41058		10.1074/jbc.M307031200	http://dx.doi.org/10.1074/jbc.M307031200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893819				2022-12-27	WOS:000185847200079
J	Wing, MR; Snyder, JT; Sondek, J; Harden, TK				Wing, MR; Snyder, JT; Sondek, J; Harden, TK			Direct activation of phospholipase C-epsilon by Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-COUPLED RECEPTOR; ALPHA-SUBUNITS; P115 RHOGEF; STIMULATION; RAS; EFFECTOR; BINDING; IDENTIFICATION	Unique among the phospholipase C isozymes, the recently identified phospholipase C-epsilon (PLC-epsilon) contains an amino-terminal CDC25 domain capable of catalyzing nucleotide exchange on Ras family GTPases as well as a tandem array of Ras-associating ( RA) domains near its carboxyl terminus that are effector binding sites for activated H-Ras and Rap. To determine whether other small GTPases activate PLC-epsilon, we measured inositol phosphate accumulation in COS-7 cells expressing a broad range of GTPase-deficient mutants of Ras superfamily proteins. RhoA, RhoB, and RhoC all markedly stimulated inositol phosphate accumulation in PLC-epsilon-expressing cells. This stimulation matched or exceeded phospholipase activation promoted by co-expression of PLC-epsilon with the known regulators Ras, Galpha(12/13), or Gbeta(1)gamma(2). In contrast, little effect was observed with the other Rho family members Rac1, Rac2, Rac3, and Cdc42. Truncation of the two carboxyl-terminal RA domains caused loss of responsiveness to H-Ras but not to Rho. Truncation of PLC-epsilon to remove the CDC25 and pleckstrin homology (PH) domains also did not cause loss of responsiveness to Rho, Galpha(12/13), or Gbeta(1)gamma(2). Comparative sequence analysis of mammalian phospholipase C isozymes revealed a unique similar to65 amino acid insert within the catalytic core of PLC-epsilon not present in PLC-beta, gamma, delta, or zeta. A PLC-epsilon construct lacking this region was no longer activated by Rho or Galpha(12/13) but retained regulation by Gbetagamma and H-Ras. GTP-dependent interaction of Rho with PLC-epsilon was illustrated in pull-down experiments with GST-Rho, and this interaction was retained in the PLC-epsilon construct lacking the unique insert within the catalytic core. These results are consistent with the conclusion that Rho family GTPases directly interact with PLC-epsilon by a mechanism independent of the CDC25 or RA domains. A unique insert within the catalytic core of PLC-epsilon imparts responsiveness to Rho, which may signal downstream of Galpha(12/13) in the regulation of PLC-epsilon, because activation by both Rho and Galpha(12/13) is lost in the absence of this sequence.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Neurobiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Harden, TK (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.			Sondek, John/0000-0002-1127-8310	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM065533, R01GM057391] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65533, GM57391, GM29316] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Blake BL, 2001, J BIOL CHEM, V276, P49267, DOI 10.1074/jbc.M106565200; BLANK JL, 1992, J BIOL CHEM, V267, P23069; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BROWN HA, 1991, MOL PHARMACOL, V40, P648; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MEISENHELDER J, 1989, CELL, V57, P1099; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALDO GL, 1991, J BIOL CHEM, V266, P14217; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; WU DQ, 1992, J BIOL CHEM, V267, P1811; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	39	80	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41253	41258		10.1074/jbc.M306904200	http://dx.doi.org/10.1074/jbc.M306904200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900402	hybrid			2022-12-27	WOS:000185847200104
J	Yanow, SK; Gold, DA; Yoo, HY; Dunphy, WG				Yanow, SK; Gold, DA; Yoo, HY; Dunphy, WG			Xenopus Drf1, a regulator of Cdc7, displays checkpoint-dependent accumulation on chromatin during an S-phase arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE REGULATION; HUMAN CDC7-RELATED KINASE; PROTEIN-KINASE; REPLICATION ORIGINS; EGG EXTRACTS; FISSION YEAST; CDC7P-DBF4P KINASE; HELICASE ACTIVITY; POLYMERASE-ALPHA	We have cloned a Xenopus Dbf4-related factor named Drf1 and characterized this protein by using Xenopus egg extracts. Drf1 forms an active complex with the kinase Cdc7. However, most of the Cdc7 in egg extracts is not associated with Drf1, which raises the possibility that some or all of the remaining Cdc7 is bound to another Dbf4-related protein. Immunodepletion of Drf1 does not prevent DNA replication in egg extracts. Consistent with this observation, Cdc45 can still associate with chromatin in Drf1-depleted extracts, albeit at significantly reduced levels. Nonetheless, Drf1 displays highly regulated binding to replicating chromatin. Treatment of egg extracts with aphidicolin results in a substantial accumulation of Drf1 on chromatin. This accumulation is blocked by addition of caffeine and by immunodepletion of either ATR or Claspin. These observations suggest that the increased binding of Drf1 to aphidicolin-treated chromatin is an active process that is mediated by a caffeine-sensitive checkpoint pathway containing ATR and Claspin. Abrogation of this pathway also leads to a large increase in the binding of Cdc45 to chromatin. This increase is substantially reduced in the absence of Drf1, which suggests that regulation of Drf1 might be involved in the suppression of Cdc45 loading during replication arrest. We also provide evidence that elimination of this checkpoint causes resumed initiation of DNA replication in both Xenopus tissue culture cells and egg extracts. Taken together, these observations argue that Drf1 is regulated by an intra-S-phase checkpoint mechanism that down-regulates the loading of Cdc45 onto chromatin containing DNA replication blocks.	CALTECH, Howard Hughes Med Inst, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Dunphy, WG (corresponding author), CALTECH, Howard Hughes Med Inst, Div Biol, 216-76, Pasadena, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043974, R01GM070891] Funding Source: NIH RePORTER; PHS HHS [AY32889] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Geraghty DS, 2000, J BIOL CHEM, V275, P18011, DOI 10.1074/jbc.M909787199; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liu QH, 2000, GENE DEV, V14, P1448; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Masai H, 2000, BIOCHEM BIOPH RES CO, V275, P228, DOI 10.1006/bbrc.2000.3281; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakamura T, 2002, MOL CELL BIOL, V22, P309, DOI 10.1128/MCB.22.1.309-320.2002; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Ogino K, 2001, J BIOL CHEM, V276, P31376, DOI 10.1074/jbc.M102197200; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	56	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41083	41092		10.1074/jbc.M307144200	http://dx.doi.org/10.1074/jbc.M307144200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12897072	hybrid, Green Accepted			2022-12-27	WOS:000185847200083
J	Bhat, R; Xue, YF; Berg, S; Hellberg, S; Ormo, M; Nilsson, Y; Radesater, AC; Jerning, E; Markgren, PO; Borgegard, T; Nylof, M; Gimenez-Cassina, A; Hernandez, F; Lucas, JJ; Diaz-Nido, J; Avila, J				Bhat, R; Xue, YF; Berg, S; Hellberg, S; Ormo, M; Nilsson, Y; Radesater, AC; Jerning, E; Markgren, PO; Borgegard, T; Nylof, M; Gimenez-Cassina, A; Hernandez, F; Lucas, JJ; Diaz-Nido, J; Avila, J			Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-LIKE PHOSPHORYLATION; PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; BETA-CATENIN; TAU-PHOSPHORYLATION; NEURONAL DEGENERATION; INDUCED NEUROTOXICITY; HIPPOCAMPAL-NEURONS; TRANSGENIC MICE; PROTEIN-TAU	Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer's disease. We report the characterization of a GSK3 inhibitor, AR-A014418, which inhibits GSK3 (IC50 = 104 +/- 27 nM), in an ATP-competitive manner (K-i = 38 nM). AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 muM) or 26 other kinases demonstrating high specificity for GSK3. We report the co-crystallization of AR-A014418 with the GSK3beta protein and provide a description of the interactions within the ATP pocket, as well as an understanding of the structural basis for the selectivity of AR-A014418. AR-A014418 inhibits tau phosphorylation at a GSK3-specific site (Ser-396) in cells stably expressing human four-repeat tau protein. AR-A014418 protects N2A neuroblastoma cells against cell death mediated by inhibition of the phosphatidylinositol 3-kinase/protein kinase B survival pathway. Furthermore, AR-A014418 inhibits neurodegeneration mediated by beta-amyloid peptide in hippocampal slices. AR-A014418 may thus have important applications as a tool to elucidate the role of GSK3 in cellular signaling and possibly in Alzheimer's disease. AR-A014418 is the first compound of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5.	AstraZeneca R&D Sodertalje, Res DMPK, S-15185 Sodertalje, Sweden; AstraZeneca R&D, S-43183 Molndal, Sweden; Univ Autonoma Madrid, Consejo Super Invest Cient, E-28049 Madrid, Spain	AstraZeneca; AstraZeneca; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Bhat, R (corresponding author), AstraZeneca R&D Sodertalje, Res DMPK, Bldg 231-213B, S-15185 Sodertalje, Sweden.	ratan.bhat@astrazeneca.com	Hernandez, Felix/L-2114-2015; Diaz-Nido, Javier/L-2371-2013; Avila, Jesus/I-2610-2015; Gimenez-Cassina, Alfredo/AAA-6550-2019; Lucas, Jose J./U-6543-2019	Hernandez, Felix/0000-0001-8753-8249; Diaz-Nido, Javier/0000-0002-0927-7925; Avila, Jesus/0000-0002-6288-0571; Gimenez-Cassina, Alfredo/0000-0002-2768-2350; Lucas, Jose J./0000-0003-1597-3916; Xue, Yafeng/0000-0002-7526-8672				Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7; Alzheimer A, 1911, Z GESAMTE NEUROL PSY, V4, P356, DOI 10.1007/BF02866241; Avila J, 2000, FEBS LETT, V476, P89, DOI 10.1016/S0014-5793(00)01676-8; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Goedert M, 2001, BIOCHEM SOC SYMP, V67, P59, DOI 10.1042/bss0670059; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Hetman M, 2000, J NEUROSCI, V20, P2567; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leroy K, 2002, ACTA NEUROPATHOL, V103, P91; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Luthman J, 1998, AMINO ACIDS, V14, P263, DOI 10.1007/BF01345273; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Salinas P C, 1999, Bipolar Disord, V1, P87, DOI 10.1034/j.1399-5618.1999.010205.x; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Smith DG, 2001, BIOORG MED CHEM LETT, V11, P635, DOI 10.1016/S0960-894X(00)00721-6; STUDER L, 1994, J COMP NEUROL, V340, P281, DOI 10.1002/cne.903400212; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; Takashima A, 1996, NEUROSCI LETT, V203, P33, DOI 10.1016/0304-3940(95)12257-5; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	52	427	450	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45937	45945		10.1074/jbc.M306268200	http://dx.doi.org/10.1074/jbc.M306268200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12928438	hybrid, Green Published			2022-12-27	WOS:000186452300107
J	Aon, MA; Cortassa, S; Marban, E; O'Rourke, B				Aon, MA; Cortassa, S; Marban, E; O'Rourke, B			Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE CARRIER; DEPENDENT ANION CHANNEL; BENZODIAZEPINE-RECEPTOR; HEART-MITOCHONDRIA; ENERGY-METABOLISM; HYDROGEN-PEROXIDE; SUPEROXIDE ANION; SINGLE MITOCHONDRIA; ION CHANNELS	Reactive oxygen species (ROS) and/or Ca2+ overload can trigger depolarization of mitochondrial inner membrane potential (DeltaPsi(m)) and cell injury. Little is known about how loss of DeltaPsi(m) in a small number of mitochondria might influence the overall function of the cell. Here we employ the narrow focal excitation volume of the two-photon microscope to examine the effect of local mitochondrial depolarization in guinea pig ventricular myocytes. Remarkably, a single local laser flash triggered synchronized and self-sustained oscillations in DeltaPsi(m), NADH, and ROS after a delay of similar to40s, in more than 70% of the mitochondrial population. Oscillations were initiated only after a specific threshold level of mitochondrially produced ROS was exceeded, and did not involve the classical permeability transition pore or intracellular Ca2+ overload. The synchronized transitions were abolished by several respiratory inhibitors or a superoxide dismutase mimetic. Anion channel inhibitors potentiated matrix ROS accumulation in the flashed region, but blocked propagation to the rest of the myocyte, suggesting that an inner membrane, super-oxide-permeable, anion channel opens in response to free radicals. The transitions in mitochondrial energetics were tightly coupled to activation of sarcolemmal K-ATP currents, causing oscillations in action potential duration, and thus might contribute to catastrophic arrhythmias during ischemia-reperfusion injury.	Johns Hopkins Univ, Inst Mol Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	O'Rourke, B (corresponding author), Johns Hopkins Univ, Inst Mol Cardiobiol, 720 Rutland Ave,844 Ross Bldg, Baltimore, MD 21205 USA.	bor@jhmi.edu	Marban, Eduardo/GWC-8514-2022; Aon, Miguel Antonio/A-6564-2008; Cortassa, Sonia/AAO-1633-2020	Aon, Miguel Antonio/0000-0002-4355-5431; Cortassa, Sonia/0000-0001-7224-9858; O'Rourke, Brian/0000-0002-5548-4853	NHLBI NIH HHS [R01HL54598, R37HL36957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036957, R01HL054598] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aon MA., 1997, DYNAMIC BIOL ORG FUN, V1st edn; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1989, J BIOL CHEM, V264, P1508; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANCE B, 1965, BIOCHEM Z, V341, P357; Cortassa S, 2003, BIOPHYS J, V84, P2734, DOI 10.1016/S0006-3495(03)75079-6; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Freeman FM, 2000, PHARMACOL BIOCHEM BE, V67, P355, DOI 10.1016/S0091-3057(00)00373-7; Gardner PR, 1996, ARCH BIOCHEM BIOPHYS, V325, P20, DOI 10.1006/abbi.1996.0003; HALLIWELL B, 1997, INTRO FREE RADICALS, P1; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JosephLiauzun E, 1997, J BIOL CHEM, V272, P28102, DOI 10.1074/jbc.272.44.28102; KINNALLY KW, 1993, P NATL ACAD SCI USA, V90, P1374, DOI 10.1073/pnas.90.4.1374; KORETSUNE Y, 1990, AM J PHYSIOL, V258, pH9, DOI 10.1152/ajpheart.1990.258.1.H9; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Murphy MP, 2001, BBA-BIOENERGETICS, V1504, P1, DOI 10.1016/S0005-2728(00)00234-6; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; O'Rourke B, 2000, J PHYSIOL-LONDON, V529, P23, DOI 10.1111/j.1469-7793.2000.00023.x; O'Rourke B, 1999, CURR TOP MEMBR, V46, P449; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; Romashko DN, 1998, P NATL ACAD SCI USA, V95, P1618, DOI 10.1073/pnas.95.4.1618; Saks VA, 2001, BIOCHEM J, V356, P643, DOI 10.1042/0264-6021:3560643; SIEMENS A, 1982, P NATL ACAD SCI-BIOL, V79, P466, DOI 10.1073/pnas.79.2.466; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZABO I, 1991, J BIOL CHEM, V266, P3376; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tsien Roger Y., 1995, P267; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Xu L, 1999, J BIOL CHEM, V274, P32680, DOI 10.1074/jbc.274.46.32680; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	60	407	425	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44735	44744		10.1074/jbc.M302673200	http://dx.doi.org/10.1074/jbc.M302673200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930841	hybrid			2022-12-27	WOS:000186306700107
J	Frank, C; Gonzalez, MM; Oinonen, C; Dunlop, TW; Carlberg, C				Frank, C; Gonzalez, MM; Oinonen, C; Dunlop, TW; Carlberg, C			Characterization of DNA complexes formed by the nuclear receptor constitutive androstane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; RESPONSIVE ENHANCER MODULE; THYROID-HORMONE; VITAMIN-D-3 RECEPTOR; ACTIVATION; MONOMERS; GENE; IDENTIFICATION; RECOGNITION; SUPERFAMILY	The nuclear receptor constitutive androstane receptor (CAR) acts as a xenobiotic sensor and regulates the expression of enzymes, such as several cytochromes P450s and the UDP-glucuronosyltransferase (UGT) type 1A1. CAR binds as a heterodimer with the retinoid X receptor (RXR) to specific DNA sites, called response elements (REs). Clusters of CAR REs, referred to as phenobarbital response enhancer modules (PBREMs), have been identified in several CAR target genes. In this study we confirm that REs formed by direct repeats of two AGTTCA hexamers with 4 spacing nucleotides are optimal for the binding of CAR-RXR heterodimers. In addition, we found that the heterodimers also form complexes on everted repeat-type arrangements with 8 spacing nucleotides. We also observed that CAR is able to bind DNA as a monomer and to interact in this form with different coregulators even in the presence of RXR. Systematic variation of the nucleotides 5'-flanking to both AGTTCA hexamers showed that the dinucleotide sequence modulates the DNA complex formation of CAR monomers and CAR-RXR heterodimer by a factor of up to 20. The highest preference was found for the sequence AG and lowest for CC. The increased DNA affinity of CAR is mediated by the positively charged arginines 90 and 91 located in the carboxyl-terminal extension of the DNA-binding domain of the receptor. Furthermore, we show that one of the three CAR REs of the human UGT1A1 PBREM is exclusively bound by CAR monomers and this is regulated by ligands that bind to this nuclear receptor. This points to a physiological role for CAR monomers. Therefore, both CAR-RXR heterodimers and CAR monomers can contribute to the gene activating function of PBREMs in CAR target genes.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				Auwerx J, 1999, CELL, V97, P161; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Carlberg C, 1999, BIOFACTORS, V10, P91, DOI 10.1002/biof.5520100202; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRONEMEYER H, 1995, NATURE, V375, P190, DOI 10.1038/375190a0; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Quack M, 2002, J CELL BIOCHEM, V86, P601, DOI 10.1002/jcb.10247; Quack M, 2001, BIOCHEM J, V360, P387, DOI 10.1042/0264-6021:3600387; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; Sierk ML, 2001, BIOCHEMISTRY-US, V40, P12833, DOI 10.1021/bi011086r; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2	42	51	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43299	43310		10.1074/jbc.M305186200	http://dx.doi.org/10.1074/jbc.M305186200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12896978	hybrid			2022-12-27	WOS:000186157000073
J	Hikino, M; Mikami, T; Faissner, A; Vilela-Silva, ACES; Pavao, MSG; Sugahara, K				Hikino, M; Mikami, T; Faissner, A; Vilela-Silva, ACES; Pavao, MSG; Sugahara, K			Oversulfated dermatan sulfate exhibits neurite outgrowth-promoting activity toward embryonic mouse hippocampal neurons - Implications of dermatan sulfate in neuritogenesis in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED MOLECULE; PHOSPHATASE ZETA/RPTP-BETA; AMYLOID PRECURSOR PROTEIN; HEPARIN COFACTOR-II; CHONDROITIN-SULFATE; IN-VITRO; HB-GAM; HEXASACCHARIDE SEQUENCES; ANTICOAGULANT ACTIVITY; INHIBITORY MOLECULES	Brain-specific chondroitin sulfate (CS) proteoglycan (PG) DSD-1-PG/6B4-PG/phosphacan isolated from neonatal mouse brains exhibits neurite outgrowth-promoting activity toward embryonic rat and mouse hippocampal neurons in vitro through the so-called DSD-1 epitope embedded in its glycosaminoglycan side chains. Oversulfated CS variants, CS-D from shark cartilage and CS-E from squid cartilage, also possess similar activities. We have proposed that the neuritogenic property of the DSD-1 epitope may be attributable to a distinct CS structure characterized by the disulfated D disaccharide unit [GlcUA(2S)-GalNAc(6S)]. In this study, we assessed neuritogenic potencies of various oversulfated dermatan sulfate (DS) preparations purified from hagfish notochord, the bodies of two kinds of ascidians and embryonic sea urchin, which are characterized by the predominant disulfated disaccharide units of [IdoUA-GalNAc(4S,6S)] (68%), [IdoUA(2S)-GalNAc(4S)](66%) plus [IdoUA(2S)-GalNAc(6S)](5%), [IdoUA(2S)-GalNAc (6S)] (>90%), and [IdoUA-GalNAc(4S,6S)] (74%), respectively. They exerted marked neurite outgrowth-promoting activities, resulting in distinct morphological features depending on the individual structural features. Such activities were not observed for a less sulfated DS preparation derived from porcine skin, which has a monosulfated disaccharide unit [IdoUA-GalNAc(4S)] as a predominant unit. The neurite outgrowth-promoting activities of these oversulfated DS preparations and DSD-1-PG were eliminated by the specific enzymatic cleavage of GalNAc-IdoUA linkages characteristic of DS using chondroitinase B. In addition, chemical analysis of the glycosaminoglycan side chains of DSD-1-PG revealed the DS-type structures. These observations suggest potential novel neurobiological functions of oversulfated DS structures and may reflect the physiological neuritogenesis during brain development by mammalian oversulfated DS structures exemplified by the DSD-1 epitope.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Ruhr Univ Bochum, Dept Cell Morphol & Mol Neurobiol, D-44801 Bochum, Germany; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim,Lab Tecido Conjunt, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil	Kobe Pharmaceutical University; Ruhr University Bochum; Universidade Federal do Rio de Janeiro	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.		Pavao, Mauro Sergio Goncalves/B-1979-2010; Faissner, Andreas/A-5314-2008	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; Faissner, Andreas/0000-0002-2211-8259				ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CACERES A, 1986, J NEUROSCI, V6, P714; CHAMAK B, 1989, DEVELOPMENT, V106, P483; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Elefteriou F, 2001, FEBS LETT, V495, P44, DOI 10.1016/S0014-5793(01)02361-4; FAISSNER A, 1995, GLIA, V13, P233, DOI 10.1002/glia.440130402; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FernaudEspinosa I, 1996, J NEUROBIOL, V30, P410, DOI 10.1002/(SICI)1097-4695(199607)30:3<410::AID-NEU9>3.0.CO;2-7; Garwood J, 1999, J NEUROSCI, V19, P3888; HIKINO M, 2002, SEIKAGAKU, V74, P734; Huston JP, 2000, NEUROSCIENCE, V100, P355, DOI 10.1016/S0306-4522(00)00270-0; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Koops A, 1996, MOL BRAIN RES, V41, P65, DOI 10.1016/0169-328X(96)00067-8; LAFONT F, 1992, DEVELOPMENT, V114, P17; LAFONT F, 1994, DEV BIOL, V165, P453, DOI 10.1006/dbio.1994.1267; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; LOCHTER A, 1993, J NEUROSCI, V13, P3986; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu T, 2001, TRENDS GLYCOSCI GLYC, V13, P563, DOI 10.4052/tigg.13.563; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V378, P78, DOI 10.1006/abbi.2000.1775; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; POOLE AR, 1986, BIOCHEM J, V236, P1; PROCHIANTZ A, 1995, NEURON, V15, P743, DOI 10.1016/0896-6273(95)90164-7; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; ROSEN L, 1980, BIOCH GLYCOPROTEINS, P491; ROUSSELET A, 1990, DEV BIOL, V137, P33, DOI 10.1016/0012-1606(90)90005-4; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; Salinero O, 2000, J NEUROSCI RES, V60, P87, DOI 10.1002/(SICI)1097-4547(20000401)60:1<87::AID-JNR9>3.0.CO;2-C; SCULLY MF, 1988, BIOCHEM J, V254, P547, DOI 10.1042/bj2540547; SMITHTHOMAS LC, 1995, J CELL SCI, V108, P1307; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; Vilela-Silva ACES, 2001, GLYCOBIOLOGY, V11, P433, DOI 10.1093/glycob/11.6.433; Yoshida K., 1993, DERMATAN SULFATE PRO, P55; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	68	104	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43744	43754		10.1074/jbc.M308169200	http://dx.doi.org/10.1074/jbc.M308169200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917413	hybrid			2022-12-27	WOS:000186157000124
J	Huang, FT; Jiang, XJ; Sorkin, A				Huang, FT; Jiang, XJ; Sorkin, A			Tyrosine phosphorylation of the beta 2 subunit of clathrin adaptor complex AP-2 reveals the role of a di-leucine motif in the epidermal growth factor receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED ENDOCYTOSIS; SORTING SIGNALS; STRUCTURAL EXPLANATION; EGF RECEPTORS; MU-2 SUBUNIT; BINDING; INTERNALIZATION; IDENTIFICATION; RECOGNITION; RESIDUES	Tyrosine phosphorylation of the beta2 subunit of clathrin adaptor complex AP-2 was detected in three types of cells treated with epidermal growth factor (EGF). The tyrosine phosphorylation was observed during recruitment of EGF receptors into coated pits at 4 degreesC and reached maximum at 37 degreesC at post-recruitment stages of endocytosis. An inhibitor of EGF receptor kinase completely abolished this phosphorylation in all cell types, whereas the inhibitor of Src family kinases partially inhibited beta2 phosphorylation in A-431 cells but not in HeLa cells. By using beta2 subunit tagged with yellow fluorescent protein that is effectively assembled into AP-2 complex, the major phosphorylation site of beta2 was mapped to Tyr-6. Analysis of cells expressing dominant-interfering mutant beta2 subunit of AP-2 suggested that beta2 phosphorylation is partially mediated by the receptor interaction with the mu2 subunit. Mutation of leucine residues 1010 and 1011 motif in the EGF receptor resulted in the severe inhibition of beta2 tyrosine phosphorylation. From these data, we propose that interactions of the EGF receptor with AP-2 mediated by the receptor (974)YRAL and di-leucine motifs may contribute to beta2 tyrosine phosphorylation. Surprisingly, mutation of the Leu-1010/Leu-1011 motif resulted in impaired degradation of EGF receptors, suggesting the role of this motif in lysosomal targeting of the receptor.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.	alexander.sorkin@uchsc.edu		Sorkin, Alexander/0000-0002-4446-1920	NCI NIH HHS [CA089151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLE S, 1989, J BIOL CHEM, V264, P20089; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Morrison P, 1996, BIOCHEMISTRY-US, V35, P14618, DOI 10.1021/bi961630+; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; Sorkina T, 1999, J CELL SCI, V112, P317; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635	37	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43411	43417		10.1074/jbc.M306072200	http://dx.doi.org/10.1074/jbc.M306072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12900408	hybrid			2022-12-27	WOS:000186157000085
J	Sakato, M; King, SM				Sakato, M; King, SM			Calcium regulates ATP-sensitive microtubule binding by Chlamydomonas outer arm dynein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITON-EXTRACTED MODELS; LIGHT-CHAIN; HEAVY-CHAIN; ALPHA-BETA; FLAGELLAR DYNEINS; DIVALENT-CATIONS; GAMMA-SUBUNIT; MOTOR DOMAIN; MUTANT; COMPLEX	The Chlamydomonas outer dynein arm contains three distinct heavy chains (alpha, beta, and gamma) that exhibit different motor properties. The LC4 protein, which binds 1 - 2 Ca2+ with K-Ca = 3 x 10(-5) M, is associated with the gamma heavy chain and has been proposed to act as a sensor to regulate dynein motor function in response to alterations in intraflagellar Ca2+ levels. Here we genetically dissect the outer arm to yield subparticles containing different motor unit combinations and assess the microtubule-binding properties of these complexes both prior to and following preincubation with tubulin and ATP, which was used to inhibit ATP-insensitive ( structural) microtubule binding. We observed that the gamma heavy chain exhibits a dominant Ca2+-independent ATP-sensitive MT binding activity in vitro that is inhibited by attachment of tubulin to the structural microtubule-binding domain. Furthermore, we show that ATP-sensitive microtubule binding by a dynein subparticle containing only the beta and gamma heavy chains does not occur at Ca2+ concentrations below pCa 6 but is maximally activated above pCa 5. This activity was not observed in mutant dyneins containing small deletions in the microtubule-binding region of the beta heavy chain or in dyneins that lack both the alpha heavy chain and the motor domain of the beta heavy chain. These findings strongly suggest that Ca2+ binding directly to a component of the dynein complex regulates ATP-sensitive interactions between the beta heavy chain and microtubules and lead to a model for how individual motor units are controlled within the outer dynein arm.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	King, SM (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, 263 Farmington Ave, Farmington, CT 06030 USA.	steve@king2.uchc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51293] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benashski SE, 1999, BIOCHEMISTRY-US, V38, P7253, DOI 10.1021/bi990466y; BESSEN M, 1980, J CELL BIOL, V86, P446, DOI 10.1083/jcb.86.2.446; BROKAW CJ, 1974, BIOCHEM BIOPH RES CO, V58, P795, DOI 10.1016/S0006-291X(74)80487-0; Casey DM, 2003, MOL BIOL CELL, V14, P3650, DOI 10.1091/mbc.E03-01-0057; DiBella LM, 2001, INT REV CYTOL, V210, P227; GIBBONS BH, 1984, NATURE, V309, P560, DOI 10.1038/309560a0; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; HAIMO LT, 1988, CELL MOTIL CYTOSKEL, V9, P129, DOI 10.1002/cm.970090205; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; Harrison A, 2002, CELL MOTIL CYTOSKEL, V52, P131, DOI 10.1002/cm.10044; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; KAMIYA R, 1984, J CELL BIOL, V98, P97, DOI 10.1083/jcb.98.1.97; KAMIYA R, 1985, J CELL SCI, V74, P181; KING SM, 1995, J CELL SCI, V108, P3757; KING SM, 1994, J BIOL CHEM, V269, P5452; KING SM, 1991, J BIOL CHEM, V266, P8401; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; LINDEMANN CB, 1988, CELL MOTIL CYTOSKEL, V10, P420, DOI 10.1002/cm.970100309; MITCHELL DR, 1985, J CELL BIOL, V100, P1228, DOI 10.1083/jcb.100.4.1228; MITCHELL DR, 1994, J CELL SCI, V107, P635; MOSS AG, 1992, J CELL BIOL, V118, P1189, DOI 10.1083/jcb.118.5.1189; MOSS AG, 1992, J CELL BIOL, V118, P1177, DOI 10.1083/jcb.118.5.1177; MOSS AG, 1999, MICROSC ANAL, V34, P7; NAITOH Y, 1973, J EXP BIOL, V58, P657; NAITOH Y, 1972, SCIENCE, V176, P523, DOI 10.1126/science.176.4034.523; Nakamura K, 1997, CELL MOTIL CYTOSKEL, V37, P338; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; PIPERNO G, 1981, CELL, V27, P331, DOI 10.1016/0092-8674(81)90416-5; PIPERNO G, 1992, J CELL BIOL, V118, P1455, DOI 10.1083/jcb.118.6.1455; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sakakibara H, 1998, J CELL SCI, V111, P1155; SAKAKIBARA H, 1991, J CELL BIOL, V113, P615, DOI 10.1083/jcb.113.3.615; SAKAKIBARA H, 1993, J CELL BIOL, V122, P653, DOI 10.1083/jcb.122.3.653; Sillen L.G., 1971, STABILITY CONSTANTS; TAKADA S, 1994, J CELL BIOL, V126, P737, DOI 10.1083/jcb.126.3.737; Wakabayashi K, 1997, CELL MOTIL CYTOSKEL, V38, P22, DOI 10.1002/(SICI)1097-0169(1997)38:1<22::AID-CM3>3.0.CO;2-J; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; Witman George B., 1993, Trends in Cell Biology, V3, P403, DOI 10.1016/0962-8924(93)90091-E; Wu HW, 2000, NAT STRUCT BIOL, V7, P575; Yang PF, 2001, J CELL BIOL, V153, P1315, DOI 10.1083/jcb.153.6.1315	42	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43571	43579		10.1074/jbc.M305894200	http://dx.doi.org/10.1074/jbc.M305894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923201	hybrid			2022-12-27	WOS:000186157000104
J	Egawa, T; Yoshioka, S; Takahashi, S; Hori, H; Nagano, S; Shimada, H; Ishimori, K; Morishima, I; Suematsu, M; Ishimura, Y				Egawa, T; Yoshioka, S; Takahashi, S; Hori, H; Nagano, S; Shimada, H; Ishimori, K; Morishima, I; Suematsu, M; Ishimura, Y			Kinetic and spectroscopic characterization of a hydroperoxy compound in the reaction of native myoglobin with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HORSERADISH-PEROXIDASE; CATALASE-PEROXIDASE; I FORMATION; MYCOBACTERIUM-TUBERCULOSIS; GEMINATE RECOMBINATION; LIGNIN PEROXIDASE; CRYSTAL-STRUCTURE; DISTAL HISTIDINE; LOW-TEMPERATURE	The reaction of metmyoglobin with H2O2 was investigated in a pH range between 8.5 and 6.0 with the aid of stopped flow-rapid scan and rapid freezing-EPR techniques. Singular value decomposition analyses of the stopped flow data at pH 8.5 revealed that a spectral species previously unknown accumulated during the reaction and exhibited a Soret absorption maximum at greater than or equal to423 nm. In the EPR experiments, the new species exhibited a set of g values at 2.32, 2.19, and 1.94, indicating that the species was assignable to a ferric hydroperoxy (Fe(III)[O-O-H](-)) compound. In contrast, the hydroperoxy compound scarcely accumulated in the reaction at pH 6.0, and the dominant intermediate species accumulated was compound I, which was derived from the oxygen-oxygen bond cleavage of the hydroperoxy compound. The accumulated amount of the hydroperoxy compound relative to compound I showed a pH dependence with an apparent pK(a) (pK(a)(app)) from 6.95 to 7.27 depending on the metmyoglobins examined. This variation in pK(a)(app) paralleled that in pK(a) of the acid-alkaline transition (pK(a)(AB)) of metmyoglobins, suggesting that the accumulation of hydroperoxy compound is controlled by the distal histidine. We propose that the H2O2 activation by metmyoglobin is promoted at the acidic condition due to the imidazolium form of the distal histidine, and we further propose that the controlled protonation state of the distal histidine is important for the facile O-O bond cleavage in heme peroxidases.	Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Osaka 5608531, Japan	Keio University; Kyoto University; Osaka University	Egawa, T (corresponding author), Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Ishimori, Koichiro/S-1247-2016; Suematsu, Makoto/I-8135-2013; Suematsu, Makoto/O-5762-2018; Ishimori, Koichiro/AAQ-4434-2021	Ishimori, Koichiro/0000-0002-5868-0462; Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336; Ishimori, Koichiro/0000-0002-5868-0462				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; Agner K., 1941, ACTA PHYSIOL SCAND, V2, P1; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, V21, P40; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, V21, P55; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BLEE E, 1990, J BIOL CHEM, V265, P12887; Brittain T, 1997, BIOCHEM J, V326, P109, DOI 10.1042/bj3260109; CUTNELL JD, 1981, J AM CHEM SOC, V103, P3567, DOI 10.1021/ja00402a053; Davydov R, 1999, J AM CHEM SOC, V121, P10654, DOI 10.1021/ja9918829; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; Denisov IG, 2002, J BIOL CHEM, V277, P42706, DOI 10.1074/jbc.M207949200; DEROPP JS, 1991, J BIOL CHEM, V266, P15001; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; ERMAN JE, 1992, J AM CHEM SOC, V114, P6592, DOI 10.1021/ja00042a068; Filizola M, 2000, J AM CHEM SOC, V122, P18, DOI 10.1021/ja992793z; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GASYNA Z, 1979, FEBS LETT, V106, P213, DOI 10.1016/0014-5793(79)80730-9; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; Golub G., 1965, SIAM J NUMER ANAL, V2, P205, DOI DOI 10.1137/0702016; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HEWSON WD, 1979, PORPHYRINS, V7, P295; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; HUG SJ, 1990, BIOCHEMISTRY-US, V29, P1475, DOI 10.1021/bi00458a019; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; LAMBRIGHT DG, 1993, BIOCHEMISTRY-US, V32, P10116, DOI 10.1021/bi00089a030; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; Matsui T, 1997, J BIOL CHEM, V272, P32735, DOI 10.1074/jbc.272.52.32735; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; NAGANO S, 1985, THESIS KYOTO U KYOTO; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; Ozaki S, 1998, J AM CHEM SOC, V120, P8020, DOI 10.1021/ja9714696; Palamakumbura AH, 1999, BIOCHEMISTRY-US, V38, P15647, DOI 10.1021/bi991497w; Palamakumbura AH, 1999, BIOCHEMISTRY-US, V38, P15653, DOI 10.1021/bi991498o; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; SATTERLEE JD, 1991, BIOCHEMISTRY-US, V30, P4398, DOI 10.1021/bi00232a005; Savenkova MI, 1996, J BIOL CHEM, V271, P24598, DOI 10.1074/jbc.271.40.24598; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SYMONS MCR, 1978, BIOCHIM BIOPHYS ACTA, V535, P241, DOI 10.1016/0005-2795(78)90090-9; Szabo Z. G., 1969, COMPREHENSIVE CHEM K, P1; TAJIMA K, 1989, INORG CHIM ACTA, V163, P115, DOI 10.1016/S0020-1693(00)87150-9; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9791, DOI 10.1021/bi9706172; Tanaka M, 2003, BIOPHYS J, V84, P1998, DOI 10.1016/S0006-3495(03)75008-5; THANABAL V, 1987, J AM CHEM SOC, V109, P7516, DOI 10.1021/ja00258a043; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; WALDA KN, 1994, BIOCHEMISTRY-US, V33, P2198, DOI 10.1021/bi00174a029; Wirstam M, 1999, J AM CHEM SOC, V121, P10178, DOI 10.1021/ja991997c; Woon DE, 1998, J PHYS CHEM A, V102, P10380, DOI 10.1021/jp9829896; YONETANI T, 1967, J BIOL CHEM, V242, P1974; Yonetani T., 1976, ENZYMES, P345	61	36	36	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41597	41606		10.1074/jbc.M210383200	http://dx.doi.org/10.1074/jbc.M210383200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902339	hybrid			2022-12-27	WOS:000185989500007
J	Hemish, J; Nakaya, N; Mittal, V; Enikolopov, G				Hemish, J; Nakaya, N; Mittal, V; Enikolopov, G			Nitric oxide activates diverse signaling pathways to regulate gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; P53; PROLIFERATION; FIBROBLASTS; INHIBITION; MICROARRAY; RESPONSES; ALPHA	Nitric oxide signaling is crucial for effecting long lasting changes in cells, including gene expression, cell cycle arrest, apoptosis, and differentiation. We have determined the temporal order of gene activation induced by NO in mammalian cells and have examined the signaling pathways that mediate the action of NO. Using microarrays to study the kinetics of gene activation by NO, we have determined that NO induces three distinct waves of gene activity. The first wave is induced within 30 min of exposure to NO and represents the primary gene targets of NO. It is followed by subsequent waves of gene activity that may reflect further cascades of NO-induced gene expression. We verified our results using quantitative real time PCR and further validated our conclusions about the effects of NO by using cytokines to induce endogenous NO production. We next applied pharmacological and genetic approaches to determine the signaling pathways that are used by NO to regulate gene expression. We used inhibitors of particular signaling pathways, as well as cells from animals with a deleted p53 gene, to define groups of genes that require phosphatidylinositol 3-kinase, protein kinase C, NF-kappaB, p53, or combinations thereof for activation by NO. Our results demonstrate that NO utilizes several independent signaling pathways to induce gene expression.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Enikolopov, G (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.		Enikolopov, Grigori N/B-7771-2009; Enikolopov, Grigori/P-5731-2019	Enikolopov, Grigori N/0000-0001-8178-8917; Enikolopov, Grigori/0000-0001-8178-8917				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bandman O, 2002, ANN NY ACAD SCI, V975, P77, DOI 10.1111/j.1749-6632.2002.tb05943.x; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Cappola TP, 2003, PHYSIOL GENOMICS, V14, P25, DOI 10.1152/physiolgenomics.00156.2002; Cardozo AK, 2001, J BIOL CHEM, V276, P48879, DOI 10.1074/jbc.M108658200; Demple B, 2002, MOL CELL BIOCHEM, V234, P11, DOI 10.1023/A:1015933216079; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GARG UC, 1990, BIOCHEM BIOPH RES CO, V171, P474, DOI 10.1016/0006-291X(90)91417-Q; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Nathan C, 2003, J CLIN INVEST, V111, P769, DOI 10.1172/JCI200318174; NESBITT JA, 1976, J BIOL CHEM, V251, P2344; Peunova N, 2001, J NEUROSCI, V21, P8809, DOI 10.1523/JNEUROSCI.21-22-08809.2001; Wang PG, 2002, CHEM REV, V102, P1091, DOI 10.1021/cr000040l; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Zamora R, 2002, NITRIC OXIDE-BIOL CH, V7, P165, DOI 10.1016/S1089-8603(02)00104-0; Zhao BT, 2003, AM J PHYSIOL-CELL PH, V284, pC1577, DOI 10.1152/ajpcell.00243.2002; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	30	125	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42321	42329		10.1074/jbc.M308192200	http://dx.doi.org/10.1074/jbc.M308192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907672	hybrid			2022-12-27	WOS:000185989500093
J	Saporita, AJ; Zhang, QH; Navai, N; Dincer, Z; Hahn, JH; Cai, XY; Wang, Z				Saporita, AJ; Zhang, QH; Navai, N; Dincer, Z; Hahn, JH; Cai, XY; Wang, Z			Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; LIVING CELLS; LOCALIZATION; DNA; TRAFFICKING; SEQUENCES; DYNAMICS; PROTEINS; MOVEMENT	Androgen receptor (AR) belongs to the steroid receptor superfamily that regulates gene expression in a ligand-dependent fashion. AR is localized to the cytoplasm in the absence of androgen and translocates into the nuclei to activate gene expression in the presence of ligand. Regulation of AR nuclear import and export represents an essential step in androgen action. A nuclear localization signal (NLS) has been identified in the DNA-binding domain and hinge region of AR and other steroid receptors. Studies on nuclear export of AR, however, are limited, and what might be the underlying mechanism regulating the intracellular localization of steroid receptors is unclear. Our studies have identified a leptomycin B-insensitive nuclear export signal (NESAR) in the ligand-binding domain of AR, which is active in the absence of androgen and repressed upon ligand binding. Consistent with its androgen-sensitivity, NESAR contains amino acid residues in the immediate vicinity of the bound ligand. NESAR is necessary for AR nuclear export and is dominant over the NLS in the DNA-binding domain and hinge region in the absence of hormone. Our findings suggest that androgen can regulate NESAR and, subsequently, the NLS of the AR, providing a mechanism by which androgen regulates AR nuclear/cytoplasmic shuttling. Estrogen receptor alpha and mineralocorticoid receptor also contain functional NES, suggesting that this ligand-regulated NES is conserved among steroid receptors.	Northwestern Univ, Freinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; Northwestern Univ, Freinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Freinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Wang, Z (corresponding author), Northwestern Univ, Freinberg Sch Med, Dept Urol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Dincer, Zehra/U-6023-2019		NCI NIH HHS [P50 CA 90386, T32 CA 80621] Funding Source: Medline; NIDDK NIH HHS [R01 DK 51193] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA080621, P50CA090386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051193] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; MAINWARING W, 1977, MECHAMISM ACTION AND, P10; Marte B, 2001, NAT CELL BIOL, V3, pE135, DOI 10.1038/35078596; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Poukka H, 2000, J CELL SCI, V113, P2991; Roy AK, 2001, ANN NY ACAD SCI, V949, P44; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; WEN W, 1994, J BIOL CHEM, V269, P32214; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	23	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41998	42005		10.1074/jbc.M302460200	http://dx.doi.org/10.1074/jbc.M302460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923188	hybrid			2022-12-27	WOS:000185989500143
J	Xu, L; Alarcon, X; Col, S; Massague, J				Xu, L; Alarcon, X; Col, S; Massague, J			Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; NUCLEOCYTOPLASMIC TRANSPORT; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN; IDENTIFICATION; RECOGNITION; CYTOPLASM; SYSTEM; SARA	Smad proteins undergo rapid nuclear translocation upon stimulation by transforming growth factor-beta (TGFbeta) and in so doing transduce the signal into the nucleus. In this report we unraveled nuclear import mechanisms of Smad3 and Smad4 that are dependent on their interaction with FG-repeat-containing nucleoporins such as CAN/Nup214, without the involvement of importin molecules that are responsible for most of the known nuclear import events. A surface hydrophobic corridor within the MH2 domain of Smad3 is critical for association with CAN/Nup214 and nuclear import, whereas Smad4 interaction with CAN/Nup214, and nuclear import requires structural elements present only in the full-length Smad4. As exemplified by the different susceptibility to inhibition of import by cytoplasmic retention factor SARA ( Smad anchor for receptor activation), such utilization of distinct domains for nuclear import of Smad3 and Smad4 suggests that nuclear transport of Smad3 and Smad4 is subject to control by different retention factors.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, Box 116,1275 York Ave, New York, NY 10021 USA.	j-massague@ski.mskcc.org		Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA 34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	37	93	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42569	42577		10.1074/jbc.M307601200	http://dx.doi.org/10.1074/jbc.M307601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917407	hybrid			2022-12-27	WOS:000185989500122
J	Charest, PG; Bouvier, M				Charest, PG; Bouvier, M			Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; RESONANCE ENERGY-TRANSFER; CONFORMATIONAL REQUIREMENTS; BETA-2-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL; INTERNALIZATION; KINASE; DESENSITIZATION	A large number of G protein-coupled receptors are palmitoylated on cysteine residues located in their carboxyl tail, but the general role of this post-translational modification remains poorly understood. Here we show that preventing palmitoylation of the V2 vasopressin receptor, by site-directed mutagenesis of cysteines 341 and 342, significantly delayed and decreased both agonist-promoted receptor endocytosis and mitogen-activated protein kinase activation. Pharmacological blockade of receptor endocytosis is without effect on the vasopressin-stimulated mitogen-activated protein kinase activity, excluding the possibility that the reduced kinase activation mediated by the palmitoylation-less mutant could result from altered receptor endocytosis. In contrast, two dominant negative mutants of beta-arrestin which inhibit receptor endocytosis also attenuated vasopressin-stimulated mitogen-activated protein kinase activity, suggesting that the scaffolding protein, beta-arrestin, represents the common link among receptor palmitoylation, endocytosis, and kinase activation. Coimmunoprecipitation and bioluminescence resonance energy transfer experiments confirmed that inhibiting receptor palmitoylation considerably reduced the vasopressin-stimulated recruitment of beta-arrestin to the receptor. Interestingly, the changes in beta-arrestin recruitment kinetics were similar to those observed for vasopressin-stimulated receptor endocytosis and mitogen-activated protein kinase activation. Taken together the results indicate that palmitoylation enhances the recruitment of beta-arrestin to the activated V2 vasopressin receptor thus facilitating processes requiring the scaffolding action of beta-arrestin.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Bouvier, M (corresponding author), Univ Montreal, Dept Biochim, CP 6128 Succursale Centreville, Montreal, PQ H3C 3J7, Canada.		Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; Cramer H, 2001, EUR J BIOCHEM, V268, P5449, DOI 10.1046/j.0014-2956.2001.02486.x; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Groarke DA, 2001, MOL PHARMACOL, V59, P375, DOI 10.1124/mol.59.2.375; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2002, J CELL SCI, V115, P455; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; PATTERSON SI, 1994, J CELL BIOL, V124, P521, DOI 10.1083/jcb.124.4.521; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pizard A, 2001, BIOCHEMISTRY-US, V40, P15743, DOI 10.1021/bi011600t; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Saouaf SJ, 1997, BIOCHEM BIOPH RES CO, V234, P325, DOI 10.1006/bbrc.1997.6638; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Thibonnier M, 1998, ADV EXP MED BIOL, V449, P251; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200	56	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41541	41551		10.1074/jbc.M306589200	http://dx.doi.org/10.1074/jbc.M306589200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900404	hybrid			2022-12-27	WOS:000185847200135
J	Endo, K; Takino, T; Miyamori, H; Kinsen, H; Yoshizaki, T; Furukawa, M; Sato, H				Endo, K; Takino, T; Miyamori, H; Kinsen, H; Yoshizaki, T; Furukawa, M; Sato, H			Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH-FACTOR; 1-MATRIX METALLOPROTEINASE; MOLECULAR-INTERACTIONS; PROMOTES ACTIVATION; POOR-PROGNOSIS; EXPRESSION; SURFACE; DIFFERENTIATION; MESOTHELIOMA	The transmembrane heparan sulfate proteoglycan syndecan-1 was identified from a human placenta cDNA library by the expression cloning method as a gene product that interacts with membrane type matrix metalloproteinase-1 (MT1-MMP). Co-expression of MT1-MMP with syndecan-1 in HEK293T cells promoted syndecan-1 shedding, and concentration of cell-associated syndecan-1 was reduced. Treatment of cells with MMP inhibitor BB-94 or tissue inhibitor of MMP (TIMP)-2 but not TIMP-1 interfered with the syndecan-1 shedding promoted by MT1-MMP expression. In contrast, syndecan-1 shedding induced by 12-O-tetradecanoylphorbol-13-acetate treatment was inhibited by BB-94 but not by either TIMP-1 or TIMP-2. Shedding of syndecan-1 was also induced by MT3-MMP but not by other MT-MMPs. Recombinant syndecan-1 core protein was shown to be cleaved by recombinant MT1-MMP or MT3-MMP preferentially at the Gly(245)-Leu(246) peptide bond. HT1080 fibrosarcoma cells stably transfected with the syndecan-1 cDNA (HT1080/SDC), which express endogenous MT1-MMP, spontaneously shed syndecan-1. Migration of HT1080/ SDC cells on collagen-coated dishes was significantly slower than that of control HT1080 cells. Treatment of HT1080/ SDC cells with BB-94 or TIMP-2 induced accumulation of syndecan-1 on the cell surface, concomitant with further retardation of cell migration. Substitution of Gly(245) of syndecan-1 with Leu significantly reduced shedding from HT1080/ SDC cells and cell migration. These results suggest that the shedding of syndecan-1 promoted by MT1-MMP through the preferential cleavage of Gly(245)-Leu(246) peptide bond stimulates cell migration.	Kanazawa Univ, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Otolaryngol, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University; Kanazawa University; Kanazawa University	Sato, H (corresponding author), Kanazawa Univ, Dept Mol Oncol & Virol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	vhsato@kenroku.kanazawa-u.ac.jp	SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015					Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; Anttonen A, 2001, LUNG CANCER, V32, P297, DOI 10.1016/S0169-5002(00)00230-0; Bayer-Garner IB, 2000, AM J DERMATOPATH, V22, P119, DOI 10.1097/00000372-200004000-00005; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; Gattei V, 1999, BRIT J HAEMATOL, V104, P152, DOI 10.1046/j.1365-2141.1999.01132.x; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Hiller O, 2000, J BIOL CHEM, V275, P33008, DOI 10.1074/jbc.M001836200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Joensuu H, 2002, CANCER RES, V62, P5210; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kiessling LL, 1998, CHEM BIOL, V5, pR49, DOI 10.1016/S1074-5521(98)90056-4; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Kumar-Singh S, 1998, J PATHOL, V186, P300, DOI 10.1002/(SICI)1096-9896(1998110)186:3<300::AID-PATH180>3.0.CO;2-Q; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Matsumoto A, 1997, INT J CANCER, V74, P482, DOI 10.1002/(SICI)1097-0215(19971021)74:5<482::AID-IJC2>3.0.CO;2-#; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Merlos-Suarez A, 1999, BIOCHEM SOC T, V27, P243, DOI 10.1042/bst0270243; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 2001, CANCER RES, V61, P8896; NOMURA H, 1995, CANCER RES, V55, P3263; NUMA F, 1995, CANCER RES, V55, P4676; Ohashi K, 2000, CANCER-AM CANCER SOC, V88, P2201, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2201::AID-CNCR2>3.3.CO;2-E; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Perrimon N, 2001, SEMIN CELL DEV BIOL, V12, P65, DOI 10.1006/scdb.2000.0237; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Pulkkinen JO, 1997, ACTA OTO-LARYNGOL, V117, P312, DOI 10.3109/00016489709117794; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Takino T, 2003, ONCOGENE, V22, P4617, DOI 10.1038/sj.onc.1206542; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; Ueno H, 1997, CANCER RES, V57, P2055; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Woods A, 2001, J CLIN INVEST, V107, P935, DOI 10.1172/JCI12802; Yamamoto H, 1999, CANCER RES, V59, P3313; Yamamoto H, 2001, CANCER-AM CANCER SOC, V91, P1324, DOI 10.1002/1097-0142(20010401)91:7<1324::AID-CNCR1135>3.0.CO;2-2; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	60	302	314	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40764	40770		10.1074/jbc.M306736200	http://dx.doi.org/10.1074/jbc.M306736200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904296	hybrid, Green Submitted			2022-12-27	WOS:000185847200044
J	Yeo, SJ; Yoon, JG; Yi, AK				Yeo, SJ; Yoon, JG; Yi, AK			Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA - Tumor necrosis factor-alpha receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA STABILITY; NF-KAPPA-B; P38 SIGNALING CASCADE; BACTERIAL-DNA; CELL-ACTIVATION; DENDRITIC CELLS; GENE-EXPRESSION; TRANSLATIONAL EFFICIENCY; 3'-UNTRANSLATED REGION	The immune stimulatory unmethylated CpG motifs present in bacterial DNA ( CpG DNA) induce expression of cyclooxygenase-2 (cox-2). The present study demonstrates that CpG DNA can up-regulate cox-2 expression by post-transcriptional mechanisms in RAW264.7 cells. To determine the CpG DNA-mediated signaling pathway that post-transcriptionally regulates cox-2 expression, a cox-2 translational reporter (COX2-3'-UTR-luciferase) was generated by inserting sequences within the 3'-untranslated region (UTR) of cox-2 to the 3' end of the luciferase gene under control of the SV40 promoter. CpG DNA-induced COX2-3'-UTR-luciferase activity was completely inhibited by an endosomal acidification inhibitor chloroquine, a Toll-like receptor 9 antagonist inhibitory CpG DNA, or overexpression of a dominant negative (DN) form of MyD88. However, overexpression of DN-IRAK-1 or DN-TRAF6 resulted in substantial, but not complete, inhibition of the CpG DNA-induced COX2-3'- UTR-luciferase activity. Activation of all three MAPKs (ERK, p38, and JNK) was required for optimal COX2-3'- UTR-luciferase activity induced by CpG DNA. Overexpression of DN-TRAF6 suppressed CpG DNA-mediated activation of p38 and JNK, but not ERK, explaining the partial inhibitory effects of DN-TRAF6 on CpG DNA-induced COX2-3'- UTR-luciferase activity. Co-expression of DN-TRAF6 and N17Ras completely inhibited CpG DNA-induced COX2-3'- UTR-luciferase activity, indicating the involvement of Ras in CpG DNA-mediated ERK and COX2-3'- UTR regulation. Collectively, our results suggest that MyD88 and MAPKs play a key regulatory role in CpG DNA-mediated cox-2 expression at the post-transcriptional level and that TRAF6 is a diverging point in the Toll-like receptor 9-signaling pathway for CpG DNA-mediated MAPK activation.	Univ Tennessee, Hlth Sci Ctr, Le Bonheur Childrens Med Ctr, Childrens Fdn Res Ctr,Dept Pediat, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Yi, AK (corresponding author), Univ Tennessee, Hlth Sci Ctr, Le Bonheur Childrens Med Ctr, Childrens Fdn Res Ctr,Dept Pediat, 50 N Dunlap St,WPT 315, Memphis, TN 38103 USA.				NIAMS NIH HHS [1R03AR47757, AR-47379] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047757, P30AR047379] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Chen CY, 2000, GENE DEV, V14, P1236; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Cowdery J, 1996, J IMMUNOL, V156, P4570; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Fitzgerald GA, 2002, AM J CARDIOL, V89, p26D; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Gay E, 2000, BIOCHEM BIOPH RES CO, V267, P509, DOI 10.1006/bbrc.1999.2000; Ghosh DK, 2001, INFECT IMMUN, V69, P7703, DOI 10.1128/IAI.69.12.7703-7710.2001; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; Jakob T, 1998, J IMMUNOL, V161, P3042; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lenert P, 2001, ANTISENSE NUCLEIC A, V11, P247, DOI 10.1089/108729001317022241; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Milas L, 2001, SEMIN RADIAT ONCOL, V11, P290, DOI 10.1053/srao.2001.26018; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; SANO H, 1995, CANCER RES, V55, P3785; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Stunz LL, 2002, EUR J IMMUNOL, V32, P1212, DOI 10.1002/1521-4141(200205)32:5<1212::AID-IMMU1212>3.0.CO;2-D; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeshita S, 2000, CELL IMMUNOL, V206, P101, DOI 10.1006/cimm.2000.1735; Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3263, DOI 10.1210/jc.87.7.3263; Tanji K, 2001, BBA-MOL CELL BIOL L, V1530, P227, DOI 10.1016/S1388-1981(01)00089-0; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Warren T L, 2000, Clin Lymphoma, V1, P57, DOI 10.3816/CLM.2000.n.005; Warren TL, 2000, J IMMUNOL, V165, P6244, DOI 10.4049/jimmunol.165.11.6244; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xu HM, 2003, J BIOL CHEM, V278, P36334, DOI 10.1074/jbc.M305698200; Yeo SJ, 2003, J BIOL CHEM, V278, P22563, DOI 10.1074/jbc.M302076200; Yi AK, 1999, INT IMMUNOL, V11, P2015, DOI 10.1093/intimm/11.12.2015; Yi AK, 1996, J IMMUNOL, V157, P5394; Yi AK, 1996, J IMMUNOL, V157, P4918; Yi AK, 1998, J IMMUNOL, V160, P1240; Yi AK, 2003, INT IMMUNOL, V15, P577, DOI 10.1093/intimm/dxg058; Yi AK, 1998, J IMMUNOL, V160, P5898; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1998, J IMMUNOL, V160, P4755; Yi AK, 1996, J IMMUNOL, V156, P558; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117	75	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40590	40600		10.1074/jbc.M306280200	http://dx.doi.org/10.1074/jbc.M306280200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902324	hybrid			2022-12-27	WOS:000185847200022
J	Zhang, GF; Dai, JY; Lu, ZB; Dunaway-Mariano, D				Zhang, GF; Dai, JY; Lu, ZB; Dunaway-Mariano, D			The phosphonopyruvate decarboxylase from Bacteroides fragilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-PHOSPHORUS BOND; ENZYME PYRUVATE DECARBOXYLASE; C-P BOND; THIAMIN DIPHOSPHATE; CRYSTAL-STRUCTURE; CAPSULAR POLYSACCHARIDES; PHOSPHOENOLPYRUVATE MUTASE; PYROPHOSPHATE-BINDING; ANGSTROM RESOLUTION; TRYPANOSOMA-CRUZI	The Bacteroides fragilis capsular polysaccharide complex is the major virulence factor for abscess formation in human hosts. Polysaccharide B of this complex contains a 2-aminoethylphosphonate functional group. This functional group is synthesized in three steps, one of which is catalyzed by phosphonopyruvate decarboxylase. In this paper, we report the cloning and overexpression of the B. fragilis phosphonopyruvate decarboxylase gene (aepY), purification of the phosphonopyruvate decarboxylase recombinant protein, and the extensive characterization of the reaction that it catalyzes. The homotrimeric ( 41,184-Da subunit) phosphonopyruvate decarboxylase catalyzes (k(cat) = 10.2 +/- 0.3 s(-1)) the decarboxylation of phosphonopyruvate (K-m = 3.2 +/- 0.2 muM) to phosphonoacetaldehyde (K-i = 15 +/- 2 muM) and carbon dioxide at an optimal pH range of 7.0-7.5. Thiamine pyrophosphate (K-m = 13 +/- 2 muM) and certain divalent metal ions (Mg(II) K-m = 82 +/- 8 muM; Mn(II) K-m = 13 +/- 1 muM; Ca(II) K-m = 78 +/- 6 muM) serve as cofactors. Phosphonopyruvate decarboxylase is a member of the alpha-ketodecarboxylase family that includes sulfopyruvate decarboxylase, acetohydroxy acid synthase/acetolactate synthase, benzoylformate decarboxylase, glyoxylate carboligase, indole pyruvate decarboxylase, pyruvate decarboxylase, the acetyl phosphate-producing pyruvate oxidase, and the acetate-producing pyruvate oxidase. The Mg( II) binding residue Asp-260, which is located within the thiamine pyrophosphate binding motif of the alpha-ketodecarboxylase family, was shown by site-directed mutagenesis to play an important role in catalysis. Pyruvate (k(cat) = 0.05 s(-1), K-m = 25 mM) and sulfopyruvate (k(cat) similar to 0.05 s(-1); K-i = 200 +/- 20 muM) are slow substrates for the phosphonopyruvate decarboxylase, indicating that this enzyme is promiscuous.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of New Mexico	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	dd39@unm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688, R01GM061099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 61099, GM 28688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON VE, 1984, BIOCHEMISTRY-US, V23, P2779, DOI 10.1021/bi00307a038; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Baker AS, 1998, BIOCHEMISTRY-US, V37, P9305, DOI 10.1021/bi972677d; BARRY RJ, 1988, BIOCHEM BIOPH RES CO, V153, P177, DOI 10.1016/S0006-291X(88)81205-1; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSAIGNE A, 1976, CR ACAD SCI D NAT, V282, P1637; Chipman D, 1998, BBA-PROTEIN STRUCT M, V1385, P401, DOI 10.1016/S0167-4838(98)00083-1; Coyne MJ, 2000, INFECT IMMUN, V68, P6176, DOI 10.1128/IAI.68.11.6176-6181.2000; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; Graupner M, 2000, J BACTERIOL, V182, P4862, DOI 10.1128/JB.182.17.4862-4867.2000; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; Jia Y, 1999, BIOCHEMISTRY-US, V38, P14165, DOI 10.1021/bi990771j; JIANG WH, 1995, J BACTERIOL, V177, P6411, DOI 10.1128/jb.177.22.6411-6421.1995; JUNG EH, 1988, INT J BIOCHEM, V20, P1255, DOI 10.1016/0020-711X(88)90228-5; Kalka-Moll WM, 2001, INFECT IMMUN, V69, P2339, DOI 10.1128/IAI.69.4.2339-2344.2001; KENNEDY KE, 1970, SCIENCE, V168, P989, DOI 10.1126/science.168.3934.989; Kim A, 1998, J BIOL CHEM, V273, P4443, DOI 10.1074/jbc.273.8.4443; Kim AD, 2002, J BACTERIOL, V184, P4134, DOI 10.1128/JB.184.15.4134-4140.2002; KIM JB, 1994, THESIS U MARYLAND CO; LANAUZE JM, 1970, BIOCHIM BIOPHYS ACTA, V212, P332, DOI 10.1016/0005-2744(70)90214-7; LIANG CR, 1968, BIOCHIM BIOPHYS ACTA, V156, P437, DOI 10.1016/0304-4165(68)90283-3; Liu SJ, 2002, BIOCHEMISTRY-US, V41, P10270, DOI 10.1021/bi026024v; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; Nakashita H, 1997, J ANTIBIOT, V50, P212, DOI 10.7164/antibiotics.50.212; Nakashita H, 2000, BBA-GENE STRUCT EXPR, V1490, P159, DOI 10.1016/S0167-4781(99)00249-3; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; Parker GF, 1999, J BACTERIOL, V181, P389, DOI 10.1128/JB.181.2.389-395.1999; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; Schwartz D, 1998, FEMS MICROBIOL LETT, V163, P149, DOI 10.1016/S0378-1097(98)00165-7; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Seto H, 1999, NAT PROD REP, V16, P589, DOI 10.1039/a809398i; Shin JEN, 1997, CARBOHYD RES, V305, P223; STEINER S, 1973, J BACTERIOL, V116, P1199, DOI 10.1128/JB.116.3.1199-1211.1973; TATE JR, 1987, ANAL BIOCHEM, V160, P78, DOI 10.1016/0003-2697(87)90616-6; Ternan NG, 1998, SYST APPL MICROBIOL, V21, P346, DOI 10.1016/S0723-2020(98)80043-X; Thompson C J, 1995, Biotechnology, V28, P197; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; TZIANABOS AO, 1992, J BIOL CHEM, V267, P18230; Tzianabos AO, 2000, INFECT IMMUN, V68, P6650, DOI 10.1128/IAI.68.12.6650-6655.2000; Wang Y, 2000, P NATL ACAD SCI USA, V97, P13478, DOI 10.1073/pnas.97.25.13478; WARREN WA, 1968, BIOCHIM BIOPHYS ACTA, V156, P340, DOI 10.1016/0304-4165(68)90263-8; WASSEF MK, 1977, BIOCHIM BIOPHYS ACTA, V486, P172, DOI 10.1016/0005-2760(77)90081-9; WHITE RH, 1986, BIOCHEMISTRY-US, V25, P5304, DOI 10.1021/bi00366a047	50	34	36	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41302	41308		10.1074/jbc.M305976200	http://dx.doi.org/10.1074/jbc.M305976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904299	hybrid			2022-12-27	WOS:000185847200109
J	Ishaq, M; DeGray, G; Natarajan, V				Ishaq, M; DeGray, G; Natarajan, V			Protein kinase C0 modulates nuclear receptor-corepressor interaction during T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; THYROID-HORMONE RECEPTORS; SMALL INTERFERING RNAS; RETINOID-X-RECEPTOR; PKC-THETA; MAMMALIAN-CELLS; IL-2 PROMOTER; LYMPHOCYTES; CALCINEURIN; TCR	Transcriptional repression by nuclear receptor corepressors plays a critical role in T cell development. However, the role of these corepressors in T cell activation is poorly understood. We report that T cell activation silenced transcription driven by nuclear receptors retinoic acid receptor, retinoid X receptor, and thyroid hormone receptor and induced silencing mediator of retinoic acid and thyroid hormone receptors (SMRT)-receptor interaction. Whereas the expression of a dominant active mutant of protein kinase Ctheta (PKCtheta) induced strong SMRT-receptor interaction in the absence of T cell activation, a dominant negative mutant of PKCtheta decreased the interaction. Loss of PKCtheta expression by induction of "RNA interference" resulted in the attenuation of basal and activation-induced SMRT-receptor interaction. We suggest that T cell activation silences nuclear receptor-dependent transactivation in part through PKCtheta-dependent enhancement of SMRT-receptor interaction.	NCI, Mol Cell Biol Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Ishaq, M (corresponding author), NCI, Mol Cell Biol Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA.				NCI NIH HHS [N0-CO12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Arendt CW, 2002, CURR OPIN IMMUNOL, V14, P323, DOI 10.1016/S0952-7915(02)00346-1; BAIER G, 1993, J BIOL CHEM, V268, P4997; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hudson DF, 2002, TRENDS CELL BIOL, V12, P281, DOI 10.1016/S0962-8924(02)02281-X; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Ishaq M, 2002, J IMMUNOL, V169, P732, DOI 10.4049/jimmunol.169.2.732; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jepsen K, 2002, J CELL SCI, V115, P689; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lin J, 2001, J CELL SCI, V114, P243; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Scherr M, 2003, CURR MED CHEM, V10, P245, DOI 10.2174/0929867033368493; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Villalba M, 1999, J IMMUNOL, V163, P5813; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	47	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39296	39302		10.1074/jbc.M302767200	http://dx.doi.org/10.1074/jbc.M302767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890684	hybrid			2022-12-27	WOS:000185713800006
J	Wegele, H; Muschler, P; Bunck, M; Reinstein, J; Buchner, J				Wegele, H; Muschler, P; Bunck, M; Reinstein, J; Buchner, J			Dissection of the contribution of individual domains to the ATPase mechanism of Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; TERMINAL DOMAINS; IN-VIVO; BINDING; HYDROLYSIS; CYCLE; HEAT-SHOCK-PROTEIN-90; RECEPTOR	Hsp90 is a dimeric, ATP-regulated molecular chaperone. Its ATPase cycle involves the N-terminal ATP binding domain (amino acids (aa) 1-272) and, in addition, to some extent the middle domain (aa 273-528) and the C-terminal dimerization domain (aa 529-709). To analyze the contribution of the different domains and the oligomeric state on the progression of the ATPase cycle of yeast Hsp90, we created deletion constructs lacking either the C-terminal or both the C-terminal and the middle domain. To test the effect of dimerization on the ATPase activity of the different constructs, we introduced a Cys residue at the C-terminal ends of the constructs, which allowed covalent dimerization. We show that all monomeric constructs tested exhibit reduced ATPase activity and a decreased affinity for ATP in comparison with wild type Hsp90. The covalently linked dimers lacking only the C-terminal domain hydrolyze ATP as efficiently as the wild type protein. Furthermore, this construct is able to trap the ATP molecule similar to the full-length protein. This demonstrates that in the ATPase cycle, the C-terminal domain can be replaced by a cystine bridge. In contrast, the ATPase activity of the artificially linked N-terminal domains remains very low and bound ATP is not trapped. Taken together, we show that both the dimerization of the N-terminal domains and the association of the N-terminal with the middle domain are important for the efficiency of the ATPase cycle. These reactions are synergistic and require Hsp90 to be in the dimeric state.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Max Planck Inst Med Res, Abt Biomol Mech, D-69120 Heidelberg, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Fersht A., 1999, STRUCTURE MECH PROTE, P103; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; GUTFREUND H, 1995, KINETICS LIFE SCI, P59; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheibel T, 1999, MOL MICROBIOL, V34, P701, DOI 10.1046/j.1365-2958.1999.01632.x; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	36	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39303	39310		10.1074/jbc.M305751200	http://dx.doi.org/10.1074/jbc.M305751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890674	hybrid			2022-12-27	WOS:000185713800007
J	Yada, T; Sato, T; Kaseyama, H; Gotoh, M; Iwasaki, H; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Watanabe, H; Narimatsu, H; Kimata, K				Yada, T; Sato, T; Kaseyama, H; Gotoh, M; Iwasaki, H; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Watanabe, H; Narimatsu, H; Kimata, K			Chondroitin sulfate synthase-3 - Molecular cloning and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; TUMOR SUPPRESSORS EXT1; N-ACETYLGALACTOSAMINYLTRANSFERASE; GLUCURONIC-ACID; HIGH-AFFINITY; EXPRESSION; GLUCURONOSYLTRANSFERASE; BIOSYNTHESIS; PROTEOGLYCAN; ENZYME	Recently, it has become evident that chondroitin sulfate (CS) glycosyltransferases, which transfer glucuronic acid and/or N-acetylgalactosamine residues from each UDP-sugar to the nonreducing terminus of the CS chain, form a gene family. We report here a novel human gene (GenBank(TM) accession number AB086062) that possesses a sequence homologous with the human chondroitin sulfate synthase-1 (CSS1) gene, formerly known as chondroitin synthase. The full-length open reading frame consists of 882 amino acids and encodes a typical type II membrane protein. This enzyme contains a beta3-glycosyltransferase motif and a beta4-glycosyltransferase motif similar to that found in CSS1. Both the enzymes were expressed in COS-7 cells as soluble proteins, and their enzymatic natures were characterized. Both glucuronyltransferase and N-acetylgalactosaminyltransferase activities were observed when chondroitin, CS polymer, and their corresponding oligosaccharides were used as the acceptor substrates, but no polymerization reaction was observed as in the case of CSS1. The new enzyme was thus designated chondroitin sulfate synthase-3 (CSS3). However, the specific activity of CSS3 was much lower than that of CSS1. The reaction products were shown to have a GlcUAbeta1-3GalNAc linkage and a GalNAcbeta1-4GlcUA linkage in the nonreducing terminus of chondroitin resulting from glucuronyltransferase activity and N-acetylgalactosaminyltransferase activity, respectively. Quantitative real time PCR analysis revealed that the transcript level of CSS3 was much lower than that of CSS1, although it was ubiquitously expressed in various human tissues. These results indicate that CSS3 is a glycosyltransferase having both glucuronyltransferase and N-acetylgalactosaminyltransferase activities. It may make a contribution to CS biosynthesis that differs from that of CSS1.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Seikagaku Corp, Tokyo 2070021, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mol & Cell Biol, Lab Gene Funct Anal, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648555, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan	Aichi Medical University; Seikagaku Corporation; National Institute of Advanced Industrial Science & Technology (AIST)	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@aichi-med-u.ac.jp	Togayachi, Akira/M-4144-2018; Sato, Takashi/M-2577-2018; Narimatsu, Hisashi/M-4757-2018	Togayachi, Akira/0000-0003-3600-9149; Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X; Watanabe, Hideto/0000-0001-5291-0696				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Kudo T, 2002, J BIOL CHEM, V277, P47724, DOI 10.1074/jbc.M205839200; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RAZIN E, 1982, J BIOL CHEM, V257, P7229; Sasai K, 2001, J BIOL CHEM, V276, P759, DOI 10.1074/jbc.M004972200; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; Wei G, 2000, J BIOL CHEM, V275, P27733; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	41	63	67	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39711	39725		10.1074/jbc.M304421200	http://dx.doi.org/10.1074/jbc.M304421200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12907687	hybrid			2022-12-27	WOS:000185713800057
J	Gonzalez, EM; Mongiat, M; Slater, SJ; Baffa, R; Iozzo, RV				Gonzalez, EM; Mongiat, M; Slater, SJ; Baffa, R; Iozzo, RV			A novel interaction between perlecan protein core and progranulin - Potential effects on tumor growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; EPITHELIAL-CELL GROWTH; BASEMENT-MEMBRANES; STABLE EXPRESSION; GENE-EXPRESSION; ANTISENSE CDNA; IN-VIVO; PRECURSOR; ANGIOGENESIS; GLYCOPROTEIN	In an in vivo search of novel partners for perlecan, a major heparan sulfate proteoglycan of basement membranes and cell surfaces, we identified progranulin, a secreted growth factor, as a strong interacting protein. Unambiguous interaction, first observed with the yeast two-hybrid system, was corroborated by co-immunoprecipitation studies using cell-free transcription/translation and transient cell transfection assays. The interaction of progranulin with perlecan domain V involved the first two laminin- and epidermal growth factor-like repeats. Within progranulin, the subdomains interacting most with perlecan harbored granulins F and B. Kinetics analysis of the interaction using surface plasmon resonance showed a saturable binding of relative low affinity (K-D similar to 1 muM). These results were supported by significant expression overlap of these two proteins in a series of ovarian tumor tissue microarrays. Progranulin was present within proliferating blood vessels of ovarian carcinomas and perivascular matrices, with a distribution similar to perlecan. Notably, both progranulin and domain V stimulated the growth of adrenal carcinoma cells. However, when used together in equimolar amounts, the two proteins counteracted each other's activity. Thus, progranulin/perlecan interaction could contribute to a fine regulation of tumor angiogenesis and could ultimately affect cancer growth.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020; Mongiat, Maurizio/H-8297-2018	Mongiat, Maurizio/0000-0001-6509-0068; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adatia R, 1997, ANN ONCOL, V8, P1257, DOI 10.1023/A:1008243115385; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; COHEN IR, 1994, CANCER RES, V54, P5771; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; He ZH, 1999, CANCER RES, V59, P3222; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jones MB, 2003, GYNECOL ONCOL, V88, pS136, DOI 10.1006/gyno.2002.6704; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	32	107	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38113	38116		10.1074/jbc.C300310200	http://dx.doi.org/10.1074/jbc.C300310200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12900424	hybrid			2022-12-27	WOS:000185575100003
J	Tang, ED; Inohara, N; Wang, CY; Nunez, G; Guan, KL				Tang, ED; Inohara, N; Wang, CY; Nunez, G; Guan, KL			Roles for homotypic interactions and transautophosphorylation in I kappa B kinase (IKK beta) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; PHOSPHORYLATION; ALPHA; RIP; COMPLEX; GAMMA; STIMULATION; SUBUNIT	The nuclear factor kappaB (NF-kappaB)/Rel family of transcription factors participates in a wide range of biological activities including inflammation, immunity, and apoptosis. NF-kappaB is kept inactive in the cytoplasm in unstimulated cells by virtue of the masking of its nuclear localization sequence by bound IkappaB protein. Cellular stimuli trigger the destruction of IkappaB proteins and the liberation of NF-kappaB to enter the nucleus and activate gene expression. A multisubunit IkappaB kinase complex (IKK) phosphorylates IkappaB proteins and mediates the activation of NF-kappaB by proinflammatory stimuli such as tumor necrosis factor alpha. Phosphorylation of IkappaB proteins triggers their polyubiquitination and their subsequent recognition and degradation by the proteasome. The IKK complex contains two catalytic subunits, IKKalpha and IKKbeta, and a noncatalytic subunit, NF-kappaB essential modifier/IKKgamma. IKK activation depends upon the phosphorylation of residues in the activation loop of IKKbeta and the subsequent activation of IKKbeta kinase activity. However, the events contributing to IKKbeta phosphorylation are not well understood. Here, we present evidence that the activation of IKKbeta depends on its ability to form homotypic interactions and to transautophosphorylate. We find that an intact leucine zipper in IKKbeta is necessary for homotypic interactions, kinase activation, and phosphorylation on its activation loop. Enforced oligomerization of an IKKbeta mutant defective in forming homotypic interactions restores kinase activation. Homotypic interactions allow IKKbeta molecules to transautophosphorylate one another on their activation loops. Finally, the oligomerization of IKKbeta is stimulated by tumor necrosis factor alpha in cultured cells. Our findings support a model whereby ligand-induced homotypic interactions between IKKbeta molecules result in IKKbeta phosphorylation and consequently IKK activation.	Univ Michigan, Dept Biol Chem, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Tang, ED (corresponding author), Univ Michigan, Dept Biol Chem, Sch Dent, Ann Arbor, MI 48109 USA.							Carter RS, 2003, J BIOL CHEM, V278, P19642, DOI 10.1074/jbc.M301705200; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Inohara N, 2000, J BIOL CHEM, V275, P27823; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; TANG ED, 2003, J BIOL CHEM; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	22	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38566	38570		10.1074/jbc.M304374200	http://dx.doi.org/10.1074/jbc.M304374200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12890679	hybrid			2022-12-27	WOS:000185575100059
J	Cheng, SL; Shao, JS; Charlton-Kachigian, N; Loewy, AP; Towler, DA				Cheng, SL; Shao, JS; Charlton-Kachigian, N; Loewy, AP; Towler, DA			Msx2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; MARROW STROMAL CELLS; VASCULAR CALCIFICATION; ARTERIAL CALCIFICATION; GENE-EXPRESSION; DEFICIENT MICE; TRANSCRIPTION; GROWTH; PROLIFERATION; OSTEOBLASTS	In the aorta, diabetes activates an osteogenic program that includes expression of bone morphogenetic protein-2 (BMP2) and the osteoblast homeoprotein Msx2. To evaluate BMP2-Msx2 signaling in vascular calcification, we studied primary aortic myofibroblasts. These cells express vascular smooth muscle cell (VSMC) markers, respond to BMP2 by up-regulating Msx2, and undergo osteogenic differentiation with BMP2 treatment or transduction with a virus encoding Msx2. The osteoblast factor osterix (Osx) is up-regulated 10-fold by Msx2, but Runx2 mRNA is unchanged; the early osteoblast marker alkaline phosphatase increases 50-fold with mineralized nodule formation enhanced 30-fold. Adipocyte markers are concomitantly suppressed. To better understand Msx2 actions on osteogenesis versus adipogenesis, mechanistic studies were extended to C3H10T1/2 mesenchymal cells. Msx2 enhances osteogenic differentiation in synergy with BMP2. Osteogenic actions depend upon intrinsic Msx2 DNA binding; the gain-of-function variant Msx2(P148H) directs enhanced mineralization, whereas the binding-deficient variant Msx2(T147A) is inactive. Adipogenesis ( lipid accumulation, Pparg expression) is inhibited by Msx2. By contrast, suppression of adipogenesis does not require Msx2 DNA binding; inhibition occurs in part via protein-protein interactions with C/EBPalpha that control Pparg transcription. Thus, Msx2 regulates osteogenic versus adipogenic differentiation of aortic myofibroblasts. Myofibroblasts capable of both fates can be diverted to the osteogenic lineage by BMP2-Msx2 signaling and contribute to vascular calcification.	Washington Univ, Med Ctr,Sch Med, Div Bone & Mineral Dis, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Med Ctr,Sch Med, Div Bone & Mineral Dis, Dept Med, Barnes Jewish Hosp N Campus,216 S Kingshighway Bl, St Louis, MO 63110 USA.			Towler, Dwight/0000-0003-2107-7923	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043731, P01AR032087] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL69229] Funding Source: Medline; NIAMS NIH HHS [P01-AR032087, R01-AR43731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Bostrom K, 2000, CRIT REV EUKAR GENE, V10, P151; Demer LL, 2002, CURR OPIN NEPHROL HY, V11, P437, DOI 10.1097/00041552-200207000-00011; Dennis JE, 2002, CELLS TISSUES ORGANS, V170, P73, DOI 10.1159/000046182; Doherty MJ, 1998, J BONE MINER RES, V13, P828, DOI 10.1359/jbmr.1998.13.5.828; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Ishimura E, 2002, DIABETOLOGIA, V45, P1446, DOI 10.1007/s00125-002-0920-8; Kalajzic I, 2001, VIROLOGY, V284, P37, DOI 10.1006/viro.2001.0903; Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parhami F, 1997, CURR OPIN LIPIDOL, V8, P312, DOI 10.1097/00041433-199710000-00010; PARK JC, 1993, AM HEART J, V125, P344, DOI 10.1016/0002-8703(93)90010-7; Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011; Rifas L, 1997, P NATL ACAD SCI USA, V94, P7549, DOI 10.1073/pnas.94.14.7549; Rosen ED, 2000, GENE DEV, V14, P1293; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Thomas T, 1999, ENDOCRINOLOGY, V140, P5036, DOI 10.1210/en.140.11.5036; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427; Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	41	279	295	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45969	45977		10.1074/jbc.M306972200	http://dx.doi.org/10.1074/jbc.M306972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925529	hybrid			2022-12-27	WOS:000186452300111
J	Rowlinson, SW; Kiefer, JR; Prusakiewicz, JJ; Pawlitz, JL; Kozak, KR; Kalgutkar, AS; Stallings, WC; Kurumbail, RG; Marnett, LJ				Rowlinson, SW; Kiefer, JR; Prusakiewicz, JJ; Pawlitz, JL; Kozak, KR; Kalgutkar, AS; Stallings, WC; Kurumbail, RG; Marnett, LJ			A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN G/H SYNTHASE-2; X-RAY-DIFFRACTION; SELECTIVE-INHIBITION; CRYSTAL-STRUCTURES; ARACHIDONIC-ACID; STRUCTURAL BASIS; NSAID BINDING; ACTIVE-SITE; H SYNTHASE	A variety of drugs inhibit the conversion of arachidonic acid to prostaglandin G(2) by the cyclooxygenase (COX) activity of prostaglandin endoperoxide synthases. Several modes of inhibitor binding in the COX active site have been described including ion pairing of carboxylic acid containing inhibitors with Arg-120 of COX-1 and COX-2 and insertion of arylsulfonamides and sulfones into the COX-2 side pocket. Recent crystallographic evidence suggests that Tyr-385 and Ser-530 chelate polar or negatively charged groups in arachidonic acid and aspirin. We tested the generality of this binding mode by analyzing the action of a series of COX inhibitors against site-directed mutants of COX-2 bearing changes in Arg-120, Tyr-355, Tyr-348, and Ser-530. Interestingly, diclofenac inhibition was unaffected by the mutation of Arg-120 to alanine but was dramatically attenuated by the S530A mutation. Determination of the crystal structure of a complex of diclofenac with murine COX-2 demonstrates that diclofenac binds to COX-2 in an inverted conformation with its carboxylate group hydrogen-bonded to Tyr-385 and Ser-530. This finding represents the first experimental demonstration that the carboxylate group of an acidic non-steroidal anti-inflammatory drug can bind to a COX enzyme in an orientation that precludes the formation of a salt bridge with Arg-120. Mutagenesis experiments suggest Ser-530 is also important in time-dependent inhibition by nimesulide and piroxicam.	Vanderbilt Univ, Sch Med,Dept Biochem, Vanderbilt Ingram Canc Ctr,Ctr Mol Toxicol, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med,Dept Chem, Vanderbilt Ingram Canc Ctr,Ctr Mol Toxicol, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Pfizer Inc, St Louis Res Labs, Chesterfield, MO 63017 USA	Vanderbilt University; Vanderbilt University; Pfizer	Kurumbail, RG (corresponding author), Pfizer Inc, St Louis Res Labs, Chesterfield, MO 63017 USA.	rgkuru@pfizer.com; marnett@toxicology.mc.vanderbilt.edu	ID, IMCACAT/D-5867-2014	Kiefer, James/0000-0001-6317-0902	NATIONAL CANCER INSTITUTE [R01CA089450, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, CA89450] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cromlish WA, 1996, BIOCHEM PHARMACOL, V52, P1777, DOI 10.1016/S0006-2952(96)00599-0; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; Fabiola GF, 1998, BIOORGAN MED CHEM, V6, P2337, DOI 10.1016/S0968-0896(98)80012-6; Garcia-Nieto R, 1999, RHEUMATOLOGY, V38, P14, DOI 10.1093/rheumatology/38.suppl_1.14; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; Guo QP, 1997, ARCH BIOCHEM BIOPHYS, V344, P150, DOI 10.1006/abbi.1997.0192; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hochgesang GP, 2000, J AM CHEM SOC, V122, P6514, DOI 10.1021/ja0003932; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Kalgutkar AS, 2000, J MED CHEM, V43, P2860, DOI 10.1021/jm000004e; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Kurumbail RG, 2001, CURR OPIN STRUC BIOL, V11, P752, DOI 10.1016/S0959-440X(01)00277-9; Llorens O, 2002, J MOL GRAPH MODEL, V20, P359, DOI 10.1016/S1093-3263(01)00135-8; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Mancini JA, 1997, MOL PHARMACOL, V51, P52, DOI 10.1124/mol.51.1.52; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563	36	234	243	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45763	45769		10.1074/jbc.M305481200	http://dx.doi.org/10.1074/jbc.M305481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925531	hybrid			2022-12-27	WOS:000186452300087
J	Vernell, R; Helin, K; Muller, H				Vernell, R; Helin, K; Muller, H			Identification of target genes of the p16(INK4A)-pRB-E2F pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P16(INK4A)-MEDIATED GROWTH SUPPRESSION; E2F TRANSCRIPTION FACTORS; CELL-CYCLE; TGF-BETA; RETINOBLASTOMA-PROTEIN; C-MYC; LYMPHOCYTE DEVELOPMENT; MICROARRAY ANALYSIS; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR	Deregulation of the retinoblastoma protein (pRB) pathway is a hallmark of human cancer. The core members of this pathway include the tumor suppressor protein, pRB, which through binding to a number of cellular proteins, most notably members of the E2F transcription factor family, regulates progression through the cell division cycle. With the aim of identifying transcriptional changes provoked by deregulation of the pRB pathway, we have used cell lines that conditionally express a constitutively active phosphorylation site mutant of pRB (pRBDeltaCDK) or p16(INK4A) (p16). The expression of pRBDeltaCDK and p16 resulted in significant repression and activation of a large number of genes as measured by high density oligonucleotide array analysis. Transcriptional changes were found in genes that are essential for DNA replication and cell proliferation. In agreement with previous results, we found a high degree of overlap between genes regulated by p16 and pRB. Data we have obtained previously for E2F family members showed that 74 of the genes repressed by pRB and p16 were induced by the E2Fs and 23 genes that were induced by pRB and p16 were repressed by the E2Fs. Thus, we have identified 97 genes as physiological targets of the pRB pathway, and the further characterization of these genes should provide insights into how this pathway controls proliferation. We show that Gibbs sampling detects enrichment of several sequence motifs, including E2F consensus binding sites, in the upstream regions of these genes and use this enrichment in an in silico filtering process to refine microarray derived gene lists.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; FIRC Inst Mol Oncol, I-20139 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	khelin@ieo.it	Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Muller, Heiko/0000-0001-9873-3146				Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BASCH RS, 1975, CELL IMMUNOL, V20, P218, DOI 10.1016/0008-8749(75)90099-4; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Geng Y, 1996, ONCOGENE, V12, P1173; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Markey MP, 2002, CANCER RES, V62, P6587; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McArthur GA, 1998, COLD SPRING HARB SYM, V63, P423, DOI 10.1101/sqb.1998.63.423; Milech N, 2001, GENE CHROMOSOME CANC, V32, P275, DOI 10.1002/gcc.1190; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SCHLESINGER DH, 1975, CELL, V5, P367, DOI 10.1016/0092-8674(75)90055-0; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; See MS, 1999, GENE, V240, P165, DOI 10.1016/S0378-1119(99)00415-1; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wong AKC, 2000, CANCER RES, V60, P6171; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	70	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46124	46137		10.1074/jbc.M304930200	http://dx.doi.org/10.1074/jbc.M304930200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12923195	hybrid			2022-12-27	WOS:000186452300130
J	Chang, JH; Mellon, E; Schanen, NC; Twiss, JL				Chang, JH; Mellon, E; Schanen, NC; Twiss, JL			Persistent TrkA activity is necessary to maintain transcription in neuronally differentiated PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; HIGH-AFFINITY RECEPTORS; NUCLEAR-PROTEIN CBP; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; SENSORY NEURONS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; FACTOR CREB	Neurotrophins are required for the differentiation and survival of several different neuronal subpopulations in the developing nervous system. The PC12 cell line responds to nerve growth factor (NGF) by withdrawing from the cell cycle and acquiring a sympathetic neuron-like phenotype. Previous studies have shown that the activation kinetics of the NGF receptor, TrkA, and downstream protein kinases appear rapid and seemingly transient after NGF treatment of naive PC12 cells. However, maintenance of the neuronal phenotype and survival of differentiated PC12 cells under serum-free conditions require constant NGF exposure. In this study we have addressed the mechanisms that NGF uses to maintain neuronal PC12 cells. We show that TrkA remains phosphorylated at a basal level throughout differentiation of the PC12 cells. The phospho-TrkA levels in the differentiated PC12 cells were diminished by both complete NGF withdrawal and pharmacological inhibition of Trk kinase activity. Intracellular sequestration of the majority of TrkA molecules ( both phosphorylated and nonphosphorylated TrkA) and persistent dephosphorylation of the small pool of cell surface TrkA renders the persistent phospho-TrkA signal in the differentiated PC12 cells resistant to partial NGF withdrawal as well as exposure to additional NGF. NGF regulated both extracellular-regulated kinases 1/2 and Akt activity in the differentiated PC12 cells via sustained TrkA activity. Moreover, analysis of transcription using activating protein 1-, serum response element-, and cyclic AMP response element- Luc reporter constructs showed that NGF regulated these promoters through TrkA activity in differentiated PC12 cells. Interestingly, the initial response of the cyclic AMP response element promoter to NGF was delayed, becoming Trk-dependent well beyond the peaks in TrkA and downstream protein kinase signal transduction.	Alfred I DuPont Hosp Children, Nemours Biomed Res, Neurosci Res Lab, Wilmington, DE 19803 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Cellular & Mol Pathol Grad Program, Los Angeles, CA 90095 USA	Nemours Alfred I. duPont Hospital for Children; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Twiss, JL (corresponding author), Alfred I DuPont Hosp Children, Nemours Biomed Res, Neurosci Res Lab, 1600 Rockland Rd, Wilmington, DE 19803 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK059752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041596] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 37874] Funding Source: Medline; NIDDK NIH HHS [DK 59752] Funding Source: Medline; NINDS NIH HHS [NS 41596] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Beattie EC, 2000, J NEUROSCI, V20, P7325; BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; BERG MM, 1992, J BIOL CHEM, V267, P13; BERND P, 1984, J BIOL CHEM, V259, P5509; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Canossa M, 1996, EMBO J, V15, P3369, DOI 10.1002/j.1460-2075.1996.tb00702.x; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes ML, 1996, J NEUROSCI, V16, P7950; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; Jiang H, 1997, J BIOL CHEM, V272, P6835, DOI 10.1074/jbc.272.11.6835; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Malcangio M, 1997, J NEUROSCI, V17, P8459; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Minneman KP, 2000, J NEUROCHEM, V74, P2392, DOI 10.1046/j.1471-4159.2000.0742392.x; MOHIUDDIN L, 1995, NEUROSCI LETT, V185, P20, DOI 10.1016/0304-3940(94)11215-5; MOLLIVER DC, 1995, J COMP NEUROL, V361, P404, DOI 10.1002/cne.903610305; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Senger DL, 1997, J CELL BIOL, V138, P411, DOI 10.1083/jcb.138.2.411; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH DS, 1989, J NEUROCHEM, V53, P800, DOI 10.1111/j.1471-4159.1989.tb11776.x; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAPLEY P, 1992, ONCOGENE, V7, P371; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsui-Pierchala BA, 1999, J NEUROSCI, V19, P8207; TWISS JL, 1995, J NEUROCHEM, V64, P550; Twiss JL, 1998, J NEUROSCI RES, V51, P442, DOI 10.1002/(SICI)1097-4547(19980215)51:4<442::AID-JNR4>3.0.CO;2-C; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Ye HH, 2003, NEURON, V39, P57, DOI 10.1016/S0896-6273(03)00266-6; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU J, 1995, J NEUROCHEM, V65, P1146	71	39	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42877	42885		10.1074/jbc.M308155200	http://dx.doi.org/10.1074/jbc.M308155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12909622	hybrid			2022-12-27	WOS:000186157000019
J	Miranda, KC; Joseph, SR; Yap, AS; Teasdale, RD; Stow, JL				Miranda, KC; Joseph, SR; Yap, AS; Teasdale, RD; Stow, JL			Contextual binding of p120(ctn) to E-cadherin at the basolateral plasma membrane in polarized epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; DI-LEUCINE MOTIF; CELL-ADHESION; P120 CATENIN; MDCK CELLS; CYTOPLASMIC TAIL; BETA-CATENIN; PROTEIN; COMPLEX; ENDOCYTOSIS	E-cadherin-catenin complexes mediate cell-cell adhesion on the basolateral membrane of epithelial cells. The cytoplasmic tail of E-cadherin supports multiple protein interactions, including binding of beta-catenin at the C terminus and of p120(ctn) to the juxtamembrane domain. The temporal assembly and polarized trafficking of the complex or its individual components to the basolateral membrane are not fully understood. In Madin-Darby canine kidney cells at steady state and after treatment with cycloheximide or temperature blocks, E-cadherin and beta-catenin localized to the Golgi complex, but p120ctn was found only at the basolateral plasma membrane. We previously identified a dileucine sorting motif (Leu(586)-Leu(587), termed S1) in the juxtamembrane domain of E-cadherin and now show that it is required to target full-length E-cadherin to the basolateral membrane. Removal of S1 resulted in missorting of E-cadherin mutants (EcadDeltaS1) to the apical membrane; beta-catenin was simultaneously missorted and appeared at the apical membrane. p120(ctn) was not mistargeted with EcadDeltaS1, but could be recruited to the E-cadherin-catenin complex only at the basolateral membrane. These findings help define the temporal assembly and sorting of the E-cadherin-catenin complex and show that membrane recruitment of p120(ctn) in polarized cells is contextual and confined to the basolateral membrane.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Stow, JL (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j.stow@imb.uq.edu.au	Teasdale, Rohan/AAD-6698-2019; Teasdale, Rohan D/B-2538-2009; Joseph, Shannon/F-9844-2011; Stow, Jennifer L/I-4723-2013; Yap, Alpha S./J-1554-2014	Teasdale, Rohan/0000-0001-7455-5269; Teasdale, Rohan D/0000-0001-7455-5269; Stow, Jennifer L/0000-0002-5409-9101; Yap, Alpha S./0000-0002-1038-8956				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Bello V, 2001, MOL BIOL CELL, V12, P3004, DOI 10.1091/mbc.12.10.3004; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DECURTIS I, 1988, EXP CELL RES, V175, P248, DOI 10.1016/0014-4827(88)90190-5; El Nemer W, 1999, J BIOL CHEM, V274, P31903, DOI 10.1074/jbc.274.45.31903; Fujita H, 1999, BIOCHEM BIOPH RES CO, V255, P54, DOI 10.1006/bbrc.1998.0140; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GALLOWAY CJ, 1988, METHOD ENZYMOL, V157, P601; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KOOY J, 1992, J BIOL CHEM, V267, P20255; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; LEVINE E, 1994, DEVELOPMENT, V120, P901; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	46	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43480	43488		10.1074/jbc.M305525200	http://dx.doi.org/10.1074/jbc.M305525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923199	hybrid			2022-12-27	WOS:000186157000093
J	Murakami, M; Yamamura, H; Suzuki, T; Kang, MG; Ohya, S; Murakami, A; Miyoshi, I; Sasano, H; Muraki, K; Hano, T; Kasai, N; Nakayama, S; Campbell, KP; Flockerzi, V; Imaizumi, Y; Yanagisawa, T; Iijima, T				Murakami, M; Yamamura, H; Suzuki, T; Kang, MG; Ohya, S; Murakami, A; Miyoshi, I; Sasano, H; Muraki, K; Hano, T; Kasai, N; Nakayama, S; Campbell, KP; Flockerzi, V; Imaizumi, Y; Yanagisawa, T; Iijima, T			Modified cardiovascular L-type channels in mice lacking the voltage-dependent Ca2+ channel beta 3 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; INACTIVATION; ALPHA(1); HEART	The beta subunits of voltage-dependent calcium channels are known to modify calcium channel currents through pore-forming alpha(1) subunits. Of the four beta subunits reported to date, the beta3 subunit is highly expressed in smooth muscle cells and is thought to consist of L-type calcium channels. To determine the role of the beta3 subunit in the voltage-dependent calcium channels of the cardiovascular system in situ, we performed a series of experiments in beta-null mice. Western blot analysis indicated a significant reduction in expression of the alpha(1) subunit in the plasma membrane of beta3-null mice. Dihydropyridine binding experiments also revealed a significant decrease in the calcium channel population in the aorta. Electrophysiological analyses indicated a 30% reduction in Ca2+ channel current density, a slower inactivation rate, and a decreased dihydropyridine-sensitive current in beta3-null mice. The reductions in the peak current density and inactivation rate were reproduced in vitro by co-expression of the calcium channel subunits in Chinese hamster ovary cells. Despite the reduced channel population, beta3-null mice showed normal blood pressure, whereas a significant reduction in dihydropyridine responsiveness was observed. A high salt diet significantly elevated blood pressure only in the beta3-null mice and resulted in hypertrophic changes in the aortic smooth muscle layer and cardiac enlargement. In conclusion, this study demonstrates the involvement and importance of the beta3 subunit of voltage-dependent calcium channels in the cardiovascular system and in regulating channel populations and channel properties in vascular smooth muscle cells.	Akita Univ, Sch Med, Dept Pharmacol, Akita 0108543, Japan; Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol & Cellular Pharmacol, Nagoya, Aichi 4678603, Japan; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Inst Anim Experimentat, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Mol Pharmacol, Sendai, Miyagi 9808575, Japan; Wakayama Med Coll, Dept Med, Div Cardiol, Wakayama 6418509, Japan; Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Nagoya, Aichi 4668550, Japan; Univ Iowa, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	Akita University; Nagoya City University; Tohoku University; Tohoku University; Tohoku University; Wakayama Medical University; Nagoya University; Howard Hughes Medical Institute; University of Iowa; Saarland University	Murakami, A (corresponding author), Akita Univ, Sch Med, Dept Pharmacol, 1-1-1 Hondou, Akita 0108543, Japan.	manabumurakami@excite.co.jp	Ohya, Susumu/AAB-3618-2020; Imaizumi, Yuji/AAF-6585-2020	Ohya, Susumu/0000-0002-5765-0667; Kang, Myoung-Goo/0000-0003-2649-219X; Campbell, Kevin/0000-0003-2066-5889				Aoyama M, 2003, BIOPHYS J, V84, P709, DOI 10.1016/S0006-3495(03)74890-5; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; BOSSE E, 1992, EMBO J, V11, P2033, DOI 10.1002/j.1460-2075.1992.tb05260.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; IMAIZUMI Y, 1990, J PHYSIOL-LONDON, V427, P301, DOI 10.1113/jphysiol.1990.sp018173; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; LACINOVA L, 1995, J PHARMACOL EXP THER, V274, P54; Murakami M, 2002, J BIOL CHEM, V277, P40342, DOI 10.1074/jbc.M203425200; Murakami M, 2000, J CARDIOVASC PHARM, V36, pS69, DOI 10.1097/00005344-200000006-00015; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NEHER E, 1992, METHOD ENZYMOL, V207, P123; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; Ohi Y, 2001, J PHYSIOL-LONDON, V534, P313, DOI 10.1111/j.1469-7793.2001.t01-3-00313.x; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STRIESSNIG J, 1986, FEBS LETT, V197, P204, DOI 10.1016/0014-5793(86)80327-1; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WELLING A, 1993, J PHYSIOL-LONDON, V471, P749, DOI 10.1113/jphysiol.1993.sp019926; WELLING A, 1995, PFLUG ARCH EUR J PHY, V429, P400, DOI 10.1007/BF00374156; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754	29	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43261	43267		10.1074/jbc.M211380200	http://dx.doi.org/10.1074/jbc.M211380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920136	hybrid, Green Submitted			2022-12-27	WOS:000186157000068
J	Rodriguez, CI; Girones, N; Fresno, M				Rodriguez, CI; Girones, N; Fresno, M			Cha, a basic helix-loop-helix transcription factor involved in the regulation of upstream stimulatory factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; T-CELL; GENE-EXPRESSION; MAMMALIAN-CELLS; FACTOR-BINDING; USF FAMILY; ACTIVATION; CD2; PROMOTER	We report here the characterization of Cha, a transcription factor of the basic helix-loop-helix (bHLH) family. The basic region of Cha shares DNA-interacting amino acids with members of class C bHLH transcription factors. In addition, the HLH region of Cha presents a Myc-type dimerization domain signature required for heterodimer formation between members of this class. Cha protein and mRNA were ubiquitously expressed in many human tissues. Electrophoretic mobility shift assays showed that Cha and upstream stimulatory factor (USF)-1 formed a complex that specifically bound to E-box DNA elements. Moreover, pull-down and co-immunoprecipitation experiments showed an interaction between Cha and USF-1. Cha did not bind to E-box DNA elements and required USF-1 for protein-DNA complex formation. Moreover, Cha inhibited USF-1-stimulated transcription of CD2 (a USF-1-dependent gene) and E-box promoter reporter plasmids. Chromatin immunoprecipitation assays showed that Cha occupied the CD2 promoter in resting, but not in mitogen-stimulated, T cells. Finally, Cha mRNA and protein expression were high in resting T cells and absent in mitogen-activated T cells and inversely correlated with CD2 expression. Contrarily, overexpression of Cha in T cells significantly reduced CD2 expression. In summary, our results indicated that Cha is a new bHLH transcription factor that negatively regulates USF-dependent transcription.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Fresno, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain.		Girones, Nuria/L-7865-2017; Gironès, Núria/AAR-7436-2020; Rodriguez, Clara I./E-5402-2012; Rodríguez, Clara/E-4835-2012	Girones, Nuria/0000-0002-8130-2750; Gironès, Núria/0000-0002-8130-2750; Rodriguez, Clara I./0000-0002-6749-6288; Girones Pujol, Nuria/0000-0002-0932-5018; Fresno Escudero, Manuel/0000-0002-9223-5477				ALCONADA A, 1994, J BIOL CHEM, V269, P13670; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CANTRELL DA, 1988, EUR J IMMUNOL, V18, P1391, DOI 10.1002/eji.1830180914; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; Giannola DM, 2000, J EXP MED, V192, P1479, DOI 10.1084/jem.192.10.1479; Girones N, 2001, J CLIN INVEST, V107, P985, DOI 10.1172/JCI10734; HAHN WC, 1993, J IMMUNOL, V150, P2607; Heckert LL, 2001, MOL ENDOCRINOL, V15, P704, DOI 10.1210/me.15.5.704; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; Howcroft TK, 1999, MOL CELL BIOL, V19, P4788; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; Krones A, 2001, ENDOCRINOLOGY, V142, P2707, DOI 10.1210/en.142.6.2707; LARSSON LG, 1994, ONCOGENE, V9, P1247; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Maruyama O, 1998, CYTOGENET CELL GENET, V82, P41, DOI 10.1159/000015061; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONOSTORI E, 1990, J IMMUNOL, V144, P1010; Moon YS, 2000, J BIOL CHEM, V275, P10121, DOI 10.1074/jbc.275.14.10121; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; Peters MA, 1997, MOL CELL BIOL, V17, P1037, DOI 10.1128/MCB.17.3.1037; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; Sambrook J., 2002, MOL CLONING LAB MANU; Sasada T, 2001, J IMMUNOL, V166, P2394, DOI 10.4049/jimmunol.166.4.2394; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Smih F, 2002, DIABETES, V51, P293, DOI 10.2337/diabetes.51.2.293; Tibaldi EV, 2002, P NATL ACAD SCI USA, V99, P7582, DOI 10.1073/pnas.112212699; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	48	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43135	43145		10.1074/jbc.M300053200	http://dx.doi.org/10.1074/jbc.M300053200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923186	hybrid			2022-12-27	WOS:000186157000054
J	Zhao, RX; Fu, XQ; Teng, LR; Li, QS; Zhao, ZHJ				Zhao, RX; Fu, XQ; Teng, LR; Li, QS; Zhao, ZHJ			Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC-CELL DEVELOPMENT; ACTIVATED PROTEIN-KINASE; CRYSTAL-STRUCTURE; NOONAN-SYNDROME; PTPN11 MUTATIONS; SH2 DOMAINS; SH-PTP2; INSULIN; PURIFICATION	SHP-2 is an Src homology 2 (SH2) domain-containing tyrosine phosphatase with crucial functions in cell signaling and major pathological implications. It stays inactive in the cytosol and is activated by binding through its SH2 domains to tyrosine-phosphorylated receptors on the cell surface. One such cell surface protein is PZR, which contains two tyrosine-based inhibition motifs responsible for binding of SHP-2. We have generated a glutathione S-transferase fusion protein carrying the tandem tyrosine-based inhibition motifs of PZR, and the protein was tyrosine-phosphorylated by co-expressing c-Src in Escherichia coli cells. The purified phosphoprotein displays a strong binding to SHP-2 and causes its activation in vitro. However, when introduced into NIH 3T3 cells by using a protein delivery reagent, it effectively inhibited the activation of ERK1/2 induced by growth factors and serum but not by phorbol ester, in reminiscence of the effects caused by expression of dominant negative SHP-2 mutants and deletion of functional SHP-2. The data suggest that the exogenously introduced PZR protein specifically binds SHP-2, blocks its translocation, and renders it functionally incompetent. This is further supported by the fact that the phosphorylated PZR protein had no inhibitory effects on fibroblasts derived from mice expressing only a mutant SHP-2 protein lacking most of the N-terminal SH2 domain. This study thus provides a novel and highly specific method to interrupt the function of SHP-2 in cells.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA; Jilin Univ, Coll Life Sci, Key Lab Mol Enzymol & Engn, Minist Educ, Changchun 130023, Peoples R China	Vanderbilt University; Jilin University	Zhao, ZHJ (corresponding author), 777,PRB,2220 Pierce Ave, Nashville, TN 37232 USA.				NCI NIH HHS [CA75218] Funding Source: Medline; NHLBI NIH HHS [HL57393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075218] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Dunican DJ, 2001, BIOPOLYMERS, V60, P45, DOI 10.1002/1097-0282(2001)60:1<45::AID-BIP1003>3.3.CO;2-0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Maheshwari M, 2002, HUM MUTAT, V20, P298, DOI 10.1002/humu.10129; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; XIAO S, 1994, J BIOL CHEM, V269, P21244; Xu MJ, 2000, J BIOL CHEM, V275, P17440, DOI 10.1074/jbc.M001313200; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035; Zhao RX, 2002, J BIOL CHEM, V277, P7882, DOI 10.1074/jbc.M111914200; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	38	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42893	42898		10.1074/jbc.M306136200	http://dx.doi.org/10.1074/jbc.M306136200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12913007	hybrid			2022-12-27	WOS:000186157000021
J	Balasubramanian, S; Kuppuswamy, D				Balasubramanian, S; Kuppuswamy, D			RGD-containing peptides activate S6K1 through beta(3) integrin in adult cardiac muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SIGNALING PATHWAY; FOCAL COMPLEX-FORMATION; MATRIX METALLOPROTEINASES; MONOCLONAL-ANTIBODIES; PROTEIN-SYNTHESIS; HEART-FAILURE; IN-VIVO; C-SRC; P70; PHOSPHORYLATION	The enzyme p70S6 kinase (S6K1) is critical for cell growth, and we have reported its activation during cardiac hypertrophy. Because cardiac hypertrophy also involves integrin activation, we analyzed whether integrins could contribute to S6K1 activation. Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation. Perturbation of specific integrin function with blocking antibodies and by overexpressing the beta(1A) cytoplasmic tail revealed that beta(3) but not beta(1) integrin mediates the RGD-induced S6K1 activation. This activation is focal adhesion complex-independent and is accompanied by the activation of extracellular signal-regulated kinases 1/2 (ERK) and mammalian target of rapamycin (mTOR). Studies using specific inhibitors and dominant negative c-Raf expression in cardiomyocytes indicate that the S6K1 activation involves mTOR, MEK/ERK, and phosphatidylinositol 3-kinase pathways and is independent of protein kinase C and c-Raf. Finally, addition of fluorescent-labeled RGD peptide to cardiomyocytes exhibits its internalization and localization to the endocytic vesicles, and pretreatment of cardiomyocytes with endocytic inhibitors reduced the S6K1 activation. These data suggest that RGD interaction with beta(3) integrin and its subsequent endocytosis trigger specific signaling pathway(s) for S6K1 activation in cardiomyocytes and that this process may contribute to hypertrophic growth and remodeling of myocardium.	Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kuppuswamy, D (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 114 Doughty St, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL 48788] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Blystone SD, 2002, J BIOL CHEM, V277, P46886, DOI 10.1074/jbc.M209506200; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Castel S, 2001, LAB INVEST, V81, P1615, DOI 10.1038/labinvest.3780375; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Erbacher P, 1999, GENE THER, V6, P138, DOI 10.1038/sj.gt.3300783; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; GARFIELD RE, 1975, LAB INVEST, V33, P418; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Goto M, 1999, J AM SOC NEPHROL, V10, P1640; Hein TW, 2001, AM J PHYSIOL-HEART C, V281, pH2378, DOI 10.1152/ajpheart.2001.281.6.H2378; HELFRICH MH, 1992, J BONE MINER RES, V7, P345; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Hoshijima M, 2002, J CLIN INVEST, V109, P849, DOI 10.1172/JCI15380; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200; Li YY, 2000, CARDIOVASC RES, V46, P214, DOI 10.1016/S0008-6363(00)00003-1; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lindemann S, 2001, J BIOL CHEM, V276, P33947, DOI 10.1074/jbc.M104281200; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MANN DL, 1991, CIRC RES, V68, P402, DOI 10.1161/01.RES.68.2.402; MARINO TA, 1983, ANAT REC, V207, P417, DOI 10.1002/ar.1092070304; Mde N. Soeiro, 2002, CELL STRUCT FUNCT, V27, P469; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nagai T, 1999, AM J CARDIOL, V83, p38H; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Pabla R, 1999, J CELL BIOL, V144, P175, DOI 10.1083/jcb.144.1.175; PAGE E, 1994, CIRC RES, V75, P335, DOI 10.1161/01.RES.75.2.335; PAGE E, 1993, AM J PHYSIOL, V365, pC986; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Perlot RL, 2002, J BONE MINER RES, V17, P66, DOI 10.1359/jbmr.2002.17.1.66; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Ross RS, 2001, CIRC RES, V88, P1112, DOI 10.1161/hh1101.091862; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Shai SY, 2002, CIRC RES, V90, P458, DOI 10.1161/hh0402.105790; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; TERADA N, 1993, J BIOL CHEM, V268, P12062; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; TRANQUI L, 1993, J CELL SCI, V106, P377; Triantafilou K, 2001, CRIT REV IMMUNOL, V21, P311; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Whittard JD, 2001, J CELL SCI, V114, P3265; WILDENTHAL K, 1980, FED PROC, V39, P37; Willey CD, 2003, J MOL CELL CARDIOL, V35, P671, DOI 10.1016/S0022-2828(03)00112-3; Wilson EM, 2001, ANN MED, V33, P623, DOI 10.3109/07853890109002108; Zhao MW, 1999, INVEST OPHTH VIS SCI, V40, P2713	65	40	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42214	42224		10.1074/jbc.M303428200	http://dx.doi.org/10.1074/jbc.M303428200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909616	hybrid			2022-12-27	WOS:000185989500080
J	Hartlieb, B; Modrof, J; Muhlberger, E; Klenk, HD; Becker, S				Hartlieb, B; Modrof, J; Muhlberger, E; Klenk, HD; Becker, S			Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; PROTEIN OLIGOMERIZATION; SECONDARY STRUCTURE; MARBURG-VIRUS; DOMAIN; PROMOTER; TRANSACTIVATION; PHOSPHORYLATION; REPLICATION; EXPRESSION	Transcription of Ebola virus ( EBOV)-specific mRNA is driven by the nucleocapsid proteins NP, VP35, and L. This process is further dependent on VP30, an essential EBOV-specific transcription factor. The present study addresses the self-assembly of VP30 and the functional significance of this process for viral transcription and propagation. Essential for oligomerization of VP30 is a region spanning amino acids 94 - 112. Within this region a cluster of four leucine residues is of critical importance. Mutation of only one of these leucine residues resulted in oligomerization-deficient VP30 molecules that were no longer able to support EBOV-specific transcription. The essential role of homo-oligomerization for the function of VP30 was further corroborated by the finding that mixed VP30 oligomers consisting of VP30 and transcriptionally inactive VP30 mutants were impaired in their ability to support EBOV transcription. The dominant negative effect of these VP30 mutants was dependent on their ability to bind to VP30. The oligomerization of VP30 could be dose dependently inhibited by a 25-mer peptide (E30(pep)-wt) derived from the presumed oligomerization domain (IC50, 1 muM). A control peptide (E30(pep)-3LA), in which three leucines were changed to alanine, had no inhibitory effect. Thus, E30(pep)-wt seemed to bind efficiently to VP30 and consequently blocked the oligomerization of the protein. When E30(pep)-wt was transfected into EBOV-infected cells, the peptide inhibited viral replication suggesting that inhibition of VP30 oligomerization represents a target for EBOV antiviral drugs.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Becker, S (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.		Modrof, Jens/AAU-4681-2020; Muhlberger, Elke/AAD-6924-2019; Modrof, Jens/AAQ-8751-2020	Modrof, Jens/0000-0001-8416-7681; Muhlberger, Elke/0000-0003-3547-9376				[Anonymous], 2001, Wkly Epidemiol Rec, V76, P41; Ashmole I, 1998, VIROLOGY, V240, P221, DOI 10.1006/viro.1997.8909; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; BECKER S, 1992, MED MICROBIOL IMMUN, V181, P43, DOI 10.1007/BF00193395; BOWEN ETW, 1977, LANCET, V1, P571; Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Choudhary SK, 2002, VIROLOGY, V302, P373, DOI 10.1006/viro.2002.1668; Conzelmann KK, 1998, ANNU REV GENET, V32, P123, DOI 10.1146/annurev.genet.32.1.123; CURRAN J, 1995, VIROLOGY, V214, P139, DOI 10.1006/viro.1995.9946; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; ELLIOTT LH, 1985, VIROLOGY, V147, P169, DOI 10.1016/0042-6822(85)90236-3; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003; Lium EK, 1998, J VIROL, V72, P7785, DOI 10.1128/JVI.72.10.7785-7795.1998; Lutzke RAP, 1998, J VIROL, V72, P4841, DOI 10.1128/JVI.72.6.4841-4848.1998; Maroun RG, 2001, BIOCHEMISTRY-US, V40, P13840, DOI 10.1021/bi011328n; Modrof J, 2003, J VIROL, V77, P3334, DOI 10.1128/JVI.77.5.3334-3338.2003; Modrof J, 2002, J BIOL CHEM, V277, P33099, DOI 10.1074/jbc.M203775200; Modrof J, 2001, VIROLOGY, V287, P171, DOI 10.1006/viro.2001.1027; Muhlberger E, 1999, J VIROL, V73, P2333; Noda T, 2002, J VIROL, V76, P4855, DOI 10.1128/JVI.76.10.4855-4865.2002; Olson VA, 2001, J VIROL, V75, P6042, DOI 10.1128/JVI.75.13.6042-6051.2001; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SANCHEZ A, 1989, VIROLOGY, V170, P81, DOI 10.1016/0042-6822(89)90354-1; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Thomas SL, 1998, J VIROL, V72, P2935, DOI 10.1128/JVI.72.4.2935-2944.1998; Timmins J, 2003, J MOL BIOL, V326, P493, DOI 10.1016/S0022-2836(02)01406-7; Volchkov VE, 2001, SCIENCE, V291, P1965, DOI 10.1126/science.1057269; Weik M, 2002, J VIROL, V76, P8532, DOI 10.1128/JVI.76.17.8532-8539.2002; *WHO, 1995, EPIDEMIOL B, V16, P16; *WHO, 1999, WKLY EPIDEMIOL REC, V74, P145	37	56	61	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41830	41836		10.1074/jbc.M307036200	http://dx.doi.org/10.1074/jbc.M307036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912982	hybrid			2022-12-27	WOS:000185989500035
J	Kok, T; Hulzebos, CV; Wolters, H; Havinga, R; Agellon, LB; Stellaard, F; Shan, B; Schwarz, M; Kuipers, F				Kok, T; Hulzebos, CV; Wolters, H; Havinga, R; Agellon, LB; Stellaard, F; Shan, B; Schwarz, M; Kuipers, F			Enterohepatic circulation of bile salts in farnesoid x receptor-deficient mice - Efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; BILIARY CHOLESTEROL SECRETION; NUCLEAR RECEPTOR; ACTIVATED RECEPTOR; CHOLIC-ACID; EXPORT PUMP; GENE; EXPRESSION; TRANSPORTERS; DISRUPTION	The bile salt-activated farnesoid X receptor (FXR; NR1H4) controls expression of several genes considered crucial in maintenance of bile salt homeostasis. We evaluated the physiological consequences of FXR deficiency on bile formation and on the kinetics of the enterohepatic circulation of cholate, the major bile salt species in mice. The pool size, fractional turnover rate, synthesis rate, and intestinal absorption of cholate were determined by stable isotope dilution and were related to expression of relevant transporters in the livers and intestines of FXR-deficient (Fxr(-/-)) mice. Fxr(-/-) mice showed only mildly elevated plasma bile salt concentrations associated with a 2.4-fold higher biliary bile salt output, whereas hepatic mRNA levels of the bile salt export pump were decreased. Cholate pool size and total bile salt pool size were increased by 67 and 39%, respectively, in Fxr(-/-) mice compared with wild-type mice. The cholate synthesis rate was increased by 85% in Fxr(-/-) mice, coinciding with a 2.5-fold increase in cholesterol 7alpha-hydroxylase (Cyp7a1) and unchanged sterol 12alpha-hydroxylase (Cyp8b1) expression in the liver. Despite a complete absence of ileal bile acid-binding protein mRNA and protein, the fractional turnover rate and cycling time of the cholate pool were not affected. The calculated amount of cholate reabsorbed from the intestine per day was similar to2-fold higher in Fxr(-/-) mice than in wild-type mice. Thus, the absence of FXR in mice is associated with defective feedback inhibition of hepatic cholate synthesis, which leads to enlargement of the circulating cholate pool with an unaltered fractional turnover rate. The absence of ileal bile acid-binding protein does not negatively interfere with the enterohepatic circulation of cholate in mice.	Univ Groningen, Univ Groningen Hosp, Ctr Liver Digest & Metab Dis,Inst Drug Explorat, Pediat Lab, NL-9713 GZ Groningen, Netherlands; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Tularik Inc, San Francisco, CA 94080 USA	University of Groningen; University of Alberta; University of Alberta	Kok, T (corresponding author), Univ Groningen, Univ Groningen Hosp, Ctr Liver Digest & Metab Dis,Inst Drug Explorat, Pediat Lab, CMC 4,Rm Y2-163,Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.	T.Kok@med.rug.nl	Hulzebos, Christian Victor/AAY-6803-2021	Hulzebos, Christian Victor/0000-0002-8159-7501; Kuipers, Folkert/0000-0003-2518-737X				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Claudel T, 2002, J CLIN INVEST, V109, P961; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; DUANE WC, 1995, J LIPID RES, V36, P96; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hofmann AF, 1999, NEWS PHYSIOL SCI, V14, P24, DOI 10.1152/physiologyonline.1999.14.1.24; Hulzebos CV, 2003, J PHARMACOL EXP THER, V304, P356, DOI 10.1124/jpet.102.041640; Hulzebos CV, 2001, J LIPID RES, V42, P1923; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kok T, 2003, BIOCHEM J, V369, P539, DOI 10.1042/BJ20020981; Kosters A, 2003, J HEPATOL, V38, P710, DOI 10.1016/S0168-8278(03)00093-X; KUIPERS F, 1988, J CLIN INVEST, V81, P1593, DOI 10.1172/JCI113493; KUIPERS F, 1985, GASTROENTEROLOGY, V88, P403, DOI 10.1016/0016-5085(85)90499-8; Kuipers F, 1996, HEPATOLOGY, V24, P241; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Labonte ED, 2003, PROTEIN EXPRES PURIF, V28, P25, DOI 10.1016/S1046-5928(02)00561-2; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Landrier JF, 2002, MOL CELL BIOCHEM, V239, P149, DOI 10.1023/A:1020557502795; Li-Hawkins J, 2002, J CLIN INVEST, V110, P1191, DOI 10.1172/JCI200216309; Lin YG, 1996, HEPATOLOGY, V23, P218; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MASHIGE F, 1976, CLIN CHIM ACTA, V70, P79, DOI 10.1016/0009-8981(76)90007-3; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; Miyake JH, 2001, J BIOL CHEM, V276, P23304, DOI 10.1074/jbc.M101853200; PARMENTIER G, 1978, J CHROMATOGR, V152, P285, DOI 10.1016/S0021-9673(00)85370-4; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; SETCHELL KD, 1988, BILE ACIDS CHEM PHYS, P457; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STELLAARD F, 1984, J LIPID RES, V25, P1313; Torchia EC, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-11; VERKADE HJ, 1995, HEPATOLOGY, V21, P1174; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wolters H, 2002, J HEPATOL, V37, P556, DOI 10.1016/S0168-8278(02)00247-7; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	55	168	171	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41930	41937		10.1074/jbc.M306309200	http://dx.doi.org/10.1074/jbc.M306309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917447	hybrid			2022-12-27	WOS:000185989500047
J	Metz, TO; Alderson, NL; Chachich, ME; Thorpe, SR; Baynes, JW				Metz, TO; Alderson, NL; Chachich, ME; Thorpe, SR; Baynes, JW			Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo - Evidence on the role of lipids in chemical modification of protein and development of diabetic complications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED GLYCATION REACTIONS; POST-AMADORI; INHIBITOR PYRIDOXAMINE; OXIDATIVE STRESS; MAILLARD REACTION; END-PRODUCTS; RISK-FACTORS; LIPOXIDATION; QUANTIFICATION; GLYCOXIDATION	Maillard or browning reactions between reducing sugars and protein lead to formation of advanced glycation end products (AGEs) and are thought to contribute to the pathogenesis of diabetic complications. AGE inhibitors such as aminoguanidine and pyridoxamine (PM) inhibit both the formation of AGEs and development of complications in animal models of diabetes. PM also inhibits the chemical modification of protein by advanced lipoxidation end products (ALEs) during lipid peroxidation reactions in vitro. We show here that several PM adducts, formed in incubations of PM with linoleate and arachidonate in vitro, are also excreted in the urine of PM-treated animals. The PM adducts N-nonanedioyl-PM (derived from linoleate), N-pentanedioyl-PM, N-pyrrolo-PM, and N-(2-formyl)-pyrrolo-PM (derived from arachidonate), and N-formyl-PM and N- hexanoyl-PM (derived from both fatty acids) were quantified by liquid chromatography-mass spectrometry analysis of rat urine. Levels of these adducts were increased 5-10-fold in the urine of PM-treated diabetic and hyperlipidemic rats, compared with control animals. We conclude that the PM functions, at least in part, by trapping intermediates in AGE/ALE formation and propose a mechanism for PM inhibition of AGE/ALE formation involving cleavage of alpha-dicarbonyl intermediates in glycoxidation and lipoxidation reactions. We also conclude that ALEs derived from polyunsaturated fatty acids are increased in diabetes and hyperlipidemia and may contribute to development of long term renal and vascular pathology in these diseases.	Univ S Carolina, Dept Chem & Biochem, Grad Sci Res Ctr, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Baynes, JW (corresponding author), Univ S Carolina, Dept Chem & Biochem, Grad Sci Res Ctr, 631 Sumter St, Columbia, SC 29208 USA.	john.baynes@sc.edu		Metz, Tom/0000-0001-6049-3968	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19971] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alderson NL, 2003, KIDNEY INT, V63, P2123, DOI 10.1046/j.1523-1755.2003.00027.x; BATTISTI WP, 2003, IN PRESS CLIN CHEM L; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; Ceriello A, 2003, DIABETES CARE, V26, P1589, DOI 10.2337/diacare.26.5.1589; Chaturvedi N, 2001, KIDNEY INT, V60, P219, DOI 10.1046/j.1523-1755.2001.00789.x; Chew E Y, 1997, Curr Opin Ophthalmol, V8, P59, DOI 10.1097/00055735-199706000-00011; CULL C, 1993, DIABETOLOGIA, V36, P1021; D'Silva C, 1998, J ORG CHEM, V63, P6715, DOI 10.1021/jo971365d; Degenhardt TP, 2002, KIDNEY INT, V61, P939, DOI 10.1046/j.1523-1755.2002.00207.x; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Glomb MA, 2001, J BIOL CHEM, V276, P41638, DOI 10.1074/jbc.M103557200; Halliwell B., 1999, FREE RADICAL BIO MED, Vthird, P246; HAYASE F, 1985, AGR BIOL CHEM TOKYO, V49, P467, DOI 10.1080/00021369.1985.10866744; Kato Y, 1999, J BIOL CHEM, V274, P20406, DOI 10.1074/jbc.274.29.20406; Khalifah RG, 1996, BIOCHEMISTRY-US, V35, P4645, DOI 10.1021/bi9525942; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; Kreisberg RA, 1998, AM J CARDIOL, V82, p67U, DOI 10.1016/S0002-9149(98)00848-0; Miyata T, 2000, J AM SOC NEPHROL, V11, P1744, DOI 10.1681/ASN.V1191744; Miyata T, 1999, KIDNEY INT, V55, P389, DOI 10.1046/j.1523-1755.1999.00302.x; Miyata TR, 1998, KIDNEY INT, V54, P1290, DOI 10.1046/j.1523-1755.1998.00093.x; Muntner P, 2000, KIDNEY INT, V58, P293, DOI 10.1046/j.1523-1755.2000.00165.x; Nagaraj RH, 2002, ARCH BIOCHEM BIOPHYS, V402, P110, DOI 10.1016/S0003-9861(02)00067-X; Newman JW, 2002, J LIPID RES, V43, P1563, DOI 10.1194/jlr.D200018-JLR200; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Spiteller G, 2001, EXP GERONTOL, V36, P1425, DOI 10.1016/S0531-5565(01)00131-0; Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; van Leiden HA, 2002, DIABETES CARE, V25, P1320, DOI 10.2337/diacare.25.8.1320; Viberti G, 2003, J HYPERTENS, V21, pS3; Voziyan PA, 2002, J BIOL CHEM, V277, P3397, DOI 10.1074/jbc.M109935200; YAMADA H, 1975, YAKUGAKU ZASSHI, V95, P487, DOI 10.1248/yakushi1947.95.5_487	35	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42012	42019		10.1074/jbc.M304292200	http://dx.doi.org/10.1074/jbc.M304292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923193	hybrid			2022-12-27	WOS:000185989500056
J	Steinbacher, S; Schiffmann, S; Richter, G; Huber, R; Bacher, A; Fischer, M				Steinbacher, S; Schiffmann, S; Richter, G; Huber, R; Bacher, A; Fischer, M			Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase from Methanococcus jannaschii in complex with divalent metal ions and the substrate ribulose 5-phosphate - Implications for the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; D-XYLOSE ISOMERASE; ESCHERICHIA-COLI; CYCLOHYDROLASE-II; CRYSTAL-STRUCTURE; RIBOFLAVIN; BIOSYNTHESIS; PURIFICATION; DEAMINASE; REDUCTASE	Skeletal rearrangements of carbohydrates are crucial for many biosynthetic pathways. In riboflavin biosynthesis ribulose 5-phosphate is converted into 3,4-dihydroxy-2-butanone 4-phosphate while its C4 atom is released as formate in a sequence of metal-dependent reactions. Here, we present the crystal structure of Methanococcus jannaschii 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with the substrate ribulose 5-phosphate at a dimetal center presumably consisting of non-catalytic zinc and calcium ions at 1.7-Angstrom resolution. The carbonyl group (O2) and two out of three free hydroxyl groups (OH3 and OH4) of the substrate are metal-coordinated. We correlate previous mutational studies on this enzyme with the present structural results. Residues of the first coordination sphere involved in metal binding are indispensable for catalytic activity. Only Glu-185 of the second coordination sphere cannot be replaced without complete loss of activity. It contacts the C3 hydrogen atom directly and probably initiates enediol formation in concert with both metal ions to start the reaction sequence. Mechanistic similarities to Rubisco acting on the similar substrate ribulose 1,5-diphosphate in carbon dioxide fixation as well as other carbohydrate (reducto-) isomerases are discussed.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Max Planck Society; Technical University of Munich	Steinbacher, S (corresponding author), CALTECH, Div Chem & Chem Engn, Mail Code 114-96, Pasadena, CA 91125 USA.	steinbac@caltech.edu	Fischer, Markus/AFT-1856-2022; Fischer, Markus J./G-9477-2012; Richter, Gerald/F-3642-2011	Fischer, Markus/0000-0001-7243-4199; Schiffmann, Susanne/0000-0001-5035-2504				ANDREWS TJ, 1991, J BIOL CHEM, V266, P9447; Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; Bacher A., 1996, ESCHERICHIA COLI SAL, V1, P657; BACHER A, 2001, BIOSYNTHESIS RIBOFLA, P61; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer S, 2003, J MOL BIOL, V326, P1463, DOI 10.1016/S0022-2836(03)00059-7; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Bornemann S, 2002, NAT PROD REP, V19, P761, DOI 10.1039/b108916c; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURROWS RB, 1978, J BACTERIOL, V136, P657, DOI 10.1128/JB.136.2.657-667.1978; CALLENS M, 1988, BIOCHEM J, V250, P285, DOI 10.1042/bj2500285; CALVIN M, 1954, Fed Proc, V13, P697; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; COLLYER CA, 1990, J MOL BIOL, V212, P211, DOI 10.1016/0022-2836(90)90316-E; Dumas R, 2001, ACCOUNTS CHEM RES, V34, P399, DOI 10.1021/ar000082w; Feierberg I, 2002, THEOR CHEM ACC, V108, P71, DOI 10.1007/s00214-002-0365-7; Fischer M, 2003, J MOL BIOL, V326, P783, DOI 10.1016/S0022-2836(02)01473-0; Fischer M, 2002, J BIOL CHEM, V277, P41410, DOI 10.1074/jbc.M206863200; FOOR F, 1975, J BIOL CHEM, V250, P3545; Garcia-Viloca M, 2002, J AM CHEM SOC, V124, P7268, DOI 10.1021/ja026383d; HARZER G, 1978, BIOCHIM BIOPHYS ACTA, V540, P48, DOI 10.1016/0304-4165(78)90433-6; HOLLANDER I, 1979, BIOCHEM BIOPH RES CO, V89, P759, DOI 10.1016/0006-291X(79)90694-6; JONES TA, 1992, MOL REPLACEMENT, P91; Kelly MJS, 2001, P NATL ACAD SCI USA, V98, P13025, DOI 10.1073/pnas.231323598; LARIMER FW, 1994, J BIOL CHEM, V269, P11114; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee J., 1985, CHEM BIOLUMINESCENCE, P401; Liao DI, 2002, BIOCHEMISTRY-US, V41, P1795, DOI 10.1021/bi015652u; Liao DI, 2001, STRUCTURE, V9, P11, DOI 10.1016/S0969-2126(00)00550-5; MEIGHEN EA, 1993, FASEB J, V7, P1016, DOI 10.1096/fasebj.7.11.8370470; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MERRILL AH, 1980, J BIOL CHEM, V255, P1335; Morell MK, 1997, J BIOL CHEM, V272, P5445, DOI 10.1074/jbc.272.9.5445; MULLER F, 1992, CHEM BIOCH FLAVOENZY, V3; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V139, P1111, DOI 10.1016/S0006-291X(86)80292-3; NIELSEN P, 1981, BIOCHIM BIOPHYS ACTA, V662, P312, DOI 10.1016/0005-2744(81)90044-9; OKANE DJ, 1992, MOL MICROBIOL, V6, P443, DOI 10.1111/j.1365-2958.1992.tb01488.x; Olson LP, 1996, BIOCHEMISTRY-US, V35, P9782, DOI 10.1021/bi952020x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peach C., 1978, BIOCHEM BIOPH RES CO, V83, P1084; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PIERCE J, 1986, J BIOL CHEM, V261, P248; PLAUT GWE, 1960, J BIOL CHEM, V235, pPC41; PLAUT GWE, 1974, ANNU REV BIOCHEM, V43, P899, DOI 10.1146/annurev.bi.43.070174.004343; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RICHARD JP, 1984, J AM CHEM SOC, V106, P4926, DOI 10.1021/ja00329a050; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Scheuring J, 2001, J ORG CHEM, V66, P3811, DOI 10.1021/jo001739u; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Steinbacher S, 2003, J BIOL CHEM, V278, P18401, DOI 10.1074/jbc.M300993200; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; TURK D, 1992, THESIS TU MUNCHEN MU; VOLK R, 1990, J BIOL CHEM, V265, P19479; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; VOLK R, 1991, J BIOL CHEM, V266, P20610; WACKER H, 1964, J BIOL CHEM, V239, P3493; Wagner T, 2000, J MOL BIOL, V301, P389, DOI 10.1006/jmbi.2000.3957; YOUNG DW, 1986, NAT PROD REP, V3, P395, DOI 10.1039/np9860300395	65	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42256	42265		10.1074/jbc.M307301200	http://dx.doi.org/10.1074/jbc.M307301200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904291	hybrid, Green Accepted			2022-12-27	WOS:000185989500085
J	Aguilera, B; Ghauharali-van der Vlugt, K; Helmond, MTJ; Out, JMM; Donker-Koopman, WE; Groener, JEM; Boot, RG; Renkema, GH; van der Marel, GA; van Boom, JH; Overkleeft, HS; Aerts, JMFG				Aguilera, B; Ghauharali-van der Vlugt, K; Helmond, MTJ; Out, JMM; Donker-Koopman, WE; Groener, JEM; Boot, RG; Renkema, GH; van der Marel, GA; van Boom, JH; Overkleeft, HS; Aerts, JMFG			Transglycosidase activity of chitotriosidase - Improved enzymatic assay for the human macrophage chitinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHERS-DISEASE; PLASMA; OLIGOSACCHARIDES; LYSOZYME; EMBRYOGENESIS; SUBSTRATE; DISTINCT; PLANT	Chitotriosidase is a chitinase that is massively expressed by lipid-laden tissue macrophages in man. Its enzymatic activity is markedly elevated in serum of patients suffering from lysosomal lipid storage disorders, sarcoidosis, thalassemia, and visceral Leishmaniasis. Monitoring of serum chitotriosidase activity in Gaucher disease patients during progression and therapeutic correction of their disease is useful to obtain insight in changes in body burden on pathological macrophages. However, accurate quantification of chitotriosidase levels by enzyme assay is complicated by apparent substrate inhibition, which prohibits the use of saturating substrate concentrations. We have therefore studied the catalytic features of chitotriosidase in more detail. It is demonstrated that the inhibition of enzyme activity at excess substrate concentration can be fully explained by transglycosylation of substrate molecules. The potential physiological consequences of the ability of chitotriosidase to hydrolyze as well as transglycosylate are discussed. The novel insight in transglycosidase activity of chitotriosidase has led to the design of a new substrate molecule, 4-methylumbelliferyl-(4-deoxy) chitobiose. With this substrate, which is no acceptor for transglycosylation, chitotriosidase shows normal Michaelis-Menten kinetics, resulting in major improvements in sensitivity and reproducibility of enzymatic activity measurements. The novel convenient chitotriosidase enzyme assay should facilitate the accurate monitoring of Gaucher disease patients receiving costly enzyme replacement therapy.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Tampere University	Aerts, JMFG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.		Aerts, Johannes/A-1028-2009; Renkema, Herma/L-1489-2015	Aerts, Johannes/0000-0001-8168-2565; Renkema, Herma/0000-0002-8174-6538; Overkleeft, Herman/0000-0001-6976-7005; Boot, Rolf/0000-0002-7031-3390				Aerts JMFG, 1997, BAILLIERE CLIN HAEM, V10, P691, DOI 10.1016/S0950-3536(97)80034-0; Bakkers J, 1999, EXS, V87, P71; Bakkers J, 1997, P NATL ACAD SCI USA, V94, P7982, DOI 10.1073/pnas.94.15.7982; Barone R, 1999, BLOOD CELL MOL DIS, V25, P1, DOI 10.1006/bcmd.1999.0221; BARTON DHR, 1975, J CHEM SOC PERK T 1, P1574, DOI 10.1039/p19750001574; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Choi EH, 2001, GENES IMMUN, V2, P248, DOI 10.1038/sj.gene.6363767; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; DELMOTTE FM, 1975, CARBOHYD RES, V40, P353, DOI 10.1016/S0008-6215(00)82616-6; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; INABA T, 1984, CHEM PHARM BULL, V32, P1597; KIM S, 1985, J ORG CHEM, V50, P1751, DOI 10.1021/jo00210a036; Mistry PK, 1997, BAILLIERE CLIN HAEM, V10, P817, DOI 10.1016/S0950-3536(97)80042-X; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Semino CE, 2000, INT J DEV BIOL, V44, P183; SHABAN M, 1971, CARBOHYD RES, V19, P311, DOI 10.1016/S0008-6215(00)86161-3; SHAHABUDDIN M, 1993, PARASITOL TODAY, V9, P252, DOI 10.1016/0169-4758(93)90069-R; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003	25	126	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40911	40916		10.1074/jbc.M301804200	http://dx.doi.org/10.1074/jbc.M301804200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890686	hybrid, Green Published			2022-12-27	WOS:000185847200062
J	Alsheikh, MK; Heyen, BJ; Randall, SK				Alsheikh, MK; Heyen, BJ; Randall, SK			Ion binding properties of the dehydrin ERD14 are dependent upon phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA L; DHN/LEA/RAB-LIKE GENES; ENDOPLASMIC-RETICULUM; DEHYDRATION STRESS; LOW-TEMPERATURE; CALCIUM; PROTEIN; COLD; EXPRESSION; PLANTS	The ERD14 protein ( early response to dehydration) is a member of the dehydrin family of proteins which accumulate in response to dehydration-related environmental stresses. Here we show the Arabidopsis dehydrin, ERD14, possesses ion binding properties. ERD14 is an in vitro substrate of casein kinase II; the phosphorylation resulting both in a shift in apparent molecular mass on SDS-PAGE gels and increased calcium binding activity. The phosphorylated protein bound significantly more calcium than the nonphosphorylated protein, with a dissociation constant of 120 muM and 2.86 mol of calcium bound per mol of protein. ERD14 is phosphorylated by extracts of cold-treated tissues, suggesting that the phosphorylation status of this protein might be modulated by cold-regulated kinases or phosphatases. Calcium binding properties of ERD14 purified from Arabidopsis extracts were comparable with phosphorylated Escherichia coli-expressed ERD14. Approximately 2 mol of phosphate were incorporated per mol of ERD14, indicating a minimum of two phosphorylation sites. Western blot analyses confirmed that threonine and serine are possible phosphorylation sites on ERD14. Utilizing matrix assisted laser desorption ionization-time of flight/ mass spectrometry we identified five phosphorylated peptides that were present in both in vivo and in vitro phosphorylated ERD14. Our results suggest that the polyserine ( S) domain is most likely the site of phosphorylation in ERD14 responsible for the activation of calcium binding.	Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA; Tabor Coll, Dept Biol, Hillsboro, KS 67063 USA; Tabor Coll, Dept Chem, Hillsboro, KS 67063 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Randall, SK (corresponding author), Indiana Univ Purdue Univ, Dept Biol, 723 W Michigan St, Indianapolis, IN 46202 USA.	srandal@iupui.edu		Randall, Stephen/0000-0002-8637-9407				BIERMANN BJ, 1994, J BIOL CHEM, V269, P25251; BUSH DS, 1993, PLANT PHYSIOL, V103, P7, DOI 10.1104/pp.103.1.7; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CECCARDI TL, 1994, PROTEIN EXPRES PURIF, V5, P266, DOI 10.1006/prep.1994.1040; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLOSE TJ, 1993, PLANT MOL BIOL, V23, P279, DOI 10.1007/BF00029004; Close TJ, 1997, PHYSIOL PLANTARUM, V100, P291, DOI 10.1034/j.1399-3054.1997.1000210.x; Close TJ, 1993, CUR TOP PL, V10, P104; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; DING JP, 1993, PLANT J, V3, P713, DOI 10.1111/j.1365-313X.1993.00713.x; Dure L, 1993, CUR TOP PL, V10, P91; Garay-Arroyo A, 2000, J BIOL CHEM, V275, P5668, DOI 10.1074/jbc.275.8.5668; GILMOUR SJ, 1992, PLANT MOL BIOL, V18, P13, DOI 10.1007/BF00018452; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; Heyen BJ, 2002, PLANT PHYSIOL, V130, P675, DOI 10.1104/pp.002550; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; Jensen AB, 1998, PLANT J, V13, P691, DOI 10.1046/j.1365-313X.1998.00069.x; Kaye C., 1995, Science Progress, V78, P271; Kim KN, 2003, PLANT CELL, V15, P411, DOI 10.1105/tpc.006858; Kitta K, 2001, BIOCHEM J, V359, P375, DOI 10.1042/0264-6021:3590375; KIYOSUE T, 1994, PLANT CELL PHYSIOL, V35, P225; KIYOSUE T, 1994, PLANT MOL BIOL, V25, P791, DOI 10.1007/BF00028874; Knight H, 1998, PLANT J, V16, P681, DOI 10.1046/j.1365-313x.1998.00332.x; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; Koag MC, 2003, PLANT PHYSIOL, V131, P309, DOI 10.1104/pp.011171; Kruger C, 2002, J BIOL CHEM, V277, P25062, DOI 10.1074/jbc.M201896200; Lewis BD, 1997, PLANT PHYSIOL, V114, P1327, DOI 10.1104/pp.114.4.1327; Li XH, 1998, PLANT CELL, V10, P119, DOI 10.1105/tpc.10.1.119; MINORSKY PV, 1989, PLANT CELL ENVIRON, V12, P137, DOI 10.1111/j.1365-3040.1989.tb01925.x; MINORSKY PV, 1989, PLANT CELL ENVIRON, V12, P119, DOI 10.1111/j.1365-3040.1989.tb01924.x; Nelson DE, 1997, PLANT PHYSIOL, V114, P29, DOI 10.1104/pp.114.1.29; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Nylander M, 2001, PLANT MOL BIOL, V45, P263, DOI 10.1023/A:1006469128280; Palva E. T., 2002, JIRCAS Working Report, P9; Persson S, 2001, PLANT PHYSIOL, V126, P1092, DOI 10.1104/pp.126.3.1092; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PLANA M, 1991, J BIOL CHEM, V266, P22510; Polisensky DH, 1996, PLANT PHYSIOL, V111, P1271, DOI 10.1104/pp.111.4.1271; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Sedbrook JC, 1996, PLANT PHYSIOL, V111, P243, DOI 10.1104/pp.111.1.243; Shinozaki K, 1996, CURR OPIN BIOTECH, V7, P161, DOI 10.1016/S0958-1669(96)80007-3; Svensson J, 2000, PROTEIN EXPRES PURIF, V20, P169, DOI 10.1006/prep.2000.1297; Sze H, 2000, ANNU REV PLANT PHYS, V51, P433, DOI 10.1146/annurev.arplant.51.1.433; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; VILARDELL J, 1990, PLANT MOL BIOL, V14, P423, DOI 10.1007/BF00028778; WELIN BV, 1995, PLANT MOL BIOL, V29, P391, DOI 10.1007/BF00043662; WELIN BV, 1994, PLANT MOL BIOL, V26, P131, DOI 10.1007/BF00039526; XING T, 1994, PROTOPLASMA, V179, P158, DOI 10.1007/BF01403954	50	159	177	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40882	40889		10.1074/jbc.M307151200	http://dx.doi.org/10.1074/jbc.M307151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917402	hybrid			2022-12-27	WOS:000185847200058
J	Broedl, UC; Maugeais, C; Marchadier, D; Glick, JM; Rader, DJ				Broedl, UC; Maugeais, C; Marchadier, D; Glick, JM; Rader, DJ			Effects of nonlipolytic ligand function of endothelial lipase on high density lipoprotein metabolism in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC LIPASE; TRANSGENIC MICE; DEFICIENT MICE; HDL CHOLESTEROL; OVEREXPRESSION; DETERMINANT; EXPRESSION; BINDING; PLASMA	Endothelial lipase (EL) influences high density lipoprotein (HDL) metabolism in vivo and mediates bridging and uptake of HDL particles independent of its lipolytic activity in vitro. To determine whether EL has a nonlipolytic ligand function in HDL metabolism in vivo, 1 x 10(11) particles of a recombinant adenovirus encoding human EL (AdEL), catalytically inactive human EL (AdEL(S149A)), or control (Adnull) were injected into wildtype, apoA-I transgenic, and hepatic lipase knockout mice. ELS149A protein was expressed at higher levels than wild-type EL. EL and ELS149A protein were both substantially increased in the postheparin plasma compared with preheparin, indicating that both the wildtype and mutant EL were bound to cell-surface heparan sulfate proteoglycans. Overexpression of wild-type EL was associated with a significantly increased postheparin-plasma phospholipase activity and dramatically decreased levels of total cholesterol, HDL cholesterol, phospholipids, and apoA-I. Injection of AdEL(S149A) did not result in increased phospholipase activity confirming that ELS149A was catalytically inactive. Expression of ELS149A did not decrease lipid or apoA-I levels in wild-type and apoA-I transgenic mice yet led to an intermediate reduction of total cholesterol, HDL cholesterol, and phospholipids in hepatic lipase-deficient mice compared with control and EL-expressing mice. Our study demonstrates for the first time that EL has both a lipolytic and nonlipolytic function in HDL metabolism in vivo. Lipolytic activity of EL, however, seems to be most important for its effects on systemic HDL metabolism.	Univ Penn, Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania	Rader, DJ (corresponding author), Univ Penn, Med Ctr, 654 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL55323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055323, R37HL055323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; BELFRAGE P, 1969, J LIPID RES, V10, P341; BLADES B, 1993, ARTERIOSCLER THROMB, V13, P1227, DOI 10.1161/01.ATV.13.8.1227; Dichek HL, 2001, J LIPID RES, V42, P201; Dichek HL, 1998, J BIOL CHEM, V273, P1896, DOI 10.1074/jbc.273.4.1896; Dugi KA, 1997, J LIPID RES, V38, P1822; Dugi KA, 2000, ARTERIOSCL THROM VAS, V20, P793, DOI 10.1161/01.ATV.20.3.793; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; Ma K, 2003, P NATL ACAD SCI USA, V100, P2748, DOI 10.1073/pnas.0438039100; MAUGEAIS C, 2003, IN PRESS CIRCULATION; McCoy MG, 2002, J LIPID RES, V43, P921; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Merkel M, 2002, J BIOL CHEM, V277, P7405, DOI 10.1074/jbc.M107914200; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; Strauss JG, 2002, BIOCHEM J, V368, P69, DOI 10.1042/BJ20020306; Ye XH, 1996, J BIOL CHEM, V271, P3639	21	54	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40688	40693		10.1074/jbc.M304367200	http://dx.doi.org/10.1074/jbc.M304367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909635	hybrid			2022-12-27	WOS:000185847200033
J	Min, JK; Kim, YM; Kim, YM; Kim, EC; Gho, YS; Kang, IJ; Lee, SY; Kong, YY; Kwon, YG				Min, JK; Kim, YM; Kim, YM; Kim, EC; Gho, YS; Kang, IJ; Lee, SY; Kong, YY; Kwon, YG			Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells - Concomitant increase of angiogenic responses to RANK ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF FAMILY-MEMBER; OSTEOCLAST DIFFERENTIATION; INDUCED CYTOKINE; NITRIC-OXIDE; FACTOR VEGF; T-CELLS; BONE; KINASE; TRANCE	Vascular endothelial growth factor ( VEGF) is known as a key regulator of angiogenesis during endochondral bone formation. Recently, we demonstrated that TNF-related activation-induced cytokine ( TRANCE or RANKL), which is essential for bone remodeling, also had an angiogenic activity. Here we report that VEGF up-regulates expression of receptor activator of NF-kappa B ( RANK) and increases angiogenic responses of endothelial cells to TRANCE. Treatment of human umbilical vein endothelial cells (HUVECs) with VEGF increased both RANK mRNA and surface protein expression. Although placenta growth factor specific to VEGF receptor-1 had no significant effect on RANK expression, inhibition of downstream signaling molecules of the VEGF receptor-2 (Flk-1/KDR) such as Src, phospholipase C, protein kinase C, and phosphatidylinositol 3'-kinase suppressed VEGF-stimulated RANK expression in HUVECs. Moreover, the MEK inhibitor PD98059 or expression of dominant negative MEK1 inhibited induction of RANK by VEGF but not the Ca2+ chelator 1,2-bis( 2-aminophenoxy) ethane-N, N, N', N'-tetraacetic acid-acetoxymethyl ester (BAPTA-AM). VEGF potentiated TRANCE-induced ERK activation and tube formation via RANK up-regulation in HUVECs. Together, these results show that VEGF enhances RANK expression in endothelial cells through Flk-1/KDR-protein kinase C-ERK signaling pathway, suggesting that VEGF plays an important role in modulating the angiogenic action of TRANCE under physiological or pathological conditions.	Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Kyung Hee Univ, Grad Sch E W Med Sci, Dept Oncol, Yongin 449701, South Korea; Hallym Univ, Div Life Sci, Chunchon 200702, Kangwon Do, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea	Kangwon National University; Kangwon National University; Kyung Hee University; Hallym University; Ewha Womans University; Ewha Womans University; Pohang University of Science & Technology (POSTECH)	Kwon, YG (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea.	ygkwon@kangwon.ac.kr		Min, Jeong-Ki/0000-0003-4924-8739				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Blum S, 2001, J BIOL CHEM, V276, P33428, DOI 10.1074/jbc.M105474200; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Carlevaro MF, 2000, J CELL SCI, V113, P59; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harper J, 1999, NAT MED, V5, P617, DOI 10.1038/9460; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HONER A, 1999, J ANAT, V194, P519; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014-5793(00)01520-9; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yan T, 2001, J CELL BIOCHEM, V83, P320, DOI 10.1002/jcb.1200	47	94	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39548	39557		10.1074/jbc.M300539200	http://dx.doi.org/10.1074/jbc.M300539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893832	hybrid			2022-12-27	WOS:000185713800036
J	Shao, JY; Prince, T; Hartson, SD; Matts, RL				Shao, JY; Prince, T; Hartson, SD; Matts, RL			Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EIF2-ALPHA KINASE; HEAT-SHOCK PROTEIN; ASSOCIATION; CONFORMATION; RECEPTOR; DOMAIN	The Hsp90 co-chaperone Cdc37 provides an essential function for the biogenesis and support of numerous protein kinases. In this report, we demonstrate that mammalian Cdc37 is phosphorylated on Ser(13) in situ in rabbit reticulocyte lysate and in cultured K562 cells and that casein kinase II is capable of quantitatively phosphorylating recombinant Cdc37 at this site. Mutation of Ser(13) to either Ala or Glu compromises the recruitment of Cdc37 to Hsp90-kinase complexes but has only modest effects on its basal (client-free) binding to Hsp90. Furthermore, Cdc37 containing the complementing Ser to Glu mutation showed altered interactions with Hsp90-kinase complexes consistent with compromised Cdc37 modulation of the Hsp90 ATP-driven reaction cycle. Thus, the data indicate that phosphorylation of Cdc37 on Ser(13) is critical for its ability to coordinate Hsp90 nucleotide-mediated conformational switching and kinase binding.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Matts, RL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, 246 NRC, Stillwater, OK 74078 USA.							Bandhakavi S, 2003, J BIOL CHEM, V278, P2829, DOI 10.1074/jbc.M206662200; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Fliss AE, 1997, MOL BIOL CELL, V8, P2501, DOI 10.1091/mbc.8.12.2501; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; MATTS RL, 1989, J BIOL CHEM, V264, P15542; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Uma S, 1997, J BIOL CHEM, V272, P11648; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x	18	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38117	38120		10.1074/jbc.C300330200	http://dx.doi.org/10.1074/jbc.C300330200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12930845	hybrid			2022-12-27	WOS:000185575100004
J	Sharma, SK; Kapoor, M; Ramya, TNC; Kumar, S; Kumar, G; Modak, R; Sharma, S; Surolia, N; Surolia, A				Sharma, SK; Kapoor, M; Ramya, TNC; Kumar, S; Kumar, G; Modak, R; Sharma, S; Surolia, N; Surolia, A			Identification, characterization, and inhibition of Plasmodium falciparum beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYDECANOYL THIOESTER DEHYDRASE; FATTY-ACID BIOSYNTHESIS; ENOYL-ACP REDUCTASE; ESCHERICHIA-COLI; AUTOMATED DOCKING; FREE-ENERGY; MALARIA; MODEL; TRICLOSAN; MECHANISM	The emergence of drug-resistant forms of Plasmodium falciparum emphasizes the need to develop new antimalarials. In this context, the fatty acid biosynthesis (FAS) pathway of the malarial parasite has recently received a lot of attention. Due to differences in the fatty acid biosynthesis systems of Plasmodium and man, this pathway is a good target for the development of new and selective therapeutic drugs directed against malaria. In continuation of these efforts we report cloning and overexpression of P. falciparum beta-hydroxyacyl-acyl carrier protein (ACP) dehydratase (PffabZ) gene that codes for a 17-kDa protein. The enzyme catalyzes the dehydration of beta-hydroxyacyl-ACP to trans-2-acyl-ACP, the third step in the elongation phase of the FAS cycle. It has a K-m of 199 muM and k(cat)/K-m of 80.4 M-1 s(-1) for the substrate analog beta-hydroxybutyryl-CoA but utilizes crotonoyl-CoA, the product of the reaction, more efficiently (K-m=86 muM, k(cat)/K-m=220 M-1 s(-1)). More importantly, we also identify inhibitors (NAS-91 and NAS-21) for the enzyme. Both the inhibitors prevented the binding of crotonoyl-CoA to PfFabZ in a competitive fashion. Indeed these inhibitors compromised the growth of P. falciparum in cultures and inhibited the parasite fatty acid synthesis pathway both in cell-free extracts as well as in situ. We modeled the structure of PfFabZ using Escherichia coli beta-hydroxydecanoyl thioester dehydratase (EcFabA) as a template. We also modeled the inhibitor complexes of PfFabZ to elucidate the mode of binding of these compounds to FabZ. The discovery of the inhibitors of FabZ, reported for the first time against any member of this family of enzymes, essential to the type II FAS pathway opens up new avenues for treating a number of infectious diseases including malaria.	Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Surolia, N (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India.	surolia@jncasr.ac.in; surolia@mbu.iisc.ernet.in	Chakravarthy, Ramya T. N./AAJ-7507-2021; Chakravarthy, Ramya/F-8924-2010; Kumar, Gyanendra/B-1751-2009; SUROLIA, AVADESHA/C-5442-2009	Kumar, Gyanendra/0000-0001-7593-0737; Modak, Rahul/0000-0002-1717-4627				Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Arnot DE, 1998, ANN TROP MED PARASIT, V92, P361, DOI 10.1080/00034989859357; ASINDI AA, 1993, TROP GEOGR MED, V45, P110; Bebernitz GR, 2001, J MED CHEM, V44, P2601, DOI 10.1021/jm010032c; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; *CHEM COMP GROUP I, 2001, MOL OP ENV MOE VERS; CHICHE L, 1990, P NATL ACAD SCI USA, V87, P3240, DOI 10.1073/pnas.87.8.3240; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBUYSERE MS, 1983, ANAL BIOCHEM, V133, P373, DOI 10.1016/0003-2697(83)90097-0; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 2002, APPL MICROBIOL BIOT, V58, P695, DOI 10.1007/s00253-001-0918-z; Heath RJ, 2000, J BIOL CHEM, V275, P40128, DOI 10.1074/jbc.M005611200; Hoang TT, 1997, J BACTERIOL, V179, P5326, DOI 10.1128/jb.179.17.5326-5332.1997; Kapoor M, 2001, BIOCHEM BIOPH RES CO, V289, P832, DOI 10.1006/bbrc.2001.6061; KASS LR, 1968, J BIOL CHEM, V243, P3223; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Marrakchi H, 2002, BIOCHEM SOC T, V30, P1050, DOI 10.1042/bst0301050; Marrakchi H, 2002, J BIOL CHEM, V277, P44809, DOI 10.1074/jbc.M208920200; McMurry LM, 1998, FEMS MICROBIOL LETT, V166, P305, DOI 10.1016/S0378-1097(98)00347-4; MEHLER EL, 1991, PROTEIN ENG, V4, P903, DOI 10.1093/protein/4.8.903; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MULVEY RS, 1974, BIOCHEMISTRY-US, V13, P782, DOI 10.1021/bi00701a021; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; RAMYA TNC, 2002, CURR SCI, V83, P101; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; SCHWAB JM, 1986, J AM CHEM SOC, V108, P5309, DOI 10.1021/ja00277a041; SHERMAN IW, 1998, MALARIA; Suarez JE, 2000, MEM I OSWALDO CRUZ, V95, P495, DOI 10.1590/S0074-02762000000400009; Surolia N, 2002, BIOESSAYS, V24, P192, DOI 10.1002/bies.10042; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; WEEKS G, 1968, J BIOL CHEM, V243, P1180; WHO, 1999, WORLD HLTH REP 1999, P49	47	89	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45661	45671		10.1074/jbc.M304283200	http://dx.doi.org/10.1074/jbc.M304283200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12930838	hybrid			2022-12-27	WOS:000186452300075
J	Kitamura, K; Tanaka, H; Nishimune, Y				Kitamura, K; Tanaka, H; Nishimune, Y			Haprin, a novel haploid germ cell-specific RING finger protein involved in the acrosome reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MAMMALIAN SPERM; ZONA-PELLUCIDA; MOUSE; MEMBRANE; IDENTIFICATION; EXPRESSION; FUSION; CDNA; ACID	The acrosome reaction (i.e. the exocytosis of the sperm vesicle) is a prerequisite for fertilization, but its molecular mechanism is largely unknown. We have identified a cDNA clone for a gene named haprin, which encodes a haploid germ cell-specific RING finger protein. This protein is a novel member of the RBCC (RING finger, B-box type zinc finger, and coiled-coil domain) motif family that has roles in several cellular processes, such as exocytosis. It is transcribed exclusively in testicular germ cells after meiotic division. Western blot and immunohistochemical analyses showed the molecular weight of Haprin protein to be M-r similar to 82,000. It was localized in the acrosomal region of elongated spermatids and mature sperm and was not present in acrosome-reacted sperm. The specific antibody against the RING finger domain of Haprin inhibited the acrosome reaction in permeabilized sperm. These results indicated that the novel RBCC protein Haprin plays a key role in the acrosome reaction and fertilization.	Osaka Univ, Microbial Dis Res Inst, Dept Sci Lab Anim Experimentat, Suita, Osaka 5650871, Japan	Osaka University	Nishimune, Y (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Sci Lab Anim Experimentat, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	nishimun@biken.osaka-u.ac.jp	Kitamura, Kouichi/L-3654-2015	Kitamura, Kouichi/0000-0001-9692-8724				Abou-Haila A, 2000, ARCH BIOCHEM BIOPHYS, V379, P173, DOI 10.1006/abbi.2000.1880; Baker SS, 2002, BIOL REPROD, V66, P57, DOI 10.1095/biolreprod66.1.57; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Breitbart H, 1997, MOL HUM REPROD, V3, P195, DOI 10.1093/molehr/3.3.195; de Carvalho CE, 2002, BIOL REPROD, V66, P785, DOI 10.1095/biolreprod66.3.785; Diaz A, 1996, ANDROLOGIA, V28, P21; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; Fujii T, 1999, GENOMICS, V57, P94, DOI 10.1006/geno.1998.5738; Fujii T, 2002, EMBO REP, V3, P367, DOI 10.1093/embo-reports/kvf073; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; HUGO F, 1986, INFECT IMMUN, V54, P641, DOI 10.1128/IAI.54.3.641-645.1986; Hutt DM, 2002, BIOL REPROD, V66, P50, DOI 10.1095/biolreprod66.1.50; Iguchi N, 1999, FEBS LETT, V456, P315, DOI 10.1016/S0014-5793(99)00967-9; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Johnson LR, 1999, BIOL REPROD, V60, P683, DOI 10.1095/biolreprod60.3.683; Kierszenbaum AL, 2000, MOL REPROD DEV, V57, P309, DOI 10.1002/1098-2795(200012)57:4&lt;309::AID-MRD1&gt;3.0.CO;2-W; Koga M, 2000, BIOL REPROD, V63, P1601, DOI 10.1095/biolreprod63.6.1601; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; LIU DY, 1994, HUM REPROD, V9, P1694, DOI 10.1093/oxfordjournals.humrep.a138776; Liu DY, 2001, HUM REPROD, V16, P1185, DOI 10.1093/humrep/16.6.1185; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; MORTIMER D, 1987, J REPROD FERTIL, V81, P127; Nakamura Y, 2002, BIOL REPROD, V67, P1, DOI 10.1095/biolreprod67.1.1; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Ramalho-Santos J, 2000, DEV BIOL, V223, P54, DOI 10.1006/dbio.2000.9745; Ramalho-Santos J, 2002, BIOL REPROD, V67, P1043, DOI 10.1095/biolreprod67.4.1043; Ramalho-Santos J, 2001, EXP CELL RES, V267, P45, DOI 10.1006/excr.2000.5119; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Tanaka H, 1999, J BIOL CHEM, V274, P17049, DOI 10.1074/jbc.274.24.17049; TANAKA H, 1994, FEBS LETT, V355, P4, DOI 10.1016/0014-5793(94)01155-9; Tanaka H, 2003, BIOL REPROD, V69, P475, DOI 10.1095/biolreprod.103.015867; Tanaka H, 2002, E SCHERING RES FDN W, P55; Tomes CN, 2002, DEV BIOL, V243, P326, DOI 10.1006/dbio.2002.0567; Tosaka Y, 2000, GENES CELLS, V5, P265, DOI 10.1046/j.1365-2443.2000.00324.x; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]	44	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44417	44423		10.1074/jbc.M304306200	http://dx.doi.org/10.1074/jbc.M304306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12917430	hybrid			2022-12-27	WOS:000186306700068
J	Boisson, B; Giglione, C; Meinnel, T				Boisson, B; Giglione, C; Meinnel, T			Unexpected protein families including cell defense components feature in the N-myristoylome of a higher eukaryote	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; MYRISTIC ACID AUXOTROPHY; GENOME-WIDE ANALYSIS; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; ENDOPLASMIC-RETICULUM; PSEUDOMONAS-SYRINGAE; PEPTIDE DEFORMYLASES; PLASMA-MEMBRANE; CRYPTOCOCCUS-NEOFORMANS	N-Myristoylation is an irreversible modification that affects the membrane binding properties of crucial cytoplasmic proteins from signal transduction cascades. We characterized the two putative N-myristoyltransferases of Arabidopsis thaliana as a means of investigating the entire N-myristoylation proteome (N-myristoylome) in a higher eukaryote. AtNMT1 compensated for the nmt1 defect in yeast, whereas AtNMT2 and chimeras of the two genes did not. Only AtNMT1 modified known N-myristoylated proteins in vitro. AtNMT1 is therefore responsible for the A. thaliana N-myristoylome, whereas AtNMT2 does not seem to have usual myristoylation activity. We began with the whole set of N-myristoylated G proteins in the A. thaliana proteome. We then used a reiterative approach, based on the in vitro N-myristoylation of more than 60 different polypeptides, to determine the substrate specificity of AtNMT1. We found that the positive charge on residue 7 of the substrate was particularly important in substrate recognition. The A. thaliana N-myristoylome consists of 437 proteins, accounting for 1.7% of the complete proteome. We demonstrated the N-myristoylation of several unexpected protein families, including innate immunity proteins, thioredoxins, components of the protein degradation pathway, transcription factors, and a crucial regulatory enzyme of glycolysis. The role of N-myristoylation is discussed in each case; in particular, this process may underlie the "guard" hypothesis of innate immunity.	CNRS, UPR2355, Inst Sci Vegetal, Prot Maturat Grp, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Meinnel, T (corresponding author), CNRS, UPR2355, Inst Sci Vegetal, Prot Maturat Grp, Batiment 23,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	meinnel@isv.cnrs-gif.fr	Boisson, Bertrand/I-2485-2017; Boisson, Bertrand/AAC-6058-2019; Meinnel, Thierry/B-9813-2016	Boisson, Bertrand/0000-0001-5240-3555; Boisson, Bertrand/0000-0001-5240-3555; Meinnel, Thierry/0000-0001-5642-8637; Giglione, Carmela/0000-0002-7475-1558				Axtell MJ, 2003, CELL, V112, P369, DOI 10.1016/S0092-8674(03)00036-9; Bhatnagar R. S., 2001, ENZYMES, VXXI, P241; Boisson B, 2003, ANAL BIOCHEM, V322, P116, DOI 10.1016/j.ab.2003.07.007; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chico JM, 2002, PLANT PHYSIOL, V128, P256, DOI 10.1104/pp.010649; COCKWELL KY, 1989, COMPUT APPL BIOSCI, V5, P227; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; DEJONGE HR, 2000, SCI STKE; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; Eberle HB, 2002, J CELL SCI, V115, P827; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Farazi TA, 2001, BIOCHEMISTRY-US, V40, P6335, DOI 10.1021/bi0101401; Frommer WB, 2003, SCIENCE, V300, P261, DOI 10.1126/science.1084120; Furumoto T, 2001, PLANT CELL PHYSIOL, V42, P1044, DOI 10.1093/pcp/pce161; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; GIGLIONE C, 1999, THESIS PARIS SUD U O; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gupta R, 2002, PLANT CELL, V14, P2495, DOI 10.1105/tpc.005702; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Ishitani M, 2000, PLANT CELL, V12, P1667, DOI 10.1105/tpc.12.9.1667; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; Joshi CP, 1997, PLANT MOL BIOL, V35, P993, DOI 10.1023/A:1005816823636; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Keddie JS, 1998, PLANT CELL, V10, P877, DOI 10.1105/tpc.10.6.877; Kim SY, 2002, PLANT PHYSIOL, V130, P688, DOI 10.1104/pp.003566; Kimura Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P341, DOI 10.1016/S0003-9861(02)00639-2; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; KISS F, 1991, ARCH BIOCHEM BIOPHYS, V287, P337, DOI 10.1016/0003-9861(91)90487-4; Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624; Lin CY, 2000, J BIOL CHEM, V275, P37815, DOI 10.1074/jbc.M002470200; Lin CY, 2002, J CELL SCI, V115, P4433, DOI 10.1242/jcs.00123; Lin SS, 2003, J BIOL CHEM, V278, P13390, DOI 10.1074/jbc.M212818200; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; Lu SX, 2002, PLANT PHYSIOL, V128, P1008, DOI 10.1104/pp.010770; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Markham JE, 2002, EUR J BIOCHEM, V269, P1267, DOI 10.1046/j.1432-1033.2002.02771.x; Maurer-Stroh S, 2002, J MOL BIOL, V317, P541, DOI 10.1006/jmbi.2002.5426; Maurer-Stroh S, 2002, J MOL BIOL, V317, P523, DOI 10.1006/jmbi.2002.5425; McElver J, 2000, PLANT CELL, V12, P1379, DOI 10.1105/tpc.12.8.1379; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; Meyer Y, 2002, METHOD ENZYMOL, V347, P394; Meyers BC, 2003, PLANT CELL, V15, P809, DOI 10.1105/tpc.009308; Mudgett MB, 1999, MOL MICROBIOL, V32, P927, DOI 10.1046/j.1365-2958.1999.01403.x; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Price HP, 2003, J BIOL CHEM, V278, P7206, DOI 10.1074/jbc.M211391200; Puri N, 1997, MOL PLANT MICROBE IN, V10, P247, DOI 10.1094/MPMI.1997.10.2.247; Qi QG, 2000, J BIOL CHEM, V275, P9673, DOI 10.1074/jbc.275.13.9673; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; Romeis T, 2001, EMBO J, V20, P5556, DOI 10.1093/emboj/20.20.5556; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; Rutherford S, 2002, CURR OPIN PLANT BIOL, V5, P518, DOI 10.1016/S1369-5266(02)00307-2; Sahrawy M, 1996, J MOL EVOL, V42, P422; Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175; Shan LB, 2000, PLANT CELL, V12, P2323, DOI 10.1105/tpc.12.12.2323; Takeuchi M, 2002, PLANT J, V31, P499, DOI 10.1046/j.1365-313X.2002.01372.x; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; Travis AJ, 1999, J BIOL CHEM, V274, P34467, DOI 10.1074/jbc.274.48.34467; Ueda T, 2001, EMBO J, V20, P4730, DOI 10.1093/emboj/20.17.4730; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040; Utsumi T, 2001, J BIOL CHEM, V276, P10505, DOI 10.1074/jbc.M006134200; Vandepoele K, 2002, PLANT CELL, V14, P903, DOI 10.1105/tpc.010445; Vernoud V, 2003, PLANT PHYSIOL, V131, P1191, DOI 10.1104/pp.013052; Villadsen D, 2001, BIOCHEM J, V359, P591, DOI 10.1042/0264-6021:3590591; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; Wilkins MR, 1999, J MOL BIOL, V289, P645, DOI 10.1006/jmbi.1999.2794; Yu YS, 2003, SCIENCE, V300, P1566, DOI 10.1126/science.1083523; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	84	117	146	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43418	43429		10.1074/jbc.M307321200	http://dx.doi.org/10.1074/jbc.M307321200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912986	hybrid			2022-12-27	WOS:000186157000086
J	Constantinescu, SN; Keren, T; Russ, WP; Ubarretxena-Belandia, I; Malka, Y; Kubatzky, KF; Engelman, DM; Lodish, HF; Henis, YI				Constantinescu, SN; Keren, T; Russ, WP; Ubarretxena-Belandia, I; Malka, Y; Kubatzky, KF; Engelman, DM; Lodish, HF; Henis, YI			The erythropoietin receptor transmembrane domain mediates complex formation with viral anemic and polycythemic gp55 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCUS-FORMING VIRUS; FACTOR-BETA RECEPTORS; SIGNAL-TRANSDUCTION; FRIEND-VIRUS; ENVELOPE GLYCOPROTEIN; INDEPENDENT GROWTH; ENDOPLASMIC-RETICULUM; HELIX ASSOCIATION; TYROSINE KINASE; TRUNCATED FORM	Erythropoietin receptor (EpoR) activation is crucial for mature red blood cell production. The murine EpoR can also be activated by the envelope protein of the polycythemic (P) spleen focus forming virus (SFFV), gp55-P. Due to differences in the TM sequence, gp55 of the anemic (A) strain SFFV, gp55-A, cannot efficiently activate the EpoR. Using antibody-mediated immunofluorescence co-patching, we show that the majority of EpoR forms hetero-oligomers at the cell surface with gp55-P and, surprisingly, with gp55-A. The EpoR TM domain is targeted by gp55-P and -A, as only chimeric receptors containing EpoR TM sequences oligomerized with gp55 proteins. Both gp55-P and gp55-A are homodimers on the cell surface, as shown by co-patching. However, when the homomeric interactions of the isolated TM domains were assayed by TOXCAT bacterial reporter system, only the TM sequence of gp55-P was dimerized. Thus, homo-oligomerization of gp55 proteins is insufficient for full EpoR activation, and a correct conformation of the dimer in the TM region is required. This is supported by the failure of gp55-A3P, a mutant protein whose TM domain can homo-oligomerize, to fully activate EpoR. As unliganded EpoR forms TM-dependent but inactive homodimers, we propose that the EpoR can be activated to different extents by homodimeric gp55 proteins, depending on the conformation of the gp55 protein dimer in the TM region.	Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Massachusetts Institute of Technology (MIT); Whitehead Institute; Tel Aviv University; Yale University; Massachusetts Institute of Technology (MIT)	Constantinescu, SN (corresponding author), Ludwig Inst Canc Res, B-1200 Brussels, Belgium.	stefan.constantinescu@bru.licr.org; henis@post.tau.ac.il	Ubarretxena-Belandia, Iban/A-8389-2009; Constantinescu, Stefan N/E-5277-2012; Ubarretxena-Belandia, Iban/AAA-8939-2019	Constantinescu, Stefan N./0000-0002-8599-2699; Henis, Yoav/0000-0002-1408-3877	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32262] Funding Source: Medline; NIGMS NIH HHS [GM54160] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHUNG SW, 1989, P NATL ACAD SCI USA, V86, P7957, DOI 10.1073/pnas.86.20.7957; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 1998, BLOOD, V91, P1163, DOI 10.1182/blood.V91.4.1163; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Fang C, 1998, VIROLOGY, V252, P46, DOI 10.1006/viro.1998.9453; FERRO FE, 1993, J BIOL CHEM, V268, P5741; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Gurezka R, 2001, J BIOL CHEM, V276, P45580, DOI 10.1074/jbc.M105362200; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; HANKINS WD, 1980, CELL, V22, P693; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KILPATRICK DR, 1989, J BIOL CHEM, V264, P10732; KOLMAR H, 1995, EMBO J, V14, P3895, DOI 10.1002/j.1460-2075.1995.tb00061.x; KOZAK SL, 1993, J VIROL, V67, P2611, DOI 10.1128/JVI.67.5.2611-2620.1993; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Leeds JA, 2001, J MOL BIOL, V313, P181, DOI 10.1006/jmbi.2001.5007; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; MIRAND EA, 1968, P SOC EXP BIOL MED, V128, P844; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUSCETTI SK, 1995, BAILLIERE CLIN HAEM, V8, P225, DOI 10.1016/S0950-3536(05)80239-2; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SHOWERS MO, 1993, MOL CELL BIOL, V13, P739, DOI 10.1128/MCB.13.2.739; SMITH SO, 1995, P NATL ACAD SCI USA, V92, P488, DOI 10.1073/pnas.92.2.488; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAMBOURIN PE, 1979, LEUKEMIA RES, V3, P117, DOI 10.1016/0145-2126(79)90009-2; Tarr K, 1997, J BIOL CHEM, V272, P9099; TUCKER SP, 1991, VIROLOGY, V185, P710, DOI 10.1016/0042-6822(91)90542-J; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	59	24	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43755	43763		10.1074/jbc.M302974200	http://dx.doi.org/10.1074/jbc.M302974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930840	hybrid			2022-12-27	WOS:000186157000125
J	Magnifico, A; Ettenberg, S; Yang, CH; Mariano, J; Tiwari, S; Fang, SY; Lipkowitz, S; Weissman, AM				Magnifico, A; Ettenberg, S; Yang, CH; Mariano, J; Tiwari, S; Fang, SY; Lipkowitz, S; Weissman, AM			WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; UBIQUITIN-PROTEIN LIGASE; EPITHELIAL NA+ CHANNEL; ROUS-SARCOMA VIRUS; C-CBL; DOWN-REGULATION; TYROSINE KINASES; IN-VIVO; NEDD4; FAMILY	Cbl proteins have RING finger-dependent ubiquitin ligase (E3) activity that is essential for down-regulation of tyrosine kinases. Here we establish that two WW domain HECT E3s, Nedd4 and Itch, bind Cbl proteins and target them for proteasomal degradation. This is dependent on the E3 activity of the HECT E3s but not on that of Cbl. Consistent with these observations, in cells expressing the epidermal growth factor receptor, Nedd4 reverses Cbl-b effects on receptor down-regulation, ubiquitylation, and proximal events in signaling. Cbl-b also targets active Src for degradation in cells, and Nedd4 similarly reverses Cbl-mediated Src degradation. These findings establish that RING finger E3s can be substrates, not only for autoubiquitylation but also for ubiquitylation by HECT E3s and suggest an additional level of regulation for Cbl substrates including protein-tyrosine kinases.	NCI, Regulat Prot Funct Lab, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20817 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Weissman, AM (corresponding author), NCI, Regulat Prot Funct Lab, Ctr Canc Res, Bldg 560,Rm 22-102, Frederick, MD 21702 USA.		Fang, Shengyun/H-3802-2011	Fang, Shengyun/0000-0001-7280-5463	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIABC009392, ZIASC007263, Z01BC009392] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 2002, TRENDS IMMUNOL, V23, P140, DOI 10.1016/S1471-4906(01)02157-3; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Patnaik A, 2002, J VIROL, V76, P2789, DOI 10.1128/JVI.76.6.2789-2795.2002; PATTERSON C, 2002, SCI STKE; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sanjay A., 2001, SCI STKE; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	59	141	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43169	43177		10.1074/jbc.M308009200	http://dx.doi.org/10.1074/jbc.M308009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12907674	hybrid			2022-12-27	WOS:000186157000058
J	Perestenko, PV; Henley, JM				Perestenko, PV; Henley, JM			Characterization of the intracellular transport of GluR1 and GluR2 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; AMPA RECEPTORS; GLUTAMATE RECEPTORS; SURFACE EXPRESSION; SYNAPTIC-TRANSMISSION; SYNAPSES; MEMBRANE; LOCALIZATION; ACTIVATION; PROTEINS	Little is known about the dynamics of the dendritic transport of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) to synapses. Here, using virally expressed green fluorescent protein (GFP)GluR1 and GFP-GluR2 and confocal photobleach techniques we show near real-time movement of these subunits in living cultured hippocampal neurons. GFP-GluR1 fluorescence was widely distributed throughout the extranuclear compartment with no evidence for discrete intracellular stores. GFP-GluR1 transport was predominantly proximal to distal at rates of 0.2 - 0.4 mum.s(-1). GFP-GluR2 fluorescence was more punctate and localized at or close to the plasma membrane. Overall, GFP-GluR2 movement was less dynamic with distinct mobile and immobile pools. Neither activation nor inhibition of surface-expressed N-methyl-D-aspartate receptors or AMPARs had any significant effect on the rates of GFP-GluR1 or GFP-GluR2 dendritic transport. These results demonstrate that GluR1 is constitutively and rapidly transported throughout the neuron. GluR2, on the other hand, is less mobile, with a majority retained in relatively immobile membrane-associated clusters, with similar to 40% showing synaptic co-localization. Furthermore, the transport of both subunits is activity-independent, suggesting that the regulated delivery of AMPARs to the vicinity of synapses is not a mechanism that is involved in processes such as synaptic plasticity.	Univ Bristol, Sch Med Sci, Dept Anat, MRC,Ctr Synapt Plast, Bristol BS8 1TD, Avon, England	University of Bristol	Henley, JM (corresponding author), Univ Bristol, Sch Med Sci, Dept Anat, MRC,Ctr Synapt Plast, Univ Walk, Bristol BS8 1TD, Avon, England.		Henley, Jeremy M/A-2776-2009	Henley, Jeremy/0000-0003-3589-8335	MRC [G9629038] Funding Source: UKRI; Medical Research Council [G9629038(61600), G9629038] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Archibald K, 1998, NEUROPHARMACOLOGY, V37, P1345, DOI 10.1016/S0028-3908(98)00135-X; BAUDE A, 1994, J NEUROSCI, V14, P2830; BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; Cottrell JR, 2000, J NEUROPHYSIOL, V84, P1573, DOI 10.1152/jn.2000.84.3.1573; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dingledine R, 1999, PHARMACOL REV, V51, P7; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Hall RA, 1997, J NEUROCHEM, V68, P625; HAMPSON DR, 1992, NEUROSCIENCE, V50, P11, DOI 10.1016/0306-4522(92)90378-F; HUH KH, 1997, SOC NEUR ABSTR, V23, P371; Kim CH, 2001, P NATL ACAD SCI USA, V98, P11725, DOI 10.1073/pnas.211132798; Kim CH, 2001, J NEUROSCI, V21, P4188, DOI 10.1523/JNEUROSCI.21-12-04188.2001; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kohrmann M, 1999, J NEUROSCI RES, V58, P831; Lochner JE, 1998, MOL BIOL CELL, V9, P2463, DOI 10.1091/mbc.9.9.2463; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Luthi A, 1999, NEURON, V24, P389, DOI 10.1016/S0896-6273(00)80852-1; Mammen AL, 1997, J NEUROSCI, V17, P7351; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; Nusser Z, 1998, NEURON, V21, P545, DOI 10.1016/S0896-6273(00)80565-6; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; Pickard L, 2000, J NEUROSCI, V20, P7922; Rao A, 1998, J NEUROSCI, V18, P1217; Richmond SA, 1996, NEUROSCIENCE, V75, P69, DOI 10.1016/0306-4522(96)00217-5; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Silverman MA, 2001, P NATL ACAD SCI USA, V98, P7051, DOI 10.1073/pnas.111146198; Takumi Y, 1999, ANN NY ACAD SCI, V868, P474, DOI 10.1111/j.1749-6632.1999.tb11316.x; Toomre D, 1999, J CELL SCI, V112, P21	41	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43525	43532		10.1074/jbc.M306206200	http://dx.doi.org/10.1074/jbc.M306206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12909632	Green Accepted, hybrid			2022-12-27	WOS:000186157000098
J	Vanwetswinkel, S; Kriek, J; Andersen, GR; Guntert, P; Dijk, J; Canters, GW; Siegal, G				Vanwetswinkel, S; Kriek, J; Andersen, GR; Guntert, P; Dijk, J; Canters, GW; Siegal, G			Solution structure of the 162 residue C-terminal domain of human elongation factor 1B gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PROFILE; TRANSFER RNA-SYNTHETASE; TORSION ANGLE DYNAMICS; NUCLEOTIDE EXCHANGE; RESONANCE ASSIGNMENTS; MESSENGER-RNA; PROTEIN-SYNTHESIS; FACTOR 1-BETA; COMPLEX; C-13	The multisubunit elongation factor 1 (eEF1) is required for the elongation step of eukaryotic protein synthesis. The eEF1 complex consists of four subunits: eEF1A, a G-protein that shuttles aminoacylated tRNAs to the ribosome; eEF1Balpha and eEF1Bbeta, two guanine nucleotide exchange factors, and eEF1Bgamma. Although its exact function remains unknown, this latter subunit is present in all eukaryotes. Recombinant human eEF1Bgamma has been purified and shown to consist of two independent domains. We have utilized high resolution NMR to determine the three-dimensional structure of the 19 kDa C-terminal fragment (domain 2). The structure consists of a five-stranded anti-parallel beta-sheet surrounded by alpha-helices and resembles a contact lens. Highly conserved residues are mainly located on the concave face, suggesting thereby that this side of the molecule might be involved in some biologically relevant interface(s). Although the isolated domain 2 appears to be mostly monomeric in solution, biochemical and structural data indicate a potential homodimer. The proposed dimer model can be further positioned within the quaternary arrangement of the whole eEF1 assembly.	Leiden Univ, Leiden Inst Chem, Gorlaeus Lab, NL-2333 CC Leiden, Netherlands; Sylvius Lab, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Univ Aarhus, Inst Mol & Struct Biol, DK-8000 Aarhus C, Denmark; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Aarhus University; RIKEN	Siegal, G (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Lab, Einsteinweg 55, NL-2333 CC Leiden, Netherlands.	g.siegal@chem.leidenuniv.nl	Güntert, Peter/L-5577-2013	Güntert, Peter/0000-0002-2911-7574; Andersen, Gregers Rom/0000-0001-6292-3319				Al-Maghrebi M, 2002, NUCLEIC ACIDS RES, V30, P5017, DOI 10.1093/nar/gkf656; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2001, NAT STRUCT BIOL, V8, P531, DOI 10.1038/88598; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BEC G, 1994, J BIOL CHEM, V269, P2086; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Cavanagh J., 1993, ANNU REP NMR SPECTRO, V27, P1; CHI KF, 1992, GASTROENTEROLOGY, V103, P98, DOI 10.1016/0016-5085(92)91101-9; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 2000, J BIOMOL NMR, V18, P129, DOI 10.1023/A:1008318805889; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; Kamiie K, 2002, BIOSCI BIOTECH BIOCH, V66, P558, DOI 10.1271/bbb.66.558; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KINZY TG, 1994, NUCLEIC ACIDS RES, V22, P2703, DOI 10.1093/nar/22.13.2703; Kobayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P509, DOI 10.1006/bbrc.2001.5799; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 2000, COMPUT PHYS COMMUN, V124, P139, DOI 10.1016/S0010-4655(99)00436-1; Kozlov G, 2000, J BIOMOL NMR, V17, P187, DOI 10.1023/A:1008363304977; KUMABE T, 1992, NUCLEIC ACIDS RES, V20, P2598, DOI 10.1093/nar/20.10.2598; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; Mansilla F, 2002, BIOCHEM J, V365, P669, DOI 10.1042/BJ20011681; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; MIMORI K, 1995, CANCER, V75, P1446, DOI 10.1002/1097-0142(19950315)75:6+<1446::AID-CNCR2820751509>3.0.CO;2-P; Minella O, 1998, BIOSCIENCE REP, V18, P119, DOI 10.1023/A:1020140527930; Monnier A, 2001, NUCLEIC ACIDS RES, V29, P1453, DOI 10.1093/nar/29.7.1453; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Perez JMJ, 1999, STRUCTURE, V7, P217, DOI 10.1016/S0969-2126(99)80027-6; Prompers JJ, 1997, PROTEIN SCI, V6, P2375; Sheu GT, 1999, MOL CELL BIOCHEM, V191, P181, DOI 10.1023/A:1006802125856; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDAMME H, 1991, EUR J BIOCHEM, V197, P505, DOI 10.1111/j.1432-1033.1991.tb15938.x; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; Vanwetswinkel S, 2003, J BIOMOL NMR, V26, P189, DOI 10.1023/A:1023504611632; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WANG AC, 1994, J MAGN RESON SER B, V105, P196, DOI 10.1006/jmrb.1994.1123; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033	52	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43443	43451		10.1074/jbc.M306031200	http://dx.doi.org/10.1074/jbc.M306031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920118	hybrid			2022-12-27	WOS:000186157000089
J	Ko, J; Na, M; Kim, S; Lee, JR; Kim, E				Ko, J; Na, M; Kim, S; Lee, JR; Kim, E			Interaction of the ERC family of RIM-binding proteins with the liprin-alpha family of multidomain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC ACTIVE ZONES; TYROSINE-PHOSPHATASE; TRANSPORT; CYTOMATRIX; PICCOLO; ASSOCIATION; VESICLE; BASSOON; MOTOR; FORMS	Liprin-alpha/SYD-2 is a family of multidomain proteins with four known isoforms. One of the reported functions of liprin-alpha is to regulate the development of presynaptic active zones, but the underlying mechanism is poorly understood. Here we report that liprin-alpha directly interacts with the ERC (ELKS-Rab6-interacting protein-CAST) family of proteins, members of which are known to bind RIMs, the active zone proteins that regulate neurotransmitter release. In vitro results indicate that ERC2/CAST, an active zone-specific isoform, interacts with all of the known isoforms of liprin-alpha and that liprin-alpha1 associates with both ERC2 and ERC1b, a splice variant of ERC1 that distributes to both cytosolic and active zone regions. ERC2 colocalizes with liprin-alpha1 in cultured neurons and forms a complex with liprin-alpha1 in brain. Liprin-alpha1, when expressed alone in cultured neurons, shows a partial synaptic localization. When coexpressed with ERC2, however, liprin-alpha1 is redistributed to synaptic sites. Moreover, roughly the first half of ERC2, which contains the liprin-alpha-binding region, is sufficient for the synaptic localization of liprin-alpha1 while the second half is not. These results suggest that the interaction between ERC2 and liprin-alpha may be involved in the presynaptic localization of liprin-alpha and the molecular organization of presynaptic active zones.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Synaptogenesis, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Kim, Eunjoon/C-1566-2011					Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; Goslin  K., 1991, CULTURING NERVE CELL, P339; Hernandez-Deviez DJ, 2002, NAT NEUROSCI, V5, P623, DOI 10.1038/nn865; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; Ko J, 2003, J NEUROSCI, V23, P1667; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Mok H, 2002, J NEUROSCI, V22, P5253; Monier S, 2002, TRAFFIC, V3, P289, DOI 10.1034/j.1600-0854.2002.030406.x; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shapira M, 2003, NEURON, V38, P237, DOI 10.1016/S0896-6273(03)00207-1; Shin H, 2003, J BIOL CHEM, V278, P11393, DOI 10.1074/jbc.M211874200; TIXIERVIDAL A, 1993, J CELL SCI, V105, P935; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Wyszynski M, 1998, NEUROPHARMACOLOGY, V37, P1335, DOI 10.1016/S0028-3908(98)00120-8; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	38	123	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42377	42385		10.1074/jbc.M307561200	http://dx.doi.org/10.1074/jbc.M307561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923177	hybrid			2022-12-27	WOS:000185989500100
J	Oe, T; Arora, JS; Lee, SH; Blair, IA				Oe, T; Arora, JS; Lee, SH; Blair, IA			A novel lipid hydroperoxide-derived cyclic covalent modification to histone H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINOLEIC-ACID; INDUCED DECOMPOSITION; PEROXIDATION; ADDUCTS; PRODUCT; SUBSTRATE; PEPTIDES; DIFFERENTIATION; METHYLATION; EXPRESSION	Previous studies have established that 4-hydroxy-2-nonenal is a lipid hydroperoxide-derived aldehydic bifunctional electrophile that reacts with DNA and proteins. However, it has now been recognized that 4-oxo-2- nonenal is also a major product of lipid hydroperoxide decomposition. Furthermore, 4-oxo-2-nonenal is more reactive than 4-hydroxy-2-nonenal toward the DNAbases 2'-deoxyguanosine, 2'-deoxyadenosine, and 2'-deoxycytidine and proteins. The formation of 4-oxo-2-nonenal can be induced through vitamin C-mediated or transition metal ion-mediated homolytic decomposition of polyunsaturated omega-3 lipid hydroperoxides such as 13(S)-hydroperoxyoctadecadienoic acid. We have discovered that synthetic 4-oxo-nonenal or 4-oxo-2-nonenal-generated from 13(S)-hydroperoxyoctadecadienoic acid recognizes the specific amino acid motifs of His(75), Ala(76), and Lys(77) in bovine histone H4. Reaction of the histidine and lysine residues with 4-oxo-2-nonenal results in the formation of a novel cyclic structure within the protein. The cyclic structure incorporates the histidine imidazole ring and a newly formed pyrrole derived from the lysine. The cyclic imidazole-pyrrole derivative that is formed from the small Nalpha-acetyl-His-Ala-Lys peptide exists as a mixture of two atropisomers that interconvert upon heating. Such lipid hydroperoxide-derived modifications could potentially modulate transcriptional activation in vivo. Furthermore, the ability to synthesize cyclic peptides using 4-oxo-2-nonenal will facilitate the preparation of novel structural analogs with potential biological activity.	Univ Penn, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Blair, IA (corresponding author), Univ Penn, Ctr Canc Pharmacol, 1254 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Oe, Tomoyuki/AAE-1514-2019; Blair, Ian A/B-3320-2010	Oe, Tomoyuki/0000-0002-3893-0815; Lee, Seon Hwa/0000-0003-1095-5516	NATIONAL CANCER INSTITUTE [R01CA095586] Funding Source: NIH RePORTER; NCI NIH HHS [CA 95586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Blair IA, 2001, EXP GERONTOL, V36, P1473, DOI 10.1016/S0531-5565(01)00133-4; Boiadjiev SE, 2002, MONATSH CHEM, V133, P1469, DOI 10.1007/s00706-002-0512-9; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Chung FL, 2000, CANCER RES, V60, P1507; DELANGE RJ, 1973, J BIOL CHEM, V248, P3261; Doorn JA, 2002, CHEM RES TOXICOL, V15, P1445, DOI 10.1021/tx025590o; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; Hamberg M, 1998, ARCH BIOCHEM BIOPHYS, V349, P376, DOI 10.1006/abbi.1997.0443; JOHNSON RS, 1987, ANAL CHEM, V59, P2621, DOI 10.1021/ac00148a019; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kawai Y, 2002, CARCINOGENESIS, V23, P485, DOI 10.1093/carcin/23.3.485; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SH, 2000, CHEM RES TOXICOL, V13, P565, DOI 10.1021/tx000057z; Lee SH, 2002, CHEM RES TOXICOL, V15, P300, DOI 10.1021/tx010147j; Lee SH, 2001, TRENDS CARDIOVAS MED, V11, P148, DOI 10.1016/S1050-1738(01)00094-9; LI P, 2002, CURR TOP MED CHEM, V3, P325; Liu ZF, 2003, CHEM RES TOXICOL, V16, P901, DOI 10.1021/tx0300030; Lloyd-Williams P, 2001, CHEM SOC REV, V30, P145, DOI 10.1039/b001971m; Picklo MJ, 2002, TOXICOL APPL PHARM, V184, P187, DOI 10.1006/taap.2002.9506; Pollack M, 2003, CHEM RES TOXICOL, V16, P893, DOI 10.1021/tx030009p; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Rindgen D, 2000, CHEM RES TOXICOL, V13, P846, DOI 10.1021/tx0000771; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Spiteller P, 2001, BBA-MOL CELL BIOL L, V1531, P188, DOI 10.1016/S1388-1981(01)00100-7; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang WH, 2003, CHEM RES TOXICOL, V16, P512, DOI 10.1021/tx020105a	35	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42098	42105		10.1074/jbc.M308167200	http://dx.doi.org/10.1074/jbc.M308167200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12930824	hybrid, Green Published			2022-12-27	WOS:000185989500067
J	Razzaq, TM; Bass, R; Vines, DJ; Werner, F; Whawell, SA; Ellis, V				Razzaq, TM; Bass, R; Vines, DJ; Werner, F; Whawell, SA; Ellis, V			Functional regulation of tissue plasminogen activator on the surface of vascular smooth muscle cells by the type-II transmembrane protein p63 (CKAP4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; GROWTH-FACTOR-BETA; ENDOPLASMIC-RETICULUM; MATRIX METALLOPROTEINASES; UROKINASE-TYPE; CELLULAR-BINDING; ANNEXIN-II; RECEPTOR; GENERATION; MIGRATION	We have demonstrated that tissue plasminogen activator (tPA) binds specifically to human vascular smooth muscle cells (VSMC) in a functionally relevant manner, both increasing plasminogen activation and decreasing tPA inhibition (Ellis, V., and Whawell, S. A. ( 1997) Blood 90, 2312-2322; Werner, F., Razzaq, T. M., and Ellis, V. ( 1999) J. Biol. Chem. 274, 21555-21561). To further understand this system we have now identified and characterized the protein responsible for this binding. Rat VSMC were surface-labeled with I-125, and cell lysates were subjected to an affinity chromatography scheme based on the previously identified tPA binding characteristics. A single radiolabeled protein of 63 kDa bound specifically and was eluted at low pH. This protein was isolated from large scale preparations of VSMC and unambiguously identified as the rat homologue of the human type-II transmembrane protein p63 (CKAP4) by matrix-assisted laser desorption ionization and nano-electrospray tandem mass spectrometry of tryptic fragments. In confirmation of this, a monoclonal antibody raised against authentic human p63 recognized the isolated protein in Western blotting. Immunofluorescence microscopy demonstrated that p63 was located principally in the endoplasmic reticulum but was also detected in significant quantities on the surface of human VSMC. In support of the hypothesis that p63 is the functional tPA binding site on VSMC, an anti-p63 monoclonal antibody was found to block tPA binding. Furthermore, heterologous expression of an N-terminally truncated mutant of p63, which targets exclusively to the plasma membrane, led to an increase in tPA-catalyzed plasminogen activation. Therefore, p63 on the surface of VSMC may contribute to the functional regulation of the plasminogen activation system in the vessel wall.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Ellis, V (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.		Ellis, Vincent/D-1860-2009; Bass, Rosemary A/A-5328-2009	Ellis, Vincent/0000-0003-1956-073X; Bass, Rosemary A/0000-0003-4997-5207; Werner, Finn/0000-0002-3930-3821				Bass R, 2002, BIOCHEM SOC T, V30, P189, DOI 10.1042/BST0300189; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOCHATONPIALLAT ML, 1992, DIFFERENTIATION, V49, P175, DOI 10.1111/j.1432-0436.1992.tb00665.x; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; Drew AF, 2000, CIRC RES, V87, P133, DOI 10.1161/01.RES.87.2.133; Dudani AK, 1996, BRIT J HAEMATOL, V95, P168, DOI 10.1046/j.1365-2141.1996.7482367.x; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Ellis V, 1997, TRENDS CARDIOVAS MED, V7, P227, DOI 10.1016/S1050-1738(97)00084-4; ELLIS V, 1989, J BIOL CHEM, V264, P2185; Ellis V, 2001, FEBS LETT, V506, P1, DOI 10.1016/S0014-5793(01)02845-9; Ellis V, 1997, BLOOD, V90, P2312, DOI 10.1182/blood.V90.6.2312.2312_2312_2322; FELEZ J, 1993, BLOOD, V82, P2433, DOI 10.1182/blood.V82.8.2433.bloodjournal8282433; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hembrough TA, 1996, BIOCHEM J, V317, P763, DOI 10.1042/bj3170763; Kenagy RD, 1996, ARTERIOSCL THROM VAS, V16, P1373, DOI 10.1161/01.ATV.16.11.1373; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; Levi M, 2001, CIRCULATION, V103, P2014; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; LIND SE, 1991, J BIOL CHEM, V266, P17673; LUPU F, 1995, ARTERIOSCL THROM VAS, V15, P1444, DOI 10.1161/01.ATV.15.9.1444; Machovich R, 1997, FEBS LETT, V407, P93, DOI 10.1016/S0014-5793(97)00303-7; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; Pignolo RJ, 1998, EXP CELL RES, V240, P305, DOI 10.1006/excr.1998.4009; REUNING U, 1994, BLOOD, V84, P3700, DOI 10.1182/blood.V84.11.3700.bloodjournal84113700; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Schafer K, 2002, CIRCULATION, V106, P1847, DOI 10.1161/01.CIR.0000031162.80988.2B; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SCHWEIZER A, 1993, EUR J CELL BIOL, V60, P366; SCHWEIZER A, 1993, J CELL SCI, V104, P685; Steins MB, 1999, ATHEROSCLEROSIS, V145, P173, DOI 10.1016/S0021-9150(99)00030-1; Tran H, 2002, J CELL SCI, V115, P2031; Ueba H, 1997, ARTERIOSCL THROM VAS, V17, P1512, DOI 10.1161/01.ATV.17.8.1512; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werner F, 1999, J BIOL CHEM, V274, P21555, DOI 10.1074/jbc.274.31.21555; Wittmann T, 2001, J CELL SCI, V114, P3795; Yakovlev S, 2000, BIOCHEMISTRY-US, V39, P15730, DOI 10.1021/bi001847a	47	46	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42679	42685		10.1074/jbc.M305695200	http://dx.doi.org/10.1074/jbc.M305695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913003	hybrid			2022-12-27	WOS:000185989500134
J	Xu, M; Welling, A; Paparisto, S; Hofmann, F; Klugbauer, N				Xu, M; Welling, A; Paparisto, S; Hofmann, F; Klugbauer, N			Enhanced expression of L-type Ca(v)1.3 calcium channels in murine embryonic hearts from Ca(v)1.2-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; MOUSE HEART; DEVELOPMENTAL-CHANGES; SINOATRIAL NODE; MESSENGER-RNA; RAT-HEART; GENE; MODULATION; SUBUNIT; CARDIOMYOCYTES	Voltage-gated calcium (Ca2+) channels play a key role in the control of heart contraction and are essential for normal heart development. The Ca(v)1.2 L-type calcium channel is the predominant isoform in cardiomyocytes and is essential for excitation-contraction coupling. Although the inactivation of the Ca(v)1.2 gene caused embryonic lethality before embryonic day E14.5, hearts were contracting before E14 depending on a dihydropyridine-sensitive calcium influx. We analyzed the consequences of the deletion of the Ca(v)1.2 channel on the expression level of other voltage-gated calcium channels in the embryonic mouse heart and isolated cardiomyocytes. A strong compensatory up-regulation of the Ca(v)1.3 calcium channel was observed on the mRNA as well as on the protein level. Reverse transcriptase PCR indicated that the recently identified new Ca(v)1.3(1b) isoform was strongly up-regulated, whereas a more moderate increase was found for the Ca(v)1.3(1a) variant. Heterologous expression of Ca(v)1.3( 1b) in HEK293 cells induced Ba2+ currents with properties similar to those found in Ca(v)1.2 (-/-) cardiomyocytes, suggesting that this isoform constitutes a major component of the residual L-type calcium current in Ca(v)1.2 (-/-) cardiomyocytes. In summary, our results imply that calcium channel expression is dynamically regulated during heart development and that the Ca(v)1.3 channel may substitute for Ca(v)1.2 during early embryogenesis.	Tech Univ Munich, Dept Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Klugbauer, N (corresponding author), Tech Univ Munich, Dept Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.		Welling, Andrea/K-6674-2017	Welling, Andrea/0000-0002-5364-4980				An RH, 1996, CIRC RES, V78, P371, DOI 10.1161/01.RES.78.3.371; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Bohn G, 2000, FEBS LETT, V481, P73, DOI 10.1016/S0014-5793(00)01979-7; Campbell DB, 1999, MOL PHARMACOL, V55, P23, DOI 10.1124/mol.55.1.23; Cribbs LL, 2001, CIRC RES, V88, P403; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Ferron L, 2002, J MOL CELL CARDIOL, V34, P533, DOI 10.1006/jmcc.2002.1535; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Huang BY, 2000, CARDIOVASC RES, V46, P442, DOI 10.1016/S0008-6363(00)00017-1; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; Klugbauer N, 2002, EUR J PHARMACOL, V447, P279, DOI 10.1016/S0014-2999(02)01850-2; Koschak A, 2001, J BIOL CHEM, V276, P22100, DOI 10.1074/jbc.M101469200; Larsen JK, 2002, J MOL CELL CARDIOL, V34, P519, DOI 10.1006/jmcc.2001.1534; Lipscombe D, 2002, CIRC RES, V90, P933, DOI 10.1161/01.RES.0000019740.52306.92; Liu W, 1999, AM J PHYSIOL-HEART C, V276, pH608, DOI 10.1152/ajpheart.1999.276.2.H608; Mangoni ME, 2003, P NATL ACAD SCI USA, V100, P5543, DOI 10.1073/pnas.0935295100; Menard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Namkung Y, 2001, J CLIN INVEST, V108, P1015, DOI 10.1172/JCI13310; Nattel S, 1999, CIRC RES, V85, P473, DOI 10.1161/01.RES.85.5.473; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Protas L, 2001, AM J PHYSIOL-HEART C, V281, pH1252, DOI 10.1152/ajpheart.2001.281.3.H1252; Seisenberger C, 2000, J BIOL CHEM, V275, P39193, DOI 10.1074/jbc.M006467200; Takimoto K, 1997, J MOL CELL CARDIOL, V29, P3035, DOI 10.1006/jmcc.1997.0532; Viatchenko-Karpinski S, 1999, P NATL ACAD SCI USA, V96, P8259, DOI 10.1073/pnas.96.14.8259; Weissgerber P, 2003, N-S ARCH PHARMACOL, V367, pR92; Yasui K, 2001, CIRC RES, V88, P536, DOI 10.1161/01.RES.88.5.536; Zhang Z, 2002, CIRC RES, V90, P981, DOI 10.1161/01.RES.0000018003.14304.E2	32	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40837	40841		10.1074/jbc.M307598200	http://dx.doi.org/10.1074/jbc.M307598200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900400	hybrid			2022-12-27	WOS:000185847200052
J	Lee, YC; Tang, YC; Chen, YH; Wong, CM; Tsou, AP				Lee, YC; Tang, YC; Chen, YH; Wong, CM; Tsou, AP			Selenite-induced survival of HuH7 hepatoma cells involves activation of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt pathway and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL DNA LOOPS; HEPATITIS-B VIRUS; SERUM-FREE MEDIUM; NF-KAPPA-B; GLUTATHIONE-PEROXIDASE; CANCER MORTALITY; THIOREDOXIN REDUCTASE; REDOX MECHANISM; SELENOPROTEIN-P; TRANSGENIC MICE	Selenium has been shown to sustain the growth of selected human hepatocellular carcinoma cell lines under serum-free conditions, but the detailed mechanism remained undetermined. In the present study, the molecular mechanism(s) involving sodium selenite (Na2SO3, Se) as a survival agent were determined. Selenite not only protects HuH7 cells from serum deprivation-induced apoptosis, it also supports its long-term growth in sodium selenite ( 10(-7) M) supplemented serum-free medium. The anti-apoptotic effect correlates with activation of focal adhesion kinase and the phosphatidylinositol 3-kinase (PI3K)-Akt kinase pathway. Using HuH7 cells stably transfected with a constitutively active Akt kinase and PI3K inhibitor LY294002, selenite-induced cell survival was shown to be PI3K-Akt-dependent. Parallel changes included a significant reduction in the intracellular reactive oxygen species content, the reversal of DNA fragmentation, and the suppression of caspase and apoptosis signal-regulating kinase 1 activities. HuH7 cells stably expressing a Rac1 mutant N17 (Rac1(N17)-HuH7) are refractory to selenite treatment. In these cells selenite supplement neither triggers Akt activation nor supports cell proliferation. Participation of Rac1 activation in this event is supported by the fact that selenite treatment drastically enhanced activation of Rac1. The exact link between selenite treatment, Rac1 activation, and activation of the focal adhesion kinase-PI 3-kinase, however, remains to be characterized. The mitogenic signaling mediated by selenite may involve unconventional growth stimuli including higher glutathione peroxidase 1 activity and higher transcription levels of selenoprotein P. The selenium-HuH7 system we have established thus provides a unique tool that will allow the biological role of selenite in growth regulation of hepatocytes to be studied in detail.	Natl Yang Ming Univ, Inst Biotechnol Med, Sch Med Technol & Engn, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Inst Genet, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Tsou, AP (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Sch Med Technol & Engn, Taipei 112, Taiwan.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Baker A, 1997, CANCER RES, V57, P5162; BARNES D, 1979, NATURE, V281, P388, DOI 10.1038/281388a0; Bergsland EK, 2001, SEMIN ONCOL, V28, P521, DOI 10.1053/sonc.2001.26955; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; BURK RF, 1983, ANNU REV NUTR, V3, P53, DOI 10.1146/annurev.nu.03.070183.000413; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; CLARK LC, 1991, ARCH ENVIRON HEALTH, V46, P37, DOI 10.1080/00039896.1991.9937427; Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ESWORTHY RS, 1995, CANCER RES, V55, P957; Fiala ES, 1998, CARCINOGENESIS, V19, P597, DOI 10.1093/carcin/19.4.597; Frydman B, 1997, CANCER RES, V57, P620; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; LAGARKOVA MA, 1995, J BIOL CHEM, V270, P20239, DOI 10.1074/jbc.270.35.20239; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Lu YP, 1997, CANCER RES, V57, P1468; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; Mostert V, 2000, ARCH BIOCHEM BIOPHYS, V376, P433, DOI 10.1006/abbi.2000.1735; MURAKAMI H, 1980, P NATL ACAD SCI-BIOL, V77, P3464, DOI 10.1073/pnas.77.6.3464; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; NIWA A, 1979, J CELL PHYSIOL, V98, P177, DOI 10.1002/jcp.1040980119; OYAMA Y, 1994, BRAIN RES, V635, P113, DOI 10.1016/0006-8993(94)91429-X; Park HS, 2000, J BIOL CHEM, V275, P8487, DOI 10.1074/jbc.275.12.8487; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHRAUZER GN, 1977, BIOINORG CHEM, V7, P35, DOI 10.1016/S0006-3061(00)80127-1; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; STADTMAN TC, 1991, J BIOL CHEM, V266, P16257; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Stapleton SR, 1997, BBA-MOL CELL RES, V1355, P259, DOI 10.1016/S0167-4889(96)00140-1; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUNDE RA, 1990, ANNU REV NUTR, V10, P451, DOI 10.1146/annurev.nu.10.070190.002315; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang HM, 2001, BIOCHEMISTRY-US, V40, P3316, DOI 10.1021/bi002786j; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; WEBBER RJ, 1988, J ORTHOP RES, V6, P13, DOI 10.1002/jor.1100060103; WU L, 1995, CARCINOGENESIS, V16, P1579, DOI 10.1093/carcin/16.7.1579; Yan J, 1998, J NEUROSCI, V18, P8682; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Yu SY, 1997, BIOL TRACE ELEM RES, V56, P117, DOI 10.1007/BF02778987; YU SY, 1988, BIOL TRACE ELEM RES, V15, P243, DOI 10.1007/BF02990141; YU SY, 1985, BIOL TRACE ELEM RES, V7, P21, DOI 10.1007/BF02916544	54	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39615	39624		10.1074/jbc.M304095200	http://dx.doi.org/10.1074/jbc.M304095200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12896980	hybrid			2022-12-27	WOS:000185713800045
J	Nemoto, T; Tanida, I; Tanida-Miyake, E; Minematsu-Ikeguchi, N; Yokota, M; Ohsumi, M; Ueno, T; Kominami, E				Nemoto, T; Tanida, I; Tanida-Miyake, E; Minematsu-Ikeguchi, N; Yokota, M; Ohsumi, M; Ueno, T; Kominami, E			The mouse APG10 homologue, an E2-like enzyme for Apg12p conjugation, facilitates MAP-LC3 modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; VACUOLE TARGETING PATHWAY; SACCHAROMYCES-CEREVISIAE; ACTIVATING ENZYME; ERYTHROID-CELLS; AUTOPHAGY; YEAST; UBIQUITIN; SYSTEM; DISEASE	Autophagy is a process for the bulk degradation of cytosolic compartments by lysosomes/vacuoles. The formation of autophagosomes involves a dynamic rearrangement of the membrane for which two ubiquitinlike modifications ( the conjugation of Apg12p and the modification of a soluble form of MAP-LC3 to a membrane-bound form) are essential. In yeast, Apg10p is an E2-like enzyme essential for Apg12p conjugation. The isolated mouse APG10 gene product interacts with mammalian Apg12p dependent on mammalian Apg7p ( E1-like enzyme), and facilitates Apg12p conjugation. The interaction of Apg10p with Apg12p is dependent on the carboxyl-terminal glycine of Apg12p. Mutational analysis of the predicted active site cysteine (Cys(161)) within mouse Apg10p shows that mutant Apg10pC161S, which can form a stable intermediate with Apg12p, inhibits Apg12p conjugation even in the presence of Apg7p, while overexpression of Apg7p facilitates formation of an Apg12p-Apg5p conjugate. Furthermore, the coexpression of Apg10p with Apg7p facilitates the modification of a soluble form of MAP-LC3 to a membrane-bound form, a second modification essential for autophagy. Mouse Apg10p interacts with MAP-LC3 in HEK293 cells, while no mutant Apg10pC161S forms any intermediate with MAP-LC3. Direct interaction between Apg10p and MAP-LC3 is also demonstrated by yeast two-hybrid analysis. The inability of mutant Apg10pC161S to form any intermediate with MAP-LC3 has ruled out the possibility that MAP-LC3 interacts with Apg10p as a substrate.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan; Teikyo Univ Sci & Technol, Dept Biosci, Yamanashi 4090193, Japan	Juntendo University	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.		Kominami, Eiki/D-3802-2009; Tanida, Isei/C-8277-2009	Tanida, Isei/0000-0001-8999-3990				Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; HEYNEN MJ, 1985, CELL TISSUE RES, V239, P235, DOI 10.1007/BF00214924; HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2002, FEBS LETT, V532, P450, DOI 10.1016/S0014-5793(02)03739-0; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; OHSHITA T, 1986, J BIOCHEM-TOKYO, V100, P623, DOI 10.1093/oxfordjournals.jbchem.a121754; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; SULLIVAN ML, 1993, J BIOL CHEM, V268, P8777; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Takano-Ohmuro H, 2000, EUR J CELL BIOL, V79, P759, DOI 10.1078/0171-9335-00096; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, BIOCHEM BIOPH RES CO, V292, P256, DOI 10.1006/bbrc.2002.6645; Tanida I, 2002, BIOCHEM BIOPH RES CO, V296, P1164, DOI 10.1016/S0006-291X(02)02057-0; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	38	71	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39517	39526		10.1074/jbc.M300550200	http://dx.doi.org/10.1074/jbc.M300550200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890687	hybrid			2022-12-27	WOS:000185713800032
J	Wu-Baer, F; Lagrazon, K; Yuan, W; Baer, R				Wu-Baer, F; Lagrazon, K; Yuan, W; Baer, R			The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN CHAIN; TUMOR-SUPPRESSOR; LIGASE ACTIVITY; CONJUGATING ENZYME; PROTEIN LIGASE; RING DOMAIN; IN-VIVO; BRCA1; COMPLEX; BARD1	The BRCA1 tumor suppressor forms a heterodimer with the BARD1 protein, and the resulting complex functions as an E3 ubiquitin ligase that catalyzes the synthesis of polyubiquitin chains. In theory, polyubiquitination can occur by isopeptide bond formation at any of the seven lysine residues of ubiquitin. The isopeptide linkage of a polyubiquitin chain is a particularly important determinant of its cellular function, such that K48-linked chains commonly target proteins for proteasomal degradation, while K63 chains serve non-proteolytic roles in various signaling pathways. To determine the isopeptide linkage formed by BRCA1/BARD1-dependent polyubiquitination, we purified a full-length heterodimeric complex and compared its linkage specificity with that of E6-AP, an E3 ligase known to induce proteolysis of its cellular substrates. Using a comprehensive mutation analysis, we found that E6-AP catalyzes the synthesis of K48-linked polyubiquitin chains. In contrast, however, the BRCA1/BARD1 heterodimer directs polymerization of ubiquitin primarily through an unconventional linkage involving lysine residue K6. Although heterologous substrates of BRCA1/BARD1 are not known, BRCA1 autoubiquitination occurs principally by conjugation with K6-linked polymers. The ability of BRCA1/BARD1 to form K6-linked polyubiquitin chains suggests that it may impart unique cellular properties to its natural enzymatic substrates.	Columbia Univ, Inst Canc Genet, Dept Pathol, New York, NY 10032 USA	Columbia University	Baer, R (corresponding author), Columbia Univ, Inst Canc Genet, Dept Pathol, 1150 St Nicholas Ave, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [CA97403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199	28	219	229	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34743	34746		10.1074/jbc.C300249200	http://dx.doi.org/10.1074/jbc.C300249200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12890688	hybrid			2022-12-27	WOS:000185164400003
J	Bell, JS; McCulloch, R				Bell, JS; McCulloch, R			Mismatch repair regulates homologous recombination, but has little influence on antigenic variation, in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN EXPRESSION SITES; SACCHAROMYCES-CEREVISIAE MSH2; MONO-ALLELIC EXPRESSION; DOUBLE-STRAND BREAKS; GENETIC-RECOMBINATION; SALMONELLA-TYPHIMURIUM; AFRICAN TRYPANOSOMES; ESCHERICHIA-COLI; IN-VIVO; SEXUAL ISOLATION	Antigenic variation is critical in the life of the African trypanosome, as it allows the parasite to survive in the face of host immunity and enhance its transmission to other hosts. Much of trypanosome antigenic variation uses homologous recombination of variant surface glycoprotein (VSG)-encoding genes into specialized transcription sites, but little is known about the processes that regulate it. Here we describe the effects on VSG switching when two central mismatch repair genes, MSH2 and MLH1, are mutated. We show that disruption of the parasite mismatch repair system causes an increased frequency of homologous recombination, both between perfectly matched DNA molecules and between DNA molecules with divergent sequences. Mismatch repair therefore provides an important regulatory role in homologous recombination in this ancient eukaryote. Despite this, the mismatch repair system has no detectable role in regulating antigenic variation, meaning that VSG switching is either immune to mismatch selection or that mismatch repair acts in a subtle manner, undetectable by current assays.	Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	McCulloch, R (corresponding author), Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.							Abdulkarim F, 1996, J MOL BIOL, V260, P506, DOI 10.1006/jmbi.1996.0418; ALANI E, 1994, GENETICS, V137, P19; Alsford NS, 2003, MOL MICROBIOL, V47, P277, DOI 10.1046/j.1365-2958.2003.03266.x; Augusto-Pinto L, 2003, GENETICS, V164, P117; Augusto-Pinto L, 2001, GENE, V272, P323, DOI 10.1016/S0378-1119(01)00549-2; Barnes DE, 2001, CURR BIOL, V11, pR455, DOI 10.1016/S0960-9822(01)00279-2; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; Blundell PA, 1996, MOL BIOCHEM PARASIT, V76, P215, DOI 10.1016/0166-6851(95)02560-X; Borst P, 1996, ARCH MED RES, V27, P379; BORST P, 1982, CELL, V29, P291, DOI 10.1016/0092-8674(82)90146-5; Borst P, 1999, TRENDS GENET, V15, P95, DOI 10.1016/S0168-9525(98)01680-1; Chaves I, 1999, EMBO J, V18, P4846, DOI 10.1093/emboj/18.17.4846; Conway C, 2002, J BIOL CHEM, V277, P21269, DOI 10.1074/jbc.M200550200; Conway C, 2002, MOL MICROBIOL, V45, P1687, DOI 10.1046/j.1365-2958.2002.03122.x; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Culligan KM, 2000, PLANT CELL, V12, P991, DOI 10.1105/tpc.12.6.991; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Datta A, 1997, P NATL ACAD SCI USA, V94, P9757, DOI 10.1073/pnas.94.18.9757; de Wind N, 2001, CURR BIOL, V11, pR545, DOI 10.1016/S0960-9822(01)00338-4; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Donelson JE, 2003, ACTA TROP, V85, P391, DOI 10.1016/S0001-706X(02)00237-1; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Eisen JA, 1998, NUCLEIC ACIDS RES, V26, P4291, DOI 10.1093/nar/26.18.4291; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Evans E, 2000, MOL CELL BIOL, V20, P7839, DOI 10.1128/MCB.20.21.7839-7844.2000; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; Gaud A, 1997, MOL BIOCHEM PARASIT, V87, P113, DOI 10.1016/S0166-6851(97)00048-0; Harfe BD, 2000, CURR BIOL, V10, P145, DOI 10.1016/S0960-9822(00)00314-6; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; HUMBERT O, 1995, P NATL ACAD SCI USA, V92, P9052, DOI 10.1073/pnas.92.20.9052; Hunter N, 1996, EMBO J, V15, P1726, DOI 10.1002/j.1460-2075.1996.tb00518.x; KAMPER SM, 1992, MOL BIOCHEM PARASIT, V53, P33, DOI 10.1016/0166-6851(92)90004-4; Lin CT, 2001, NUCLEIC ACIDS RES, V29, P3304, DOI 10.1093/nar/29.16.3304; Lipkin SM, 2002, NAT GENET, V31, P385, DOI 10.1038/ng931; Majewski J, 1998, GENETICS, V148, P13; Majewski J, 2000, J BACTERIOL, V182, P1016, DOI 10.1128/JB.182.4.1016-1023.2000; Malik HS, 2000, TRENDS BIOCHEM SCI, V25, P414, DOI 10.1016/S0968-0004(00)01623-6; McCulloch R, 1997, MOL CELL BIOL, V17, P833, DOI 10.1128/MCB.17.2.833; McCulloch R, 1999, GENE DEV, V13, P2875, DOI 10.1101/gad.13.21.2875; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; Navarro M, 1999, EMBO J, V18, P2265, DOI 10.1093/emboj/18.8.2265; Nicholson A, 2000, GENETICS, V154, P133; Papadopoulou B, 1997, NUCLEIC ACIDS RES, V25, P4278, DOI 10.1093/nar/25.21.4278; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PAYS E, 1985, PROG NUCLEIC ACID RE, V32, P1, DOI 10.1016/S0079-6603(08)60344-X; PETIT MA, 1991, GENETICS, V129, P327; Porter G, 1996, GENETICS, V143, P755; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Richardson AR, 2001, MOL MICROBIOL, V40, P645, DOI 10.1046/j.1365-2958.2001.02408.x; Roberts Michael S., 1993, Genetics, V134, P401; Robinson NP, 1999, MOL CELL BIOL, V19, P5839; Robinson NP, 2002, J BIOL CHEM, V277, P26185, DOI 10.1074/jbc.M203205200; Rosenberg SM, 2001, NAT REV GENET, V2, P504, DOI 10.1038/35080556; Saparbaev M, 1996, GENETICS, V142, P727; SHEN P, 1986, GENETICS, V112, P441; Shen SY, 2001, MOL BIOCHEM PARASIT, V113, P171, DOI 10.1016/S0166-6851(00)00383-2; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Tran H, 1997, MOL CELL BIOL, V17, P1027, DOI 10.1128/MCB.17.2.1027; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; Vanhamme L, 2001, INT J PARASITOL, V31, P523, DOI 10.1016/S0020-7519(01)00143-6; Vanhamme L, 2000, MOL MICROBIOL, V36, P328, DOI 10.1046/j.1365-2958.2000.01844.x; Vulic M, 1997, P NATL ACAD SCI USA, V94, P9763, DOI 10.1073/pnas.94.18.9763; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6; ZAHRT TC, 1994, J BACTERIOL, V176, P1527, DOI 10.1128/jb.176.5.1527-1529.1994; ZAWADZKI P, 1995, GENETICS, V140, P917	77	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45182	45188		10.1074/jbc.M308123200	http://dx.doi.org/10.1074/jbc.M308123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933800	hybrid			2022-12-27	WOS:000186452300018
J	Chen, Y; Takizawa, N; Crowley, JL; Oh, SW; Gatto, CL; Kambara, T; Sato, O; Li, XD; Ikebe, M; Luna, EJ				Chen, Y; Takizawa, N; Crowley, JL; Oh, SW; Gatto, CL; Kambara, T; Sato, O; Li, XD; Ikebe, M; Luna, EJ			F-actin and myosin II binding domains in supervillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAINS; SMOOTH-MUSCLE MYOSIN; LIPID RAFTS; PLASMA-MEMBRANE; PROTEINS; SPECTRIN; GELSOLIN; SURFACE; LOCALIZATION; CALDESMON	Detergent-resistant membranes contain signaling and integral membrane proteins that organize cholesterol-rich domains called lipid rafts. A subset of these detergent-resistant membranes (DRM-H) exhibits a higher buoyant density (similar to1.16 g/ml) because of association with membrane skeleton proteins, including actin, myosin II, myosin 1G, fodrin, and an actin- and membrane-binding protein called supervillin (Nebl, T., Pestonjamasp, K. N., Leszyk, J. D., Crowley, J. L., Oh, S. W., and Luna, E. J. (2002) J. Biol. Chem. 277, 43399-43409). To characterize interactions among DRM-H cytoskeletal proteins, we investigated the binding partners of the novel supervillin N terminus, specifically amino acids 1-830. We find that the supervillin N terminus binds directly to myosin II, as well as to F-actin. Three F-actin-binding sites were mapped to sequences within amino acids similar to280-342, similar to344-422, and similar to700-830. Sequences with combinations of these sites promote F-actin cross-linking and/or bundling. Supervillin amino acids 1-174 specifically interact with the S2 domain in chicken gizzard myosin and nonmuscle myosin IIA (MYH-9) but exhibit little binding to skeletal muscle myosin II. Direct or indirect binding to filamin also was observed. Overexpression of supervillin amino acids 1-174 in COS7 cells disrupted the localization of myosin IIB without obviously affecting actin filaments. Taken together, these results suggest that supervillin may mediate actin and myosin II filament organization at cholesterol-rich membrane domains.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Luna, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Biotech 4,Ste 306,377 Plantat St, Worcester, MA 01605 USA.	Elizabeth.Luna@umassmed.edu	Luna, Elizabeth/B-4364-2012		NIAMS NIH HHS [AR41653] Funding Source: Medline; NIGMS NIH HHS [GM55834, GM33048, R01 GM033048] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033048] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AguadoVelasco C, 1997, P NATL ACAD SCI USA, V94, P9684, DOI 10.1073/pnas.94.18.9684; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Arhets P, 1998, MOL BIOL CELL, V9, P1537, DOI 10.1091/mbc.9.6.1537; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; BRAUN J, 1978, J CELL BIOL, V79, P409, DOI 10.1083/jcb.79.2.409; BURNS CG, 1995, P NATL ACAD SCI USA, V92, P8244, DOI 10.1073/pnas.92.18.8244; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DAHL SC, 1994, J CELL BIOL, V125, P1057, DOI 10.1083/jcb.125.5.1057; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FOWLER V, 1980, J CELL BIOL, V85, P361, DOI 10.1083/jcb.85.2.361; FOWLER VM, 1981, J CELL BIOL, V88, P388, DOI 10.1083/jcb.88.2.388; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; GRIFFITH LM, 1978, J CELL BIOL, V78, P958, DOI 10.1083/jcb.78.3.958; Gusev NB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1112, DOI 10.1023/A:1012480829618; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Holowka D, 2000, J CELL SCI, V113, P1009; Ikebe M, 1998, BIOCHEMISTRY-US, V37, P13285, DOI 10.1021/bi981130b; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1988, J BIOL CHEM, V263, P3055; Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7; KHREBTUKOVA IA, 1991, EXP CELL RES, V194, P48, DOI 10.1016/0014-4827(91)90128-H; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kohama K, 1996, TRENDS PHARMACOL SCI, V17, P284, DOI 10.1016/0165-6147(96)10033-X; Kolega J, 1998, J CELL SCI, V111, P2085; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Kunst G, 2000, CIRC RES, V86, P51, DOI 10.1161/01.RES.86.1.51; Kwiatkowska K, 1999, BIOCHEM BIOPH RES CO, V259, P287, DOI 10.1006/bbrc.1999.0769; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luna EJ, 1997, SOC GEN PHY, V52, P3; Luna EJ, 1998, METHOD ENZYMOL, V298, P32, DOI 10.1016/S0076-6879(98)98006-5; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Morgan KG, 2001, J APPL PHYSIOL, V91, P953, DOI 10.1152/jappl.2001.91.2.953; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Oh SW, 2003, J CELL SCI, V116, P2261, DOI 10.1242/jcs.00422; Pappin D J, 1997, Methods Mol Biol, V64, P165; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Pestonjamasp KN, 1997, J CELL BIOL, V139, P1255, DOI 10.1083/jcb.139.5.1255; Pierini LM, 2003, J BIOL CHEM, V278, P10831, DOI 10.1074/jbc.M212386200; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; Pope RK, 1998, GENOMICS, V52, P342, DOI 10.1006/geno.1998.5466; Pradhan D, 2002, IMMUNITY, V17, P303, DOI 10.1016/S1074-7613(02)00396-5; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Saitoh T, 2001, FEBS LETT, V509, P365, DOI 10.1016/S0014-5793(01)03186-6; Sata M, 1996, J CLIN INVEST, V98, P2866, DOI 10.1172/JCI119115; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SPECKART G, 1986, J QUANTITATIVE CRIMI, V0002; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STARR R, 1971, FEBS LETT, V15, P40, DOI 10.1016/0014-5793(71)80075-3; SWAFFIELD JC, 1996, CURRENT PROTOCOLS MO; Takizawa N, 2003, AM J PHYSIOL-CELL PH, V284, pC250, DOI 10.1152/ajpcell.00153.2002; Ting HJ, 2002, P NATL ACAD SCI USA, V99, P661, DOI 10.1073/pnas.022469899; VARMA M, 1988, MUTAT RES, V199, P437, DOI 10.1016/0027-5107(88)90220-5; von Haller PD, 2001, PROTEOMICS, V1, P1010; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; Wang CLA, 2001, CELL BIOCHEM BIOPHYS, V35, P275, DOI 10.1385/CBB:35:3:275; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125	76	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46094	46106		10.1074/jbc.M305311200	http://dx.doi.org/10.1074/jbc.M305311200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12917436	hybrid			2022-12-27	WOS:000186452300127
J	Aracena, P; Sanchez, G; Donoso, P; Hamilton, SL; Hidalgo, C				Aracena, P; Sanchez, G; Donoso, P; Hamilton, SL; Hidalgo, C			S-glutathionylation decreases Mg2+ inhibition and S-nitrosylation enhances Ca2+ activation of RyR1 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; JUN DNA-BINDING; SKELETAL-MUSCLE; RYANODINE RECEPTOR; HYDROGEN-PEROXIDE; NITRIC-OXIDE; REDOX SENSOR; CHANNEL/RYANODINE RECEPTOR; ENDOGENOUS EFFECTORS	We have analyzed the effects of the endogenous redoxactive agents S-nitrosoglutathione and glutathione disulfide, and the NO donor NOR-3, on calcium release kinetics mediated by ryanodine receptor channels. Incubation of triad-enriched sarcoplasmic reticulum vesicles isolated from mammalian skeletal muscle with these three agents elicits different responses. Glutathione disulfide significantly reduces the inhibitory effect of Mg2+ without altering Ca2+ activation of release kinetics, whereas NOR-3 enhances Ca2+ activation of release kinetics without altering Mg2+ inhibition. Incubation with S-nitrosoglutathione produces both effects; it significantly enhances Ca2+ activation of release kinetics and diminishes the inhibitory effect of Mg2+ on this process. Triad incubation with [S-35] nitrosoglutathione at pCa 5 promoted S-35 incorporation into 2.5 cysteine residues per channel monomer; this incorporation decreased significantly at pCa 9. These findings indicate that S-nitrosoglutathione supports S-glutathionylation as well as the reported S-nitrosylation of ryanodine receptor channels ( Sun, J., Xu, L., Eu, J. P., Stamler, J. S., and Meissner, G. ( 2003) J. Biol. Chem. 278, 8184 - 8189). The combined results suggest that S-glutathionylation of specific cysteine residues can modulate channel inhibition by Mg2+, whereas S-nitrosylation of different cysteines can modulate the activation of the channel by Ca2+. Possible physiological and pathological implications of the activation of skeletal Ca2+ release channels by endogenous redox species are discussed.	Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 7, Chile; Univ Chile, Fac Med, Ctr Fondo Invest Avanzada, Areas Prioritarias Estudios Mol Celula, Santiago 7, Chile; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Universidad de Chile; Universidad de Chile; Baylor College of Medicine	Hidalgo, C (corresponding author), Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Casilla 70005, Santiago 7, Chile.		Aracena, Paula/A-5607-2012; HIDALGO, Cecilia/H-7107-2013	Aracena, Paula/0000-0002-2144-6875; Hamilton, Susan/0000-0003-0241-9369	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802, R01AR044864] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41802, AR44864] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; ARACENA P, 2003, P 11 BIENN M SOC FRE, P221; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Dalle-Donne I, 2003, FREE RADICAL BIO MED, V34, P23, DOI 10.1016/S0891-5849(02)01182-6; Donoso P, 1997, ARCH BIOCHEM BIOPHYS, V341, P295, DOI 10.1006/abbi.1997.9960; Donoso P, 2000, BIOPHYS J, V79, P279, DOI 10.1016/S0006-3495(00)76290-4; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Elferink JGR, 1999, GEN PHARMACOL, V33, P1, DOI 10.1016/S0306-3623(98)00258-4; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Feng W, 2002, METHOD ENZYMOL, V353, P240; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Haarmann CS, 1999, BIOPHYS J, V77, P3010, DOI 10.1016/S0006-3495(99)77132-8; Hamilton SL, 2000, ANTIOXID REDOX SIGN, V2, P41, DOI 10.1089/ars.2000.2.1-41; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Hidalgo C, 2000, BIOL RES, V33, P113; HIDALGO C, 1993, J BIOL CHEM, V268, P15111; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOSHITA M, 1993, EXPERIENTIA, V49, P282, DOI 10.1007/BF01923402; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAU KHW, 1983, J BIOL CHEM, V258, P2321; LEE HB, 1994, J BIOL CHEM, V269, P13305; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; LIU GH, 1994, J BIOL CHEM, V269, P33028; Lu YF, 2002, J NEUROPHYSIOL, V88, P1270, DOI 10.1152/jn.2002.88.3.1270; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Mallis RJ, 2000, ARCH BIOCHEM BIOPHYS, V383, P60, DOI 10.1006/abbi.2000.2048; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Oba T, 2000, AM J PHYSIOL-CELL PH, V279, pC1366, DOI 10.1152/ajpcell.2000.279.5.C1366; Oba T, 2002, AM J PHYSIOL-CELL PH, V282, pC684, DOI 10.1152/ajpcell.01273.2000; Padgett C. M., 1995, AM J PHYSIOL, V269, pC739; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; Pessah IN, 2001, PEST MANAG SCI, V57, P941, DOI 10.1002/ps.391; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; PORTER MC, 1999, J BIOL CHEM, V274, P36831; POSTERINO GS, 2003, J PHYSL, V347, P807; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Reddy S, 2000, BIOCHEM J, V347, P821, DOI 10.1042/0264-6021:3470821; Reid MB, 2001, J APPL PHYSIOL, V90, P724, DOI 10.1152/jappl.2001.90.2.724; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Rose CR, 2001, NEURON, V31, P519, DOI 10.1016/S0896-6273(01)00402-0; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Sanchez G, 2003, BIOPHYS J, V84, P2319, DOI 10.1016/S0006-3495(03)75037-1; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Suko J, 1998, BBA-MOL CELL RES, V1404, P435, DOI 10.1016/S0167-4889(98)00075-5; Suko J, 1999, BBA-MOL CELL RES, V1451, P271, DOI 10.1016/S0167-4889(99)00098-1; Sun JH, 2003, J BIOL CHEM, V278, P8184, DOI 10.1074/jbc.M211940200; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Suzuki YJ, 1998, FREE RADICAL BIO MED, V24, P318, DOI 10.1016/S0891-5849(97)00227-X; Svoboda K, 1999, NEURON, V22, P427, DOI 10.1016/S0896-6273(00)80698-4; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Wang W, 1998, PHARMACOL REV, V50, P335; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46; Zucchi R, 1997, PHARMACOL REV, V49, P1	87	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42927	42935		10.1074/jbc.M306969200	http://dx.doi.org/10.1074/jbc.M306969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920114	hybrid			2022-12-27	WOS:000186157000026
J	Goralska, M; Holley, BL; McGahan, MC				Goralska, M; Holley, BL; McGahan, MC			Identification of a mechanism by which lens epithelial cells limit accumulation of overexpressed ferritin H-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERFERRITINEMIA-CATARACT SYNDROME; IRON-RESPONSIVE ELEMENT; CANINE SERUM FERRITIN; TRANSCRIPTIONAL REGULATION; HELA-CELLS; L-SUBUNIT; GENE; MOUSE; LIVER; ALPHA	The primary cultures of canine lens epithelial cells were transiently transfected with cDNAs for dog ferritin H- or L-chains in order to study differential expression of these chains. By using chain-specific antibodies, we determined that at 48 h after transfection overexpression of L-chain was much higher (9-fold over control) than that of H-chain (1.7-fold). We discovered that differentially transfected cells secrete overexpressed chains as homopolymeric ferritin into the media. Forty-eight hours after transfection accumulation of H- ferritin in the media was much higher (3-fold) than that of L-ferritin. This resulted in lowering of the concentration of H- chain in the cytosol. Co-transfection of cells with both H- and L-chain cDNAs increased the intracellular levels of H- chain and eliminated secretion of H-ferritin to the media. We concluded that lens epithelial cells differentially regulate concentration of both ferritin chains in the cytosol. The overexpressed L-chain accumulated in the cytosol as predominantly homopolymeric L-ferritin. This is in contrast to H-chain, which is removed to the media unless there is an L-chain available to form heteropolymeric ferritin. These data indicate that the inability of cells to more strictly control cytosolic levels of L-chain may augment its accumulation in lenses of humans with hereditary hyperferritinemia cataract syndrome, which is caused by overexpression of L-chain due to mutation in the regulatory element in the untranslated region of the mRNA of the chain.	N Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC 27606 USA	University of North Carolina; North Carolina State University	Goralska, M (corresponding author), N Carolina State Univ, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.							ADDISON JM, 1984, FEBS LETT, V175, P333, DOI 10.1016/0014-5793(84)80763-2; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; Brooks DG, 2002, INVEST OPHTH VIS SCI, V43, P1121; Cicilano M, 1999, HAEMATOLOGICA, V84, P489; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Cozzi A, 2003, FEBS LETT, V537, P187, DOI 10.1016/S0014-5793(03)00114-5; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Fan HZ, 1996, FEBS LETT, V382, P145, DOI 10.1016/0014-5793(96)00143-3; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; GIRELLI D, 1995, BLOOD, V86, P4050, DOI 10.1182/blood.V86.11.4050.bloodjournal86114050; Goralska M, 2001, INVEST OPHTH VIS SCI, V42, P1721; Grace JE, 2000, ARCH BIOCHEM BIOPHYS, V384, P116, DOI 10.1006/abbi.2000.2068; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Miyazaki E, 2002, GUT, V50, P413, DOI 10.1136/gut.50.3.413; Orino K, 2003, BIOMETALS, V16, P341, DOI 10.1023/A:1020659317564; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; Watanabe K, 2000, BIOMETALS, V13, P319, DOI 10.1023/A:1009276323707	23	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42920	42926		10.1074/jbc.M305827200	http://dx.doi.org/10.1074/jbc.M305827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920121	hybrid			2022-12-27	WOS:000186157000025
J	Huggins, KW; Camarota, LM; Howles, PN; Hui, DY				Huggins, KW; Camarota, LM; Howles, PN; Hui, DY			Pancreatic triglyceride lipase deficiency minimally affects dietary fat absorption but dramatically decreases dietary cholesterol absorption in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA RATIO METHOD; ESTER HYDROLYSIS; INTESTINAL-CELLS; BILE SALTS; DIGESTION; TRANSPORT; TETRAHYDROLIPSTATIN; INHIBITOR; SITE; GENE	This study generated pancreatic triglyceride lipase (PTL)-null mice to test the hypothesis that PTL-mediated hydrolysis of dietary triglyceride is necessary for efficient dietary cholesterol absorption. The PTL-/- mice grew normally and displayed similar body weight as their PTL+/+ littermates. Plasma lipid levels between animals of various PTL genotypes were similar when they were maintained on either a basal low fat diet or a western-type high fat/high cholesterol diet. Although the lack of a functional PTL delayed fat absorption during the initial hour of feeding a bolus load of olive oil containing [H-3] triolein and [C-14] cholesterol, the rate of [H-3] triolein absorption was similar between PTL+/+ and PTL-/- mice after the initial 1-h period. Importantly, comparison of fecal fat content revealed similar overall fat absorption efficiency between PTL+/+ and PTL-/- mice. In contrast, the PTL-/- mice displayed significant decrease in both the rate and the amount of cholesterol absorbed after a single meal. The plasma appearance of [C-14] cholesterol was found to be 75% lower ( p < 0.0005) in PTL-/- mice compared with PTL+/+ mice after 4 h. The total amount of [C-14] cholesterol excreted in the feces was 45% higher ( p < 0.0004) in PTL-/- mice compared with PTL-/- mice over a 24-h period. These results indicate that the delayed fat digestion due to PTL deficiency results in a significant reduction in cholesterol absorption, although other enzymes in the digestive tract may compensate for the lack of PTL in PTL-/- mice in fat digestion and absorption.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	huidy@email.uc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010065] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54504, DK10065] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BHAT SG, 1982, BIOCHEM BIOPH RES CO, V109, P486, DOI 10.1016/0006-291X(82)91747-8; BITMAN J, 1981, J LIQ CHROMATOGR, V4, P1007, DOI 10.1080/01483918108059601; BORGSTROM B, 1960, J CLIN INVEST, V39, P809, DOI 10.1172/JCI104100; BORGSTROM B, 1963, GASTROENTEROLOGY, V45, P229; BRANNON PM, 1990, ANNU REV NUTR, V10, P85, DOI 10.1146/annurev.nu.10.070190.000505; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; D'Agostino D, 2002, J BIOL CHEM, V277, P7170, DOI 10.1074/jbc.M108328200; Dawson PA, 1999, CURR OPIN LIPIDOL, V10, P315, DOI 10.1097/00041433-199908000-00005; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; FERNANDEZ E, 1989, BIOCHIM BIOPHYS ACTA, V1001, P249, DOI 10.1016/0005-2760(89)90107-0; FIGARELLA C, 1980, J PEDIATR-US, V96, P412, DOI 10.1016/S0022-3476(80)80683-4; GALLO LL, 1977, P SOC EXP BIOL MED, V156, P277; GRUNDY SM, 1968, J LIPID RES, V9, P374; HADVARY P, 1988, BIOCHEM J, V256, P357, DOI 10.1042/bj2560357; HAUPTMAN JB, 1992, AM J CLIN NUTR, V55, P309; HERNELL O, 1990, BIOCHEMISTRY-US, V29, P2041, DOI 10.1021/bi00460a012; HERNELL O, 1990, ACTA PAEDIATR SCAND, P20; Hernell O., 1992, SEMINARS GASTROINTES, V3, P189; HOGAN S, 1987, INT J OBESITY, V11, P35; HOLT PR, 1986, LIPIDS, V21, P444, DOI 10.1007/BF02536401; Homan R, 1998, J LIPID RES, V39, P1197; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; Huggins KW, 2002, AM J PHYSIOL-ENDOC M, V283, pE994, DOI 10.1152/ajpendo.00110.2002; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGUMSKY M, 1990, GUT, V31, P1416, DOI 10.1136/gut.31.12.1416; LOPEZCANDALES A, 1993, BIOCHEMISTRY-US, V32, P12085, DOI 10.1021/bi00096a019; Love MW, 1998, CURR OPIN LIPIDOL, V9, P225, DOI 10.1097/00041433-199806000-00007; LOWE ME, 1994, GASTROENTEROLOGY, V107, P1524, DOI 10.1016/0016-5085(94)90559-2; LOWE ME, 1989, J BIOL CHEM, V264, P20042; Lowe ME, 2002, J LIPID RES, V43, P2007, DOI 10.1194/jlr.R200012-JLR200; Lowe ME, 1998, J BIOL CHEM, V273, P31215, DOI 10.1074/jbc.273.47.31215; Lowe ME, 1999, METH MOL B, V109, P59; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackay K, 1997, J BIOL CHEM, V272, P13380, DOI 10.1074/jbc.272.20.13380; Mardones P, 2001, J LIPID RES, V42, P170; Miled N, 2000, BIOCHIMIE, V82, P973, DOI 10.1016/S0300-9084(00)01179-2; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; ROSSI SS, 1987, J LIPID RES, V28, P589; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SIMS HF, 1993, GENE, V131, P281, DOI 10.1016/0378-1119(93)90307-O; SWELL L, 1958, P SOC EXP BIOL MED, V98, P174, DOI 10.3181/00379727-98-23979; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; Tsuchiya T, 1996, AM J PHYSIOL-GASTR L, V271, pG681, DOI 10.1152/ajpgi.1996.271.4.G681; TURLEY SD, 1994, J LIPID RES, V35, P328; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; Wang DQH, 2003, J LIPID RES, V44, P1042, DOI 10.1194/jlr.D200041-JLR200; Young SC, 1999, BIOCHEM J, V339, P615, DOI 10.1042/0264-6021:3390615; ZILVERSMIT DB, 1974, J LIPID RES, V15, P465; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	52	41	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42899	42905		10.1074/jbc.M303422200	http://dx.doi.org/10.1074/jbc.M303422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12915407	hybrid			2022-12-27	WOS:000186157000022
J	Murphy, GJ; Gottgens, B; Vegiopoulos, A; Sanchez, MJ; Leavitt, AD; Watson, SP; Green, AR; Frampton, J				Murphy, GJ; Gottgens, B; Vegiopoulos, A; Sanchez, MJ; Leavitt, AD; Watson, SP; Green, AR; Frampton, J			Manipulation of mouse hematopoietic progenitors by specific retroviral infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A AVIAN-LEUKOSIS; GENE-TRANSFER; LEUKEMIA-VIRUS; VIVO EXPANSION; STEM-CELLS; RECEPTOR; VECTORS; MICE; LIGAND; SCL	Previous studies have identified an enhancer 3' of the scl gene that can direct transgene expression to hematopoietic progenitors and stem cells. Here we use this enhancer to restrict expression of the avian leukosis virus receptor, TVA, to hematopoietic stem cells and progenitors in bone marrow and fetal liver and demonstrate that retroviral infection can be used to specifically introduce exogenous sequences. We show that a majority of CFU-S-12 multipotential progenitor cells can be transduced in vitro. Uniquely, transduction of TVA(+) progenitors with a retrovirus encoding a puromycin resistance gene allows selection and expansion of a multipotential hematopoietic progenitor population that can be superinfected with high efficiency. Using this system we show for the first time that v-Myb oncoproteins expressed from avian viruses can induce a leukemic transformation in the mouse. The phenotype of the transformed cells is similar to that which is seen in the chicken and is likewise dependent on the particular structure of v-Myb. This implies that the basic mechanisms of action of mutated transcription factors in the etiology of leukemia are conserved between birds and mammals.	Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Calif San Francisco, Dept Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Birmingham; University of Oxford; University of Cambridge; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Oxford	Frampton, J (corresponding author), Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England.	j.frampton@bham.ac.uk	Watson, Stephen P/Q-6292-2016; Sanchez, Maria Jose/P-4716-2016	Watson, Stephen P/0000-0002-7846-7423; Sanchez, Maria Jose/0000-0003-3464-6224; Gottgens, Berthold/0000-0001-6302-5705; Green, Anthony/0000-0002-9795-0218				BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Begley CG, 1999, BLOOD, V93, P2760; Coligan J, 1995, CURRENT PROTOCOLS IM; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; FEDERSPIEL MJ, 1994, P NATL ACAD SCI USA, V91, P11241, DOI 10.1073/pnas.91.23.11241; Federspiel MJ, 1997, METHOD CELL BIOL, V52, P179, DOI 10.1016/S0091-679X(08)60379-9; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Heim DA, 2000, IMMUNOL REV, V178, P29, DOI 10.1034/j.1600-065X.2000.17802.x; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; HOGAN B, 1986, MANIPULATING MOUSE E; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Kobari L, 1998, BONE MARROW TRANSPL, V21, P759, DOI 10.1038/sj.bmt.1701199; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lin AH, 2001, HUM GENE THER, V12, P323, DOI 10.1089/10430340150503957; MILLER AD, 1997, DEV APPL RETROVIRAL; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; Murphy GJ, 1999, P NATL ACAD SCI USA, V96, P3065, DOI 10.1073/pnas.96.6.3065; Psarras K, 2000, CYTOKINE, V12, P786, DOI 10.1006/cyto.1999.0619; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; Sanchez MJ, 1999, DEVELOPMENT, V126, P3891; Sanchez MJ, 2001, DEVELOPMENT, V128, P4815; Schwarzenberger P, 1996, BLOOD, V87, P472, DOI 10.1182/blood.V87.2.472.bloodjournal872472; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Stein CS, 2001, MOL THER, V3, P850, DOI 10.1006/mthe.2001.0325; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Veiby OP, 1996, J IMMUNOL, V157, P2953; Yajima T, 1998, HUM GENE THER, V9, P779, DOI 10.1089/hum.1998.9.6-779; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993	31	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43556	43563		10.1074/jbc.M302717200	http://dx.doi.org/10.1074/jbc.M302717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928443	Green Published, hybrid			2022-12-27	WOS:000186157000102
J	Pei, Y; Shuman, S				Pei, Y; Shuman, S			Characterization of the Schizosaccharomyces pombe Cdk9/Pch1 protein kinase - Spt5 phosphorylation, autophosphorylation, and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CYCLIN-DEPENDENT KINASE; CARBOXY-TERMINAL DOMAIN; TRANSCRIPTION ELONGATION-FACTOR; T-LOOP PHOSPHORYLATION; PRE-MESSENGER-RNA; VIRUS TYPE-1 TAT; P-TEFB; CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE	Schizosaccharomyces pombe Cdk9/Pch1 protein kinase is a functional ortholog of the essential Saccharomyces cerevisiae Bur1/Bur2 kinase and a putative ortholog of metazoan P-TEFb (Cdk9/cyclin T). SpCdk9/Pch1 phosphorylates of the carboxyl-terminal domain (CTD) of the S. pombe transcription elongation factor Spt5, which consists of 18 tandem repeats of a nonapeptide of consensus sequence (1)TPAWNSGSK(9). We document the divalent cation dependence and specificity of SpCdk9/Pch1, its NTP dependence and specificity, the dependence of Spt5-CTD phosphorylation on the number of tandem nonamer repeats, and the specificity for phosphorylation of the Spt5-CTD on threonine at position 1 within the nonamer element. SpCdk9/Pch1 also phosphorylates the CTD heptaptide repeat array of the largest subunit of S. pombe RNA polymerase II (consensus sequence YSPTSPS) and does so exclusively on serine. SpCdk9/Pch1 catalyzes autophosphorylation of the kinase and cyclin subunits of the kinase complex. The distribution of phosphorylation sites on SpCdk9 (86% Ser(P), 11% Thr(P), 3% Tyr(P)) is distinct from that on Pch1 (2% Ser(P), 98% Thr(P)). We conducted a structure-guided mutational analysis of SpCdk9, whereby a total of 29 new mutations of 12 conserved residues were tested for in vivo function by complementation of a yeast bur1Delta mutant. We identified many lethal and conditional mutations of side chains implicated in binding ATP and the divalent cation cofactor, phosphoacceptor substrate recognition, and T-loop dynamics. We surmise that the lethality of the of T212A mutation in the T-loop reflects an essential phosphorylation event, insofar as the conservative T212S change rescued wild-type growth; the phosphomimetic T212E change rescued growth at 30degreesC; and the effects of mutating the T-loop threonine were phenocopied by mutations in the three conserved arginines predicted to chelate the phosphate on the T-loop threonine.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.		Pei, Yi/D-8998-2011	Pei, Yi/0000-0002-3466-760X	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Chen JY, 2000, MOL CELL BIOL, V20, P8696, DOI 10.1128/MCB.20.23.8696-8708.2000; Chiu YL, 2002, MOL CELL, V10, P585, DOI 10.1016/S1097-2765(02)00630-5; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cross FR, 1998, MOL CELL BIOL, V18, P2923, DOI 10.1128/MCB.18.5.2923; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Furnari BA, 1997, J BIOL CHEM, V272, P12100, DOI 10.1074/jbc.272.18.12100; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guo S, 2000, NATURE, V408, P366, DOI 10.1038/35042590; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Lavoie SB, 2001, J MOL BIOL, V312, P675, DOI 10.1006/jmbi.2001.4991; Levine K, 1998, MOL CELL BIOL, V18, P290, DOI 10.1128/MCB.18.1.290; Lindstrom DL, 2003, MOL CELL BIOL, V23, P1368, DOI 10.1128/MCB.23.4.1368-1378.2003; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Pei Y, 2003, J BIOL CHEM, V278, P7180, DOI 10.1074/jbc.M211713200; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 1999, J VIROL, V73, P5448, DOI 10.1128/JVI.73.7.5448-5458.1999; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANTOS RC, 1995, MOL CELL BIOL, V15, P5482; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yao S, 2000, MOL CELL BIOL, V20, P7080, DOI 10.1128/MCB.20.19.7080-7087.2000; Yao S, 2002, MOL CELL BIOL, V22, P6750, DOI 10.1128/MCB.22.19.6750-6758.2002; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	49	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43346	43356		10.1074/jbc.M307319200	http://dx.doi.org/10.1074/jbc.M307319200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904290	hybrid			2022-12-27	WOS:000186157000078
J	He, YY; Huang, JL; Gentry, JB; Chignell, CF				He, YY; Huang, JL; Gentry, JB; Chignell, CF			Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EGF RECEPTOR; C-CBL; MALIGNANT-MELANOMA; ULTRAVIOLET-LIGHT; RING FINGER; INTERNALIZATION; UBIQUITINATION; ACTIVATION; APOPTOSIS	Activation of the epidermal growth factor (EGF) receptor by EGF, its ligand, results in receptor internalization and down-regulation, which requires receptor kinase activity, phosphorylation, and ubiquitination. In contrast, we have found here in human HaCaT keratinocytes that exposure to UVA induces EGF receptor internalization and down-regulation without receptor phosphorylation and ubiquitination. The presence of the receptor kinase activity inhibitor AG1478 increased UVA-induced receptor down-regulation, whereas it inhibited EGF-induced receptor down-regulation. These observations demonstrate that, in contrast to EGF, receptor kinase activity is not required for receptor downregulation by UVA. Concurrent with receptor down-regulation, caspases were activated by UVA exposure. The presence of caspase inhibitors blocked receptor downregulation in a pattern similar to poly(ADP)-ribose polymerase cleavage. Much more receptor down-regulation was observed after UVA exposure in apoptotic detached cells in which caspase is activated completely. These results indicate that UVA-induced receptor downregulation is dependent on caspase activation. Similar to UVA, both UVB and UVC induced receptor downregulation, in which receptor kinase activity is not required, whereas caspase activation is involved. Inhibition of EGF receptor down-regulation increased receptor activation and activation of its downstream survival signaling ERK and AKT after UVA exposure. Preventing the activation of each of these pathways enhanced apoptosis induced by UVA. These findings suggest that EGF receptor down-regulation by UVA may play an important role in the execution of the cell suicide program by attenuating its anti-apoptotic function and thereby preventing cell transformation and tumorigenesis in vivo.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050046, ZIAES050046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; [Anonymous], 2002, FED REGISTER, V67, P77283; Aubin F, 2001, PRESSE MED, V30, P546; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; de Melker AA, 2001, J CELL SCI, V114, P2167; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Gasparro FP, 1998, PHOTOCHEM PHOTOBIOL, V68, P243, DOI 10.1111/j.1751-1097.1998.tb09677.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; HELDIN CH, 1979, NATURE, V282, P419, DOI 10.1038/282419a0; HELIN K, 1991, J BIOL CHEM, V266, P8363; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; Iordanov MS, 2002, MOL CELL BIOL, V22, P5380, DOI 10.1128/MCB.22.15.5380-5394.2002; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Oksvold MP, 2002, J CELL SCI, V115, P793; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Pathak Madhu A., 1996, Journal of Dermatology (Tokyo), V23, P783; Pourzand C, 1999, PHOTOCHEM PHOTOBIOL, V70, P380, DOI 10.1111/j.1751-1097.1999.tb08239.x; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUNGER TM, 1995, HAUTARZT, V46, P394, DOI 10.1007/s001050050272; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SORKIN A, 1991, J BIOL CHEM, V266, P8355; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	42	42	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42457	42465		10.1074/jbc.M303376200	http://dx.doi.org/10.1074/jbc.M303376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12930839	hybrid			2022-12-27	WOS:000185989500110
J	Holmes, A; Abraham, DJ; Chen, YJ; Denton, C; Xu, SW; Black, CM; Leask, A				Holmes, A; Abraham, DJ; Chen, YJ; Denton, C; Xu, SW; Black, CM; Leask, A			Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; COLLAGEN GENE-EXPRESSION; TRANSCRIPTION FACTOR SP1; FACTOR-BETA; SYSTEMIC-SCLEROSIS; SKIN SCLEROSIS; TGF-BETA; IN-VITRO; FIBROSIS; CELLS	Fibrotic diseases such as scleroderma (systemic sclerosis, SSc) are characterized by an excessive production of extracellular matrix and profibrotic proteins such as connective tissue growth factor (CTGF). In normal dermal fibroblasts, CTGF is not expressed unless induced by proteins such as tumor growth factor-beta (TGFbeta). Conversely, in fibroblasts cultured from fibrotic lesions CTGF mRNA and protein are constitutively expressed, even in the absence of exogenously added TGFbeta. Thus, studying the mechanism underlying CTGF overexpression in SSc fibroblasts is likely to yield valuable insights into the basis of the fibrotic phenotype of SSc and possibly other scarring disease. CTGF overexpression is mediated primarily by sequences in the CTGF promoter. In this report, we identify the minimal promoter element involved with the overexpression of CTGF in SSc fibroblasts. This element is distinct from the element necessary and sufficient for the induction of CTGF expression by TGFbeta in normal fibroblasts. Within this region is a functional Sp1 binding site. Blocking Sp1 activity reduces the elevated, constitutive levels of CTGF promoter activity and protein expression observed in SSc fibroblasts. Relative to those prepared from normal dermal fibroblasts, nuclear extracts prepared from SSc fibroblasts possess increased Sp1 binding activity. Removal of phosphate groups from nuclear extracts enhanced Sp1 binding activity, suggesting that phosphorylation of Sp1 normally reduces Sp1 binding to DNA. Thus, the constitutive overexpression of CTGF in SSc fibroblasts seems to be independent of TGFbeta signaling but dependent at least in part on Sp1.	UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, Dept Med, London NW3 2PF, England; FibroGen Inc, San Francisco, CA 94080 USA	University of London; University College London; UCL Medical School; FibroGen	Leask, A (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, Dept Med, Rowland Hill St, London NW3 2PF, England.	a.leask@rfc.ucl.ac.uk	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045879] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 45879] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; Cotton SA, 1998, J PATHOL, V184, P4, DOI 10.1002/(SICI)1096-9896(199801)184:1<4::AID-PATH968>3.0.CO;2-0; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GRUSCHWITZ M, 1990, J INVEST DERMATOL, V94, P197, DOI 10.1111/1523-1747.ep12874503; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Ihn H, 2000, ARTHRITIS RHEUM, V43, P2240, DOI 10.1002/1529-0131(200010)43:10<2240::AID-ANR11>3.0.CO;2-2; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KIKUCHI K, 1992, BIOCHEM BIOPH RES CO, V187, P45, DOI 10.1016/S0006-291X(05)81456-1; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; MCWHIRTER A, 1994, LAB INVEST, V71, P885; MORELAND LW, 1992, AM J MED, V93, P628, DOI 10.1016/0002-9343(92)90195-H; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; Querfeld C, 1999, J DERMATOL SCI, V21, P13, DOI 10.1016/S0923-1811(99)00008-0; Sato S, 2000, J RHEUMATOL, V27, P149; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2001, J INVEST DERMATOL, V116, P755, DOI 10.1046/j.1523-1747.2001.01326.x; Watkin RD, 2003, TOXICOLOGY, V184, P157, DOI 10.1016/S0300-483X(02)00577-2; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	42	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41728	41733		10.1074/jbc.M305019200	http://dx.doi.org/10.1074/jbc.M305019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888575	hybrid			2022-12-27	WOS:000185989500023
J	Pradip, D; Peng, XD; Durden, DL				Pradip, D; Peng, XD; Durden, DL			Rac2 specificity in macrophage integrin signaling - Potential role for Syk kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; RHO GTPASES; MAST-CELLS; PROTOONCOGENE PRODUCT; FIBRONECTIN FRAGMENTS; HEMATOPOIETIC-CELLS; LIGAND RECOGNITION; OXIDASE ACTIVATION; ACTIN CYTOSKELETON	Herein we report that, despite the similarity of Rac2 to Rac1 (92% amino acid identity), macrophages derived from Rac2-/- mice, which continue to express Rac1, display a marked defect in alpha(v)beta(3)/alpha(v)beta(5) and alpha(4)beta(1) integrin-directed migration measured on vitronectin and fibronectin fragments (FN-H296), respectively. In contrast, mouse embryo fibroblasts derived from the Rac2 knockout mice utilize Rac1 for migration via alpha(v)beta(3)/alpha(v)beta(5) and alpha(4)beta(1). The genetic reconstitution of bone marrow-derived macrophages (BMMtheta) with Rac2 restores the integrin-dependent migration of Rac2-deficient macrophages on vitronectin (VN) and FN-H296. The levels of GTP-Rac2 generated upon specific integrin engagement in wild type macrophages parallels the phenotypic defect observed in Rac2-deficient macrophages; i.e. FN-H296, alpha(4)beta(1) > VN, alpha(v)beta(3)/alpha(v)beta(5) > FN-CH271, alpha(5)beta(1) > intact FN. In a COS7 cell system, the expression of Syk kinase alone is sufficient to convert the alpha(4)beta(1) migration response to Rac2 dependence. Therefore, we present the first evidence that the alpha(4)beta(1) receptor in blood cells has evolved a Syk-Rac2 signaling axis to transmit signals required for integrin-directed migration suggesting that Syk kinase in part encodes myeloid Rac2 specificity in vivo.	Indiana Univ, Sch Med,Sect Hematol Oncol, Dept Pediat Biochem & Mol Biol, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Durden, DL (corresponding author), Indiana Univ, Sch Med,Sect Hematol Oncol, Dept Pediat Biochem & Mol Biol, Herman B Wells Ctr Pediat Res, 1044 W Walnut St, Indianapolis, IN 46202 USA.				NATIONAL CANCER INSTITUTE [R56CA094233, P01CA081403, R01CA094233] Funding Source: NIH RePORTER; NCI NIH HHS [CA 94233, CA 81403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1997, J CELL SCI, V110, P707; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; Fernandez JA, 1999, J BIOL CHEM, V274, P1401, DOI 10.1074/jbc.274.3.1401; Gotoh A, 1997, CELL GROWTH DIFFER, V8, P721; Gu Y, 2002, MOL CELL BIOL, V22, P7645, DOI 10.1128/MCB.22.21.7645-7657.2002; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; Hong JJ, 2002, J BIOL CHEM, V277, P31703, DOI 10.1074/jbc.M201362200; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Jones GE, 1998, CELL ADHES COMMUN, V6, P237, DOI 10.3109/15419069809004479; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; Kim JS, 2002, BLOOD, V99, P694, DOI 10.1182/blood.V99.2.694; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kyono WT, 1998, J IMMUNOL, V161, P5555; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mocsai A, 2003, BLOOD, V101, P4155, DOI 10.1182/blood-2002-07-2346; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; MOULD AP, 1991, J BIOL CHEM, V266, P3579; Park RK, 1999, J IMMUNOL, V163, P6023; Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821; Pollok KE, 1998, J VIROL, V72, P4882, DOI 10.1128/JVI.72.6.4882-4892.1998; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Suen PW, 1999, J CELL SCI, V112, P4067; Suzuki T, 1998, J IMMUNOL, V161, P3694; Tao W, 2002, BLOOD, V100, P1679, DOI 10.1182/blood.V100.5.1679.h81702001679_1679_1688; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; VAN AL, 1997, GENE DEV, V11, P2295; van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687; Williams DA, 2000, BLOOD, V96, P1646; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	56	40	41	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41661	41669		10.1074/jbc.M306491200	http://dx.doi.org/10.1074/jbc.M306491200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917394	hybrid			2022-12-27	WOS:000185989500015
J	Russell, DL; Doyle, KMH; Ochsner, SA; Sandy, JD; Richards, JS				Russell, DL; Doyle, KMH; Ochsner, SA; Sandy, JD; Richards, JS			Processing and localization of ADAMTS-1 and proteolytic cleavage of versican during cumulus matrix expansion and ovulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-DIFFERENTIATION FACTOR-9; FACTOR-STIMULATED GENE-6; EXTRACELLULAR-MATRIX; GRANULOSA-CELLS; HYALURONIC-ACID; MICE LACKING; FOLLICULAR DEVELOPMENT; THROMBOSPONDIN MOTIFS; REGULATED EXPRESSION; PERICELLULAR MATRIX	ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin motifs-1) is a member of the ADAMTS family of metalloproteases which, together with ADAMTS-4 and ADAMTS-5, has been shown to degrade members of the lectican family of proteoglycans. ADAMTS-1 mRNA is induced in granulosa cells of periovulatory follicles by the luteinizing hormone surge through a progesterone receptor-dependent mechanism. Female progesterone receptor knockout (PRKO) mice are infertile primarily due to ovulatory failure and lack the normal periovulatory induction of ADAMTS-1 mRNA. We therefore investigated the protein localization and function of ADAMTS-1 in ovulating ovaries. Antibodies against two specific peptide regions, the pro-domain and the metalloprotease domain of ADAMTS-1, were generated. Pro-ADAMTS-1 of 110 kDa was identified in mural granulosa cells and appears localized to cytoplasmic secretory vesicles. The mature (85-kDa pro-domain truncated) form accumulated in the extracellular matrix of the cumulus oocyte complex (COC) during the process of matrix expansion. Each form of ADAMTS-1 protein increased >10-fold after the ovulatory luteinizing hormone surge in wild-type but not PRKO mice. Versican is also localized selectively to the ovulating COC matrix and was found to be cleaved yielding a 70-kDaN-terminal fragment immunopositive for the neoepitope DPEAAE generated by ADAMTS-1 and ADAMTS-4 protease activity. This extracellular processing of versican was reduced in ADAMTS-1-deficient PRKO mouse ovaries. These observations suggest that one function of ADAMTS-1 in ovulation is to cleave versican in the expanded COC matrix and that the anovulatory phenotype of PRKO mice is at least partially due to loss of this function.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Shriners Hosp Children, Tampa, FL 33612 USA	Baylor College of Medicine; State University System of Florida; University of South Florida	Richards, JS (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Russell, Darryl L/I-6654-2012	Russell, Darryl L/0000-0002-4930-7658; Ochsner, Scott/0000-0003-1099-7863				Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Camaioni A, 1996, ARCH BIOCHEM BIOPHYS, V325, P190, DOI 10.1006/abbi.1996.0024; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; Curry TE, 2001, BIOL REPROD, V65, P855, DOI 10.1095/biolreprod65.3.855; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Elvin JA, 2000, P NATL ACAD SCI USA, V97, P10288, DOI 10.1073/pnas.180295197; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; Espey LL, 2000, BIOL REPROD, V62, P1090, DOI 10.1095/biolreprod62.4.1090; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gensberg K, 1998, SEMIN CELL DEV BIOL, V9, P11, DOI 10.1006/scdb.1997.0196; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Hsieh M, 2002, ENDOCRINOLOGY, V143, P898, DOI 10.1210/en.143.3.898; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lebaron RG, 1996, PERSPECT DEV NEUROBI, V3, P261; LEE GM, 1993, J CELL BIOL, V123, P1899, DOI 10.1083/jcb.123.6.1899; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Lydon JP, 1996, J STEROID BIOCHEM, V56, P67, DOI 10.1016/0960-0760(95)00254-5; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P1008, DOI 10.1210/en.2002-220435; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Richards JS, 2002, RECENT PROG HORM RES, V57, P195, DOI 10.1210/rp.57.1.195; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; ROZEN S, 1998, PRIMER3 SOFTWARE DIS; Russell DL, 2003, ENDOCRINOLOGY, V144, P1020, DOI 10.1210/en.2002-220434; Salustri A, 1999, HUM REPROD UPDATE, V5, P293, DOI 10.1093/humupd/5.4.293; SALUSTRI A, 1992, DEV BIOL, V151, P541, DOI 10.1016/0012-1606(92)90192-J; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Talbot P, 2003, BIOL REPROD, V68, P1, DOI 10.1095/biolreprod.102.007856; Tirone E, 1997, J BIOL CHEM, V272, P4787, DOI 10.1074/jbc.272.8.4787; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; UJITA M, 1994, J BIOL CHEM, V269, P27603; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Wight TN, 2002, CURR OPIN CELL BIOL, V14, P617, DOI 10.1016/S0955-0674(02)00375-7; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Yoshioka S, 2000, ENDOCRINOLOGY, V141, P4114, DOI 10.1210/en.141.11.4114; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	59	210	221	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42330	42339		10.1074/jbc.M300519200	http://dx.doi.org/10.1074/jbc.M300519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907688	hybrid			2022-12-27	WOS:000185989500094
J	Vuocolo, S; Purev, E; Zhang, DM; Bartek, J; Hansen, K; Soprano, DR; Soprano, KJ				Vuocolo, S; Purev, E; Zhang, DM; Bartek, J; Hansen, K; Soprano, DR; Soprano, KJ			Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced growth suppression of ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; CANCER STATISTICS; CYCLIN-A; P130; PHOSPHORYLATION; PRB; P107; PRB2/P130; FAMILY; DIFFERENTIATION	Levels of Rb2/p130 protein are increased 5-10-fold following all-trans-retinoic acid (ATRA) treatment of the retinoid-sensitive ovarian adenocarcinoma cell line CAOV3, but not the retinoid-resistant adenocarcinoma cell line SKOV3. We found that this increase in Rb2/p130 protein levels in ATRA-treated CAOV3 cells was the result of an increased protein stability. Moreover, Rb2/ p130 exhibited a decreased ubiquitination following ATRA treatment. Because phosphorylation frequently mediates ubiquitination of proteins, we examined the serine/threonine phosphatase activity in our CAOV3 cells following ATRA treatment. A significant increase in Ser/Thr phosphatase activity was found, which correlated with a rise in the level of protein phosphatase 2A (PP2A) catalytic subunit-alpha. In addition, co-immunoprecipitation and glutathione S-transferase pull- down studies demonstrated that PP2A and Rb2/ p130 associate. We have made use of a battery of Rb2/ p130 mutants to determine the sites dephosphorylated in response to ATRA treatment of CAOV3 cells. Obligate CDK4 phosphorylation sites seemed most important to the stability of the protein and are among the candidate sites that are dephosphorylated by PP2A following ATRA treatment. Finally, using both small interfering RNA specific to the catalytic subunit of PP2A and a variant of the SKOV3 cell line that overexpresses PP2A, we have shown that modulation of PP2A protein levels correlates with the ability of ATRA to inhibit growth of ovarian carcinoma cells. Our data suggest that ATRA mediates growth inhibition by stabilizing Rb2/p130 via a mechanism that involves induction of PP2A, an enzyme that can potentially dephosphorylate Rb2/p130, thereby protecting it from degradation by the proteasome.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Danish Cancer Society	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	sopranok@temple.edu	Bartek, Jiri/G-5870-2014	Hansen, Klaus/0000-0001-9657-8816	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64965] Funding Source: Medline; NIAID NIH HHS [5T32 AI 0710] Funding Source: Medline; NIDCR NIH HHS [DE 13139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chen MH, 2002, MECH DEVELOP, V114, P205, DOI 10.1016/S0925-4773(02)00066-7; Claudio PP, 1996, CANCER RES, V56, P2003; Corbeil HB, 1997, ONCOGENE, V15, P657, DOI 10.1038/sj.onc.1201224; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Daly M, 1998, SEMIN ONCOL, V25, P255; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoskins WJ, 1995, J CELL BIOCHEM, P189; Laidley CW, 1999, BIOORGAN MED CHEM, V7, P2937, DOI 10.1016/S0968-0896(99)00239-4; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1995, ONCOGENE, V11, P801; Mayol Xavier, 1998, Frontiers in Bioscience, V3, pD11; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; SASAKI K, 1994, BIOCHEM J, V298, P259, DOI 10.1042/bj2980259; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Stiegler P, 1999, ANAL QUANT CYTOL, V21, P363; Stiegler P, 1998, CANCER RES, V58, P5049; Sueoka N, 1999, CANCER RES, V59, P3838; TAWARA I, 1993, FEBS LETT, V321, P224, DOI 10.1016/0014-5793(93)80113-9; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu SJ, 1998, ONCOGENE, V17, P2839, DOI 10.1038/sj.onc.1202208; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O	51	37	39	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41881	41889		10.1074/jbc.M302715200	http://dx.doi.org/10.1074/jbc.M302715200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12915404	hybrid			2022-12-27	WOS:000185989500041
J	Castillo, EA; Vivancos, AP; Jones, N; Ayte, J; Hidalgo, E				Castillo, EA; Vivancos, AP; Jones, N; Ayte, J; Hidalgo, E			Schizosaccharomyces pombe cells lacking the Ran-binding protein Hba1 show a multidrug resistance phenotype due to constitutive nuclear accumulation of Pap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PAP1; STRESS-ACTIVATED KINASE; BREFELDIN-A RESISTANCE; FISSION YEAST; OXIDATIVE STRESS; NUCLEOCYTOPLASMIC TRANSPORT; CAFFEINE-RESISTANCE; ESCHERICHIA-COLI; EXPORT SIGNAL; GENE	In Schizosaccharomyces pombe, the transcription factor Pap1, and the mitogen-activated protein kinase Sty1 are excluded from the nucleus in a Crm1-dependent manner under non-stressed conditions. Upon oxidant treatment, both Sty1 and Pap1 concentrate into the nucleus, due to an enhanced import or an impaired export. Hba1, a protein that when overexpressed confers brefeldin A resistance, contains a Ran binding domain. The purpose of this project was to understand at the molecular level the role of Hba1 in the S. pombe oxidative stress response. Fluorescent and confocal microscopy studies demonstrate that Hba1 is located at the nucleoplasm and not at the nuclear envelope. We also demonstrate that either multiple copies or deletion of the hba1 gene induces nuclear accumulation of Pap1 and Sty1. We propose that Hba1 assists Crm1 to export some nuclear export signal-containing proteins. Pap1 nuclear accumulation is sufficient for constitutive activation of its specific antioxidant response. On the contrary, constitutive nuclear localization of Sty1 in the Deltahba1 strain does not trigger the Sty1-specific, Atf1-dependent antioxidant response in the absence of stress. We conclude that the increased multidrug resistance of strains lacking or overexpressing Hba1 is due to the accumulation of Pap1 in the nucleus under non-stressed conditions.	Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, Barcelona 08003, Spain; Christie Hosp NHS Trust, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England	Pompeu Fabra University; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Hidalgo, E (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, C Dr Aiguader 80, Barcelona 08003, Spain.	elena.hidalgo@upf.edu	Vivancos, Ana/AAG-8331-2019; Hidalgo, Elena/K-2919-2014; Ayte, Jose/L-5217-2014	Vivancos, Ana/0000-0003-2888-6512; Hidalgo, Elena/0000-0002-3768-6785; Ayte, Jose/0000-0002-6354-0536				Alfa C, 1993, EXPT FISSION YEAST L; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Benko Z, 1997, CURR GENET, V31, P481, DOI 10.1007/s002940050233; Benko Z, 1998, MOL GEN GENET, V260, P434, DOI 10.1007/s004380050914; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Castillo EA, 2002, MOL MICROBIOL, V45, P243, DOI 10.1046/j.1365-2958.2002.03020.x; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Degols G, 1996, MOL CELL BIOL, V16, P2870; Englmeier L, 2001, EMBO REP, V2, P926, DOI 10.1093/embo-reports/kve200; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Lindsay ME, 2001, J CELL BIOL, V153, P1391, DOI 10.1083/jcb.153.7.1391; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mueller L, 1998, FEBS LETT, V427, P330, DOI 10.1016/S0014-5793(98)00459-1; Nemergut ME, 2002, J BIOL CHEM, V277, P17385, DOI 10.1074/jbc.c100620200; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Nguyen AN, 2002, MOL BIOL CELL, V13, P2651, DOI 10.1091/mbc.02-03-0043; NISHI K, 1992, MOL MICROBIOL, V6, P761, DOI 10.1111/j.1365-2958.1992.tb01526.x; Noguchi E, 1999, J BIOCHEM-TOKYO, V125, P574, DOI 10.1093/oxfordjournals.jbchem.a022323; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Sies H., 1991, OXIDATIVE STRESS OXI; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Taura T, 1997, J BIOL CHEM, V272, P31877, DOI 10.1074/jbc.272.50.31877; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Turi TG, 1996, J BIOL CHEM, V271, P9166, DOI 10.1074/jbc.271.15.9166; TURI TG, 1995, BIOCHEM BIOPH RES CO, V213, P410, DOI 10.1006/bbrc.1995.2147; TURI TG, 1994, J BIOL CHEM, V269, P24229; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	48	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40565	40572		10.1074/jbc.M305859200	http://dx.doi.org/10.1074/jbc.M305859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896976	hybrid			2022-12-27	WOS:000185847200019
J	Dunne, A; Ejdeback, M; Ludidi, PL; O'Neill, LAJ; Gay, NJ				Dunne, A; Ejdeback, M; Ludidi, PL; O'Neill, LAJ; Gay, NJ			Structural complementarity of Toll/interleukin-1 receptor domains in toll-like receptors and the adaptors Mal and MyD88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AB-INITIO CONSTRUCTION; SIGNALING PATHWAY; DROSOPHILA TOLL; MOLECULAR CHARACTERIZATION; POLYPEPTIDE FRAGMENTS; IL-1 RECEPTOR; RECOGNITION; TRANSDUCTION; SURFACES; PROTEINS	The Toll/interleukin 1 receptor (TIR) domain is a region found in the cytoplasmic tails of members of the Toll-like receptor/interleukin-1 receptor superfamily. The domain is essential for signaling and is also found in the adaptor proteins Mal (MyD88 adaptor-like) and MyD88, which function to couple activation of the receptor to downstream signaling components. Experimental structures of two Toll/interleukin 1 receptor domains reveal a alpha-beta-fold similar to that of the bacterial chemotaxis protein CheY, and other evidence suggests that the adaptors can make heterotypic interactions with both the receptors and themselves. Here we show that the purified TIR domains of Mal and MyD88 can form stable heterodimers and also that Mal homodimers and oligomers are dissociated in the presence of ATP. To identify structural features that may contribute to the formation of signaling complexes, we produced models of the TIR domains from human Toll-like receptor 4 (TLR4), Mal, and MyD88. We found that although the overall fold is conserved the electrostatic surface potentials are quite distinct. Docking studies of the models suggest that Mal and MyD88 bind to different regions in TLRs 2 and 4, a finding consistent with a cooperative role of the two adaptors in signaling. Mal and MyD88 are predicted to interact at a third non-overlapping site, suggesting that the receptor and adaptors may form heterotetrameric complexes. The theoretical model of the interactions is supported by experimental data from glutathione S-transferase pull-downs and co-immunoprecipitations. Neither theoretical nor experimental data suggest a direct role for the conserved proline in the BB-loop in the association of TLR4, Mal, and MyD88. Finally we show a sequence relationship between the Drosophila protein Tube and Mal that may indicate a functional equivalence of these two adaptors in the Drosophila and vertebrate Toll pathways.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Dublin Trinity Coll, Inst Biochem & Biotechnol, Dublin 2, Ireland	University of Cambridge; Trinity College Dublin	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England.		Ejdebäck, Mikael/H-5796-2012	Ejdebäck, Mikael/0000-0002-3053-4543; dunne, aisling/0000-0002-2342-9518; O'Neill, Luke/0000-0002-4333-2748				Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Burke DF, 1999, PROTEINS, P55; de Bakker PIW, 2003, PROTEINS, V51, P21, DOI 10.1002/prot.10235; DePristo MA, 2003, PROTEINS, V51, P41, DOI 10.1002/prot.10285; DUNNE A, 2003, SCI STKE; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Hardiman G, 1996, ONCOGENE, V13, P2467; HOPP TP, 1995, PROTEIN SCI, V4, P1851, DOI 10.1002/pro.5560040920; Horng T, 2001, P NATL ACAD SCI USA, V98, P12654, DOI 10.1073/pnas.231471798; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Kambris Z, 2003, EMBO REP, V4, P64, DOI 10.1038/sj.embor.embor714; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Ronni T, 2003, MOL CELL BIOL, V23, P2543, DOI 10.1128/MCB.23.7.2543-2555.2003; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Simonovic M, 2001, J BIOL CHEM, V276, P28637, DOI 10.1074/jbc.C100295200; Tao X, 2002, BIOCHEM BIOPH RES CO, V299, P216, DOI 10.1016/S0006-291X(02)02581-0; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; Tovchigrechko A, 2002, PROTEIN SCI, V11, P1888, DOI 10.1110/ps.4730102; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; VAKSER IA, 1995, PROTEIN ENG, V8, P371, DOI 10.1093/protein/8.4.371; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Zhu XY, 1997, J BIOL CHEM, V272, P23758, DOI 10.1074/jbc.272.38.23758	36	159	169	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41443	41451		10.1074/jbc.M301742200	http://dx.doi.org/10.1074/jbc.M301742200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888566	hybrid, Green Published			2022-12-27	WOS:000185847200124
J	Foster, JS; Fernando, RI; Ishida, N; Nakayama, KI; Wimalasena, J				Foster, JS; Fernando, RI; Ishida, N; Nakayama, KI; Wimalasena, J			Estrogens down-regulate p27(Kip1) in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR; CDK INHIBITORS; MCF-7 CELLS; S-PHASE; CYTOPLASMIC LOCALIZATION; E-CDK2 ACTIVATION; DIRECT BINDING	The cyclin-dependent kinase (CDK) inhibitor p27(Kip1) plays a key role in growth and development of the mammary epithelium and in breast cancer. p27(Kip1) levels are regulated through ubiquitin/proteasome-mediated proteolysis, promoted by CDK2 and the F box protein Skp2 at the G(1)/S transition, and independent of Skp2 in mid-G(1). We investigated the respective roles of Skp2 and subcellular localization of p27(Kip1) in down-regulation of p27(Kip1) induced in MCF-7 cells by estrogens. 17beta-Estradiol treatment increased Skp2 expression in MCF-7 cells; however, this increase was prevented by G(1) blockade mediated by p16(Ink4a) or the CDK inhibitor roscovitine, whereas down-regulation of p27(Kip1) was maintained. Exogenous Skp2 prevented growth arrest of MCF-7 cells by antiestrogen, coinciding with decreased p27(Kip1) expression. Under conditions of G1 blockade, p27(Kip1) was stabilized by inhibition of CRM1-dependent nuclear export with leptomycin B or by mutation of p27(Kip1) (Ser(10) --> Ala; S10A) interfering with CRM1/ p27(Kip1) interaction. Antisense Skp2 oligonucleotides and a dominant-interfering Cul-1(1-452) mutant prevented down-regulation of p27(Kip1)S10A, whereas Skp2 overexpression elicited its destruction in mitogen- deprived cells. Active mediators of the extracellular signal-regulated kinase (ERK) pathway including Raf-1(caax) induced cytoplasmic localization of p27(Kip1) in antiestrogen-treated cells and prevented accumulation of p27(Kip1) in these cells independent of Skp2 expression and coinciding with ERK activation. Genetic or chemical blockade of the ERK pathway prevented down-regulation and cytoplasmic localization of p27(Kip1) in response to estrogen. Our studies indicate that estrogens elicit down-regulation of p27(Kip1) in MCF-7 cells through Skp2-dependent and -independent mechanisms that depend upon subcellular localization of p27(Kip1) and require the participation of mediators of the Ras/Raf-1/ERK signaling pathway.	Univ Tennessee, Med Ctr, Program Comparat & Expt Med, Grad Sch Med,Dept Obstet & Gynecol, Knoxville, TN 37920 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan	University of Tennessee System; University of Tennessee Health Science Center; Kyushu University	Wimalasena, J (corresponding author), Univ Tennessee, Med Ctr, Program Comparat & Expt Med, Grad Sch Med,Dept Obstet & Gynecol, 1924 Alcoa Highway, Knoxville, TN 37920 USA.				NCI NIH HHS [CA84048] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084048] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Ahamed S, 2002, MOL CARCINOGEN, V34, P45, DOI 10.1002/mc.10048; Ahamed S, 2001, MOL CARCINOGEN, V30, P88, DOI 10.1002/1098-2744(200102)30:2&lt;88::AID-MC1017&gt;3.0.CO;2-E; Bilodeau M, 1999, FEBS LETT, V452, P247, DOI 10.1016/S0014-5793(99)00629-8; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; DUBIK D, 1988, J BIOL CHEM, V263, P12705; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lenferink AEG, 2001, CANCER RES, V61, P6583; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moeller SJ, 2003, MOL CELL BIOL, V23, P3735, DOI 10.1128/MCB.23.11.3735-3752.2003; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Prall OWJ, 2001, J BIOL CHEM, V276, P45433, DOI 10.1074/jbc.M104752200; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sugiyama Y, 2001, J BIOL CHEM, V276, P12084, DOI 10.1074/jbc.M010811200; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tan P, 1997, CANCER RES, V57, P1259; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	84	87	92	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41355	41366		10.1074/jbc.M302830200	http://dx.doi.org/10.1074/jbc.M302830200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904306	hybrid			2022-12-27	WOS:000185847200116
J	Kwak, JC; Ongusaha, PP; Ouchi, T; Lee, SW				Kwak, JC; Ongusaha, PP; Ouchi, T; Lee, SW			IFI16 as a negative regulator in the regulation of p53 and p21(Waf1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-INDUCIBLE PROTEIN; CELL-PROLIFERATION; 204 GENE; IFI-16; EXPRESSION; GROWTH; CANCER; TRANSCRIPTION; DOMAIN; DEGRADATION	IFI16 is a member of the HIN-200 family ( hematopoietic interferon-inducible nuclear antigens with 200 amino acid repeats) that contains a DNA binding domain, a transcriptional regulatory domain, and DAPIN/ PAAD, a protein domain associated with interferon response. It can function as a transcription repressor and directly binds p53. Although the structural and biochemical properties of IFI16 are known, the physiological relevance of these properties in the cellular context is still elusive. Here we report that the inhibition of endogenous IFI16 expression by small interfering RNA ( siRNA) induces p21(Waf1) mRNA and protein expression through p53 but does not induce pro-apoptotic p53 target genes. This rapid induction of p21 was wild-type p53-dependent and resulted in cell cycle arrest along with a marked reduction of phosphorylated Rb in normally growing cells. We also showed that the repression of IFI16 affects p53 transcriptional activity at the p21 promoter as well as the protein stability of p53 and p21. Our findings identified a new role for IFI16 in modulating p53 function and its target gene regulation in the control of cell cycle regulation.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Canc Biol Program, Boston, MA 02115 USA; Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Icahn School of Medicine at Mount Sinai	Lee, SW (corresponding author), Harvard Univ, Sch Med, Inst Med, 4 Blackfan Circle,Rm 921, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA078356, R01CA085214, R01CA085681] Funding Source: NIH RePORTER; NCI NIH HHS [CA85681, CA78356, CA85214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Clarke CJP, 2003, J CELL BIOCHEM, V89, P80, DOI 10.1002/jcb.10475; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DAWSON MJ, 1995, J CELL BIOCHEM, V57, P39, DOI 10.1002/jcb.240570106; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369	31	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40899	40904		10.1074/jbc.M308012200	http://dx.doi.org/10.1074/jbc.M308012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12925527	hybrid			2022-12-27	WOS:000185847200060
J	Selmi, B; Deval, J; Alvarez, K; Boretto, J; Sarfati, S; Guerreiro, C; Canard, B				Selmi, B; Deval, J; Alvarez, K; Boretto, J; Sarfati, S; Guerreiro, C; Canard, B			The Y181C substitution in 3 '-azido-3 '-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3 '-azido-3 '-deoxythymidine 5 '-monophosphate-terminated primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORANOPHOSPHATE NUCLEOTIDE ANALOGS; IN-VITRO SELECTION; RESISTANCE MUTATIONS; NUCLEOSIDE ANALOG; DNA-SYNTHESIS; ZIDOVUDINE RESISTANCE; HIV-1 REPLICATION; DRUG-RESISTANCE; AZT RESISTANCE; M184V MUTATION	Resistance to zidovudine (3'- azido-3'-deoxythymidine, AZT) by the human immunodeficiency virus, type 1, requires multiple amino acid substitutions such as D67N/ K70R/T215F/K219Q in the viral reverse transcriptase (RT). In this background of AZT resistance, additional "suppressive" substitutions such as Y181C restore sensitivity to AZT. In order to characterize the mechanism of this AZT resistance suppression, the Y181C substitution was introduced into both wild-type and AZT-resistant reverse transcriptase. The introduction of the Y181C substitution suppresses the increased repair ( or unblocking) of the AZTMP-terminated primer provided by the AZT resistance substitutions in RT using either DNA or RNA templates, independently from the RT RNase H activity. Contrary to wild-type RT, the low level of unblocking activity is not due to inhibition by the next correct nucleotide binding to the RT/AZTMP-terminated primer complex. When Y181C is added to the AZT resistance substitutions, ATP binds with less affinity to the AZTMP-terminated primer-RT binary complex. These results provide an insight into one possible molecular mechanism of re-sensitization of AZT-resistant viruses by suppressive substitutions.	CNRS, F-13288 Marseille 09, France; Univ Aix Marseille 1, UMR 6098, F-13288 Marseille, France; Univ Aix Marseille 2, UMR 6098, F-13288 Marseille 09, France; Inst Pasteur, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Canard, B (corresponding author), CNRS, ESIL Case 925,163 Ave Luminy, F-13288 Marseille 09, France.		ALVAREZ, Karine/T-6326-2017	Canard, Bruno/0000-0003-4924-1991				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arion D, 2000, J BIOL CHEM, V275, P9251, DOI 10.1074/jbc.275.13.9251; Balzarini J, 1999, BIOCHEM PHARMACOL, V58, P1; Bazmi HZ, 2000, ANTIMICROB AGENTS CH, V44, P1783, DOI 10.1128/AAC.44.7.1783-1788.2000; Boretto J, 2001, ANAL BIOCHEM, V292, P139, DOI 10.1006/abio.2001.5045; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; Boyer PL, 2002, J VIROL, V76, P9143, DOI 10.1128/JVI.76.18.9143-9151.2002; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; Deval J, 2002, J BIOL CHEM, V277, P42097, DOI 10.1074/jbc.M206725200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Isel C, 2001, J BIOL CHEM, V276, P48725, DOI 10.1074/jbc.M108352200; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; Mas A, 2002, J MOL BIOL, V323, P181, DOI 10.1016/S0022-2836(02)00911-7; Mas A, 2000, EMBO J, V19, P5752, DOI 10.1093/emboj/19.21.5752; MELLORS JW, 1995, ANTIMICROB AGENTS CH, V39, P1087, DOI 10.1128/AAC.39.5.1087; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; Ren JS, 1998, P NATL ACAD SCI USA, V95, P9518, DOI 10.1073/pnas.95.16.9518; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; Rigourd M, 2000, J BIOL CHEM, V275, P26944; SCHATZ O, 1989, FEBS LETT, V257, P279; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; Selmi B, 2001, J BIOL CHEM, V276, P13965, DOI 10.1074/jbc.M009837200; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; Tachedjian G, 1998, ANTIMICROB AGENTS CH, V42, P3038, DOI 10.1128/AAC.42.11.3038; TACHEDJIAN G, 1995, VIROLOGY, V212, P58, DOI 10.1006/viro.1995.1453; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	60	44	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40464	40472		10.1074/jbc.M302928200	http://dx.doi.org/10.1074/jbc.M302928200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902345	hybrid			2022-12-27	WOS:000185847200007
J	Song, OK; Wang, XR; Waterborg, JH; Sternglanz, R				Song, OK; Wang, XR; Waterborg, JH; Sternglanz, R			An N-alpha-acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 and H2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; EUKARYOTIC PROTEINS; YEAST; IDENTIFICATION; REPRESSION; SEQUENCE; GENE	A yeast gene has been identified that encodes a novel, evolutionarily conserved N-alpha-acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 and H2A. The gene has been named NAT4. Recombinant Nat4 protein acetylated a peptide corresponding to the N-terminal tail of H4, but not an H3 peptide nor the peptide adrenocorticotropin. H4 and H2A are N-terminally acetylated in all species from yeast to mammals and hence blocked from sequencing by Edman degradation. In contrast, H4 and H2A purified from a nat4 mutant were unacetylated and could be sequenced. Analysis of yeast histones by acid-urea gel electrophoresis showed that all the H4 and H2A from the mutant migrated more rapidly than the same histones from a wild type strain, consistent with the histones from the mutant having one extra positive charge due to one less acetylated amino group. A comparison of yeast proteins from wild type and a nat4 mutant by two-dimensional gel electrophoresis showed no evidence that other yeast proteins are substrates of this acetyltransferase. Thus, Nat4 may be dedicated specifically to the N-terminal acetylation of histones H4 and H2A. Surprisingly, nat4 mutants grow at a normal rate and have no readily observable phenotypes.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Missouri System; University of Missouri Kansas City	Sternglanz, R (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Waterborg, Jakob H./J-5479-2013	Waterborg, Jakob H./0000-0002-2881-4634; wang, isabel/0000-0003-3264-7071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R56GM028220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDT WF, 1980, EUR J BIOCHEM, V110, P67, DOI 10.1111/j.1432-1033.1980.tb04841.x; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DELANGE RJ, 1969, J BIOL CHEM, V244, P319; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FASSLER JS, 1988, GENETICS, V118, P203; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; TAKAKURA H, 1992, J BIOL CHEM, V267, P5442; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	19	91	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38109	38112		10.1074/jbc.C300355200	http://dx.doi.org/10.1074/jbc.C300355200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12915400	hybrid			2022-12-27	WOS:000185575100002
J	Adams, DJ; Beveridge, DJ; van der Weyden, L; Mangs, H; Leedman, PJ; Morris, BJ				Adams, DJ; Beveridge, DJ; van der Weyden, L; Mangs, H; Leedman, PJ; Morris, BJ			HADHB, HuR, and CP1 bind to the distal 3 '-untranslated region of human renin mRNA and differentially modulate renin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; BETA-OXIDATION ENZYMES; 3' UNTRANSLATED REGION; PROTEIN-BINDING; GENE-EXPRESSION; IN-VITRO; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; POLY(C)-BINDING PROTEIN; GLUCOSE-TRANSPORTER; RESPONSIVE ELEMENT	Production of renin is critically dependent on modulation of REN mRNA stability. Here we sought to elucidate the molecular mechanisms involved. Transfections of renin-expressing Calu-6 cells with reporter constructs showed that a cis-acting 34-nucleotide AU-rich "renin stability regulatory element" in the REN 3'-untranslated region (3'-UTR) contributes to basal REN mRNA instability. Yeast three-hybrid screening with the REN 3/-UTR as bait isolated HADHB (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase ( trifunctional protein) beta-subunit) as a novel REN mRNA-binding protein. Recombinant HADHB bound specifically to the 3'-UTR of REN mRNA, as did the known mRNA stabilizers HuR and CP1 ( poly( C)binding protein-1). This required the renin stability regulatory element. Forskolin, which augments REN mRNA stability in Calu-6 cells, increased binding of several proteins, including HuR and CP1, to the REN 3'-UTR, whereas 4-bromocrotonic acid, a specific thiolase inhibitor, decreased binding and elevated renin protein levels. Upon decreasing HADHB mRNA with RNA interference, renin protein and mRNA stability increased, whereas RNA interference against HuR caused these to decrease. Immunoprecipitation and reverse transcription-PCR of Calu-6 extracts confirmed that HADHB, HuR, and CP1 each associate with REN mRNA in vivo. Intracellular imaging revealed distinct localization of HADHB to mitochondria, HuR to nuclei, and CP1 throughout the cell. Immunohistochemistry demonstrated enrichment of HADHB in renin-producing renal juxtaglomerular cells. In conclusion, HADHB, HuR, and CP1 are novel REN mRNA-binding proteins that target a cis-element in the 3'-UTR of REN mRNA and regulate renin production. cAMP- mediated increased REN mRNA stability may involve stimulation of HuR and CP1, whereas REN mRNA decay may involve thiolase-dependent pathways.	Univ Sydney, Sch Med Sci, Basic & Clin Genom Lab, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia; Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Ctr Med Res,Sch Med & Pharmacol,Lab Canc Med, Perth, WA 6000, Australia	University of Sydney; University of Sydney; Royal Perth Hospital; University of Western Australia	Morris, BJ (corresponding author), Univ Sydney, Sch Med Sci, Basic & Clin Genom Lab, Bldg F13, Sydney, NSW 2006, Australia.		Leedman, Peter J/O-4044-2014; van der Weyden, Louise/AAV-5711-2021	van der Weyden, Louise/0000-0002-0645-1879; Adams, David/0000-0001-9490-0306				Adams DJ, 2001, J CELL BIOL, V154, P25, DOI 10.1083/jcb.200010059; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brennan LE, 1999, GENE, V228, P85, DOI 10.1016/S0378-1119(99)00003-7; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN M, 1993, HYPERTENSION, V21, P36, DOI 10.1161/01.HYP.21.1.36; CHRZANOWSKALIGHTOWLERS ZMA, 1994, J BIOL CHEM, V269, P27322; Clausmeyer S, 1999, CIRC RES, V84, P337, DOI 10.1161/01.RES.84.3.337; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; DONG Y, 1989, J BIOL CHEM, V264, P13679; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hollams EM, 2002, NEUROCHEM RES, V27, P957, DOI 10.1023/A:1020992418511; Huang S, 1996, J CELL BIOCHEM, V62, P191, DOI 10.1002/(SICI)1097-4644(199608)62:2<191::AID-JCB7>3.0.CO;2-N; IZAI K, 1992, J BIOL CHEM, V267, P1027; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KAMIJO T, 1994, BIOCHEM BIOPH RES CO, V199, P818, DOI 10.1006/bbrc.1994.1302; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kiledjian M, 1999, METHODS, V17, P84, DOI 10.1006/meth.1998.0710; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lang JA, 1996, AM J PHYSIOL-RENAL, V271, pF94, DOI 10.1152/ajprenal.1996.271.1.F94; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lightowlers RN, 1996, BIOCHEM SOC T, V24, P527, DOI 10.1042/bst0240527; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; Mintz PJ, 2000, J STRUCT BIOL, V129, P241, DOI 10.1006/jsbi.2000.4213; MIURA S, 1994, J BIOCHEM-TOKYO, V115, P1064, DOI 10.1093/oxfordjournals.jbchem.a124458; MORRIS BJ, 2000, HDB PHYSL 7, V3, P3; NAGAKAWA J, 1995, P NATL ACAD SCI USA, V92, P2051; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Park YW, 1999, BIOTECHNIQUES, V26, P1102, DOI 10.2144/99266st01; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PREISS T, 1993, J BIOL CHEM, V268, P24523; Rouillard JM, 2000, MOL GEN GENET, V262, P1103, DOI 10.1007/PL00008653; SCHULZ H, 1987, LIFE SCI, V40, P1443, DOI 10.1016/0024-3205(87)90375-4; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; Sinn PL, 1999, HYPERTENSION, V33, P900, DOI 10.1161/01.HYP.33.3.900; SMITH DL, 1994, BBA-GENE STRUCT EXPR, V1219, P465, DOI 10.1016/0167-4781(94)90073-6; SMITH DL, 1994, BIOCHEM BIOPH RES CO, V200, P320, DOI 10.1006/bbrc.1994.1451; Takami S, 1996, Hypertens Res, V19, P51, DOI 10.1291/hypres.19.51; Thomson AM, 2000, J BIOL CHEM, V275, P31609, DOI 10.1074/jbc.M002354200; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; van der Weyden L, 2000, HYPERTENSION, V36, P1093, DOI 10.1161/01.HYP.36.6.1093; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Ying LH, 1997, J BIOL CHEM, V272, P2412; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	74	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44894	44903		10.1074/jbc.M307782200	http://dx.doi.org/10.1074/jbc.M307782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933794	hybrid			2022-12-27	WOS:000186306700125
J	Boorman, JP; Beato, M; Groot-Kormelink, PJ; Broadbent, SD; Sivilotti, LG				Boorman, JP; Beato, M; Groot-Kormelink, PJ; Broadbent, SD; Sivilotti, LG			The effects of beta 3 subunit incorporation on the pharmacology and single channel properties of oocyte-expressed human alpha 3 beta 4 neuronal nicotinic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING; CELL-LINE; DETERMINANTS; PERMEABILITY; SENSITIVITY; CURRENTS	We compared the main properties of human recombinant alpha3beta4beta3 neuronal nicotinic receptors with those of alpha3beta4 receptors, expressed in Xenopus oocytes. beta3 incorporation decreased the channel mean open time ( from 5.61 to 1.14 ms, after approximate correction for missed gaps) and burst length. There was also an increase in single channel slope conductance from 28.8 picosiemens (alpha3beta4) to 46.7 picosiemens (alpha3beta4beta3; in low divalent external solution). On the other hand, the calcium permeability ( determined by a reversal potential method in chloride-depleted oocytes) and the pharmacological properties of beta3-containing receptors differed little from those of alpha3beta4. The main pharmacological difference in alpha3beta4beta3 "triplet" receptors was a 3-fold decrease in the potency of lobeline relative to acetylcholine. Nevertheless, there was no change in the rank order of potency for agonists (epibatidine>>lobeline>cytisine, 1,1-dimethyl-4-phenylpiperazinium iodide, nicotine>acetylcholine>carbachol for both receptors; measured at low agonist concentrations). Sensitivity to the competitive antagonists trimetaphan (0.2-1 muM) and dihydro-beta-erythroidine (30 muM) was similar for the two combinations, with a Schild K-B for trimetaphan of 76 and 66 nM on alpha3beta4 and alpha3beta4beta3, respectively. The change in single channel conductance confirms that beta3 replaces a beta4 subunit in the pentamer. The absence of pronounced differences in the pharmacological profile of the triplet receptor argues against a role for the beta3 subunit in the formation of agonist binding sites, whereas the changes in channel kinetics suggest an important effect on receptor gating. The shortening of the burst length of beta3-containing receptors implies that any synaptic currents mediated by such channels would have faster decay kinetics.	Univ London, Sch Pharm, Dept Pharmacol, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Sivilotti, LG (corresponding author), UCL, Dept Biol, London WC1E 6BT, England.	l.sivilotti@ucl.ac.uk	Sivilotti, Lucia/D-8919-2011; Beato, Marco/C-1713-2008	Sivilotti, Lucia/0000-0003-2510-8424; Broadbent, Steven/0000-0002-7872-3968; Beato, Marco/0000-0002-7283-8318	MRC [G118/2] Funding Source: UKRI; Medical Research Council [G118/2] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; ASCHER P, 1979, J PHYSIOL-LONDON, V295, P139, DOI 10.1113/jphysiol.1979.sp012958; Boorman JPB, 2000, J PHYSIOL-LONDON, V529, P565, DOI 10.1111/j.1469-7793.2000.00565.x; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; ChavezNoriega LE, 1997, J PHARMACOL EXP THER, V280, P346; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; COLQUHOUN D, 1971, LECTURES BIOSTATISTI, P293; CONNOLLY JG, 1995, J PHYSIOL-LONDON, V484, P87, DOI 10.1113/jphysiol.1995.sp020650; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COVERNTON PJO, 1994, J PHYSIOL-LONDON, V481, P27, DOI 10.1113/jphysiol.1994.sp020416; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; Gerzanich V, 1998, J PHARMACOL EXP THER, V286, P311; Giniatullin RA, 2000, MOL PHARMACOL, V58, P778, DOI 10.1124/mol.58.4.778; Groot-Kormelink PJ, 1998, J BIOL CHEM, V273, P15317, DOI 10.1074/jbc.273.25.15317; GrootKormelink PJ, 1997, FEBS LETT, V400, P309, DOI 10.1016/S0014-5793(96)01383-X; Harvey SC, 1996, J NEUROCHEM, V67, P1953; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; Harvey SC, 1996, J NEUROSCI, V16, P3798; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Lewis TM, 1997, J PHYSIOL-LONDON, V505, P299, DOI 10.1111/j.1469-7793.1997.299bb.x; MATHIE A, 1991, J PHYSIOL-LONDON, V439, P717, DOI 10.1113/jphysiol.1991.sp018690; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Meyer EL, 2001, MOL PHARMACOL, V60, P568; Nelson ME, 1999, J PHYSIOL-LONDON, V516, P657, DOI 10.1111/j.1469-7793.1999.0657u.x; QUICK MW, 1994, METH NEUROSCI, V19, P261; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; SANDS SB, 1993, BIOPHYS J, V65, P2614, DOI 10.1016/S0006-3495(93)81296-7; SINE SM, 1981, J BIOL CHEM, V256, P6692; Sivilotti LG, 1997, J PHYSIOL-LONDON, V500, P123, DOI 10.1113/jphysiol.1997.sp022004; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; Xiao YX, 1998, MOL PHARMACOL, V54, P322, DOI 10.1124/mol.54.2.322	32	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44033	44040		10.1074/jbc.M211719200	http://dx.doi.org/10.1074/jbc.M211719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12912995	hybrid			2022-12-27	WOS:000186306700019
J	Kuang, DH; Yao, Y; Wang, MH; Pattabiraman, N; Kotra, LP; Hampson, DR				Kuang, DH; Yao, Y; Wang, MH; Pattabiraman, N; Kotra, LP; Hampson, DR			Molecular similarities in the ligand binding pockets of an odorant receptor and the metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; CALCIUM-SENSING RECEPTOR; EXTRACELLULAR CA2+-SENSING RECEPTOR; AMINO-TERMINAL DOMAINS; ACTIVATION PROCESS; MULTIGENE FAMILY; STRUCTURAL BASIS; MGLUR4 SUBTYPE; TASTE RECEPTOR; PROTEINS	The 5.24 odorant receptor is an amino acid sensing receptor that is expressed in the olfactory epithelium of fish. The 5.24 receptor is a G-protein-coupled receptor that shares amino acid sequence identity to mammalian pheromone receptors, the calcium-sensing receptor, the T1R taste receptors, and the metabotropic glutamate receptors (mGluRs). It is most potently activated by the basic amino acids L-lysine and L-arginine. In this study we generated a homology model of the ligand binding domain of the 5.24 receptor based on the crystal structure of mGluR1 and examined the proposed lysine binding pocket using site-directed mutagenesis. Mutants of truncated glycosylated versions of the receptor containing only the extracellular domain were analyzed in a radioligand binding assay, whereas the analogous full-length membrane-bound mutants were studied using a fluorescence-based functional assay. In silico analysis predicted that aspartate 388 interacts with the terminal amino group on the side chain of the docked lysine molecule. This prediction was supported by experimental observations demonstrating that mutation of this residue caused a 26-fold reduction in the affinity for L-lysine but virtually no change in the affinity for the polar amino acid L-glutamine. In addition, mutations in four highly conserved residues ( threonine 175, tyrosine 223, and aspartates 195 and 309) predicted to establish interactions with the alpha amino group of the bound lysine ligand greatly reduced or eliminated binding and receptor activation. These results define the essential features of amino acid selectivity within the 5.24 receptor binding pocket and highlight an evolutionarily conserved motif required for ligand recognition in amino acid activated receptors in the G-protein-coupled receptor superfamily.	Univ Toronto, Dept Pharmaceut Sci, Toronto, ON M5S 2S2, Canada; Univ Toronto, Inst Drug Res, Toronto, ON M5S 2S2, Canada; Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA	University of Toronto; University of Toronto; Georgetown University	Hampson, DR (corresponding author), Univ Toronto, Dept Pharmaceut Sci, 19 Russell St, Toronto, ON M5S 2S2, Canada.		Kuang, Donghui/H-3518-2013	Kotra, Lakshmi P./0000-0002-7071-4637				Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bertrand HO, 2002, J MED CHEM, V45, P3171, DOI 10.1021/jm010323l; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CASE DA, 2001, AMBER VERSION 7 0; Chaudhari N, 2000, NAT NEUROSCI, V3, P113, DOI 10.1038/72053; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Costantino G, 1999, J MED CHEM, V42, P5390, DOI 10.1021/jm990353c; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; KANG JS, 1995, J NEUROPHYSIOL, V73, P172, DOI 10.1152/jn.1995.73.1.172; KUANG D, 2002, SOC NEUR ABSTR; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Malherbe P, 2001, MOL PHARMACOL, V60, P944, DOI 10.1124/mol.60.5.944; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; Nearing J, 2002, P NATL ACAD SCI USA, V99, P9231, DOI 10.1073/pnas.152294399; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Peltekova V, 2000, MOL BRAIN RES, V76, P180, DOI 10.1016/S0169-328X(00)00029-2; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Rosemond E, 2002, J BIOL CHEM, V277, P7333, DOI 10.1074/jbc.M110476200; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Yao Y, 2003, J NEUROCHEM, V86, P947, DOI 10.1046/j.1471-4159.2003.01906.x; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200	45	44	48	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42551	42559		10.1074/jbc.M307120200	http://dx.doi.org/10.1074/jbc.M307120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912984	hybrid			2022-12-27	WOS:000185989500120
J	Maehashi, E; Sato, C; Ohta, K; Harada, Y; Matsuda, T; Hirohashi, N; Lennarz, WJ; Kitajima, K				Maehashi, E; Sato, C; Ohta, K; Harada, Y; Matsuda, T; Hirohashi, N; Lennarz, WJ; Kitajima, K			Identification of the sea urchin 350-kDa sperm-binding protein as a new sialic acid-binding lectin that belongs to the heat shock protein 110 family - Implication of its binding to gangliosides in sperm lipid rafts in fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG RECEPTOR; VITELLINE LAYER; LOW-DENSITY; MEMBRANE; FRACTION; GAMETE; HSP70; GLYCOPROTEIN; SEQUENCE; LIGANDS	The 350-kDa sperm-binding protein (SBP), a species-specific sperm-binding protein, is localized in the vitelline layer of sea urchin eggs. In this study, we have shown for the first time that sperm gangliosides are ligands for the intact glycosylated SBP. Using recombinant fragments of the SBP, the N-terminal heat shock protein 110-like domain was shown to be responsible for the binding. The intact SBP could bind various gangliosides, and the binding was sialidase-sensitive and inhibited by sialyllactose, thus indicating that it is the sialic acid-binding protein. Calcium and magnesium ions were not required but they did enhance the binding activity of SBP. The observation that bacterially expressed recombinant SBP and the sialidase-treated intact glycosylated SBP lost divalent cation-dependent enhancement of binding activity suggests that the sialylated carbohydrate moieties of the SBP may be involved in this property. Furthermore, the SBP was shown to bind sperm lipid rafts, in which gangliosides are enriched, and this binding was lost upon sialidase treatment of the lipid rafts. Finally, liposomes containing the ganglioside specifically inhibited fertilization. Taken together, these results allow us to identify SBP as a member of a new class of sialic acid-binding lectin belonging to the Hsp110 family, and indicate that SBP may be involved in interaction of sperm with the vitelline layer of the egg.	Nagoya Univ, Grad Sch Agr Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Nagoya University; Nagoya University; Nagoya University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kitajima, K (corresponding author), Nagoya Univ, Grad Sch Agr Sci, Nagoya, Aichi 4648601, Japan.	kitajima@agr.nagoya-u.ac.jp	Naganawa, Shinji/I-1572-2012; SATO, Chihiro/B-7396-2014	Naganawa, Shinji/0000-0002-0214-613X; 				Ahnonkitpanit V, 1999, BIOL REPROD, V61, P749, DOI 10.1095/biolreprod61.3.749; Cameron RA, 1996, DEV BIOL, V180, P348, DOI 10.1006/dbio.1996.0307; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; DHUME ST, 1995, GLYCOBIOLOGY, V5, P11, DOI 10.1093/glycob/5.1.11; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; Fuchizawa S, 1998, BIOCHEM BIOPH RES CO, V248, P505, DOI 10.1006/bbrc.1998.9002; Giusti AF, 1997, DEV BIOL, V184, P10, DOI 10.1006/dbio.1997.8507; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; Hirohashi N, 1998, DEV BIOL, V201, P270, DOI 10.1006/dbio.1998.8984; Hirohashi N, 1998, DEV BIOL, V204, P305, DOI 10.1006/dbio.1998.9015; Hirohashi N, 2001, DEV GROWTH DIFFER, V43, P247, DOI 10.1046/j.1440-169x.2001.00571.x; Ijuin T, 1996, GLYCOCONJUGATE J, V13, P401, DOI 10.1007/BF00731473; Just ML, 1997, DEV BIOL, V184, P25, DOI 10.1006/dbio.1997.8504; Kitazume S, 1996, J BIOL CHEM, V271, P6694, DOI 10.1074/jbc.271.12.6694; KitazumeKawaguchi S, 1997, P NATL ACAD SCI USA, V94, P3650, DOI 10.1073/pnas.94.8.3650; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LINGWOOD CA, 1985, CAN J BIOCHEM CELL B, V63, P1077, DOI 10.1139/o85-134; Mamelak D, 2001, J BIOL CHEM, V276, P449, DOI 10.1074/jbc.M006732200; Mamelak D, 2001, BIOCHEMISTRY-US, V40, P3572, DOI 10.1021/bi001643u; Mengerink KJ, 2001, GLYCOBIOLOGY, V11, p37R, DOI 10.1093/glycob/11.4.37R; NAGAI Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P146; Nagai Y., 1995, BIOL SIALIC ACIDS, P197; OHLENDIECK K, 1994, J CELL BIOL, V125, P817, DOI 10.1083/jcb.125.4.817; OHLENDIECK K, 1993, J CELL BIOL, V122, P887, DOI 10.1083/jcb.122.4.887; OHLENDIECK K, 1994, DEV BIOL, V165, P53, DOI 10.1006/dbio.1994.1233; Ohta K, 1999, BIOCHEM BIOPH RES CO, V258, P616, DOI 10.1006/bbrc.1999.0686; Ohta K, 2000, GLYCOCONJUGATE J, V17, P205, DOI 10.1023/A:1026589223811; OHTA K, 1999, GLYCOCONJUGATE J, V16, pS63; OKUMURA Y, 1994, BBA-BIOMEMBRANES, V1194, P335, DOI 10.1016/0005-2736(94)90316-6; Renkonen R, 1998, ADV EXP MED BIOL, V435, P63; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sharon N., 1997, GLYCOSCIENCES STATUS, P133; SHIMODA Y, 1994, BIOCHEMISTRY-US, V33, P1202, DOI 10.1021/bi00171a020; Stears RL, 1997, DEV BIOL, V187, P200, DOI 10.1006/dbio.1997.8608; TANPHAICHITR N, 1993, DEV BIOL, V156, P164, DOI 10.1006/dbio.1993.1067; VACQUIER VD, 1977, P NATL ACAD SCI USA, V74, P2456, DOI 10.1073/pnas.74.6.2456; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; White D, 2000, BIOL REPROD, V63, P147, DOI 10.1095/biolreprod63.1.147; Yu S, 2002, P NATL ACAD SCI USA, V99, P2854, DOI 10.1073/pnas.052707599; YU S, 1995, GLYCOBIOLOGY, V5, P207	40	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42050	42057		10.1074/jbc.M307493200	http://dx.doi.org/10.1074/jbc.M307493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917406	hybrid			2022-12-27	WOS:000185989500061
J	Gladue, RP; Tylaska, LA; Brissette, WH; Lira, PD; Kath, JC; Poss, CS; Brown, MF; Paradis, TJ; Conklyn, MJ; Ogborne, KT; McGlynn, MA; Lillie, BM; DiRico, AP; Mairs, EN; McElroy, EB; Martin, WH; Stock, IA; Shepard, RM; Showell, HJ; Neote, K				Gladue, RP; Tylaska, LA; Brissette, WH; Lira, PD; Kath, JC; Poss, CS; Brown, MF; Paradis, TJ; Conklyn, MJ; Ogborne, KT; McGlynn, MA; Lillie, BM; DiRico, AP; Mairs, EN; McElroy, EB; Martin, WH; Stock, IA; Shepard, RM; Showell, HJ; Neote, K			CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CCR1; RHEUMATOID-ARTHRITIS; SYNOVIAL TISSUE; CUTANEOUS INJECTION; UP-REGULATION; RANTES; EXPRESSION; RECRUITMENT; TNF; CELLS	The chemokines CCL3 and CCL5, as well as their shared receptor CCR1, are believed to play a role in the pathogenesis of several inflammatory diseases including rheumatoid arthritis, multiple sclerosis, and transplant rejection. In this study we describe the pharmacological properties of a novel small molecular weight CCR1 antagonist, CP-481,715 (quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3-fluorobenzyl)-2(S), 7-dihydroxy7- methyloctyl] amide). Radiolabeled binding studies indicate that CP-481,715 binds to human CCR1 with a K-d of 9.2 nM and displaces I-125-labeled CCL3 from CCR1-transfected cells with an IC50 of 74 nM. CP-481,715 lacks intrinsic agonist activity but fully blocks the ability of CCL3 and CCL5 to stimulate receptor signaling (guanosine 5'-O-(thiotriphosphate) incorporation; IC50 = 210 nM), calcium mobilization (IC50 = 71 nM), monocyte chemotaxis (IC50 = 55 nM), and matrix metalloproteinase 9 release (IC50 = 54 nM). CP- 481,715 retains activity in human whole blood, inhibiting CCL3-induced CD11b up-regulation and actin polymerization (IC50 = 165 and 57 nM, respectively) on monocytes. Furthermore, it behaves as a competitive and reversible antagonist. CP- 481,715 is > 100-fold selective for CCR1 as compared with a panel of G-protein-coupled receptors including related chemokine receptors. Evidence for its potential use in human disease is suggested by its ability to inhibit 90% of the monocyte chemotactic activity present in 11/15 rheumatoid arthritis synovial fluid samples. These data illustrate that CP- 481,715 is a potent and selective antagonist for CCR1 with therapeutic potential for rheumatoid arthritis and other inflammatory diseases.	Pfizer Inc, Global Res & Dev, Dept Immunol, Groton, CT 06340 USA	Pfizer	Gladue, RP (corresponding author), Pfizer Inc, Global Res & Dev, Dept Immunol, MS 8220-2410,Eastern Point Rd, Groton, CT 06340 USA.	Ronald_P_Gladue@Groton.Pfizer.com						AlMughales J, 1996, CLIN EXP IMMUNOL, V106, P230, DOI 10.1046/j.1365-2249.1996.d01-836.x; Barnes DA, 1998, J CLIN INVEST, V101, P2910, DOI 10.1172/JCI2172; Barr AJ, 1997, J BIOL CHEM, V272, P32979, DOI 10.1074/jbc.272.52.32979; Beck LA, 1997, J IMMUNOL, V159, P2962; Colantonio L, 1999, BLOOD, V94, P2981, DOI 10.1182/blood.V94.9.2981.421k27_2981_2989; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Conklyn MJ, 1996, CYTOKINE, V8, P762, DOI 10.1006/cyto.1996.0101; CUTOLO M, 1993, CLIN EXP RHEUMATOL, V11, P331; Dayer JM, 2002, JOINT BONE SPINE, V69, P123, DOI 10.1016/S1297-319X(02)00363-9; Dunne JL, 2002, BLOOD, V99, P336, DOI 10.1182/blood.V99.1.336; Ellingsen T, 2000, SCAND J RHEUMATOL, V29, P216; FAHEY TJ, 1992, J IMMUNOL, V148, P2764; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; Gao W, 2000, J CLIN INVEST, V105, P35, DOI 10.1172/JCI8126; Horuk R, 2000, MED RES REV, V20, P155, DOI 10.1002/(SICI)1098-1128(200003)20:2<155::AID-MED3>3.0.CO;2-G; Jenkins JK, 2002, AM J MED SCI, V323, P171, DOI 10.1097/00000441-200204000-00002; KASAMA T, 1995, J CLIN INVEST, V95, P2868, DOI 10.1172/JCI117993; Katrib A, 2001, RHEUMATOLOGY, V40, P988, DOI 10.1093/rheumatology/40.9.988; Katschke KJ, 2001, ARTHRITIS RHEUM, V44, P1022, DOI 10.1002/1529-0131(200105)44:5<1022::AID-ANR181>3.3.CO;2-E; Klier CM, 2001, BIOL CHEM, V382, P1405, DOI 10.1515/BC.2001.173; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; Lee SC, 2000, J IMMUNOL, V164, P3392, DOI 10.4049/jimmunol.164.6.3392; Liang M, 2000, J BIOL CHEM, V275, P19000, DOI 10.1074/jbc.M001222200; Luttichau H R, 2000, Curr Opin Drug Discov Devel, V3, P610; Makki RF, 2000, CLIN EXP RHEUMATOL, V18, P391; Meyer O, 2000, PRESSE MED, V29, P463; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; ROBINSON E, 1995, CLIN EXP IMMUNOL, V101, P398; Robinson SC, 2002, EUR J IMMUNOL, V32, P404, DOI 10.1002/1521-4141(200202)32:2<404::AID-IMMU404>3.0.CO;2-X; Rottman JB, 2000, EUR J IMMUNOL, V30, P2372, DOI 10.1002/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO;2-D; SCHILD HO, 1949, BRIT J PHARM CHEMOTH, V4, P277, DOI 10.1111/j.1476-5381.1949.tb00548.x; Tak PP, 1997, ARTHRITIS RHEUM, V40, P217, DOI 10.1002/art.1780400206; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; Volin MV, 1998, CLIN IMMUNOL IMMUNOP, V89, P44, DOI 10.1006/clin.1998.4590; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; Weber C, 2001, BLOOD, V97, P1144, DOI 10.1182/blood.V97.4.1144	41	74	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40473	40480		10.1074/jbc.M306875200	http://dx.doi.org/10.1074/jbc.M306875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909630	hybrid			2022-12-27	WOS:000185847200008
J	Carter, JM; Waite, KA; Campenot, RB; Vance, JE; Vance, DE				Carter, JM; Waite, KA; Campenot, RB; Vance, JE; Vance, DE			Enhanced expression and activation of CTP : phosphocholine cytidylyltransferase beta 2 during neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPASE-C; PC12 CELLS; RAT-BRAIN; TRANSCRIPTION; GENE; DIACYLGLYCEROL; IDENTIFICATION; DEPHOSPHORYLATION	During differentiation neurons increase phospholipid biosynthesis to provide new membrane for neurite growth. We studied the regulation of phosphatidylcholine ( PC) biosynthesis during differentiation of two neuronal cell lines: PC12 cells and Neuro2a cells. We hypothesized that in PC12 cells nerve growth factor (NGF) would up-regulate the activity and expression of the rate-limiting enzyme in PC biosynthesis, CTP: phosphocholine cytidylyltransferase (CT). During neurite outgrowth, NGF doubled the amount of cellular PC and CT activity. CTbeta2 mRNA increased within 1 day of NGF application, prior to the formation of visible neurites, and continued to increase during neurite growth. When neurites retracted in response to NGF withdrawal, CTbeta2 mRNA, protein, and CT activity decreased. NGF specifically activated CTbeta2 by promoting its translocation from cytosol to membranes. In contrast, NGF did not alter CTalpha expression or translocation. The increase in both CTbeta2 mRNA and CT activity was inhibited by U0126, an inhibitor of mitogen-activated kinase/extracellular signal-regulated kinase kinase 1/2 (MEK1/2). In Neuro2a cells, retinoic acid significantly increased CT activity (by 54%) and increased CTbeta2 protein, coincident with neurite outgrowth but did not change CTalpha expression. Together, these data suggest that the CTbeta2 isoform of CT is specifically up-regulated and activated during neuronal differentiation to increase PC biosynthesis for growing neurites.	Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Dept Biochem, Edmonton, AB T6G 2S2, Canada.			Carter, Jodi/0000-0002-5973-0732				Araki W, 1997, P NATL ACAD SCI USA, V94, P11946, DOI 10.1073/pnas.94.22.11946; Bakovic M, 2000, J LIPID RES, V41, P583; Bakovic M, 2003, J BIOL CHEM, V278, P14753, DOI 10.1074/jbc.M300162200; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Bodennec J, 2002, FASEB J, V16, P1814, DOI 10.1096/fj.02-0149fje; DECHAVES EP, 1995, J CELL BIOL, V128, P913, DOI 10.1083/jcb.128.5.913; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Kano Y, 2002, NEUROCHEM RES, V27, P1655, DOI 10.1023/A:1021639128120; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; PELECH SL, 1981, J BIOL CHEM, V256, P8283; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; SHEA TB, 1985, DEV BRAIN RES, V21, P307, DOI 10.1016/0165-3806(85)90220-2; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SLACK BE, 1991, J BIOL CHEM, V266, P24503; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; STROSZNAJDER J, 1979, BIOCHIM BIOPHYS ACTA, V574, P48, DOI 10.1016/0005-2760(79)90083-3; TANAKA T, 1987, BIOCHIM BIOPHYS ACTA, V922, P85, DOI 10.1016/0005-2760(87)90248-7; Torocsik B, 2002, J NEUROSCI, V22, P8971; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE D, 2003, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WIESPRECHT M, 1994, FEBS LETT, V353, P221; Xiong Y, 2000, NEUROSCI LETT, V283, P129, DOI 10.1016/S0304-3940(00)00929-0; Zhou AW, 1997, PEPTIDES, V18, P1179, DOI 10.1016/S0196-9781(97)00184-8	31	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44988	44994		10.1074/jbc.M307336200	http://dx.doi.org/10.1074/jbc.M307336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12928431	hybrid			2022-12-27	WOS:000186306700135
J	Sathish, HA; Stein, RA; Yang, GY; Mchaourab, HS				Sathish, HA; Stein, RA; Yang, GY; Mchaourab, HS			Mechanism of chaperone function in small heat-shock proteins - Fluorescence studies of the conformations of T4 lysozyme bound to alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; A-CRYSTALLIN; SUBUNIT EXCHANGE; SECONDARY STRUCTURE; MISSENSE MUTATION; 2-MODE BINDING; EXCITED-STATES; IN-VITRO; SPECTROSCOPY; DYNAMICS	To further develop the mechanistic understanding of small heat-shock protein ( sHSP) chaperone activity, we investigate the nature of the intermediate states recognized by alpha-crystallin and the conformations that are stably bound. The model substrates consist of a set of well characterized, destabilized T4 Lysozyme (T4L) mutants that have been shown to differentially bind alpha-crystallin in a manner that reflects their free-energy of unfolding. A new approach for the detection of complex formation is introduced based on the conformational sensitivity of the fluorescent probe bimane, site-specifically introduced in T4L. Emission spectra of bimanelabeled T4L reveal two distinct patterns of intensity changes upon binding that depend on the molar ratio of alpha-crystallin to T4L. This directly demonstrates the two-mode nature of the binding process by the alpha-crystallins. Biphasic binding isotherms, obtained and analyzed over a wide range of T4L concentrations, demonstrate a substantially quenched bimane fluorescence in the low affinity-bound T4L that is similar to the quenching level observed due to denaturant unfolding. Furthermore, the pattern of intensity changes that occur upon binding of a T4L variant, bimane-labeled at an alternative solvent-exposed site, establishes a direct correlation between the quenching level observed in binding and unfolding. The results can be interpreted in terms of a model where alpha-crystallin binds at least two conformationally distinct non-native states of T4L, one of which is substantially unfolded and is bound with low affinity. A high affinity binding mode to compact states may be relevant to chaperone function in the lens, where protein damage is unlikely to cause global unfolding.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, 741 Light Hall, Nashville, TN 37232 USA.	hassane.mchaourab@vanderbilt.edu			NEI NIH HHS [EY-R0112683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012683] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Cobb BA, 2002, BIOCHEMISTRY-US, V41, P483, DOI 10.1021/bi0112457; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Englander SW, 1998, TRENDS BIOCHEM SCI, V23, P378, DOI 10.1016/S0968-0004(98)01281-X; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Grantcharova V, 2001, CURR OPIN STRUC BIOL, V11, P70, DOI 10.1016/S0959-440X(00)00176-7; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Pace CN, 2000, PROTEINS, P1; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Verschuure P, 2002, J MOL CELL CARDIOL, V34, P117, DOI 10.1006/jmcc.2001.1493; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang ZX, 1996, FEBS LETT, V392, P245, DOI 10.1016/0014-5793(96)00818-6; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060	38	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44214	44221		10.1074/jbc.M307578200	http://dx.doi.org/10.1074/jbc.M307578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12928430	hybrid			2022-12-27	WOS:000186306700041
J	Benko, S; Love, JD; Beladi, M; Schwabe, JWR; Nagy, L				Benko, S; Love, JD; Beladi, M; Schwabe, JWR; Nagy, L			Molecular determinants of the balance between co-repressor and co-activator recruitment to the retinoic acid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTORS; LIGAND-BINDING DOMAIN; THYROID-HORMONE; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL REPRESSION; HISTONE ACETYLTRANSFERASE; INTERACTING DOMAINS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; COMPLEX	The repressive and activating states of nuclear hormone receptors are achieved through the recruitment of cofactor proteins. The binding of co-repressors and coactivators is believed to be mutually exclusive and principally regulated by ligand binding. To understand the molecular determinants of the switch induced by ligand in the retinoic acid receptor and in particular the intrinsic role of the ligand binding domain (LBD) in cofactor binding and release, we carried out extensive mutational analysis of surface residues of the LBD. As seen previously we found that co-repressor and co-activator molecules bind to overlapping docking sites on the surface of the retinoic acid receptor alpha LBD. Perturbation of this surface impaired both co- activator and co- repressor association resulting in a transcriptionally inert receptor. Unexpectedly mutation of two residues, Trp-225 and Ala-392, which lie outside the docking site, had opposite effects on co- activator and co- repressor binding. W225A was a constitutive repressor that failed to bind co- activator and exhibited an increased, and ligand-insensitive, interaction with co- repressor. A392R, on the other hand, had reduced affinity for co- repressors and increased affinity for co- activators and behaved as a constitutive, but still ligand-inducible, activator. Analysis of known structures showed that these mutations lie in the proximity of helix 12 (H12), and their effects are likely to be the result of perturbations in the behavior of H12. These data suggest that residues in the close vicinity of H12 regulate cofactor affinity and determine the basal activity of receptors.	Univ Debrecen, Med & Hlth Sci Ctr, Res Ctr Mol Med, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Debrecen; MRC Laboratory Molecular Biology	Nagy, L (corresponding author), Univ Debrecen, Med & Hlth Sci Ctr, Res Ctr Mol Med, Dept Biochem & Mol Biol, Nagyerdei Krt 98, H-4012 Debrecen, Hungary.		Schwabe, John WR/A-9132-2008; Nagy, Laszlo/A-3814-2008	Schwabe, John WR/0000-0003-2865-4383; Nagy, Laszlo/0000-0001-6653-2155				BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Collins SJ, 2002, LEUKEMIA, V16, P1896, DOI 10.1038/sj.leu.2402718; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Gelman L, 1999, CELL MOL LIFE SCI, V55, P932, DOI 10.1007/s000180050345; Ghosh JC, 2002, P NATL ACAD SCI USA, V99, P5842, DOI 10.1073/pnas.092043399; Glass CK, 2000, GENE DEV, V14, P121; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hellal-Levy C, 2000, MOL ENDOCRINOL, V14, P1210, DOI 10.1210/me.14.8.1210; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Johnson BA, 2000, J MOL BIOL, V298, P187, DOI 10.1006/jmbi.2000.3636; Kallenberger BC, 2003, NAT STRUCT BIOL, V10, P136, DOI 10.1038/nsb892; Lee WY, 2002, BIOCHEMISTRY-US, V41, P2500, DOI 10.1021/bi011764+; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Malloy PJ, 2002, MOL ENDOCRINOL, V16, P2538, DOI 10.1210/me.2002-0152; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Pike ACW, 2000, BIOCHEM SOC T, V28, P396, DOI 10.1042/0300-5127:0280396; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang JS, 1999, MOL CELL BIOL, V19, P6448	58	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43797	43806		10.1074/jbc.M306199200	http://dx.doi.org/10.1074/jbc.M306199200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917445	hybrid, Green Published			2022-12-27	WOS:000186157000130
J	Angelaccio, S; Chiaraluce, R; Consalvi, V; Buchenau, B; Giangiacomo, L; Bossa, F; Contestabile, R				Angelaccio, S; Chiaraluce, R; Consalvi, V; Buchenau, B; Giangiacomo, L; Bossa, F; Contestabile, R			Catalytic and thermodynamic properties of tetrahydromethanopterindependent serine hydroxymethyltransferase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SECONDARY STRUCTURE; ANGSTROM RESOLUTION; NEURAL-NETWORK; D-ALANINE; PURIFICATION; TRANSHYDROXYMETHYLASE; BINDING	The reaction catalyzed by serine hydroxymethyltransferase (SHMT), the transfer of Cbeta of serine to tetrahydropteroylglutamate, represents in Eucarya and Eubacteria a major source of one-carbon (C-1) units for several essential biosynthetic processes. In many Archaea, C-1 units are carried by modified pterin-containing compounds, which, although structurally related to tetrahydropteroylglutamate, play a distinct functional role. Tetrahydromethanopterin, and a few variants of this compound, are the modified folates of methanogenic and sulfate-reducing Archaea. Little information on SHMT from Archaea is available, and the metabolic role of the enzyme in these organisms is not clear. This contribution reports on the purification and characterization of recombinant SHMT from the hyperthermophilic methanogen Methanococcus jannaschii. The enzyme was characterized with respect to its catalytic, spectroscopic, and thermodynamic properties. Tetrahydromethanopterin was found to be the preferential pteridine substrate. Tetrahydropteroylglutamate could also take part in the hydroxymethyltransferase reaction, although with a much lower efficiency. The catalytic features of the enzyme with substrate analogues and in the absence of a pteridine substrate were also very similar to those of SHMT isolated from Eucarya or Eubacteria. On the other hand, the M. jannaschii enzyme showed increased thermoactivity and resistance to denaturating agents with respect to the enzyme purified from mesophilic sources. The results reported suggest that the active site structure and the mechanism of SHMT are conserved in the enzyme from M. jannaschii, which appear to differ only in its ability to bind and use a modified folate as substrate and increased thermal stability.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, Ctr Eccellenza Biol & Med Mol, I-00185 Rome, Italy; Univ Marburg, Max Planck Inst Terr Mikrobiol, D-35043 Marburg, Germany; Univ Marburg, Fachbereich Biol, Mikrobiol Lab, D-35043 Marburg, Germany	Sapienza University Rome; Sapienza University Rome; Max Planck Society; Philipps University Marburg; Philipps University Marburg	Contestabile, R (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Angelaccio, Sebastiana/D-2842-2011; Contestabile, Roberto/J-3467-2019; consalvi, valerio/F-1918-2011; Chiaraluce, Roberta/F-1920-2011	Contestabile, Roberto/0000-0002-5235-9993; 				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; [Anonymous], 1998, COMPREHENSIVE BIOL C; ARRIODUPONT M, 1971, BIOCHEM BIOPH RES CO, V44, P653, DOI 10.1016/S0006-291X(71)80133-X; Bertoldi M, 2002, BIOCHEMISTRY-US, V41, P9153, DOI 10.1021/bi025649q; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; CHEN MS, 1973, J BIOL CHEM, V248, P7979; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DelleFratte S, 1997, J BACTERIOL, V179, P7456, DOI 10.1128/jb.179.23.7456-7461.1997; Fu TF, 2003, J BIOL CHEM, V278, P2645, DOI 10.1074/jbc.M210649200; Fu TF, 2001, ANAL BIOCHEM, V290, P359, DOI 10.1006/abio.2001.4994; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOYT JC, 1986, ARCH MICROBIOL, V145, P153, DOI 10.1007/BF00446773; Ionescu RM, 2000, BIOCHEMISTRY-US, V39, P9540, DOI 10.1021/bi000511y; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON WC, 1992, METHOD ENZYMOL, V210, P426; Lin ZS, 1998, CAN J MICROBIOL, V44, P652, DOI 10.1139/cjm-44-7-652; MADEN BE, 2000, BIOCHEM J, V350, P509; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Paiardini A, 2003, PROTEINS, V50, P122, DOI 10.1002/prot.10268; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; Rost B, 1996, METHOD ENZYMOL, V266, P525; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Scarsdale JN, 2000, J MOL BIOL, V296, P155, DOI 10.1006/jmbi.1999.3453; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH L, 1964, J BIOL CHEM, V239, P3801; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; SHALTIEL S, 1970, BIOCHEM BIOPH RES CO, V41, P594, DOI 10.1016/0006-291X(70)90054-9; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; Szebenyi DME, 2000, BIOCHEMISTRY-US, V39, P13313, DOI 10.1021/bi000635a; Trivedi V, 2002, J BIOL CHEM, V277, P17161, DOI 10.1074/jbc.M111976200; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; Vorholt JA, 1998, J BACTERIOL, V180, P5351, DOI 10.1128/JB.180.20.5351-5356.1998; Wasserfallen A, 2000, INT J SYST EVOL MICR, V50, P43, DOI 10.1099/00207713-50-1-43; WHITE RH, 1991, J BACTERIOL, V173, P1987, DOI 10.1128/jb.173.6.1987-1991.1991; Wyman J, 1943, J BIOL CHEM, V147, P297	42	23	25	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41789	41797		10.1074/jbc.M306747200	http://dx.doi.org/10.1074/jbc.M306747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902326	hybrid			2022-12-27	WOS:000185989500030
J	Kim, SJ; Hwang, SG; Kim, IC; Chun, JS				Kim, SJ; Hwang, SG; Kim, IC; Chun, JS			Actin cytoskeletal architecture regulates nitric oxide-induced apoptosis, dedifferentiation, and cyclooxygenase-2 expression in articular chondrocytes via mitogen-activated protein kinase and protein kinase C pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROSTAGLANDIN E-2; RETINOIC ACID; GROWTH-FACTOR; MESSENGER-RNA; IN-VITRO; F-ACTIN; DISRUPTION; ALPHA; PHENOTYPE	Nitric oxide (NO) in articular chondrocytes regulates differentiation, survival, and inflammatory responses by modulating ERK-1 and -2, p38 kinase, and protein kinase C (PKC) alpha and zeta. In this study, we investigated the effects of the actin cytoskeletal architecture on NO-induced dedifferentiation, apoptosis, cyclooxygenase (COX)-2 expression, and prostaglandin E-2 production in articular chondrocytes, with a focus on ERK-1/-2, p38 kinase, and PKC signaling. Disruption of the actin cytoskeleton by cytochalasin D (CD) inhibited NO-induced apoptosis, dedifferentiation, COX-2 expression, and prostaglandin E-2 production in chondrocytes cultured on plastic or during cartilage explants culture. CD treatment did not affect ERK-1/-2 activation but blocked the signaling events necessary for NO-induced dedifferentiation, apoptosis, and COX-2 expression such as activation of p38 kinase and inhibition of PKCalpha and -zeta. CD also suppressed activation of downstream signaling of p38 kinase and PKC, such as NF-kappaB activation, p53 accumulation, and caspase-3 activation, which are necessary for NO-induced apoptosis. NO production in articular chondrocytes caused down-regulation of phosphatidylinositol (PI) 3-kinase and Akt activities. The down-regulation of PI 3-kinase and Akt was blocked by CD treatment, and the CD effects on apoptosis, p38 kinase, and PKCalpha and -zeta were abolished by the inhibition of PI 3-kinase with LY294002. Our results collectively indicate that the actin cytoskeleton mediates NO-induced regulatory effects in chondrocytes by modulating down-regulation of PI 3-kinase and Akt, activation of p38 kinase, and inhibition of PKCalpha and -zeta.	Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea; Kongju Natl Univ, Dept Biol Sci, Gongju 314701, Chungnam, South Korea	Gwangju Institute of Science & Technology (GIST); Kongju National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea.	jschun@kjist.ac.kr						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281-199905000-00009; Bando M, 2002, BIOCHEM BIOPH RES CO, V290, P268, DOI 10.1006/bbrc.2001.6199; BENYA PD, 1988, J CELL BIOL, V106, P161, DOI 10.1083/jcb.106.1.161; BENYA PD, 1993, EXP CELL RES, V204, P268, DOI 10.1006/excr.1993.1033; BROWN PD, 1988, J CELL BIOL, V106, P171, DOI 10.1083/jcb.106.1.171; Cash DE, 1997, J CELL BIOL, V136, P445, DOI 10.1083/jcb.136.2.445; Clancy R, 1999, OSTEOARTHR CARTILAGE, V7, P399, DOI 10.1053/joca.1998.0223; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Demoor-Fossard M, 1998, BBA-GENE STRUCT EXPR, V1398, P179, DOI 10.1016/S0167-4781(98)00044-X; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Huh YH, 2003, J BIOL CHEM, V278, P9691, DOI 10.1074/jbc.M211360200; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Karino A, 1996, FEBS LETT, V398, P317, DOI 10.1016/S0014-5793(96)01266-5; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kim JA, 2002, NEUROPHARMACOLOGY, V42, P1109, DOI 10.1016/S0028-3908(02)00052-7; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Korichneva I, 1999, J CELL SCI, V112, P2521; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1051, P266, DOI 10.1016/0167-4889(90)90132-W; Lim YB, 2000, BIOCHEM BIOPH RES CO, V273, P609, DOI 10.1006/bbrc.2000.2987; Lim YB, 2003, J CELL BIOCHEM, V88, P713, DOI 10.1002/jcb.10389; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LOTY S, 1995, BIOL CELL, V83, P149, DOI 10.1016/0248-4900(96)81303-7; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Melamed I, 1999, CELL IMMUNOL, V194, P136, DOI 10.1006/cimm.1999.1506; Oh CD, 2003, J BIOL CHEM, V278, P36563, DOI 10.1074/jbc.M304857200; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sawyer SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1038, DOI 10.1152/ajpcell.2001.281.3.C1038; Schwartz Z, 1998, ENDOCRINOLOGY, V139, P1825, DOI 10.1210/en.139.4.1825; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Suria H, 1999, LIFE SCI, V65, P2697, DOI 10.1016/S0024-3205(99)00538-X; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; Vinall RL, 2002, EXP CELL RES, V272, P32, DOI 10.1006/excr.2001.5395; Weston AD, 2000, J CELL BIOL, V148, P679, DOI 10.1083/jcb.148.4.679; White SR, 2001, AM J RESP CELL MOL, V24, P282, DOI 10.1165/ajrcmb.24.3.3995; Yamazaki Y, 2000, EXP CELL RES, V259, P64, DOI 10.1006/excr.2000.4970; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115	53	66	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42448	42456		10.1074/jbc.M304887200	http://dx.doi.org/10.1074/jbc.M304887200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907684	hybrid			2022-12-27	WOS:000185989500109
J	Onuma, M; Bub, JD; Rummel, TL; Iwamoto, Y				Onuma, M; Bub, JD; Rummel, TL; Iwamoto, Y			Prostate cancer cell-adipocyte interaction - Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; NECROSIS-FACTOR-ALPHA; N-TERMINAL KINASE; PROTEIN-KINASE; INSULIN-RESISTANCE; ACTIVATION DOMAIN; RECEPTOR ISOFORMS; BODY-WEIGHT; OB/OB MICE; OBESE GENE	Prostate cancer is one of the leading causes of death among men in the United States, and acquisition of hormone resistance (androgen independence) by cancer cells is a fatal event during the natural history of prostate cancer. Obesity is another serious health problem and has been shown to be associated with prostate cancer. However, little is known about the molecular basis of this association. Here we show that factor(s) secreted from adipocytes stimulate prostate cancer cell proliferation. Leptin is one of the major adipose cytokines, and it controls body weight homeostasis through food intake and energy expenditure. We identify leptin as a novel growth factor in androgen-independent prostate cancer cell growth. Strikingly, leptin stimulates cell proliferation specifically in androgen-independent DU145 and PC-3 prostate cancer cells but not in androgen-dependent LNCaP-FGC cells, although both cell types express functional leptin receptor isoforms. c-Jun NH2-terminal kinase (JNK) has been shown recently to play a crucial role in obesity and insulin resistance. Intriguingly, leptin induces JNK activation in androgen-independent prostate cancer cells, and the pharmacological inhibition of JNK blocked the leptin stimulation of androgen-independent prostate cancer cell proliferation. This suggests that JNK activation is required for leptin-mediated, androgen-independent prostate cancer cell proliferation. Furthermore, other cytokines produced by adipocytes and critical for body weight homeostasis cooperate with leptin in androgen-independent prostate cancer cell proliferation: interleukin-6 and insulin-like growth factor I demonstrate additive and synergistic effects on the leptin stimulation of androgen-independent prostate cancer cell proliferation, respectively. Therefore, adipose cytokines, as well as JNK, are key mediators between obesity and hormone-resistant prostate cancer and could be therapeutic targets.	Med Coll Wisconsin, Dept Urol, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Iwamoto, Y (corresponding author), Med Coll Wisconsin, Dept Urol, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA.	yiwamoto@mcw.edu						Amling CL, 2001, UROLOGY, V58, P723, DOI 10.1016/S0090-4295(01)01373-5; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chung TDK, 1999, PROSTATE, V38, P199; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Frank S, 2000, J CLIN INVEST, V106, P501, DOI 10.1172/JCI9148; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Furuya Y, 1998, Int J Urol, V5, P134, DOI 10.1111/j.1442-2042.1998.tb00261.x; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hsing AW, 2000, CANCER EPIDEM BIOMAR, V9, P1335; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; Kaicer E, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104819; KEY T, 1995, CANCER SURV, V23, P63; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Mix H, 2000, GUT, V47, P481, DOI 10.1136/gut.47.4.481; Mizokami A, 2000, J UROLOGY, V164, P800, DOI 10.1016/S0022-5347(05)67318-1; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Mori S, 1999, BIOCHEM BIOPH RES CO, V257, P609, DOI 10.1006/bbrc.1999.0515; Okamoto M, 1997, CANCER RES, V57, P141; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Platz EA, 2002, J NUTR, V132, p3471S, DOI 10.1093/jn/132.11.3471S; Potapova O, 2002, CANCER RES, V62, P3257; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ring BD, 2000, ENDOCRINOLOGY, V141, P446, DOI 10.1210/en.141.1.446; Rodriguez C, 2001, CANCER EPIDEM BIOMAR, V10, P345; Schnabl B, 2001, HEPATOLOGY, V34, P953, DOI 10.1053/jhep.2001.28790; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimizu H, 1997, PEPTIDES, V18, P1263, DOI 10.1016/S0196-9781(97)00137-X; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Stattin P, 2001, J CLIN ENDOCR METAB, V86, P1341, DOI 10.1210/jc.86.3.1341; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Zachow RJ, 1997, ENDOCRINOLOGY, V138, P847, DOI 10.1210/en.138.2.847; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	147	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42660	42667		10.1074/jbc.M304984200	http://dx.doi.org/10.1074/jbc.M304984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902351	hybrid			2022-12-27	WOS:000185989500132
J	Vasiljeva, L; Merits, A; Golubtsov, A; Sizemskaja, V; Kaariainen, L; Ahola, T				Vasiljeva, L; Merits, A; Golubtsov, A; Sizemskaja, V; Kaariainen, L; Ahola, T			Regulation of the sequential processing of Semliki Forest virus replicase polyprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND RNA-SYNTHESIS; SINDBIS VIRUS; NONSTRUCTURAL POLYPROTEIN; CRYSTAL-STRUCTURE; PROTEIN NSP2; TEMPORAL REGULATION; MINUS-STRAND; CLEAVAGE; SITE; COMPLEXES	The replication of most positive-strand RNA viruses and retroviruses is regulated by proteolytic processing. Alphavirus replicase proteins are synthesized as a polyprotein, called P1234, which is cleaved into nsP1, nsP2, nsP3, and nsP4 by the carboxyl-terminal protease domain of nsP2. The cleavage intermediate P123 + nsP4 synthesizes minus-strand copies of the viral RNA genome, whereas the completely processed complex is required for plus-strand synthesis. To understand the mechanisms responsible for this sequential proteolysis, we analyzed in vitro translated Semliki Forest virus polyproteins containing noncleavable processing sites or various deletions. Processing of each of the three sites in vitro required a different type of activity. Site 3/4 was cleaved in trans by nsP2, its carboxyl-terminal fragment Pro39, and by all polyprotein proteases. Site 1/2 was cleaved in cis with a half-life of about 20-30 min. Site 2/3 was cleaved rapidly in trans but only after release of nsP1 from the polyprotein exposing an "activator" sequence present in the amino terminus of nsP2. Deletion of amino-terminal amino acids of nsP2 or addition of extra amino acid residues to its amino terminus specifically inhibited the protease activity that processes the 2/3 site. This sequence of delayed processing of P1234 would explain the accumulation of P123 plus nsP4, the early short-lived minus-strand replicase. The polyprotein stage would allow correct assembly and membrane association of the RNA-polymerase complex. Late in infection free nsP2 would cleave at site 2/3 yielding P12 and P34, the products of which, nsP1-4, are distributed to the plasma membrane, nucleus, cytoplasmic aggregates, and proteasomes, respectively.	Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Estonian Bioctr, EE-51010 Tartu, Estonia; Inst Mol & Cellular Biol, EE-51010 Tartu, Estonia	University of Helsinki; Estonian Biocentre	Kaariainen, L (corresponding author), Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Program Cellular Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Merits, Andres/H-3125-2015; Lulla, Valeria/W-1994-2019	Merits, Andres/0000-0001-8193-0071; Lulla, Valeria/0000-0002-6605-0727; Golubtsov, Andrey/0000-0002-1418-7692; Vasiljeva, Lidia/0000-0002-1244-8772				Ahola T, 1999, EMBO J, V18, P3164, DOI 10.1093/emboj/18.11.3164; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; de Cedron MG, 1999, FEBS LETT, V448, P19, DOI 10.1016/S0014-5793(99)00321-X; DEGROOT RJ, 1990, EMBO J, V9, P2631, DOI 10.1002/j.1460-2075.1990.tb07445.x; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DING MX, 1989, VIROLOGY, V171, P280, DOI 10.1016/0042-6822(89)90539-4; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; Griffin D.E., 2001, FIELDS VIROLOGY, P917; HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989; Kaariainen L, 2002, PROG NUCLEIC ACID RE, V71, P187, DOI 10.1016/S0079-6603(02)71044-1; KERANEN S, 1983, J VIROL, V47, P505; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kujala P, 2001, J VIROL, V75, P3873, DOI 10.1128/JVI.75.8.3873-3884.2001; LACHMI BE, 1976, P NATL ACAD SCI USA, V73, P1936, DOI 10.1073/pnas.73.6.1936; LEHTOVAARA P, 1980, EUR J BIOCHEM, V112, P461; Lemm JA, 1998, J VIROL, V72, P6546, DOI 10.1128/JVI.72.8.6546-6553.1998; LEMM JA, 1993, J VIROL, V67, P1905, DOI 10.1128/JVI.67.4.1905-1915.1993; LEMM JA, 1993, J VIROL, V67, P1916, DOI 10.1128/JVI.67.4.1916-1926.1993; LEMM JA, 1994, EMBO J, V13, P2925, DOI 10.1002/j.1460-2075.1994.tb06587.x; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Merits A, 2001, J GEN VIROL, V82, P765, DOI 10.1099/0022-1317-82-4-765; PERANEN J, 1995, VIROLOGY, V208, P610, DOI 10.1006/viro.1995.1192; PERANEN J, 1990, J VIROL, V64, P1888; RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994; Salonen A, 2003, J VIROL, V77, P1691, DOI 10.1128/JVI.77.3.1691-1702.2003; Schlesinger S, 2001, EXPERT OPIN BIOL TH, V1, P177, DOI 10.1517/14712598.1.2.177; SHIRAKO Y, 1990, VIROLOGY, V177, P54, DOI 10.1016/0042-6822(90)90459-5; SHIRAKO Y, 1994, J VIROL, V68, P1874, DOI 10.1128/JVI.68.3.1874-1885.1994; Smerdou C, 1999, CURR OPIN MOL THER, V1, P244; STRAUSS EG, 1992, VIROLOGY, V191, P932, DOI 10.1016/0042-6822(92)90268-T; TAKKINEN K, 1991, J GEN VIROL, V72, P1627, DOI 10.1099/0022-1317-72-7-1627; Vasiljeva L, 2001, J BIOL CHEM, V276, P30786, DOI 10.1074/jbc.M104786200; Vasiljeva L, 2000, J BIOL CHEM, V275, P17281, DOI 10.1074/jbc.M910340199; WANG YF, 1994, J VIROL, V68, P6466, DOI 10.1128/JVI.68.10.6466-6475.1994; Weston J, 2002, J VIROL, V76, P6155, DOI 10.1128/JVI.76.12.6155-6163.2002; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	39	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41636	41645		10.1074/jbc.M307481200	http://dx.doi.org/10.1074/jbc.M307481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917405	hybrid			2022-12-27	WOS:000185989500012
J	Berg, P				Berg, P			Moments of discovery: My favorite experiments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL ADENYLATES; ENZYMATIC MECHANISM		Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Berg, P (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.							BERG P, 1958, J BIOL CHEM, V233, P608; BERG P, 1958, P NATL ACAD SCI USA, V44, P78, DOI 10.1073/pnas.44.2.78; BERG P, 1954, J BIOL CHEM, V210, P657; BERG P, 1956, J BIOL CHEM, V222, P991; BERG P, 1956, J BIOL CHEM, V222, P1025; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; GOLDTHWAIT DA, 1996, BIOGR MEM NATL ACAD, V69, P3; HOAGLAND MB, 1958, J BIOL CHEM, V231, P241; JONES ME, 1953, J AM CHEM SOC, V75, P3285; KORNBERG A, 1950, J BIOL CHEM, V182, P779; SCHRECKER AW, 1950, J BIOL CHEM, V182, P795	11	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40417	40424		10.1074/jbc.X300004200	http://dx.doi.org/10.1074/jbc.X300004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893814	hybrid			2022-12-27	WOS:000185847200001
J	Miller, MT; Gerratana, B; Stapon, A; Townsend, CA; Rosenzweig, AC				Miller, MT; Gerratana, B; Stapon, A; Townsend, CA; Rosenzweig, AC			Crystal structure of carbapenam synthetase (CarA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM SYNTHETASE; KINETIC MECHANISM; BIOSYNTHESIS; PROGRAM; SUBSTRATE; SYNTHASE; SERRATIA; REVEALS; GENES	Carbapenam synthetase (CarA) is an ATP/Mg2+-dependent enzyme that catalyzes formation of the beta-lactam ring in (5R)-carbapenem-3-carboxylic acid biosynthesis. CarA is homologous to beta-lactam synthetase (beta-LS), which is involved in clavulanic acid biosynthesis. The catalytic cycles of CarA and beta-LS mediate substrate adenylation followed by beta-lactamization via a tetrahedral intermediate or transition state. Another member of this family of ATP/Mg2+-dependent enzymes, asparagine synthetase (AS-B), catalyzes intermolecular, rather than intramolecular, amide bond formation in asparagine biosynthesis. The crystal structures of apo-CarA and CarA complexed with the substrate (2S,5S)-5-carboxymethylproline (CMPr), ATP analog alpha,beta-methyleneadenosine 5'-triphosphate (AMP-CPP), and a single Mg2+ ion have been determined. CarA forms a tetramer. Each monomer resembles beta-LS and AS-B in overall fold, but key differences are observed. The N-terminal domain lacks the glutaminase active site found in AS-B, and an extended loop region not observed in beta-LS or AS-B is present. Comparison of the C-terminal synthetase active site to that in beta-LS reveals that the ATP binding site is highly conserved. By contrast, variations in the substrate binding pocket reflect the different substrates of the two enzymes. The Mg2+ coordination is also different. Several key residues in the active site are conserved between CarA and beta-LS, supporting proposed roles in beta-lactam formation. These data provide further insight into the structures of this class of enzymes and suggest that CarA might be a versatile target for protein engineering experiments aimed at developing improved production methods and new carbapenem antibiotics.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	Northwestern University; Northwestern University; Johns Hopkins University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	amyr@northwestern.edu	Gerratana, Barbara/B-7448-2009	Stapon, Anthony/0000-0002-7858-1613	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014937, R37AI014937] Funding Source: NIH RePORTER; NIAID NIH HHS [AI14937] Funding Source: Medline; NIGMS NIH HHS [GM008061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann BO, 2000, BIOCHEMISTRY-US, V39, P11187, DOI 10.1021/bi000709i; Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boehlein SK, 1998, BIOCHEMISTRY-US, V37, P13230, DOI 10.1021/bi981058h; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clifton IJ, 2003, J BIOL CHEM, V278, P20843, DOI 10.1074/jbc.M213054200; Coulton S, 1996, Prog Med Chem, V33, P99, DOI 10.1016/S0079-6468(08)70304-7; DeLano W.L, PYMOL MOL GRAPHICS S; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Gerratana B, 2003, BIOCHEMISTRY-US, V42, P7836, DOI 10.1021/bi034361d; HAYNIE DT, 2001, BIOL THERMODYNAMICS, P127; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li RF, 2000, J AM CHEM SOC, V122, P9296, DOI 10.1021/ja001723l; McGowan SJ, 1999, ANTON LEEUW INT J G, V75, P135, DOI 10.1023/A:1001768428383; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; McGowan SJ, 1997, MOL MICROBIOL, V26, P545, DOI 10.1046/j.1365-2958.1997.6001974.x; McGowan SJ, 1998, TRENDS MICROBIOL, V6, P203, DOI 10.1016/S0966-842X(98)01251-7; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller MT, 2002, P NATL ACAD SCI USA, V99, P14752, DOI 10.1073/pnas.232361199; Miller MT, 2001, NAT STRUCT BIOL, V8, P684, DOI 10.1038/90394; NEU HC, 1994, CURR OPIN INFECT DIS, V7, pS3; PARKER WL, 1982, J ANTIBIOT, V35, P653, DOI 10.7164/antibiotics.35.653; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; SALOWE SP, 1990, BIOCHEMISTRY-US, V29, P6499, DOI 10.1021/bi00479a023; Stapon A, 2003, J AM CHEM SOC, V125, P8486, DOI 10.1021/ja034248a; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thomson NR, 2000, MOL MICROBIOL, V36, P539, DOI 10.1046/j.1365-2958.2000.01872.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	36	34	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40996	41002		10.1074/jbc.M307901200	http://dx.doi.org/10.1074/jbc.M307901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890666	hybrid			2022-12-27	WOS:000185847200073
J	Roucou, X; Guo, Q; Zhang, Y; Goodyer, CG; LeBlanc, AC				Roucou, X; Guo, Q; Zhang, Y; Goodyer, CG; LeBlanc, AC			Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRPSC-LIKE CONFORMATION; DE-NOVO GENERATION; CONVERSION; PROTEASOME; APOPTOSIS; MITOCHONDRIA; DEGRADATION; SUPPRESSES; STABILITY; TRANSPORT	Recently, it was observed that reverse-translocated cytosolic PrP and PrP expressed in the cytosol induce rapid death in neurons (Ma, J., Wollmann, R., and Lindquist, S. ( 2002) Science 298, 1781 - 1785). In this study, we investigated whether accumulation of prion protein ( PrP) in the cytosol is toxic to human neurons in primary culture. We show that in these neurons, a single PrP isoform lacking signal peptide accumulates in the cytosol of neurons treated with epoxomicin, a specific proteasome inhibitor. Therefore, endogenously expressed PrP is subject to the endoplasmic reticulum-associated degradation (ERAD) pathway and is degraded by the proteasome in human primary neurons. In contrast to its toxicity in N2a cells, reverse-translocated PrP (ERAD-PrP) is not toxic even when neurons are microinjected with cDNA constructs to overexpress either wild-type PrP or mutant PrPD178N. We found that ERAD-PrP in human neurons remains detergent-soluble and proteinase K-sensitive, in contrast to its detergent-insoluble and proteinase K-resistant state in N2a cells. Furthermore, not only is microinjection of a cDNA construct expressing CyPrP not toxic, it protects these neurons against Bax-mediated cell death. We conclude that in human neurons, ERAD-PrP is not converted naturally into a form reminiscent of scrapie PrP and that PrP located in the cytosol retains its protective function against Bax. Thus, it is unlikely that simple accumulation of PrP in the cytosol can cause neurodegeneration in prion diseases.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	LeBlanc, AC (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Ch Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	andrea.leblanc@mcgill.ca						BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hall GF, 2001, AM J PATHOL, V158, P235, DOI 10.1016/S0002-9440(10)63962-4; Harris CA, 2001, J BIOL CHEM, V276, P37754; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LEBLANC A, 1998, HDB AGING BRAIN, P201; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Stockel J, 2001, J MOL BIOL, V313, P861, DOI 10.1006/jmbi.2001.5085; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zhang Y, 2002, APOPTOSIS TECHNIQUES, P83; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	40	134	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40877	40881		10.1074/jbc.M306177200	http://dx.doi.org/10.1074/jbc.M306177200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917444	hybrid			2022-12-27	WOS:000185847200057
J	Zhao, XX; Carnevale, KA; Cathcart, MK				Zhao, XX; Carnevale, KA; Cathcart, MK			Human monocytes use Rac1, not Rac2, in the NADPH oxidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; COMPONENTS P47(PHOX); HUMAN NEUTROPHILS; P67(PHOX); ACTIVATION; BINDING; TRANSLOCATION; GTP; PHOSPHORYLATION; DISSOCIATION	Phagocyte NADPH oxidase is critical for defense against pathogens and contributes to inflammatory tissue injury. One component of the NADPH oxidase complex is the small GTP-binding protein Rac. There are two isoforms of Rac, and Rac2 is the predominant isoform in neutrophils and has been shown to be essential for NADPH oxidase activity. In primary human monocytes we report that in contrast to neutrophils, Rac1 is the predominantly expressed isoform. Upon monocyte activation by a variety of agents, we found that Rac1 dissociates from Rho GDP dissociation inhibitor ( RhoGDI) and translocates to the membrane. We also found that Rac1 interacts with two other NADPH oxidase components, p67phox and p47phox, upon monocyte activation. These data indicate that Rac1, and not Rac2, is a component of the activated NADPH oxidase in monocytes. This finding suggests that it may be possible to selectively interfere with either monocyte or neutrophil NADPH oxidase activity, thereby selectively targeting chronic versus acute inflammatory processes.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cathcart, MK (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL61971, HL51068] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051068, R01HL061971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; DUSI S, 1995, BIOCHEM J, V308, P991, DOI 10.1042/bj3080991; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; Forbes LV, 1999, FEBS LETT, V449, P225, DOI 10.1016/S0014-5793(99)00444-5; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JOHNSTON RB, 1981, METHODS STUDYING MON, P489; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matos P, 2000, BIOCHEM BIOPH RES CO, V277, P741, DOI 10.1006/bbrc.2000.3743; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	29	82	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40788	40792		10.1074/jbc.M302208200	http://dx.doi.org/10.1074/jbc.M302208200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912997	hybrid			2022-12-27	WOS:000185847200047
J	Hanson, ES; Rawlins, ML; Leibold, EA				Hanson, ES; Rawlins, ML; Leibold, EA			Oxygen and iron regulation of iron regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; ELEMENT-BINDING PROTEIN; PROLYL 4-HYDROXYLASES; ACONITASE ACTIVITY; MOLECULAR CONTROL; HIF-ALPHA; DEGRADATION; HYDROXYLATION/; INHIBITION; FAMILY	Iron regulatory protein 2 (IRP2) is a central regulator of cellular iron homeostasis due to its regulation of specific mRNAs encoding proteins of iron uptake and storage. Iron regulates IRP2 by mediating its rapid proteasomal degradation, where hypoxia and the hypoxia mimetics CoCl2 and desferrioxamine (DFO) stabilize it. Previous studies showed that iron-mediated degradation of IRP2 requires the presence of critical cysteines that reside within a 73-amino acid unique region. Here we show that a mutant IRP2 protein lacking this 73-amino acid region degraded at a rate similar to that of wild-type IRP2. In addition, DFO and hypoxia blocked the degradation of both the wild- type and mutant IRP2 proteins. Recently, members of the 2-oxoglutarate (2-OG)- dependent dioxygenase family have been shown to hydroxylate hypoxia-inducible factor-1alpha (HIF-1alpha), a modification required for its ubiquitination and proteasomal degradation. Since 2-OG-dependent dioxygenases require iron and oxygen, in addition to 2-OG, for substrate hydroxylation, we hypothesized that this activity may be involved in the regulation of IRP2 stability. To test this we used the 2-OG-dependent dioxygenase inhibitor dimethyloxalylglycine (DMOG) and showed that it blocked iron-mediated IRP2 degradation. In addition, hypoxia, DFO and DMOG blocked IRP2 ubiquitination. These data indicate that the region of IRP2 that is involved in IRP2 iron-mediated degradation lies outside of the 73-amino acid unique region and suggest a model whereby 2-OG-dependent dioxygenase activity may be involved in the oxygen and iron regulation of IRP2 protein stability.	Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Div Hematol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Hanson, ES (corresponding author), Univ Utah, Eccles Program Human Mol Biol & Genet, 15 N 2030 E Rm 4200, Salt Lake City, UT 84112 USA.				NIDDK NIH HHS [DK02960] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CUNLIFFE CJ, 1992, J MED CHEM, V35, P2652, DOI 10.1021/jm00092a016; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	32	128	133	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40337	40342		10.1074/jbc.M302798200	http://dx.doi.org/10.1074/jbc.M302798200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888568	hybrid			2022-12-27	WOS:000185713800127
J	Hewetson, A; Chilton, BS				Hewetson, A; Chilton, BS			An Sp1-NF-Y/progesterone receptor DNA binding-dependent mechanism regulates progesterone-induced transcriptional activation of the rabbit RUSH/SMARCA3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWNSTREAM PROMOTER ELEMENT; NEGATIVE AUTOREGULATION; UTEROGLOBIN PROMOTER; INHIBITOR-1 GENE; NF-Y; EXPRESSION; PROLACTIN; CLONING; SP1; PROTEINS	Steroids regulate alternative splicing of rabbit RUSH/SMARCA3, an SWI/SNF-related transcription factor. Transactivation was evaluated in 2057 bp of genomic sequence. Truncation analysis identified a minimal 252-bp region with strong basal promoter activity in transient transfection assays. The size of the 5'-untranslated region (233 bp) and the transcription start site were determined by primer extension analysis. The transcription start site mapped to a consensus initiator (Inr) element in a TATA-less region with a downstream promoter element (+29). These elements were authenticated by mutation/deletion analysis. The Inr/downstream promoter element combination is conserved in the putative core promoter (-35/+35) of the human ortholog, suggesting that transcription initiation is similarly conserved. Two Sp1 sites that are also conserved in the putative promoter of human SMARCA3 and a RUSH binding site (-616/-611) that is unique to the rabbit promoter repress basal transcription. These sites were variously authenticated by gel shift and chromatin immunoprecipitation assays. Analysis of the proximal promoter showed the -162/+90 region was required for progesterone responsiveness in transient transfection assays. Subsequent mutation/deletion analysis revealed a progesterone receptor half-site mediated induction by progesterone. An overlapping Y-box (in the reverse AT-TGG orientation) repressed basal transcription and progesterone-induced transcriptional activation in the presence of the Sp1 sites. The specificity of progesterone receptor and transcription factor NF-Y binding were authenticated by gel shift assays. Chromatin immunoprecipitation assays confirmed the Y-box effects were mediated in a DNA binding-dependent fashion. This represents a unique regulatory scenario in which ligand-dependent transactivation by the progesterone receptor is subject to Sp1/NF-Y repression.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Chilton, BS (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, 3601 4th St,Mail Stop 6540, Lubbock, TX 79430 USA.			Chilton, Beverly/0000-0002-8066-8697	NICHD NIH HHS [HD29457] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029457] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; AVIA H, 1972, P NATL ACAD SCI USA, V69, P1408; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CHILTON BS, 1988, MOL ENDOCRINOL, V2, P1169, DOI 10.1210/mend-2-12-1169; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Croager EJ, 2000, AM J PATHOL, V156, P1723, DOI 10.1016/S0002-9440(10)65043-2; Devine JH, 1999, MOL CELL ENDOCRINOL, V151, P49, DOI 10.1016/S0303-7207(99)00013-1; Ding H, 1998, HUM MOL GENET, V7, P1681, DOI 10.1093/hmg/7.11.1681; Ding H, 1996, DNA CELL BIOL, V15, P429, DOI 10.1089/dna.1996.15.429; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Farsetti A, 2001, ENDOCRINOLOGY, V142, P3380, DOI 10.1210/en.142.8.3380; FLISS AE, 1991, ENDOCRINOLOGY, V129, P697, DOI 10.1210/endo-129-2-697; Gong XH, 1997, DEV BIOL, V183, P166, DOI 10.1006/dbio.1996.8486; HAMMINK M, 1990, ONCOGENE, V5, P1843; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HaywardLester A, 1996, MOL ENDOCRINOL, V10, P1335, DOI 10.1210/me.10.11.1335; Hewetson A, 1997, MOL CELL ENDOCRINOL, V136, P1, DOI 10.1016/S0303-7207(97)00203-7; Hewetson A, 2002, MOL ENDOCRINOL, V16, P2101, DOI 10.1210/me.2002-0064; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; KLEISSANFRANCISCO S, 1993, MOL ENDOCRINOL, V7, P214, DOI 10.1210/me.7.2.214; Krikun G, 2002, J SOC GYNECOL INVEST, V9, P329, DOI 10.1016/S1071-5576(02)00168-5; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; LI WI, 1989, ENDOCRINOLOGY, V125, P2862, DOI 10.1210/endo-125-6-2862; Mahajan MC, 2002, BLOOD, V99, P348, DOI 10.1182/blood.V99.1.348; Mallick S, 1997, DNA CELL BIOL, V16, P807, DOI 10.1089/dna.1997.16.807; Mansharamani M, 2001, J BIOL CHEM, V276, P3641, DOI 10.1074/jbc.M004231200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MUKHERJEE AB, 1993, MOL CELL ENDOCRINOL, V94, P15; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; SHERIDAN PL, 1995, J BIOL CHEM, V270, P4575, DOI 10.1074/jbc.270.9.4575; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Zhang Q, 1997, GENE, V202, P31, DOI 10.1016/S0378-1119(97)00446-0; Zhou TY, 2001, J BIOL CHEM, V276, P25503, DOI 10.1074/jbc.M102875200	41	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40177	40185		10.1074/jbc.M303921200	http://dx.doi.org/10.1074/jbc.M303921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890680	hybrid			2022-12-27	WOS:000185713800111
J	Rhie, A; Kirby, L; Sayer, N; Wellesley, R; Disterer, P; Sylvester, I; Gill, A; Hope, J; James, W; Tahiri-Alaoui, A				Rhie, A; Kirby, L; Sayer, N; Wellesley, R; Disterer, P; Sylvester, I; Gill, A; Hope, J; James, W; Tahiri-Alaoui, A			Characterization of 2 '-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; NMR STRUCTURE; NUCLEOCAPSID PROTEIN; SPONGIFORM ENCEPHALOPATHIES; PEPTIDE PRP106-126; SCRAPIE ISOFORM; N-TERMINUS; PRP; RNA; AGGREGATION	We have isolated artificial ligands or aptamers for infectious prions in order to investigate conformational aspects of prion pathogenesis. The aptamers are 2'-fluoro-modified RNA produced by in vitro selection from a large, randomized library. One of these ligands (aptamer SAF-93) had more than 10-fold higher affinity for PrPSc than for recombinant PrPC and inhibited the accumulation of PrPres in near physiological cell-free conversion assay. To understand the molecular basis of these properties and to distinguish specific from nonspecific aptamer-PrP interactions, we studied deletion mutants of bovine PrP in denatured, alpha-helix-rich and beta-sheet-rich forms. We provide evidence that, like scrapie-associated fibrils (SAF), the beta-oligomer of PrP bound to SAF-93 with at least 10-fold higher affinity than did the alpha-form. This differential affinity could be explained by the existence of two binding sites within the PrP molecule. Site 1 lies within residues 23-110 in the unstructured N terminus and is a nonspecific RNA binding site found in all forms of PrP. The region between residue 90 and 110 forms a hinge region that is occluded in the alpha-rich form of PrP but becomes exposed in the denatured form of PrP. Site 2 lies in the region C-terminal of residue 110. This site is beta-sheet conformation-specific and is not recognized by control RNAs. Taken together, these data provide for the first time a specific ligand for a disease conformation-associated site in a region of PrP critical for conformational conversion. This aptamer could provide tools for the further analysis of the processes of PrP misfolding during prion disease and leads for the development of diagnostic and therapeutic approaches to TSEs.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Inst Anim Hlth, Newbury RG20 7NN, Berks, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Tahiri-Alaoui, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		james, william/H-4289-2013; Hope, James/C-4966-2011; Gill, Andrew C/A-5219-2009; Gill, ANdrew/GRO-1248-2022; Disterer, Petra/C-9709-2014	james, william/0000-0002-2506-1198; Gill, Andrew C/0000-0001-5201-9473; Disterer, Petra/0000-0001-9702-9974	Biotechnology and Biological Sciences Research Council [BBS/E/I/00000973, BBS/E/I/00000877] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ADAMS TE, 1992, GENE, V122, P371, DOI 10.1016/0378-1119(92)90229-I; AKOWITZ A, 1994, NUCLEIC ACIDS RES, V22, P1101, DOI 10.1093/nar/22.6.1101; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 2000, BIOCHEM J, V346, P785, DOI 10.1042/0264-6021:3460785; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; HEIDENREICH O, 1995, NUCLEIC ACIDS RES, V23, P2223, DOI 10.1093/nar/23.12.2223; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; Kirby L, 2003, J GEN VIROL, V84, P1013, DOI 10.1099/vir.0.18903-0; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X; Nandi PK, 1998, ARCH VIROL, V143, P1251, DOI 10.1007/s007050050373; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; Singh N, 2002, FRONT BIOSCI-LANDMRK, V7, pA60, DOI 10.2741/singh; SKLAVIADIS T, 1993, P NATL ACAD SCI USA, V90, P5713, DOI 10.1073/pnas.90.12.5713; Steitz TA, 1999, RNA WORLD, P427; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Tahiri-Alaoui A, 2003, PROTEIN SCI, V12, P600, DOI 10.1110/ps.0236703; Tahiri-Alaoui A, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e45; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuerk C, 1997, Methods Mol Biol, V67, P219; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	58	151	168	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39697	39705		10.1074/jbc.M305297200	http://dx.doi.org/10.1074/jbc.M305297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902353	hybrid, Green Accepted			2022-12-27	WOS:000185713800055
J	Pappalardo, L; Janausch, IG; Vijayan, V; Zientz, E; Junker, J; Peti, W; Zweckstetter, M; Unden, G; Griesinger, C				Pappalardo, L; Janausch, IG; Vijayan, V; Zientz, E; Junker, J; Peti, W; Zweckstetter, M; Unden, G; Griesinger, C			The NMR structure of the sensory domain of the membranous two-component fumarate sensor (histidine protein kinase) DcuS of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; DIPOLAR COUPLINGS; GENE-EXPRESSION; RECEPTOR; SYSTEM; ALIGNMENT	The structure of the water-soluble, periplasmic domain of the fumarate sensor DcuS (DcuS-pd) has been determined by NMR spectroscopy in solution. DcuS is a prototype for a sensory histidine kinase with transmembrane signal transfer. DcuS belongs to the CitA family of sensors that are specific for sensing di- and tricarboxylates. The periplasmic domain is folded autonomously and shows helices at the N and the C terminus, suggesting direct linking or connection to helices in the two transmembrane regions. The structure constitutes a novel fold. The nearest structural neighbor is the Per-Arnt-Sim domain of the photoactive yellow protein that binds small molecules covalently. Residues Arg(107), His(110), and Arg(147) are essential for fumarate sensing and are found clustered together. The structure constitutes the first periplasmic domain of a two component sensory system and is distinctly different from the aspartate sensory domain of the Tar chemotaxis sensor.	Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Mainz, Inst Mikrobiol & Weinforsch, D-55099 Mainz, Germany	Max Planck Society; Johannes Gutenberg University of Mainz	Griesinger, C (corresponding author), Max Planck Inst Biophys Chem, Fassberg 11, D-37077 Gottingen, Germany.		Junker, Jochen/B-4487-2009; Pappalardo, Lucia/ABA-9311-2020; Peti, Wolfgang/L-3492-2014	Junker, Jochen/0000-0003-4002-4405; Pappalardo, Lucia/0000-0002-4491-2082; vijayan, vinesh/0000-0001-5483-1860; Zweckstetter, Markus/0000-0002-2536-6581				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863; Chou JJ, 2001, J AM CHEM SOC, V123, P3844, DOI 10.1021/ja015660y; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Golby P, 1999, J BACTERIOL, V181, P1238, DOI 10.1128/JB.181.4.1238-1248.1999; Hansen MR, 1998, J AM CHEM SOC, V120, P11210, DOI 10.1021/ja9829665; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Janausch IG, 2002, J BIOL CHEM, V277, P39809, DOI 10.1074/jbc.M204482200; Janausch IG, 2002, BBA-BIOENERGETICS, V1553, P39, DOI 10.1016/S0005-2728(01)00233-X; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Koradi R, 1996, J MOL GRAPHICS, V14, P29; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Parac TN, 2001, J BIOMOL NMR, V19, P91, DOI 10.1023/A:1008301425100; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; VUISTER GW, 1992, J AM CHEM SOC, V114, P9674, DOI 10.1021/ja00050a066; YEH JI, 1993, J BIOL CHEM, V268, P9787; Zientz E, 1998, J BACTERIOL, V180, P5421, DOI 10.1128/JB.180.20.5421-5425.1998; Zweckstetter M, 2001, J BIOMOL NMR, V20, P365, DOI 10.1023/A:1011263920003	22	87	89	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39185	39188		10.1074/jbc.C300344200	http://dx.doi.org/10.1074/jbc.C300344200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12907689	Green Published, hybrid			2022-12-27	WOS:000185575100132
J	Fieger, CB; Sassetti, CM; Rosen, SD				Fieger, CB; Sassetti, CM; Rosen, SD			Endoglycan, a member of the CD34 family, functions as an L-selectin ligand through modification with tyrosine sulfation and sialyl Lewis x	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; P-SELECTIN; GLYCOPROTEIN LIGAND; LEUKOCYTE ACCUMULATION; VASCULAR ADDRESSIN; EXPRESSION CLONING; HUMAN NEUTROPHILS; O-GLYCANS; IDENTIFICATION; DISTINCT	During lymphocyte homing to secondary lymphoid organs and instances of inflammatory trafficking, the rolling of leukocytes on vascular endothelium is mediated by transient interactions between L-selectin on leukocytes and several carbohydrate-modified ligands on the endothelium. Most L-selectin ligands such as CD34 and podocalyxin present sulfated carbohydrate structures (6-sulfated sialyl Lewis x or 6-sulfo-sLex) as a recognition determinant within their heavily glycosylated mucin domains. We recently identified endoglycan as a new member of the CD34 family. We report here that endoglycan, like the two other members of this family (CD34 and podocalyxin) can function as a L-selectin ligand. However, endoglycan employs a different binding mechanism, interacting with L-selectin through sulfation on two tyrosine residues and O-linked sLex structures that are presented within its highly acidic amino-terminal region. Our analysis establishes striking parallels with PSGL-1, a leukocyte ligand that interacts with all three selectins, mediating leukocyte-endothelial, leukocyte-leukocyte, and platelet-leukocyte interactions. Since the distribution of endoglycan includes hematopoietic precursors and leukocyte subpopulations, in addition to endothelial cells, our findings suggest several potential settings for endoglycan-mediated adhesion events.	Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, Program Immunol, Box 0452,513 Parnasus Ave, San Francisco, CA 94143 USA.	sdr@itsa.ucsf.edu		Rosen, Steven/0000-0002-6245-701X	NIGMS NIH HHS [R37GM23547, GM57411] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057411, R37GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, J BIOL CHEM, V266, P14869; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; Doyonnas R, 2001, J EXP MED, V194, P13, DOI 10.1084/jem.194.1.13; Eriksson EE, 2001, J EXP MED, V194, P205, DOI 10.1084/jem.194.2.205; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; Galustian C, 2002, IMMUNOLOGY, V105, P350, DOI 10.1046/j.1365-2567.2002.01369.x; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hirata T, 2002, J IMMUNOL, V169, P4307, DOI 10.4049/jimmunol.169.8.4307; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; Kanamori A, 2002, J BIOL CHEM, V277, P32578, DOI 10.1074/jbc.M204400200; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LEY K, 1993, BLOOD, V82, P1632; McEver RP, 1997, J CLIN INVEST, V100, pS97; McNagny KM, 1997, J CELL BIOL, V138, P1395, DOI 10.1083/jcb.138.6.1395; MITOMA J, 2003, J BIOL CHEM; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramos CL, 1998, BLOOD, V91, P1067, DOI 10.1182/blood.V91.3.1067.1067_1067_1075; Rodgers SD, 2001, BIOPHYS J, V81, P2001, DOI 10.1016/S0006-3495(01)75850-X; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Samulowitz U, 2002, AM J PATHOL, V160, P1669, DOI 10.1016/S0002-9440(10)61114-5; Sassetti C, 2000, J BIOL CHEM, V275, P9001, DOI 10.1074/jbc.275.12.9001; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SASSETTI C, 1999, THESIS U CALIFORNIA; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; Xia LJ, 2002, J CLIN INVEST, V109, P939; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	53	55	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27390	27398		10.1074/jbc.M304204200	http://dx.doi.org/10.1074/jbc.M304204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12889478	hybrid			2022-12-27	WOS:000184242700009
J	McBryant, SJ; Park, YJ; Abernathy, SM; Laybourn, PJ; Nyborg, JK; Luger, K				McBryant, SJ; Park, YJ; Abernathy, SM; Laybourn, PJ; Nyborg, JK; Luger, K			Preferential binding of the histone (H3-H4)(2) tetramer by NAP1 is mediated by the amino-terminal histone tails	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PROTEIN-1; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; CORE PARTICLE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; MOLECULAR-CLONING; DNA-REPLICATION; H2A/H2B DIMER; HUMAN-CELLS	The yeast nucleosome assembly protein 1 (yNAP1) participates in many diverse activities, such as the assembly of newly synthesized DNA into chromatin and the rearrangement of nucleosomes during transcriptional activation. yNAP1 does not require ATP hydrolysis to perform these functions and is a valuable tool for in vitro chromatin assembly. Using recombinant histone complexes, we show that yNAP1 has a preference for binding the (H3-H4)(2) tetramer over the (H2A-H2B) dimer. We find that the loss of the histone tails abrogates this preference for H3 and H4, and we demonstrate a direct interaction between yNAP1 and the amino-terminal tails of H3 and H4. yNAP1 binds to one histone fold domain, thus specifying the stoichiometry of the complexes formed with the histone dimer and tetramer. Finally, we provide evidence that the acidic carboxyl-terminal region of yNAP1, although dispensable for nucleosome assembly in vitro, contributes to binding via structure-independent electrostatic interactions. Our results are consistent with recent mechanistic investigations of NAP1 and expand our understanding of the histone chaperone family of assembly factors.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Luger, K (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, 316 MRB, Ft Collins, CO 80523 USA.		Park, Young-Jun/AAF-6249-2021	Park, Young-Jun/0000-0003-2901-6949; SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331	NCI NIH HHS [R01 CA080002-05, CA80002, R01 CA080002] Funding Source: Medline; NIGMS NIH HHS [GM067777, R01 GM067777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Croston G.E., 1991, Protein Expression and Purification, V2, P162, DOI 10.1016/1046-5928(91)90066-R; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; DYER PN, 2003, IN PRESS METHODS ENZ; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Namboodiri VMH, 2003, STRUCTURE, V11, P175, DOI 10.1016/S0969-2126(03)00007-8; Nishiyama N, 2001, GENE, V280, P107, DOI 10.1016/S0378-1119(01)00778-8; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; Pilon J, 1997, PROTEIN EXPRES PURIF, V10, P132, DOI 10.1006/prep.1996.0716; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SMITH RM, 1989, J BIOL CHEM, V264, P10574; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Terrell AR, 2002, J BIOL CHEM, V277, P31038, DOI 10.1074/jbc.M204662200; Thiriet C, 2001, GENE DEV, V15, P2048, DOI 10.1101/gad.910201; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Widlund HR, 2000, BIOCHEMISTRY-US, V39, P3835, DOI 10.1021/bi991957l; Yoon HW, 1995, MOL GEN GENET, V249, P465, DOI 10.1007/BF00290572; Zheng CY, 2003, BIOPOLYMERS, V68, P539, DOI 10.1002/bip.10303; Zimmerman ZA, 2001, MOL BIOL CELL, V12, P201, DOI 10.1091/mbc.12.1.201	63	88	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44574	44583		10.1074/jbc.M305636200	http://dx.doi.org/10.1074/jbc.M305636200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12928440	hybrid			2022-12-27	WOS:000186306700087
J	Robas, N; Mead, E; Fidock, M				Robas, N; Mead, E; Fidock, M			MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FAMILY; NEUROPEPTIDE; GPCRS; DISCOVERY; LIGANDS; GPR7	MrgX2 is a recently identified orphan G-protein-coupled receptor whose ligand and physiological function were unknown. Here we describe cortistatin, a neuropeptide for which no specific receptor has been identified previously, as a high potency ligand at MrgX2. Cortistatin has several biological functions including roles in sleep regulation, locomotor activity, and cortical function. Using a "reverse pharmacology" approach, we have identified a number of additional cyclic peptide agonists for MrgX2, determined their rank order of potency, and demonstrated that this receptor has a pharmacological profile distinct from the other characterized members of the Mrg (Mas-related genes) family. In MrgX2-expressing cells, cortistatin-stimulated increases in intracellular Ca2+ but had no effect on basal or forskolin-stimulated cAMP levels, suggesting that this receptor is G(q)-coupled. Immunohistochemical and quantitative PCR studies show MrgX2 to have a limited expression profile, both peripheral and within the central nervous system, with highest levels in dorsal root ganglion.	Pfizer Global Res & Dev, Dept Target Genom, Sandwich CT13 N9J, Kent, England	Pfizer	Fidock, M (corresponding author), Pfizer Global Res & Dev, Dept Target Genom, Sandwich CT13 N9J, Kent, England.			Hargreaves, Emma/0000-0001-7887-2018				BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Bender E, 2002, P NATL ACAD SCI USA, V99, P8573, DOI 10.1073/pnas.122016499; Cassoni P, 2002, J ENDOCRINOL INVEST, V25, P362, DOI 10.1007/BF03344019; Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; Criado JR, 1999, J NEUROSCI RES, V56, P611, DOI 10.1002/(SICI)1097-4547(19990615)56:6<611::AID-JNR7>3.3.CO;2-7; deLecea L, 1997, GENOMICS, V42, P499, DOI 10.1006/geno.1997.4763; deLecea L, 1996, NATURE, V381, P242, DOI 10.1038/381242a0; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; Fukusumi S, 1997, BIOCHEM BIOPH RES CO, V232, P157, DOI 10.1006/bbrc.1997.6252; Han SK, 2002, P NATL ACAD SCI USA, V99, P14740, DOI 10.1073/pnas.192565799; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Kask A, 1998, ENDOCRINOLOGY, V139, P5006, DOI 10.1210/en.139.12.5006; Lee DK, 1999, MOL BRAIN RES, V71, P96, DOI 10.1016/S0169-328X(99)00171-0; Lembo PMC, 2002, NAT NEUROSCI, V5, P201, DOI 10.1038/nn815; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; PANGALOS MN, 2002, UNDERSTANDING G PROT, P176; Siehler S, 1999, N-S ARCH PHARMACOL, V360, P510, DOI 10.1007/s002109900143; Spier AD, 2000, BRAIN RES REV, V33, P228, DOI 10.1016/S0165-0173(00)00031-X; Tanaka H, 2003, P NATL ACAD SCI USA, V100, P6251, DOI 10.1073/pnas.0837789100; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238	21	183	206	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44400	44404		10.1074/jbc.M302456200	http://dx.doi.org/10.1074/jbc.M302456200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12915402	hybrid			2022-12-27	WOS:000186306700065
J	Head, JF; Mealy, TR; McCormack, FX; Seaton, BA				Head, JF; Mealy, TR; McCormack, FX; Seaton, BA			Crystal structure of trimeric carbohydrate recognition and neck domains of surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEINS; HELICAL COILED-COIL; PULMONARY SURFACTANT; INNATE IMMUNITY; PHOSPHOLIPID AGGREGATION; SPECIFICALLY BINDS; LECTIN DOMAINS; HUMAN LUNG; PHOSPHATIDYLINOSITOL; LIPOPOLYSACCHARIDE	Surfactant protein A (SP-A), one of four proteins associated with pulmonary surfactant, binds with high affinity to alveolar phospholipid membranes, positioning the protein at the first line of defense against inhaled pathogens. SP-A exhibits both calcium-dependent carbohydrate binding, a characteristic of the collectin family, and specific interactions with lipid membrane components. The crystal structure of the trimeric carbohydrate recognition domain and neck domain of SP-A was solved to 2.1-Angstrom resolution with multiwavelength anomalous dispersion phasing from samarium. Two metal-binding sites were identified, one in the highly conserved lectin site and the other 8.5 Angstrom away. The interdomain carbohydrate recognition domain-neck angle is significantly less in SP-A than in the homologous collectins, surfactant protein D, and mannose-binding protein. This conformational difference may endow the SP-A trimer with a more extensive hydrophobic surface capable of binding lipophilic membrane components. The appearance of this surface suggests a putative binding region for membrane-derived SP-A ligands such as phosphatidylcholine and lipid A, the endotoxic lipid component of bacterial lipopolysaccharide that mediates the potentially lethal effects of Gram-negative bacterial infection.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ Cincinnati, Dept Internal Med, Div Pulm Crit Care Med, Cincinnati, OH 45267 USA	Boston University; University System of Ohio; University of Cincinnati	Seaton, BA (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA.		McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464; Head, James/0000-0002-6226-4146; Seaton, Barbara/0000-0003-4654-7709				BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; CROUCH E, 1994, J BIOL CHEM, V269, P17311; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCTURE, V8, P585; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; JONES TA, 1992, O MANUAL; KALINA M, 1995, AM J PHYSIOL-LUNG C, V268, pL144, DOI 10.1152/ajplung.1995.268.1.L144; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; Kovacs H, 2002, J BIOMOL NMR, V24, P89, DOI 10.1023/A:1020980006628; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LeVine AM, 1997, J IMMUNOL, V158, P4336; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P8092, DOI 10.1021/bi970313f; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; Ochs M, 2002, AM J RESP CELL MOL, V26, P91, DOI 10.1165/ajrcmb.26.1.4570; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palaniyar N, 1998, J STRUCT BIOL, V122, P297, DOI 10.1006/jsbi.1998.4004; Palaniyar N, 2000, BIOCHEMISTRY-US, V39, P6310, DOI 10.1021/bi992793b; Pattanajitvilai S, 1998, J BIOL CHEM, V273, P5702, DOI 10.1074/jbc.273.10.5702; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; Radaev S, 2001, IMMUNITY, V15, P1039, DOI 10.1016/S1074-7613(01)00241-2; Sahly H, 2002, J IMMUNOL, V169, P3267, DOI 10.4049/jimmunol.169.6.3267; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; Veldhuizen RAW, 1996, BIOCHEM J, V313, P835, DOI 10.1042/bj3130835; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Zhang M, 1998, BIOCHEMISTRY-US, V37, P16481, DOI 10.1021/bi9817966; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	54	89	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43254	43260		10.1074/jbc.M305628200	http://dx.doi.org/10.1074/jbc.M305628200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12913002	hybrid			2022-12-27	WOS:000186157000067
J	Bist, P; Rao, DN				Bist, P; Rao, DN			Identification and mutational analysis of Mg2+ binding site in EcoP15I DNA methyltransferase - Involvement in target base eversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE2+-MEDIATED OXIDATIVE CLEAVAGE; RESTRICTION-ENDONUCLEASE; ACTIVE-SITE; MODIFICATION METHYLASE; RECOGNITION SEQUENCE; CATALYTIC PROPERTIES; ESCHERICHIA-COLI; ENZYMES; CALCIUM; PURIFICATION	EcoP15I DNA methyltransferase catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the N-6 position of the second adenine within the double-stranded DNA sequence 5'-CAGCAG-3'. To achieve catalysis, the enzyme requires a magnesium ion. Binding of magnesium to the enzyme induces significant conformational changes as monitored by circular dichroism spectroscopy. EcoP15I DNA methyltransferase was rapidly inactivated by micromolar concentrations of ferrous sulfate in the presence of ascorbate at pH 8.0. The inactivated enzyme was cleaved into two fragments with molecular masses of 36 and 35 kDa. Using this affinity cleavage assay, we have located the magnesium binding-like motif to amino acids 355 - 377 of EcoP15I DNA methyltransferase. Sequence homology comparisons between EcoP15I DNA methyltransferase and other restriction endonucleases allowed us to identify a PD(X)(n)(D/E) XK-like sequence as the putative magnesium ion binding site. Point mutations generated in this region were analyzed for their role in methyltransferase activity, metal coordination, and substrate binding. Although the mutant methyltransferases bind DNA and S-adenosyl-L-methionine as well as the wild-type enzyme does, they are inactive primarily because of their inability to flip the target base. Collectively, these data are consistent with the fact that acidic amino acid residues of the region 355 - 377 in EcoP15I DNA methyltransferase are important for the critical positioning of magnesium ions for catalysis. This is the first example of metal-dependent function of a DNA methyltransferase. These findings provide impetus for exploring the role(s) of metal ions in the structure and function of DNA methyltransferases.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rao, DN (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	dnrao@biochem.iisc.ernet.in	BIST, PRADEEP/AAG-7986-2019					AHAMD I, 1994, J MOL BIOL, V242, P378, DOI 10.1006/jmbi.1994.1588; Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; Ahmad I, 1996, J MOL BIOL, V259, P229, DOI 10.1006/jmbi.1996.0315; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujnicki JM, 2001, J MOL MICROB BIOTECH, V3, P69; Cao WG, 1998, J BIOL CHEM, V273, P33002, DOI 10.1074/jbc.273.49.33002; Cesnaviciene E, 2001, J MOL BIOL, V314, P205, DOI 10.1006/jmbi.2001.5049; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; COX JA, 1981, BIOCHEMISTRY-US, V20, P5430, DOI 10.1021/bi00522a012; DYDEN DTF, 1999, S ADENOSYLMETHIONINE, P283; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; HADI SM, 1983, J MOL BIOL, V165, P19, DOI 10.1016/S0022-2836(83)80240-X; Hlavaty JJ, 2000, BIOCHEMISTRY-US, V39, P3097, DOI 10.1021/bi992268c; HUMBELIN M, 1988, J MOL BIOL, V200, P23, DOI 10.1016/0022-2836(88)90330-0; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6043, DOI 10.1093/nar/20.22.6043; Jose TJ, 1999, J BIOL INORG CHEM, V4, P814, DOI 10.1007/s007750050355; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Kong HM, 1997, NUCLEIC ACIDS RES, V25, P3687, DOI 10.1093/nar/25.18.3687; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagunavicius A, 2003, J MOL BIOL, V326, P1051, DOI 10.1016/S0022-2836(03)00020-2; LAUTENBERGER JA, 1972, J BIOL CHEM, V247, P6176; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Marks P, 2003, NUCLEIC ACIDS RES, V31, P2803, DOI 10.1093/nar/gkg399; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Raghavendra NK, 2003, NUCLEIC ACIDS RES, V31, P1888, DOI 10.1093/nar/gkg275; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; Reddy YVR, 1998, J BIOL CHEM, V273, P23866, DOI 10.1074/jbc.273.37.23866; Reddy YVR, 2000, J MOL BIOL, V298, P597, DOI 10.1006/jmbi.2000.3673; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Soundararajan M, 2002, J BIOL CHEM, V277, P887, DOI 10.1074/jbc.M109100200; Tucholski J, 1998, GENE, V223, P293, DOI 10.1016/S0378-1119(98)00450-8; Vanamee ES, 2001, J MOL BIOL, V309, P69, DOI 10.1006/jmbi.2001.4635; Viadiu H, 1998, NAT STRUCT BIOL, V5, P910, DOI 10.1038/2352; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002	42	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41837	41848		10.1074/jbc.M307053200	http://dx.doi.org/10.1074/jbc.M307053200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917398	hybrid			2022-12-27	WOS:000185989500036
J	Brumaghim, JL; Li, Y; Henle, E; Linn, S				Brumaghim, JL; Li, Y; Henle, E; Linn, S			Effects of hydrogen peroxide upon nicotinamide nucleotide metabolism in Escherichia coli - Changes in enzyme levels and nicotinamide nucleotide pools and studies of the oxidation of NAD(P)H by Fe(III)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE-DEFICIENT ERYTHROCYTES; DNA-DAMAGE; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; DIPHOSPHOPYRIDINE NUCLEOTIDE; 3-DIMENSIONAL STRUCTURE; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; STRESS RESPONSES; GALLIUM COMPLEX; FENTON REACTION	DNA is damaged in vivo by the Fenton reaction mediated by Fe2+ and cellular reductants such as NADH, which reduce Fe3+ to Fe2+ and allow the recycling of iron. To study the response of Escherichia coli to such cycling, the activities of several enzymes involved in nicotinamide nucleotide metabolism were measured following an H2O2 challenge. NADPH-dependent peroxidase, NADH/NADP(+) transhydrogenase, and glucose-6-phosphate dehydrogenase were most strongly induced, increasing 2.5-3-fold. In addition, the cellular ratios of NADPH to NADH increased 6- or 92-fold 15 min after exposure to 0.5 or 5 mM H2O2, respectively. In vitro, NADH was oxidized by Fe3+ up to 16-fold faster than NADPH, despite their identical reduction potentials. To understand this rate difference, the interactions of Fe3+ and Ga3+ with NAD(P) H were examined by H-1, C-13, and P-31 NMR spectroscopy. Association with NADH occurred primarily with adenine at N7 and the amino group, but for NADPH, strong metal interactions also occurred at the 2'-phosphate group. Interaction of M3+ (Fe3+ or Ga3+) with the adenine ring would bring it into close proximity to the redox-active nicotinamide ring in the folded form of NAD( P) H, but interaction of M3+ with the 2'-phosphate group would avoid this close contact. In addition, as determined by absorbance spectroscopy, the energy of the charge-transfer species was significantly higher for the Fe3+.NADPH complex than for the Fe3+.NADH complex. We therefore suggest that upon exposure to H2O2 the NADH pool is depleted, and NADPH, which is less reactive with Fe3+, functions as the major nicotinamide nucleotide reductant.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Linn, S (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, Barker Hall, Berkeley, CA 94720 USA.	slinn@socrates.berkeley.edu		Brumaghim, Julia/0000-0002-9274-014X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019020] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES 07075, P30 ES 01986] Funding Source: Medline; NIGMS NIH HHS [R01 GM 19020] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON RA, 1988, BIOCHEMISTRY-US, V37, P15965; BAES CF, 1976, HYDROLYSIS CATIONS, P27; BARBIERI JT, 1989, J BACTERIOL, V171, P4362, DOI 10.1128/JB.171.8.4362-4369.1989; Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGG PD, 1972, BIOCHEM BIOPH RES CO, V47, P1248, DOI 10.1016/0006-291X(72)90969-2; CAVARI BZ, 1968, J BACTERIOL, V96, P751, DOI 10.1128/JB.96.3.751-759.1968; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; COVES J, 1991, BIOCHEM BIOPH RES CO, V178, P54, DOI 10.1016/0006-291X(91)91778-B; Cusumano M, 1997, J INORG BIOCHEM, V65, P137, DOI 10.1016/S0162-0134(96)00100-6; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; Du F, 2001, J INORG BIOCHEM, V83, P101, DOI 10.1016/S0162-0134(00)00185-9; ELMAHDAOUI L, 1995, J BIOMOL STRUCT DYN, V13, P69, DOI 10.1080/07391102.1995.10508822; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GERLI GC, 1982, SCAND J HAEMATOL, V29, P135; Goth L, 2000, LANCET, V356, P1820, DOI 10.1016/S0140-6736(00)03238-4; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; GUTMAN M, 1968, BIOCHEMISTRY-US, V7, P2778, DOI 10.1021/bi00848a012; GUTMAN M, 1973, BIOCHEMISTRY-US, V12, P2314, DOI 10.1021/bi00736a020; Gutteridge JMC, 2000, ANN NY ACAD SCI, V899, P136, DOI 10.1111/j.1749-6632.2000.tb06182.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HILLAR A, 1994, BIOCHEM J, V300, P531, DOI 10.1042/bj3000531; HUGICLEARY D, 1987, J AM CHEM SOC, V109, P4444, DOI 10.1021/ja00249a003; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; Kapinos LE, 2001, INORG CHEM, V40, P2500, DOI 10.1021/ic0009775; Kersting B, 1996, J AM CHEM SOC, V118, P5712, DOI 10.1021/ja953545f; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KLAIDMAN LK, 1995, ANAL BIOCHEM, V228, P312, DOI 10.1006/abio.1995.1356; Kong J, 2000, J COMPUT CHEM, V21, P1532, DOI 10.1002/1096-987X(200012)21:16<1532::AID-JCC10>3.0.CO;2-W; KORNBERG A, 1950, J BIOL CHEM, V182, P763; LEE CP, 1964, BIOCHIM BIOPHYS ACTA, V81, P187, DOI 10.1016/0926-6569(64)90353-0; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Liu GD, 2001, ANAL SCI, V17, P1031, DOI 10.2116/analsci.17.1031; Lloyd RV, 1997, FREE RADICAL BIO MED, V22, P885, DOI 10.1016/S0891-5849(96)00432-7; LUNDQUIST R, 1971, J BIOL CHEM, V246, P1107; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; MEZZETTI A, 1990, J MOL CELL CARDIOL, V22, P935, DOI 10.1016/0022-2828(90)91033-4; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; NORLAND S, 1987, MICROBIAL ECOL, V13, P95, DOI 10.1007/BF02011246; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; Obrey SJ, 2000, J CHEM CRYSTALLOGR, V30, P61, DOI 10.1023/A:1009502317489; OLIVERA BM, 1967, P NATL ACAD SCI USA, V57, P1700, DOI 10.1073/pnas.57.6.1700; OLSINKI R, 2002, FREE RADIC BIOL MED, V33, P192; OPPENHEIMER NJ, 1978, BIOCHEMISTRY-US, V17, P2613, DOI 10.1021/bi00606a024; OPPENHEIMER NJ, 1987, PYRIDINE NUCLEOTIDE, VA, P185; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PARK UE, 1989, J BACTERIOL, V171, P2173, DOI 10.1128/jb.171.4.2173-2180.1989; Peskin AV, 1996, FREE RADICAL BIO MED, V20, P313, DOI 10.1016/0891-5849(96)02053-9; PRIETOALAMO MJ, 1993, CARCINOGENESIS, V14, P237, DOI 10.1093/carcin/14.2.237; Qian SY, 1999, FREE RADICAL BIO MED, V26, P1447, DOI 10.1016/S0891-5849(99)00002-7; Rai P, 2001, J MOL BIOL, V312, P1089, DOI 10.1006/jmbi.2001.5010; RIZZO V, 1987, PYRIDINE NUCLEOTIDE, VA, P99; SCOTT MD, 1993, BIOCHIM BIOPHYS ACTA, V1181, P163, DOI 10.1016/0925-4439(93)90106-B; SCOTT MD, 1991, BLOOD, V77, P2059; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SINHA BK, 1989, CANCER RES, V49, P3844; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Sorokin VA, 1997, J MOL STRUCT, V408, P233, DOI 10.1016/S0022-2860(96)09724-4; STEPHAN H, 1993, LIEBIGS ANN CHEM, P43; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; STRYER L, 1988, BIOCHEMISTRY-US, P400; TYRRELL RM, 1989, PHOTOCHEM PHOTOBIOL, V49, P407, DOI 10.1111/j.1751-1097.1989.tb09187.x; Wasielewski E, 2002, BIOCHEMISTRY-US, V41, P12488, DOI 10.1021/bi025990a; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; ZEREZ CR, 1987, J BACTERIOL, V169, P184, DOI 10.1128/jb.169.1.184-188.1987; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	74	73	73	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42495	42504		10.1074/jbc.M306251200	http://dx.doi.org/10.1074/jbc.M306251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913009	hybrid			2022-12-27	WOS:000185989500114
J	Carrillo, JJ; Pediani, J; Milligan, G				Carrillo, JJ; Pediani, J; Milligan, G			Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; HORMONE RECEPTOR; SIGNAL-TRANSDUCTION; SPLICE VARIANT; CELL-SURFACE; HETERODIMERIZATION; OLIGOMERIZATION; ACTIVATION; FUSION; EXPRESSION	The histamine H1 receptor and the alpha(1b)-adrenoreceptor are G protein-coupled receptors that elevate intracellular [Ca2+] via activation of G(q)/G(11). Assessed by coimmunoprecipitation and time-resolved fluorescence resonance energy transfer they both exist as homodimers. The addition of the G protein G(11)alpha to the C terminus of these receptors did not prevent dimerization. Agonists produced a large stimulation of guanosine 5'-3-O-([S-35] thio) triphosphate ([S-35] GTPgammaS) binding to receptor-G protein fusions containing wild type forms of both polypeptides. For both receptors this was abolished by incorporation of G208AG(11)alpha into the fusions. Mutation of a highly conserved leucine in intracellular loop 2 of each receptor also eliminated agonist function but not binding. Co-expression of the two non-functional but complementary fusion constructs reconstituted agonist-mediated binding of [S-35] GTPgammaS in membranes of HEK293 cells and elevation of [Ca2+](i) in mouse embryo fibroblasts lacking both G(q) and G(11). Co-expression of the histamine H1 receptor- and the alpha(1b)-adrenoreceptor-G(11)alpha fusions allowed detection of functional hetero- dimeric complexes, whereas co-expression of histamine H1 receptor-G(11)alpha with increasing amounts of L151Dalpha(1b)-adrenoreceptor resulted in decreasing levels of histamine-stimulated [S-35] GTPgammaS binding. Co-expression of the alpha(1b)-adrenoreceptor with a fusion protein incorporating the N-terminal domain and transmembrane helix 1 of the alpha(1b)-adrenoreceptor and G(11)alpha did not result in agonist activation of the G protein but did indicate a role for transmembrane helix 1 in dimerization. These data demonstrate that dimers of these class A receptors function via trans-activation of associated G proteins.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011; Pediani, John/F-2708-2019	Milligan, Graeme/0000-0002-6946-3519; Pediani, John/0000-0001-6615-537X				AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; Carrillo JJ, 2002, J PHARMACOL EXP THER, V302, P1080, DOI 10.1124/jpet.102.035501; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Faber JE, 2001, J PHARMACOL EXP THER, V298, P441; Filizola M, 2002, BIOPOLYMERS, V66, P317, DOI 10.1002/bip.10311; Filizola M, 2002, PROTEIN ENG, V15, P881, DOI 10.1093/protein/15.11.881; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gouldson PR, 2001, PROTEIN ENG, V14, P759, DOI 10.1093/protein/14.10.759; Greasley PJ, 2001, J BIOL CHEM, V276, P46485, DOI 10.1074/jbc.M105791200; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Guzzi F, 2001, BIOCHEM J, V355, P323, DOI 10.1042/0264-6021:3550323; HERBERT TE, 1996, J BIOL CHEM, V271, P16384; Ji IH, 2002, MOL ENDOCRINOL, V16, P1299, DOI 10.1210/me.16.6.1299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; Lee CW, 2002, J BIOL CHEM, V277, P15795, DOI 10.1074/jbc.M111818200; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lee TW, 1999, BIOCHEMISTRY-US, V38, P13801, DOI 10.1021/bi9908282; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liu S, 2002, J BIOL CHEM, V277, P25707, DOI 10.1074/jbc.M201015200; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; Milligan G, 2002, METHOD ENZYMOL, V343, P260; Milligan G, 2001, J CELL SCI, V114, P1265; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; Molinari P, 2003, J BIOL CHEM, V278, P15778, DOI 10.1074/jbc.M300731200; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Salim K, 2002, J BIOL CHEM, V277, P15482, DOI 10.1074/jbc.M201539200; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; TAKAGISHI T, 1995, AM J PATHOL, V146, P981; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745	58	108	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42578	42587		10.1074/jbc.M306165200	http://dx.doi.org/10.1074/jbc.M306165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920117	hybrid			2022-12-27	WOS:000185989500123
J	de Bruin, A; Maiti, B; Jakoi, L; Timmers, C; Buerki, R; Leone, G				de Bruin, A; Maiti, B; Jakoi, L; Timmers, C; Buerki, R; Leone, G			Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; ARABIDOPSIS; PROTEINS; COMPLEX; GENE; RB	The mammalian E2F family of transcription factors plays a crucial role in the regulation of cellular proliferation, apoptosis, and differentiation. Consistent with its biological role in a number of important cellular processes, E2F regulates the expression of genes involved in cell cycle, DNA replication, DNA repair, and mitosis. It has proven difficult, however, to determine the specific roles played by the various known family members in these cellular processes. The work presented here now extends the complexity of this family even further by the identification of a novel E2F family member, which we now term E2F7. Like the expression of the known E2F activators, E2F1, E2F2, and E2F3, the expression of E2F7 is growth-regulated, at least in part, through E2F binding elements on its promoter, and its protein product is localized to the nucleus and associates with DNA E2F recognition sites with high affinity. A number of salient features, however, make this member unique among the E2F family. First, the E2F7 gene encodes a protein that possesses two distinct DNA-binding domains and that lacks a dimerization domain as well as a transcriptional activation and a retinoblastoma-binding domain. In contrast to the E2F activators, E2F7 can block the E2F-dependent activation of a subset of E2F target genes as well as mitigate cellular proliferation of mouse embryo fibroblasts. These findings identify E2F7 as a novel member of the mammalian E2F transcription factor family that has properties of a transcriptional repressor capable of negatively influencing cellular proliferation.	Ohio State Univ, Dept Mol Virol Immunol & Med genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Mol Genet, Columbus, OH 43210 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Genet, Durham, NC 27710 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Duke University; Howard Hughes Medical Institute	Leone, G (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med genet, Human Canc Genet Program, Columbus, OH 43210 USA.		de Bruin, Alain/AAL-9195-2020	de Bruin, Alain/0000-0001-8579-2649				Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Mariconti L, 2002, J BIOL CHEM, V277, P9911, DOI 10.1074/jbc.M110616200; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	18	161	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42041	42049		10.1074/jbc.M308105200	http://dx.doi.org/10.1074/jbc.M308105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12893818	hybrid			2022-12-27	WOS:000185989500060
J	Takahashi, T; Yamashita, H; Nagano, Y; Nakamura, T; Ohmori, H; Avraham, H; Avraham, S; Yasuda, M; Matsumoto, M				Takahashi, T; Yamashita, H; Nagano, Y; Nakamura, T; Ohmori, H; Avraham, H; Avraham, S; Yasuda, M; Matsumoto, M			Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-synuclein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PARKINSONS-DISEASE; BINDING-PROTEIN; LEWY BODIES; HUMAN BRAIN; SRC-FAMILY; PYK2; EXPRESSION; SYSTEM; STRESS	alpha-Synuclein is a presynaptic protein involved in the pathogenesis of several neurodegenerative diseases, such as Parkinson's disease. Pyk2/related adhesion focal tyrosine kinase (RAFTK) tyrosine kinase is an upstream regulator of Src family kinases in the central nervous system that is involved in alpha-synuclein phosphorylation. The present study reports the cloning and characterization of a novel adaptor protein, Pyk2/RAFTK-associated protein (PRAP), that specifically binds to Pyk2/RAFTK and inhibits alpha-synuclein tyrosine phosphorylation. PRAP contains a coiled-coil domain, a pleckstrin homology domain, and a SH3 domain; the SH3 domain binds to the proline-rich domain of Pyk2/RAFTK. PRAP was observed to be present throughout the brain, including substantia nigra dopaminergic neurons, in which it localized to the cytoplasm. PRAP was found to function as a substrate for Src family kinases, such as c-Src or Fyn, but not for Pyk2/RAFTK. Hyperosmotic stress induced phosphorylation of tyrosine 125 of alpha-synuclein via Pyk2/RAFTK, which acted through Src family kinases. Such phosphorylation was inhibited by PRAP expression, suggesting that PRAP negatively regulates alpha-synuclein phosphorylation following cell stress. In conclusion, PRAP functions as a downstream target for Pyk2/RAFTK and plays a role in alpha-synuclein phosphorylation.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, Hiroshima 7348551, Japan; Hiroshima Int Univ, Fac Hlth Sci, Dept Clin Engn, Hiroshima 7290695, Japan; Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Hiroshima University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Yamashita, H (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			Avraham, Hava/0000-0002-7545-3640; NAGANO, YOSHITO/0000-0002-7974-4824				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Andreev J, 1999, MOL CELL BIOL, V19, P2338; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Kouroku Y, 1998, BIOCHEM BIOPH RES CO, V252, P738, DOI 10.1006/bbrc.1998.9637; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Menegon A, 1999, EUR J NEUROSCI, V11, P3777, DOI 10.1046/j.1460-9568.1999.00798.x; Nagano Y, 2001, NEUROSCI LETT, V316, P103, DOI 10.1016/S0304-3940(01)02330-8; Nakamura T, 2002, FEBS LETT, V521, P190, DOI 10.1016/S0014-5793(02)02861-2; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Ohmori H, 1999, J NEUROCHEM, V72, P1497, DOI 10.1046/j.1471-4159.1999.721497.x; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Verney C, 2001, J COMP NEUROL, V429, P45, DOI 10.1002/1096-9861(20000101)429:1<45::AID-CNE4>3.0.CO;2-J; Yamashita H, 1999, J BIOL CHEM, V274, P29897, DOI 10.1074/jbc.274.42.29897; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	35	25	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42225	42233		10.1074/jbc.M213217200	http://dx.doi.org/10.1074/jbc.M213217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12893833	hybrid			2022-12-27	WOS:000185989500081
J	Yamaguchi, J; Gamble, MV; Conlon, D; Liang, JS; Ginsberg, HN				Yamaguchi, J; Gamble, MV; Conlon, D; Liang, JS; Ginsberg, HN			The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; APOLIPOPROTEIN-B; INTRACELLULAR DEGRADATION; BREFELDIN-A; APO-B; SECRETION; LIVER; APOPROTEIN; B100; TRIACYLGLYCEROL	The site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identified definitively. We employed several strategies to address this question. First, McA RH7777 cells were pulse-labeled for 20 min with [S-35]methionine/cysteine and chased for 1 h (Chase I) to allow study of newly synthesized apoB100 LDL/HDL remaining in the endoplasmic reticulum (ER). After Chase I, cells were incubated for another hour (C2) with/without brefeldin A (BFA) and nocodazole (Noc) (to block ER to Golgi trafficking) and with/without oleic acid (OA). OA treatment alone during C2 increased VLDL secretion. This was prevented by the addition of BFA/Noc in C2. When C2 media were replaced by control media for another 1-h chase (C3), VLDL formed during OA treatment in C2 were secreted into C3 medium. Thus, OA-induced conversion of apoB100 LDL/HDL to VLDL during C2 occurred in the ER. Next, newly synthesized apoB100 lipoproteins were trapped in the Golgi by treatment with Noc and monensin during Chase I (C1), and C2 was carried out in the presence of BFA/Noc with/without OA and without monensin. Under these conditions, OA treatment during C2 did not stimulate VLDL secretion. The same pulse/chase protocols were followed by iodixanol subcellular fractionation, extraction of lipoproteins from ER and Golgi, and sucrose gradient separation of extracted lipoproteins. Cells treated with BFA/Noc and OA in C2 had VLDL in the ER. In the absence of OA, only LDL/HDL were present in the ER. The density of Golgi lipoproteins in these cells was not affected by OA. Similar results were obtained when ER were immuno-isolated with anti-calnexin antibodies. In conclusion, apoB100 bulk lipidation, resulting in conversion of LDL/HDL to VLDL, can occur in the ER, but not in the Golgi, in McA RH7777 cells.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, PH 10-305,630 W 168th St, New York, NY 10032 USA.	hng1@columbia.edu	Adiels, Martin/C-9278-2011	Conlon, Donna/0000-0002-9471-3081	NHLBI NIH HHS [HL 55368] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1994, J BIOL CHEM, V269, P25879; Cartwright IJ, 2001, J BIOL CHEM, V276, P48048, DOI 10.1074/jbc.M104229200; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GLAUMANN H, 1975, J CELL BIOL, V64, P356, DOI 10.1083/jcb.64.2.356; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; SWIFT LL, 1995, J LIPID RES, V36, P395; Swift LL, 2001, J LIPID RES, V42, P218; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	31	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42643	42651		10.1074/jbc.M306920200	http://dx.doi.org/10.1074/jbc.M306920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917397	hybrid			2022-12-27	WOS:000185989500130
J	Yokota, S; Yokosawa, N; Kubota, T; Okabayashi, T; Arata, S; Fujii, N				Yokota, S; Yokosawa, N; Kubota, T; Okabayashi, T; Arata, S; Fujii, N			Suppression of thermotolerance in mumps virus-infected cells is caused by lack of HSP27 induction contributed by STAT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; V-PROTEIN; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; ALPHA-INTERFERON; CYTOSOLIC CHAPERONIN; ANTIVIRAL ACTIONS; GAMMA-INTERFERON; RECEPTOR COMPLEX; C-PROTEINS	Viral infection modulates the regulation of apoptosis in host cells. Here, we report a novel mechanism by which human cells infected with mumps virus become susceptible to apoptosis caused by extracellular stresses. Mumps virus stimulates proteasome-dependent degradation of STAT-1 by action of viral accessory protein V, resulting in a severe decrease in STAT-1 protein in infected cells. We exposed mumps virus-infected and uninfected cells to heat and chemical stress. The infected cells failed to acquire resistance to apoptotic stimuli (thermotolerance) after exposure to these mild stresses. The induction of HSP27 by stress exposure was dramatically suppressed in the infected cells, but HSP70 induction was not affected. STAT-1 was required for transcriptional activation of the HSP27 gene, but not for the HSP70 gene, and cDNA transfection of STAT-1 in mumps virus-infected cells restored thermotolerance. Phosphorylated heat shock factor-1 (HSF-1) and STAT-1 phosphorylated on neither tyrosine nor serine residues were co-transported to the nucleus in response to stress. Furthermore, overexpression of unphosphorylatable mutants of STAT-1 also restored thermotolerance in mumps virus-infected cells. These lines of evidence indicate that the induction of HSP27 by stress requires STAT-1 in addition to the activated HSF-1. Furthermore, STAT-1 required for the induction of HSP27 worked independent to its phosphorylation. Thus, HSP27-dependent thermotolerance is suppressed by mumps virus infection through the destruction of STAT-1. The lack of thermotolerance should allow the infected cells to be eliminated by apoptosis and might be a host defense against viral infection.	Sapporo Med Univ, Sch Med, Dept Microbiol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Showa Univ, Ctr Biotechnol, Tokyo 1428555, Japan	Sapporo Medical University; Showa University	Fujii, N (corresponding author), Sapporo Med Univ, Sch Med, Dept Microbiol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.		Yokota, Shin-ichi/K-8139-2019	Yokota, Shin-ichi/0000-0002-0831-3429				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Alcami A, 2000, IMMUNOL TODAY, V21, P447, DOI 10.1016/S0167-5699(00)01699-6; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Didcock L, 1999, J VIROL, V73, P9928, DOI 10.1128/JVI.73.12.9928-9933.1999; FUJII N, 1988, J GEN VIROL, V69, P2085, DOI 10.1099/0022-1317-69-8-2085; FUJII N, 1990, J GEN VIROL, V71, P3071, DOI 10.1099/0022-1317-71-12-3071; Fujii N, 1994, Prog Mol Subcell Biol, V14, P150; Fujimoto I, 2000, J VIROL, V74, P3399, DOI 10.1128/JVI.74.7.3399-3403.2000; GAESTEL M, 1993, GENE, V128, P279, DOI 10.1016/0378-1119(93)90575-N; Gao J, 2001, J VIROL, V75, P1124, DOI 10.1128/JVI.75.3.1124-1131.2001; Garcin D, 1999, J VIROL, V73, P6559, DOI 10.1128/JVI.73.8.6559-6565.1999; GERNER EW, 1975, NATURE, V256, P500, DOI 10.1038/256500a0; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Gotoh B, 2001, MICROBIOL IMMUNOL, V45, P787, DOI 10.1111/j.1348-0421.2001.tb01315.x; Hariya Y, 1999, J INTERF CYTOK RES, V19, P479, DOI 10.1089/107999099313929; Hariya Y, 2000, MICROBIOL IMMUNOL, V44, P537, DOI 10.1111/j.1348-0421.2000.tb02531.x; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENLE KJ, 1978, CANCER RES, V38, P1843; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kato A, 2001, J VIROL, V75, P3802, DOI 10.1128/JVI.75.8.3802-3810.2001; Komatsu T, 2000, J VIROL, V74, P2477, DOI 10.1128/JVI.74.5.2477-2480.2000; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kubota T, 2002, J VIROL, V76, P12676, DOI 10.1128/JVI.76.24.12676-12682.2002; Kubota T, 2001, BIOCHEM BIOPH RES CO, V283, P255, DOI 10.1006/bbrc.2001.4764; LANDRY J, 1982, CANCER RES, V42, P2457; Latchman David S, 2002, Prog Mol Subcell Biol, V28, P253; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nishio M, 2001, J VIROL, V75, P9165, DOI 10.1128/JVI.75.19.9165-9176.2001; Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1379/1466-1268(1998)003<0228:HSPROS>2.3.CO;2; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Stephanou A, 1999, HANDB EXP PHARM, V136, P153; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yokosawa N, 2002, J VIROL, V76, P12683, DOI 10.1128/JVI.76.24.12683-12690.2002; Yokosawa N, 1998, ARCH VIROL, V143, P1985, DOI 10.1007/s007050050434; Yokota S, 2000, EUR J BIOCHEM, V267, P1658, DOI 10.1046/j.1432-1327.2000.01157.x; Yokota S, 2003, VIROLOGY, V306, P135, DOI 10.1016/S0042-6822(02)00026-0; Yokota S, 2001, VIROLOGY, V286, P119, DOI 10.1006/viro.2001.0941; Yokota S, 1999, J BIOL CHEM, V274, P37070, DOI 10.1074/jbc.274.52.37070; Yonekura N, 2003, CELL DEATH DIFFER, V10, P313, DOI 10.1038/sj.cdd.4401169; Yonekura Noriyuki, 2000, Tumor Research, V35, P25	60	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41654	41660		10.1074/jbc.M305701200	http://dx.doi.org/10.1074/jbc.M305701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917439	hybrid			2022-12-27	WOS:000185989500014
J	Busse, M; Kusche-Gullberg, M				Busse, M; Kusche-Gullberg, M			In vitro polymerization of heparan sulfate backbone by the EXT proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; D-GLUCOSAMINYLTRANSFERASE REACTIONS; TUMOR SUPPRESSORS EXT1; GENE FAMILY; GOLGI-APPARATUS; BIOSYNTHESIS; GLYCOSAMINOGLYCANS; GLUCURONOSYLTRANSFERASE; IDENTIFICATION; PROTEOGLYCANS	Multiple exosotoses is a dominantly inherited bone disorder caused by defects in EXT1 and EXT2, genes encoding glycosyltransferases involved in heparan sulfate chain elongation. Heparan sulfate polymerization occurs by the alternating addition of glucuronic acid and N-acetylglucosamine units to the nonreducing end of the polysaccharide. EXT1 and EXT2 are suggested to be dual glucuronyl/N-acetylglucosaminyltransferases, and a heterooligomeric complex of EXT1 and EXT2 (EXT1/2) is considered to be the biological functional polymerization unit. Here, we have investigated the in vitro polymerization capacities of recombinant soluble EXT1, EXT2, and EXT1/2 complex on exogenous oligosaccharide acceptors derived from Escherichia coli K5 capsular polysaccharide. Incubations of recombinant EXT1 or EXT1/2 complex with H-3-labeled oligosaccharide acceptors and the appropriate nucleotide sugars resulted in conversion of the acceptors to higher molecular weight compounds but with different efficacies for EXT1 and EXT1/2. In contrast, incubations with recombinant EXT2 resulted in the addition of a single glucuronic acid but no further polymerization. These results indicate that EXT1 alone and the EXT1/2 heterocomplex can act as heparan sulfate polymerases in vitro without the addition of additional auxiliary proteins.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Uppsala University	Kusche-Gullberg, M (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, Box 582, S-75123 Uppsala, Sweden.	Marion.Kusche@imbim.uu.se	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V268, P860, DOI 10.1006/bbrc.2000.2219; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; LIND T, 1993, J BIOL CHEM, V268, P20705; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Wei G, 2000, J BIOL CHEM, V275, P27733; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; Wuyts W, 1996, HUM MOL GENET, V5, P1547, DOI 10.1093/hmg/5.10.1547; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	30	52	53	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41333	41337		10.1074/jbc.M308314200	http://dx.doi.org/10.1074/jbc.M308314200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907669	hybrid			2022-12-27	WOS:000185847200113
J	Pawar, A; Botolin, D; Mangelsdorf, DJ; Jump, DB				Pawar, A; Botolin, D; Mangelsdorf, DJ; Jump, DB			The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; S14 GENE; CHOLESTEROL 7-ALPHA-HYDROXYLASE; TRANSCRIPTION FACTOR; NUCLEAR RECEPTORS; RESPONSE ELEMENT; PPAR-ALPHA; RAT-LIVER; SUPPRESSION; METABOLISM	Liver X receptors (LXR) alpha and beta play an important role in regulating the expression of genes involved in hepatic bile and fatty acid synthesis, glucose metabolism, as well as sterol efflux. Studies with human embryonic kidney 293 cells indicate that unsaturated fatty acids interfere with oxysterols binding to LXR and antagonize oxysterol-induced LXRalpha activity. In this report, we evaluated the effects of unsaturated fatty acids on LXR-regulated hepatic gene expression. The LXR agonist, T1317, induced mRNAs encoding sterol regulatory element-binding protein 1c (SREBP-1c) and two SREBP-1c-regulated lipogenic genes, e. g. fatty-acid synthase and the S14 protein in primary hepatocytes. Treatment of hepatocytes with eicosapentaenoic acid (20:5n-3) suppressed these mRNAs in the absence and presence of T1317. The cis-regulatory elements targeted by T1317 were not required for fatty-acid suppression of FAS or S14 promoter activity. In contrast to SREBP-1-regulated lipogenic genes, 20: 5n-3 had no effect on the T1317 induction of ABCG5 or ABCG8 in the rat hepatoma cell line, FTO-2B. These two genes require LXR but not SREBP-1c for their expression. Feeding rats a diet supplemented with fish oil suppressed hepatic SREBP-1c-regulated genes and induced PPARalpha-regulated genes but had no effect on the LXR-regulated transcripts, CYP7A1, ABCG5, or ABCG8. Transfection studies, using either full-length hLXRalpha or a chimera containing only the LXRalpha ligand binding domain, indicate that a wide array of unsaturated fatty acids had little effect on LXRalpha activity in primary hepatocytes or FTO-2B. These studies suggest that LXRalpha is not a target for unsaturated fatty acid regulation in primary rat hepatocytes or in liver. Thus, oxysterol/LXR-mediated regulation of transcripts involved in bile acid synthesis or sterol efflux appear insensitive to dietary unsaturated fatty acids. The unsaturated fatty acid suppression of SREBP-1 and its targeted lipogenic genes is independent of LXRalpha.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Mol Biol, E Lansing, MI 48824 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	Michigan State University; Michigan State University; Michigan State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 3165 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.		Pawar, Anjali/AAT-8945-2020	Pawar, Anjali/0000-0002-2133-8663; Mangelsdorf, David/0000-0002-4355-0796	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43220, R01 DK043220] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Botolin D, 2003, J BIOL CHEM, V278, P6959, DOI 10.1074/jbc.M212846200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chan DC, 2002, EUR J CLIN INVEST, V32, P429, DOI 10.1046/j.1365-2362.2002.01001.x; Cheema SK, 1997, J LIPID RES, V38, P315; Cheema SK, 1999, J NUTR, V129, P1718, DOI 10.1093/jn/129.9.1718; Cheema SK, 2000, J BIOL CHEM, V275, P12530, DOI 10.1074/jbc.275.17.12530; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Jump DB, 2001, J BIOL CHEM, V276, P34419, DOI 10.1074/jbc.M105471200; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Laffitte BA, 2003, MOL CELL BIOL, V23, P2182, DOI 10.1128/MCB.23.6.2182-2191.2003; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Mater MK, 1999, J LIPID RES, V40, P1045; Nordoy A, 2001, NUTR METAB CARDIOVAS, V11, P7; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pan DA, 2000, J LIPID RES, V41, P742; Pawar A, 2003, J BIOL CHEM, V278, P35931, DOI 10.1074/jbc.M306238200; Pawar A, 2002, J BIOL CHEM, V277, P39243, DOI 10.1074/jbc.M206170200; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Tobin KAR, 2002, J BIOL CHEM, V277, P10691, DOI 10.1074/jbc.M109771200; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200; Zvibel I, 1998, DIFFERENTIATION, V63, P215, DOI 10.1111/j.1432-0436.1998.00215.x	45	120	124	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40736	40743		10.1074/jbc.M307973200	http://dx.doi.org/10.1074/jbc.M307973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917410	hybrid			2022-12-27	WOS:000185847200040
J	Phillips, RM; Six, DA; Dennis, EA; Ghosh, P				Phillips, RM; Six, DA; Dennis, EA; Ghosh, P			In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A(2) inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; EXOENZYME-S; CYSTIC-FIBROSIS; ARACHIDONIC-ACID; EPITHELIAL-CELLS; SECRETION; PNEUMONIA; MACROPHAGES; EXPRESSION; CLONING	A number of clinical isolates of Pseudomonas aeruginosa are cytotoxic to mammalian cells due to the action of the 74-kDa protein ExoU, which is secreted into host cells by the type III secretion system and whose function is unknown. Here we report that the swift and profound cytotoxicity induced by purified ExoU or by an ExoU-expressing strain of P. aeruginosa is blocked by various inhibitors of cytosolic (cPLA(2)) and Ca2+-independent (iPLA(2)) phospholipase A(2) enzymes. In contrast, no cytoprotection is offered by inhibitors of secreted phospholipase A(2) enzymes or by a number of inhibitors of signal transduction pathways. This suggests that phospholipase A(2) inhibitors may represent a novel mode of treatment for acute P. aeruginosa infections. We find that 300 - 600 molecules of ExoU/cell are required to achieve half-maximal cell killing and that ExoU localizes to the host cell plasma membrane in punctate fashion. We also show that ExoU interacts in vitro with an inhibitor of cPLA(2) and iPLA(2) enzymes and contains a putative serine-aspartate catalytic dyad homologous to those found in cPLA(2) and iPLA(2) enzymes. Mutation of either the serine or the aspartate renders ExoU non-cytotoxic. Although no phospholipase or esterase activity is detected in vitro, significant phospholipase activity is detected in vivo, suggesting that ExoU requires one or more host cell factors for activation as a membrane-lytic and cytotoxic phospholipase.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, P (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0314,9500 Gilman Dr, La Jolla, CA 92093 USA.		Dennis, Edward A./M-5554-2019; Six, David A/D-6523-2011	Dennis, Edward A./0000-0003-3738-3140; Six, David A/0000-0002-9013-1711; DuBois, Rebecca/0000-0003-4185-5673	NCI NIH HHS [T32 CA09523] Funding Source: Medline; NIDDK NIH HHS [DK07202] Funding Source: Medline; NIGMS NIH HHS [GM20501, GM64611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afessa B, 2000, CHEST, V117, P1017, DOI 10.1378/chest.117.4.1017; Allewelt M, 2000, INFECT IMMUN, V68, P3998, DOI 10.1128/IAI.68.7.3998-4004.2000; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Brennan AL, 2002, CURR OPIN INFECT DIS, V15, P175, DOI 10.1097/00001432-200204000-00013; CLARKE MSF, 1992, J CELL SCI, V102, P533; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Evans DJ, 1998, INFECT IMMUN, V66, P1453, DOI 10.1128/IAI.66.4.1453-1459.1998; Feltman H, 2001, MICROBIOL-SGM, V147, P2659, DOI 10.1099/00221287-147-10-2659; Finck-Barbancon V, 1998, J BACTERIOL, V180, P6224; Finck-Barbancon V, 2001, J BACTERIOL, V183, P4330, DOI 10.1128/JB.183.14.4330-4344.2001; FinckBarbancon V, 1997, MOL MICROBIOL, V25, P547, DOI 10.1046/j.1365-2958.1997.4891851.x; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Garrity-Ryan L, 2000, INFECT IMMUN, V68, P7100, DOI 10.1128/IAI.68.12.7100-7113.2000; Geiser TK, 2001, CELL MICROBIOL, V3, P223, DOI 10.1046/j.1462-5822.2001.00107.x; Girod A, 2002, J GEN VIROL, V83, P973, DOI 10.1099/0022-1317-83-5-973; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Hauser AR, 1999, INFECT IMMUN, V67, P5530, DOI 10.1128/IAI.67.10.5530-5537.1999; Hauser AR, 1998, MOL MICROBIOL, V27, P807, DOI 10.1046/j.1365-2958.1998.00727.x; Hauser AR, 2002, CRIT CARE MED, V30, P521, DOI 10.1097/00003246-200203000-00005; Hirschberg HJHB, 2001, EUR J BIOCHEM, V268, P5037, DOI 10.1046/j.0014-2956.2001.02411.x; Kazmierczak BI, 2002, INFECT IMMUN, V70, P2198, DOI 10.1128/IAI.70.4.2198-2205.2002; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; Kokotos G, 2002, J MED CHEM, V45, P2891, DOI 10.1021/jm025538p; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; Kurahashi K, 1999, J CLIN INVEST, V104, P743, DOI 10.1172/JCI7124; Leidich SD, 1998, J BIOL CHEM, V273, P26078, DOI 10.1074/jbc.273.40.26078; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; Moss J, 2001, INFECT IMMUN, V69, P1185, DOI 10.1128/IAI.69.2.1185-1188.2001; OJCIUS DM, 1995, INFECT IMMUN, V63, P3069, DOI 10.1128/IAI.63.8.3069-3072.1995; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Roy-Burman A, 2001, J INFECT DIS, V183, P1767, DOI 10.1086/320737; Sawa T, 1999, NAT MED, V5, P392, DOI 10.1038/7391; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tevzadze GG, 2000, CHROMOSOMA, V109, P72, DOI 10.1007/s004120050414; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; WANG LX, 1992, J BIOL CHEM, V267, P18983; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053; Zadori Z, 2001, DEV CELL, V1, P291, DOI 10.1016/S1534-5807(01)00031-4	49	135	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41326	41332		10.1074/jbc.M302472200	http://dx.doi.org/10.1074/jbc.M302472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12915403	hybrid, Green Published			2022-12-27	WOS:000185847200112
J	Sokolowski, F; Modler, AJ; Masuch, R; Zirwer, D; Baier, M; Lutsch, G; Moss, DA; Gast, K; Naumann, D				Sokolowski, F; Modler, AJ; Masuch, R; Zirwer, D; Baier, M; Lutsch, G; Moss, DA; Gast, K; Naumann, D			Formation of critical oligomers is a key event during conformational transition of recombinant Syrian hamster prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; BETA-SHEETS; SCRAPIE; CONVERSION; AGGREGATION; MECHANISM; RIBONUCLEASE-T1; DIFFERENTIATION	We have investigated the conformational transition and aggregation process of recombinant Syrian hamster prion protein (SHaPrP(90-232)) by Fourier transform infrared spectroscopy, circular dichroism spectroscopy, light scattering, and electron microscopy under equilibrium and kinetic conditions. SHaPrP(90-232) showed an infrared absorbance spectrum typical of proteins with a predominant alpha-helical structure both at pH 7.0 and at pH 4.2 in the absence of guanidine hydrochloride. At pH 4.2 and destabilizing conditions (0.3 - 2 M guanidine hydrochloride), the secondary structure of SHaPrP(90-232) was transformed to a strongly hydrogen- bonded, most probably intermolecularly arranged antiparallel beta-sheet structure as indicated by dominant amide I band components at 1620 and 1691 cm(-1). Kinetic analysis of the transition process showed that the decrease in alpha-helical structures and the increase in beta-sheet structures occurred concomitantly according to a bimolecular reaction. However, the concentration dependence of the corresponding rate constant pointed to an apparent third order reaction. No beta-sheet structure was formed within the dead time ( 190 ms) of the infrared experiments. Light scattering measurements revealed that the structural transition of SHaPrP(90-232) was accompanied by formation of oligomers, whose size was linearly dependent on protein concentration. Extrapolation to zero protein concentration yielded octamers as the smallest oligomers, which are considered as "critical oligomers." The small oligomers showed spherical and annular shapes in electron micrographs. Critical oligomers seem to play a key role during the transition and aggregation process of SHaPrP(90-232). A new model for the structural transition and aggregation process of the prion protein is described.	Robert Koch Inst, D-13353 Berlin, Germany; Free Univ Berlin, Fachbereich Biol, D-14195 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; Forschungszentrum Karlsruhe, D-76344 Eggenstein Leopoldshafen, Germany	Robert Koch Institute; Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Helmholtz Association; Karlsruhe Institute of Technology	Sokolowski, F (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.							Alvarez-Martinez MT, 2003, BBA-PROTEINS PROTEOM, V1645, P228, DOI 10.1016/S1570-9639(02)00536-8; Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chitnumsub P, 1999, BIOORGAN MED CHEM, V7, P39, DOI 10.1016/S0968-0896(98)00222-3; FABIAN H, 2002, HDB VIBRATIONAL SPEC, V5, P3399; Gast K, 1997, EUR BIOPHYS J BIOPHY, V25, P211, DOI 10.1007/s002490050033; Glockshuber R, 2001, ADV PROTEIN CHEM, V57, P83; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Kubelka J, 2001, J AM CHEM SOC, V123, P12048, DOI 10.1021/ja0116627; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lu BY, 2002, BIOCHEM J, V364, P81, DOI 10.1042/bj3640081; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; MASUCH R, 2003, IN PRESS APPL SPECTR, V57; MAUSER H, 1974, FORMALE KINETIK; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Moritz R, 2002, BIOPOLYMERS, V67, P145, DOI 10.1002/bip.10083; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Reinstadler D, 1999, PROTEINS, V34, P303, DOI 10.1002/(SICI)1097-0134(19990215)34:3<303::AID-PROT4>3.0.CO;2-H; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Vanik DL, 2002, J BIOL CHEM, V277, P49065, DOI 10.1074/jbc.M207511200; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Wisniewski T, 1998, AMYLOID, V5, P212; Wuthrich K, 2001, ADV PROTEIN CHEM, V57, P55; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Yamada N, 1998, J AM CHEM SOC, V120, P12192, DOI 10.1021/ja981363q; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	55	119	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40481	40492		10.1074/jbc.M304391200	http://dx.doi.org/10.1074/jbc.M304391200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917432	hybrid			2022-12-27	WOS:000185847200009
J	Hol, EM; van Dijk, R; Gerez, L; Sluijs, JA; Hobo, B; Tonk, MT; de Haan, A; Kamphorst, W; Fischer, DF; Benne, R; van Leeuwen, FW				Hol, EM; van Dijk, R; Gerez, L; Sluijs, JA; Hobo, B; Tonk, MT; de Haan, A; Kamphorst, W; Fischer, DF; Benne, R; van Leeuwen, FW			Frameshifted beta-amyloid precursor protein (APP(+1)) is a secretory protein, and the level of APP(+1) in cerebrospinal fluid is linked to Alzheimer pathology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MILD COGNITIVE IMPAIRMENT; BIOCHEMICAL MARKERS; DISEASE PATIENTS; ALPHA-SECRETASE; HUMAN-BRAIN; TAU; DEMENTIA; CULTURES; CELLS	Molecular misreading of the beta-amyloid precursor protein (APP) gene generates mRNA with dinucleotide deletions in GAGAG motifs. The resulting truncated and partly frameshifted APP protein ( APP(+1)) accumulates in the dystrophic neurites and the neurofibrillary tangles in the cortex and hippocampus of Alzheimer patients. In contrast, we show here that neuronal cells transfected with APP(+1) proficiently secreted APP(+1). Because various secretory APP isoforms are present in cerebrospinal fluid (CSF), this study aimed to determine whether APP(+1) is also a secretory protein that can be detected in CSF. Post-mortem CSF was obtained at autopsy from 50 non-demented controls and 122 Alzheimer patients; all subjects were staged for neuropathology (Braak score). Unexpectedly, we found that the APP(+1) level in the CSF of non-demented controls was much higher (1.75 ng/ml) than in the CSF of Alzheimer patients (0.51 ng/ml) ( p < 0.001), and the level of APP(+1) in CSF was inversely correlated with the severity of the neuropathology. Moreover the earliest neuropathological changes are already reflected in a significant decrease of the APP(+1) level in CSF. These data show that APP(+1) is normally secreted by neurons, preventing intraneuronal accumulation of APP(+1) in brains of nondemented controls without neurofibrillary pathology.	Netherlands Inst Brain Res, Grad Sch Neurosci, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Pathol, NL-1081 HV Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Hol, EM (corresponding author), Netherlands Inst Brain Res, Grad Sch Neurosci, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.		Hol, Elly/J-2025-2019; Hol, Elly M/F-1891-2013	Hol, Elly/0000-0001-5604-2603; Hol, Elly M/0000-0001-5604-2603; Fischer, David/0000-0002-6690-0197				Alafuzoff I, 1993, J Neural Transm Suppl, V39, P235; Andreasen N, 2002, PEPTIDES, V23, P1205, DOI 10.1016/S0196-9781(02)00056-6; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conover WJ, 1980, PRACTICAL NONPARAMET, P229; Cummings JL, 2002, JAMA-J AM MED ASSOC, V287, P2335, DOI 10.1001/jama.287.18.2335; de Leon MJ, 2002, NEUROSCI LETT, V333, P183, DOI 10.1016/S0304-3940(02)01038-8; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hersberger M, 2001, J NEUROCHEM, V76, P1308, DOI 10.1046/j.1471-4159.2001.00122.x; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Hol EM, 1998, PROG BRAIN RES, V117, P379; Hook VYH, 2002, J NEUROCHEM, V81, P237; Khachaturian ZS, 2002, NEUROBIOL AGING, V23, P509, DOI 10.1016/S0197-4580(01)00350-5; Klunk WE, 2002, NEUROBIOL AGING, V23, P517, DOI 10.1016/S0197-4580(01)00349-9; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; MAY C, 1990, NEUROLOGY, V40, P500, DOI 10.1212/WNL.40.3_Part_1.500; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; Papassotiropoulos A, 2002, NEUROBIOL AGING, V23, P513, DOI 10.1016/S0197-4580(01)00348-7; Peraus GC, 1997, J NEUROSCI, V17, P7714; RAVID R, 1992, PROG BRAIN RES, V93, P83; Riemenschneider M, 2002, ARCH NEUROL-CHICAGO, V59, P1729, DOI 10.1001/archneur.59.11.1729; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sennvik K, 2000, NEUROSCI LETT, V278, P169, DOI 10.1016/S0304-3940(99)00929-5; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Sjogren M, 2001, J NEUROL NEUROSUR PS, V70, P624, DOI 10.1136/jnnp.70.5.624; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Storey E, 1999, EUR J NEUROSCI, V11, P1779, DOI 10.1046/j.1460-9568.1999.00599.x; TANNA NK, 1991, RADIOLOGY, V178, P123, DOI 10.1148/radiology.178.1.1984290; Teunissen CE, 2002, NEUROBIOL AGING, V23, P485, DOI 10.1016/S0197-4580(01)00328-1; van den Hurk WH, 2001, J BIOL CHEM, V276, P11496, DOI 10.1074/jbc.M011040200; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Zhou JN, 2003, J PINEAL RES, V35, P125, DOI 10.1034/j.1600-079X.2003.00065.x	38	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39637	39643		10.1074/jbc.M302295200	http://dx.doi.org/10.1074/jbc.M302295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900421	hybrid			2022-12-27	WOS:000185713800048
J	Sturniolo, MT; Dashti, SR; Deucher, A; Rorke, EA; Broome, AM; Chandraratna, RAS; Keepers, T; Eckert, RL				Sturniolo, MT; Dashti, SR; Deucher, A; Rorke, EA; Broome, AM; Chandraratna, RAS; Keepers, T; Eckert, RL			A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; RADIATION-INDUCED APOPTOSIS; CROSS-LINKING; BIOLOGICAL-ACTIVITY; CORNIFIED ENVELOPE; DOWN-REGULATION; CELL-DEATH; GENE; IDENTIFICATION; INVOLUCRIN	Tazarotene-induced protein 3 (TIG3) is a recently discovered regulatory protein that is expressed in the suprabasal epidermis. In the present study, we show that TIG3 regulates keratinocyte viability and proliferation. TIG3-dependent reduction in keratinocyte viability is accompanied by a substantial increase in the number of sub-G(1) cells, nuclear shrinkage, and increased formation of cornified envelope-like structures. TIG3 localizes to the membrane fraction, and TIG3- dependent differentiation is associated with increased type I transglutaminase activity. Microscopic localization and isopeptide cross-linking studies suggest that TIG3 and type I transglutaminase co-localize in membranes. Markers of apoptosis, including caspases and poly( ADP-ribose) polymerase, are not activated by TIG3, and caspase inhibitors do not stop the TIG3- dependent reduction in cell viability. Truncation of the carboxyl-terminal membrane-anchoring domain results in a complete loss of TIG3 activity. The morphology of the TIG3- positive cells and the effects on cornified envelope formation suggest that TIG3 is an activator of terminal keratinocyte differentiation. Our studies suggest that TIG3 facilitates the terminal stages in keratinocyte differentiation via activation of type I transglutaminase.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Dept Chem, Irvine, CA 92713 USA; Allergan Pharmaceut Inc, Dept Biol, Irvine, CA 92713 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; AbbVie; Allergan; AbbVie; Allergan	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu		Broome, Ann-Marie/0000-0002-2384-5212; Dashti, Shervin/0000-0002-1552-9738	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041456, R55AR041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41456] Funding Source: Medline; NIGMS NIH HHS [T32GM07250] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama H, 1999, J BIOL CHEM, V274, P32192, DOI 10.1074/jbc.274.45.32192; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Autuori F, 1998, Adv Biochem Eng Biotechnol, V62, P129, DOI 10.1007/BFb0102308; BENINATI S, 1995, BIOCHEM J, V305, P725, DOI 10.1042/bj3050725; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Deucher A, 2000, INT J ONCOL, V17, P1195; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Duvic M, 2000, CLIN CANCER RES, V6, P3249; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V277, P655, DOI 10.1006/bbrc.2000.3698; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; Gentile V, 1998, ARCH BIOCHEM BIOPHYS, V352, P314, DOI 10.1006/abbi.1998.0592; GOLDSMITH LA, 1983, J INVEST DERMATOL, V80, pS39, DOI 10.1111/1523-1747.ep12537077; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAJNAL A, 1994, ONCOGENE, V9, P479; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Nicoletti VG, 2003, NEUROCHEM RES, V28, P187, DOI 10.1023/A:1022316914492; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Rice R H, 1988, Adv Exp Med Biol, V231, P51; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Robinson NA, 1998, J BIOL CHEM, V273, P2721, DOI 10.1074/jbc.273.5.2721; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Steinert P M, 1995, Cell Death Differ, V2, P33; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Takahashi H, 1999, EXP CELL RES, V249, P291, DOI 10.1006/excr.1999.4476; Teraki Y, 1999, EUR J DERMATOL, V9, P413; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; YUSPA SH, 1982, J BIOL CHEM, V257, P9906	42	59	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48066	48073		10.1074/jbc.M307215200	http://dx.doi.org/10.1074/jbc.M307215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12928434	hybrid			2022-12-27	WOS:000186731400086
J	Ohashi, K; Osuga, J; Tozawa, R; Kitamine, T; Yagyu, H; Sekiya, M; Tomita, S; Okazaki, H; Tamura, Y; Yahagi, N; Iizuka, Y; Harada, K; Gotoda, T; Shimano, H; Yamada, N; Ishibashi, S				Ohashi, K; Osuga, J; Tozawa, R; Kitamine, T; Yagyu, H; Sekiya, M; Tomita, S; Okazaki, H; Tamura, Y; Yahagi, N; Iizuka, Y; Harada, K; Gotoda, T; Shimano, H; Yamada, N; Ishibashi, S			Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A-REDUCTASE; HMG-COA REDUCTASE; IMPLANTATION MOUSE EMBRYOS; RECEPTOR KNOCKOUT MICE; 3-HYDROXY-3-METHYGLUTARYL COENZYME; CHOLESTEROL-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; FEEDBACK-REGULATION; LIPID-METABOLISM; PREGNANT RATS	The endoplasmic reticulum (ER) enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which converts HMG-CoA to mevalonate, catalyzes the rate-limiting step in cholesterol biosynthesis. Because this mevalonate pathway also produces several non-sterol isoprenoid compounds, the level of HMG-CoA reductase activity may coordinate many cellular processes and functions. We used gene targeting to knock out the mouse HMG-CoA reductase gene. The heterozygous mutant mice (Hmgcr +/-) appeared normal in their development and gross anatomy and were fertile. Although HMG-CoA reductase activities were reduced in Hmgcr +/- embryonic fibroblasts, the enzyme activities and cholesterol biosynthesis remained unaffected in the liver from Hmgcr +/ - mice, suggesting that the haploid amount of Hmgcr gene is not rate-limiting in the hepatic cholesterol homeostasis. Consistently, plasma lipoprotein profiles were similar between Hmgcr +/- and Hmgcr +/+ mice. In contrast, the embryos homozygous for the Hmgcr mutant allele were recovered at the blastocyst stage, but not at E8.5, indicating that HMG-CoA reductase is crucial for early development of the mouse embryos. The lethal phenotype was not completely rescued by supplementing the dams with mevalonate. Although it has been postulated that a second, peroxisome-specific HMG-CoA reductase could substitute for the ER reductase in vitro, we speculate that the putative peroxisomal reductase gene, if existed, does not fully compensate for the lack of the ER enzyme at least in embryogenesis.	Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, Minami Kawachi, Tochigi 3290498, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Tokyo 1138655, Japan; Tokyo Womens Med Univ Sch Med, Ctr Diabet, Tokyo 1620054, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan	Jichi Medical University; University of Tokyo; Tokyo Women's Medical University; University of Tsukuba	Ishibashi, S (corresponding author), Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.		Shimano, Hitoshi/V-1761-2019; Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; Yahagi, Naoya/0000-0002-1823-1865; 				Aboushadi N, 2000, BIOCHEMISTRY-US, V39, P237, DOI 10.1021/bi9916325; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; Breitling R, 2002, J LIPID RES, V43, P2031, DOI 10.1194/jlr.R200010-JLR200; BREWER LM, 1993, TERATOLOGY, V47, P137, DOI 10.1002/tera.1420470206; BROWN MS, 1980, J LIPID RES, V21, P505; CARR BR, 1985, J CLIN INVEST, V76, P1946, DOI 10.1172/JCI112192; Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4; Crouse JR, 1998, ATHEROSCLEROSIS, V138, P11, DOI 10.1016/S0021-9150(98)00014-8; DOSTAL LA, 1994, TERATOLOGY, V50, P387, DOI 10.1002/tera.1420500604; Eisele B, 1997, J LIPID RES, V38, P564; Engfelt WH, 1998, J LIPID RES, V39, P2182; Engfelt WH, 1997, J BIOL CHEM, V272, P24579, DOI 10.1074/jbc.272.39.24579; ENGSTROM W, 1987, ANTICANCER RES, V7, P337; Feingold K R, 1980, Metabolism, V29, P285; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hoffmann GF, 1997, PEDIATR RES, V41, P541, DOI 10.1203/00006450-199704000-00014; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; HRAB RV, 1994, TERATOLOGY, V50, P19, DOI 10.1002/tera.1420500104; HWA JJ, 1992, J LIPID RES, V33, P711; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Istvan ES, 2000, BBA-MOL CELL BIOL L, V1529, P9, DOI 10.1016/S1388-1981(00)00134-7; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; KANEKO I, 1978, EUR J BIOCHEM, V87, P313; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; LEONARD S, 1988, BIOCHIM BIOPHYS ACTA, V947, P101, DOI 10.1016/0304-4157(88)90021-4; LISCUM L, 1985, J BIOL CHEM, V260, P522; Marek KW, 1999, GLYCOBIOLOGY, V9, P1263; MINSKER DH, 1983, TERATOLOGY, V28, P449, DOI 10.1002/tera.1420280316; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; Osuga J, 1998, J CLIN INVEST, V102, P386, DOI 10.1172/JCI1124; Porter FD, 2002, J CLIN INVEST, V110, P715, DOI 10.1172/JCI200216386; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; PRATT HPM, 1982, DEV BIOL, V89, P101, DOI 10.1016/0012-1606(82)90298-6; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SHAPIRO DJ, 1969, BIOCHEM BIOPH RES CO, V37, P867, DOI 10.1016/0006-291X(69)90972-3; SURANI MAH, 1983, J EMBRYOL EXP MORPH, V75, P205; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tozawa R, 1999, J BIOL CHEM, V274, P30843, DOI 10.1074/jbc.274.43.30843; VAN AL, 1997, GENE DEV, V11, P2295; Van Doren M, 1998, NATURE, V396, P466, DOI 10.1038/24871; von Keutz E, 1998, AM J CARDIOL, V82, p11J, DOI 10.1016/S0002-9149(98)00424-X; Wagner AH, 2002, ARTERIOSCL THROM VAS, V22, P1784, DOI 10.1161/01.ATV.0000037098.20829.31; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; WISE L D, 1990, Oyo Yakuri, V39, P143; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; WOODWARD HD, 1988, J BIOL CHEM, V263, P2513; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	53	81	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42936	42941		10.1074/jbc.M307228200	http://dx.doi.org/10.1074/jbc.M307228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920113	hybrid			2022-12-27	WOS:000186157000027
J	Alic, N; Higgins, VJ; Pichova, A; Breitenbach, M; Dawes, IW				Alic, N; Higgins, VJ; Pichova, A; Breitenbach, M; Dawes, IW			Lipid hydroperoxides activate the mitogen-activated protein kinase Mpk1p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINOLEIC-ACID HYDROPEROXIDE; SIGNAL-TRANSDUCTION PATHWAY; OXIDATIVE STRESS-RESPONSE; POLARIZED CELL-GROWTH; MAP KINASE; TRANSCRIPTION FACTOR; BIOLOGICAL-SYSTEMS; GENE-EXPRESSION; ELEMENT STRE; CYCLE ARREST	Saccharomyces cerevisiae is capable of responding to oxidants, including lipid peroxidation products. We investigate here the role of the mitogen-activated protein kinase Mpk1p in protection against linoleic acid hydroperoxide (LoaOOH), a product of radical attack on an unsaturated lipid. MPK1 was found to be required for resistance to LoaOOH. Furthermore, Mpk1p was rapidly and transiently phosphorylated in response to LoaOOH. This phosphorylation was dose-dependent and stimulated by sublethal concentrations as low as 1 muM in the external medium. Such low doses have been shown to result in resistance to subsequent challenge with a higher dose through the process of adaptation. However MPK1 was not essential for this adaptive response. MPK1 was also not involved in cell cycle modulation and acted independently of the cell cycle-regulating Oca1p. Transcriptional profiling of the mpk1Delta cells during LoaOOH stress indicated that Mpk1p may be important in effecting changes to the cell surface and metabolism during LoaOOH exposure. Furthermore, it revealed that Mpk1p is required for the regulation of 97 LoaOOH-responsive transcripts. Evidence is presented that the activation of Mpk1p may be caused by the activation of protein kinase C by LoaOOH.	Univ New S Wales, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia; Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia; Salzburg Univ, Dept Genet, A-5020 Salzburg, Austria; Acad Sci Czech Republ, Inst Microbiol, Prague, Czech Republic	University of New South Wales Sydney; University of New South Wales Sydney; Salzburg University; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Dawes, IW (corresponding author), Univ New S Wales, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia.		Alic, Nazif/B-4665-2009	Alic, Nazif/0000-0003-0356-6600				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Alic N, 2001, MOL BIOL CELL, V12, P1801, DOI 10.1091/mbc.12.6.1801; Binley KM, 1999, YEAST, V15, P1459, DOI 10.1002/(SICI)1097-0061(199910)15:14<1459::AID-YEA472>3.0.CO;2-A; Brachmann CB, 1998, YEAST, V14, P115; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Charizanis C, 1999, MOL GEN GENET, V262, P437, DOI 10.1007/s004380051103; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Degols G, 1996, MOL CELL BIOL, V16, P2870; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; Evans MV, 1998, J BACTERIOL, V180, P483, DOI 10.1128/JB.180.3.483-490.1998; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; Girotti AW, 1998, J LIPID RES, V39, P1529; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Higgins VJ, 2002, YEAST, V19, P203, DOI 10.1002/yea.811; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jung US, 2002, MOL MICROBIOL, V46, P781, DOI 10.1046/j.1365-2958.2002.03198.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Kaul N, 1998, ARCH BIOCHEM BIOPHYS, V350, P79, DOI 10.1006/abbi.1997.0487; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Singh KK, 2000, FREE RADICAL BIO MED, V29, P1043, DOI 10.1016/S0891-5849(00)00432-9; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; SWEETMAN LL, 1995, ARCH BIOCHEM BIOPHYS, V323, P97, DOI 10.1006/abbi.1995.0014; Winkler A, 2002, EUKARYOT CELL, V1, P163, DOI 10.1128/EC.1.2.163-173.2002; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	47	35	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41849	41855		10.1074/jbc.M307760200	http://dx.doi.org/10.1074/jbc.M307760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912987	hybrid			2022-12-27	WOS:000185989500037
J	Kuge, O; Hasegawa, K; Ohsawa, T; Saito, K; Nishijima, M				Kuge, O; Hasegawa, K; Ohsawa, T; Saito, K; Nishijima, M			Purification and characterization of Chinese hamster phosphatidylserine synthase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OVARY CELLS; RAT-BRAIN; MAMMALIAN-CELLS; GENETIC-EVIDENCE; ANNEXIN-V; PHOSPHOLIPIDS; MEMBRANE; BIOSYNTHESIS; ACTIVATION	Phosphatidylserine (PtdSer) in mammalian cells is synthesized through the action of PtdSer synthase (PSS) 1 and 2, which catalyze the conversion of phosphatidylcholine and phosphatidylethanolamine, respectively, to PtdSer. The PtdSer synthesis in intact cells and an isolated membrane fraction is inhibited by exogenous PtdSer, indicating that inhibition of PtdSer synthases by PtdSer is important for the regulation of PtdSer biosynthesis. In this study, to examine whether the inhibition occurs through the direct interaction of PtdSer with the synthases or is mediated by unidentified factor(s), we purified a FLAG and HA peptide-tagged form of Chinese hamster PSS 2 to near homogeneity. The purified enzyme, as well as the crude enzyme in a membrane fraction, was inhibited on the addition of PtdSer to the enzyme assay mixture. In contrast to PtdSer, phosphatidylcholine and phosphatidylethanolamine did not significantly inhibit the purified enzyme. Furthermore, PtdSer-resistant PtdSer synthesis was observed on cell-free assaying of the membrane fraction prepared from a Chinese hamster ovary cell strain whose PtdSer synthesis in vivo is not inhibited by exogenous PtdSer. These results suggested that the interaction of PtdSer with PSS 2 or a very minor protein co-purified with PSS 2 was critical for the regulation of PSS 2 activity in intact cells.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Kyowa Hakko Co Ltd, Tokyo Res Labs, Machida, Tokyo 1940023, Japan	National Institute of Infectious Diseases (NIID); Kyowa Kirin Ltd	Kuge, O (corresponding author), Kyushu Univ, Fac & Grad Sch Sci, Dept Chem, Higashi Ku, Hakozaki 6-10-1, Fukuoka 8128581, Japan.			Kuge, Osamu/0000-0003-4962-3519				BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; CALDERON C, 1994, J EXP MED, V180, P945, DOI 10.1084/jem.180.3.945; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HASEGAWA K, 1989, J BIOL CHEM, V264, P19887; KATO M, 1990, J BIOL CHEM, V265, P794; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; Kuge O, 1999, J BIOL CHEM, V274, P23844, DOI 10.1074/jbc.274.34.23844; Kuge O, 1997, BBA-LIPID LIPID MET, V1348, P151, DOI 10.1016/S0005-2760(97)00137-9; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; Saito K, 1998, J BIOL CHEM, V273, P17199, DOI 10.1074/jbc.273.27.17199; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P304, DOI 10.1016/0003-9861(75)90345-8; SATTA N, 1994, J IMMUNOL, V153, P3245; SUZUKI TT, 1985, J BIOL CHEM, V260, P1394; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TUMA PL, 1993, J BIOL CHEM, V268, P17240; YADA Y, 1990, J BIOL CHEM, V265, P19237; ZWAAL RFA, 1989, MOL CELL BIOCHEM, V91, P23, DOI 10.1007/BF00228075	31	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42692	42698		10.1074/jbc.M307270200	http://dx.doi.org/10.1074/jbc.M307270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912985	hybrid			2022-12-27	WOS:000185989500136
J	Booth, RE; Tong, QS; Medina, J; Snyder, PM; Patel, P; Stockand, JD				Booth, RE; Tong, QS; Medina, J; Snyder, PM; Patel, P; Stockand, JD			A region directly following the second transmembrane domain in gamma ENaC is required for normal channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; SENSITIVE NA+ CHANNEL; ALPHA-SUBUNIT; LIDDLES-SYNDROME; PLASMA-MEMBRANE; APICAL MEMBRANE; EXPRESSION; TERMINUS; KINASE; CELLS	We used a yeast one-hybrid complementation screen to identify regions within the cytosolic tails of the mouse alpha, beta, and gamma epithelial Na+ channel (ENaC) important to protein-protein and/or protein-lipid interactions at the plasma membrane. The cytosolic COOH terminus of alphaENaC contained a strongly interactive domain just distal to the second transmembrane region (TM2) between Met(610) and Val(632). Likewise, gammaENaC contained such a domain just distal to TM2 spanning Gln(573)-Pro(600). Interactive domains were also localized within Met(1)-Gln(54) and the last 17 residues of alpha- and betaENaC, respectively. Confocal images of Chinese hamster ovary cells transfected with enhanced green fluorescent fusion proteins of the cytosolic tails of mENaC subunits were consistent with results in yeast. Fusion proteins of the NH2 terminus of alphaENaC and the COOH termini of all three subunits co-localized with a plasma membrane marker. The functional importance of the membrane interactive domain in the COOH terminus of gammaENaC was established with whole-cell patch clamp experiments of wild type (alpha, beta, and gamma) and mutant (alpha, beta, and gamma(DeltaQ573-P600)) mENaC reconstituted in Chinese hamster ovary cells. Mutant channels had about 13% of the activity of wild type channels with 0.33 +/- 0.14 versus 2.5 +/- 0.80 nA of amiloride-sensitive inward current at - 80 mV. Single channel analysis of recombinant channels demonstrated that mutant channels had a decrease in P-o with 0.16 +/- 0.03 versus 0.67 +/- 0.07 for wild type. Mutant gammaENaC associated normally with the other two subunits in co-immunoprecipitation studies and localized to the plasma membrane in membrane labeling experiments and when visualized with evanescent-field fluorescence microscopy. Similar to deletion of Gln(573)-Pro(600), deletion of Gln(573)-Arg(583) but not Thr(584)-Pro(600) decreased ENaC activity. The current results demonstrate that residues within Gln(573)-Arg(583) of gammaENaC are necessary for normal channel gating.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Texas System; University of Texas Health San Antonio; University of Iowa; University of Iowa	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Stockand, James/0000-0002-3817-4319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK59594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Berdiev BK, 1998, BIOPHYS J, V75, P2292, DOI 10.1016/S0006-3495(98)77673-8; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Dinudom A, 2001, J BIOL CHEM, V276, P13744, DOI 10.1074/jbc.M011273200; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Gamper N, 2003, J NEUROSCI, V23, P84; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Gupta SS, 2000, FEBS LETT, V481, P77, DOI 10.1016/S0014-5793(00)01977-3; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; Heda GD, 2000, BIOCHEM BIOPH RES CO, V271, P659, DOI 10.1006/bbrc.2000.2684; Hendron E, 2002, J BIOL CHEM, V277, P34480, DOI 10.1074/jbc.M204615200; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ji HL, 1999, J BIOL CHEM, V274, P37693, DOI 10.1074/jbc.274.53.37693; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Munn AL, 2000, MICROSC RES TECHNIQ, V51, P547, DOI 10.1002/1097-0029(20001215)51:6<547::AID-JEMT5>3.0.CO;2-D; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 1999, J BIOL CHEM, V274, P26912, DOI 10.1074/jbc.274.38.26912; Stockand JD, 2001, AM J PHYSIOL-CELL PH, V281, pC773, DOI 10.1152/ajpcell.2001.281.3.C773; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Thomas CP, 1998, AM J PHYSIOL-CELL PH, V274, pC1312, DOI 10.1152/ajpcell.1998.274.5.C1312; Volk KA, 2001, J BIOL CHEM, V276, P43887, DOI 10.1074/jbc.M108714200; Volk KA, 2000, AM J PHYSIOL-CELL PH, V278, pC1047, DOI 10.1152/ajpcell.2000.278.5.C1047; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	52	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41367	41379		10.1074/jbc.M305400200	http://dx.doi.org/10.1074/jbc.M305400200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12897071	hybrid			2022-12-27	WOS:000185847200117
J	Fernandez, FR; Morales, E; Rashid, AJ; Dunn, RJ; Turner, RW				Fernandez, FR; Morales, E; Rashid, AJ; Dunn, RJ; Turner, RW			Inactivation of Kv3.3 potassium channels in heterologous expression systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; K+ CHANNELS; DROSOPHILA MUSCLE; BURST DISCHARGE; PROTEIN-KINASE; MESSENGER-RNA; RAT-BRAIN; TRANSLATION; INITIATION; EUKARYOTES	Kv3.3 K+ channels are believed to incorporate an NH2-terminal domain to produce an intermediate rate of inactivation relative to the fast inactivating K+ channels Kv3.4 and Kv1.4. The rate of Kv3.3 inactivation has, however, been difficult to establish given problems in obtaining consistent rates of inactivation in expression systems. This study characterized the properties of AptKv3.3, the teleost homologue of Kv3.3, when expressed in Chinese hamster ovary (CHO) or human embryonic kidney (HEK) cells. We show that the properties of AptKv3.3 differ significantly between CHO and HEK cells, with the largest difference occurring in the rate and voltage dependence of inactivation. While AptKv3.3 in CHO cells showed a fast and voltage-dependent rate of inactivation consistent with N-type inactivation, currents in HEK cells showed rates of inactivation that were voltage-independent and more consistent with a slower C-type inactivation. Examination of the mRNA sequence revealed that the first methionine start site had a weak Kozak consensus sequence, suggesting that the lack of inactivation in HEK cells could be due to translation at a second methionine start site downstream of the NH2-terminal coding region. Mutating the nucleotide sequence surrounding the first methionine start site to one more closely resembling a Kozak consensus sequence produced currents that inactivated with a fast and voltage-dependent rate of inactivation in both CHO and HEK cells. These results indicate that under the appropriate conditions Kv3.3 channels can exhibit fast and reliable inactivation that approaches that more typically expected of "A"-type K+ currents.	Univ Calgary, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Montreal Gen Hosp, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Neurol, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Biol, Montreal, PQ H3G 1A4, Canada	University of Calgary; McGill University; McGill University; McGill University	Turner, RW (corresponding author), Univ Calgary, Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Fernandez, Fernando/G-9398-2018	Fernandez, Fernando/0000-0001-9308-3594				ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; CRITZ SD, 1993, J NEUROCHEM, V60, P1175, DOI 10.1111/j.1471-4159.1993.tb03273.x; DEMIERA EV, 1994, HDB MEMBRANE CHANNEL, P41; DEMIERA EV, 1992, P ROY SOC LOND B BIO, V248, P9, DOI [DOI 10.1098/RSPB.1992.0036, 10.1098/rspb.1992.0036]; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Doiron B, 2001, J NEUROPHYSIOL, V86, P1523, DOI 10.1152/jn.2001.86.4.1523; DRAIN P, 1994, NEURON, V12, P1097, DOI 10.1016/0896-6273(94)90317-4; Franqueza L, 1999, CARDIOVASC RES, V41, P212, DOI 10.1016/S0008-6363(98)00220-X; Hashimoto Y, 2000, J BIOL CHEM, V275, P9358, DOI 10.1074/jbc.275.13.9358; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Jiang B, 2002, MOL CELL BIOCHEM, V238, P69, DOI 10.1023/A:1019907104763; Johnston D, 2000, J PHYSIOL-LONDON, V525, P75, DOI 10.1111/j.1469-7793.2000.00075.x; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Kentros C., 1992, Society for Neuroscience Abstracts, V18, P1093; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lee TE, 1996, J MEMBRANE BIOL, V151, P225, DOI 10.1007/s002329900073; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; Martina M, 2003, J NEUROSCI, V23, P5698; Migliore M, 1999, J COMPUT NEUROSCI, V7, P5, DOI 10.1023/A:1008906225285; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; Noonan L, 2003, J NEUROSCI, V23, P1524, DOI 10.1523/JNEUROSCI.23-04-01524.2003; Petersen KR, 1999, PFLUG ARCH EUR J PHY, V437, P381, DOI 10.1007/s004240050792; Rae JL, 2000, EXP EYE RES, V70, P339, DOI 10.1006/exer.1999.0796; Rashid AJ, 2001, J COMP NEUROL, V441, P234, DOI 10.1002/cne.1409; Rashid AJ, 2001, J NEUROSCI, V21, P125, DOI 10.1523/JNEUROSCI.21-01-00125.2001; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; Roeper J, 1997, J NEUROSCI, V17, P3379; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; Rudy B, 1999, ANN NY ACAD SCI, V868, P304, DOI 10.1111/j.1749-6632.1999.tb11295.x; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Velasco I, 1998, Neurobiology (Bp), V6, P23; Watanabe S, 2002, P NATL ACAD SCI USA, V99, P8366, DOI 10.1073/pnas.122210599; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	40	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40890	40898		10.1074/jbc.M304235200	http://dx.doi.org/10.1074/jbc.M304235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12923191	hybrid			2022-12-27	WOS:000185847200059
J	Rosell, A; Valencia, E; Ochoa, WF; Fita, I; Pares, X; Farres, J				Rosell, A; Valencia, E; Ochoa, WF; Fita, I; Pares, X; Farres, J			Complete reversal of coenzyme specificity by concerted mutation of three consecutive residues in alcohol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID SUBSTITUTIONS; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; CATALYTIC EFFICIENCY; DINUCLEOTIDE BINDING; COFACTOR SPECIFICITY; HUMAN BETA-1-BETA-1; RANA-PEREZI; PROTEIN	Gastric tissues from amphibian Rana perezi express the only vertebrate alcohol dehydrogenase (ADH8) that is specific for NADP( H) instead of NAD(H). In the crystallographic ADH8-NADP(+) complex, a binding pocket for the extra phosphate group of coenzyme is formed by ADH8-specific residues Gly(223)-Thr(224)-His(225), and the highly conserved Leu(200) and Lys(228). To investigate the minimal structural determinants for coenzyme specificity, several ADH8 mutants involving residues 223 to 225 were engineered and kinetically characterized. Computer-assisted modeling of the docked coenzymes was also performed with the mutant enzymes and compared with the wild-type crystallographic binary complex. The G223D mutant, having a negative charge in the phosphate-binding site, still preferred NADP( H) over NAD( H), as did the T224I and H225N mutants. Catalytic efficiency with NADP( H) dropped dramatically in the double mutants, G223D/T224I and T224I/H225N, and in the triple mutant, G223D/T224I/ H225N (k(cat)/K(m)NADPH = 760 mM(-1) min(-1)), as compared with the wild-type enzyme (k(cat)/K(m)NADPH = 133,330 mM(-1) min(-1)). This was associated with a lower binding affinity for NADP(+) and a change in the rate-limiting step. Conversely, in the triple mutant, catalytic efficiency with NAD( H) increased, reaching values (k(cat)/K(m)NADH = 155,000 mM(-1) min(-1)) similar to those of the wild-type enzyme with NADP( H). The complete reversal of ADH8 coenzyme specificity was therefore attained by the substitution of only three consecutive residues in the phosphate-binding site, an unprecedented achievement within the ADH family.	Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain; Consejo Super Invest Cient, IBMB, E-08034 Barcelona, Spain	Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Farres, J (corresponding author), Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain.		Farrés, Jaume/F-8648-2016; Pares, Xavier/K-8228-2017	Farrés, Jaume/0000-0001-9069-3987; Pares, Xavier/0000-0002-5071-9465				BACKER PJ, 1992, J MOL BIOL, V228, P662; Banfield MJ, 2001, J MOL BIOL, V306, P239, DOI 10.1006/jmbi.2000.4381; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; BOSRON WF, 1979, BIOCHEMISTRY-US, V18, P1101, DOI 10.1021/bi00573a026; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C I, 1980, Experientia Suppl, V36, P40; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burdette DS, 1996, BIOCHEM J, V316, P115, DOI 10.1042/bj3160115; Burnell JC, 1989, HUMAN METABOLISM ALC, V2, P65; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; CEDERLUND E, 1991, BIOCHEMISTRY-US, V30, P2811, DOI 10.1021/bi00225a011; CHEN Z, 1991, EUR J BIOCHEM, V202, P263, DOI 10.1111/j.1432-1033.1991.tb16371.x; Cleland W W, 1979, Methods Enzymol, V63, P103; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; Fan F, 1999, ARCH BIOCHEM BIOPHYS, V367, P240, DOI 10.1006/abbi.1999.1242; FAN F, 1991, BIOCHEMISTRY-US, V30, P6397, DOI 10.1021/bi00240a008; FAN F, 1995, BIOCHEMISTRY-US, V34, P4709, DOI 10.1021/bi00014a027; FARRES J, 1994, EUR J BIOCHEM, V224, P549, DOI 10.1111/j.1432-1033.1994.00549.x; FEENEY R, 1990, BIOCHEM BIOPH RES CO, V166, P667, DOI 10.1016/0006-291X(90)90861-G; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Korkhin Y, 1998, J MOL BIOL, V278, P967, DOI 10.1006/jmbi.1998.1750; KUMAR A, 1992, P NATL ACAD SCI USA, V89, P10188, DOI 10.1073/pnas.89.21.10188; LAUVERGEAT V, 1995, BIOCHEMISTRY-US, V34, P12426, DOI 10.1021/bi00038a041; Lee SL, 2003, FEBS LETT, V544, P143, DOI 10.1016/S0014-5793(03)00492-7; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; METZGER MH, 1995, EUR J BIOCHEM, V228, P50, DOI 10.1111/j.1432-1033.1995.tb20227.x; MITTL PRE, 1994, PROTEIN SCI, V3, P1504, DOI 10.1002/pro.5560030916; MITTL PRE, 1993, J MOL BIOL, V231, P191, DOI 10.1006/jmbi.1993.1274; NELSON M, 1992, METHOD ENZYMOL, V216, P279; OHLSSON I, 1974, J MOL BIOL, V89, P339, DOI 10.1016/0022-2836(74)90523-3; Peralba JM, 1999, ADV EXP MED BIOL, V463, P343; Peralba JM, 1999, J BIOL CHEM, V274, P26021, DOI 10.1074/jbc.274.37.26021; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; Rosell A, 2003, J MOL BIOL, V330, P75, DOI 10.1016/S0022-2836(03)00431-5; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; STONE CL, 1993, J BIOL CHEM, V268, P892; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; Svensson S, 2000, J MOL BIOL, V302, P441, DOI 10.1006/jmbi.2000.4039; Valencia E, 2003, ACTA CRYSTALLOGR D, V59, P334, DOI 10.1107/S090744490201661X; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558	46	43	47	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40573	40580		10.1074/jbc.M307384200	http://dx.doi.org/10.1074/jbc.M307384200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902331	hybrid			2022-12-27	WOS:000185847200020
J	Wang, GL; Wei, LN; Loh, HH				Wang, GL; Wei, LN; Loh, HH			Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation - Involvement of Sp3 and A methyl-CpG-binding protein, MBD2, in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; CYTOSINE METHYLATION; PROMOTER; EXPRESSION; ACTIVATION; FAMILY; IDENTIFICATION; SITE	Opioid receptors are expressed in a cell type-specific manner. Here we show that the mouse delta-opioid receptor (mDOR) gene is regulated by promoter region CpG methylation. The mDOR promoter containing a putative CpG island is highly methylated in Neuro2A cells, correlating with the repression of this gene in these cells. This is in contrast with the unmethylated state of the mDOR promoter in NS20Y cells, which express a high level of mDOR. Repression of mDOR transcription in Neuro2A cells could be partially relieved by chemically induced demethylation with 5-aza-2'-deoxycytidine. In addition, in vitro methylation of the luciferase reporter gene driven by the mDOR promoter resulted in an inhibition of transcription in NS20Y cells. Methyl-CpG-binding protein complex 1 (MeCP1) has been implicated in methylation-mediated transcriptional repression of several genes. Electrophoretic mobility shift assays showed that fully methylated, but not unmethylated, mDOR promoter fragment formed a MeCP1-like protein complex that contained methyl-CpG-binding domain protein 2 (MBD2) and Sp3. Furthermore, the expression level of Sp3 was decreased when Neuro2A cells were demethylated with 5-aza-2'-deoxycytidine, and increasing Sp3 levels in Schneider's Drosophila line 2 cells led to the repression of mDOR promoter activity when the promoter was methylated. These results demonstrate that Sp3 and MBD2 are involved in the transcriptional repression of mDOR in Neuro2A cells through binding to the methylated CpG sites in the promoter region and may play a role in the cell type-specific expression of mDOR.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wang, GL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [K05DA070554, K02DA013926, R01DA001583, R37DA001583, P50DA011806] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00546, K02-DA13926, K05-DA-70554, DA-11806, DA-01583] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Feng Q, 2001, GENE DEV, V15, P827; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu HC, 1999, J BIOL CHEM, V274, P23617, DOI 10.1074/jbc.274.33.23617; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Smirnov D, 2001, MOL PHARMACOL, V60, P331, DOI 10.1124/mol.60.2.331; Sun P, 2001, J BIOL CHEM, V276, P45462, DOI 10.1074/jbc.M104793200; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200	32	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40550	40556		10.1074/jbc.M302879200	http://dx.doi.org/10.1074/jbc.M302879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890683	hybrid			2022-12-27	WOS:000185847200017
J	Waris, G; Livolsi, A; Imbert, V; Peyron, JF; Siddiqui, A				Waris, G; Livolsi, A; Imbert, V; Peyron, JF; Siddiqui, A			RETRACTED: Hepatitis C virus NS5A and subgenomic replicon activate NF-kappa B via tyrosine phosphorylation of I kappa B alpha and its degradation by calpain protease (Retracted article. See vol. 94, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							RNA-POLYMERASE; 5A PROTEIN; PROTEOLYSIS; CALPASTATIN; INHIBITION; KINASE; REPLICATION; EXPRESSION; INFECTION; TRANSPORT	Hepatitis C virus nonstructural protein 5A (NS5A) has been implicated in the HCV antiviral resistance, replication, and transactivation of cellular gene expression. We have recently shown that HCV NS5A activates NF-kappaB via oxidative stress ( 22). In this study, we investigate the molecular mechanism(s) of NF-kappaB activation in response to oxidative stress induced by NS5A protein. In contrast to the classic Ser(32,36) phosphorylation of IkappaBalpha, we report here that tyrosine phosphorylation of IkappaBalpha at Tyr(42) and Tyr(305) residues is induced by the HCV NS5A and the subgenomic replicons in the NF-kappaB activation process. Use of IkappaBalpha-Tyr(42,305) double mutant provided the evidence for their key role in the activation of NF-kappaB. Activation of NF-kappaB was blocked by a series of tyrosine kinase inhibitors but not by IkappaB kinase inhibitor BAY 11-7085. More specifically, a ZAP-70 knock-out cell line expressing NS5A and other nonstructural proteins respectively prevented the NF-kappaB activation, indicating the involvement of ZAP-70 as a probable tyrosine kinase in the activation process. Evidence is also presented for the possible role of calpain proteases in the NS5A-induced IkappaBalpha degradation. These studies collectively define an alternate pathway of NF-kappaB activation by NS5A alone or in the context of the HCV subgenomic replicon. Constitutive activation of NF-kappaB by HCV has implications in the chronic liver disease including hepatocellular carcinoma associated with HCV infection.	Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Fac Med, INSERM, U526, F-06107 Nice 2, France	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Siddiqui, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, B-172, Denver, CO 80262 USA.	aleem.siddiqui@uchsc.edu	IMBERT, VERONIQUE/I-6093-2016	IMBERT, VERONIQUE/0000-0003-2103-6718	NIDDK NIH HHS [DK61566] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061566] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson M, 1998, OPHTHALMIC RES, V30, P157, DOI 10.1159/000055469; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barnoy S, 2000, BIOCHEM J, V351, P413, DOI 10.1042/0264-6021:3510413; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; Boya P, 2001, HEPATOLOGY, V34, P1041, DOI 10.1053/jhep.2001.29002; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; KOLYKHALOV AA, 1994, J VIROL, V68, P7525, DOI 10.1128/JVI.68.11.7525-7533.1994; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; LIVOLSI A, 2001, EUR J BIOCHEM, V268, P1; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Miyoshi H, 1996, GASTROENTEROLOGY, V110, P1897, DOI 10.1053/gast.1996.v110.pm8964416; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; PLAGEMANN PGW, 1991, ARCH VIROL, V120, P165, DOI 10.1007/BF01310473; REED KC, 1974, BIOCHEM J, V140, P143, DOI 10.1042/bj1400143; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Reyes GR, 2002, J BIOMED SCI, V9, P187, DOI 10.1007/BF02256065; RUIZ J, 1992, HEPATOLOGY, V16, P637, DOI 10.1002/hep.1840160305; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SHERLOCK S, 1993, CURR OPIN GASTROEN, V9, P341; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Siebenlist U, 2001, NATURE, V412, P601, DOI 10.1038/35088174; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; YING WL, 1991, BIOCHEMISTRY-US, V30, P4949, DOI 10.1021/bi00234a016; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zwacka RM, 1998, HEPATOLOGY, V28, P1022, DOI 10.1002/hep.510280417	59	101	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40778	40787		10.1074/jbc.M303248200	http://dx.doi.org/10.1074/jbc.M303248200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909638	hybrid			2022-12-27	WOS:000185847200046
J	Chen, YH; Layne, MD; Chung, SW; Ejima, K; Baron, RM; Yet, SF; Perrella, MA				Chen, YH; Layne, MD; Chung, SW; Ejima, K; Baron, RM; Yet, SF; Perrella, MA			Elk-3 is a transcriptional repressor of nitric-oxide synthase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; TRANSFORMING GROWTH-FACTOR-BETA-1; ETS FAMILY; SEPTIC SHOCK; DISEASE; RAS; INHIBITION	The inducible isoform of nitric-oxide synthase (NOS2), a key enzyme catalyzing the dramatic increase in nitric oxide by lipopolysaccharide (LPS), plays an important role in the pathophysiology of endotoxemia and sepsis. Recent evidence suggests that Ets transcription factors may contribute to NOS2 induction by inflammatory stimuli. In this study, we investigated the role of Ets transcription factors in the regulation of NOS2 by LPS and transforming growth factor (TGF)-beta1. Transient transfection assays in macrophages showed that Ets-2 produced an increase in NOS2 promoter activity, whereas the induction by Ets-1 was modest and NERF2 had no effect. Elk-3 (Net/Erp/Sap-2a) markedly repressed NOS2 promoter activity in a dose-dependent fashion, and overexpression of Elk-3 blunted the induction of endogenous NOS2 message. Mutation of the Net inhibitory domain of Elk-3, but not the C-terminal-binding protein interaction domain, partially alleviated this repressive effect. We also found that deletion of the Ets domain of Elk-3 completely abolished its repressive effect on the NOS2 promoter. LPS administration to macrophages led to a dose-dependent decrease in endogenous Elk-3 mRNA levels, and this decrease in Elk-3 preceded the induction of NOS2 mRNA. In a mouse model of endotoxemia, the expression of Elk-3 in kidney, lung, and heart was significantly down-regulated after systemic administration of LPS, and this down-regulation also preceded NOS2 induction. Moreover, TGF-beta1 significantly increased endogenous Elk-3 mRNA levels that had been down-regulated by LPS in macrophages. This increase in Elk-3 correlated with a TGF-beta1-induced down-regulation of NOS2. Taken together, our data suggest that Elk-3 is a strong repressor of NOS2 promoter activity and mRNA levels and that endogenous expression of Elk-3 inversely correlates with NOS2. Thus, Elk-3 may serve as an important mediator of NOS2 gene expression.	Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Kaohsiung Med Univ, Dept Internal Med, Div Infect Dis, Kaohsiung 807, Taiwan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kaohsiung Medical University	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St,TH-1327A, Boston, MA 02115 USA.		Yet, Shaw-Fang/B-1067-2010; Chen, Yen-Hsu/D-5484-2009; Yet, Shaw-Fang/O-8583-2019	Chen, Yen-hsu/0000-0002-8667-4844; Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60788] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Ejima K, 2002, ANTIOXID REDOX SIGN, V4, P569, DOI 10.1089/15230860260220067; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pellacani A, 2001, J BIOL CHEM, V276, P1653, DOI 10.1074/jbc.M008170200; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1996, P NATL ACAD SCI USA, V93, P2054, DOI 10.1073/pnas.93.5.2054; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Rees DD, 1998, BRIT J PHARMACOL, V124, P540, DOI 10.1038/sj.bjp.0701815; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	32	35	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39572	39577		10.1074/jbc.M308179200	http://dx.doi.org/10.1074/jbc.M308179200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12896968	hybrid			2022-12-27	WOS:000185713800039
J	Ferrari, A; Hoerndli, F; Baechi, T; Nitsch, RM; Gotz, J				Ferrari, A; Hoerndli, F; Baechi, T; Nitsch, RM; Gotz, J			beta-amyloid induces paired helical filament-like tau filaments in tissue culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; P301L TAU; NEUROFIBRILLARY DEGENERATION; ALZHEIMERS-DISEASE; PROTEIN; CELLS; PHOSPHORYLATION; MUTATIONS; DEMENTIA; AMYOTROPHY	Paired helical filaments (PHF) are the principal pathologic components of neurofibrillary tangles in Alzheimer's disease (AD). To reproduce the formation of PHF in tissue culture, we stably expressed human tau with and without pathogenic mutations in human SH-SY5Y cells and exposed them for 5 days to aggregated synthetic beta-amyloid peptide (Abeta(42)). This caused a decreased solubility of tau along with the generation of PHF-like tau-containing filaments. These were 20 nm wide and had periodicities of 130-140 nm in the presence of P301L mutant tau or 150-160 nm in the presence of wild-type tau. Mutagenesis of the phosphoepitope serine 422 of tau prevented both the Abeta(42)-mediated decrease in solubility and the generation of PHF-like filaments, suggesting a role of serine 422 or its phosphorylation in tau filament formation. Together, our data underscore a role of Abeta(42) in the formation of PHF-like filaments. Our culture system will be useful to map phosphoepitopes of tau involved in PHF formation and to identify and characterize modifiers of the tau pathology. Further adaptation of the system may allow the screening and validation of compounds designed to prevent PHF formation.	Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland; Univ Zurich, Cent Lab Electron Microscopy, CH-8028 Zurich, Switzerland	University of Zurich; University of Zurich	Gotz, J (corresponding author), Univ Zurich, Div Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.		Götz, Jürgen/C-2448-2014	Götz, Jürgen/0000-0001-8501-7896; Hoerndli, Frederic/0000-0001-6838-0386				Abraha A, 2000, J CELL SCI, V113, P3737; Berry RW, 2003, BIOCHEMISTRY-US, V42, P8325, DOI 10.1021/bi027348m; Bussiere T, 1999, ACTA NEUROPATHOL, V97, P221, DOI 10.1007/s004010050978; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Gotz J, 2001, BRAIN RES REV, V35, P266, DOI 10.1016/S0165-0173(01)00055-8; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Haque N, 1999, BRAIN RES, V838, P69, DOI 10.1016/S0006-8993(99)01622-4; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Ishihara T, 2001, AM J PATHOL, V158, P555, DOI 10.1016/S0002-9440(10)63997-1; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Perez M, 2002, EUR J BIOCHEM, V269, P1484, DOI 10.1046/j.1432-1033.2002.02794.x; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Uberti D, 1997, NEUROSCI LETT, V235, P149, DOI 10.1016/S0304-3940(97)00715-5; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	28	149	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40162	40168		10.1074/jbc.M308243200	http://dx.doi.org/10.1074/jbc.M308243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893817	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000185713800109
J	Karlson, U; Pejler, G; Tomasini-Johansson, B; Hellman, L				Karlson, U; Pejler, G; Tomasini-Johansson, B; Hellman, L			Extended substrate specificity of rat mast cell protease 5, a rodent alpha-chymase with elastase-like primary specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM CRYSTAL-STRUCTURE; HUMAN CATHEPSIN-G; SERINE PROTEASES; ANGIOTENSIN-II; GRANULE PROTEASES; HUMAN HEART; HEPARIN; INHIBITORS; TRYPTASE; CLONING	Chymases are mast cell serine proteases with chymotrypsin-like primary substrate specificity. Amino acid sequence comparisons of alpha-chymases from different species indicated that certain rodent alpha-chymases have a restricted S1 pocket that could only accommodate small amino acids, i.e. they may, despite being classified as chymases, in fact display elastase-like substrate specificity. To explore this possibility, the alpha-chymase, rat mast cell protease 5 (rMCP-5), was produced as a proenzyme with a His(6) purification tag and an enterokinase-susceptible peptide replacing the natural propeptide. After removal of the purification tag/enterokinase site by enterokinase digestion, rMCP-5 bound the serine-protease-specific inhibitor diisopropyl fluorophosphate, showing that rMCP-5 was catalytically active. The primary specificity was investigated with chromogenic substrates of the general sequence succinyl-Ala-Ala- Pro-X-p-nitroanilide, where the X was Ile, Val, Ala, Phe or Leu. The activity was highest toward substrates with Val or Ala in the P1 position, whereas low activity toward the peptide with a P1 Phe was observed, indicating that the substrate specificity of rMCP-5 indeed is elastase-like. The extended substrate specificity was examined utilizing a phage-displayed random nonapeptide library. The preferred cleavage sequence was resolved as P4-(Gly/Pro/Val), P3-(Leu/Val/Glu), P2-(Leu/Val/Thr), P1( Val/Ala/Ile), P1'-(Xaa), and P2'-(Glu/ Leu/Asp). Hence, the extended substrate specificity is similar to human chymase in most positions except for the P1 position. We conclude that the rat alpha-chymase has converted to elastase-like substrate specificity, perhaps associated with an adoption of new biological targets, separate from those of human alpha-chymase.	Uppsala Univ, Biomed Ctr, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, SE-75123 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences	Hellman, L (corresponding author), Uppsala Univ, Biomed Ctr, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.							BASTOS M, 1995, P NATL ACAD SCI USA, V92, P6738, DOI 10.1073/pnas.92.15.6738; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Guo CY, 2001, J CLIN INVEST, V107, P703, DOI 10.1172/JCI9997; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; IDE H, 1995, BIOCHEM J, V311, P675, DOI 10.1042/bj3110675; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1994, ALLERGY PROC, V15, P303, DOI 10.2500/108854194778816472; Karlson L, 2002, J BIOL CHEM, V277, P18579, DOI 10.1074/jbc.M110356200; Kunori Y, 2002, EUR J BIOCHEM, V269, P5921, DOI 10.1046/j.1432-1033.2002.03316.x; Lindstedt L, 2001, ATHEROSCLEROSIS, V155, P87, DOI 10.1016/S0021-9150(00)00544-X; Lunderius C, 2000, EUR J IMMUNOL, V30, P3396, DOI 10.1002/1521-4141(2000012)30:12<3396::AID-IMMU3396>3.0.CO;2-O; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P3730, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3730::AID-IMMU3730&gt;3.0.CO;2-0; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P1022, DOI 10.1002/(SICI)1521-4141(199803)28:03<1022::AID-IMMU1022>3.0.CO;2-1; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; Mellon MB, 2002, J IMMUNOL, V168, P290, DOI 10.4049/jimmunol.168.1.290; PEJLER G, 1995, EUR J BIOCHEM, V233, P192, DOI 10.1111/j.1432-1033.1995.192_1.x; Pereira PJB, 1999, J MOL BIOL, V286, P163, DOI 10.1006/jmbi.1998.2462; PERONA JJ, 1995, PROTEIN SCI, V4, P337; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REILLY CF, 1982, J BIOL CHEM, V257, P8619; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SALI A, 1993, J BIOL CHEM, V268, P9023; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; Solivan S, 2002, FEBS LETT, V512, P133, DOI 10.1016/S0014-5793(02)02242-1; Takai S, 1996, LIFE SCI, V58, P591, DOI 10.1016/0024-3205(95)02328-3; URATA H, 1990, J BIOL CHEM, V265, P22348; Vernersson M, 2002, FASEB J, V16, P875, DOI 10.1096/fj.01-0879fje; WEIDNER N, 1993, PATHOL RES PRACT, V189, P156, DOI 10.1016/S0344-0338(11)80086-5; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144	39	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39625	39631		10.1074/jbc.M301512200	http://dx.doi.org/10.1074/jbc.M301512200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900423	hybrid			2022-12-27	WOS:000185713800046
J	Dahl, NK; Jiang, LW; Chernova, MN; Stuart-Tilley, AK; Shmukler, BE; Alper, SL				Dahl, NK; Jiang, LW; Chernova, MN; Stuart-Tilley, AK; Shmukler, BE; Alper, SL			Deficient HCO3- transport in an AE1 mutant with normal Cl- transport can be rescued by carbonic anhydrase II presented on an adjacent AE1 protomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; ANION-EXCHANGER BAND-3; RED-BLOOD-CELLS; SOUTHEAST-ASIAN OVALOCYTES; XENOPUS-OOCYTES; GLYCOPHORIN-A; FUNCTIONAL CONSEQUENCES; ERYTHROCYTE-MEMBRANE; AUTOSOMAL-DOMINANT; CL-/HCO3-EXCHANGER	Cl-/HCO3- exchange activity mediated by the AE1 anion exchanger is reduced by carbonic anhydrase II (CA2) inhibition or by prevention of CA2 binding to the AE1 C-terminal cytoplasmic tail. This type of AE1 inhibition is thought to represent reduced metabolic channeling of HCO3- to the intracellular HCO3- binding site of AE1. To test the hypothesis that CA2 binding might itself allosterically activate AE1 in Xenopus oocytes, we compared Cl-/Cl- and Cl-/HCO3- exchange activities of AE1 polypeptides with truncation and missense mutations in the C-terminal tail. The distal renal tubular acidosis-associated AE1 901X mutant exhibited both Cl-/Cl- and Cl-/HCO3- exchange activities. In contrast, AE1 896X, 891X, and AE1 missense mutants in the CA2 binding site were inactive as Cl-/HCO3- exchangers despite exhibiting normal Cl-/Cl- exchange activities. Co-expression of CA2 enhanced wild-type AE1-mediated Cl-/HCO3- exchange, but not Cl-/Cl- exchange. CA2 co-expression could not rescue Cl-/HCO3- exchange activity in AE1 mutants selectively impaired in Cl-/HCO3- exchange. However, co-expression of transport-incompetent AE1 mutants with intact CA2 binding sites completely rescued Cl-/HCO3- exchange by an AE1 missense mutant devoid of CA2 binding, with activity further enhanced by CA2 co-expression. The same transport-incompetent AE1 mutants failed to rescue Cl-/HCO3- exchange by the AE1 truncation mutant 896X, despite preservation of the latter's core CA2 binding site. These data increase the minimal extent of a functionally defined CA2 binding site in AE1. The inter-protomeric rescue of HCO3- transport within the AE1 dimer shows functional proximity of the C-terminal cytoplasmic tail of one protomer to the anion translocation pathway in the adjacent protomer within the AE1 heterodimer. The data strongly support the hypothesis that an intact transbilayer anion translocation pathway is completely contained within an AE1 monomer.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Mol Med Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Unit, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Alper, SL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Mol Med Unit, RW763 E,330 Brookline Ave, Boston, MA 02215 USA.		Dahl, Neera/AAI-7380-2021; Dahl, Neera/AAV-4856-2021		NIDDK NIH HHS [T32DK007199, DK43495] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043495, R37DK043495, T32DK007199] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alper SL, 2002, J NEPHROL, V15, pS41; Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; ARONSSON G, 1995, BIOCHEMISTRY-US, V34, P2153, DOI 10.1021/bi00007a008; Bruce LJ, 2000, BIOCHEM J, V350, P41, DOI 10.1042/0264-6021:3500041; BRUCE LJ, 1994, BLOOD, V84, P916; Bruce LJ, 2002, BLOOD, V100, P1878, DOI 10.1182/blood-2002-03-0706; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; Cheidde L, 2002, J AM SOC NEPHROL, V13, p575A; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; CHERNOVA MN, 1995, J MEMBRANE BIOL, V148, P203; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; Chishti A H, 1998, Curr Opin Hematol, V5, P116; COUSIN JL, 1976, J PHYSIOL-LONDON, V256, P61, DOI 10.1113/jphysiol.1976.sp011311; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Devonald MAJ, 2002, J AM SOC NEPHROL, V13, p57A; DOLDER M, 1993, J MOL BIOL, V231, P119, DOI 10.1006/jmbi.1993.1261; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1994, MOL MEMBR BIOL, V11, P31, DOI 10.3109/09687689409161027; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; GROVES JD, 1992, J BIOL CHEM, V267, P22163; Groves JD, 1999, BIOCHEM J, V344, P699, DOI 10.1042/0264-6021:3440699; GROVES JD, 1993, FEBS LETT, V330, P186, DOI 10.1016/0014-5793(93)80270-5; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; JENNINGS ML, 1995, BIOCHEMISTRY-US, V34, P3588, DOI 10.1021/bi00011a013; Jiang LW, 1997, AM J PHYSIOL-CELL PH, V272, pC191, DOI 10.1152/ajpcell.1997.272.1.C191; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Kere J, 1999, AM J PHYSIOL-GASTR L, V276, pG7, DOI 10.1152/ajpgi.1999.276.1.G7; Knauf PA, 2002, P NATL ACAD SCI USA, V99, P10861, DOI 10.1073/pnas.162402399; Knauf PA, 2002, IMA VOL MATH APPL, V129, P85; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Kuma H, 2002, BIOCHEMISTRY-US, V41, P3311, DOI 10.1021/bi011678+; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; LINDENTHAL S, 1991, P NATL ACAD SCI USA, V88, P6540, DOI 10.1073/pnas.88.15.6540; Liu DS, 1996, BIOCHEMISTRY-US, V35, P15228, DOI 10.1021/bi961443b; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Peters LL, 1999, J CLIN INVEST, V103, P1527, DOI 10.1172/JCI5766; Quilty JA, 2002, BIOCHEM J, V368, P895, DOI 10.1042/BJ20020574; Quilty JA, 2002, AM J PHYSIOL-RENAL, V282, pF810, DOI 10.1152/ajprenal.00216.2001; Reithmeier RAF, 2001, BLOOD CELL MOL DIS, V27, P85, DOI 10.1006/bcmd.2000.0353; Salhany JM, 2003, BIOCHEMISTRY-US, V42, P1589, DOI 10.1021/bi0205294; SALHANY JM, 1978, BIOCHEMISTRY-US, V17, P3354, DOI 10.1021/bi00609a028; SARABIA VE, 1993, J BIOL CHEM, V268, P10676; SCHNELL KF, 1984, PFLUG ARCH EUR J PHY, V402, P197, DOI 10.1007/BF00583335; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SCHWARTZ GJ, 1993, AM J PHYSIOL, V265, pF764, DOI 10.1152/ajprenal.1993.265.6.F764; Scozzafava A, 2002, BIOORG MED CHEM LETT, V12, P1177, DOI 10.1016/S0960-894X(02)00121-X; Spitzer KW, 2002, J PHYSIOL-LONDON, V541, P159, DOI 10.1113/jphysiol.2001.013268; Sterling D, 2002, BIOCHEM CELL BIOL, V80, P483, DOI 10.1139/O02-152; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Sterling D, 2002, AM J PHYSIOL-CELL PH, V283, pC1522, DOI 10.1152/ajpcell.00115.2002; Stewart AK, 2002, J GEN PHYSIOL, V120, P707, DOI 10.1085/jgp.20028641; Tanner MJA, 2002, CURR OPIN HEMATOL, V9, P133, DOI 10.1097/00062752-200203000-00009; Tanphaichitr VS, 1998, J CLIN INVEST, V102, P2173, DOI 10.1172/JCI4836; Taylor AM, 2001, BIOCHEM J, V359, P661, DOI 10.1042/0264-6021:3590661; Toye AM, 2002, BLOOD, V99, P342, DOI 10.1182/blood.V99.1.342; Tsuganezawa H, 2001, J BIOL CHEM, V276, P8180, DOI 10.1074/jbc.M004513200; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; Zhang DC, 2000, BLOOD, V96, P2925; Zhang Y, 1996, J BIOL CHEM, V271, P5741, DOI 10.1074/jbc.271.10.5741; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200; Zolotarev AS, 1999, BIOCHEMISTRY-US, V38, P8521, DOI 10.1021/bi990337h	68	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44949	44958		10.1074/jbc.M308660200	http://dx.doi.org/10.1074/jbc.M308660200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933803	hybrid			2022-12-27	WOS:000186306700131
J	Hafez, I; Stolpe, A; Lindau, M				Hafez, I; Stolpe, A; Lindau, M			Compound exocytosis and cumulative fusion in eosinophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITANCE MEASUREMENTS; SCHISTOSOMA-MANSONI; GRANULE MEMBRANES; CELL; DEGRANULATION; SECRETION; RESOLUTION; MECHANISM; PROTEINS; PH	Focal release of cytotoxic proteins by eosinophils onto the target surface plays an important role in parasite killing. Degranulation was stimulated by intracellular application of calcium and guanosine 5'-3-O-(thio)triphosphate via the recording patch pipette or via streptolysin-O permeabilization. Exocytotic fusion was monitored by capacitance measurements, whereas release of fluorescent weak bases, which accumulate selectively within eosinophil granules, was followed by fluorescence imaging. Several distinct types of granule fusion events were directly observed by simultaneous capacitance and fluorescence measurements. These are fusion of a single granule with the plasma membrane, intracellular granule-granule fusion, fusion of large compounds of pre-fused granules with the plasma membrane ( compound exocytosis), and sequential fusion of granules to granules previously fused to the plasma membrane. Extensive granule-granule fusion was also observed by electron microscopy of permeabilized cells. All these fusion mechanisms contribute to focal release. The coexistence of distinct modes of exocytosis suggests that their regulation may modulate effector functions of eosinophils during helminth infection and allergic response.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA	Cornell University	Lindau, M (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.	ml95@cornell.edu	Lindau, Manfred/ABD-3449-2021	Lindau, Manfred/0000-0002-5722-9557	NINDS NIH HHS [R01 NS038200-01A2, R01NS38200, R01 NS038200, R01 NS038200-03, R01 NS038200-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038200] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Angleson JK, 1999, NAT NEUROSCI, V2, P440, DOI 10.1038/8107; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; Butterworth A E, 1977, Curr Top Microbiol Immunol, V77, P127; Cochilla AJ, 2000, J CELL BIOL, V150, P839, DOI 10.1083/jcb.150.4.839; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DVORAK AM, 1981, LAB INVEST, V44, P174; GLAUERT AM, 1978, J CELL SCI, V34, P173, DOI 10.1007/BF01944659; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hartmann J, 2003, J BIOL CHEM, V278, P44929, DOI 10.1074/jbc.M306014200; HENDERSON WR, 1985, J CELL SCI, V73, P33; HENDERSON WR, 1983, AM J PATHOL, V111, P341; Hoffmann HJ, 2001, BIOCHEM BIOPH RES CO, V282, P194, DOI 10.1006/bbrc.2001.4499; Kurashima K, 1996, LAB INVEST, V75, P689; Lacy P, 2001, J ALLERGY CLIN IMMUN, V107, P671, DOI 10.1067/mai.2001.113562; Lacy P, 2001, CURR OPIN ALLERGY CL, V1, P79, DOI 10.1097/00130832-200102000-00014; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; LINDAU M, 1994, ANN NY ACAD SCI, V710, P232, DOI 10.1111/j.1749-6632.1994.tb26631.x; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Logan MR, 2002, J ALLERGY CLIN IMMUN, V109, P299, DOI 10.1067/mai.2002.121453; Mair N, 1999, AM J PHYSIOL-LUNG C, V276, pL376, DOI 10.1152/ajplung.1999.276.2.L376; MCLAREN DJ, 1977, CLIN EXP IMMUNOL, V30, P105; Meeusen ENT, 2000, PARASITOL TODAY, V16, P95, DOI 10.1016/S0169-4758(99)01607-5; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Niemeyer BA, 2000, J CELL SCI, V113, P4055; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; SCEPEK S, 1993, EMBO J, V12, P1811, DOI 10.1002/j.1460-2075.1993.tb05829.x; SCEPEK S, 1994, PARASITOL TODAY, V10, P276, DOI 10.1016/0169-4758(94)90146-5; TAI PC, 1981, BRIT J HAEMATOL, V49, P219, DOI 10.1111/j.1365-2141.1981.tb07218.x; Thompson RE, 2001, BIOPHYS J, V81, P937, DOI 10.1016/S0006-3495(01)75752-9; Walsh GM, 1999, CRIT REV CL LAB SCI, V36, P453, DOI 10.1080/10408369991239277; Yoo SH, 1996, J BIOL CHEM, V271, P1558	32	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44921	44928		10.1074/jbc.M306013200	http://dx.doi.org/10.1074/jbc.M306013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923203	Green Published, hybrid			2022-12-27	WOS:000186306700128
J	Babu, E; Kanai, Y; Chairoungdua, A; Kim, DK; Iribe, Y; Tangtrongsup, S; Jutabha, P; Li, YW; Ahmed, N; Sakamoto, S; Anzai, N; Nagamori, S; Endou, H				Babu, E; Kanai, Y; Chairoungdua, A; Kim, DK; Iribe, Y; Tangtrongsup, S; Jutabha, P; Li, YW; Ahmed, N; Sakamoto, S; Anzai, N; Nagamori, S; Endou, H			Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; ORGANIC ANION TRANSPORTER; 4F2 HEAVY-CHAIN; FUNCTIONAL-CHARACTERIZATION; EXPRESSION CLONING; SUBSTRATE SELECTIVITY; MOLECULAR-BIOLOGY; MEMBRANE-PROTEIN; LIVER-CELL; RAT-LIVER	A cDNA that encodes a novel Na+-independent neutral amino acid transporter was isolated from FLC4 human hepatocarcinoma cells by expression cloning. When expressed in Xenopus oocytes, the encoded protein designated LAT3 (L-type amino acid transporter 3) transported neutral amino acids such as L-leucine, L-isoleucine, L-valine, and L-phenylalanine. The LAT3-mediated transport was Na+-independent and inhibited by 2-aminobicyclo[ 2.2.1] heptane-2-carboxylic acid, consistent with the properties of system L. Distinct from already known system L transporters LAT1 and LAT2, which form heterodimeric complex with 4F2 heavy chain, LAT3 was functional by itself in Xenopus oocytes. The deduced amino acid sequence of LAT3 was identical to the gene product of POV1 reported as a prostate cancer-upregulated gene whose function was not determined, whereas it did not exhibit significant similarity to already identified transporters. The Eadie-Hofstee plots of LAT3-mediated transport were curvilinear, whereas the low affinity component is predominant at physiological plasma amino acid concentration. In addition to amino acid substrates, LAT3 recognized amino acid alcohols. The transport of L-leucine was electroneutral and mediated by a facilitated diffusion. In contrast, L-leucinol, L-valinol, and L-phenylalaninol, which have a net positive charge induced inward currents under voltage clamp, suggesting these compounds are transported by LAT3. LAT3-mediated transport was inhibited by the pretreatment with N-ethylmaleimide, consistent with the property of system L2 originally characterized in hepatocyte primary culture. Based on the substrate selectivity, affinity, and N-ethylmaleimide sensitivity, LAT3 is proposed to be a transporter subserving system L2. LAT3 should denote a new family of organic solute transporters.	Kyorin Univ, Sch Med, Dept Gen Med, Tokyo 1818611, Japan; Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo 1818611, Japan; Chiba Univ, Sch Med, Dept Urol, Chuo Ku, Chiba 2608670, Japan; Chosun Univ, Coll Dent, Dept Oral Physiol, Gwangju 501759, South Korea	Kyorin University; Kyorin University; Chiba University; Chosun University	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Gen Med, 6-20-2 Shinkawa, Tokyo 1818611, Japan.		Jutabha, Promsuk/AAE-9872-2022; ANZAI, NAOHIKO/K-9492-2017; Jutabha, Promsuk/AFF-4363-2022; Tangtrongsup, Sahatchai/U-6745-2019	ANZAI, NAOHIKO/0000-0003-0605-0458; Tangtrongsup, Sahatchai/0000-0001-9417-7736				Aoki Y, 1998, VIROLOGY, V250, P140, DOI 10.1006/viro.1998.9361; Asghar M, 2002, AM J PHYSIOL-RENAL, V283, pF350, DOI 10.1152/ajprenal.00361.2001; BELL GI, 1993, J BIOL CHEM, V268, P19161; Chairoungdua A, 2001, J BIOL CHEM, V276, P49390, DOI 10.1074/jbc.M107517200; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1975, CURRENT TOPICS MEMBR, V6, P227; Cole KA, 1998, GENOMICS, V51, P282, DOI 10.1006/geno.1998.5359; COONS DM, 1995, J BACTERIOL, V177, P3251, DOI 10.1128/jb.177.11.3251-3258.1995; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; Gallardo MA, 1996, J MEMBRANE BIOL, V152, P57, DOI 10.1007/s002329900085; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2000, J BIOL CHEM, V275, P20787, DOI 10.1074/jbc.M000634200; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kim D, 2002, BBA-BIOMEMBRANES, V1565, P112, DOI 10.1016/S0005-2736(02)00516-3; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; KUBAR J, 1990, CELL SIGNAL, V2, P587, DOI 10.1016/0898-6568(90)90081-K; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Matsuo H, 2002, J BIOL CHEM, V277, P21017, DOI 10.1074/jbc.M200019200; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; MITSUMOTO Y, 1986, J BIOL CHEM, V261, P4549; Mizoguchi K, 2001, KIDNEY INT, V59, P1821, DOI 10.1046/j.1523-1755.2001.0590051821.x; Nagamori S, 2000, J GASTROENTEROL, V35, P493, DOI 10.1007/s005350070071; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NOVAK DA, 1994, BIOCHEM J, V301, P671, DOI 10.1042/bj3010671; OXENDER DL, 1963, NATURE, V197, P765, DOI 10.1038/197765a0; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Romero MF, 1998, METHOD ENZYMOL, V296, P17; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SALTER M, 1986, BIOCHEM J, V233, P499, DOI 10.1042/bj2330499; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Sekine T, 2000, PFLUG ARCH EUR J PHY, V440, P337, DOI 10.1007/s004240000297; Sekine T, 1998, AM J PHYSIOL-RENAL, V275, pF298, DOI 10.1152/ajprenal.1998.275.2.F298; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Skotheim RI, 2002, CANCER RES, V62, P2359; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4	51	185	193	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43838	43845		10.1074/jbc.M305221200	http://dx.doi.org/10.1074/jbc.M305221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930836	hybrid			2022-12-27	WOS:000186157000134
J	Seo, SJ; Cheon, HM; Sun, JX; Sappington, TW; Raikhel, AS				Seo, SJ; Cheon, HM; Sun, JX; Sappington, TW; Raikhel, AS			Tissue- and stage-specific expression of two lipophorin receptor variants with seven and eight ligand-binding repeats in the adult mosquito	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LYSOSOMAL ASPARTIC PROTEASE; MESSENGER-RNA DEGRADATION; CHICKEN OOCYTE RECEPTOR; GENE FAMILY-MEMBER; FAT-BODY CELLS; VITELLOGENIN RECEPTORS; LDL-RECEPTOR; MOLECULAR CHARACTERIZATION; AEDES-AEGYPTI	We identified two splice variants of lipophorin receptor (LpR) gene products specific to the mosquito fat body (AaLpRfb) and ovary ( AaLpRov) with respective molecular masses of 99.3 and 128.9 kDa. Each LpR variant encodes a member of the low density lipoprotein receptor family with five characteristic domains: 1) ligand recognition, 2) epidermal growth factor precursor, 3) putative O-linked sugar, 4) single membrane-spanning domains, and 5) the cytoplasmic tail with a highly conserved internalization signal FDNPVY. Proposed phylogenetic relationships among low density lipoprotein receptor superfamily members suggest that the LpRs of insects are more closely related to vertebrate low density lipoprotein receptors and very low density lipoprotein receptor/vitellogenin receptor than to insect vitellogenin receptor/yolk protein receptors. Two mosquito LpR isoforms differ in their amino termini, the ligand-binding domains, and O-linked sugar domains, which are generated by differential splicing. Polymerase chain reaction and Southern blot hybridization analyses show that these two transcripts originated from a single gene. Significantly, the putative ligand-binding domain consists of seven and eight complement-type, cysteine-rich repeats in AaLpRfb and AaLRov, respectively. Seven cysteine-rich repeats in AaLpRfb are identical to the second through eighth repeats of AaLpRov. Previous analyses ( 1) have indicated that the AaLpRov transcript is present exclusively in ovarian germ-line cells, nurse cells, and oocytes throughout the previtellogenic and vitellogenic stages, with the peak at 24 - 30 h after blood meal, coincident with the peak of yolk protein uptake. In contrast, the fat body-specific AaLpRfb transcript expression is restricted to the postvitellogenic period, during which yolk protein production is terminated and the fat body is transformed to a storage depot of lipid, carbohydrate, and protein.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Gyeongsang Natl Univ, Coll Nat Sci, Div Life Sci, Jinju 660701, Gyeongnam, South Korea; Michigan State Univ, Dept Entomol, E Lansing, MI 48824 USA; Iowa State Univ, USDA ARS, Ames, IA 50011 USA	University of California System; University of California Riverside; Gyeongsang National University; Michigan State University; Iowa State University; United States Department of Agriculture (USDA)	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Sun, Jianxin/B-5866-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716, R01AI036959, R01AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI024716, AI 024716, AI 36959] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arrese EL, 2001, INSECT BIOCHEM MOLEC, V31, P7, DOI 10.1016/S0965-1748(00)00102-8; BAUERFEIND R, 1992, J INSECT PHYSIOL, V38, P185, DOI 10.1016/0022-1910(92)90067-N; BOROVSKY D, 1985, ARCH INSECT BIOCHEM, V2, P333, DOI 10.1002/arch.940020402; BUJO H, 1995, P NATL ACAD SCI USA, V92, P9905, DOI 10.1073/pnas.92.21.9905; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cheon HM, 2001, INSECT BIOCHEM MOLEC, V31, P753, DOI 10.1016/S0965-1748(01)00068-6; Cho WL, 1999, J BIOL CHEM, V274, P13311, DOI 10.1074/jbc.274.19.13311; CHO WL, 1992, J BIOL CHEM, V267, P21823; CHO WL, 1991, P NATL ACAD SCI USA, V88, P10821, DOI 10.1073/pnas.88.23.10821; CHO WL, 1991, INSECT BIOCHEM, V21, P165, DOI 10.1016/0020-1790(91)90047-I; Cho WL, 2001, INSECT BIOCHEM MOLEC, V31, P283, DOI 10.1016/S0965-1748(00)00175-2; Dantuma NP, 1999, J LIPID RES, V40, P973; Dantuma NP, 1997, J LIPID RES, V38, P254; Dantuma NP, 1998, J LIPID RES, V39, P1877; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DEITSCH KW, 1993, INSECT MOL BIOL, V242, P205; DHADIALLA TS, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P275; Gliemann J, 1998, BIOL CHEM, V379, P951; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; KAWOOYA JK, 1988, J BIOL CHEM, V263, P8740; Kokoza VA, 1997, J BIOL CHEM, V272, P1164, DOI 10.1074/jbc.272.2.1164; LAW JH, 1989, J BIOL CHEM, V264, P16335; Lee CS, 2003, INSECT BIOCHEM MOLEC, V33, P761, DOI 10.1016/S0965-1748(03)00066-3; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; Magrane J, 1998, J LIPID RES, V39, P2172; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MEOLA R, 1972, J MED ENTOMOL, V9, P99, DOI 10.1093/jmedent/9.1.99; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NIMPF J, 2000, BIOCHIM BIOPHYS ACTA, V1259, P287; OCHMAN H, 1988, GENETICS, V120, P621; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; POLVINO WJ, 1992, SOMAT CELL MOLEC GEN, V18, P443, DOI 10.1007/BF01233084; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V42, P527; Ryan RO, 2000, ANNU REV ENTOMOL, V45, P233, DOI 10.1146/annurev.ento.45.1.233; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAMBROOK J, 1989, MOL LAB MANUAL; Sappington TW, 1996, P NATL ACAD SCI USA, V93, P8934, DOI 10.1073/pnas.93.17.8934; Sappington TW, 1998, INSECT BIOCHEM MOLEC, V28, P277, DOI 10.1016/S0965-1748(97)00110-0; Sappington TW, 1998, J MOL EVOL, V46, P476, DOI 10.1007/PL00006328; Schneider WJ, 1996, INT REV CYTOL, V166, P103, DOI 10.1016/S0074-7696(08)62507-3; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Sun JX, 2000, INSECT BIOCHEM MOLEC, V30, P1161, DOI 10.1016/S0965-1748(00)00093-X; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TELFER WH, 1991, INSECT BIOCHEM, V21, P653, DOI 10.1016/0020-1790(91)90036-E; TSUCHIDA K, 1990, J BIOL CHEM, V265, P5761; Van Hoof D, 2003, J LIPID RES, V44, P1431, DOI 10.1194/jlr.M300022-JLR200; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	57	38	41	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41954	41962		10.1074/jbc.M308200200	http://dx.doi.org/10.1074/jbc.M308200200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917414	hybrid, Green Submitted			2022-12-27	WOS:000185989500050
J	Ceni, C; Muller-Steffner, H; Lund, F; Pochon, N; Schweitzer, A; De Waard, M; Schuber, F; Villaz, M; Moutin, MJ				Ceni, C; Muller-Steffner, H; Lund, F; Pochon, N; Schweitzer, A; De Waard, M; Schuber, F; Villaz, M; Moutin, MJ			Evidence for an intracellular ADP-ribosyl cyclase/NAD(+)-glycohydrolase in brain from CD38-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; RAT CARDIAC MYOCYTES; SURFACE-MOLECULE; CYCLASE ACTIVITY; NEUROTRANSMITTER RELEASE; FUNCTIONAL EXPRESSION; RYANODINE RECEPTOR; ANTIGEN CD38; CA2+ RELEASE; CELLS	Cyclic ADP-ribose, a metabolite of NAD(+), is known to modulate intracellular calcium levels and signaling in various cell types, including neural cells. The enzymes responsible for producing cyclic ADP-ribose in the cytoplasm of mammalian cells remain unknown; however, two mammalian enzymes that are capable of producing cyclic ADP-ribose extracellularly have been identified, CD38 and CD157. The present study investigated whether an ADP-ribosyl cyclase/NAD(+)-glycohydrolase independent of CD38 is present in brain tissue. To address this question, NAD(+) metabolizing activities were accurately examined in developing and adult Cd38(-/-) mouse brain protein extracts and cells. Low ADP-ribosyl cyclase and NAD(+)-glycohydrolase activities ( in the range of pmol of product formed/mg of protein/min) were detected in Cd38(-/-) brain at all developmental stages studied. Both activities were found to be associated with cell membranes. The activities were significantly higher in Triton X-100-treated neural cells compared with intact cells, suggesting an intracellular location of the novel cyclase. The cyclase and glycohydrolase activities were optimal at pH 6.0 and were inhibited by zinc, properties which are distinct from those of CD157. Both activities were enhanced by guanosine 5'-O-(3-thiotriphosphate), a result suggesting that the novel enzyme may be regulated by a G protein-dependent mechanism. Altogether our results indicate the presence of an intracellular membrane-bound ADP-ribosyl cyclase/NAD(+)-glycohydrolase distinct from CD38 and from CD157 in mouse brain. This novel enzyme, which is more active in the developing brain than in the adult tissue, may play an important role in cyclic ADP-ribose-mediated calcium signaling during brain development as well as in adult tissue.	CEA, DRDC, INSERM, EMI 9931,Lab Canaux Ion & Signalisat, F-38051 Grenoble 9, France; Univ Strasbourg, Fac Pharm, CNRS, UMR 7514,Lab Chim Bioorgan, F-67400 Strasbourg, France; CEA, DRDC, INSERM, U366,Lab Cytosquelette, F-38051 Grenoble, France; Trudeau Inst Inc, Saranac Lake, NY 12983 USA	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Trudeau Institute	Moutin, MJ (corresponding author), CEA, DRDC, INSERM, EMI 9931,Lab Canaux Ion & Signalisat, 17 Ave Martyrs, F-38051 Grenoble 9, France.	moutin@dsvgre.cea.fr	Moutin, Marie-Jo/P-7518-2017; De Waard, Michel/G-7406-2014	Moutin, Marie-Jo/0000-0003-2681-9818; De Waard, Michel/0000-0002-2782-9615	NIAID NIH HHS [AI43929] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI043929] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Augustin A, 2000, BIOCHEM J, V345, P43, DOI 10.1042/0264-6021:3450043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budde T, 2000, NEURON, V26, P483, DOI 10.1016/S0896-6273(00)81180-0; Cakir-Kiefer C, 2000, BIOCHEM J, V349, P203, DOI 10.1042/0264-6021:3490203; Ceni C, 2003, BIOCHEM J, V370, P175, DOI 10.1042/BJ20020604; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; Graeff RM, 1998, J BIOL CHEM, V273, P118, DOI 10.1074/jbc.273.1.118; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Higashida H, 1997, J BIOL CHEM, V272, P31272, DOI 10.1074/jbc.272.50.31272; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Hussain AMM, 1998, PROTEIN EXPRES PURIF, V12, P133, DOI 10.1006/prep.1997.0811; ITOH M, 1994, BIOCHEM BIOPH RES CO, V203, P1309, DOI 10.1006/bbrc.1994.2325; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; Kajimoto Y, 1996, BIOCHEM BIOPH RES CO, V219, P941, DOI 10.1006/bbrc.1996.0327; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; Lee Hon Cheung, 1998, Cell Biochemistry and Biophysics, V28, P1, DOI 10.1007/BF02738306; LI Q, 1994, BIOCHEM BIOPH RES CO, V202, P629, DOI 10.1006/bbrc.1994.1974; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; Missiaen L, 1998, BIOCHEM J, V329, P489, DOI 10.1042/bj3290489; MIZUGUCHI M, 1995, BRAIN RES, V697, P235, DOI 10.1016/0006-8993(95)00885-T; Morikawa H, 2003, J NEUROSCI, V23, P149; Mothet JP, 1998, J PHYSIOL-LONDON, V507, P405, DOI 10.1111/j.1469-7793.1998.405bt.x; Noda M, 2003, J NEUROCHEM, V84, P222, DOI 10.1046/j.1471-4159.2003.01518.x; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Pollock J, 1999, CELL CALCIUM, V26, P139, DOI 10.1054/ceca.1999.0064; Reyes-Harde M, 1999, P NATL ACAD SCI USA, V96, P4061, DOI 10.1073/pnas.96.7.4061; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TWU JS, 1977, ARCH BIOCHEM BIOPHYS, V184, P249, DOI 10.1016/0003-9861(77)90348-4; Vanlingen S, 2001, BIOCHEM PHARMACOL, V61, P803, DOI 10.1016/S0006-2952(01)00540-8; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; Walseth TF, 1997, METHOD ENZYMOL, V280, P287; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; Yamamoto-Katayama S, 2002, J MOL BIOL, V316, P711, DOI 10.1006/jmbi.2001.5386	43	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40670	40678		10.1074/jbc.M301196200	http://dx.doi.org/10.1074/jbc.M301196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909645	hybrid			2022-12-27	WOS:000185847200031
J	Lopez, RG; Carron, C; Ghysdael, J				Lopez, RG; Carron, C; Ghysdael, J			v-SRC specifically regulates the nucleo-cytoplasmic delocalization of the major isoform of TEL (ETV6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTIONAL REPRESSOR ACTIVITY; PUTATIVE TUMOR-SUPPRESSOR; RAS-TRANSFORMED-CELLS; ETS DOMAIN PROTEIN; NUCLEAR EXPORT; DNA-BINDING; HISTONE DEACETYLASE-3; STAT3 ACTIVATION; FUSION PROTEIN	TEL is a frequent target of chromosomal translocations in human cancer and an alleged tumor suppressor gene. TEL encodes two isoforms: a major TEL-M1 isoform as well as TEL-M43, which lacks the first 42 amino acid residues of TEL-M1. Both isoforms are potent transcriptional repressors that can inhibit RAS-induced transformation. Here we show that the v-SRC protein-tyrosine kinase relieves the repressive activity of TEL-M1, an activity that is associated with the v-SRC-induced delocalization of TEL-M1 from the nucleus to the cytoplasm. TEL-M1 delocalization requires the kinase activity of v-SRC and is not induced by oncogenic RAS or AKT. Cytoplasmic delocalization of TEL-M1 in response to v-SRC critically depends upon its unique aminoterminal domain (SRCD domain) because (i) v-SRC did not inhibit the repressive properties of TEL-M43, nor affected TEL-M43 nuclear localization; (ii) fusion of the first 52 amino acid residues of TEL-M1 to FLI-1, an ETS protein insensitive to v-SRC-induced delocalization, is sufficient to confer v-SRC-induced delocalization to this TEL/FLI-1 chimeric protein. The v-SRC-induced nucleo-cytoplasmic delocalization of TEL-M1 does not involve phosphorylation of the SRCD and does not require TEL self-association and repressive domains. Finally, enforced expression of the v-SRC-insensitive TEL-M43, but not of TEL-M1, inhibits v-SRC-induced transformation of NIH3T3 fibroblasts. These results identify a regulatory domain in TEL that specifically impinges on the subcellular localization of its major TEL-M1 isoform. They, furthermore, indicate that inhibition of TEL-M1 nuclear function is required for v-SRC to induce cellular transformation.	Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Ghysdael, J (corresponding author), Inst Curie, CNRS, UMR 146, Ctr Univ,Bat 110, F-91405 Orsay, France.	Jacques.Ghysdael@curie.u-psud.fr	Carron, Clémence/AAG-6304-2021; GHYSDAEL, Jacques/F-3377-2013	Carron, Clemence/0000-0002-8776-7380				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Boccuni P, 2003, J BIOL CHEM, V278, P15412, DOI 10.1074/jbc.M300592200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Ducret C, 1999, MOL CELL BIOL, V19, P7076; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Griesinger F, 2002, BRIT J HAEMATOL, V119, P454, DOI 10.1046/j.1365-2141.2002.03850.x; Guidez F, 2000, BLOOD, V96, P2557; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Montpetit A, 2001, ONCOGENE, V20, P3437, DOI 10.1038/sj.onc.1204444; Nordentoft I, 2003, BIOCHEM J, V374, P165, DOI 10.1042/BJ20030087; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Peeters P, 1997, CANCER RES, V57, P564; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Van Rompaey L, 2002, BIOCHEM BIOPH RES CO, V291, P820, DOI 10.1006/bbrc.2002.6513; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100	56	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41316	41325		10.1074/jbc.M306435200	http://dx.doi.org/10.1074/jbc.M306435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893822	hybrid			2022-12-27	WOS:000185847200111
J	Saito, H; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Phillips, MC; Lund-Katz, S				Saito, H; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Phillips, MC; Lund-Katz, S			Effects of polymorphism on the lipid interaction of human apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; LDL RECEPTOR-BINDING; HUMAN PLASMA-LIPOPROTEINS; LOW-DENSITY LIPOPROTEINS; E ISOFORMS; EXCHANGEABLE APOLIPOPROTEIN; ALZHEIMERS-DISEASE; CONFORMATIONAL-CHANGES; APOLIPOPHORIN-III; AQUEOUS-SOLUTION	ApoE exists as three common isoforms, apoE2, apoE3, and apoE4; apoE2 and apoE3 preferentially bind to high density lipoproteins, whereas apoE4 prefers very low density lipoproteins ( VLDL). To understand the molecular basis for the different lipoprotein distributions of these isoforms in human plasma, we examined the lipid- binding properties of the apoE isoforms and some mutants using lipid emulsions. With both large ( 120 nm) and small ( 35 nm) emulsion particles, the binding affinity of apoE4 was much higher than that of apoE2 and apoE3, whereas the maximal binding capacities were similar among the three isoforms. The 22-kDa N-terminal fragment of apoE4 displayed a much higher binding capacity than did apoE2 and apoE3. The apoE4(E255A) mutant, which has no electrostatic interaction between Arg(61) and Glu(255), showed binding behavior similar to that of apoE3, indicating that N- and C-terminal domain interaction in apoE4 is responsible for its high affinity for lipid. In addition, the apoE3( P267A) mutant, which is postulated to contain a long alpha-helix in the C-terminal domain, had significantly decreased binding capacities for both sizes of emulsion particle, suggesting that the apoE4 preference for VLDL is not due to a stabilized long alpha-helical structure. Isothermal titration calorimetry measurements showed that there is no significant difference in thermodynamic parameters for emulsion binding among the apoE isoforms. However, fluorescence measurements of 8-anilino-1-naphthalenesulfonic acid binding to apoE indicated that apoE4 has more exposed hydrophobic surface compared with apoE3 mainly due to the different tertiary organization of the C-terminal domain. The less organized structure in the C-terminal domain of apoE4 leads to the higher affinity for lipid, contributing to its preferential association with VLDL. In fact, we found that apoE4 binds to VLDL with higher affinity compared with apoE3.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst,Abramson Res Ctr, Philadelphia, PA 19104 USA; Natl Inst Hlth Sci, Osaka Branch, Osaka 5400006, Japan; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Inst Cardiovasc Res, San Francisco, CA 94141 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institute of Health Sciences - Japan; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Lund-Katz, S (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst,Abramson Res Ctr, Abramson Res Bldg,Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56083] Funding Source: Medline; NIA NIH HHS [AG20235] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acharya P, 2002, BBA-MOL CELL BIOL L, V1584, P9, DOI 10.1016/S1388-1981(02)00263-9; AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; Boyle KE, 1999, BBA-PROTEIN STRUCT M, V1430, P302, DOI 10.1016/S0167-4838(99)00009-6; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; deKnijff P, 1996, CURR OPIN LIPIDOL, V7, P59, DOI 10.1097/00041433-199604000-00002; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DERKSEN A, 1989, BIOCHEMISTRY-US, V28, P900, DOI 10.1021/bi00428a074; Dong J, 2000, J LIPID RES, V41, P1783; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; Lund-Katz S, 2001, J LIPID RES, V42, P894; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; Mahley RW, 1999, J LIPID RES, V40, P1933; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Massey JB, 1998, BIOPHYS J, V74, P869, DOI 10.1016/S0006-3495(98)74010-X; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; Perugini MA, 2002, EUR J BIOCHEM, V269, P5939, DOI 10.1046/j.1432-1033.2002.03319.x; Pillot T, 1999, J NEUROCHEM, V72, P230, DOI 10.1046/j.1471-4159.1999.0720230.x; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Saito H, 1997, J LIPID RES, V38, P287; Saito H, 2003, J BIOL CHEM, V278, P14782, DOI 10.1074/jbc.M213207200; Saito H, 2001, LANGMUIR, V17, P2528, DOI 10.1021/la001583t; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; SEGREST JP, 1992, J LIPID RES, V33, P141; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Weers PMM, 2003, BIOPHYS CHEM, V100, P481, DOI 10.1016/S0301-4622(02)00300-9; Weers PMM, 2001, BIOCHEMISTRY-US, V40, P7754, DOI 10.1021/bi010410f; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	55	70	77	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40723	40729		10.1074/jbc.M304814200	http://dx.doi.org/10.1074/jbc.M304814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917433	hybrid			2022-12-27	WOS:000185847200038
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DISULFIDE CROSS-LINKING; CYSTEINE-SCANNING MUTAGENESIS; TRANSMEMBRANE SEGMENTS; COVALENT MODIFICATION; MEMBRANE TOPOLOGY; DOMAIN; SITE; TRANSPORTER; NUCLEOTIDE	The human multidrug resistance P-glycoprotein (P-gp, ABCB1) transports a wide variety of structurally diverse compounds out of the cell. The drug-binding pocket of P-gp is located in the transmembrane domains. Although occupation of the drug-binding pocket by one molecule is sufficient to activate the ATPase activity of P-gp, the drug-binding pocket may be large enough to accommodate two different substrates at the same time. In this study, we used cysteine-scanning mutagenesis to test whether P-gp could simultaneously interact with the thiol-reactive drug substrate, Tris-(2-maleimidoethyl)amine (TMEA) and a second drug substrate. TMEA is a cross-linker substrate of P-gp that allowed us to test for stimulation of cross-linking by a second substrate such as calcein-acetoxymethyl ester, colchicine, demecolcine, cyclosporin A, rhodamine B, progesterone, and verapamil. We report that verapamil induced TMEA cross-linking of mutant F343C(TM6)/V982C(TM12). By contrast, no cross-linked product was detected in mutants F343C(TM6), V982C(TM12), or F343C(TM6)/V982C(TM12) in the presence of TMEA alone. The verapamil-stimulated ATPase activity of mutant F343C(TM6)/V982C(TM12) in the presence of TMEA decreased with increased cross-linking of the mutant protein. These results show that binding of verapamil must induce changes in the drug-binding pocket (induced-fit mechanism) resulting in exposure of residues F343C(TM6)/V982C(TM12) to TMEA. The results also indicate that the common drug-binding pocket in P-gp is large enough to accommodate both verapamil and TMEA simultaneously and suggests that the substrates must occupy different regions in the common drug-binding pocket.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED M, 1994, J BIOL CHEM, V269, P28506; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Brooun A, 1999, J BACTERIOL, V181, P5131, DOI 10.1128/JB.181.16.5131-5133.1999; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Garrigos M, 1997, EUR J BIOCHEM, V244, P664, DOI 10.1111/j.1432-1033.1997.00664.x; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kenyon G L, 1977, Methods Enzymol, V47, P407; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Thomas Hilary, 2003, Cancer Control, V10, P159; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200	47	155	159	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39706	39710		10.1074/jbc.M308559200	http://dx.doi.org/10.1074/jbc.M308559200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12909621	hybrid			2022-12-27	WOS:000185713800056
J	Luo, B; Prescott, SM; Topham, MK				Luo, B; Prescott, SM; Topham, MK			Protein kinase C alpha phosphorylates and negatively regulates diacylglycerol kinase zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; CELL-CYCLE; ASSOCIATION; RELEASE; BINDING; CLONING; FAMILY	Diacylglycerol kinase (DGK) terminates diacylglycerol (DAG) signaling by phosphorylating DAG to produce phosphatidic acid, which also has signaling properties. Thus, precise control of DGK activity is essential for proper signal transduction. We demonstrated previously that a peptide corresponding to the myristoylated alanine-rich C kinase substrate ( MARCKS) phosphorylation site domain (PSD) in DGKzeta was phosphorylated in vitro by an active fragment of protein kinase C (PKC). In the present study, we tested full-length DGKzeta and found that PKCalpha phosphorylated DGKzeta on serines within the MARCKS PSD in vitro and in vivo. DGKzeta also coimmunoprecipitated with PKCalpha, suggesting that they reside in a regulated signaling complex. We then tested whether phosphorylation affected DAG kinase activity. We found that a mutant ( DGKzeta S/D) in which serines within the MARCKS PSD were altered to aspartates ( to mimic phosphorylation) had lower activity compared with wild-type DGKzeta or a control mutant (DGKzeta S/N) in which the same serines were changed to asparagines. Furthermore, activation of PKCalpha by phorbol 12-myristate 13-acetate inhibited the activity of wild-type DGKzeta, but not DGKzeta S/D, in human embryonic kidney 293 cells. These results suggest that by phosphorylating the MARCKS PSD, PKCalpha attenuates DGKzeta activity. Supporting this, we found that cells expressing DGKzeta S/D had higher DAG levels and grew more rapidly compared with cells expressing DGKzeta S/N that could not be phosphorylated. Taken together, these results indicate that PKCalpha phosphorylates DGKzeta in cells, and this phosphorylation inhibits its kinase activity to remove cellular DAG, thereby affecting cell growth.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Topham, MK (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84132 USA.	matt.topham@hci.utah.edu						Balciunaite E, 2000, CURR BIOL, V10, P261, DOI 10.1016/S0960-9822(00)00358-4; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; Divecha N, 1997, BIOCHEM SOC T, V25, P571, DOI 10.1042/bst0250571; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KEIZER J, 1995, MOL BIOL CELL, V6, P945, DOI 10.1091/mbc.6.8.945; Luo B, 2003, J CELL BIOL, V160, P929, DOI 10.1083/jcb.200208120; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pawson T, 2000, GENE DEV, V14, P1027; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rojnuckarin P, 2001, BLOOD, V97, P154, DOI 10.1182/blood.V97.1.154; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; Smith PJ, 2002, SIGHT SOUND, V12, P32; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130	39	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39542	39547		10.1074/jbc.M307153200	http://dx.doi.org/10.1074/jbc.M307153200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890670	hybrid			2022-12-27	WOS:000185713800035
J	Perez, CF; Mukherjee, S; Allen, PD				Perez, CF; Mukherjee, S; Allen, PD			Amino acids 1-1,680 of ryanodine receptor type 1 hold critical determinants of skeletal type for excitation-contraction coupling - Role of divergence domain D2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIHYDROPYRIDINE RECEPTOR; CENTRAL CORE DISEASE; II-III LOOP; CALCIUM-RELEASE UNITS; CA2+ RELEASE; RYR1; REGIONS; IDENTIFICATION; LOCALIZATION; SEQUENCE	To identify domains of the ryanodine receptor (RyR1) that are functionally relevant for excitation-contraction (EC) coupling in vivo, we have studied the ability of RyR1/RyR3 chimera to rescue skeletal EC coupling in dyspedic myotubes. In this work we show that chimeric receptors containing amino acids 1 - 1,680 of RyR1 were able to render depolarization-induced Ca2+ release to RyR3. Within this region, residues 1,272 - 1,455, containing divergent domain D2 of RyR1, proved to be a critical element because the absence of this region selectively abolished depolarization-evoked Ca2+ transients without affecting chemically induced activation. Although the D2 domain by itself failed to restore skeletal EC coupling to RyR3, the addition of the D2 region resulted in a dramatic enhancement of EC coupling restored by an RyR3 chimera containing amino acids 1,681 - 3,770 of RyR1. These results suggest that although the D2 domain of RyR1 plays a key role during EC coupling, additional region(s) from the N-terminal end of RyR1 as well as previously identified regions of the central portion of the receptor are needed in order to allow normal EC coupling.	Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Perez, CF (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol, 75 Francis St, Boston, MA 02115 USA.				FIC NIH HHS [F05TW05455] Funding Source: Medline; NIAMS NIH HHS [P01AR47605] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW005455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047605] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIREY JA, 1990, J BIOL CHEM, V265, P14187; Avila G, 2003, J GEN PHYSIOL, V121, P277, DOI 10.1085/jgp.200308791; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Buck ED, 1997, J BIOL CHEM, V272, P7360, DOI 10.1074/jbc.272.11.7360; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Dirksen RT, 2002, TRENDS CARDIOVAS MED, V12, P189, DOI 10.1016/S1050-1738(02)00163-9; Dulhunty AF, 2002, PROG BIOPHYS MOL BIO, V79, P45, DOI 10.1016/S0079-6107(02)00013-5; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; Mouton J, 2001, BIOCHEM J, V354, P597, DOI 10.1042/0264-6021:3540597; Murray BE, 1997, BIOCHEM J, V324, P689, DOI 10.1042/bj3240689; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161	33	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39644	39652		10.1074/jbc.M305160200	http://dx.doi.org/10.1074/jbc.M305160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900411	hybrid			2022-12-27	WOS:000185713800049
J	Richter, S; Lamppa, GK				Richter, S; Lamppa, GK			Structural properties of the chloroplast stromal processing peptidase required for its function in transit peptide removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; INSULIN-DEGRADING ENZYME; PROTEIN IMPORT; BETA-SUBUNIT; ACTIVE-SITE; CATALYTIC-ACTIVITY; ESCHERICHIA-COLI; CYSTEINE SWITCH; SIGNAL PEPTIDE; RAT-LIVER	The stromal processing peptidase (SPP) catalyzes removal of transit peptides from a diversity of precursor proteins imported into chloroplasts. SPP contains an HXXEH zinc-binding motif characteristic of members of the metallopeptidase family M16. We previously found that the three steps of precursor processing by SPP (i.e. transit peptide binding, removal, and conversion to a degradable subfragment) are mediated by features that reside in the C-terminal 10 - 15 residues of the transit peptide. In this study, we performed a mutational analysis of SPP to identify structural elements that determine its function. SPP loses the ability to proteolytically remove the transit peptide when residues of the HXXEH motif, found in an N-terminal region, are mutated. Deletion of 240 amino acids from its C terminus also abolishes activity. Interestingly, however, SPP can still carry out the initial binding step, recognizing the C-terminal residues of the transit peptide. Hence, transit peptide binding and removal are two separable steps of the overall processing reaction. Transit peptide conversion to a subfragment also depends on the HXXEH motif. The precursor of SPP, containing an unusually long transit peptide itself, is not proteolytically active. Thus, the SPP precursor is synthesized as a latent form of the metallopeptidase.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Lamppa, GK (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.	gklamppa@midway.uchicago.edu						ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Chen K, 2000, BIOCHEM SOC T, V28, P485, DOI 10.1042/0300-5127:0280485; CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; deChateau M, 1996, P NATL ACAD SCI USA, V93, P8490, DOI 10.1073/pnas.93.16.8490; GEHM BD, 1993, J BIOL CHEM, V268, P7943; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kojima K, 1998, J BIOL CHEM, V273, P32542, DOI 10.1074/jbc.273.49.32542; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer U, 1996, MOL MICROBIOL, V21, P301, DOI 10.1046/j.1365-2958.1996.6481362.x; Makarova KS, 1999, PROTEIN SCI, V8, P2537; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Richter S, 1999, J CELL BIOL, V147, P33, DOI 10.1083/jcb.147.1.33; Richter S, 1998, MOL GEN GENET, V257, P534, DOI 10.1007/s004380050679; Richter S, 2002, J BIOL CHEM, V277, P43888, DOI 10.1074/jbc.M206020200; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Stahl A, 2002, J BIOL CHEM, V277, P41931, DOI 10.1074/jbc.M205500200; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vothknecht UC, 2000, BIOL CHEM, V381, P887, DOI 10.1515/BC.2000.110; Wan JX, 1998, PLANT J, V15, P459, DOI 10.1046/j.1365-313X.1998.00224.x; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; Zhong R, 2003, PLANT J, V34, P802, DOI 10.1046/j.1365-313X.2003.01772.x	48	43	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39497	39502		10.1074/jbc.M305729200	http://dx.doi.org/10.1074/jbc.M305729200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888578	hybrid			2022-12-27	WOS:000185713800029
J	Harper, N; Hughes, MA; Farrow, SN; Cohen, GM; MacFarlane, M				Harper, N; Hughes, MA; Farrow, SN; Cohen, GM; MacFarlane, M			Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; P55 TNF RECEPTOR; CYTOCHROME-C; HUMAN-MELANOMA; CD95-MEDIATED APOPTOSIS; MITOCHONDRIAL RELEASE; DOWN-REGULATION; CD95 FAS/APO-1	We have further examined the mechanism by which phorbol ester-mediated protein kinase C (PKC) activation protects against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity. We now report that activation of PKC targets death receptor signaling complex formation. Pre-treatment with 12-O-tetradecanoylphorbol-13-acetate (PMA) led to inhibition of TRAIL-induced apoptosis in HeLa cells, which was characterized by a reduction in phosphatidylserine (PS) externalization, decreased caspase-8 processing, and incomplete maturation and activation of caspase-3. These effects of PMA were completely abrogated by the PKC inhibitor, bisindolylmaleimide I (Bis I), clearly implicating PKC in the protective effect of PMA. TRAIL-induced mitochondrial release of the apoptosis mediators cytochrome c and Smac was blocked by PMA. This, together with the observed decrease in Bid cleavage, suggested that PKC activation modulates apical events in TRAIL signaling upstream of mitochondria. This was confirmed by analysis of TRAIL death-inducing signaling complex formation, which was disrupted in PMA-treated cells as evidenced by a marked reduction in Fas-associated death domain protein (FADD) recruitment, an effect that could not be explained by any change in FADD phosphorylation state. In an in vitro binding assay, the intracellular domains of both TRAIL-R1 and TRAIL-R2 bound FADD: activation of PKC significantly inhibited this interaction suggesting that PKC may be targeting key apical components of death receptor signaling. Significantly, this effect was not confined to TRAIL, because isolation of the native TNF receptor signaling complex revealed that PKC activation also inhibited TNF receptor-associated death domain protein recruitment to TNF-R1 and TNF-induced phosphorylation of IkappaB-alpha. Taken together, these results show that PKC activation specifically inhibits the recruitment of key obligatory death domain-containing adaptor proteins to their respective membrane-associated signaling complexes, thereby modulating TRAIL-induced apoptosis and TNF-induced NF-kappaB activation, respectively.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Glaxo SmithKline Med Res Ctr, Stevenage SG1 2NY, Herts, England	University of Leicester; GlaxoSmithKline	MacFarlane, M (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mm21@le.ac.uk	Cohen, Gerald M/A-1687-2008					AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Frankel SK, 2001, BIOCHEM BIOPH RES CO, V288, P313, DOI 10.1006/bbrc.2001.5761; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; McFarlane SM, 2002, FEBS LETT, V515, P119, DOI 10.1016/S0014-5793(02)02450-X; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Ryu SW, 2003, J BIOL CHEM, V278, P24003, DOI 10.1074/jbc.M302200200; Sarker M, 2002, ONCOGENE, V21, P4323, DOI 10.1038/sj.onc.1205523; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; Varadhachary AS, 2001, J IMMUNOL, V166, P6564, DOI 10.4049/jimmunol.166.11.6564; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	82	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44338	44347		10.1074/jbc.M307376200	http://dx.doi.org/10.1074/jbc.M307376200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920112	hybrid			2022-12-27	WOS:000186306700057
J	Wang, N; Lan, D; Gerbod-Giannone, M; Linsel-Nitschke, P; Jehle, AW; Chen, WG; Martinez, LO; Tall, AR				Wang, N; Lan, D; Gerbod-Giannone, M; Linsel-Nitschke, P; Jehle, AW; Chen, WG; Martinez, LO; Tall, AR			ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; MUTATIONS; RECEPTOR; IDENTIFICATION; MECHANISMS; SECRETION; PROMOTER; CELLS; LIVER	ATP-binding cassette transporter 1 (ABCA1), the defective transporter in Tangier disease, binds and promotes cellular cholesterol and phospholipid efflux to apolipoprotein I (apoA-I). Based on a high degree of sequence homology between ABCA1 and ABCA7, a transporter of unknown function, we investigated the possibility that ABCA7 might be involved in apolipoprotein binding and lipid efflux. Similarly to cells expressing ABCA1, HEK293 cells overexpressing ABCA7 showed specific binding and cross-linking of lipid-poor apoA-I. ABCA7 expression increased cellular phosphatidylcholine and sphingomyelin efflux to apoA-I in a manner similar to ABCA1 but had no effect on cholesterol efflux. Western analysis showed a high protein level of ABCA7 in mouse spleen, lung, adrenal, and brain but low expression in liver. In contrast to ABCA1, ABCA7 showed moderate basal mRNA and protein levels in macrophages and lymphocytes but no induction by liver X receptor activation. These studies show that ABCA7 has the ability to bind apolipoproteins and promote efflux of cellular phospholipids without cholesterol, and they suggest a possible role of ABCA7 in cellular phospholipid metabolism in peripheral tissues.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.	nw30@columbia.edu	Tall, Alan/AAT-8528-2021; Martinez, Laurent O./ABD-6880-2020; Martinez, Laurent O/B-8343-2015	Martinez, Laurent O./0000-0002-0985-3152; Martinez, Laurent O/0000-0002-0985-3152	NHLBI NIH HHS [HL22682, HL54591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682, P01HL054591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Broccardo C, 2001, CYTOGENET CELL GENET, V92, P264, DOI 10.1159/000056914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kaminski WE, 2000, BIOCHEM BIOPH RES CO, V273, P532, DOI 10.1006/bbrc.2000.2954; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sasaki M, 2003, BIOCHEM BIOPH RES CO, V304, P777, DOI 10.1016/S0006-291X(03)00659-4; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; Small DM, 2003, P NATL ACAD SCI USA, V100, P4, DOI 10.1073/pnas.0237205100; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD	31	149	159	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42906	42912		10.1074/jbc.M307831200	http://dx.doi.org/10.1074/jbc.M307831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917409	hybrid			2022-12-27	WOS:000186157000023
J	Araki, T; Nawa, H; Neel, BG				Araki, T; Nawa, H; Neel, BG			Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-BETA; SRC FAMILY KINASES; PHOSPHOTYROSINE PHOSPHATASE SYP; PROTEIN-KINASE; PTP-ALPHA; SIGNAL-TRANSDUCTION; BINDING-SITE; IN-VIVO; CELL; CORKSCREW	The protein-tyrosine phosphatase Shp2 is required for normal activation of the ERK mitogen-activated protein kinase in multiple receptor tyrosine kinase signaling pathways. In fibroblasts, Shp2 undergoes phosphorylation at two C-terminal tyrosyl residues in response to some (fibroblast growth factor and platelet-derived growth factor (PDGF)) but not all (epidermal growth factor and insulin-like growth factor) growth factors. Whereas the catalytic activity of Shp2 is required for all Shp2 actions, the effect of tyrosyl phosphorylation on Shp2 function has been controversial. To clarify the role of Shp2 tyrosyl phosphorylation, we infected Shp2-mutant fibroblasts with retroviruses expressing wild type Shp2 or mutants of either (Y542F or Y580F) or both (Y542F, Y580F) C-terminal tyrosines. Compared with wild type cells, ERK activation was decreased in Y542F- or Y580F-infected cells in response to fibroblast growth factor and PDGF but not the epidermal growth factor. Mutation of both phosphorylation sites resulted in a further decrease in growth factor-evoked ERK activation, although not to the level of the vector control. Immunoblot analyses confirm that Tyr-542 and Tyr-580 are the major sites of Shp2 tyrosyl phosphorylation and that Tyr-542 is the major Grb2 binding site. However, studies with antibodies specific for individual Shp2 phosphorylation sites reveal unexpected complexity in the mechanism of Shp2 tyrosyl phosphorylation by different receptor tyrosine kinases. Moreover, because Y580F mutants retain nearly wild type Grb2-binding ability, yet exhibit defective PDGF-evoked ERK activation, our results show that the association of Grb2 with Shp2 is not sufficient for promoting full ERK activation in response to these growth factors, thereby arguing strongly against the "Grb2-adapter" model of Shp2 action.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Canc Biol Program,Div Hematol Oncol, Boston, MA 02215 USA; Niigata Univ, Brain Res Inst, Dept Mol Neurobiol, Niigata 9518585, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Niigata University	Araki, T (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Canc Biol Program,Div Hematol Oncol, Boston, MA 02215 USA.	taraki@bidmc.harvard.edu		Araki, Toshiyuki/0000-0002-1179-4534	NCI NIH HHS [R01 CA 49152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Allard JD, 1998, J BIOL CHEM, V273, P13129, DOI 10.1074/jbc.273.21.13129; Araki T, 2000, J NEUROCHEM, V74, P659, DOI 10.1046/j.1471-4159.2000.740659.x; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Keegan K, 1996, ONCOGENE, V12, P1537; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SU J, 1994, J BIOL CHEM, V269, P18731; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	53	166	170	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41677	41684		10.1074/jbc.M306461200	http://dx.doi.org/10.1074/jbc.M306461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923167	hybrid			2022-12-27	WOS:000185989500017
J	Oberley, MJ; Inman, DR; Farnham, PJ				Oberley, MJ; Inman, DR; Farnham, PJ			E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; CHROMATIN IMMUNOPRECIPITATION; DIHYDROFOLATE-REDUCTASE; TARGETED DELETION; DNA-REPAIR; IDENTIFICATION; PROMOTER; MYC; FAMILY	E2F6 contains a DNA binding domain that is very similar to that of the other members of the E2F family of transcriptional regulators. However, E2F6 cannot bind to all promoters that contain consensus E2F-binding sites. Therefore, we used a combination of chromatin immunoprecipitation and genomic microarrays to identify promoters bound by E2F6 in human cells. Although most of the identified promoters were bound by multiple E2F family members, one promoter was bound only by E2F6. To determine which of the newly identified promoters were regulated by E2F6, we reduced the level of E2F6 by using RNA interference technology. We found that mRNA transcribed from promoters bound by E2F6 was increased after reduction of the amount of E2F6 protein in the cell. Interestingly, many of the E2F6-regulated genes encoded functions involved in tumor suppression and the maintenance of chromatin structure. Specifically, our results suggest that E2F6 represses transcription of the brca1, ctip, art27, hp1alpha, and the rbap48 genes. E2F6 has been postulated to mediate transcriptional repression by recruiting a histone H3 methyltransferase to the DNA. However, we found that the E2F6-regulated promoters did not contain histone H3 methylated at lysine 9. To determine the mechanism by which E2F6 regulates transcription, we performed chromatin immunoprecipitation before and after the introduction of small inhibitory ribonucleic acids specific to E2F6. We found that depletion of E2F6 resulted in the recruitment of E2F1 to the target promoters. In summary, we have identified 48 endogenous target genes of E2F6 and have shown that E2F6 can repress target promoters in a manner that does not require histone H3 methylation at lysine 9.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu	Oberley, Matthew/I-8107-2019; Oberley, Matthew/L-4326-2019	Oberley, Matthew/0000-0001-6419-2513; Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA 09135, CA 45240, CA 14520] Funding Source: Medline; NIEHS NIH HHS [ES 07015-24] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014520, R01CA045240, R29CA045240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kennedy RD, 2002, LANCET, V360, P1007, DOI 10.1016/S0140-6736(02)11087-7; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Kirschmann DA, 2000, CANCER RES, V60, P3359; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lavia P, 1999, BIOESSAYS, V21, P221; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Markus SM, 2002, MOL BIOL CELL, V13, P670, DOI 10.1091/mbc.01-10-0513; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Moriuchi M, 1999, J IMMUNOL, V162, P5986; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; OBERLEY MJ, 2003, IN PRESS METHODS ENZ; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pearson A, 1997, ONCOGENE, V15, P2643, DOI 10.1038/sj.onc.1201451; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Schroer A, 1999, GENOMICS, V56, P340, DOI 10.1006/geno.1998.5712; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379; Yan PS, 2001, CANCER RES, V61, P8375	49	69	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42466	42476		10.1074/jbc.M307733200	http://dx.doi.org/10.1074/jbc.M307733200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909625	hybrid			2022-12-27	WOS:000185989500111
J	Ren, XH; Mody, I				Ren, XH; Mody, I			gamma-hydroxybutyrate reduces mitogen-activated protein kinase phosphorylation via GABA(B) receptor activation in mouse frontal cortex and hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; IN-VIVO; DOPAMINE NEURONS; MAP KINASE; RAT-BRAIN; POSTSYNAPTIC POTENTIALS; AMINOBUTYRIC-ACID; COUPLED RECEPTORS; ABSENCE SEIZURES; BINDING-SITES	Hydroxybutyrate (GHB) naturally occurs in the brain, but its exogenous administration induces profound effects on the central nervous system in animals and humans. The intracellular signaling mechanisms underlying its actions remain unclear. In the present study, the effects of GHB on the activation (phosphorylation) of mitogen-activated protein kinases (MAP kinases), extracellular signal-regulated kinase 1 and 2 (ERK1/2), were investigated. Acute administration of GHB (500 mg/kg, intraperitoneal) induced a fast and long lasting inhibition of MAP kinase phosphorylation in both frontal cortex and hippocampus. The reduced MAP kinase phosphorylation was observed in the CA1 and CA3 areas but not in the dentate gyrus. Pretreatment with the specific gamma-aminobutyric acid, type B (GABA(B)), receptor antagonist CGP56999A (20 mg/kg, intraperitoneal) prevented the action of GHB, and the effect of GHB was mimicked by baclofen, a selective GABAB receptor agonist, whereas the high affinity GHB receptor antagonist NCS-382 (200 mg/kg, intraperitoneal) had no effect on GHB-inhibited MAP kinase phosphorylation. Moreover, the GHB dehydrogenase inhibitor valproate (500 mg/kg, intraperitoneal), which inhibits the conversion of GHB into GABA, failed to block the effect of GHB on MAP kinase phosphorylation. Altogether, these data suggest that GHB, administered in vivo, reduces MAP kinase phosphorylation via a direct activation of GABAB receptors by GHB. In contrast, GHB (10 mM for 15 min) was found ineffective on MAP kinase phosphorylation in brain slices, indicating important differences in the conditions required for the second messenger activating action of GHB.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mody, I (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, RNRC 3-155,710 Westwood Plaza, Los Angeles, CA 90095 USA.				NIDA NIH HHS [DA 14947] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014947] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; BANERJEE PK, 1993, NEUROSCIENCE, V56, P11, DOI 10.1016/0306-4522(93)90557-V; Barbaccia ML, 2002, NEUROPHARMACOLOGY, V42, P782, DOI 10.1016/S0028-3908(02)00026-6; Bernasconi R, 1999, TRENDS PHARMACOL SCI, V20, P135, DOI 10.1016/S0165-6147(99)01341-3; Berton F, 1999, EUR J PHARMACOL, V380, P109, DOI 10.1016/S0014-2999(99)00515-4; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Brunzell DH, 2003, J NEUROCHEM, V84, P1431, DOI 10.1046/j.1471-4159.2003.01640.x; Carai MAM, 2001, EUR J PHARMACOL, V428, P315, DOI 10.1016/S0014-2999(01)01334-6; Cash CD, 1999, BIOCHEM PHARMACOL, V58, P1815, DOI 10.1016/S0006-2952(99)00265-8; Choe ES, 2002, NEUROPSYCHOPHARMACOL, V27, P565; Cook CD, 2002, PSYCHOPHARMACOLOGY, V160, P99, DOI 10.1007/s00213-001-0951-8; Cousins MS, 2002, DRUG ALCOHOL DEPEN, V65, P209, DOI 10.1016/S0376-8716(01)00163-6; Derkinderen P, 2003, J NEUROSCI, V23, P2371; ENGBERG G, 1993, N-S ARCH PHARMACOL, V348, P491; Erhardt S, 1998, N-S ARCH PHARMACOL, V357, P611, DOI 10.1007/PL00005215; Ferraro L, 2001, J NEUROCHEM, V78, P929, DOI 10.1046/j.1471-4159.2001.00530.x; GALLIMBERTI L, 1989, LANCET, V2, P787; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; Gobaille S, 1999, J PHARMACOL EXP THER, V290, P303; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hafen E, 1998, SCIENCE, V280, P1212, DOI 10.1126/science.280.5367.1212; Hechler V, 1997, J PHARMACOL EXP THER, V281, P753; Hu RQ, 2000, NEUROPHARMACOLOGY, V39, P427, DOI 10.1016/S0028-3908(99)00152-5; ITO Y, 1995, J NEUROCHEM, V65, P75; Jensen K, 2001, CEREB CORTEX, V11, P424, DOI 10.1093/cercor/11.5.424; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kalluri HSG, 2002, EUR J PHARMACOL, V439, P53, DOI 10.1016/S0014-2999(01)01599-0; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; KAUFMAN EE, 1990, BIOCHEM PHARMACOL, V40, P2637, DOI 10.1016/0006-2952(90)90581-5; Kleinschmidt S, 1999, EUR J ANAESTH, V16, P23, DOI 10.1046/j.1365-2346.1999.00393.x; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kyosseva SV, 2001, NEUROPSYCHOPHARMACOL, V24, P267, DOI 10.1016/S0893-133X(00)00180-9; Licata SC, 2003, J NEUROCHEM, V85, P14, DOI 10.1046/j.1471-4159.2003.01662.x; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Madden TE, 1998, J PHARMACOL EXP THER, V287, P261; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; MAMELAK M, 1986, SLEEP, V9, P285, DOI 10.1093/sleep/9.1.285; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mathivet P, 1997, EUR J PHARMACOL, V321, P67, DOI 10.1016/S0014-2999(96)00916-8; McLean HA, 1996, J NEUROPHYSIOL, V76, P1036, DOI 10.1152/jn.1996.76.2.1036; Nava F, 2001, EUR J PHARMACOL, V430, P261, DOI 10.1016/S0014-2999(01)01163-3; Nestler EJ, 2002, NAT NEUROSCI, V5, P1076, DOI 10.1038/nn945; Nicholson KL, 2001, DRUG ALCOHOL DEPEN, V63, P1, DOI 10.1016/S0376-8716(00)00191-5; Nissbrandt H, 1996, J NEURAL TRANSM, V103, P1255, DOI 10.1007/BF01271186; Okun MS, 2001, J PHARM PHARM SCI, V4, P167; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosen MI, 1996, NEUROPSYCHOPHARMACOL, V14, P187, DOI 10.1016/0893-133X(95)00087-T; Schulz S, 1998, EUR J NEUROSCI, V10, P1196, DOI 10.1046/j.1460-9568.1998.00103.x; SHUMATE JS, 1979, RES COMMUN CHEM PATH, V25, P241; SNEAD OC, 1994, BRAIN RES, V659, P147, DOI 10.1016/0006-8993(94)90874-5; Snead OC, 2000, J NEUROCHEM, V75, P1986, DOI 10.1046/j.1471-4159.2000.0751986.x; SNEAD OC, 1978, NEUROLOGY, V28, P636, DOI 10.1212/WNL.28.7.636; SNEAD OC, 1976, NEUROLOGY, V26, P51, DOI 10.1212/WNL.26.1.51; SNEAD OC, 1980, NEUROPHARMACOLOGY, V19, P47, DOI 10.1016/0028-3908(80)90165-3; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Takaki M, 2001, J NEUROCHEM, V79, P679, DOI 10.1046/j.1471-4159.2001.00615.x; Timby N, 2000, AM J MED, V108, P518, DOI 10.1016/S0002-9343(99)00468-4; TREMBLAY E, 1995, J NEUROCHEM, V65, P863; Vanhoose AM, 2002, J BIOL CHEM, V277, P9049, DOI 10.1074/jbc.M108309200; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; XIE XM, 1992, EUR J PHARMACOL, V212, P291, DOI 10.1016/0014-2999(92)90347-7; XIE XM, 1992, EUR J PHARMACOL, V223, P193, DOI 10.1016/0014-2999(92)94839-N; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	65	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42006	42011		10.1074/jbc.M304238200	http://dx.doi.org/10.1074/jbc.M304238200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923192	hybrid			2022-12-27	WOS:000185989500055
J	Tremblay, JJ; Viger, RS				Tremblay, JJ; Viger, RS			A mutated form of steroidogenic factor 1 (SF-1 G35E) that causes sex reversal in humans fails to synergize with transcription factor GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULLERIAN-INHIBITING SUBSTANCE; NUCLEAR RECEPTOR SF-1; VENTROMEDIAL HYPOTHALAMIC NUCLEUS; MULTIPLE GONADAL PROMOTERS; FACTOR-I; WILMS-TUMOR; ADRENAL DEVELOPMENT; GENE-TRANSCRIPTION; BINDING-PROTEINS; SERTOLI-CELLS	Steroidogenic factor 1 (SF-1) is a transcription factor belonging to the nuclear receptor superfamily. SF-1 regulates the expression of many genes involved in reproduction, steroidogenesis, and sexual differentiation. An important SF-1 target for male sexual differentiation is the gene encoding the Mullerian-inhibiting substance hormone that induces regression of the Mullerian ducts in the developing male embryo. Not long ago, a mutation (G35E) in the human SF-1 gene was identified as the cause of sex reversal and adrenal failure in a phenotypically female but genotypically XY individual. This suggested that the mutated SF-1 protein might interfere with the expression of SF-1 target gene(s) involved in the male sexual differentiation pathway, such as MIS. Surprisingly, the initial biochemical characterization of the SF-1 G35E mutant revealed that it could bind and activate the MIS promoter as efficiently as wild-type SF-1. MIS expression, however, does not rely solely on SF-1 but rather requires the concerted action of several transcription factors including GATA-4. We have previously reported that GATA-4 and SF-1 transcriptionally cooperate to synergistically activate the MIS promoter. Thus, we hypothesized that the phenotype observed with the SF-1 G35E mutation could be explained, at least in part, by a failure and/or a disruption of GATA-4/SF-1 synergism. We found that the SF-1 G35E mutant failed to synergize with GATA-4 despite a direct physical interaction between the two proteins. Interestingly, the SF-1 G35E mutant also disrupted transcriptional synergism between wild-type SF-1 and GATA-4, indicating that it could act as a dominant negative competitor. Thus, our results strengthen the importance of a GATA-4/SF-1 cooperation for MIS transcription and reveal that disruption of this synergism might be responsible for some cases of abnormal sex differentiation in humans.	CHU Laval, Ctr Rech, Ontogeny Reprod Res Unit, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Obstet & Gynecol, Ctr Rech Biol Reprod, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Viger, RS (corresponding author), CHU Laval, Ctr Rech, Ontogeny Reprod Res Unit, Rm T1-49,2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	Robert.Viger@crchul.ulaval.ca	Tremblay, Jacques J./AAO-2491-2021	Tremblay, Jacques J./0000-0002-4738-6284				Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; Achermann JC, 2002, J CLIN ENDOCR METAB, V87, P1829, DOI 10.1210/jc.87.4.1829; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; BEHRINGER RR, 1994, CURR TOP DEV BIOL, V29, P171, DOI 10.1016/S0070-2153(08)60550-5; Bland ML, 2000, P NATL ACAD SCI USA, V97, P14488, DOI 10.1073/pnas.97.26.14488; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORREA RV, 2001, PEDIATR RES, V49, P55; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; de Santa Barbara P, 2000, DEV DYNAM, V217, P293, DOI 10.1002/(SICI)1097-0177(200003)217:3<293::AID-DVDY7>3.0.CO;2-P; Giuili G, 1997, DEVELOPMENT, V124, P1799; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 2000, J BIOL CHEM, V275, P31708, DOI 10.1074/jbc.M002892200; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lu JR, 1999, MOL CELL BIOL, V19, P4495; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Rajpert-De Meyts E, 1999, J CLIN ENDOCR METAB, V84, P3836, DOI 10.1210/jc.84.10.3836; Robert NM, 2002, ENDOCRINOLOGY, V143, P3963, DOI 10.1210/en.2002-220280; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; Teixeira J, 2001, ENDOCR REV, V22, P657, DOI 10.1210/er.22.5.657; Tremblay AJ, 2001, BIOL REPROD, V64, P1191, DOI 10.1095/biolreprod64.4.1191; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; Tremblay JJ, 2001, ENDOCRINOLOGY, V142, P977, DOI 10.1210/en.142.3.977; Tremblay JJ, 2001, MOL ENDOCRINOL, V15, P1636, DOI 10.1210/me.15.9.1636; Viger RS, 1998, DEVELOPMENT, V125, P2665; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Watanabe K, 2000, P NATL ACAD SCI USA, V97, P1624, DOI 10.1073/pnas.97.4.1624; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794	41	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42637	42642		10.1074/jbc.M305485200	http://dx.doi.org/10.1074/jbc.M305485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907682	hybrid			2022-12-27	WOS:000185989500129
J	Blanc, V; Kennedy, S; Davidson, NO				Blanc, V; Kennedy, S; Davidson, NO			A novel nuclear localization signal in the auxiliary domain of apobec-1 complementation factor regulates nucleocytoplasmic import and shuttling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; MOLECULAR-CLONING; BINDING PROTEIN; EXPORT SIGNAL; CATALYTIC SUBUNIT; LEPTOMYCIN B; IDENTIFICATION; TRANSPORT; CYTIDINE; MODULATE	C to U editing of the nuclear apolipoprotein B ( apoB) transcript is mediated by a core enzyme containing a catalytic deaminase, apobec-1, and an RNA binding subunit, apobec-1 complementation factor (ACF). ACF expression is predominantly nuclear, including mutant proteins with deletions of a putative nuclear localization signal. We have now identified a novel 41-residue motif (ANS) in the auxiliary domain of ACF that functions as an authentic nuclear localization signal. ANS-green fluorescence protein and ANS-beta-galactosidase chimeras were both expressed exclusively in the nucleus, whereas wild-type chimeras or an ACF deletion mutant lacking the ANS were cytoplasmic. Nuclear accumulation of ACF is transcription-dependent, temperature-sensitive, and reversible, features reminiscent of a shuttling protein. ACF relocates to the cytoplasm after actinomycin D treatment, an effect blocked by the CRM1 inhibitor leptomycin B. Heterokaryon assays confirmed directly that ACF shuttles in vivo. ACF binds to the protein carrier, transportin 2 in vivo, and colocalizes to the nucleus as determined by confocal microscopy. Coimmunoprecipitation experiments revealed that transportin 2 binds directly to the ANS motif. These data suggest that directed nuclear localization and compartmentalization of the core complex of the apoB RNA editing enzyme is regulated through a dominant targeting sequence ( ANS) contained within ACF.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.	nod@im.wustl.edu			NHLBI NIH HHS [HL-38180] Funding Source: Medline; NIDDK NIH HHS [DK-56260, DK-52574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, R01DK056260] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Blanc V, 2001, J BIOL CHEM, V276, P46386, DOI 10.1074/jbc.M107654200; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 2002, RNA, V8, P69, DOI 10.1017/S1355838202015649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Moore MJ, 2001, SCIENCE, V294, P1841, DOI 10.1126/science.1067676; Mukhopadhyay D, 2003, ENDOCRINOLOGY, V144, P711, DOI 10.1210/en.2002-220741; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Sowden MP, 2002, J CELL SCI, V115, P1027; Sowden MP, 2001, BIOCHEM J, V359, P697, DOI 10.1042/0264-6021:3590697; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang Y, 1997, P NATL ACAD SCI USA, V94, P13075, DOI 10.1073/pnas.94.24.13075; Yang Y, 2001, EXP CELL RES, V267, P153, DOI 10.1006/excr.2001.5255	37	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41198	41204		10.1074/jbc.M302951200	http://dx.doi.org/10.1074/jbc.M302951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896982	hybrid			2022-12-27	WOS:000185847200097
J	Porcellini, A; Messina, S; De Gregorio, G; Feliciello, A; Carlucci, A; Barone, M; Picascia, A; De Blasi, A; Avvedimento, EV				Porcellini, A; Messina, S; De Gregorio, G; Feliciello, A; Carlucci, A; Barone, M; Picascia, A; De Blasi, A; Avvedimento, EV			The expression of the thyroid-stimulating hormone (TSH) receptor and the cAMP-dependent protein kinase RII beta regulatory subunit confers TSH-cAMP-dependent growth to mouse fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN RECEPTOR; CELL-GROWTH; MESSENGER-RNA; PC12 CELLS; PHOSPHORYLATION; PATHWAY; PROLIFERATION; LOCALIZATION; INHIBITION; ACTIVATION	TSH activates its specific receptor in thyroid cells and induces cAMP, a robust stimulator of thyroid cell proliferation. Conversely, cAMP is a potent inhibitor of growth in mouse fibroblasts. To dissect the signals mediating cAMP-dependent growth, we have expressed in mouse fibroblasts the human thyrotropin receptor (TSHR) or a constitutively active mutant, under the control of the tetracyclin promoter. Both TSHR and cAMP levels were modulated by tetracyclin. In the presence of serum, activation of TSHR by TSH induced growth arrest. In the absence of serum, cells expressing TSHR stimulated with TSH, replicated their DNA, but underwent apoptosis. Co-expression of cAMP-dependent protein kinase (PKA) regulatory subunit type II ( RIIbeta) inhibited apoptosis and stimulated the growth of cells only in the presence of TSH. Expression of RIIbeta-PKA, in the absence of TSHR, induced apoptosis, which was reversed by cAMP. Growth, stimulated by TSHR-RIIbeta-PKA in mouse fibroblasts, was also dependent on Rap1 activity, indicating cAMP-dependent growth in thyroid cells. As for the molecular mechanism underlying these effects, we found that in normal fibroblasts, TSH induced AKT and ERK1/2 only in cells expressing TSHR and RII. Similarly, activation of TSHR increased cAMP levels greatly, but was unable to stimulate CREB phosphorylation and transcription of cAMP-induced genes in the absence of RII. These data provide a simple explanation for the anti-proliferative and proliferative effects of cAMP in different cell types and indicate that RII-PKAII complements TSHR action by stably propagating robust cAMP signals in cell compartments.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; IRCCS, Ist Neurol Mediterraneo Neuromed, Dipartimento Patol Mol, I-86077 Pozzilli, Italy; IRCCS, Ist Neurol Mediterraneo Neuromed, Dipartimento Neurobiol Cellulare & Mol, I-86077 Pozzilli, Italy; Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Mol & Cellulare L Calif, I-80131 Naples, Italy; Univ Naples Federico II, Consiglio Nazl Ric, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	Sapienza University Rome; IRCCS Neuromed; IRCCS Neuromed; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Porcellini, A (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy.		Porcellini, Antonio/E-1900-2011; Porcellini, Antonio/AAC-6097-2019	Porcellini, Antonio/0000-0001-6882-9518; Feliciello, Antonio/0000-0002-7932-2170; BARONE, Maria Vittoria/0000-0001-6190-4917				Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; Cassano S, 1999, J BIOL CHEM, V274, P32574, DOI 10.1074/jbc.274.46.32574; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Costanzo V, 1999, CURR BIOL, V9, P903, DOI 10.1016/S0960-9822(99)80395-9; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Du Villard J, 2000, ONCOGENE, V19, P4896, DOI 10.1038/sj.onc.1203852; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; GUIZOUARN H, 1993, J BIOL CHEM, V268, P8632; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; PERSANI L, 1993, J ENDOCRINOL INVEST, V16, P511, DOI 10.1007/BF03348894; Porcellini A, 1997, ONCOGENE, V15, P781, DOI 10.1038/sj.onc.1201240; PORCELLINI A, 1995, ONCOGENE, V11, P1089; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Suh JM, 2003, J BIOL CHEM, V278, P21960, DOI 10.1074/jbc.M300805200; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TORTORA G, 1994, CELL GROWTH DIFFER, V5, P753; van Oirschot BA, 2001, J BIOL CHEM, V276, P33854, DOI 10.1074/jbc.M104395200; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	44	21	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40621	40630		10.1074/jbc.M307501200	http://dx.doi.org/10.1074/jbc.M307501200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902333	hybrid			2022-12-27	WOS:000185847200026
J	Ralton, JE; Naderer, T; Piraino, HL; Bashtannyk, TA; Callaghan, JM; McConville, MJ				Ralton, JE; Naderer, T; Piraino, HL; Bashtannyk, TA; Callaghan, JM; McConville, MJ			Evidence that intracellular beta 1-2 mannan is a virulence factor in Leishmania parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEXICANA; LIPOPHOSPHOGLYCAN; MANNOSE; BIOSYNTHESIS; AMASTIGOTES; MACROPHAGES; DISRUPTION; DONOVANI; PATHWAY; GENE	The protozoan parasite Leishmania mexicana proliferates within macrophage phagolysosomes in the mammalian host. In this study we provide evidence that a novel class of intracellular beta1-2 mannan oligosaccharides is important for parasite survival in host macrophages. Mannan ( degree of polymerization 4 - 40) is expressed at low levels in non-pathogenic promastigote stages but constitutes 80 and 90% of the cellular carbohydrate in the two developmental stages that infect macrophages, non-dividing promastigotes, and lesion-derived amastigotes, respectively. Mannan is catabolized when parasites are starved of glucose, suggesting a reserve function, and developmental stages having low mannan levels or L. mexicana GDPMP mutants lacking all mannose molecules are highly sensitive to glucose starvation. Environmental stresses, such as mild heat shock or the heat shock protein-90 inhibitor, geldanamycin, that trigger the differentiation of promastigotes to amastigotes, result in a 10-25-fold increase in mannan levels. Developmental stages with low mannan levels or L. mexicana mutants lacking mannan do not survive heat shock and are unable to differentiate to amastigotes or infect macrophages in vitro. In contrast, a L. mexicana mutant deficient only in components of the mannose-rich surface glycocalyx differentiates normally and infects macrophages in vitro. Collectively, these data provide strong evidence that mannan accumulation is important for parasite differentiation and survival in macrophages.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	University of Melbourne	McConville, MJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	malcolmm@unimelb.edu.au		Naderer, Thomas/0000-0003-2691-0283				Barrett MP, 1997, PARASITOL TODAY, V13, P11, DOI 10.1016/S0169-4758(96)10075-2; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; Burchmore RJS, 2001, INT J PARASITOL, V31, P1311, DOI 10.1016/S0020-7519(01)00259-4; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1016/S0168-6445(00)00059-0; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; GORIN PAJ, 1979, J PROTOZOOL, V26, P473, DOI 10.1111/j.1550-7408.1979.tb04656.x; Hilley JD, 2000, MOL BIOL CELL, V11, P1183, DOI 10.1091/mbc.11.4.1183; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; KEEGAN FP, 1993, J EUKARYOT MICROBIOL, V40, P730, DOI 10.1111/j.1550-7408.1993.tb04467.x; KEEGAN FP, 1992, MOL BIOCHEM PARASIT, V53, P193, DOI 10.1016/0166-6851(92)90021-B; MALLINSON DJ, 1989, PARASITOLOGY, V98, P7, DOI 10.1017/S0031182000059631; MANNERS DJ, 1982, ENCY PLANT PHYSL A, V13; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MENDONCAPREVIATO L, 1979, BIOCHEMISTRY-US, V18, P149, DOI 10.1021/bi00568a023; MOTTRAM JC, 1985, EXP PARASITOL, V59, P265, DOI 10.1016/0014-4894(85)90081-5; Naderer T, 2002, MOL BIOCHEM PARASIT, V125, P147, DOI 10.1016/S0166-6851(02)00236-0; Nitz M, 2002, J BIOL CHEM, V277, P3440, DOI 10.1074/jbc.M109274200; Opperdoes FR, 2001, INT J PARASITOL, V31, P482, DOI 10.1016/S0020-7519(01)00155-2; PREVIATO JO, 1982, EXP PARASITOL, V53, P170, DOI 10.1016/0014-4894(82)90058-3; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; Ralton JE, 2002, BIOCHEM J, V363, P365, DOI 10.1042/0264-6021:3630365; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; SCHLEIN Y, 1986, Parasitology Today, V2, P175, DOI 10.1016/0169-4758(86)90150-X; Schluepmann H, 2003, P NATL ACAD SCI USA, V100, P6849, DOI 10.1073/pnas.1132018100; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; VanHellemond JJ, 1997, MOL BIOCHEM PARASIT, V85, P135, DOI 10.1016/S0166-6851(97)02828-4; Wiesgigl M, 2001, MOL BIOL CELL, V12, P3307, DOI 10.1091/mbc.12.11.3307; WINTER G, 1994, J CELL SCI, V107, P2471	37	82	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40757	40763		10.1074/jbc.M307660200	http://dx.doi.org/10.1074/jbc.M307660200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902334	hybrid			2022-12-27	WOS:000185847200043
J	Tateno, H; Goldstein, IJ				Tateno, H; Goldstein, IJ			Molecular cloning, expression, and characterization of novel hemolytic lectins from the mushroom Laetiporus sulphureus, which show homology to bacterial toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERTEBRATE CUCUMARIA-ECHINATA; SEPTICUM ALPHA-TOXIN; MARASMIUS-OREADES; HIGH-AFFINITY; CEL-III; BINDING; PROTEINS; GAL-ALPHA-1,3GAL; AEROLYSIN; MEMBRANE	We describe herein the cDNA cloning, expression, and characterization of a hemolytic lectin and its related species from the parasitic mushroom Laetiporus sulphureus. The lectin designated LSL ( L. sulphureus lectin), is a tetramer composed of subunits of similar to 35 kDa associated by non-covalent bonds. From a cDNA library, three similar full-length cDNAs, termed LSLa, LSLb, and LSLc, were generated, each of which had an open reading frame of 945 bp encoding 315 amino acid residues. These proteins share 80 - 90% sequence identity and showed structural similarity to bacterial toxins: mosquitocidal toxin (MTX2) from Bacillus sphaericus and alpha toxin from Clostridium septicum. Native and recombinant forms of LSL showed hemagglutination and hemolytic activity and both activities were inhibited by N-acetyllactosamine, whereas a C-terminal deletion mutant of LSLa (LSLa-D1) retained hemagglutination, but not hemolytic activity, indicating the N-terminal domain is a carbohydrate recognition domain and the C-terminal domain functions as an oligomerization domain. The LSL-mediated hemolysis was protected osmotically by polyethylene glycol 4000 and maltohexaose. Inhibition studies showed that lacto-N-neotetraose (Galbeta1-4GlcNAcbeta1-3Gal beta1-4Glc) was the best inhibitor for LSL. These results indicate that LSL is a novel pore-forming lectin homologous to bacterial toxins.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Goldstein, IJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Tateno, Hiroaki/M-2706-2018	Tateno, Hiroaki/0000-0003-3006-1659	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLARD J, 1995, INFECT IMMUN, V63, P340, DOI 10.1128/IAI.63.1.340-344.1995; BUCKLEY JT, 1999, COMPREHENSIVE SOURCE, P362; Chan SW, 1996, J BIOL CHEM, V271, P14183, DOI 10.1074/jbc.271.24.14183; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; HATAKEYAMA T, 1995, J BIOL CHEM, V270, P3560, DOI 10.1074/jbc.270.8.3560; Hatakeyama T, 1996, J BIOL CHEM, V271, P16915, DOI 10.1074/jbc.271.28.16915; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; KONSKA G, 1994, J BIOCHEM-TOKYO, V116, P519, DOI 10.1093/oxfordjournals.jbchem.a124555; Kruger RP, 2002, J BIOL CHEM, V277, P15002, DOI 10.1074/jbc.M200165200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mo HQ, 2000, J BIOL CHEM, V275, P10623, DOI 10.1074/jbc.275.14.10623; Mo HQ, 2001, EUR J BIOCHEM, V268, P2609, DOI 10.1046/j.1432-1327.2001.02148.x; Novak T.P., 1975, BIOCHIM BIOPHYS ACTA, V393, P115; Olsnes S, 2001, TOXICON, V39, P1723, DOI 10.1016/S0041-0101(01)00158-1; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Thanabalu T, 1996, GENE, V170, P85, DOI 10.1016/0378-1119(95)00836-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; WARREN L, 1959, J BIOL CHEM, V234, P1971; Winter HC, 2002, J BIOL CHEM, V277, P14996, DOI 10.1074/jbc.M200161200; YANG JT, 1986, METHOD ENZYMOL, V130, P208	27	56	64	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40455	40463		10.1074/jbc.M306836200	http://dx.doi.org/10.1074/jbc.M306836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900403	hybrid			2022-12-27	WOS:000185847200006
J	Cao, C; Leng, YM; Huang, W; Liu, X; Kufe, D				Cao, C; Leng, YM; Huang, W; Liu, X; Kufe, D			Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; DEPENDENT PROTEIN-KINASE; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; CELLULAR-RESPONSE; ACTIVATION; CELLS; MICE; SUSCEPTIBILITY; SENSITIVITY	The c-Abl and Arg tyrosine kinases are activated in the cellular response to oxidative stress. The present studies demonstrate that c-Abl and Arg associate with glutathione peroxidase 1 (GPx1) and that this interaction is regulated by intracellular oxidant levels. The c-Abl and Arg SH3 domains bind directly to a proline-rich site in GPx1 at amino acids 132 - 145. GPx1 also functions as a substrate for c-Abl- and Arg-mediated phosphorylation on Tyr-96. The results further show that c-Abl and Arg stimulate GPx activity and that these kinases contribute to GPx-mediated protection of cells against oxidative stress. Our findings provide the first evidence that GPx1 is regulated by a signaling pathway that is activated in the oxidative stress response.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Beijing Inst Technol, Beijing 100850, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Beijing Institute of Technology	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA98626, CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA098626, R56CA098626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Duval C, 2002, BIOCHEM J, V367, P889, DOI 10.1042/BJ20020625; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Kim-Han JS, 1998, FREE RADICAL BIO MED, V25, P512, DOI 10.1016/S0891-5849(98)00076-8; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KOLESNICHENKO LS, 1986, DOKL AKAD NAUK SSSR+, V287, P735; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Miller S, 2002, BBA-MOL BASIS DIS, V1588, P85, DOI 10.1016/S0925-4439(02)00143-6; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P237, DOI 10.1159/000013847; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Schnurr K, 2000, PROTEIN EXPRES PURIF, V19, P403, DOI 10.1006/prep.2000.1262; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998	23	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39609	39614		10.1074/jbc.M305770200	http://dx.doi.org/10.1074/jbc.M305770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893824	hybrid			2022-12-27	WOS:000185713800044
J	Mateo, J; Kreda, S; Henry, CE; Harden, TK; Boyer, JL				Mateo, J; Kreda, S; Henry, CE; Harden, TK; Boyer, JL			Requirement of Cys(399) for processing of the human ecto-ATPase (NTPDase2) and its implications for determination of the activities of splice variants of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; QUATERNARY STRUCTURE; PHOSPHODIESTERASE-I; MOLECULAR-CLONING; SECRETORY PATHWAY; CD39; APYRASE; PROTEIN	Ecto-ATPase (CD39L1) corresponds to the type 2 enzyme of the ecto-nucleoside triphosphate diphosphohydrolase family (E-NTPDase). We have isolated from human ECV304 cells three cDNAs with high homology with members of the E-NTPDase family that encode predicted proteins of 495, 472, and 450 amino acids. Sequencing of a genomic DNA clone confirmed that these three sequences correspond to splice variants of the human ecto-ATPase (NTPDase2alpha, -2beta, and -2gamma). Although all three enzyme forms were expressed heterologously to similar levels in Chinese hamster ovary cells clone K-1 (CHO-K1) cells, only the 495-amino acid protein (NTPDase2alpha exhibited ecto-ATPase activity. Immunolocalization studies demonstrated that NTPDase2alpha is fully processed and trafficked to the plasma membrane, whereas the NTPDase2beta and -2gamma splice variants were retained in not fully glycosylated forms in the endoplasmic reticulum. The potential roles of two highly conserved residues, Cys(399) and Asn(443), in the activity and cellular trafficking of the ecto-ATPase were examined. Mutation of Cys(399), which is absent in NTPDase2beta and -2gamma, produced a protein completely devoid of nucleotidase activity, while mutation of Asn(443) to Asp resulted in substantial loss of activity. Neither the Cys(399) nor Asn(443) mutants were fully glycosylated, and both were retained in the endoplasmic reticulum. These results indicate that the lack of ecto-nucleotidase activity exhibited by NTPDase2beta and -2gamma and the (CS)-S-399 mutant, as well as the large reduction of activity in the N443D mutant are due to alterations in the folding/maturation of these proteins.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Harden, TK (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365,Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.		de Castro, Jesus Mateo/N-4434-2014	de Castro, Jesus Mateo/0000-0003-4459-7083	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054889, R01HL054889, P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54889, HL34322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Boyer JL, 1997, MOL PHARMACOL, V52, P928, DOI 10.1124/mol.52.6.928; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruess Michael, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology, V362, P392; Burnstock G, 1996, LANCET, V347, P1604, DOI 10.1016/S0140-6736(96)91082-X; Chadwick BP, 1997, MAMM GENOME, V8, P668, DOI 10.1007/s003359900534; CHE MX, 1992, J BIOL CHEM, V267, P9684; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Failer BU, 2003, EUR J BIOCHEM, V270, P1802, DOI 10.1046/j.1432-1033.2003.03542.x; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fuss B, 1997, J NEUROSCI, V17, P9095; Gao L, 1998, J BIOL CHEM, V273, P15358, DOI 10.1074/jbc.273.25.15358; Grinthal A, 2000, BIOCHEMISTRY-US, V39, P9, DOI 10.1021/bi991751k; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Heine P, 2001, EUR J BIOCHEM, V268, P364, DOI 10.1046/j.1432-1327.2001.01896.x; Hicks-Berger CA, 2000, IUBMB LIFE, V50, P43; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KANSAS GS, 1991, J IMMUNOL, V146, P2235; KAWAGOE H, 1995, GENOMICS, V30, P380, DOI 10.1006/geno.1995.0036; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Mateo J, 1999, BRIT J PHARMACOL, V128, P396, DOI 10.1038/sj.bjp.0702805; Milgram SL, 1997, J CELL SCI, V110, P695; Mulero JJ, 2000, BIOCHEMISTRY-US, V39, P12924, DOI 10.1021/bi000960y; MURATA J, 1994, J BIOL CHEM, V269, P30479; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PLESNER L, 1995, INT REV CYTOL, V158, P141; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTE EJ, 1999, BIOCHEMISTRY-US, V38, P2248; Smith TM, 1999, BIOCHEMISTRY-US, V38, P1509, DOI 10.1021/bi9821768; Stout JG, 1996, BIOCHEMISTRY-US, V35, P8289, DOI 10.1021/bi960563g; Vasconcelos EG, 1996, J BIOL CHEM, V271, P22139, DOI 10.1074/jbc.271.36.22139; Vlajkovic SM, 1999, MOL BRAIN RES, V73, P85, DOI 10.1016/S0169-328X(99)00244-2; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WARD CL, 1994, J BIOL CHEM, V269, P25710; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; [No title captured]	44	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39960	39968		10.1074/jbc.M307854200	http://dx.doi.org/10.1074/jbc.M307854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888562	hybrid, Green Published			2022-12-27	WOS:000185713800084
J	Matsuda, S; Matsuda, Y; D'Adamio, L				Matsuda, S; Matsuda, Y; D'Adamio, L			Amyloid beta protein precursor (A beta PP), but not A beta PP-like protein 2, is bridged to the kinesin light chain by the scaffold protein JNK-interacting protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL-TRANSPORT; SECRETASE; FRAGMENT; COMPLEX; DOMAIN; CARGO; BINDS; NOTCH	Proteolytic processing of amyloid beta protein precursor (AbetaPP) generates peptides that regulate normal cell signaling and are implicated in Alzheimer's disease pathogenesis. AbetaPP processing also occurs in nerve processes where AbetaPP is transported from the cell body by kinesin-I, a microtubule motor composed of two kinesin heavy chain and two kinesin light chain (Klc) subunits. AbetaPP transport is supposedly mediated by the direct AbetaPP-Klc1 interaction. Here we demonstrate that the AbetaPP-Klc1 interaction is not direct but is mediated by JNK-interacting protein 1 (JIP1). The phosphotyrosine binding domain of JIP1 binds the cytoplasmic tail of AbetaPP, whereas the JIP1 C-terminal region interacts with the tetratrico-peptide repeats of Klc1. We also show that JIP1 does not bridge the AbetaPP gene family member AbetaPP-like protein 2, APLP2, to Klc1. These results support a model where JIP1 mediates the interaction of AbetaPP to the motor protein kinesin-I and that this JIP1 function is unique for AbetaPP relative to its family member APLP2. Our data suggest that kinesin-I-dependent neuronal AbetaPP transport, which controls AbetaPP processing, may be regulated by JIP1.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	D'Adamio, L (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu		D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882	NIA NIH HHS [R01 AG22024-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG022024] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; D'Adamio L, 2002, RES PER ALZ, P101; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Matsuda S, 2001, J NEUROSCI, V21, P6597; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sisodia SS, 2002, SCIENCE, V295, P805, DOI 10.1126/science.1069661; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	22	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38601	38606		10.1074/jbc.M304379200	http://dx.doi.org/10.1074/jbc.M304379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12893827	hybrid			2022-12-27	WOS:000185575100064
